,pmid,sentence_id,sentences,section_name,index,starts,ends,limitation_annotation,categories,category_spans,category_annotation,coarse_grained_categories
0,PMC116603,18067,House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care [ISRCTN63308372],Title,[109780],[32643],[122],[False],[0],[0],[False],['0']
1,PMC116603,18068,Background,Abstract,[109785],[123],[134],[False],[0],[0],[False],['0']
2,PMC116603,18069,The house dust mite is the most important environmental allergen implicated in the aetiology of childhood asthma in the UK.,Abstract,[109790],[135],[258],[False],[0],[0],[False],['0']
3,PMC116603,18070,"Dust mite barrier bedding is relatively inexpensive, convenient to use, and of proven effectiveness in reducing mattress house dust mite load, but no studies have evaluated its clinical effectiveness in the control of childhood asthma when dispensed in primary care.",Abstract,[109795],[259],[525],[False],[0],[0],[False],['0']
4,PMC116603,18071,We therefore aimed to evaluate the effectiveness of house dust mite barrier bedding in children with asthma treated in primary care.,Abstract,[109800],[526],[658],[False],[0],[0],[False],['0']
5,PMC116603,18072,Methods,Methods,[109805],[659],[667],[False],[0],[0],[False],['0']
6,PMC116603,18073,"Pragmatic, randomised, double-blind, placebo controlled trial conducted in eight family practices in England.",Methods,[109810],[668],[777],[False],[0],[0],[False],['0']
7,PMC116603,18074,Forty-seven children aged 5 to 14 years with confirmed house dust mite sensitive asthma were randomised to receive six months treatment with either house dust mite barrier or placebo bedding.,Methods,[109815],[778],[969],[False],[0],[0],[False],['0']
8,PMC116603,18075,Peak expiratory flow was the main outcome measure of interest; secondary outcome measures included asthma symptom scores and asthma medication usage.,Methods,[109820],[970],[1119],[False],[0],[0],[False],['0']
9,PMC116603,18076,Results,Results,[109825],[1120],[1128],[False],[0],[0],[False],['0']
10,PMC116603,18077,"No difference was noted in mean monthly peak expiratory flow, asthma symptom score, medication usage or asthma consultations, between children who received active bedding and those who received placebo bedding.",Results,[109830],[1129],[1339],[False],[0],[0],[False],['0']
11,PMC116603,18078,Conclusions,Conclusions,[109835],[1340],[1352],[False],[0],[0],[False],['0']
12,PMC116603,18079,Treating house dust mite sensitive asthmatic children in primary care with house dust mite barrier bedding for six months failed to improve peak expiratory flow.,Conclusions,[109840],[1353],[1514],[False],[0],[0],[False],['0']
13,PMC116603,18080,Results strongly suggest that the intervention made no impact upon other clinical features of asthma.,Conclusions,[109845],[1515],[1616],[False],[0],[0],[False],['0']
14,PMC116603,18081,Background,Background,[109850],[1617],[1629],[False],[0],[0],[False],['0']
15,PMC116603,18082,Asthma is now the commonest chronic disease of childhood in the UK and evidence strongly suggests recent increases in prevalence and severity of the condition.,Background,[109855],[1630],[1789],[False],[0],[0],[False],['0']
16,PMC116603,18083,"[1-3] Aetiologically, changes to the indoor environment have been implicated in both these increases; proliferation in British homes of soft furnishings, wall-to-wall carpets, central heating, and double glazing, together with the tendency for children to spend more time indoors, have all combined to increase exposure to airborne indoor allergens.",Background,[109860],[1790],[2139],[False],[0],[0],[False],['0']
17,PMC116603,18084,[4] This pathophysiological element in the aetiology of asthma is reflected in the current British Thoracic Society Guidelines on Asthma Management which advise allergen avoidance should be considered in the treatment of all patients with asthma.,Background,[109865],[2140],[2386],[False],[0],[0],[False],['0']
18,PMC116603,18085,[5],Background,[109870],[2387],[2390],[False],[0],[0],[False],['0']
19,PMC116603,18086,"The allergen most commonly implicated in the UK is house dust mite, mattresses, bedding, and carpets forming its most important domestic reservoirs.",Background,[109875],[2391],[2537],[False],[0],[0],[False],['0']
20,PMC116603,18087,"A number of approaches to decreasing house dust mite exposure have been tried, of which house dust mite impermeable bedding is the most promising.",Background,[109880],[2538],[2684],[False],[0],[0],[False],['0']
21,PMC116603,18088,"[6] New semi-permeable (microporous) barrier bedding interventions are convenient and offer several potential advantages including easy compliance, a preventive approach to individual disease control and relatively low cost (Allerayde single bed set €153 + VAT).",Background,[109885],[2685],[2947],[False],[0],[0],[False],['0']
22,PMC116603,18089,"Though routine use of bedding interventions in dust mite sensitive children with asthma is both logical and safe, uncertainty remains about its clinical effectiveness.",Background,[109890],[2948],[3114],[False],[0],[0],[False],['0']
23,PMC116603,18090,"[7] The majority of children with asthma are managed almost exclusively in general practice, where the potential role of barrier bedding is unknown.",Background,[109895],[3115],[3263],[False],[0],[0],[False],['0']
24,PMC116603,18091,We sought to evaluate the effectiveness of semipermeable house dust mite barrier bedding in children sensitised to the dust mite in a placebo controlled trial conducted from primary care.,Background,[109900],[3264],[3451],[False],[0],[0],[False],['0']
25,PMC116603,18092,Methods,Methods,[109905],[3452],[3459],[False],[0],[0],[False],['0']
26,PMC116603,18093,"Study sample, inclusion and exclusion criteria","Methods|Study sample, inclusion and exclusion criteria",[109910],[3460],[3506],[False],[0],[0],[False],['0']
27,PMC116603,18094,The study was conducted between 1998 and 1999 in eight group practices recruited from the database of the National Respiratory Training Centre.,"Methods|Study sample, inclusion and exclusion criteria",[109915],[3507],[3650],[False],[0],[0],[False],['0']
28,PMC116603,18095,"Practices satisfying the study inclusion criteria were those that operated a dedicated nurse-led asthma clinic, and employed nurses who had received formal training in asthma and allergy on courses run by the National Asthma & Respiratory Training Centre.","Methods|Study sample, inclusion and exclusion criteria",[109920],[3651],[3906],[False],[0],[0],[False],['0']
29,PMC116603,18096,Ethical approval was obtained from the North London Multi-centre and relevant Local Research Ethics Committees.,"Methods|Study sample, inclusion and exclusion criteria",[109925],[3907],[4018],[False],[0],[0],[False],['0']
30,PMC116603,18097,"Parents of children aged 5–14 years with a recorded diagnosis of asthma and who had been prescribed one or more asthma treatments in the preceding six months, were contacted by telephone.","Methods|Study sample, inclusion and exclusion criteria",[109930],[4019],[4206],[False],[0],[0],[False],['0']
31,PMC116603,18098,"Children with a clinical history suggestive of house dust mite allergy, as judged by a positive response to the question 'has your child's asthma ever got worse when the bed is made or when the vacuuming or dusting is done?'","Methods|Study sample, inclusion and exclusion criteria",[109935],[4207],[4431],[False],[0],[0],[False],['0']
32,PMC116603,18099,were offered skin prick tests by practice nurses.,"Methods|Study sample, inclusion and exclusion criteria",[109940],[4432],[4481],[False],[0],[0],[False],['0']
33,PMC116603,18100,Prick tests were performed on the volar aspect of the forearm using standardised ALK Soluprik extracts of Dermatophagoides pteronyssinus (Der p1) and using positive (histamine dihydrochloride) and negative (allergen diluent) controls and were measured at 15 minutes.,"Methods|Study sample, inclusion and exclusion criteria",[109945],[4482],[4748],[False],[0],[0],[False],['0']
34,PMC116603,18101,A positive response to Der p1 was defined as a weal of at least five millimetres greater than that induced by the negative control.,"Methods|Study sample, inclusion and exclusion criteria",[109950],[4749],[4880],[False],[0],[0],[False],['0']
35,PMC116603,18102,Only children with both subjective and objective evidence of allergy to the house dust mite were invited to participate.,"Methods|Study sample, inclusion and exclusion criteria",[109955],[4881],[5001],[False],[0],[0],[False],['0']
36,PMC116603,18103,"Exclusion criteria were dermographism (because of the difficulty in interpreting skin prick test results), children who did not use a duvet, those already using allergy control bedding, and cat or dog ownership.","Methods|Study sample, inclusion and exclusion criteria",[109960],[5002],[5213],[False],[0],[0],[False],['0']
37,PMC116603,18104,Pet owners were excluded because co-sensitivity in dust mite sensitive individuals is common and the additional allergen load from the pet could swamp any effect of the barrier bedding.,"Methods|Study sample, inclusion and exclusion criteria",[109965],[5214],[5399],[False],[0],[0],[False],['0']
38,PMC116603,18105,Written consent from parents and verbal consent from children aged seven and over was obtained in all cases.,"Methods|Study sample, inclusion and exclusion criteria",[109970],[5400],[5508],[False],[0],[0],[False],['0']
39,PMC116603,18106,Randomisation and intervention,Randomisation and intervention,[109975],[5509],[5540],[False],[0],[0],[False],['0']
40,PMC116603,18107,To eliminate possible allocation bias centralised randomisation of individual patients was performed using numbers generated from a random numbers table.,Randomisation and intervention,[109980],[5541],[5694],[False],[0],[0],[False],['0']
41,PMC116603,18108,"Bedding sets comprising mattress, duvet and pillow covers were posted from the randomisation centre directly to the homes of recruited children.",Randomisation and intervention,[109985],[5695],[5839],[False],[0],[0],[False],['0']
42,PMC116603,18109,"Bedding consisted of either Allerayde Perfect house dust mite impermeable covers or identical looking placebo covers produced by the same company, and was supplied to patients in the study free of charge, to be used for six months.",Randomisation and intervention,[109990],[5840],[6071],[False],[0],[0],[False],['0']
43,PMC116603,18110,"Both subjects and nurses were blinded to which trial arm children were allocated to, as were those responsible for data analysis; the trial code was broken after data analysis had been completed.",Randomisation and intervention,[109995],[6072],[6267],[False],[0],[0],[False],['0']
44,PMC116603,18111,To ensure that only the effect of the bedding was being evaluated all patients were given identical advice and written instructions regarding ways to minimise house dust mite exposure at home.,Randomisation and intervention,[110000],[6268],[6460],[False],[0],[0],[False],['0']
45,PMC116603,18112,"Parents were asked to keep a daily symptom diary for their child detailing individual asthma (cough, wheeze, shortness of breath and chest tightness) and rhinitis (sneeze, runny nose, blocked nose) symptoms on a four-point Likert scale (0–3).",Randomisation and intervention,[110005],[6461],[6703],[False],[0],[0],[False],['0']
46,PMC116603,18113,"Each symptom score was tallied and summed together to produce a 28-day composite score for asthma, and for rhinitis.",Randomisation and intervention,[110010],[6704],[6820],[False],[0],[0],[False],['0']
47,PMC116603,18114,"Such symptom scores could vary between 0 (no symptoms) and 336 for asthma, between 0 (no symptoms) and 252 for rhinitis.",Randomisation and intervention,[110015],[6821],[6941],[False],[0],[0],[False],['0']
48,PMC116603,18115,Details of daily usage of asthma medication and episodes of night-time waking were also recorded.,Randomisation and intervention,[110020],[6942],[7039],[False],[0],[0],[False],['0']
49,PMC116603,18116,"Each practice nurse reviewed children at monthly intervals for six months, measured peak expiratory flow (recording the best reading from three attempts), assessed asthma control, and asked parents whether the bedding covers issued were still being used.",Randomisation and intervention,[110025],[7040],[7294],[False],[0],[0],[False],['0']
50,PMC116603,18117,"At the two-month post-intervention assessment, and thereafter, patients whose asthma control was considered good by the nurses were advised to reduce inhaled steroid use by 50%, in the context of clear instructions regarding steps to be taken should asthma symptoms deteriorate.",Randomisation and intervention,[110030],[7295],[7573],[False],[0],[0],[False],['0']
51,PMC116603,18118,"In the event of acute exacerbations of asthma nurses recommended a standardised protocol regarding indications for use of oral steroids, which were to be used in consultation with the general practitioner.",Randomisation and intervention,[110035],[7574],[7779],[False],[0],[0],[False],['0']
52,PMC116603,18119,"The initial assessment, involving skin prick testing, was performed in the patient's home.",Randomisation and intervention,[110040],[7780],[7870],[False],[0],[0],[False],['0']
53,PMC116603,18120,"Thereafter, children were seen at monthly intervals in the practice asthma clinic until the final assessment, which was performed at the child's home.",Randomisation and intervention,[110045],[7871],[8021],[False],[0],[0],[False],['0']
54,PMC116603,18121,"On completing the study, nurses checked paper and electronic medical records to extract data on all non-study related practice consultations, and accident & emergency department consultations for asthma, hospital admissions for asthma, and details of the number of courses of oral steroids prescribed during the study period.",Randomisation and intervention,[110050],[8022],[8347],[False],[0],[0],[False],['0']
55,PMC116603,18122,Statistical methods,Statistical methods,[110055],[8348],[8368],[False],[0],[0],[False],['0']
56,PMC116603,18123,"To detect an average within person change of 10% or more in peak expiratory flow (PEF) from baseline reading at the start of the study with 80% power at the 5% significance level (assuming a within person standard deviation of 35 l/min), we estimated that 21 patients were needed in each arm of the study.",Statistical methods,[110060],[8369],[8674],[False],[0],[0],[False],['0']
57,PMC116603,18124,Normally distributed data were analysed using student t-test and mean values and standard deviations calculated; the Mann Whitney test was used for non-parametric data and medians and inter-quartile ranges calculated.,Statistical methods,[110065],[8675],[8892],[False],[0],[0],[False],['0']
58,PMC116603,18125,Categorical data were analysed using Chi-square test or Fisher's exact test in the event of small numbers.,Statistical methods,[110070],[8893],[8999],[False],[0],[0],[False],['0']
59,PMC116603,18126,SPSS Windows Version 7.5 was used for all statistical analyses.,Statistical methods,[110075],[9000],[9063],[False],[0],[0],[False],['0']
60,PMC116603,18127,Results,Results,[110080],[9064],[9072],[False],[0],[0],[False],['0']
61,PMC116603,18128,Baseline data,Results|Baseline data,[110085],[9073],[9086],[False],[0],[0],[False],['0']
62,PMC116603,18129,"The combined list size of study practices was 55,687, of whom 6095 patients were aged 5–14 years of whom 1157 (19%) had a recorded diagnosis of asthma.",Results|Baseline data,[110090],[9087],[9238],[False],[0],[0],[False],['0']
63,PMC116603,18130,Four hundred and seventy two children were approached to join the study 47 of whom satisfied the inclusion criteria.,Results|Baseline data,[110095],[9239],[9355],[False],[0],[0],[False],['0']
64,PMC116603,18131,Reasons for excluding patients are summarised in Table 1.,Results|Baseline data,[110100],[9356],[9413],[False],[0],[0],[False],['0']
65,PMC116603,18132,"Forty-three children (92%) completed the study (Figure 1), all of whom reported use of bed covers supplied for the duration of the trial.",Results|Baseline data,[110105],[9414],[9551],[False],[0],[0],[False],['0']
66,PMC116603,18133,Three of the children lost to follow-up failed to attend for scheduled reviews; parents of the fourth child stated they no longer wished to participate.,Results|Baseline data,[110110],[9552],[9704],[False],[0],[0],[False],['0']
67,PMC116603,18134,Mean age of children was 11.0 years (sd 2.26) with a preponderance of boys (62%).,Results|Baseline data,[110115],[9705],[9786],[False],[0],[0],[False],['0']
68,PMC116603,18135,The treatment arm contained 26 (55%) children and the placebo group 21 (45%).,Results|Baseline data,[110120],[9787],[9864],[False],[0],[0],[False],['0']
69,PMC116603,18136,"Details of age, sex, baseline asthma symptom scores, medication usage, and peak expiratory flow measures for each group are given in Table 2.",Results|Baseline data,[110125],[9865],[10006],[False],[0],[0],[False],['0']
70,PMC116603,18137,"There was no major difference between groups in baseline skin prick test weal diameter to house dust mite, or in the proportion of households with a smoker, bedroom central heating, double-glazing or wall-to-wall carpets.",Results|Baseline data,[110130],[10007],[10228],[False],[0],[0],[False],['0']
71,PMC116603,18138,"Peak expiratory flow, symptom scores, and health care utilisation",Results,[110135],[10229],[10295],[False],[0],[0],[False],['0']
72,PMC116603,18139,Comparisons of changes in peak expiratory flow and other clinical data are summarised in Table 3.,Results,[110140],[10296],[10393],[False],[0],[0],[False],['0']
73,PMC116603,18140,"The results show that whilst mean peak expiratory flow increased in both groups when compared to baseline, there was no significant difference in the increases achieved when comparing active and placebo treated groups.",Results,[110145],[10394],[10612],[False],[0],[0],[False],['0']
74,PMC116603,18141,"Although mean asthma, rhinitis and night-time waking scores decreased from baseline in both groups, differences were not significant when comparing placebo and active treatment arms.",Results,[110150],[10613],[10795],[False],[0],[0],[False],['0']
75,PMC116603,18142,"Of interest is that these tendencies towards improvement in symptomatic and clinical outcomes, when compared to baseline, were seen in the context of reductions in mean inhaled corticosteroid usage when compared with baseline usage.",Results,[110155],[10796],[11028],[False],[0],[0],[False],['0']
76,PMC116603,18143,Only four children (two in each arm) required courses of oral steroid throughout the study and there were no asthma-related hospital admissions during this time period.,Results,[110160],[11029],[11197],[False],[0],[0],[False],['0']
77,PMC116603,18144,Discussion,Discussion,[110165],[11198],[11209],[False],[0],[0],[False],['0']
78,PMC116603,18145,In a carefully selected population of HDM sensitive children 6 months community based treatment with allergy control bedding achieved no significant improvement in peak expiratory flow in those treated with impermeable bedding covers compared with those treated with placebo covers.,Discussion,[110170],[11210],[11492],[False],[0],[0],[False],['0']
79,PMC116603,18146,The trial results also suggest that HDM impermeable covers made no impact on other clinical features of asthma.,Discussion,[110175],[11493],[11604],[False],[0],[0],[False],['0']
80,PMC116603,18147,"The trial was sufficiently powered to detect a clinically significant improvement for our main outcome measure of interest, peak expiratory flow, but this is not true of the other outcome measures studied.",Discussion,[110180],[11605],[11810],[False],[0],[0],[False],['0']
81,PMC116603,18148,One possible reason for the lack of effect is that families did not comply with the intervention.,Discussion,[110185],[11811],[11908],[True],['NonstandardTreatmentCharacteristics'],['families did not comply with the intervention'],[True],['Intervention']
82,PMC116603,18149,"Although we did not measure compliance directly, self-reported compliance was very good, and nurses did not report any lack of bedding usage in home assessments undertaken at the end of the study when each child's bed was inspected to see if the covers were still in place.",Discussion,[110195],[11909],[12182],[False],[0],[0],[False],['0']
83,PMC116603,18150,Another possible explanation for the lack of effect is that the pragmatic intervention employed failed to reduce house dust mite load sufficiently.,Discussion,[110200],[12183],[12330],[False],[0],[0],[False],['0']
84,PMC116603,18151,"Due to an ambiguity in the sampling protocol, we were unable, in this study, to obtain valid information on post-intervention house dust mite loads, but data from other studies show bedding covers of the sort we supplied to be highly effective in reducing mattress dust mite load.",Discussion,[110206],[12331],[12611],[True],['OutcomeMeasures'],"['we were unable, in this study, to obtain valid information on post-intervention house dust mite loads']",[True],['OutcomeMeasures']
85,PMC116603,18152,[8] A further possible explanation could be that the patients recruited on average suffered relatively mild disease (reflected by their low baseline asthma symptom scores); they were therefore sufficiently well controlled on existing treatment for little scope to remain for clinical improvement (Table 2).,Discussion,[110217],[12612],[12918],[True],['VerySpecificPopulation'],['patients recruited on average suffered relatively mild disease'],[True],['Population']
86,PMC116603,18153,The majority of asthmatic children managed in primary care have mild to moderate disease; in an attempt to maximise the chances of detecting clinical improvement we only recruited children who had active asthma (as evidenced by recent prescription for asthma medication) in whom attempts were made to reduce inhaled steroid use in a standardised manner.,Discussion,[110225],[12919],[13271],[False],[0],[0],[False],['0']
87,PMC116603,18154,We used PEF as our primary outcome measure of interest since this is the objective measure most commonly used by general practitioners and paediatricians; spirometry would not have been feasible in such young children.,Discussion,[110233],[13272],[13490],[True],['RelevantOutcomeExcluded'],['We used PEF as our primary outcome measure of interest'],[True],['OutcomeMeasures']
88,PMC116603,18155,"Because of concerns regarding the validity of self-recorded PEF in children, however, we opted for nurse-supervised clinic based recording rather than early morning PEF, another possible explanation for our failure to detect a difference.",Discussion,[110244],[13491],[13729],[True],['ValidityOfMeasurement'],['we opted for nurse-supervised clinic based recording'],[True],['OutcomeMeasures']
89,PMC116603,18156,"Finally, there is the possibility that the intervention reduced dust mite load but this failed to produce measurable clinical impact on patients.",Discussion,[110250],[13730],[13875],[False],[0],[0],[False],['0']
90,PMC116603,18157,[9],Discussion,[110255],[13876],[13879],[False],[0],[0],[False],['0']
91,PMC116603,18158,Allergen avoidance measures are likely to be of most benefit in patients truly sensitive to the allergen in question.,Discussion,[110260],[13880],[13996],[False],[0],[0],[False],['0']
92,PMC116603,18159,We therefore only included children with unequivocal allergy to the house dust mite as determined by both a subjective clinical history and objective positive weal and flare response on skin prick testing.,Discussion,[110265],[13997],[14202],[False],[0],[0],[False],['0']
93,PMC116603,18160,"Our findings suggest firstly that allergy to this organism, defined by a positive history and skin prick test of five millimetres or more, may not be as prevalent in GP registered populations as previously suspected.",Discussion,[110270],[14203],[14419],[False],[0],[0],[False],['0']
94,PMC116603,18161,"Clinical history alone appears to have low predictive value for allergy to dust mite in asthmatic children,[10] and house dust mite barrier bedding has at most only a minor impact on health outcomes for children with mild asthma in non pet owning families managed in general practice.",Discussion,[110275],[14420],[14704],[False],[0],[0],[False],['0']
95,PMC116603,18162,The rationale for offering patients advice in general practice about house dust mite avoidance for asthma (or for other house dust mite associated conditions such as perennial rhinitis) requires recourse to objective tests such as skin prick testing.,Discussion,[110280],[14705],[14955],[False],[0],[0],[False],['0']
96,PMC116603,18163,"Very few general practitioners currently perform skin prick testing, lacking both the training and financial support to do so.",Discussion,[110285],[14956],[15082],[False],[0],[0],[False],['0']
97,PMC116603,18164,[11] The alternative of radio-allergo absorbent testing (RAST) is more expensive.,Discussion,[110290],[15083],[15164],[False],[0],[0],[False],['0']
98,PMC116603,18165,"Our study adds support to the conclusions of a recent meta-analysis of house dust mite avoidance measures in asthma patients, which concluded that existing interventions designed to decrease domestic dust mite exposure are of little, if any, clinical benefit.",Discussion,[110295],[15165],[15423],[False],[0],[0],[False],['0']
99,PMC116603,18166,"[12] Our results, in conjunction with those of the meta-analysis, lead us to question whether routine use of house dust mite barrier bedding as treatment for mildly affected asthmatic children can be justified in the clinical setting of general practice.",Discussion,[110300],[15424],[15678],[False],[0],[0],[False],['0']
100,PMC116603,18167,"Further explanatory and pragmatic intervention studies are required, to estimate the value, if any, of mite reduction strategies in mite sensitive asthmatic children with more severe disease.",Discussion,[110305],[15679],[15870],[False],[0],[0],[False],['0']
101,PMC116603,18168,Conclusions,Conclusions,[110310],[15871],[15882],[False],[0],[0],[False],['0']
102,PMC116603,18169,"In a carefully selected population of HDM sensitive children, 6 months community based treatment with allergy control bedding achieved no significant improvement in peak expiratory flow in those treated with impermeable bedding covers compared with those treated with placebo covers.",Conclusions,[110315],[15883],[16166],[False],[0],[0],[False],['0']
103,PMC116603,18170,"Until the results of other trials evaluating the role of house dust mite barrier bedding become available, we recommend that topical corticosteroids remain the treatment of choice in those children with persistent asthma symptoms.",Conclusions,[110320],[16167],[16397],[False],[0],[0],[False],['0']
104,PMC116603,18171,Competing interests,Competing interests,[110325],[16398],[16418],[False],[0],[0],[False],['0']
105,PMC116603,18172,"AS has received a small travel grant from Allerayde, a manufacturer of house dust mite barrier bedding.",Competing interests,[110330],[16419],[16522],[False],[0],[0],[False],['0']
106,PMC116603,18173,Authors' contributions,Authors' contributions,[110335],[16523],[16546],[False],[0],[0],[False],['0']
107,PMC116603,18174,"AS was responsible for the day-to-day management of the project, this involving contributing to the design of the study protocol, obtaining ethics approval, data collection and analysis, and co-ordinating the writing up of the paper.",Authors' contributions,[110340],[16547],[16780],[False],[0],[0],[False],['0']
108,PMC116603,18175,"BH contributed to design of study protocols, interpretation of results and writing up of the manuscript.",Authors' contributions,[110345],[16781],[16885],[False],[0],[0],[False],['0']
109,PMC116603,18176,"BS conceived the idea for this project, contributed to design of study protocols, interpretation of results and writing up of the manuscript.",Authors' contributions,[110350],[16886],[17027],[False],[0],[0],[False],['0']
110,PMC116603,18177,"GB secured funding for the project, contributed to study design and the interpretation of results.",Authors' contributions,[110355],[17028],[17126],[False],[0],[0],[False],['0']
111,PMC116603,18178,"MH assisted in co-ordinating the study; she was actively involved in supervising practice recruitment, nurse training and designing study protocols.",Authors' contributions,[110360],[17127],[17275],[False],[0],[0],[False],['0']
112,PMC116603,18179,"SD conceived the idea for this project, contributed to the design of study protocols, interpretation of results, and writing up of the paper.",Authors' contributions,[110365],[17276],[17417],[False],[0],[0],[False],['0']
113,PMC116603,18180,All authors read and approved the final manuscript.,Authors' contributions,[110370],[17418],[17469],[False],[0],[0],[False],['0']
114,PMC116603,18181,Pre-publication history,Pre-publication history,[110375],[17470],[17494],[False],[0],[0],[False],['0']
115,PMC116603,18182,The pre-publication history for this paper can be accessed here:,Pre-publication history,[110380],[17495],[17559],[False],[0],[0],[False],['0']
116,PMC116603,18183,Acknowledgements,Acknowledgements,[110385],[17560],[17578],[False],[0],[0],[False],['0']
117,PMC116603,18184,"We thank the nurses whose dedication made this study possible: Diana Beken, Liz Bryant, Joan Flemming, Frances Fry, Wendy Johnson, Janetta Kennedy, Judith McAllister and Catherine Tutt.",Acknowledgements,[110390],[17579],[17764],[False],[0],[0],[False],['0']
118,PMC116603,18185,"Thanks also to Dr Meinir Jones and Dr Paul Cullinan of the National Heart & Lung Institute for their advice, ALK Abello for supplying the skin prick test kits and solutions and Allerayde for supplying bedding at a subsidised rate.",Acknowledgements,[110395],[17765],[17995],[False],[0],[0],[False],['0']
119,PMC116603,18186,"This study was supported by a project grant from the National Respiratory Training Centre, Warwick.",Acknowledgements,[110400],[17996],[18095],[False],[0],[0],[False],['0']
120,PMC116603,18187,AS initiated this study whilst funded by the London Academic Training Scheme; he currently holds a NHS R&D National Primary Care Training Award.,Acknowledgements,[110405],[18096],[18240],[False],[0],[0],[False],['0']
430,PMC1277826,18923,A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744],Title,[112454],[24969],[222],[False],[0],[0],[False],['0']
431,PMC1277826,18924,Background,Abstract,[112455],[223],[234],[False],[0],[0],[False],['0']
432,PMC1277826,18925,Complicated intra-abdominal infections (cIAI) remain challenging to treat because of their polymicrobial etiology including multi-drug resistant bacteria.,Abstract,[112456],[235],[389],[False],[0],[0],[False],['0']
433,PMC1277826,18926,"The efficacy and safety of tigecycline, an expanded broad-spectrum glycylcycline antibiotic, was compared with imipenem/cilastatin (IMI/CIS) in patients with cIAI.",Abstract,[112457],[390],[553],[False],[0],[0],[False],['0']
434,PMC1277826,18927,Methods,Methods,[112458],[554],[562],[False],[0],[0],[False],['0']
435,PMC1277826,18928,"A prospective, double-blind, multinational trial was conducted in which patients with cIAI randomly received intravenous (IV) tigecycline (100 mg initial dose, then 50 mg every 12 hours [q12h]) or IV IMI/CIS (500/500 mg q6h or adjusted for renal dysfunction) for 5 to14 days.",Methods,[112459],[563],[838],[False],[0],[0],[False],['0']
436,PMC1277826,18929,Clinical response at the test-of-cure (TOC) visit (14–35 days after therapy) for microbiologically evaluable (ME) and microbiological modified intent-to-treat (m-mITT) populations were the co-primary efficacy endpoint populations.,Methods,[112460],[839],[1069],[False],[0],[0],[False],['0']
437,PMC1277826,18930,Results,Results,[112461],[1070],[1078],[False],[0],[0],[False],['0']
438,PMC1277826,18931,A total of 825 patients received ≥ 1 dose of study drug.,Results,[112462],[1079],[1135],[False],[0],[0],[False],['0']
439,PMC1277826,18932,"The primary diagnoses for the ME group were complicated appendicitis (59%), and intestinal (8.8%) and gastric/duodenal perforations (4.6%).",Results,[112463],[1136],[1275],[False],[0],[0],[False],['0']
440,PMC1277826,18933,"For the ME group, clinical cure rates at TOC were 80.6% (199/247) for tigecycline versus 82.4% (210/255) for IMI/CIS (95% CI -8.4, 5.1 for non-inferiority tigecycline versus IMI/CIS).",Results,[112464],[1276],[1459],[False],[0],[0],[False],['0']
441,PMC1277826,18934,"Corresponding clinical cure rates within the m-mITT population were 73.5% (227/309) for tigecycline versus 78.2% (244/312) for IMI/CIS (95% CI -11.0, 2.5).",Results,[112465],[1460],[1615],[False],[0],[0],[False],['0']
442,PMC1277826,18935,"Nausea (31.0% tigecycline, 24.8% IMI/CIS [P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [P = 0.435]) were the most frequently reported adverse events.",Results,[112466],[1616],[1837],[False],[0],[0],[False],['0']
443,PMC1277826,18936,Conclusion,Conclusion,[112467],[1838],[1849],[False],[0],[0],[False],['0']
444,PMC1277826,18937,This study demonstrates that tigecycline is as efficacious as imipenem/cilastatin in the treatment of patients with cIAI.,Conclusion,[112468],[1850],[1971],[False],[0],[0],[False],['0']
445,PMC1277826,18938,Background,Background,[112469],[1972],[1984],[False],[0],[0],[False],['0']
446,PMC1277826,18939,"Complicated intra-abdominal infections are characterized as local or systemic infections secondary to a physical perforation in the gastrointestinal tract or via a necrotic gut wall into the peritoneal space, leading to abscess formation or peritonitis [1].",Background,[112470],[1985],[2242],[False],[0],[0],[False],['0']
447,PMC1277826,18940,These infections require a combination of appropriate and timely surgical source control and broad spectrum antimicrobial therapy for optimal outcome.,Background,[112471],[2243],[2393],[False],[0],[0],[False],['0']
448,PMC1277826,18941,"Nearly all intra-abdominal infections are caused by multiple microorganisms resident in the gastrointestinal tract; these include aerobes and facultative and obligate anaerobes [2], with Enterobacteriaceae (eg, Escherichia coli) isolated most frequently [1,3].",Background,[112472],[2394],[2654],[False],[0],[0],[False],['0']
449,PMC1277826,18942,"Although isolation of enterococci from an intra-abdominal source were once suggestive of normal flora, these bacteria are now recognized as true pathogens, with upwards of one third of intra-abdominal cultures yielding enterococci [2].",Background,[112473],[2655],[2890],[False],[0],[0],[False],['0']
450,PMC1277826,18943,"In fact, the isolation of Enterococcus spp.",Background,[112474],[2891],[2934],[False],[0],[0],[False],['0']
451,PMC1277826,18944,from an intra-abdominal focus of infection has been linked with treatment failure [4].,Background,[112475],[2935],[3021],[False],[0],[0],[False],['0']
452,PMC1277826,18945,"Treatment of complicated intra-abdominal infections remains a challenge, primarily because of their polymicrobial etiology coupled with the high risk of complications and death.",Background,[112476],[3022],[3199],[False],[0],[0],[False],['0']
453,PMC1277826,18946,"Because frequently recovered isolates may possess multiple resistance factors (eg, extended spectrum beta-lactamases [ESBLs]) that express antimicrobial resistance, empiric antimicrobial therapy should have anticipated activity against these difficult-to-treat isolates [1,5].",Background,[112477],[3200],[3476],[False],[0],[0],[False],['0']
454,PMC1277826,18947,"As such, combination antibiotic therapy has often been a standard of care for treatment of these infections [1].",Background,[112478],[3477],[3589],[False],[0],[0],[False],['0']
455,PMC1277826,18948,"The recent 2003 guidelines of the Infectious Diseases Society of America (IDSA) advocates broad-spectrum single or combination therapy (eg, carbapenem or piperacillin/tazobactam monotherapy, third- or fourth-generation cephalosporins or fluoroquinolones plus metronidazole) for high-risk patients with severe or postoperative nosocomial intra-abdominal infections wherein polymicrobial infection and/or resistant flora are more prevalent [1].",Background,[112479],[3590],[4032],[False],[0],[0],[False],['0']
456,PMC1277826,18949,"When very resistant bacteria are suspected (eg, vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa), however, a complex multidrug regimen is recommended [1].",Background,[112480],[4033],[4242],[False],[0],[0],[False],['0']
457,PMC1277826,18950,"The initial selection of antimicrobial therapy for treatment of intra-abdominal infections is extremely important because inappropriate empiric antimicrobial therapy has been associated with delayed clinical resolution, increased length of hospital stay, and an increased risk of mortality [6,7].",Background,[112481],[4243],[4539],[False],[0],[0],[False],['0']
458,PMC1277826,18951,Adequate surgical source control is also an important determinant of outcome; insufficient drainage and repair may compromise the effectiveness of antibiotic therapy [1].,Background,[112482],[4540],[4710],[False],[0],[0],[False],['0']
459,PMC1277826,18952,"Tigecycline is a novel, first-in-class, glycylcycline antibiotic with expanded broad-spectrum wide in vitro activity against the microorganisms commonly encountered in intra-abdominal infections.",Background,[112483],[4711],[4906],[False],[0],[0],[False],['0']
460,PMC1277826,18953,"Specifically, tigecycline's spectrum of in vitro activity includes aerobic and facultative gram-positive and gram-negative bacteria and anaerobic bacteria [8-11].",Background,[112484],[4907],[5069],[False],[0],[0],[False],['0']
461,PMC1277826,18954,"Tigecycline also provides in vitro activity against antibiotic-resistant bacteria such as vancomycin-resistant Enterococcus faecalis and E. faecium, ESBL-producing enteric gram-negative bacteria, and methicillin-resistant S. aureus [8-16].",Background,[112485],[5070],[5309],[False],[0],[0],[False],['0']
462,PMC1277826,18955,The primary objective of this multicenter trial was to evaluate the efficacy and safety of tigecycline monotherapy compared with imipenem/cilastatin in the treatment of hospitalized adult patients with complicated intra-abdominal infections.,Background,[112486],[5310],[5551],[False],[0],[0],[False],['0']
463,PMC1277826,18956,A second goal of the study was to evaluate the in vitro susceptibility of tigecycline against common bacteria implicated as causes of intra-abdominal infection.,Background,[112487],[5552],[5712],[False],[0],[0],[False],['0']
464,PMC1277826,18957,Methods,Methods,[112488],[5713],[5721],[False],[0],[0],[False],['0']
465,PMC1277826,18958,Study design and enrollment criteria,Methods|Study design and enrollment criteria,[112489],[5722],[5758],[False],[0],[0],[False],['0']
466,PMC1277826,18959,"This was a phase 3, multicenter, double-blind (third-party unblinded) trial of adult patients who were candidates for or had undergone a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess and had a known or suspected diagnosis of complicated intra-abdominal infection.",Methods|Study design and enrollment criteria,[112490],[5759],[6056],[False],[0],[0],[False],['0']
467,PMC1277826,18960,All patients were hospitalized at the time of study entry.,Methods|Study design and enrollment criteria,[112491],[6057],[6115],[False],[0],[0],[False],['0']
468,PMC1277826,18961,"Before screening of the first patient, the protocol was reviewed and approved by the institutional review board or ethical review committee at each participating center.",Methods|Study design and enrollment criteria,[112492],[6116],[6285],[False],[0],[0],[False],['0']
469,PMC1277826,18962,Written informed consent was obtained from each patient or his or her legal representative before the start of any study procedures.,Methods|Study design and enrollment criteria,[112493],[6286],[6418],[False],[0],[0],[False],['0']
470,PMC1277826,18963,The trial was conducted in accordance with the Declaration of Helsinki.,Methods|Study design and enrollment criteria,[112494],[6419],[6490],[False],[0],[0],[False],['0']
471,PMC1277826,18964,Inclusion criteria,Inclusion criteria,[112495],[6491],[6510],[False],[0],[0],[False],['0']
472,PMC1277826,18965,Men and women were eligible for inclusion if they were 18 years of age or older and required a surgical procedure for a complicated intra-abdominal infection.,Inclusion criteria,[112496],[6511],[6669],[False],[0],[0],[False],['0']
473,PMC1277826,18966,"Complicated intra-abdominal infections included conditions such as an intra-abdominal abscess (including liver and spleen) that developed in a postsurgical patient after receiving standard antibacterial therapy (ie, at least 48 hours, but note more than 5 days of antibiotics); appendicitis complicated by perforation and/or a periappendiceal abscess; perforated diverticulitis complicated by abscess formation or fecal contamination; complicated cholecystitis with evidence of perforation, empyema, or gangrene; perforation of a gastric or duodenal ulcer with symptoms exceeding 24 hours; purulent peritonitis or peritonitis associated with fecal contamination; or perforation of the large or small intestine with abscess or fecal contamination.",Inclusion criteria,[112497],[6670],[7416],[False],[0],[0],[False],['0']
474,PMC1277826,18967,"In addition, patients could not have received more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin, gentamicin) after the baseline intra-abdominal culture was obtained from the infected site.",Inclusion criteria,[112498],[7417],[7706],[False],[0],[0],[False],['0']
475,PMC1277826,18968,Exclusion criteria,Exclusion criteria,[112499],[7707],[7726],[False],[0],[0],[False],['0']
476,PMC1277826,18969,Patients were not allowed to participate if they had any concomitant condition that precluded evaluation of a response or made it unlikely that the planned course of therapy could be completed.,Exclusion criteria,[112500],[7727],[7920],[False],[0],[0],[False],['0']
477,PMC1277826,18970,"Other primary reasons for ineligibility included the following: preoperative suspicion of a diagnosis of spontaneous bacterial peritonitis, simple cholecystitis, gangrenous cholecystitis without rupture, simple appendicitis, acute suppurative cholangitis, pancreatic abscess, or infected necrotizing pancreatitis; Acute Physiologic and Chronic Health Evaluation (APACHE) II score greater than 30; active or treated leukemia or systemic malignancy within the prior 3 months or metastatic malignancy to the abdomen within the prior 6 months; known acquired immunodeficiency syndrome (AIDS); presence of any uncontrolled central nervous system disease; pregnant or breastfeeding women; known or suspected hypersensitivity to either study drug or to related compounds; concomitant ganciclovir therapy; significant hepatic disease (ie, aspartate aminotransferase [AST] or alanine aminotransferase [ALT] level > 10 times the upper limit of normal [ULN] or total bilirubin value > 3 times the ULN) or acute hepatic failure or acute decompensation of chronic hepatic failure; significant renal disease (ie, calculated creatinine clearance < 41 mL/min/1.73 m2 after adequate hydration); neutropenia with absolute neutrophil count < 1000/mm3, with counts as low as 500/mm3 permitted if due to the acute infectious process; current intra-abdominal infection known to be caused by one or more bacterial isolates not susceptible to either of the study drugs (eg, P. aeruginosa, Proteus mirabilis); surgical procedure requiring that fascia or deep muscular layers be left open or expectation of planned abdominal re-exploration either in or out of the operating room; and administration of intraoperative antibacterial irrigants or peritoneal antibacterial agents (eg, irrigants, antibiotic-impregnated sponges).",Exclusion criteria,[112501],[7921],[9719],[False],[0],[0],[False],['0']
478,PMC1277826,18971,"Any patient requiring additional systemic antibacterial therapy, for any reason, was not allowed to participate in the trial.",Exclusion criteria,[112502],[9720],[9845],[False],[0],[0],[False],['0']
479,PMC1277826,18972,Antimicrobial regimens,Antimicrobial regimens,[112503],[9846],[9869],[False],[0],[0],[False],['0']
480,PMC1277826,18973,"Patients were stratified at randomization into 2 groups based on their scores on APACHE II: ≤15, or >15 but <31.",Antimicrobial regimens,[112504],[9870],[9982],[False],[0],[0],[False],['0']
481,PMC1277826,18974,"Using a 1:1 ratio, patients were randomly assigned to receive either tigecycline (initial 100-mg dose given by intravenous [IV] infusion over a 30-minute period, followed by 50 mg IV every 12 hours) or IV imipenem/cilastatin (500 mg/500 mg every 6 hours or dose-adjusted based on weight and creatinine clearance).",Antimicrobial regimens,[112505],[9983],[10296],[False],[0],[0],[False],['0']
482,PMC1277826,18975,Patients randomized to tigecycline received a 100 mL normal saline intravenous infusion 6 hours after active drug each day in order to maintain the blind.,Antimicrobial regimens,[112506],[10297],[10451],[False],[0],[0],[False],['0']
483,PMC1277826,18976,"Unless the patient was a clinical failure (see definition below), the duration of study drug therapy ranged from 5 to 14 days.",Antimicrobial regimens,[112507],[10452],[10578],[False],[0],[0],[False],['0']
484,PMC1277826,18977,"Study drug was administered only when there was a strong suspicion (ie, elevated white blood cell count, elevated band cell counts [ie, evidence of a ""shift to the left""], fever, or highly suggestive radiographic findings) or a confirmed diagnosis of an intra-abdominal infection (presence of pus within the abdominal cavity), and a baseline intra-abdominal culture was obtained from the site of infection.",Antimicrobial regimens,[112508],[10579],[10985],[False],[0],[0],[False],['0']
485,PMC1277826,18978,Patients could be enrolled before drainage of the intra-abdominal infection and may have received up to 2 doses of study drug before the baseline cultures were obtained.,Antimicrobial regimens,[112509],[10986],[11155],[False],[0],[0],[False],['0']
486,PMC1277826,18979,Patients did not receive more than 1 dose (or combination) of parenteral nonstudy antibacterial drugs after the baseline intra-abdominal cultures were obtained.,Antimicrobial regimens,[112510],[11156],[11316],[False],[0],[0],[False],['0']
487,PMC1277826,18980,"However, wound irrigation solutions of sterile water or normal saline and topical antiseptics were permitted throughout the course of the study.",Antimicrobial regimens,[112511],[11317],[11461],[False],[0],[0],[False],['0']
488,PMC1277826,18981,Clinical evaluations,Clinical evaluations,[112512],[11462],[11483],[False],[0],[0],[False],['0']
489,PMC1277826,18982,The clinical status of the intra-abdominal infection was assessed at serial visits throughout the study by the presence or absence of the following signs and symptoms: fever; localized or diffuse abdominal wall rigidity or involuntary guarding; abdominal tenderness or pain; ileus or hypoactive bowel sounds; nausea or vomiting.,Clinical evaluations,[112513],[11484],[11812],[False],[0],[0],[False],['0']
490,PMC1277826,18983,The clinical response to study drug was determined by the investigator.,Clinical evaluations,[112514],[11813],[11884],[False],[0],[0],[False],['0']
491,PMC1277826,18984,"At the test-of-cure visit (14–35 days after therapy), each patient's response was categorized as one of the following: Cure – the course of study drug and the initial intervention (operative and/or radiologically guided drainage procedure) resolved the intra-abdominal infectious process; Failure – the patient required additional antibacterial therapy other than the study drug, the patient required additional surgical or radiologic intervention to cure the infection, death due to infection occurred after 48 hours of therapy, the patient received an extended course of study drug (ie, >120% of the planned number of doses), or the patient was prematurely discontinued from study drug due to an adverse event (after receiving at least 8 doses in 5 days) and required additional antibiotic therapy or surgical intervention; and Indeterminate – the patients was lost to follow-up, or died within 48 hours after the first dose of study drug for any reason, or died after 48 hours because of noninfectious-related reasons (as judged by the investigator).",Clinical evaluations,[112515],[11885],[12938],[False],[0],[0],[False],['0']
492,PMC1277826,18985,Microbiologic evaluations,Microbiologic evaluations,[112516],[12939],[12965],[False],[0],[0],[False],['0']
493,PMC1277826,18986,Baseline aerobic and anaerobic cultures from the primary intra-abdominal site of infection and two sets of blood cultures were obtained within 24 hours of the first dose of study drug.,Microbiologic evaluations,[112517],[12966],[13150],[False],[0],[0],[False],['0']
494,PMC1277826,18987,"All aerobic and anaerobic bacterial isolates, regardless of the source of cultured material, were identified and tested at a central laboratory (Covance Central Laboratory Services, Inc., Indianapolis, IN, or Geneva, Switzerland) by using a standard procedure approved by the National Committee of Clinical Laboratory Standards (NCCLS) Subcommittee on Antimicrobial Susceptibility Testing.",Microbiologic evaluations,[112518],[13151],[13540],[False],[0],[0],[False],['0']
495,PMC1277826,18988,"For tigecycline, provisional minimum inhibitory concentration (MIC) breakpoints were used (susceptible ≤2 mg/L; intermediate 4 mg/L; resistant ≥8 mg/L).",Microbiologic evaluations,[112519],[13541],[13693],[False],[0],[0],[False],['0']
496,PMC1277826,18989,"Based on the results of the baseline intra-abdominal culture, the susceptibilities of identified organisms, and the clinical outcome of the patient, the investigator also determined the microbiologic response at the patient level and at the isolate level.",Microbiologic evaluations,[112520],[13694],[13949],[False],[0],[0],[False],['0']
497,PMC1277826,18990,"Microbiologic response by patient was categorized at the test-of-cure visit as eradication, persistence, superinfection (ie, the emergence of a new isolate was documented at the site of infection with worsening signs and symptoms of infection).",Microbiologic evaluations,[112521],[13950],[14194],[False],[0],[0],[False],['0']
498,PMC1277826,18991,"The microbiologic response for each baseline isolate at the test-of-cure visit was described according to the following definitions: eradication, persistence, or indeterminate.",Microbiologic evaluations,[112522],[14195],[14371],[False],[0],[0],[False],['0']
499,PMC1277826,18992,"Because many patients did not have follow-up cultures, many microbiologic responses both at the patient and isolate level were categorized as either presumed eradication or presumed persistence.",Microbiologic evaluations,[112523],[14372],[14566],[False],[0],[0],[False],['0']
500,PMC1277826,18993,Safety/tolerability assessments,Safety/tolerability assessments,[112524],[14567],[14599],[False],[0],[0],[False],['0']
501,PMC1277826,18994,All patients who received at least one dose of study drug were evaluated for safety (modified intent-to-treat [mITT] population).,Safety/tolerability assessments,[112525],[14600],[14729],[False],[0],[0],[False],['0']
502,PMC1277826,18995,"Safety was assessed from serial medical history and physical examinations, reports of clinical adverse events, and findings from routine electrocardiograms (ECGs), and serum chemistry, hematology, coagulation, and urinalysis tests.",Safety/tolerability assessments,[112526],[14730],[14961],[False],[0],[0],[False],['0']
503,PMC1277826,18996,"Adverse events were recorded throughout the study period, up to and including the test-of-cure visit.",Safety/tolerability assessments,[112527],[14962],[15063],[False],[0],[0],[False],['0']
504,PMC1277826,18997,"Before unblinding, the investigator categorized the severity of each adverse event and the potential for relationship to study drug.",Safety/tolerability assessments,[112528],[15064],[15196],[False],[0],[0],[False],['0']
505,PMC1277826,18998,"Serious adverse events (ie, those that were life-threatening, led to prolongation of the existing hospitalization, caused persistent or significant disability or incapacity, or death) were also recorded.",Safety/tolerability assessments,[112529],[15197],[15400],[False],[0],[0],[False],['0']
506,PMC1277826,18999,Analysis populations,Analysis populations,[112530],[15401],[15422],[False],[0],[0],[False],['0']
507,PMC1277826,19000,"Several subpopulations of patients were assessed for safety, clinical, and bacteriologic outcomes.",Analysis populations,[112531],[15423],[15521],[False],[0],[0],[False],['0']
508,PMC1277826,19001,"Patients who satisfied the inclusion/exclusion criteria were included in the intent-to-treat (ITT) population, whereas the subset of patients who received at least 1 dose of study drug made up the mITT population.",Analysis populations,[112532],[15522],[15735],[False],[0],[0],[False],['0']
509,PMC1277826,19002,"Those patients in the mITT population who had clinical evidence of a complicated intra-abdominal infection, by meeting the minimal disease criteria, and had a confirmed baseline isolate made up the microbiological-modified (m-mITT) population.",Analysis populations,[112533],[15736],[15979],[False],[0],[0],[False],['0']
510,PMC1277826,19003,"From this latter group, the microbiologically evaluable (ME) population was defined as those who met all inclusion/exclusion criteria; had at least 5 days of therapy; did not receive concomitant antibiotics after the baseline intra-abdominal culture was obtained through the test-of-cure visit; had a test-of-cure visit 14 to 35 days after the first dose of study drug; and had a baseline intra-abdominal culture containing at least one causative isolate that was susceptible to both study drugs.",Analysis populations,[112534],[15980],[16476],[False],[0],[0],[False],['0']
511,PMC1277826,19004,"If these criteria were not met at any time during the study, the patient was declared non-evaluable and the outcome of cure/failure/indeterminate was analyzed within the m-mITT population.",Analysis populations,[112535],[16477],[16665],[False],[0],[0],[False],['0']
512,PMC1277826,19005,Patients were considered nonevaluable for inclusion in the ME population if death occurred or if they withdrew from the study <48 hours after the first dose of study drug.,Analysis populations,[112536],[16666],[16837],[False],[0],[0],[False],['0']
513,PMC1277826,19006,Statistical analysis,Statistical analysis,[112537],[16838],[16859],[False],[0],[0],[False],['0']
514,PMC1277826,19007,The primary endpoints of the study were clinical response at the test-of-cure visit (14–35 days after therapy) for the m-mITT and ME populations.,Statistical analysis,[112538],[16860],[17005],[False],[0],[0],[False],['0']
515,PMC1277826,19008,"Secondary analyses included bacteriologic response at the test-of cure visit by patient and isolate, as well as clinical response rates stratified as monomicrobial versus polymicrobial, and by isolate.",Statistical analysis,[112539],[17006],[17207],[False],[0],[0],[False],['0']
516,PMC1277826,19009,"Statistical analysis was performed by the Clinical Biostatistics department of Wyeth Research, Collegeville, PA. Categorical baseline demographic and medical variables were analyzed using the Fisher exact test.",Statistical analysis,[112540],[17208],[17418],[False],[0],[0],[False],['0']
517,PMC1277826,19010,Continuous variables were compared using a one-way analysis of variance (ANOVA) model with treatment as a factor.,Statistical analysis,[112541],[17419],[17532],[False],[0],[0],[False],['0']
518,PMC1277826,19011,Between-group comparisons of adverse events were analyzed by using the Fisher exact test.,Statistical analysis,[112542],[17533],[17622],[False],[0],[0],[False],['0']
519,PMC1277826,19012,"For laboratory tests, vital signs, and ECG results, within-group changes from baseline were analyzed by using a paired t-test and between-group comparisons were made by using the analysis of covariance, adjusting for baseline value.",Statistical analysis,[112543],[17623],[17855],[False],[0],[0],[False],['0']
520,PMC1277826,19013,The difference between treatment groups in the percentage of premature withdrawal from study drug was evaluated by using a 2-sided Fisher exact test.,Statistical analysis,[112544],[17856],[18005],[False],[0],[0],[False],['0']
521,PMC1277826,19014,The noninferiority efficacy of tigecycline compared with imipenem/cilastatin was evaluated for clinical and microbiologic responses by using a 2-sided 95% confidence interval (CI) for the true difference in efficacy (tigecycline minus imipenem/cilastatin) adjusted for the stratification variable APACHE II score and corrected for continuity.,Statistical analysis,[112545],[18006],[18348],[False],[0],[0],[False],['0']
522,PMC1277826,19015,Noninferiority was concluded if the lower limit of the 2-sided 95% CI was greater than or equal to -15%.,Statistical analysis,[112546],[18349],[18453],[False],[0],[0],[False],['0']
523,PMC1277826,19016,"For all subpopulation analyses (eg, monomicrobial versus polymicrobial infection), an adjusted difference between treatment groups with its 95% CI was calculated from a generalized linear model with a binomial probability function and an identity link (SAS® Proc GENMOD).",Statistical analysis,[112547],[18454],[18725],[False],[0],[0],[False],['0']
524,PMC1277826,19017,Interaction effects were tested at the 0.10 level of significance.,Statistical analysis,[112548],[18726],[18792],[False],[0],[0],[False],['0']
525,PMC1277826,19018,"With the planned sample size (n = 788) and an evaluability rate of 50%, the trial had a power of at least 90% to determine the noninferiority of tigecycline compared with imipenem/cilastatin.",Statistical analysis,[112549],[18793],[18984],[False],[0],[0],[False],['0']
526,PMC1277826,19019,Results,Results,[112550],[18985],[18993],[False],[0],[0],[False],['0']
527,PMC1277826,19020,Figure 1 Patient disposition and analysis population..,Results,[112551],[18994],[19048],[False],[0],[0],[False],['0']
528,PMC1277826,19021,"Eight hundred ninety-eight (898) patients were screened for study participation at 96 sites in 17 countries in the United States, Canada, Europe, Latin America, India, and Asia from November 2002 to August 2004.",Results,[112552],[19049],[19261],[False],[0],[0],[False],['0']
529,PMC1277826,19022,"Of these, 64 patients did not meet protocol requirements (Figure 1).",Results,[112553],[19262],[19330],[False],[0],[0],[False],['0']
530,PMC1277826,19023,"The remaining 834 patients were randomized in a 1:1 ratio to one of the two treatment regimens and represented the ITT population; however, 9 patients never received study drug.",Results,[112554],[19331],[19508],[False],[0],[0],[False],['0']
531,PMC1277826,19024,"Accordingly, 825 patients (413 tigecycline, 412 imipenem/cilastatin) comprised the mITT (safety) population.",Results,[112555],[19509],[19617],[False],[0],[0],[False],['0']
532,PMC1277826,19025,The majority of the mITT population (98%; 807 of 825) had clinical evidence of a complicated intra-abdominal infection (clinical mITT population).,Results,[112556],[19618],[19764],[False],[0],[0],[False],['0']
533,PMC1277826,19026,"Within this latter cohort, 692 patients were clinically evaluable (clinically evaluable [CE] population).",Results,[112557],[19765],[19870],[False],[0],[0],[False],['0']
534,PMC1277826,19027,"One hundred thirty three (133; 16.1%) mITT patients (72 tigecycline, 61 imipenem/cilastatin) were not included in the CE population for the following primary reasons (patients could have been excluded for more than one reason): no clinical evaluation at the test-of-cure visit (n = 47); entry criteria not met (n = 28); blind broken (n = 22); and received more than 1 dose of a nonstudy antibiotic after pretherapy culture (n = 12).",Results,[112558],[19871],[20303],[False],[0],[0],[False],['0']
535,PMC1277826,19028,"From the mITT population, 621 of 825 (75%) patients had a pretherapy isolate isolated and comprised the m-mITT population.",Results,[112559],[20304],[20426],[False],[0],[0],[False],['0']
536,PMC1277826,19029,"A total of 502 m-mITT patients (247 tigecycline, 255 imipenem/cilastatin) met both clinical evaluability criteria and had a pretherapy isolate isolated from an intra-abdominal source (ME population).",Results,[112560],[20427],[20626],[False],[0],[0],[False],['0']
537,PMC1277826,19030,Demographic/baseline medical characteristics,Demographic/baseline medical characteristics,[112561],[20627],[20672],[False],[0],[0],[False],['0']
538,PMC1277826,19031,The demographic characteristics for the 502 ME patients were comparable between the two treatment groups (Table 1).,Demographic/baseline medical characteristics,[112562],[20673],[20788],[False],[0],[0],[False],['0']
539,PMC1277826,19032,The study population was of mixed racial/ethnic background with whites (41.8%) and Hispanics (19.5%) represented most often.,Demographic/baseline medical characteristics,[112563],[20789],[20913],[False],[0],[0],[False],['0']
540,PMC1277826,19033,There was a predominance of men (67.5%) and the mean age of enrolled patients was 43 years old.,Demographic/baseline medical characteristics,[112564],[20914],[21009],[False],[0],[0],[False],['0']
541,PMC1277826,19034,"Complicated appendicitis (59%) was the most common intra-abdominal infection diagnosis, followed by perforated intestine (8.8%) and gastric/duodenal ulcer (4.6%).",Demographic/baseline medical characteristics,[112565],[21010],[21172],[False],[0],[0],[False],['0']
542,PMC1277826,19035,No significant differences between the treatment groups were observed in the number or types of infections diagnosed at baseline.,Demographic/baseline medical characteristics,[112566],[21173],[21302],[False],[0],[0],[False],['0']
543,PMC1277826,19036,The severity of intra-abdominal illness was similar in each treatment group (mean APACHE II score was ~5.7).,Demographic/baseline medical characteristics,[112567],[21303],[21411],[False],[0],[0],[False],['0']
544,PMC1277826,19037,Clinical efficacy,Clinical efficacy,[112568],[21412],[21430],[False],[0],[0],[False],['0']
545,PMC1277826,19038,"For the ME population, clinical cure rates were 80.6% for tigecycline and 82.4% for imipenem/cilastatin (95% CI -9.0, 5.4; Table 2).",Clinical efficacy,[112569],[21431],[21563],[False],[0],[0],[False],['0']
546,PMC1277826,19039,"Corresponding clinical cure rates for the m-mITT population were 73.5% and 78.2% (95% CI -11.8, 2.3), respectively.",Clinical efficacy,[112570],[21564],[21679],[False],[0],[0],[False],['0']
547,PMC1277826,19040,"For both the ME and m-mITT populations, tigecycline was efficacious and statistically noninferior to imipenem/cilastatin.",Clinical efficacy,[112571],[21680],[21801],[False],[0],[0],[False],['0']
548,PMC1277826,19041,"Multiple subgroup analyses of clinical responses (eg, age, sex, race, geographic location) found consistently efficacious clinical responses between the treatment groups.",Clinical efficacy,[112572],[21802],[21972],[False],[0],[0],[False],['0']
549,PMC1277826,19042,No significant treatment differences in clinical response were observed between the two treatment groups when patients were stratified by the number of isolated baseline isolates (Table 2).,Clinical efficacy,[112573],[21973],[22162],[False],[0],[0],[False],['0']
550,PMC1277826,19043,"For the ME population, tigecycline had a 89.8% clinical cure rate at the test-of-cure visit for monomicrobial infections and a 75.3% clinical cure rate for polymicrobial infections.",Clinical efficacy,[112574],[22163],[22344],[False],[0],[0],[False],['0']
551,PMC1277826,19044,"Similar rates were observed for recipients of imipenem/cilastatin (88.5% and 78.1%, respectively).",Clinical efficacy,[112575],[22345],[22443],[False],[0],[0],[False],['0']
552,PMC1277826,19045,"For complicated appendicitis, the most frequent diagnosis, clinical cure rates at the test-of-cure visit was 84.2% for tigecycline and 86.2% for imipenem/cilastatin (Table 3).",Clinical efficacy,[112576],[22444],[22619],[False],[0],[0],[False],['0']
553,PMC1277826,19046,"In both treatment groups, lower clinical cure rates (≤72%) were observed in patients who had intra-abdominal abscess, complicated diverticulitis, or intestinal perforation (Table 3).",Clinical efficacy,[112577],[22620],[22802],[False],[0],[0],[False],['0']
554,PMC1277826,19047,"Overall, there were no significant differences in clinical cure rates between tigecycline and imipenem/cilastatin based on primary intra-abdominal diagnosis.",Clinical efficacy,[112578],[22803],[22960],[False],[0],[0],[False],['0']
555,PMC1277826,19048,A total of 14 tigecycline- and 27 imipenem/cilastatin-treated patients in the ME population had a positive pretherapy blood culture.,Clinical efficacy,[112579],[22961],[23093],[False],[0],[0],[False],['0']
556,PMC1277826,19049,Clinical cure in patients with bacteremia was reported for 71.4% of tigecycline and 74.1% of imipenen/cilastatin recipients.,Clinical efficacy,[112580],[23094],[23218],[False],[0],[0],[False],['0']
557,PMC1277826,19050,Microbiologic efficacy,Microbiologic efficacy,[112581],[23219],[23242],[False],[0],[0],[False],['0']
558,PMC1277826,19051,"For the ME population, eradication of intra-abdominal isolates at the patient level was reported for 80.6% of tigecycline- and 82.4% of imipenem/cilastatin-treated patients (95% CI -9.0, 5.4), indicating that tigecycline was efficacious and statistically noninferior to imipenem/cilastatin (Table 4).",Microbiologic efficacy,[112582],[23243],[23543],[False],[0],[0],[False],['0']
559,PMC1277826,19052,No significant differences between the treatment groups were found when eradication rates were stratified by monomicrobial versus polymicrobial infection (Table 4).,Microbiologic efficacy,[112583],[23544],[23708],[False],[0],[0],[False],['0']
560,PMC1277826,19053,"Generally, eradication rates at the test-of-cure visit for the most commonly isolated intra-abdominal isolates were similar between the two treatment groups (Table 5).",Microbiologic efficacy,[112584],[23709],[23876],[False],[0],[0],[False],['0']
561,PMC1277826,19054,"For E. coli, the most commonly isolated aerobe, eradication rates were 80.4% for tigecycline versus 83.5% for imipenem/cilastatin.",Microbiologic efficacy,[112585],[23877],[24007],[False],[0],[0],[False],['0']
562,PMC1277826,19055,"Corresponding eradication rates for Klebsiella spp, the second most frequently isolated gram-negative aerobe, were 87.1% and 85.7%, respectively.",Microbiologic efficacy,[112586],[24008],[24153],[False],[0],[0],[False],['0']
563,PMC1277826,19056,A total of 6 ESBL-producing E. coli and 7 ESBL-producing K. pneumoniae isolates were identified pretherapy.,Microbiologic efficacy,[112587],[24154],[24261],[False],[0],[0],[False],['0']
564,PMC1277826,19057,"The majority of these isolates were eradicated by tigecycline: 83% (5/6) and 71% (5/7), respectively.",Microbiologic efficacy,[112588],[24262],[24363],[False],[0],[0],[False],['0']
565,PMC1277826,19058,Eradication rates for Bacteroides fragilis were 69.8% for tigecycline and 72.5% for imipenem/cilastatin.,Microbiologic efficacy,[112589],[24364],[24468],[False],[0],[0],[False],['0']
566,PMC1277826,19059,Pretherapy in vitro activity against baseline isolates for tigecycline and imipenem/cilastatin are shown in Table 6.,Microbiologic efficacy,[112590],[24469],[24585],[False],[0],[0],[False],['0']
567,PMC1277826,19060,The mean MIC for tigecycline against the most commonly isolated aerobes and anaerobes was ≤2.0 mg/L.,Microbiologic efficacy,[112591],[24586],[24686],[False],[0],[0],[False],['0']
568,PMC1277826,19061,No pretherapy isolates displayed resistance to tigecycline based on the provisional breakpoints used.,Microbiologic efficacy,[112592],[24687],[24788],[False],[0],[0],[False],['0']
569,PMC1277826,19062,Bacterial susceptibilities to tigecycline appeared to be consistent with clinical responses.,Microbiologic efficacy,[112593],[24789],[24881],[False],[0],[0],[False],['0']
570,PMC1277826,19063,Safety and tolerability,Safety and tolerability,[112594],[24882],[24906],[False],[0],[0],[False],['0']
571,PMC1277826,19064,Data from all patients in the mITT population (n = 825) were analyzed for safety.,Safety and tolerability,[112595],[24907],[24988],[False],[0],[0],[False],['0']
572,PMC1277826,19065,The m-ITT population received a median of 7 days of tigecycline or imipenem/cilastatin treatment.,Safety and tolerability,[112596],[24989],[25086],[False],[0],[0],[False],['0']
573,PMC1277826,19066,"Regardless of study drug causality, the frequency and distribution of treatment-emergent adverse events occurring in at least 3% of patients in either treatment group were similar to those observed in the imipenem/cilastatin treatment group.",Safety and tolerability,[112597],[25087],[25328],[False],[0],[0],[False],['0']
574,PMC1277826,19067,The majority of these adverse events were related to study medication (56%) and were mild to moderate in intensity (94%).,Safety and tolerability,[112598],[25329],[25450],[False],[0],[0],[False],['0']
575,PMC1277826,19068,"Digestive system (56.9% vs 49.8%, P = 0.043), nausea (31.0% tigecycline, 24.8% imipenem/cilastatin; P = 0.052), vomiting (25.7% tigecycline, 19.4% imipenem/cilastatin; P = 0.037), and diarrhea (21.3% tigecycline, 18.9% imipenem/cilastatin; P = 0.435) were the most frequently reported adverse events in both treatment groups.",Safety and tolerability,[112599],[25451],[25776],[False],[0],[0],[False],['0']
576,PMC1277826,19069,The majority of patients in both treatment groups experienced mild to moderate nausea and/or vomiting (94%).,Safety and tolerability,[112600],[25777],[25885],[False],[0],[0],[False],['0']
577,PMC1277826,19070,There was no significant difference between the treatment groups in the number of patients who required antiemetic therapy for nausea and/or vomiting.,Safety and tolerability,[112601],[25886],[26036],[False],[0],[0],[False],['0']
578,PMC1277826,19071,"No tigecycline-treated patient has a positive Clostridium difficile toxin assay, nor developed C. difficile associated diarrhea.",Safety and tolerability,[112602],[26037],[26165],[False],[0],[0],[False],['0']
579,PMC1277826,19072,"In the tigecycline group, infections (13.6% vs 7.5%, P = 0.006), hypoproteinemia (8.0% vs 4.1%, P = 0.028), and dyspnea (6.8% vs 2.9%, P = 0.014) were statistically higher than in the imipenem/cilastatin treatment group.",Safety and tolerability,[112603],[26166],[26386],[False],[0],[0],[False],['0']
580,PMC1277826,19073,The difference in infection rates between the treatment groups was primarily due to the development of secondary wound infections.,Safety and tolerability,[112604],[26387],[26517],[False],[0],[0],[False],['0']
581,PMC1277826,19074,No apparent trends or risk factors were identified in the development of secondary wound infections in either treatment group.,Safety and tolerability,[112605],[26518],[26644],[False],[0],[0],[False],['0']
582,PMC1277826,19075,"One hundred forty-five (145) patients had one or more serious adverse events during the study (81 [19.6%] tigecycline, 64 [15.5%] imipenem/cilastatin) (P = 0.143).",Safety and tolerability,[112606],[26645],[26808],[False],[0],[0],[False],['0']
583,PMC1277826,19076,"The most frequently reported serious adverse events were abnormal healing (14 tigecycline, 6 imipenem/cilastatin), abscess (10 tigecycline, 8 imipenem/cilastatin), and infection (10 tigecycline, 9 imipenem/cilastatin).",Safety and tolerability,[112607],[26809],[27027],[False],[0],[0],[False],['0']
584,PMC1277826,19077,Significantly more patients treated with tigecycline (6 [1.5%]) versus none treated with imipenem/cilastatin reported pneumonia as a serious adverse event (P = 0.031).,Safety and tolerability,[112608],[27028],[27195],[False],[0],[0],[False],['0']
585,PMC1277826,19078,Adverse events were the primary reason for early withdrawal of study drug.,Safety and tolerability,[112609],[27196],[27270],[False],[0],[0],[False],['0']
586,PMC1277826,19079,A total of 27 (6.5%) tigecycline- and 15 (3.6%) imipenem/cilastatin-treated patients discontinued treatment prematurely because of an adverse event (P = 0.080).,Safety and tolerability,[112610],[27271],[27431],[False],[0],[0],[False],['0']
587,PMC1277826,19080,"A total of 10 (2.5%) tigecycline- and 4 (1.0%) imipenem/cilastatin-treated patients stopped therapy prematurely secondary to either nausea (6 tigecycline, 2 imipenem/cilastatin) and/or vomiting (4 tigecycline, 2 imipenem/cilastatin).",Safety and tolerability,[112611],[27432],[27665],[False],[0],[0],[False],['0']
588,PMC1277826,19081,There were no significant differences between treatment groups in any single adverse event leading to the discontinuation of study drug.,Safety and tolerability,[112612],[27666],[27802],[False],[0],[0],[False],['0']
589,PMC1277826,19082,Twenty-nine (29) patients died during the study: 17 patients in the tigecycline group and 12 patients in the imipenem/cilastatin treatment group.,Safety and tolerability,[112613],[27803],[27948],[False],[0],[0],[False],['0']
590,PMC1277826,19083,"Only two of the deaths, both in the tigecycline group, were considered by the investigators to be possibly related to study drug secondary to treatment failure.",Safety and tolerability,[112614],[27949],[28109],[False],[0],[0],[False],['0']
591,PMC1277826,19084,The first patient was a 78 year old female who received tigecycline for one week.,Safety and tolerability,[112615],[28110],[28191],[False],[0],[0],[False],['0']
592,PMC1277826,19085,Two days following discontinuation of therapy the patient developed septic shock; she died one day later.,Safety and tolerability,[112616],[28192],[28297],[False],[0],[0],[False],['0']
593,PMC1277826,19086,"The second patient, a 23 year old female, presented with sepsis and received 3 days of tigecycline therapy.",Safety and tolerability,[112617],[28298],[28405],[False],[0],[0],[False],['0']
594,PMC1277826,19087,On day 3 she was found to have pneumonia and progressed to multiple organ failure with sepsis and died the same day.,Safety and tolerability,[112618],[28406],[28522],[False],[0],[0],[False],['0']
595,PMC1277826,19088,"Few clinically important or unexpected changes in any routine hematologic or serum chemistry tests, vital signs, or ECG data were associated with the use of tigecycline or imipenem/cilastatin.",Safety and tolerability,[112619],[28523],[28715],[False],[0],[0],[False],['0']
596,PMC1277826,19089,"However, significantly more patients treated with imipenem/cilastatin (312/410, 76.1%) than those treated with tigecycline (275/408, 67.4%) had 1 or more laboratory findings of potential clinical importance (P = 0.007).",Safety and tolerability,[112620],[28716],[28935],[False],[0],[0],[False],['0']
597,PMC1277826,19090,"Imipenem/cilastatin-treated patients had significantly lower serum potassium (≤3 mmol/L; P = 0.004), phosphorus values (≤ 0.8 mmol/L; P < 0.001), and lymphocytes values (≤0.6 cells × 109/L; P < 0.001).",Safety and tolerability,[112621],[28936],[29137],[False],[0],[0],[False],['0']
598,PMC1277826,19091,"Yet, significantly more patients treated with tigecycline than those treated with imipenem/cilastatin had clinically significant hypoproteinemia (≤35 g/L; P = 0.001).",Safety and tolerability,[112622],[29138],[29304],[False],[0],[0],[False],['0']
599,PMC1277826,19092,No significant changes in QTc interval were observed in either treatment group at any time point.,Safety and tolerability,[112623],[29305],[29402],[False],[0],[0],[False],['0']
600,PMC1277826,19093,Discussion,Discussion,[112624],[29403],[29414],[False],[0],[0],[False],['0']
601,PMC1277826,19094,"This large trial demonstrated that tigecycline (100 mg initial dose, followed by 50 mg q12 hours) is effective for the treatment of hospitalized adult patients with complicated intra-abdominal infections.",Discussion,[112625],[29415],[29619],[False],[0],[0],[False],['0']
602,PMC1277826,19095,"For patients with proven bacterial infections, clinical cure rates were 80.6% for tigecycline versus 82.4% for imipenem/cilastatin at the test-of-cure visit, demonstrating that tigecycline met the statistical criteria for noninferiority compared with the carbapenem regimen.",Discussion,[112626],[29620],[29894],[False],[0],[0],[False],['0']
603,PMC1277826,19096,"We also observed that tigecycline's clinical efficacy was similarly effective in patients who had either monomicrobial versus polymicrobial infection, as well as across the variety of anatomical infections encountered.",Discussion,[112627],[29895],[30113],[False],[0],[0],[False],['0']
604,PMC1277826,19097,"While many previous studies have reported a higher percentage of polymicrobial infection from intra-abdominal sites, the lower rates seen with tigecycline may be explained by a larger proportion of patients with appendicitis as the source of infection.",Discussion,[112628],[30114],[30366],[False],[0],[0],[False],['0']
605,PMC1277826,19098,"Overall, the efficacy of tigecycline was consistent among all predefined populations analyzed (m-mITT, c-mITT, CE) and consistent across different species of infecting bacteria.",Discussion,[112629],[30367],[30544],[False],[0],[0],[False],['0']
606,PMC1277826,19099,This large study extends the findings of two other studies that evaluated tigecycline's efficacy in the treatment of complicated intra-abdominal infections.,Discussion,[112630],[30545],[30701],[False],[0],[0],[False],['0']
607,PMC1277826,19100,"In a small, open-label, phase 2 tigecycline trial of 66 hospitalized patients with primarily perforated appendicitis, cure rates at the test-of-cure visit and end-of-treatment visit were 67% and 76%, respectively [17].",Discussion,[112631],[30702],[30920],[False],[0],[0],[False],['0']
608,PMC1277826,19101,A similarly designed phase 3 trial reported comparable clinical cure rates for the m-mITT cohort of 86.6% (279/322) for tigecycline compared with 84.6% (270/319) for imipenem/cilastatin therapy [18].,Discussion,[112632],[30921],[31120],[False],[0],[0],[False],['0']
609,PMC1277826,19102,The current trial demonstrated that tigecycline was effective at eradicating commonly encountered aerobic and anaerobic intestinal bacteria.,Discussion,[112633],[31121],[31261],[False],[0],[0],[False],['0']
610,PMC1277826,19103,Overall eradication rates were nearly identical in the two treatment groups: 80.6% after tigecycline therapy compared with 82.4% in the imipenem/cilastatin group.,Discussion,[112634],[31262],[31424],[False],[0],[0],[False],['0']
611,PMC1277826,19104,More than 80% of E. coli and Klebsiella spp.,Discussion,[112635],[31425],[31469],[False],[0],[0],[False],['0']
612,PMC1277826,19105,"(the two most frequently isolated gram-negative aerobes) were eradicated by tigecycline, followed by 78% of Streptococcus spp, and 70% of B. fragilis.",Discussion,[112636],[31470],[31620],[False],[0],[0],[False],['0']
613,PMC1277826,19106,"Comparable eradication rates were observed following imipenem/cilastatin therapy, further establishing that tigecycline was at least as effective as the standard carbapenem regimen.",Discussion,[112637],[31621],[31802],[False],[0],[0],[False],['0']
614,PMC1277826,19107,These data support in vitro observations that tigecycline has broad-spectrum activity against common isolates found in intra-abdominal infections [8-16].,Discussion,[112638],[31803],[31956],[False],[0],[0],[False],['0']
615,PMC1277826,19108,"While the etiologic role of P. aeruginosa remains unclear in patients with community-acquired intra-abdominal infections, tigecycline lacks reliable in vitro activity against this organism [8,9,11,13] despite a 72% eradication rate in this study.",Discussion,[112639],[31957],[32203],[False],[0],[0],[False],['0']
616,PMC1277826,19109,"Because few resistant isolates were isolated in the current trial, we could not conclusively establish the in vivo effectiveness of tigecycline against organisms that typically convey resistance (eg, E. faecalis, methicillin-sensitive and -resistant S. aureus, ESBL-producing Enterobacter spp.).",Discussion,[112640],[32204],[32499],[True],['VerySpecificPopulation'],['few resistant isolates were isolated'],[True],['Population']
617,PMC1277826,19110,"However, tigecycline successfully eradicated the majority (77%) of the 13 ESBL-producing E. coli and K. pneumoniae that were recovered from patients with cIAI.",Discussion,[112641],[32500],[32659],[False],[0],[0],[False],['0']
618,PMC1277826,19111,"These limited data confirm tigecycline's documented in vitro activity against many gram-positive and gram-negative bacterial isolates that typically are resistant [11,16,19].",Discussion,[112642],[32660],[32834],[False],[0],[0],[False],['0']
619,PMC1277826,19112,"Both tigecycline and imipenem/cilastatin were well tolerated in the current trial, with a similar frequency and distribution of treatment-emergent adverse events.",Discussion,[112643],[32835],[32997],[False],[0],[0],[False],['0']
620,PMC1277826,19113,"Nausea, vomiting, and diarrhea were the most frequently reported adverse events in both the tigecycline and imipenem/cilastatin treatment groups.",Discussion,[112644],[32998],[33143],[False],[0],[0],[False],['0']
621,PMC1277826,19114,"Although the individual adverse events of nausea and vomiting occurred at higher rates after tigecycline compared with imipenem/cilastatin therapy, only the incidence of vomiting was found to be significantly higher in tigecycline recipients.",Discussion,[112645],[33144],[33386],[False],[0],[0],[False],['0']
622,PMC1277826,19115,"Furthermore, the majority of nausea/vomiting events in both treatment groups were of mild to moderate intensity (94%).",Discussion,[112646],[33387],[33505],[False],[0],[0],[False],['0']
623,PMC1277826,19116,"Supporting this fact, these gastrointestinal adverse events rarely led to early discontinuation of therapy in either treatment group (<2%) and there was no difference in the number of patients requiring interventional antiemetic therapy between the tigecycline and imipenem/cilastatin groups.",Discussion,[112647],[33506],[33798],[False],[0],[0],[False],['0']
624,PMC1277826,19117,It is also noteworthy that tigecycline monotherapy was not associated with the development of C. difficile diarrhea.,Discussion,[112648],[33799],[33915],[False],[0],[0],[False],['0']
625,PMC1277826,19118,These findings support previous safety data from phase 2 and 3 studies [20-25].,Discussion,[112649],[33916],[33995],[False],[0],[0],[False],['0']
626,PMC1277826,19119,Conclusion,Conclusion,[112650],[33996],[34007],[False],[0],[0],[False],['0']
627,PMC1277826,19120,"Tigecycline is an effective and well-tolerated monotherapy option for the treatment of patients with complicated intra-abdominal infections, with comparable efficacy to imipenem/cilastatin.",Conclusion,[112651],[34008],[34197],[False],[0],[0],[False],['0']
628,PMC1277826,19121,"Because of the rising rates of antibiotic-resistant bacteria, both in the community and hospital settings, there remains a need for new antibiotic options.",Conclusion,[112652],[34198],[34353],[False],[0],[0],[False],['0']
629,PMC1277826,19122,"According, tigecycline is a promising new monotherapy when empiric coverage is needed against both gram-positive and non-pseudomonal gram-negative bacteria, including improved in vitro activity against certain resistant isolates.",Conclusion,[112653],[34354],[34583],[False],[0],[0],[False],['0']
630,PMC1277826,19123,List of abbreviations,List of abbreviations,[112654],[34584],[34606],[False],[0],[0],[False],['0']
631,PMC1277826,19124,AIDS – acquired immunodeficiency syndrome,List of abbreviations|AIDS – acquired immunodeficiency syndrome,[112655],[34607],[34648],[False],[0],[0],[False],['0']
632,PMC1277826,19125,ALT – alanine aminotransferase,List of abbreviations|ALT – alanine aminotransferase,[112656],[34649],[34679],[False],[0],[0],[False],['0']
633,PMC1277826,19126,ANOVA – analysis of variance,List of abbreviations|ANOVA – analysis of variance,[112657],[34680],[34708],[False],[0],[0],[False],['0']
634,PMC1277826,19127,APACHE – Acute Physiologic and Chronic Health Evaluation,List of abbreviations|APACHE – Acute Physiologic and Chronic Health Evaluation,[112658],[34709],[34765],[False],[0],[0],[False],['0']
635,PMC1277826,19128,AST – aspartate aminotransferase,List of abbreviations|AST – aspartate aminotransferase,[112659],[34766],[34798],[False],[0],[0],[False],['0']
636,PMC1277826,19129,CE – clinically evaluable,List of abbreviations|CE – clinically evaluable,[112660],[34799],[34824],[False],[0],[0],[False],['0']
637,PMC1277826,19130,cIAI – complicated intra-abdominal infections,List of abbreviations|cIAI – complicated intra-abdominal infections,[112661],[34825],[34870],[False],[0],[0],[False],['0']
638,PMC1277826,19131,CI – confidence interval,List of abbreviations|CI – confidence interval,[112662],[34871],[34895],[False],[0],[0],[False],['0']
639,PMC1277826,19132,c-mITT – clinical modified intent-to-treat,List of abbreviations|CI – confidence interval,[112663],[34896],[34938],[False],[0],[0],[False],['0']
640,PMC1277826,19133,ECG – electrocardiograms,List of abbreviations|ECG – electrocardiograms,[112664],[34939],[34963],[False],[0],[0],[False],['0']
641,PMC1277826,19134,ESBL – extended spectrum beta-lactamases,List of abbreviations|ESBL – extended spectrum beta-lactamases,[112665],[34964],[35004],[False],[0],[0],[False],['0']
642,PMC1277826,19135,IDSA – Infectious Diseases Society of America,List of abbreviations|IDSA – Infectious Diseases Society of America,[112666],[35005],[35050],[False],[0],[0],[False],['0']
643,PMC1277826,19136,IMI/CIS – imipenem/cilastatin,List of abbreviations|IDSA – Infectious Diseases Society of America,[112667],[35051],[35080],[False],[0],[0],[False],['0']
644,PMC1277826,19137,ITT – intent-to-treat,List of abbreviations|ITT – intent-to-treat,[112668],[35081],[35102],[False],[0],[0],[False],['0']
645,PMC1277826,19138,IV – intravenous,List of abbreviations|IV – intravenous,[112669],[35103],[35119],[False],[0],[0],[False],['0']
646,PMC1277826,19139,ME – microbiologically evaluable,List of abbreviations|ME – microbiologically evaluable,[112670],[35120],[35152],[False],[0],[0],[False],['0']
647,PMC1277826,19140,MIC – minimum inhibitory concentration,List of abbreviations|MIC – minimum inhibitory concentration,[112671],[35153],[35191],[False],[0],[0],[False],['0']
648,PMC1277826,19141,m-mITT – microbiologically modified intent-to-treat,List of abbreviations|MIC – minimum inhibitory concentration,[112672],[35192],[35243],[False],[0],[0],[False],['0']
649,PMC1277826,19142,MRSA – methicillin-resistant Staphylococcus aureus,List of abbreviations|MRSA – methicillin-resistant Staphylococcus aureus,[112673],[35244],[35294],[False],[0],[0],[False],['0']
650,PMC1277826,19143,NCCLS – National Committee of Clinical Laboratory Standards,List of abbreviations|MRSA – methicillin-resistant Staphylococcus aureus,[112674],[35295],[35354],[False],[0],[0],[False],['0']
651,PMC1277826,19144,q12h – every 12 hours,List of abbreviations|MRSA – methicillin-resistant Staphylococcus aureus,[112675],[35355],[35376],[False],[0],[0],[False],['0']
652,PMC1277826,19145,SD – standard deviation,List of abbreviations|SD – standard deviation,[112676],[35377],[35400],[False],[0],[0],[False],['0']
653,PMC1277826,19146,TOC – test-of-cure,List of abbreviations|TOC – test-of-cure,[112677],[35401],[35419],[False],[0],[0],[False],['0']
654,PMC1277826,19147,ULN – upper limit of normal,List of abbreviations|ULN – upper limit of normal,[112678],[35420],[35447],[False],[0],[0],[False],['0']
655,PMC1277826,19148,VRE – Vancomycin-Resistant Enterococci,List of abbreviations|VRE – Vancomycin-Resistant Enterococci,[112679],[35448],[35486],[False],[0],[0],[False],['0']
656,PMC1277826,19149,Competing interests,Competing interests,[112680],[35487],[35507],[False],[0],[0],[False],['0']
657,PMC1277826,19150,Financial competing interests: Drs.,Competing interests,[112681],[35508],[35543],[False],[0],[0],[False],['0']
658,PMC1277826,19151,"Oliva, Rekha, Yellin, Paternak, and Campos are investigators for this tigecycline study sponsored by Wyeth.",Competing interests,[112682],[35544],[35651],[False],[0],[0],[False],['0']
659,PMC1277826,19152,Dr. Oliva is an investigator for a clinical trial sponsored by Roche.,Competing interests,[112683],[35652],[35721],[False],[0],[0],[False],['0']
660,PMC1277826,19153,Drs.,Competing interests,[112684],[35722],[35726],[False],[0],[0],[False],['0']
661,PMC1277826,19154,"Rose, Babinchak, Ellis-Grosse, and Loh are employees of Wyeth.",Competing interests,[112685],[35727],[35789],[False],[0],[0],[False],['0']
662,PMC1277826,19155,None of the authors have non-financial competing interests to disclose.,Competing interests,[112686],[35790],[35861],[False],[0],[0],[False],['0']
663,PMC1277826,19156,Authors' contributions,Authors' contributions,[112687],[35862],[35885],[False],[0],[0],[False],['0']
664,PMC1277826,19157,"The first five authors were investigators in the clinical trial and enrolled the highest number of evaluable patients (MEO, AR, AY, JP, MC).",Authors' contributions,[112688],[35886],[36026],[False],[0],[0],[False],['0']
665,PMC1277826,19158,"Authors GMR, TB, EE-G, EL made substantial contributions to the conception and design of the study.",Authors' contributions,[112689],[36027],[36126],[False],[0],[0],[False],['0']
666,PMC1277826,19159,All authors made substantial contributions acquisition of data and analysis and interpretation of data.,Authors' contributions,[112690],[36127],[36230],[False],[0],[0],[False],['0']
667,PMC1277826,19160,"Each author (MEO, AR, AY, JP, MC, GMR, TB, EE-G, EL) was involved in critically revising the paper for intellectual content and has given final approval of this version to be published.",Authors' contributions,[112691],[36231],[36416],[False],[0],[0],[False],['0']
668,PMC1277826,19161,Pre-publication history,Pre-publication history,[112692],[36417],[36441],[False],[0],[0],[False],['0']
669,PMC1277826,19162,The pre-publication history for this paper can be accessed here:,Pre-publication history,[112693],[36442],[36506],[False],[0],[0],[False],['0']
670,PMC1277826,19163,Acknowledgements,Acknowledgements,[112694],[36507],[36525],[False],[0],[0],[False],['0']
671,PMC1277826,19164,This study was supported by Wyeth Research.,Acknowledgements,[112695],[36526],[36569],[False],[0],[0],[False],['0']
672,PMC1277826,19165,"We thank the tigecycline 301 study group investigators for their valuable involvement in this study: Fathi Abuzgaya, Louis H. Alarcon, Marc Alpert, Eduardo G. Arathoon, Rebeca Georgina Northland Areyuna, Annadan C. Ashok, Jeffrey A. Bailey, Ian McNicoll Baird, Philip S. Barie, M.Y.",Acknowledgements,[112696],[36570],[36852],[False],[0],[0],[False],['0']
673,PMC1277826,19166,"Bapaye, Robert W. Beart, Jr, Jean-François Bellemare, Guillermo Alberto Benchetrit, German Berbel, Carlos Enrique Bergallo, Joaquin Bermejo, Thomas B. Berne, Marcela Alicia Vera Blanch, John MA Bohnen, Patricia Brown, Maria Isabel Campos, Iris Lorena Cazali (Leal), Nicolas V. Christou, Daniel Jorge Curcio, Alexey Datsenko, Mario Del Castillo, E. Patchen Dellinger, Sanjay P. Desmukh, Puneet Dhar, Julia Garcia-Diaz, John W. Drover, John M.A.",Acknowledgements,[112697],[36853],[37296],[False],[0],[0],[False],['0']
674,PMC1277826,19167,"Embil, Zilvinas Endzinas, David Evans, Peter Fomin, Joseph Fraiz, Amalia Rodriquez French, Gary E. Garber, Doria Grimard, Gene Grindlinger, Virsing Punabhai Hathila, Ernesto Julio Jakob, Abel Jasovich, A.",Acknowledgements,[112698],[37297],[37501],[False],[0],[0],[False],['0']
675,PMC1277826,19168,"Mark Joffe, Ashok Tarachandji Kamble, Ricardo Eiji Kawamoto, Paul Kearney, Min-Ja Kim, Yang Soo Kim, Robert G. Kingman, Stanley R. Klein, Wen-Je Ko, William K.K, Lau, Patrick C. Lee, Dawei Liu, Carlos Lovesio, John Mazuski, Charles Morrow, Chau Nguyen, Maria Eugenia Oliva, Maria Costa Orlando, Guilermo M. Ruiz-Palacios (Santos), Eduardo Parra-Davila, Jacyr Pasternak, Andrejs Pavars, André Poirer, Germain Poirer, Guntars Pupelis, K. Ramachandra Pai, Hariharan Ramesh, M.K.",Acknowledgements,[112699],[37502],[37977],[False],[0],[0],[False],['0']
676,PMC1277826,19169,"Ramesh, Arturas Razbadauskas, Arcot Rekha, Ronald D. Robertson, Ori D. Rotstein, Rajkumar Janavicularm Sankaran, Ragulagedda Adikesava Sastry, Yan-Shen Shan, Rabih Salloum, Stephen D. Shafran, Jae-Hoon Song, Yaoqing Tang, Osvaldo Teglia, Jüri Teras, Shirin Towfigh, Tiit Vaasna, Walter Vasen, Carlos Rodolfo, Mejia Villatoro, Ramses Wassef, Junmin Wei, John Weigelt, Samuel E. Wilson, Yonghong Xiao, Lunan Yan, Albert E. Yellin, Dah-Shyong Yu, Yingyuan Zhang, and Juan Carlos Zlocowski.",Acknowledgements,[112700],[37978],[38464],[False],[0],[0],[False],['0']
677,PMC1277826,19170,We thank Wyeth Research employee Patricia Bradford for microbiological analysis and Upside Endeavors for professional medical writing services.,Acknowledgements,[112701],[38465],[38608],[False],[0],[0],[False],['0']
678,PMC1277826,19171,"Wyeth Research, Collegeville, PA, supported and funded this study.",Acknowledgements,[112702],[38609],[38675],[False],[0],[0],[False],['0']
1552,PMC2629563,12571,Nitric Oxide Administration Using an Oxygen Hood: A Pilot Trial,Title,[76635],[33256],[63],[False],[0],[0],[False],['0']
1553,PMC2629563,12572,Background,Abstract,[76637],[64],[75],[False],[0],[0],[False],['0']
1554,PMC2629563,12573,We have shown earlier that inhaled nitric oxide (iNO) administered by oxygen hood reduces pulmonary hypertension in an animal model (J Perinatol 2002; 22:50-6).,Abstract,[76639],[76],[236],[False],[0],[0],[False],['0']
1555,PMC2629563,12574,Our objective in this study was to determine feasibility of iNO by oxygen hood in neonates with elevated alveolar-arterial oxygen gradients (A-aDO ).,Abstract,[76641],[237],[386],[False],[0],[0],[False],['0']
1556,PMC2629563,12575,Methods/Principal Findings,Methods/Principal Findings,[76643],[387],[414],[False],[0],[0],[False],['0']
1557,PMC2629563,12576,Masked randomized controlled pilot trial.,Methods/Principal Findings,[76645],[415],[456],[False],[0],[0],[False],['0']
1558,PMC2629563,12577,"Inclusion criteria were: gestation≥34 weeks, age<7 days, with post-ductal arterial line, and A-aDO  400–600.",Methods/Principal Findings,[76647],[457],[565],[False],[0],[0],[False],['0']
1559,PMC2629563,12578,Infants were randomized to study gas (iNO 20 ppm or equivalent O  flow) for 1 hr which was then weaned over the next 4 hours.,Methods/Principal Findings,[76649],[566],[691],[False],[0],[0],[False],['0']
1560,PMC2629563,12579,Primary outcome was PaO  one hour post-randomization.,Methods/Principal Findings,[76651],[692],[745],[False],[0],[0],[False],['0']
1561,PMC2629563,12580,Four infants each were randomized to iNO or O  (controls).,Methods/Principal Findings,[76653],[746],[804],[False],[0],[0],[False],['0']
1562,PMC2629563,12581,"Two of the four infants given iNO had an increase in PaO  of >100 torr, while oxygenation was unchanged in the controls.",Methods/Principal Findings,[76655],[805],[925],[False],[0],[0],[False],['0']
1563,PMC2629563,12582,Methemoglobinemia and other adverse effects were not noted in any infant.,Methods/Principal Findings,[76657],[926],[999],[False],[0],[0],[False],['0']
1564,PMC2629563,12583,Environmental levels of NO and NO  were minimal (<1 ppm) at >0.3 m from the hood.,Methods/Principal Findings,[76659],[1000],[1081],[False],[0],[0],[False],['0']
1565,PMC2629563,12584,Conclusions,Conclusions,[76661],[1082],[1094],[False],[0],[0],[False],['0']
1566,PMC2629563,12585,Administration of iNO by oxygen hood is feasible.,Conclusions,[76663],[1095],[1144],[False],[0],[0],[False],['0']
1567,PMC2629563,12586,Larger randomized controlled trials are required to measure the efficacy and determine an appropriate target population for this technique.,Conclusions,[76665],[1145],[1284],[False],[0],[0],[False],['0']
1568,PMC2629563,12587,Trial Registration,Trial Registration,[76667],[1285],[1304],[False],[0],[0],[False],['0']
1569,PMC2629563,12588,ClinicalTrials.gov NCT00041548,Trial Registration,[76669],[1305],[1335],[False],[0],[0],[False],['0']
1570,PMC2629563,12589,Introduction,Introduction,[76671],[1336],[1351],[False],[0],[0],[False],['0']
1571,PMC2629563,12590,Severe neonatal pulmonary hypertension affects approximately 1 in 500 term neonates [1].,Introduction,[76673],[1352],[1440],[False],[0],[0],[False],['0']
1572,PMC2629563,12591,Large clinical trials have shown that inhaled nitric oxide (iNO) improves oxygenation in approximately 50% of infants who receive nitric oxide [2].,Introduction,[76675],[1441],[1588],[False],[0],[0],[False],['0']
1573,PMC2629563,12592,Analysis of results from three major trials [3]–[5] indicates that the use of extracorporeal membrane oxygenation (ECMO) decreased from 54% to 38% [6].,Introduction,[76677],[1589],[1740],[False],[0],[0],[False],['0']
1574,PMC2629563,12593,"However, all controlled studies to date have studied nitric oxide administration to neonates who are already on mechanical ventilation.",Introduction,[76679],[1741],[1876],[False],[0],[0],[False],['0']
1575,PMC2629563,12594,The use of iNO administered by oxygen hood has not been systematically evaluated.,Introduction,[76681],[1877],[1958],[False],[0],[0],[False],['0']
1576,PMC2629563,12595,"Conventionally, neonates with hypoxemia and adequate respiratory effort are first adminstered oxygen by oxygen hood.",Introduction,[76683],[1959],[2075],[False],[0],[0],[False],['0']
1577,PMC2629563,12596,"If oxygenation is inadequate despite a high concentration of inspired oxygen (FiO ) or if respiratory acidosis occurs, the infant is placed on a mechanical ventilator.",Introduction,[76685],[2076],[2243],[False],[0],[0],[False],['0']
1578,PMC2629563,12597,"If oxygenation continues to be inadequate despite increased ventilator settings, rescue therapies such as iNO are attempted.",Introduction,[76687],[2244],[2368],[False],[0],[0],[False],['0']
1579,PMC2629563,12598,"However, mechanical ventilation by itself can lead to or potentiate lung injury and predispose to chronic lung disease, and high mean airway pressures may also decrease pulmonary blood flow and cardiac output.",Introduction,[76689],[2369],[2578],[False],[0],[0],[False],['0']
1580,PMC2629563,12599,"It is possible that earlier administration of iNO to neonates with abnormal gas exchange, rather than later as a rescue therapy, might accelerate the transition of the circulation from the fetal to neonatal physiology and improve oxygenation.",Introduction,[76691],[2579],[2821],[False],[0],[0],[False],['0']
1581,PMC2629563,12600,This may in turn decrease the need for mechanical ventilation and its associated morbidity.,Introduction,[76693],[2822],[2913],[False],[0],[0],[False],['0']
1582,PMC2629563,12601,This study was designed as a pilot trial to evaluate the feasibility of NO administered by hood in neonates with elevated alveolar-arterial oxygen gradients (A-a DO ).,Introduction,[76695],[2914],[3081],[False],[0],[0],[False],['0']
1583,PMC2629563,12602,"Subsequent larger trials could determine if this method of NO administration can decrease the need for mechanical ventilation, ECMO, or other adverse outcomes.",Introduction,[76697],[3082],[3241],[False],[0],[0],[False],['0']
1584,PMC2629563,12603,Methods,Methods,[76699],[3242],[3250],[False],[0],[0],[False],['0']
1585,PMC2629563,12604,The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.,Methods,[76701],[3251],[3386],[False],[0],[0],[False],['0']
1586,PMC2629563,12605,Ethics statement: The study protocol was approved by the Institutional Review Board of the University of Alabama at Birmingham and parent(s) provided informed written consent before enrollment.,Methods,[76703],[3387],[3580],[False],[0],[0],[False],['0']
1587,PMC2629563,12606,Enrollment was done by the principal investigators (NA and WAC) or research coordinator (CR).,Methods,[76705],[3581],[3674],[False],[0],[0],[False],['0']
1588,PMC2629563,12607,"Study design and protocol: This was a masked randomized controlled pilot trial on infants with elevated alveolar-arterial oxygen gradients (A-aDO ) admitted to the Regional Neonatal ICU of the University of Alabama at Birmingham, a regional perinatal center.",Methods,[76707],[3675],[3933],[False],[0],[0],[False],['0']
1589,PMC2629563,12608,The ClinicalTrials.gov Identifier for this study is NCT 00041548 (http://www.clinicaltrials.gov/ct2/show/NCT00041548).,Methods,[76709],[3934],[4052],[False],[0],[0],[False],['0']
1590,PMC2629563,12609,The CONSORT flowchart is shown as  Figure 1 .,Methods,[76711],[4053],[4098],[False],[0],[0],[False],['0']
1591,PMC2629563,12610,"The inclusion criteria were: gestation ≥34 weeks at birth; age <7 days, post-ductal arterial line, and an A-aDO  of 400 to 600 on two blood gases at least 30 minutes apart.",Methods,[76713],[4099],[4271],[False],[0],[0],[False],['0']
1592,PMC2629563,12611,"After informed consent, infants were randomized using shuffled opaque envelopes to study gas (iNO at 20 ppm or equivalent flow of O ) for 1 hour.",Methods,[76715],[4272],[4417],[False],[0],[0],[False],['0']
1593,PMC2629563,12612,The gas was then weaned hourly over the next 4 hours (20 ppm→ 10 → 5 → 2.5 → 1 → off).,Methods,[76717],[4418],[4504],[False],[0],[0],[False],['0']
1594,PMC2629563,12613,"It was planned that if a greater than 5% drop in oxygen saturation was observed during weaning, the study gas would be increased to the previous concentration and weaning would be done at 2 hourly intervals.",Methods,[76719],[4505],[4712],[False],[0],[0],[False],['0']
1595,PMC2629563,12614,No weaning of FiO  was to be done while the study gas was being weaned.,Methods,[76721],[4713],[4784],[False],[0],[0],[False],['0']
1596,PMC2629563,12615,"It was planned that if a greater than 5% drop in oxygen saturation or >5% methemoglobin was observed, the study gas would be rapidly weaned over 30 minutes and the infant would exit the study.",Methods,[76723],[4785],[4977],[False],[0],[0],[False],['0']
1597,PMC2629563,12616,"The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood; Maxtex® Inc.) using an INOvent (Datex-Ohmeda), using the arrangement as shown in  Figure 2 .",Methods,[76725],[4978],[5141],[False],[0],[0],[False],['0']
1598,PMC2629563,12617,"The INOvent® was prepared by performing a low range (air) calibration and the standard pre-use procedures (leak test, system purge, and performance test).",Methods,[76727],[5142],[5296],[False],[0],[0],[False],['0']
1599,PMC2629563,12618,The INOvent® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber.,Methods,[76729],[5297],[5419],[False],[0],[0],[False],['0']
1600,PMC2629563,12619,A minimum gas flow of 10 liters per minute of study gas was used to avoid accumulation of nitrogen dioxide (NO ) within the oxyhood.,Methods,[76731],[5420],[5552],[False],[0],[0],[False],['0']
1601,PMC2629563,12620,"Monitoring of the three inspired gas values (O , NO , NO) was done by placing the end of the sample line inside the oxyhood.",Methods,[76733],[5553],[5677],[False],[0],[0],[False],['0']
1602,PMC2629563,12621,"Due to mixing of exhaled gases inside the oxyhood, the “Set NO” was usually set 1–2 ppm higher to achieve the desired measured NO.",Methods,[76735],[5678],[5808],[False],[0],[0],[False],['0']
1603,PMC2629563,12622,"If the baby was randomized to the control group, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the “Low NO Pressure” alarm.",Methods,[76737],[5809],[5974],[False],[0],[0],[False],['0']
1604,PMC2629563,12623,"A “Masking Shield” covered the Display/Control Panel and cylinder gauges, in order to maintain masking.",Methods,[76739],[5975],[6078],[False],[0],[0],[False],['0']
1605,PMC2629563,12624,Only the respiratory therapist and research coordinator was aware of the allocation assignment.,Methods,[76741],[6079],[6174],[False],[0],[0],[False],['0']
1606,PMC2629563,12625,"Scavenging of the NO was not required as initial bench testing using 20 ppm of NO showed only trace amounts of NO (<1 ppm), comparable to routine use of iNO in mechanically ventilated neonates.",Methods,[76743],[6175],[6368],[False],[0],[0],[False],['0']
1607,PMC2629563,12626,The primary outcome was the PaO  one hour after the first hour of study gas.,Methods,[76745],[6369],[6445],[False],[0],[0],[False],['0']
1608,PMC2629563,12627,"Secondary outcomes included: (1) A-a DO  after one hour of exposure to treatment gas, (2) oxygen saturation by pulse oximetry (SpO ), (3) need for mechanical ventilation, (4) duration of oxygen therapy, (5) methemoglobin level in post-ductal arterial blood,* (6) Platelet count,* (7) Systemic blood pressure,* and (8) Environmental NO and NO  exposure* (* Safety indicators).",Methods,[76747],[6446],[6821],[False],[0],[0],[False],['0']
1609,PMC2629563,12628,"The planned sample size for this study was 40, with 20 per group (nitric oxide or oxygen).",Methods,[76749],[6822],[6912],[False],[0],[0],[False],['0']
1610,PMC2629563,12629,"The power of the study was 85% with n = 20 in each group, α = 0.05, assuming a difference in PaO  of 25% with a standard deviation at 0.25 of mean.",Methods,[76751],[6913],[7060],[False],[0],[0],[False],['0']
1611,PMC2629563,12630,A non-parametric t-test was planned to evaluate the primary outcome of PaO  after the first hour of study gas.,Methods,[76753],[7061],[7171],[False],[0],[0],[False],['0']
1612,PMC2629563,12631,Results,Results,[76755],[7172],[7180],[False],[0],[0],[False],['0']
1613,PMC2629563,12632,"Eight term or near-term (36 or more completed weeks) appropriate for gestational age (2.5–4 kg birth weight) infants were enrolled over a three year period (May 2002–June 2005;  Figure 1 ), and the study was terminated due to slow enrollment.",Results,[76757],[7181],[7423],[False],[0],[0],[False],['0']
1614,PMC2629563,12633,Enrollment was slow as most infants transferred to our regional perinatal center for respiratory failure were already intubated either by the referring center or by our transport team.,Results,[76759],[7424],[7608],[False],[0],[0],[False],['0']
1615,PMC2629563,12634,"Four infants were white, five were female, and six were diagnosed with idiopathic persistent pulmonary hypertension of the newborn (PPHN), while one infant had early onset gram negative (E. coli) sepsis, and another had meconium aspiration syndrome (Table 1).",Results,[76761],[7609],[7868],[False],[0],[0],[False],['0']
1616,PMC2629563,12635,All infants were receiving 90–95% O  at enrollment.,Results,[76763],[7869],[7920],[False],[0],[0],[False],['0']
1617,PMC2629563,12636,Four infants were randomized to iNO and four to O  (controls).,Results,[76765],[7921],[7983],[False],[0],[0],[False],['0']
1618,PMC2629563,12637,"Two of the four infants given iNO had an increase in PaO  of >100 torr, while oxygenation was essentially unchanged in the controls, although one patient had a small increase (+22 torr) ( Figure 3 , Table 1).",Results,[76767],[7984],[8192],[False],[0],[0],[False],['0']
1619,PMC2629563,12638,The median PaO  after the first hour of study gas in the infants receiving iNO was 139 torr (25th–75th centile: 66–215 torr) versus 88 torr (66–114) in the infants receiving O  (controls) (p NS).,Results,[76769],[8193],[8388],[False],[0],[0],[False],['0']
1620,PMC2629563,12639,"However, the small sample size indicates that statistical analysis would not be useful in this pilot study due to lack of statistical power.",Results,[76771],[8389],[8529],[False],[0],[0],[False],['0']
1621,PMC2629563,12640,"No methemoglobinemia (all levels <2% in both groups), hypotension (drop in systemic blood pressure >10%), thrombocytopenia/excessive bleeding or other adverse effects were noted in any of the infants.",Results,[76773],[8530],[8730],[False],[0],[0],[False],['0']
1622,PMC2629563,12641,No “rebound phenomenon” was noted on weaning of the study gas.,Results,[76775],[8731],[8793],[False],[0],[0],[False],['0']
1623,PMC2629563,12642,NO  within the hood was less than 1 ppm in all infants over the duration of the study.,Results,[76777],[8794],[8880],[False],[0],[0],[False],['0']
1624,PMC2629563,12643,Environmental levels of NO and NO  were minimal (<1 ppm) to undetectable at >0.3 m from the hood at the bedside.,Results,[76779],[8881],[8993],[False],[0],[0],[False],['0']
1625,PMC2629563,12644,Discussion,Discussion,[76781],[8994],[9005],[False],[0],[0],[False],['0']
1626,PMC2629563,12645,This pilot trial demonstrates the technique and feasibility of iNO administration using an oxygen hood and a commercial iNO delivery device.,Discussion,[76783],[9006],[9146],[False],[0],[0],[False],['0']
1627,PMC2629563,12646,This trial had an inadequate sample size to demonstrate efficacy or safety.,Discussion,[76785],[9147],[9222],[True],['SampleSize'],['an inadequate sample size'],[True],['UnderpoweredStudy']
1628,PMC2629563,12647,"However, the efficacy and safety of iNO in intubated infants is already known [2]–[6], and the purpose of this pilot trial was to show if iNO could be administered into an oxygen hood in the clinical setting.",Discussion,[76789],[9223],[9431],[False],[0],[0],[False],['0']
1629,PMC2629563,12648,"Two of the four infants who received iNO had an increase in PaO  >100 torr, while none of the infants in the oxygen control groups had a similar increase.",Discussion,[76791],[9432],[9586],[False],[0],[0],[False],['0']
1630,PMC2629563,12649,Neonates with hypoxemia (PaO  <50 torr) or respiratory acidosis while on 100% oxygen at the onset are usually intubated and mechanically ventilated.,Discussion,[76793],[9587],[9735],[False],[0],[0],[False],['0']
1631,PMC2629563,12650,"The A-a DO  usually is >600 torr in this situation, and often more than 630 torr, depending on the PaCO .",Discussion,[76795],[9736],[9841],[False],[0],[0],[False],['0']
1632,PMC2629563,12651,"However, neonates who present with markedly elevated A-a DO  (>400 torr) but with adequate oxygenation (PaO  50–150 torr on FiO  ≥0.95), respiratory effort, and acid-base status often present a dilemma – to intubate and mechanically ventilate or not?",Discussion,[76797],[9842],[10092],[False],[0],[0],[False],['0']
1633,PMC2629563,12652,"These neonates with either a severe V/Q mismatch (intra-pulmonary shunt) or right to left shunts (extra-pulmonary shunt) (frequently both mechanisms may be operative to a variable degree) are often maintained on high oxygen concentrations (FiO  >0.7) delivered by oxygen hood, in an attempt to maintain adequate oxygenation and possibly accelerate the spontaneous resolution of elevated pulmonary pressures and minimize the risk of hypoxic pulmonary vasoconstriction or V/Q mismatch without resorting to mechanical ventilation.",Discussion,[76799],[10093],[10620],[False],[0],[0],[False],['0']
1634,PMC2629563,12653,"While some of these neonates improve spontaneously, others persist with high A-a DO  and ultimately require mechanical ventilation and occasionally ECMO.",Discussion,[76801],[10621],[10774],[False],[0],[0],[False],['0']
1635,PMC2629563,12654,It is possible that these infants may benefit from iNO by oxygen hood.,Discussion,[76803],[10775],[10845],[False],[0],[0],[False],['0']
1636,PMC2629563,12655,"Since the observation that iNO can cause selective pulmonary vasodilation in neonates [7], [8], multiple randomized controlled trials [3]–[6] have been performed and a systematic review indicates that iNO may benefit neonates with hypoxemic respiratory failure [2].",Discussion,[76805],[10846],[11111],[False],[0],[0],[False],['0']
1637,PMC2629563,12656,"The majority of the available literature as briefly described above deals with neonates on mechanical ventilation, since NO has been used so far as a “rescue” therapy for infants not responding to conventional, and in some cases, high frequency ventilation.",Discussion,[76807],[11112],[11369],[False],[0],[0],[False],['0']
1638,PMC2629563,12657,The current practice of intubation and mechanical ventilation of the majority of infants with hypoxemic respiratory failure makes it difficult to evaluate non-invasive methods of iNO delivery such as by oxygen hood.,Discussion,[76809],[11370],[11585],[False],[0],[0],[False],['0']
1639,PMC2629563,12658,"iNO has also been delivered by nasopharyngeal tube [9], pulsed nasal cannula, and face mask [10].",Discussion,[76811],[11586],[11683],[False],[0],[0],[False],['0']
1640,PMC2629563,12659,"However, due to entrainment of room air and varying contributions from mouth breathing, the actual delivered NO level by nasal or nasopharyngeal cannulae cannot be ascertained with accuracy.",Discussion,[76813],[11684],[11874],[False],[0],[0],[False],['0']
1641,PMC2629563,12660,"Especially during weaning, it is important that the iNO be reduced gradually and carefully controlled in order to avoid rebound pulmonary hypertension.",Discussion,[76815],[11875],[12026],[False],[0],[0],[False],['0']
1642,PMC2629563,12661,The delivered oxygen and iNO concentrations may possibly be regulated better with the oxygen hood than with the nasal cannulae.,Discussion,[76817],[12027],[12154],[False],[0],[0],[False],['0']
1643,PMC2629563,12662,"The other problem with nasal cannulae is that the presence of a nasal prong(s) will partially occlude the nostrils and increase airway resistance significantly, further compromising respiratory effort and oxygenation in a neonate with abnormal gas exchange.",Discussion,[76819],[12155],[12412],[False],[0],[0],[False],['0']
1644,PMC2629563,12663,A major proportion of morbidity and mortality in term neonates is due to hypoxemic respiratory failure.,Discussion,[76821],[12413],[12516],[False],[0],[0],[False],['0']
1645,PMC2629563,12664,"Fortunately, the incidence of hypoxic respiratory failure in newborn infants has decreased in recent years, but this has led to poor accrual for clinical trials on PPHN [11].",Discussion,[76823],[12517],[12691],[False],[0],[0],[False],['0']
1646,PMC2629563,12665,A limitation of our pilot trial in a regional perinatal center is that many potential subjects were transported already intubated.,Discussion,[76826],[12692],[12822],[True],['Population'],['many potential subjects were transported already intubated'],[True],['Population']
1647,PMC2629563,12666,"Randomized multi-center clinical trials involving large delivery centers are required to determine if non-invasive administration of iNO into an oxygen hood decreases the need for mechanical ventilation and subsequent need for ECMO in this population, and if this improved short-term outcome results in a lower mortality, earlier discharge and both direct and indirect cost savings.",Discussion,[76829],[12823],[13205],[False],[0],[0],[False],['0']
1648,PMC2629563,12667,Competing Interests: The authors have declared that no competing interests exist.Funding: Funded in part by National Institute of Child Health and Human Development K08 HD046513 and by the Pulmonary Hypertension Association PHA 0526041H.,,[76831],[13206],[13445],[False],[0],[0],[False],['0']
1649,PMC2629563,12668,"Nitric Oxide for this pilot trial was provided by INO Therapeutics, Inc.",,[76833],[13446],[13518],[False],[0],[0],[False],['0']
1650,PMC2629563,12669,"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",,[76835],[13519],[13644],[False],[0],[0],[False],['0']
2633,PMC2917572,17817,Preoperative gait patterns and BMI are associated with tibial component migration,Title,[108505],[28191],[81],[False],[0],[0],[False],['0']
2634,PMC2917572,17818,Background and purpose,Abstract,[108510],[82],[105],[False],[0],[0],[False],['0']
2635,PMC2917572,17819,There is no standard for patient triage in total knee arthroplasty (TKA) based on joint functional characteristics.,Abstract,[108515],[106],[221],[False],[0],[0],[False],['0']
2636,PMC2917572,17820,"This is largely due to the lack of objective postoperative measurement of success in TKA in terms of function and longevity, and the lack of knowledge of preoperative metrics that influence outcome.",Abstract,[108520],[222],[420],[False],[0],[0],[False],['0']
2637,PMC2917572,17821,We examined the association between the preoperative mechanical environment of the patients knee joint during gait and the post-TKA stability of the tibial component as measured with radiostereometric analysis (RSA).,Abstract,[108525],[421],[637],[False],[0],[0],[False],['0']
2638,PMC2917572,17822,Methods,Methods,[108530],[638],[646],[False],[0],[0],[False],['0']
2639,PMC2917572,17823,37 subjects were recruited out of a larger randomized RSA trial.,Methods,[108535],[647],[711],[False],[0],[0],[False],['0']
2640,PMC2917572,17824,3-dimensional gait analysis was performed in the preoperative week.,Methods,[108540],[712],[779],[False],[0],[0],[False],['0']
2641,PMC2917572,17825,Longitudinal RSA data were gathered postoperatively at 6 months and 1 year.,Methods,[108545],[780],[855],[False],[0],[0],[False],['0']
2642,PMC2917572,17826,Results,Results,[108550],[856],[864],[False],[0],[0],[False],['0']
2643,PMC2917572,17827,We found a statistically significant association between the pattern of the knee adduction moment during gait preoperatively and the total migration of the implant at 6 months postoperatively.,Results,[108555],[865],[1057],[False],[0],[0],[False],['0']
2644,PMC2917572,17828,"A substantial proportion of the variability in the total postoperative tibial component migration (R2 = 0.45) was explained by a combination of implant type, preoperative knee joint loading patterns during gait, and body mass index at 6 months postoperatively.",Results,[108560],[1058],[1318],[False],[0],[0],[False],['0']
2645,PMC2917572,17829,The relationships did not remain statistically significant at 1 year postoperatively.,Results,[108565],[1319],[1404],[False],[0],[0],[False],['0']
2646,PMC2917572,17830,Interpretation,Interpretation,[108570],[1405],[1420],[False],[0],[0],[False],['0']
2647,PMC2917572,17831,"Our findings support the hypothesis that preoperative functional characteristics of patients, and particularly joint loading patterns during activities of daily living, are important for outcome in TKA.",Interpretation,[108575],[1421],[1623],[False],[0],[0],[False],['0']
2648,PMC2917572,17832,"This represents a first step in the development of predictive models of objective TKA outcome based on preoperative patient characteristics, which may lead to better treatment strategies.",Interpretation,[108580],[1624],[1811],[False],[0],[0],[False],['0']
2649,PMC2917572,17833,ClinicalTrials.gov (NCT00405379),Interpretation,[108585],[1812],[1844],[False],[0],[0],[False],['0']
2650,PMC2917572,17834,Introduction,Introduction,[108590],[1845],[1859],[False],[0],[0],[False],['0']
2651,PMC2917572,17835,"Total knee arthroplasty (TKA) for end-stage osteoarthritis (OA) is highly effective according to the commonly employed self-report measures of pain and function, and patients are generally very satisfied with the results of the procedure (Robertsson and Dunbar 2001).",Introduction,[108595],[1860],[2127],[False],[0],[0],[False],['0']
2652,PMC2917572,17836,Aseptic loosening of the tibial component is the leading cause of revision surgery (CIHI 2006).,Introduction,[108600],[2128],[2223],[False],[0],[0],[False],['0']
2653,PMC2917572,17837,Subjective outcome questionnaires tend to reflect the reduction of symptoms associated with TKA and not the functional state of the joint.,Introduction,[108605],[2224],[2362],[False],[0],[0],[False],['0']
2654,PMC2917572,17838,"They are therefore insensitive for detection of the early manifestations of aseptic loosening, and often problems associated with implant design or surgical technique do not become apparent for many years after surgery.",Introduction,[108610],[2363],[2582],[False],[0],[0],[False],['0']
2655,PMC2917572,17839,"Radiostereometric analysis (RSA) is a highly accurate technique for measurement of the relative movement between segments, and it is beginning to be used in orthopedic practice as an objective measure of post-TKA implant stability (Albrektsson et al.",Introduction,[108615],[2583],[2833],[False],[0],[0],[False],['0']
2656,PMC2917572,17840,"1992, Ryd et al.",Introduction,[108620],[2834],[2850],[False],[0],[0],[False],['0']
2657,PMC2917572,17841,"1995, Dunbar et al.",Introduction,[108625],[2851],[2870],[False],[0],[0],[False],['0']
2658,PMC2917572,17842,2009).,Introduction,[108630],[2871],[2877],[False],[0],[0],[False],['0']
2659,PMC2917572,17843,RSA has been shown to measure movement of the tibial component of a TKA within the native surrounding bone with high accuracy (Ryd 1986).,Introduction,[108635],[2878],[3015],[False],[0],[0],[False],['0']
2660,PMC2917572,17844,"Early migration of implant components, as measured with RSA, has also been shown to be predictive of later loosening and thus failure of the implant (Ryd et al.",Introduction,[108640],[3016],[3176],[False],[0],[0],[False],['0']
2661,PMC2917572,17845,1995).,Introduction,[108645],[3177],[3183],[False],[0],[0],[False],['0']
2662,PMC2917572,17846,RSA is therefore a sensitive and accurate tool that can be used early on postoperatively to predict long-term outcomes.,Introduction,[108650],[3184],[3303],[False],[0],[0],[False],['0']
2663,PMC2917572,17847,"Despite these advances in using RSA as an objective measure of postoperative outcome, the question still remaining is why some implants remain stable for years postoperatively while others migrate continuously and must eventually be revised.",Introduction,[108655],[3304],[3545],[False],[0],[0],[False],['0']
2664,PMC2917572,17848,"While patient selection can affect surgical outcome, little is known about which preoperative metrics are predictive of long-term implant fixation.",Introduction,[108660],[3546],[3693],[False],[0],[0],[False],['0']
2665,PMC2917572,17849,"Intuitively, one could predict that the mechanical environment of the knee joint would influence the mechanical fixation of the implant, and walking is the best model to measure this effect as it is the most common and repetitive dynamic human task (Guccione 1994).",Introduction,[108665],[3694],[3959],[False],[0],[0],[False],['0']
2666,PMC2917572,17850,"Yet, there have been very few studies dealing with the association between dynamic joint loading during gait and postoperative implant migration.",Introduction,[108670],[3960],[4105],[False],[0],[0],[False],['0']
2667,PMC2917572,17851,Hilding et al.,Introduction,[108675],[4106],[4120],[False],[0],[0],[False],['0']
2668,PMC2917572,17852,"(1995, 1999) found that patients whose implants were continuously migrating in RSA follow-up examinations walked with higher peak knee flexion moments during gait both before and after TKA surgery.",Introduction,[108680],[4121],[4318],[False],[0],[0],[False],['0']
2669,PMC2917572,17853,"However, they did not find any association between implant migration and the knee adduction moment, the measure of gait most commonly associated with severity of knee OA, progression, and surgical outcome (Prodromos et al.",Introduction,[108685],[4319],[4541],[False],[0],[0],[False],['0']
2670,PMC2917572,17854,"1985, Hurwitz et al.",Introduction,[108690],[4542],[4562],[False],[0],[0],[False],['0']
2671,PMC2917572,17855,"2002, Miyazaki et al.",Introduction,[108695],[4563],[4584],[False],[0],[0],[False],['0']
2672,PMC2917572,17856,2002).,Introduction,[108700],[4585],[4591],[False],[0],[0],[False],['0']
2673,PMC2917572,17857,This may be due to the analysis method employed in the study.,Introduction,[108705],[4592],[4653],[False],[0],[0],[False],['0']
2674,PMC2917572,17858,The gait variables analyzed were peak values extracted from the waveform pattern of the gait measures over the gait cycle.,Introduction,[108710],[4654],[4776],[False],[0],[0],[False],['0']
2675,PMC2917572,17859,Recent work by our group has shown that the time pattern of the knee adduction over the gait cycle may be a more significant indicator of disease severity than the commonly analyzed peak value of the moment during gait (Landry et al.,Introduction,[108715],[4777],[5010],[False],[0],[0],[False],['0']
2676,PMC2917572,17860,"2007, Astephen et al.",Introduction,[108720],[5011],[5032],[False],[0],[0],[False],['0']
2677,PMC2917572,17861,2008a).,Introduction,[108725],[5033],[5040],[False],[0],[0],[False],['0']
2678,PMC2917572,17862,"Body mass is an additional factor that influences joint loading, and it is highly associated with OA of the knee.",Introduction,[108730],[5041],[5154],[False],[0],[0],[False],['0']
2679,PMC2917572,17863,Obesity is one of the most cited risk factors for development of knee OA (Felson et al.,Introduction,[108735],[5155],[5242],[False],[0],[0],[False],['0']
2680,PMC2917572,17864,"1988a), and more than 80% of Canadian adults treated with TKA are either overweight or obese (CIHI 2006).",Introduction,[108740],[5243],[5348],[False],[0],[0],[False],['0']
2681,PMC2917572,17865,Understanding how body mass relates to implant loading and consequent long-term outcome is particularly important in orthopedic triage and surgical planning and design.,Introduction,[108745],[5349],[5517],[False],[0],[0],[False],['0']
2682,PMC2917572,17866,The primary objective of this study was to investigate the associations between the preoperative knee adduction moment during gait and BMI and early implant migration as measured with RSA at 6 months postoperatively on the other.,Introduction,[108750],[5518],[5747],[False],[0],[0],[False],['0']
2683,PMC2917572,17867,A secondary objective was to examine the multivariate association between preoperative joint loading and BMI on the one hand and post-TKA implant migration on the other.,Introduction,[108755],[5748],[5917],[False],[0],[0],[False],['0']
2684,PMC2917572,17868,Patients and methods,Patients and methods,[108760],[5918],[5939],[False],[0],[0],[False],['0']
2685,PMC2917572,17869,Figure 1.,Patients and methods,[108765],[5940],[5949],[False],[0],[0],[False],['0']
2686,PMC2917572,17870,CONSORT flow diagram..,Patients and methods,[108770],[5950],[5972],[False],[0],[0],[False],['0']
2687,PMC2917572,17871,This study involved a subset of patients (40) who took part in a larger randomized controlled trial (n = 70).,Patients and methods,[108775],[5973],[6083],[False],[0],[0],[False],['0']
2688,PMC2917572,17872,The study was registered at ClinicalTrials.gov (NCT00405379) and was performed in accordance with the Declaration of Helsinki.,Patients and methods,[108780],[6084],[6210],[False],[0],[0],[False],['0']
2689,PMC2917572,17873,Patients with end-stage primary knee OA were recruited from the TKA waiting list at the Orthopaedic Clinic of Halifax Infirmary.,Patients and methods,[108785],[6211],[6339],[False],[0],[0],[False],['0']
2690,PMC2917572,17874,"Patients were randomized to receive the Nexgen LPS Trabecular Metal tibial monoblock component (n = 37) (Zimmer, Warsaw, IN) or the cemented NexGen Option Stemmed tibial component (n = 33) (also Zimmer).",Patients and methods,[108790],[6340],[6543],[False],[0],[0],[False],['0']
2691,PMC2917572,17875,"The duration of t,he study was 2 years from the time of surgery, and the primary endpoint was RSA migration data at 2 years.",Patients and methods,[108795],[6544],[6668],[False],[0],[0],[False],['0']
2692,PMC2917572,17876,"Surgery was performed by 4 experienced consultant knee surgeons using a standardized protocol: posterior cruciate ligament resection, patellar resurfacing with a cemented inlay component, cementing of the femoral component, and RSA marker placement of 0.8-mm beads.",Patients and methods,[108800],[6669],[6934],[False],[0],[0],[False],['0']
2693,PMC2917572,17877,4–6 tantalum markers were placed around the periphery of the polyethylene component and 8–20 tantalum markers were inserted into the proximal tibia.,Patients and methods,[108805],[6935],[7083],[False],[0],[0],[False],['0']
2694,PMC2917572,17878,"The postoperative protocol was standardized with the use of continuous passive motion as tolerated, and patients were allowed full weight bearing immediately after surgery.",Patients and methods,[108810],[7084],[7256],[False],[0],[0],[False],['0']
2695,PMC2917572,17879,No drains were used.,Patients and methods,[108815],[7257],[7277],[False],[0],[0],[False],['0']
2696,PMC2917572,17880,"Of these 70 patients, 40 of them (20 Trabecular Metal, 20 Cemented NexGen) were recruited to undergo 3-dimensional gait analysis testing within a week before surgery (Figure 1).",Patients and methods,[108820],[7278],[7455],[False],[0],[0],[False],['0']
2697,PMC2917572,17881,"Patients were included in the gait analysis part of the study if they were able to walk along a 6-m walkway without a walking aid, and they were excluded if they had any neuromuscular disease, cardiovascular disorders, or had had lower limb surgery (with the exception of exploratory arthroscopy, lavage of the knee joint, or partial menisectomy at least 1 year before entry into the study).",Patients and methods,[108825],[7456],[7847],[False],[0],[0],[False],['0']
2698,PMC2917572,17882,Informed consent was obtained from all participants in accordance with the Ethics Review Board of the Capital District Health Authority.,Patients and methods,[108830],[7848],[7984],[False],[0],[0],[False],['0']
2699,PMC2917572,17883,Gait analysis,Gait analysis,[108835],[7985],[7999],[False],[0],[0],[False],['0']
2700,PMC2917572,17884,"During the gait trials, 3-dimensional movement of the affected lower limb and external ground reaction forces were recorded with a synchronized Optotrak 3020 motion capture (Northern Digital Inc., Waterloo, ON) and force platform system (AMTI, Watertown, MA).",Gait analysis,[108840],[8000],[8259],[False],[0],[0],[False],['0']
2701,PMC2917572,17885,"Walking speed was monitored using infrared timing gates, and participants were required to complete 5 trials within 5% of their self-selected walking velocity.",Gait analysis,[108845],[8260],[8419],[False],[0],[0],[False],['0']
2702,PMC2917572,17886,"Triads with 3 infrared light-emitting diodes were placed on the pelvis, thigh, leg, and foot segments of the affected leg.",Gait analysis,[108850],[8420],[8542],[False],[0],[0],[False],['0']
2703,PMC2917572,17887,"Individual diodes were placed on the greater trochanter, lateral epicondyle, lateral malleolus, and shoulder.",Gait analysis,[108855],[8543],[8652],[False],[0],[0],[False],['0']
2704,PMC2917572,17888,"These and 8 virtual markers (right and left anterior superior iliac spines, medial epicondyle, tibial tuberosity, fibular head, medial malleolus, second metatarsal, and heel) were used to define anatomical coordinate systems in each of the lower extremity segments (Landry et al.",Gait analysis,[108860],[8653],[8932],[False],[0],[0],[False],['0']
2705,PMC2917572,17889,2007).,Gait analysis,[108865],[8933],[8939],[False],[0],[0],[False],['0']
2706,PMC2917572,17890,3-dimensional joint angles at the knee were calculated over a complete gait cycle using a least-squares optimization routine (Challis 1995).,Gait analysis,[108870],[8940],[9080],[False],[0],[0],[False],['0']
2707,PMC2917572,17891,"Net joint moments at the knee were calculated with an inverse dynamics procedure (Braune and Fischer 1987), normalized to body mass and the anatomical joint coordinate system described by Grood and Suntay (1983).",Gait analysis,[108875],[9081],[9293],[False],[0],[0],[False],['0']
2708,PMC2917572,17892,"All joint angles and moments were time-normalized and defined with 101 data points, 1 for each percentage of the gait cycle.",Gait analysis,[108880],[9294],[9418],[False],[0],[0],[False],['0']
2709,PMC2917572,17893,Radiostereometric analysis,Radiostereometric analysis,[108885],[9419],[9446],[False],[0],[0],[False],['0']
2710,PMC2917572,17894,"Within 4 days of surgery and at 6 and 12 months postoperatively, the knee was placed within a biplanar calibration box (Tilly Medical Products AB, Lund, Sweden), and simultaneous digital stereo radiographs were taken with the tubes oriented orthogonally.",Radiostereometric analysis,[108890],[9447],[9701],[False],[0],[0],[False],['0']
2711,PMC2917572,17895,"RSA analysis was performed with MB-RSA (MEDIS, Leiden).",Radiostereometric analysis,[108895],[9702],[9757],[False],[0],[0],[False],['0']
2712,PMC2917572,17896,RSA results at 6 months and 1 year were reported as maximum total point motion (MTPM) and 6 degrees-of-freedom translations and rotations.,Radiostereometric analysis,[108900],[9758],[9896],[False],[0],[0],[False],['0']
2713,PMC2917572,17897,MTPM is the 3-dimensional (3D) vector magnitude of the marker that has exhibited the most migration between examinations.,Radiostereometric analysis,[108905],[9897],[10018],[False],[0],[0],[False],['0']
2714,PMC2917572,17898,"The RSA calculations gave the relative motion of the rigid body defined by the beads in the prostheses, with respect to the rigid body defined by the beads in the tibia in 3 dimensions.",Radiostereometric analysis,[108910],[10019],[10204],[False],[0],[0],[False],['0']
2715,PMC2917572,17899,Rigid body rotations of the prosthesis were calculated about a coordinate system centered at the volumetric center of the implant with axes aligned to the anatomical directions.,Radiostereometric analysis,[108915],[10205],[10382],[False],[0],[0],[False],['0']
2716,PMC2917572,17900,All translations and rotations were calculated for a right-hand coordinate system with the signs corrected to comply with the standards presented by Valstar et al.,Radiostereometric analysis,[108920],[10383],[10546],[False],[0],[0],[False],['0']
2717,PMC2917572,17901,(2005).,Radiostereometric analysis,[108925],[10547],[10554],[False],[0],[0],[False],['0']
2718,PMC2917572,17902,"MTPM for each participant was calculated using fictive markers, a set of virtual points defined in the rigid body of the implant.",Radiostereometric analysis,[108930],[10555],[10684],[False],[0],[0],[False],['0']
2719,PMC2917572,17903,Fictive markers are used to standardize the MTPM calculations in cases where the prosthesis bead placement is not uniform across all subjects (Nilsson et al.,Radiostereometric analysis,[108935],[10685],[10842],[False],[0],[0],[False],['0']
2720,PMC2917572,17904,"1999, Valstar et al.",Radiostereometric analysis,[108940],[10843],[10863],[False],[0],[0],[False],['0']
2721,PMC2917572,17905,2005).,Radiostereometric analysis,[108945],[10864],[10870],[False],[0],[0],[False],['0']
2722,PMC2917572,17906,6 fictive markers were placed at the periphery of the implant volume.,Radiostereometric analysis,[108950],[10871],[10940],[False],[0],[0],[False],['0']
2723,PMC2917572,17907,The rotations and translations of the rigid body defined by the tantalum beads in the polyethylene about the volumetric centroid of the prosthesis were then applied to the fictive points to calculate the MTPM for each follow-up.,Radiostereometric analysis,[108955],[10941],[11169],[False],[0],[0],[False],['0']
2724,PMC2917572,17908,The limit of rigid body fitting was a maximum of 0.2 mm for the tibial segment and 0.2 mm for the prosthesis segment.,Radiostereometric analysis,[108960],[11170],[11287],[False],[0],[0],[False],['0']
2725,PMC2917572,17909,"In any cases where the rigid body errors exceeded the threshold due to a loose bead, that bead was removed from the analysis.",Radiostereometric analysis,[108965],[11288],[11413],[False],[0],[0],[False],['0']
2726,PMC2917572,17910,"The condition number did not exceed 40 at any follow-up examination, indicating that there was adequate distribution of beads in the rigid body (Valstar et al.",Radiostereometric analysis,[108970],[11414],[11573],[False],[0],[0],[False],['0']
2727,PMC2917572,17911,2005).,Radiostereometric analysis,[108975],[11574],[11580],[False],[0],[0],[False],['0']
2728,PMC2917572,17912,The accuracy of the RSA system was assessed with a standard phantom study protocol.,Radiostereometric analysis,[108980],[11581],[11664],[False],[0],[0],[False],['0']
2729,PMC2917572,17913,Accuracy was represented as half of the average width of the 95% prediction interval in a regression analysis of true and measured translations of a phantom.,Radiostereometric analysis,[108985],[11665],[11822],[False],[0],[0],[False],['0']
2730,PMC2917572,17914,Precision was evaluated with double-examination analysis (Valstar et al.,Radiostereometric analysis,[108990],[11823],[11895],[False],[0],[0],[False],['0']
2731,PMC2917572,17915,"2005), and represented as the 95% confidence interval of the measurements from 11 double clinical examinations.",Radiostereometric analysis,[108995],[11896],[12007],[False],[0],[0],[False],['0']
2732,PMC2917572,17916,Statistics,Statistics,[109000],[12008],[12019],[False],[0],[0],[False],['0']
2733,PMC2917572,17917,The 3-dimensional angles and moments at the knee joint for the 5 gait trials were averaged to create ensemble average profiles for each measure and subject.,Statistics,[109005],[12020],[12176],[False],[0],[0],[False],['0']
2734,PMC2917572,17918,"Each measure was represented as a waveform (101 data points each to represent one complete gait cycle, from 0 to 100%).",Statistics,[109010],[12177],[12296],[False],[0],[0],[False],['0']
2735,PMC2917572,17919,It was hypothesized that knee joint loading patterns would be more associated with implant migration than movement patterns.,Statistics,[109015],[12297],[12421],[False],[0],[0],[False],['0']
2736,PMC2917572,17920,"Thus, the 3 dimensions of net knee joint moments (3 measurements in total) were included in the analysis.",Statistics,[109020],[12422],[12527],[False],[0],[0],[False],['0']
2737,PMC2917572,17921,"Principal component analysis (PCA), a multivariate statistical analysis technique, was applied to each gait waveform measure (X = 101 × 37; see below) separately to extract the pattern of variability of each of the measures over the gait cycle.",Statistics,[109025],[12528],[12772],[False],[0],[0],[False],['0']
2738,PMC2917572,17922,"PCA has been shown to be an effective tool in the reduction and interpretation of gait waveform data (Deluzio and Astephen 2007), extracting the most important patterns of variability within subject waveforms called principal components (PCs).",Statistics,[109030],[12773],[13016],[False],[0],[0],[False],['0']
2739,PMC2917572,17923,"Each gait waveform is presented by a matrix, X, which is a 101 (stride normalized data points) by 37 (number of subjects) matrix of a knee moment waveform (knee adduction, flexion, or rotation moment).",Statistics,[109035],[13017],[13218],[False],[0],[0],[False],['0']
2740,PMC2917572,17924,"PCs are the eigenvectors of the covariance matrix of X (101-dimensional), and capture the different principal patterns of variability in the original waveform data.",Statistics,[109040],[13219],[13383],[False],[0],[0],[False],['0']
2741,PMC2917572,17925,The projection of each subjects waveform data onto a PC results in a set of discrete PC scores with which to compare the gait waveform patterns between subjects.,Statistics,[109045],[13384],[13545],[False],[0],[0],[False],['0']
2742,PMC2917572,17926,Differences in PC scores for a given gait measure therefore reflect differences in one of the principal patterns within the waveform data.,Statistics,[109050],[13546],[13684],[False],[0],[0],[False],['0']
2743,PMC2917572,17927,"Most of the variability within the original data (> 90%) is generally captured in the first few principal components extracted, so the first 3 PCs of each of the 3 dimensions of knee moments were extracted for further analysis (3 PCs × 3 gait measures = 9 variables in total).",Statistics,[109055],[13685],[13961],[False],[0],[0],[False],['0']
2744,PMC2917572,17928,"PCs were interpreted by examining the pattern of the eigenvector over the gait cycle, as well as by examining subject waveforms in the fifth and ninety-fifth percentiles of the PC scores (Deluzio and Astephen 2007).",Statistics,[109060],[13962],[14177],[False],[0],[0],[False],['0']
2745,PMC2917572,17929,"Due to the non-parametric distribution of the MTPM data, a log transformation was applied to the data for further statistical modeling.",Statistics,[109065],[14178],[14313],[False],[0],[0],[False],['0']
2746,PMC2917572,17930,"Pearson correlations were used to examine the relationships between the first principal component (PC) score for each gait variable (3 dimensions of knee joint moments) and BMI with log MTPM, and the association between the knee adduction moment PC1 and varus tilt of the implant postoperatively.",Statistics,[109070],[14314],[14610],[False],[0],[0],[False],['0']
2747,PMC2917572,17931,A Bonferroni-corrected level of significance of p = 0.01 was used to account for 5 statistical comparisons (p = 0.05/5 = 0.01; using p = 0.05 for each individual test).,Statistics,[109075],[14611],[14779],[False],[0],[0],[False],['0']
2748,PMC2917572,17932,"2 multiple linear regression models were defined with log MTPM (at 6 months and 1 year) as the dependent variable, and implant type, BMI, and the first principal component scores of the knee adduction moment and the knee flexion moment as the independent variables.",Statistics,[109080],[14780],[15045],[False],[0],[0],[False],['0']
2749,PMC2917572,17933,"These particular PC scores were chosen for the multivariate model because PC1 of the knee adduction moment represents the overall magnitude of the varus/valgus moment on the knee joint during the stance phase of walking, which is the gait variable most commonly used as a metric of frontal plane loading and most commonly associated with progression of knee osteoarthritis (Hurwitz et al.",Statistics,[109085],[15046],[15434],[False],[0],[0],[False],['0']
2750,PMC2917572,17934,"2002, Mundermann et al.",Statistics,[109090],[15435],[15458],[False],[0],[0],[False],['0']
2751,PMC2917572,17935,"2004, Landry et al.",Statistics,[109095],[15459],[15478],[False],[0],[0],[False],['0']
2752,PMC2917572,17936,"2007, Astephen et al.",Statistics,[109100],[15479],[15500],[False],[0],[0],[False],['0']
2753,PMC2917572,17937,2008a).,Statistics,[109105],[15501],[15508],[False],[0],[0],[False],['0']
2754,PMC2917572,17938,"PC1 of the knee flexion moment also represents the overall magnitude of the moment during stance, and this measure has been shown in previous studies to be associated with implant migration (Hilding et al.",Statistics,[109110],[15509],[15714],[False],[0],[0],[False],['0']
2755,PMC2917572,17939,1996).,Statistics,[109115],[15715],[15721],[False],[0],[0],[False],['0']
2756,PMC2917572,17940,"Factors were kept in the multivariate model if they contributed in a statistically significant way to the explanation of log MTPM, given the other factors in the model (p < 0.01).",Statistics,[109120],[15722],[15901],[False],[0],[0],[False],['0']
2757,PMC2917572,17941,Only those PCs that were statistically significantly correlated to RSA data or included in the multivariate models were interpreted.,Statistics,[109125],[15902],[16034],[False],[0],[0],[False],['0']
2758,PMC2917572,17942,"Multiple regression model diagnostics included residual analyses, multicollinearity analyses, and inferential analyses.",Statistics,[109130],[16035],[16154],[False],[0],[0],[False],['0']
2759,PMC2917572,17943,Results,Results,[109135],[16155],[16163],[False],[0],[0],[False],['0']
2760,PMC2917572,17944,"3 subjects were lost to follow-up at 6 months postoperatively, leaving 19 TM and 18 NG patients.",Results,[109140],[16164],[16260],[False],[0],[0],[False],['0']
2761,PMC2917572,17945,"1 patient died, and 2 missed RSA follow-up examinations.",Results,[109145],[16261],[16317],[False],[0],[0],[False],['0']
2762,PMC2917572,17946,"4 additional subjects were lost to follow-up at 1 year, leaving 17 TM and 16 NG patients for the 1-year RSA results.",Results,[109150],[16318],[16434],[False],[0],[0],[False],['0']
2763,PMC2917572,17947,The 4 additional patients who were lost at 1 year missed their 1-year follow-up RSA appointments.,Results,[109155],[16435],[16532],[False],[0],[0],[False],['0']
2764,PMC2917572,17948,"The TM and NG groups were similar in terms of age, BMI, and gait speed (Table 1).",Results,[109160],[16533],[16614],[False],[0],[0],[False],['0']
2765,PMC2917572,17949,The mean MTPM for the total group was 0.62 mm at 6 months and 0.63 mm at 1 year (Table 2).,Results,[109165],[16615],[16705],[False],[0],[0],[False],['0']
2766,PMC2917572,17950,There was no statistically significant difference in MTPM between the TM and NG groups at either 6 months (p = 0.2) or 1 year (p = 0.1).,Results,[109170],[16706],[16842],[False],[0],[0],[False],['0']
2767,PMC2917572,17951,There was no statistically significant difference in MTPM between the 6-month follow-up and the 1-year follow-up (p = 0.9).,Results,[109175],[16843],[16966],[False],[0],[0],[False],['0']
2768,PMC2917572,17952,"There was a statistically significant difference in translation in the y-direction (proximal-distal) between the groups at 6 months and 1 year, with the TM group showing more distal migration at both follow-up times (p < 0.001).",Results,[109180],[16967],[17195],[False],[0],[0],[False],['0']
2769,PMC2917572,17953,None of the subjects included in this analysis were considered to have more continuous migration (with migration at 12–24 months all < 0.2 mm) (Ryd et al.,Results,[109185],[17196],[17350],[False],[0],[0],[False],['0']
2770,PMC2917572,17954,1995); the longitudinal RSA results of these subjects have been reported previously (Dunber et al.,Results,[109190],[17351],[17449],[False],[0],[0],[False],['0']
2771,PMC2917572,17955,2009).,Results,[109195],[17450],[17456],[False],[0],[0],[False],['0']
2772,PMC2917572,17956,"Results of the phantom study showed that the accuracy of the RSA system was 0.02 mm, 0.02 mm, 0.06 mm, and 0.03 mm for the x-, y-, and z-directions and MTPM, respectively.",Results,[109200],[17457],[17628],[False],[0],[0],[False],['0']
2773,PMC2917572,17957,"The precision of the RSA system was 0.07 mm, 0.07 mm, 0.11 mm, 0.16°, 0.15°, 0.12°, and 0.10 mm for the x-, y-, and z-translations, the x-, y-, and z- rotations, and MTPM, respectively.",Results,[109205],[17629],[17814],[False],[0],[0],[False],['0']
2774,PMC2917572,17958,Principal component and RSA correlation analysis,Principal component and RSA correlation analysis,[109210],[17815],[17864],[False],[0],[0],[False],['0']
2775,PMC2917572,17959,"A statistically significant correlation was found between the first principal component (PC1) extracted from the knee adduction moments and log MTPM at 6 months (r2 = 0.24 (0.04–0.50), p = 0.002) (Figure 2).",Principal component and RSA correlation analysis,[109215],[17865],[18072],[False],[0],[0],[False],['0']
2776,PMC2917572,17960,"PC1 of the knee adduction moment was also associated with Rz at 6 months (r2 = 0.15 (0.005–0.41), p = 0.02), which represented the varus/valgus tilt of the implant within the tibia, but this association was not statistically significant.",Principal component and RSA correlation analysis,[109220],[18073],[18310],[False],[0],[0],[False],['0']
2777,PMC2917572,17961,"BMI was associated with log MTPM at 6 months (r2 = 0.14 (0.004–0.40), p = 0.02), but the correlation was not statistically significant with the Bonferroni correction.",Principal component and RSA correlation analysis,[109225],[18311],[18477],[False],[0],[0],[False],['0']
2778,PMC2917572,17962,"However, because the p-value was small, this factor was included in the multivariate model.",Principal component and RSA correlation analysis,[109230],[18478],[18569],[False],[0],[0],[False],['0']
2779,PMC2917572,17963,There were no statistically significant correlations between any individual factors and log MTPM at 1 year.,Principal component and RSA correlation analysis,[109235],[18570],[18677],[False],[0],[0],[False],['0']
2780,PMC2917572,17964,"The correlation between PC1 of the knee adduction moment and log MTPM was not as strong at 1 year and was no longer significant (r2 = 0.16 (0.01–0.43), p = 0.02).",Principal component and RSA correlation analysis,[109240],[18678],[18840],[False],[0],[0],[False],['0']
2781,PMC2917572,17965,The original knee adduction moment waveforms for all patients preoperatively during gait are shown in Figure 3a.,Principal component and RSA correlation analysis,[109245],[18841],[18953],[False],[0],[0],[False],['0']
2782,PMC2917572,17966,"PC1 of the knee adduction moment explained 85% of the variability in the original knee adduction moment waveforms and was interpreted as the overall magnitude of the moment during the stance phase of the gait cycle, because the loading vector was constant and positive over the majority of the stance phase (Figure 3b).",Principal component and RSA correlation analysis,[109250],[18954],[19273],[False],[0],[0],[False],['0']
2783,PMC2917572,17967,Example knee adduction moment waveforms with high and low PC1 scores (ninety-fifth and fifth percentiles) illustrate this interpretation (Figure 3c).,Principal component and RSA correlation analysis,[109255],[19274],[19423],[False],[0],[0],[False],['0']
2784,PMC2917572,17968,"Higher PC1 scores, and therefore higher magnitudes of knee adduction moment during stance preoperatively, were associated with higher total motion of the tibial component (MTPM) and greater varus tilt relative to the surrounding bone at 6 months postoperatively.",Principal component and RSA correlation analysis,[109260],[19424],[19686],[False],[0],[0],[False],['0']
2785,PMC2917572,17969,"The results of the multiple linear regression analysis for MTPM at 6 months showed that log MTPM was well explained by the combination of implant group, PC1 of the knee adduction moment, BMI, and PC1 of the knee flexion moment (R2 = 0.45 (0.19–0.67), R2 adjusted = 0.39, p = 0.001).",Principal component and RSA correlation analysis,[109265],[19687],[19969],[False],[0],[0],[False],['0']
2786,PMC2917572,17970,All variables included were statistically significant in the model (p < 0.10).,Principal component and RSA correlation analysis,[109270],[19970],[20048],[False],[0],[0],[False],['0']
2787,PMC2917572,17971,"For the multivariate model with log MTPM at 1 year using the same 4 factors, only PC1 of the knee adduction moment and BMI remained significant in the model (implant group: p = 0.1; BMI: p = 0.04; PC1 knee adduction moment: p = 0.09; PC1 knee flexion moment: p = 0.33).",Principal component and RSA correlation analysis,[109275],[20049],[20318],[False],[0],[0],[False],['0']
2788,PMC2917572,17972,A second multivariate model with only PC1 of the knee adduction moment and BMI showed that BMI was no longer significantly associated?,Principal component and RSA correlation analysis,[109280],[20319],[20453],[False],[0],[0],[False],['0']
2789,PMC2917572,17973,in the multivariate model with PC1 of the knee adduction moment (BMI: p = 0.13; PC1 knee adduction moment: p = 0.04).,Principal component and RSA correlation analysis,[109285],[20454],[20571],[False],[0],[0],[False],['0']
2790,PMC2917572,17974,"The final model for log MTPM at 1 year therefore only included PC1 of the knee adduction moment, and the strength of the relationship was reduced (R2 = 0.16 (0.01–0.43), R2 adjusted = 0.14, p = 0.02).",Principal component and RSA correlation analysis,[109290],[20572],[20772],[False],[0],[0],[False],['0']
2791,PMC2917572,17975,"Residual, influence, and multicolinearity tests indicated that there was no violation of model assumptions, no multicolinearity problems, and the residuals followed a normal distribution.",Principal component and RSA correlation analysis,[109295],[20773],[20960],[False],[0],[0],[False],['0']
2792,PMC2917572,17976,"In the multivariate models, higher knee adduction moments during stance were again associated with higher MTPM.",Principal component and RSA correlation analysis,[109300],[20961],[21072],[False],[0],[0],[False],['0']
2793,PMC2917572,17977,PC1 of the knee flexion moment explained 74% of the variability in the original knee flexion moment waveforms.,Principal component and RSA correlation analysis,[109305],[21073],[21183],[False],[0],[0],[False],['0']
2794,PMC2917572,17978,It was interpreted as the overall magnitude of the moment during the stance phase of the gait cycle (Figure 4).,Principal component and RSA correlation analysis,[109310],[21184],[21295],[False],[0],[0],[False],['0']
2795,PMC2917572,17979,Higher PC1 scores were associated with higher flexion moment magnitudes during stance.,Principal component and RSA correlation analysis,[109315],[21296],[21382],[False],[0],[0],[False],['0']
2796,PMC2917572,17980,"In the multivariate models, MTPM was associated with lower knee flexion moment PC1 scores or lower magnitudes of flexion moment during stance.",Principal component and RSA correlation analysis,[109320],[21383],[21525],[False],[0],[0],[False],['0']
2797,PMC2917572,17981,"Also in the multivariate model, having an uncemented TM implant was also associated with higher migration at 6 months and 1 year than having a cemented NG.",Principal component and RSA correlation analysis,[109325],[21526],[21681],[False],[0],[0],[False],['0']
2798,PMC2917572,17982,"Thus, in combination, higher knee adduction moments and lower knee flexion moments during stance, an uncemented implant and higher BMI preoperatively were associated with higher MTPM of the implant within the tibia at 6 months postoperatively.",Principal component and RSA correlation analysis,[109330],[21682],[21925],[False],[0],[0],[False],['0']
2799,PMC2917572,17983,The results of the regression analyses are summarized in Table 3.,Principal component and RSA correlation analysis,[109335],[21926],[21991],[False],[0],[0],[False],['0']
2800,PMC2917572,17984,Discussion,Discussion,[109340],[21992],[22003],[False],[0],[0],[False],['0']
2801,PMC2917572,17985,Our findings support the hypothesis that preoperative knee joint loading patterns during gait are associated with the postoperative migration of the tibial component of a TKA implant within the surrounding bone.,Discussion,[109345],[22004],[22215],[False],[0],[0],[False],['0']
2802,PMC2917572,17986,The dynamic knee adduction moment during gait is the mechanical variable most associated with knee osteoarthritis both pre- and postoperatively (Prodromos et al.,Discussion,[109350],[22216],[22377],[False],[0],[0],[False],['0']
2803,PMC2917572,17987,"1985, Miyazaki et al.",Discussion,[109355],[22378],[22399],[False],[0],[0],[False],['0']
2804,PMC2917572,17988,"2002, Hurwitz et al.",Discussion,[109360],[22400],[22420],[False],[0],[0],[False],['0']
2805,PMC2917572,17989,2002).,Discussion,[109365],[22421],[22427],[False],[0],[0],[False],['0']
2806,PMC2917572,17990,While the knee adduction moment has been identified as predictive of the outcome of high tibial osteotomy knee surgery (Prodromos et al.,Discussion,[109370],[22428],[22564],[False],[0],[0],[False],['0']
2807,PMC2917572,17991,"1985), our study is the first to indicate that there is a statistical association between the preoperative knee adduction moment and an objective outcome of TKR surgery.",Discussion,[109375],[22565],[22734],[False],[0],[0],[False],['0']
2808,PMC2917572,17992,We found that there was a correlation between the overall magnitude of the knee adduction moment during stance preoperatively and postoperative migration of the tibial component within the surrounding bone.,Discussion,[109380],[22735],[22941],[False],[0],[0],[False],['0']
2809,PMC2917572,17993,The only other authors to examine the association between preoperative gait patterns and postoperative implant migration did not report any relationship between the knee adduction moment and excessive postoperative migration (Hilding et al.,Discussion,[109385],[22942],[23182],[False],[0],[0],[False],['0']
2810,PMC2917572,17994,1995).,Discussion,[109390],[23183],[23189],[False],[0],[0],[False],['0']
2811,PMC2917572,17995,This previous study examined the differences between a group whose implant stabilized within the body and a group “at risk” of early loosening.,Discussion,[109395],[23190],[23333],[False],[0],[0],[False],['0']
2812,PMC2917572,17996,Our study instead investigated the associations between preoperative gait patterns and the continuum of migration values postoperatively rather than differences in dichotomous subject groups.,Discussion,[109400],[23334],[23525],[False],[0],[0],[False],['0']
2813,PMC2917572,17997,We feel that this information may be associated with a potential mechanism of loosening rather than being diagnostic of loosening.,Discussion,[109405],[23526],[23656],[False],[0],[0],[False],['0']
2814,PMC2917572,17998,"Additionally, we employed principal component analysis, which extracts and analyses variability in the continuous pattern of gait measures as they change throughout the gait cycle, rather than the commonly employed subjective extraction of parameters from the waveform.",Discussion,[109410],[23657],[23926],[False],[0],[0],[False],['0']
2815,PMC2917572,17999,"This analysis technique is capable of identifying shape changes in gait measures that may not be reflected in peak values alone, and that may be important in understanding differences between subject gait patterns (Deluzio and Astephen 2007).",Discussion,[109415],[23927],[24169],[False],[0],[0],[False],['0']
2816,PMC2917572,18000,PCA may have provided the additional sensitivity required to identify the potential importance of the knee adduction moment.,Discussion,[109420],[24170],[24294],[False],[0],[0],[False],['0']
2817,PMC2917572,18001,"The added usefulness of PCA in understanding gait patterns associated with knee osteoarthritis has been demonstrated in a number of previous studies (Astephen and Deluzio 2005, Deluzio and Astephen 2007, Landry et al.",Discussion,[109425],[24295],[24512],[False],[0],[0],[False],['0']
2818,PMC2917572,18002,"2007, Astephen et al.",Discussion,[109430],[24513],[24534],[False],[0],[0],[False],['0']
2819,PMC2917572,18003,2008b).,Discussion,[109435],[24535],[24542],[False],[0],[0],[False],['0']
2820,PMC2917572,18004,Hilding et al.,Discussion,[109440],[24543],[24557],[False],[0],[0],[False],['0']
2821,PMC2917572,18005,(1999) observed that a group of TKA patients found to be “at risk” of early aseptic loosening walked with higher knee flexion moments (mean and peak value) during gait both pre- and postoperatively.,Discussion,[109445],[24558],[24756],[False],[0],[0],[False],['0']
2822,PMC2917572,18006,"Somewhat in contrast, we found higher levels of migration to be associated with a pattern of a more constant extension moment during the stance phase of gait.",Discussion,[109450],[24757],[24915],[False],[0],[0],[False],['0']
2823,PMC2917572,18007,Walking with a constant external knee extension moment would reflect a more stiff-kneed walking pattern (i.e.,Discussion,[109455],[24916],[25025],[False],[0],[0],[False],['0']
2824,PMC2917572,18008,"less range of flexion/extension angle), which would not have the characteristic load acceptance phase and associated mid-stance knee flexion angle during early stance of an asymptomatic pattern.",Discussion,[109460],[25026],[25220],[False],[0],[0],[False],['0']
2825,PMC2917572,18009,"This pattern would therefore also be associated with greater impact loading during early stance due to the lack of shock absorbency, which may have a detrimental effect on the mechanical stability of the implant.",Discussion,[109465],[25221],[25433],[False],[0],[0],[False],['0']
2826,PMC2917572,18010,The difference between our results and those of Hilding et al.,Discussion,[109470],[25434],[25496],[False],[0],[0],[False],['0']
2827,PMC2917572,18011,"(1995, 1999) may again be attributed to the differences in our study populations and analysis techniques.",Discussion,[109475],[25497],[25602],[False],[0],[0],[False],['0']
2828,PMC2917572,18012,Our results reflect the multivariate association of gait measures with the continuum of migration early in the postoperative period.,Discussion,[109480],[25603],[25735],[False],[0],[0],[False],['0']
2829,PMC2917572,18013,"Knee OA is a complex, multifactorial disease process that involves the interactions between multiple factors, and combinations of mechanical variables have been shown to be more important in describing disease severity than individual factors alone (Astephen and Deluzio 2005, Astephen et al.",Discussion,[109485],[25736],[26028],[False],[0],[0],[False],['0']
2830,PMC2917572,18014,2008b).,Discussion,[109490],[26029],[26036],[False],[0],[0],[False],['0']
2831,PMC2917572,18015,It is therefore likely that multivariate combinations of preoperative mechanical factors would be more important to surgical outcome than any individual factor alone.,Discussion,[109495],[26037],[26203],[False],[0],[0],[False],['0']
2832,PMC2917572,18016,"As expected, our results showed that postoperative implant migration was better explained by a combination of preoperative biomechanical variables than the knee adduction moment alone.",Discussion,[109500],[26204],[26388],[False],[0],[0],[False],['0']
2833,PMC2917572,18017,"This combination associates differences in the loading pattern within the joint in 2 anatomical planes (flexion/extension, abduction/adduction) and over the stance phase of the gait cycle, with higher postoperative migration.",Discussion,[109505],[26389],[26614],[False],[0],[0],[False],['0']
2834,PMC2917572,18018,Most patients who undergo total knee arthroplasty in Canada are overweight or obese (CIHI 2006).,Discussion,[109510],[26615],[26711],[False],[0],[0],[False],['0']
2835,PMC2917572,18019,"Obesity is one of the most cited risk factors for knee OA (Felson and Chaisson 1997, Manek et al.",Discussion,[109515],[26712],[26809],[False],[0],[0],[False],['0']
2836,PMC2917572,18020,2003).,Discussion,[109520],[26810],[26816],[False],[0],[0],[False],['0']
2837,PMC2917572,18021,It has been associated with an increased risk of radiographic and symptomatic OA (Felson et al.,Discussion,[109525],[26817],[26912],[False],[0],[0],[False],['0']
2838,PMC2917572,18022,"1988b, Spector et al.",Discussion,[109530],[26913],[26934],[False],[0],[0],[False],['0']
2839,PMC2917572,18023,1994) and accelerated disease progression (Schouten et al.,Discussion,[109535],[26935],[26993],[False],[0],[0],[False],['0']
2840,PMC2917572,18024,1992).,Discussion,[109540],[26994],[27000],[False],[0],[0],[False],['0']
2841,PMC2917572,18025,"Apart from the additive affect of increased body weight to joint loading during gait, obesity can cause immobility and movement adaptations that may adversely affect the loading environment within the joint, increasing the potential for injury (Wearing et al.",Discussion,[109545],[27001],[27260],[False],[0],[0],[False],['0']
2842,PMC2917572,18026,2006).,Discussion,[109550],[27261],[27267],[False],[0],[0],[False],['0']
2843,PMC2917572,18027,It has been shown that obese individuals walk with increased total energy expenditure (Browning et al.,Discussion,[109555],[27268],[27370],[False],[0],[0],[False],['0']
2844,PMC2917572,18028,"2006), and with increased magnitude and rate of ground reaction force.",Discussion,[109560],[27371],[27441],[False],[0],[0],[False],['0']
2845,PMC2917572,18029,"In our study, the combination of increased BMI and altered joint loading during gait preoperatively was associated with postoperative implant migration, which supports the notion that BMI is an important factor in patient triage and implant selection.",Discussion,[109565],[27442],[27693],[False],[0],[0],[False],['0']
2846,PMC2917572,18030,"In previous work on multivariate studies of knee OA, we have identified the added importance of BMI in combination with other gait characteristics (Astephen and Deluzio 2005, Astephen et al.",Discussion,[109570],[27694],[27884],[False],[0],[0],[False],['0']
2847,PMC2917572,18031,2008a).,Discussion,[109575],[27885],[27892],[False],[0],[0],[False],['0']
2848,PMC2917572,18032,"The results of this study further support the multivariate role of obesity in OA pathomechanics and surgical outcome, where the detrimental loading on the joint is dependent on the interaction between the static mass of the patient and the dynamic mechanical environment.",Discussion,[109580],[27893],[28164],[False],[0],[0],[False],['0']
2849,PMC2917572,18033,The most important conclusion from our work is the recognition of a multivariate statistical association between joint loading during gait and BMI with implant migration.,Discussion,[109585],[28165],[28335],[False],[0],[0],[False],['0']
2850,PMC2917572,18034,"While a larger sample size would be required to more definitively define the multivariate form of the relationship between MTPM and joint loading, this is a first step in our understanding of joint function and TKA outcome.",Discussion,[109590],[28336],[28559],[True],['SampleSize'],['a larger sample size would be required'],[True],['UnderpoweredStudy']
2851,PMC2917572,18035,The results of this study support the need for further investigation into the myriad of preoperative factors that can predict objective post-TKA outcome.,Discussion,[109600],[28560],[28713],[False],[0],[0],[False],['0']
2852,PMC2917572,18036,"The unexplained variability in postoperative implant migration may be accounted for by the differences in other patient characteristics not included in the current analysis such as bone density, sex, bone morphology, implant sizing and positioning, realignment of the joint intraoperatively, and other surgical factors.",Discussion,[109606],[28714],[29033],[True],['ConfoundingFactors'],['differences in other patient characteristics not included in the current analysis'],[True],['StatisticalAnalysis']
2853,PMC2917572,18037,"The multivariate statistical association between preoperative knee joint loading and postoperative implant migration was stronger at 6 months postoperatively than at 1 year, although migration values were similar between the 2 time points.",Discussion,[109615],[29034],[29273],[False],[0],[0],[False],['0']
2854,PMC2917572,18038,The knee adduction moment magnitude was the only statistically significant factor included in the regression model for MTPM at 1 year.,Discussion,[109620],[29274],[29408],[False],[0],[0],[False],['0']
2855,PMC2917572,18039,"It is intuitive that if the loading environment of the knee joint preoperatively would translate into the postoperative period, the relationship would weaken further into the postoperative period as biological mechanisms (i.e.",Discussion,[109625],[29409],[29635],[False],[0],[0],[False],['0']
2856,PMC2917572,18040,bone ingrowth in uncemented implants.,Discussion,[109630],[29636],[29673],[False],[0],[0],[False],['0']
2857,PMC2917572,18041,"Also, because none of these implants migrated continuously, the predominant motion of the implant within the bone occurred early in the postoperative period (as shown in a previous study (Dunbar et al.",Discussion,[109635],[29674],[29875],[False],[0],[0],[False],['0']
2858,PMC2917572,18042,"2009)), and so the association was more pronounced in this early preoperative period.",Discussion,[109640],[29876],[29961],[False],[0],[0],[False],['0']
2859,PMC2917572,18043,"While the goal of this study was to examine the association between preoperative function and postoperative implant longevity, it is important to realize the functional adaptations that are provided by the implant post-surgically.",Discussion,[109645],[29962],[30192],[False],[0],[0],[False],['0']
2860,PMC2917572,18044,Part of the standard operative procedure in TKA involves a correction of varus deformity to more neutral alignment.,Discussion,[109650],[30193],[30308],[False],[0],[0],[False],['0']
2861,PMC2917572,18045,While some studies have associated static joint alignment and dynamic frontal plane joint loading (Olney et al.,Discussion,[109655],[30309],[30420],[False],[0],[0],[False],['0']
2862,PMC2917572,18046,"1994, Hurwitz et al.",Discussion,[109660],[30421],[30441],[False],[0],[0],[False],['0']
2863,PMC2917572,18047,"2002), others have not (Prodromos et al.",Discussion,[109665],[30442],[30482],[False],[0],[0],[False],['0']
2864,PMC2917572,18048,1985).,Discussion,[109670],[30483],[30489],[False],[0],[0],[False],['0']
2865,PMC2917572,18049,This raises the question of whether metrics of dynamic (i.e.,Discussion,[109675],[30490],[30550],[False],[0],[0],[False],['0']
2866,PMC2917572,18050,the knee adduction moment during gait) or static joint alignment should be used as surgical indicators in TKA.,Discussion,[109680],[30551],[30661],[False],[0],[0],[False],['0']
2867,PMC2917572,18051,"The findings of a related study by our group showed that the overall magnitude of the dynamic knee adduction moment during gait decreased from the preoperative to the postoperative state; however, the pattern of frontal plane loading during gait did not return to normal (Hatfield et al.",Discussion,[109685],[30662],[30949],[False],[0],[0],[False],['0']
2868,PMC2917572,18052,2010).,Discussion,[109690],[30950],[30956],[False],[0],[0],[False],['0']
2869,PMC2917572,18053,"This study provides an indication that preoperative gait dynamics are associated with postoperative movement of the implant within the bone, but it was limited in terms of the number of variables investigated.",Discussion,[109697],[30957],[31166],[True],['ConfoundingFactors'],['the number of variables investigated'],[True],['StatisticalAnalysis']
2870,PMC2917572,18054,"While half of the variability in postoperative outcome is significant, future work should aim to capture and model all sources of variability, which include intraoperative and postoperative factors such as details of the surgical procedure, postoperative rehabilitation, bone density, etc.",Discussion,[109705],[31167],[31456],[False],[0],[0],[False],['0']
2871,PMC2917572,18055,A second limitation of the study was sample size.,Discussion,[109713],[31457],[31506],[True],['SampleSize'],['sample size'],[True],['UnderpoweredStudy']
2872,PMC2917572,18056,"While some statistically significant correlations have been identified, the study may have been underpowered to be able to detect statistically significant correlations with other metrics.",Discussion,[109724],[31507],[31695],[True],['UnderpoweredStudy'],['the study may have been underpowered'],[True],['UnderpoweredStudy']
2873,PMC2917572,18057,Future multivariate analyses with more variables will require larger patient populations.,Discussion,[109730],[31696],[31785],[False],[0],[0],[False],['0']
2874,PMC2917572,18058,"Providing objective information on implant survivorship based on preoperative metrics can have substantial implications for patient triage, implant design, and surgical technique.",Discussion,[109735],[31786],[31965],[False],[0],[0],[False],['0']
2875,PMC2917572,18059,"Such investigations are becoming increasingly important with the growing need for implant longevity and functionality, considering the expanding younger and more active patient demographic for TKR.",Discussion,[109740],[31966],[32163],[False],[0],[0],[False],['0']
2876,PMC2917572,18060,Acknowledgements,Acknowledgements,[109745],[32164],[32181],[False],[0],[0],[False],['0']
2877,PMC2917572,18061,"JAW: gait analysis, statistical analysis, and preparation of manuscript.",Acknowledgements,[109750],[32182],[32254],[False],[0],[0],[False],['0']
2878,PMC2917572,18062,DW: RSA analysis and preparation of manuscript.,Acknowledgements,[109755],[32255],[32302],[False],[0],[0],[False],['0']
2879,PMC2917572,18063,KD: study design and collection and analysis of gait data.,Acknowledgements,[109760],[32303],[32361],[False],[0],[0],[False],['0']
2880,PMC2917572,18064,MD: study design and collection and analysis of RSA data.,Acknowledgements,[109765],[32362],[32419],[False],[0],[0],[False],['0']
2881,PMC2917572,18065,This research was supported by the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC).,Acknowledgements,[109770],[32420],[32577],[False],[0],[0],[False],['0']
2882,PMC2917572,18066,Funds were received by Zimmer for the RSA portion of this study.,Acknowledgements,[109775],[32578],[32642],[False],[0],[0],[False],['0']
2883,PMC2924475,21081,Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial,Title,[127158],[26846],[167],[False],[0],[0],[False],['0']
2884,PMC2924475,21082,Objective To study rates of relapse in remitted patients with first episode psychosis who either continued or discontinued antipsychotic drugs after at least one year of maintenance treatment.,Abstract,[127165],[168],[362],[False],[0],[0],[False],['0']
2885,PMC2924475,21083,"Design 12 month randomised, double blind, placebo controlled trial.",Abstract,[127172],[363],[430],[False],[0],[0],[False],['0']
2886,PMC2924475,21084,Setting Early psychosis outpatient clinics in Hong Kong.,Abstract,[127179],[431],[487],[False],[0],[0],[False],['0']
2887,PMC2924475,21085,Participants 178 patients with first episode psychosis who had received at least one year of antipsychotic drug treatment between September 2003 and July 2006 and had no positive symptoms of psychosis.,Abstract,[127186],[488],[689],[False],[0],[0],[False],['0']
2888,PMC2924475,21086,Interventions Patients received either maintenance treatment with quetiapine (400 mg/day) or placebo and were followed up for the next 12 months or until a relapse occurred.,Abstract,[127193],[690],[863],[False],[0],[0],[False],['0']
2889,PMC2924475,21087,"Main outcome measure Relapse assessed monthly and defined as re-emergence of psychotic symptoms (delusions, conceptual disorganisation, hallucinations, suspiciousness, and unusual thought content) according to predefined thresholds.",Abstract,[127200],[864],[1096],[False],[0],[0],[False],['0']
2890,PMC2924475,21088,Results 178 patients were randomised (89 to quetiapine and 89 to placebo).,Abstract,[127207],[1097],[1171],[False],[0],[0],[False],['0']
2891,PMC2924475,21089,The Kaplan-Meier estimate of the risk of relapse at 12 months was 41% (95% confidence interval 29% to 53%) for the quetiapine group and 79% (68% to 90%) for the placebo group (P<0.001).,Abstract,[127214],[1172],[1357],[False],[0],[0],[False],['0']
2892,PMC2924475,21090,"Although quetiapine was generally well tolerated, the rate of discontinuation due to adverse or serious adverse events was greater in the quetiapine group (18%; 16/89) than in the placebo group (8%; 7/89) (relative risk 2.29, 95% confidence interval 0.99 to 5.28; χ2=3.20, df=1; P=0.07).",Abstract,[127221],[1358],[1645],[False],[0],[0],[False],['0']
2893,PMC2924475,21091,"Conclusion In a group of asymptomatic patients with first episode psychosis and at least one year of previous antipsychotic drug treatment, maintenance treatment with quetiapine compared with placebo resulted in a substantially lower rate of relapse during the following year.",Abstract,[127228],[1646],[1922],[False],[0],[0],[False],['0']
2894,PMC2924475,21092,Trial registration Clinical trials NCT00334035.,Abstract,[127235],[1923],[1970],[False],[0],[0],[False],['0']
2895,PMC2924475,21093,Introduction,Introduction,[127242],[1971],[1984],[False],[0],[0],[False],['0']
2896,PMC2924475,21094,"Prevention of relapse is an important target in the treatment of schizophrenia and related psychotic conditions.1 In first episode psychosis, more than 80% of patients treated achieve a full response in psychotic symptoms,2 yet as many as 80% have a relapse within five years.3 Relapse compromises the outcome of psychotic disorders and is associated with substantial risks and costs.4 With each relapse, the response of symptoms to treatment seems to take approximately 50% longer and is increasingly difficult to re-establish.5 Prevention of relapse is particularly important in the early course of illness, when symptoms and disabilities may be less entrenched.",Introduction,[127249],[1985],[2649],[False],[0],[0],[False],['0']
2897,PMC2924475,21095,"Strategies to improve adherence and minimise early relapses are major focuses in treatment programmes and clinical research.1 For chronic psychotic illness, maintenance antipsychotic drug treatment is efficacious for preventing relapse.",Introduction,[127256],[2650],[2886],[False],[0],[0],[False],['0']
2898,PMC2924475,21096,The rate of relapse after discontinuation of drug treatment in chronic schizophrenia is approximately 53% compared with 16% for patients maintained on antipsychotic drugs.6 Atypical antipsychotic drugs may have some benefits compared with typical antipsychotics in preventing relapse in chronic illness.7 8 The biological mechanism underlying relapse is not fully understood; a hyperdopaminergic state resulting from dysregulation and endogenous sensitisation of the central meso-limbic and meso-cortical dopamine systems have been proposed.9,Introduction,[127263],[2887],[3429],[False],[0],[0],[False],['0']
2899,PMC2924475,21097,"For patients with first episode psychosis, the few randomised placebo controlled trials of relapse prevention were carried out in patients soon after discharge from hospital.10 11 12 Kane et al randomised 30 patients with at least four weeks of stable remission after admission to hospital (17 placebo v 13 fluphenazine) and found that 41% in the placebo group relapsed (defined as substantial clinical deterioration with marked social impairment) compared with none in the maintenance group.11 Crow et al randomised 120 patients within one month of discharge (66 on placebo v 54 on antipsychotics) and found that 62% of the placebo group and 46% of the maintenance group relapsed (resumption of drug or readmission to hospital) over the next 24 months.10 Hogarty et al studied 75 patients with two months of antipsychotic treatment after discharge from hospital and found that relapse (unequivocal clinical deterioration or imminent readmission) occurred in 64% of the placebo group and 43% of the maintenance group.12",Introduction,[127270],[3430],[4449],[False],[0],[0],[False],['0']
2900,PMC2924475,21098,"Clinical guidelines recommend maintenance drug treatment for the first year after the onset of illness, but no consensus exists regarding longer periods of maintenance treatment.13 14 15 16 Some authors estimated that up to a quarter of patients with first episode psychosis may not need long term maintenance treatment,17 whereas others question whether it should ever be discontinued.16 18 Two recent studies investigated first episode patients with somewhat longer periods of remission.",Introduction,[127277],[4450],[4939],[False],[0],[0],[False],['0']
2901,PMC2924475,21099,"Gitlin et al randomised 108 patients previously treated with depot fluphenazine for one year to placebo and maintenance groups (54 each) for three months, followed by a crossover of treatment in the next three months, then open label discontinuation.19 Exacerbation was defined as a recurrence of mild psychotic symptoms (a 2 point change, to a score >3, on any of three brief psychiatric rating scale psychosis items).",Introduction,[127284],[4940],[5359],[False],[0],[0],[False],['0']
2902,PMC2924475,21100,Relapse was defined as a recurrence of severe psychotic symptoms (a rating of 6 or 7 on any of three brief psychiatric rating scale psychosis items).,Introduction,[127291],[5360],[5509],[False],[0],[0],[False],['0']
2903,PMC2924475,21101,"Unfortunately, interpretation of the effect of drug treatment was complicated by persistence of the depot fluphenazine in the placebo group.",Introduction,[127298],[5510],[5650],[False],[0],[0],[False],['0']
2904,PMC2924475,21102,"After open label discontinuation, 78% had an exacerbation or relapse in the next 12 months.",Introduction,[127305],[5651],[5742],[False],[0],[0],[False],['0']
2905,PMC2924475,21103,"However, without randomisation and blinding, the effects of participants’ and raters’ expectations on the assessments remain uncertain.",Introduction,[127312],[5743],[5878],[False],[0],[0],[False],['0']
2906,PMC2924475,21104,"In another study of drug discontinuation, Wunderink et al randomised 128 patients who were in remission for six months (65 open withdrawal, 63 open continuation of drug).20 The study did not involve a placebo control.",Introduction,[127319],[5879],[6096],[False],[0],[0],[False],['0']
2907,PMC2924475,21105,Relapse (clinical deterioration with one or more score in the severe range of 5 or more in the positive and negative syndrome scale positive subscale21) was more frequent in the discontinuation group (43%) than in the maintenance treatment group (21%).,Introduction,[127326],[6097],[6349],[False],[0],[0],[False],['0']
2908,PMC2924475,21106,"In the context of the limited available evidence, discontinuation of drug treatment is perceived as a viable option for patients with first episode psychosis after at least one year of antipsychotic drug treatment without relapse.3 22 Longer term maintenance treatment, with its associated long term side effects,10 is often unacceptable to first episode patients.18 Currently, decisions and guidelines on discontinuation must be made without directly relevant, randomised, placebo controlled data.",Introduction,[127333],[6350],[6848],[False],[0],[0],[False],['0']
2909,PMC2924475,21107,"In addition, no robust predictors exist to identify patients at low risk of relapse.23",Introduction,[127340],[6849],[6935],[False],[0],[0],[False],['0']
2910,PMC2924475,21108,Methods,Methods,[127347],[6936],[6944],[False],[0],[0],[False],['0']
2911,PMC2924475,21109,This double blind randomised controlled study aimed to investigate the effect of discontinuing maintenance treatment in a group of first episode patients who had completed at least one year of antipsychotic drug treatment with no relapses.,Methods,[127354],[6945],[7184],[False],[0],[0],[False],['0']
2912,PMC2924475,21110,"Additionally, to optimise the clinical relevance of the study and the likelihood of successful discontinuation, we enrolled only patients clinically judged to be free of psychotic symptoms for at least eight weeks.",Methods,[127361],[7185],[7399],[False],[0],[0],[False],['0']
2913,PMC2924475,21111,"Our primary hypothesis was that even for this group of patients selected for their good response, more patients randomised from existing treatment to placebo (discontinuation) than patients randomised to maintenance treatment (standardised to quetiapine) would relapse during one year of follow-up.",Methods,[127368],[7400],[7698],[False],[0],[0],[False],['0']
2914,PMC2924475,21112,We investigated readmission to hospital as a secondary outcome and also did an exploratory analysis of potential predictors of relapse.,Methods,[127375],[7699],[7834],[False],[0],[0],[False],['0']
2915,PMC2924475,21113,Study sites and participants,Methods|Study sites and participants,[127382],[7835],[7863],[False],[0],[0],[False],['0']
2916,PMC2924475,21114,Psychiatric care for first episode psychosis in Hong Kong is provided by specialised teams covering the entire population of approximately seven million.,Methods|Study sites and participants,[127389],[7864],[8017],[False],[0],[0],[False],['0']
2917,PMC2924475,21115,"The Early Assessment Service for Young People with Psychosis (EASY) evaluates more than 600 new cases a year and provides comprehensive, guideline based case management for the first three years of illness.24 To enter the EASY programme, patients must have first episode psychosis, defined by continuously present psychotic symptoms since onset, no previous psychotic episodes, and no previous treatment or remission.",Methods|Study sites and participants,[127396],[8018],[8435],[False],[0],[0],[False],['0']
2918,PMC2924475,21116,"Inclusion criteria for the study included a diagnosis of schizophrenia or non-affective psychosis (schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, or psychosis not otherwise specified) according to the Diagnostic and Statistical Manual for Mental Disorders, fourth edition (DSM-IV).25 Experienced (equivalent to royal college or board certified) psychiatrists confirmed the diagnosis according to the Chinese version of the structured clinical interview for DSM-IV.26 In addition, patients had to be aged 18 to 65, to have received antipsychotic drug treatment continuously for at least 12 months, and to have no history of relapse (defined as any increase in positive symptoms leading to adjustment of drug treatment or readmission to hospital).",Methods|Study sites and participants,[127403],[8436],[9213],[False],[0],[0],[False],['0']
2919,PMC2924475,21117,"We ascertained this with information from patients, carers, case managers, clinicians, and clinical records.",Methods|Study sites and participants,[127410],[9214],[9322],[False],[0],[0],[False],['0']
2920,PMC2924475,21118,"Patients had to be non-psychotic at study entry, as defined by having below threshold scores on five key psychotic symptoms on the positive and negative syndrome scale (table 1),21 as well as free of positive symptoms of psychosis for at least eight weeks.",Methods|Study sites and participants,[127417],[9323],[9579],[False],[0],[0],[False],['0']
2921,PMC2924475,21119,Patients also had to score 2 (borderline or questionable mental illness) or below on the clinical global impressions scale.27,Methods|Study sites and participants,[127424],[9580],[9705],[False],[0],[0],[False],['0']
2922,PMC2924475,21120,"Exclusion criteria were drug induced psychosis and current treatment with clozapine or depot antipsychotics or with mood stabilising drugs (lithium, valproate, or carbamazepine).",Methods|Study sites and participants,[127431],[9706],[9884],[False],[0],[0],[False],['0']
2923,PMC2924475,21121,"Other exclusion criteria included poor adherence to treatment (missing >50% of drug, >50% non-attendance at follow-up clinic visits, or a history of patient initiated discontinuation of treatment), and risk of suicide or violence.",Methods|Study sites and participants,[127438],[9885],[10115],[False],[0],[0],[False],['0']
2924,PMC2924475,21122,All participants gave written informed consent.,Methods|Study sites and participants,[127445],[10116],[10163],[False],[0],[0],[False],['0']
2925,PMC2924475,21123,"All study participants were monitored by specialised clinical teams, as well as by the research team, and had access to a dedicated telephone hotline.",Methods|Study sites and participants,[127452],[10164],[10314],[False],[0],[0],[False],['0']
2926,PMC2924475,21124,Randomisation and blinding,Methods|Randomisation and blinding,[127459],[10315],[10341],[False],[0],[0],[False],['0']
2927,PMC2924475,21125,We randomised patients to maintenance with quetiapine (400 mg/day) or placebo of identical appearance for the next 12 months.,Methods|Randomisation and blinding,[127466],[10342],[10467],[False],[0],[0],[False],['0']
2928,PMC2924475,21126,"AstraZeneca generated a randomisation sequence by computer, with a fixed block size of four without stratification.",Methods|Randomisation and blinding,[127473],[10468],[10583],[False],[0],[0],[False],['0']
2929,PMC2924475,21127,"AstraZeneca prepared individually numbered sets of study drugs, packed them according to the randomisation sequence, and then shipped them to the study team in numbered but apparently identical sets.",Methods|Randomisation and blinding,[127480],[10584],[10783],[False],[0],[0],[False],['0']
2930,PMC2924475,21128,Study investigators assigned the study drug sets to participants consecutively according to the sequence of study entry.,Methods|Randomisation and blinding,[127487],[10784],[10904],[False],[0],[0],[False],['0']
2931,PMC2924475,21129,"Investigators, patients, and all research staff were blind to the study drugs and the block size.",Methods|Randomisation and blinding,[127494],[10905],[11002],[False],[0],[0],[False],['0']
2932,PMC2924475,21130,Study design,Methods|Study design,[127501],[11003],[11015],[False],[0],[0],[False],['0']
2933,PMC2924475,21131,Patients had been treated with several different antipsychotic drugs for the 12 months before screening for entry to the study (table 2).,Methods|Study design,[127508],[11016],[11153],[False],[0],[0],[False],['0']
2934,PMC2924475,21132,We chose to randomise patients to a single antipsychotic drug or to placebo for prevention of relapse.,Methods|Study design,[127515],[11154],[11256],[False],[0],[0],[False],['0']
2935,PMC2924475,21133,This strategy avoids possible differences between subgroups of patients taking different maintenance drugs.,Methods|Study design,[127522],[11257],[11364],[False],[0],[0],[False],['0']
2936,PMC2924475,21134,Atypical antipsychotics are increasingly chosen for maintenance treatment in first episode psychosis.,Methods|Study design,[127529],[11365],[11466],[False],[0],[0],[False],['0']
2937,PMC2924475,21135,"Among the three atypical antipsychotics available in Hong Kong at the time we started the study, we were able to obtain matching placebo tablets from the manufacturer only for quetiapine.",Methods|Study design,[127536],[11467],[11654],[False],[0],[0],[False],['0']
2938,PMC2924475,21136,We chose a dose of 400 mg/day on the basis of the usual effective dose in patients with chronic illness; this dose has been shown to be efficacious for first episode patients.28,Methods|Study design,[127543],[11655],[11832],[False],[0],[0],[False],['0']
2939,PMC2924475,21137,We achieved transition to the study drug by cross-tapering over four to six weeks.,Methods|Study design,[127550],[11833],[11915],[False],[0],[0],[False],['0']
2940,PMC2924475,21138,We then assessed patients 12 times in the following year at approximately monthly intervals or until they had a relapse.,Methods|Study design,[127557],[11916],[12036],[False],[0],[0],[False],['0']
2941,PMC2924475,21139,"We assessed adherence to treatment by clinical interviews with participants and informants, as well as by pill counting.",Methods|Study design,[127564],[12037],[12157],[False],[0],[0],[False],['0']
2942,PMC2924475,21140,Outcome measures,Methods|Outcome measures,[127571],[12158],[12174],[False],[0],[0],[False],['0']
2943,PMC2924475,21141,"As patients were non-psychotic at entry to the study, we defined relapse as the reappearance of definite psychotic symptoms (beyond ratings of “questionable” or “within limits of normal experience”) according to predefined thresholds (table 1), together with a clinical global impressions score of 3 or above.",Methods|Outcome measures,[127578],[12175],[12484],[False],[0],[0],[False],['0']
2944,PMC2924475,21142,This approach is consistent with earlier studies of relapse29; it represents a categorical shift in illness state.,Methods|Outcome measures,[127585],[12485],[12599],[False],[0],[0],[False],['0']
2945,PMC2924475,21143,Our definitions are similar to the “exacerbation” described by Gitlin et al and are more liberal in defining relapse than the requirement for “substantial” or “unequivocal” deterioration or readmission to hospital used in other studies.10 11 12 19 The lower threshold for defining relapse allowed recurrence of psychotic symptoms to be recognised early and appropriate interventions to be started.,Methods|Outcome measures,[127592],[12600],[12997],[False],[0],[0],[False],['0']
2946,PMC2924475,21144,We used alternative thresholds for defining relapse in secondary analyses (see below).,Methods|Outcome measures,[127599],[12998],[13084],[False],[0],[0],[False],['0']
2947,PMC2924475,21145,Nine trained clinicians assessed the inter-rater reliability for each of the positive symptoms by using an independent sample of 20 patients (weighted κ=0.72-0.92).,Methods|Outcome measures,[127606],[13085],[13249],[False],[0],[0],[False],['0']
2948,PMC2924475,21146,A secondary relapse related measure was readmission to hospital.,Methods|Outcome measures,[127613],[13250],[13314],[False],[0],[0],[False],['0']
2949,PMC2924475,21147,"To assess the functional implications of relapse, employment status (employed or otherwise) was reported at baseline and follow-up.",Methods|Outcome measures,[127620],[13315],[13446],[False],[0],[0],[False],['0']
2950,PMC2924475,21148,Table 3 describes potential predictor variables for relapse and their measurements.,Methods|Outcome measures,[127627],[13447],[13530],[False],[0],[0],[False],['0']
2951,PMC2924475,21149,Side effects and adverse events,Methods|Side effects and adverse events,[127634],[13531],[13562],[False],[0],[0],[False],['0']
2952,PMC2924475,21150,"We assessed side effects monthly with the Udvalg for Kliniske Undersøgelser scale.36 We assessed movement disorders with the Barnes akathisia rating scale,37 the abnormal involuntary movement scale,38 and the Simpson Angus scale.39 We measured body weight and body mass index at baseline and at six and 12 months.",Methods|Side effects and adverse events,[127641],[13563],[13876],[False],[0],[0],[False],['0']
2953,PMC2924475,21151,"We defined adverse events as adverse occurrences that may have been related to the drug and serious adverse events as death, hospital admission, or persistent incapacity.",Methods|Side effects and adverse events,[127648],[13877],[14047],[False],[0],[0],[False],['0']
2954,PMC2924475,21152,Statistical analysis,Methods|Statistical analysis,[127655],[14048],[14068],[False],[0],[0],[False],['0']
2955,PMC2924475,21153,"We estimated statistical power according to Collett (1994),40 by first determining the required number of outcome events (relapses).",Methods|Statistical analysis,[127662],[14069],[14201],[False],[0],[0],[False],['0']
2956,PMC2924475,21154,"Because some relapses during the transition from drug at entry to study drug could be related to the transition itself, we planned to ensure that the comparison of post-transition relapses would have sufficient power.",Methods|Statistical analysis,[127669],[14202],[14419],[False],[0],[0],[False],['0']
2957,PMC2924475,21155,No controlled study data for this group had been reported in the literature at the time we were planning the study; naturalistic studies suggested a range of relapse rates from 30% to 55%.,Methods|Statistical analysis,[127676],[14420],[14608],[False],[0],[0],[False],['0']
2958,PMC2924475,21156,We aimed to be able to detect an effect that would result in a post-transition relapse rate of 45% in the discontinuation group and 25% in the maintenance group (a hazard ratio of 0.48).,Methods|Statistical analysis,[127683],[14609],[14795],[False],[0],[0],[False],['0']
2959,PMC2924475,21157,"To detect this effect with a type I error of 0.05 (two tailed), and a power of 0.8, we needed a total of at least 58 post-transition relapses.40 We therefore planned to recruit patients until at least 58 post-transition relapses took place.",Methods|Statistical analysis,[127690],[14796],[15036],[False],[0],[0],[False],['0']
2960,PMC2924475,21158,"We stopped recruitment when 60 post-transition relapses had occurred in the study, after 178 patients had been randomised.",Methods|Statistical analysis,[127697],[15037],[15159],[False],[0],[0],[False],['0']
2961,PMC2924475,21159,"Subsequent to our data collection, a randomised open label study of discontinuation versus maintenance treatment reported relapse rates of 43% and 21%, giving a hazard ratio of 0.42.20 Our study would have a power of 0.9 in detecting a similar effect.",Methods|Statistical analysis,[127704],[15160],[15411],[False],[0],[0],[False],['0']
2962,PMC2924475,21160,We used SPSS software (version 16.0) for the statistical analysis.,Methods|Statistical analysis,[127711],[15412],[15478],[False],[0],[0],[False],['0']
2963,PMC2924475,21161,All tests were two tailed with a significance level of P<0.05.,Methods|Statistical analysis,[127718],[15479],[15541],[False],[0],[0],[False],['0']
2964,PMC2924475,21162,We included all completers (either reaching the end of the study or relapsing) and all discontinued participants.,Methods|Statistical analysis,[127725],[15542],[15655],[False],[0],[0],[False],['0']
2965,PMC2924475,21163,The primary outcome measure was reappearance of definite psychotic symptoms.,Methods|Statistical analysis,[127732],[15656],[15732],[False],[0],[0],[False],['0']
2966,PMC2924475,21164,"The positive and negative syndrome scale scores of two patients were missing at the point of relapse (as they were admitted to hospital before the research team was notified), but in both cases clinical information indicated that they were experiencing considerable hallucinations and delusions.",Methods|Statistical analysis,[127739],[15733],[16028],[False],[0],[0],[False],['0']
2967,PMC2924475,21165,We assigned both cases as relapses and treated them as such in the survival analysis.,Methods|Statistical analysis,[127746],[16029],[16114],[False],[0],[0],[False],['0']
2968,PMC2924475,21166,We calculated the relapse-free survival time from randomisation to the last visit or relapse.,Methods|Statistical analysis,[127753],[16115],[16208],[False],[0],[0],[False],['0']
2969,PMC2924475,21167,Patients who discontinued from the study (mostly because of adverse events) continued to be managed by their usual clinical teams.,Methods|Statistical analysis,[127760],[16209],[16339],[False],[0],[0],[False],['0']
2970,PMC2924475,21168,Their team physicians decided whether to continue further maintenance treatment while remaining blinded to the patients’ study treatments (active or placebo).,Methods|Statistical analysis,[127767],[16340],[16498],[False],[0],[0],[False],['0']
2971,PMC2924475,21169,"As this trial specific scenario would not occur in routine clinical practice, we censored data from patients who discontinued at the time of discontinuation in the primary survival analysis.",Methods|Statistical analysis,[127774],[16499],[16689],[False],[0],[0],[False],['0']
2972,PMC2924475,21170,This approach is acceptable for an explanatory efficacy study to provide the most meaningful estimate of the effect of maintenance treatment with the study drug.41 We used the Kaplan-Meier method to construct survival curves and the log-rank test to compare them.,Methods|Statistical analysis,[127781],[16690],[16953],[False],[0],[0],[False],['0']
2973,PMC2924475,21171,"We planned a post-transition subgroup analysis excluding early relapses (occurring within 60 days of randomisation, and thus possibly related to switching medication).",Methods|Statistical analysis,[127788],[16954],[17121],[False],[0],[0],[False],['0']
2974,PMC2924475,21172,"Two post hoc sensitivity analyses assessed the impact of more stringent criteria for relapse: two or more psychotic symptoms above threshold, and any psychotic symptom with a score of 5 (moderately severe) or above.",Methods|Statistical analysis,[127795],[17122],[17337],[False],[0],[0],[False],['0']
2975,PMC2924475,21173,We censored patients with less severe psychotic symptoms.,Methods|Statistical analysis,[127802],[17338],[17395],[False],[0],[0],[False],['0']
2976,PMC2924475,21174,A secondary post hoc analysis evaluated the rates of hospital admission for all causes in the two treatment groups (Fisher’s exact test for small number of counts).,Methods|Statistical analysis,[127809],[17396],[17560],[False],[0],[0],[False],['0']
2977,PMC2924475,21175,Two further post hoc sensitivity analyses evaluated the effects of including estimates for post-discontinuation data.,Methods|Statistical analysis,[127816],[17561],[17678],[False],[0],[0],[False],['0']
2978,PMC2924475,21176,"In the first analysis, we estimated the worst case scenario by treating all discontinuations as relapses.42 In the second analysis, we made a clinically pragmatic estimate by using data from case notes about relapses for the period after discontinuation from the study.",Methods|Statistical analysis,[127823],[17679],[17948],[False],[0],[0],[False],['0']
2979,PMC2924475,21177,"In addition, we categorised patients into four groups on the basis of changes in their occupational functioning: from employed to unemployed, from unemployed to employed, employed with no change, and unemployed with no change.",Methods|Statistical analysis,[127830],[17949],[18175],[False],[0],[0],[False],['0']
2980,PMC2924475,21178,We used χ2 tests to compare the proportion of participants with these changes between the two treatment groups.,Methods|Statistical analysis,[127837],[18176],[18287],[False],[0],[0],[False],['0']
2981,PMC2924475,21179,We compared discontinuations due to all causes and those due to adverse events and serious adverse events by using relative risk and χ2 tests.,Methods|Statistical analysis,[127844],[18288],[18430],[False],[0],[0],[False],['0']
2982,PMC2924475,21180,We compared side effects at baseline and at follow-up by using χ2 tests or Fisher’s exact test if the number of side effects in a group was less than five.,Methods|Statistical analysis,[127851],[18431],[18586],[False],[0],[0],[False],['0']
2983,PMC2924475,21181,We compared body weight and body mass index between the maintenance and placebo groups by using t tests both at baseline and at the end of the study.,Methods|Statistical analysis,[127858],[18587],[18736],[False],[0],[0],[False],['0']
2984,PMC2924475,21182,We used χ2 tests to compare the proportions of participants with body mass index of 23 or above and with weight gain of 7% or more between the two groups.,Methods|Statistical analysis,[127865],[18737],[18891],[False],[0],[0],[False],['0']
2985,PMC2924475,21183,"Lastly, we further compared changes in weight or body mass index between the two groups by linear regression analysis, with the change as the dependent variable, the treatment group denoted by an indicator, and adjustment by weight or body mass index at baseline by group and previous drug type (typical or atypical).",Methods|Statistical analysis,[127872],[18892],[19209],[False],[0],[0],[False],['0']
2986,PMC2924475,21184,We validated the fitted models by diagnostic residual plots.,Methods|Statistical analysis,[127879],[19210],[19270],[False],[0],[0],[False],['0']
2987,PMC2924475,21185,We used univariate Cox proportional hazards models to analyse the potential predictors of relapse.,Methods|Statistical analysis,[127886],[19271],[19369],[False],[0],[0],[False],['0']
2988,PMC2924475,21186,We included variables with P≤0.1 in a multivariate Cox regression analysis with forward selection.,Methods|Statistical analysis,[127893],[19370],[19468],[False],[0],[0],[False],['0']
2989,PMC2924475,21187,"We assessed the proportional hazard assumption by the method described in Lin et al,43 using SAS 9.1.3.",Methods|Statistical analysis,[127900],[19469],[19572],[False],[0],[0],[False],['0']
2990,PMC2924475,21188,"We checked associations between the predictors by using Pearson correlation (continuous variables), χ2 test (categorical variables), or Wilcoxon rank sum test (continuous and categorical variables).",Methods|Statistical analysis,[127907],[19573],[19771],[False],[0],[0],[False],['0']
2991,PMC2924475,21189,We re-fitted the selected Cox model to all patients with non-missing predictors to obtain more precise estimates.,Methods|Statistical analysis,[127914],[19772],[19885],[False],[0],[0],[False],['0']
2992,PMC2924475,21190,We calculated relative risk as the ratio between the outcome (relapse) rate in the population exposed to the risk factor (placebo) divided by the outcome rate in the population not exposed to the risk factor (maintenance quetiapine).,Methods|Statistical analysis,[127921],[19886],[20119],[False],[0],[0],[False],['0']
2993,PMC2924475,21191,Results,Results,[127928],[20120],[20128],[False],[0],[0],[False],['0']
2994,PMC2924475,21192,Study population,Results|Study population,[127935],[20129],[20145],[False],[0],[0],[False],['0']
2995,PMC2924475,21193,"Between September 2003 and July 2006, we assessed consecutive patients already enrolled in the early psychosis programme for eligibility to participate in the relapse prevention study.",Results|Study population,[127942],[20146],[20330],[False],[0],[0],[False],['0']
2996,PMC2924475,21194,We screened 1606 patients for eligibility (fig 1).,Results|Study population,[127949],[20331],[20381],[False],[0],[0],[False],['0']
2997,PMC2924475,21195,Schizophrenia was the most common diagnosis in enrolled patients (table 4).,Results|Study population,[127956],[20382],[20457],[False],[0],[0],[False],['0']
2998,PMC2924475,21196,"Before randomisation, patients had received antipsychotic drugs for a median of 21 months (618 (interquartile range 472-784) days) (table 2).",Results|Study population,[127963],[20458],[20599],[False],[0],[0],[False],['0']
2999,PMC2924475,21197,"The total symptom severity scores were low, and the median global severity of illness rating was 1, or “not mentally ill.” The level of functioning as assessed by the rating scales and proportion employed was moderately high.",Results|Study population,[127970],[20600],[20825],[False],[0],[0],[False],['0']
3000,PMC2924475,21198,Baseline variables in the group randomised to quetiapine did not differ from those randomised to placebo (all P>0.05).,Results|Study population,[127977],[20826],[20944],[False],[0],[0],[False],['0']
3001,PMC2924475,21199,"Including patients who completed the study, relapsed, or were withdrawn, the median duration of follow-up was 145 (41-351) days for the quetiapine group and 106 (57-243) days for the placebo group.",Results|Study population,[127984],[20945],[21142],[False],[0],[0],[False],['0']
3002,PMC2924475,21200,Primary outcome: relapse,Results|Study population,[127991],[21143],[21167],[False],[0],[0],[False],['0']
3003,PMC2924475,21201,"Twenty-seven of 89 patients relapsed in the quetiapine group, and 56 of 89 patients relapsed in the placebo group.",Results|Study population,[127998],[21168],[21282],[False],[0],[0],[False],['0']
3004,PMC2924475,21202,"The Kaplan-Meier estimate of the proportion relapsed at 12 months was 41% (95% confidence interval 29% to 53%) in the quetiapine group and 79% (68% to 90%) in the placebo group (χ2=15.65, df=1; P<0.001 by log-rank) (fig 2).",Results|Study population,[128005],[21283],[21506],[False],[0],[0],[False],['0']
3005,PMC2924475,21203,"In the post-transition subgroup analysis excluding the 23 patients who relapsed within 60 days, fewer patients in the quetiapine group relapsed (22% (17/79); 12 month Kaplan-Meier estimate 32%, 19% to 45%) than in the placebo group (57% (43/76); 75%, 62% to 89%) (χ2=19.17, df=1; P<0.001 by log-rank).",Results|Study population,[128012],[21507],[21808],[False],[0],[0],[False],['0']
3006,PMC2924475,21204,"In relapses, specific symptoms that scored at or above the threshold included delusions (72%; 58/81), hallucinations (54%; 44/81), suspiciousness (38%; 31/81), conceptual disorganisation (30%; 24/81), and unusual thought content (23%; 19/81); 68% (55/81) of patients had two or more types of psychotic symptom.",Results|Study population,[128019],[21809],[22119],[False],[0],[0],[False],['0']
3007,PMC2924475,21205,The most common co-occurring psychotic symptoms were delusions and hallucinations (37%; 30/81) and delusions and suspiciousness (31%; 25/81).,Results|Study population,[128026],[22120],[22261],[False],[0],[0],[False],['0']
3008,PMC2924475,21206,"The magnitude of the highest score of the five key symptoms defining relapse did not differ between relapsing patients in the two treatment groups (mean (SD) 4.30 (0.91) in quetiapine group (n=27) v 4.50 (0.82) in placebo group (n=54); t=−1.02, df=79; P=0.31).",Results|Study population,[128033],[22262],[22522],[False],[0],[0],[False],['0']
3009,PMC2924475,21207,"Nor did we find a difference in the magnitude of the change in score from baseline for these symptoms (mean (SD) 3.22 (1.01) in quetiapine group v 3.46 (0.82) in placebo group; t=−1.15, df=79; P=0.25).",Results|Study population,[128040],[22523],[22724],[False],[0],[0],[False],['0']
3010,PMC2924475,21208,"We found no significant correlation between severity of symptoms at relapse and the time to receiving treatment (r=−0.37, P=0.06 for quetiapine group; r=0.07, P=0.61 for placebo group).",Results|Study population,[128047],[22725],[22910],[False],[0],[0],[False],['0']
3011,PMC2924475,21209,"We did two sensitivity analyses defining relapse with more stringent criteria: two or more psychotic symptoms above the threshold, and requiring a score of 5 (moderately severe) to define relapse.",Results|Study population,[128054],[22911],[23107],[False],[0],[0],[False],['0']
3012,PMC2924475,21210,We censored patients with less severe psychotic symptoms.,Results|Study population,[128061],[23108],[23165],[False],[0],[0],[False],['0']
3013,PMC2924475,21211,"When we used the first criterion, the quetiapine group showed a significantly lower relapse rate (30%, 95% confidence interval 18% to 42%) than did the placebo group (68%, 56% to 80%) (χ2=14.67, df=1; P<0.001 by log-rank).",Results|Study population,[128068],[23166],[23388],[False],[0],[0],[False],['0']
3014,PMC2924475,21212,"When we used the second criterion, the quetiapine group also showed a significantly lower relapse rate (27%, 15% to 39%) than did the placebo group (63%, 46% to 79%) (χ2=11.81, df=1; P=0.001 by log-rank).",Results|Study population,[128075],[23389],[23593],[False],[0],[0],[False],['0']
3015,PMC2924475,21213,"In the post hoc sensitivity analysis of the worst case scenario, we treated all discontinuations/dropouts as having relapsed at point of discontinuation.",Results|Study population,[128082],[23594],[23747],[False],[0],[0],[False],['0']
3016,PMC2924475,21214,"The Kaplan-Meier estimate of the proportion of relapse at 12 months was 62% (51% to 72%) in the quetiapine group and 85% (76% to 93%) in the placebo group (χ2=5.59, df=1; P=0.018 by log-rank).",Results|Study population,[128089],[23748],[23940],[False],[0],[0],[False],['0']
3017,PMC2924475,21215,We did another post hoc sensitivity analysis with information from case notes about relapses for the post-discontinuation period.,Results|Study population,[128096],[23941],[24070],[False],[0],[0],[False],['0']
3018,PMC2924475,21216,This provides a pragmatic estimate by including all clinically significant relapses in the post-discontinuation period.,Results|Study population,[128103],[24071],[24190],[False],[0],[0],[False],['0']
3019,PMC2924475,21217,"The Kaplan-Meier estimate of the proportion of relapse at 12 months was 41% (30% to 51%) in the quetiapine group and 69% (59% to 79%) in the placebo group (χ2=14.25, df=1; P<0.001 by log-rank).",Results|Study population,[128110],[24191],[24384],[False],[0],[0],[False],['0']
3020,PMC2924475,21218,Secondary outcome measures,Results|Secondary outcome measures,[128117],[24385],[24411],[False],[0],[0],[False],['0']
3021,PMC2924475,21219,"Readmission to hospital was more common in the placebo group (16% (14/89); 12 relapse, 2 serious adverse events) than in the quetiapine group (6% (5/89); 4 relapse, 1 serious adverse event) (Fisher’s exact test (two tailed) P<0.05).",Results|Secondary outcome measures,[128124],[24412],[24644],[False],[0],[0],[False],['0']
3022,PMC2924475,21220,The groups did not differ in baseline occupational status—open employment: quetiapine group 70% (62/89); placebo group 73% (65/89).,Results|Secondary outcome measures,[128131],[24645],[24776],[False],[0],[0],[False],['0']
3023,PMC2924475,21221,Some participants lost open employment status in the study period—quetiapine group 27% (17/62); placebo group 32% (21/65).,Results|Secondary outcome measures,[128138],[24777],[24899],[False],[0],[0],[False],['0']
3024,PMC2924475,21222,"Changes in occupational status (from employed to unemployed, from unemployed to employed, employed with no change, or unemployed with no change) during the study did not differ statistically between the two treatment groups (χ2=1.52, df=3; P=0.68).",Results|Secondary outcome measures,[128145],[24900],[25148],[False],[0],[0],[False],['0']
3025,PMC2924475,21223,Predictors of relapse,Results|Predictors of relapse,[128152],[25149],[25170],[False],[0],[0],[False],['0']
3026,PMC2924475,21224,We studied predetermined potential predictors of relapse initially with a univariate Cox regression model.,Results|Predictors of relapse,[128159],[25171],[25277],[False],[0],[0],[False],['0']
3027,PMC2924475,21225,We then entered variables with P values of 0.1 or below into a multivariate Cox regression.,Results|Predictors of relapse,[128166],[25278],[25369],[False],[0],[0],[False],['0']
3028,PMC2924475,21226,We found the assumption of proportionality to be valid.,Results|Predictors of relapse,[128173],[25370],[25425],[False],[0],[0],[False],['0']
3029,PMC2924475,21227,"Significant independent predictors of relapse were maintenance treatment, pre-morbid schizoid and schizotypal traits, functioning, and diagnosis of schizophrenia (table 3).",Results|Predictors of relapse,[128180],[25426],[25598],[False],[0],[0],[False],['0']
3030,PMC2924475,21228,"Side effects, adverse events, and discontinuations",Results|Predictors of relapse,[128187],[25599],[25649],[False],[0],[0],[False],['0']
3031,PMC2924475,21229,"Patients taking quetiapine reported more side effects (sleepiness or sedation, reduced salivation, and constipation) than did those taking placebo (table 5).",Results|Predictors of relapse,[128194],[25650],[25807],[False],[0],[0],[False],['0']
3032,PMC2924475,21230,Only 11% (20/178; 9 in quetiapine group and 11 in placebo group) of patients had a Simpson Angus scale score above zero at baseline.,Results|Predictors of relapse,[128201],[25808],[25940],[False],[0],[0],[False],['0']
3033,PMC2924475,21231,Those previously treated with typical antipsychotics had higher mean scores (P=0.02).,Results|Predictors of relapse,[128208],[25941],[26026],[False],[0],[0],[False],['0']
3034,PMC2924475,21232,Most (145/168; 76 in quetiapine group and 69 in placebo group) had no change in these scores during the study.,Results|Predictors of relapse,[128215],[26027],[26137],[False],[0],[0],[False],['0']
3035,PMC2924475,21233,"Five had a higher score (four in placebo group, one in quetiapine group), and 18 had lower scores (nine in each group).",Results|Predictors of relapse,[128222],[26138],[26257],[False],[0],[0],[False],['0']
3036,PMC2924475,21234,We found no difference in the change in scores between the two groups.,Results|Predictors of relapse,[128229],[26258],[26328],[False],[0],[0],[False],['0']
3037,PMC2924475,21235,"Only two participants had positive abnormal involuntary movement scale scores at baseline (one in quetiapine group, one in placebo group); both scores decreased during the study.",Results|Predictors of relapse,[128236],[26329],[26507],[False],[0],[0],[False],['0']
3038,PMC2924475,21236,Two other patients in the placebo group (one previously treated with a typical antipsychotic and one with an atypical antipsychotic) had an increase in this score during the study.,Results|Predictors of relapse,[128243],[26508],[26688],[False],[0],[0],[False],['0']
3039,PMC2924475,21237,"Four patients had positive scores for akathisia at baseline (all in placebo group), and six had positive scores at follow-up (four in quetiapine group, two in placebo group).",Results|Predictors of relapse,[128250],[26689],[26863],[False],[0],[0],[False],['0']
3040,PMC2924475,21238,"Six patients had an increased score (four in quetiapine group, two in placebo group), and four had a reduced score at follow-up (all in placebo group).",Results|Predictors of relapse,[128257],[26864],[27015],[False],[0],[0],[False],['0']
3041,PMC2924475,21239,Table 6 shows changes in body weight and body mass index; it also shows some summary statistics by subsets.,Results|Predictors of relapse,[128264],[27016],[27123],[False],[0],[0],[False],['0']
3042,PMC2924475,21240,"We found an overall trend for weight reduction, which was greater in the placebo group (mean (SD) −3.08 (8.22) kg) than in the quetiapine group (−0.75 (4.65) kg) (P=0.02).",Results|Predictors of relapse,[128271],[27124],[27295],[False],[0],[0],[False],['0']
3043,PMC2924475,21241,"Baseline weight had a significant effect on the change in weight for the placebo group; heavier patients at baseline had more weight reduction (unstandardised regression coefficient −0.19, 95% confidence interval −0.28 to −0.10; P<0.001).",Results|Predictors of relapse,[128278],[27296],[27534],[False],[0],[0],[False],['0']
3044,PMC2924475,21242,"The baseline effect was not significant for the quetiapine group (regression coefficient −0.08, −0.17 to 0.2; P=0.11).",Results|Predictors of relapse,[128285],[27535],[27653],[False],[0],[0],[False],['0']
3045,PMC2924475,21243,Previous drug type had a minor effect on weight change (typical antipsychotic 1.72 (−0.15 to 3.59) kg more than atypical antipsychotic; P=0.07).,Results|Predictors of relapse,[128292],[27654],[27798],[False],[0],[0],[False],['0']
3046,PMC2924475,21244,Weight change over time did not differ between the groups after adjustment for weight at baseline (placebo group 5.39 (−3.22 to 14.0) kg more than quetiapine group; P=0.22).,Results|Predictors of relapse,[128299],[27799],[27972],[False],[0],[0],[False],['0']
3047,PMC2924475,21245,"The body mass index at baseline had a significant effect on the change in body mass index for the placebo group (regression coefficient −0.25, −0.35 to −0.15; P<0.001) but not for the quetiapine group (regression coefficient −0.06, −0.16 to 0.40; P=0.26).",Results|Predictors of relapse,[128306],[27973],[28228],[False],[0],[0],[False],['0']
3048,PMC2924475,21246,"Previous drug type had no significant effect on body mass index (typical antipsychotic 0.57 (−0.12 to 1.26) kg more than atypical; P=0.11), but the mean change in body mass index differed somewhat between the groups (placebo group 3.74 (0.17 to 7.31) kg more than quetiapine group; P=0.04) after adjustment for body mass index at baseline.",Results|Predictors of relapse,[128313],[28229],[28568],[False],[0],[0],[False],['0']
3049,PMC2924475,21247,No diabetes or ketoacidosis emerged during the study period.,Results|Predictors of relapse,[128320],[28569],[28629],[False],[0],[0],[False],['0']
3050,PMC2924475,21248,Figure 1 gives reasons for discontinuation.,Results|Predictors of relapse,[128327],[28630],[28673],[False],[0],[0],[False],['0']
3051,PMC2924475,21249,"Adverse events that occurred in more than one case were fatigue, sedation, or tiredness (n=9; 7 in quetiapine group, 2 in placebo group), dizziness (n=7; all in quetiapine group), nausea (n=2; both in quetiapine group), limb weakness (n=2; both in quetiapine group), and insomnia (n=2; 1 in quetiapine group, 1 in placebo group).",Results|Predictors of relapse,[128334],[28674],[29003],[False],[0],[0],[False],['0']
3052,PMC2924475,21250,Three serious adverse events occurred.,Results|Predictors of relapse,[128341],[29004],[29042],[False],[0],[0],[False],['0']
3053,PMC2924475,21251,"One patient taking quetiapine was admitted to hospital after impulsive self-laceration following an argument with a partner, and one assigned to placebo was admitted after a non-fatal overdose of hypnotics during an adjustment reaction to financial difficulties.",Results|Predictors of relapse,[128348],[29043],[29305],[False],[0],[0],[False],['0']
3054,PMC2924475,21252,Both were discontinued.,Results|Predictors of relapse,[128355],[29306],[29329],[False],[0],[0],[False],['0']
3055,PMC2924475,21253,"A third patient in the placebo group had transient repetitive imagery for three days and was briefly admitted for observation, but continued.",Results|Predictors of relapse,[128362],[29330],[29471],[False],[0],[0],[False],['0']
3056,PMC2924475,21254,"The rate of discontinuation for both adverse events and serious adverse events was higher for the quetiapine group (18%; 16/89) than the placebo group (8%; 7/89) (relative risk 2.29, 95% confidence interval 0.99 to 5.28; χ2=3.20, df=1; P=0.07).",Results|Predictors of relapse,[128369],[29472],[29716],[False],[0],[0],[False],['0']
3057,PMC2924475,21255,"Other reasons for discontinuation included need for a mood stabiliser (n=3; 2 in quetiapine group, 1 in placebo group), inability to tolerate the transition protocol (n=7; 4 in quetiapine group, 3 in placebo group), and unwillingness to attend the study assessments (n=1; in placebo group).",Results|Predictors of relapse,[128376],[29717],[30007],[False],[0],[0],[False],['0']
3058,PMC2924475,21256,"Discontinuation for all causes did not differ significantly between the quetiapine group (31%; 28/89) and the placebo group (20%; 18/89) (relative risk 1.32, 0.98 to 1.77; χ2=2.38, df=1; P=0.12).",Results|Predictors of relapse,[128383],[30008],[30203],[False],[0],[0],[False],['0']
3059,PMC2924475,21257,Discussion,Discussion,[128390],[30204],[30215],[False],[0],[0],[False],['0']
3060,PMC2924475,21258,"In patients with first episode psychosis, antipsychotic treatment is often discontinued after one year of good response.",Discussion,[128397],[30216],[30336],[False],[0],[0],[False],['0']
3061,PMC2924475,21259,"We investigated patients selected from a representative, population based sample.",Discussion,[128404],[30337],[30418],[False],[0],[0],[False],['0']
3062,PMC2924475,21260,This group of patients represents those with the best chance of successful discontinuation of treatment.,Discussion,[128411],[30419],[30523],[False],[0],[0],[False],['0']
3063,PMC2924475,21261,We found a much higher rate of relapse in patients randomised to placebo (79%) than in those receiving active maintenance treatment (41%).,Discussion,[128418],[30524],[30662],[False],[0],[0],[False],['0']
3064,PMC2924475,21262,"A subgroup analysis excluding patients with early relapse (possibly related to transition to the study drug), sensitivity analyses, and comparison of rates of admission to hospital were all consistent with the primary outcome analysis.",Discussion,[128425],[30663],[30898],[False],[0],[0],[False],['0']
3065,PMC2924475,21263,Comparison with other studies,Discussion|Comparison with other studies,[128432],[30899],[30928],[False],[0],[0],[False],['0']
3066,PMC2924475,21264,"The rate of relapse in the placebo group in our study is higher than in some studies,10 12 but it is lower than in others.11 19 The relapse rate in the maintenance group is comparable to that in previous studies.10 12 Our definition of relapse signified the re-emergence of psychotic symptoms in patients who were not psychotic at baseline, consistent with the approach of Vaughn et al.29 This definition of relapse is relevant to real life decisions about treatment, as most clinicians would recommend resumption of antipsychotic treatment in this situation.",Discussion|Comparison with other studies,[128439],[30929],[31488],[False],[0],[0],[False],['0']
3067,PMC2924475,21265,"As in other studies with intensive follow-up and monitoring,19 20 relapses were detected relatively early, in most cases before pronounced deterioration and need for hospital admission.",Discussion|Comparison with other studies,[128446],[31489],[31674],[False],[0],[0],[False],['0']
3068,PMC2924475,21266,"The level of severity of symptoms that we used to define relapse is described in some other studies as an “exacerbation.”19 However, the relapses into psychosis in our study were not trivial and in most cases involved two or more types of psychotic symptoms.",Discussion|Comparison with other studies,[128453],[31675],[31933],[False],[0],[0],[False],['0']
3069,PMC2924475,21267,"Predictors of relapse included premorbid schizoid and schizotypal traits and low psychosocial functioning, as in earlier studies.10 11 Importantly, we found that relapse was related neither to the type (atypical or typical) nor to the duration of previous antipsychotic treatment.",Discussion|Comparison with other studies,[128460],[31934],[32214],[False],[0],[0],[False],['0']
3070,PMC2924475,21268,Limitations of study,Discussion|Limitations of study,[128467],[32215],[32235],[False],[0],[0],[False],['0']
3071,PMC2924475,21269,The study has several limitations.,Discussion|Limitations of study,[128474],[32236],[32270],[False],[0],[0],[False],['0']
3072,PMC2924475,21270,The choice of a design with a standardised drug treatment and a placebo control required switching of drugs.,Discussion|Limitations of study,[128481],[32271],[32379],[True],['NonstandardTreatmentCharacteristics'],['The choice of a design with a standardised drug treatment and a placebo control required switching of drugs'],[True],['Intervention']
3073,PMC2924475,21271,"This design, however, has the advantages of randomisation and a double blind placebo control.",Discussion|Limitations of study,[128495],[32380],[32473],[False],[0],[0],[False],['0']
3074,PMC2924475,21272,"Without a double blind control, the effects of patients’ and clinicians’ expectations cannot be assessed and the magnitude of the benefits of maintenance cannot be quantified.",Discussion|Limitations of study,[128502],[32474],[32649],[False],[0],[0],[False],['0']
3075,PMC2924475,21273,We evaluated the effects of switching by a subgroup analysis that excluded patients who relapsed within two months of the switch period.,Discussion|Limitations of study,[128509],[32650],[32786],[False],[0],[0],[False],['0']
3076,PMC2924475,21274,The 12 month Kaplan-Meier estimate of a 41% relapse rate in the primary analysis included patients who might have relapsed as a result of switching in itself.,Discussion|Limitations of study,[128516],[32787],[32945],[False],[0],[0],[False],['0']
3077,PMC2924475,21275,"The post-transition subgroup analysis, which excluded patients who relapsed early, resulted in a lower 32% relapse rate.",Discussion|Limitations of study,[128523],[32946],[33066],[False],[0],[0],[False],['0']
3078,PMC2924475,21276,"Although the study focused on the impact of antipsychotic maintenance on relapse, psychosocial factors such as expressed emotion also contribute to the risk of relapse.45 These factors must also be taken into consideration in clinical decision making for the individual patient.",Discussion|Limitations of study,[128530],[33067],[33346],[False],[0],[0],[False],['0']
3079,PMC2924475,21277,Use of illicit substances could also increase the risk of relapse.,Discussion|Limitations of study,[128537],[33347],[33413],[False],[0],[0],[False],['0']
3080,PMC2924475,21278,"However, as the overall prevalence of substance misuse is much lower in Hong Kong than in some other populations,46 we did not do regular laboratory monitoring of illicit substance use.",Discussion|Limitations of study,[128545],[33414],[33599],[True],['RelevantOutcomeExcluded'],['we did not do regular laboratory monitoring of illicit substance use'],[True],['OutcomeMeasures']
3081,PMC2924475,21279,"Finally, although quetiapine seems to be as effective as other antipsychotic drugs in the treatment of first episode psychosis,47 48 our design does not consider the question of the relative advantages or disadvantages of quetiapine compared with other antipsychotics as a maintenance treatment.",Discussion|Limitations of study,[128560],[33600],[33895],[True],['Intervention'],['our design does not consider the question of the relative advantages or disadvantages of quetiapine compared with other antipsychotics as a maintenance treatment'],[True],['Intervention']
3082,PMC2924475,21280,Other antipsychotics could have different efficacies.,Discussion|Limitations of study,[128572],[33896],[33949],[False],[0],[0],[False],['0']
3083,PMC2924475,21281,"Other atypical antipsychotics could be equally effective at a different cost, depending on regional pricing and availability of generic drugs.",Discussion|Limitations of study,[128582],[33950],[34092],[True],['Intervention'],['Other atypical antipsychotics could be equally effective at a different cost'],[True],['Intervention']
3084,PMC2924475,21282,"As a final consideration, this study specifically targeted a cohort of patients likely to have a better outcome, and for whom discontinuation of treatment was a realistic consideration.",Discussion|Limitations of study,[128597],[34093],[34278],[True],['VerySpecificPopulation'],['this study specifically targeted a cohort of patients likely to have a better outcome'],[True],['Population']
3085,PMC2924475,21283,"Although we did not recruit patients with residual psychotic symptoms, or those who already had at least one relapse, discontinuation in these patients would probably result in an even higher risk of relapse than found in this study.",Discussion|Limitations of study,[128612],[34279],[34512],[True],['VerySpecificPopulation'],"['we did not recruit patients with residual psychotic symptoms, or those who already had at least one relapse']",[True],['Population']
3086,PMC2924475,21284,The low rate of substance misuse and high rate of employment in this group also need to be taken into consideration before generalising the findings to other settings.,Discussion|Limitations of study,[128627],[34513],[34680],[True],['VerySpecificPopulation'],['The low rate of substance misuse and high rate of employment in this group'],[True],['Population']
3087,PMC2924475,21285,Conclusion and implications,Discussion|Conclusion and implications,[128635],[34681],[34708],[False],[0],[0],[False],['0']
3088,PMC2924475,21286,"In summary, even patients with good response in positive symptoms and good functioning after a first episode of psychosis have a high risk of relapse, but this can be reduced with maintenance drug treatment.",Discussion|Conclusion and implications,[128642],[34709],[34916],[False],[0],[0],[False],['0']
3089,PMC2924475,21287,"On the other hand, maintenance treatment with atypical antipsychotic drugs is still associated with appreciable side effects (table 5).",Discussion|Conclusion and implications,[128649],[34917],[35052],[False],[0],[0],[False],['0']
3090,PMC2924475,21288,This result highlights the challenges confronting clinicians and patients considering discontinuation of treatment after a single psychotic episode.,Discussion|Conclusion and implications,[128656],[35053],[35201],[False],[0],[0],[False],['0']
3091,PMC2924475,21289,"These data provide a strong case for continuation of maintenance treatment to beyond one year after a first episode of psychosis, but we also acknowledge that the clinical decision for maintenance treatment must be made in an individualised manner taking into consideration factors such as side effects and the availability of effective monitoring for relapse.",Discussion|Conclusion and implications,[128663],[35202],[35562],[False],[0],[0],[False],['0']
3092,PMC2924475,21290,"Currently identified predictors of relapse are still relatively non-specific, and further research is needed to inform decisions on maintenance or discontinuation for individual patients.",Discussion|Conclusion and implications,[128670],[35563],[35750],[False],[0],[0],[False],['0']
3093,PMC3002766,4593,"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial",Title,[25752],[37630],[144],[False],[0],[0],[False],['0']
3094,PMC3002766,4594,Objectives,Abstract,[25754],[145],[156],[False],[0],[0],[False],['0']
3095,PMC3002766,4595,Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity.,Abstract,[25756],[157],[286],[False],[0],[0],[False],['0']
3096,PMC3002766,4596,"In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%.",Abstract,[25758],[287],[414],[False],[0],[0],[False],['0']
3097,PMC3002766,4597,"The present study (RAPIDS-2, for ‘RAndomized, double-blind, Placebo-controlled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis’) was conducted to more fully evaluate the effects of bosentan treatment on DUs associated with SSc.",Abstract,[25760],[415],[703],[False],[0],[0],[False],['0']
3098,PMC3002766,4598,Methods,Abstract,[25762],[704],[711],[False],[0],[0],[False],['0']
3099,PMC3002766,4599,"This double-blind, placebo-controlled trial conducted at 41 centres in Europe and North America randomised 188 patients with SSc with at least 1 active DU (‘cardinal ulcer’) to bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98) or matching placebo (n=90; total 24 weeks).",Abstract,[25764],[712],[1027],[False],[0],[0],[False],['0']
3100,PMC3002766,4600,The two primary end points were the number of new DUs and the time to healing of the cardinal ulcer.,Abstract,[25766],[1028],[1128],[False],[0],[0],[False],['0']
3101,PMC3002766,4601,"Secondary end points included pain, disability and safety.",Abstract,[25768],[1129],[1187],[False],[0],[0],[False],['0']
3102,PMC3002766,4602,Results,Abstract,[25770],[1188],[1195],[False],[0],[0],[False],['0']
3103,PMC3002766,4603,"Over 24 weeks, bosentan treatment was associated with a 30% reduction in the number of new DUs compared with placebo (mean±standard error: 1.9±0.2 vs 2.7±0.3 new ulcers; p=0.04).",Abstract,[25772],[1196],[1374],[False],[0],[0],[False],['0']
3104,PMC3002766,4604,This effect was greater in patients who entered the trial with more DUs.,Abstract,[25774],[1375],[1447],[False],[0],[0],[False],['0']
3105,PMC3002766,4605,There was no difference between treatments in healing rate of the cardinal ulcer or secondary end points of pain and disability.,Abstract,[25776],[1448],[1576],[False],[0],[0],[False],['0']
3106,PMC3002766,4606,Peripheral oedema and elevated aminotransferases were associated with bosentan treatment.,Abstract,[25778],[1577],[1666],[False],[0],[0],[False],['0']
3107,PMC3002766,4607,Conclusions,Abstract,[25780],[1667],[1678],[False],[0],[0],[False],['0']
3108,PMC3002766,4608,Bosentan treatment reduced the occurrence of new DUs in patients with SSc but had no effect on DU healing.,Abstract,[25782],[1679],[1785],[False],[0],[0],[False],['0']
3109,PMC3002766,4609,Bosentan was well tolerated and may be a useful adjunct in the management of patients with SSc with recurrent DUs.,Abstract,[25784],[1786],[1900],[False],[0],[0],[False],['0']
3110,PMC3002766,4610,Introduction,Introduction,[25786],[1901],[1914],[False],[0],[0],[False],['0']
3111,PMC3002766,4611,"Intimal hyperplasia, endothelial dysfunction and occlusive vasculopathy are ubiquitous features of systemic sclerosis (SSc).",Introduction,[25788],[1915],[2039],[False],[0],[0],[False],['0']
3112,PMC3002766,4612,"These vascular lesions are the underlying basis of important clinical syndromes in SSc, including scleroderma renal crisis, pulmonary arterial hypertension (PAH) and Raynaud's phenomenon.",Introduction,[25790],[2040],[2227],[False],[0],[0],[False],['0']
3113,PMC3002766,4613,"Patients with SSc are at high risk for the development of ischaemic digital ulcers (DUs), which occur in 35% to 60% of patients with SSc and are an important source of morbidity.",Introduction,[25792],[2228],[2406],[False],[0],[0],[False],['0']
3114,PMC3002766,4614,"Among a cohort of 2080 patients with SSc identified between 1972 and 1995 and prospectively followed-up for a mean of 10 years, 58% of patients had a history of DUs.",Introduction,[25794],[2407],[2572],[False],[0],[0],[False],['0']
3115,PMC3002766,4615,"Of all patients with SSc, 32% (666 patients) had persistent or recurrent DUs for ≥6 months; of these, 30% (197 patients) had severe DUs (complicated by gangrene, or requiring digital sympathectomy or amputation).",Introduction,[25796],[2573],[2785],[False],[0],[0],[False],['0']
3116,PMC3002766,4616,"In one series, the incidence of finger amputation as a consequence of DUs was 1.2% per patient-year.",Introduction,[25798],[2786],[2886],[False],[0],[0],[False],['0']
3117,PMC3002766,4617,"The pathogenesis of DUs is thought to include many of the hallmark processes of critical tissue ischaemia, such as impaired afferent vasomotion, microvascular disruption, reduced venous drainage, increased local platelet activation and increased leucocyte adherence.",Introduction,[25800],[2887],[3153],[False],[0],[0],[False],['0']
3118,PMC3002766,4618,"As a result, no single pharmacological treatment is entirely effective.",Introduction,[25802],[3154],[3225],[False],[0],[0],[False],['0']
3119,PMC3002766,4619,"Nifedipine and intravenous iloprost reduced the frequency and severity of SSc-related Raynaud's phenomenon attacks, and iloprost was shown to improve DU healing in another trial that included patients with active DUs.",Introduction,[25804],[3226],[3443],[False],[0],[0],[False],['0']
3120,PMC3002766,4620,Few studies have been specifically designed to examine efficacy in the prevention or treatment of DUs.,Introduction,[25806],[3444],[3546],[False],[0],[0],[False],['0']
3121,PMC3002766,4621,Nifedipine and intravenous iloprost resulted in the reduction from baseline in the mean number of DUs in a small study.,Introduction,[25808],[3547],[3666],[False],[0],[0],[False],['0']
3122,PMC3002766,4622,"Similarly, a trial in patients with severe PAH associated with SSc indicated there may be a beneficial effect of epoprostenol on the number of DUs.",Introduction,[25810],[3667],[3814],[False],[0],[0],[False],['0']
3123,PMC3002766,4623,"In a recent small placebo-controlled study, atorvastatin reduced the number of new DUs in association with improvement in markers of endothelial function.",Introduction,[25812],[3815],[3969],[False],[0],[0],[False],['0']
3124,PMC3002766,4624,Indirect evidence implicates endothelin (ET) as a potential mediator of the vascular dysfunction in SSc.,Introduction,[25814],[3970],[4074],[False],[0],[0],[False],['0']
3125,PMC3002766,4625,"Plasma ET concentrations are increased in patients with SSc, and there is evidence for increased ETB receptor expression in lung, skin and blood vessels in this disease.",Introduction,[25816],[4075],[4244],[False],[0],[0],[False],['0']
3126,PMC3002766,4626,Other actions of ET relevant to SSc include proinflammatory and proliferative effects as well as mediation of vasoconstriction.,Introduction,[25818],[4245],[4372],[False],[0],[0],[False],['0']
3127,PMC3002766,4627,ET receptor antagonists including bosentan are now commonly used for the treatment of PAH in SSc.,Introduction,[25820],[4373],[4470],[False],[0],[0],[False],['0']
3128,PMC3002766,4628,"A previous double-blind, randomised, placebo-controlled trial investigated the role of bosentan in the reduction of new DUs in 122 patients with SSc and a history of DUs within the previous year.",Introduction,[25822],[4471],[4666],[False],[0],[0],[False],['0']
3129,PMC3002766,4629,"After 16 weeks of treatment, patients receiving bosentan had a 48% reduction in the mean number of new DUs compared with placebo (1.4 vs 2.7 new ulcers; p=0.01), but there were no differences between treatments in end points assessing DU healing in the 63% of patients with active DUs at baseline.",Introduction,[25824],[4667],[4964],[False],[0],[0],[False],['0']
3130,PMC3002766,4630,"The present study (RAPIDS-2, for ‘RAndomized, double-blind, Placebo-controlled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis’) was designed to further investigate the effects of bosentan as a treatment for DUs secondary to SSc over a 24-week treatment period in a larger population of patients, all of whom had active DUs at study entry.",Introduction,[25826],[4965],[5365],[False],[0],[0],[False],['0']
3131,PMC3002766,4631,The primary objectives were to evaluate the effect of bosentan on the reduction of new DUs and healing of DUs in patients with SSc.,Introduction,[25828],[5366],[5497],[False],[0],[0],[False],['0']
3132,PMC3002766,4632,"Secondary objectives were to evaluate the effect of bosentan on pain and disability, as well as its tolerability and safety in these patients.",Introduction,[25830],[5498],[5640],[False],[0],[0],[False],['0']
3133,PMC3002766,4633,Patients and methods,Patients and methods,[25832],[5641],[5662],[False],[0],[0],[False],['0']
3134,PMC3002766,4634,Study design,Patients and methods|Study design,[25834],[5663],[5675],[False],[0],[0],[False],['0']
3135,PMC3002766,4635,"This double-blind, randomised, parallel-group, placebo-controlled study consisted of a ≤2-week screening period, a 24-week treatment period and an 8-week post-treatment follow-up period.",Patients and methods|Study design,[25836],[5676],[5862],[False],[0],[0],[False],['0']
3136,PMC3002766,4636,The study was approved by local ethics committees and conducted in accordance with the amended Declaration of Helsinki.,Patients and methods|Study design,[25838],[5863],[5982],[False],[0],[0],[False],['0']
3137,PMC3002766,4637,All patients gave written informed consent.,Patients and methods|Study design,[25840],[5983],[6026],[False],[0],[0],[False],['0']
3138,PMC3002766,4638,Settings and participants,Patients and methods|Settings and participants,[25842],[6027],[6052],[False],[0],[0],[False],['0']
3139,PMC3002766,4639,The study was conducted from October 2003 to May 2005 at 41 centres in Europe and North America.,Patients and methods|Settings and participants,[25844],[6053],[6149],[False],[0],[0],[False],['0']
3140,PMC3002766,4640,"Recruited patients were ≥18 years old, with SSc as defined by the preliminary classification criteria of the American College of Rheumatology (ACR) and at least one active DU (onset between 1 week and 3 months prior to randomisation) that was selected by the investigator and termed the ‘cardinal ulcer’ (painful area, ≥2 mm in diameter with visible depth and loss of dermis, amenable to healing and in a location judged compatible with a vascular aetiology, specified by protocol as volar surface of the digit distal to the proximal interphalangeal digital crease).",Patients and methods|Settings and participants,[25846],[6150],[6716],[False],[0],[0],[False],['0']
3141,PMC3002766,4641,"Patients were excluded if they had received intravenous prostanoids within the previous 3 months, had used phosphodiesterase inhibitors other than for intermittent treatment of male erectile dysfunction, or had received inhaled or oral prostanoids or injected botulinum toxin in an affected finger within 1 month.",Patients and methods|Settings and participants,[25848],[6717],[7030],[False],[0],[0],[False],['0']
3142,PMC3002766,4642,Patients were also excluded if they received systemic antibiotics to treat infected DUs within 2 weeks prior to randomisation.,Patients and methods|Settings and participants,[25850],[7031],[7157],[False],[0],[0],[False],['0']
3143,PMC3002766,4643,"Also excluded were patients with body weight <40 kg, severe PAH (WHO class III/IV), moderate to severe hepatic impairment or serum aminotransferase levels >3 times the upper limit of the normal range (ULN).",Patients and methods|Settings and participants,[25852],[7158],[7364],[False],[0],[0],[False],['0']
3144,PMC3002766,4644,Contraceptive measures and monthly pregnancy testing were required during and for 3 months after the end of study treatment.,Patients and methods|Settings and participants,[25854],[7365],[7489],[False],[0],[0],[False],['0']
3145,PMC3002766,4645,Randomisation and interventions,Patients and methods|Randomisation and interventions,[25856],[7490],[7521],[False],[0],[0],[False],['0']
3146,PMC3002766,4646,"After screening, patients were randomised to bosentan or placebo (1:1 ratio) by sequential allocation of randomisation numbers distributed to each centre in blocks of four.",Patients and methods|Randomisation and interventions,[25858],[7522],[7694],[False],[0],[0],[False],['0']
3147,PMC3002766,4647,Patients received bosentan 62.5 mg twice daily for 4 weeks and then 125 mg twice daily for the remainder of the treatment period or matching placebo.,Patients and methods|Randomisation and interventions,[25860],[7695],[7844],[False],[0],[0],[False],['0']
3148,PMC3002766,4648,"The dose could remain at or be decreased to the starting dose due to intolerance, with possible subsequent increase to the target dose.",Patients and methods|Randomisation and interventions,[25862],[7845],[7980],[False],[0],[0],[False],['0']
3149,PMC3002766,4649,"Concomitant use of systemic antibiotics, analgaesics and topical treatments for wound care were allowed, and randomised treatment was administered in addition to the usual, stable (over the previous month) treatment for Raynaud's phenomenon.",Patients and methods|Randomisation and interventions,[25864],[7981],[8222],[False],[0],[0],[False],['0']
3150,PMC3002766,4650,"Patients who required parenteral, oral or inhaled prostanoid treatment during the study were first discontinued from study treatment.",Patients and methods|Randomisation and interventions,[25866],[8223],[8356],[False],[0],[0],[False],['0']
3151,PMC3002766,4651,"Use of glibenclamide, fluconazole, calcineurin inhibitors or ciclosporin A was not allowed due to potential drug interactions.",Patients and methods|Randomisation and interventions,[25868],[8357],[8483],[False],[0],[0],[False],['0']
3152,PMC3002766,4652,Outcomes,Patients and methods|Outcomes,[25870],[8484],[8492],[False],[0],[0],[False],['0']
3153,PMC3002766,4653,The two primary end points were (1) the mean number of new DUs per patient assessed by the investigator up to week 24 and (2) the time to healing of the cardinal ulcer up to week 24 in patients with cardinal ulcer healing maintained for 12 or more weeks.,Patients and methods|Outcomes,[25872],[8493],[8747],[False],[0],[0],[False],['0']
3154,PMC3002766,4654,"Healing was defined as complete epithelialisation, regardless of residual pain.",Patients and methods|Outcomes,[25874],[8748],[8827],[False],[0],[0],[False],['0']
3155,PMC3002766,4655,Maintenance of cardinal ulcer healing required no recurrence at or contiguous to the original location at week 24 (if healing occurred before or at week 12) or during 12 weeks of observation with permissible extension of the treatment period (if healing occurred after week 12).,Patients and methods|Outcomes,[25876],[8828],[9106],[False],[0],[0],[False],['0']
3156,PMC3002766,4656,"To verify that the effect of treatment would not vary substantially across relevant baseline subgroups, the number of new DUs up to week 24 was additionally analysed in subgroups based on predefined baseline factors associated with disease severity.",Patients and methods|Outcomes,[25878],[9107],[9356],[False],[0],[0],[False],['0']
3157,PMC3002766,4657,"Secondary and exploratory end points included: (1) reduction of new DUs and overall DU number (proportions of patients with no new DUs and with each number of new DUs up to week 24, time to onset of each number of new DUs up to week 24 and change from baseline to week 24 in total number of all DUs), (2) healing (time to healing of all baseline DUs and of all new DUs through week 24, and proportions of patients with healing of all DUs by the end of week 24) and (3) pain and disability parameters (changes from baseline to week 24: in pain of the cardinal ulcer and overall hand pain assessed on visual analogue scales; hand disability index (an averaged score from the three Health Assessment Questionnaire (HAQ) domains of dressing/grooming, grip and hygiene); and HAQ disability index).",Patients and methods|Outcomes,[25880],[9357],[10149],[False],[0],[0],[False],['0']
3158,PMC3002766,4658,"Post hoc analyses included: (1) the number of new DUs up to week 12 in the overall patient population and in subgroups defined by randomisation month (October–February or autumn–winter and March–September or spring–summer) and (2) number of new DUs, time to each successive new DU and total number of DUs through week 24 in subgroups defined by the number of DUs at baseline (<4 and ≥4).",Patients and methods|Outcomes,[25882],[10150],[10537],[False],[0],[0],[False],['0']
3159,PMC3002766,4659,"Patients were evaluated at randomisation/baseline and every 4 weeks during treatment (or premature withdrawal, week 24 and, if applicable, 12 weeks after healing of the cardinal ulcer), with DUs assessed at each study visit.",Patients and methods|Outcomes,[25884],[10538],[10762],[False],[0],[0],[False],['0']
3160,PMC3002766,4660,Safety was continually monitored.,Patients and methods|Outcomes,[25886],[10763],[10796],[False],[0],[0],[False],['0']
3161,PMC3002766,4661,Statistical methods,Patients and methods|Statistical methods,[25888],[10797],[10816],[False],[0],[0],[False],['0']
3162,PMC3002766,4662,"Efficacy analyses were performed on all treated patients using SAS software (SAS Institute, Cary, North Carolina, USA).",Patients and methods|Statistical methods,[25890],[10817],[10936],[False],[0],[0],[False],['0']
3163,PMC3002766,4663,Means±SEs are presented for numerical variables and Kaplan–Meier estimates for time-to-event variables.,Patients and methods|Statistical methods,[25892],[10937],[11040],[False],[0],[0],[False],['0']
3164,PMC3002766,4664,Treatment effects for the primary end points were evaluated using the Pitman permutation (new DUs) and log-rank test with asymptotic approximation (time to healing of the cardinal ulcer).,Patients and methods|Statistical methods,[25894],[11041],[11228],[False],[0],[0],[False],['0']
3165,PMC3002766,4665,"Missing data on new DUs were imputed using extrapolation, with the incidence rate of new DUs at the last assessment corrected for the missing time period.",Patients and methods|Statistical methods,[25896],[11229],[11383],[False],[0],[0],[False],['0']
3166,PMC3002766,4666,The worst of either the calculated number or observed values at week 24 was used for patients who prematurely discontinued study treatment.,Patients and methods|Statistical methods,[25898],[11384],[11523],[False],[0],[0],[False],['0']
3167,PMC3002766,4667,"Patients with no valid assessment post baseline (three patients on bosentan, one on placebo) were excluded from the main analysis.",Patients and methods|Statistical methods,[25900],[11524],[11654],[False],[0],[0],[False],['0']
3168,PMC3002766,4668,Treatment effects for new DUs in predefined subgroups were presented as point estimates and 95% two-sided CIs.,Patients and methods|Statistical methods,[25902],[11655],[11765],[False],[0],[0],[False],['0']
3169,PMC3002766,4669,"For exploratory purposes, statistical tests of treatment difference were provided for planned secondary/exploratory and unplanned post hoc efficacy analyses and included the Pitman permutation (for changes from baseline), the Fisher exact test (for proportions) and the log-rank test (for times to event), each performed without correction for multiple testing.",Patients and methods|Statistical methods,[25904],[11766],[12127],[False],[0],[0],[False],['0']
3170,PMC3002766,4670,"Placebo-corrected changes from baseline, RR and HRs from Cox modelling were each reported with 95% CIs where appropriate.",Patients and methods|Statistical methods,[25906],[12128],[12249],[False],[0],[0],[False],['0']
3171,PMC3002766,4671,"Safety and baseline data were summarised descriptively, with no statistical testing planned or given.",Patients and methods|Statistical methods,[25908],[12250],[12351],[False],[0],[0],[False],['0']
3172,PMC3002766,4672,Results,Results,[25910],[12352],[12360],[False],[0],[0],[False],['0']
3173,PMC3002766,4673,"The two treatment groups were well matched with respect to demographic features, baseline disease characteristics and concomitant treatment for DUs at baseline (table 1).",Results,[25912],[12361],[12531],[False],[0],[0],[False],['0']
3174,PMC3002766,4674,"All 188 randomised patients received study treatment, with mean exposures of 22.7±0.9 and 24.5±0.9 weeks in the bosentan and placebo groups, respectively.",Results,[25914],[12532],[12686],[False],[0],[0],[False],['0']
3175,PMC3002766,4675,"The treatment period was completed by 75/98 (76.5%) and 73/90 (81.1%) patients, respectively (figure 1), with 9.2% and 7.8%, respectively, discontinued due to an adverse event.",Results,[25916],[12687],[12863],[False],[0],[0],[False],['0']
3176,PMC3002766,4676,Study flow diagram.,Results|Study flow diagram.,[25918],[12864],[12883],[False],[0],[0],[False],['0']
3177,PMC3002766,4677,Demographics and baseline characteristics of the study population,Results|Demographics and baseline characteristics of the study population,[25920],[12884],[12949],[False],[0],[0],[False],['0']
3178,PMC3002766,4678,"Characteristic	Placebo (n=90)	Bosentan (n=98)	 	Men/women, % of patients	20/80	22/78	 	Age in years, mean (SD)	50.7 (12.0)	48.4 (12.9)	 	Weight in kg, mean (SD)	66.5 (15.8)	64.7 (13.6)	 	Caucasian/black/other,* % of patients	83/6/11	87/7/6	 	Smoking status,† % of patients	 	 Never/previous/current	56/23/22	64/23/13	 	SSc characteristics	 	 Limited/diffuse,‡ % of patients	58/42	60/40	 	 Time from diagnosis of scleroderma to randomisation in years, mean (SD)	8.7 (7.7)	8.7 (8.4)	 	DU characteristics	 	 Number at baseline, mean (SD)	3.6 (3.3)	3.7 (4.4)	 	 Time from first occurrence of DUs to randomisation in years,† mean (SD)	6.4 (7.1)	7.4 (8.7)	 	Selected concomitant medication at baseline, % of patients	 	 Calcium channel blockers	56	50	 	 Anti-inflammatory and antirheumatic products	37	40	 	 ACE inhibitors	14	16	 	 Peripheral vasodilators§	10	13	 	 Angiotensin II receptor blockers	9	8	 	 Phosphodiesterase inhibitor (sildenafil)	3	3",Results|Demographics and baseline characteristics of the study population,[25922],[12950],[13894],[False],[0],[0],[False],['0']
3179,PMC3002766,4679,"Other races included Asian, Hispanic, Indian, Native American and mixed.",Results|Demographics and baseline characteristics of the study population,[25924],[13895],[13970],[False],[0],[0],[False],['0']
3180,PMC3002766,4680,"Smoking status was available for 88 and 94 patients in the placebo and bosentan groups, respectively, and the time from first occurrence of DUs to randomisation for 89 and 98 patients, respectively.",Results|Demographics and baseline characteristics of the study population,[25926],[13971],[14169],[False],[0],[0],[False],['0']
3181,PMC3002766,4681,Limited=skin thickening only distal to the elbows and knees.,Results|Demographics and baseline characteristics of the study population,[25928],[14170],[14230],[False],[0],[0],[False],['0']
3182,PMC3002766,4682,Diffuse=skin thickening proximal to the elbows or knees or affecting the trunk.,Results|Demographics and baseline characteristics of the study population,[25930],[14231],[14310],[False],[0],[0],[False],['0']
3183,PMC3002766,4683,"As defined by the WHO Drug Dictionary and included pentoxifylline, buflomedil, ginkgo tree leaves extract and ginkgo biloba.",Results|Demographics and baseline characteristics of the study population,[25932],[14311],[14435],[False],[0],[0],[False],['0']
3184,PMC3002766,4684,"ACE, angiotensin-converting enzyme; DU, digital ulcer; SSc, systemic sclerosis.",Results|Demographics and baseline characteristics of the study population,[25934],[14436],[14515],[False],[0],[0],[False],['0']
3185,PMC3002766,4685,Primary end points,Results|Primary end points,[25936],[14516],[14534],[False],[0],[0],[False],['0']
3186,PMC3002766,4686,New DUs,Results|New DUs,[25938],[14535],[14542],[False],[0],[0],[False],['0']
3187,PMC3002766,4687,"After 24 weeks of bosentan treatment there was a 30% reduction in the occurrence of new DUs compared with placebo in the study population (1.9 (95% CI 1.4 to 2.3) vs 2.7 (2.0 to 3.4) new DUs, p=0.0351, figure 2).",Results|New DUs,[25940],[14543],[14755],[False],[0],[0],[False],['0']
3188,PMC3002766,4688,"Fewer new DUs were observed with bosentan than placebo in all subgroups except among current smokers (table 2, subgroup analyses).",Results|New DUs,[25942],[14756],[14886],[False],[0],[0],[False],['0']
3189,PMC3002766,4689,"This included subgroups of limited and diffuse SSc, with no difference between the two subgroups in the treatment effect (overlapping 95% CIs).",Results|New DUs,[25944],[14887],[15030],[False],[0],[0],[False],['0']
3190,PMC3002766,4690,Mean number of new digital ulcers in the study population up to weeks 12 and 24. p Values were determined using the Pitman permutation.,Results|New DUs,[25946],[15031],[15166],[False],[0],[0],[False],['0']
3191,PMC3002766,4691,Two patients on bosentan had no week 12 assessment.,Results|New DUs,[25948],[15167],[15218],[False],[0],[0],[False],['0']
3192,PMC3002766,4692,Number of new DUs up to week 24 in predefined and post hoc subgroups of patients,Results|New DUs,[25950],[15219],[15299],[False],[0],[0],[False],['0']
3193,PMC3002766,4693,	Number of new DUs			 		n	Placebo	n	Bosentan	Treatment effect	p Value*	 	Planned subgroup analyses	 	 SSc classification:	 	 Diffuse	37	2.7 (1.7 to 3.7)	37	2.1 (1.4 to 2.9)	−0.6 (−1.8 to 0.6)	0.35	 	 Limited	52	2.7 (1.7 to 3.7)	59	1.7 (1.1 to 2.2)	−1.0 (−2.1 to 0.0)	0.06	 	 Time from diagnosis of DU to randomisation:	 	 ≤5 years	49	2.7 (1.7 to 3.8)	54	1.7 (1.2 to 2.2)	−1.0 (−2.2 to 0.1)	0.07	 	 >5 years	39	2.7 (1.9 to 3.6)	41	2.1 (1.2 to 2.9)	−0.7 (−1.8 to 0.5)	0.26	 	 Systemic antibiotics for DU:	 	 Yes	11	5.0 (1.4 to 8.6)	16	2.6 (1.1 to 4.0)	−2.5 (−5.7 to 0.8)	0.14	 	 No	77	2.4 (1.8 to 3.0)	76	1.7 (1.2 to 2.2)	−0.7 (−1.5 to 0.1)	0.07	 	 Local treatment for DU:	 	 Yes	24	2.8 (1.7 to 3.9)	33	2.1 (1.3 to 2.9)	−0.7 (−2.0 to 0.6)	0.28	 	 No	64	2.7 (1.8 to 3.6)	61	1.8 (1.2 to 2.3)	−0.9 (−2.0 to 0.1)	0.07	 	 Dose adjustment of treatment for Raynaud's phenomenon:	 	 Yes	19	3.5 (1.8 to 5.3)	22	1.8 (0.9 to 2.6)	−1.8 (−3.6 to 0.1)	0.05	 	 No	69	2.5 (1.8 to 3.3)	72	1.9 (1.4 to 2.4)	−0.6 (−1.5 to 0.3)	0.20	 	 Smoking habit at baseline:	 	 Never	49	3.0 (2.1 to 4.0)	58	2.2 (1.6 to 2.9)	−0.8 (−1.9 to 0.3)	0.15	 	 Previous	20	3.3 (1.3 to 5.3)	22	1.3 (0.7 to 2.0)	−2.0 (−4.0 to −0.1)	0.04	 	 Current	19	1.3 (0.6 to 2.0)	12	1.5 (0.4 to 2.6)	0.2 (−1.0 to 1.3)	0.82	 	Post hoc subgroup analyses	 	 Number DUs at baseline:	 	 <4	60	1.9 (1.3 to 2.5)	59	1.6 (1.1 to 2.0)	−0.3 (−1.1 to 0.4)	0.39	 	 ≥4	29	4.4 (2.8 to 6.1)	36	2.4 (1.5 to 3.2)	−2.1 (−3.8 to −0.4)	0.02	 	 Randomisation month:†	 	 October 2003 to February 2004	37	1.3 (0.7 to 1.9)	29	0.7 (0.4 to 1.0)	−0.6 (−1.3 to 0.1)	0.12	 	 March 2004 to September 2004	52	1.3 (0.7 to 1.8)	64	0.8 (0.5 to 1.2)	−0.4 (−1.0 to 0.2)	0.20,Results|New DUs,[25952],[15300],[16979],[False],[0],[0],[False],['0']
3194,PMC3002766,4694,Data are mean (95% CIs).,Results|New DUs,[25954],[16980],[17007],[False],[0],[0],[False],['0']
3195,PMC3002766,4695,Exploratory p value determined using the Pitman permutation.,Results|New DUs,[25956],[17008],[17068],[False],[0],[0],[False],['0']
3196,PMC3002766,4696,Analysis confined to the first 12 weeks of treatment to avoid overlap of seasons.,Results|New DUs,[25958],[17069],[17150],[False],[0],[0],[False],['0']
3197,PMC3002766,4697,"DU, digital ulcer; SSc, systemic sclerosis.",Results|New DUs,[25960],[17151],[17194],[False],[0],[0],[False],['0']
3198,PMC3002766,4698,Healing of the cardinal ulcer,Results|Healing of the cardinal ulcer,[25962],[17195],[17224],[False],[0],[0],[False],['0']
3199,PMC3002766,4699,"No difference between bosentan and placebo treatments was observed in the time to healing of the cardinal ulcer (HR 0.91 (95% CI 0.61 to 1.35), p=0.63, figure 3).",Results|Healing of the cardinal ulcer,[25964],[17225],[17387],[False],[0],[0],[False],['0']
3200,PMC3002766,4700,"At week 24, more than 50% of patients in both groups had healing of the cardinal ulcer maintained for at least 12 weeks.",Results|Healing of the cardinal ulcer,[25966],[17388],[17508],[False],[0],[0],[False],['0']
3201,PMC3002766,4701,Kaplan–Meier estimates of time to complete healing of the cardinal ulcer.,Results|Healing of the cardinal ulcer,[25968],[17509],[17582],[False],[0],[0],[False],['0']
3202,PMC3002766,4702,Secondary and exploratory end points,Results|Secondary and exploratory end points,[25970],[17583],[17619],[False],[0],[0],[False],['0']
3203,PMC3002766,4703,New DUs,Results|New DUs,[25972],[17620],[17627],[False],[0],[0],[False],['0']
3204,PMC3002766,4704,"The proportion of patients with no new DUs up to week 24 was similar with bosentan and placebo (observed in 32/95 (33.7%) and 26/89 (29.2%) patients, respectively, RR 1.15 (95% CI 0.75 to 1.77); p=0.53).",Results|New DUs,[25974],[17628],[17831],[False],[0],[0],[False],['0']
3205,PMC3002766,4705,"The proportion of patients with one or more new DU was 66.3% (63/95) on bosentan compared with 70.8% (63/89) on placebo; the difference in observed proportions between treatments was greater in patients with multiple new DUs (18.9% vs 29.2% with ≥4, 10.5% vs 29.8% with ≥5, etc; figure 4).",Results|New DUs,[25976],[17832],[18121],[False],[0],[0],[False],['0']
3206,PMC3002766,4706,The maximum number of new DUs per patient was 10 on bosentan and 16 on placebo.,Results|New DUs,[25978],[18122],[18201],[False],[0],[0],[False],['0']
3207,PMC3002766,4707,"Time-to-event analyses up to week 24 indicated an increasing reduction in risk with bosentan compared with placebo for the appearance of each successive new DU, with a HR of 0.45 (95% CI 0.21 to 0.95, p=0.03) for the fifth new DU.",Results|New DUs,[25980],[18202],[18432],[False],[0],[0],[False],['0']
3208,PMC3002766,4708,"However, the mean total number of DUs (baseline and new) per patient decreased to a similar extent in the bosentan and placebo groups (−1.7.",Results|New DUs,[25982],[18433],[18573],[False],[0],[0],[False],['0']
3209,PMC3002766,4709,"(95% CI −2.3 to −1.0) and −1.5 (−2.3 to −0.7) DUs, respectively; p=0.76).",Results|New DUs,[25984],[18574],[18647],[False],[0],[0],[False],['0']
3210,PMC3002766,4710,Proportions of patients with new digital ulcers (DUs) by number of new DUs up to week 24.,Results|New DUs,[25986],[18648],[18737],[False],[0],[0],[False],['0']
3211,PMC3002766,4711,Patients in the placebo group had up to 16 new DUs.,Results|New DUs,[25988],[18738],[18789],[False],[0],[0],[False],['0']
3212,PMC3002766,4712,DU healing,Results|DU healing,[25990],[18790],[18800],[False],[0],[0],[False],['0']
3213,PMC3002766,4713,"No treatment effects were observed in the times to healing up to week 24 for all baseline DUs (HR 0.94 (95% CI 0.65 to 1.37), p=0.74) or of all new DUs (HR 1.40 (0.78 to 2.51), p=0.26).",Results|DU healing,[25992],[18801],[18986],[False],[0],[0],[False],['0']
3214,PMC3002766,4714,"Healing of all DUs (baseline and new combined) at week 24 was observed in 35/95 (36.8%) and 35/89 (39.3%) of patients on bosentan and placebo, respectively (RR 0.94 (95% CI 0.65 to 1.35), p=0.76).",Results|DU healing,[25994],[18987],[19183],[False],[0],[0],[False],['0']
3215,PMC3002766,4715,Pain and disability,Results|Pain and disability,[25996],[19184],[19203],[False],[0],[0],[False],['0']
3216,PMC3002766,4716,"Patient-rated measures of overall hand pain and pain of the cardinal ulcer, as assessed by visual analogue scales, showed no differential treatment effect in pain at week 24 (mean treatment effects of −1.7 (95% CI −11.4 to 7.9), p=0.73 and −1.6 (−11.5 to 8.3), p=0.75, respectively).",Results|Pain and disability,[25998],[19204],[19487],[False],[0],[0],[False],['0']
3217,PMC3002766,4717,"The changes from baseline in the HAQ disability index and hand disability index at week 24 were also similar in both treatment groups (−0.04 (95% CI −0.15 to 0.08), p=0.51 and −0.04 (−0.20 to 0.12), p=0.62, respectively).",Results|Pain and disability,[26000],[19488],[19709],[False],[0],[0],[False],['0']
3218,PMC3002766,4718,Post hoc analyses of new DUs,Results|Post hoc analyses of new DUs,[26002],[19710],[19738],[False],[0],[0],[False],['0']
3219,PMC3002766,4719,"In unplanned post hoc analyses in subgroups defined by the number of DUs at baseline, the mean treatment effect with bosentan was −2.1 (95% CI −3.8 to −0.4) new DUs (p=0.02) in patients with at least four DUs at baseline and −0.3 (−1.1 to 0.4) new DUs (p=0.39) in patients with less than four DUs at baseline (table 2).",Results|Post hoc analyses of new DUs,[26004],[19739],[20058],[False],[0],[0],[False],['0']
3220,PMC3002766,4720,"In both subgroups, the estimated proportion of patients without each subsequent new DU was larger in the bosentan than placebo group except the first new DU (table 3), and the difference between treatment groups was larger among patients with at least four new DUs than in those with fewer than four new DUs.",Results|Post hoc analyses of new DUs,[26006],[20059],[20367],[False],[0],[0],[False],['0']
3221,PMC3002766,4721,"No difference between treatments was observed in the mean total number of DUs (baseline plus new) per patient among patients with at least four DUs at baseline (−3.4 (95% CI −4.8 to −1.9) on bosentan and −3.6 (−5.4 to −1.7) DUs on placebo) and those with fewer than four DUs at baseline (−0.6 (−1.0 to −0.2) and −0.5 (−1.1 to 0.1) DUs, respectively).",Results|Post hoc analyses of new DUs,[26008],[20368],[20718],[False],[0],[0],[False],['0']
3222,PMC3002766,4722,Kaplan–Meier estimates of patients without subsequent new DUs at week 20 by number of DUs at baseline,Results|Post hoc analyses of new DUs,[26010],[20719],[20820],[False],[0],[0],[False],['0']
3223,PMC3002766,4723,	<4 DUs at baseline	≥4 DUs at baseline	 	Event-free rate (%)	Placebo (n=61)	Bosentan (n=61)	Placebo (n=29)	Bosentan (n=37)	 	First new DU	45.8	47.7	24.1	23.4	 	Second new DU	66.5	70.1	44.8	57.3	 	Third new DU	84.2	85.0	55.2	75.3	 	Fourth new DU	84.0	96.1	58.6	84.2	 	Fifth new DU	92.9	98.0	72.4	90.6,Results|Post hoc analyses of new DUs,[26012],[20821],[21120],[False],[0],[0],[False],['0']
3224,PMC3002766,4724,"DU, digital ulcer.","Results|DU, digital ulcer.",[26014],[21121],[21142],[False],[0],[0],[False],['0']
3225,PMC3002766,4725,"An analysis of subgroups based on randomisation month (October–February, March–September) confined to the first 12 weeks of treatment (to avoid overlapping time periods) found no effect of season on the treatment effect (table 2).","Results|DU, digital ulcer.",[26016],[21143],[21373],[False],[0],[0],[False],['0']
3226,PMC3002766,4726,Safety and tolerability,Results|Safety and tolerability,[26018],[21374],[21397],[False],[0],[0],[False],['0']
3227,PMC3002766,4727,"Serious adverse events occurred in 9.4% and 16.7% of patients on bosentan and placebo, respectively (table 4), with only one serious event (pneumonia) reported for more than one patient on bosentan.",Results|Safety and tolerability,[26020],[21398],[21596],[False],[0],[0],[False],['0']
3228,PMC3002766,4728,One patient on placebo died from acute respiratory distress syndrome during the post-treatment follow-up.,Results|Safety and tolerability,[26022],[21597],[21702],[False],[0],[0],[False],['0']
3229,PMC3002766,4729,The proportions of patients experiencing at least one adverse event were similar in both treatment groups (table 4).,Results|Safety and tolerability,[26024],[21703],[21819],[False],[0],[0],[False],['0']
3230,PMC3002766,4730,Adverse events occurring in more patients on bosentan than placebo included peripheral oedema (18.8% vs 4.4%) and events denoting elevated aminotransferases (12.5% vs 2.2%).,Results|Safety and tolerability,[26026],[21820],[21993],[False],[0],[0],[False],['0']
3231,PMC3002766,4731,"These adverse events resulted in premature discontinuation of bosentan treatment in 2.1% and 5.2% of patients, respectively (vs none on placebo).",Results|Safety and tolerability,[26028],[21994],[22139],[False],[0],[0],[False],['0']
3232,PMC3002766,4732,"Overall, adverse events led to the discontinuation of study treatment in 15.6% of patients on bosentan and 12.2% on placebo.",Results|Safety and tolerability,[26030],[22140],[22264],[False],[0],[0],[False],['0']
3233,PMC3002766,4733,Laboratory tests identified increased aminotransferases to >3×ULN in 10/95 (10.5%) patients on bosentan (which included one patient with an elevation to >8×ULN) and 1/88 (1.1%) patients on placebo.,Results|Safety and tolerability,[26032],[22265],[22462],[False],[0],[0],[False],['0']
3234,PMC3002766,4734,"In all cases on bosentan, elevated aminotransferases resolved during continued treatment, after a decrease in dose, or following temporary or permanent treatment discontinuation.",Results|Safety and tolerability,[26034],[22463],[22641],[False],[0],[0],[False],['0']
3235,PMC3002766,4735,Summary of adverse events occurring during and up to 1 day after the end of study treatment,Results|Safety and tolerability,[26036],[22642],[22733],[False],[0],[0],[False],['0']
3236,PMC3002766,4736,"Adverse event, n (%)	Placebo (n=90)	Bosentan (n=96)	 	All patients with ≥1 adverse event	76 (84.4)	83 (86.5)	 	Peripheral oedema	4 (4.4)	18 (18.8)	 	Elevated aminotransferases*	2 (2.2)	12 (12.5)	 	Arthralgia	6 (6.7)	10 (10.4)	 	Headache	11 (12.2)	9 (9.4)	 	Infected skin ulcer	6 (6.7)	9 (9.4)	 	Upper respiratory tract infection	7 (7.8)	8 (8.3)	 	Diarrhoea	8 (8.9)	6 (6.3)	 	Pain in extremity	4 (4.4)	6 (6.3)	 	Nausea	11 (12.2)	5 (5.2)	 	Skin ulcer/disease progression	7 (7.8)	5 (5.2)	 	Urinary tract infection	3 (3.3)	5 (5.2)	 	Dermatitis	2 (2.2)	5 (5.2)	 	Other†	70 (77.8)	78 (81.3)	 	All patients with ≥1 serious adverse event	15 (16.7)	9 (9.4)",Results|Safety and tolerability,[26038],[22734],[23381],[False],[0],[0],[False],['0']
3237,PMC3002766,4737,"Reported by investigators as alanine aminotransferase increased, aspartate aminotransferase increased and liver function test abnormal.",Results|Safety and tolerability,[26040],[23382],[23520],[False],[0],[0],[False],['0']
3238,PMC3002766,4738,Includes all adverse events with an incidence on bosentan <5%.,Results|Safety and tolerability,[26042],[23521],[23583],[False],[0],[0],[False],['0']
3239,PMC3002766,4739,Discussion,Discussion,[26044],[23584],[23595],[False],[0],[0],[False],['0']
3240,PMC3002766,4740,"In this randomised, placebo-controlled trial, bosentan treatment was associated with a 30% reduction in the number of new DUs over the 24-week treatment period but did not result in a treatment effect on healing of the cardinal ulcer.",Discussion,[26046],[23596],[23830],[False],[0],[0],[False],['0']
3241,PMC3002766,4741,"The reduction of new DUs was more pronounced among patients with multiple DUs; large numbers of new DUs were less likely to occur, and the appearance of each successive new DU was delayed in patients on bosentan compared with those on placebo.",Discussion,[26048],[23831],[24074],[False],[0],[0],[False],['0']
3242,PMC3002766,4742,"Based on post hoc analyses, the reduction of new DUs appeared to be greater in patients with at least four DUs at baseline.",Discussion,[26050],[24075],[24198],[False],[0],[0],[False],['0']
3243,PMC3002766,4743,"The mean total number of DUs per patient at week 24 was similar in the two treatment groups, and no treatment effects were observed in the other measures of healing or patient-rated measures of pain and disability used.",Discussion,[26052],[24199],[24418],[False],[0],[0],[False],['0']
3244,PMC3002766,4744,This is the second randomised placebo-controlled trial to show a reduction in the number of new DUs in susceptible patients with SSc treated with bosentan.,Discussion,[26054],[24419],[24574],[False],[0],[0],[False],['0']
3245,PMC3002766,4745,"Consistent with the first trial, the observed treatment effect was greater in patients with multiple DUs, while there was no effect on healing parameters.",Discussion,[26056],[24575],[24729],[False],[0],[0],[False],['0']
3246,PMC3002766,4746,"The reduction of new DUs without effect on healing in bosentan-treated patients did not translate into a smaller ulcer burden, as was seen in the previous study.",Discussion,[26058],[24730],[24891],[False],[0],[0],[False],['0']
3247,PMC3002766,4747,"In this study, similar reductions in the overall number of DUs (present at baseline and/or new) occurred in both groups.",Discussion,[26060],[24892],[25012],[False],[0],[0],[False],['0']
3248,PMC3002766,4748,The difference between studies could not be explained by a seasonal effect on the appearance of new DUs due to the different enrolment periods (October–September vs October–February in the first study).,Discussion,[26062],[25013],[25215],[False],[0],[0],[False],['0']
3249,PMC3002766,4749,"Raynaud's phenomenon is thought to be more severe and new DUs more frequent during the autumn and winter, but the numbers of new DUs in autumn/winter and spring/summer randomisation subgroups were nearly identical.",Discussion,[26064],[25216],[25430],[False],[0],[0],[False],['0']
3250,PMC3002766,4750,"The patient populations for the two studies appeared similar except that in the earlier study, 38% of patients had no active DU at baseline.",Discussion,[26066],[25431],[25571],[False],[0],[0],[False],['0']
3251,PMC3002766,4751,"Patients in the earlier study had fewer DUs to heal, perhaps giving more weight to prevention in the reduction of overall ulcer burden.",Discussion,[26068],[25572],[25707],[False],[0],[0],[False],['0']
3252,PMC3002766,4752,The reduction of new DUs with bosentan also did not translate into measurable decreases in pain or disability compared with placebo.,Discussion,[26070],[25708],[25840],[False],[0],[0],[False],['0']
3253,PMC3002766,4753,"Explanations could include (1) the expected result, given no differences in total number of DUs between treatment groups, (2) a lack of sensitivity to change and discriminative value in the current instruments used to assess hand function in SSc and (3) bosentan treatment does not improve pain and disability in spite of the reduction of new DUs.",Discussion,[26072],[25841],[26188],[False],[0],[0],[False],['0']
3254,PMC3002766,4754,Improvement in hand function was seen in the previous study.,Discussion,[26074],[26189],[26249],[False],[0],[0],[False],['0']
3255,PMC3002766,4755,"A clear picture of the overall benefits of treatment on patient well-being remains elusive, as remaining DUs and the underlying healing rate may confound overall assessments.",Discussion,[26076],[26250],[26424],[False],[0],[0],[False],['0']
3256,PMC3002766,4756,"In this study, both groups had an equal opportunity for benefit so it may be inferred that in the future, a long-term study on prevention of new ulcers must examine if patient benefit would result, as opposed to the design adopted in the present study.",Discussion,[26078],[26425],[26677],[False],[0],[0],[False],['0']
3257,PMC3002766,4757,The increased incidence of elevated aminotransferases with bosentan in this and other studies reinforces the need for continual monitoring of liver function with this treatment.,Discussion,[26080],[26678],[26855],[False],[0],[0],[False],['0']
3258,PMC3002766,4758,"The incidence, severity and resolution of these abnormalities in this study were similar to previous reports.",Discussion,[26082],[26856],[26965],[False],[0],[0],[False],['0']
3259,PMC3002766,4759,The increased incidence of peripheral oedema with bosentan was not previously reported in patients with DUs but has been seen in other patient populations.,Discussion,[26084],[26966],[27121],[False],[0],[0],[False],['0']
3260,PMC3002766,4760,"This was a large and complex controlled trial, but there are limitations to the data interpretation.",Discussion,[26086],[27122],[27222],[False],[0],[0],[False],['0']
3261,PMC3002766,4761,The definition of an active DU used in this trial may not match criteria used in other centres.,Discussion,[26088],[27223],[27318],[True],['DiagnosticCriteria'],['The definition of an active DU used in this trial'],[True],['Population']
3262,PMC3002766,4762,The clinical utility of this promising approach to treatment may be challenged.,Discussion,[26093],[27319],[27398],[True],['Generalization'],['he clinical utility of this promising approach to treatment'],[True],['Generalization']
3263,PMC3002766,4763,"In a patient encountered with a single DU, initiation of bosentan would not be expected to facilitate healing, and at least 66% of all bosentan-treated subjects would develop at least one additional DU over 6 months of follow-up.",Discussion,[26096],[27399],[27628],[False],[0],[0],[False],['0']
3264,PMC3002766,4764,"However, in those patients presenting with multiple DUs (at least four), the effect of bosentan treatment on the reduction of new DUs offers greater potential benefit.",Discussion,[26098],[27629],[27796],[False],[0],[0],[False],['0']
3265,PMC3002766,4765,"Major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that reduced occurrence of DUs would ultimately reduce the risk of same in an appropriate population.",Discussion,[26100],[27797],[28097],[False],[0],[0],[False],['0']
3266,PMC3002766,4766,"In conclusion, two randomised trials have shown that bosentan treatment reduces the occurrence of new DUs compared with placebo in patients with SSc but has no effect on DU healing.",Discussion,[26102],[28098],[28279],[False],[0],[0],[False],['0']
3267,PMC3002766,4767,Bosentan was well tolerated and may be a useful adjunct in the management of patients with SSc and recurrent DUs.,Discussion,[26104],[28280],[28393],[False],[0],[0],[False],['0']
3268,PMC3002766,4768,"Funding This study was funded by Actelion Pharmaceuticals, Allschwil, Switzerland.",Discussion,[26106],[28394],[28476],[False],[0],[0],[False],['0']
3269,PMC3002766,4769,"Competing interests MMC has received fees for speaking and research grant from Actelion Pharmaceuticals and Pfizer, and has received fees for speaking from Glaxo-Smith-Kline Beecham.",Discussion,[26108],[28477],[28659],[False],[0],[0],[False],['0']
3270,PMC3002766,4770,"CPD has received research grant funding to support clinical research fellows, honoraria for lecturing and been a consultant to Actelion Pharmaceuticals, Encysive Pharmaceuticals, Genzyme, Aspreva Pharmaceuticals, Pfizer, Biovitrum and DiGNA.",Discussion,[26110],[28660],[28901],[False],[0],[0],[False],['0']
3271,PMC3002766,4771,"DEF has received grants for research from Actelion and Gilead, has consulted regarding trial design for the same companies and has received funds for being a Continuing Medical Education speaker from Actelion.",Discussion,[26112],[28902],[29111],[False],[0],[0],[False],['0']
3272,PMC3002766,4772,"MDM has received honoraria from Actelion Pharmaceuticals for speaking to doctor groups, as well as funds to cover travel expenses and research costs to conduct clinical trials of bosentan.",Discussion,[26114],[29112],[29300],[False],[0],[0],[False],['0']
3273,PMC3002766,4773,MDM has received payments from Novartis to participate in a Data Safety Monitoring Board for a clinical trial of a drug not currently on the market; and to conduct a clinical trial of a new agent for scleroderma.,Discussion,[26116],[29301],[29513],[False],[0],[0],[False],['0']
3274,PMC3002766,4774,MDM has received funds from MediQuest to conduct a clinical trial of topical nitroglycerin preparation to treat Raynaud's phenomenon.,Discussion,[26118],[29514],[29647],[False],[0],[0],[False],['0']
3275,PMC3002766,4775,VMH has received honoraria and travel expenses from Actelion Pharmaceuticals for serving on an advisory board.,Discussion,[26120],[29648],[29758],[False],[0],[0],[False],['0']
3276,PMC3002766,4776,PC has received fees from Actelion Pharmaceuticals as a speaker and moderator at the ‘Journée Française de la Sclérodermie Systémique’ in 2006 and 2007 and for participation in the Scientific Board on Systemic Sclerosis (2003–2008).,Discussion,[26122],[29759],[29991],[False],[0],[0],[False],['0']
3277,PMC3002766,4777,FMW has been compensated for presenting in lecture format materials and data from studies related to the use of bosentan; FMW was an investigator in the RAPIDS-2 trial supported by Actelion.,Discussion,[26124],[29992],[30182],[False],[0],[0],[False],['0']
3278,PMC3002766,4778,"BJF has received funds for consulting from Actelion, Encysive and Gilead, for research from Actelion, and for speaking from Encysive and Gilead.",Discussion,[26126],[30183],[30327],[False],[0],[0],[False],['0']
3279,PMC3002766,4779,"PAM has received research funding from the following companies, each of which are involved in research related to the topic of this article: Actelion, Encysive, Genentech, Genzyme and Novartis.",Discussion,[26128],[30328],[30521],[False],[0],[0],[False],['0']
3280,PMC3002766,4780,JEP has been a consultant and speaker for Actelion.,Discussion,[26130],[30522],[30573],[False],[0],[0],[False],['0']
3281,PMC3002766,4781,Research in this study and other studies was funded by Actelion.,Discussion,[26132],[30574],[30638],[False],[0],[0],[False],['0']
3282,PMC3002766,4782,MKD has received honoraria and travel expenses from Actelion Pharmaceuticals for serving on an advisory board and was an investigator for the RAPIDS-2 trial supported by Actelion.,Discussion,[26134],[30639],[30818],[False],[0],[0],[False],['0']
3283,PMC3002766,4783,"BH has received speaker honoraria from Actelion Pharmaceuticals, the manufacturer of bosentan.",Discussion,[26136],[30819],[30913],[False],[0],[0],[False],['0']
3284,PMC3002766,4784,TAM has been paid honoraria by Actelion for giving lectures unrelated to Actelion products.,Discussion,[26138],[30914],[31005],[False],[0],[0],[False],['0']
3285,PMC3002766,4785,FK is a full-time employee of and holds stock options in Actelion Pharmaceuticals.,Discussion,[26140],[31006],[31088],[False],[0],[0],[False],['0']
3286,PMC3002766,4786,AM is a full-time employee of Actelion Pharmaceuticals Italia Srl and holds stock options in Actelion Pharmaceuticals.,Discussion,[26142],[31089],[31207],[False],[0],[0],[False],['0']
3287,PMC3002766,4787,"JHK received research funding from the following companies, each of which are involved in research related to the topic of this article: Actelion and Genzyme.",Discussion,[26144],[31208],[31366],[False],[0],[0],[False],['0']
3288,PMC3002766,4788,"JRS has funded research and a consultancy agreement with Actelion Pharmaceuticals, the sponsor of this study.",Discussion,[26146],[31367],[31476],[False],[0],[0],[False],['0']
3289,PMC3002766,4789,"JS, in the past, received honoraria for lectures supported by Actelion.",Discussion,[26148],[31477],[31548],[False],[0],[0],[False],['0']
3290,PMC3002766,4790,"He also has funded research and consultancy relationships with Pfizer, Encysive, United Therapeutics, Centocor, FibroGen, Bristol-Myers Squibb, Lilly, Genzyme and Gilead, all of which have commercial interests in treating scleroderma and its vascular complications.",Discussion,[26150],[31549],[31814],[False],[0],[0],[False],['0']
3291,PMC3002766,4791,No conflicts of interest are reported by CMB and NJS.,Discussion,[26152],[31815],[31868],[False],[0],[0],[False],['0']
3292,PMC3002766,4792,Contributors The Steering Committee (consisting of six of the authors) along with the study's sponsor (Actelion Pharmaceuticals) designed the trial and supervised its conduct.,Discussion,[26154],[31869],[32044],[False],[0],[0],[False],['0']
3293,PMC3002766,4793,The investigators and sponsor collected trial data.,Discussion,[26156],[32045],[32096],[False],[0],[0],[False],['0']
3294,PMC3002766,4794,"The authors had full access to the data, prepared the manuscript without compensation by the sponsor and had full responsibility for the final decision to submit the paper.",Discussion,[26158],[32097],[32269],[False],[0],[0],[False],['0']
3295,PMC3002766,4795,Medical writing assistance with the development of the manuscript was provided by Dr Karen Manchester (funded by Actelion Pharmaceuticals).,Discussion,[26160],[32270],[32409],[False],[0],[0],[False],['0']
3296,PMC3002766,4796,"Ethics approval This study was conducted with the approval of the Local Ethics Committees at each of 41 study sites in Austria, Canada, France, Germany, Italy, Spain, Switzerland, UK and USA.",Discussion,[26162],[32410],[32601],[False],[0],[0],[False],['0']
3297,PMC3002766,4797,Provenance and peer review Not commissioned; externally peer reviewed.,Discussion,[26164],[32602],[32672],[False],[0],[0],[False],['0']
4854,PMC3103669,5605,"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study",Title,[34246],[61509],[148],[False],[0],[0],[False],['0']
4855,PMC3103669,5606,Objective,Abstract,[34252],[149],[159],[False],[0],[0],[False],['0']
4856,PMC3103669,5607,"This study assessed the efficacy and safety of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, for prophylaxis against acute gouty arthritis flares in patients initiating urate-lowering treatment.",Abstract,[34258],[160],[376],[False],[0],[0],[False],['0']
4857,PMC3103669,5608,Methods,Abstract,[34264],[377],[384],[False],[0],[0],[False],['0']
4858,PMC3103669,5609,"In this double-blind, double-dummy, dose-ranging study, 432 patients with gouty arthritis initiating allopurinol treatment were randomised 1:1:1:1:1:1:2 to receive: a single dose of canakinumab, 25, 50, 100, 200, or 300 mg subcutaneously; 4×4-weekly doses of canakinumab (50+50+25+25 mg subcutaneously); or daily colchicine 0.5 mg orally for 16 weeks.",Abstract,[34270],[385],[736],[False],[0],[0],[False],['0']
4859,PMC3103669,5610,Patients recorded details of flares in diaries.,Abstract,[34276],[737],[784],[False],[0],[0],[False],['0']
4860,PMC3103669,5611,The study aimed to determine the canakinumab dose having equivalent efficacy to colchicine 0.5 mg at 16 weeks.,Abstract,[34282],[785],[895],[False],[0],[0],[False],['0']
4861,PMC3103669,5612,Results,Abstract,[34288],[896],[903],[False],[0],[0],[False],['0']
4862,PMC3103669,5613,A dose-response for canakinumab was not apparent with any of the four predefined dose-response models.,Abstract,[34294],[904],[1006],[False],[0],[0],[False],['0']
4863,PMC3103669,5614,The estimated canakinumab dose with equivalent efficacy to colchicine was below the range of doses tested.,Abstract,[34300],[1007],[1113],[False],[0],[0],[False],['0']
4864,PMC3103669,5615,"At 16 weeks, there was a 62% to 72% reduction in the mean number of flares per patient for canakinumab doses ≥50 mg versus colchicine based on a negative binomial model (rate ratio: 0.28–0.38, p≤0.0083), and the percentage of patients experiencing ≥1 flare was significantly lower for all canakinumab doses (15% to 27%) versus colchicine (44%, p<0.05).",Abstract,[34306],[1114],[1466],[False],[0],[0],[False],['0']
4865,PMC3103669,5616,"There was a 64% to 72% reduction in the risk of experiencing ≥1 flare for canakinumab doses ≥50 mg versus colchicine at 16 weeks (hazard ratio (HR): 0.28–0.36, p≤0.05).",Abstract,[34312],[1467],[1635],[False],[0],[0],[False],['0']
4866,PMC3103669,5617,The incidence of adverse events was similar across treatment groups.,Abstract,[34318],[1636],[1704],[False],[0],[0],[False],['0']
4867,PMC3103669,5618,Conclusions,Abstract,[34324],[1705],[1716],[False],[0],[0],[False],['0']
4868,PMC3103669,5619,Single canakinumab doses ≥50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg.,Abstract,[34330],[1717],[1855],[False],[0],[0],[False],['0']
4869,PMC3103669,5620,Introduction,Introduction,[34336],[1856],[1869],[False],[0],[0],[False],['0']
4870,PMC3103669,5621,"Gouty arthritis is a painful inflammatory arthritis that becomes increasingly prevalent with age, affecting around 10% of men and 6% of women over 70 years old.",Introduction,[34342],[1870],[2030],[False],[0],[0],[False],['0']
4871,PMC3103669,5622,"It results from deposition of monosodium urate (MSU) crystals in joints, which leads to painful inflammatory acute gouty arthritis flares.",Introduction,[34348],[2031],[2169],[False],[0],[0],[False],['0']
4872,PMC3103669,5623,An increasing number of patients have comorbidities which make standard therapies inappropriate.,Introduction,[34354],[2170],[2266],[False],[0],[0],[False],['0']
4873,PMC3103669,5624,"Such patients may develop difficult-to-treat disease, characterised by frequent flares and persistent inflammation between flares which contribute to joint damage and have a major impact on health-related quality of life and an individual's ability to work.",Introduction,[34360],[2267],[2524],[False],[0],[0],[False],['0']
4874,PMC3103669,5625,Long-standing elevated body uric acid pools can lead to increased serum urate (SU) levels and formation of MSU crystals.,Introduction,[34366],[2525],[2645],[False],[0],[0],[False],['0']
4875,PMC3103669,5626,"An important goal in the long-term management of gouty arthritis is the reduction of SU levels to below 6 mg/dl so as to prevent formation of new crystals, dissolve existing crystals and ultimately decrease the incidence of flares.",Introduction,[34372],[2646],[2877],[False],[0],[0],[False],['0']
4876,PMC3103669,5627,This is achieved with urate lowering therapies (ULT).,Introduction,[34378],[2878],[2931],[False],[0],[0],[False],['0']
4877,PMC3103669,5628,Allopurinol is the most commonly used ULT and the current standard of care.,Introduction,[34384],[2932],[3007],[False],[0],[0],[False],['0']
4878,PMC3103669,5629,"During the first weeks and months after initiating ULT, rapid reductions in SU levels can induce acute gouty arthritis flares.",Introduction,[34390],[3008],[3134],[False],[0],[0],[False],['0']
4879,PMC3103669,5630,"Therefore, when initiating a patient on ULT, prophylactic low-dose anti-inflammatory treatment is recommended to prevent flares and foster compliance with ULT.",Introduction,[34396],[3135],[3294],[False],[0],[0],[False],['0']
4880,PMC3103669,5631,"Low-dose colchicine is the most commonly prescribed drug for prophylaxis in patients initiating ULT, but it has significant shortcomings.",Introduction,[34402],[3295],[3432],[False],[0],[0],[False],['0']
4881,PMC3103669,5632,Some patients have contraindications to colchicine whereas others do not tolerate colchicine or still experience flares.,Introduction,[34408],[3433],[3553],[False],[0],[0],[False],['0']
4882,PMC3103669,5633,Evidence for the efficacy of colchicine as prophylaxis against flares comes from two small studies and a larger study performed 50 years ago.,Introduction,[34414],[3554],[3695],[False],[0],[0],[False],['0']
4883,PMC3103669,5634,"Three recent trials used colchicine for prophylaxis in patients initiating ULT (with febuxostat), but provide limited data on the efficacy of colchicine.",Introduction,[34420],[3696],[3849],[False],[0],[0],[False],['0']
4884,PMC3103669,5635,There is therefore a need for more rigorous assessment of the efficacy of colchicine as prophylaxis against flares following ULT initiation and the introduction of alternative therapies.,Introduction,[34426],[3850],[4036],[False],[0],[0],[False],['0']
4885,PMC3103669,5636,"Several lines of evidence suggest that the proinflammatory cytokine, interleukin 1β (IL-1β), plays a key role in mediating the initiation of inflammation in gouty arthritis in a similar manner to that occurring in the hereditary autoinflammatory syndrome, cryopyrin-associated periodic syndrome (CAPS), and may also contribute to joint destruction in gouty arthritis.",Introduction,[34432],[4037],[4404],[False],[0],[0],[False],['0']
4886,PMC3103669,5637,"This suggests that selective blockade of IL-1β signalling may provide effective prophylaxis against flares in patients with gouty arthritis and is supported by results showing that IL-1β blockade with canakinumab, a fully human monoclonal antibody to IL-1β with a half-life of 3–4 weeks, can effectively reduce pain, inflammation and the risk of recurrent flares in patients with acute gouty arthritis.",Introduction,[34438],[4405],[4807],[False],[0],[0],[False],['0']
4887,PMC3103669,5638,"Here, we report the results of a dose-ranging, active-controlled phase II trial to assess the efficacy, safety and tolerability of canakinumab as prophylaxis against flares in patients initiating allopurinol treatment.",Introduction,[34444],[4808],[5026],[False],[0],[0],[False],['0']
4888,PMC3103669,5639,Methods,Methods,[34450],[5027],[5035],[False],[0],[0],[False],['0']
4889,PMC3103669,5640,Study design,Methods|Study design,[34456],[5036],[5048],[False],[0],[0],[False],['0']
4890,PMC3103669,5641,"This was a 24-week, dose-ranging, multicentre, double-blind, double-dummy, active-controlled study and was approved by all responsible independent ethics committees.",Methods|Study design,[34462],[5049],[5214],[False],[0],[0],[False],['0']
4891,PMC3103669,5642,"The study was performed in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice and the ethical principles laid down in the Declaration of Helsinki, and all patients provided written informed consent.",Methods|Study design,[34468],[5215],[5566],[False],[0],[0],[False],['0']
4892,PMC3103669,5643,The trial was registered with http://www.clinicaltrials.gov (registration number: NCT00819585).,Methods|Study design,[34474],[5567],[5662],[False],[0],[0],[False],['0']
4893,PMC3103669,5644,"At screening, patients indicated which of their joints was most affected by previous gouty arthritis flares.",Methods|Study design,[34480],[5663],[5771],[False],[0],[0],[False],['0']
4894,PMC3103669,5645,"Eligible patients were subsequently randomised 1:1:1:1:1:1:2 to receive a single dose of canakinumab, 25 mg, 50 mg, 100 mg, 200 mg, or 300 mg on day 1, or four canakinumab doses administered at 4-weekly intervals (50 mg on day 1 and at week 4, and 25 mg at weeks 8 and 12), or daily oral doses of colchicine 0.5 mg given for 16 weeks.",Methods|Study design,[34486],[5772],[6106],[False],[0],[0],[False],['0']
4895,PMC3103669,5646,"In order to achieve blinding for patients and investigators, all patients received subcutaneous injections of canakinumab or canakinumab placebo on day 1, and at weeks 4, 8 and 12, and took capsules of colchicine or colchicine placebo daily for 16 weeks (see supplementary material for details).",Methods|Study design,[34492],[6107],[6402],[False],[0],[0],[False],['0']
4896,PMC3103669,5647,Patients were followed for 24 weeks.,Methods|Study design,[34498],[6403],[6439],[False],[0],[0],[False],['0']
4897,PMC3103669,5648,Allopurinol treatment (100–300 mg) was initiated at baseline or within 1 month before baseline and was administered to all randomised patients once daily for 24 weeks (see supplementary material for details).,Methods|Study design,[34504],[6440],[6648],[False],[0],[0],[False],['0']
4898,PMC3103669,5649,Patients could receive rescue medication as needed (see supplementary material for details).,Methods|Study design,[34510],[6649],[6741],[False],[0],[0],[False],['0']
4899,PMC3103669,5650,Patients,Methods|Patients,[34516],[6742],[6750],[False],[0],[0],[False],['0']
4900,PMC3103669,5651,"Inclusion criteria were: age 18–80 years, diagnosis of gouty arthritis as defined by the American College of Rheumatology 1977 preliminary criteria, having had at least two gouty arthritis flares in the previous year, body mass index (BMI) of ≤40 kg/m2 and willingness to initiate allopurinol treatment or having initiated allopurinol treatment within 1 month of screening.",Methods|Patients,[34522],[6751],[7124],[False],[0],[0],[False],['0']
4901,PMC3103669,5652,"Key exclusion criteria were: having a gouty arthritis flare within 2 weeks of screening, present at screening, or having pain associated with a flare at screening; history of allergy, contraindication, or intolerance to allopurinol or colchicine (see supplementary material for further details).",Methods|Patients,[34528],[7125],[7420],[False],[0],[0],[False],['0']
4902,PMC3103669,5653,Assessments,Methods|Assessments,[34534],[7421],[7432],[False],[0],[0],[False],['0']
4903,PMC3103669,5654,Flares were patient reported.,Methods|Assessments,[34540],[7433],[7462],[False],[0],[0],[False],['0']
4904,PMC3103669,5655,"For each flare, patients recorded in a diary the start date, the most affected joint on that day and the severity of pain (see supplementary material for further details).",Methods|Assessments,[34546],[7463],[7634],[False],[0],[0],[False],['0']
4905,PMC3103669,5656,Patients also recorded rescue medication use and pain for at least 7 days after the onset of the flare or longer if the flares persisted for more than 7 days.,Methods|Assessments,[34552],[7635],[7793],[False],[0],[0],[False],['0']
4906,PMC3103669,5657,"Safety assessments were performed at scheduled visits (2, 4, 8, 12, 16, 20 and 24 weeks) and included collection of blood samples for assessment of the inflammatory marker, C reactive protein (CRP), haematology and immunogenicity (at baseline and weeks 8, 16 and 24) and doctor's assessments of local tolerability at sites of subcutaneous injections.",Methods|Assessments,[34558],[7794],[8144],[False],[0],[0],[False],['0']
4907,PMC3103669,5658,Adverse events (AEs) were reported throughout the study.,Methods|Assessments,[34564],[8145],[8201],[False],[0],[0],[False],['0']
4908,PMC3103669,5659,"The primary outcome was determination of the canakinumab dose producing equivalent efficacy to that achieved with colchicine 0.5 mg, with respect to the mean number of flares per patient occurring within 16 weeks post randomisation (ie, the target dose).",Methods|Assessments,[34570],[8202],[8456],[False],[0],[0],[False],['0']
4909,PMC3103669,5660,"Secondary efficacy outcomes included: mean number of flares per patient, proportion of patients with at least one flare, time to first flare, average duration of flares and CRP levels (see supplementary material for further details).",Methods|Assessments,[34576],[8457],[8690],[False],[0],[0],[False],['0']
4910,PMC3103669,5661,"Safety variables included the incidence of AEs, serious AEs (SAEs) and infectious AEs, the incidence and severity of injection-site reactions, and immunogenicity.",Methods|Assessments,[34582],[8691],[8853],[False],[0],[0],[False],['0']
4911,PMC3103669,5662,Sample size determination and statistical analysis,Methods|Sample size determination and statistical analysis,[34588],[8854],[8904],[False],[0],[0],[False],['0']
4912,PMC3103669,5663,A sample size of 350 patients (50 patients in each of the 5 canakinumab single-dose groups and 100 patients in the colchicine group) was considered sufficient to give a 95% confidence interval (CI) of the target dose with reasonable precision.,Methods|Sample size determination and statistical analysis,[34594],[8905],[9148],[False],[0],[0],[False],['0']
4913,PMC3103669,5664,In order to increase the precision of the analysis the planned total sample size of 400 was increased to approximately 440 patients (see supplementary material for more details).,Methods|Sample size determination and statistical analysis,[34600],[9149],[9327],[False],[0],[0],[False],['0']
4914,PMC3103669,5665,A preplanned interim analysis was performed when 200 patients had completed 16 weeks.,Methods|Sample size determination and statistical analysis,[34606],[9328],[9413],[False],[0],[0],[False],['0']
4915,PMC3103669,5666,Efficacy and safety analyses were then performed when all patients had completed the study (24 weeks).,Methods|Sample size determination and statistical analysis,[34612],[9414],[9516],[False],[0],[0],[False],['0']
4916,PMC3103669,5667,"For determination of the primary outcome, the number of flares per patient during 16 weeks was modelled using a negative binomial distribution and a common overdispersion (variance divided by expectation minus 1) for all treatment arms (see supplementary material for more details).",Methods|Sample size determination and statistical analysis,[34618],[9517],[9799],[False],[0],[0],[False],['0']
4917,PMC3103669,5668,The main secondary outcome was the mean number of flares per patient at 16 weeks.,Methods|Sample size determination and statistical analysis,[34624],[9800],[9881],[False],[0],[0],[False],['0']
4918,PMC3103669,5669,"Data were analysed according to an analysis of covariance (ANCOVA) with treatment group, allopurinol dose at baseline and BMI at baseline as covariates.",Methods|Sample size determination and statistical analysis,[34630],[9882],[10034],[False],[0],[0],[False],['0']
4919,PMC3103669,5670,"However, as the distribution of flares per patient was observed to be skewed, the preplanned ANCOVA was considered inappropriate for these data.",Methods|Sample size determination and statistical analysis,[34636],[10035],[10179],[False],[0],[0],[False],['0']
4920,PMC3103669,5671,"Therefore a post hoc analysis using a negative binomial model with treatment group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for secondary outcomes).",Methods|Sample size determination and statistical analysis,[34642],[10180],[10503],[False],[0],[0],[False],['0']
4921,PMC3103669,5672,Results,Results,[34648],[10504],[10512],[False],[0],[0],[False],['0']
4922,PMC3103669,5673,Baseline demographics and disease characteristics,Results|Baseline demographics and disease characteristics,[34654],[10513],[10562],[False],[0],[0],[False],['0']
4923,PMC3103669,5674,"Between December 2008 and August 2009, 432 patients from 75 centres in 16 countries were randomised to treatment; 391 patients (90.5%) completed the study (figure 1).",Results|Baseline demographics and disease characteristics,[34660],[10563],[10729],[False],[0],[0],[False],['0']
4924,PMC3103669,5675,Demographic and baseline disease characteristics were generally well balanced across treatment groups (table 1).,Results|Baseline demographics and disease characteristics,[34666],[10730],[10842],[False],[0],[0],[False],['0']
4925,PMC3103669,5676,Most patients were men (89% to 100%) and 28% to 44% had had gouty arthritis for at least 10 years.,Results|Baseline demographics and disease characteristics,[34672],[10843],[10941],[False],[0],[0],[False],['0']
4926,PMC3103669,5677,"At baseline, many patients had very high SU levels (≥9 mg/dl; 35% to 55%).",Results|Baseline demographics and disease characteristics,[34678],[10942],[11016],[False],[0],[0],[False],['0']
4927,PMC3103669,5678,The mean number of flares in the past year ranged from 3.6 to 4.7 for the different treatment groups.,Results|Baseline demographics and disease characteristics,[34684],[11017],[11118],[False],[0],[0],[False],['0']
4928,PMC3103669,5679,"Approximately 6% of patients had reduced renal function, defined as having an estimated creatinine clearance rate (CrCl) below the normal range for age and sex (table 1).",Results|Baseline demographics and disease characteristics,[34690],[11119],[11289],[False],[0],[0],[False],['0']
4929,PMC3103669,5680,Patient disposition.,Results|Baseline demographics and disease characteristics,[34696],[11290],[11310],[False],[0],[0],[False],['0']
4930,PMC3103669,5681,"Patients were recruited from the following countries (number of centres): Argentina (1), Belgium (2), Columbia (5), Czech Republic (5), Germany (5), Guatemala (5), Hungary (4), Poland (2), Portugal (3), Russia (7), Singapore (1), Slovakia (6), South Africa (4), Spain (4), Taiwan (4), Turkey (8), UK (2) and USA (20).",Results|Baseline demographics and disease characteristics,[34702],[11311],[11628],[False],[0],[0],[False],['0']
4931,PMC3103669,5682,Demographic and baseline characteristics (safety set),Results|Demographic and baseline characteristics (safety set),[34708],[11629],[11682],[False],[0],[0],[False],['0']
4932,PMC3103669,5683,"Variable	Canakinumab 25 mg n=55	Canakinumab 50 mg n=54	Canakinumab 100 mg n=54	Canakinumab 200 mg n=54	Canakinumab 300 mg n=53	Canakinumab every 4 weeks n=53	Colchicine 0.5 mg n=108	 	Male, n (%)	55 (100.0)	51 (94.4)	48 (88.9)	50 (92.6)	51 (96.2)	49 (92.5)	101 (93.5)	 	Age, years	 	 Mean (SD)	50.7 (9.72)	54.4 (12.18)	51.3 (12.41)	52.6 (10.78)	52.4 (11.30)	52.8 (10.38)	52.4 (10.69)	 	 Median (range)	52.0 (27–78)	53.0 (32–78)	51.0 (27–79)	53.5 (29–74)	51.0 (30–74)	53.0 (23–72)	54.0 (20–77)	 	Race, n (%)	 	 Caucasian	42 (76.4)	43 (79.6)	36 (66.7)	39 (72.2)	36 (67.9)	41 (77.4)	87 (80.6)	 	 Black	1 (1.8)	1 (1.9)	2 (3.7)	2 (3.7)	3 (5.7)	3 (5.7)	4 (3.7)	 	 Asian	4 (7.3)	4 (7.4)	10 (18.5)	5 (9.3)	4 (7.5)	2 (3.8)	5 (4.6)	 	 Other	8 (14.5)	6 (11.1)	6 (11.1)	8 (14.8)	10 (18.9)	7 (13.2)	12 (11.1)	 	BMI, kg/m2	 	 Mean (SD)	31.03 (4.63)	30.51 (4.35)	29.88 (4.69)	30.60 (4.12)	30.63 (4.64)	29.62 (4.32)	30.30 (4.66)	 	 Median (range)	30.0 (22–40)	29.9 (22–40)	29.8 (21–40)	30.4 (20–38)	30.4 (17–40)	29.7 (18–38)	29.2 (22–40)	 	Classification of gouty arthritis, n (%)*	 	 Acute monoarticular gouty arthritis	15 (27.3)	19 (35.2)	20 (37.0)	11 (20.4)	17 (32.1)	20 (37.7)	37 (34.3)	 	 Acute oligoarticular gouty arthritis	27 (49.1)	10 (18.5)	22 (40.7)	20 (37.0)	14 (26.4)	13 (24.5)	28 (25.9)	 	 Acute polyarticular gouty arthritis	13 (23.6)	25 (46.3)	12 (22.2)	23 (42.6)	22 (41.5)	20 (37.7)	43 (39.8)	 	Duration of gouty arthritis, n (%)	 	 <1 year	3 (5.5)	3 (5.6)	2 (3.7)	6 (11.1)	4 (7.5)	2 (3.8)	9 (8.3)	 	 1–5 years	13 (23.6)	23 (42.6)	25 (46.3)	14 (25.9)	20 (37.7)	15 (28.3)	39 (36.1)	 	 6–10 years	15 (27.3)	6 (11.1)	12 (22.2)	15 (27.8)	10 (18.9)	18 (34.0)	27 (25.0)	 	 >10 years	24 (43.6)	22 (40.7)	15 (27.8)	19 (35.2)	19 (35.8)	18 (34.0)	33 (30.6)	 	Number of flares in previous year	 	 Mean (SD)	3.7 (2.27)	4.3 (2.82)	3.6 (2.26)	4.7 (4.51)	4.5 (3.68)	4.4 (4.13)	4.3 (3.82)	 	 Median (range)	3.0 (1–14)	3.0 (2–14)	3.0 (2–12)	3.0 (1–25)	4.0 (2–20)	3.0 (2–24)	3.0 (1–25)	 	Allopurinol dose at baseline, mg daily	 	 Mean (SD)	261.8 (65.2)	263.0 (65.3)	263.0 (65.3)	257.4 (66.2)	264.2 (65.3)	258.5 (66.3)	261.1 (65.3)	 	 Median (range)	300.0 (100–300)	300.0 (100–300)	300.0 (100–300)	300.0 (100–300)	300.0 (100–300)	300.0 (100–300)	300.0 (100–300)	 	 Patients starting allopurinol before baseline, n (%)	6 (10.9)	8 (14.8)	10 (18.5)	8 (14.8)	6 (11.3)	8 (15.1)	12 (11.1)	 	Creatinine clearance (ml/min),† n (%)	 	 Low	2 (3.6)	2 (3.7)	2 (3.7)	4 (7.4)	7 (13.2)	2 (3.8)	6 (5.6)	 	 Normal	31 (56.4)	27 (50.0)	27 (50.0)	26 (48.1)	19 (35.8)	27 (50.9)	58 (53.7)	 	 High	22 (40.0)	25 (46.3)	25 (46.3)	24 (44.4)	27 (50.9)	24 (45.3)	44 (40.7)	 	Serum urate, n (%)	 	 ≥6 mg/dl	50 (90.9)	48 (88.9)	49 (90.7)	50 (92.6)	49 (92.5)	46 (85.2)	96 (88.9)	 	 ≥9 mg/dl	30 (54.5)	19 (35.2)	20 (37.0)	28 (51.9)	25 (47.2)	22 (41.5)	51 (47.2)	 	CRP, mg/l	 	 Mean (SD)	5.9 (9.88)	9.1 (18.84)	4.5 (8.02)	8.7 (15.40)	7.8 (15.98)	5.9 (6.59)	5.9 (8.30)	 	 Median (range)	2.9 (0–70)	3.4 (0–93)	1.8 (0–51)	3.7 (0–93)	3.2 (0–81)	3.1 (0–30)	2.7 (0–49)	 	SAA, mg/l	 	 Mean (SD)	8.7 (11.90)‡	18.8 (53.89)	8.2 (17.35)‡	18.3 (61.46)§	15.6 (61.90)‡	12.4 (22.47)‡	11.5 (28.71)¶	 	 Median (range)	3.8 (1–61)	4.9 (0–364)	3.7 (0–120)	5.5 (1–438)	4.3 (1–446)	4.8 (0–139)	4.6 (0–270)	 	HAQ SDI score	 	 Mean (SD)	0.38 (0.47)‡	0.48 (0.60)	0.39 (0.59)	0.38 (0.55)	0.35 (0.58)‡	0.42 (0.63)	0.42 (0.66)	 	 Median (range)	0.25 (0–2.0)	0.25 (0–2.1)	0.06 (0–2.6)	0 (0–2.5)	0 (0–2.1)	0.13 (0–2.1)	0.06 (0–2.8)	 	Employment status	 	 Working in paid, unpaid or voluntary employment	40 (72.7)	28 (51.9)	35 (64.8)	37 (68.5)	37 (69.8)	35 (66.0)	73 (67.6)",Results|Demographic and baseline characteristics (safety set),[34714],[11683],[15274],[False],[0],[0],[False],['0']
4933,PMC3103669,5684,p=0.016 from χ2 test for comparability across all groups.,Results|Demographic and baseline characteristics (safety set),[34720],[15275],[15335],[False],[0],[0],[False],['0']
4934,PMC3103669,5685,Creatinine clearance estimated using the Cockcroft–Gault formula.,Results|Demographic and baseline characteristics (safety set),[34726],[15336],[15401],[False],[0],[0],[False],['0']
4935,PMC3103669,5686,"Normal range for women aged: 16–50 years, 65–110 ml/min; 51–70 years, 50–90 ml/min; 71–110 years, 35–60 ml/min.",Results|Demographic and baseline characteristics (safety set),[34732],[15402],[15513],[False],[0],[0],[False],['0']
4936,PMC3103669,5687,"Normal range for men aged: 16–50 years, 80–125 ml/min; 51–70 years, 55–100 ml/min; 71–110 years, 40–75 ml/min.",Results|Demographic and baseline characteristics (safety set),[34738],[15514],[15624],[False],[0],[0],[False],['0']
4937,PMC3103669,5688,Data missing for one patient.,Results|Data missing for one patient.,[34744],[15625],[15654],[False],[0],[0],[False],['0']
4938,PMC3103669,5689,Data missing for two patients.,Results|Data missing for two patients.,[34750],[15655],[15685],[False],[0],[0],[False],['0']
4939,PMC3103669,5690,Data missing for four patients.,Results|Data missing for four patients.,[34756],[15686],[15717],[False],[0],[0],[False],['0']
4940,PMC3103669,5691,"BMI, body mass index; CRP, C reactive protein; HAQ SDI, Health Assessment Questionnaire Standard Disability Index; SAA, serum amyloid A; SD, standard deviation.",Results|Data missing for four patients.,[34762],[15718],[15878],[False],[0],[0],[False],['0']
4941,PMC3103669,5692,Primary outcome: determination of canakinumab target dose,Results|Data missing for four patients.,[34768],[15879],[15936],[False],[0],[0],[False],['0']
4942,PMC3103669,5693,No evidence of a dose-response was seen in any of the four predefined dose response models.,Results|Data missing for four patients.,[34774],[15937],[16028],[False],[0],[0],[False],['0']
4943,PMC3103669,5694,The estimated canakinumab dose with equivalent efficacy to colchicine was below the range of canakinumab doses tested.,Results|Data missing for four patients.,[34780],[16029],[16147],[False],[0],[0],[False],['0']
4944,PMC3103669,5695,Secondary outcomes,Results|Secondary outcomes,[34786],[16148],[16166],[False],[0],[0],[False],['0']
4945,PMC3103669,5696,Clinical outcomes,Results|Clinical outcomes,[34792],[16167],[16184],[False],[0],[0],[False],['0']
4946,PMC3103669,5697,"The least-squares (LS) mean number of flares per patient for the 16 weeks (according to the preplanned ANCOVA) was lower for all canakinumab doses compared with colchicine 0.5 mg; differences were statistically significant for the canakinumab 100 mg and 300 mg doses (p≤0.05, table 2).",Results|Clinical outcomes,[34798],[16185],[16470],[False],[0],[0],[False],['0']
4947,PMC3103669,5698,(The LS mean number of flares per patient is the best-fitting unbiased estimate calculated from the ANCOVA model.),Results|Clinical outcomes,[34804],[16471],[16585],[False],[0],[0],[False],['0']
4948,PMC3103669,5699,"However, as the distribution of flares per patient was observed to be skewed (most patients had no or few flares and few had many flares), the preplanned ANCOVA was considered inappropriate for these data.",Results|Clinical outcomes,[34810],[16586],[16791],[False],[0],[0],[False],['0']
4949,PMC3103669,5700,Therefore a post hoc analysis using a negative binomial model (the model used for the primary outcome) was performed after unblinding at 16 weeks.,Results|Clinical outcomes,[34816],[16792],[16938],[False],[0],[0],[False],['0']
4950,PMC3103669,5701,"According to this analysis, there was a 62% to 72% reduction in the mean number of flares per patient for canakinumab doses ≥50 mg versus colchicine (rate ratio: 0.28–0.38, p≤0.0083) (table 2).",Results|Clinical outcomes,[34822],[16939],[17132],[False],[0],[0],[False],['0']
4951,PMC3103669,5702,Summary of efficacy parameters at 16 weeks (full analysis set),Results|Clinical outcomes,[34828],[17133],[17195],[False],[0],[0],[False],['0']
4952,PMC3103669,5703,Variable	Canakinumab 25 mg n=55	Canakinumab 50 mg n=54	Canakinumab 100 mg n=54	Canakinumab 200 mg n=54	Canakinumab 300 mg n=53	Canakinumab every 4 weeks n=54	Colchicine 0.5 mg n=108	 	Mean number of flares per patient	 	ANCOVA (preplanned analysis)*	 	 Least-squares mean (SE)	0.51 (0.19)	0.45 (0.19)	0.23 (0.19)	0.41 (0.19)	0.23 (0.19)	0.70 (0.19)	0.75 (0.14)	 	 Estimate difference to colchicine (95% CI)	−0.24 (−0.67 to 0.19)	−0.30 (−0.73 to 0.13)	−0.52 (−0.95 to −0.08)†	−0.34 (−0.77 to 0.10)	−0.52 (−0.95 to −0.08)†	−0.05 (−0.48 to 0.38)		 	Negative binomial model (post hoc analysis)‡	 	 Rate ratio estimate (95% CI)	0.60 (0.34 to 1.06)	0.34 (0.17 to 0.69)§	0.28 (0.13 to 0.60)§	0.37 (0.19 to 0.72)§	0.29 (0.14 to 0.60)§	0.38 (0.19 to 0.77)§	NA	 	Patients experiencing ≥1 flare	 	 n (%)	15 (27.3)	9 (16.7)	8 (14.8)	10 (18.5)	8 (15.1)	9 (16.7)	48 (44.4)	 	 Estimated OR (95% CI)¶	0.47 (0.23 to 0.95)†	0.25 (0.11 to 0.56)†	0.22 (0.09 to 0.51)†	0.28 (0.13 to 0.61)†	0.22 (0.10 to 0.52)†	0.25 (0.11 to 0.56)†	NA	 	Time to first flare**	 	 HR (95% CI)	0.57 (0.32 to 1.02)	0.32 (0.16 to 0.66)†	0.28 (0.13 to 0.58)†	0.36 (0.18 to 0.71)†	0.28 (0.13 to 0.60)†	0.32 (0.16 to 0.66)†	NA	 	Average duration of all flares	 	 No.,Results|Clinical outcomes,[34834],[17196],[18416],[False],[0],[0],[False],['0']
4953,PMC3103669,5704,of patients with flares	15	9	8	9	8	9	48	 	 Least-squares mean (SD)*	4.62 (0.97)	3.66 (1.20)	2.80 (1.35)	3.59 (1.25)	3.09 (1.28)	3.33 (1.23)	5.08 (0.62)	 	 Estimated difference (95% CI)	−0.46 (−2.59 to 1.67)	−1.42 (−4.00 to 1.16)	−2.28 (−5.02 to 0.47)	−1.49 (−4.08 to 1.10)	−1.98 (−4.70 to 0.73)	−1.75 (−4.34 to 0.84)	NA,Results|Clinical outcomes,[34840],[18417],[18736],[False],[0],[0],[False],['0']
4954,PMC3103669,5705,"ANCOVA with treatment group, allopurinol dose at baseline and BMI at baseline as covariates.",Results|Clinical outcomes,[34846],[18737],[18832],[False],[0],[0],[False],['0']
4955,PMC3103669,5706,p≤0.05 versus colchicine 0.5 mg group.,Results|Clinical outcomes,[34852],[18833],[18871],[False],[0],[0],[False],['0']
4956,PMC3103669,5707,"Post hoc analysis: Rate ratio estimated from negative binomial model with treatment group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset.",Results|Clinical outcomes,[34858],[18872],[19063],[False],[0],[0],[False],['0']
4957,PMC3103669,5708,Estimates represent the ratio of mean number of gouty arthritis flares per patient in comparison with the colchicine 0.5 mg group.,Results|Clinical outcomes,[34864],[19064],[19194],[False],[0],[0],[False],['0']
4958,PMC3103669,5709,p≤0.0083 (Bonferroni correction 0.05/6) versus colchicine 0.5 mg group.,Results|Clinical outcomes,[34870],[19195],[19266],[False],[0],[0],[False],['0']
4959,PMC3103669,5710,"Logistical regression with treatment group, allopurinol dose at baseline and BMI at baseline as covariates.",Results|Clinical outcomes,[34876],[19267],[19374],[False],[0],[0],[False],['0']
4960,PMC3103669,5711,An OR >1 indicates that a gouty arthritis flare is more likely to occur in comparison with the colchicine 0.5 mg group.,Results|Clinical outcomes,[34882],[19375],[19494],[False],[0],[0],[False],['0']
4961,PMC3103669,5712,"Cox's proportional hazard regression model with treatment group, allopurinol dose at baseline and BMI at baseline as covariates.",Results|Clinical outcomes,[34888],[19495],[19623],[False],[0],[0],[False],['0']
4962,PMC3103669,5713,"ANCOVA, analysis of covariance; BMI, body mass index; CI, confidence interval; HR, hazard ratio; NA, not applicable; OR, odds ratio; SE, standard error.",Results|Clinical outcomes,[34894],[19624],[19776],[False],[0],[0],[False],['0']
4963,PMC3103669,5714,"The percentage of patients experiencing at least one flare in the 16-week period was lower for all canakinumab groups versus colchicine 0.5 mg (canakinumab, 15% to 27%; colchicine, 44%, p≤0.05), and all patients receiving canakinumab were significantly less likely to experience at least one flare compared with patients treated with colchicine (estimated odds ratio (OR) vs colchicine: 0.22–0.47, p≤0.05) (table 2).",Results|Clinical outcomes,[34900],[19777],[20193],[False],[0],[0],[False],['0']
4964,PMC3103669,5715,"In addition, time to first new gouty arthritis flare was longer with all canakinumab groups compared with colchicine 0.5 mg (figure 2) and there was a 64% to 72% reduction in the risk of experiencing at least one flare for canakinumab doses ≥50 mg versus colchicine at 16 weeks (HR: 0.28–0.36, p≤0.05) (table 2).",Results|Clinical outcomes,[34906],[20194],[20506],[False],[0],[0],[False],['0']
4965,PMC3103669,5716,The average duration (LS mean) for all flares over the 16-week period was shorter in all canakinumab groups compared with colchicine 0.5 mg: 2.8–4.6 days versus 5.1 days (table 2).,Results|Clinical outcomes,[34912],[20507],[20687],[False],[0],[0],[False],['0']
4966,PMC3103669,5717,"Differences in average duration between all canakinumab groups versus colchicine 0.5 mg, however, were not statistically significant.",Results|Clinical outcomes,[34918],[20688],[20821],[False],[0],[0],[False],['0']
4967,PMC3103669,5718,Time to first acute gouty arthritis flare after randomisation (Kaplan–Meier estimate).,Results|Clinical outcomes,[34924],[20822],[20908],[False],[0],[0],[False],['0']
4968,PMC3103669,5719,CRP levels,Results|CRP levels,[34930],[20909],[20919],[False],[0],[0],[False],['0']
4969,PMC3103669,5720,An initial decrease in median CRP levels was seen in all treatment groups (figure 3).,Results|CRP levels,[34936],[20920],[21005],[False],[0],[0],[False],['0']
4970,PMC3103669,5721,"For all canakinumab doses ≥50 mg, median CRP values remained consistently lower than in the colchicine group throughout the study and were below the upper limit of the normal range (ULN, 3.0 mg/dl) up to week 24.",Results|CRP levels,[34942],[21006],[21218],[False],[0],[0],[False],['0']
4971,PMC3103669,5722,Median C reactive protein levels over time.,Results|CRP levels,[34948],[21219],[21262],[False],[0],[0],[False],['0']
4972,PMC3103669,5723,"CRP, C reactive protein; q4wk, every 4 weeks; ULN, upper limit of the normal range.",Results|CRP levels,[34954],[21263],[21346],[False],[0],[0],[False],['0']
4973,PMC3103669,5724,SU levels,Results|SU levels,[34960],[21347],[21356],[False],[0],[0],[False],['0']
4974,PMC3103669,5725,"At baseline, 85.2% to 92.6% of patients had SU levels ≥6 mg/dl (table 1).",Results|SU levels,[34966],[21357],[21430],[False],[0],[0],[False],['0']
4975,PMC3103669,5726,"At 16 weeks 38.9% to 53.7% of patients treated with canakinumab and 46.3% of patients treated with colchicine achieved SU levels <6 mg/dl and similar results were reported for week 24 (canakinumab, 37.0% to 50.9%; colchicine, 41.7%).",Results|SU levels,[34972],[21431],[21664],[False],[0],[0],[False],['0']
4976,PMC3103669,5727,Safety and tolerability,Results|Safety and tolerability,[34978],[21665],[21688],[False],[0],[0],[False],['0']
4977,PMC3103669,5728,Safety results for the individual dose groups are summarised in table 3.,Results|Safety and tolerability,[34984],[21689],[21761],[False],[0],[0],[False],['0']
4978,PMC3103669,5729,The incidence of AEs over the 24-week period was similar across the six canakinumab groups (51.9% to 58.5%) and for the colchicine group (53.7%) (table 3).,Results|Safety and tolerability,[34990],[21762],[21917],[False],[0],[0],[False],['0']
4979,PMC3103669,5730,"Most AEs were mild or moderate in severity, and there was no evidence of a dose-response for any AE.",Results|Safety and tolerability,[34996],[21918],[22018],[False],[0],[0],[False],['0']
4980,PMC3103669,5731,SAEs were reported in 14 (4.3%) patients treated with canakinumab and 6 (5.6%) patients treated with colchicine; 2 were considered by the investigator to be possibly related to study medication: erysipelas of the left leg in the canakinumab 25 mg group and cancer of the right kidney in the colchicine group.,Results|Safety and tolerability,[35002],[22019],[22327],[False],[0],[0],[False],['0']
4981,PMC3103669,5732,"One death occurred in the colchicine group, a possible myocardial infarction, but was not regarded by the investigator as being related to study medication.",Results|Safety and tolerability,[35008],[22328],[22484],[False],[0],[0],[False],['0']
4982,PMC3103669,5733,"Five further patients discontinued due to SAEs (canakinumab, n=4 (1.2%); colchicine, n=1 (0.9%)).",Results|Safety and tolerability,[35014],[22485],[22582],[False],[0],[0],[False],['0']
4983,PMC3103669,5734,Infectious AEs were reported in 58 (18.0%) patients receiving canakinumab and 13 (12.0%) patients receiving colchicine 0.5 mg (table 3).,Results|Safety and tolerability,[35020],[22583],[22719],[False],[0],[0],[False],['0']
4984,PMC3103669,5735,There was no clear pattern with respect to the incidence of infections with either treatment.,Results|Safety and tolerability,[35026],[22720],[22813],[False],[0],[0],[False],['0']
4985,PMC3103669,5736,"The only infections occurring in more than 1% of patients receiving canakinumab were upper respiratory tract infections (3.7%), nasopharyngitis (3.7%) and influenza (1.2%).",Results|Safety and tolerability,[35032],[22814],[22986],[False],[0],[0],[False],['0']
4986,PMC3103669,5737,Upper respiratory tract infections (3.7%) and cystitis (1.9%) were the only infections occurring in more than 1% of patients receiving colchicine.,Results|Safety and tolerability,[35038],[22987],[23133],[False],[0],[0],[False],['0']
4987,PMC3103669,5738,"Six serious infections (erysipelas, gangrene, sepsis, tonsillitis, ear infection and pneumonia) were reported in four patients receiving canakinumab (table 3).",Results|Safety and tolerability,[35044],[23134],[23293],[False],[0],[0],[False],['0']
4988,PMC3103669,5739,Only the case of erysipelas was considered to be possibly related to study medication.,Results|Safety and tolerability,[35050],[23294],[23380],[False],[0],[0],[False],['0']
4989,PMC3103669,5740,No serious infections were reported in patients receiving colchicine.,Results|Safety and tolerability,[35056],[23381],[23450],[False],[0],[0],[False],['0']
4990,PMC3103669,5741,Injection-site reactions were reported in 20 (6.2%) patients treated with canakinumab and 4 (3.7%) patients in the colchicine group.,Results|Safety and tolerability,[35062],[23451],[23583],[False],[0],[0],[False],['0']
4991,PMC3103669,5742,All events were mild except for one moderate event in the canakinumab 50 mg group.,Results|Safety and tolerability,[35068],[23584],[23666],[False],[0],[0],[False],['0']
4992,PMC3103669,5743,One patient (in the 50 mg group) developed low levels of anti-canakinumab antibodies at week 24.,Results|Safety and tolerability,[35074],[23667],[23763],[False],[0],[0],[False],['0']
4993,PMC3103669,5744,Adverse events (safety set),Results|Adverse events (safety set),[35080],[23764],[23791],[False],[0],[0],[False],['0']
4994,PMC3103669,5745,Variable	Canakinumab 25 mg n=55	Canakinumab 50 mg n=54	Canakinumab 100 mg n=54	Canakinumab 200 mg n=54	Canakinumab 300 mg n=53	Canakinumab every 4 weeks n=53	Canakinumab Any dose n=323	Colchicine 0.5 mg n=108	 	Any SAE	2 (3.6)	2 (3.7)	3 (5.6)	3 (5.6)	3 (5.7)	1 (1.9)	14 (4.3)	6 (5.6)	 	SAE leading to discontinuation	1 (1.8)	0	1 (1.9)	2 (3.7)	0	0	4 (1.2)	2 (1.9)	 	Any serious infectious AE	1 (1.8)	0	0	2 (3.7)	0	1 (1.9)	4 (1.2)	0	 	Any AE	29 (52.7)	30 (55.6)	28 (51.9)	28 (51.9)	29 (54.7)	31 (58.5)	175 (54.2)	58 (53.7)	 	Any severe AE	4 (7.3)	4 (7.4)	2 (3.7)	3 (5.6)	1 (1.9)	0	14 (4.3)	6 (5.6)	 	Any infectious AE	11 (20.0)	8 (14.8)	10 (18.5)	11 (20.4)	8 (15.1)	10 (18.9)	58 (18.0)	13 (12.0)	 	Injection-site reaction	5 (9.1)	4 (7.4)	4 (7.4)	3 (5.6)	2 (3.8)	2 (3.8)	20 (6.2)	4 (3.7)	 	AE reported in >5% of patients in any group	 	 Headache	4 (7.3)	3 (5.6)	1 (1.9)	2 (3.7)	6 (11.3)	3 (5.7)	19 (5.9)	6 (5.6)	 	 Arthralgia	4 (7.3)	5 (9.3)	4 (7.4)	2 (3.7)	3 (5.7)	2 (3.8)	20 (6.2)	3 (2.8)	 	 Hypertension	6 (10.9)	2 (3.7)	2 (3.7)	5 (9.3)	4 (7.5)	2 (3.8)	21 (6.5)	1 (0.9)	 	 Upper respiratory tract infection	2 (3.6)	1 (1.9)	2 (3.7)	3 (5.6)	1 (1.9)	3 (5.7)	12 (3.7)	4 (3.7)	 	 Back pain	3 (5.5)	3 (5.6)	1 (1.9)	3 (5.6)	0	0	10 (3.1)	4 (3.7)	 	 Nasopharyngitis	5 (9.1)	2 (3.7)	2 (3.7)	0	0	3 (5.7)	12 (3.7)	1 (0.9)	 	 Diarrhoea	3 (5.5)	1 (1.9)	2 (3.7)	3 (5.6)	1 (1.9)	0	10 (3.1)	2 (1.9)	 	 Nausea	2 (3.6)	1 (1.9)	3 (5.6)	0	0	1 (1.9)	7 (2.2)	1 (0.9)	 	 Elevated alanine aminotransferase	3 (5.5)	1 (1.9)	0	1 (1.9)	0	0	5 (1.5)	1 (0.9)	 	 Elevated aspartate aminotransferase	3 (5.5)	1 (1.9)	0	1 (1.9)	0	0	5 (1.5)	1 (0.9)	 	 Rash	1 (1.8)	1 (1.9)	0	0	0	3 (5.7)	5 (1.5)	1 (0.9)	 	 Sinus congestion	0	0	0	0	3 (5.7)	0	3 (0.9)	1 (0.9),Results|Adverse events (safety set),[35086],[23792],[25511],[False],[0],[0],[False],['0']
4995,PMC3103669,5746,"AE, adverse event; SAE, serious AE.",Results|Adverse events (safety set),[35092],[25512],[25550],[False],[0],[0],[False],['0']
4996,PMC3103669,5747,Discussion,Discussion,[35098],[25551],[25562],[False],[0],[0],[False],['0']
4997,PMC3103669,5748,"This is the largest randomised, double-blind, active-controlled, multicentre trial reported in English in the medical literature to date assessing prophylaxis against acute gouty arthritis flares during the initiation of ULT.",Discussion,[35104],[25563],[25788],[False],[0],[0],[False],['0']
4998,PMC3103669,5749,"We herein report that a single dose of canakinumab, 50–300 mg, or 4-weekly doses given over 4 months (two doses of 50 mg and two of 25 mg) produced a 62% to 72% reduction in the mean number of flares per patient and a 64% to 72% reduction in the risk of experiencing ≥1 flare at 16 weeks compared with colchicine.",Discussion,[35110],[25789],[26102],[False],[0],[0],[False],['0']
4999,PMC3103669,5750,"In addition, the percentage of patients experiencing at least one flare at 16 weeks was significantly lower for all canakinumab doses compared with colchicine.",Discussion,[35116],[26103],[26262],[False],[0],[0],[False],['0']
5000,PMC3103669,5751,"Target SU levels (<6 mg/dl) were achieved in 39% to 54% of patients treated with canakinumab and 46% of patients treated with colchicine at 16 weeks, consistent with results of other recent studies of allopurinol treatment in patients who were hyperuricaemic.",Discussion,[35122],[26263],[26522],[False],[0],[0],[False],['0']
5001,PMC3103669,5752,All canakinumab doses were well tolerated.,Discussion,[35128],[26523],[26565],[False],[0],[0],[False],['0']
5002,PMC3103669,5753,These results suggest that canakinumab can provide effective prophylaxis against gouty arthritis flares and is well tolerated in patients initiating ULT.,Discussion,[35134],[26566],[26719],[False],[0],[0],[False],['0']
5003,PMC3103669,5754,The results of this study validate the concept that IL-1β is a key mediator in the generation of acute gouty arthritis flares and hence an appropriate therapeutic target for treatment of acute gouty arthritis and prevention of flares.,Discussion,[35140],[26720],[26954],[False],[0],[0],[False],['0']
5004,PMC3103669,5755,"This has previously been demonstrated in a phase II, dose-ranging study of canakinumab as treatment for acute flares in patients with difficult-to-treat gouty arthritis.",Discussion,[35146],[26955],[27124],[False],[0],[0],[False],['0']
5005,PMC3103669,5756,"In this earlier study the highest dose of canakinumab tested, 150 mg, demonstrated consistently superior efficacy to triamcinolone acetonide 40 mg across all efficacy measures assessed including pain reduction at 72 h post dose, time to a 50% reduction in pain and the risk of recurrent flares.",Discussion,[35152],[27125],[27419],[False],[0],[0],[False],['0']
5006,PMC3103669,5757,"Therefore, the canakinumab 150 mg dose has been chosen for further assessment as treatment of acute gouty arthritis in phase III trials.",Discussion,[35158],[27420],[27556],[False],[0],[0],[False],['0']
5007,PMC3103669,5758,"Rilonacept, another inhibitor of IL-1β signalling in development, has demonstrated efficacy with weekly doses of 160 mg in the prevention of flares in patients initiating ULT compared with placebo, but has apparently failed to demonstrate efficacy in the treatment of acute gouty arthritis.",Discussion,[35164],[27557],[27847],[False],[0],[0],[False],['0']
5008,PMC3103669,5759,The study reported here aimed to determine the dose of canakinumab for further study as prophylaxis for patients initiating ULT.,Discussion,[35170],[27848],[27976],[False],[0],[0],[False],['0']
5009,PMC3103669,5760,"However, no dose-response was evident with respect to the primary endpoint and the estimated dose with equivalent efficacy to colchicine was below the range of canakinumab doses tested.",Discussion,[35176],[27977],[28162],[False],[0],[0],[False],['0']
5010,PMC3103669,5761,Results of secondary outcomes indicated that single canakinumab doses of 50–300 mg or 4-weekly doses given over 4 months have similar efficacy across all clinical endpoints assessed and are superior to colchicine 0.5 mg.,Discussion,[35182],[28163],[28383],[False],[0],[0],[False],['0']
5011,PMC3103669,5762,The results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ULT when given at doses lower than those used to treat acute gouty arthritis flares.,Discussion,[35188],[28384],[28591],[False],[0],[0],[False],['0']
5012,PMC3103669,5763,Accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult-to-treat disease.,Discussion,[35194],[28592],[28789],[False],[0],[0],[False],['0']
5013,PMC3103669,5764,Such patients frequently have comorbidities and may be unable to receive standard anti-inflammatory therapies.,Discussion,[35200],[28790],[28900],[False],[0],[0],[False],['0']
5014,PMC3103669,5765,Results of a recent phase II study in patients with contraindications to non-steroidal anti-inflammatory drugs and/or colchicine have shown that canakinumab 150 mg provided effective pain relief and reduced the risk of new flares.,Discussion,[35206],[28901],[29131],[False],[0],[0],[False],['0']
5015,PMC3103669,5766,This suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment options due to comorbidities.,Discussion,[35212],[29132],[29279],[False],[0],[0],[False],['0']
5016,PMC3103669,5767,Ongoing phase III studies in this setting should help confirm the value of canakinumab for the treatment of this growing patient population who for whom improved treatment options are urgently required.,Discussion,[35218],[29280],[29482],[False],[0],[0],[False],['0']
5017,PMC3103669,5768,Canakinumab was generally well tolerated.,Discussion,[35224],[29483],[29524],[False],[0],[0],[False],['0']
5018,PMC3103669,5769,"Few patients experienced SAEs, severe AEs, or injection-site reactions.",Discussion,[35230],[29525],[29596],[False],[0],[0],[False],['0']
5019,PMC3103669,5770,"No organ toxicity and no dose-response for any AE were observed, and only one SAE was reported that was considered possibly related to canakinumab treatment.",Discussion,[35236],[29597],[29754],[False],[0],[0],[False],['0']
5020,PMC3103669,5771,"The safety profile of canakinumab reported here is consistent with that previously reported for treatment of acute gouty arthritis, and for patients with CAPS receiving canakinumab 150 mg at 8-week intervals for up to 48 weeks.",Discussion,[35242],[29755],[29982],[False],[0],[0],[False],['0']
5021,PMC3103669,5772,Colchicine doses of 0.5–1.0 mg/day are recommended by The European League Against Rheumatism and the British Society for Rheumatology for prophylaxis against flares in patients initiating ULT.,Discussion,[35248],[29983],[30175],[False],[0],[0],[False],['0']
5022,PMC3103669,5773,In this study we used a colchicine dose of 0.5 mg/day.,Discussion,[35254],[30176],[30230],[False],[0],[0],[False],['0']
5023,PMC3103669,5774,The choice of dose was based on the clinical experience of the investigators and results of a study indicating that a dose of 0.6 mg/day is better tolerated than a higher dose.,Discussion,[35260],[30231],[30407],[False],[0],[0],[False],['0']
5024,PMC3103669,5775,"In this particular study, the planned dose of colchicine prophylaxis was 0.6 mg twice daily.",Discussion,[35266],[30408],[30500],[False],[0],[0],[False],['0']
5025,PMC3103669,5776,"However, dosing was reduced to once daily in approximately two-thirds of patients and 38% of patients experienced diarrhoea.",Discussion,[35272],[30501],[30625],[False],[0],[0],[False],['0']
5026,PMC3103669,5777,"In three other recent studies in patients initiating ULT, a colchicine dose of 0.6 mg/day was employed as prophylaxis and significant rates of diarrhoea were not reported.",Discussion,[35278],[30626],[30797],[False],[0],[0],[False],['0']
5027,PMC3103669,5778,The rates of flares reported in these studies during colchicine prophylaxis (10% to 15% per month) are comparable with those reported in our study for the colchicine group.,Discussion,[35284],[30798],[30970],[False],[0],[0],[False],['0']
5028,PMC3103669,5779,There are a number of limitations to this study.,Discussion,[35290],[30971],[31019],[False],[0],[0],[False],['0']
5029,PMC3103669,5780,"First, colchicine 0.5 mg was only given for 16 weeks.",Discussion,[35296],[31020],[31073],[True],['FollowUpDuration'],['colchicine 0.5 mg was only given for 16 weeks'],[True],['StudyDuration']
5030,PMC3103669,5781,The risk of flares following initiation of ULT is known to extend for up to a year or longer; thus a more prolonged period of colchicine prophylaxis may have been appropriate.,Discussion,[35309],[31074],[31249],[True],['FollowUpDuration'],['a more prolonged period of colchicine prophylaxis may have been appropriate'],[True],['StudyDuration']
5031,PMC3103669,5782,"However, key efficacy outcomes including the primary outcome were assessed at 16 weeks.",Discussion,[35320],[31250],[31337],[False],[0],[0],[False],['0']
5032,PMC3103669,5783,"Second, occurrence and duration of flares was dependent on patients’ assessment.",Discussion,[35328],[31338],[31418],[True],['PrecisionOfMeasurement'],['occurrence and duration of flares was dependent on patients’ assessment'],[True],['OutcomeMeasures']
5033,PMC3103669,5784,This reflects the fact that there are currently no validated endpoints for the assessment of gouty arthritis flares.,Discussion,[35341],[31419],[31535],[True],['OutcomeMeasures'],['there are currently no validated endpoints for the assessment of gouty arthritis flares'],[True],['OutcomeMeasures']
5034,PMC3103669,5785,Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) have suggested possible endpoints for use in studies of gouty arthritis but these have yet to be validated.,Discussion,[35350],[31536],[31710],[False],[0],[0],[False],['0']
5035,PMC3103669,5786,The endpoints used in our study overlap with those suggested by OMERACT and use of patient self-reporting for flares is unlikely to have had an impact on the results.,Discussion,[35356],[31711],[31877],[False],[0],[0],[False],['0']
5036,PMC3103669,5787,"Third, the study population is probably not representative of all patients who would benefit from canakinumab.",Discussion,[35366],[31878],[31988],[True],['Generalization'],['the study population is probably not representative of all patients who would benefit from canakinumab'],[True],['Generalization']
5037,PMC3103669,5788,This reflects the need to exclude patients with possible risks associated with either treatment and the use of the exclusion criteria generally used in clinical trials in patients with gouty arthritis.,Discussion,[35374],[31989],[32190],[False],[0],[0],[False],['0']
5038,PMC3103669,5789,"Fourth, allopurinol treatment was initiated at 300 mg (or 100 mg or 200 mg if creatinine clearance was <90 ml/min) instead of slowly up-titrating from a dose of 50–100 mg, as suggested in treatment recommendations.",Discussion,[35385],[32191],[32405],[True],['NonstandardTreatmentCharacteristics'],"['allopurinol treatment was initiated at 300 mg (or 100 mg or 200 mg if creatinine clearance was <90 ml/min) instead of slowly up-titrating from a dose of 50–100 mg, as suggested in treatment recommendations']",[True],['Intervention']
5039,PMC3103669,5791,"However, giving allopurinol at a fixed dose is a very common practice throughout Europe.",Discussion,[35404],[32490],[32578],[False],[0],[0],[False],['0']
5040,PMC3103669,5792,"In conclusion, in this double-blind, active-controlled, multicentre study assessing prophylaxis against gouty arthritis flares during the initiation of ULT, a single canakinumab dose of 50–300 mg or 4-weekly dosing over 4 months provided effective prophylaxis against flares, was superior to the standard of care (colchicine) and was well tolerated.",Discussion,[35410],[32579],[32928],[False],[0],[0],[False],['0']
5041,PMC3103669,5793,Further studies of canakinumab 150 mg are being conducted to determine the full potential of this new drug for the prevention of flares in patients with gouty arthritis.,Discussion,[35416],[32929],[33098],[False],[0],[0],[False],['0']
5042,PMC3103669,5794,"Funding The study was funded by Novartis Pharma AG, Basel, Switzerland.",Discussion,[35422],[33099],[33170],[False],[0],[0],[False],['0']
5043,PMC3103669,5795,"The study was designed by Novartis Pharma AG (Sarah Magliano, Marianne Notter, Dominik Richard and PS) in conjunction with NS and AS.",Discussion,[35428],[33171],[33304],[False],[0],[0],[False],['0']
5044,PMC3103669,5796,Data were collected and analysed by Novartis according to the prespecified protocol.,Discussion,[35434],[33305],[33389],[False],[0],[0],[False],['0']
5045,PMC3103669,5797,"All authors, including UA, PS, GK and AB who are employees of Novartis, together with Kirstin Stricker, Novartis Pharma AG, were involved in the decision to publish.",Discussion,[35440],[33390],[33555],[False],[0],[0],[False],['0']
5046,PMC3103669,5798,All authors including those who are employees of Novartis were involved in the interpretation of the data and the writing of the paper.,Discussion,[35446],[33556],[33691],[False],[0],[0],[False],['0']
5047,PMC3103669,5799,"Medical writing and editorial assistance were provided by Rowena Hughes and Gemma Carter, Oxford PharmaGenesis Ltd, following teleconferences with all authors during which the data, its interpretation and the content of the paper were discussed; this was funded by Novartis Pharma AG.",Discussion,[35452],[33692],[33976],[False],[0],[0],[False],['0']
5048,PMC3103669,5800,All authors approved the submitted paper.,Discussion,[35458],[33977],[34018],[False],[0],[0],[False],['0']
5049,PMC3103669,5801,"Competing interests NS: grant, travel expenses and payment for advisory board membership from Novartis Pharma, payment for development of educational presentations from Takeda and payment for advisory board membership from Savient, URL Pharma and Enzyme Rx.",Discussion,[35464],[34019],[34276],[False],[0],[0],[False],['0']
5050,PMC3103669,5802,"H-YL, EM and JR report no conflicts of interest.",Discussion,[35470],[34277],[34325],[False],[0],[0],[False],['0']
5051,PMC3103669,5803,MDeM: payment from Novartis for development of educational presentations.,Discussion,[35476],[34326],[34399],[False],[0],[0],[False],['0']
5052,PMC3103669,5804,"PS, UA, GK and AB are employees of Novartis and report having equity interests in Novartis.",Discussion,[35482],[34400],[34491],[False],[0],[0],[False],['0']
5053,PMC3103669,5805,"AS: payment from Novartis for board membership, consultancy and travel expenses.",Discussion,[35488],[34492],[34572],[False],[0],[0],[False],['0']
5054,PMC3103669,5806,Ethics approval This study was approved by all responsible independent ethics committees.,Discussion,[35494],[34573],[34662],[False],[0],[0],[False],['0']
5055,PMC3103669,5807,Provenance and peer review Not commissioned; externally peer reviewed.,Discussion,[35500],[34663],[34733],[False],[0],[0],[False],['0']
5694,PMC3208022,27423,Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: Lighten Up randomised controlled trial,Title,[163671],[61556],[182],[False],[0],[0],[False],['0']
5695,PMC3208022,27424,Objective To assess the effectiveness of a range of weight management programmes in terms of weight loss.,Abstract,[163680],[183],[289],[False],[0],[0],[False],['0']
5696,PMC3208022,27425,Design Eight arm randomised controlled trial.,Abstract,[163689],[290],[335],[False],[0],[0],[False],['0']
5697,PMC3208022,27426,"Setting Primary care trust in Birmingham, England.",Abstract,[163698],[336],[386],[False],[0],[0],[False],['0']
5698,PMC3208022,27427,Participants 740 obese or overweight men and women with a comorbid disorder identified from general practice records.,Abstract,[163707],[387],[504],[False],[0],[0],[False],['0']
5699,PMC3208022,27428,"Interventions Weight loss programmes of 12 weeks’ duration: Weight Watchers; Slimming World; Rosemary Conley; group based, dietetics led programme; general practice one to one counselling; pharmacy led one to one counselling; choice of any of the six programmes.",Abstract,[163716],[505],[767],[False],[0],[0],[False],['0']
5700,PMC3208022,27429,The comparator group was provided with 12 vouchers enabling free entrance to a local leisure (fitness) centre.,Abstract,[163725],[768],[878],[False],[0],[0],[False],['0']
5701,PMC3208022,27430,Main outcome measures The primary outcome was weight loss at programme end (12 weeks).,Abstract,[163734],[879],[965],[False],[0],[0],[False],['0']
5702,PMC3208022,27431,"Secondary outcomes were weight loss at one year, self reported physical activity, and percentage weight loss at programme end and one year.",Abstract,[163743],[966],[1105],[False],[0],[0],[False],['0']
5703,PMC3208022,27432,Results Follow-up data were available for 658 (88.9%) participants at programme end and 522 (70.5%) at one year.,Abstract,[163752],[1106],[1218],[False],[0],[0],[False],['0']
5704,PMC3208022,27433,"All programmes achieved significant weight loss from baseline to programme end (range 1.37 kg (general practice) to 4.43 kg (Weight Watchers)), and all except general practice and pharmacy provision resulted in significant weight loss at one year.",Abstract,[163761],[1219],[1466],[False],[0],[0],[False],['0']
5705,PMC3208022,27434,"At one year, only the Weight Watchers group had significantly greater weight loss than did the comparator group (2.5 (95% confidence interval 0.8 to 4.2) kg greater loss,).",Abstract,[163770],[1467],[1639],[False],[0],[0],[False],['0']
5706,PMC3208022,27435,The commercial programmes achieved significantly greater weight loss than did the primary care programmes at programme end (mean difference 2.3 (1.3 to 3.4) kg).,Abstract,[163779],[1640],[1801],[False],[0],[0],[False],['0']
5707,PMC3208022,27436,The primary care programmes were the most costly to provide.,Abstract,[163788],[1802],[1862],[False],[0],[0],[False],['0']
5708,PMC3208022,27437,Participants allocated to the choice arm did not have better outcomes than those randomly allocated to a programme.,Abstract,[163797],[1863],[1978],[False],[0],[0],[False],['0']
5709,PMC3208022,27438,"Conclusions Commercially provided weight management services are more effective and cheaper than primary care based services led by specially trained staff, which are ineffective.",Abstract,[163806],[1979],[2158],[False],[0],[0],[False],['0']
5710,PMC3208022,27439,Trial registration Current Controlled Trials ISRCTN25072883.,Abstract,[163815],[2159],[2219],[False],[0],[0],[False],['0']
5711,PMC3208022,27440,Introduction,Introduction,[163824],[2220],[2233],[False],[0],[0],[False],['0']
5712,PMC3208022,27441,"The World Health Organization has described the increase in obesity worldwide as a “global epidemic,”1 and it is associated with several chronic medical conditions.2 Obesity is now very common—for example, almost a quarter of the population of England are now classified as obese,3 as defined by the WHO’s criterion of a body mass index of 30 or above.1",Introduction,[163833],[2234],[2587],[False],[0],[0],[False],['0']
5713,PMC3208022,27442,"Guidelines recommend that primary care physicians in England should identify people with obesity and offer clinical management,4 but few options for treatment exist in traditional primary care settings.",Introduction,[163842],[2588],[2790],[False],[0],[0],[False],['0']
5714,PMC3208022,27443,One widely available option is a commercial weight management programme.,Introduction,[163851],[2791],[2863],[False],[0],[0],[False],['0']
5715,PMC3208022,27444,"In some areas, the English National Health Service offers these services free to patients, and some evidence supports the effectiveness of such provision.",Introduction,[163860],[2864],[3018],[False],[0],[0],[False],['0']
5716,PMC3208022,27445,"A randomised trial of 400 overweight and obese adults in the United States showed that people offered two years’ free use of a commercial weight management service lost 2.0 kg, whereas those offered two consultations with a dietitian and self help resources lost 0.2 kg at the end of two years.5 (These figures were calculated according to intention to treat, using baseline observation carried forward for missing data.",Introduction,[163869],[3019],[3439],[False],[0],[0],[False],['0']
5717,PMC3208022,27446,"Unless otherwise indicated, all figures quoted in this paper use this convention.)",Introduction,[163878],[3440],[3522],[False],[0],[0],[False],['0']
5718,PMC3208022,27447,"Another trial comparing a very similar control group with a different commercially available intervention, which supplied pre-packaged “diet” foods,6 had similar conclusions, with weight loss at one year of 6.6 kg versus 0.7 kg.",Introduction,[163887],[3523],[3751],[False],[0],[0],[False],['0']
5719,PMC3208022,27448,"More recently, a trial offering six months’ free use of commercial weight loss programmes led to weight loss of 5-6 kg compared with 0.6 kg in the control group, who were asked not to try to control their weight.7 Thus good evidence shows that commercial weight management services can be effective, but all existing trials investigated the effectiveness of prolonged treatment programmes that are not available in the English NHS nor in many other health systems.",Introduction,[163896],[3752],[4216],[False],[0],[0],[False],['0']
5720,PMC3208022,27449,"An alternative, potentially widely available, management option for obesity is for primary care teams to treat their obese patients themselves.",Introduction,[163905],[4217],[4360],[False],[0],[0],[False],['0']
5721,PMC3208022,27450,"A well known primary care programme, the Counterweight programme, has shown promising results in an uncontrolled trial.8 9 10 However, a cluster randomised trial showed that weight loss among obese patients offered treatment by primary care teams who had received well planned training in obesity management (4.5 hours’ total training) was less than 1 kg and was similar to the weight loss seen in control practices.11 Therefore, insufficient evidence exists for the effectiveness of obesity management in primary care.",Introduction,[163914],[4361],[4880],[False],[0],[0],[False],['0']
5722,PMC3208022,27451,We therefore investigated the effectiveness of several pragmatic interventions in primary care patients recruited in the English NHS.,Introduction,[163923],[4881],[5014],[False],[0],[0],[False],['0']
5723,PMC3208022,27452,"These included more modest entitlement to free commercial weight loss management programmes, primary care management, and a minimal intervention control.",Introduction,[163932],[5015],[5168],[False],[0],[0],[False],['0']
5724,PMC3208022,27453,Methods,Methods,[163941],[5169],[5177],[False],[0],[0],[False],['0']
5725,PMC3208022,27454,"The protocol for the study, describing the study design, is available online.12 Lighten Up was a randomised controlled trial with patients individually allocated to one of eight study groups.",Methods,[163950],[5178],[5369],[False],[0],[0],[False],['0']
5726,PMC3208022,27455,We compared six weight loss programmes with a minimal intervention comparator group provided with 12 vouchers enabling free entrance to a local leisure (fitness) centre.,Methods,[163959],[5370],[5539],[False],[0],[0],[False],['0']
5727,PMC3208022,27456,"Three weight loss programmes were provided by commercial operators: Weight Watchers, Slimming World, and Rosemary Conley.",Methods,[163968],[5540],[5661],[False],[0],[0],[False],['0']
5728,PMC3208022,27457,Three were provided by the NHS: a group weight loss programme (Size Down) and two primary care programmes—nurse led one to one support in general practice and one to one support by a pharmacist.,Methods,[163977],[5662],[5856],[False],[0],[0],[False],['0']
5729,PMC3208022,27458,The final study arm allowed for participants to choose one of the six interventions.,Methods,[163986],[5857],[5941],[False],[0],[0],[False],['0']
5730,PMC3208022,27459,Population,Methods|Population,[163995],[5942],[5952],[False],[0],[0],[False],['0']
5731,PMC3208022,27460,"Eligible participants were registered with general practices in South Birmingham Primary Care Trust, were aged at least 18 years, and had a raised body mass index recorded in their primary care notes within the previous 15 months.",Methods|Population,[164004],[5953],[6183],[False],[0],[0],[False],['0']
5732,PMC3208022,27461,The body mass index threshold for invitation was that which makes them eligible for primary care obesity management services in the NHS and varied according to ethnic group and the presence or absence of comorbidities (box 1).,Methods|Population,[164013],[6184],[6410],[False],[0],[0],[False],['0']
5733,PMC3208022,27462,The threshold for invitation for people with no obesity related comorbidity was a body mass index of 30 or above.,Methods|Population,[164022],[6411],[6524],[False],[0],[0],[False],['0']
5734,PMC3208022,27463,"For people of South Asian ethnicity, this threshold was lower.",Methods|Population,[164031],[6525],[6587],[False],[0],[0],[False],['0']
5735,PMC3208022,27464,The general practitioner had to confirm that the patient had no medical contraindications for any of the intervention programmes before a letter of invitation was sent.,Methods|Population,[164040],[6588],[6756],[False],[0],[0],[False],['0']
5736,PMC3208022,27465,We excluded patients if they were unable to understand English or were pregnant.,Methods|Population,[164049],[6757],[6837],[False],[0],[0],[False],['0']
5737,PMC3208022,27466,Seventeen practices took part.,Methods|Population,[164058],[6838],[6868],[False],[0],[0],[False],['0']
5738,PMC3208022,27467,Recruitment took place from January to May 2009.,Methods|Population,[164067],[6869],[6917],[False],[0],[0],[False],['0']
5739,PMC3208022,27468,"Eligible patients were invited to participate in the trial by a standard letter from their general practitioner, which included the patients’ information leaflet and a free telephone number for a call centre managing the recruitment and randomisation.",Methods|Population,[164076],[6918],[7169],[False],[0],[0],[False],['0']
5740,PMC3208022,27469,"The nurses at the call centre provided more information to patients about the trial, collected baseline information, took verbal consent, and randomised patients to the trial arms.",Methods|Population,[164085],[7170],[7350],[False],[0],[0],[False],['0']
5741,PMC3208022,27470,"The nurses then booked participants into their first treatment session and sent confirmation, along with verification of consent and information on how to withdraw from the trial if they changed their minds.",Methods|Population,[164094],[7351],[7558],[False],[0],[0],[False],['0']
5742,PMC3208022,27471,"Participants allocated to the general practice, pharmacy, or minimal intervention (comparator) groups were sent details about how to arrange their first session.",Methods|Population,[164103],[7559],[7720],[False],[0],[0],[False],['0']
5743,PMC3208022,27472,"We randomised participants from practices with personnel trained to provide the practice based weight management programme (n=7) to all eight arms with a block size of 35, whereas we randomised people from other practices (n=10) to one of seven groups (excluding general practice) in a block size of 13.",Methods|Population,[164112],[7721],[8024],[False],[0],[0],[False],['0']
5744,PMC3208022,27473,"An independent statistician prepared two separate randomisation sequences, and, to ensure blinding, the allocations were placed in opaque, consecutively numbered envelopes, which the call centre staff used in order.",Methods|Population,[164121],[8025],[8240],[False],[0],[0],[False],['0']
5745,PMC3208022,27474,"The block sizes were determined to achieve one to one randomisation across groups, except for the two primary care arms, for which spaces were limited and allocation was in a ratio of 1 to 0.7 compared with the other groups.",Methods|Population,[164130],[8241],[8465],[False],[0],[0],[False],['0']
5746,PMC3208022,27475,Interventions,Methods|Interventions,[164139],[8466],[8479],[False],[0],[0],[False],['0']
5747,PMC3208022,27476,"The participants allocated to the commercial operators Weight Watchers, Slimming World, and Rosemary Conley had a choice of locations and times for the programme.13 14 15 Participants were provided with vouchers that exempted them from paying for 12 consecutive weeks of the programmes.",Methods|Interventions,[164148],[8480],[8766],[False],[0],[0],[False],['0']
5748,PMC3208022,27477,"Each programme was provided in accordance with the respective organisation’s guidance and ran continuously, with no set start date; the group leaders were trained by the respective organisations.",Methods|Interventions,[164157],[8767],[8962],[False],[0],[0],[False],['0']
5749,PMC3208022,27478,The trial participants attended alongside people who paid to attend the programmes.,Methods|Interventions,[164166],[8963],[9046],[False],[0],[0],[False],['0']
5750,PMC3208022,27479,The Size Down Programme is an NHS group based programme led by food advisers recruited from the local community and trained by the dietetics department; sessions took place in various community venues.,Methods|Interventions,[164175],[9047],[9248],[False],[0],[0],[False],['0']
5751,PMC3208022,27480,"All members of the group started together and followed a prescribed course of six sessions, with follow-up weighing sessions at nine and 12 weeks.",Methods|Interventions,[164184],[9249],[9395],[False],[0],[0],[False],['0']
5752,PMC3208022,27481,Participants randomised to the general practice or pharmacy arms attended 12 one to one sessions in the general practice or pharmacy.,Methods|Interventions,[164193],[9396],[9529],[False],[0],[0],[False],['0']
5753,PMC3208022,27482,Appointments were made at a time mutually convenient to the participant and the nurse/pharmacist.,Methods|Interventions,[164202],[9530],[9627],[False],[0],[0],[False],['0']
5754,PMC3208022,27483,Staff delivering these programmes had attended a three day training course on weight management in adults delivered by dietitians experienced in the management of obesity.,Methods|Interventions,[164211],[9628],[9799],[False],[0],[0],[False],['0']
5755,PMC3208022,27484,"This included key messages on diet and physical activity, doing a behavioural assessment, goal setting, plans for change, dealing with resistance, enhancing motivation, and weight maintenance.",Methods|Interventions,[164220],[9800],[9992],[False],[0],[0],[False],['0']
5756,PMC3208022,27485,It included both practical tasks and informational components.,Methods|Interventions,[164229],[9993],[10055],[False],[0],[0],[False],['0']
5757,PMC3208022,27486,"Participants allocated to the comparator group were sent vouchers for 12 free sessions at a local authority run leisure centre (a council run facility open to all members of the public and usually consisting of a swimming pool, fitness suite, and other sports halls or courts).",Methods|Interventions,[164238],[10056],[10333],[False],[0],[0],[False],['0']
5758,PMC3208022,27487,Participants were not given an appointment to attend and were given no individual advice or support on diet or physical activity.,Methods|Interventions,[164247],[10334],[10463],[False],[0],[0],[False],['0']
5759,PMC3208022,27488,"Box 2 gives further details of the interventions, and fuller details are online.12",Methods|Interventions,[164256],[10464],[10546],[False],[0],[0],[False],['0']
5760,PMC3208022,27489,Data collection,Methods|Data collection,[164265],[10547],[10562],[False],[0],[0],[False],['0']
5761,PMC3208022,27490,Baseline data,Methods|Baseline data,[164274],[10563],[10576],[False],[0],[0],[False],['0']
5762,PMC3208022,27491,"Baseline weight and height were collected when participants attended the first session of their weight loss programme or, in the case of the minimal intervention comparator, at the leisure centre.",Methods|Baseline data,[164283],[10577],[10773],[False],[0],[0],[False],['0']
5763,PMC3208022,27492,Weight was measured without shoes in light clothing.,Methods|Baseline data,[164292],[10774],[10826],[False],[0],[0],[False],['0']
5764,PMC3208022,27493,"As some commercial programmes collected self reported height, height was re-measured using a Seca Leicester portable height measure at the one year follow-up.",Methods|Baseline data,[164301],[10827],[10985],[False],[0],[0],[False],['0']
5765,PMC3208022,27494,A researcher contacted participants who did not attend their first session to obtain a weight and height measurement.,Methods|Baseline data,[164310],[10986],[11103],[False],[0],[0],[False],['0']
5766,PMC3208022,27495,"The call centre collected other data at baseline, before randomisation: demographic data, current physical activity levels (using the International Physical Activity Questionnaire-short form (IPAQ-short)),16 and use of weight loss drugs.",Methods|Baseline data,[164319],[11104],[11341],[False],[0],[0],[False],['0']
5767,PMC3208022,27496,Outcome assessment,Methods|Outcome assessment,[164328],[11342],[11360],[False],[0],[0],[False],['0']
5768,PMC3208022,27497,The primary outcome was weight loss at three months’ follow-up (programme end).,Methods|Outcome assessment,[164337],[11361],[11440],[False],[0],[0],[False],['0']
5769,PMC3208022,27498,"Secondary outcomes were changes in self reported physical activity, weight loss at one year, and percentage weight loss at three months and one year.",Methods|Outcome assessment,[164346],[11441],[11590],[False],[0],[0],[False],['0']
5770,PMC3208022,27499,Follow-up assessments took place between April 2009 and August 2010.,Methods|Outcome assessment,[164355],[11591],[11659],[False],[0],[0],[False],['0']
5771,PMC3208022,27500,"Attendance at the programmes, apart from the minimal intervention comparator, was reported by the individual programme providers.",Methods|Outcome assessment,[164364],[11660],[11789],[False],[0],[0],[False],['0']
5772,PMC3208022,27501,"If participants were still attending their allocated weight loss intervention at programme end, the service providers weighed them and provided this data to the research team.",Methods|Outcome assessment,[164373],[11790],[11965],[False],[0],[0],[False],['0']
5773,PMC3208022,27502,We contacted participants who were no longer attending their allocated programme and offered them follow-up at home or another convenient location.,Methods|Outcome assessment,[164382],[11966],[12113],[False],[0],[0],[False],['0']
5774,PMC3208022,27503,"If participants declined to be followed up in person, we asked them to self report their weight.",Methods|Outcome assessment,[164391],[12114],[12210],[False],[0],[0],[False],['0']
5775,PMC3208022,27504,The IPAQ-short was re-administered by phone to all participants at three months.,Methods|Outcome assessment,[164400],[12211],[12291],[False],[0],[0],[False],['0']
5776,PMC3208022,27505,We sent participants who had dropped out of their allocated programme an open ended question asking for their views about the weight loss programme to which they had been allocated.,Methods|Outcome assessment,[164409],[12292],[12473],[False],[0],[0],[False],['0']
5777,PMC3208022,27506,"A trained practice nurse, health trainer, or researcher blinded to the allocation group did the one year assessment at the participant’s general practice or home.",Methods|Outcome assessment,[164418],[12474],[12636],[False],[0],[0],[False],['0']
5778,PMC3208022,27507,"This included assessment of weight and height, the IPAQ-short, and a free text question about their opinion of the service and whether they had tried any other weight loss programmes or strategies over the course of the year.",Methods|Outcome assessment,[164427],[12637],[12862],[False],[0],[0],[False],['0']
5779,PMC3208022,27508,"The scales used for weight measurement during the study period in the practices and by the weight management services were all checked with standardised weights, unless a record of recent calibration was available.",Methods|Outcome assessment,[164436],[12863],[13077],[False],[0],[0],[False],['0']
5780,PMC3208022,27509,Sample size,Sample size,[164445],[13078],[13090],[False],[0],[0],[False],['0']
5781,PMC3208022,27510,"To detect a 2 (SD 3.2) kg difference in weight loss at the three months’ follow-up between any of the planned interventions and the comparator group, with 90% power and 5% significance level and assuming 20% loss to follow-up, we needed 70 participants randomised to each group.",Sample size,[164454],[13091],[13369],[False],[0],[0],[False],['0']
5782,PMC3208022,27511,The sample size calculation did not take account of adjustments for multiple comparisons.,Sample size,[164463],[13370],[13459],[False],[0],[0],[False],['0']
5783,PMC3208022,27512,"To account for dropouts, we allocated 100 participants to each arm, except for the general practice and pharmacy arms.",Sample size,[164472],[13460],[13578],[False],[0],[0],[False],['0']
5784,PMC3208022,27513,"Because of limited availability, provision of these programmes was restricted to 70 participants per arm, resulting in a total sample size of 740 participants.",Sample size,[164481],[13579],[13738],[False],[0],[0],[False],['0']
5785,PMC3208022,27514,"We selected the 2 kg difference as being achievable from previous published studies,7 17 and an important contribution towards a 5% weight loss, which is associated with clinically meaningful health benefits.18 19",Sample size,[164490],[13739],[13952],[False],[0],[0],[False],['0']
5786,PMC3208022,27515,Analyses,Sample size|Analyses,[164499],[13953],[13961],[False],[0],[0],[False],['0']
5787,PMC3208022,27516,We did all analyses according to intention to treat and using Stata v11.0 and SPSS v17.0.,Sample size|Analyses,[164508],[13962],[14051],[False],[0],[0],[False],['0']
5788,PMC3208022,27517,"We preferred objectively measured weight, but we used self reported weights when they were the only measures available.",Sample size|Analyses,[164517],[14052],[14171],[False],[0],[0],[False],['0']
5789,PMC3208022,27518,We assumed participants for whom weight at follow-up was not available to have their baseline weight for the primary analyses.,Sample size|Analyses,[164526],[14172],[14298],[False],[0],[0],[False],['0']
5790,PMC3208022,27519,We also did a sensitivity analysis using the last recorded weight as the follow-up weight.,Sample size|Analyses,[164535],[14299],[14389],[False],[0],[0],[False],['0']
5791,PMC3208022,27520,"For the outcomes measured on a continuous scale (weight loss, self reported physical activity), we investigated differences between the seven intervention groups and the minimal exercise comparator group by using least squares linear regression.",Sample size|Analyses,[164544],[14390],[14635],[False],[0],[0],[False],['0']
5792,PMC3208022,27521,"Between group analyses are expressed as both unadjusted and adjusted differences (corrected for baseline score for weight and physical activity, age, sex, and ethnicity).",Sample size|Analyses,[164553],[14636],[14806],[False],[0],[0],[False],['0']
5793,PMC3208022,27522,"To adjust for multiple analyses, we applied a Bonferroni correction to each pair-wise comparison between intervention and control to maintain a 5% type I error rate across the seven comparisons made.",Sample size|Analyses,[164562],[14807],[15006],[False],[0],[0],[False],['0']
5794,PMC3208022,27523,"A secondary pre-specified analysis compared the outcomes of the commercial weight loss programmes (Weight Watchers, Slimming World, and Rosemary Conley) with those of the primary care programmes (general practice and pharmacy based interventions), as these programmes are widely generalisable.",Sample size|Analyses,[164571],[15007],[15300],[False],[0],[0],[False],['0']
5795,PMC3208022,27524,This analysis adjusted for the clustering of patients within their allocated treatment groups.,Sample size|Analyses,[164580],[15301],[15395],[False],[0],[0],[False],['0']
5796,PMC3208022,27525,We present the proportions of each group that achieved at least 5% weight loss at programme end and one year descriptively.,Sample size|Analyses,[164589],[15396],[15519],[False],[0],[0],[False],['0']
5797,PMC3208022,27526,We examined the effect of choosing a weight loss programme over being allocated to one by using a regression model that compared the programme randomised or chosen with the minimal intervention comparator but additionally included a single term to assess whether having chosen the programme had an additional beneficial effect over being randomised to the programme.,Sample size|Analyses,[164598],[15520],[15886],[False],[0],[0],[False],['0']
5798,PMC3208022,27527,We extended the model to examine whether any interaction existed between individual programmes and choice.,Sample size|Analyses,[164607],[15887],[15993],[False],[0],[0],[False],['0']
5799,PMC3208022,27528,"In an exploratory subgroup analysis, we examined weight loss separately in men and women by using a regression model, with the arm to which they were allocated and age as covariates.",Sample size|Analyses,[164616],[15994],[16176],[False],[0],[0],[False],['0']
5800,PMC3208022,27529,"Furthermore, we examined whether the effects of each intervention varied by sex by adding multiplicative interaction terms for intervention by sex to the model.",Sample size|Analyses,[164625],[16177],[16337],[False],[0],[0],[False],['0']
5801,PMC3208022,27530,"This is because commercial weight loss interventions are almost invariably run by women and treat their clients in groups dominated by women, so the effectiveness might vary by sex.",Sample size|Analyses,[164634],[16338],[16519],[False],[0],[0],[False],['0']
5802,PMC3208022,27531,Costs,Sample size|Costs,[164643],[16520],[16525],[False],[0],[0],[False],['0']
5803,PMC3208022,27532,We ascertained the price to the primary care trust of each programme and of sending out invitation letters from practices.,Sample size|Costs,[164652],[16526],[16648],[False],[0],[0],[False],['0']
5804,PMC3208022,27533,"We calculated the cost of the call centre that coordinated the service as an average per person, based on the cost of staff employed over a 12 month period and the number of clients who used the service over this time period.",Sample size|Costs,[164661],[16649],[16874],[False],[0],[0],[False],['0']
5805,PMC3208022,27534,Results,Results,[164670],[16875],[16883],[False],[0],[0],[False],['0']
5806,PMC3208022,27535,"Of the 8810 people invited, 1011 (11.5%) joined the Lighten Up service (740 as part of the trial and a further 271 in a pilot or after recruitment to the trial had finished).",Results,[164679],[16884],[17058],[False],[0],[0],[False],['0']
5807,PMC3208022,27536,"At programme end, 658 (88.9%) participants were followed up; 522 (70.5%) were followed up at one year (fig 1).",Results,[164688],[17059],[17169],[False],[0],[0],[False],['0']
5808,PMC3208022,27537,Table 1 shows the baseline characteristics of participants.,Results,[164697],[17170],[17229],[False],[0],[0],[False],['0']
5809,PMC3208022,27538,"Participants who were lost to follow-up at programme end tended to be younger than those who were followed up, but they were similar in terms of body mass index at the start of the programme, sex, ethnicity, and index of multiple deprivation score.",Results,[164706],[17230],[17478],[False],[0],[0],[False],['0']
5810,PMC3208022,27539,Weight loss at programme end,Results|Weight loss at programme end,[164715],[17479],[17507],[False],[0],[0],[False],['0']
5811,PMC3208022,27540,"The primary outcome of weight change at programme end was available for 587 (79.3%) participants, of which 233 (39.7%) weights were self reported.",Results|Weight loss at programme end,[164724],[17508],[17654],[False],[0],[0],[False],['0']
5812,PMC3208022,27541,"All programmes, including the minimal intervention comparator group, achieved statistically significant weight loss from baseline to the three month end of programme, with the mean weight loss ranging from 4.4 (SD 4.3) kg (Weight Watchers) to 1.4 (4.1) kg (general practice provision) in the primary analysis (missing data imputed with baseline value) (table 2).",Results|Weight loss at programme end,[164733],[17655],[18017],[False],[0],[0],[False],['0']
5813,PMC3208022,27542,"In the between group analyses, only the commercial providers (Weight Watchers and Rosemary Conley) had a statistically significantly greater weight loss and percentage weight loss than the exercise only comparator (tables 3 and 4).",Results|Weight loss at programme end,[164742],[18018],[18249],[False],[0],[0],[False],['0']
5814,PMC3208022,27543,"The findings did not differ when we adjusted the results for baseline weight, age, sex, or ethnic group.",Results|Weight loss at programme end,[164751],[18250],[18354],[False],[0],[0],[False],['0']
5815,PMC3208022,27544,"In the sensitivity analysis (with last recorded value used to impute missing data), the arm randomised to Slimming World also achieved a statistically significantly greater weight loss than the minimal intervention comparator in the unadjusted analysis (web appendix).",Results|Weight loss at programme end,[164760],[18355],[18623],[False],[0],[0],[False],['0']
5816,PMC3208022,27545,The proportion of participants in each arm who achieved at least 5% weight loss at programme end ranged from 16% to 46% (between general practice and Weight Watchers) (table 5).,Results|Weight loss at programme end,[164769],[18624],[18801],[False],[0],[0],[False],['0']
5817,PMC3208022,27546,Weight loss at one year,Results|Weight loss at one year,[164778],[18802],[18825],[False],[0],[0],[False],['0']
5818,PMC3208022,27547,"At one year, follow-up weight was recorded for 503 (68%) participants, of which 87 (17.3%) weights were self reported.",Results|Weight loss at one year,[164787],[18826],[18944],[False],[0],[0],[False],['0']
5819,PMC3208022,27548,Statistically significant weight loss from baseline to one year follow-up occurred in all groups apart from those in the primary care arms (general practice and pharmacy) (table 2).,Results|Weight loss at one year,[164796],[18945],[19126],[False],[0],[0],[False],['0']
5820,PMC3208022,27549,"In the between group analyses, only the Weight Watchers arm achieved a statistically significantly greater weight loss and percentage weight loss than the exercise only comparator (tables 3 and 4).",Results|Weight loss at one year,[164805],[19127],[19324],[False],[0],[0],[False],['0']
5821,PMC3208022,27550,"These findings did not differ in the sensitivity analyses, when the last recorded weight was used in the imputation (web appendix).",Results|Weight loss at one year,[164814],[19325],[19456],[False],[0],[0],[False],['0']
5822,PMC3208022,27551,The proportion of participants in each arm who achieved at least 5% weight loss at one year ranged from 14% to 31% (between pharmacy and Weight Watchers) (table 5).,Results|Weight loss at one year,[164823],[19457],[19621],[False],[0],[0],[False],['0']
5823,PMC3208022,27552,"At one year, 449 (60.7%) of the sample provided information about whether they were still trying to lose weight.",Results|Weight loss at one year,[164832],[19622],[19734],[False],[0],[0],[False],['0']
5824,PMC3208022,27553,"Of these, 177 (39%) respondents reported continuing to use the weight loss methods learnt from the programme they were allocated to; the highest proportions were from those allocated to Size Down (n=29; 53%) and Weight Watchers (34; 45%).",Results|Weight loss at one year,[164841],[19735],[19973],[False],[0],[0],[False],['0']
5825,PMC3208022,27554,"The participants who reported continuing to use the methods from their allocated weight loss programme had lost weight (0.57 (5.6) kg) from programme end to the one year follow-up, whereas those who had changed to another method had gained 1.17 (5.6) kg and those who had stopped trying to lose weight had gained 1.18 (6.0) kg (P=0.01).",Results|Weight loss at one year,[164850],[19974],[20310],[False],[0],[0],[False],['0']
5826,PMC3208022,27555,Per protocol analyses,Results|Per protocol analyses,[164859],[20311],[20332],[False],[0],[0],[False],['0']
5827,PMC3208022,27556,"To determine the weight loss in more adherent participants, we did a post hoc analysis of weight loss at programme end and at one year in participants who had started their programme (n=599).",Results|Per protocol analyses,[164868],[20333],[20524],[False],[0],[0],[False],['0']
5828,PMC3208022,27557,Within group weight loss was slightly higher than for the whole sample but retained the same differences between the study arms.,Results|Per protocol analyses,[164877],[20525],[20653],[False],[0],[0],[False],['0']
5829,PMC3208022,27558,"At programme end, with baseline observation carried forward, the general practice participants still had the lowest weight loss from baseline (1.91 (95% confidence interval 0.86 to 2.96) kg) and Weight Watchers had the largest weight loss (4.83 (3.97 to 5.70) kg).",Results|Per protocol analyses,[164886],[20654],[20918],[False],[0],[0],[False],['0']
5830,PMC3208022,27559,We saw a similar picture at one year.,Results|Per protocol analyses,[164895],[20919],[20956],[False],[0],[0],[False],['0']
5831,PMC3208022,27560,Effect of choice,Results|Effect of choice,[164904],[20957],[20973],[False],[0],[0],[False],['0']
5832,PMC3208022,27561,"In the choice arm, 71 (71%) participants chose one of the commercial providers (Weight Watchers 29 (29%), Slimming World 14 (14%), Rosemary Conley 28 (28%)), 16 (16%) chose the Size Down programme, 3 (3%) chose general practice, and 10 (10%) chose pharmacy provision.",Results|Effect of choice,[164913],[20974],[21241],[False],[0],[0],[False],['0']
5833,PMC3208022,27562,Women were more likely than men to choose one of the commercial providers (57 (81%) v 14 (47%)).,Results|Effect of choice,[164922],[21242],[21338],[False],[0],[0],[False],['0']
5834,PMC3208022,27563,We found no statistically significant difference in weight loss achieved at programme end or one year follow-up between participants who chose their programme and those who were randomised to the same programme (adjusted mean difference 0.19 (95% confidence interval −0.7 to 1.1) kg at programme end and 0.01 (−1.3 to 1.3) kg at one year.,Results|Effect of choice,[164931],[21339],[21677],[False],[0],[0],[False],['0']
5835,PMC3208022,27564,We found no statistically significant interaction between choice and programme.,Results|Effect of choice,[164940],[21678],[21757],[False],[0],[0],[False],['0']
5836,PMC3208022,27565,Effect of sex,Results|Effect of sex,[164949],[21758],[21771],[False],[0],[0],[False],['0']
5837,PMC3208022,27566,"In adjusted models, sex had no effect on weight loss at programme end or one year.",Results|Effect of sex,[164958],[21772],[21854],[False],[0],[0],[False],['0']
5838,PMC3208022,27567,Nor did we find any statistically significant interaction between sex and the weight loss programme.,Results|Effect of sex,[164967],[21855],[21955],[False],[0],[0],[False],['0']
5839,PMC3208022,27568,Commercial programmes versus one to one primary care programmes,Results|Effect of sex,[164976],[21956],[22019],[False],[0],[0],[False],['0']
5840,PMC3208022,27569,"In the pre-specified secondary analysis comparing the commercial programmes with the primary care programmes, participants randomised to the commercial programmes lost 2.3 (1.3 to 3.4) kg more than did those allocated to the primary care programmes at programme end (P=0.004).",Results|Effect of sex,[164985],[22020],[22296],[False],[0],[0],[False],['0']
5841,PMC3208022,27570,"In the analysis adjusted for age, ethnicity, sex, weight, and physical activity at baseline, the additional weight loss in the commercial groups was 2.3 (1.3 to 3.4) kg.",Results|Effect of sex,[164994],[22297],[22466],[False],[0],[0],[False],['0']
5842,PMC3208022,27571,"At one year, the difference was 1.7 (0.5 to 3.0) kg (P=0.02) unadjusted and 1.6 (0.3 to 2.9) kg (P=0.06) in the adjusted model.",Results|Effect of sex,[165003],[22467],[22594],[False],[0],[0],[False],['0']
5843,PMC3208022,27572,"Mean weight loss at one year, with baseline value used for imputation, was 0.8 (SD 4.7) kg for primary care and 2.5 (6.2) kg for commercial programmes.",Results|Effect of sex,[165012],[22595],[22746],[False],[0],[0],[False],['0']
5844,PMC3208022,27573,Self reported physical activity,Results|Self reported physical activity,[165021],[22747],[22778],[False],[0],[0],[False],['0']
5845,PMC3208022,27574,Self reported physical activity increased between baseline and follow-up in all groups (table 2).,Results|Self reported physical activity,[165030],[22779],[22876],[False],[0],[0],[False],['0']
5846,PMC3208022,27575,The smallest increase in activity was in those allocated to the general practice arm.,Results|Self reported physical activity,[165039],[22877],[22962],[False],[0],[0],[False],['0']
5847,PMC3208022,27576,"When we compared the change in physical activity with that in the comparator group at programme end, only the pharmacy group reported statistically significantly more activity in the unadjusted analysis.",Results|Self reported physical activity,[165048],[22963],[23166],[False],[0],[0],[False],['0']
5848,PMC3208022,27577,"At one year follow-up, only participants allocated to Weight Watchers reported more activity than the comparator group, although this was not statistically significant.",Results|Self reported physical activity,[165057],[23167],[23335],[False],[0],[0],[False],['0']
5849,PMC3208022,27578,Those allocated to the general practice arm were doing statistically significantly less physical activity than the comparator group (table 6).,Results|Self reported physical activity,[165066],[23336],[23478],[False],[0],[0],[False],['0']
5850,PMC3208022,27579,Attendance at programmes,Results|Attendance at programmes,[165075],[23479],[23503],[False],[0],[0],[False],['0']
5851,PMC3208022,27580,Figure 2 shows the attendance at the programmes.,Results|Attendance at programmes,[165084],[23504],[23552],[False],[0],[0],[False],['0']
5852,PMC3208022,27581,"The pharmacy and general practice groups had the highest proportions of participants attending less than 25% of sessions (54% (n=38) and 44% (31)), whereas Weight Watchers and the choice groups had the highest proportions attending 50% or more sessions (70% (70) and 74% (74)).",Results|Attendance at programmes,[165093],[23553],[23830],[False],[0],[0],[False],['0']
5853,PMC3208022,27582,"In the open ended feedback, 10 participants allocated to Rosemary Conley reported difficulties with completing the exercise part of the classes owing to arthritis and other musculoskeletal problems.",Results|Attendance at programmes,[165102],[23831],[24029],[False],[0],[0],[False],['0']
5854,PMC3208022,27583,Costs,Results|Costs,[165111],[24030],[24035],[False],[0],[0],[False],['0']
5855,PMC3208022,27584,Table 7 shows the costs of the programmes.,Results|Costs,[165120],[24036],[24078],[False],[0],[0],[False],['0']
5856,PMC3208022,27585,"These include the costs of the provider’s service and the cost of the searches in general practice, invitation letters, and provision of call centre support.",Results|Costs,[165129],[24079],[24236],[False],[0],[0],[False],['0']
5857,PMC3208022,27586,Discussion,Discussion,[165138],[24237],[24248],[False],[0],[0],[False],['0']
5858,PMC3208022,27587,"For our primary outcome of weight loss at programme end, although all the interventions resulted in a significant weight loss from baseline, only participants in the commercially run programmes (Weight Watchers and Rosemary Conley) had significantly greater weight loss than did those in the comparator group.",Discussion,[165147],[24249],[24558],[False],[0],[0],[False],['0']
5859,PMC3208022,27588,"At one year follow-up, participants in all the programmes apart from the one to one programmes in primary care and pharmacy settings had a significant weight loss from baseline, but only those allocated to Weight Watchers had a significantly greater loss than the comparator group.",Discussion,[165156],[24559],[24840],[False],[0],[0],[False],['0']
5860,PMC3208022,27589,Attendance seemed to be an important factor; the highest attendance rate was in Weight Watchers and the lowest for the primary care programmes.,Discussion,[165165],[24841],[24984],[False],[0],[0],[False],['0']
5861,PMC3208022,27590,Meaning of findings,Discussion|Meaning of findings,[165174],[24985],[25004],[False],[0],[0],[False],['0']
5862,PMC3208022,27591,"Although interventions varied in the emphasis that they placed on physical activity, all groups showed some increase in physical activity.",Discussion|Meaning of findings,[165183],[25005],[25143],[False],[0],[0],[False],['0']
5863,PMC3208022,27592,The typical participant did no moderate or vigorous activity (which does not include walking) at baseline and was doing 50-60 minutes a week at 12 weeks and about half that at one year follow-up.,Discussion|Meaning of findings,[165192],[25144],[25339],[False],[0],[0],[False],['0']
5864,PMC3208022,27593,Those in the exercise only comparator group were doing a similar amount to participants in other arms.,Discussion|Meaning of findings,[165201],[25340],[25442],[False],[0],[0],[False],['0']
5865,PMC3208022,27594,"All interventions therefore seemed to act as a spur for people to do what they already knew they should be doing, a conclusion that is supported by qualitative feedback from participants (data not shown).",Discussion|Meaning of findings,[165210],[25443],[25647],[False],[0],[0],[False],['0']
5866,PMC3208022,27595,"This activity was probably insufficient to account for weight loss in the comparator group, and this weight loss probably represents what might be achieved by people responding to a spur to action.",Discussion|Meaning of findings,[165219],[25648],[25845],[False],[0],[0],[False],['0']
5867,PMC3208022,27596,We believe that the comparator group was therefore a true control group.,Discussion|Meaning of findings,[165228],[25846],[25918],[False],[0],[0],[False],['0']
5868,PMC3208022,27597,The comparator group achieved statistically significant weight loss from baseline to follow-up at both programme end and one year.,Discussion|Meaning of findings,[165237],[25919],[26049],[False],[0],[0],[False],['0']
5869,PMC3208022,27598,This is probably a reflection of the motivation of those people who accepted the invitation to the weight loss programme.,Discussion|Meaning of findings,[165246],[26050],[26171],[False],[0],[0],[False],['0']
5870,PMC3208022,27599,"A meta-analysis of cohort studies showed that over four years of follow-up, obese people lose weight.20 The weight loss in our comparator group was only slightly greater than this “natural” weight loss observed in cohorts receiving no intervention.",Discussion|Meaning of findings,[165255],[26172],[26420],[False],[0],[0],[False],['0']
5871,PMC3208022,27600,"It is presumably a result of efforts by people to lose weight, most of which are unaided by specific interventions.",Discussion|Meaning of findings,[165264],[26421],[26536],[False],[0],[0],[False],['0']
5872,PMC3208022,27601,Our study shows that 12 week weight management courses are effective in producing clinically significant weight loss in a proportion of their clients.,Discussion|Meaning of findings,[165273],[26537],[26687],[False],[0],[0],[False],['0']
5873,PMC3208022,27602,Almost a third of people allocated to the Weight Watchers group achieved a clinically important 5% reduction in body weight at one year follow-up.,Discussion|Meaning of findings,[165282],[26688],[26834],[False],[0],[0],[False],['0']
5874,PMC3208022,27603,"This level of weight loss has been shown to reduce the risk of progression to diabetes.18 19 Other trials of commercial providers have shown greater weight loss, but these interventions were of longer duration.5 21 In a trial in the United Kingdom, Germany, and Australia, Jebb reported a 4.0 kg average weight loss after a one year Weight Watchers programme,21 which is only marginally greater than the 3.5 (SD 6.9) kg loss we found at one year as a result of a 12 week programme.",Discussion|Meaning of findings,[165291],[26835],[27316],[False],[0],[0],[False],['0']
5875,PMC3208022,27604,"In the United States, Heshka and colleagues reported that one year’s free access to Weight Watchers resulted in a weight reduction of 3.5 kg at one year.5 Truby and colleagues evaluated a six month programme in a volunteer sample recruited from a national media campaign and reported a 6.6 (SD 5.4) kg loss in those allocated to Weight Watchers and a 6.3 (6.1) kg loss in those allocated to Rosemary Conley at the six month follow-up.7 At one year, data were available only for completers, but with baseline observation carried forward the mean weight loss was 4.6 kg for the Weight Watchers and 5.3 kg for the Rosemary Conley groups.",Discussion|Meaning of findings,[165300],[27317],[27951],[False],[0],[0],[False],['0']
5876,PMC3208022,27605,The greater weight loss in these trials suggests that longer interventions might be somewhat more effective.,Discussion|Meaning of findings,[165309],[27952],[28060],[False],[0],[0],[False],['0']
5877,PMC3208022,27606,We did not find statistically significant benefits from the programmes in primary care.,Discussion|Meaning of findings,[165318],[28061],[28148],[False],[0],[0],[False],['0']
5878,PMC3208022,27607,"The Counterweight Project Team reported promising results from their weight management programme in primary care in the UK,8 9 10 but this was not a randomised trial.",Discussion|Meaning of findings,[165327],[28149],[28315],[False],[0],[0],[False],['0']
5879,PMC3208022,27608,"Using baseline observation carried forward, the mean weight loss at one year in the Counterweight programme was 1.3 kg, which is slightly greater than the 0.8 kg we report.",Discussion|Meaning of findings,[165336],[28316],[28488],[False],[0],[0],[False],['0']
5880,PMC3208022,27609,"Hardcastle and colleagues reported statistically significant weight loss at six months’ follow-up in a randomised controlled trial of a primary care based weight loss programme compared with a no intervention control, with weight loss of 0.7 kg, similar to our findings.22 Lower weight loss in general practice or pharmacies may be due to several factors.",Discussion|Meaning of findings,[165345],[28489],[28844],[False],[0],[0],[False],['0']
5881,PMC3208022,27610,"Firstly, although the primary care practitioners were trained in weight management counselling before the start of Lighten Up, they had considerably less experience of weight management than did counsellors/group leaders of other programmes, and this is one of a multitude of other roles they have in primary care.",Discussion|Meaning of findings,[165354],[28845],[29159],[False],[0],[0],[False],['0']
5882,PMC3208022,27611,"Secondly, primary care and pharmacy sessions were one to one and the dynamic of the group may be an important element in supporting successful weight loss.23 Thirdly, feedback from participants who did not complete the full programme suggested that they had difficulties in arranging convenient sessions so these often did not occur on a weekly basis, unlike the commercial programmes, which occur weekly at a regular time.",Discussion|Meaning of findings,[165363],[29160],[29583],[False],[0],[0],[False],['0']
5883,PMC3208022,27612,"Finally, some evidence suggests that primary care practitioners have little faith in their ability to effect positive change in their patients’ weight.24 Analogous data from smoking cessation programmes show that primary care based services are less effective than dedicated cessation services.25 26 This could indicate a generic problem with supporting behavioural change in primary care that needs further investigation.",Discussion|Meaning of findings,[165372],[29584],[30006],[False],[0],[0],[False],['0']
5884,PMC3208022,27613,The proportions of recruited participants who did not start the programmes varied considerably between the study groups.,Discussion|Meaning of findings,[165381],[30007],[30127],[False],[0],[0],[False],['0']
5885,PMC3208022,27614,This may well be related to the process for taking up the intervention.,Discussion|Meaning of findings,[165390],[30128],[30199],[False],[0],[0],[False],['0']
5886,PMC3208022,27615,"In the primary care programmes and minimal intervention comparator, participants were provided with details about how to make their first appointment, whereas for the commercial programmes participants were booked directly on to a programme and provided with details of the venue and time of their first session.",Discussion|Meaning of findings,[165399],[30200],[30512],[False],[0],[0],[False],['0']
5887,PMC3208022,27616,"The Size Down group was a closed group in which all participants started together, so some people had to wait several weeks before a new group started.",Discussion|Meaning of findings,[165408],[30513],[30664],[False],[0],[0],[False],['0']
5888,PMC3208022,27617,This may have accounted for the high proportion who did not start this programme.,Discussion|Meaning of findings,[165417],[30665],[30746],[False],[0],[0],[False],['0']
5889,PMC3208022,27618,This has implications for the planning of future similar programmes.,Discussion|Meaning of findings,[165426],[30747],[30815],[False],[0],[0],[False],['0']
5890,PMC3208022,27619,"Concerns have been raised about whether the commercial programmes are acceptable to men, as they are generally run by and attended by women.21 As with other weight loss trials,5 7 8 9 10 21 22 27 we had more female participants, so men seem to be less likely to accept the offer of this form of help.",Discussion|Meaning of findings,[165435],[30816],[31116],[False],[0],[0],[False],['0']
5891,PMC3208022,27620,"However, we found no evidence that outcomes were worse for men attending the commercial group based programmes.",Discussion|Meaning of findings,[165444],[31117],[31228],[False],[0],[0],[False],['0']
5892,PMC3208022,27621,"We did assign some of the commercial groups as “male friendly” so that men would know that there would be other male attendees, and in the case of a Rosemary Conley class a group walk was available as an alternative to the group exercise session.",Discussion|Meaning of findings,[165453],[31229],[31475],[False],[0],[0],[False],['0']
5893,PMC3208022,27622,"Men in the choice arm were more likely to select the NHS programmes, including the group based Size Down programme, possibly because of the female image of the commercial programmes, although almost half did select a commercial programme.",Discussion|Meaning of findings,[165462],[31476],[31714],[False],[0],[0],[False],['0']
5894,PMC3208022,27623,Two previous weight loss trials have investigated the effect of being allocated a choice of intervention.,Discussion|Meaning of findings,[165471],[31715],[31820],[False],[0],[0],[False],['0']
5895,PMC3208022,27624,"Burke and colleagues randomised participants either to choose one of two dietary regimens or to have this allocated randomly.28 The diets were equally effective in promoting weight loss, but people randomly allocated to a diet achieved significantly greater weight loss than did those allocated to choose their preferred diet (about 3.5 kg greater at 18 months).",Discussion|Meaning of findings,[165480],[31821],[32183],[False],[0],[0],[False],['0']
5896,PMC3208022,27625,"Renjilian and colleagues randomised participants to either choose between individual and group treatment for weight loss or be allocated the treatment modality that they did not prefer.23 The trial showed that group treatment was more effective than one to one treatment, but the differences in weight loss between those randomised to choice and those randomised to receive the modality they did not choose were small and non-significant.",Discussion|Meaning of findings,[165489],[32184],[32622],[False],[0],[0],[False],['0']
5897,PMC3208022,27626,"Taken together with our results, these data indicate that choice of treatment programme is not important in the efficacy of weight management programmes.",Discussion|Meaning of findings,[165498],[32623],[32776],[False],[0],[0],[False],['0']
5898,PMC3208022,27627,"As long as people are prepared to participate, they will probably benefit.",Discussion|Meaning of findings,[165507],[32777],[32851],[False],[0],[0],[False],['0']
5899,PMC3208022,27628,"Promoting choice in health interventions risks promoting less effective options, as happened here in the Lighten Up trial.",Discussion|Meaning of findings,[165516],[32852],[32974],[False],[0],[0],[False],['0']
5900,PMC3208022,27629,People seem to be unable to choose a programme for weight management that is more effective for them than one simply allocated at random.,Discussion|Meaning of findings,[165525],[32975],[33112],[False],[0],[0],[False],['0']
5901,PMC3208022,27630,"To illustrate the potential importance to public health of the effects of the commercial weight loss interventions, we constructed a life table.",Discussion|Meaning of findings,[165534],[33113],[33257],[False],[0],[0],[False],['0']
5902,PMC3208022,27631,"Firstly, we calculated the age and sex specific mortality rates for people of ideal body mass index from published UK data (available from the authors).",Discussion|Meaning of findings,[165543],[33258],[33410],[False],[0],[0],[False],['0']
5903,PMC3208022,27632,"Secondly, we applied the hazard ratio for an increase to a body mass index of 34 (the mean of our trial population).29 We then used these rates to produce a life table from age 49 years (the mean age in the trial).",Discussion|Meaning of findings,[165552],[33411],[33625],[False],[0],[0],[False],['0']
5904,PMC3208022,27633,"In the most effective intervention, participants lost 1.3 kg/m2 on average, and we recalculated the life table on the basis of this reduced body mass index.",Discussion|Meaning of findings,[165561],[33626],[33782],[False],[0],[0],[False],['0']
5905,PMC3208022,27634,The difference in life expectancy was about one year.,Discussion|Meaning of findings,[165570],[33783],[33836],[False],[0],[0],[False],['0']
5906,PMC3208022,27635,"If we assumed that the people randomised to this intervention continued to weigh 1.3 kg/m2 less throughout life, then the cost per life year saved was about £77 (€88; $122).",Discussion|Meaning of findings,[165579],[33837],[34010],[False],[0],[0],[False],['0']
5907,PMC3208022,27636,"These benefits are not discounted and make many assumptions, but they illustrate that this intervention could be very cost effective, with the critical factor being duration of maintenance of weight loss.",Discussion|Meaning of findings,[165588],[34011],[34215],[False],[0],[0],[False],['0']
5908,PMC3208022,27637,"A two year study of a commercial programme showed minor weight regain in the second year, but the intervention was available to participants during that time.5 More intensive interventions on weight loss in the diabetes prevention studies have shown a declining but small persistent advantage over 10 years for those receiving the intensive intervention,30 but whether weight loss persists from a 12 week intervention of the kind we examined is unknown.",Discussion|Meaning of findings,[165597],[34216],[34669],[False],[0],[0],[False],['0']
5909,PMC3208022,27638,"Given the potential effect on the population, this is a priority for further research, as is research on prevention of weight regain.",Discussion|Meaning of findings,[165606],[34670],[34803],[False],[0],[0],[False],['0']
5910,PMC3208022,27639,Strengths and limitations of study,Discussion|Strengths and limitations of study,[165615],[34804],[34838],[False],[0],[0],[False],['0']
5911,PMC3208022,27640,"This trial was an evaluation of a range of weight management programmes in a real service context, and we have shown that robust evaluation of new services is possible.",Discussion|Strengths and limitations of study,[165624],[34839],[35007],[False],[0],[0],[False],['0']
5912,PMC3208022,27641,"We kept data collection to a minimum to encourage people to take part, thus increasing the generalisability of the results.",Discussion|Strengths and limitations of study,[165633],[35008],[35131],[False],[0],[0],[False],['0']
5913,PMC3208022,27642,"However, unlike most other trials,7 8 9 10 21 we have measured self reported physical activity to determine the contribution this makes to weight loss.",Discussion|Strengths and limitations of study,[165642],[35132],[35283],[False],[0],[0],[False],['0']
5914,PMC3208022,27643,"The population was more diverse than in many previous trials8 9 10 17 31; 13% of the sample were from an ethnic minority group, more than 30% were men, and 73.4% were from the two most socioeconomically disadvantaged fifths of the population.",Discussion|Strengths and limitations of study,[165651],[35284],[35526],[False],[0],[0],[False],['0']
5915,PMC3208022,27644,"The characteristics of our recruited participants reflect the population of the primary care trust well; 23.5% of the participants were in the bottom 10% of socioeconomic deprivation, which is similar to that for the primary care trust, and the 13% of participants from a minority ethnic group is slightly lower than the local prevalence of 18%.",Discussion|Strengths and limitations of study,[165660],[35527],[35872],[False],[0],[0],[False],['0']
5916,PMC3208022,27645,"In one practice for which data were available, we investigated how the characteristics of people who were invited differed from those who joined the study.",Discussion|Strengths and limitations of study,[165669],[35873],[36028],[False],[0],[0],[False],['0']
5917,PMC3208022,27646,"We found no difference in ethnicity, mean age, or socioeconomic deprivation, but, as expected, women were more likely to accept the invitation to take part.",Discussion|Strengths and limitations of study,[165678],[36029],[36185],[False],[0],[0],[False],['0']
5918,PMC3208022,27647,"Our follow-up rates at one year compare well with other studies of weight management interventions, which reduced bias from attrition.7 8 9 10 21",Discussion|Strengths and limitations of study,[165687],[36186],[36331],[False],[0],[0],[False],['0']
5919,PMC3208022,27648,Our trial has some limitations.,Discussion|Strengths and limitations of study,[165696],[36332],[36363],[False],[0],[0],[False],['0']
5920,PMC3208022,27649,"It was powered only to compare individual programmes with the comparator group, not to make head to head comparisons between programmes.",Discussion|Strengths and limitations of study,[165705],[36364],[36500],[True],['UnderpoweredStudy'],['It was powered only to compare individual programmes with the comparator group'],[True],['UnderpoweredStudy']
5921,PMC3208022,27650,"Where we were unable to get an objective weight measurement, we asked participants to self report.",Discussion|Strengths and limitations of study,[165724],[36501],[36599],[True],['PrecisionOfMeasurement'],['we asked participants to self report'],[True],['OutcomeMeasures']
5922,PMC3208022,27651,"However, we do not believe that this will have led to overestimation of weight loss, as those who self reported their weight at the time of predicted programme end had a smaller weight loss than did those who provided an objective measure of weight, but some measurement error may exist.",Discussion|Strengths and limitations of study,[165743],[36600],[36887],[True],['PrecisionOfMeasurement'],['some measurement error may exist'],[True],['OutcomeMeasures']
5923,PMC3208022,27652,"The self reported physical activity seems high and, as reported previously,32 33 is likely to be an overestimate.",Discussion|Strengths and limitations of study,[165762],[36888],[37001],[True],['PrecisionOfMeasurement'],"['The self reported physical activity seems high and, as reported previously,32 33 is likely to be an overestimate']",[True],['OutcomeMeasures']
5924,PMC3208022,27653,"However, as we had baseline measures, we are able to present change in activity, and differences in overestimation between trial arms are unlikely.",Discussion|Strengths and limitations of study,[165777],[37002],[37149],[False],[0],[0],[False],['0']
5925,PMC3208022,27654,"To increase the uptake and follow-up rates, we kept data collection to a minimum, so we do not have data on health outcomes or on the previous strategies for weight loss used by the participants.",Discussion|Strengths and limitations of study,[165790],[37150],[37345],[True],['MissingData'],['we do not have data on health outcomes or on the previous strategies for weight loss used by the participants'],[True],['MissingData']
5926,PMC3208022,27655,The response rate to the invitation was 11.5%.,Discussion|Strengths and limitations of study,[165804],[37346],[37392],[False],[0],[0],[False],['0']
5927,PMC3208022,27656,These are likely to be people who were most motivated to change.,Discussion|Strengths and limitations of study,[165818],[37393],[37457],[True],['VerySpecificPopulation'],['These are likely to be people who were most motivated to change'],[True],['Population']
5928,PMC3208022,27657,"Invitation was by post, and a face to face invitation in the context of a consultation might result in higher uptake of the service.",Discussion|Strengths and limitations of study,[165831],[37458],[37590],[False],[0],[0],[False],['0']
5929,PMC3208022,27658,"Attendance data were provided by the providers of the weight management programmes and could not be independently validated, so they may be subject to some errors.",Discussion|Strengths and limitations of study,[165846],[37591],[37754],[True],['PrecisionOfMeasurement'],['they may be subject to some errors'],[True],['OutcomeMeasures']
5930,PMC3208022,27659,The costs that we present are the direct costs of the programme to the primary care trust; we have not tried to determine cost to primary care from a change in consultation rates or drugs or the costs to the participants of attending the programmes or purchasing any products from the commercial programmes.,Discussion|Strengths and limitations of study,[165865],[37755],[38062],[True],['MissingData'],['we have not tried to determine cost'],[True],['MissingData']
5931,PMC3208022,27660,We could not unpick the elements associated with greater weight loss in people who attended the commercial programmes.,Discussion|Strengths and limitations of study,[165884],[38063],[38181],[True],['ConfoundingFactors'],['We could not unpick the elements associated with greater weight loss in people who attended the commercial programmes'],[True],['StatisticalAnalysis']
5932,PMC3208022,27661,"This might have been due to the group based approach, the skills and background of the group leaders, the regularity of sessions, or easy booking for the first session and no scheduling requirements thereafter.",Discussion|Strengths and limitations of study,[165894],[38182],[38392],[False],[0],[0],[False],['0']
5933,PMC3208022,27662,Conclusion,Discussion|Conclusion,[165903],[38393],[38403],[False],[0],[0],[False],['0']
5934,PMC3208022,27663,Our findings suggest that a 12 week group based dedicated programme of weight management can result in clinically useful amounts of weight loss that are sustained at one year in an unselected primary care population with obesity.,Discussion|Conclusion,[165912],[38404],[38633],[False],[0],[0],[False],['0']
5935,PMC3208022,27664,Interventions provided by primary care showed no evidence of effectiveness.,Discussion|Conclusion,[165921],[38634],[38709],[False],[0],[0],[False],['0']
5936,PMC3208022,27665,The only programme to achieve statistically significantly greater weight loss than the comparator group was Weight Watchers.,Discussion|Conclusion,[165930],[38710],[38834],[False],[0],[0],[False],['0']
5937,PMC3208022,27666,Further research should explore the optimal duration of such programmes.,Discussion|Conclusion,[165939],[38835],[38907],[False],[0],[0],[False],['0']
8904,PMC3424202,14674,Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated  Plasmodium falciparum  malaria in India,Title,[88556],[33582],[152],[False],[0],[0],[False],['0']
8905,PMC3424202,14675,Background,Abstract,[88560],[153],[164],[False],[0],[0],[False],['0']
8906,PMC3424202,14676,"Resistance in Plasmodium falciparum to commonly used anti-malarial drugs, especially chloroquine, is being increasingly documented in India.",Abstract,[88564],[165],[305],[False],[0],[0],[False],['0']
8907,PMC3424202,14677,"By 2007, the first-line treatment for uncomplicated malaria has been revised to recommend artemisinin-based combination therapy (ACT) for all confirmed P. falciparum cases.",Abstract,[88568],[306],[478],[False],[0],[0],[False],['0']
8908,PMC3424202,14678,Objective,Objective,[88572],[479],[489],[False],[0],[0],[False],['0']
8909,PMC3424202,14679,"The objective of this study was to compare the efficacy, safety and tolerability between dihydroartemisinin-piperaquine (DP) and artesunate plus mefloquine (A + M) drug combinations in the treatment of uncomplicated P. falciparum malaria in India.",Objective,[88576],[490],[737],[False],[0],[0],[False],['0']
8910,PMC3424202,14680,Methods,Methods,[88580],[738],[746],[False],[0],[0],[False],['0']
8911,PMC3424202,14681,"Between 2006 and 2007, 150 patients with acute uncomplicated P. falciparum malaria were enrolled, randomized to DP (101) or A + M (49) and followed up for 63 days as part of an open-label, non-inferiority, randomized, phase III multicenter trial in Asia.",Methods,[88584],[747],[1001],[False],[0],[0],[False],['0']
8912,PMC3424202,14682,Results,Results,[88588],[1002],[1010],[False],[0],[0],[False],['0']
8913,PMC3424202,14683,"The heterogeneity analysis showed no statistically significant difference between India and the other countries involved in the phase III study, for both the PCR-corrected and uncorrected cure rates.",Results,[88592],[1011],[1210],[False],[0],[0],[False],['0']
8914,PMC3424202,14684,"As shown at the whole study level, both forms of ACT were highly efficacious in India.",Results,[88596],[1211],[1297],[False],[0],[0],[False],['0']
8915,PMC3424202,14685,"In fact, in the per protocol population, the 63-day cure rates were 100% for A + M and 98.8% for DP.",Results,[88600],[1298],[1398],[False],[0],[0],[False],['0']
8916,PMC3424202,14686,"The DP combination exerted a significant post-treatment prophylactic effect, and compared with A + M a significant reduction in the incidence of new infections for DP was observed (respectively 17.1% versus 7.5% of patients experienced new infection within follow up).",Results,[88604],[1399],[1667],[False],[0],[0],[False],['0']
8917,PMC3424202,14687,Parasite and fever clearance was rapid in both treatment arms (median time to parasite clearance of one day for both groups).,Results,[88608],[1668],[1793],[False],[0],[0],[False],['0']
8918,PMC3424202,14688,"Both DP and A + M were well tolerated, with the majority of adverse events of mild or moderate severity.",Results,[88612],[1794],[1898],[False],[0],[0],[False],['0']
8919,PMC3424202,14689,"The frequencies of individual adverse events were generally similar between treatments, although the incidence of post treatment adverse events was slightly higher in patients who received A + M with respect to those treated with DP.",Results,[88616],[1899],[2132],[False],[0],[0],[False],['0']
8920,PMC3424202,14690,Conclusion,Conclusion,[88620],[2133],[2144],[False],[0],[0],[False],['0']
8921,PMC3424202,14691,DP is a new ACT displaying high efficacy and safety in the treatment of uncomplicated P. falciparum malaria and could potentially be considered for the first-line treatment of uncomplicated falciparum malaria in India.,Conclusion,[88624],[2145],[2363],[False],[0],[0],[False],['0']
8922,PMC3424202,14692,Trial registration,Trial registration,[88628],[2364],[2383],[False],[0],[0],[False],['0']
8923,PMC3424202,14693,Current Controlled Trials ISRCTN 81306618,Trial registration,[88632],[2384],[2425],[False],[0],[0],[False],['0']
8924,PMC3424202,14694,Background,Background,[88636],[2426],[2438],[False],[0],[0],[False],['0']
8925,PMC3424202,14695,"Malaria continues to be a major public health challenge in South East Asia, where 30% of the global population is estimated to be at risk of malaria.",Background,[88640],[2439],[2588],[False],[0],[0],[False],['0']
8926,PMC3424202,14696,India alone contributes about 70% of reported cases [1].,Background,[88644],[2589],[2645],[False],[0],[0],[False],['0']
8927,PMC3424202,14697,"More than two-third of the Indian population lives in endemic areas where, overall, two million cases and 1,000 deaths attributable to malaria are reported annually [2].",Background,[88648],[2646],[2815],[False],[0],[0],[False],['0']
8928,PMC3424202,14698,"There are regional variations in the prevalence and transmission of the disease due to the presence of different parasite species (mainly Plasmodium falciparum and Plasmodium vivax), mosquito vectors, ecological conditions, and socio-economic factors.",Background,[88652],[2816],[3067],[False],[0],[0],[False],['0']
8929,PMC3424202,14699,"The Annual Parasite Incidence (API), an indicator of the disease incidence, is reportedly less than two in most parts of India.",Background,[88656],[3068],[3195],[False],[0],[0],[False],['0']
8930,PMC3424202,14700,"However, endemic regions with an API greater than five are spread in the states of Rajasthan, Gujarat, Karnataka, Goa, Southern Madhya Pradesh, Chhattisgarh, Jharkhand, Orissa and the North-Eastern states [3].",Background,[88660],[3196],[3405],[False],[0],[0],[False],['0']
8931,PMC3424202,14701,"Resistance of P. falciparum to the commonly used anti-malarial drugs, especially chloroquine, has been progressively reported in India [4].",Background,[88664],[3406],[3545],[False],[0],[0],[False],['0']
8932,PMC3424202,14702,"Assam was the first Indian state to report cases of chloroquine-resistant malaria, as early as 1973.",Background,[88668],[3546],[3646],[False],[0],[0],[False],['0']
8933,PMC3424202,14703,"In the following decades, chloroquine resistance has been documented throughout the Indian subcontinent.",Background,[88672],[3647],[3751],[False],[0],[0],[False],['0']
8934,PMC3424202,14704,More than 80% of the therapeutic efficacy studies conducted from 2001–2007 indicate failure to chloroquine beyond cut-off level of 10% [5].,Background,[88676],[3752],[3891],[False],[0],[0],[False],['0']
8935,PMC3424202,14705,"As a consequence, the drug policy has been revised and artemisinin combination therapy (ACT) was introduced by the National Vector Borne Disease Control Programme as the first-line treatment of falciparum malaria in 117 districts, which represented more than 90% of the reported P. falciparum cases [6].",Background,[88680],[3892],[4195],[False],[0],[0],[False],['0']
8936,PMC3424202,14706,"By 2010, artesunate plus sulphadoxine/pyrimethamine (AS + SP) was adopted as the first-line treatment for confirmed cases of uncomplicated P. falciparum malaria.",Background,[88684],[4196],[4357],[False],[0],[0],[False],['0']
8937,PMC3424202,14707,"However, more investigations are needed for new fixed-dose combinations to facilitate the National Programme in adopting the most effective, easy to administer, feasible, safe and cost-effective strategy.",Background,[88688],[4358],[4562],[False],[0],[0],[False],['0']
8938,PMC3424202,14708,"Combination of artesunate and mefloquine (A + M) has been used widely for many years in South-East Asian countries, such as Thailand and Cambodia, and remains highly effective for uncomplicated P. falciparum malaria.",Background,[88692],[4563],[4779],[False],[0],[0],[False],['0']
8939,PMC3424202,14709,"Under the WHO system of efficacy assessment, more than 95% of patients remain free of malaria 28 days after A + M treatment [7].",Background,[88696],[4780],[4908],[False],[0],[0],[False],['0']
8940,PMC3424202,14710,"However, the neuropsychiatric effects of mefloquine are often problematic.",Background,[88700],[4909],[4983],[False],[0],[0],[False],['0']
8941,PMC3424202,14711,"No co-formulations are commercially available, but in some countries (i.e.",Background,[88704],[4984],[5058],[False],[0],[0],[False],['0']
8942,PMC3424202,14712,Cambodia) it is available a blister pack containing separate tablets of each constituent drug to be administered over three days.,Background,[88708],[5059],[5188],[False],[0],[0],[False],['0']
8943,PMC3424202,14713,Dihydroartemisinin-piperaquine (DP) is a potential alternative; it is a fixed-dose formulation to be taken once a day over a full treatment course of three days.,Background,[88712],[5189],[5350],[False],[0],[0],[False],['0']
8944,PMC3424202,14714,"In the last decade, several clinical trials evaluating the DP combination for the treatment of uncomplicated P. falciparum and P. vivax malaria have been conducted in Asian countries.",Background,[88716],[5351],[5534],[False],[0],[0],[False],['0']
8945,PMC3424202,14715,"The overall 28-day cure rates (Kaplan-Meier estimates) for the DP treatment consistently exceeded 97% in China, Myanmar, Cambodia, Laos, Thailand and Vietnam [8].",Background,[88720],[5535],[5697],[False],[0],[0],[False],['0']
8946,PMC3424202,14716,"Recently, a DP formulation produced under Good Manufacturing Practices (GMP) has been developed by Sigma-Tau (Rome, Italy), in collaboration with Medicines for Malaria Venture (MMV).",Background,[88724],[5698],[5880],[False],[0],[0],[False],['0']
8947,PMC3424202,14717,"During years 2005–2007, a phase III multicenter study comparing this novel formulation with artesunate plus mefloquine for the treatment of acute uncomplicated P. falciparum malaria was carried out in India and two other Asian countries (Laos and Thailand) [9].",Background,[88728],[5881],[6142],[False],[0],[0],[False],['0']
8948,PMC3424202,14718,"In the present report, more detailed results obtained by the Indian centres are reported and the possible role of the DP combination in controlling and eliminating malaria in India is discussed.",Background,[88732],[6143],[6337],[False],[0],[0],[False],['0']
8949,PMC3424202,14719,Methods,Methods,[88736],[6338],[6346],[False],[0],[0],[False],['0']
8950,PMC3424202,14720,"Study sites, patients, clinical procedures, and laboratory analysis",Methods,[88740],[6347],[6414],[False],[0],[0],[False],['0']
8951,PMC3424202,14721,"Three Indian centres (Figure 1) including 150 patients, were part of the Phase III multicentre study [9] and are considered in this paper: Down Town Hospital, Guwahati (State of Assam); Goa Medical College and Hospital (State of Goa); and Wenlock District Government Hospital, Mangalore (State of Karnataka).",Methods,[88744],[6415],[6723],[False],[0],[0],[False],['0']
8952,PMC3424202,14722,The sample size calculation was only performed for the whole multicenter study.,Methods,[88748],[6724],[6803],[False],[0],[0],[False],['0']
8953,PMC3424202,14723,"The Indian study was conducted over one malaria season, with patients screened from November 2006 to February 2007.",Methods,[88752],[6804],[6919],[False],[0],[0],[False],['0']
8954,PMC3424202,14724,"The selected centres are situated in areas of perennial transmission (Assam), perennial transmission with a seasonal peak from June to September (Goa), and transmission active in post-monsoon months (Karnataka).",Methods,[88756],[6920],[7131],[False],[0],[0],[False],['0']
8955,PMC3424202,14725,"Chloroquine (CQ) resistance was present at all study sites, with site records showing 28-day treatment failure rates of 32% in Assam (in 2002), 54% in Goa (in 2007) and 67% in Mangalore City (in 2005).",Methods,[88760],[7132],[7333],[False],[0],[0],[False],['0']
8956,PMC3424202,14726,ACT represents the standard treatment in Goa and Mangalore (specifically artesunate plus sulphadoxine/pyrimethamine) and Assam.,Methods,[88764],[7334],[7461],[False],[0],[0],[False],['0']
8957,PMC3424202,14727,"For this reason, the study protocol was amended in April 2006, requiring the prohibition of chloroquine during the study.",Methods,[88768],[7462],[7583],[False],[0],[0],[False],['0']
8958,PMC3424202,14728,Patient inclusion and exclusion criteria have been reported elsewhere [9].,Methods,[88772],[7584],[7658],[False],[0],[0],[False],['0']
8959,PMC3424202,14729,"Briefly, males and females aged from 18 to 65 years with fever or history of fever (≥37.5°C) and microscopically confirmed P. falciparum mono- or mixed-infection (asexual forms parasitaemia ≥80 per μL ≤200,000 per μL) were eligible for the study.",Methods,[88776],[7659],[7905],[False],[0],[0],[False],['0']
8960,PMC3424202,14730,Local regulations were followed in India that required all recruited patients to be aged 18 years and over.,Methods,[88780],[7906],[8013],[False],[0],[0],[False],['0']
8961,PMC3424202,14731,"Key exclusion criteria were: severe malaria, treatment with mefloquine in the 60 days prior to screening, treatment with DP in the three months prior to screening and >4% parasitized red blood cells.",Methods,[88784],[8014],[8213],[False],[0],[0],[False],['0']
8962,PMC3424202,14732,Pregnant or lactating women were not eligible for the study.,Methods,[88788],[8214],[8274],[False],[0],[0],[False],['0']
8963,PMC3424202,14733,"At presentation, venous blood samples were taken for parasite count, haematology, biochemistry, and 3 blood spots were collected onto 3MM filter paper (Whatman, Maidstone, United Kingdom) for genotyping by polymerase chain reaction (PCR) in the event of reappearance of P. falciparum during follow-up [10].",Methods,[88792],[8275],[8581],[False],[0],[0],[False],['0']
8964,PMC3424202,14734,Urine was collected for urinalysis and β-HCG pregnancy test (for the women of child bearing age).,Methods,[88796],[8582],[8679],[False],[0],[0],[False],['0']
8965,PMC3424202,14735,"A 12-lead electrocardiogram (ECG) (CarTouch, Cardionics SA, Belgium) was obtained.",Methods,[88800],[8680],[8762],[False],[0],[0],[False],['0']
8966,PMC3424202,14736,"If the study inclusion criteria were met, the patients were randomly assigned to receive either A) A + M: artesunate (Artesunate, 100 oblong Lactab; Mepha, Aesch-Basel Switzerland), 4 mg/kg/day for 3 days (Days 0–2) plus mefloquine (Mephaquin, Lactab; Mepha, Aesch-Basel Switzerland) 15 mg base/kg on day 1 and 10 mg base/kg on day 2, or B) DP: Dihydroartemisinin-piperaquine (Sigma-Tau, Rome, Italy) 2.1/16.8 mg/kg in a single daily dose for 3 days.",Methods,[88804],[8763],[9213],[False],[0],[0],[False],['0']
8967,PMC3424202,14737,Each tablet contained 40 mg of DHA and 320 mg of piperaquine.,Methods,[88808],[9214],[9275],[False],[0],[0],[False],['0']
8968,PMC3424202,14738,"The Food and Drug Department, Ministry of Health, India approved the use of both A + M and DP in this trial.",Methods,[88812],[9276],[9384],[False],[0],[0],[False],['0']
8969,PMC3424202,14739,"The treatment choice was kept in a sealed opaque envelope, which was opened only after the decision to recruit had been made.",Methods,[88816],[9385],[9510],[False],[0],[0],[False],['0']
8970,PMC3424202,14740,"An unequal randomization, 2:1 (DP:A + M), was used to provide more precise estimates of DP cure rates, as well as to provide more patients for the safety database of DP.",Methods,[88820],[9511],[9680],[False],[0],[0],[False],['0']
8971,PMC3424202,14741,Axillary temperature was measured every six hours.,Methods,[88824],[9681],[9731],[False],[0],[0],[False],['0']
8972,PMC3424202,14742,Study drug administration was observed directly by the study physician.,Methods,[88828],[9732],[9803],[False],[0],[0],[False],['0']
8973,PMC3424202,14743,"Study medications were given as tablets or fractions of tablets, according to body weight, given orally with a glass of water.",Methods,[88832],[9804],[9930],[False],[0],[0],[False],['0']
8974,PMC3424202,14744,Patients were observed for one hour to ensure that the medications were not vomited or regurgitated.,Methods,[88836],[9931],[10031],[False],[0],[0],[False],['0']
8975,PMC3424202,14745,"Patients were observed daily until parasites cleared, then weekly for 63 days from the start of treatment, or at other times if he/she felt unwell.",Methods,[88840],[10032],[10179],[False],[0],[0],[False],['0']
8976,PMC3424202,14746,At each visit finger prick blood was taken for a malaria smear and haematocrit.,Methods,[88844],[10180],[10259],[False],[0],[0],[False],['0']
8977,PMC3424202,14747,Blood spots were collected onto filter papers from those patients with reappearance of asexual parasitaemia for parasite genotyping [11].,Methods,[88848],[10260],[10397],[False],[0],[0],[False],['0']
8978,PMC3424202,14748,Twelve-lead ECGs were obtained on days 2 and 7 and on days 28 and 63 if the results were abnormal on day 7; ECGs were also obtained on the day of P. falciparum recurrence.,Methods,[88852],[10398],[10569],[False],[0],[0],[False],['0']
8979,PMC3424202,14749,Venous blood samples were taken for haematologic and biochemical analysis on days 28 and 63 if the results were abnormal on day 28 and were also performed on the day of P. falciparum recurrence.,Methods,[88856],[10570],[10764],[False],[0],[0],[False],['0']
8980,PMC3424202,14750,"Patients with treatment failure were withdrawn from the study, treated, and followed up as per local practice.",Methods,[88860],[10765],[10875],[False],[0],[0],[False],['0']
8981,PMC3424202,14751,They did not have to undergo efficacy evaluation thereafter.,Methods,[88864],[10876],[10936],[False],[0],[0],[False],['0']
8982,PMC3424202,14752,Patients requiring rescue therapy were treated with artesunate 2 mg/kg/day orally for seven days plus doxycycline if there was no contraindication.,Methods,[88868],[10937],[11084],[False],[0],[0],[False],['0']
8983,PMC3424202,14753,Any patient diagnosed with severe malaria or danger signs during follow-up was referred for treatment with parenteral artesunate and supportive measures at the local facility or hospital.,Methods,[88872],[11085],[11272],[False],[0],[0],[False],['0']
8984,PMC3424202,14754,Those patients who received additional courses of therapy were also followed-up for 63 days.,Methods,[88876],[11273],[11365],[False],[0],[0],[False],['0']
8985,PMC3424202,14755,Potential adverse events were recorded.,Methods,[88880],[11366],[11405],[False],[0],[0],[False],['0']
8986,PMC3424202,14756,Written informed consent was obtained from all participants.,Methods,[88884],[11406],[11466],[False],[0],[0],[False],['0']
8987,PMC3424202,14757,"Ethical clearance for the study was granted by the following ethics committees: Institutional Ethics Committee, National Institute of Malaria Research (ICMR), Delhi, India; Goa Medical College and Hospitals Local Ethics Committee, Goa, India; Institutional Ethics Committee, Kasturba Medical College, Mangalore, India.",Methods,[88888],[11467],[11785],[False],[0],[0],[False],['0']
8988,PMC3424202,14758,The trial registration number is ISRCTN 81306618.,Methods,[88892],[11786],[11835],[False],[0],[0],[False],['0']
8989,PMC3424202,14759,The trial was monitored by MDS Pharma Services.,Methods,[88896],[11836],[11883],[False],[0],[0],[False],['0']
8990,PMC3424202,14760,Parasite counts in thick and thin films stained with Giemsa were obtained daily until parasite clearance and then weekly from day 7 up to day 63 [9].,Methods,[88900],[11884],[12033],[False],[0],[0],[False],['0']
8991,PMC3424202,14761,"At screening, parasite density was calculated by counting the number of asexual parasites per 500 leukocytes in the thick blood film, based on an assumed white cell count of 8000 cells/μL.",Methods,[88904],[12034],[12222],[False],[0],[0],[False],['0']
8992,PMC3424202,14762,"After randomization, parasite density was calculated as: (number of parasites counted x 8000)/(number of leukocytes counted).",Methods,[88908],[12223],[12348],[False],[0],[0],[False],['0']
8993,PMC3424202,14763,"For samples with higher level of parasitemia (>3 parasites/1000 red blood cells), parasite density was calculated from the thin film as: (number of P. falciparum trophozoites per 1000 red blood cells x haematocrit x 125.6).",Methods,[88912],[12349],[12572],[False],[0],[0],[False],['0']
8994,PMC3424202,14764,Polymerase chain reaction amplification was performed on paired samples for parasite genotyping to distinguish between reinfection and recrudescence.,Methods,[88916],[12573],[12722],[False],[0],[0],[False],['0']
8995,PMC3424202,14765,"To this aim, three spots of blood were collected onto 3MM filter paper (Whatman, UK).",Methods,[88920],[12723],[12808],[False],[0],[0],[False],['0']
8996,PMC3424202,14766,Filter papers were dried and individually stored in a plastic bag containing silica gel.,Methods,[88924],[12809],[12897],[False],[0],[0],[False],['0']
8997,PMC3424202,14767,"All filter papers were subsequently transferred to the Institute of Tropical Medicine (Antwerp, Belgium) where centralized genotyping was conducted; deoxyribonucleic acid was purified as described elsewhere [9].",Methods,[88928],[12898],[13109],[False],[0],[0],[False],['0']
8998,PMC3424202,14768,"Three polymorphic genetic markers, MSP1, MSP2 and GluRP were used to distinguish recrudescence from new infections [12].",Methods,[88932],[13110],[13230],[False],[0],[0],[False],['0']
8999,PMC3424202,14769,Recrudescence was defined as at least one identical allele for each of the three markers in the pre-treatment and post-treatment samples.,Methods,[88936],[13231],[13368],[False],[0],[0],[False],['0']
9000,PMC3424202,14770,New infections were diagnosed when all alleles for at least one of the markers differed between the two samples.,Methods,[88940],[13369],[13481],[False],[0],[0],[False],['0']
9001,PMC3424202,14771,Outcomes of the study,Outcomes of the study,[88944],[13482],[13504],[False],[0],[0],[False],['0']
9002,PMC3424202,14772,"The primary endpoint of the study was the PCR-corrected cure rate on day 63, based on the adequate clinical and parasitological response (ACPR), which was defined as the absence of parasitaemia irrespective of the patient’s body temperature, with the patient not meeting any of the criteria of early treatment failure or late clinical or parasitological failure [13].",Outcomes of the study,[88948],[13505],[13872],[False],[0],[0],[False],['0']
9003,PMC3424202,14773,"This definition of cure rate, which was agreed with the Data Monitoring and the Clinical Development Committees, was based on a pre-defined procedure that expanded the WHO definitions with a set of specific rules [9].",Outcomes of the study,[88952],[13873],[14090],[False],[0],[0],[False],['0']
9004,PMC3424202,14774,"Secondary endpoints included PCR-corrected adequate clinical and parasitological response on days 28 and 42, PCR-uncorrected adequate clinical and parasitological response (PCR-uncorrected), proportion of patients with treatment failure, proportion of aparasitaemic patients, proportion of afebrile patients, number of new infections, gametocyte carriage and the safety profile of the two treatments including adverse events and electrocardiograph parameters.",Outcomes of the study,[88956],[14091],[14550],[False],[0],[0],[False],['0']
9005,PMC3424202,14775,Statistical analysis,Statistical analysis,[88960],[14551],[14572],[False],[0],[0],[False],['0']
9006,PMC3424202,14776,The Breslow-Day heterogeneity test or a logistic regression model [14] were used to verify homogeneity of results (PCR-corrected and uncorrected cure rates at day 63) across India and the other countries involved in the phase III study [9].,Statistical analysis,[88964],[14573],[14813],[False],[0],[0],[False],['0']
9007,PMC3424202,14777,A p-value lower than 0.1 was considered statistically significant for interpreting the heterogeneity tests.,Statistical analysis,[88968],[14814],[14921],[False],[0],[0],[False],['0']
9008,PMC3424202,14778,"The two most extreme populations, i.e.",Statistical analysis,[88972],[14922],[14960],[False],[0],[0],[False],['0']
9009,PMC3424202,14779,"Intention to Treat (ITT) and Per Protocol (PP) populations, were presented in this work, in line with the presentation of the whole study results [9].",Statistical analysis,[88976],[14961],[15111],[False],[0],[0],[False],['0']
9010,PMC3424202,14780,The ITT population was defined as all randomized patients who took at least one dose of study treatment.,Statistical analysis,[88980],[15112],[15216],[False],[0],[0],[False],['0']
9011,PMC3424202,14781,"In this population, all patients lost to follow-up and all the withdrawals for reasons that could be interpreted as treatment-related (i.e.",Statistical analysis,[88984],[15217],[15356],[False],[0],[0],[False],['0']
9012,PMC3424202,14782,"vomiting of study drugs or withdrawal of informed consent), as well as patients for whom the PCR was missing at two consecutive scheduled visits, patients who had experienced AEs resembling the recurrence of malaria or had taken drugs with a known or suspected antimalarial action, were evaluated as failures after being reviewed at the Data Review Meeting.",Statistical analysis,[88988],[15357],[15714],[False],[0],[0],[False],['0']
9013,PMC3424202,14783,"The PP population was defined as all randomized patients who were eligible according to the main (pre-defined) protocol inclusion and exclusion criteria, received at least 80% of the study medication, underwent the day 63 assessment, took no other anti-malarial drugs (excluding rescue therapies) and, in the presence of asexual parasite stages on thick or thin blood smears, had an evaluable PCR test.",Statistical analysis,[88992],[15715],[16117],[False],[0],[0],[False],['0']
9014,PMC3424202,14784,Patients who missed visits from day 1 to day 3 were excluded from the PP population.,Statistical analysis,[88996],[16118],[16202],[False],[0],[0],[False],['0']
9015,PMC3424202,14785,"Patients with missing parasitaemia at two consecutive scheduled visits were considered as failures if occurred before day 4, otherwise they were excluded from the PP population.",Statistical analysis,[89000],[16203],[16380],[False],[0],[0],[False],['0']
9016,PMC3424202,14786,"The analysis of the PCR-corrected and uncorrected cure rates at day 63, 42 and 28 was based on simple proportions and 95% (two-sided) confidence intervals (CIs) were computed on the difference between the treatment proportions.",Statistical analysis,[89004],[16381],[16608],[False],[0],[0],[False],['0']
9017,PMC3424202,14787,"Survival analysis techniques were applied for analysing time to parasite clearance and estimating the rate of new infections and true treatment failure, as established by the WHO [13].",Statistical analysis,[89008],[16609],[16793],[False],[0],[0],[False],['0']
9018,PMC3424202,14788,"The latter analysis, based on the standard definitions of early/late clinical and parasitological failure, consisted in computing the true treatment failure (TTF) as the sum of the early and late (either LPF or LCF) treatment failures occurring until day 13 (recrudescence by default) and the late treatment failures from day 14 onwards classified as recrudescence by PCR analysis.",Statistical analysis,[89012],[16794],[17175],[False],[0],[0],[False],['0']
9019,PMC3424202,14789,"In the survival analysis performed for new infections (ITT population), lost to follow-up, informative withdrawals, recrudescences, patients with missing PCR and all the successes were censored.",Statistical analysis,[89016],[17176],[17370],[False],[0],[0],[False],['0']
9020,PMC3424202,14790,"In the survival analysis performed for true treatment failures (PP population), patients withdrawing the study, with a new infection, with missing PCR and all the successes were censored.",Statistical analysis,[89020],[17371],[17558],[False],[0],[0],[False],['0']
9021,PMC3424202,14791,"Rates of person-fever-days and person-gametocyte-weeks were calculated as the number of weeks in which fever was present or blood slides were positive for gametocytes, respectively, divided by the number of follow-up weeks and expressed per 1,000 person-weeks.",Statistical analysis,[89024],[17559],[17819],[False],[0],[0],[False],['0']
9022,PMC3424202,14792,The ITT population was used for all safety assessments.,Statistical analysis,[89028],[17820],[17875],[False],[0],[0],[False],['0']
9023,PMC3424202,14793,Adverse events were coded using the MedDRA dictionary (MedDRA V8.1).,Statistical analysis,[89032],[17876],[17944],[False],[0],[0],[False],['0']
9024,PMC3424202,14794,Proportions of patients experiencing at least one adverse event were compared between treatments using the Pearson Chi square test.,Statistical analysis,[89036],[17945],[18076],[False],[0],[0],[False],['0']
9025,PMC3424202,14795,Results,Results,[89040],[18077],[18085],[False],[0],[0],[False],['0']
9026,PMC3424202,14796,Trial profile and baseline characteristics,Results|Trial profile and baseline characteristics,[89044],[18086],[18128],[False],[0],[0],[False],['0']
9027,PMC3424202,14797,"A total of 154 Indian patients were screened, with 101 patients randomized to the DP arm and 49 patients randomized to the A + M arm (Figure 2).",Results|Trial profile and baseline characteristics,[89048],[18129],[18273],[False],[0],[0],[False],['0']
9028,PMC3424202,14798,"Three centres with distinct background in terms of parasite transmission, resistance and seasonality were selected: Guwahati in the Assam region, an area of perennial malaria transmission (CQ treatment failure rate ~30%), where 46 (DP) and 22 (A + M) patients were enrolled; Goa, characterized by perennial transmission with a seasonal peak in June-September (CQ treatment failure rate ~50%), where 19 and (DP) and 9 (A + M) patients were enrolled; Mangalore in the Karnataka state, a seasonal transmission area during post-monsoon months (CQ treatment failure rate ~70%), where 36 and (DP) and 18 (A + M) patients were enrolled.",Results|Trial profile and baseline characteristics,[89052],[18274],[18903],[False],[0],[0],[False],['0']
9029,PMC3424202,14799,"At enrolment, the DP and A + M groups had similar demographic and clinical characteristics except that the geometric mean parasitaemia was higher in the DP group compared to A + M arm (Table 1).",Results|Trial profile and baseline characteristics,[89056],[18904],[19098],[False],[0],[0],[False],['0']
9030,PMC3424202,14800,All patients were febrile at the time of enrollment with the exception of two subjects in the DP arm who were afebrile at admission but had a history of fever prior to admission.,Results|Trial profile and baseline characteristics,[89060],[19099],[19277],[False],[0],[0],[False],['0']
9031,PMC3424202,14801,All patients were adults (aged > 18 years) in accordance to the local Authority regulations.,Results|Trial profile and baseline characteristics,[89064],[19278],[19370],[False],[0],[0],[False],['0']
9032,PMC3424202,14802,"Out of the 150 randomized patients, 126 (84%) completed the study until day 63; 23 patients (15 patients in the DP arm; 8 patients in the A + M arm) were lost to follow-up and one patient in the DP arm discontinued the study after the first drug administration because of adverse events.",Results|Trial profile and baseline characteristics,[89068],[19371],[19658],[False],[0],[0],[False],['0']
9033,PMC3424202,14803,The proportion of patients lost to follow-up was about 16% in both the two treatment groups.,Results|Trial profile and baseline characteristics,[89072],[19659],[19751],[False],[0],[0],[False],['0']
9034,PMC3424202,14804,"However, the majority of the patients which have been lost during follow up in both DP (13 out of 15 patients; 2 of them at day 7 visit, 3 at day 14, 3 at day 21, 1 at day 28, 2 at day 35 and 2 at day 42) and A + M (7 out of 8 patients; 2 of them at day 7 visit, 2 at day 14, 1 at day 28 and 2 at day 35) arms were enrolled at the Mangalore center.",Results|Trial profile and baseline characteristics,[89076],[19752],[20100],[False],[0],[0],[False],['0']
9035,PMC3424202,14805,Twenty-nine patients (21 patients in the DP arm and 8 in the A + M arm) were excluded from the PP population because lost to follow-up before or at Day 63 (see above) or had major protocol violations.,Results|Trial profile and baseline characteristics,[89080],[20101],[20301],[False],[0],[0],[False],['0']
9036,PMC3424202,14806,Major protocol violations occurred only in the DP arm: PCR missing or indeterminate or not done before or at day 63 (3 patients); subjects not taking at least 80% of the study drug medication (1 patient); subjects having haemoglobin value below the lower limit (< 5 g/dL) at day 0 or missing at day 0 and day 7 (2 patients) and no availability of the Day 63 assessment (2 patients).,Results|Trial profile and baseline characteristics,[89084],[20302],[20684],[False],[0],[0],[False],['0']
9037,PMC3424202,14807,Clinical and parasitological outcomes,Clinical and parasitological outcomes,[89088],[20685],[20723],[False],[0],[0],[False],['0']
9038,PMC3424202,14808,One early treatment failure (ETF) was observed in the DP arm due to an adverse event (grand mal convulsion) occurring after the first drug administration.,Clinical and parasitological outcomes,[89092],[20724],[20878],[False],[0],[0],[False],['0']
9039,PMC3424202,14809,"Due to this event, the study drug was discontinued and his malaria was successfully treated with primaquine plus quinine.",Clinical and parasitological outcomes,[89096],[20879],[21000],[False],[0],[0],[False],['0']
9040,PMC3424202,14810,No late treatment failure (LTF) was observed in both ITT and PP populations for the A + M study group at the end of follow up (day 63).,Clinical and parasitological outcomes,[89100],[21001],[21136],[False],[0],[0],[False],['0']
9041,PMC3424202,14811,"For the DP arm, two late clinical failures were observed in the PP population due to recurrent parasitaemia occurring in two patients at day 39 and day 45, respectively.",Clinical and parasitological outcomes,[89104],[21137],[21306],[False],[0],[0],[False],['0']
9042,PMC3424202,14812,"In the analysis of the PCR-corrected cure rate at day 63, DP was found to be similar to A + M (Table 2 and Figure 3).",Clinical and parasitological outcomes,[89108],[21307],[21424],[False],[0],[0],[False],['0']
9043,PMC3424202,14813,"For the ITT population, cure rates were 80.2% (DP) and 83.7% (A + M) (95% CI for DP minus A + M: -16.4% to 9.5%); for the PP population, cure rates were 98.8% (DP) and 100% (A + M) (95% CI: -3.7% to 1.2%).",Clinical and parasitological outcomes,[89112],[21425],[21630],[False],[0],[0],[False],['0']
9044,PMC3424202,14814,"These results were similar to those obtained at the overall phase III study level: slightly lower for ITT and quite the same for PP (at the whole study level, the comparison DP vs A + M was 87.9% vs 86.6% in ITT, and 98.7% vs 97.0% in PP).",Clinical and parasitological outcomes,[89116],[21631],[21870],[False],[0],[0],[False],['0']
9045,PMC3424202,14815,The heterogeneity analysis showed no statistically significant difference between India and the other considered countries in both the PCR-corrected and uncorrected cure rates at day 63.,Clinical and parasitological outcomes,[89120],[21871],[22057],[False],[0],[0],[False],['0']
9046,PMC3424202,14816,The 95% CIs are quite wider as compared to those obtained in the phase III study as result of the small size of the Indian sample.,Clinical and parasitological outcomes,[89124],[22058],[22188],[False],[0],[0],[False],['0']
9047,PMC3424202,14817,"When looking at the PCR-uncorrected cure rate at day 63, results were in favour of DP.",Clinical and parasitological outcomes,[89128],[22189],[22275],[False],[0],[0],[False],['0']
9048,PMC3424202,14818,In the ITT population the cure rates were 74.3% (DP) and 69.4% (A + M) with a difference of 4.9% (95% CI for DP-A + M: -10.6% to 20.3%) while in the PP populations the cure rates were 91.3% (DP) and 82.9% (A + M) with a difference of 8.4% (95% CI for DP-A + M: -4.8% to 21.4%).,Clinical and parasitological outcomes,[89132],[22276],[22553],[False],[0],[0],[False],['0']
9049,PMC3424202,14819,"With respect to the overall phase III findings, the Indian results were better in terms of absolute values (at the whole study level, the comparison DP vs A + M was 67.3% vs 59.6% in ITT, and 75.5% vs 66.4% in PP).",Clinical and parasitological outcomes,[89136],[22554],[22768],[False],[0],[0],[False],['0']
9050,PMC3424202,14820,As for the other time-points (day 42 and day 28) analogous findings were observed in all study populations (data not shown).,Clinical and parasitological outcomes,[89140],[22769],[22893],[False],[0],[0],[False],['0']
9051,PMC3424202,14821,"The treatment difference on uncorrrected cure rates was mainly due to new infections (Figure 4), which are higher in the A + M arm, as shown by the Kaplan-Meier estimates of the proportion of patients with new infections at day 63: 7-8% (DP) and 17% (A + M) in both ITT and PP populations.",Clinical and parasitological outcomes,[89144],[22894],[23183],[False],[0],[0],[False],['0']
9052,PMC3424202,14822,"These results are similar to those obtained at the overall study level when looking at the comparison between treatments, but lower in terms of absolute values (at the whole study level, Kaplan-Meier estimates were 22.7% and 23.4% for DP, and 30.3% and 31.4% for A + M, in the ITT and PP populations, respectively.",Clinical and parasitological outcomes,[89148],[23184],[23498],[False],[0],[0],[False],['0']
9053,PMC3424202,14823,"The new infections (6 patients in the DP arm and 7 patients in the A + M arm) were mainly observed in Mangalore (12 patients; 6 for DP and 6 for A + M) and mostly occurred after 42 days of follow up (11 patients from day 45, one at day 16 and one at day 21); only one new infection occurred in a patient who was assigned to the A + M arm at the Goa centre.",Clinical and parasitological outcomes,[89152],[23499],[23855],[False],[0],[0],[False],['0']
9054,PMC3424202,14824,"Notably, 12 out of 13 new infections were due to a Plasmodium species different from P. falciparum.",Clinical and parasitological outcomes,[89156],[23856],[23955],[False],[0],[0],[False],['0']
9055,PMC3424202,14825,Parasite clearance was rapid in both treatment groups (Table 3).,Clinical and parasitological outcomes,[89160],[23956],[24020],[False],[0],[0],[False],['0']
9056,PMC3424202,14826,Proportions of aparasitaemic patients were similar for the two arms for the 63-day duration of the study; 93.1% of DP-treated patients and 91.8% of A + M-treated patients were aparasitaemic on day 2 and 100% of patients in each arm were aparasitaemic on day 7 (ITT population).,Clinical and parasitological outcomes,[89164],[24021],[24298],[False],[0],[0],[False],['0']
9057,PMC3424202,14827,Kaplan-Meier estimates of median time to parasite clearance were 1 day for each treatment group in all the analysis populations.,Clinical and parasitological outcomes,[89168],[24299],[24427],[False],[0],[0],[False],['0']
9058,PMC3424202,14828,"Fever clearance was also fast in both arms (Table 3) and proportions of afebrile patients were comparable to those observed for aparasitaemic patients, with superimposable profiles.",Clinical and parasitological outcomes,[89172],[24428],[24609],[False],[0],[0],[False],['0']
9059,PMC3424202,14829,"Fever prevalence, calculated as the number of days in which temperature was greater or equal to 37.5 °C during the first week divided by the total number of follow-up days in the first week, was similar for DP- and A + M-treated patients; 260/695 (374.1) versus 125/334 (374.3) (p = 0.994) respectively.",Clinical and parasitological outcomes,[89176],[24610],[24913],[False],[0],[0],[False],['0']
9060,PMC3424202,14830,"The gametocyte carriage was assessed at weekly visits, from day 7 onwards.",Clinical and parasitological outcomes,[89180],[24914],[24988],[False],[0],[0],[False],['0']
9061,PMC3424202,14831,The time to clearance of gametocytes is reported in Table 4.,Clinical and parasitological outcomes,[89184],[24989],[25049],[False],[0],[0],[False],['0']
9062,PMC3424202,14832,"In the A + M group, there were no patients with gametocytes at day 7.",Clinical and parasitological outcomes,[89188],[25050],[25119],[False],[0],[0],[False],['0']
9063,PMC3424202,14833,"As for the DP group, most of the patients (93%) cleared their gametocytaemia by day 7.",Clinical and parasitological outcomes,[89192],[25120],[25206],[False],[0],[0],[False],['0']
9064,PMC3424202,14834,"At day 14, five patients in the DP arm (5%) still had gametocytes in their peripheral blood and all of them cleared gametocytaemia by day 28.",Clinical and parasitological outcomes,[89196],[25207],[25348],[False],[0],[0],[False],['0']
9065,PMC3424202,14835,"The overall gametocyte prevalence throughout the study (from day 7 to day 63) in the DP group, estimated as person-gametocyte-weeks, was 22.1 weeks/1,000 patients in the ITT population and 13.7 weeks/1000 patients in the PP population.",Clinical and parasitological outcomes,[89200],[25349],[25584],[False],[0],[0],[False],['0']
9066,PMC3424202,14836,Blood haemoglobin (Hb) was evaluated weekly.,Clinical and parasitological outcomes,[89204],[25585],[25629],[False],[0],[0],[False],['0']
9067,PMC3424202,14837,"In the ITT population, 5 (5%) patients in DP and 4 (8%) patients in A + M presented with an Hb level < 70 g/L.",Clinical and parasitological outcomes,[89208],[25630],[25740],[False],[0],[0],[False],['0']
9068,PMC3424202,14838,Three of these patients (two in the DP group and one in the A + M group) worsened at day 7 and a SAE was communicated by the investigator (see below); all the other patients stabilized or improved their anaemic status by the following visit.,Clinical and parasitological outcomes,[89212],[25741],[25982],[False],[0],[0],[False],['0']
9069,PMC3424202,14839,There was no apparent difference between treatment groups.,Clinical and parasitological outcomes,[89216],[25983],[26041],[False],[0],[0],[False],['0']
9070,PMC3424202,14840,"In the ITT population, the mean Hb fell from 105.8 g/l (DP) and 104.5 g/L (A + M) on day 0 to 103.2 g/l (DP) and 100.6 g/l (A + M) on day 7, before increasing steadily thereafter ( 5).",Clinical and parasitological outcomes,[89220],[26042],[26226],[False],[0],[0],[False],['0']
9071,PMC3424202,14841,Such changes in Hb are expected in acute malaria.,Clinical and parasitological outcomes,[89224],[26227],[26276],[False],[0],[0],[False],['0']
9072,PMC3424202,14842,Adverse events,Adverse events,[89228],[26277],[26292],[False],[0],[0],[False],['0']
9073,PMC3424202,14843,"Both DP and A + M were well tolerated with the majority of adverse events of mild or moderate severity, and consistent with symptoms attributable to malaria.",Adverse events,[89232],[26293],[26450],[False],[0],[0],[False],['0']
9074,PMC3424202,14844,"The frequencies of individual adverse events were generally similar between treatments, although the incidence of post treatment adverse events (AEs) was slightly higher in patients who received A + M with respect to those treated with DP (Table 6).",Adverse events,[89236],[26451],[26700],[False],[0],[0],[False],['0']
9075,PMC3424202,14845,"In particular, the highest differences in favour of DP were observed for asthenia (DP:10%; A + M: 18%; p = 0.144) and decreasing number of red blood cells (DP: 11%; A + M: 20%; p = 0.115); a result in the opposite direction was for the event “Eosinophils count increased” (DP: 13%; A + M: 4%; p = 0.092), but none of these AEs was judged by the investigator as serious.",Adverse events,[89240],[26701],[27070],[False],[0],[0],[False],['0']
9076,PMC3424202,14846,Six serious adverse events (SAE) were observed during the study until day 63 of follow up: five in the DP arm and one in the A + M group.,Adverse events,[89244],[27071],[27208],[False],[0],[0],[False],['0']
9077,PMC3424202,14847,All patients recovered completed by the end of the study.,Adverse events,[89248],[27209],[27266],[False],[0],[0],[False],['0']
9078,PMC3424202,14848,"In the DP group, five SAE occurred in five patients.",Adverse events,[89252],[27267],[27319],[False],[0],[0],[False],['0']
9079,PMC3424202,14849,"One patient (24 years old male, weight 54 kg) developed malaria of moderate severity on day 39 which was considered not to be related to the study drug by the investigator.",Adverse events,[89256],[27320],[27492],[False],[0],[0],[False],['0']
9080,PMC3424202,14850,His malaria was treated with oral quinine (1800 mg/day) for six days.,Adverse events,[89260],[27493],[27562],[False],[0],[0],[False],['0']
9081,PMC3424202,14851,He made a full recovery.,Adverse events,[89264],[27563],[27587],[False],[0],[0],[False],['0']
9082,PMC3424202,14852,"One subject (male, aged 20 years, weight 61 kg) had Wolff-Parkinson-White (WPW) syndrome diagnosed on day 2.",Adverse events,[89268],[27588],[27696],[False],[0],[0],[False],['0']
9083,PMC3424202,14853,The investigator thought this was possibly related to DP.,Adverse events,[89272],[27697],[27754],[False],[0],[0],[False],['0']
9084,PMC3424202,14854,"However, since WPW is a congenital cardiac conduction anomaly it cannot be caused by DP.",Adverse events,[89276],[27755],[27843],[False],[0],[0],[False],['0']
9085,PMC3424202,14855,"One patient (male, aged 38 years, weight 57 kg), with no history of convulsions, suffered a grand mal convulsion three hours after the first DP dose.",Adverse events,[89280],[27844],[27993],[False],[0],[0],[False],['0']
9086,PMC3424202,14856,The event was treated with i.v.,Adverse events,[89284],[27994],[28025],[False],[0],[0],[False],['0']
9087,PMC3424202,14857,phenytoin 900 mg/day and diazepam 10 mg/day.,Adverse events,[89288],[28026],[28070],[False],[0],[0],[False],['0']
9088,PMC3424202,14858,DP was discontinued and his malaria was treated with primaquine 45 mg/day orally and quinine 600 mg/day orally.,Adverse events,[89292],[28071],[28182],[False],[0],[0],[False],['0']
9089,PMC3424202,14859,He recovered completely.,Adverse events,[89296],[28183],[28207],[False],[0],[0],[False],['0']
9090,PMC3424202,14860,In the investigator’s opinion the convulsion was possibly related to DP.,Adverse events,[89300],[28208],[28280],[False],[0],[0],[False],['0']
9091,PMC3424202,14861,Two patients developed worsening anaemia that was considered unlikely to be related to DP by the investigators.,Adverse events,[89304],[28281],[28392],[False],[0],[0],[False],['0']
9092,PMC3424202,14862,"In particular, the first patient (male, aged 35 years, weight 50 kg) was anaemic at enrolment (Hb 45 g/dL).",Adverse events,[89308],[28393],[28500],[False],[0],[0],[False],['0']
9093,PMC3424202,14863,The anaemia worsened by day 7 (Hb 40 g/dL) which was considered a life-threatening SAE.,Adverse events,[89312],[28501],[28588],[False],[0],[0],[False],['0']
9094,PMC3424202,14864,Ferric ammonium citrate 320 mg/day was started on day 7 and continued up to study completion.,Adverse events,[89316],[28589],[28682],[False],[0],[0],[False],['0']
9095,PMC3424202,14865,"The second patient (female, aged 25 years, weight 39 kg) was anaemic at enrolment (Hb 50 g/dL).",Adverse events,[89320],[28683],[28778],[False],[0],[0],[False],['0']
9096,PMC3424202,14866,The anaemia worsened by day 7 (Hb 40 g/dL) which was considered a life-threatening SAE by the investigator.,Adverse events,[89324],[28779],[28886],[False],[0],[0],[False],['0']
9097,PMC3424202,14867,Ferric ammonium citrate 320 mg/day was started on day 7 and continued until day 35.,Adverse events,[89328],[28887],[28970],[False],[0],[0],[False],['0']
9098,PMC3424202,14868,"In the A + M group, one SAE (severe anaemia) occurred in one patient.",Adverse events,[89332],[28971],[29040],[False],[0],[0],[False],['0']
9099,PMC3424202,14869,"The subject (female, 40 years, weight 42 kg) was anaemic at enrolment (Hb 50 g/dL) and became severely anaemic by day 8 (Hb 45 g/dL).",Adverse events,[89336],[29041],[29174],[False],[0],[0],[False],['0']
9100,PMC3424202,14870,She was treated with ferric ammonium citrate 320 mg/day and recovered fully.,Adverse events,[89340],[29175],[29251],[False],[0],[0],[False],['0']
9101,PMC3424202,14871,The investigator thought it unlikely that the anaemia was related to the investigational drug.,Adverse events,[89344],[29252],[29346],[False],[0],[0],[False],['0']
9102,PMC3424202,14872,No deaths were observed during the study.,Adverse events|No deaths were observed during the study.,[89348],[29347],[29388],[False],[0],[0],[False],['0']
9103,PMC3424202,14873,Discussion,Discussion,[89352],[29389],[29400],[False],[0],[0],[False],['0']
9104,PMC3424202,14874,Malaria is one of major public health problems in India.,Discussion,[89356],[29401],[29457],[False],[0],[0],[False],['0']
9105,PMC3424202,14875,Malaria in India contributes significantly to the world malaria burden.,Discussion,[89360],[29458],[29529],[False],[0],[0],[False],['0']
9106,PMC3424202,14876,The National Vector Borne Disease Control Program of India reported around 1.6 million cases and 1100 malaria deaths in 2009 [15].,Discussion,[89364],[29530],[29660],[False],[0],[0],[False],['0']
9107,PMC3424202,14877,"Some experts argue that this is an underestimation and that the actual number of malaria cases per year is likely between 9 and 50 times greater, with an approximate 13-fold underestimation of malaria-related mortality.",Discussion,[89368],[29661],[29880],[False],[0],[0],[False],['0']
9108,PMC3424202,14878,"The exact numbers remain the subject of debate and require further study [15,16].",Discussion,[89372],[29881],[29962],[False],[0],[0],[False],['0']
9109,PMC3424202,14879,Undebated is that the problem of malaria in India is substantial.,Discussion,[89376],[29963],[30028],[False],[0],[0],[False],['0']
9110,PMC3424202,14880,"In 2005–2007 a phase III, multi country trial of oral DP versus A + M was conducted in 1150 Asian patients with acute uncomplicated P. falciparum malaria [9].",Discussion,[89380],[30029],[30187],[False],[0],[0],[False],['0']
9111,PMC3424202,14881,"This study included three Indian sites, the data of which are extracted and analysed in this work.",Discussion,[89384],[30188],[30286],[False],[0],[0],[False],['0']
9112,PMC3424202,14882,The heterogeneity analysis was performed to verify homogeneity of results across India and the other countries involved in this phase III study.,Discussion,[89388],[30287],[30431],[False],[0],[0],[False],['0']
9113,PMC3424202,14883,It was shown that the overall results of the phase III study also applied to India.,Discussion,[89392],[30432],[30515],[False],[0],[0],[False],['0']
9114,PMC3424202,14884,"However, it must be noted that the Indian sample size is about 13% of the overall Asian phase III study, meaning that the Indian results are less precise than those obtained at the whole study level, determining cure rates to be estimated within wide confidence limits, even if the rate of success is similar to that reported using DP in other regions of Asia [9].",Discussion,[89396],[30516],[30880],[True],['UnderpoweredStudy'],['the Indian results are less precise than those obtained at the whole study level'],[True],['UnderpoweredStudy']
9115,PMC3424202,14885,"One of the strengths of this study is that it was done in settings of different transmission and had a prolonged follow-up period of 63 days not to miss late reinfections and to reflect the terminal half-lives of the drugs [17,18].",Discussion,[89404],[30881],[31112],[False],[0],[0],[False],['0']
9116,PMC3424202,14886,One of the study limitations is that it was not blinded so that an influence on the evaluation of the tolerability cannot be excluded.,Discussion,[89409],[31113],[31247],[True],['Blinding'],['it was not blinded'],[True],['Blinding']
9117,PMC3424202,14887,"In terms of robustness of the trial, this weakness was mitigated with a blinded randomization procedure.",Discussion,[89416],[31248],[31352],[False],[0],[0],[False],['0']
9118,PMC3424202,14888,"In 2010, artesunate plus sulphadoxine-pyrimethamine combination became the first-line treatment for confirmed P. falciparum malaria in India.",Discussion,[89420],[31353],[31494],[False],[0],[0],[False],['0']
9119,PMC3424202,14889,These products are only available as co-blistered formulations and are only prescribed for adults above 15 years of age [6].,Discussion,[89424],[31495],[31619],[False],[0],[0],[False],['0']
9120,PMC3424202,14890,"As DP is a fixed dose combination could potentially yield better compliance, and less risk of diverting the co-blistered artesunate into monotherapy.",Discussion,[89428],[31620],[31769],[False],[0],[0],[False],['0']
9121,PMC3424202,14891,"Artemisinin monotherapy use was widespread across India, and this is thought to be one of the key drivers to the possible creation of resistance to artemisinins, the backbone of worldwide treatment of malaria.",Discussion,[89432],[31770],[31979],[False],[0],[0],[False],['0']
9122,PMC3424202,14892,"In addition, with the spread of chloroquine (CQ)-resistant malaria in India, sulphadoxine-pyrimethamine (SP) alone and more recently in combination with artesunate is used first line treatment for malaria.",Discussion,[89436],[31980],[32185],[False],[0],[0],[False],['0']
9123,PMC3424202,14893,"Due to continuous drug pressure, the P. falciparum parasite is now exhibiting resistance to anti-folates, though for the time being most parasites are sensitive to the drug.",Discussion,[89440],[32186],[32359],[False],[0],[0],[False],['0']
9124,PMC3424202,14894,The reported resistance strains have been shown to be so because of mutations in candidate genes dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps)[19].,Discussion,[89444],[32360],[32530],[False],[0],[0],[False],['0']
9125,PMC3424202,14895,The use of a highly effective safe fixed dose ACT might help reduce the drug pressure on SP.,Discussion,[89448],[32531],[32623],[False],[0],[0],[False],['0']
9126,PMC3424202,14896,One of the limitations of this study is the lack of children below 18 years of age.,Discussion,[89454],[32624],[32707],[True],['VerySpecificPopulation'],['the lack of children below 18\u2009years of age'],[True],['Population']
9127,PMC3424202,14897,The burden in children in India remains [20] significant.,Discussion,[89460],[32708],[32765],[False],[0],[0],[False],['0']
9128,PMC3424202,14898,In other geographic areas DP has been shown to be useful in both children and adults.,Discussion,[89464],[32766],[32851],[False],[0],[0],[False],['0']
9129,PMC3424202,14899,The use of the drug in Indian children needs to be studied.,Discussion,[89468],[32852],[32911],[False],[0],[0],[False],['0']
9130,PMC3424202,14900,"This is the first study of the use of DP in the Indian population, with 101 patients receiving the combination.",Discussion,[89472],[32912],[33023],[False],[0],[0],[False],['0']
9131,PMC3424202,14901,"It provides information on DP in communities in Assam, Goa and Mangalore.",Discussion,[89476],[33024],[33097],[False],[0],[0],[False],['0']
9132,PMC3424202,14902,"These Indian communities had notable levels of chloroquine resistance, with historical site records showing treatment failure rates for chloroquine treatment ranging from 32% to 67% (based on a 28 days of follow-up).",Discussion,[89480],[33098],[33314],[False],[0],[0],[False],['0']
9133,PMC3424202,14903,"Based on the structural similarities of chloroquine and piperaquine, there was the theoretical potential for cross-resistance to chloroquine which might have resulted in a low response to DP.",Discussion,[89487],[33315],[33506],[True],['Intervention'],['potential for cross-resistance to chloroquine'],[True],['Intervention']
9134,PMC3424202,14904,"However, the DP combination appeared to be unaffected by any potential cross-resistance, and performed uniformly well in all Indian settings.",Discussion,[89492],[33507],[33648],[False],[0],[0],[False],['0']
9135,PMC3424202,14905,The DP combination exerted a significant post-treatment prophylactic effect in this study.,Discussion,[89496],[33649],[33739],[False],[0],[0],[False],['0']
9136,PMC3424202,14906,Significant reductions in the incidence of new infections for DP compared with A + M were seen.,Discussion,[89500],[33740],[33835],[False],[0],[0],[False],['0']
9137,PMC3424202,14907,"Higher uncorrected cure rates were observed in the DP arm than with A + M, as the uncorrected cure rate endpoint includes new infections as well as recurrence of infection.",Discussion,[89504],[33836],[34008],[False],[0],[0],[False],['0']
9138,PMC3424202,14908,This effect is thought to be caused by residual levels of drug remaining in the body because of the longer half-life of piperaquine.,Discussion,[89508],[34009],[34141],[False],[0],[0],[False],['0']
9139,PMC3424202,14909,"The post-treatment prophylaxis was better for DP reflecting the differential terminal half-life of piperaquine and mefloquine (22–25 days versus 14 days, respectively).",Discussion,[89512],[34142],[34310],[False],[0],[0],[False],['0']
9140,PMC3424202,14910,The post-treatment prophylactic effect is of particular importance in regions with a high risk of new infection.,Discussion,[89516],[34311],[34423],[False],[0],[0],[False],['0']
9141,PMC3424202,14911,This can reduce the risk of anaemia and allow patients more time for haematological recovery between infections.,Discussion,[89520],[34424],[34536],[False],[0],[0],[False],['0']
9142,PMC3424202,14912,Mefloquine has been linked with adverse events of gastrointestinal and central nervous system origin [21].,Discussion,[89524],[34537],[34643],[False],[0],[0],[False],['0']
9143,PMC3424202,14913,"In this study, the frequency of reporting of nausea, vomiting and dizziness was 2–3 fold higher in the A + M arm than the DP arm.",Discussion,[89528],[34644],[34773],[False],[0],[0],[False],['0']
9144,PMC3424202,14914,Vomiting soon after dosing is an important determinant of treatment efficacy as attaining and maintaining effective systemic levels of anti-malarial drugs is essential to disease outcome.,Discussion,[89532],[34774],[34961],[False],[0],[0],[False],['0']
9145,PMC3424202,14915,"For patients to access DP via public sector healthcare systems, this fixed dose combination requires regulatory approval.",Discussion,[89536],[34962],[35083],[False],[0],[0],[False],['0']
9146,PMC3424202,14916,"In conclusion, the fixed dose dihydroartemisinin-piperaquine in this study emerged as a highly efficacious treatment for P. falciparum malaria in India.",Discussion,[89540],[35084],[35236],[False],[0],[0],[False],['0']
9147,PMC3424202,14917,The combination of DP provided some protection against new infections post treatment.,Discussion,[89544],[35237],[35322],[False],[0],[0],[False],['0']
9148,PMC3424202,14918,"DP can play an important role in controlling and eliminating malaria in India, possibly in the context of multiple first-line treatments of uncomplicated falciparum malaria, which will reduce drug pressure on existing combinations.",Discussion,[89548],[35323],[35554],[False],[0],[0],[False],['0']
9149,PMC3424202,14919,Competing interest,Competing interest,[89552],[35555],[35574],[False],[0],[0],[False],['0']
9150,PMC3424202,14920,"Nicola Gargano, Silva Tommasini, Antonella Bacchieri and Marco Corsi were from Sigma-Tau developing the product.",Competing interest,[89556],[35575],[35687],[False],[0],[0],[False],['0']
9151,PMC3424202,14921,None of the other authors has any conflict of interest.,Competing interest,[89560],[35688],[35743],[False],[0],[0],[False],['0']
9152,PMC3424202,14922,Authors’ contributions,Authors’ contributions,[89564],[35744],[35767],[False],[0],[0],[False],['0']
9153,PMC3424202,14923,"NG, ST, AB, and MC: Development and manufacturing of drug, DU: Manuscript preparation and overall coordination of study, PCB, BHK and ND: Medical supervision and patient care during clinical trial at Down town, Wenlock Government District and Goa Medical College hospitals respectively, VD, SKG and AK enrolment of patients, follow up and coordination at respective study sites, BS: parasitological assessment and quality assurance, NV: Overall coordination, protocol development, review and editing of manuscript.",Authors’ contributions,[89568],[35768],[36282],[False],[0],[0],[False],['0']
9154,PMC3424202,14924,All authors read and approved the final manuscript.,Authors’ contributions,[89572],[36283],[36334],[False],[0],[0],[False],['0']
9155,PMC3424202,14925,Acknowledgements,Acknowledgements,[89576],[36335],[36352],[False],[0],[0],[False],['0']
9156,PMC3424202,14926,"We are very grateful to all patients who participated in the study and all staff, medical collaborating hospitals for help.",Acknowledgements,[89580],[36353],[36476],[False],[0],[0],[False],['0']
9157,PMC3424202,14927,We are thankful to ICMR for permitting to take clinical trial.,Acknowledgements,[89584],[36477],[36539],[False],[0],[0],[False],['0']
9158,PMC3424202,14928,This paper bears the NIMR publication screening committee approval no.,Acknowledgements,[89588],[36540],[36610],[False],[0],[0],[False],['0']
9159,PMC3424202,14929,001/2012.,Acknowledgements,[89592],[36611],[36620],[False],[0],[0],[False],['0']
9160,PMC3441849,16214,Early cessation of breastfeeding amongst women in South Africa: an area needing urgent attention to improve child health,Title,[97750],[39696],[120],[False],[0],[0],[False],['0']
9161,PMC3441849,16215,Background,Abstract,[97754],[121],[132],[False],[0],[0],[False],['0']
9162,PMC3441849,16216,Breastfeeding is a critical component of interventions to reduce child mortality.,Abstract,[97758],[133],[214],[False],[0],[0],[False],['0']
9163,PMC3441849,16217,Exclusive breastfeeding practice is extremely low in South Africa and there has been no improvement in this over the past ten years largely due to fears of HIV transmission.,Abstract,[97762],[215],[388],[False],[0],[0],[False],['0']
9164,PMC3441849,16218,Early cessation of breastfeeding has been found to have negative effects on child morbidity and survival in several studies in Africa.,Abstract,[97766],[389],[523],[False],[0],[0],[False],['0']
9165,PMC3441849,16219,This paper reports on determinants of early breastfeeding cessation among women in South Africa.,Abstract,[97770],[524],[620],[False],[0],[0],[False],['0']
9166,PMC3441849,16220,Methods,Methods,[97774],[621],[629],[False],[0],[0],[False],['0']
9167,PMC3441849,16221,"This is a sub group analysis of a community-based cluster-randomized trial (PROMISE EBF) promoting exclusive breastfeeding in three South African sites (Paarl in the Western Cape Province, and Umlazi and Rietvlei in KwaZulu-Natal) between 2006 and 2008 (ClinicalTrials.gov no: NCT00397150).",Methods,[97778],[630],[920],[False],[0],[0],[False],['0']
9168,PMC3441849,16222,"Infant feeding recall of 22 food and fluid items was collected at 3, 6, 12 and 24 weeks postpartum.",Methods,[97782],[921],[1020],[False],[0],[0],[False],['0']
9169,PMC3441849,16223,Women’s experiences of breast health problems were also collected at the same time points.,Methods,[97786],[1021],[1111],[False],[0],[0],[False],['0']
9170,PMC3441849,16224,999 women who ever breastfed were included in the analysis.,Methods,[97790],[1112],[1171],[False],[0],[0],[False],['0']
9171,PMC3441849,16225,"Univariable and multivariable logistic regression analysis adjusting for site, arm and cluster, was performed to determine predictors of stopping breastfeeding by 12 weeks postpartum.",Methods,[97794],[1172],[1355],[False],[0],[0],[False],['0']
9172,PMC3441849,16226,Results,Results,[97798],[1356],[1364],[False],[0],[0],[False],['0']
9173,PMC3441849,16227,"By 12 weeks postpartum, 20% of HIV-negative women and 40% of HIV-positive women had stopped all breastfeeding.",Results,[97802],[1365],[1475],[False],[0],[0],[False],['0']
9174,PMC3441849,16228,"About a third of women introduced other fluids, most commonly formula milk, within the first 3 days after birth.",Results,[97806],[1476],[1588],[False],[0],[0],[False],['0']
9175,PMC3441849,16229,"Antenatal intention not to breastfeed and being undecided about how to feed were most strongly associated with stopping breastfeeding by 12 weeks (Adjusted odds ratio, AOR 5.6, 95% CI 3.4 – 9.5 and AOR 4.1, 95% CI 1.6 – 10.8, respectively).",Results,[97810],[1589],[1829],[False],[0],[0],[False],['0']
9176,PMC3441849,16230,"Also important was self-reported breast health problems associated with a 3-fold risk of stopping breastfeeding (AOR 3.1, 95%CI 1.7 – 5.7) and the mother having her own income doubled the risk of stopping breastfeeding (AOR 1.9, 95% CI 1.3 – 2.8).",Results,[97814],[1830],[2077],[False],[0],[0],[False],['0']
9177,PMC3441849,16231,Conclusion,Conclusion,[97818],[2078],[2089],[False],[0],[0],[False],['0']
9178,PMC3441849,16232,Early cessation of breastfeeding is common amongst both HIV-negative and positive women in South Africa.,Conclusion,[97822],[2090],[2194],[False],[0],[0],[False],['0']
9179,PMC3441849,16233,There is an urgent need to improve antenatal breastfeeding counselling taking into account the challenges faced by working women as well as early postnatal lactation support to prevent breast health problems.,Conclusion,[97826],[2195],[2403],[False],[0],[0],[False],['0']
9180,PMC3441849,16234,Background,Background,[97830],[2404],[2416],[False],[0],[0],[False],['0']
9181,PMC3441849,16235,South Africa is one of five countries in Southern Africa that is considered to have made no progress between 1990 and 2008 in reducing mortality amongst children younger than five years (Millennium Development Goal 4) [1].,Background,[97834],[2417],[2639],[False],[0],[0],[False],['0']
9182,PMC3441849,16236,"In this period, the under-5-mortality rate rose from 56 to 67 per 1000 live births, with 57 percent of all child deaths attributable to HIV/AIDS, followed by pneumonia, diarrhoea and undernutrition [2].",Background,[97838],[2640],[2842],[False],[0],[0],[False],['0']
9183,PMC3441849,16237,"Even before the emergence of the HIV epidemic in South Africa, breastfeeding practices were sub optimal.",Background,[97842],[2843],[2947],[False],[0],[0],[False],['0']
9184,PMC3441849,16238,"Although initiation of breastfeeding is high, Demographic and Health Surveys have reported a decline in initiation from 87% in 1998 [3] to 82% in 2003 [4].",Background,[97846],[2948],[3103],[False],[0],[0],[False],['0']
9185,PMC3441849,16239,Exclusive breastfeeding in South Africa is extremely low and has not improved over the past thirteen years; 7% under six months in 1998 [3] and 8% under 6 months in 2003 [4].,Background,[97850],[3104],[3278],[False],[0],[0],[False],['0']
9186,PMC3441849,16240,"In 2001, with the introduction of the Prevention of Mother to Child HIV Transmission (PMTCT) programme guidelines were released by the National Department of Health regarding infant feeding advice to be given to HIV-positive women.",Background,[97854],[3279],[3510],[False],[0],[0],[False],['0']
9187,PMC3441849,16241,"Given the existing knowledge at the time, those guidelines recommended abrupt cessation of breastfeeding at four months for HIV- positive women who chose to breastfeed [5].",Background,[97858],[3511],[3683],[False],[0],[0],[False],['0']
9188,PMC3441849,16242,Furthermore provision was made for free formula milk to be provided from public health facilities for HIV-positive women choosing not to breastfeed.,Background,[97862],[3684],[3832],[False],[0],[0],[False],['0']
9189,PMC3441849,16243,"This policy did not seem unusual in South Africa, where formula milk has been dispensed for many years as part of the ‘Protein Energy Malnutrition scheme’ to rehabilitate malnourished children [6], and in which there has been no enforcement of, or legislation based on, the International Code of Marketing Breast Milk Substitutes.",Background,[97866],[3833],[4163],[False],[0],[0],[False],['0']
9190,PMC3441849,16244,"Furthermore, from 2001 to present there has been no investment in advocacy or media to promote breastfeeding, partly due to fears of HIV transmission through breast milk [7].",Background,[97870],[4164],[4338],[False],[0],[0],[False],['0']
9191,PMC3441849,16245,"When the PMTCT programme was first implemented there was very little evidence [8] regarding the risk of HIV transmission with different breastfeeding practices; hence any type of breastfeeding (exclusive or mixed) was feared to carry a large risk of HIV transmission and research across Africa has found that health workers commonly overestimate this risk when counselling mothers [9,10].",Background,[97874],[4339],[4727],[False],[0],[0],[False],['0']
9192,PMC3441849,16246,"The World Health Organisation (WHO) recommends exclusive breastfeeding during the first six months of life for optimal growth, development and health.",Background,[97878],[4728],[4878],[False],[0],[0],[False],['0']
9193,PMC3441849,16247,"Breastfeeding should continue up to two years or more and nutritionally adequate, safe, and appropriately-fed complementary foods should be introduced at the age of six months to meet the evolving needs of the growing infant [11].",Background,[97882],[4879],[5109],[False],[0],[0],[False],['0']
9194,PMC3441849,16248,"The WHO recommendation at the time of this study regarding infant feeding for HIV positive women was exclusive breastfeeding for the first six months of life unless replacement feeding is acceptable, feasible, affordable, sustainable and safe [12].",Background,[97886],[5110],[5358],[False],[0],[0],[False],['0']
9195,PMC3441849,16249,"Exclusive breastfeeding could make a large contribution to child survival, being the single most effective intervention for reducing under five mortality in low income settings [13].",Background,[97890],[5359],[5541],[False],[0],[0],[False],['0']
9196,PMC3441849,16250,Analyses of risks associated with partial or no breastfeeding have suggested that high coverage of promotion of exclusive breastfeeding could lead to a 11.6% reduction in the number of infant deaths and avert 21.9 million disability adjusted life years (8.6%) [14].,Background,[97894],[5542],[5807],[False],[0],[0],[False],['0']
9197,PMC3441849,16251,Early cessation or not breastfeeding is therefore associated with disadvantages in terms of survival and morbidity amongst both HIV exposed and unexposed infants [15-19].,Background,[97898],[5808],[5978],[False],[0],[0],[False],['0']
9198,PMC3441849,16252,"Poor breastfeeding technique especially latching and positioning are known to predispose women to breast health problems including mastitis, cracked nipples and engorgement [20].",Background,[97902],[5979],[6157],[False],[0],[0],[False],['0']
9199,PMC3441849,16253,"These conditions are known to interfere with the success and duration of optimal breast-feeding practice in the first 6 months after birth [21] and in the case of sub clinical mastitis, increasing the risk of postnatal HIV transmission [22-24].",Background,[97906],[6158],[6402],[False],[0],[0],[False],['0']
9200,PMC3441849,16254,This paper reports on factors associated with cessation of breastfeeding by 12 weeks postpartum amongst HIV-positive and negative women in South Africa using infant feeding information from a large multi country community randomised trial known as PROMISE EBF.,Background,[97910],[6403],[6663],[False],[0],[0],[False],['0']
9201,PMC3441849,16255,The trial aimed to increase the practice of exclusive breastfeeding through supportive counselling to mothers during home visits by community peer supporters.,Background,[97914],[6664],[6822],[False],[0],[0],[False],['0']
9202,PMC3441849,16256,The intervention had effects of public health significance in terms of substantial behavioural changes in two of the countries where EBF prevalence at 12 weeks in the intervention and control groups were respectively 79.1% and 34.6% in Burkina Faso and 81.6% and 43.9% in Uganda [25].,Background,[97918],[6823],[7107],[False],[0],[0],[False],['0']
9203,PMC3441849,16257,"In South Africa, a similar relative increase was noted (10.5% and 6.2%) but the public health benefit is unlikely to be significant since the absolute change was small.",Background,[97922],[7108],[7276],[False],[0],[0],[False],['0']
9204,PMC3441849,16258,The aim of this paper is to describe determinants of cessation of breastfeeding by 12 weeks which need to be addressed in order to improve the success and public health impact of breastfeeding promotion programmes in South Africa.,Background,[97926],[7277],[7507],[False],[0],[0],[False],['0']
9205,PMC3441849,16259,Methods,Methods,[97930],[7508],[7516],[False],[0],[0],[False],['0']
9206,PMC3441849,16260,This study used infant feeding data from a community-based cluster-randomized trial promoting exclusive breastfeeding by peer-counsellors in three South African sites between 2006 and 2008 (ClinicalTrials.gov no: NCT00397150).,Methods,[97934],[7517],[7743],[False],[0],[0],[False],['0']
9207,PMC3441849,16261,"A total of 34 clusters from three areas in South Africa were chosen: Paarl in Western Cape Province (peri-urban), and Umlazi (urban) and Rietvlei (rural) in KwaZulu-Natal Province.",Methods,[97938],[7744],[7924],[False],[0],[0],[False],['0']
9208,PMC3441849,16262,"Infant mortality rate (IMR) and antenatal HIV prevalence at the time of the study were 40/1000 and 10% in the Paarl site, 60/1000 and 42% in the Umlazi site and 99/1000 and 34% in Rietvlei site [4,26].",Methods,[97942],[7925],[8126],[False],[0],[0],[False],['0']
9209,PMC3441849,16263,A detailed description of the methodology for the trial is described elsewhere [25].,Methods,[97946],[8127],[8211],[False],[0],[0],[False],['0']
9210,PMC3441849,16264,"In short, mothers in the intervention clusters received one antenatal and four postnatal visits at weeks 1, 4, 7 and 10 postpartum by peer counsellors promoting and supporting exclusive infant feeding practices (breast or formula).",Methods,[97950],[8212],[8443],[False],[0],[0],[False],['0']
9211,PMC3441849,16265,"For breastfeeding women, peer counsellors were trained to support and encourage exclusive breastfeeding for the first six months.",Methods,[97954],[8444],[8573],[False],[0],[0],[False],['0']
9212,PMC3441849,16266,In the control clusters mothers received the same number of visits from peer counsellors who provided information to mothers about accessing social welfare grants.,Methods,[97958],[8574],[8737],[False],[0],[0],[False],['0']
9213,PMC3441849,16267,This information was not believed to have any impact on infant feeding practices.,Methods,[97962],[8738],[8819],[False],[0],[0],[False],['0']
9214,PMC3441849,16268,Recruitment was a two-stage procedure.,Methods,[97966],[8820],[8858],[False],[0],[0],[False],['0']
9215,PMC3441849,16269,"In the last trimester of pregnancy, a total of 1276 women were recruited from the three South African sites.",Methods,[97970],[8859],[8967],[False],[0],[0],[False],['0']
9216,PMC3441849,16270,"At the 3-week assessment the mother-infant pairs were assessed and a total of 139 were excluded due to relocation or being lost-to-follow-up (95), stillbirth (9), twin delivery (11) or death of the infant (23) or mother (1) before 3 weeks after birth.",Methods,[97974],[8968],[9219],[False],[0],[0],[False],['0']
9217,PMC3441849,16271,"Thus, 1137 mother-infant pairs were enrolled into the study.",Methods,[97978],[9220],[9280],[False],[0],[0],[False],['0']
9218,PMC3441849,16272,"The mother-infant pairs were scheduled to be interviewed at recruitment late in pregnancy and at 3, 6, 12 and 24 weeks after birth.",Methods,[97982],[9281],[9412],[False],[0],[0],[False],['0']
9219,PMC3441849,16273,Interview visits were regarded as timely if they were done in the following time ranges: 3 weeks (1.5–4.5); 6 weeks (4.5–9); 12 weeks (9–18).,Methods,[97986],[9413],[9554],[False],[0],[0],[False],['0']
9220,PMC3441849,16274,The recruitment interview focused mainly on socio-economic wealth and socio-demographic characteristics.,Methods,[97990],[9555],[9659],[False],[0],[0],[False],['0']
9221,PMC3441849,16275,"The follow-up interviews addressed infant feeding using 24 hour, 7 day and since birth recall of 22 specified fluid and food items, mother’s experiences of breast health problems including cracked nipples, engorgement, infection and abscess, infant morbidity and anthropometric measurements.",Methods,[97994],[9660],[9951],[False],[0],[0],[False],['0']
9222,PMC3441849,16276,Data management,Data management,[97998],[9952],[9968],[False],[0],[0],[False],['0']
9223,PMC3441849,16277,Data was collected through interviews by trained data collectors who were kept uninformed about the allocation assignment and kept separate from the intervention team.,Data management,[98002],[9969],[10136],[False],[0],[0],[False],['0']
9224,PMC3441849,16278,Data was subsequently double entered using EpiData (version 3.1) and analysis was done with Stata (version 10) and SAS (version 9.2).,Data management,[98006],[10137],[10270],[False],[0],[0],[False],['0']
9225,PMC3441849,16279,Analysis,Analysis,[98010],[10271],[10280],[False],[0],[0],[False],['0']
9226,PMC3441849,16280,Of the 1137 women enrolled in the study only women who ever breastfed were included in this analysis (n = 999).,Analysis,[98014],[10281],[10392],[False],[0],[0],[False],['0']
9227,PMC3441849,16281,"Complete cessation of breastfeeding by 3 weeks was defined as no breastfeeding in the 24 hours and 7 days prior to the 3 week interview and no breastfeeding reported (24 hour and 7 day recall) at the 6, 12 and 24 week interview.",Analysis,[98018],[10393],[10621],[False],[0],[0],[False],['0']
9228,PMC3441849,16282,Complete cessation of breastfeeding by 6 weeks was defined as no breastfeeding in the 24 hours and 7 days prior to the 6 week interview and no breastfeeding reported (24 hour and 7 day recall) at the 12 and 24 week interview.,Analysis,[98022],[10622],[10847],[False],[0],[0],[False],['0']
9229,PMC3441849,16283,Complete cessation of breastfeeding by 12 weeks was defined as no breastfeeding in the 24 hours and 7 days prior to the 12 week interview and no breastfeeding reported (24 hour and 7 day recall) at the final 24 week interview.,Analysis,[98026],[10848],[11074],[False],[0],[0],[False],['0']
9230,PMC3441849,16284,Pooled estimates for the prevalence of stopping breastfeeding were calculated over the three sites.,Analysis,[98030],[11075],[11174],[False],[0],[0],[False],['0']
9231,PMC3441849,16285,These were unweighted estimates since the sites and clusters included in the trial were purposely selected.,Analysis,[98034],[11175],[11282],[False],[0],[0],[False],['0']
9232,PMC3441849,16286,"Breast health problems were recorded at 3, 6, 12 and 24 weeks postpartum.",Analysis,[98038],[11283],[11356],[False],[0],[0],[False],['0']
9233,PMC3441849,16287,The data collected at the 6 week interview was used for this analysis and included problems occurring between birth and 6 weeks.,Analysis,[98042],[11357],[11485],[False],[0],[0],[False],['0']
9234,PMC3441849,16288,"A composite measure of household socio economic status was constructed with the use of multiple correspondence analysis based on ownership of assets including mobile phone and television, and house characteristics including water source, roof material and toilet type.",Analysis,[98046],[11486],[11754],[False],[0],[0],[False],['0']
9235,PMC3441849,16289,"This method is analogous to principal component analysis, and better suited for categorical data [27].",Analysis,[98050],[11755],[11857],[False],[0],[0],[False],['0']
9236,PMC3441849,16290,The children’s families were grouped into quintiles on the basis of socioeconomic rank.,Analysis,[98054],[11858],[11945],[False],[0],[0],[False],['0']
9237,PMC3441849,16291,Univariable and multivariable logistic regression analysis was performed.,Analysis,[98058],[11946],[12019],[False],[0],[0],[False],['0']
9238,PMC3441849,16292,All variables in Table 1 (baseline characteristics) as well as explanatory variables that were either clinically (e.g.,Analysis,[98062],[12020],[12138],[False],[0],[0],[False],['0']
9239,PMC3441849,16293,breast health problems) or epidemiologically (e.g.,Analysis,[98066],[12139],[12189],[False],[0],[0],[False],['0']
9240,PMC3441849,16294,mothers HIV status) important were evaluated as potential determinants of early breastfeeding cessation.,Analysis,[98070],[12190],[12294],[False],[0],[0],[False],['0']
9241,PMC3441849,16295,Variables were retained in the models if they were either at least of marginal significance or played a confounding role [28].,Analysis,[98074],[12295],[12421],[False],[0],[0],[False],['0']
9242,PMC3441849,16296,The variable breast problems included a category of women missing at the six weeks interview (unable to be located for an interview) to assess the effect of loss to follow up since this was the only variable in the model that was not collected at baseline (recruitment interview in late pregnancy).,Analysis,[98078],[12422],[12720],[False],[0],[0],[False],['0']
9243,PMC3441849,16297,"Model 1 includes the most proximal independent predictors (infant feeding intention, breast problems and HIV status) and model two includes the factors in model one as well as socio economic related factors (mother having own source of income and site).",Analysis,[98082],[12721],[12974],[False],[0],[0],[False],['0']
9244,PMC3441849,16298,The models were adjusted for cluster and arm to account for the community randomised trial design.,Analysis,[98086],[12975],[13073],[False],[0],[0],[False],['0']
9245,PMC3441849,16299,The Hosmer-Lemeshow test indicated a good model fit (0.23).,Analysis,[98090],[13074],[13133],[False],[0],[0],[False],['0']
9246,PMC3441849,16300,Ethics,Ethics,[98094],[13134],[13141],[False],[0],[0],[False],['0']
9247,PMC3441849,16301,Ethical approval was granted by the Ethics Committee of the Medical Research Council South Africa.,Ethics,[98098],[13142],[13240],[False],[0],[0],[False],['0']
9248,PMC3441849,16302,Signed or thumb-printed informed consent was obtained from each mother prior to study participation.,Ethics,[98102],[13241],[13341],[False],[0],[0],[False],['0']
9249,PMC3441849,16303,"This study is registered with ClinicalTrials.gov, number NCT00397150.",Ethics,[98106],[13342],[13411],[False],[0],[0],[False],['0']
9250,PMC3441849,16304,Results,Results,[98110],[13412],[13420],[False],[0],[0],[False],['0']
9251,PMC3441849,16305,Baseline characteristics of breastfeeding women,Results|Baseline characteristics of breastfeeding women,[98114],[13421],[13468],[False],[0],[0],[False],['0']
9252,PMC3441849,16306,Table 1 shows baseline characteristics of women by study site.,Results|Baseline characteristics of breastfeeding women,[98118],[13469],[13531],[False],[0],[0],[False],['0']
9253,PMC3441849,16307,The median maternal age was 22 years in Rietvlei and Umlazi and 24 years in Paarl.,Results|Baseline characteristics of breastfeeding women,[98122],[13532],[13614],[False],[0],[0],[False],['0']
9254,PMC3441849,16308,Completed years of education ranged from a median of 9 in Rietvlei to 11 in Umlazi.,Results|Baseline characteristics of breastfeeding women,[98126],[13615],[13698],[False],[0],[0],[False],['0']
9255,PMC3441849,16309,The majority of women in Rietvlei were married whilst most women in Paarl and Umlazi were single.,Results|Baseline characteristics of breastfeeding women,[98130],[13699],[13796],[False],[0],[0],[False],['0']
9256,PMC3441849,16310,Over 95% of women in all three sites had attended antenatal care.,Results|Baseline characteristics of breastfeeding women,[98134],[13797],[13862],[False],[0],[0],[False],['0']
9257,PMC3441849,16311,"Large differences are noted (as expected due to purposive selection) in socio economic status and access to basic infrastructure (electricity, piped water and flush toilet) between the three sites with Rietvlei being notably poorer compared to Paarl and Umlazi.",Results|Baseline characteristics of breastfeeding women,[98138],[13863],[14124],[False],[0],[0],[False],['0']
9258,PMC3441849,16312,Infant feeding practices between birth and 12 weeks amongst breastfeeding women,Results,[98142],[14125],[14205],[False],[0],[0],[False],['0']
9259,PMC3441849,16313,"Figure 1 shows a flow chart of breastfeeding initiation and cessation amongst HIV-negative and positive women at birth, 3, 6 and 12 weeks postpartum.",Results,[98146],[14206],[14355],[False],[0],[0],[False],['0']
9260,PMC3441849,16314,Almost all (97%) HIV-negative women and less than half (42%) of the HIV-positive women ever breastfed while the remainder never breastfed their infants.,Results,[98150],[14356],[14508],[False],[0],[0],[False],['0']
9261,PMC3441849,16315,"Seventy two (8%) HIV-negative and 28 (38%) HIV- positive women who breastfed, had intended antenatally not to breastfeed.",Results,[98154],[14509],[14630],[False],[0],[0],[False],['0']
9262,PMC3441849,16316,"Of the women who breastfed their infants, just over half of the HIV-negative women and almost a third of HIV-positive women initiated breastfeeding within one hour of birth.",Results,[98158],[14631],[14804],[False],[0],[0],[False],['0']
9263,PMC3441849,16317,"Within the first three days after birth, 276 (31%) HIV-negative women and 22 (37%) HIV-positive women had given their infants something other than breast milk to drink, most commonly sugar water (32%), formula milk (25%) and water (21%).",Results,[98162],[14805],[15042],[False],[0],[0],[False],['0']
9264,PMC3441849,16318,"By three weeks postpartum, 62 (7%) and 12 (18%) HIV-negative and positive women respectively had stopped breastfeeding and by six weeks postpartum this had increased to 116 (13%) and 23 (32%) respectively.",Results,[98166],[15043],[15248],[False],[0],[0],[False],['0']
9265,PMC3441849,16319,By 12 weeks 178 (20%) HIV-negative women and 27 (41%) HIV-positive women who initiated breastfeeding had stopped all breastfeeding (Figure 1).,Results,[98170],[15249],[15391],[False],[0],[0],[False],['0']
9266,PMC3441849,16320,Predictors of stopping breastfeeding by 12 weeks,Infant feeding practices between birth and 12 weeks amongst breastfeeding women,[98174],[15392],[15441],[False],[0],[0],[False],['0']
9267,PMC3441849,16321,Table 2 shows the univariable and multivariable analyses of breastfeeding cessation by 12weeks.,Infant feeding practices between birth and 12 weeks amongst breastfeeding women,[98178],[15442],[15537],[False],[0],[0],[False],['0']
9268,PMC3441849,16322,"The most important predictors of stopping breastfeeding were an intention to not breastfeed antenatally (AOR 5.6, 95% CI 3.4 – 9.4) or being undecided with regard to feeding intention (AOR 4.1, 95% CI 1.5 – 10.8), breast health problems (AOR 3.1, 95% CI 1.7 – 5.7), and mother having her own source of income (AOR 1.9, 95% CI 1.3 – 2.8).",Infant feeding practices between birth and 12 weeks amongst breastfeeding women,[98182],[15538],[15875],[False],[0],[0],[False],['0']
9269,PMC3441849,16323,"Being HIV positive, although predictive on univariable analysis, was no longer significant after adjusting for antenatal feeding intention and breast problems.",Infant feeding practices between birth and 12 weeks amongst breastfeeding women,[98186],[15876],[16035],[False],[0],[0],[False],['0']
9270,PMC3441849,16324,"Adjusting for study site and arm did not alter the magnitude of the main effects (final model 2), hence the peer counselling intervention had no effect on early breastfeeding cessation.",Infant feeding practices between birth and 12 weeks amongst breastfeeding women,[98190],[16036],[16221],[False],[0],[0],[False],['0']
9271,PMC3441849,16325,Breast health problems,Breast health problems,[98194],[16222],[16245],[False],[0],[0],[False],['0']
9272,PMC3441849,16326,Overall 92 (11%) breastfeeding women experienced a breast health problem between birth and 6 weeks postpartum.,Breast health problems,[98198],[16246],[16356],[False],[0],[0],[False],['0']
9273,PMC3441849,16327,Of these women 73 specified the type of problem they experienced and the most common problems reported were cracked nipples (35/73; 48%) followed by engorgement (16/73; 22%) and infection (15/73; 20%).,Breast health problems,[98202],[16357],[16558],[False],[0],[0],[False],['0']
9274,PMC3441849,16328,"There were differences in the prevalence of breast health problems by site, with 56 women in Umlazi (17%) experiencing a breast health problem compared to 19 in Rietvlei (9%) and 17 in Paarl (6%) (p = 0.00), possibly due to the higher HIV prevalence in the Umlazi site.",Breast health problems,[98206],[16559],[16828],[False],[0],[0],[False],['0']
9275,PMC3441849,16329,Breast health problems were more common amongst HIV-positive women (13/63; 21%) compared to negative women (79/778; 10%) (p = 0.01) and amongst women who were mixed feeding (82/688; 12%) compared with predominantly breastfeeding (breastmilk with addition of water and other non nutritive liquids) (9/155; 6%) (p = 0.02).,Breast health problems,[98210],[16829],[17149],[False],[0],[0],[False],['0']
9276,PMC3441849,16330,Discussion,Discussion,[98214],[17150],[17161],[False],[0],[0],[False],['0']
9277,PMC3441849,16331,"To our knowledge, this study is the first to describe factors associated with early cessation of breastfeeding amongst a large, mostly HIV-negative sample of women in South Africa.",Discussion,[98218],[17162],[17342],[False],[0],[0],[False],['0']
9278,PMC3441849,16332,"The study has revealed sub-optimal early feeding practices, starting with low initiation of breastfeeding within one hour of birth, early introduction of other fluids and a steady increase in women stopping all breastfeeding between birth and twelve weeks postpartum.",Discussion,[98222],[17343],[17610],[False],[0],[0],[False],['0']
9279,PMC3441849,16333,An antenatal intention not to breastfeed or being undecided about how to feed were the strongest predictors of breastfeeding cessation by 12 weeks.,Discussion,[98226],[17611],[17758],[False],[0],[0],[False],['0']
9280,PMC3441849,16334,Experiencing a breast health problem and the mother having her own source of income also increased the likelihood of stopping breastfeeding by three and two fold respectively.,Discussion,[98230],[17759],[17934],[False],[0],[0],[False],['0']
9281,PMC3441849,16335,Over two thirds of the breastfeeding HIV-positive women had intended antenatally not to breastfeed and an intention not to breastfeed was found to be the strongest predictor of early breastfeeding cessation.,Discussion,[98234],[17935],[18142],[False],[0],[0],[False],['0']
9282,PMC3441849,16336,The peer counsellors in the PROMISE intervention did not counsel women on infant feeding choices since that was the role of health care workers in the antenatal clinics.,Discussion,[98238],[18143],[18312],[False],[0],[0],[False],['0']
9283,PMC3441849,16337,The peer counsellors supported the choice that the women had made based on the antenatal counselling received.,Discussion,[98242],[18313],[18423],[False],[0],[0],[False],['0']
9284,PMC3441849,16338,"Qualitative research undertaken during the PROMISE study [29] found that despite the availability of free formula milk for HIV-positive women, stigma associated with the collection of the free milk discourages women from carrying out their intention to not breastfeed.",Discussion,[98246],[18424],[18692],[False],[0],[0],[False],['0']
9285,PMC3441849,16339,"Poor quality of antenatal infant feeding counselling for HIV-positive women has been well described in South Africa [7,30]; the concerning finding from this study, however, is that even in the presence of postnatal home visits from peer breastfeeding counsellors, early introduction of formula milk and a steady increase in breastfeeding cessation amongst HIV negative women could not be prevented.",Discussion,[98250],[18693],[19091],[False],[0],[0],[False],['0']
9286,PMC3441849,16340,"This scenario is unique, as in the rest of Africa, formula milk is uncommon in the first six months.",Discussion,[98254],[19092],[19192],[False],[0],[0],[False],['0']
9287,PMC3441849,16341,Our study found that women who had their own source of income were twice as likely to stop breastfeeding by 12 weeks.,Discussion,[98258],[19193],[19310],[False],[0],[0],[False],['0']
9288,PMC3441849,16342,This income may be related to employment with little or no maternity leave provision.,Discussion,[98262],[19311],[19396],[False],[0],[0],[False],['0']
9289,PMC3441849,16343,It would also enable the purchase of formula milk and a means to replace breastmilk.,Discussion,[98266],[19397],[19481],[False],[0],[0],[False],['0']
9290,PMC3441849,16344,A cross sectional survey of feeding practices amongst HIV-positive women in Uganda also found that women who were socio-economically better off were more likely to stop breastfeeding earlier (median of 8 months compared to 17 in the poorest quintile) [31].,Discussion,[98270],[19482],[19738],[False],[0],[0],[False],['0']
9291,PMC3441849,16345,"Among the HIV-positive women in this study who chose to breastfeed, almost half of them stopped breastfeeding before 12 weeks.",Discussion,[98274],[19739],[19865],[False],[0],[0],[False],['0']
9292,PMC3441849,16346,This is earlier than the national recommendation at the time of the study of abrupt cessation at four months [5].,Discussion,[98278],[19866],[19979],[False],[0],[0],[False],['0']
9293,PMC3441849,16347,Early cessation of breastfeeding amongst HIV infected infants has been shown to be detrimental to survival in a large randomised trial in Zambia [18].,Discussion,[98282],[19980],[20130],[False],[0],[0],[False],['0']
9294,PMC3441849,16348,Infected infants who were weaned from breast milk by five months had a 74% mortality rate at 24 months compared to 55% amongst those with prolonged breastfeeding [18].,Discussion,[98286],[20131],[20298],[False],[0],[0],[False],['0']
9295,PMC3441849,16349,This risk continued into the second year of life with weaning before 18 months of age associated with increased risk of child death compared to breastfeeding beyond 18 months [32].,Discussion,[98290],[20299],[20479],[False],[0],[0],[False],['0']
9296,PMC3441849,16350,An earlier study conducted at the same sites as the PROMISE study found that health workers suggesting formula use was the strongest predictor of complete breastfeeding cessation by 24 weeks amongst HIV-positive women [16].,Discussion,[98294],[20480],[20703],[False],[0],[0],[False],['0']
9297,PMC3441849,16351,"Evidence from South Africa and Zambia led to a change in the WHO HIV and infant feeding recommendations in 2010 [33] which now state that at six months, if replacement feeding is still not acceptable, feasible, affordable, sustainable and safe, continuation of breastfeeding with additional complementary foods is recommended.",Discussion,[98298],[20704],[21030],[False],[0],[0],[False],['0']
9298,PMC3441849,16352,The lack of an effect of the peer counsellors on breastfeeding cessation raises questions regarding the quality of their counselling.,Discussion,[98302],[21031],[21164],[False],[0],[0],[False],['0']
9299,PMC3441849,16353,Further qualitative research undertaken during the trial has highlighted that in some instances women feared the peer counsellor visits and questioned their intentions [34].,Discussion,[98306],[21165],[21338],[False],[0],[0],[False],['0']
9300,PMC3441849,16354,Under these circumstances it would be difficult for the peer counsellors to influence women’s feeding practices.,Discussion,[98310],[21339],[21451],[False],[0],[0],[False],['0']
9301,PMC3441849,16355,"In contrast, qualitative research undertaken in the Ugandan site of this trial, where the intervention had a large effect, found that over 95% of the women expressed satisfaction with the peer counselling they received [35].",Discussion,[98314],[21452],[21676],[False],[0],[0],[False],['0']
9302,PMC3441849,16356,"Furthermore, in Uganda the peer counsellors were selected by their communities [36] while in South Africa a formal advertising, short listing and interview process was followed according to local employment processes [34].",Discussion,[98318],[21677],[21899],[False],[0],[0],[False],['0']
9303,PMC3441849,16357,"In this study, almost a quarter of HIV-positive women and 10% of negative women experienced a breast health problem before six weeks postpartum.",Discussion,[98322],[21900],[22044],[False],[0],[0],[False],['0']
9304,PMC3441849,16358,An intervention study in South Africa that provided regular home counselling to support exclusive breastfeeding found a low prevalence of breast health problems with no significant differences between HIV-positive and negative women[37].,Discussion,[98326],[22045],[22282],[False],[0],[0],[False],['0']
9305,PMC3441849,16359,"As with our study, this study also found that women who had not exclusively breast-fed their infants were more likely to experience breast health problems compared with women who had exclusively breast-fed [37].",Discussion,[98330],[22283],[22494],[False],[0],[0],[False],['0']
9306,PMC3441849,16360,A similar finding has recently been reported from Zambia where non-exclusive breastfeeding resulted in twice the risk of experiencing a breast problem compared with exclusive breastfeeding [38].,Discussion,[98334],[22495],[22689],[False],[0],[0],[False],['0']
9307,PMC3441849,16361,"Due to temporal uncertainty, reverse causality should be considered in understanding the relationship between breast health problems and breastfeeding cessation; did the infrequent/ceasing breastfeeding lead to breast problems or did the occurrence of breast problems lead to breastfeeding cessation?",Discussion,[98338],[22690],[22990],[False],[0],[0],[False],['0']
9308,PMC3441849,16362,Our study had several potential limitations.,Discussion,[98342],[22991],[23035],[False],[0],[0],[False],['0']
9309,PMC3441849,16363,The sites where this research was undertaken were purposely selected and the infrastructural conditions differed greatly between them.,Discussion,[98346],[23036],[23170],[True],['Setting'],['the infrastructural conditions differed greatly between them'],[True],['Setting']
9310,PMC3441849,16364,"They do, however, reflect a range in which many settings in South Africa could be comparable; either urban, peri-urban or rural areas.",Discussion,[98354],[23171],[23305],[False],[0],[0],[False],['0']
9311,PMC3441849,16365,"Pregnant women were recruited from within the communities with no other selection criteria except living in one of the study clusters, being pregnant and not planning to move away in the subsequent year.",Discussion,[98359],[23306],[23509],[True],['DiagnosticCriteria'],"['no other selection criteria except living in one of the study clusters, being pregnant and not planning to move away in the subsequent year']",[True],['Population']
9312,PMC3441849,16366,Postnatal inclusion criteria were a singleton live birth with no severe malformation which could interfere with breastfeeding.,Discussion,[98366],[23510],[23636],[False],[0],[0],[False],['0']
9313,PMC3441849,16367,"The HIV-positive sample in the study was fairly small, which limited our ability to conduct detailed sub group analysis.",Discussion,[98372],[23637],[23757],[True],['SampleSize'],['The HIV-positive sample in the study was fairly small'],[True],['UnderpoweredStudy']
9314,PMC3441849,16368,"There may be other factors associated with breastfeeding cessation in our sample that we did not measure, such as advertising or promotion of formula in health facilities and communities.",Discussion,[98381],[23758],[23945],[True],['ConfoundingFactors'],['other factors associated with breastfeeding cessation in our sample that we did not measure'],[True],['StatisticalAnalysis']
9315,PMC3441849,16369,"Further research, possibly qualitative in design, is needed to explore these aspects to understand more fully the drivers of breastfeeding cessation.",Discussion,[98386],[23946],[24095],[False],[0],[0],[False],['0']
9316,PMC3441849,16370,The study also has several strengths compared to many studies assessing infant feeding.,Discussion,[98390],[24096],[24183],[False],[0],[0],[False],['0']
9317,PMC3441849,16371,The total study sample was large and infant feeding data were rigorously collected using both 24 hour and previous 7 day recall at four times during the first half of infancy.,Discussion,[98394],[24184],[24359],[False],[0],[0],[False],['0']
9318,PMC3441849,16372,"In this study, despite a programme of home visitation in addition to routine facility infant feeding counselling, breastfeeding practices were poor.",Discussion,[98398],[24360],[24508],[False],[0],[0],[False],['0']
9319,PMC3441849,16373,"Improving breastfeeding practices in South Africa will require more effort including clear and consistent messages from health workers and community based workers and greatly improved breastfeeding support especially during the antenatal and early postnatal periods to ensure appropriate feeding choices, correct lactation techniques and optimal breastfeeding duration (see Table 3).",Discussion,[98402],[24509],[24892],[False],[0],[0],[False],['0']
9320,PMC3441849,16374,Conclusion,Conclusion,[98406],[24893],[24904],[False],[0],[0],[False],['0']
9321,PMC3441849,16375,Increasing the duration of breastfeeding amongst women in South Africa is critical in order for the public health benefits of breastfeeding on child survival to be realised.,Conclusion,[98410],[24905],[25078],[False],[0],[0],[False],['0']
9322,PMC3441849,16376,"There is an urgent need to develop and implement clear and consistent antenatal counselling messages to enable women to make appropriate infant feeding choices, especially for working women, together with early postnatal support to improve lactation techniques and prevent breast health problems.",Conclusion,[98414],[25079],[25375],[False],[0],[0],[False],['0']
9323,PMC3441849,16377,Competing interests,Competing interests,[98418],[25376],[25396],[False],[0],[0],[False],['0']
9324,PMC3441849,16378,The authors declare they have no competing interests.,Competing interests,[98422],[25397],[25450],[False],[0],[0],[False],['0']
9325,PMC3441849,16379,Authors’ contributions,Authors’ contributions,[98426],[25451],[25474],[False],[0],[0],[False],['0']
9326,PMC3441849,16380,"TD, DS, DJ, SS and CL planned and wrote the paper.",Authors’ contributions,[98430],[25475],[25525],[False],[0],[0],[False],['0']
9327,PMC3441849,16381,SS and CL were study statisticians.,Authors’ contributions,[98434],[25526],[25561],[False],[0],[0],[False],['0']
9328,PMC3441849,16382,"DS, IE, EE and LF contributed to manuscript design and content.",Authors’ contributions,[98438],[25562],[25625],[False],[0],[0],[False],['0']
9329,PMC3441849,16383,"IE, WZ, MC, DJ and TD had particular responsibility for study implementation.",Authors’ contributions,[98442],[25626],[25703],[False],[0],[0],[False],['0']
9330,PMC3441849,16384,TT was the central PI.,Authors’ contributions,[98446],[25704],[25726],[False],[0],[0],[False],['0']
9331,PMC3441849,16385,All authors read and contributed towards the final draft.,Authors’ contributions,[98450],[25727],[25784],[False],[0],[0],[False],['0']
9332,PMC3441849,16386,Pre-publication history,Pre-publication history,[98454],[25785],[25809],[False],[0],[0],[False],['0']
9333,PMC3441849,16387,The pre-publication history for this paper can be accessed here:,Pre-publication history,[98458],[25810],[25874],[False],[0],[0],[False],['0']
9334,PMC3441849,16388,http://www.biomedcentral.com/1471-2431/12/105/prepub,Pre-publication history,[98462],[25875],[25927],[False],[0],[0],[False],['0']
9335,PMC3441849,16389,Acknowledgments,Acknowledgments,[98466],[25928],[25944],[False],[0],[0],[False],['0']
9336,PMC3441849,16390,We thank the mothers and their families for their contribution to this study.,Acknowledgments,[98470],[25945],[26022],[False],[0],[0],[False],['0']
9337,PMC3441849,16391,We also thank the data collectors and local study teams for their contribution.,Acknowledgments,[98474],[26023],[26102],[False],[0],[0],[False],['0']
9338,PMC3441849,16392,This paper is dedicated to Dr Mark Colvin who tragically died after the paper was submitted.,Acknowledgments,[98478],[26103],[26195],[False],[0],[0],[False],['0']
9339,PMC3441849,16393,"An outstanding scientist, colleague and friend he will be greatly missed.",Acknowledgments,[98482],[26196],[26269],[False],[0],[0],[False],['0']
9340,PMC3441849,16394,"The study was part of the European Union-funded project PROMISE-EBF (contract no INCO-CT 2004–003660, http://www.promiseresearch.org).",Acknowledgments,[98486],[26270],[26404],[False],[0],[0],[False],['0']
9341,PMC3441849,16395,It was also financially supported through the Swedish International Development Cooperation Agency and the South African National Research Foundation (NRF).,Acknowledgments,[98490],[26405],[26561],[False],[0],[0],[False],['0']
9342,PMC3441849,16396,"The Promise-EBF study group List of Members for the PROMISE-EBF Study Group Steering Committee: Thorkild Tylleskär, Philippe Van de Perre, Eva-Charlotte Ekström, Nicolas Meda, James K. Tumwine, Chipepo Kankasa, Debra Jackson Participating countries and investigators: Norway: Thorkild Tylleskär, Ingunn MS Engebretsen, Lars T Fadnes, Eli Fjeld Falnes, Knut Fylkesnes, Jørn Klungsøyr, Anne Nordrehaug-Åstrøm, Øystein Evjen Olsen, Bjarne Robberstad, Halvor Sommerfelt France: Philippe Van de Perre Sweden: Eva-Charlotte Ekström, Barni Nor Burkina Faso: Nicolas Meda, Abdoulaye Hama Diallo, Thomas Ouedrago, Jeremi Rouamba, Bernadette Traoré, Germain Traoré, Emmanuel Zabsonré Uganda: James K. Tumwine, Caleb Bwengye, Charles Karamagi, Victoria Nankabirwa, Jolly Nankunda, Grace Ndeezi, Margaret Wandera Zambia: Chipepo Kankasa, Mary Katepa-Bwalya, Chafye Siuluta, Seter Siziya South Africa: Debra Jackson, Mickey Chopra, Mark Colvin, Tanya Doherty, Ameena E Goga, Carl Lombard, Lungiswa Nkonki, David Sanders, Rebecca Shanmugan, Wesley Solomons, Wanga Zembe Country PI first, others in alphabetical order of surname.",Acknowledgments,[98494],[26562],[27676],[False],[0],[0],[False],['0']
9861,PMC3542201,25176,"A pilot randomized controlled trial comparing the efficacy of exercise, spinal manipulation, and neuro emotional technique for the treatment of pregnancy-related low back pain",Title,[148305],[39812],[175],[False],[0],[0],[False],['0']
9862,PMC3542201,25177,Background,Abstract,[148312],[176],[187],[False],[0],[0],[False],['0']
9863,PMC3542201,25178,"This pilot randomized controlled trial evaluated the feasibility of conducting a full scale study and compared the efficacy of exercise, spinal manipulation, and a mind-body therapy called Neuro Emotional Technique for the treatment of pregnancy-related low back pain, a common morbidity of pregnancy.",Abstract,[148319],[188],[489],[False],[0],[0],[False],['0']
9864,PMC3542201,25179,Methods,Abstract,[148326],[490],[497],[False],[0],[0],[False],['0']
9865,PMC3542201,25180,Healthy pregnant women with low back pain of insidious onset were eligible to enroll in the study at any point in their pregnancy.,Abstract,[148333],[498],[628],[False],[0],[0],[False],['0']
9866,PMC3542201,25181,"Once enrolled, they remained in the study until they had their babies.",Abstract,[148340],[629],[699],[False],[0],[0],[False],['0']
9867,PMC3542201,25182,Women were randomly allocated into one of three treatment groups using opaque envelopes.,Abstract,[148347],[700],[788],[False],[0],[0],[False],['0']
9868,PMC3542201,25183,The treatment schedule paralleled the prenatal care schedule and women received individualized intervention.,Abstract,[148354],[789],[897],[False],[0],[0],[False],['0']
9869,PMC3542201,25184,Our null hypothesis was that spinal manipulation and Neuro Emotional Technique would perform no better than exercise in enhancing function and decreasing pain.,Abstract,[148361],[898],[1057],[False],[0],[0],[False],['0']
9870,PMC3542201,25185,Our primary outcome measure was the Roland Morris Disability Questionnaire and our secondary outcome measure was the Numeric Pain Rating Scale.,Abstract,[148368],[1058],[1201],[False],[0],[0],[False],['0']
9871,PMC3542201,25186,Intention to treat analysis was conducted.,Abstract,[148375],[1202],[1244],[False],[0],[0],[False],['0']
9872,PMC3542201,25187,"For the primary analysis, regression was conducted to compare groups on the outcome measure scores.",Abstract,[148382],[1245],[1344],[False],[0],[0],[False],['0']
9873,PMC3542201,25188,"In a secondary responder analysis, difference in proportions of participants in attaining 30% and 50% improvement were calculated.",Abstract,[148389],[1345],[1475],[False],[0],[0],[False],['0']
9874,PMC3542201,25189,"Feasibility factors for conducting a future larger trial were also evaluated such as recruitment, compliance to study protocols, cost, and adverse events.",Abstract,[148396],[1476],[1630],[False],[0],[0],[False],['0']
9875,PMC3542201,25190,Results,Abstract,[148403],[1631],[1638],[False],[0],[0],[False],['0']
9876,PMC3542201,25191,"Fifty-seven participants were randomized into the exercise (n = 22), spinal manipulation (n = 15), and Neuro Emotional Technique (n = 20) treatment arms.",Abstract,[148410],[1639],[1792],[False],[0],[0],[False],['0']
9877,PMC3542201,25192,At least 50% of participants in each treatment group experienced clinically meaningful improvement in symptoms for the Roland Morris Disability Questionnaire.,Abstract,[148417],[1793],[1951],[False],[0],[0],[False],['0']
9878,PMC3542201,25193,At least 50% of the exercise and spinal manipulation participants also experienced clinically meaningful improvement for the Numeric Pain Rating Scale.,Abstract,[148424],[1952],[2103],[False],[0],[0],[False],['0']
9879,PMC3542201,25194,There were no clinically meaningful or statistically significant differences between groups in any analysis.,Abstract,[148431],[2104],[2212],[False],[0],[0],[False],['0']
9880,PMC3542201,25195,Conclusions,Abstract,[148438],[2213],[2224],[False],[0],[0],[False],['0']
9881,PMC3542201,25196,"This pilot study demonstrated feasibility for recruitment, compliance, safety, and affordability for conducting a larger study in the future.",Abstract,[148445],[2225],[2366],[False],[0],[0],[False],['0']
9882,PMC3542201,25197,"Spinal manipulation and exercise generally performed slightly better than did Neuro Emotional Technique for improving function and decreasing pain, but the study was not powered to detect the between-group differences as statistically significant.",Abstract,[148452],[2367],[2614],[False],[0],[0],[False],['0']
9883,PMC3542201,25198,Trial registration,Abstract,[148459],[2615],[2633],[False],[0],[0],[False],['0']
9884,PMC3542201,25199,ClinicalTrials.gov (Identifier: NCT00937365).,Abstract,[148466],[2634],[2679],[False],[0],[0],[False],['0']
9885,PMC3542201,25200,Background,Background,[148473],[2680],[2691],[False],[0],[0],[False],['0']
9886,PMC3542201,25201,"Pregnancy-related low back pain (PRLBP) is pain of insidious onset in the lumbar or sacroiliac region that begins during pregnancy [1,2].",Background,[148480],[2692],[2829],[False],[0],[0],[False],['0']
9887,PMC3542201,25202,"Over half of all pregnant women experience PRLBP [3,4] and the natural trajectory of the condition is intensification of pain over the course of pregnancy [2,5].",Background,[148487],[2830],[2991],[False],[0],[0],[False],['0']
9888,PMC3542201,25203,"Low back pain experienced due to pregnancy is poorly understood and conjectured to result from suboptimal biomechanics [6], an increase in relaxin [7], or the evolution to bipedalism [8].",Background,[148494],[2992],[3179],[False],[0],[0],[False],['0']
9889,PMC3542201,25204,The literature on risk factors for PRLBP is inconsistent.,Background,[148501],[3180],[3237],[False],[0],[0],[False],['0']
9890,PMC3542201,25205,"In a summary review of 25 studies of risk factors for PRLBP the only consistent risk factor was a history of lumbar, pubic symphysis, or sacroiliac pain [9].",Background,[148508],[3238],[3395],[False],[0],[0],[False],['0']
9891,PMC3542201,25206,"PRLBP is often (68%) unreported to health care providers [4], despite two thirds of pregnant women requiring sick leave secondary to PRLBP [10].",Background,[148515],[3396],[3540],[False],[0],[0],[False],['0']
9892,PMC3542201,25207,"Of those mothers who report pain, only 25% are given recommendations for symptom management [4].",Background,[148522],[3541],[3637],[False],[0],[0],[False],['0']
9893,PMC3542201,25208,"Over one third of untreated women continue to experience low back pain in the year after pregnancy [4,11,12]; this trend persists up to six years postpartum [13].",Background,[148529],[3638],[3800],[False],[0],[0],[False],['0']
9894,PMC3542201,25209,Those women who continue to experience low back pain in the postpartum are also more susceptible to concomitant morbidities such as postpartum depression [14].,Background,[148536],[3801],[3960],[False],[0],[0],[False],['0']
9895,PMC3542201,25210,For these reasons effective management of PRLBP is important to investigate.,Background,[148543],[3961],[4037],[False],[0],[0],[False],['0']
9896,PMC3542201,25211,"Exercise [15], spinal manipulative therapy (SMT) [16,17], and a mind-body therapy called Neuro Emotional Technique (NET) that addresses the emotional component of a condition [18] have been demonstrated to be effective treatments for low back pain in non-pregnant populations.",Background,[148550],[4038],[4314],[False],[0],[0],[False],['0']
9897,PMC3542201,25212,"Exercise [19,20] and chiropractic SMT [21,22] have also been demonstrated to decrease PRLBP, however the quality of the chiropractic SMT studies is poor to moderate [23].",Background,[148557],[4315],[4485],[False],[0],[0],[False],['0']
9898,PMC3542201,25213,One pilot randomized controlled trial of osteopathic SMT for PRLBP was identified [24].,Background,[148564],[4486],[4573],[False],[0],[0],[False],['0']
9899,PMC3542201,25214,In that study no high velocity low amplitude thrusts were used.,Background,[148571],[4574],[4637],[False],[0],[0],[False],['0']
9900,PMC3542201,25215,"The study reported PRLBP did improve in the treatment group, but did not reach statistical significance when compared to the control group.",Background,[148578],[4638],[4777],[False],[0],[0],[False],['0']
9901,PMC3542201,25216,"Roland Morris disability scores worsened in all groups, although the control group worsened more than the treatment group.",Background,[148585],[4778],[4900],[False],[0],[0],[False],['0']
9902,PMC3542201,25217,No studies were identified that evaluated NET for the treatment of PRLBP.,Background,[148592],[4901],[4974],[False],[0],[0],[False],['0']
9903,PMC3542201,25218,Our pilot study responded to the Cochrane Review’s call for more research on the treatment of PRLBP [2].,Background,[148599],[4975],[5079],[False],[0],[0],[False],['0']
9904,PMC3542201,25219,"In this study we evaluated the feasibility of conducting a larger randomized trial with consideration to recruitment, compliance to study protocols, cost, and adverse events.",Background,[148606],[5080],[5254],[False],[0],[0],[False],['0']
9905,PMC3542201,25220,The pilot was also designed to compare the three treatment groups in order to estimate an effect size for disability and pain outcomes to inform the sample size of a future randomized controlled trial.,Background,[148613],[5255],[5456],[False],[0],[0],[False],['0']
9906,PMC3542201,25221,Methods,Methods,[148620],[5457],[5465],[False],[0],[0],[False],['0']
9907,PMC3542201,25222,Design,Methods|Design,[148627],[5466],[5472],[False],[0],[0],[False],['0']
9908,PMC3542201,25223,This pilot parallel group design randomized controlled trial was conducted at Oregon Health & Science University through the Department of Obstetrics & Gynecology between August 2009 and April 2011.,Methods|Design,[148634],[5473],[5671],[False],[0],[0],[False],['0']
9909,PMC3542201,25224,A total of 57 participants were enrolled.,Methods|Design,[148641],[5672],[5713],[False],[0],[0],[False],['0']
9910,PMC3542201,25225,"The trial evaluated the relative efficacy [25] of individualized treatment with exercise (control) (n = 22), SMT (n = 15), or NET (n = 20) for pregnancy-related low back pain.",Methods|Design,[148648],[5714],[5889],[False],[0],[0],[False],['0']
9911,PMC3542201,25226,The intervention is discussed in detail below.,Methods|Design,[148655],[5890],[5936],[False],[0],[0],[False],['0']
9912,PMC3542201,25227,Our primary null hypothesis was that SMT and NET performed no better than exercise for the treatment of PRLBP as measured by the Roland Morris Disability Questionnaire.,Methods|Design,[148662],[5937],[6105],[False],[0],[0],[False],['0']
9913,PMC3542201,25228,Our secondary null hypothesis was that SMT and NET performed no better than exercise for the treatment of PRLBP as measured by an 11-point Numeric Pain Rating Scale.,Methods|Design,[148669],[6106],[6271],[False],[0],[0],[False],['0']
9914,PMC3542201,25229,"All participants gave oral and written informed consent and received $20 for each study visit, which took about one hour to complete.",Methods|Design,[148676],[6272],[6405],[False],[0],[0],[False],['0']
9915,PMC3542201,25230,The study was approved by Oregon Health & Science University’s Institutional Review Board.,Methods|Design,[148683],[6406],[6496],[False],[0],[0],[False],['0']
9916,PMC3542201,25231,Study participants,Methods|Study participants,[148690],[6497],[6515],[False],[0],[0],[False],['0']
9917,PMC3542201,25232,Women were eligible for the study if they were pregnant with a singleton and had low back pain of unknown origin that began during pregnancy and was reproducible by manual palpation.,Methods|Study participants,[148697],[6516],[6698],[False],[0],[0],[False],['0']
9918,PMC3542201,25233,"Women with health conditions that contraindicated exercise (heart disease, diabetes, thyroid disease, hypertension, Body Mass Index greater than 40, infection, incompetent cervix, bleeding, ruptured membranes, severe anemia, intrauterine growth restriction, poorly controlled seizure disorder, thrombophlebitis, decreased fetal movement, amniotic fluid leakage) [26] or manipulation (unrelenting fever, unrelenting night pain, loss of bowel or bladder control, progressive neurological deficit, direct trauma, unexplained weight loss, radiating pain below the knee, cancer, spinal fracture or tumors, blood dyscrasias) [27] were excluded from consideration along with women who smoked, consumed alcohol, were medicated with anti-depressants, or had a Roland Morris score above 20 or below 4 [28].",Methods|Study participants,[148704],[6699],[7495],[False],[0],[0],[False],['0']
9919,PMC3542201,25234,"Women were also excluded if they were planning to move during pregnancy, did not read and write English, were not willing to comply with the study visit schedule, or were not willing to be randomized into any of the treatment arms.",Methods|Study participants,[148711],[7496],[7727],[False],[0],[0],[False],['0']
9920,PMC3542201,25235,Before being randomized participants identified their treatment preference (i.e.,Methods|Study participants,[148718],[7728],[7808],[False],[0],[0],[False],['0']
9921,PMC3542201,25236,"exercise, SMT, NET, or none).",Methods|Study participants,[148725],[7809],[7838],[False],[0],[0],[False],['0']
9922,PMC3542201,25237,Treatment preference is a well known predictor of outcomes and thus is a potential confounding variable [29-31].,Methods|Study participants,[148732],[7839],[7951],[False],[0],[0],[False],['0']
9923,PMC3542201,25238,"The randomization schedule was completed prior to initiating the study and was concealed from all study staff by using consecutively numbered, sealed, opaque envelopes for each strata of preference group.",Methods|Study participants,[148739],[7952],[8156],[False],[0],[0],[False],['0']
9924,PMC3542201,25239,"Once a participant was found to be eligible, she would open the consecutive envelope in her preference strata in the presence of the researcher.",Methods|Study participants,[148746],[8157],[8301],[False],[0],[0],[False],['0']
9925,PMC3542201,25240,Participants and the practitioner providing the intervention were not blinded to the intervention after randomization.,Methods|Study participants,[148753],[8302],[8420],[False],[0],[0],[False],['0']
9926,PMC3542201,25241,Study protocol,Methods|Study protocol,[148760],[8421],[8435],[False],[0],[0],[False],['0']
9927,PMC3542201,25242,"Study participants were recruited by fliers in prenatal clinics and by community, magazine, and internet announcements in the Portland, Oregon metropolitan area.",Methods|Study protocol,[148767],[8436],[8597],[False],[0],[0],[False],['0']
9928,PMC3542201,25243,"Potential participants were first screened by phone and if study eligibility requirements were met, the initial study visit was scheduled.",Methods|Study protocol,[148774],[8598],[8736],[False],[0],[0],[False],['0']
9929,PMC3542201,25244,At the initial screening and prior to randomization each treatment group was described so all participants were familiar with all treatments.,Methods|Study protocol,[148781],[8737],[8878],[False],[0],[0],[False],['0']
9930,PMC3542201,25245,Participants could enter the study at any point in their pregnancy and remained in the study until they had their baby.,Methods|Study protocol,[148788],[8879],[8998],[False],[0],[0],[False],['0']
9931,PMC3542201,25246,All participants continued to receive their usual obstetric or midwifery prenatal care following randomization.,Methods|Study protocol,[148795],[8999],[9110],[False],[0],[0],[False],['0']
9932,PMC3542201,25247,"The RCT treatment schedule paralleled the prenatal care schedule (once monthly until 28 weeks gestation, twice monthly until 36 weeks gestation, and weekly thereafter).",Methods|Study protocol,[148802],[9111],[9279],[False],[0],[0],[False],['0']
9933,PMC3542201,25248,"When the participant arrived for each study treatment visit she completed the primary and secondary outcome measures, drew a pain diagram, and responded to questions about adverse events, treatment by other practitioners, new injuries, and use of medication.",Methods|Study protocol,[148809],[9280],[9538],[False],[0],[0],[False],['0']
9934,PMC3542201,25249,After filling out the paperwork all participants were palpated and assessed with standard orthopedic and neurologic exams to ensure they were safe to treat.,Methods|Study protocol,[148816],[9539],[9695],[False],[0],[0],[False],['0']
9935,PMC3542201,25250,Each was also palpated to determine if intersegmental dysfunctions were present.,Methods|Study protocol,[148823],[9696],[9776],[False],[0],[0],[False],['0']
9936,PMC3542201,25251,"Following the assessment each participant was treated in accordance with the protocol for their treatment arm, which is described below.",Methods|Study protocol,[148830],[9777],[9913],[False],[0],[0],[False],['0']
9937,PMC3542201,25252,Intervention,Methods|Intervention,[148837],[9914],[9926],[False],[0],[0],[False],['0']
9938,PMC3542201,25253,The lead author served as the therapist and has practiced chiropractic medicine for 15 years.,Methods|Intervention,[148844],[9927],[10020],[False],[0],[0],[False],['0']
9939,PMC3542201,25254,At the baseline visit she screened volunteers for study eligibility through case history and standard orthopedic and neurologic tests.,Methods|Intervention,[148851],[10021],[10155],[False],[0],[0],[False],['0']
9940,PMC3542201,25255,Participants in all three treatment groups were advised to use ice after each treatment since a little soreness is commonly experienced after treatment.,Methods|Intervention,[148858],[10156],[10308],[False],[0],[0],[False],['0']
9941,PMC3542201,25256,Exercise,Methods|Exercise,[148865],[10309],[10317],[False],[0],[0],[False],['0']
9942,PMC3542201,25257,"Exercise participants were given a booklet and enthusiastically instructed on pelvic tilts, pelvic floor, gluteus maximus, latissimus dorsi, and hip adductor strengthening exercises to promote low back stability and flexibility.",Methods|Exercise,[148872],[10318],[10546],[False],[0],[0],[False],['0']
9943,PMC3542201,25258,The specific exercises in the booklet have been shown to decrease PRLBP [32].,Methods|Exercise,[148879],[10547],[10624],[False],[0],[0],[False],['0']
9944,PMC3542201,25259,The booklet also instructed exercise participants on recommendations for postural and movement patterns that help alleviate low back pain.,Methods|Exercise,[148886],[10625],[10763],[False],[0],[0],[False],['0']
9945,PMC3542201,25260,"Finally, warnings in the booklet about when to stop exercising were reviewed with the participant.",Methods|Exercise,[148893],[10764],[10862],[False],[0],[0],[False],['0']
9946,PMC3542201,25261,At each study visit exercises and lifestyle suggestions were reviewed and practiced with participants.,Methods|Exercise,[148900],[10863],[10965],[False],[0],[0],[False],['0']
9947,PMC3542201,25262,"Additional individualized stretching or strengthening exercises were prescribed, demonstrated, and practiced at each study visit based on muscle strength and flexibility assessment.",Methods|Exercise,[148907],[10966],[11147],[False],[0],[0],[False],['0']
9948,PMC3542201,25263,Exercises took about 15 min to perform at home and participants were requested to exercise five times weekly.,Methods|Exercise,[148914],[11148],[11257],[False],[0],[0],[False],['0']
9949,PMC3542201,25264,Spinal Manipulative Therapy,Methods|Spinal Manipulative Therapy,[148921],[11258],[11285],[False],[0],[0],[False],['0']
9950,PMC3542201,25265,Participants in the SMT group were palpated to determine if each had intersegmental dysfunction prior to manipulating [33].,Methods|Spinal Manipulative Therapy,[148928],[11286],[11409],[False],[0],[0],[False],['0']
9951,PMC3542201,25266,"Hypomobile joints were isolated through positioning, then a slow force was applied to preload the joint at the physiological end range.",Methods|Spinal Manipulative Therapy,[148935],[11410],[11545],[False],[0],[0],[False],['0']
9952,PMC3542201,25267,"After loading the joint, a high velocity, low amplitude thrust was applied to the isolated joint to move it just past the physiological end range in the side posture position for lumbar and sacroiliac lesions.",Methods|Spinal Manipulative Therapy,[148942],[11546],[11755],[False],[0],[0],[False],['0']
9953,PMC3542201,25268,"The thrust was applied in the direction, velocity, and amplitude as determined by the clinician from the palpation exam findings [33].",Methods|Spinal Manipulative Therapy,[148949],[11756],[11890],[False],[0],[0],[False],['0']
9954,PMC3542201,25269,A hypermobile joint or region was stabilized by creating a fulcrum at a specific joint by the participant lying on padded blocks [34].,Methods|Spinal Manipulative Therapy,[148956],[11891],[12025],[False],[0],[0],[False],['0']
9955,PMC3542201,25270,"The blocks were always used to adjust a Sacro Occipital Technique Category II pelvis, and the Activator was always used to adjust the pubic symphysis [35].",Methods|Spinal Manipulative Therapy,[148963],[12026],[12181],[False],[0],[0],[False],['0']
9956,PMC3542201,25271,Neuro emotional technique,Methods|Neuro emotional technique,[148970],[12182],[12207],[False],[0],[0],[False],['0']
9957,PMC3542201,25272,Neuro Emotional Technique (NET) is a chiropractic mind-body technique that combines desensitization procedures (such as relaxed breathing and visualization) with elements of Five Element Chinese medicine (such as the association of emotions with certain organs or meridians) and chiropractic medicine (the adjustment of the spinal levels that innervate the organ in question) in an attempt to address cognitive distortions through the use of a semantic algorithm [36].,Methods|Neuro emotional technique,[148977],[12208],[12676],[False],[0],[0],[False],['0']
9958,PMC3542201,25273,"The reliability and validity of the manual muscle testing used to guide the technique are unknown [37], but muscle testing is considered to be part of the treatment package of NET.",Methods|Neuro emotional technique,[148984],[12677],[12857],[False],[0],[0],[False],['0']
9959,PMC3542201,25274,The NET standard protocol was followed [38].,Methods|Neuro emotional technique,[148991],[12858],[12902],[False],[0],[0],[False],['0']
9960,PMC3542201,25275,Outcomes,Methods|Outcomes,[148998],[12903],[12911],[False],[0],[0],[False],['0']
9961,PMC3542201,25276,"At each assessment visit, each participant completed a form indicating if she was following the study protocol, was taking any pain medication, had been injured outside of the study, or had experienced any adverse effects as a result of the intervention.",Methods|Outcomes,[149005],[12912],[13166],[False],[0],[0],[False],['0']
9962,PMC3542201,25277,Participants were asked to rate their low back function and pain “today” as measured by the Roland Morris Disability Questionnaire (primary outcome) and an 11-point Numeric Pain Rating Scale (secondary outcome).,Methods|Outcomes,[149012],[13167],[13378],[False],[0],[0],[False],['0']
9963,PMC3542201,25278,"The Roland Morris Disability Questionnaire is a 24-item index of activities of daily living related to low back function that has been shown to be valid, reliable, and sensitive for measuring changes in mild to moderate disability [39,40].",Methods|Outcomes,[149019],[13379],[13618],[False],[0],[0],[False],['0']
9964,PMC3542201,25279,The 11-point Numeric Pain Rating Scale (0–10) has been shown to be valid [41].,Methods|Outcomes,[149026],[13619],[13697],[False],[0],[0],[False],['0']
9965,PMC3542201,25280,"A four point change on the Roland Morris Disability Questionnaire, a two point change on the Numeric Pain Rating Scale, or a 30% change in either from the baseline is considered to be clinically meaningful within-persons [41-44].",Methods|Outcomes,[149033],[13698],[13927],[False],[0],[0],[False],['0']
9966,PMC3542201,25281,Statistical analysis,Methods|Statistical analysis,[149040],[13928],[13948],[False],[0],[0],[False],['0']
9967,PMC3542201,25282,Intention-to-treat analysis was conducted with participants included in the original assigned group.,Methods|Statistical analysis,[149047],[13949],[14049],[False],[0],[0],[False],['0']
9968,PMC3542201,25283,"In the primary analysis, linear regression was used to compare the three groups with follow-up disability and pain scores as continuous dependent variables.",Methods|Statistical analysis,[149054],[14050],[14206],[False],[0],[0],[False],['0']
9969,PMC3542201,25284,"The covariates included in all between group models were gestational age at entrance into the study, baseline score of the outcome measure, maternal age, and history of low back pain.",Methods|Statistical analysis,[149061],[14207],[14390],[False],[0],[0],[False],['0']
9970,PMC3542201,25285,The endpoint was the eighth study visit assessment or the last study visit if the participant did not complete eight visits.,Methods|Statistical analysis,[149068],[14391],[14515],[False],[0],[0],[False],['0']
9971,PMC3542201,25286,A secondary responder analysis was conducted for the Roland Morris Disability Questionnaire and Numeric Pain Rating Scale.,Methods|Statistical analysis,[149075],[14516],[14638],[False],[0],[0],[False],['0']
9972,PMC3542201,25287,"Two categorical outcome variables were created to reflect a minimum of 50% improvement (yes/no), and a minimum of 30% improvement (yes/no).",Methods|Statistical analysis,[149082],[14639],[14778],[False],[0],[0],[False],['0']
9973,PMC3542201,25288,Differences in the proportion of responders between groups were then calculated.,Methods|Statistical analysis,[149089],[14779],[14859],[False],[0],[0],[False],['0']
9974,PMC3542201,25289,"Thirty percent improvement is considered to be the minimal change needed to identify clinically meaningful improvement [44,45].",Methods|Statistical analysis,[149096],[14860],[14987],[False],[0],[0],[False],['0']
9975,PMC3542201,25290,"However, 50% improvement is typically the standard used in responder analysis [46,47].",Methods|Statistical analysis,[149103],[14988],[15074],[False],[0],[0],[False],['0']
9976,PMC3542201,25291,"Missing data were imputed using the last observation carried forward [48,49].",Methods|Statistical analysis,[149110],[15075],[15152],[False],[0],[0],[False],['0']
9977,PMC3542201,25292,"Although last observation carried forward method of controlling for missingness is biased toward participants not worsening over the remaining segment of the study, we elected to use this method so our results could be compared with a similarly designed osteopathic trial of treatment for pregnancy related low back pain [24].",Methods|Statistical analysis,[149117],[15153],[15479],[False],[0],[0],[False],['0']
9978,PMC3542201,25293,"To determine if this approach was appropriate for our data, we also conducted a sensitivity analysis excluding participants with only baseline data.",Methods|Statistical analysis,[149124],[15480],[15628],[False],[0],[0],[False],['0']
9979,PMC3542201,25294,Statistical significance was set at 0.05 for all tests with no correction for multiple group comparisons.,Methods|Statistical analysis,[149131],[15629],[15734],[False],[0],[0],[False],['0']
9980,PMC3542201,25295,Sample size was limited by available funds and the enrollment window established for this pilot; it was not determined by a priori power analysis.,Methods|Statistical analysis,[149138],[15735],[15881],[False],[0],[0],[False],['0']
9981,PMC3542201,25296,A post hoc power analysis was conducted to identify what effect sizes were detectable with 80% power at the 0.05 level of significance.,Methods|Statistical analysis,[149145],[15882],[16017],[False],[0],[0],[False],['0']
9982,PMC3542201,25297,A study is said to be adequately powered if the detectable effect size is no larger than a clinically important difference between groups.,Methods|Statistical analysis,[149152],[16018],[16156],[False],[0],[0],[False],['0']
9983,PMC3542201,25298,"Statistical analysis was performed with SPSS v18.0 (SPSS, Inc, Chicago, IL).",Methods|Statistical analysis,[149159],[16157],[16233],[False],[0],[0],[False],['0']
9984,PMC3542201,25299,Results,Results,[149166],[16234],[16242],[False],[0],[0],[False],['0']
9985,PMC3542201,25300,We screened 138 pregnant women (approximately 10 per month) for eligibility and 57 were randomized (Figure 1).,Results,[149173],[16243],[16353],[False],[0],[0],[False],['0']
9986,PMC3542201,25301,"Twenty-two participants were randomized into the exercise group, 20 were randomized into the NET group, and 15 were randomized into the SMT group.",Results,[149180],[16354],[16500],[False],[0],[0],[False],['0']
9987,PMC3542201,25302,Six exercise participants and one NET participant discontinued the study after the first visit for reasons listed in Figure 1.,Results,[149187],[16501],[16627],[False],[0],[0],[False],['0']
9988,PMC3542201,25303,Participant baseline characteristics,Results|Participant baseline characteristics,[149194],[16628],[16664],[False],[0],[0],[False],['0']
9989,PMC3542201,25304,"Baseline health characteristics and demographics were somewhat balanced across groups (Tables 1, 2 and 3).",Results|Participant baseline characteristics,[149201],[16665],[16771],[False],[0],[0],[False],['0']
9990,PMC3542201,25305,"Women in the exercise group were less likely to be married, to work during pregnancy, and to have good or quite good self-perceived general health status prior to pregnancy.",Results|Participant baseline characteristics,[149208],[16772],[16945],[False],[0],[0],[False],['0']
9991,PMC3542201,25306,"Additionally, their low back pain began earlier in pregnancy and they were more likely to be taking medication for pain, and to have missed work because of the pain than were the women in the other treatment groups.",Results|Participant baseline characteristics,[149215],[16946],[17161],[False],[0],[0],[False],['0']
9992,PMC3542201,25307,"Finally, women in the exercise group also entered the study earlier in their pregnancies than those in the NET or SMT groups, and perhaps because of this had a lower BMI at their first study visit.",Results|Participant baseline characteristics,[149222],[17162],[17359],[False],[0],[0],[False],['0']
9993,PMC3542201,25308,"If the seven women who withdrew from the study immediately upon randomization were not included in the descriptive analysis, the study groups were balanced across all variables except women in the exercise group were less likely to have good or quite good health prior to pregnancy.",Results|Participant baseline characteristics,[149229],[17360],[17642],[False],[0],[0],[False],['0']
9994,PMC3542201,25309,Outcomes data,Results|Outcomes data,[149236],[17643],[17656],[False],[0],[0],[False],['0']
9995,PMC3542201,25310,"The majority in all three groups had clinically meaningful improvement in function (4 point or 30% improvement on the Roland-Morris), and the majority of participants in the exercise and SMT groups also had clinically meaningful improvement in pain (2 point or 30% improvement on the numeric rating scale) (Tables 4 &5).",Results|Outcomes data,[149243],[17657],[17977],[False],[0],[0],[False],['0']
9996,PMC3542201,25311,The SMT group attained a minimal clinical important improvement in 80% of the participants for function and 67% for pain.,Results|Outcomes data,[149250],[17978],[18099],[False],[0],[0],[False],['0']
9997,PMC3542201,25312,Smaller proportions were observed in the other two groups.,Results|Outcomes data,[149257],[18100],[18158],[False],[0],[0],[False],['0']
9998,PMC3542201,25313,Between-groups comparisons,Results|Between-groups comparisons,[149264],[18159],[18185],[False],[0],[0],[False],['0']
9999,PMC3542201,25314,No statistically significant differences between groups were noted in either the Roland Morris Disability Questionnaire or Numeric Pain Rating Scale scores in the pair-wise comparison of treatment groups in either the primary or secondary analyses (Tables 6 &7).,Results|Between-groups comparisons,[149271],[18186],[18448],[False],[0],[0],[False],['0']
10000,PMC3542201,25315,"All confidence intervals were wide for the between-groups comparisons, demonstrating imprecision in the treatment effect point estimates and lack of power to detect differences between groups.",Results|Between-groups comparisons,[149278],[18449],[18641],[False],[0],[0],[False],['0']
10001,PMC3542201,25316,Sensitivity analysis,Results|Sensitivity analysis,[149285],[18642],[18662],[False],[0],[0],[False],['0']
10002,PMC3542201,25317,The results of the sensitivity analysis were consistent with the primary analysis when the seven individuals with only baseline data were excluded.,Results|Sensitivity analysis,[149292],[18663],[18810],[False],[0],[0],[False],['0']
10003,PMC3542201,25318,One comparison (Exercise vs. NET) became statistically significant for the Numeric Pain Rating Scale.,Results|Sensitivity analysis,[149299],[18811],[18912],[False],[0],[0],[False],['0']
10004,PMC3542201,25319,The primary analysis was the most conservative analysis performed.,Results|Sensitivity analysis,[149306],[18913],[18979],[False],[0],[0],[False],['0']
10005,PMC3542201,25320,"This suggests that our method of imputing missing data using last observation carried forward did not bias our results toward the group with more dropouts, as is sometimes the case.",Results|Sensitivity analysis,[149313],[18980],[19161],[False],[0],[0],[False],['0']
10006,PMC3542201,25321,Post hoc power analysis,Results|Post hoc power analysis,[149320],[19162],[19185],[False],[0],[0],[False],['0']
10007,PMC3542201,25322,The study had 80% power to detect mean between-group differences of approximately 4.7 points on the Roland-Morris and 1.8 points on the Numeric Pain Rating Scale at the .05 level of significance.,Results|Post hoc power analysis,[149327],[19186],[19381],[False],[0],[0],[False],['0']
10008,PMC3542201,25323,"The study was not powered to detect a minimal clinically important differences between groups [50,51].",Results|Post hoc power analysis,[149334],[19382],[19484],[False],[0],[0],[False],['0']
10009,PMC3542201,25324,Feasibility evaluation,Results|Feasibility evaluation,[149341],[19485],[19507],[False],[0],[0],[False],['0']
10010,PMC3542201,25325,Adherence to care,Results|Adherence to care,[149348],[19508],[19525],[False],[0],[0],[False],['0']
10011,PMC3542201,25326,Three of the 16 exercise participants who had more than one study visit did not follow the prescribed study visit schedule.,Results|Adherence to care,[149355],[19526],[19649],[False],[0],[0],[False],['0']
10012,PMC3542201,25327,"Because study participants could enter the study at any point in their pregnancy, 5 (23%) exercise participants, 6 (30%) NET participants, and 3 (20%) SMT participants completed eight study visits.",Results|Adherence to care,[149362],[19650],[19847],[False],[0],[0],[False],['0']
10013,PMC3542201,25328,Seven (38%) of the exercise participants who had more than one study visit reported that they did not perform their exercises at least five times a week.,Results|Adherence to care,[149369],[19848],[20001],[False],[0],[0],[False],['0']
10014,PMC3542201,25329,"However, all seven reported between 40% - 100% improvement in function.",Results|Adherence to care,[149376],[20002],[20073],[False],[0],[0],[False],['0']
10015,PMC3542201,25330,Five of the seven reported 50%-75% improvement in pain intensity; pain intensity did not change for one participant and worsened for another who did not perform her exercises regularly.,Results|Adherence to care,[149383],[20074],[20259],[False],[0],[0],[False],['0']
10016,PMC3542201,25331,Study costs,Results|Study costs,[149390],[20260],[20271],[False],[0],[0],[False],['0']
10017,PMC3542201,25332,"The study cost for recruitment, participation, software, and supplies was approximately $210 per participant.",Results|Study costs,[149397],[20272],[20381],[False],[0],[0],[False],['0']
10018,PMC3542201,25333,A subsample also participated in more extensive data collection and a three month postpartum follow-up that will be reported in a future article.,Results|Study costs,[149404],[20382],[20527],[False],[0],[0],[False],['0']
10019,PMC3542201,25334,"The subsample’s additional expense for participation, lab work, and maternal-infant attachment assessment were approximately $250 for each person.",Results|Study costs,[149411],[20528],[20674],[False],[0],[0],[False],['0']
10020,PMC3542201,25335,Care outside the study,Results|Care outside the study,[149418],[20675],[20697],[False],[0],[0],[False],['0']
10021,PMC3542201,25336,Only two NET study participants reported accessing care for their low back pain outside of the study.,Results|Care outside the study,[149425],[20698],[20799],[False],[0],[0],[False],['0']
10022,PMC3542201,25337,One of these NET participants did so after she injured her back lifting a box and required care while the study clinician was out of town.,Results|Care outside the study,[149432],[20800],[20938],[False],[0],[0],[False],['0']
10023,PMC3542201,25338,A third exercise participant failed to report whether she had sought care for her low back pain outside of the study at one of the study visits.,Results|Care outside the study,[149439],[20939],[21083],[False],[0],[0],[False],['0']
10024,PMC3542201,25339,Adverse outcomes,Results|Adverse outcomes,[149446],[21084],[21100],[False],[0],[0],[False],['0']
10025,PMC3542201,25340,No adverse events were reported by study participants in any group.,Results|Adverse outcomes,[149453],[21101],[21168],[False],[0],[0],[False],['0']
10026,PMC3542201,25341,"However, 6% of exercise and SMT study visits produced soreness, while 18% of NET study visits produced soreness.",Results|Adverse outcomes,[149460],[21169],[21281],[False],[0],[0],[False],['0']
10027,PMC3542201,25342,Participant feedback,Results|Participant feedback,[149467],[21282],[21302],[False],[0],[0],[False],['0']
10028,PMC3542201,25343,Study participants were asked for feedback about the study when they reached 37 weeks gestation.,Results|Participant feedback,[149474],[21303],[21399],[False],[0],[0],[False],['0']
10029,PMC3542201,25344,All women reported enjoying participating in the study.,Results|Participant feedback,[149481],[21400],[21455],[False],[0],[0],[False],['0']
10030,PMC3542201,25345,All but one mother surveyed reported satisfaction with the improvement she experienced in symptoms or in stabilization of symptoms.,Results|Participant feedback,[149488],[21456],[21587],[False],[0],[0],[False],['0']
10031,PMC3542201,25346,"Because pregnancy-related low back pain worsens over the course of pregnancy, women were satisfied with their outcome even if symptoms did not improve because they compared their pain and disability for this pregnancy with those from a previous pregnancy.",Results|Participant feedback,[149495],[21588],[21843],[False],[0],[0],[False],['0']
10032,PMC3542201,25347,I found the study very helpful in getting rid of a large amount of pain I have been experiencing since the beginning of my pregnancy.,Results|Participant feedback,[149502],[21844],[21977],[False],[0],[0],[False],['0']
10033,PMC3542201,25348,"The exercise allowed me to do activities that otherwise would have been too painful to participate in, and I believe it has helped prepare my body for labor and after the baby arrives (EX19).",Results|Participant feedback,[149509],[21978],[22169],[False],[0],[0],[False],['0']
10034,PMC3542201,25349,I noticed a dramatic decrease in the amount and intensity of the low back pain I experienced.,Results|Participant feedback,[149516],[22170],[22263],[False],[0],[0],[False],['0']
10035,PMC3542201,25350,I also was able to become aware of some issues regarding this pregnancy and my past that I wasn’t aware of consciously.,Results|Participant feedback,[149523],[22264],[22383],[False],[0],[0],[False],['0']
10036,PMC3542201,25351,That was helpful because it made me make more of an effort to bond with this baby when sometimes I would feel distracted (i.e.,Results|Participant feedback,[149530],[22384],[22510],[False],[0],[0],[False],['0']
10037,PMC3542201,25352,when work/family responsibilities would take over) (NET05).,Results|Participant feedback,[149537],[22511],[22570],[False],[0],[0],[False],['0']
10038,PMC3542201,25353,I think the study was really good for me.,Results|Participant feedback,[149544],[22571],[22612],[False],[0],[0],[False],['0']
10039,PMC3542201,25354,"I feel much better, the pain decreased a lot.",Results|Participant feedback,[149551],[22613],[22658],[False],[0],[0],[False],['0']
10040,PMC3542201,25355,I also think that my baby liked it.,Results|Participant feedback,[149558],[22659],[22694],[False],[0],[0],[False],['0']
10041,PMC3542201,25356,I really enjoy being on this study and I definitely recommend it for all pregnant women.,Results|Participant feedback,[149565],[22695],[22783],[False],[0],[0],[False],['0']
10042,PMC3542201,25357,It also helped me to feel more relaxed (SMT05).,Results|Participant feedback,[149572],[22784],[22831],[False],[0],[0],[False],['0']
10043,PMC3542201,25358,Discussion,Discussion,[149579],[22832],[22844],[False],[0],[0],[False],['0']
10044,PMC3542201,25359,This was the first identified RCT to compare the relative efficacy of three conservative interventions for the treatment of PRLBP and to show improvement in pain and function with care.,Discussion,[149586],[22845],[23030],[False],[0],[0],[False],['0']
10045,PMC3542201,25360,The function and pain improvement within the SMT and exercise groups were clinically meaningful (dependent t-test p < 0.002)).,Discussion,[149593],[23031],[23157],[False],[0],[0],[False],['0']
10046,PMC3542201,25361,"This is important because the only other RCT identified to use manual medicine intervention for the treatment of PRLBP was an osteopathic pilot study that found Roland Morris Disability scores worsened over time in all groups, but function deteriorated less in the osteopathic manipulation group than in the placebo or control group.",Discussion,[149600],[23158],[23491],[False],[0],[0],[False],['0']
10047,PMC3542201,25362,"They also found pain intensity improved by less than half a point on a 11-point pain scale in the osteopathic manipulation group, and there was no statistically significant difference from the placebo or control groups [24].",Discussion,[149607],[23492],[23716],[False],[0],[0],[False],['0']
10048,PMC3542201,25363,"In the osteopathic pilot RCT [24], our pilot RCT, and other studies [4] PRLBP was mild to moderate in severity and provoked mild to moderate disability.",Discussion,[149614],[23717],[23869],[False],[0],[0],[False],['0']
10049,PMC3542201,25364,Participants in our study had Roland Morris scores that were approximately 2 points worse at study entrance than those in the osteopathic study.,Discussion,[149621],[23870],[24014],[False],[0],[0],[False],['0']
10050,PMC3542201,25365,Our participants experienced Numeric Pain Rating Scale scores that were about 1 point less intense than in the osteopathic study.,Discussion,[149628],[24015],[24144],[False],[0],[0],[False],['0']
10051,PMC3542201,25366,In contrast to the osteopathic PRLBP pilot our participants experienced more improvement in their Roland Morris scores than in their pain scores.,Discussion,[149635],[24145],[24290],[False],[0],[0],[False],['0']
10052,PMC3542201,25367,This could be due to a floor effect for the pain score since our baseline pain measures were lower than in the osteopathic study.,Discussion,[149642],[24291],[24420],[False],[0],[0],[False],['0']
10053,PMC3542201,25368,We have demonstrated the feasibility of recruiting a sufficient sample in a reasonable time for a future full-scale RCT and that there is reasonable adherence to treatment and compliance with follow-up.,Discussion,[149649],[24421],[24623],[False],[0],[0],[False],['0']
10054,PMC3542201,25369,We found that only 11% of our study participants preferred to be randomized into the exercise group while 28% preferred NET and 35% preferred SMT.,Discussion,[149656],[24624],[24770],[False],[0],[0],[False],['0']
10055,PMC3542201,25370,"This could explain, in part, why we had 27% attrition from the exercise group immediately following randomization while only one participant (5%) in the NET arm withdrew immediately following randomization, and no SMT participants withdrew immediately following randomization.",Discussion,[149663],[24771],[25047],[False],[0],[0],[False],['0']
10056,PMC3542201,25371,Exercise appears to appeal to only a sub-group of women.,Discussion,[149670],[25048],[25104],[False],[0],[0],[False],['0']
10057,PMC3542201,25372,"Thus, because all treatments were associated with some improvement, a future large randomized controlled trial for the conservative treatment of pregnancy-related low back pain might consider comparing SMT, which performed better than other treatment interventions and was preferred by participants, to a standard of care control group so the number of participants in each study arm would be reasonable to recruit and retain.",Discussion,[149677],[25105],[25531],[False],[0],[0],[False],['0']
10058,PMC3542201,25373,"It is important to further investigate conservative intervention options such as manual medicine, exercise, and mind-body therapy for the treatment of PRLBP, since pharmaceutical management of pain during pregnancy has been poorly researched and the short- and long-term consequences of pharmaceutical management during pregnancy are largely unknown for the mother and the fetus [52].",Discussion,[149684],[25532],[25916],[False],[0],[0],[False],['0']
10059,PMC3542201,25374,"Additionally, passive intervention for the treatment of PRLBP using support belts is not well substantiated by the literature [53].",Discussion,[149691],[25917],[26048],[False],[0],[0],[False],['0']
10060,PMC3542201,25375,In non-pregnant populations the use of support belts promotes deconditioning and the possibility of injury [54].,Discussion,[149698],[26049],[26161],[False],[0],[0],[False],['0']
10061,PMC3542201,25376,"The potential safety of exercise, SMT, and NET for a pregnant population with low back pain was demonstrated in this pilot study and paralleled the safety demonstrated for SMT in non-pregnant populations [17,23,55-58].",Discussion,[149705],[26162],[26380],[False],[0],[0],[False],['0']
10062,PMC3542201,25377,"If safety and effectiveness can be demonstrated in a larger study of conservative intervention for PRLBP, chiropractic care for PRLPB might be a valuable option since chiropractic low back pain management is approximately 60% more cost effective in a non-pregnant population than traditional biomedical care after controlling for case complexity [59].",Discussion,[149712],[26381],[26732],[False],[0],[0],[False],['0']
10063,PMC3542201,25378,"Finally, although this pilot study was not powered for generalizability, it did substantiate other reports that exercise and manual medicine care for PRLBP are beneficial with low associated risk [21,23,60].",Discussion,[149719],[26733],[26940],[True],['UnderpoweredStudy'],['this pilot study was not powered for generalizability'],[True],['UnderpoweredStudy']
10064,PMC3542201,25379,"Another reason it is important to further investigate the treatment of PRLBP is because it appears to signify an underlying weakness in the musculoskeletal system that, if not addressed during pregnancy, portends future suffering.",Discussion,[149733],[26941],[27171],[False],[0],[0],[False],['0']
10065,PMC3542201,25380,"Women who experience PRLBP and are not treated during pregnancy are at increased risk of experiencing back pain at 3, 6, and 12 months postpartum, and at 3 and 6 years postpartum when compared with women who did not have back pain during pregnancy and women who had back pain during pregnancy and received treatment [13,61,62].",Discussion,[149740],[27172],[27499],[False],[0],[0],[False],['0']
10066,PMC3542201,25381,"Treatment of PRLBP might not only alleviate low back pain during pregnancy, but could prevent future episodes of low back pain thus saving the health care system unnecessary expenditures [63].",Discussion,[149747],[27500],[27692],[False],[0],[0],[False],['0']
10067,PMC3542201,25382,Pregnancy is widely conceptualized as a testing ground for unmasking weaknesses in organ systems that would not appear until later life but for pregnancy [64].,Discussion,[149754],[27693],[27852],[False],[0],[0],[False],['0']
10068,PMC3542201,25383,Pregnancy disorders predicting later related health problems have been best established for gestational diabetes predicting diabetes type II [65] and for preeclampsia predicting chronic hypertension [66].,Discussion,[149761],[27853],[28057],[False],[0],[0],[False],['0']
10069,PMC3542201,25384,"Biomechanical evidence suggests that the female lumbar spine is well designed to respond to fetal load [8], thus PRLBP is not necessarily an inherent morbidity of pregnancy, but might be another warning sign of future ill health just as are gestational diabetes and preeclampsia.",Discussion,[149768],[28058],[28337],[False],[0],[0],[False],['0']
10070,PMC3542201,25385,Limitations and future directions,Discussion|Limitations and future directions,[149775],[28338],[28371],[False],[0],[0],[False],['0']
10071,PMC3542201,25386,This feasibility study was designed to inform the construction of a future sufficiently powered RCT of PRLBP.,Discussion|Limitations and future directions,[149782],[28372],[28481],[False],[0],[0],[False],['0']
10072,PMC3542201,25387,Several limitations flawed this study.,Discussion|Limitations and future directions,[149789],[28482],[28520],[False],[0],[0],[False],['0']
10073,PMC3542201,25388,One major limitation was that the first author conducted all aspects of the trail including provision of care to all study participants.,Discussion|Limitations and future directions,[149798],[28521],[28657],[True],['StudyTeam'],['the first author conducted all aspects of the trail including provision of care to all study participants'],[True],['Blinding']
10074,PMC3542201,25389,"As a result, she was not blinded to intervention during the analysis phase, insufficient time was available for satisfactory recruiting, and treatment effects could be related to investigator proclivities rather than to the modalities themselves.",Discussion|Limitations and future directions,"[149811, 149813]","[28658, 28658]","[28904, 28904]","[True, True]","['StudyTeam', 'StudyTeam']","['she was not blinded to intervention', 'treatment effects could be related to investigator proclivities']","[True, True]",['Blinding']
10075,PMC3542201,25390,"In a future well funded study separate individuals will randomize participants, treat participants, and analyze the data.",Discussion|Limitations and future directions,[149824],[28905],[29026],[False],[0],[0],[False],['0']
10076,PMC3542201,25391,"Also, more active engagement of prenatal care practitioners can be ensured to enhance recruitment by building on the relationships that were formed during this study.",Discussion|Limitations and future directions,[149831],[29027],[29193],[False],[0],[0],[False],['0']
10077,PMC3542201,25392,Another limitation was that allowing women to enter the study at any point in their pregnancy made it difficult for latecomers to complete the treatment protocols before birth and also complicated the analysis.,Discussion|Limitations and future directions,[149842],[29194],[29404],[True],['DiagnosticCriteria'],['allowing women to enter the study at any point in their pregnancy made it difficult for latecomers to complete the treatment protocols'],[True],['Population']
10078,PMC3542201,25393,We suggest the next trial should be designed so women enter the study at approximately the same point in pregnancy (e.g.,Discussion|Limitations and future directions,[149852],[29405],[29525],[False],[0],[0],[False],['0']
10079,PMC3542201,25394,28–32 weeks) and complete the eight study visits by 37 weeks gestation.,Discussion|Limitations and future directions,[149859],[29526],[29597],[False],[0],[0],[False],['0']
10080,PMC3542201,25395,Toward the beginning of the study we also had difficulty retaining the first women who were randomized into the exercise treatment arm.,Discussion|Limitations and future directions,[149871],[29598],[29733],[True],['Population'],['we also had difficulty retaining the first women who were randomized into the exercise treatment arm'],[True],['Population']
10081,PMC3542201,25396,By mid-study we had resolved that issue by strenuous vetting of potential participants to be certain they were willing to participate in the exercise arm of the study.,Discussion|Limitations and future directions,[149880],[29734],[29901],[False],[0],[0],[False],['0']
10082,PMC3542201,25397,"Finally, the imputation method of last observation carried forward could bias the outcome in favor of the treatment group that had more people who withdrew early in the study or for the group with more women who arrived at their 8th study visit earlier in pregnancy.",Discussion|Limitations and future directions,[149893],[29902],[30168],[True],['StatisticalAnalysis'],['the imputation method of last observation carried forward'],[True],['StatisticalAnalysis']
10083,PMC3542201,25398,This is so because low back pain tends to intensify throughout pregnancy.,Discussion|Limitations and future directions,[149901],[30169],[30242],[False],[0],[0],[False],['0']
10084,PMC3542201,25399,"However, we found that the results for the exercise group and NET group were worse when the seven participants who only had baseline measures were included.",Discussion|Limitations and future directions,[149908],[30243],[30399],[False],[0],[0],[False],['0']
10085,PMC3542201,25400,This suggests imputation by last observation carried forward was a conservative means of inferring outcome and did not prejudicially preference the group with early withdrawals in our study.,Discussion|Limitations and future directions,[149915],[30400],[30590],[False],[0],[0],[False],['0']
10086,PMC3542201,25401,Conclusion,Conclusion,[149922],[30591],[30602],[False],[0],[0],[False],['0']
10087,PMC3542201,25402,"This pilot RCT demonstrated that a larger study is feasible in terms of recruitment in a reasonable timeframe, adequate adherence to care, compliance with follow-up, and safety.",Conclusion,[149929],[30603],[30780],[False],[0],[0],[False],['0']
10088,PMC3542201,25403,All three interventions appear to provide clinically meaningful improvement in function and pain intensity.,Conclusion,[149936],[30781],[30888],[False],[0],[0],[False],['0']
10089,PMC3542201,25404,"However, although no between-groups differences were noted in function and pain intensity following treatment, exercise and SMT might have larger treatment effect sizes than does NET.",Conclusion,[149943],[30889],[31072],[False],[0],[0],[False],['0']
10090,PMC3542201,25405,All three interventions merit further investigation.,Conclusion,[149950],[31073],[31125],[False],[0],[0],[False],['0']
10091,PMC3542201,25406,Competing interests,Competing interests,[149957],[31126],[31146],[False],[0],[0],[False],['0']
10092,PMC3542201,25407,"This study was funded in part by The ONE Foundation, the research division of the Neuro Emotional Technique.",Competing interests,[149964],[31147],[31255],[False],[0],[0],[False],['0']
10093,PMC3542201,25408,The ONE Foundation did not contribute to the study in any other way.,Competing interests,[149971],[31256],[31324],[False],[0],[0],[False],['0']
10094,PMC3542201,25409,The authors declare that they have no competing interests.,Competing interests,[149978],[31325],[31383],[False],[0],[0],[False],['0']
10095,PMC3542201,25410,Authors’ contributions,Authors’ contributions,[149985],[31384],[31407],[False],[0],[0],[False],['0']
10096,PMC3542201,25411,"CDP was responsible for all aspects of the study including study design, recruitment, randomization, treatment, analysis and interpretation of findings, and manuscript preparation.",Authors’ contributions,[149992],[31408],[31588],[False],[0],[0],[False],['0']
10097,PMC3542201,25412,"MH was involved in study design, logistics, interpretation of findings, and manuscript preparation.",Authors’ contributions,[149999],[31589],[31688],[False],[0],[0],[False],['0']
10098,PMC3542201,25413,"WTG was involved in study design, acquisition of funding, logistics, and manuscript preparation.",Authors’ contributions,[150006],[31689],[31785],[False],[0],[0],[False],['0']
10099,PMC3542201,25414,All authors read and approved the final manuscript.,Authors’ contributions,[150013],[31786],[31837],[False],[0],[0],[False],['0']
10100,PMC3542201,25415,Acknowledgements,Acknowledgements,[150020],[31838],[31855],[False],[0],[0],[False],['0']
10101,PMC3542201,25416,This study was funded by The ONE Foundation and The Tartar Foundation.,Acknowledgements,[150027],[31856],[31926],[False],[0],[0],[False],['0']
10102,PMC3542201,25417,CDP was funded by the National Center for Complementary & Alternative Medicine/National Institutes of Health T32AT0026888.,Acknowledgements,[150034],[31927],[32049],[False],[0],[0],[False],['0']
10103,PMC3542201,25418,MH was funded by the University of Western States.,Acknowledgements,[150041],[32050],[32100],[False],[0],[0],[False],['0']
10104,PMC3542201,25419,WTG was funded by National Institute of Child Health & Human Development/National Institutes of Health RO1 HD049541.,Acknowledgements,[150048],[32101],[32217],[False],[0],[0],[False],['0']
10105,PMC3551748,20718,Female partners of opioid-injecting men in the Republic of Georgia: an initial characterization,Title,[122484],[26629],[95],[False],[0],[0],[False],['0']
10106,PMC3551748,20719,Background,Abstract,[122498],[96],[107],[False],[0],[0],[False],['0']
10107,PMC3551748,20720,HIV and Hepatitis C virus (HCV) infections are strongly related to injection drug use in the Republic of Georgia.,Abstract,[122512],[108],[221],[False],[0],[0],[False],['0']
10108,PMC3551748,20721,"Little information is available about HIV and HCV status, sexual risk, support for their partner, and risk for physical violence among the female partners of opioid-injecting men in the Republic of Georgia, many of whom may not be using drugs, yet may be at high risk of being infected with HIV and HCV from their drug-using partners.",Abstract,[122526],[222],[556],[False],[0],[0],[False],['0']
10109,PMC3551748,20722,Methods,Abstract,[122540],[557],[564],[False],[0],[0],[False],['0']
10110,PMC3551748,20723,"In order to better understand the risks for females whose partners are injecting drugs, the present study conducted an initial investigation of the non-substance-using female partners of 40 opioid-injecting men who were participating in a clinical trial examining the feasibility and efficacy of a 22-week comprehensive intervention that paired behavioral treatment with naltrexone.",Abstract,[122554],[565],[947],[False],[0],[0],[False],['0']
10111,PMC3551748,20724,The 40 female partners were assessed at their male partners’ study intake.,Abstract,[122568],[948],[1022],[False],[0],[0],[False],['0']
10112,PMC3551748,20725,Results,Abstract,[122582],[1023],[1030],[False],[0],[0],[False],['0']
10113,PMC3551748,20726,"The female sample was 32.3 years old (SD=6.7), 37 (93%) were married, with 15.5 years of education.",Abstract,[122596],[1031],[1130],[False],[0],[0],[False],['0']
10114,PMC3551748,20727,"A majority reported at least partial employment the majority of the time during the past 3 years, with only one woman reported being unemployed most of the time during the past 3 years.",Abstract,[122610],[1131],[1316],[False],[0],[0],[False],['0']
10115,PMC3551748,20728,They self-reported they were 3% HIV-positive and 8% HCV-positive.,Abstract,[122624],[1317],[1382],[False],[0],[0],[False],['0']
10116,PMC3551748,20729,Their HIV sex risk scores indicated a relatively low risk.,Abstract,[122638],[1383],[1441],[False],[0],[0],[False],['0']
10117,PMC3551748,20730,"However, only 4 (10%) women reported using a condom most of the time while having sex and 15 (38%) report not having had sex during the last 30 days.",Abstract,[122652],[1442],[1591],[False],[0],[0],[False],['0']
10118,PMC3551748,20731,"Experiences of interpersonal violence were common, with 42% reporting physical abuse by their partner during the last year and 48% reporting feeling unsafe in their current relationship.",Abstract,[122666],[1592],[1778],[False],[0],[0],[False],['0']
10119,PMC3551748,20732,Conclusions,Abstract,[122680],[1779],[1790],[False],[0],[0],[False],['0']
10120,PMC3551748,20733,"The alarmingly high rate of failure to use barrier protection methods, together with the high percentage who did not know their HIV and HCV status, suggest that it may be beneficial to include non-substance-using female partners in prevention programs along with their partners to reduce the risk of HIV and HCV spreading from the population of injection-drug–using males into the general population.",Abstract,[122694],[1791],[2191],[False],[0],[0],[False],['0']
10121,PMC3551748,20734,[This secondary analysis study was funded by an international supplement to the parent randomized clinical trial “Treating the Partners of Drug Using Pregnant Women: Stage II (HOPE)”.,Abstract,[122708],[2192],[2375],[False],[0],[0],[False],['0']
10122,PMC3551748,20735,ClinicalTrials.gov Identifier: NCT00496990.],Abstract,[122722],[2376],[2420],[False],[0],[0],[False],['0']
10123,PMC3551748,20736,Background,Background,[122736],[2421],[2432],[False],[0],[0],[False],['0']
10124,PMC3551748,20737,In the Republic of Georgia there has been a swift and consistent rise in the number of individuals registered as HIV-positive since 1994 [1].,Background,[122750],[2433],[2574],[False],[0],[0],[False],['0']
10125,PMC3551748,20738,"As of September, 2012 there were a cumulative 3,400 HIV-positive cases registered with the National AIDS Centre, with the overall number of people living with HIV/AIDS estimated to be more than 4,000 [2].",Background,[122764],[2575],[2779],[False],[0],[0],[False],['0']
10126,PMC3551748,20739,"Among injection-drug-using adults, the HIV prevalence rate was estimated to be about 1½% in 2010 [3].",Background,[122778],[2780],[2881],[False],[0],[0],[False],['0']
10127,PMC3551748,20740,This rate is about 2½ times higher than the average prevalence in Europe [4].,Background,[122792],[2882],[2959],[False],[0],[0],[False],['0']
10128,PMC3551748,20741,The prevalence of hepatitis C (HCV) is estimated to be in the range of 50-70% [5].,Background,[122806],[2960],[3042],[False],[0],[0],[False],['0']
10129,PMC3551748,20742,"This HCV epidemic in Georgia is a major public health concern, and is being driven by injection-drug-using adults.",Background,[122820],[3043],[3157],[False],[0],[0],[False],['0']
10130,PMC3551748,20743,"However, other non-drug-using groups have been affected as well, with HCV prevalence in the general population estimated to be 6.7% [6].",Background,[122834],[3158],[3294],[False],[0],[0],[False],['0']
10131,PMC3551748,20744,"Although the overall prevalence of HIV in Georgia is low compared to other former Soviet Union states, the dramatic increase in HIV and AIDS remains a cause for serious concern and there is an urgent need to address the spread of HIV/AIDS.",Background,[122848],[3295],[3534],[False],[0],[0],[False],['0']
10132,PMC3551748,20745,Injection drug use has a central role in the increased HIV prevalence in the region [7].,Background,[122862],[3535],[3623],[False],[0],[0],[False],['0']
10133,PMC3551748,20746,Prevalence of injection drug use is estimated to be about 1½% in the adult population.,Background,[122876],[3624],[3710],[False],[0],[0],[False],['0']
10134,PMC3551748,20747,"Popular injection drugs include heroin and the buprenorphine-mono product, and more recently home-produced amphetamine type stimulants and opioids.",Background,[122890],[3711],[3858],[False],[0],[0],[False],['0']
10135,PMC3551748,20748,The vast majority (98%) of known opioid injectors in Georgia are men.,Background,[122904],[3859],[3928],[False],[0],[0],[False],['0']
10136,PMC3551748,20749,About 60% of all HIV-infected males in Georgia use injection drugs [1].,Background,[122918],[3929],[4000],[False],[0],[0],[False],['0']
10137,PMC3551748,20750,"Many opioid-injecting men are married to illicit-drug-free women, and have never been in drug treatment [8].",Background,[122932],[4001],[4109],[False],[0],[0],[False],['0']
10138,PMC3551748,20751,"While partners and wives of opioid-injecting men in Georgia are exposed to several risk factors resulting from their male partner’s substance addiction, little if any research has been conducted regarding these women.",Background,[122946],[4110],[4327],[False],[0],[0],[False],['0']
10139,PMC3551748,20752,One of the health risks illicit-drug-free women involved with opioid-injecting men face is having their partner infect them with HIV or HCV.,Background,[122960],[4328],[4468],[False],[0],[0],[False],['0']
10140,PMC3551748,20753,Injection drug use is the primary cause of the HIV and HCV epidemics in adult males in the region.,Background,[122974],[4469],[4567],[False],[0],[0],[False],['0']
10141,PMC3551748,20754,"Among the majority of men (67.7%) with HIV in the Southern Caucasus region, HIV infection is attributed to injection drug use.",Background,[122988],[4568],[4694],[False],[0],[0],[False],['0']
10142,PMC3551748,20755,"In contrast, the majority of women (93.6%) with HIV have been infected through heterosexual contact with an opioid-injecting male partner [7,9,10].",Background,[123002],[4695],[4842],[False],[0],[0],[False],['0']
10143,PMC3551748,20756,In Georgia more than 70% of the HIV-positive women infected with HIV through heterosexual contact were partners of injection-drug-using males [11].,Background,[123016],[4843],[4990],[False],[0],[0],[False],['0']
10144,PMC3551748,20757,"In any culture, substance use is often accompanied by intimate partner violence [12,13].",Background,[123030],[4991],[5079],[False],[0],[0],[False],['0']
10145,PMC3551748,20758,"In Georgia, this can be deeply influenced by social norms and traditions, and cultural environment that stipulates the asymmetry in gender roles and the marked difference in the level of women’s freedom and independence [14].",Background,[123044],[5080],[5305],[False],[0],[0],[False],['0']
10146,PMC3551748,20759,"In the general population, 9.1 % of women who have ever been married or had an intimate partner have experienced violence from their husbands/partners, and 3.9% of having experienced sexual violence.",Background,[123058],[5306],[5505],[False],[0],[0],[False],['0']
10147,PMC3551748,20760,"On the other hand, 78.3% of women think that family problems should only be discussed within a family, and 52.1% of women think that if a man mistreats his wife, others outside the family should not intervene [15].",Background,[123072],[5506],[5720],[False],[0],[0],[False],['0']
10148,PMC3551748,20761,"In addition, it has been suggested that the recent economic development weakened men’s position and, against the normative stereotypes, facilitated women’s rising dominance through increased employment opportunities.",Background,[123086],[5721],[5937],[False],[0],[0],[False],['0']
10149,PMC3551748,20762,“Having lost their traditional position in the family (together with their selfesteem) men need to reaffirm their rights and they often do it through drinking and showing their physical power while being drunk” [15].,Background,[123100],[5938],[6154],[False],[0],[0],[False],['0']
10150,PMC3551748,20763,Prevalence of male physical aggression towards female partners is approximately six times higher among couples where the man has alcohol or drug problems compared to couples where the man does not have substance abuse problems [16].,Background,[123114],[6155],[6387],[False],[0],[0],[False],['0']
10151,PMC3551748,20764,"Opioids may not typically lead to more aggression [12], but multi-substance use is common among individuals that use opioids [17] and the majority of injecting-drug-using adults in Georgia seem to use poly-substances [5,18].",Background,[123128],[6388],[6612],[False],[0],[0],[False],['0']
10152,PMC3551748,20765,This research would strongly suggest that Georgian women in relationships with opioid-injecting men are likely to be at increased risk of experiencing intimate partner violence.,Background,[123142],[6613],[6790],[False],[0],[0],[False],['0']
10153,PMC3551748,20766,The present secondary analysis study has two primary aims.,Background,[123156],[6791],[6849],[False],[0],[0],[False],['0']
10154,PMC3551748,20767,The first aim was to examine HIV and HCV prevalence among the illicit-drug-free female partners of opioid-injecting men in the Republic of Georgia.,Background,[123170],[6850],[6997],[False],[0],[0],[False],['0']
10155,PMC3551748,20768,The second aim was to examine the prevalence of interpersonal violence and feeling unsafe in their current relationship among these women.,Background,[123184],[6998],[7136],[False],[0],[0],[False],['0']
10156,PMC3551748,20769,Methods,Methods,[123198],[7137],[7145],[False],[0],[0],[False],['0']
10157,PMC3551748,20770,Setting,Methods|Setting,[123212],[7146],[7153],[False],[0],[0],[False],['0']
10158,PMC3551748,20771,The study was conducted at the Alternative Georgia ( http://www.altgeorgia.ge/?lang=2) field site.,Methods|Setting,[123226],[7154],[7252],[False],[0],[0],[False],['0']
10159,PMC3551748,20772,"This independent nonprofit research institution is located in a central district of Tbilisi, Georgia.",Methods|Setting,[123240],[7253],[7354],[False],[0],[0],[False],['0']
10160,PMC3551748,20773,Participants,Methods|Participants,[123254],[7355],[7367],[False],[0],[0],[False],['0']
10161,PMC3551748,20774,"To describe the participants in the present study, we first describe their opioid-injecting- male partners, who were the primary focus of the parent study [2].",Methods|Participants,[123268],[7368],[7527],[False],[0],[0],[False],['0']
10162,PMC3551748,20775,"Male participants were recruited by flyers, word-of mouth, and advertisements given to harm reduction programs and hospital staff.",Methods|Participants,[123282],[7528],[7658],[False],[0],[0],[False],['0']
10163,PMC3551748,20776,Face-to-face screening interviews on the research site were conducted.,Methods|Participants,[123296],[7659],[7729],[False],[0],[0],[False],['0']
10164,PMC3551748,20777,A total of 74 men between May 2006 and January 2009 were screened.,Methods|Participants,[123310],[7730],[7796],[False],[0],[0],[False],['0']
10165,PMC3551748,20778,"Of these men, 19 failed to show for their initial intake appointment, while 55 were evaluated for eligibility on the following criteria: 18 years or older, having a current illicit-drug-free intimate female partner with whom they had regular contact, lack of current suicidal ideation, meeting DSM-IV criteria for current opioid dependence, not meeting DSM-IV criteria for thought disorder and free of cognitive impairment that prevent them from completing the study [19,20]).",Methods|Participants,[123324],[7797],[8273],[False],[0],[0],[False],['0']
10166,PMC3551748,20779,Men who indicated current physical abuse of their female partner to an extent that might be life threatening were excluded from the study.,Methods|Participants,[123338],[8274],[8412],[False],[0],[0],[False],['0']
10167,PMC3551748,20780,"Men who indicated no current physical abuse towards their female partner, or physical abuse that would not be deemed to cause serious physical harm, were included in the study.",Methods|Participants,[123352],[8413],[8589],[False],[0],[0],[False],['0']
10168,PMC3551748,20781,"Following successful administration of baseline screening instruments, 20 men were randomized to behavioral treatment+naltrexone and 20 men to “usual care”.",Methods|Participants,[123366],[8590],[8746],[False],[0],[0],[False],['0']
10169,PMC3551748,20782,All 40 men were then asked to provide a blood sample to test for HIV and HCV.,Methods|Participants,[123380],[8747],[8824],[False],[0],[0],[False],['0']
10170,PMC3551748,20783,"One of the men (3%) was HIV-positive, 22 (55%) were HIV negative, 13 (33%) refused to provide blood for testing and 4 (10%) dropped out of the study; 24 (60%) men tested positive for HCV, 5 (13%) men tested negative, 7 (18%) refused to provide blood for testing, and 4 (10%) then dropped out of the study [19].",Methods|Participants,[123394],[8825],[9135],[False],[0],[0],[False],['0']
10171,PMC3551748,20784,After their opioid-injecting male partners had consented to participate in the study and had been screened the female partners were informed about the study by their male partners.,Methods|Participants,[123408],[9136],[9316],[False],[0],[0],[False],['0']
10172,PMC3551748,20785,The female partners were invited to visit the research site and sign a written informed consent.,Methods|Participants,[123422],[9317],[9413],[False],[0],[0],[False],['0']
10173,PMC3551748,20786,"All 40 female partners visited and consented to participate in the study, and all self-reported no prior history of illicit drug use as part of a baseline intake that also collected demographic data.",Methods|Participants,[123436],[9414],[9613],[False],[0],[0],[False],['0']
10174,PMC3551748,20787,All female participants received cash equivalent of $18 US for their interview.,Methods|Participants,[123450],[9614],[9693],[False],[0],[0],[False],['0']
10175,PMC3551748,20788,"The behavioral treatment plus naltrexone intervention for the male participants utilized counseling sessions with Motivational Interviewing for both the male participant and the couple, monetary rewards for drug abstinence, and detoxification followed by naltrexone treatment.",Methods|Participants,[123464],[9694],[9970],[False],[0],[0],[False],['0']
10176,PMC3551748,20789,"Male participants in the usual care treatment arm were provided once-a-week individualized drug education sessions together with referrals to detoxification and aftercare, at their request.",Methods|Participants,[123478],[9971],[10160],[False],[0],[0],[False],['0']
10177,PMC3551748,20790,The project was approved by the Institutional Review Boards of the Georgian HIV/AIDS Patients Support Foundation and Johns Hopkins University.,Methods|Participants,[123492],[10161],[10303],[False],[0],[0],[False],['0']
10178,PMC3551748,20791,Measures,Methods|Measures,[123506],[10304],[10312],[False],[0],[0],[False],['0']
10179,PMC3551748,20792,"All measures were translated into Georgian, and then independently back-translated into English to determine accuracy of the initial translation.",Methods|Measures,[123520],[10313],[10458],[False],[0],[0],[False],['0']
10180,PMC3551748,20793,"Questions were examined for cultural appropriateness and were adjusted to reflect the Georgian local socio-cultural context, such as specifics of local education system, income rates, illicit drugs availability, and so forth.",Methods|Measures,[123534],[10459],[10684],[False],[0],[0],[False],['0']
10181,PMC3551748,20794,Any final adjustments to each measure were undertaken following examination of the original scale and the back-translation.,Methods|Measures,[123548],[10685],[10808],[False],[0],[0],[False],['0']
10182,PMC3551748,20795,The Baltimore risk assessment battery (BRAB),Methods|Measures,[123562],[10809],[10853],[False],[0],[0],[False],['0']
10183,PMC3551748,20796,"To measure HIV drug-risk, a modified version of the HIV Risk Assessment Battery (RAB) was used, the Baltimore Risk Assessment Battery [21,22].",Methods|Measures,[123576],[10854],[10996],[False],[0],[0],[False],['0']
10184,PMC3551748,20797,"The BRAB sex-risk score included 9 questions: (1) sexual orientation [score: 0 (Heterosexual) or 1 (bisexual)], (2) number of male partners, (3) number of female partners, (4) frequency of exchanging sex for drugs, (5) frequency of exchanging drugs for sex, (6) frequency of exchanging sex for money, (7) consistency of condom use, (8) frequency of exchanging money for sex, and (9) frequency of sex with someone of known HIV/AIDS positive status.",Methods|Measures,[123590],[10997],[11444],[False],[0],[0],[False],['0']
10185,PMC3551748,20798,"Questions (2)-(9) used 4-point rating scales, scored 0–3.",Methods|Measures,[123604],[11445],[11502],[False],[0],[0],[False],['0']
10186,PMC3551748,20799,"Possible scores range from 0 to 25, inclusive, with higher scores indicating greater HIV sex-risk behavior.",Methods|Measures,[123618],[11503],[11610],[False],[0],[0],[False],['0']
10187,PMC3551748,20800,Partner support questionnaire (PSQ),Methods|Partner support questionnaire (PSQ),[123632],[11611],[11646],[False],[0],[0],[False],['0']
10188,PMC3551748,20801,"The PSQ, based on the self-report Norbeck Social Support Questionnaire [23], is a 16-item questionnaire, with each item scored on a 5-point scale, from 0 = “never” to 4 = “very often”.",Methods|Partner support questionnaire (PSQ),[123646],[11647],[11831],[False],[0],[0],[False],['0']
10189,PMC3551748,20802,"It asks the respondent to rate herself on various aspects of her support for her partner in reaching and maintaining drug abstinence (e.g., “Do you compliment your partner on not using heroin”; “Do you help your partner to think of things to do other than using heroin”).",Methods|Partner support questionnaire (PSQ),[123660],[11832],[12103],[False],[0],[0],[False],['0']
10190,PMC3551748,20803,"Possible scores ranges from 0 to 64, inclusive, with higher scores indicating greater support.",Methods|Partner support questionnaire (PSQ),[123674],[12104],[12198],[False],[0],[0],[False],['0']
10191,PMC3551748,20804,"Two additional binary items were added to the end of the PSQ: “Have you been hit, kicked, punched, or otherwise hurt by your partner within the past year?",Methods|Partner support questionnaire (PSQ),[123688],[12199],[12353],[False],[0],[0],[False],['0']
10192,PMC3551748,20805,(past month for follow-up assessments)” and “Do you feel safe in your current relationship?’ which were not scored as part of the PSQ.,Methods|Partner support questionnaire (PSQ),[123702],[12354],[12488],[False],[0],[0],[False],['0']
10193,PMC3551748,20806,These two items were examined separately in order to assess if the women had experienced interpersonal violence during the year prior to the interview and whether they felt safe in their current relationships.,Methods|Partner support questionnaire (PSQ),[123716],[12489],[12698],[False],[0],[0],[False],['0']
10194,PMC3551748,20807,Statistical analyses,Methods|Statistical analyses,[123730],[12699],[12719],[False],[0],[0],[False],['0']
10195,PMC3551748,20808,"Descriptive information on background characteristics, HIV and HCV status, sex risk, physical abuse, and feeling unsafe in the current relationship is presented in terms of frequencies and percentages or means and standard deviations.",Methods|Statistical analyses,[123744],[12720],[12954],[False],[0],[0],[False],['0']
10196,PMC3551748,20809,Results,Results,[123758],[12955],[12963],[False],[0],[0],[False],['0']
10197,PMC3551748,20810,Participant characteristics,Results|Participant characteristics,[123772],[12964],[12991],[False],[0],[0],[False],['0']
10198,PMC3551748,20811,"On average, the women, all of whom were Caucasian, the majority of whom being native Georgian (88%), with the remaining 12% nationals of neighboring countries (Russia, Armenia, and Azerbaijan), were 32.3 years old, 37 (93%) were married, with an average 15.5 years of education (Table  1).",Results|Participant characteristics,[123786],[12992],[13281],[False],[0],[0],[False],['0']
10199,PMC3551748,20812,A majority reported at least partial employment the majority of the time during the past 3 years.,Results|Participant characteristics,[123800],[13282],[13379],[False],[0],[0],[False],['0']
10200,PMC3551748,20813,Only one woman reported being unemployed most of the time during the past 3 years.,Results|Participant characteristics,[123814],[13380],[13462],[False],[0],[0],[False],['0']
10201,PMC3551748,20814,"The most common employment occupation was business manager (33%) followed by clerical/sales and semiskilled, each reported by 13%.",Results|Participant characteristics,[123828],[13463],[13593],[False],[0],[0],[False],['0']
10202,PMC3551748,20815,Prevalence of HIV and HCV,Results|Prevalence of HIV and HCV,[123842],[13594],[13619],[False],[0],[0],[False],['0']
10203,PMC3551748,20816,HIV and HCV status of the women participants was determined by self-report.,Results|Prevalence of HIV and HCV,[123856],[13620],[13695],[False],[0],[0],[False],['0']
10204,PMC3551748,20817,Positive HIV status was reported by one woman.,Results|Prevalence of HIV and HCV,[123870],[13696],[13742],[False],[0],[0],[False],['0']
10205,PMC3551748,20818,She indicated that she was infected with HIV following sexual contact with her husband who got infected in prison due to sharing syringes.,Results|Prevalence of HIV and HCV,[123884],[13743],[13881],[False],[0],[0],[False],['0']
10206,PMC3551748,20819,Negative HIV status was reported by 20 women and 15 reported they were unaware of their HIV status (Table  2).,Results|Prevalence of HIV and HCV,[123898],[13882],[13992],[False],[0],[0],[False],['0']
10207,PMC3551748,20820,"Positive HCV status was reported by 3 women, 24 reported negative HCV status, and 9 women reported they were unaware of their HCV status.",Results|Prevalence of HIV and HCV,[123912],[13993],[14130],[False],[0],[0],[False],['0']
10208,PMC3551748,20821,Four female participants dropped out of the prior to the self-reported assessment of their HIV and HCV status.,Results|Prevalence of HIV and HCV,[123926],[14131],[14241],[False],[0],[0],[False],['0']
10209,PMC3551748,20822,These 4 women participants were the partners of the men who had refused to provide a blood sample for testing and dropped out of the study.,Results|Prevalence of HIV and HCV,[123940],[14242],[14381],[False],[0],[0],[False],['0']
10210,PMC3551748,20823,"Given the relatively large percentage of the sample unaware of their HIV and HCV status, answers to these two questions were examined for their male partners.",Results|Prevalence of HIV and HCV,[123954],[14382],[14540],[False],[0],[0],[False],['0']
10211,PMC3551748,20824,"Of the 15 women who did not know their HIV status, 13 of their male partners had refused to provide blood for testing, while of the 9 women who were unaware of their HCV status, 7 of their male partners refused to undergo HCV testing.",Results|Prevalence of HIV and HCV,[123968],[14541],[14775],[False],[0],[0],[False],['0']
10212,PMC3551748,20825,Sex risk,Results|Sex risk,[123982],[14776],[14784],[False],[0],[0],[False],['0']
10213,PMC3551748,20826,"Because of the lack of variability in responding to the items on this scale (see following), no internal consistency reliability for the BRAB HIV sex risk scale is reported.",Results|Sex risk,[123996],[14785],[14958],[False],[0],[0],[False],['0']
10214,PMC3551748,20827,The BRAB HIV sex risk score (Table  3) does indicate a relatively low risk for the women.,Results|Sex risk,[124010],[14959],[15048],[False],[0],[0],[False],['0']
10215,PMC3551748,20828,"All women reported themselves to be exclusively heterosexual, and no women reported she had exchanged sex for drugs or money, or exchanged drugs or money for sex.",Results|Sex risk,[124024],[15049],[15211],[False],[0],[0],[False],['0']
10216,PMC3551748,20829,"However, only 4 (10%) women reported using a condom most of the time while having sex and 15 (38%) report not having had sex during the last 30 days.",Results|Sex risk,[124038],[15212],[15361],[False],[0],[0],[False],['0']
10217,PMC3551748,20830,"Of these 15 women, 7 (47%) of their male partners indicated that they had not had sex in the last 30 days, with 2 of the remaining 8 men indicating they used condoms “all of the time”, 1 “most of the time”, and 5 “some of the time”.",Results|Sex risk,[124052],[15362],[15594],[False],[0],[0],[False],['0']
10218,PMC3551748,20831,"One woman reported having HIV-positive male partner (one of the male participants in the parent study was HIV-positive), and indicated that she had used condoms “most of the time” in the last 30 days.",Results|Sex risk,[124066],[15595],[15795],[False],[0],[0],[False],['0']
10219,PMC3551748,20832,Twenty women (51%) were not at all worried and 7 (18%) were considerably or extremely concerned about getting HIV/AIDS.,Results|Sex risk,[124080],[15796],[15915],[False],[0],[0],[False],['0']
10220,PMC3551748,20833,Partner support,Results|Partner support,[124094],[15916],[15931],[False],[0],[0],[False],['0']
10221,PMC3551748,20834,"The PSQ had an internal consistency reliability α = .78 in this sample, indicating that the scale score could be considered a reliable measure of partner support.",Results|Partner support,[124108],[15932],[16094],[False],[0],[0],[False],['0']
10222,PMC3551748,20835,"The women generally believed they often provided support (see Table  3), with scores ranging from 22 to 50, inclusive.",Results|Partner support,[124122],[16095],[16213],[False],[0],[0],[False],['0']
10223,PMC3551748,20836,"Assuming the theoretical midpoint of the scale would be 32 (an average item score of 2 = “sometimes”), only 3 women provided support that might be seen as less than adequate.",Results|Partner support,[124136],[16214],[16388],[False],[0],[0],[False],['0']
10224,PMC3551748,20837,Physical abuse and safety,Results|Physical abuse and safety,[124150],[16389],[16414],[False],[0],[0],[False],['0']
10225,PMC3551748,20838,"Physical abuse by their partner within the last year was reported by 42% of the women, and 48% said they felt unsafe in their current relationship.",Results|Physical abuse and safety,[124164],[16415],[16562],[False],[0],[0],[False],['0']
10226,PMC3551748,20839,Discussion,Discussion,[124178],[16563],[16574],[False],[0],[0],[False],['0']
10227,PMC3551748,20840,Female partners of injection-drug-using men in the Republic of Georgia are at high risk for contracting HIV and HCV [9].,Discussion,[124192],[16575],[16695],[False],[0],[0],[False],['0']
10228,PMC3551748,20841,"This is the first study that describes the prevalence of HIV and HCV among this recently identified high-risk group of illicit-drug-free female partners of opioid-injecting men in the Republic of Georgia, almost all of whom were married.",Discussion,[124206],[16696],[16933],[False],[0],[0],[False],['0']
10229,PMC3551748,20842,"When asked about their HIV status only one woman reported that she was HIV-positive, half said they were HIV negative, and more than one third stated they were never tested.",Discussion,[124220],[16934],[17107],[False],[0],[0],[False],['0']
10230,PMC3551748,20843,"A small number of women reported being infected with HCV, almost two-thirds said they were HCV-negative, and close to one in four stated they were unaware of their status.",Discussion,[124234],[17108],[17279],[False],[0],[0],[False],['0']
10231,PMC3551748,20844,It has been reported that stigma against and fear of discrimination has led many people in Georgia to conceal a positive HIV status [24].,Discussion,[124248],[17280],[17417],[False],[0],[0],[False],['0']
10232,PMC3551748,20845,"This situation might be the case for some of the women in the present study as well, and may extend to revealing HCV status.",Discussion,[124262],[17418],[17542],[False],[0],[0],[False],['0']
10233,PMC3551748,20846,Kirtadze et al.,Discussion,[124276],[17543],[17558],[False],[0],[0],[False],['0']
10234,PMC3551748,20847,[25] examined the attitudes and beliefs of 34 health service providers in Georgia who had contact with injection-drug-using women.,Discussion,[124290],[17559],[17689],[False],[0],[0],[False],['0']
10235,PMC3551748,20848,"These providers indicated less tolerance towards such women, believing they were failures as a good mother, wife, or child.",Discussion,[124304],[17690],[17813],[False],[0],[0],[False],['0']
10236,PMC3551748,20849,"The authors concluded that drug-using women in Georgian culture were “twice stigmatized” – as failed mothers/wives/daughters, and as less acceptable than men, even drug-using men.",Discussion,[124318],[17814],[17993],[False],[0],[0],[False],['0']
10237,PMC3551748,20850,"In addition, the parent study records suggest that male participants refused HIV testing due to the fear of being diagnosed positive (e.g., “It is better if I do not know if I am infected”), and refused HCV testing due to lack of available treatment options (e.g., “even if I am positive there is no treatment that I can afford”).",Discussion,[124332],[17994],[18324],[False],[0],[0],[False],['0']
10238,PMC3551748,20851,"This might well explain low motivation of participants, both, males and females, to know their health status.",Discussion,[124346],[18325],[18434],[False],[0],[0],[False],['0']
10239,PMC3551748,20852,Half the women reported not being worried about contracting HIV/AIDS and less than one in five reported being considerably or extremely worried about being infected with HIV/AIDS.,Discussion,[124360],[18435],[18614],[False],[0],[0],[False],['0']
10240,PMC3551748,20853,The low prevalence of concern is surprising since a majority of women with HIV in Georgia have been infected from a partner who injects drugs [9].,Discussion,[124374],[18615],[18761],[False],[0],[0],[False],['0']
10241,PMC3551748,20854,The limited understanding of and attitude towards HIV/AIDS in Georgia suggests that there may be a serious lack of available information about risk factors for HIV infection [6].,Discussion,[124388],[18762],[18940],[False],[0],[0],[False],['0']
10242,PMC3551748,20855,"Alternately, there may be a taboo among Georgian women to express worry about contracting HIV/HCV, due to the heavy social stigma associated with these infections.",Discussion,[124402],[18941],[19104],[False],[0],[0],[False],['0']
10243,PMC3551748,20856,"Moreover, the fear of being arrested and a lack of trust in health care providers contribute to the fact that only about 5% of injection-drug-using adults in Georgia are tested for HIV on a regular basis [7].",Discussion,[124416],[19105],[19313],[False],[0],[0],[False],['0']
10244,PMC3551748,20857,"Therefore, it may be the case that the prevalence of HIV is notably higher among injection-drug-using adults than what has been estimated.",Discussion,[124430],[19314],[19452],[False],[0],[0],[False],['0']
10245,PMC3551748,20858,"Moreover, despite a low average sex risk score, only 1 in 10 women reported that her partner used a condom most of the time.",Discussion,[124444],[19453],[19577],[False],[0],[0],[False],['0']
10246,PMC3551748,20859,"The women may be influenced by the widespread belief among Georgian women that if they are not injecting drugs or are sex workers, they are not at risk of HIV or HCV infection [7].",Discussion,[124458],[19578],[19758],[False],[0],[0],[False],['0']
10247,PMC3551748,20860,Safe sex would be a protective factor against HIV and HCV for the women.,Discussion,[124472],[19759],[19831],[False],[0],[0],[False],['0']
10248,PMC3551748,20861,"However, other studies have also found that sexually active women in Georgia rarely use or discuss using condoms with their partners [24].",Discussion,[124486],[19832],[19970],[False],[0],[0],[False],['0']
10249,PMC3551748,20862,More than a third of the women reported not having had sex during the last 30 days.,Discussion,[124500],[19971],[20054],[False],[0],[0],[False],['0']
10250,PMC3551748,20863,These results merit further research to determine the extent that low rates of sexual activity are related to the slow spread of HIV and HCV among women in the Republic of Georgia.,Discussion,[124514],[20055],[20235],[False],[0],[0],[False],['0']
10251,PMC3551748,20864,Previous research has revealed a low level of knowledge of HIV risk factors and high prevalence of unsafe sex among the general population in Georgia [6].,Discussion,[124528],[20236],[20390],[False],[0],[0],[False],['0']
10252,PMC3551748,20865,Inadequate knowledge of HIV risk factors and methods for HIV risk reduction seem to be a widespread problem in Georgia [6].,Discussion,[124542],[20391],[20514],[False],[0],[0],[False],['0']
10253,PMC3551748,20866,"Results of the present study would suggest that unsafe sex frequently occurs in an extremely high-risk population, non-drug-using female partners of injection-drug-using men.",Discussion,[124556],[20515],[20689],[False],[0],[0],[False],['0']
10254,PMC3551748,20867,High-risk injection practices are common in the Republic of Georgia.,Discussion,[124570],[20690],[20758],[False],[0],[0],[False],['0']
10255,PMC3551748,20868,"Previous research reported that in some subgroups more than four out of five opioid-injecting drug-using men in Georgia are sharing needles with others [26,27].",Discussion,[124584],[20759],[20919],[False],[0],[0],[False],['0']
10256,PMC3551748,20869,"Thus, even if the opioid-injecting male partners of illicit-drug-free females are not having sex with other women or men, the male partner remains at high risk of getting infected with HIV and HCV and passing these infections to his female partner through sexual contact.",Discussion,[124598],[20920],[21191],[False],[0],[0],[False],['0']
10257,PMC3551748,20870,The women generally perceived themselves as supportive of their partners’ efforts to reach and maintain abstinence.,Discussion,[124612],[21192],[21307],[False],[0],[0],[False],['0']
10258,PMC3551748,20871,Seventeen women (43%) had experienced physical abuse by their partner within the last year prior to the interview and close to half reported feeling unsafe in their current relationship.,Discussion,[124626],[21308],[21494],[False],[0],[0],[False],['0']
10259,PMC3551748,20872,"In a study including more than 1,000 women in the general population in Georgia, 6% reported experiencing physical violence and 11% sexual violence during the last five years.",Discussion,[124640],[21495],[21670],[False],[0],[0],[False],['0']
10260,PMC3551748,20873,"This study measured all physical and sexual violence, not just violence by partner [28].",Discussion,[124654],[21671],[21759],[False],[0],[0],[False],['0']
10261,PMC3551748,20874,"Another study including close to 8,000 women in Georgia reported that 2% had experienced physical abuse and 3% sexual abuse by a partner during the last 12 months [27].",Discussion,[124668],[21760],[21928],[False],[0],[0],[False],['0']
10262,PMC3551748,20875,Females in a relationship with an opioid-injection drug-using male partner seem to be at increased risk of experiencing interpersonal violence compared to the general population of women in Georgia.,Discussion,[124682],[21929],[22127],[False],[0],[0],[False],['0']
10263,PMC3551748,20876,Another health risk is that the drug-injecting man will initiate his partner into drug use.,Discussion,[124696],[22128],[22219],[False],[0],[0],[False],['0']
10264,PMC3551748,20877,"Women commonly start using drugs because of their partner [29,30].",Discussion,[124710],[22220],[22286],[False],[0],[0],[False],['0']
10265,PMC3551748,20878,Preventing female partners of opioid-injecting men from initiating drug use is a critically important goal.,Discussion,[124724],[22287],[22394],[False],[0],[0],[False],['0']
10266,PMC3551748,20879,"Including these women in their partner’s treatment program might enable them to improve their relationship with their partner, learn how to resist the use of illicit drugs, and better support their partner in his rehabilitation.",Discussion,[124738],[22395],[22623],[False],[0],[0],[False],['0']
10267,PMC3551748,20880,Study limitations,Discussion|Study limitations,[124752],[22624],[22641],[False],[0],[0],[False],['0']
10268,PMC3551748,20881,"First, the sample size of the present study was relatively small.",Discussion|Study limitations,[124766],[22642],[22707],[True],['SampleSize'],['the sample size of the present study was relatively small'],[True],['UnderpoweredStudy']
10269,PMC3551748,20882,"Therefore, the findings need to be interpreted with restraint.",Discussion|Study limitations,[124794],[22708],[22770],[False],[0],[0],[False],['0']
10270,PMC3551748,20883,"Second, selection bias that attracted motivated males in a stable relationship with an interest in treatment might have operated to yield a sample of men who are more likely to engage in safe sex practices.",Discussion|Study limitations,[124809],[22771],[22977],[True],['VerySpecificPopulation'],['selection bias that attracted motivated males in a stable relationship with an interest in treatment'],[True],['Population']
10271,PMC3551748,20884,"It is difficult to determine the extent to which this statement might be true, given the high non-response rate regarding HIV and HCV infection for the male as well as the female participants.",Discussion|Study limitations,[124836],[22978],[23170],[False],[0],[0],[False],['0']
10272,PMC3551748,20885,Selection bias may have been further compounded by attrition.,Discussion|Study limitations,[124852],[23171],[23232],[True],['HighLossToFollowUp'],['attrition'],[True],['MissingData']
10273,PMC3551748,20886,"Thus, the small sample size and the impact of both selection bias and attrition may have adversely impacted the ability to determine precise estimates of HIV and HCV in the population of non-substance-using female partners of injection-drug-using men.",Discussion|Study limitations,"[124881, 124882, 124883]","[23233, 23233, 23233]","[23484, 23484, 23484]","[True, True, True]","['SampleSize', 'VerySpecificPopulation', 'HighLossToFollowUp']","['the small sample size', 'selection bias', 'attrition']","[True, True, True]","['Population', 'UnderpoweredStudy', 'MissingData']"
10274,PMC3551748,20887,"Third, a relatively large number of men who expressed an interest in participation in the parent study failed to enter the study: 19/74 (26%) failed to show up for their intake appointment, and 15/74 (20%) were determined to be ineligible.",Discussion|Study limitations,[124912],[23485],[23724],[True],['Population'],['a relatively large number of men who expressed an interest in participation in the parent study failed to enter the study'],[True],['Population']
10275,PMC3551748,20888,"Because information on the women in the present study is gathered from the female partners of the male participants, such a relatively high rate of participant loss potentially limits the generalizability of the findings.",Discussion|Study limitations,"[124941, 124942]","[23725, 23725]","[23946, 23946]","[True, True]","['Population', 'Generalization']","['a relatively high rate of participant loss', 'limits the generalizability of the findings']","[True, True]","['Generalization', 'Population']"
10276,PMC3551748,20889,"However, the rate of non-participation is not unexpected, because the parent study focused on attracting non-treatment-seeking men into treatment.",Discussion|Study limitations,[124962],[23947],[24093],[False],[0],[0],[False],['0']
10277,PMC3551748,20890,"Fourth, stigma and the attendant fear of disclosure may have operated to restrict the range of responding and increase the chances of socially desirable responding, also limiting our ability to generalize our findings.",Discussion|Study limitations,"[124985, 124986]","[24094, 24094]","[24312, 24312]","[True, True]","['Generalization', 'PrecisionOfMeasurement']","['limiting our ability to generalize our findings', 'stigma and the attendant fear of disclosure may have operated to restrict the range of responding and increase the chances of socially desirable responding']","[True, True]","['OutcomeMeasures', 'Generalization']"
10278,PMC3551748,20891,"Fifth, HIV and HCV status was based on self-report measures.",Discussion|Study limitations,[125015],[24313],[24373],[True],['PrecisionOfMeasurement'],['self-report measures'],[True],['OutcomeMeasures']
10279,PMC3551748,20892,"Thus, the reliability of such data depends on truthful answers from respondents.",Discussion|Study limitations,[125032],[24374],[24454],[False],[0],[0],[False],['0']
10280,PMC3551748,20893,"Sixth, there was a relatively large amount of missing data on for the questions regarding HIV and HCV status, because the women failed to answer these questions.",Discussion|Study limitations,[125058],[24455],[24616],[True],['MissingData'],['missing data'],[True],['MissingData']
10281,PMC3551748,20894,"Being either HIV-positive or HCV-positive is associated with considerable stigma in Georgia, and fear of stigmatization may have influenced some respondents to refuse to answer these questions – or, potentially to answer in socially desirable ways.",Discussion|Study limitations,[125074],[24617],[24865],[False],[0],[0],[False],['0']
10282,PMC3551748,20895,"Finally, information on sexual violence or abuse independent of physical violence was not collected.",Discussion|Study limitations,[125101],[24866],[24966],[True],['RelevantOutcomeExcluded'],['information on sexual violence or abuse independent of physical violence was not collected'],[True],['OutcomeMeasures']
10283,PMC3551748,20896,Strengths of the study,Discussion|Strengths of the study,[125116],[24967],[24989],[False],[0],[0],[False],['0']
10284,PMC3551748,20897,"Research on non-opioid-injecting female partners of opioid-injecting men is scarce, both in the Republic of Georgia and elsewhere [31].",Discussion|Strengths of the study,[125130],[24990],[25125],[False],[0],[0],[False],['0']
10285,PMC3551748,20898,"Information about HIV status, HCV status, sex risk behavior, concern about getting HIV and interpersonal violence may prove invaluable for designing HIV interventions for injection-drug-using men and their female partners.",Discussion|Strengths of the study,[125144],[25126],[25348],[False],[0],[0],[False],['0']
10286,PMC3551748,20899,We can envision that public health efforts should be focused in two directions.,Discussion|Strengths of the study,[125158],[25349],[25428],[False],[0],[0],[False],['0']
10287,PMC3551748,20900,"First, efforts need to be made to provide additional information to potentially sexually active Georgian women – particularly female partners of injection-drug-using men – that barrier protection methods are the best protection against HIV and and HCV infection.",Discussion|Strengths of the study,[125172],[25429],[25691],[False],[0],[0],[False],['0']
10288,PMC3551748,20901,"Second, providing couples therapy in some form, even if only for 2–3 sessions, may allow for direct outreach and education of both members of the couple on the risks of HIV and HCV infection.",Discussion|Strengths of the study,[125186],[25692],[25883],[False],[0],[0],[False],['0']
10289,PMC3551748,20902,Conclusions,Conclusions,[125200],[25884],[25896],[False],[0],[0],[False],['0']
10290,PMC3551748,20903,"In settings where prevalence of HIV/AIDS is low, the epidemic is mostly concentrated within specific groups, as is the case of Georgia, in injecting-drug-using adults.",Conclusions,[125214],[25897],[26064],[False],[0],[0],[False],['0']
10291,PMC3551748,20904,Preventive interventions should target populations at risk for HIV transmission.,Conclusions,[125228],[26065],[26145],[False],[0],[0],[False],['0']
10292,PMC3551748,20905,Such targeted evidence-based interventions have maximal impact in terms of both preventing the spread of infection and allowing for the most efficient allocation of limited financial resources.,Conclusions,[125242],[26146],[26339],[False],[0],[0],[False],['0']
10293,PMC3551748,20906,"A high proportion of the women in the present study had never been tested for HIV and HCV, and reported no motivation to do so when offered.",Conclusions,[125256],[26340],[26480],[False],[0],[0],[False],['0']
10294,PMC3551748,20907,"This, along with the low reporting of condom use, strongly indicate the need for targeted education efforts that would provide information about disease development and treatment options, and would encourage this population to seek appropriate counseling and testing.",Conclusions,[125270],[26481],[26748],[False],[0],[0],[False],['0']
10295,PMC3551748,20908,"Prevention programs should educate both the injection-drug-using male and his female partner in the risks of HIV and HCV transmission from unprotected sex, and thereby to reduce the risk of HIV and HCV transmission from the population of injection-drug–using individuals into the general population.",Conclusions,[125284],[26749],[27048],[False],[0],[0],[False],['0']
10296,PMC3551748,20909,These women are also at alarming risk compared to the general population of women for experiencing interpersonal violence.,Conclusions,[125298],[27049],[27171],[False],[0],[0],[False],['0']
10297,PMC3551748,20910,Competing interests,Competing interests,[125312],[27172],[27192],[False],[0],[0],[False],['0']
10298,PMC3551748,20911,The authors declare they have no competing interests.,Competing interests,[125326],[27193],[27246],[False],[0],[0],[False],['0']
10299,PMC3551748,20912,Authors’ contributions,Authors’ contributions,[125340],[27247],[27270],[False],[0],[0],[False],['0']
10300,PMC3551748,20913,"HEJ designed the initial study and protocol, while DO and IK provided input into the refinement of the protocol.",Authors’ contributions,[125354],[27271],[27383],[False],[0],[0],[False],['0']
10301,PMC3551748,20914,DO was Principal Investigator at the Republic of Georgia site where the protocol was implemented and was responsible for the medical screening and naltrexone treatment and monitoring.,Authors’ contributions,[125368],[27384],[27567],[False],[0],[0],[False],['0']
10302,PMC3551748,20915,IK was responsible for data collection and patient management.,Authors’ contributions,[125382],[27568],[27630],[False],[0],[0],[False],['0']
10303,PMC3551748,20916,KEO’G conducted the data analyses.,Authors’ contributions,[125396],[27631],[27665],[False],[0],[0],[False],['0']
10304,PMC3551748,20917,IOL wrote the first draft of the manuscript.,Authors’ contributions,[125410],[27666],[27710],[False],[0],[0],[False],['0']
10305,PMC3551748,20918,All authors discussed the results and implications and commented on the manuscript at all stages.,Authors’ contributions,[125424],[27711],[27808],[False],[0],[0],[False],['0']
10306,PMC3551748,20919,All authors have approved the final manuscript.,Authors’ contributions,[125438],[27809],[27856],[False],[0],[0],[False],['0']
10307,PMC3551748,20920,"No honorarium, grant, or other form of payment was given to any author or any other individual to produce the manuscript.",Authors’ contributions,[125452],[27857],[27978],[False],[0],[0],[False],['0']
10308,PMC3551748,20921,Acknowledgements,Acknowledgements,[125466],[27979],[27996],[False],[0],[0],[False],['0']
10309,PMC3551748,20922,"This research was supported by an international supplement to grant R01DA13496-03A1 from the National Institute on Drug Abuse (Hendrée E. Jones, PI).",Acknowledgements,[125480],[27997],[28146],[False],[0],[0],[False],['0']
10310,PMC3551748,20923,"NIDA played no role in the: 1) study design; 2) collection, analysis, and interpretation of data; 3) writing of the report; and 4) decision to submit or where to submit the paper for publication.",Acknowledgements,[125494],[28147],[28342],[False],[0],[0],[False],['0']
11560,PMC3648471,12327,Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial,Title,[76391],[43498],[183],[False],[0],[0],[False],['0']
11561,PMC3648471,12328,Background,Abstract,[76392],[184],[195],[False],[0],[0],[False],['0']
11562,PMC3648471,12329,Flupirtine is an analgesic with muscle-relaxing properties that activates Kv7 potassium channels.,Abstract,[76393],[196],[293],[False],[0],[0],[False],['0']
11563,PMC3648471,12330,Kv7 channels are expressed along myelinated and unmyelinated peripheral axons where their activation is expected to reduce axonal excitability and potentially contribute to flupirtine’s clinical profile.,Abstract,[76394],[294],[497],[False],[0],[0],[False],['0']
11564,PMC3648471,12331,Trial design,Trial design,[76395],[498],[511],[False],[0],[0],[False],['0']
11565,PMC3648471,12332,"To investigate the electrical excitability of peripheral myelinated axons following orally administered flupirtine, in-vitro experiments on isolated peripheral nerve segments were combined with a randomised, double-blind, placebo-controlled, phase I clinical trial (RCT).",Trial design,[76396],[512],[783],[False],[0],[0],[False],['0']
11566,PMC3648471,12333,Methods,Methods,[76397],[784],[792],[False],[0],[0],[False],['0']
11567,PMC3648471,12334,Threshold tracking was used to assess the electrical excitability of myelinated axons in isolated segments of human sural nerve in vitro and motoneurones to abductor pollicis brevis (APB) in situ in healthy subjects.,Methods,[76398],[793],[1009],[False],[0],[0],[False],['0']
11568,PMC3648471,12335,"In addition, the effect of flupirtine on ectopic action potential generation in myelinated axons was examined using ischemia of the lower arm.",Methods,[76399],[1010],[1152],[False],[0],[0],[False],['0']
11569,PMC3648471,12336,Results,Results,[76400],[1153],[1161],[False],[0],[0],[False],['0']
11570,PMC3648471,12337,Flupirtine (3-30 μM) shortened the relative refractory period and increased post-conditioned superexcitability in human myelinated axons in vitro.,Results,[76401],[1162],[1308],[False],[0],[0],[False],['0']
11571,PMC3648471,12338,"Similarly, in healthy subjects the relative refractory period of motoneurones to APB was reduced 2 hours after oral flupirtine but not following placebo.",Results,[76402],[1309],[1462],[False],[0],[0],[False],['0']
11572,PMC3648471,12339,Whether this effect was due to a direct action of flupirtine on peripheral axons or temperature could not be resolved.,Results,[76403],[1463],[1581],[False],[0],[0],[False],['0']
11573,PMC3648471,12340,Flupirtine (200 mg p.o.),Results,[76404],[1582],[1606],[False],[0],[0],[False],['0']
11574,PMC3648471,12341,also reduced ectopic axonal activity induced by 10 minutes of lower arm ischemia.,Results,[76405],[1607],[1688],[False],[0],[0],[False],['0']
11575,PMC3648471,12342,"In particular, high frequency (ca.",Results,[76406],[1689],[1723],[False],[0],[0],[False],['0']
11576,PMC3648471,12343,200 Hz) components of EMG were reduced in the post-ischemic period.,Results,[76407],[1724],[1791],[False],[0],[0],[False],['0']
11577,PMC3648471,12344,"Finally, visual analogue scale ratings of sensations perceived during the post-ischemic period were reduced following flupirtine (200 mg p.o.",Results,[76408],[1792],[1933],[False],[0],[0],[False],['0']
11578,PMC3648471,12345,).,Results,[76409],[1934],[1936],[False],[0],[0],[False],['0']
11579,PMC3648471,12346,Conclusions,Conclusions,[76410],[1937],[1948],[False],[0],[0],[False],['0']
11580,PMC3648471,12347,Clinical doses of flupirtine reduce the excitability of peripheral myelinated axons.,Conclusions,[76411],[1949],[2033],[False],[0],[0],[False],['0']
11581,PMC3648471,12348,Trial registration,Trial registration,[76412],[2034],[2053],[False],[0],[0],[False],['0']
11582,PMC3648471,12349,ClinicalTrials registration is NCT01450865.,Trial registration,[76413],[2054],[2097],[False],[0],[0],[False],['0']
11583,PMC3648471,12350,Background,Background,[76414],[2098],[2110],[False],[0],[0],[False],['0']
11584,PMC3648471,12351,"Blockade of voltage-dependent sodium channels has been successful in the treatment of some forms of clinical pain, e.g.",Background,[76415],[2111],[2230],[False],[0],[0],[False],['0']
11585,PMC3648471,12352,"diabetic polyneuropathy, lumbar radiculopathies, complex regional pain syndrome, neuralgic pain and traumatic peripheral nerve injuries for review: [1].",Background,[76416],[2231],[2383],[False],[0],[0],[False],['0']
11586,PMC3648471,12353,"A group of compounds which might also influence axonal excitability are synthetic activators of slow axonal Kv7 potassium channels, such as flupirtine which has recently been used in the treatment regimens of patients with peripheral neuropathies [2].",Background,[76417],[2384],[2635],[False],[0],[0],[False],['0']
11587,PMC3648471,12354,The target of such strategies is the K 7 (formerly KCNQ/M) family of potassium channels.,Background,[76418],[2636],[2724],[False],[0],[0],[False],['0']
11588,PMC3648471,12355,"Five genes (KCNQ1-5) encode Kv7 subunits, each with 6 trans-membrane spanning domains, a P-loop and a conserved A-domain in the cytoplasmic C-terminal region.",Background,[76419],[2725],[2883],[False],[0],[0],[False],['0']
11589,PMC3648471,12356,"Neurones express four Kv7 subunits (Kv7.2-Kv7.5) that co-assemble to form either homo- or hetero-tetrameric voltage-gated channels [3,4] and channel activity can be readily inhibited by agonist action at Gq/11-coupled receptors [5].",Background,[76420],[2884],[3116],[False],[0],[0],[False],['0']
11590,PMC3648471,12357,"In rodents, Kv7.2 is found at nodes of Ranvier in peripheral nerve [6] and in motoneurones in the spinal ventral horn [7], while Kv7.3 is expressed in myelinating Schwann cells [8].",Background,[76421],[3117],[3298],[False],[0],[0],[False],['0']
11591,PMC3648471,12358,"In myelinated axons of smaller calibre, both Kv7.2 and Kv7.3 subunits are found nodally [6] Similarly, Kv7.2, Kv7.3 and Kv7.5 are found along somatic unymelinated axons [9] visceral unmyelinated axons [10] and in baroreceptor nerve terminals [11].",Background,[76422],[3299],[3546],[False],[0],[0],[False],['0']
11592,PMC3648471,12359,The presence of axonal Kv7 subunits has also been confirmed functionally in peripheral nerve.,Background,[76423],[3547],[3640],[False],[0],[0],[False],['0']
11593,PMC3648471,12360,The synthetic Kv7 channel activator retigabine shifts the activation of myelinated axons in the hyperpolarizing direction [6] and reduces the electrical threshold of unmyelinated axons in human sural nerve [12].,Background,[76424],[3641],[3852],[False],[0],[0],[False],['0']
11594,PMC3648471,12361,"Similarly, flupirtine increases the electrical threshold of myelinated axons in rat sural [13] nerve.",Background,[76425],[3853],[3954],[False],[0],[0],[False],['0']
11595,PMC3648471,12362,"Kv7 channels activate in response to depolarization, beginning at around -60 mV, and deactivate slowly but do not inactivate [4].",Background,[76426],[3955],[4084],[False],[0],[0],[False],['0']
11596,PMC3648471,12363,The slow time course of voltage activation and lack of inactivation of Kv7 channels suggests that one role of Kv7 in peripheral axons may be to limit the extent of repetitive burst discharges.,Background,[76427],[4085],[4277],[False],[0],[0],[False],['0']
11597,PMC3648471,12364,"Consistent with this, the phenotype accompanying dominant-negative mutations in KCNQ2 (Kv7.2) and on occasion KCNQ3 (Kv7.3) is benign familial neonatal convulsions BFNC; [14].",Background,[76428],[4278],[4453],[False],[0],[0],[False],['0']
11598,PMC3648471,12365,"In some patients with BFNC, myokymia symptoms are reported and characterized by spontaneous involuntary muscle fasciculations [7,15-17].",Background,[76429],[4454],[4590],[False],[0],[0],[False],['0']
11599,PMC3648471,12366,"Myokymic symptoms arise from hyperexcitability of motoneurones expressing Kv7.2 [18] and are associated with a point mutation of arginine at position 207 in KCNQ2 that neutralizes the third of six positive charges in the voltage-sensing S4 segment, leading to a slowing and a depolarizing shift of activation [7,17].",Background,[76430],[4591],[4907],[False],[0],[0],[False],['0']
11600,PMC3648471,12367,Pharmacological activation of Kv7 thus offers an important therapeutic strategy for reducing hyperexcitability.,Background,[76431],[4908],[5019],[False],[0],[0],[False],['0']
11601,PMC3648471,12368,The current study has examined the profile of action of the Kv7 channel activator flupirtine by examining its effects on peripheral myelinated axons at clinically achieved concentrations.,Background,[76432],[5020],[5207],[False],[0],[0],[False],['0']
11602,PMC3648471,12369,Materials and methods,Materials and methods,[76433],[5208],[5230],[False],[0],[0],[False],['0']
11603,PMC3648471,12370,Ethics,Materials and methods|Ethics,[76434],[5231],[5237],[False],[0],[0],[False],['0']
11604,PMC3648471,12371,Protocol and consent forms were approved by the Committee for Ethics of the University of Munich and ethical approval to study drug effects in healthy volunteers was provided by the German Federal Institute for Drugs and Medical Devices.,Materials and methods|Ethics,[76435],[5238],[5475],[False],[0],[0],[False],['0']
11605,PMC3648471,12372,In accord with the declaration of Helsinki (Seoul 2008) all participants provided their written informed consent prior to participation in the study.,Materials and methods|Ethics,[76436],[5476],[5625],[False],[0],[0],[False],['0']
11606,PMC3648471,12373,ClinicalTrials registration is NCT01450865.,Materials and methods|Ethics,[76437],[5626],[5669],[False],[0],[0],[False],['0']
11607,PMC3648471,12374,In vitro studies,In vitro studies,[76438],[5670],[5687],[False],[0],[0],[False],['0']
11608,PMC3648471,12375,"  Segments of sural and peroneal nerve were obtained from patients previously scheduled for biopsy (n=7; 1 female, 6 male, age range: 48–80).",In vitro studies,[76439],[5688],[5829],[False],[0],[0],[False],['0']
11609,PMC3648471,12376,The diagnosis precipitating biopsy was typically polyneuropathy of unknown aetiology.,In vitro studies,[76440],[5830],[5915],[False],[0],[0],[False],['0']
11610,PMC3648471,12377,Patients were informed about the procedure by an anaesthesiologist prior to surgery.,In vitro studies,[76441],[5916],[6000],[False],[0],[0],[False],['0']
11611,PMC3648471,12378,"Upon surgical removal nerve segments were immediately placed in physiological solution containing (in mM): 117 NaCl, 3.6 KCl, 2.5 CaCl , 1.2 MgCl , 1.2 NaH PO , 25 NaHCO , 11 D-glucose (bubbled to pH 7.4 with 95 % O  – 5 % CO ).",In vitro studies,[76442],[6001],[6229],[False],[0],[0],[False],['0']
11612,PMC3648471,12379,  Individual fascicles were isolated from nerve segments and teased apart with fine forceps.,In vitro studies,[76443],[6230],[6322],[False],[0],[0],[False],['0']
11613,PMC3648471,12380,"After incubating in PBS containing 0.3% collagenase (30 min, room temp.)",In vitro studies,[76444],[6323],[6395],[False],[0],[0],[False],['0']
11614,PMC3648471,12381,"and washing twice in PBS, preparations were mounted on gelatine-coated slides, dried overnight and fixed in 4% paraformaldehyde for 30 minutes.",In vitro studies,[76445],[6396],[6539],[False],[0],[0],[False],['0']
11615,PMC3648471,12382,"For immunostaining, preparations were blocked in PBS containing 0.2% Triton 100 and 10% natural goat serum at room temperature for 40 minutes, followed by overnight incubation at 4°C with rabbit anti-KCNQ2-N antibodies diluted 1:200 [19] raised and affinity-purified as previously described [19,20].",In vitro studies,[76446],[6540],[6839],[False],[0],[0],[False],['0']
11616,PMC3648471,12383,"KCNQ2 antibodies were directed against residues 13–37 of the conserved intracellular N-terminal region [21,22].",In vitro studies,[76447],[6840],[6951],[False],[0],[0],[False],['0']
11617,PMC3648471,12384,"Monoclonal antibodies against peripherin (diluted 1:200) and the alpha subunits of voltage-gated (NaV) sodium channels (panNaV, diluted 1:200) were used.",In vitro studies,[76448],[6952],[7105],[False],[0],[0],[False],['0']
11618,PMC3648471,12385,"After incubation with the primary antibody, slides were washed three times in PBS and incubated with fluorescein- and rhodamine-conjugated donkey cross-affinity-purified secondary antibodies at room temperature for two hours (all diluted 1:400).",In vitro studies,[76449],[7106],[7351],[False],[0],[0],[False],['0']
11619,PMC3648471,12386,Slides were then washed three times with PBS and covered with Aqua-Poly/Mount Coverslipping medium.,In vitro studies,[76450],[7352],[7451],[False],[0],[0],[False],['0']
11620,PMC3648471,12387,"Digital images were taken with a laser-scanning confocal microscope (Bio-Rad MRC-1024, Bio-Rad Laboratories GmbH, Munich, Germany).",In vitro studies,[76451],[7452],[7583],[False],[0],[0],[False],['0']
11621,PMC3648471,12388,No evidence of antibody cross-reactivity was observed in multilabeling experiments with single label and secondary-only controls.,In vitro studies,[76452],[7584],[7713],[False],[0],[0],[False],['0']
11622,PMC3648471,12389,  Nerve fascicles were mounted between stimulating and recording electrodes in an organ bath perfused continuously with physiological solution tempered to 32°C.,In vitro studies,[76453],[7714],[7874],[False],[0],[0],[False],['0']
11623,PMC3648471,12390,"Constant current was used for stimulation (1 ms, A395, WPI, Sarasota, USA) and extracellular signals were amplified (NPI, Tamm, Germany), filtered (30 Hz - 1.3 kHz), sampled (BNC 2120, National Instruments, USA) and stored to disk.",In vitro studies,[76454],[7875],[8106],[False],[0],[0],[False],['0']
11624,PMC3648471,12391,"Electrical excitability of myelinated axons was assessed using the TRONDXS4 protocol in QTRAC (© Prof. Bostock, Institute of Neurology, London, UK).",In vitro studies,[76455],[8107],[8255],[False],[0],[0],[False],['0']
11625,PMC3648471,12392,Clinical trial,Clinical trial,[76456],[8256],[8271],[False],[0],[0],[False],['0']
11626,PMC3648471,12393,"  Volunteers were recruited for a randomised, double-blind, placebo-controlled, two-way, cross-over clinical phase I trial (RCT) to investigate the effect of oral flupirtine on the electrical excitability of peripheral myelinated axons.",Clinical trial,[76457],[8272],[8508],[False],[0],[0],[False],['0']
11627,PMC3648471,12394,"Exclusion criteria were: ongoing medication, prevailing organic disease, previous forearm trauma, primary organ failure, pregnancy or breast-feeding.",Clinical trial,[76458],[8509],[8658],[False],[0],[0],[False],['0']
11628,PMC3648471,12395,"All female participants were subject to a pregnancy test (Cyclotest, UEBE, Wertheim, Germany) prior to inclusion.",Clinical trial,[76459],[8659],[8772],[False],[0],[0],[False],['0']
11629,PMC3648471,12396,"Subjects were assigned randomly to a study arm in accordance with an algorithm developed by the Institute of Medical Information Technology, Biometry and Epidemiology, University of Munich, Germany (IBE), stratifying for gender.",Clinical trial,[76460],[8773],[9001],[False],[0],[0],[False],['0']
11630,PMC3648471,12397,Subjects received a set of sealed sequentially numbered pill-boxes each containing either flupirtine or placebo tablets to be taken prior to the recording sessions.,Clinical trial,[76461],[9002],[9166],[False],[0],[0],[False],['0']
11631,PMC3648471,12398,Both the subjects and study physicians were blind to the group allocation.,Clinical trial,[76462],[9167],[9241],[False],[0],[0],[False],['0']
11632,PMC3648471,12399,Preliminary results indicated that a sample size of 12 would be needed to detect a decrease in the primary outcome measure (RRP) with 80% power at a significance level of 5%.,Clinical trial,[76463],[9242],[9416],[False],[0],[0],[False],['0']
11633,PMC3648471,12400,"With provision for drop-outs, 20 subjects were recruited, with an allocation ratio of 1:1.",Clinical trial,[76464],[9417],[9507],[False],[0],[0],[False],['0']
11634,PMC3648471,12401,Participants were evaluated on seven occasions in which motor axon excitability parameters and ischemic EMG signals were recorded (Additional file 1: Figure S1).,Clinical trial,[76465],[9508],[9669],[False],[0],[0],[False],['0']
11635,PMC3648471,12402,"The first 3 recording sessions, scheduled not less than 48 hours apart, were used to establish baseline values.",Clinical trial,[76466],[9670],[9781],[False],[0],[0],[False],['0']
11636,PMC3648471,12403,"The 4th recording session comprised 2 sequential recordings of axonal excitability, one immediately prior to pharmacologic intervention and a second two hours after.",Clinical trial,[76467],[9782],[9947],[False],[0],[0],[False],['0']
11637,PMC3648471,12404,EMG during ischemia was only recorded after medication.,Clinical trial,[76468],[9948],[10003],[False],[0],[0],[False],['0']
11638,PMC3648471,12405,The 5th session was a control recording performed 48 hours after the 4th.,Clinical trial,[76469],[10004],[10077],[False],[0],[0],[False],['0']
11639,PMC3648471,12406,The 6th recording session was scheduled 7 ± 1 days after the 5th and comprised 2 sequential recordings immediately before and 2 hours after medication.,Clinical trial,[76470],[10078],[10229],[False],[0],[0],[False],['0']
11640,PMC3648471,12407,The final (7th) recording session was a control recording performed 48 hours after the 6th.,Clinical trial,[76471],[10230],[10321],[False],[0],[0],[False],['0']
11641,PMC3648471,12408,"A pain questionnaire was assessed after the 3rd, the 4th and the 6th session.",Clinical trial,[76472],[10322],[10399],[False],[0],[0],[False],['0']
11642,PMC3648471,12409,"At the time of examination, subjects lay comfortably in a temperature controlled room.",Clinical trial,[76473],[10400],[10486],[False],[0],[0],[False],['0']
11643,PMC3648471,12410,  The primary outcome measure was the relative refractory period (RRP) as determined with threshold tracking.,Clinical trial,[76474],[10487],[10596],[False],[0],[0],[False],['0']
11644,PMC3648471,12411,All other indices were considered secondary outcome measures.,Clinical trial,[76475],[10597],[10658],[False],[0],[0],[False],['0']
11645,PMC3648471,12412,  All experiments were performed by the same examiner.,Clinical trial,[76476],[10659],[10713],[False],[0],[0],[False],['0']
11646,PMC3648471,12413,"Skin temperature was determined at the wrist at the end of each recording session using a thermocouple (Voltcraft, Hirschau, Germany).",Clinical trial,[76477],[10714],[10848],[False],[0],[0],[False],['0']
11647,PMC3648471,12414,The median nerve of the right hand was used for nerve excitability studies.,Clinical trial,[76478],[10849],[10924],[False],[0],[0],[False],['0']
11648,PMC3648471,12415,"A gel disc electrode (H92SG, Kendall-Arbo, Neustadt, Germany) positioned at the wrist between palmaris longus and flexor carpi radialis tendons served as the cathode.",Clinical trial,[76479],[10925],[11091],[False],[0],[0],[False],['0']
11649,PMC3648471,12416,The anode was placed over the course of the median nerve approximately 2 cm proximal to the cathode.,Clinical trial,[76480],[11092],[11192],[False],[0],[0],[False],['0']
11650,PMC3648471,12417,EMG from abductor pollicis brevis (APB) was recorded from one electrode situated over the motor point and a second electrode over the proximal interphalangeal joint.,Clinical trial,[76481],[11193],[11358],[False],[0],[0],[False],['0']
11651,PMC3648471,12418,"Constant current pulses (DS5, Digitimer, UK) were used to determine electrical excitability in QTRAC using the TRONDXM4 protocol with same measures as for in vitro experiments (see above).",Clinical trial,[76482],[11359],[11547],[False],[0],[0],[False],['0']
11652,PMC3648471,12419,"The EMG signal was amplified (gain 200-500x), filtered (bandpass 0.3 Hz to 10 kHz) and sampled at 50 kHz (BNC-2120, National Instruments, Austin, USA).",Clinical trial,[76483],[11548],[11699],[False],[0],[0],[False],['0']
11653,PMC3648471,12420,  A cuff around the upper arm inflated to >200mmHg was used to examine flupirtine and placebo effects on ischemic and post-ischemic EMG from APB.,Clinical trial,[76484],[11700],[11845],[False],[0],[0],[False],['0']
11654,PMC3648471,12421,Muscle fasciculations are known to appear in some subjects upon recovery from a 10 minute period of ischemia of the lower arm with the intensity and incidence increasing with the period of ischemia [23].,Clinical trial,[76485],[11846],[12049],[False],[0],[0],[False],['0']
11655,PMC3648471,12422,"EMG signals were filtered, amplified and sampled at 20 kHz (ADInstruments GmbH, Spechbach, Germany).",Clinical trial,[76486],[12050],[12150],[False],[0],[0],[False],['0']
11656,PMC3648471,12423,EMG was recorded continuously over a 21 minute period comprising one minute baseline followed by 10 minutes of ischemia and a further 10 minutes post-ischemia.,Clinical trial,[76487],[12151],[12310],[False],[0],[0],[False],['0']
11657,PMC3648471,12424,"Volunteers rated the intensity of sensations before, during and after ischemia on a visual analogue scale (0–100 mm with 0 being no pain and 100 being maximal pain) and completed the Short Form McGill Pain Questionnaire (SF-MPQ) for sensations experienced during the first 5 minutes following release of the pressure cuff, i.e.",Clinical trial,[76488],[12311],[12638],[False],[0],[0],[False],['0']
11658,PMC3648471,12425,post-ischemia.,Clinical trial,[76489],[12639],[12653],[False],[0],[0],[False],['0']
11659,PMC3648471,12426,The SF-MPQ comprises eleven sensory and four affective pain descriptors that can be ranked in intensity from 0 = none to 3 = severe[24].,Clinical trial,[76490],[12654],[12790],[False],[0],[0],[False],['0']
11660,PMC3648471,12427,"The sum of ranked values provides a sensory (SPRI; 0–33), an affective (APRI; 0–12) and a total pain score (TPRI; 0–45).",Clinical trial,[76491],[12791],[12911],[False],[0],[0],[False],['0']
11661,PMC3648471,12428,Data analysis,Data analysis,[76492],[12912],[12926],[False],[0],[0],[False],['0']
11662,PMC3648471,12429,  Electrical excitability of myelinated axons determined both in vitro and in vivo were analyzed off-line with the MEM routine in QTRAC.,Data analysis,[76493],[12927],[13063],[False],[0],[0],[False],['0']
11663,PMC3648471,12430,"Six parameters were taken directly from the QTRAC analysis, namely the strength-duration time constant, rheobase current, refractoriness at 2 and 2.5 ms, superexcitability at 5 and 7 ms and during the 90-100 ms hyperpolarizing and depolarizing current pulses of the threshold electrotonus.",Data analysis,[76494],[13064],[13353],[False],[0],[0],[False],['0']
11664,PMC3648471,12431,"The relative refractory period was determined using custom written software in Igor Pro (WaveMetrics, Lake Oswego, USA) by determining the first zero crossing of an exponential fit to recovery cycle data points less than 5 ms.",Data analysis,[76495],[13354],[13580],[False],[0],[0],[False],['0']
11665,PMC3648471,12432,  Rectified and integrated EMG was used to quantify continuous signals.,Data analysis,[76496],[13581],[13652],[False],[0],[0],[False],['0']
11666,PMC3648471,12433,EMG power was calculated by discrete fast Fourier transform (FFT) of EMG recorded in the time domain.,Data analysis,[76497],[13653],[13754],[False],[0],[0],[False],['0']
11667,PMC3648471,12434,Statistics,Statistics,[76498],[13755],[13766],[False],[0],[0],[False],['0']
11668,PMC3648471,12435,Mean and standard deviation are used for population descriptors while mean and standard error of the mean are indicated for comparisons between groups.,Statistics,[76499],[13767],[13918],[False],[0],[0],[False],['0']
11669,PMC3648471,12436,Normality was tested using Kolmogorov-Smirnov analysis.,Statistics,[76500],[13919],[13974],[False],[0],[0],[False],['0']
11670,PMC3648471,12437,For parametric datasets Student’s paired t-test was used for pairwise comparisons.,Statistics,[76501],[13975],[14057],[False],[0],[0],[False],['0']
11671,PMC3648471,12438,Unpaired datasets were compared using one-way ANOVA with post hoc Tukey-Kramer.,Statistics,[76502],[14058],[14137],[False],[0],[0],[False],['0']
11672,PMC3648471,12439,"Non-parametric datasets were analysed using Wilcoxon ranked sign test for paired data, and Kruskal-Wallis ANOVA with post hoc Mann–Whitney-U tests for non-paired data.",Statistics,[76503],[14138],[14305],[False],[0],[0],[False],['0']
11673,PMC3648471,12440,The level of statistical significance is indicated throughout with * for p < 0.05 and ** for p < 0.01.,Statistics,[76504],[14306],[14408],[False],[0],[0],[False],['0']
11674,PMC3648471,12441,Chemicals and drugs,Chemicals and drugs,[76505],[14409],[14429],[False],[0],[0],[False],['0']
11675,PMC3648471,12442,"Triton 100, natural goat serum and the monoclonal antibody against panNaV were purchased from Sigma-Aldrich (Munich, Germany), the monoclonal antibody against peripherin was obtained from Chemicon (EMD Millipore Corporation, Billerica, USA).",Chemicals and drugs,[76506],[14430],[14671],[False],[0],[0],[False],['0']
11676,PMC3648471,12443,"Anti-KCNQ2/Kv7.2 was kindly provided by M. Schwake (Kiel, Germany).",Chemicals and drugs,[76507],[14672],[14739],[False],[0],[0],[False],['0']
11677,PMC3648471,12444,"Fluorescein-and rhodamine-conjugated donkey cross-affinity-purified secondary antibodies were purchased from Invitrogen (Paisley, UK).",Chemicals and drugs,[76508],[14740],[14874],[False],[0],[0],[False],['0']
11678,PMC3648471,12445,"Aqua-Poly/Mount Coverslipping Medium was purchased from Polysciences Europe (Eppelheim, Germany).",Chemicals and drugs,[76509],[14875],[14972],[False],[0],[0],[False],['0']
11679,PMC3648471,12446,"Flupirtine (in vitro) was purchased from Sigma (Taufkirchen, Germany) and XE991 from Biotrend (Wangen, Switzerland).",Chemicals and drugs,[76510],[14973],[15089],[False],[0],[0],[False],['0']
11680,PMC3648471,12447,The final concentration of test substances used in vitro was achieved by diluting stock solutions in the perfusing solution on the day of the experiment.,Chemicals and drugs,[76511],[15090],[15243],[False],[0],[0],[False],['0']
11681,PMC3648471,12448,"Blinded oral preparations of flupirtine 100 mg (AWD.pharma GmbH & Co.KG, Radebeul, Germany) and placebo tablets (7 mm capsules (Winthrop Arzneimittel GmbH, Frankfurt, Germany) were performed by the Pharmaceutical Department, University of Munich encapsulating both in gelatine (size 00, white opaque; Shionogl Qualicaps S.A., Alcobendas / Madrid, Spain) containing lactose, ferric oxide and food colouring E172 (all Fagron GmbH, Barsbüttel, Germany).",Chemicals and drugs,[76512],[15244],[15694],[False],[0],[0],[False],['0']
11682,PMC3648471,12449,Results,Results,[76513],[15695],[15703],[False],[0],[0],[False],['0']
11683,PMC3648471,12450,Immunohistochemistry of human A-fibre,Results|Immunohistochemistry of human A-fibre,[76514],[15704],[15741],[False],[0],[0],[False],['0']
11684,PMC3648471,12451,"Using polyclonal antibodies, Kv7.2 subunits could be identified at nodes of Ranvier in teased fibre preparations of human sural nerve (Figure 1).",Results|Immunohistochemistry of human A-fibre,[76515],[15742],[15887],[False],[0],[0],[False],['0']
11685,PMC3648471,12452,"Nodes of Ranvier were identified using DIC images to delineate myelinating Schwann cells and co-labeling with mouse PanNa  (voltage-gated sodium channels, Figure 1 vi-viii).",Results|Immunohistochemistry of human A-fibre,[76516],[15888],[16061],[False],[0],[0],[False],['0']
11686,PMC3648471,12453,"Notably, Kv7.2 was also detected along unmyelinated fibres co-labeled with peripherin (Figure 1 iv, v).",Results|Immunohistochemistry of human A-fibre,[76517],[16062],[16165],[False],[0],[0],[False],['0']
11687,PMC3648471,12454,In vitro assessment of human A-fibre excitability,Results,[76518],[16166],[16216],[False],[0],[0],[False],['0']
11688,PMC3648471,12455,Recordings were made from twenty-one individual fascicles of human sural nerve.,Results,[76519],[16217],[16296],[False],[0],[0],[False],['0']
11689,PMC3648471,12456,"The average compound A-fibre response to supra-maximal electrical stimulation (0.1 ms, 11.03 ± 5.43 mA) was 4.97 ± 1.65 mV and had a latency to half-maximum of 0.82 ± 0.05 ms.",Results,[76520],[16297],[16472],[False],[0],[0],[False],['0']
11690,PMC3648471,12457,Pooled data for each electrical excitability parameter determined using the TRONDXS4 protocol in QTRAC is shown in Table 1.,Results,[76521],[16473],[16596],[False],[0],[0],[False],['0']
11691,PMC3648471,12458,"Under control conditions, the strength-duration time constant was 0.11 ± 0.02 μs and the rheobase current 8.53 ± 2.55 μA.",Results,[76522],[16597],[16718],[False],[0],[0],[False],['0']
11692,PMC3648471,12459,"ANOVA indicated that neither flupirtine (3-30 μM; strength-duration time constant F (3:43) 2.00, p = 0.13; rheobase F (3:43) 0.22, p = 0.88) nor XE991 (10 μM; strength-duration time constant F (1:26) 1.45, p = 0.24; rheobase F (1:26) 0.27, p = 0.87) had a significant effect on these indices of excitability.",Results,[76523],[16719],[17027],[False],[0],[0],[False],['0']
11693,PMC3648471,12460,"Similarly, threshold changes observed during application of depolarizing and hyperpolarizing conditioning currents were also not significantly affected by flupirtine (<30μM, see Table 1).",Results,[76524],[17028],[17215],[False],[0],[0],[False],['0']
11694,PMC3648471,12461,"Flupirtine (10-30 μM) did however reduce the RRP (ANOVA F (3:48) 8.61, p < 0.01) determined in human A-fibres in vitro and this in a concentration-dependent manner (see Figure 2B&C, Table 1; post-hoc Tukey-Kramer p < 0.01for 10 μM and 3 μM).",Results,[76525],[17216],[17457],[False],[0],[0],[False],['0']
11695,PMC3648471,12462,"Importantly, these effects could be reversed by bath application of the specific Kv7 channel blocker XE911 (10 μM; Figure 2 B&C and Table 1; ANOVA F (3:36) 7.46, p < 0.01; post-hoc Tukey-Kramer p < 0.05 for flupirtine 30 μM).",Results,[76526],[17458],[17683],[False],[0],[0],[False],['0']
11696,PMC3648471,12463,"Flupirtine (30 μM) also reduced refractoriness at 2.5 ms (Figure 2D; ANOVA F (3:48) 5.39, p < 0.01; post-hoc Tukey-Kramer p < 0.01).",Results,[76527],[17684],[17816],[False],[0],[0],[False],['0']
11697,PMC3648471,12464,"Similarly, flupirtine produced a concentration-dependent increase in the magnitude of post-spike superexcitability at 5 ms (Figure 2F and Table 1; ANOVA F (3:48) 11.56, p < 0.01; post-hoc Tukey-Kramer p < 0.01 for flupirtine 10 μM and 30 μM) and at 7 ms (Figure 2G; ANOVA F (3:48) 7.31, p < 0.01; post-hoc Tukey-Kramer p < 0.01 for flupirtine 30 μM).",Results,[76528],[17817],[18167],[False],[0],[0],[False],['0']
11698,PMC3648471,12465,"Since the RRP is determined from a fit to 3 or more data points, we consider this the most reliable index of changes in excitability.",Results,[76529],[18168],[18301],[False],[0],[0],[False],['0']
11699,PMC3648471,12466,In vivo assessment of human A-fibre excitability,In vitro assessment of human A-fibre excitability,[76530],[18302],[18351],[False],[0],[0],[False],['0']
11700,PMC3648471,12467,"Twenty volunteers (10 male, 10 female; age 28.3 ± 4.4 years) were randomly allocated to a study arm and received both placebo and flupirtine (200 mg p.o.)",In vitro assessment of human A-fibre excitability,[76531],[18352],[18506],[False],[0],[0],[False],['0']
11701,PMC3648471,12468,capsules to be taken in a cross-over design.,In vitro assessment of human A-fibre excitability,[76532],[18507],[18551],[False],[0],[0],[False],['0']
11702,PMC3648471,12469,The trial was enroled between October 2009 and August 2010.,In vitro assessment of human A-fibre excitability,[76533],[18552],[18611],[False],[0],[0],[False],['0']
11703,PMC3648471,12470,"None of the subjects dropped out, all subjects received the allocated interventions and the follow-up was complete.",In vitro assessment of human A-fibre excitability,[76534],[18612],[18727],[False],[0],[0],[False],['0']
11704,PMC3648471,12471,Statistical analysis of electrical excitability datasets from the initial three recording sessions revealed no time dependent differences in any of the excitability parameters and further comparisons between this ‘baseline’ dataset and each of the two pre interventional sessions also showed no differences amongst excitability parameters.,In vitro assessment of human A-fibre excitability,[76535],[18728],[19067],[False],[0],[0],[False],['0']
11705,PMC3648471,12472,"Consequently, all five baseline datasets were pooled and used as the baseline values for statistical comparisons.",In vitro assessment of human A-fibre excitability,[76536],[19068],[19181],[False],[0],[0],[False],['0']
11706,PMC3648471,12473,Compound muscle action potential (CMAP) responses were recorded from APB in response to supra-maximal electrical stimulation (4.40 ± 0.22 mA) in 20 volunteers.,In vitro assessment of human A-fibre excitability,[76537],[19182],[19341],[False],[0],[0],[False],['0']
11707,PMC3648471,12474,CMAPs had an amplitude of 8.59 ± 0.54 mV and a latency to half-maximum of 7.40 ± 0.22 ms.,In vitro assessment of human A-fibre excitability,[76538],[19342],[19431],[False],[0],[0],[False],['0']
11708,PMC3648471,12475,The strength-duration time constant was 0.48 ± 0.01 μs and the rheobase current 2.87 ± 0.14 mA.,In vitro assessment of human A-fibre excitability,[76539],[19432],[19527],[False],[0],[0],[False],['0']
11709,PMC3648471,12476,Neither flupirtine (200 mg p.o.),In vitro assessment of human A-fibre excitability,[76540],[19528],[19560],[False],[0],[0],[False],['0']
11710,PMC3648471,12477,nor placebo affected these measures of excitability (Table 2).,In vitro assessment of human A-fibre excitability,[76541],[19561],[19623],[False],[0],[0],[False],['0']
11711,PMC3648471,12478,"Consistent with observations made in vitro, RRP in motoaxons to APB was reduced 2 hours after oral flupirtine (200 mg p.o.",In vitro assessment of human A-fibre excitability,[76542],[19624],[19746],[False],[0],[0],[False],['0']
11712,PMC3648471,12479,"; baseline 3.40 ± 0.07 ms versus flupirtine 3.23 ± 0.09 ms; p < 0.01 paired t-test; see Figure 3B&C and Table 2) but not placebo (3.45 ± 0.12 ms, p = 0.53).",In vitro assessment of human A-fibre excitability,[76543],[19747],[19903],[False],[0],[0],[False],['0']
11713,PMC3648471,12480,Oral flupirtine also reduced refractoriness at 2 ms and 2.5 ms (Figure 3D&E and Table 2).,In vitro assessment of human A-fibre excitability,[76544],[19904],[19993],[False],[0],[0],[False],['0']
11714,PMC3648471,12481,"In contrast to the effect of flupirtine in vitro, the magnitude of superexcitability at both 5 and 7 ms determined in vivo was not affected by flupirtine (200 mg p.o; Figure 3F&G).",In vitro assessment of human A-fibre excitability,[76545],[19994],[20174],[False],[0],[0],[False],['0']
11715,PMC3648471,12482,Flupirtine and placebo were also both without effect on de- and hyperpolarizing threshold electrotonus in vivo (Table 2).,In vitro assessment of human A-fibre excitability,[76546],[20175],[20296],[False],[0],[0],[False],['0']
11716,PMC3648471,12483,Recordings from APB during ischemia,Recordings from APB during ischemia,[76547],[20297],[20332],[False],[0],[0],[False],['0']
11717,PMC3648471,12484,"Cuff-induced (200 mmHg) ischemia, induced a substantial increase in surface EMG activity in all 20 subjects (Figure 4A).",Recordings from APB during ischemia,[76548],[20333],[20453],[False],[0],[0],[False],['0']
11718,PMC3648471,12485,"EMG activity began on average 68.25 ± 8.72 s after cuff inflation and persisted for 288.65 ± 22.93 s. The total rectified integrated EMG during the baseline period of ischemia was 1.08 ± 0.12 V.s and this was reduced to 0.80 ± 0.08 V.s (p < 0.01, paired t-test) 2 hours after flupirtine (200 mg) but not placebo (0.98 ± 0.13 V.s; p = 0.29).",Recordings from APB during ischemia,[76549],[20454],[20794],[False],[0],[0],[False],['0']
11719,PMC3648471,12486,"Interestingly, in eleven subjects an increase in surface EMG was also observed in the post-ischemic period (Figure 4A).",Recordings from APB during ischemia,[76550],[20795],[20914],[False],[0],[0],[False],['0']
11720,PMC3648471,12487,"Post-ischemic EMG activity began on average 125.80 ± 21.11 s after release of the cuff, persisted for 295.20 ± 27.85 s and the total rectified integrated EMG in the 10 minute period following release of the cuff was 0.85 ± 0.10 V.s.",Recordings from APB during ischemia,[76551],[20915],[21147],[False],[0],[0],[False],['0']
11721,PMC3648471,12488,"Consistent with its effect on EMG activity in the peri-ischemic period, flupirtine also reduced total integrated EMG activity in the post-ischemic period (200 mg p.o.",Recordings from APB during ischemia,[76552],[21148],[21314],[False],[0],[0],[False],['0']
11722,PMC3648471,12489,"; 0.58 ± 0.05 V.s; p = 0.023 paired t-test, see Figure 4D&E) and this effect was not significant following placebo (0.72 ± 0.09 V.s; p = 0.24).",Recordings from APB during ischemia,[76553],[21315],[21458],[False],[0],[0],[False],['0']
11723,PMC3648471,12490,"Under baseline conditions, the surface EMG signal recorded in the post-ischemic period exhibited pronounced high frequency motor unit action potential discharges (MUAP; see insets in Figure 4A&D).",Recordings from APB during ischemia,[76554],[21459],[21654],[False],[0],[0],[False],['0']
11724,PMC3648471,12491,The uniformity of MUAP shape and grouping of these discharges suggest that they arose from repetitive discharges in single motor units.,Recordings from APB during ischemia,[76555],[21655],[21790],[False],[0],[0],[False],['0']
11725,PMC3648471,12492,The incidence of such high frequency burst discharges was higher in the post-ischemic period than during ischemia.,Recordings from APB during ischemia,[76556],[21791],[21905],[False],[0],[0],[False],['0']
11726,PMC3648471,12493,This is evident in the running power spectral density plots shown below the raw EMG traces in Figure 4A&D.,Recordings from APB during ischemia,[76557],[21906],[22012],[False],[0],[0],[False],['0']
11727,PMC3648471,12494,"Following flupirtine, post-ischemic high frequency repetitive discharges are also evident in surface EMG recordings however the length of each burst was curtailed (Figure 4D, inset).",Recordings from APB during ischemia,[76558],[22013],[22195],[False],[0],[0],[False],['0']
11728,PMC3648471,12495,The tendency for flupirtine to curtail high frequency motor unit discharge is shown in the normalised power spectral density plots (PSD; Figure 4C&F) where the relative power in the 150-200Hz band for post-ischemic discharge is reduced following flupirtine (Figure 4F).,Recordings from APB during ischemia,[76559],[22196],[22465],[False],[0],[0],[False],['0']
11729,PMC3648471,12496,Assessment of sensations during and after ischemia,Assessment of sensations during and after ischemia,[76560],[22466],[22517],[False],[0],[0],[False],['0']
11730,PMC3648471,12497,Cuff-induced ischemia affects both motor and sensory axons.,Assessment of sensations during and after ischemia,[76561],[22518],[22577],[False],[0],[0],[False],['0']
11731,PMC3648471,12498,"To assess the sensory component, a visual analogue scale (VAS) was used to rate the intensity of painful sensations during and after ischemia.",Assessment of sensations during and after ischemia,[76562],[22578],[22720],[False],[0],[0],[False],['0']
11732,PMC3648471,12499,The VAS comprised a 0 point anchor indicating no pain and an anchor at 100 as the most intense pain imaginable.,Assessment of sensations during and after ischemia,[76563],[22721],[22832],[False],[0],[0],[False],['0']
11733,PMC3648471,12500,"Averaged across three baseline recordings, pain was rated at 31.1 ± 20.9 mm during ischemia and 33.2 ± 25.4 mm in the postischemic period (Figure 5A).",Assessment of sensations during and after ischemia,[76564],[22833],[22983],[False],[0],[0],[False],['0']
11734,PMC3648471,12501,"Two hours after oral flupirtine (200 mg) the average ischemic pain rating was 23.2 ± 16.8 mm VAS, (p = 0.12 paired t-test) and 19.6 ± 20.3 mm in the post-ischemic period (-41%, p = 0.03).",Assessment of sensations during and after ischemia,[76565],[22984],[23171],[False],[0],[0],[False],['0']
11735,PMC3648471,12502,"Oral placebo did not change either the ischemic (30.5 ± 20.6 mm VAS, -1.7%, p = 0.70 paired t-test) nor the post-ischemic pain rating (32.8 ± 27.1 mm VAS, -1.2%, p = 0.69; Figure 5A).",Assessment of sensations during and after ischemia,[76566],[23172],[23355],[False],[0],[0],[False],['0']
11736,PMC3648471,12503,The SF-MPQ was used to assess the intensity and quality of sensations arising in the 10 minute period following release of the cuff.,Assessment of sensations during and after ischemia,[76567],[23356],[23488],[False],[0],[0],[False],['0']
11737,PMC3648471,12504,"Under baseline conditions, total rating index in the postischemic period was 14.1 ± 1.5 with a sensory and affective component scores of 11.0 ± 1.2 and 3.1 ± 3.0 respectively (Figure 5B).",Assessment of sensations during and after ischemia,[76568],[23489],[23676],[False],[0],[0],[False],['0']
11738,PMC3648471,12505,Two hours after flupirtine (200 mg p.o.),Assessment of sensations during and after ischemia,[76569],[23677],[23717],[False],[0],[0],[False],['0']
11739,PMC3648471,12506,"the total intensity rating (−45% to 7.8 ± 1.0, p < 0.01, paired t-test) and sensory component scores were reduced (-48%, 5.8 ± 0.7, p < 0.01, paired t-test).",Assessment of sensations during and after ischemia,[76570],[23718],[23875],[False],[0],[0],[False],['0']
11740,PMC3648471,12507,"In contrast, total intensity ratings were not affected 2 hours after oral placebo (12.0 ± 1.3, p = 0.25, Figure 5B).",Assessment of sensations during and after ischemia,[76571],[23876],[23992],[False],[0],[0],[False],['0']
11741,PMC3648471,12508,The SF-MPQ offers descriptors to qualitatively describe sensations.,Assessment of sensations during and after ischemia,[76572],[23993],[24060],[False],[0],[0],[False],['0']
11742,PMC3648471,12509,"Under baseline conditions, the average rating of ‘throbbing’, ‘shooting’, ’stabbing’, ‘sharp’ and ‘hot-burning’ during ischemia was mild-moderate (Figure 5C).",Assessment of sensations during and after ischemia,[76573],[24061],[24219],[False],[0],[0],[False],['0']
11743,PMC3648471,12510,"For the affective descriptors, only ‘sickening’ was rated as moderate.",Assessment of sensations during and after ischemia,[76574],[24220],[24290],[False],[0],[0],[False],['0']
11744,PMC3648471,12511,Two hours after oral flupirtine (200 mg p.o.),Assessment of sensations during and after ischemia,[76575],[24291],[24336],[False],[0],[0],[False],['0']
11745,PMC3648471,12512,the ratings of ‘hot-burning’ (p < 0.01 Kruskal-Wallis) and ‘throbbing’(p = 0.04) were reduced from moderate to mild.,Assessment of sensations during and after ischemia,[76576],[24337],[24453],[False],[0],[0],[False],['0']
11746,PMC3648471,12513,Discussion,Discussion,[76577],[24454],[24465],[False],[0],[0],[False],['0']
11747,PMC3648471,12514,Strength and limitations,Discussion|Strength and limitations,[76578],[24466],[24490],[False],[0],[0],[False],['0']
11748,PMC3648471,12515,The primary strength of this study examining drug-induced effects on axonal excitability in vivo and in vitro is the ability to compare and thus judge target engagement and the efficacy of pharmacological compounds on peripheral myelinated axons.,Discussion|Strength and limitations,[76579],[24491],[24737],[False],[0],[0],[False],['0']
11749,PMC3648471,12516,"In particular, the ability to expose nerve segments to high concentrations provides a basis for the interpretation of subtle changes in excitability detected in people in situ, where dose is limited.",Discussion|Strength and limitations,[76580],[24738],[24937],[False],[0],[0],[False],['0']
11750,PMC3648471,12517,Segments of human nerve material were obtained at biopsy and are thus potentially pathological.,Discussion|Strength and limitations,[76581],[24938],[25033],[True],['ValidityOfMeasurement'],['Segments of human nerve material were obtained at biopsy and are thus potentially pathological'],[True],['OutcomeMeasures']
11751,PMC3648471,12518,"Previous experiments indicate however that the electrical excitability of nerve fascicles obtained from patients at biopsy is not correlated in a systematic way with the underlying pathology [25,26].",Discussion|Strength and limitations,[76582],[25034],[25233],[False],[0],[0],[False],['0']
11752,PMC3648471,12519,Generalizability,Generalizability,[76583],[25234],[25251],[False],[0],[0],[False],['0']
11753,PMC3648471,12520,A common deficit encountered during the clinical and pre-clinical development phases of pharmacological compounds targeting peripheral nerve is the inability to determine directly the axonal effects in people.,Generalizability,[76584],[25252],[25461],[False],[0],[0],[False],['0']
11754,PMC3648471,12521,"To address this, standardized measures of axonal excitability were used to examine the effect of flupritine on human peripheral nerve in vitro and in situ.",Generalizability,[76585],[25462],[25617],[False],[0],[0],[False],['0']
11755,PMC3648471,12522,Demonstrable changes in the excitability of myelinated axons were observed in vitro (Figure 2) and in motoraxons in situ (Figure 3).,Generalizability,[76586],[25618],[25750],[False],[0],[0],[False],['0']
11756,PMC3648471,12523,This confirmation of target engagement was shown to be therapeutically relevant with flupirtine suppressing ectopic axonal activity evoked by ischemia (Figure 4).,Generalizability,[76587],[25751],[25913],[False],[0],[0],[False],['0']
11757,PMC3648471,12524,Interpretation,Interpretation,[76588],[25914],[25929],[False],[0],[0],[False],['0']
11758,PMC3648471,12525,"Kv7.2 subunits were identified nodally in large diameter myelinated axons in human sural nerve (Figure 1) consistent with previous reports using myelinated rat axons [6,8,9].",Interpretation,[76589],[25930],[26104],[False],[0],[0],[False],['0']
11759,PMC3648471,12526,Kv7.2 expression was also evident along unmyelinated axons [27] where it is also postulated to regulate excitability (6) and suppress axonal discharge [28].,Interpretation,[76590],[26105],[26261],[False],[0],[0],[False],['0']
11760,PMC3648471,12527,"From voltage clamp studies performed on single nodes of Ranvier of myelinated axons from human nerve, it is possible that up to 30% of the slow potassium current may be active at rest [6].",Interpretation,[76591],[26262],[26450],[False],[0],[0],[False],['0']
11761,PMC3648471,12528,"Since, flupirtine shifts the voltage-dependent activation of cell-expressed Kv7.2 in the hyperpolarizing direction [29] it would be expected to hyperpolarize axons by increasing the number of open Kv7 channels at resting membrane potentials around −60 to −70 mV.",Interpretation,[76592],[26451],[26713],[False],[0],[0],[False],['0']
11762,PMC3648471,12529,"For the human myelinated axons examined here, flupirtine (3-30μM) produced a concentration-dependent shortening of the relative refractory period and an increase in post-spike superexcitability in vitro, as well as a comparable reduction in the RRP in vivo (2 hours after oral flupirtine)..",Interpretation,[76593],[26714],[27004],[False],[0],[0],[False],['0']
11763,PMC3648471,12530,"The increase in post-spike superexcitability seen in vitro (Figure 2C) was only apparent for flupirtine concentrations above 10 μM (Figure 2F,G).",Interpretation,[76594],[27005],[27150],[False],[0],[0],[False],['0']
11764,PMC3648471,12531,"Previous reports indicate that the peak plasma concentration of flupirtine reaches values in the range of 5 to 6.5 μM, 2 hours after oral flupirtine 200 mg; [30-32].",Interpretation,[76595],[27151],[27316],[False],[0],[0],[False],['0']
11765,PMC3648471,12532,"This concentration is below that at which effects can be detected in vitro and potentially accounts for the lack of effect of flupirtine on the superexcitable phase in motor axons as well as the modest effect of flupirtine on the RRP in vivo (Figure 3B,C).",Interpretation,[76596],[27317],[27573],[False],[0],[0],[False],['0']
11766,PMC3648471,12533,"The modest reduction in the value of the relative refractory period in motoraxons to APB may well be secondary to a change in temperature, specifically a warming of peripheral nerve.",Interpretation,[76597],[27574],[27756],[False],[0],[0],[False],['0']
11767,PMC3648471,12534,Propofol was recently reported to shorten the relative refractory period in motoaxons and this effect was attributed to a non-specific increase in skin temperature [33].,Interpretation,[76598],[27757],[27926],[False],[0],[0],[False],['0']
11768,PMC3648471,12535,"Although no global differences in skin temperature were detected between baseline, placebo and flupirtine recording sessions, flupirtine could potentially lead to a warming of peripheral nerve either directly by relaxing vascular smooth muscle [34] or indirectly through suppression of activity in sympathetic neurones [35].",Interpretation,[76599],[27927],[28251],[False],[0],[0],[False],['0']
11769,PMC3648471,12536,The only other study examining the effects of flupirtine on peripheral axons in people used a 400 mg oral dose and they reported no change in soleus H-reflex latency but a reduction in medium latency flexor reflex responses evoked with 5 pulses at 200 Hz [36].,Interpretation,[76600],[28252],[28512],[False],[0],[0],[False],['0']
11770,PMC3648471,12537,It is possible that this effect of flupirtine reflects the ability of slow axonal potassium channels to suppress high frequency discharge.,Interpretation,[76601],[28513],[28651],[False],[0],[0],[False],['0']
11771,PMC3648471,12538,Flupirtine is however also reported to act as an agonist at GABA  receptors in DRG neurones [37].,Interpretation,[76602],[28652],[28749],[False],[0],[0],[False],['0']
11772,PMC3648471,12539,"While an agonist action of flupritine at GABA  receptors may contribute to flupritine’s ability to alter spinal reflex latency, peripheral axons maintain a high intra-axonal chloride concentration and thus activation of GABA  receptors alone cannot account for an increase in post-spike superexcitability or a shortening of the relative refractory period in peripheral myelinated axons.",Interpretation,[76603],[28750],[29136],[False],[0],[0],[False],['0']
11773,PMC3648471,12540,"Interestingly, post-spike recovery cycles recorded from myelinated sural nerve axons in vitro (Figure 1B) appear to lack the late phase of sub-excitability (between ca.",Interpretation,[76604],[29137],[29305],[False],[0],[0],[False],['0']
11774,PMC3648471,12541,7 and 100 ms) which is otherwise prominent in recovery cycles from median nerve motor axons in vivo (Figure 2B).,Interpretation,[76605],[29306],[29418],[False],[0],[0],[False],['0']
11775,PMC3648471,12542,"Recordings in people indicate that late sub-normality is typically smaller in sural nerve than it is in median nerve [38] and that, sural axons thus have less slow nodal potassium channels (Kv7) [38].",Interpretation,[76606],[29419],[29619],[False],[0],[0],[False],['0']
11776,PMC3648471,12543,"Post-ischemic EMG activity arises axonally [39,40] and for a 10 minute period of ischemia affects predominantly myelinated axons [41,42].",Interpretation,[76607],[29620],[29757],[False],[0],[0],[False],['0']
11777,PMC3648471,12544,"In myelinated sensory axons, ectopic activity produces paraesthesias and in motor axons fasciculations are observed [42], with the former being more susceptible due to a more pronounced persistent nodal sodium current [43].",Interpretation,[76608],[29758],[29981],[False],[0],[0],[False],['0']
11778,PMC3648471,12545,"During the period of ischemia, ectopic activity in myelinated axons is typically attributed to a protracted axonal depolarization arising chiefly from a reduction in electrogenic Na+/K+-ATPase activity and possibly a resultant accumulation of extracellular potassium, particularly in the adaxonal space [44].",Interpretation,[76609],[29982],[30290],[False],[0],[0],[False],['0']
11779,PMC3648471,12546,"Activation of slowly activating, non-inactivating Kv7 channels by flupirtine should adequately counter slow depolarization and indeed flupirtine effectively reduced total EMG activity during ischemia (Figure 4).",Interpretation,[76610],[30291],[30502],[False],[0],[0],[False],['0']
11780,PMC3648471,12547,Post-ischemic EMG activity comprises high frequency components (Figure 4) and microneurographic recordings from myelinated axons in people following ischemia also show prominent high frequency burst discharges ca.,Interpretation,[76611],[30503],[30716],[False],[0],[0],[False],['0']
11781,PMC3648471,12548,"200 Hz; [41,42].",Interpretation,[76612],[30717],[30733],[False],[0],[0],[False],['0']
11782,PMC3648471,12549,"Although high frequency bursts still occurred in the post-ischemic period following flupirtine, there was a reduction in the burst duration, i.e.",Interpretation,[76613],[30734],[30879],[False],[0],[0],[False],['0']
11783,PMC3648471,12550,number of impulses (Figure 4).,Interpretation,[76614],[30880],[30910],[False],[0],[0],[False],['0']
11784,PMC3648471,12551,Flupirtine’s (200 mg p.o) curtailing of action potential burst length in human motoneurones is consistent with previous observations in rat peripheral myelinated axons using retigabine [6] and hippocampal CA1 neurones [45] and suggests that flupirtine may be beneficial in limiting the duration of ectopic bursts in peripheral axons.,Interpretation,[76615],[30911],[31244],[False],[0],[0],[False],['0']
11785,PMC3648471,12552,"Changes in the excitability of peripheral myelinated axons in people (Figures 2 and 3) were comparable with those seen in vitro using human sural nerve segments, suggesting that flupirtine affects Kv7 subunits expressed in peripheral nerve.",Interpretation,[76616],[31245],[31485],[False],[0],[0],[False],['0']
11786,PMC3648471,12553,Conclusion and clincial implications,Conclusion and clincial implications,[76617],[31486],[31523],[False],[0],[0],[False],['0']
11787,PMC3648471,12554,The synthetic Kv7-channel activator flupirtine has been used clinically in Europe for over two decades and its analgesic effects have long been associated with an action on neurones in the CNS.,Conclusion and clincial implications,[76618],[31524],[31717],[False],[0],[0],[False],['0']
11788,PMC3648471,12555,"Using a unique combination of in vitro and in vivo methodologies, the clinical profile of flupirtine is shown here to extend to effects on peripheral myelinated axons, reducing their excitability and suppressing aberrant post-ischemic axonal discharge.",Conclusion and clincial implications,[76619],[31718],[31970],[False],[0],[0],[False],['0']
11789,PMC3648471,12556,This highlights the potential benefit of Kv7 channel activators for clinical strategies aimed at reducing hyperexcitability and ectopic discharge in peripheral axons.,Conclusion and clincial implications,[76620],[31971],[32137],[False],[0],[0],[False],['0']
11790,PMC3648471,12557,Competing interest,Competing interest,[76621],[32138],[32157],[False],[0],[0],[False],['0']
11791,PMC3648471,12558,The authors declare that they have no competing interests.,Competing interest,[76622],[32158],[32216],[False],[0],[0],[False],['0']
11792,PMC3648471,12559,Authors’ contributions,Authors’ contributions,[76623],[32217],[32240],[False],[0],[0],[False],['0']
11793,PMC3648471,12560,"JF conceived of the study, performed the experiments, analyzed the data and wrote the manuscript.",Authors’ contributions,[76624],[32241],[32338],[False],[0],[0],[False],['0']
11794,PMC3648471,12561,"RS conceived of the study, performed the experiments, analyzed the data and wrote the manuscript.",Authors’ contributions,[76625],[32339],[32436],[False],[0],[0],[False],['0']
11795,PMC3648471,12562,"BA carried out the immunohistochemical experiments, analyzed the data and and helped to draft the manuscript.",Authors’ contributions,[76626],[32437],[32546],[False],[0],[0],[False],['0']
11796,PMC3648471,12563,"PML conceived of the study, and participated in its design and coordination.",Authors’ contributions,[76627],[32547],[32623],[False],[0],[0],[False],['0']
11797,PMC3648471,12564,"DI conceived of the study, and participated in its design and coordination.",Authors’ contributions,[76628],[32624],[32699],[False],[0],[0],[False],['0']
11798,PMC3648471,12565,"RWC conceived of the study, performed the experiments, analyzed the data and wrote the manuscript.",Authors’ contributions,[76629],[32700],[32798],[False],[0],[0],[False],['0']
11799,PMC3648471,12566,All authors read and approved the final manuscript.,Authors’ contributions,[76630],[32799],[32850],[False],[0],[0],[False],['0']
11800,PMC3648471,12567,Acknowledgments,Acknowledgments,[76631],[32851],[32868],[False],[0],[0],[False],['0']
11801,PMC3648471,12568,"We would like to thank Prof. Michael Schwake, PhD, Assistant Professor at the Unit of Molecular Cell Biology and Transgenic Research, Institute of Biochemistry, University of Kiel, for the primary Kv7.2 antibody.",Acknowledgments,[76632],[32869],[33081],[False],[0],[0],[False],['0']
11802,PMC3648471,12569,We want to thank all the volunteers who participated in this trial.Funding,Acknowledgments,[76633],[33082],[33156],[False],[0],[0],[False],['0']
11803,PMC3648471,12570,This work was supported by the Ludwig-Maximilians-University of Munich (FöFoLe 650 awarded to JF).,Acknowledgments,[76634],[33157],[33255],[False],[0],[0],[False],['0']
13629,PMC3851000,24541,"Randomized controlled trial of Family Nurture Intervention in the NICU: assessments of length of stay, feasibility and safety",Title,[143694],[32623],[125],[False],[0],[0],[False],['0']
13630,PMC3851000,24542,Background,Abstract,[143699],[126],[137],[False],[0],[0],[False],['0']
13631,PMC3851000,24543,"While survival rates for preterm infants have increased, the risk for adverse long-term neurodevelopmental and behavioral outcomes remains very high.",Abstract,[143704],[138],[287],[False],[0],[0],[False],['0']
13632,PMC3851000,24544,"In response to the need for novel, evidence-based interventions that prevent such outcomes, we have assessed Family Nurture Intervention (FNI), a novel dual mother-infant intervention implemented while the infant is in the Neonatal Intensive Care Unit (NICU).",Abstract,[143709],[288],[547],[False],[0],[0],[False],['0']
13633,PMC3851000,24545,"Here, we report the first trial results, including the primary outcome measure, length of stay in the NICU and, the feasibility and safety of its implementation in a high acuity level IV NICU.",Abstract,[143714],[548],[740],[False],[0],[0],[False],['0']
13634,PMC3851000,24546,Methods,Abstract,[143719],[741],[748],[False],[0],[0],[False],['0']
13635,PMC3851000,24547,"The FNI trial is a single center, parallel-group, randomized controlled trial at Morgan Stanley Children’s Hospital for mothers and their singleton or twin infants of 26–34 weeks gestation.",Abstract,[143724],[749],[938],[False],[0],[0],[False],['0']
13636,PMC3851000,24548,Families were randomized to standard care (SC) or (FNI).,Abstract,[143729],[939],[995],[False],[0],[0],[False],['0']
13637,PMC3851000,24549,FNI was implemented by nurture specialists trained to facilitate affective communication between mother and infant during specified calming interactions.,Abstract,[143734],[996],[1149],[False],[0],[0],[False],['0']
13638,PMC3851000,24550,"These interactions included scent cloth exchange, sustained touch, vocal soothing and eye contact, wrapped or skin-to-skin holding, plus family-based support interactions.",Abstract,[143739],[1150],[1321],[False],[0],[0],[False],['0']
13639,PMC3851000,24551,Results,Abstract,[143744],[1322],[1329],[False],[0],[0],[False],['0']
13640,PMC3851000,24552,A total of 826 infants born between 26 and 34 weeks during the 3.5 year study period were admitted to the NICU.,Abstract,[143749],[1330],[1441],[False],[0],[0],[False],['0']
13641,PMC3851000,24553,"After infant and mother screening plus exclusion due to circumstances that prevented the family from participating, 373 infants were eligible for the study.",Abstract,[143754],[1442],[1598],[False],[0],[0],[False],['0']
13642,PMC3851000,24554,"Of these, we were unable to schedule a consent meeting with 56, and consent was withheld by 165.",Abstract,[143759],[1599],[1695],[False],[0],[0],[False],['0']
13643,PMC3851000,24555,Consent was obtained for 150 infants from 115 families.,Abstract,[143764],[1696],[1751],[False],[0],[0],[False],['0']
13644,PMC3851000,24556,"The infants were block randomized to groups of N = 78, FNI and N = 72, SC.",Abstract,[143769],[1752],[1826],[False],[0],[0],[False],['0']
13645,PMC3851000,24557,"Sixteen (9.6%) of the randomized infants did not complete the study to home discharge, 7% of those randomized to SC and 12% of FNI infants.",Abstract,[143774],[1827],[1966],[False],[0],[0],[False],['0']
13646,PMC3851000,24558,Mothers in the intervention group engaged in 3 to 4 facilitated one- to two-hour sessions/week.,Abstract,[143779],[1967],[2062],[False],[0],[0],[False],['0']
13647,PMC3851000,24559,Intent to treat analyses revealed no significant difference between groups in medical complications.,Abstract,[143784],[2063],[2163],[False],[0],[0],[False],['0']
13648,PMC3851000,24560,The mean length of stay was not significantly affected by the intervention.,Abstract,[143789],[2164],[2239],[False],[0],[0],[False],['0']
13649,PMC3851000,24561,Conclusion,Abstract,[143794],[2240],[2250],[False],[0],[0],[False],['0']
13650,PMC3851000,24562,"There was no significant effect demonstrated with this intervention amount on the primary short-term outcome, length of stay.",Abstract,[143799],[2251],[2376],[False],[0],[0],[False],['0']
13651,PMC3851000,24563,FNI can be safely and feasibly implemented within a level IV NICU.,Abstract,[143804],[2377],[2443],[False],[0],[0],[False],['0']
13652,PMC3851000,24564,Trial registration,Abstract,[143809],[2444],[2462],[False],[0],[0],[False],['0']
13653,PMC3851000,24565,Clinicaltrials.gov: NCT01439269,Abstract,[143814],[2463],[2494],[False],[0],[0],[False],['0']
13654,PMC3851000,24566,Background,Background,[143819],[2495],[2506],[False],[0],[0],[False],['0']
13655,PMC3851000,24567,Survival rates of preterm infants have increased with improved care and technology over the past 20 years.,Background,[143824],[2507],[2613],[False],[0],[0],[False],['0']
13656,PMC3851000,24568,"Yet, the risks for long-term adverse neurodevelopmental and behavioral outcomes remain unacceptably high.",Background,[143829],[2614],[2719],[False],[0],[0],[False],['0']
13657,PMC3851000,24569,"These include attention deficits [1], executive dysfunction [2,3], depression and psychotic disorders [4], and autism spectrum disorder [5].",Background,[143834],[2720],[2860],[False],[0],[0],[False],['0']
13658,PMC3851000,24570,"Accordingly, there have been increasing calls for novel evidence-based interventions that can that can limit or overcome long-term developmental morbidities that accompany preterm birth [6,7], as well as for more rigorous randomized controlled trials (RCTs) to validate the results [8].",Background,[143839],[2861],[3147],[False],[0],[0],[False],['0']
13659,PMC3851000,24571,"In addition to several new pharmaceutical and medical interventions, there have been many interventions aimed at improving outcomes for the infant through enrichment of the infant’s NICU environment, including increased parent involvement in infant care [9].",Background,[143844],[3148],[3406],[False],[0],[0],[False],['0']
13660,PMC3851000,24572,"The best studied of these latter approaches are Newborn Developmental Care and Assessment Program (NIDCAP) [10,11], skin-to-skin care [12,13], and massage therapy [14-16].",Background,[143849],[3407],[3578],[False],[0],[0],[False],['0']
13661,PMC3851000,24573,"However, for a variety of reasons that may include cost of implementation, demand on resources, insufficient evidence for long-term effectiveness and resistance to change, these NICU interventions have yet to be universally adopted.",Background,[143854],[3579],[3811],[False],[0],[0],[False],['0']
13662,PMC3851000,24574,The Family Nurture Intervention (FNI) protocol was designed to induce a connection between the mother and her preterm infant as early as possible and to engage support from the husband and family members in these efforts in order to alter the developmental trajectory of the preterm infant.,Background,[143859],[3812],[4102],[False],[0],[0],[False],['0']
13663,PMC3851000,24575,Our hypothesis was that one of the earliest consequences of this change in trajectory would be a decrease in length of stay.,Background,[143864],[4103],[4227],[False],[0],[0],[False],['0']
13664,PMC3851000,24576,"While some aspects of FNI are similar to other mother-infant interventions, several aspects make FNI novel.",Background,[143869],[4228],[4335],[False],[0],[0],[False],['0']
13665,PMC3851000,24577,FNI focuses on the mother and infant as a dyad and therefore seeks to positively effect a change in the co-regulatory relationship between infant and mother.,Background,[143874],[4336],[4493],[False],[0],[0],[False],['0']
13666,PMC3851000,24578,FNI does this by facilitating affective communication and an emotional connection between the two.,Background,[143879],[4494],[4592],[False],[0],[0],[False],['0']
13667,PMC3851000,24579,"It does so in the very early stages of NICU care when infants are confined to the incubator by using scent cloth exchange, sustained touch, vocal soothing and eye contact.",Background,[143884],[4593],[4764],[False],[0],[0],[False],['0']
13668,PMC3851000,24580,"At later stages, when the infants are stable and can remain outside the incubator, FNI facilitates wrapped or skin-to-skin holding and as much engagement of mothers in daily infant care as possible.",Background,[143889],[4765],[4963],[False],[0],[0],[False],['0']
13669,PMC3851000,24581,"Throughout the hospitalization, FNI facilitates family-based support for mother-infant interactions.",Background,[143894],[4964],[5064],[False],[0],[0],[False],['0']
13670,PMC3851000,24582,There are several notable differences between our intervention and trial design and those mentioned above.,Background,[143899],[5065],[5171],[False],[0],[0],[False],['0']
13671,PMC3851000,24583,None of these studies have examined the effects of facilitated affective communication between mother and infant using an RCT design.,Background,[143904],[5172],[5305],[False],[0],[0],[False],['0']
13672,PMC3851000,24584,"Furthermore, no other trial has specifically identified the “Calming Cycle” [17] as the central intervention feature.",Background,[143909],[5306],[5423],[False],[0],[0],[False],['0']
13673,PMC3851000,24585,"And, in surveying the literature, few trials incorporate strategies that increase mother-infant interactions early in the NICU while the infant is confined to the isolette, fewer still that aim at providing the mother and family with a parenting strategy that can be employed throughout infant development at home.",Background,[143914],[5424],[5738],[False],[0],[0],[False],['0']
13674,PMC3851000,24586,"In this first report of our RCT, we present the primary outcome (length of stay; LOS) [17,18].",Background,[143919],[5739],[5833],[False],[0],[0],[False],['0']
13675,PMC3851000,24587,"Length of stay was chosen because we thought it would be an early maker for effectiveness of the intervention, and because it has been an important outcome variable for other NICU intervention studies, including NIDCAP, kangaroo care and massage therapy [8,13,16], though results were not always consistent.",Background,[143924],[5834],[6141],[False],[0],[0],[False],['0']
13676,PMC3851000,24588,"In addition, the cost/day of moderately preterm infants (32–34 weeks GA) has been estimated at $1734/day [19].",Background,[143929],[6142],[6252],[False],[0],[0],[False],['0']
13677,PMC3851000,24589,"Thus, any decrease in LOS associated with FNI could present a significant economic benefit.",Background,[143934],[6253],[6344],[False],[0],[0],[False],['0']
13678,PMC3851000,24590,"In contrast, an increase in LOS could negatively impact adoption of the intervention.",Background,[143939],[6345],[6430],[False],[0],[0],[False],['0']
13679,PMC3851000,24591,This first report also addresses concerns raised prior to the start of the trial about the safety of FNI for this fragile patient group and the possibility that this intervention could increase infection and complications due to increased touch and scent cloth exchange.,Background,[143944],[6431],[6701],[False],[0],[0],[False],['0']
13680,PMC3851000,24592,"Thus, assessing safety and feasibility was an essential component of this trial and results will guide the development of NICU interventions by us and others, and at the same time expand our understanding of what minimal risk approaches can be tolerated by premature infants, their parents and, very importantly, the NICU staff.",Background,[143949],[6702],[7030],[False],[0],[0],[False],['0']
13681,PMC3851000,24593,We report here that FNI did not significantly affect length of stay in the NICU.,Background,[143954],[7031],[7111],[False],[0],[0],[False],['0']
13682,PMC3851000,24594,Results show that FNI is practicable within a level IV NICU environment and is safe for preterm infants born between 26 and 34 weeks of gestation.,Background,[143959],[7112],[7258],[False],[0],[0],[False],['0']
13683,PMC3851000,24595,Methods,Methods,[143964],[7259],[7267],[False],[0],[0],[False],['0']
13684,PMC3851000,24596,"This study is a single center, parallel-group RCT.",Methods,[143969],[7268],[7318],[False],[0],[0],[False],['0']
13685,PMC3851000,24597,"Full details of the trial design, methods, outcome measures, and hypotheses have been published elsewhere [17].",Methods,[143974],[7319],[7430],[False],[0],[0],[False],['0']
13686,PMC3851000,24598,"A sample size of 150 (75 per group) was projected to have power of 1-β = .8, with significance level α = .05 and a medium effect size of approximately d = 0.4.",Methods,[143979],[7431],[7590],[False],[0],[0],[False],['0']
13687,PMC3851000,24599,"This was determined to be sufficient to detect a group difference of 5.3 days in length of hospital stay from admission to the NICU until discharge home [18], and also gave sufficient power for secondary outcome analyses [17].",Methods,[143984],[7591],[7817],[False],[0],[0],[False],['0']
13688,PMC3851000,24600,"As reported in the manuscript, all infants included in this RCT were between 26 and 35 GA.",Methods,[143989],[7818],[7908],[False],[0],[0],[False],['0']
13689,PMC3851000,24601,The original protocol restricted the gestational ages of the infants to 26 to 32 weeks.,Methods,[143994],[7909],[7996],[False],[0],[0],[False],['0']
13690,PMC3851000,24602,"After a few months, we decided to increase the age to 35 weeks in order to increase enrollment.",Methods,[143999],[7997],[8092],[False],[0],[0],[False],['0']
13691,PMC3851000,24603,"At the same, we decided to conduct a small pilot study in late preterm infants (34 - 35 weeks) using the same intervention and protocol.",Methods,[144004],[8093],[8229],[False],[0],[0],[False],['0']
13692,PMC3851000,24604,We therefore modified the recruitment protocol to include infants between ages of 26 and 34 weeks.,Methods,[144009],[8230],[8328],[False],[0],[0],[False],['0']
13693,PMC3851000,24605,There were no deviations in implementation of the original or amended approved protocol.,Methods,[144014],[8329],[8417],[False],[0],[0],[False],['0']
13694,PMC3851000,24606,Subjects,Methods|Subjects,[144019],[8418],[8426],[False],[0],[0],[False],['0']
13695,PMC3851000,24607,Mothers gave informed consent for their infants’ and their own participation.,Methods|Subjects,[144024],[8427],[8504],[False],[0],[0],[False],['0']
13696,PMC3851000,24608,"Preterm infants born at Morgan Stanley Children’s Hospital at Columbia University Medical Center and admitted to the NICU were eligible for the study if they were 1) born between 26 and 35 weeks postmenstrual age, 2) free of major congenital defects, 3) singleton or twin gestation and, 4) above the third percentile of weight for gestational age at birth.",Methods|Subjects,[144029],[8505],[8861],[False],[0],[0],[False],['0']
13697,PMC3851000,24609,"Infants were excluded if their mother 1) had a history of drug dependence, psychosis or other severe mental health problems, 2) could not speak adequate English for obtaining consent, 3) was younger than 18 years of age, 4) did not have support from at least one additional adult in the home, 5) was too ill to participate.",Methods|Subjects,[144034],[8862],[9185],[False],[0],[0],[False],['0']
13698,PMC3851000,24610,"Additional factors that prevented participation were: 1) anticipated infant discharge within less than 10 days, 2) inability of the mother to meet the visitation goal of 4 times/week, 3) inability of the family to participate in post-discharge follow-up, 4) prior enrollment of the mother and/or infant in a competing study, 5) withholding of approval by attending physician, 6) infant death.",Methods|Subjects,[144039],[9186],[9578],[False],[0],[0],[False],['0']
13699,PMC3851000,24611,Randomization,Methods|Randomization,[144044],[9579],[9592],[False],[0],[0],[False],['0']
13700,PMC3851000,24612,The study coordinator performed randomization and group assignment.,Methods|Randomization,[144049],[9593],[9660],[False],[0],[0],[False],['0']
13701,PMC3851000,24613,Block randomization between Intervention (FNI) and Standard Care (SC) groups was employed to maintain equivalence of group sizes prospectively.,Methods|Randomization,[144054],[9661],[9804],[False],[0],[0],[False],['0']
13702,PMC3851000,24614,"Prepared and numbered envelopes (six assignments per block) were selected consecutively for group assignment, with a single draw for twins.",Methods|Randomization,[144059],[9805],[9944],[False],[0],[0],[False],['0']
13703,PMC3851000,24615,Twins were assigned jointly to either intervention or control groups because it was deemed neither ethical nor feasible to expect a mother to adopt different nurturing approaches for each of her twins.,Methods|Randomization,[144064],[9945],[10146],[False],[0],[0],[False],['0']
13704,PMC3851000,24616,No stratification by gestational age or twin status was used in the randomization procedure.,Methods|Randomization,[144069],[10147],[10239],[False],[0],[0],[False],['0']
13705,PMC3851000,24617,Blinding,Methods|Blinding,[144074],[10240],[10248],[False],[0],[0],[False],['0']
13706,PMC3851000,24618,"Blinding of intervention team, nursing and medical staff was not possible in this trial; Nurture Specialists had to know to whom they were to administer the intervention, and the study staff had to know from which mothers certain data were to be collected.",Methods|Blinding,[144079],[10249],[10505],[False],[0],[0],[False],['0']
13707,PMC3851000,24619,"Blinding of the mothers was also not possible, given that all mothers were in the same NICU and knew in advance their group assignment.",Methods|Blinding,[144084],[10506],[10641],[False],[0],[0],[False],['0']
13708,PMC3851000,24620,Intervention,Methods|Intervention,[144089],[10642],[10654],[False],[0],[0],[False],['0']
13709,PMC3851000,24621,FNI is based on the hypothesis that adverse consequences of prolonged separation of mother and infant following preterm birth can be ameliorated by a dyadic intervention comprising repeated experience with calming activities.,Methods|Intervention,[144094],[10655],[10880],[False],[0],[0],[False],['0']
13710,PMC3851000,24622,"These activities occur during calming sessions that are facilitated by Nurture Specialists, former NICU nurses trained in implementing the FNI protocol.",Methods|Intervention,[144099],[10881],[11033],[False],[0],[0],[False],['0']
13711,PMC3851000,24623,Nurture Specialists also involve and engage family members in reassuring and calming the mother and in providing continued support for her when the infant was discharged.,Methods|Intervention,[144104],[11034],[11204],[False],[0],[0],[False],['0']
13712,PMC3851000,24624,"Calming session activities engage the mother and infant reciprocally in physical, sensory and emotional experiences.",Methods|Intervention,[144109],[11205],[11321],[False],[0],[0],[False],['0']
13713,PMC3851000,24625,Each session was comprised of as many of the calming procedures as possible or warranted by the infant’s distress.,Methods|Intervention,[144114],[11322],[11436],[False],[0],[0],[False],['0']
13714,PMC3851000,24626,"Specific methods used in FNI are described briefly below and, in more detail, in a prior publication [17].",Methods|Intervention,[144119],[11437],[11543],[False],[0],[0],[False],['0']
13715,PMC3851000,24627,"Prior to engaging in any of the FNI activities, mothers and family members were instructed in infection prevention procedures.",Methods|Intervention,[144124],[11544],[11670],[False],[0],[0],[False],['0']
13716,PMC3851000,24628,The FNI calming procedures were as follows.,Methods|Intervention,[144129],[11671],[11714],[False],[0],[0],[False],['0']
13717,PMC3851000,24629,Scent cloth exchange,Methods|Scent cloth exchange,[144134],[11715],[11735],[False],[0],[0],[False],['0']
13718,PMC3851000,24630,Mothers were instructed to exchange special 12 by 16 inch cotton cloths with their infants on a daily basis.,Methods|Scent cloth exchange,[144139],[11736],[11844],[False],[0],[0],[False],['0']
13719,PMC3851000,24631,The mother’s scent cloth was worn close to her skin overnight and was placed with the infant each day; the infant’s scent cloth was placed in bed with the infant during the preceding 24 hours and was taken home each day by the mother.,Methods|Scent cloth exchange,[144144],[11845],[12079],[False],[0],[0],[False],['0']
13720,PMC3851000,24632,Calming touch,Methods|Calming touch,[144149],[12080],[12093],[False],[0],[0],[False],['0']
13721,PMC3851000,24633,Mothers were shown how to calm their infants using firm sustained touch by cupping one hand around the infants’ legs and feet and placing the other hand on the abdomen.,Methods|Calming touch,[144154],[12094],[12262],[False],[0],[0],[False],['0']
13722,PMC3851000,24634,"While engaging in calming touch, the Nurture Specialist prompted the mother to communicate her thoughts and emotions to the infant in her native language.",Methods|Calming touch,[144159],[12263],[12417],[False],[0],[0],[False],['0']
13723,PMC3851000,24635,During all of these activities the mother was encouraged to seek and maintain eye contact with her infant as much as possible.,Methods|Calming touch,[144164],[12418],[12544],[False],[0],[0],[False],['0']
13724,PMC3851000,24636,Holding,Methods|Holding,[144169],[12545],[12552],[False],[0],[0],[False],['0']
13725,PMC3851000,24637,"When infants could be taken out of the incubator, the Nurture Specialists assisted the mother to engage in skin-to-skin or wrapped calming sessions.",Methods|Holding,[144174],[12553],[12701],[False],[0],[0],[False],['0']
13726,PMC3851000,24638,"Nurture Specialists aimed to facilitate holding sessions at least four times per week; however, mothers were encouraged to engage in all calming techniques at all of their visits.",Methods|Holding,[144179],[12702],[12881],[False],[0],[0],[False],['0']
13727,PMC3851000,24639,"Although feeding is a critical mother-infant interaction, feeding was not included as one of the facilitated mother-infant activities because the NICU employed a feeding specialist for all mothers.",Methods|Holding,[144184],[12882],[13079],[False],[0],[0],[False],['0']
13728,PMC3851000,24640,"However, the nurture specialists encouraged mothers to feed, change, and bathe their infants.",Methods|Holding,[144189],[13080],[13173],[False],[0],[0],[False],['0']
13729,PMC3851000,24641,Fathers were also encouraged to engage in these activities.,Methods|Holding,[144194],[13174],[13233],[False],[0],[0],[False],['0']
13730,PMC3851000,24642,Standard care,Standard care,[144199],[13234],[13248],[False],[0],[0],[False],['0']
13731,PMC3851000,24643,Mothers in the Standard Care (SC) group followed hospital protocol.,Standard care,[144204],[13249],[13316],[False],[0],[0],[False],['0']
13732,PMC3851000,24644,"SC mothers were able to engage in nurturing activities of their choosing, which in this NICU included skin-to-skin or non-skin-to-skin holding.",Standard care,[144209],[13317],[13460],[False],[0],[0],[False],['0']
13733,PMC3851000,24645,"These activities of SC mothers were optional and not documented by the study staff; however, SC mothers recorded these activities on a self-report visit log.",Standard care,[144214],[13461],[13618],[False],[0],[0],[False],['0']
13734,PMC3851000,24646,Outcome measures,Standard care|Outcome measures,[144219],[13619],[13635],[False],[0],[0],[False],['0']
13735,PMC3851000,24647,Intervention fidelity,Standard care|Intervention fidelity,[144224],[13636],[13657],[False],[0],[0],[False],['0']
13736,PMC3851000,24648,"The amount of the intervention varied according to the needs and availability of the infant, the mother and the family.",Standard care|Intervention fidelity,[144229],[13658],[13777],[False],[0],[0],[False],['0']
13737,PMC3851000,24649,Mothers recruited into the study and assigned to the FNI group were asked to complete four facilitated one-hour intervention calming sessions per week for the duration of the NICU stay.,Standard care|Intervention fidelity,[144234],[13778],[13963],[False],[0],[0],[False],['0']
13738,PMC3851000,24650,"In addition, mothers were asked to exchange scent cloths with their babies upon each NICU visit for the duration of the NICU stay.",Standard care|Intervention fidelity,[144239],[13964],[14094],[False],[0],[0],[False],['0']
13739,PMC3851000,24651,"However, FNI mothers who consulted with our nurture specialists more frequently performed more FNI.",Standard care|Intervention fidelity,[144244],[14095],[14194],[False],[0],[0],[False],['0']
13740,PMC3851000,24652,We targeted a minimum weekly amount of FNI knowing that target duration (weeks) was dependent on infants’ LOS.,Standard care|Intervention fidelity,[144249],[14195],[14305],[False],[0],[0],[False],['0']
13741,PMC3851000,24653,Implementation of the mother-infant activities during each visit was documented on check lists by the Nurture Specialists.,Standard care|Intervention fidelity,[144254],[14306],[14428],[False],[0],[0],[False],['0']
13742,PMC3851000,24654,"Mother-infant activities in the NICU, with or without Nurture Specialist support, were also self-recorded by FNI mothers with the aid of a NICU visit log.",Standard care|Intervention fidelity,[144259],[14429],[14583],[False],[0],[0],[False],['0']
13743,PMC3851000,24655,"Given the limitations of self-report data, potentially compounded by changes to the data collection format during the trial, outcomes reported here are limited to scent cloth exchanges per week (FNI group only) and frequency and duration of holding sessions, either in or out of the isolette.",Standard care|Intervention fidelity,[144264],[14584],[14876],[False],[0],[0],[False],['0']
13744,PMC3851000,24656,Safety,Standard care|Safety,[144269],[14877],[14883],[False],[0],[0],[False],['0']
13745,PMC3851000,24657,Safety of the intervention was determined by examining specific clinical characteristics of infants during hospitalization and at discharge (Table 1).,Standard care|Safety,[144274],[14884],[15034],[False],[0],[0],[False],['0']
13746,PMC3851000,24658,"These parameters including infant mortality, infections and gastrointestinal, neurological and cardiac disorders, were obtained by study staff from hospital records.",Standard care|Safety,[144279],[15035],[15200],[False],[0],[0],[False],['0']
13747,PMC3851000,24659,Length of stay,Standard care|Length of stay,[144284],[15201],[15215],[False],[0],[0],[False],['0']
13748,PMC3851000,24660,"The primary outcome of the RCT, Length of Stay (LOS), was the duration of hospitalization from date of birth to date of discharge home [18].",Standard care|Length of stay,[144289],[15216],[15356],[False],[0],[0],[False],['0']
13749,PMC3851000,24661,"Measurement of LOS for infants discharged elsewhere (i.e., not home) ceased on the day of discharge.",Standard care|Length of stay,[144294],[15357],[15457],[False],[0],[0],[False],['0']
13750,PMC3851000,24662,These cases are included in the intent-to-treat analysis.,Standard care|Length of stay,[144299],[15458],[15515],[False],[0],[0],[False],['0']
13751,PMC3851000,24663,Statistical methods,Statistical methods,[144304],[15516],[15536],[False],[0],[0],[False],['0']
13752,PMC3851000,24664,"Data from the infant, family and nurture assessment measures were entered via Citrix application server software into a central customized Scientific Information Retrieval (SIR) database and exported into SPSS v20 for analysis.",Statistical methods,[144309],[15537],[15764],[False],[0],[0],[False],['0']
13753,PMC3851000,24665,"In the intent-to-treat analysis, LOS was compared for the two study groups using survival analysis: the Kaplan-Meier estimator and the log-rank test.",Statistical methods,[144314],[15765],[15914],[False],[0],[0],[False],['0']
13754,PMC3851000,24666,"Data collection ceased prior to discharge home for infants who were transferred to another hospital, died or withdrew from study (data right censored).",Statistical methods,[144319],[15915],[16066],[False],[0],[0],[False],['0']
13755,PMC3851000,24667,FNI subject participation was assessed by frequency and duration of Nurture Specialist-supported calming sessions.,Statistical methods,[144324],[16067],[16181],[False],[0],[0],[False],['0']
13756,PMC3851000,24668,Comparisons between groups with regard to calming activities were made with Student’s t-tests.,Statistical methods,[144329],[16182],[16276],[False],[0],[0],[False],['0']
13757,PMC3851000,24669,"With regard to missing data, we took a conservative approach.",Statistical methods,[144334],[16277],[16338],[False],[0],[0],[False],['0']
13758,PMC3851000,24670,In the case that data were missing it was assumed there was no activity or event.,Statistical methods,[144339],[16339],[16420],[False],[0],[0],[False],['0']
13759,PMC3851000,24671,These cases were assigned a null value for the analysis.,Statistical methods,[144344],[16421],[16477],[False],[0],[0],[False],['0']
13760,PMC3851000,24672,IRB,Statistical methods|IRB,[144349],[16478],[16481],[False],[0],[0],[False],['0']
13761,PMC3851000,24673,Ethical approval for this study was obtained from the Institutional Review Board (IRB) of Columbia University Medical Center and was in accordance with the Helsinki Declaration.,Statistical methods|IRB,[144354],[16482],[16659],[False],[0],[0],[False],['0']
13762,PMC3851000,24674,An independent Data and Safety Monitoring Board (DSMB) was appointed to oversee the implementation of the study.,Statistical methods|IRB,[144359],[16660],[16772],[False],[0],[0],[False],['0']
13763,PMC3851000,24675,The trial is registered at ClinicalTrials.gov with registration number NCT01439269.,Statistical methods|IRB,[144364],[16773],[16856],[False],[0],[0],[False],['0']
13764,PMC3851000,24676,Results,Results,[144369],[16857],[16865],[False],[0],[0],[False],['0']
13765,PMC3851000,24677,Recruitment and retention of subjects,Results|Recruitment and retention of subjects,[144374],[16866],[16903],[False],[0],[0],[False],['0']
13766,PMC3851000,24678,Enrollment for the FNI-NICU study began in January 2009.,Results|Recruitment and retention of subjects,[144379],[16904],[16960],[False],[0],[0],[False],['0']
13767,PMC3851000,24679,Recruitment ended in June of 2012 and the last infant in the study was discharged in September of 2012.,Results|Recruitment and retention of subjects,[144384],[16961],[17064],[False],[0],[0],[False],['0']
13768,PMC3851000,24680,The recruitment cascade for the study is given in Figure 1.,Results|Recruitment and retention of subjects,[144389],[17065],[17124],[False],[0],[0],[False],['0']
13769,PMC3851000,24681,There were 826 age-eligible infants admitted to the NICU during the study period.,Results|Recruitment and retention of subjects,[144394],[17125],[17206],[False],[0],[0],[False],['0']
13770,PMC3851000,24682,"Of these, 124 infants were excluded for infant-related exclusion criteria (congenital anomalies and <3rd percentile for weight).",Results|Recruitment and retention of subjects,[144399],[17207],[17335],[False],[0],[0],[False],['0']
13771,PMC3851000,24683,"An additional 170 infants were excluded for the following maternal indications: non-English speaking (97), postpartum illness (21), psychiatric history (15), substance abuse history (10), age <18 years (10), and no adult support at home (17).",Results|Recruitment and retention of subjects,[144404],[17336],[17578],[False],[0],[0],[False],['0']
13772,PMC3851000,24684,"Of the remaining 532 infants, no consent was attempted for 159 infants due to an inability to participate.",Results|Recruitment and retention of subjects,[144409],[17579],[17685],[False],[0],[0],[False],['0']
13773,PMC3851000,24685,"These participation exclusions included: discharge was anticipated in 10 days or less (117), family was moving out of the area and would not be able to participate in follow-up (20), attending physician did not approve approach to consent (18), infant died (3), infant was enrolled in another study that precluded second enrollment (1).",Results|Recruitment and retention of subjects,[144414],[17686],[18022],[False],[0],[0],[False],['0']
13774,PMC3851000,24686,"Of the remaining 373 infants, consent was not obtainable because the mother was not available to schedule a consent meeting (56).",Results|Recruitment and retention of subjects,[144419],[18023],[18152],[False],[0],[0],[False],['0']
13775,PMC3851000,24687,"Of the remaining eligible infants consent was denied for 167: not interested (34), overwhelmed (29), father refused (30), did not want to commit the required time (29), never agreed after repeated contact (45).",Results|Recruitment and retention of subjects,[144424],[18153],[18363],[False],[0],[0],[False],['0']
13776,PMC3851000,24688,Consent was obtained for 150 infants from 115 families.,Results|Recruitment and retention of subjects,[144429],[18364],[18419],[False],[0],[0],[False],['0']
13777,PMC3851000,24689,The infants of these families were randomized to the two trial arms (72 Standard Care and 78 FNI infants).,Results|Recruitment and retention of subjects,[144434],[18420],[18526],[False],[0],[0],[False],['0']
13778,PMC3851000,24690,The unequal distribution of infants was due to a greater number of families with twins being randomized to the FNI arm of the trial.,Results|Recruitment and retention of subjects,[144439],[18527],[18659],[False],[0],[0],[False],['0']
13779,PMC3851000,24691,"Overall, N = 16 (10.6%) infants were lost to follow-up (LTFU), prior to achieving the primary endpoint (5 SC and 11 FNI).",Results|Recruitment and retention of subjects,[144444],[18660],[18781],[False],[0],[0],[False],['0']
13780,PMC3851000,24692,This left 67 infants in each group who were discharged home.,Results|Recruitment and retention of subjects,[144449],[18782],[18842],[False],[0],[0],[False],['0']
13781,PMC3851000,24693,"In the SC group, all 5 LTFU infants were discharged to another hospital.",Results|Recruitment and retention of subjects,[144454],[18843],[18915],[False],[0],[0],[False],['0']
13782,PMC3851000,24694,"In the FNI group, 1 infant died, 5 were discharged to another hospital and, 5 infants had consent withdrawn; 2 (twins) due to the fathers’ concerns about infections, 1 because the father did not want the infant enrolled in a research study, and 2 twins because the mother was not able to meet the time/visit commitments required.",Results|Recruitment and retention of subjects,[144459],[18916],[19245],[False],[0],[0],[False],['0']
13783,PMC3851000,24695,Demographics and clinical information,Results|Demographics and clinical information,[144464],[19246],[19283],[False],[0],[0],[False],['0']
13784,PMC3851000,24696,Baseline demographic information for study participants is presented in Table 2.,Results|Demographics and clinical information,[144469],[19284],[19364],[False],[0],[0],[False],['0']
13785,PMC3851000,24697,Clinical information is provided in Table 3.,Results|Demographics and clinical information,[144474],[19365],[19409],[False],[0],[0],[False],['0']
13786,PMC3851000,24698,There were no significant differences between groups.,Results|Demographics and clinical information,[144479],[19410],[19463],[False],[0],[0],[False],['0']
13787,PMC3851000,24699,"Consistent with risk of pre-term delivery, antenatal treatment with steroids was high (93%), as was use of labor suppressants (82%).",Results|Demographics and clinical information,[144484],[19464],[19596],[False],[0],[0],[False],['0']
13788,PMC3851000,24700,"Consistent with the study design, the mean gestational age of enrolled infants was between 30 and 31 weeks for both groups.",Results|Demographics and clinical information,[144489],[19597],[19720],[False],[0],[0],[False],['0']
13789,PMC3851000,24701,"Overall, the rate of C-section for singleton gestations was not different for SC and FNI mothers (55% vs. 59%).",Results|Demographics and clinical information,[144494],[19721],[19832],[False],[0],[0],[False],['0']
13790,PMC3851000,24702,"However, C-sections for twin gestations were less frequent in the SC group (81% vs. 100%).",Results|Demographics and clinical information,[144499],[19833],[19923],[False],[0],[0],[False],['0']
13791,PMC3851000,24703,"The rate of C-section in singletons is slightly higher than the national average in preterms as of 2006 [20], which at the time was trending upward.",Results|Demographics and clinical information,[144504],[19924],[20072],[False],[0],[0],[False],['0']
13792,PMC3851000,24704,Intervention fidelity,Results|Intervention fidelity,[144509],[20073],[20094],[False],[0],[0],[False],['0']
13793,PMC3851000,24705,Intervention activity was reported in two ways.,Results|Intervention fidelity,[144514],[20095],[20142],[False],[0],[0],[False],['0']
13794,PMC3851000,24706,Nurture Specialists recorded each session with the mother.,Results|Intervention fidelity,[144519],[20143],[20201],[False],[0],[0],[False],['0']
13795,PMC3851000,24707,"In addition, mothers recorded sessions with their infants in a log.",Results|Intervention fidelity,[144524],[20202],[20269],[False],[0],[0],[False],['0']
13796,PMC3851000,24708,"According to the Nurture Specialist records, facilitated calming sessions occurred on average 3.5 times per week (median = 3.7; IQR = 2.7 – 4.1) over the course of the infants’ hospitalization.",Results|Intervention fidelity,[144529],[20270],[20463],[False],[0],[0],[False],['0']
13797,PMC3851000,24709,"These sessions were divided amongst scent cloth exchanges (median = 2.6 times per week, IQR = 1.9 – 3.7), sessions of vocal soothing and comfort touch (median = 3.2 times per week, IQR = 2.4 – 3.8), and skin-to-skin holding (median = 1.9 times per week, IQR = 1.3 – 2.7).",Results|Intervention fidelity,[144534],[20464],[20735],[False],[0],[0],[False],['0']
13798,PMC3851000,24710,The overall number of facilitated calming sessions was slightly below the planned minimum of 4 times per week.,Results|Intervention fidelity,[144539],[20736],[20846],[False],[0],[0],[False],['0']
13799,PMC3851000,24711,"However, 84% of sessions were >1 h in duration (average 1.6 h/session or 6.4 h/week), which slightly exceeded our target of 4 h/week of facilitated FNI activities.",Results|Intervention fidelity,[144544],[20847],[21010],[False],[0],[0],[False],['0']
13800,PMC3851000,24712,"Based on an average LOS of 47.4 days (see LOS section), the average total duration of FNI facilitated activities was 43 hours per subject.",Results|Intervention fidelity,[144549],[21011],[21149],[False],[0],[0],[False],['0']
13801,PMC3851000,24713,"Weekly rate of visits did not differ by mother’s educational group (F = .049, p = .953).",Results|Intervention fidelity,[144554],[21150],[21238],[False],[0],[0],[False],['0']
13802,PMC3851000,24714,"The weekly rate of visits also did not differ by infant’s gestational age (F = −.242, p = .09).",Results|Intervention fidelity,[144559],[21239],[21334],[False],[0],[0],[False],['0']
13803,PMC3851000,24715,"According to the Mother’s logs, there was little, if any, difference in the amount of specified nurture activities from those facilitated by the Nurture Specialist.",Results|Intervention fidelity,[144564],[21335],[21499],[False],[0],[0],[False],['0']
13804,PMC3851000,24716,"Mothers’ logs reflected more frequent skin-to-skin holding sessions by FNI mothers (FNI 2.0 ± 0.17; SC 0.8 ± 0.14 times per week, p < 0.001) on average.",Results|Intervention fidelity,[144569],[21500],[21652],[False],[0],[0],[False],['0']
13805,PMC3851000,24717,"When these activities did take place, there were of longer duration (FNI 83 ± 5; SC 63 ± 4 minutes/session, p < 0.01) on average.",Results|Intervention fidelity,[144574],[21653],[21782],[False],[0],[0],[False],['0']
13806,PMC3851000,24718,Mothers in the FNI group reported scent cloth exchanges at an average rate of 2.7 ± 0.2 times per week.,Results|Intervention fidelity,[144579],[21783],[21886],[False],[0],[0],[False],['0']
13807,PMC3851000,24719,FNI mothers also reported more frequent infant diaper changes on average than SC mothers (FNI 3.9 ± 0.46; SC 2.5 ± 0.23 times per week; p = 0.01).,Results|Intervention fidelity,[144584],[21887],[22033],[False],[0],[0],[False],['0']
13808,PMC3851000,24720,Safety,Results|Safety,[144589],[22034],[22040],[False],[0],[0],[False],['0']
13809,PMC3851000,24721,The incidence of infant mortality during the study was 1 death in each study group.,Results|Safety,[144594],[22041],[22124],[False],[0],[0],[False],['0']
13810,PMC3851000,24722,The death in the FNI group occurred in the Columbia NICU.,Results|Safety,[144599],[22125],[22182],[False],[0],[0],[False],['0']
13811,PMC3851000,24723,The baby was a twin who developed a volvulus with bowel necrosis progressing to overwhelming sepsis and expired within 24 hours of surgical bowel resection.,Results|Safety,[144604],[22183],[22339],[False],[0],[0],[False],['0']
13812,PMC3851000,24724,The other twin had no infectious complications and was discharged home.,Results|Safety,[144609],[22340],[22411],[False],[0],[0],[False],['0']
13813,PMC3851000,24725,The death in the SC group occurred in an outside NICU to which the baby had been transferred when the family relocated.,Results|Safety,[144614],[22412],[22531],[False],[0],[0],[False],['0']
13814,PMC3851000,24726,The cause of death was attributed to unresolved chronic lung disease while in a NICU to which the infant had been transferred.,Results|Safety,[144619],[22532],[22658],[False],[0],[0],[False],['0']
13815,PMC3851000,24727,The incidence of major pathological diagnoses recorded for the 134 infants discharged from the Columbia NICU are summarized in Table 1.,Results|Safety,[144624],[22659],[22794],[False],[0],[0],[False],['0']
13816,PMC3851000,24728,"There were no significant differences between the FNI and SC groups in the diagnosis or treatment for sepsis, necrotizing enterocolitis, neurological conditions, renal disorders or retinopathy of prematurity.",Results|Safety,[144629],[22795],[23003],[False],[0],[0],[False],['0']
13817,PMC3851000,24729,There was a non-significant trend for increased diagnosis of patent ductus arteriosis (PDA) in FNI infants (p = .055) but not for surgical closure of the ductus or other cardiac conditions.,Results|Safety,[144634],[23004],[23193],[False],[0],[0],[False],['0']
13818,PMC3851000,24730,There was a trend toward a decreased incidence of feeding problems in the FNI group (p = .062).,Results|Safety,[144639],[23194],[23289],[False],[0],[0],[False],['0']
13819,PMC3851000,24731,There was evidence at discharge of severe bronchopulmonary dysplasia in 2 SC infants (discharged on nasal cannula oxygen).,Results|Safety,[144644],[23290],[23412],[False],[0],[0],[False],['0']
13820,PMC3851000,24732,No FNI infants were discharged on oxygen.,Results|Safety,[144649],[23413],[23454],[False],[0],[0],[False],['0']
13821,PMC3851000,24733,Length of stay (LOS),Results|Length of stay (LOS),[144654],[23455],[23475],[False],[0],[0],[False],['0']
13822,PMC3851000,24734,"All 150 infants were included in an initial intent-to-treat analysis; 16 infants who were not discharged to their home (transferred to other NICUs) were considered as LTFU and their data were right-censored at the date of last contact, or death [21].",Results|Length of stay (LOS),[144659],[23476],[23726],[False],[0],[0],[False],['0']
13823,PMC3851000,24735,All other infants (N = 134) were followed until discharge home from our NICU.,Results|Length of stay (LOS),[144664],[23727],[23804],[False],[0],[0],[False],['0']
13824,PMC3851000,24736,"LOS ranged from 5 to 212 days, with a median of 35.5 (IQR 20 – 60) days.",Results|Length of stay (LOS),[144669],[23805],[23877],[False],[0],[0],[False],['0']
13825,PMC3851000,24737,"Kaplan-Meier survival analysis (time to event, discharge home) produced an estimated mean (±SD) LOS of 47.4 ± 27.4 days for the FNI group and 50.8 ± 45.8 days for the SC group.",Results|Length of stay (LOS),[144674],[23878],[24054],[False],[0],[0],[False],['0']
13826,PMC3851000,24738,"Although mean LOS was 3.4 days shorter in the FNI group, median LOS was 4 days longer in the FNI group (SC median = 36, 95% CI = 29 – 43; FNI median = 40, 95% CI = 30 – 50) with no significant difference between the groups (Mantel-Cox log-rank χ2 = 0.163, df = 1, p = .687).",Results|Length of stay (LOS),[144679],[24055],[24329],[False],[0],[0],[False],['0']
13827,PMC3851000,24739,"Controlling for gestational age at birth, a proportional hazards model revealed no significant association between LOS and amount of FNI (expressed as a weekly rate of facilitated visits) in intervention group infants (β = .959, Wald χ2 = .340, df = 1, p = .560).",Results|Length of stay (LOS),[144684],[24330],[24593],[False],[0],[0],[False],['0']
13828,PMC3851000,24740,Discussion,Discussion,[144689],[24594],[24605],[False],[0],[0],[False],['0']
13829,PMC3851000,24741,The overall goal of our NICU research program is to determine whether perinatal and long-term development can be improved by the earliest possible implementation of biologically important mother-infant interactions in the NICU.,Discussion,[144694],[24606],[24833],[False],[0],[0],[False],['0']
13830,PMC3851000,24742,"While we found no impact of FNI upon LOS, the primary outcome of this trial, we did find that the intervention was safe and feasible to implement within a high-acuity, level IV NICU environment.",Discussion,[144699],[24834],[25028],[False],[0],[0],[False],['0']
13831,PMC3851000,24743,"In brief, we found that mothers were willing to engage in FNI activities and that these activities could be done within the context of a level IV NICU.",Discussion,[144704],[25029],[25180],[False],[0],[0],[False],['0']
13832,PMC3851000,24744,"In addition, we found the intervention did not increase medical risks.",Discussion,[144709],[25181],[25251],[False],[0],[0],[False],['0']
13833,PMC3851000,24745,"Although FNI encouraged skin-to-skin holding, which has been shown to decrease LOS in preterm infants [13], the intervention also includes interactions not previously well studied in preterm infants (e.g.",Discussion,[144714],[25252],[25456],[False],[0],[0],[False],['0']
13834,PMC3851000,24746,"scent cloth exchange, and repeated novel calming interactions, and family sessions).",Discussion,[144719],[25457],[25541],[False],[0],[0],[False],['0']
13835,PMC3851000,24747,"Therefore, we were attuned to the possibility that FNI might either decrease or, perhaps increase, LOS.",Discussion,[144724],[25542],[25645],[False],[0],[0],[False],['0']
13836,PMC3851000,24748,"Contrary to both alternatives, results from the study showed that infants randomized to FNI showed no significant difference in LOS, compared with infants receiving standard care.",Discussion,[144729],[25646],[25825],[False],[0],[0],[False],['0']
13837,PMC3851000,24749,"In order to support a broader implementation of FNI in other NICUs, it was important to determine that the intervention would not interfere with standard care, that it could be carried out fully and that it was medically safe.",Discussion,[144734],[25826],[26052],[False],[0],[0],[False],['0']
13838,PMC3851000,24750,Some doctors and nurses expressed concerns that infants in the intervention group would be subjected to increased risk of infection and potentially other adverse medical consequence associated with repeated removal of the infants from the controlled environment of the incubator or bassinet.,Discussion,[144739],[26053],[26344],[False],[0],[0],[False],['0']
13839,PMC3851000,24751,Clinical outcomes during the course of stay in the NICU and at the time of discharge proved these concerns to be unwarranted.,Discussion,[144744],[26345],[26470],[False],[0],[0],[False],['0']
13840,PMC3851000,24752,"There was no evidence for any increase in sepsis, necrotizing enterocolitis, seizures, retinopathy, or in the need for oxygen or greater medication in the FNI group.",Discussion,[144749],[26471],[26636],[False],[0],[0],[False],['0']
13841,PMC3851000,24753,We found that intervention mothers met with the nurture specialists on average 3.5 times a week for slightly greater than one hour per session and that they willingly engaged in all of the FNI calming activities.,Discussion,[144754],[26637],[26849],[False],[0],[0],[False],['0']
13842,PMC3851000,24754,The high rate of study retention in the FNI group after consent (86%) suggests that the intensive involvement required of participating mothers did not deter participation.,Discussion,[144759],[26850],[27022],[False],[0],[0],[False],['0']
13843,PMC3851000,24755,"FNI mothers did engage in skin-to-skin holding for greater duration and frequency and, as a further measure of maternal involvement we quantified the number of times the mother changed her baby’s diapers, which was significantly increased in the FNI group.",Discussion,[144764],[27023],[27279],[False],[0],[0],[False],['0']
13844,PMC3851000,24756,We found that LOS was not significantly affected by FNI.,Discussion,[144769],[27280],[27336],[False],[0],[0],[False],['0']
13845,PMC3851000,24757,"In our study, mothers in the FNI group engaged in skin-to-skin care, on average, less than 1 hour/day.",Discussion,[144774],[27337],[27439],[False],[0],[0],[False],['0']
13846,PMC3851000,24758,This is considerably less than reported for previous studies of intermittent skin-to-skin care in which significant effects of LOS were found.,Discussion,[144779],[27440],[27582],[False],[0],[0],[False],['0']
13847,PMC3851000,24759,In these studies mothers engaged in skin-to-skin care for between 1 and 6 hours each day [22-24].,Discussion,[144784],[27583],[27680],[False],[0],[0],[False],['0']
13848,PMC3851000,24760,Another important difference between these prior studies and ours was the range of birth weights of the infants enrolled.,Discussion,[144789],[27681],[27802],[False],[0],[0],[False],['0']
13849,PMC3851000,24761,"In one of these, all babies enrolled were less than 1500 g [24], and in the other two, the standard deviation of birth weights in the study infants was between 110 and 120 g [22,23], whereas in our study the SDs of birth weights were nearly 4 times greater (SC = 439 g; FNI = 396 g).",Discussion,[144794],[27803],[28086],[False],[0],[0],[False],['0']
13850,PMC3851000,24762,"Had infants been exposed to a higher dose of maternal scent via the scent cloth, or if mothers had engaged in more frequent and longer skin-to-skin sessions and other FNI calming activities, we might have obtained a significant effect on LOS.",Discussion,[144799],[28087],[28329],[False],[0],[0],[False],['0']
13851,PMC3851000,24763,"There was a large variance in LOS in both groups (SC standard deviation = 46 days, FNI standard deviation = 27 days) largely due to a wide range of gestational ages.",Discussion,[144804],[28330],[28495],[False],[0],[0],[False],['0']
13852,PMC3851000,24764,"Thus, the effect on LOS might have been reduced had we enrolled infants with a narrower age range.",Discussion,[144809],[28496],[28594],[False],[0],[0],[False],['0']
13853,PMC3851000,24765,Limitations,Discussion|Limitations,[144814],[28595],[28606],[False],[0],[0],[False],['0']
13854,PMC3851000,24766,A significant limitation of this trial was that a large number of families declined to participate.,Discussion|Limitations,[144820],[28607],[28706],[True],['VerySpecificPopulation'],['a large number of families declined to participate'],[True],['Population']
13855,PMC3851000,24767,"This was largely due to the considerable study burden imposed by the trial: for both groups, the protocol included multiple time consuming physiological and neurobehavioral assessments during the NICU stay and during multiple follow-up visits over a two-year period; for the intervention group, mothers were additionally asked to meet regularly with the Nurture Specialists throughout the NICU stay and the families were asked to meet once prior to discharge.",Discussion|Limitations,[144829],[28707],[29166],[False],[0],[0],[False],['0']
13856,PMC3851000,24768,"In future studies of FNI, we plan to reduce study burden by separating the intervention portion of the study from the follow-up.",Discussion|Limitations,[144834],[29167],[29295],[False],[0],[0],[False],['0']
13857,PMC3851000,24769,We believe this will significantly help to reduce the refusal rate.,Discussion|Limitations,[144839],[29296],[29363],[False],[0],[0],[False],['0']
13858,PMC3851000,24770,There was no indication that anyone refused because they did not want to do nurture.,Discussion|Limitations,[144844],[29364],[29448],[False],[0],[0],[False],['0']
13859,PMC3851000,24771,"Therefore, we do not see the low percentage of study enrollment itself as an impediment to intervention acceptance in the NICU.",Discussion|Limitations,[144849],[29449],[29576],[False],[0],[0],[False],['0']
13860,PMC3851000,24772,"Another limitation to consider is that the sample might be biased towards those who had better support systems, more time and fewer competing responsibilities.",Discussion|Limitations,[144856],[29577],[29736],[True],['VerySpecificPopulation'],"['the sample might be biased towards those who had better support systems, more time and fewer competing responsibilities']",[True],['Population']
13861,PMC3851000,24773,We believe this to be a limitation that worked against us.,Discussion|Limitations,[144864],[29737],[29795],[False],[0],[0],[False],['0']
13862,PMC3851000,24774,"These mothers would be more similar to each other than to the rest of the population and more likely to give lots of attention to the baby, whichever group they were assigned to.",Discussion|Limitations,[144869],[29796],[29974],[False],[0],[0],[False],['0']
13863,PMC3851000,24775,"So, the self-selected sample would make it harder to show an effect, not easier.",Discussion|Limitations,[144874],[29975],[30055],[False],[0],[0],[False],['0']
13864,PMC3851000,24776,Contamination is a potential limitation in this study.,Discussion|Limitations,[144879],[30056],[30110],[True],['Patient'],['Contamination'],[True],['Blinding']
13865,PMC3851000,24777,It was impossible to prevent some communication between subjects in the FNI and SC groups.,Discussion|Limitations,[144892],[30111],[30201],[True],['Patient'],['It was impossible to prevent some communication between subjects in the FNI and SC groups'],[True],['Blinding']
13866,PMC3851000,24778,"However, the great majority of the mothers on our 80 bed capacity unit were not in the study.",Discussion|Limitations,[144899],[30202],[30295],[False],[0],[0],[False],['0']
13867,PMC3851000,24779,"Usually, there were fewer than 3 study mothers in the NICU, thus limiting the chances of contamination; the maximum number of enrolled subjects at one time was 4 FNI mothers and 2 SC mothers.",Discussion|Limitations,[144904],[30296],[30487],[False],[0],[0],[False],['0']
13868,PMC3851000,24780,"Occasionally, SC mothers expressed regret at their group designation.",Discussion|Limitations,[144909],[30488],[30557],[False],[0],[0],[False],['0']
13869,PMC3851000,24781,One SC mother tried scent cloth exchange with her infant.,Discussion|Limitations,[144914],[30558],[30615],[False],[0],[0],[False],['0']
13870,PMC3851000,24782,A limitation of this report is that longer-term follow-up assessments of neurophysiologic and cognitive and behavioral development were not available.,Discussion|Limitations,[144923],[30616],[30766],[True],['MissingData'],['longer-term follow-up assessments of neurophysiologic and cognitive and behavioral development were not available'],[True],['MissingData']
13871,PMC3851000,24783,"However, they are on-going and will continue until at least two years of age.",Discussion|Limitations,[144929],[30767],[30844],[False],[0],[0],[False],['0']
13872,PMC3851000,24784,These longer-term assessments will be used to test the hypothesis that FNI leads to improved neurobehavioral outcomes of prematurely born infants.,Discussion|Limitations,[144934],[30845],[30991],[False],[0],[0],[False],['0']
13873,PMC3851000,24785,"Nevertheless, we have documented improved EEG activity in FNI infants compared with SC infants at near to term [25], which supports that FNI may indeed be associated with improved neurodevelopmental outcomes.",Discussion|Limitations,[144939],[30992],[31200],[False],[0],[0],[False],['0']
13874,PMC3851000,24786,Conclusions,Conclusions,[144944],[31201],[31213],[False],[0],[0],[False],['0']
13875,PMC3851000,24787,"FNI did not significantly affect the primary outcome of this study, LOS in the NICU.",Conclusions,[144949],[31214],[31298],[False],[0],[0],[False],['0']
13876,PMC3851000,24788,"Nonetheless, this trial did demonstrate that FNI is safe in a high acuity NICU.",Conclusions,[144954],[31299],[31378],[False],[0],[0],[False],['0']
13877,PMC3851000,24789,"In addition, we found that mothers were willing to engage in the study intervention activities, and that FNI was compatible with routine NICU activities.",Conclusions,[144959],[31379],[31532],[False],[0],[0],[False],['0']
13878,PMC3851000,24790,Abbreviations,Abbreviations,[144964],[31533],[31547],[False],[0],[0],[False],['0']
13879,PMC3851000,24791,FNI: Family nurture intervention; LOS: Length of stay; LTFU: Lost to follow-up; NICU: Neonatal intensive care unit; RCT: Randomized controlled trial; SC: Standard care.,Abbreviations,[144969],[31548],[31716],[False],[0],[0],[False],['0']
13880,PMC3851000,24792,Competing interests,Competing interests,[144974],[31717],[31737],[False],[0],[0],[False],['0']
13881,PMC3851000,24793,The authors declare that they have no competing interests.,Competing interests,[144979],[31738],[31796],[False],[0],[0],[False],['0']
13882,PMC3851000,24794,Authors’ contributions,Authors’ contributions,[144984],[31797],[31820],[False],[0],[0],[False],['0']
13883,PMC3851000,24795,"MGW and MMM conceived of the study, shared in the responsibility for the conduct of the RCT, and participated in the preparation of all drafts of the manuscript.",Authors’ contributions,[144989],[31821],[31982],[False],[0],[0],[False],['0']
13884,PMC3851000,24796,MGW designed the interventions and trained the personnel who facilitated the interventions.,Authors’ contributions,[144994],[31983],[32074],[False],[0],[0],[False],['0']
13885,PMC3851000,24797,MAH advised on the trial design and methodology and participated in the preparation of the final drafts of the manuscript.,Authors’ contributions,[144999],[32075],[32197],[False],[0],[0],[False],['0']
13886,PMC3851000,24798,"RIS advised on the methodology, acted as liaison with medical staff and participated in the preparation of the manuscript.",Authors’ contributions,[145004],[32198],[32320],[False],[0],[0],[False],['0']
13887,PMC3851000,24799,HA advised on data management and participated in the preparation of the manuscript.,Authors’ contributions,[145009],[32321],[32405],[False],[0],[0],[False],['0']
13888,PMC3851000,24800,JA designed and performed statistical and power analyses and participated in the preparation of the manuscript.,Authors’ contributions,[145014],[32406],[32517],[False],[0],[0],[False],['0']
13889,PMC3851000,24801,RJL advised on the trial design and methodology and participated in the preparation of the final drafts of the manuscript.,Authors’ contributions,[145019],[32518],[32640],[False],[0],[0],[False],['0']
13890,PMC3851000,24802,MMM advised on methodology and data acquisition and participated in the writing all drafts of the manuscript.,Authors’ contributions,[145024],[32641],[32750],[False],[0],[0],[False],['0']
13891,PMC3851000,24803,"The FNI Trial Group advised on recruitment, data acquisition, data analysis, methodology and/or preparation and editing of the manuscript.",Authors’ contributions,[145029],[32751],[32889],[False],[0],[0],[False],['0']
13892,PMC3851000,24804,All authors read and approved the final manuscript.,Authors’ contributions,[145034],[32890],[32941],[False],[0],[0],[False],['0']
13893,PMC3851000,24805,Authors’ information,Authors’ information,[145039],[32942],[32963],[False],[0],[0],[False],['0']
13894,PMC3851000,24806,"MGW is Assistant Professor of Clinical Psychiatry (Division of Developmental Neuroscience), and Pathology & Cell Biology and Pediatrics.",Authors’ information,[145044],[32964],[33100],[False],[0],[0],[False],['0']
13895,PMC3851000,24807,She is a board certified child psychiatrist who has treated children with a wide range of developmental and behavioral disorders for more than 35 years with family nurture therapy.,Authors’ information,[145049],[33101],[33281],[False],[0],[0],[False],['0']
13896,PMC3851000,24808,MAH is a Professor Emeritus and founder of the Division of Developmental Psychobiology (now Developmental Neuroscience) in the Department of Psychiatry at Columbia University and New York State Psychiatric Institute.,Authors’ information,[145054],[33282],[33498],[False],[0],[0],[False],['0']
13897,PMC3851000,24809,He was the first Director of the Sackler Institute for Developmental Psychobiology at Columbia University.,Authors’ information,[145059],[33499],[33605],[False],[0],[0],[False],['0']
13898,PMC3851000,24810,RIS is Professor of Pediatrics and Obstetrics and Gynecology.,Authors’ information,[145064],[33606],[33667],[False],[0],[0],[False],['0']
13899,PMC3851000,24811,He is the past Director and Principal Investigator for the Perinatal Emphasis Research Center from the National Institute of Child Health & Development.,Authors’ information,[145069],[33668],[33820],[False],[0],[0],[False],['0']
13900,PMC3851000,24812,"In his collaboration with the NICU Study, Dr. Stark engaged in the study design and methods.",Authors’ information,[145074],[33821],[33913],[False],[0],[0],[False],['0']
13901,PMC3851000,24813,"Dr. Stark brings years of clinical and translational experience to the study team, providing insights on patient care, sleep studies, and EEGs.",Authors’ information,[145079],[33914],[34057],[False],[0],[0],[False],['0']
13902,PMC3851000,24814,"HFA is an Associate Clinical Professor of Neuroscience and Biostatistics at the Mailman School of Public Health, Columbia University, and Director of the Data Coordinating Center at New York State Psychiatric Institute and Columbia University Medical Center.",Authors’ information,[145084],[34058],[34316],[False],[0],[0],[False],['0']
13903,PMC3851000,24815,Dr. Andrews has extensive experience in the design of data systems and statistical analysis for clinic trials.,Authors’ information,[145089],[34317],[34427],[False],[0],[0],[False],['0']
13904,PMC3851000,24816,"JA is a registered psychologist, a doctoral candidate in the Epidemiology Department, Mailman School of Public Health, Columbia University, and data analyst with the FNI-NICU study.",Authors’ information,[145094],[34428],[34609],[False],[0],[0],[False],['0']
13905,PMC3851000,24817,"Ms. Austin has a broad experience of research, monitoring and evaluation of large international programs supporting reproductive and maternal health.",Authors’ information,[145099],[34610],[34759],[False],[0],[0],[False],['0']
13906,PMC3851000,24818,SBG is currently the Director of Elegant Brain Sciences.,Authors’ information,[145104],[34760],[34816],[False],[0],[0],[False],['0']
13907,PMC3851000,24819,Dr. Glickstein has conducted many studies of brain development and behavior in animal models.,Authors’ information,[145109],[34817],[34910],[False],[0],[0],[False],['0']
13908,PMC3851000,24820,Dr. Glickstein participates in literature research and manuscript preparation and editing.,Authors’ information,[145114],[34911],[35001],[False],[0],[0],[False],['0']
13909,PMC3851000,24821,RJL is Managing Director of the BrainGut Initiative and supervises staff involved in the Initiative’s studies and research.,Authors’ information,[145119],[35002],[35125],[False],[0],[0],[False],['0']
13910,PMC3851000,24822,Mr. Ludwig also actively participates in manuscript preparation and editing.,Authors’ information,[145124],[35126],[35202],[False],[0],[0],[False],['0']
13911,PMC3851000,24823,MMM is Chief of the Division of Developmental Neuroscience in the Department of Psychiatry at New York State Psychiatric Institute.,Authors’ information,[145129],[35203],[35334],[False],[0],[0],[False],['0']
13912,PMC3851000,24824,He has conducted numerous studies in both animal models and human infant related to development of physiological systems and behavior.,Authors’ information,[145134],[35335],[35469],[False],[0],[0],[False],['0']
13913,PMC3851000,24825,He is past president of the International Society of Developmental Psychobiology.,Authors’ information,[145139],[35470],[35551],[False],[0],[0],[False],['0']
13914,PMC3851000,24826,"FNI Trial Group: Ladan Afifi, Amy Bechar, Beatrice S. Beebe, Susan A. Brunelli, Kathryn E. Carnazza, Christine Y. Chang, Patricia A. Farrell, Ewelina S. Fiedor, Qais Karim, Shanna Kofman, Yasmine A. Koukaz, Mary T. McKiernan, William P. Fifer and Sorana Sopterian are members of the Department of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY, USA.",Authors’ information,[145144],[35552],[35933],[False],[0],[0],[False],['0']
13915,PMC3851000,24827,"David A. Bateman, Phillip G. Grieve, John M. Lorenz, Richard A. Polin and Rakesh Sahni are members of the Department of Pediatrics, Columbia University College of Physicians & Surgeons, New York, NY, USA.",Authors’ information,[145149],[35934],[36138],[False],[0],[0],[False],['0']
13916,PMC3851000,24828,"David P. Merle is a member of the Mailman School of Public Health, Columbia University, New York, NY, USA.",Authors’ information,[145154],[36139],[36245],[False],[0],[0],[False],['0']
13917,PMC3851000,24829,"Amie A. Hane is a member of the Department of Psychology, Williams College, Williamstown, MA, USA.",Authors’ information,[145159],[36246],[36344],[False],[0],[0],[False],['0']
13918,PMC3851000,24830,Pre-publication history,Pre-publication history,[145164],[36345],[36369],[False],[0],[0],[False],['0']
13919,PMC3851000,24831,The pre-publication history for this paper can be accessed here:,Pre-publication history,[145169],[36370],[36434],[False],[0],[0],[False],['0']
13920,PMC3851000,24832,http://www.biomedcentral.com/1471-2431/13/148/prepub,Pre-publication history,[145174],[36435],[36487],[False],[0],[0],[False],['0']
13921,PMC3851000,24833,Acknowledgments,Acknowledgments,[145179],[36488],[36504],[False],[0],[0],[False],['0']
13922,PMC3851000,24834,We would like to thank the NICU staff at the Morgan Stanley Children’s Hospital of New York as well as the participating families for their invaluable assistance to our program of research.,Acknowledgments,[145184],[36505],[36694],[False],[0],[0],[False],['0']
13923,PMC3851000,24835,"We also want to acknowledge and thank our Performance and Safety Monitoring Board for their thoughtful contributions to the conduct of this study (Bruce Levin, Ph.D., Michael Weitzman, M.D.",Acknowledgments,[145189],[36695],[36884],[False],[0],[0],[False],['0']
13924,PMC3851000,24836,"and Deborah E. Campbell, M.D.).",Acknowledgments,[145194],[36885],[36916],[False],[0],[0],[False],['0']
13925,PMC3851000,24837,"Funding for this project was provided by the Einhorn Family Charitable Trust and the Fleur Fairman Family to the BrainGut Initiative at Columbia University Medical Center and, in part, by Columbia University’s CTSA grant ULI RR024156 from NCRR/NIH.",Acknowledgments,[145199],[36917],[37165],[False],[0],[0],[False],['0']
13926,PMC3851000,24838,"The funding sources had no influence upon the study design, data collection, analysis and interpretation of data, nor participated in the writing of the manuscript or submission/publication process.",Acknowledgments,[145204],[37166],[37364],[False],[0],[0],[False],['0']
15032,PMC3882723,25900,Quarterly vs. yearly clinical follow-up of remotely monitored recipients of prophylactic implantable cardioverter-defibrillators: results of the REFORM trial,Title,[153250],[36016],[157],[False],[0],[0],[False],['0']
15033,PMC3882723,25901,Aims,Abstract,[153261],[158],[163],[False],[0],[0],[False],['0']
15034,PMC3882723,25902,The rapidly increasing number of patients with implantable cardioverter-defibrillators (ICD) places a large burden on follow-up providers.,Abstract,[153272],[164],[302],[False],[0],[0],[False],['0']
15035,PMC3882723,25903,This study investigated the possibility of longer in-office follow-up intervals in primary prevention ICD patients under remote monitoring with automatic daily data transmissions from the implant memory.,Abstract,[153283],[303],[506],[False],[0],[0],[False],['0']
15036,PMC3882723,25904,Methods and results,Abstract,[153294],[507],[526],[False],[0],[0],[False],['0']
15037,PMC3882723,25905,"Conducted in 155 ICD recipients with MADIT II indications, the study compared the burden of scheduled and unscheduled ICD follow-up visits, quality of life (SF-36), and clinical outcomes in patients randomized to either 3- or 12-month follow-up intervals in the period between 3 and 27 months after implantation.",Abstract,[153305],[527],[839],[False],[0],[0],[False],['0']
15038,PMC3882723,25906,Remote monitoring (Biotronik Home Monitoring) was used equally in all patients.,Abstract,[153316],[840],[919],[False],[0],[0],[False],['0']
15039,PMC3882723,25907,"In contrast to previous clinical studies, no calendar-based remote data checks were performed between scheduled in-office visits.",Abstract,[153327],[920],[1049],[False],[0],[0],[False],['0']
15040,PMC3882723,25908,"Compared with the 3-month follow-up interval, the 12-month interval resulted in a minor increase in the number of unscheduled follow-ups (0.64 vs. 0.27 per patient-year; P = 0.03) and in a major reduction in the total number of in-office ICD follow-ups (1.60 vs. 3.85 per patient-year; P < 0.001).",Abstract,[153338],[1050],[1347],[False],[0],[0],[False],['0']
15041,PMC3882723,25909,"No significant difference was found in mortality, hospitalization rate, or hospitalization length during the 2-year observation period, but more patients were lost to follow-up in the 12-month group (10 vs. 3; P = 0.04).",Abstract,[153349],[1348],[1568],[False],[0],[0],[False],['0']
15042,PMC3882723,25910,The SF-36 scores favoured the 12-month intervals in the domains ‘social functioning’ and ‘mental health’.,Abstract,[153360],[1569],[1674],[False],[0],[0],[False],['0']
15043,PMC3882723,25911,Conclusion,Abstract,[153371],[1675],[1685],[False],[0],[0],[False],['0']
15044,PMC3882723,25912,"In prophylactic ICD recipients under automatic daily remote monitoring, the extension of the 3-month in-office follow-up interval to 12 months appeared to safely reduce the ICD follow-up burden during 27 months after implantation.",Abstract,[153382],[1686],[1916],[False],[0],[0],[False],['0']
15045,PMC3882723,25913,ClinicalTrials.gov Identifier,Abstract,[153393],[1917],[1946],[False],[0],[0],[False],['0']
15046,PMC3882723,25914,NCT00401466 (http://www.clinicaltrials.gov/ct2/show/NCT00401466).,Abstract,[153404],[1947],[2012],[False],[0],[0],[False],['0']
15047,PMC3882723,25915,Introduction,Introduction,[153415],[2013],[2026],[False],[0],[0],[False],['0']
15048,PMC3882723,25916,"Most patients receiving an implantable cardioverter-defibrillator (ICD) for a primary prevention indication have a low rate of events necessitating visits to the ICD clinic.1,2 However, regular follow-up is still considered important to monitor ICD function and the patient's condition.",Introduction,[153426],[2027],[2313],[False],[0],[0],[False],['0']
15049,PMC3882723,25917,"Expert consensus advocates clinical checks every 3–6 months, with an increased frequency in response to product advisories.3 Alternatively, ICD function and medical events recorded by the implant can be analysed using remote monitoring technology.3–6 Two large randomized clinical trials have shown that the replacement of regular clinic visits with remote data checks results in a faster reaction after events requiring intervention in parallel with a reduced number of in-hospital follow-up examinations.7,8 In both trials, longer in-hospital follow-up intervals combined with remote monitoring were compared with standard follow-up intervals without remote monitoring.7,8",Introduction,[153437],[2314],[2988],[False],[0],[0],[False],['0']
15050,PMC3882723,25918,"Because remote monitoring is about to become the standard of care, it would be of interest to compare longer (e.g.",Introduction,[153448],[2989],[3103],[False],[0],[0],[False],['0']
15051,PMC3882723,25919,yearly) and standard in-hospital follow-up intervals in patients undergoing the same kind of remote monitoring in both study arms in order to assess the isolated effect of less frequent in-hospital follow-up.,Introduction,[153459],[3104],[3312],[False],[0],[0],[False],['0']
15052,PMC3882723,25920,"Furthermore, the necessity of calendar-based remote follow-up sessions in the form used in the aforementioned trials7,8 can be questioned for remote systems capable of automatic physician alerting to relevant medical and technical events.",Introduction,[153470],[3313],[3551],[False],[0],[0],[False],['0']
15053,PMC3882723,25921,The REFORM trial randomized patients receiving prophylactic ICD treatment for MADIT II indications to either yearly or quarterly clinic visits.,Introduction,[153481],[3552],[3695],[False],[0],[0],[False],['0']
15054,PMC3882723,25922,All patients were equally monitored using a remote monitoring system with fully automatic daily transmission and physician alerting after predefined events.,Introduction,[153492],[3696],[3852],[False],[0],[0],[False],['0']
15055,PMC3882723,25923,"The ICD follow-up burden (scheduled and unscheduled clinic visits), generic quality of life (QoL), and clinical outcomes were compared.",Introduction,[153503],[3853],[3988],[False],[0],[0],[False],['0']
15056,PMC3882723,25924,Methods,Methods,[153514],[3989],[3997],[False],[0],[0],[False],['0']
15057,PMC3882723,25925,"The Remote Follow-Up for ICD-Therapy in Patients Meeting MADIT II Criteria (REFORM) study was a randomized, non-blinded, parallel-design trial, in which three German and two Czech medical centres participated.",Methods,[153525],[3998],[4207],[False],[0],[0],[False],['0']
15058,PMC3882723,25926,The study was conducted in accordance with the Declaration of Helsinki.,Methods,[153536],[4208],[4279],[False],[0],[0],[False],['0']
15059,PMC3882723,25927,The protocol was approved by the Ethics Committees of the participating institutions.,Methods,[153547],[4280],[4365],[False],[0],[0],[False],['0']
15060,PMC3882723,25928,All patients gave their written informed consent to participate in the trial.,Methods,[153558],[4366],[4443],[False],[0],[0],[False],['0']
15061,PMC3882723,25929,Patient selection,Methods|Patient selection,[153569],[4444],[4461],[False],[0],[0],[False],['0']
15062,PMC3882723,25930,"To be enrolled, patients had to meet the MADIT II trial enrolment criteria; that is, to be survivors of a myocardial infarction and to have a left-ventricular ejection fraction of <30%.9 The exclusion criteria were myocardial infarction within 30 days before enrolment, New York Heart Association functional class IV, a secondary prevention indication for ICD therapy, or living in an area lacking the GSM mobile phone coverage needed for remote monitoring transmission.",Methods|Patient selection,[153580],[4462],[4932],[False],[0],[0],[False],['0']
15063,PMC3882723,25931,Patients indicated for cardiac pacing were excluded for safety concerns because the ICDs used in this trial did not have the capability to automatically measure the pacing threshold.,Methods|Patient selection,[153591],[4933],[5115],[False],[0],[0],[False],['0']
15064,PMC3882723,25932,"Furthermore, patients indicated for cardiac resynchronization therapy (CRT) according to clinically accepted criteria at the time of enrolment were not included because the required remote monitoring system was not available for devices providing CRT.",Methods|Patient selection,[153602],[5116],[5367],[False],[0],[0],[False],['0']
15065,PMC3882723,25933,Remote monitoring,Methods|Remote monitoring,[153613],[5368],[5385],[False],[0],[0],[False],['0']
15066,PMC3882723,25934,"The ICDs used were equipped with the Home Monitoring (HM) capability (Biotronik, Berlin, Germany) described previously.5,6,10–15 Briefly, the implant transmits data once per day, comprising counts of arrhythmia episodes and therapies, rhythm information, and technical parameters.",Methods|Remote monitoring,[153624],[5386],[5666],[False],[0],[0],[False],['0']
15067,PMC3882723,25935,Transmission of intracardiac electrograms was available in only a few devices used in this study.,Methods|Remote monitoring,[153635],[5667],[5764],[False],[0],[0],[False],['0']
15068,PMC3882723,25936,The message sent by the implant is relayed by the patient device to the HM Service Center (HMSC) via the mobile phone network.,Methods|Remote monitoring,[153646],[5765],[5891],[False],[0],[0],[False],['0']
15069,PMC3882723,25937,"The HMSC makes the data available to the treating physician on a secure internet site, and also sends alerts by e-mail or SMS if the data meet user-defined criteria.",Methods|Remote monitoring,[153657],[5892],[6057],[False],[0],[0],[False],['0']
15070,PMC3882723,25938,"For long-term performance, HM was designed to require the patient only to switch on the patient device and keep it by the bedside.",Methods|Remote monitoring,[153668],[6058],[6188],[False],[0],[0],[False],['0']
15071,PMC3882723,25939,Transmission performance is calculated as the number of days with data transmission divided by the total number of days since the first message.,Methods|Remote monitoring,[153679],[6189],[6333],[False],[0],[0],[False],['0']
15072,PMC3882723,25940,Study protocol,Methods|Study protocol,[153690],[6334],[6348],[False],[0],[0],[False],['0']
15073,PMC3882723,25941,Figure 1 Clinical follow-up schedule.,Methods|Study protocol,[153701],[6349],[6386],[False],[0],[0],[False],['0']
15074,PMC3882723,25942,Full circles indicate the phase affected by patient randomization to quarterly (Q-group) or yearly (Y-group) routine in-office ICD follow-ups.,Methods|Study protocol,[153712],[6387],[6529],[False],[0],[0],[False],['0']
15075,PMC3882723,25943,"For the whole duration of the study, all patients were under automatic, daily Home Monitoring surveillance, without calendar-based remote follow-up sessions.",Methods|Study protocol,[153723],[6530],[6687],[False],[0],[0],[False],['0']
15076,PMC3882723,25944,"ICD, implantable cardioverter-defibrillator..",Methods|Study protocol,[153734],[6688],[6733],[False],[0],[0],[False],['0']
15077,PMC3882723,25945,Patients were evenly randomized to quarterly clinic visits (Q-group) or yearly clinic visits (Y-group).,Methods|Study protocol,[153745],[6734],[6837],[False],[0],[0],[False],['0']
15078,PMC3882723,25946,"After implantation of a single- or dual-chamber ICD (Belos®, Lexos®, or Lumos®; Biotronik, Berlin, Germany), patients in both study arms received the HM patient device.",Methods|Study protocol,[153756],[6838],[7006],[False],[0],[0],[False],['0']
15079,PMC3882723,25947,"They were under continuous, automatic remote monitoring during the entire study.",Methods|Study protocol,[153767],[7007],[7087],[False],[0],[0],[False],['0']
15080,PMC3882723,25948,The response to HM alerts was left to the investigators' discretion.,Methods|Study protocol,[153778],[7088],[7156],[False],[0],[0],[False],['0']
15081,PMC3882723,25949,No calendar-based remote data checks or remote follow-up sessions were scheduled.,Methods|Study protocol,[153789],[7157],[7238],[False],[0],[0],[False],['0']
15082,PMC3882723,25950,All treatments up to the 3-month follow-up were done according to institutional standards and were equal in both study arms (Figure 1).,Methods|Study protocol,[153800],[7239],[7374],[False],[0],[0],[False],['0']
15083,PMC3882723,25951,"At the 3-month follow-up, all patients' ventricular function was re-evaluated.",Methods|Study protocol,[153811],[7375],[7454],[False],[0],[0],[False],['0']
15084,PMC3882723,25952,An improved left-ventricular ejection fraction (≥30%) or the development of a permanent pacing indication was ground for exclusion from the trial.,Methods|Study protocol,[153822],[7455],[7601],[False],[0],[0],[False],['0']
15085,PMC3882723,25953,The devices were programmed as follows: ventricular demand pacing with 40 beats per min (bpm); ventricular tachycardia zone from 180 bpm with anti-tachycardia pacing therapy; ventricular fibrillation zone from 200 bpm with shock therapy; stability and sudden onset criteria for arrhythmia discrimination ‘ON’.,Methods|Study protocol,[153833],[7602],[7911],[False],[0],[0],[False],['0']
15086,PMC3882723,25954,This programming was subject to adjustments after the occurrence of a first event.,Methods|Study protocol,[153844],[7912],[7994],[False],[0],[0],[False],['0']
15087,PMC3882723,25955,Patients were followed for 2 years after the 3-month follow-up.,Methods|Study protocol,[153855],[7995],[8058],[False],[0],[0],[False],['0']
15088,PMC3882723,25956,They were instructed to refer to the investigational site for ICD-related issues and heart rhythm disorders.,Methods|Study protocol,[153866],[8059],[8167],[False],[0],[0],[False],['0']
15089,PMC3882723,25957,"Care for the patients' concomitant diseases, most prominently heart failure, was provided by specialists as clinically indicated; however, they had no role in the study.",Methods|Study protocol,[153877],[8168],[8337],[False],[0],[0],[False],['0']
15090,PMC3882723,25958,Study data were collected by staff dedicated to the trial under the direct supervision of the principal investigators.,Methods|Study protocol,[153888],[8338],[8456],[False],[0],[0],[False],['0']
15091,PMC3882723,25959,Data management was provided by the sponsor.,Methods|Study protocol,[153899],[8457],[8501],[False],[0],[0],[False],['0']
15092,PMC3882723,25960,Data processing was supervised by the clinical team of the first author.,Methods|Study protocol,[153910],[8502],[8574],[False],[0],[0],[False],['0']
15093,PMC3882723,25961,Scheduled follow-up visits,Methods|Scheduled follow-up visits,[153921],[8575],[8601],[False],[0],[0],[False],['0']
15094,PMC3882723,25962,"Patients assigned to the Q-group were scheduled to return for outpatient visits every 3 months, and those assigned to the Y-group had visits at 3, 15, and 27 months after discharge (Figure 1).",Methods|Scheduled follow-up visits,[153932],[8602],[8794],[False],[0],[0],[False],['0']
15095,PMC3882723,25963,A follow-up examination was classified as regular if occurring within a window of 4 weeks before or after an appropriate date relative to the discharge date.,Methods|Scheduled follow-up visits,[153943],[8795],[8952],[False],[0],[0],[False],['0']
15096,PMC3882723,25964,"At each outpatient visit, the ICD was interrogated and tested and its memory was analysed in order to adapt patient management accordingly.",Methods|Scheduled follow-up visits,[153954],[8953],[9092],[False],[0],[0],[False],['0']
15097,PMC3882723,25965,"The generic health-related QoL was assessed by the 36-item General Health Survey (SF-36) questionnaire at baseline, 15-month follow-up, and 27-month follow-up, in both study arms.",Methods|Scheduled follow-up visits,[153965],[9093],[9272],[False],[0],[0],[False],['0']
15098,PMC3882723,25966,Unscheduled follow-up visits,Methods|Unscheduled follow-up visits,[153976],[9273],[9301],[False],[0],[0],[False],['0']
15099,PMC3882723,25967,"Patients were seen outside of the scheduled visits for the following pre-specified HM alerts: (i) elective battery replacement indicator; (ii) any lead impedance out of range; (iii) delivery of a first shock after discharge of the patient from the hospital; (iv) delivery of ≥5 episodes of anti-tachycardia pacing; (v) delivery of ≥2 shocks per month for the first time, or occurrence of ≥2 supraventricular tachycardia or VT episodes per week.",Methods|Unscheduled follow-up visits,[153987],[9302],[9746],[False],[0],[0],[False],['0']
15100,PMC3882723,25968,"Patients could also be seen at unscheduled visits due to HM trend data or for any other reason, upon the patient's request or initiated by the investigator.",Methods|Unscheduled follow-up visits,[153998],[9747],[9903],[False],[0],[0],[False],['0']
15101,PMC3882723,25969,Scheduled and unscheduled follow-up examinations were conducted similarly.,Methods|Unscheduled follow-up visits,[154009],[9904],[9978],[False],[0],[0],[False],['0']
15102,PMC3882723,25970,"To get an estimate of additional patient contacts to medical professionals, the patients were instructed to notify such visits in a diary and were interviewed at each ICD follow-up.",Methods|Unscheduled follow-up visits,[154020],[9979],[10160],[False],[0],[0],[False],['0']
15103,PMC3882723,25971,Study hypothesis and endpoints,Methods|Study hypothesis and endpoints,[154031],[10161],[10191],[False],[0],[0],[False],['0']
15104,PMC3882723,25972,"The primary study hypothesis was that the rate of unscheduled ICD follow-up visits in the Y-group would exceed the rate in the Q-group by <1.0 per patient-year, after the 3-month follow-up point.",Methods|Study hypothesis and endpoints,[154042],[10192],[10387],[False],[0],[0],[False],['0']
15105,PMC3882723,25973,A confirmation of this non-inferiority hypothesis would mean that the total rate of scheduled and unscheduled ICD follow-up visits would be substantially lower in the Y-group than in the Q-group.,Methods|Study hypothesis and endpoints,[154053],[10388],[10583],[False],[0],[0],[False],['0']
15106,PMC3882723,25974,"Secondary endpoints were the intra-individual difference in QoL scores between 27 months and baseline, total and cardiovascular mortality, and the rate and duration of all hospitalizations and cardiovascular hospitalizations.",Methods|Study hypothesis and endpoints,[154064],[10584],[10809],[False],[0],[0],[False],['0']
15107,PMC3882723,25975,"Furthermore, we made a post-hoc analysis of all available arrhythmia and therapy data (12 different items) extracted from the HMSC database.",Methods|Study hypothesis and endpoints,[154075],[10810],[10950],[False],[0],[0],[False],['0']
15108,PMC3882723,25976,"The data comprised, per study group, the numbers of patients fulfilling various criteria such as having episodes in different arrhythmia zones, started or delivered therapies, or unsuccessful maximum-energy shocks.",Methods|Study hypothesis and endpoints,[154086],[10951],[11165],[False],[0],[0],[False],['0']
15109,PMC3882723,25977,The underlying arrhythmias in this analysis were not adjudicated by the investigator.,Methods|Study hypothesis and endpoints,[154097],[11166],[11251],[False],[0],[0],[False],['0']
15110,PMC3882723,25978,"Shock therapy was considered ineffective if the device delivered more than one shock during one arrhythmia episode, and this could include cases of repeated shocks in episodes of supraventricular tachycardia.",Methods|Study hypothesis and endpoints,[154108],[11252],[11460],[False],[0],[0],[False],['0']
15111,PMC3882723,25979,Statistical analysis,Methods|Statistical analysis,[154119],[11461],[11481],[False],[0],[0],[False],['0']
15112,PMC3882723,25980,The sample size was based on the primary study hypothesis and calculated on a Blackwelder-type test of non-inferiority.,Methods|Statistical analysis,[154130],[11482],[11601],[False],[0],[0],[False],['0']
15113,PMC3882723,25981,"Unscheduled ICD follow-up visits were assumed to occur independently from one other, to have a daily probability (equivalent to 0.21 or 0.96 visits per patient-year in the Q-group and the Y-group, respectively), and, hence, to obey binomial distribution.",Methods|Statistical analysis,[154141],[11602],[11856],[False],[0],[0],[False],['0']
15114,PMC3882723,25982,"Assuming a 2-year attrition rate of 28% in both groups, a sample of 150 patients needed to remain in the study after the 3-month follow-up (for 1-ß = 80%).",Methods|Statistical analysis,[154152],[11857],[12012],[False],[0],[0],[False],['0']
15115,PMC3882723,25983,All patients with baseline QoL data were included in the intention-to-treat based QoL analysis.,Methods|Statistical analysis,[154163],[12013],[12108],[False],[0],[0],[False],['0']
15116,PMC3882723,25984,Missing 27-month QoL data were accounted for using the last-observation-carried-forward (LOCF) method.,Methods|Statistical analysis,[154174],[12109],[12211],[False],[0],[0],[False],['0']
15117,PMC3882723,25985,"Due to slight post-implantation increase in patients' QoL and greater loss to follow-up in the Y-group, this approach can be considered conservative.",Methods|Statistical analysis,[154185],[12212],[12361],[False],[0],[0],[False],['0']
15118,PMC3882723,25986,"For normally distributed continuous data (verified using the Shapiro–Wilk test), mean values and standard deviations were calculated.",Methods|Statistical analysis,[154196],[12362],[12495],[False],[0],[0],[False],['0']
15119,PMC3882723,25987,"For non-normally distributed data, median values, interquartile ranges (IQR), and mean values, if appropriate for comparison with reference data, are shown.",Methods|Statistical analysis,[154207],[12496],[12652],[False],[0],[0],[False],['0']
15120,PMC3882723,25988,"For categorical data, the absolute and relative frequencies were calculated.",Methods|Statistical analysis,[154218],[12653],[12729],[False],[0],[0],[False],['0']
15121,PMC3882723,25989,Continuous data were compared using the t-test (if normally distributed) or the Wilcoxon–Mann–Whitney rank test (if non-normally distributed).,Methods|Statistical analysis,[154229],[12730],[12872],[False],[0],[0],[False],['0']
15122,PMC3882723,25990,Categorical data were compared with a χ² test according to Pearson's or Fisher's exact test as appropriate.,Methods|Statistical analysis,[154240],[12873],[12980],[False],[0],[0],[False],['0']
15123,PMC3882723,25991,"One-sided statistical significance for the primary study hypothesis, or two-sided statistical significance for all other tests, was established as P < 0.05.",Methods|Statistical analysis,[154251],[12981],[13137],[False],[0],[0],[False],['0']
15124,PMC3882723,25992,Results,Results,[154262],[13138],[13146],[False],[0],[0],[False],['0']
15125,PMC3882723,25993,Table 1 Baseline patient characteristics.,Results,[154273],[13147],[13188],[False],[0],[0],[False],['0']
15126,PMC3882723,25994,"Of 155 patients enrolled in the study, 78 were randomly assigned to the Q-group and 77 to the Y-group.",Results,[154284],[13189],[13291],[False],[0],[0],[False],['0']
15127,PMC3882723,25995,The baseline characteristics of the two study groups were similar (Table 1).,Results,[154295],[13292],[13368],[False],[0],[0],[False],['0']
15128,PMC3882723,25996,The patients were 63 ± 10 years old.,Results,[154306],[13369],[13405],[False],[0],[0],[False],['0']
15129,PMC3882723,25997,The mean ejection fraction was 25 ± 5%.,Results,[154317],[13406],[13445],[False],[0],[0],[False],['0']
15130,PMC3882723,25998,All patients had a history of myocardial infarction.,Results,[154328],[13446],[13498],[False],[0],[0],[False],['0']
15131,PMC3882723,25999,"As REFORM was planned before publication of major CRT trials, ventricular dyssynchrony and QRS duration were not systematically evaluated at enrolment.",Results,[154339],[13499],[13650],[False],[0],[0],[False],['0']
15132,PMC3882723,26000,Table 2 Reasons for early terminations and the length of follow-up.,Results,[154350],[13651],[13719],[False],[0],[0],[False],['0']
15133,PMC3882723,26001,"At the 3-month follow-up, nine patients (5.8%) were excluded due to either improved left-ventricular ejection fraction (≥30%) or development of a permanent pacing indication (Table 2).",Results,[154361],[13720],[13904],[False],[0],[0],[False],['0']
15134,PMC3882723,26002,"Additional 48 patients (31%) terminated the study prematurely due to death, heart transplantation, pacing system upgrade to biventricular ICD, or other reasons listed in Table 2, among which only loss to follow-up differed significantly between the two groups (three in the Q-group vs. 10 in the Y-group, P = 0.04).",Results,[154372],[13905],[14220],[False],[0],[0],[False],['0']
15135,PMC3882723,26003,"The remaining 98 patients (63.2%) completed the study as planned, at the 27-month follow-up.",Results,[154383],[14221],[14313],[False],[0],[0],[False],['0']
15136,PMC3882723,26004,"The median (IQR) follow-up duration in all 155 patients was 26.6 (14.6–27.5) months; in 57 patients with early study termination, 7.8 (3.5–15.1) months.",Results,[154394],[14314],[14466],[False],[0],[0],[False],['0']
15137,PMC3882723,26005,One patient assigned to the Y-group preferred to see the physician more often than once a year.,Results,[154405],[14467],[14563],[False],[0],[0],[False],['0']
15138,PMC3882723,26006,"According to the intention-to-treat principle, he was evaluated within the Y-group, with all clinic visits other than those at 3, 15, and 27 months classified as unscheduled patient-initiated follow-ups.",Results,[154416],[14564],[14767],[False],[0],[0],[False],['0']
15139,PMC3882723,26007,"The first HM transmission occurred at 5 ± 18 days (median, 1 day) after patient discharge.",Results,[154427],[14768],[14858],[False],[0],[0],[False],['0']
15140,PMC3882723,26008,"Subsequently, HM data were received on 87.1% (83 648 out of 96 066) of all days, including all enrolled patients.",Results,[154438],[14859],[14972],[False],[0],[0],[False],['0']
15141,PMC3882723,26009,The transmission performance did not differ significantly between the Q-group (85.0%) and Y-group (89.0%).,Results,[154449],[14973],[15079],[False],[0],[0],[False],['0']
15142,PMC3882723,26010,Primary study hypothesis,Results|Primary study hypothesis,[154460],[15080],[15104],[False],[0],[0],[False],['0']
15143,PMC3882723,26011,"Of 145 patients (72 Q-group, 73 Y-group) remaining in the study after the 3-month follow-up, 50 patients (17Q/33Y) had 94 unscheduled in-office ICD follow-ups (24Q, 70Y) until 27 months.",Results|Primary study hypothesis,[154471],[15105],[15291],[False],[0],[0],[False],['0']
15144,PMC3882723,26012,The mean (median; IQR) number of unscheduled follow-ups per patient-year was 0.27 (0.00; 0.00–0.35) in the Q-group and 0.64 (0.00; 0.00–1.00) in the Y-group (P = 0.03).,Results|Primary study hypothesis,[154482],[15292],[15460],[False],[0],[0],[False],['0']
15145,PMC3882723,26013,"As the increase in the Y-group did not exceed one additional visit per patient-year (P < 0.001), the primary study hypothesis was met.",Results|Primary study hypothesis,[154493],[15461],[15595],[False],[0],[0],[False],['0']
15146,PMC3882723,26014,Table 3 Reasons for unscheduled implantable cardioverter-defibrillator follow-up visits after the 3-month follow-up.,Results|Primary study hypothesis,[154504],[15596],[15712],[False],[0],[0],[False],['0']
15147,PMC3882723,26015,The reasons for 94 unscheduled follow-ups are listed in Table 3.,Results|Primary study hypothesis,[154515],[15713],[15777],[False],[0],[0],[False],['0']
15148,PMC3882723,26016,Nearly two-thirds of unscheduled follow-ups were initiated by physicians (n = 61; 64.9%) and one-third was initiated by patients (n = 33; 35.1%).,Results|Primary study hypothesis,[154526],[15778],[15923],[False],[0],[0],[False],['0']
15149,PMC3882723,26017,"The most frequently claimed reason was ‘arrhythmia and/or ICD therapy’ (five in the Q-group, 21 in the Y-group).",Results|Primary study hypothesis,[154537],[15924],[16036],[False],[0],[0],[False],['0']
15150,PMC3882723,26018,"This marked difference between the two groups can be attributed to a less need to see the affected patient outside regular follow-up schedule in the Q-group, because of the relative proximity of the next regular visit.",Results|Primary study hypothesis,[154548],[16037],[16255],[False],[0],[0],[False],['0']
15151,PMC3882723,26019,"Similarly, the number of unscheduled visits caused by ‘patient malaise or need for reassurance’ in susceptible patients increased directly proportionally to the prolongation of the regular follow-up interval, with nine such visits in the Y-group and one in the Q-group.",Results|Primary study hypothesis,[154559],[16256],[16525],[False],[0],[0],[False],['0']
15152,PMC3882723,26020,"Furthermore, during ‘hospital stay or visits unrelated to ICD treatment,’ unscheduled follow-ups were undertaken more frequently in the Y-group (n = 10) than in the Q-group (n = 5), reflecting a greater likelihood for the physician to check the ICD function opportunely in a patient who was not supposed to be seen soon (or was not seen recently) on a regular basis.",Results|Primary study hypothesis,[154570],[16526],[16892],[False],[0],[0],[False],['0']
15153,PMC3882723,26021,Figure 2 The mean numbers of FUs per patient-year after the 3-month follow-up.,Results|Primary study hypothesis,[154581],[16893],[16972],[False],[0],[0],[False],['0']
15154,PMC3882723,26022,"ICD, implantable cardioverter-defibrillator; FU, in-office ICD follow-up; Q-group, quarterly routine FU; Y-group, yearly routine FU.",Results|Primary study hypothesis,[154592],[16973],[17105],[False],[0],[0],[False],['0']
15155,PMC3882723,26023,All patients were under close Home Monitoring surveillance..,Results|Primary study hypothesis,[154603],[17106],[17166],[False],[0],[0],[False],['0']
15156,PMC3882723,26024,Figure 3 Cumulative number of unscheduled and total follow-up visits from post-implant discharge up to and including 27-month follow-up.,Results|Primary study hypothesis,[154614],[17167],[17303],[False],[0],[0],[False],['0']
15157,PMC3882723,26025,"Even if not required by study protocol, 1-month follow-up was performed in most patents and is categorized as unscheduled follow-up; it had no influence on study endpoints, for it occurred before the active study period.",Results|Primary study hypothesis,[154625],[17304],[17524],[False],[0],[0],[False],['0']
15158,PMC3882723,26026,"Unsched., unscheduled; other abbreviations as in Figure 2..",Results|Primary study hypothesis,[154636],[17525],[17584],[False],[0],[0],[False],['0']
15159,PMC3882723,26027,The total number of scheduled and unscheduled follow-up visits after the 3-month follow-up was 421 (Q-group) and 184 (Y-group).,Results|Primary study hypothesis,[154647],[17585],[17712],[False],[0],[0],[False],['0']
15160,PMC3882723,26028,The corresponding mean (median; IQR) values per patient-year were 3.85 (3.90; 3.42–4.15) in the Q-group and 1.60 (1.10; 1.00–2.01) in the Y-group (P < 0.001) (Figure 2).,Results|Primary study hypothesis,[154658],[17713],[17882],[False],[0],[0],[False],['0']
15161,PMC3882723,26029,"Of note, the total number of follow-up visits up to and including the mandatory 3-month follow-up was 144 (Q-group) vs. 146 (Y-group).",Results|Primary study hypothesis,[154669],[17883],[18017],[False],[0],[0],[False],['0']
15162,PMC3882723,26030,The cumulative number of unscheduled and total follow-up visits after device implantation in each group is illustrated in Figure 3.,Results|Primary study hypothesis,[154680],[18018],[18149],[False],[0],[0],[False],['0']
15163,PMC3882723,26031,Secondary study endpoints and further analyses,Results|Secondary study endpoints and further analyses,[154691],[18150],[18198],[False],[0],[0],[False],['0']
15164,PMC3882723,26032,Table 4 Hospitalizations and implantable cardioverter-defibrillator therapy delivery after the 3-month follow-up.,Results|Secondary study endpoints and further analyses,[154702],[18199],[18312],[False],[0],[0],[False],['0']
15165,PMC3882723,26033,"Thirteen patients (8.4%) died during the study (Table 2), all except two for cardiovascular reasons.",Results|Secondary study endpoints and further analyses,[154713],[18313],[18413],[False],[0],[0],[False],['0']
15166,PMC3882723,26034,"Of the 145 patients remaining in the study after the 3-month follow-up, 70 patients experienced 170 hospitalizations (0.74 per patient-year), lasting for a median (IQR) of 5 (2–10) days.",Results|Secondary study endpoints and further analyses,[154724],[18414],[18600],[False],[0],[0],[False],['0']
15167,PMC3882723,26035,"Cardiovascular reasons caused 68% of the hospitalizations, lasting for 4 (2–9) days.",Results|Secondary study endpoints and further analyses,[154735],[18601],[18685],[False],[0],[0],[False],['0']
15168,PMC3882723,26036,There were no significant differences between the study groups in these aspects.,Results|Secondary study endpoints and further analyses,[154746],[18686],[18766],[False],[0],[0],[False],['0']
15169,PMC3882723,26037,"Likewise, the 12 items extracted from the HMSC database did not differ between the two study arms (all P ≥ 0.4).",Results|Secondary study endpoints and further analyses,[154757],[18767],[18879],[False],[0],[0],[False],['0']
15170,PMC3882723,26038,"As shown in Table 4, 50 patients received ICD therapy, 45 had at least one shock charging, and six had an unsuccessful maximum energy shock.",Results|Secondary study endpoints and further analyses,[154768],[18880],[19020],[False],[0],[0],[False],['0']
15171,PMC3882723,26039,"Figure 4 Mean intra-individual changes in quality-of-life (SF-36) scores from baseline to 27 months are shown, generated according to the last-observation-carried-forward method.",Results|Secondary study endpoints and further analyses,[154779],[19021],[19200],[False],[0],[0],[False],['0']
15172,PMC3882723,26040,"Grey columns denote the Q-group (57 patients); black columns, the Y-group (55 patients).",Results|Secondary study endpoints and further analyses,[154790],[19201],[19289],[False],[0],[0],[False],['0']
15173,PMC3882723,26041,A positive column height indicates improved quality of life at 27 months and a negative height indicates a deterioration.,Results|Secondary study endpoints and further analyses,[154801],[19290],[19411],[False],[0],[0],[False],['0']
15174,PMC3882723,26042,A statistically significant difference in the heights of the paired white and black columns is indicated by the P-value seen above the columns..,Results|Secondary study endpoints and further analyses,[154812],[19412],[19556],[False],[0],[0],[False],['0']
15175,PMC3882723,26043,"The SF-36 questionnaire was filled out by 112 patients at baseline, of which 54 answered the questionnaire also at the 27-month follow-up, and 23 answered it at the 15-month but not the 27-month follow-up.",Results|Secondary study endpoints and further analyses,[154823],[19557],[19762],[False],[0],[0],[False],['0']
15176,PMC3882723,26044,"Evaluated according to the LOCF method, the mean intra-individual changes in different SF-36 domains from baseline to 27 months are shown in Figure 4.",Results|Secondary study endpoints and further analyses,[154834],[19763],[19913],[False],[0],[0],[False],['0']
15177,PMC3882723,26045,"A significant difference was found in the domains ‘social functioning’ and ‘mental health,’ in favour of the Y-group.",Results|Secondary study endpoints and further analyses,[154845],[19914],[20031],[False],[0],[0],[False],['0']
15178,PMC3882723,26046,"Patients from the Q-group reported 1005 additional visits to medical professionals after the 3-month follow-up, and patients from the Y-group 942 visits.",Results|Secondary study endpoints and further analyses,[154856],[20032],[20186],[False],[0],[0],[False],['0']
15179,PMC3882723,26047,"Neither the percentage of patients reporting such visits (75% in the Q-group vs. 65% in the Y-group, including those who terminated the study prematurely) nor the number of visits per patient (median 7.7 vs. 7.9, respectively) differed statistically significantly between the two groups.",Results|Secondary study endpoints and further analyses,[154867],[20187],[20474],[False],[0],[0],[False],['0']
15180,PMC3882723,26048,Loss to follow-up,Results|Loss to follow-up,[154878],[20475],[20492],[False],[0],[0],[False],['0']
15181,PMC3882723,26049,"Of the 10 patients lost to follow-up in the Y-group, four had HM data transmissions up to 27 months after implantation (they did not die), one patient was lost at day 5, before any methodological difference took place between the two groups (Figure 1), and five patients were lost at ∼3, 7, 8, 10, and 24 months after implantation.",Results|Loss to follow-up,[154889],[20493],[20824],[False],[0],[0],[False],['0']
15182,PMC3882723,26050,"In these five patients, and in the three patients in the Q-group who were lost to follow-up at ∼3, 16, and 17 months, death cannot be excluded.",Results|Loss to follow-up,[154900],[20825],[20968],[False],[0],[0],[False],['0']
15183,PMC3882723,26051,"Even if all these uncertain patients had died, the mortality in both groups would have remained similar (10-Q vs. 11-Y; P = 0.80).",Results|Loss to follow-up,[154911],[20969],[21099],[False],[0],[0],[False],['0']
15184,PMC3882723,26052,Discussion,Discussion,[154922],[21100],[21111],[False],[0],[0],[False],['0']
15185,PMC3882723,26053,Main findings,Discussion|Main findings,[154933],[21112],[21125],[False],[0],[0],[False],['0']
15186,PMC3882723,26054,"In remotely monitored patients with primary prevention ICDs and no cardiac pacing indications, scheduling yearly instead of quarterly follow-up visits resulted in 0.37 more unscheduled follow-up visits per patient-year.",Discussion|Main findings,[154944],[21126],[21345],[False],[0],[0],[False],['0']
15187,PMC3882723,26055,"However, the total rate of follow-up visits was reduced by 58% from 3.85 to 1.60 per patient-year.",Discussion|Main findings,[154955],[21346],[21444],[False],[0],[0],[False],['0']
15188,PMC3882723,26056,"A favourable impact of longer follow-up interval on the patients' QoL was observed, while no impact on patient mortality, hospitalization rate, or other clinical outcomes was evident after the 2-year observation period.",Discussion|Main findings,[154966],[21445],[21664],[False],[0],[0],[False],['0']
15189,PMC3882723,26057,Reduction of follow-up burden,Discussion|Reduction of follow-up burden,[154977],[21665],[21694],[False],[0],[0],[False],['0']
15190,PMC3882723,26058,"Since the completion of the MADIT II trial, primary prevention of sudden cardiac death has become the major indication for ICD implantation.",Discussion|Reduction of follow-up burden,[154988],[21695],[21835],[False],[0],[0],[False],['0']
15191,PMC3882723,26059,The resulting proliferation of ICDs and the parallel introduction of CRT have created a new challenge for individual caregivers and the healthcare system.,Discussion|Reduction of follow-up burden,[154999],[21836],[21990],[False],[0],[0],[False],['0']
15192,PMC3882723,26060,"The simplest solution, in-office follow-up interval lengthening, may delay the detection of potentially important medical events and device failures,16–20 and is therefore not acceptable without a remote access to the information stored in implanted devices' memories.5–8,21,22",Discussion|Reduction of follow-up burden,[155010],[21991],[22268],[False],[0],[0],[False],['0']
15193,PMC3882723,26061,"Previously, the TRUST7 and CONNECT8 trials investigated remote follow-up in ICD recipients.",Discussion|Reduction of follow-up burden,[155021],[22269],[22360],[False],[0],[0],[False],['0']
15194,PMC3882723,26062,TRUST enrolled a typical contemporary ICD population and used the same remote monitoring system as REFORM.,Discussion|Reduction of follow-up burden,[155032],[22361],[22467],[False],[0],[0],[False],['0']
15195,PMC3882723,26063,"Replacing follow-up visits at 6, 9, and 12 months by scheduled checks of remote data in the HM study arm reduced the number of total in-hospital follow-ups by 45%.7 Even higher reduction in REFORM (58%) can be attributed to starting the observation period after the mandatory 3-month follow-up.",Discussion|Reduction of follow-up burden,[155043],[22468],[22762],[False],[0],[0],[False],['0']
15196,PMC3882723,26064,"The numbers of unscheduled visits per patient-year were similar in TRUST (0.78, HM group) and REFORM (0.64, Y-group).",Discussion|Reduction of follow-up burden,[155054],[22763],[22880],[False],[0],[0],[False],['0']
15197,PMC3882723,26065,"In a mixed population of ICD and CRT patients, the CONNECT trial replaced visits at 3, 6, 9, and 12 months with remote follow-ups performed using a substantially different technology (Medtronic CareLink).8 The increase in the number of unscheduled clinic visits in CONNECT (0.29 per patient-year)8 was, however, similar to that in TRUST (0.28) and REFORM (0.37).",Discussion|Reduction of follow-up burden,[155065],[22881],[23243],[False],[0],[0],[False],['0']
15198,PMC3882723,26066,Quality of life,Discussion|Quality of life,[155076],[23244],[23259],[False],[0],[0],[False],['0']
15199,PMC3882723,26067,"The term ‘follow-up burden’ is mainly understood as the hospital's burden, taxed by limited resources and budgets.",Discussion|Quality of life,[155087],[23260],[23374],[False],[0],[0],[False],['0']
15200,PMC3882723,26068,"The patient, however, may also perceive follow-up visits as a burden.23 In REFORM, mental health and social functioning were improved in the Y-group at 27 months compared to baseline, while they deteriorated in the Q-group.",Discussion|Quality of life,[155098],[23375],[23598],[False],[0],[0],[False],['0']
15201,PMC3882723,26069,The recent literature mostly relates QoL in ICD recipients to the number of ICD shocks.,Discussion|Quality of life,[155109],[23599],[23686],[False],[0],[0],[False],['0']
15202,PMC3882723,26070,"However, the necessity of frequent follow-up examinations may also require consideration, since patients undergoing less frequent clinical examinations might feel less ill and less distracted from their normal lives.",Discussion|Quality of life,[155120],[23687],[23903],[False],[0],[0],[False],['0']
15203,PMC3882723,26071,"REFORM offers a first indication that most patients have positive attitude to longer follow-up intervals, although the cohort studied was too small for final answer.",Discussion|Quality of life,[155131],[23904],[24069],[False],[0],[0],[False],['0']
15204,PMC3882723,26072,"As some patients may not agree with the mainstream opinion (one patient randomized to the Y-group wanted to see his physician more often), physicians should carefully discuss the pros and cons of remote monitoring concepts with patients.24",Discussion|Quality of life,[155142],[24070],[24309],[False],[0],[0],[False],['0']
15205,PMC3882723,26073,Safety aspects,Discussion|Safety aspects,[155153],[24310],[24324],[False],[0],[0],[False],['0']
15206,PMC3882723,26074,The main concern about lengthening follow-up visit intervals is that patient condition deterioration may remain undetected for a longer time.,Discussion|Safety aspects,[155164],[24325],[24466],[False],[0],[0],[False],['0']
15207,PMC3882723,26075,"Additional physiological sensors are therefore desirable to mirror patient health status.25 However, in REFORM, no significant difference was found between the Y-group and the Q-group regarding mortality, hospitalization rate, or hospitalization length, neither for all causes nor for cardiovascular causes.",Discussion|Safety aspects,[155175],[24467],[24774],[False],[0],[0],[False],['0']
15208,PMC3882723,26076,"Likewise, the incidence of arrhythmias and therapies, as indicated by a variety of device counters, did not differ significantly between the two groups.",Discussion|Safety aspects,[155186],[24775],[24927],[False],[0],[0],[False],['0']
15209,PMC3882723,26077,These findings are in agreement with TRUST where mortality and adverse event rate were equal in both groups.,Discussion|Safety aspects,[155197],[24928],[25036],[False],[0],[0],[False],['0']
15210,PMC3882723,26078,"Albeit, patient exclusion criteria were more stringent in REFORM in that patients with any cardiac pacing indication were excluded; in TRUST, only pacemaker dependent patients were left out.",Discussion|Safety aspects,[155208],[25037],[25227],[False],[0],[0],[False],['0']
15211,PMC3882723,26079,"Also CONNECT identified no safety issues, but unlike REFORM and TRUST patients, CONNECT patients were contacted by telephone for remote follow-ups and had thereby the opportunity to report health-related issues.",Discussion|Safety aspects,[155219],[25228],[25439],[False],[0],[0],[False],['0']
15212,PMC3882723,26080,"Recently, the EVOLVO study showed that remote monitoring of heart failure patients with ICDs or an ICD for CRT reduces emergency department and urgent in-office visits and, in general, total healthcare use.26",Discussion|Safety aspects,[155230],[25440],[25648],[False],[0],[0],[False],['0']
15213,PMC3882723,26081,The REFORM study adds three safety relevant aspects to the growing evidence favouring longer follow-up intervals in remotely monitored patients.,Discussion|Safety aspects,[155241],[25649],[25793],[False],[0],[0],[False],['0']
15214,PMC3882723,26082,"First, the follow-up period was 27 months, or 1 year longer than that in TRUST and CONNECT.",Discussion|Safety aspects,[155252],[25794],[25885],[False],[0],[0],[False],['0']
15215,PMC3882723,26083,"Secondly, we did not schedule remote data checks in 3-month intervals, but relied entirely on automatic HM alerts.",Discussion|Safety aspects,[155263],[25886],[26000],[False],[0],[0],[False],['0']
15216,PMC3882723,26084,Our results support the assumption that regular remote data checks are not needed in a sufficiently reliable and frequent automatic alerting system.,Discussion|Safety aspects,[155274],[26001],[26149],[False],[0],[0],[False],['0']
15217,PMC3882723,26085,"Thirdly, both our study groups were under the equal remote surveillance.",Discussion|Safety aspects,[155285],[26150],[26222],[False],[0],[0],[False],['0']
15218,PMC3882723,26086,One might argue that TRUST and CONNECT only show that the safety of longer follow-up intervals with remote monitoring is not inferior to standard follow-up intervals without remote monitoring.,Discussion|Safety aspects,[155296],[26223],[26415],[False],[0],[0],[False],['0']
15219,PMC3882723,26087,"The best possible care in theory, however, should combine standard follow-up intervals with remote monitoring.",Discussion|Safety aspects,[155307],[26416],[26526],[False],[0],[0],[False],['0']
15220,PMC3882723,26088,"Yet, REFORM findings do not support the superiority of this option over 12-month follow-up intervals.",Discussion|Safety aspects,[155318],[26527],[26628],[False],[0],[0],[False],['0']
15221,PMC3882723,26089,The only concerning result is that more patients were lost to follow-up in the Y-group (10 vs. 3; P = 0.04).,Discussion|Safety aspects,[155339],[26629],[26737],[True],['HighLossToFollowUp'],['more patients were lost to follow-up in the Y-group'],[True],['MissingData']
15222,PMC3882723,26090,The administration staff in follow-up facilities may therefore need to adapt their efforts in tracking patients with longer follow-up intervals.,Discussion|Safety aspects,[155351],[26738],[26882],[False],[0],[0],[False],['0']
15223,PMC3882723,26091,"Based on the information provided in the last section of Results, however, it is unlikely that the larger loss to follow-up in the Y-group may have hidden a significant increase in mortality.",Discussion|Safety aspects,[155362],[26883],[27074],[False],[0],[0],[False],['0']
15224,PMC3882723,26092,"Moreover, as hospitalizations were calculated per patient-year, the greater patient attrition in the Y-group should not have influenced group comparisons importantly (Table 4).",Discussion|Safety aspects,[155373],[27075],[27251],[False],[0],[0],[False],['0']
15225,PMC3882723,26093,"Of note, cumulative follow-up duration was numerically even longer in the Y-group (117.9 months) than in the Q-group (111.6 months) (Table 4).",Discussion|Safety aspects,[155384],[27252],[27394],[False],[0],[0],[False],['0']
15226,PMC3882723,26094,"Both TRUST and CONNECT investigated the median time from clinical event to clinical decision and found remarkable improvements in the remote monitoring arms (<2 days to clinical decision in TRUST and 4.6 days in CONNECT).7,8 REFORM did not investigate this issue because remote monitoring was equally used in both study arms, but it corroborated the other two trials in that follow-up interval lengthening is feasible and that physician can rely on remote monitoring information to decide on the necessity of an unscheduled in-office ICD follow-up.",Discussion|Safety aspects,[155395],[27395],[27943],[False],[0],[0],[False],['0']
15227,PMC3882723,26095,"As the reimbursement for, and legal aspects of, remote monitoring are unsolved in many countries, a broader clinical implementation of the concepts proposed in these trials may, however, be delayed.27",Discussion|Safety aspects,[155406],[27944],[28144],[False],[0],[0],[False],['0']
15228,PMC3882723,26096,Study limitations,Discussion|Study limitations,[155417],[28145],[28162],[False],[0],[0],[False],['0']
15229,PMC3882723,26097,The investigators were aware of the patients' group assignment when deciding on the need for unscheduled ICD follow-ups.,Discussion|Study limitations,[155428],[28163],[28283],[True],['StudyTeam'],"[""The investigators were aware of the patients' group assignment""]",[True],['Blinding']
15230,PMC3882723,26098,This could have introduced a bias such may be inclination not to initiate unscheduled ICD follow-ups for borderline reasons in the Y-group.,Discussion|Study limitations,[155450],[28284],[28423],[False],[0],[0],[False],['0']
15231,PMC3882723,26099,"A blinded approach, however, was not possible because all patient's data were needed to judge on the necessity of an in-office follow-up.",Discussion|Study limitations,[155462],[28424],[28561],[True],['Blinding'],"['A blinded approach, however, was not possible']",[True],['Blinding']
15232,PMC3882723,26100,"Likewise, the QoL results could have been affected by the patient's knowledge of group assignment.",Discussion|Study limitations,[155485],[28562],[28660],[True],['Patient'],"[""the patient's knowledge of group assignment""]",[True],['Blinding']
15233,PMC3882723,26101,Our analysis was restricted to ICD-related visits because the follow-up burden at ICD and CRT follow-up clinics has been increasing exponentially.,Discussion|Study limitations,[155505],[28661],[28807],[False],[0],[0],[False],['0']
15234,PMC3882723,26102,"Although we also assessed the number of patient contacts to other physicians (for concomitant diseases) based on patient diary and on interviews at each ICD follow-up, these data might have been biased towards less contacts reported in the Y-group because patients may have more difficulty in remembering all contacts since 12 months than since 3 months ago.",Discussion|Study limitations,[155519],[28808],[29166],[True],['PrecisionOfMeasurement'],['these data might have been biased towards less contacts reported in the Y-group'],[True],['OutcomeMeasures']
15235,PMC3882723,26103,The total economic effect of our follow-up concept will need to be investigated.,Discussion|Study limitations,[155527],[29167],[29247],[False],[0],[0],[False],['0']
15236,PMC3882723,26104,More than one-third of the enrolled patients did not reach the regular end of the study.,Discussion|Study limitations,[155542],[29248],[29336],[True],['MissingData'],['More than one-third of the enrolled patients did not reach the regular end of the study'],[True],['MissingData']
15237,PMC3882723,26105,"The drop-out rate was only slightly higher than expected and was reasonably balanced between study groups, eventually not affecting the evaluation of primary study hypothesis that reached statistical significance.",Discussion|Study limitations,[155560],[29337],[29550],[False],[0],[0],[False],['0']
15238,PMC3882723,26106,"On the other hand, a larger study cohort would have enhanced the accuracy of secondary endpoints evaluation.",Discussion|Study limitations,[155576],[29551],[29659],[True],['SampleSize'],['a larger study cohort would have enhanced the accuracy of secondary endpoints evaluation'],[True],['UnderpoweredStudy']
15239,PMC3882723,26107,"In addition, only half of the enrolled patients contributed to the QoL analysis; the rest of patients did not fill out the QoL questionnaire either at baseline or at a later time-point.",Discussion|Study limitations,"[155599, 155600]","[29660, 29660]","[29845, 29845]","[True, True]","['MissingData', 'MissingData']","['only half of the enrolled patients contributed to the QoL analysis', 'the rest of patients did not fill out the QoL questionnaire either at baseline or at a later time-point']","[True, True]",['MissingData']
15240,PMC3882723,26108,"REFORM results are not transferrable to patients receiving ICDs for secondary prevention or an ICD for CRT, who potentially have different needs for remote monitoring and for in-office follow-up visits.",Discussion|Study limitations,[155623],[29846],[30048],[True],['Generalization'],['REFORM results are not transferrable to patients receiving ICDs for secondary prevention or an ICD for CRT'],[True],['Generalization']
15241,PMC3882723,26109,"The follow-up duration of 27 months was insufficient to evaluate the results towards the end of the device's life cycle, when the risk of failures increases.",Discussion|Study limitations,[155646],[30049],[30206],[True],['FollowUpDuration'],['The follow-up duration of 27 months was insufficient'],[True],['StudyDuration']
15242,PMC3882723,26110,Conclusion,Discussion|Conclusion,[155648],[30207],[30217],[False],[0],[0],[False],['0']
15243,PMC3882723,26111,"In prophylactic ICD recipients without cardiac pacing indications and under automatic daily remote monitoring, the extension of the 3-month follow-up interval to 12 months appeared to safely reduce the ICD follow-up burden during 27 months after implantation.",Discussion|Conclusion,[155659],[30218],[30477],[False],[0],[0],[False],['0']
15244,PMC3882723,26112,"In contrast to the previous trials, we did not schedule regular remote data checks but fully relied on automatic HM alerts.",Discussion|Conclusion,[155670],[30478],[30601],[False],[0],[0],[False],['0']
15245,PMC3882723,26113,The SF-36 scores favoured the 12-month interval in the domains ‘social functioning’ and ‘mental health’.,Discussion|Conclusion,[155681],[30602],[30706],[False],[0],[0],[False],['0']
15246,PMC3882723,26114,Funding,Funding,[155692],[30707],[30715],[False],[0],[0],[False],['0']
15247,PMC3882723,26115,The study was supported by,Funding|The study was supported by  ,[155703],[30716],[30742],[False],[0],[0],[False],['0']
15248,PMC3882723,26116,  G.H.,Funding|The study was supported by  ,[155714],[30743],[30751],[False],[0],[0],[False],['0']
15249,PMC3882723,26117,"received research grants, travel grants and honoraria for lectures from Biotronik.",Funding|The study was supported by  ,[155725],[30752],[30834],[False],[0],[0],[False],['0']
15250,PMC3882723,26118,Acknowledgements,Acknowledgements,[155736],[30835],[30852],[False],[0],[0],[False],['0']
15251,PMC3882723,26119,"The authors acknowledge the contribution of Heinrich Beilmann, PhD, to study management, Jürgen Schrader, PhD, to data analysis and manuscript conception, Jochen Proff to publication process coordination and scientific discussion, and Dejan Danilovic, PhD, to critical reading and editorial assistance.",Acknowledgements,[155747],[30853],[31155],[False],[0],[0],[False],['0']
16585,PMC4022270,30141,The effect of a pre- and postoperative orthogeriatric service on cognitive function in patients with hip fracture: randomized controlled trial (Oslo Orthogeriatric Trial),Title,[181885],[27784],[170],[False],[0],[0],[False],['0']
16586,PMC4022270,30142,Background,Abstract,[181891],[171],[182],[False],[0],[0],[False],['0']
16587,PMC4022270,30143,Delirium is a common complication in patients with hip fractures and is associated with an increased risk of subsequent dementia.,Abstract,[181897],[183],[312],[False],[0],[0],[False],['0']
16588,PMC4022270,30144,The aim of this trial was to evaluate the effect of a pre- and postoperative orthogeriatric service on the prevention of delirium and longer-term cognitive decline.,Abstract,[181903],[313],[477],[False],[0],[0],[False],['0']
16589,PMC4022270,30145,Methods,Abstract,[181909],[478],[485],[False],[0],[0],[False],['0']
16590,PMC4022270,30146,"This was a single-center, prospective, randomized controlled trial in which patients with hip fracture were randomized to treatment in an acute geriatric ward or standard orthopedic ward.",Abstract,[181915],[486],[673],[False],[0],[0],[False],['0']
16591,PMC4022270,30147,Inclusion and randomization took place in the Emergency Department at Oslo University hospital.,Abstract,[181921],[674],[769],[False],[0],[0],[False],['0']
16592,PMC4022270,30148,The key intervention in the acute geriatric ward was Comprehensive Geriatric Assessment including daily interdisciplinary meetings.,Abstract,[181927],[770],[901],[False],[0],[0],[False],['0']
16593,PMC4022270,30149,Primary outcome was cognitive function four months after surgery measured using a composite outcome incorporating the Clinical Dementia Rating Scale (CDR) and the 10 words learning and recalls tasks from the Consortium to Establish a Registry for Alzheimer’s Disease battery (CERAD).,Abstract,[181933],[902],[1185],[False],[0],[0],[False],['0']
16594,PMC4022270,30150,"Secondary outcomes were pre- and postoperative delirium, delirium severity and duration, mortality and mobility (measured by the Short Physical Performance Battery (SPPB)).",Abstract,[181939],[1186],[1358],[False],[0],[0],[False],['0']
16595,PMC4022270,30151,Patients were assessed four and twelve months after surgery by evaluators blind to allocation.,Abstract,[181945],[1359],[1453],[False],[0],[0],[False],['0']
16596,PMC4022270,30152,Results,Abstract,[181951],[1454],[1461],[False],[0],[0],[False],['0']
16597,PMC4022270,30153,A total of 329 patients were included.,Abstract,[181957],[1462],[1500],[False],[0],[0],[False],['0']
16598,PMC4022270,30154,"There was no significant difference in cognitive function four months after surgery between patients treated in the acute geriatric and the orthopedic wards (mean 54.7 versus 52.9, 95% confidence interval for the difference -5.9 to 9.5; P = 0.65).",Abstract,[181963],[1501],[1748],[False],[0],[0],[False],['0']
16599,PMC4022270,30155,"There was also no significant difference in delirium rates (49% versus 53%, P = 0.51) or four month mortality (17% versus 15%, P = 0.50) between the intervention and the control group.",Abstract,[181969],[1749],[1933],[False],[0],[0],[False],['0']
16600,PMC4022270,30156,"In a pre-planned sub-group analysis, participants living in their own home at baseline who were randomized to orthogeriatric care had better mobility four months after surgery compared with patients randomized to the orthopedic ward, measured with SPPB (median 6 versus 4, 95% confidence interval for the median difference 0 to 2; P = 0.04).",Abstract,[181975],[1934],[2275],[False],[0],[0],[False],['0']
16601,PMC4022270,30157,Conclusions,Abstract,[181981],[2276],[2287],[False],[0],[0],[False],['0']
16602,PMC4022270,30158,Pre- and postoperative orthogeriatric care given in an acute geriatric ward was not effective in reducing delirium or long-term cognitive impairment in patients with hip fracture.,Abstract,[181987],[2288],[2467],[False],[0],[0],[False],['0']
16603,PMC4022270,30159,"The intervention had, however, a positive effect on mobility in patients not admitted from nursing homes.",Abstract,[181993],[2468],[2573],[False],[0],[0],[False],['0']
16604,PMC4022270,30160,Trial registration,Abstract,[181999],[2574],[2592],[False],[0],[0],[False],['0']
16605,PMC4022270,30161,ClinicalTrials.gov,Abstract,[182005],[2593],[2611],[False],[0],[0],[False],['0']
16606,PMC4022270,30162,"NCT01009268 Registered November 5, 2009",Abstract,[182011],[2612],[2651],[False],[0],[0],[False],['0']
16607,PMC4022270,30163,Background,Background,[182017],[2652],[2663],[False],[0],[0],[False],['0']
16608,PMC4022270,30164,"More than 30% of individuals 65-years-old or older experience at least one fall each year, and the prevalence increases with age [1].",Background,[182023],[2664],[2797],[False],[0],[0],[False],['0']
16609,PMC4022270,30165,"Ten percent of falls result in serious injuries [2], with hip fracture as one of the most feared consequences.",Background,[182029],[2798],[2908],[False],[0],[0],[False],['0']
16610,PMC4022270,30166,"In the European Union it was estimated that 615,000 new hip fractures occurred in 2010, and the number of hip fractures is expected to increase in the years to come [3].",Background,[182035],[2909],[3078],[False],[0],[0],[False],['0']
16611,PMC4022270,30167,"Patients with hip fracture are often frail, have multiple co-morbidities including cognitive impairment, and there is usually polypharmacy [4].",Background,[182041],[3079],[3222],[False],[0],[0],[False],['0']
16612,PMC4022270,30168,"To address these patients' needs, different models of orthogeriatric co-management have been developed.",Background,[182047],[3223],[3326],[False],[0],[0],[False],['0']
16613,PMC4022270,30169,Models range from a limited consultation or liaison service through to integrated orthogeriatric units [5].,Background,[182053],[3327],[3434],[False],[0],[0],[False],['0']
16614,PMC4022270,30170,"Few of these models have been evaluated in randomized controlled trials (RCTs), and the heterogeneity of interventions, outcomes and populations makes it difficult to draw conclusions regarding the superiority of one particular model [5-7].",Background,[182059],[3435],[3675],[False],[0],[0],[False],['0']
16615,PMC4022270,30171,"Geriatric intervention might be especially beneficial in the vulnerable period prior to surgery, but most studies are limited to postoperative orthogeriatric intervention [8].",Background,[182065],[3676],[3851],[False],[0],[0],[False],['0']
16616,PMC4022270,30172,"A common complication of hip fracture is delirium, a syndrome of acute change in cognition and alertness, and altered, often psychotic, behavior [9].",Background,[182071],[3852],[4001],[False],[0],[0],[False],['0']
16617,PMC4022270,30173,About 40% to 50% of hip fracture patients are reported to develop delirium in the peri-operative period [10].,Background,[182077],[4002],[4111],[False],[0],[0],[False],['0']
16618,PMC4022270,30174,"Delirium is particularly common in patients with pre-existing dementia [11], despite which patients with dementia are often excluded from studies [12].",Background,[182083],[4112],[4263],[False],[0],[0],[False],['0']
16619,PMC4022270,30175,"Delirium in the peri-operative phase is associated with increased risk of death, institutionalization and subsequent dementia [13].",Background,[182089],[4264],[4395],[False],[0],[0],[False],['0']
16620,PMC4022270,30176,"Multifactorial intervention can prevent delirium in hip fracture patients [14-16], but it is not yet established if preventing delirium can reduce long-term cognitive decline.",Background,[182095],[4396],[4571],[False],[0],[0],[False],['0']
16621,PMC4022270,30177,"In 2008, we established an orthogeriatric service at our hospital, comprising pre- and postoperative care of hip fracture patients in the acute geriatric ward.",Background,[182101],[4572],[4731],[False],[0],[0],[False],['0']
16622,PMC4022270,30178,We evaluated this model by a RCT in which hip fracture patients receiving usual care in the orthopedic ward comprised the control group.,Background,[182107],[4732],[4868],[False],[0],[0],[False],['0']
16623,PMC4022270,30179,"We hypothesized that the intervention could prevent delirium-associated long-term cognitive decline and, thus, chose cognitive function four months after surgery as the primary outcome.",Background,[182113],[4869],[5054],[False],[0],[0],[False],['0']
16624,PMC4022270,30180,Methods,Methods,[182119],[5055],[5063],[False],[0],[0],[False],['0']
16625,PMC4022270,30181,Project context,Methods|Project context,[182125],[5064],[5079],[False],[0],[0],[False],['0']
16626,PMC4022270,30182,"In 2008, orthogeriatric care at Oslo University Hospital was reorganized and became a part of the acute geriatric ward.",Methods|Project context,[182131],[5080],[5199],[False],[0],[0],[False],['0']
16627,PMC4022270,30183,The new service had the capacity to serve approximately half of the patients admitted with hip fracture.,Methods|Project context,[182137],[5200],[5304],[False],[0],[0],[False],['0']
16628,PMC4022270,30184,The remaining patients were treated in the orthopedic ward.,Methods|Project context,[182143],[5305],[5364],[False],[0],[0],[False],['0']
16629,PMC4022270,30185,"To evaluate the new model, we randomly allocated patients between the acute geriatric and the orthopedic wards.",Methods|Project context,[182149],[5365],[5476],[False],[0],[0],[False],['0']
16630,PMC4022270,30186,The first hip fracture patient was admitted to the acute geriatric ward in June 2008 and after a pilot period inclusion in the study started in September 2009.,Methods|Project context,[182155],[5477],[5636],[False],[0],[0],[False],['0']
16631,PMC4022270,30187,The recruitment ended in January 2012.,Methods|Project context,[182161],[5637],[5675],[False],[0],[0],[False],['0']
16632,PMC4022270,30188,The study protocol containing further information is published elsewhere [17].,Methods|Project context,[182167],[5676],[5754],[False],[0],[0],[False],['0']
16633,PMC4022270,30189,Study design,Methods|Study design,[182173],[5755],[5767],[False],[0],[0],[False],['0']
16634,PMC4022270,30190,"We carried out a randomized, controlled, single-blind trial comparing pre- and postoperative orthogeriatric care integrated in the acute geriatric ward to usual care in the orthopedic ward.",Methods|Study design,[182179],[5768],[5957],[False],[0],[0],[False],['0']
16635,PMC4022270,30191,"Inclusion and randomization took place in the emergency department, overseen by the duty orthopedic surgeon.",Methods|Study design,[182185],[5958],[6066],[False],[0],[0],[False],['0']
16636,PMC4022270,30192,"Allocation was by sealed, opaque, numbered envelopes.",Methods|Study design,[182191],[6067],[6120],[False],[0],[0],[False],['0']
16637,PMC4022270,30193,Randomization was based on computer-generated random numbers (blocks of variable and unknown size) and was carried out by a statistician (ES) not involved in the clinical service.,Methods|Study design,[182197],[6121],[6300],[False],[0],[0],[False],['0']
16638,PMC4022270,30194,Randomization was stratified according to whether or not the patients were admitted from nursing homes.,Methods|Study design,[182203],[6301],[6404],[False],[0],[0],[False],['0']
16639,PMC4022270,30195,"Included patients were transferred directly from the emergency department to the allocated ward, and had their entire hospital stay in the same ward except for time in the operating theater and a few hours in the postoperative care unit.",Methods|Study design,[182209],[6405],[6642],[False],[0],[0],[False],['0']
16640,PMC4022270,30196,Operative and anesthetic procedures were the same in the two groups.,Methods|Study design,[182215],[6643],[6711],[False],[0],[0],[False],['0']
16641,PMC4022270,30197,Study participants,Methods|Study participants,[182221],[6712],[6730],[False],[0],[0],[False],['0']
16642,PMC4022270,30198,"All patients admitted acutely to Oslo University Hospital with a hip fracture (a femoral neck fracture, a trochanteric or a sub-trochanteric fracture) were eligible for inclusion.",Methods|Study participants,[182227],[6731],[6910],[False],[0],[0],[False],['0']
16643,PMC4022270,30199,Patients were excluded if the hip fracture was a part of a high energy trauma (defined as a fall from higher than one meter) or if they were moribund on admission.,Methods|Study participants,[182233],[6911],[7074],[False],[0],[0],[False],['0']
16644,PMC4022270,30200,Intervention and control,Methods|Intervention and control,[182239],[7075],[7099],[False],[0],[0],[False],['0']
16645,PMC4022270,30201,Patients randomized to intervention were treated in the acute geriatric ward (Table  1).,Methods|Intervention and control,[182245],[7100],[7188],[False],[0],[0],[False],['0']
16646,PMC4022270,30202,"This was a 20 bed ward, mainly admitting patients suffering from acute medical disorders superimposed upon frailty, co-morbidities and polypharmacy.",Methods|Intervention and control,[182251],[7189],[7337],[False],[0],[0],[False],['0']
16647,PMC4022270,30203,The only surgical patients treated in the ward were the hip fracture patients included in the trial.,Methods|Intervention and control,[182257],[7338],[7438],[False],[0],[0],[False],['0']
16648,PMC4022270,30204,"On average during the inclusion period, two to four beds were used for hip fracture patients.",Methods|Intervention and control,[182263],[7439],[7532],[False],[0],[0],[False],['0']
16649,PMC4022270,30205,The acute geriatric ward was regularly full or over-crowded.,Methods|Intervention and control,[182269],[7533],[7593],[False],[0],[0],[False],['0']
16650,PMC4022270,30206,"To avoid randomization violation, the ward was instructed to admit included hip fracture patients even if the ward was full.",Methods|Intervention and control,[182275],[7594],[7718],[False],[0],[0],[False],['0']
16651,PMC4022270,30207,"Thus, some hip fracture patients had to be treated in the corridor until a room was available, usually within the first 24 hours.",Methods|Intervention and control,[182281],[7719],[7848],[False],[0],[0],[False],['0']
16652,PMC4022270,30208,A key element of the intervention was a Comprehensive Geriatric Assessment (CGA) as a basis for treatment planning.,Methods|Intervention and control,[182287],[7849],[7964],[False],[0],[0],[False],['0']
16653,PMC4022270,30209,"All team members (geriatrician, nurse, physiotherapist and occupational therapist) were expected to assess patients during their first day on the ward, and the team had daily meetings to co-ordinate treatment and to plan discharge.",Methods|Intervention and control,[182293],[7965],[8196],[False],[0],[0],[False],['0']
16654,PMC4022270,30210,"Clinical routines were developed based on a literature search, experience from earlier orthogeriatric models and the pilot phase prior to the start of randomization.",Methods|Intervention and control,[182299],[8197],[8362],[False],[0],[0],[False],['0']
16655,PMC4022270,30211,Checklists were printed out and made immediately available for the treatment team for each patient.,Methods|Intervention and control,[182305],[8363],[8462],[False],[0],[0],[False],['0']
16656,PMC4022270,30212,"Details about the clinical routines have been published [17] and included medication reviews, early and intensive mobilization, optimizing pre- and postoperative nutrition and early discharge planning.",Methods|Intervention and control,[182311],[8463],[8664],[False],[0],[0],[False],['0']
16657,PMC4022270,30213,"The control group was treated in the orthopedic ward, a 52 bed ward admitting a range of elective and non-elective orthopedic patients.",Methods|Intervention and control,[182317],[8665],[8800],[False],[0],[0],[False],['0']
16658,PMC4022270,30214,The staff-patient ratio was similar to that of the acute geriatric ward (Table  1).,Methods|Intervention and control,[182323],[8801],[8884],[False],[0],[0],[False],['0']
16659,PMC4022270,30215,"There were, however, no multidisciplinary meetings and no geriatric assessments.",Methods|Intervention and control,[182329],[8885],[8965],[False],[0],[0],[False],['0']
16660,PMC4022270,30216,"Early mobilization was emphasized, and hip fracture patients were seen by a physiotherapist soon after surgery.",Methods|Intervention and control,[182335],[8966],[9077],[False],[0],[0],[False],['0']
16661,PMC4022270,30217,"The postoperative care unit was within the orthopedic ward, where all patients (including those allocated to intervention) were observed after surgery.",Methods|Intervention and control,[182341],[9078],[9229],[False],[0],[0],[False],['0']
16662,PMC4022270,30218,All patients included in the trial were offered a control in the orthopedic outpatient clinic four months after surgery.,Methods|Intervention and control,[182347],[9230],[9350],[False],[0],[0],[False],['0']
16663,PMC4022270,30219,There was no additional intervention after discharge from hospital.,Methods|Intervention and control,[182353],[9351],[9418],[False],[0],[0],[False],['0']
16664,PMC4022270,30220,Measurements,Methods|Measurements,[182359],[9419],[9431],[False],[0],[0],[False],['0']
16665,PMC4022270,30221,Social and demographic information was collected during the acute stay.,Methods|Measurements,[182365],[9432],[9503],[False],[0],[0],[False],['0']
16666,PMC4022270,30222,"Information regarding surgical and anesthetic procedures, medical diagnoses (Charlson comorbidity index [18]), drug use and complications was also collected.",Methods|Measurements,[182371],[9504],[9661],[False],[0],[0],[False],['0']
16667,PMC4022270,30223,Proxies were interviewed regarding pre-fracture Activities of Daily Living (Barthel ADL Index (BADL [19]) and Nottingham Extended ADL Index (NEADL [20])) and cognitive function (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE [21])).,Methods|Measurements,[182377],[9662],[9915],[False],[0],[0],[False],['0']
16668,PMC4022270,30224,Estimated height was derived using knee-heel length [22] and the patients were weighed using a chair scale.,Methods|Measurements,[182383],[9916],[10023],[False],[0],[0],[False],['0']
16669,PMC4022270,30225,"Mobilization after surgery was used as a process measure, recorded on day two post-surgery from case notes and observations.",Methods|Measurements,[182389],[10024],[10148],[False],[0],[0],[False],['0']
16670,PMC4022270,30226,"From September 2011, mobility was recorded with the activPAL™ body-worn sensor system [23].",Methods|Measurements,[182395],[10149],[10240],[False],[0],[0],[False],['0']
16671,PMC4022270,30227,The sensor was attached on the anterior aspect of the non-affected thigh as soon as possible after surgery and worn until discharge.,Methods|Measurements,[182401],[10241],[10373],[False],[0],[0],[False],['0']
16672,PMC4022270,30228,All patients were screened once daily for delirium using the Confusion Assessment Method (CAM) [24] preoperatively and until the fifth postoperative day (all) or until discharge (delirious patients).,Methods|Measurements,[182407],[10374],[10573],[False],[0],[0],[False],['0']
16673,PMC4022270,30229,The study geriatrician or a study nurse completed all the assessments.,Methods|Measurements,[182413],[10574],[10644],[False],[0],[0],[False],['0']
16674,PMC4022270,30230,"If the nurse was unsure about the diagnosis, the study geriatrician was consulted.",Methods|Measurements,[182419],[10645],[10727],[False],[0],[0],[False],['0']
16675,PMC4022270,30231,"The CAM score was based on information from nurses, close relatives and hospital records related to the preceding 24 hours, in combination with a 10 to 30 minute interview with the patient.",Methods|Measurements,[182425],[10728],[10917],[False],[0],[0],[False],['0']
16676,PMC4022270,30232,"Tests of cognition, attention and alertness included the digit span test (forward and backward), orientation and delayed recall (from the Memorial Delirium Assessment Scale (MDAS) [25]).",Methods|Measurements,[182431],[10918],[11104],[False],[0],[0],[False],['0']
16677,PMC4022270,30233,Delirium severity was measured with MDAS.,Methods|Measurements,[182437],[11105],[11146],[False],[0],[0],[False],['0']
16678,PMC4022270,30234,"Patients were assessed regularly on weekdays, but staff members who had been working during weekends were interviewed every Monday, and the case notes scrutinized in order to ascertain potential episodes of delirium.",Methods|Measurements,[182443],[11147],[11363],[False],[0],[0],[False],['0']
16679,PMC4022270,30235,The mean number of delirium assessments during the stay was 5.7 (SD 2.7).,Methods|Measurements,[182449],[11364],[11437],[False],[0],[0],[False],['0']
16680,PMC4022270,30236,Follow up visits were carried out four and twelve months after surgery (with a time window of ± three weeks) by study nurses blind to allocation and to all clinical data during the original hospital stay.,Methods|Measurements,[182455],[11438],[11642],[False],[0],[0],[False],['0']
16681,PMC4022270,30237,The patients were assessed in their current place of residence.,Methods|Measurements,[182461],[11643],[11706],[False],[0],[0],[False],['0']
16682,PMC4022270,30238,"Each visit typically lasted for two to three hours, and the evaluators started the assessment with the cognitive tests of the primary outcome.",Methods|Measurements,[182467],[11707],[11849],[False],[0],[0],[False],['0']
16683,PMC4022270,30239,"At each follow-up visit, proxies were interviewed regarding physical (ADL) and cognitive function, using the same scoring systems as during the index stay.",Methods|Measurements,[182473],[11850],[12005],[False],[0],[0],[False],['0']
16684,PMC4022270,30240,Mobility at the follow-up visits was assessed with the short physical performance battery (SPPB) [26].,Methods|Measurements,[182479],[12006],[12108],[False],[0],[0],[False],['0']
16685,PMC4022270,30241,Weight at follow-up was assessed using a standing scale that was calibrated to the chair scale used during hospital stay.,Methods|Measurements,[182485],[12109],[12230],[False],[0],[0],[False],['0']
16686,PMC4022270,30242,Patients and proxies were asked about any hospital readmissions since surgery.,Methods|Measurements,[182491],[12231],[12309],[False],[0],[0],[False],['0']
16687,PMC4022270,30243,"One specialist in geriatric medicine (TBW) and one specialist in old age psychiatry (KE) independently assessed whether the patients fulfilled the International Classification of Diseases, version 10 (ICD-10) criteria for dementia at baseline and 12 months after surgery.",Methods|Measurements,[182497],[12310],[12581],[False],[0],[0],[False],['0']
16688,PMC4022270,30244,"The assessors had access to all clinical data, but were blinded to allocation and delirium status during hospital stay.",Methods|Measurements,[182503],[12582],[12701],[False],[0],[0],[False],['0']
16689,PMC4022270,30245,The inter-rater agreement upon the dementia diagnosis was satisfactory (kappa 0.87 at baseline and 0.83 at 12 months); disagreements were resolved through discussion.,Methods|Measurements,[182509],[12702],[12868],[False],[0],[0],[False],['0']
16690,PMC4022270,30246,Primary outcome,Methods|Primary outcome,[182515],[12869],[12884],[False],[0],[0],[False],['0']
16691,PMC4022270,30247,"The primary outcome was cognitive function four months after surgery, which was expected to show a wide range of severity from severe dementia to no cognitive impairment.",Methods|Primary outcome,[182521],[12885],[13055],[False],[0],[0],[False],['0']
16692,PMC4022270,30248,"To be able to measure differences in both the higher and the lower spectrum of cognitive function, we combined two scales:",Methods|Primary outcome,[182527],[13056],[13178],[False],[0],[0],[False],['0']
16693,PMC4022270,30249,– The 10 words test from the Consortium to Establish a Registry for Alzheimer’s disease battery (CERAD) [27].,Methods|Primary outcome,[182533],[13179],[13288],[False],[0],[0],[False],['0']
16694,PMC4022270,30250,In this memory test patients are asked to recall 10 words after having them presented orally or visually.,Methods|Primary outcome,[182539],[13289],[13394],[False],[0],[0],[False],['0']
16695,PMC4022270,30251,We used the immediate and delayed recall tasks of the test.,Methods|Primary outcome,[182545],[13395],[13454],[False],[0],[0],[False],['0']
16696,PMC4022270,30252,This test is shown to be sensitive for memory changes in persons with good cognitive functioning [28].,Methods|Primary outcome,[182551],[13455],[13557],[False],[0],[0],[False],['0']
16697,PMC4022270,30253,– The Clinical Dementia Rating scale (CDR [29]).,Methods|Primary outcome,[182557],[13558],[13606],[False],[0],[0],[False],['0']
16698,PMC4022270,30254,CDR is based on information from the best available sources as a combination of patient and proxy information and is sensitive for cognitive changes in patients with dementia.,Methods|Primary outcome,[182563],[13607],[13782],[False],[0],[0],[False],['0']
16699,PMC4022270,30255,We used the ‘sum of boxes’ scoring adding up to a sum score ranging from zero (no dementia symptoms) to 18 (severe dementia).,Methods|Primary outcome,[182569],[13783],[13908],[False],[0],[0],[False],['0']
16700,PMC4022270,30256,In most studies the sum score is shown to correlate highly with the original categorical score of zero to three [30].,Methods|Primary outcome,[182575],[13909],[14026],[False],[0],[0],[False],['0']
16701,PMC4022270,30257,"To construct the combined outcome measure, we normalized these scales into a 0 to 100 scoring (CDR had to be reversed since it is scaled in the opposite direction).",Methods|Primary outcome,[182581],[14027],[14191],[False],[0],[0],[False],['0']
16702,PMC4022270,30258,"The CDR carried a 50% weighting, and the immediate and delayed recall parts of the 10 word test each contributed 25% in the combined measure.",Methods|Primary outcome,[182587],[14192],[14333],[False],[0],[0],[False],['0']
16703,PMC4022270,30259,"Thus, a higher score on the primary outcome indicated better cognitive performance.",Methods|Primary outcome,[182593],[14334],[14417],[False],[0],[0],[False],['0']
16704,PMC4022270,30260,Secondary outcomes,Methods|Secondary outcomes,[182599],[14418],[14436],[False],[0],[0],[False],['0']
16705,PMC4022270,30261,"Secondary outcomes included preoperative delirium, delirium severity, length of stay, mortality, mobility, place of residence, ADL function and weight changes at the follow up controls.",Methods|Secondary outcomes,[182605],[14437],[14622],[False],[0],[0],[False],['0']
16706,PMC4022270,30262,"CDR and the 10 words test were analyzed separately, in addition to other measures of cognition (Mini-mental state examination (MMSE) [31], clock drawing test [32], IQCODE).",Methods|Secondary outcomes,[182611],[14623],[14795],[False],[0],[0],[False],['0']
16707,PMC4022270,30263,Statistical analyses,Methods|Statistical analyses,[182617],[14796],[14816],[False],[0],[0],[False],['0']
16708,PMC4022270,30264,No pre-trial data were available to carry out precise power estimates.,Methods|Statistical analyses,[182623],[14817],[14887],[False],[0],[0],[False],['0']
16709,PMC4022270,30265,"Based upon previous experience with the CDR, we judged 300 patients to be sufficient to detect clinically meaningful differences [30].",Methods|Statistical analyses,[182629],[14888],[15022],[False],[0],[0],[False],['0']
16710,PMC4022270,30266,"As 20% of hip fracture patients can be expected to die within four months of surgery, we aimed to randomize 370 patients.",Methods|Statistical analyses,[182635],[15023],[15144],[False],[0],[0],[False],['0']
16711,PMC4022270,30267,Recruitment ended after randomization of 332 patients due to resource constraints.,Methods|Statistical analyses,[182641],[15145],[15227],[False],[0],[0],[False],['0']
16712,PMC4022270,30268,A statistical analysis plan (SAP) was developed (and published online) prior to un-blinding of the data [33].,Methods|Statistical analyses,[182647],[15228],[15337],[False],[0],[0],[False],['0']
16713,PMC4022270,30269,The primary analysis was carried out blind to allocation by the study statistician (ES).,Methods|Statistical analyses,[182653],[15338],[15426],[False],[0],[0],[False],['0']
16714,PMC4022270,30270,The primary analysis was carried out as a modified intention-to-treat analysis including patients with CDR and a complete 10-word test at the four-month control.,Methods|Statistical analyses,[182659],[15427],[15588],[False],[0],[0],[False],['0']
16715,PMC4022270,30271,"Two patients were sent to the ward opposite to randomization allocation, and these patients were analyzed according to the group in which they were treated (Figure  1).",Methods|Statistical analyses,[182665],[15589],[15757],[False],[0],[0],[False],['0']
16716,PMC4022270,30272,"Three moribund patients (two randomized to the acute geriatric ward and one to the orthopedic ward) were recruited in error, and were excluded from the primary analysis.",Methods|Statistical analyses,[182671],[15758],[15927],[False],[0],[0],[False],['0']
16717,PMC4022270,30273,The primary outcome was not normally distributed but the sample size was large and parametric methods could therefore be applied.,Methods|Statistical analyses,[182677],[15928],[16057],[False],[0],[0],[False],['0']
16718,PMC4022270,30274,"To adjust for any inequality in the distribution of important prognostic variables between the intervention and control group, we performed a linear regression with the primary outcome as the dependent variable, and variables with known or believed influence on the outcome were included in the model in a stepwise manner, in addition to the randomization group.",Methods|Statistical analyses,[182683],[16058],[16420],[False],[0],[0],[False],['0']
16719,PMC4022270,30275,"If their introduction to the model changed the effect estimate for the randomization variable by 10% or more, they were included in the final model.",Methods|Statistical analyses,[182689],[16421],[16569],[False],[0],[0],[False],['0']
16720,PMC4022270,30276,Variables were removed by stepwise backwards elimination until the final model was reached.,Methods|Statistical analyses,[182695],[16570],[16661],[False],[0],[0],[False],['0']
16721,PMC4022270,30277,"Age (negatively skewed) and waiting time to surgery (positively skewed) had non-normal distributions, and were squared and log transformed, respectively, to achieve better fit of the model.",Methods|Statistical analyses,[182701],[16662],[16851],[False],[0],[0],[False],['0']
16722,PMC4022270,30278,"Secondary outcomes were analyzed by the Mann–Whitney test, t-tests and Chi-square tests depending on data distribution.",Methods|Statistical analyses,[182707],[16852],[16971],[False],[0],[0],[False],['0']
16723,PMC4022270,30279,"Pre-planned subgroup analyses were carried out in patients admitted from nursing homes, and in patients with and without pre-fracture dementia.",Methods|Statistical analyses,[182713],[16972],[17115],[False],[0],[0],[False],['0']
16724,PMC4022270,30280,"All statistical analyses were performed using IBM SPSS Statistics version 20, except for median differences and corresponding 95% confidence intervals that were estimated by the Hodges Lehmann estimator using StatXact 8.0.",Methods|Statistical analyses,[182719],[17116],[17338],[False],[0],[0],[False],['0']
16725,PMC4022270,30281,Sensitivity analyses,Methods|Sensitivity analyses,[182725],[17339],[17359],[False],[0],[0],[False],['0']
16726,PMC4022270,30282,As a sensitivity analysis we analyzed the primary outcome with the non-parametric Mann–Whitney test.,Methods|Sensitivity analyses,[182731],[17360],[17460],[False],[0],[0],[False],['0']
16727,PMC4022270,30283,"We also carried out sensitivity analyses including the three moribund patients who were erroneously recruited, and a strict intention to treat analysis with all patients analyzed according to allocation.",Methods|Sensitivity analyses,[182737],[17461],[17664],[False],[0],[0],[False],['0']
16728,PMC4022270,30284,Missing values for the primary outcome were imputed in different ways in order to explore their potential influence on the results:,Methods|Sensitivity analyses,[182743],[17665],[17796],[False],[0],[0],[False],['0']
16729,PMC4022270,30285,"– if a patient had the combined outcome available after twelve but not four months, those values were imputed in the four-month dataset (ten patients).",Methods|Sensitivity analyses,[182749],[17797],[17948],[False],[0],[0],[False],['0']
16730,PMC4022270,30286,– imputation of the worst possible score for all patients who had died.,Methods|Sensitivity analyses,[182755],[17949],[18020],[False],[0],[0],[False],['0']
16731,PMC4022270,30287,– imputation of the worst possible score for all missing patients.,Methods|Sensitivity analyses,[182761],[18021],[18087],[False],[0],[0],[False],['0']
16732,PMC4022270,30288,– imputation of the mean score for the randomization group the patient belonged to for all missing patients.,Methods|Sensitivity analyses,[182767],[18088],[18196],[False],[0],[0],[False],['0']
16733,PMC4022270,30289,Ethical considerations,Methods|Ethical considerations,[182773],[18197],[18219],[False],[0],[0],[False],['0']
16734,PMC4022270,30290,The study was conducted in accordance with the Declaration of Helsinki.,Methods|Ethical considerations,[182779],[18220],[18291],[False],[0],[0],[False],['0']
16735,PMC4022270,30291,Informed consent was obtained from the patients or substitute decision-makers if patients did not have capacity to consent.,Methods|Ethical considerations,[182785],[18292],[18415],[False],[0],[0],[False],['0']
16736,PMC4022270,30292,The study was approved by the Regional Committee for Ethics in Medical Research in Norway (REK S-09169a) and the Data Protection Officer at Oslo University Hospital (Ref.,Methods|Ethical considerations,[182791],[18416],[18586],[False],[0],[0],[False],['0']
16737,PMC4022270,30293,1361).,Methods|Ethical considerations,[182797],[18587],[18593],[False],[0],[0],[False],['0']
16738,PMC4022270,30294,Results,Results,[182803],[18594],[18602],[False],[0],[0],[False],['0']
16739,PMC4022270,30295,"Between 17 September 2009 and 5 January 2012, 446 patients were assessed for eligibility and 332 were included (Figure  1).",Results,[182809],[18603],[18726],[False],[0],[0],[False],['0']
16740,PMC4022270,30296,"Non-included patients were younger than included patients (median 81 versus 85 years; P ≤0.001) and more were men (35.3% versus 25.1%, P = 0.01).",Results,[182815],[18727],[18872],[False],[0],[0],[False],['0']
16741,PMC4022270,30297,"Half of the included patients at baseline were considered to have dementia, and one third were living in nursing homes.",Results,[182821],[18873],[18992],[False],[0],[0],[False],['0']
16742,PMC4022270,30298,Patients randomized to the intervention group and the control group were well matched in all important baseline variables (Table  2).,Results,[182827],[18993],[19126],[False],[0],[0],[False],['0']
16743,PMC4022270,30299,"In total, 35 patients (11%) were lost to follow up at four months, 14 from the intervention group and 21 from the control group (P = 0.23).",Results,[182833],[19127],[19266],[False],[0],[0],[False],['0']
16744,PMC4022270,30300,"Of patients lost to the four month follow up, only 2 (7%) were living in a nursing home before the fracture, compared to 73 (30%) patients who were followed-up (P = 0.002).",Results,[182839],[19267],[19439],[False],[0],[0],[False],['0']
16745,PMC4022270,30301,"Patients lost to follow up were younger (median age 83 versus 85, P = 0.19) and fewer were considered to have dementia before the fracture (12/35 (34%) versus 112/242 (46%), P = 0.18); however, these differences were not significant.",Results,[182845],[19440],[19673],[False],[0],[0],[False],['0']
16746,PMC4022270,30302,The final twelve month follow up was completed in December 2012.,Results,[182851],[19674],[19738],[False],[0],[0],[False],['0']
16747,PMC4022270,30303,Impact of intervention during hospital stay,Results|Impact of intervention during hospital stay,[182857],[19739],[19782],[False],[0],[0],[False],['0']
16748,PMC4022270,30304,"There was no difference in delirium rates between the intervention and control groups (49% versus 53%, P = 0.51) (Table  3).",Results|Impact of intervention during hospital stay,[182863],[19783],[19907],[False],[0],[0],[False],['0']
16749,PMC4022270,30305,"There was also no difference in delirium duration (median three versus four days, P = 0.85) or delirium severity measured with MDAS (median 21.5 versus 20, P = 0.44).",Results|Impact of intervention during hospital stay,[182869],[19908],[20074],[False],[0],[0],[False],['0']
16750,PMC4022270,30306,"Fewer patients treated in the acute geriatric ward were discharged with ongoing delirium (15% versus 26%, P = 0.01).",Results|Impact of intervention during hospital stay,[182875],[20075],[20191],[False],[0],[0],[False],['0']
16751,PMC4022270,30307,"The median length of stay was three days longer in the intervention group (median eleven versus eight days, P ≤0.001).",Results|Impact of intervention during hospital stay,[182881],[20192],[20310],[False],[0],[0],[False],['0']
16752,PMC4022270,30308,"Patients in the intervention group had a longer waiting time for surgery, but this difference was not statistically significant (median 26 versus 24 hours, P = 0.54).",Results|Impact of intervention during hospital stay,[182887],[20311],[20477],[False],[0],[0],[False],['0']
16753,PMC4022270,30309,There was a trend to greater mobilization in the intervention group on the second day after surgery (86% versus 80%).,Results|Impact of intervention during hospital stay,[182893],[20478],[20595],[False],[0],[0],[False],['0']
16754,PMC4022270,30310,"In 46 patients, mobilization after surgery was assessed with activPAL™ activity sensors.",Results|Impact of intervention during hospital stay,[182899],[20596],[20684],[False],[0],[0],[False],['0']
16755,PMC4022270,30311,"During the first five days after surgery, the patients were mobilized for a longer time in the standing or stepping position in the intervention group (median 29 minutes versus 17 minutes).",Results|Impact of intervention during hospital stay,[182905],[20685],[20874],[False],[0],[0],[False],['0']
16756,PMC4022270,30312,Primary outcome - cognitive function four months after surgery,Results|Impact of intervention during hospital stay,[182911],[20875],[20937],[False],[0],[0],[False],['0']
16757,PMC4022270,30313,"The primary outcome could be computed in 228 patients and there was no significant difference between patients treated in the acute geriatric ward and the orthopedic ward after four months (mean 54.7 versus 52.9, 95% confidence interval for the difference -5.9 to 9.5; P = 0.65) (Table  4).",Results|Impact of intervention during hospital stay,[182917],[20938],[21228],[False],[0],[0],[False],['0']
16758,PMC4022270,30314,"There was also no difference in the combined outcome after twelve months (mean 51.0 versus 49.1, 95% confidence interval for the difference -7.7 to 11.4; P = 0.69).",Results|Impact of intervention during hospital stay,[182923],[21229],[21393],[False],[0],[0],[False],['0']
16759,PMC4022270,30315,The Mann–Whitney test gave essentially the same results as the t-test at four and twelve months.,Results|Impact of intervention during hospital stay,[182929],[21394],[21490],[False],[0],[0],[False],['0']
16760,PMC4022270,30316,"A linear regression with the primary outcome as the dependent variable (Table  5) identified four significant predictors associated with poorer score: if the patient was admitted from a nursing home, IQCODE at baseline above 3.44, older age, and delirium during the hospital stay.",Results|Impact of intervention during hospital stay,[182935],[21491],[21771],[False],[0],[0],[False],['0']
16761,PMC4022270,30317,Secondary outcomes and subgroup analyses,Results|Secondary outcomes and subgroup analyses,[182941],[21772],[21812],[False],[0],[0],[False],['0']
16762,PMC4022270,30318,"Patients treated in the acute geriatric ward performed better on all cognitive measures; CERAD immediate recall (median 12.5 versus 11.5) and delayed recall (median 3 versus 2) , approved clock drawing test (49% versus 40%), MMSE (median 24 versus 23) and CDR (1.5 versus 2.5).",Results|Secondary outcomes and subgroup analyses,[182947],[21813],[22090],[False],[0],[0],[False],['0']
16763,PMC4022270,30319,They also had better ADL function measured with the BADL Index (median 17 versus 16) and NEADL (median 26.5 versus 22).,Results|Secondary outcomes and subgroup analyses,[182953],[22091],[22210],[False],[0],[0],[False],['0']
16764,PMC4022270,30320,"None of these differences were, however, statistically significant.",Results|Secondary outcomes and subgroup analyses,[182959],[22211],[22278],[False],[0],[0],[False],['0']
16765,PMC4022270,30321,"Patients randomized to the acute geriatric ward had better mobility four months after surgery, measured with SPPB (median 4 versus 3, 95% confidence interval for the median difference 0 to 2; P = 0.13) (Table  4).",Results|Secondary outcomes and subgroup analyses,[182965],[22279],[22492],[False],[0],[0],[False],['0']
16766,PMC4022270,30322,"This difference was statistically significant in the pre-specified subgroup analysis restricted to patients living in their own home before the fracture (median 6 versus 4, 95% confidence interval for the median difference 0 to 2; P = 0.04).",Results|Secondary outcomes and subgroup analyses,[182971],[22493],[22734],[False],[0],[0],[False],['0']
16767,PMC4022270,30323,"Subgroup analyses stratified according to pre-fracture dementia status and nursing home residence gave no other significant differences, except that patients from nursing homes randomized to intervention were more often mobilized the second day after surgery (Additional files 1, 2 and 3).",Results|Secondary outcomes and subgroup analyses,[182977],[22735],[23024],[False],[0],[0],[False],['0']
16768,PMC4022270,30324,Twenty-eight (17%) patients treated in the acute geriatric ward and 24 (15%) treated in the orthopedic ward were dead four months after the surgery (P = 0.50).,Results|Secondary outcomes and subgroup analyses,[182983],[23025],[23184],[False],[0],[0],[False],['0']
16769,PMC4022270,30325,"In both groups, 21% of the patients were readmitted during the first four months after surgery.",Results|Secondary outcomes and subgroup analyses,[182989],[23185],[23280],[False],[0],[0],[False],['0']
16770,PMC4022270,30326,The results at the 12-month follow up were similar to those after four months.,Results|Secondary outcomes and subgroup analyses,[182995],[23281],[23359],[False],[0],[0],[False],['0']
16771,PMC4022270,30327,Sensitivity analyses,Results|Sensitivity analyses,[183001],[23360],[23380],[False],[0],[0],[False],['0']
16772,PMC4022270,30328,Several sensitivity analyses were performed and they showed no substantial differences from the primary analysis.,Results|Sensitivity analyses,[183007],[23381],[23494],[False],[0],[0],[False],['0']
16773,PMC4022270,30329,Discussion,Discussion,[183013],[23495],[23506],[False],[0],[0],[False],['0']
16774,PMC4022270,30330,"In this randomized controlled trial of patients with hip fracture, we found no evidence that cognitive function four months after surgery was improved in patients treated pre- and postoperatively in an acute geriatric ward, compared to usual care in an orthopedic ward.",Discussion,[183019],[23507],[23776],[False],[0],[0],[False],['0']
16775,PMC4022270,30331,Delirium rates were equally high in both groups.,Discussion,[183025],[23777],[23825],[False],[0],[0],[False],['0']
16776,PMC4022270,30332,"There was, however, a trend that the intervention had a positive effect on mobility.",Discussion,[183031],[23826],[23910],[False],[0],[0],[False],['0']
16777,PMC4022270,30333,Strength and weaknesses,Discussion|Strength and weaknesses,[183037],[23911],[23934],[False],[0],[0],[False],['0']
16778,PMC4022270,30334,The main strength of this study was the randomized controlled design with blinded outcome assessments.,Discussion|Strength and weaknesses,[183043],[23935],[24037],[False],[0],[0],[False],['0']
16779,PMC4022270,30335,"Also, the inclusion of process measures, such as objective mobilization scores, confirms that the intervention was being delivered as intended.",Discussion|Strength and weaknesses,[183049],[24038],[24181],[False],[0],[0],[False],['0']
16780,PMC4022270,30336,The inclusion of patients from nursing homes and those with dementia enhances generalizability as such patients are frequently excluded from trials [34].,Discussion|Strength and weaknesses,[183055],[24182],[24335],[False],[0],[0],[False],['0']
16781,PMC4022270,30337,"On the other hand, nursing home patients are so frail and cognitively impaired that they may be unlikely to benefit from the intervention.",Discussion|Strength and weaknesses,[183061],[24336],[24474],[False],[0],[0],[False],['0']
16782,PMC4022270,30338,"To assess the efficacy in such patients, other outcomes than those we chose might be more feasible [35].",Discussion|Strength and weaknesses,[183067],[24475],[24579],[True],['RelevantOutcomeExcluded'],['other outcomes than those we chose might be more feasible'],[True],['OutcomeMeasures']
16783,PMC4022270,30339,The combined outcome measure was designed to measure cognition in patients representing a broad spectrum of cognitive function and was based upon well-validated components.,Discussion|Strength and weaknesses,[183079],[24580],[24752],[False],[0],[0],[False],['0']
16784,PMC4022270,30340,"However, the scale combination has not been validated and, thus, we cannot be sure that it was sensitive to the intervention.",Discussion|Strength and weaknesses,"[183086, 183087]","[24753, 24753]","[24878, 24878]","[True, True]","['ValidityOfMeasurement', 'ResponsivenessOfMeasurement']","['the scale combination has not been validated', 'we cannot be sure that it was sensitive to the intervention']","[True, True]",['OutcomeMeasures']
16785,PMC4022270,30341,"As with all service evaluations, blinding of assessments during hospital stay was impossible and may have introduced bias.",Discussion|Strength and weaknesses,[183100],[24879],[25001],[True],['Blinding'],['blinding of assessments during hospital stay was impossible'],[True],['Blinding']
16786,PMC4022270,30342,Inclusion was terminated before the intended sample size aim was reached.,Discussion|Strength and weaknesses,[183107],[25002],[25075],[True],['SampleSize'],['Inclusion was terminated before the intended sample size aim was reached'],[True],['UnderpoweredStudy']
16787,PMC4022270,30343,"However, as there were few differences between the groups in any of the secondary cognitive outcomes, and sub-group analyses also failed to show any substantial differences, it is reasonable to conclude that this intervention had no effect on cognition.",Discussion|Strength and weaknesses,[183115],[25076],[25329],[False],[0],[0],[False],['0']
16788,PMC4022270,30344,Comparison with other studies,Discussion|Comparison with other studies,[183121],[25330],[25359],[False],[0],[0],[False],['0']
16789,PMC4022270,30345,The impact of orthogeriatric intervention on long-term cognitive function has not previously been assessed.,Discussion|Comparison with other studies,[183127],[25360],[25467],[False],[0],[0],[False],['0']
16790,PMC4022270,30346,Several studies have demonstrated that orthogeriatric care can prevent delirium in hip fracture patients.,Discussion|Comparison with other studies,[183133],[25468],[25573],[False],[0],[0],[False],['0']
16791,PMC4022270,30347,"A recently published non-randomized controlled trial from Belgium [15] showed that an intervention provided by an inpatient geriatric consultation team was effective in reducing the incidence of delirium (37.2% versus 53.2%, P = 0.04), in keeping with a similar American RCT [16].",Discussion|Comparison with other studies,[183139],[25574],[25854],[False],[0],[0],[False],['0']
16792,PMC4022270,30348,"In both the American and the Belgian studies, all patients received standard treatment from the orthopedic team, whereas in our model orthopedic treatment (besides surgery) was limited to consultation service.",Discussion|Comparison with other studies,[183145],[25855],[26064],[False],[0],[0],[False],['0']
16793,PMC4022270,30349,"A possible explanation for the lack of effect of our model could, therefore, be limited access to orthopedic expertise.",Discussion|Comparison with other studies,[183151],[26065],[26184],[False],[0],[0],[False],['0']
16794,PMC4022270,30350,Few studies have compared pre- and postoperative intervention provided in a geriatric ward with usual care in an orthopedic ward.,Discussion|Comparison with other studies,[183157],[26185],[26314],[False],[0],[0],[False],['0']
16795,PMC4022270,30351,"In comparison with usual care, such models have shown promising results, but cognition has seldom been assessed [5,6].",Discussion|Comparison with other studies,[183163],[26315],[26433],[False],[0],[0],[False],['0']
16796,PMC4022270,30352,"To our knowledge, the only RCT evaluating a geriatrician-led fracture service (were geriatricians have the primary responsibility for the patients) is a Swedish study [36].",Discussion|Comparison with other studies,[183169],[26434],[26606],[False],[0],[0],[False],['0']
16797,PMC4022270,30353,"Although no preoperative intervention was included, the study showed that significantly more patients allocated to intervention regained independence in personal ADL performance at four and twelve months after surgery.",Discussion|Comparison with other studies,[183175],[26607],[26825],[False],[0],[0],[False],['0']
16798,PMC4022270,30354,The model was also effective in preventing postoperative delirium and reducing delirium duration [14].,Discussion|Comparison with other studies,[183181],[26826],[26928],[False],[0],[0],[False],['0']
16799,PMC4022270,30355,"In spite of the fact that we also included preoperative intervention, we were not able to prevent delirium.",Discussion|Comparison with other studies,[183187],[26929],[27036],[False],[0],[0],[False],['0']
16800,PMC4022270,30356,A likely explanation is that usual care was better in our study since the delirium rates both in the intervention and the control group were lower than in the Swedish study.,Discussion|Comparison with other studies,[183193],[27037],[27210],[False],[0],[0],[False],['0']
16801,PMC4022270,30357,"The orthopedic ward in our study provided a short waiting time for surgery, similar staffing as in the geriatric ward, personnel with earlier experience with orthogeriatric models and delirium prevention, physiotherapy for most hip fracture patients, and an integrated post-operative care unit.",Discussion|Comparison with other studies,[183199],[27211],[27505],[False],[0],[0],[False],['0']
16802,PMC4022270,30358,Orthogeriatric intervention is often reported to reduce waiting time for surgery (see Liem [37] for an overview).,Discussion|Comparison with other studies,[183205],[27506],[27619],[False],[0],[0],[False],['0']
16803,PMC4022270,30359,"In our study, however, the waiting time for surgery was two hours longer in the intervention group.",Discussion|Comparison with other studies,[183211],[27620],[27719],[False],[0],[0],[False],['0']
16804,PMC4022270,30360,"Both the intervention (26 hours) and the control group (24 hours) waited, however, for a short time compared to other orthogeriatric studies reporting a waiting time of two to three days and even longer [38-42], indicating that the control group received a good quality service.",Discussion|Comparison with other studies,[183217],[27720],[27998],[False],[0],[0],[False],['0']
16805,PMC4022270,30361,"Mobility has been assessed in several studies, but mostly by questionnaire.",Discussion|Comparison with other studies,[183223],[27999],[28074],[False],[0],[0],[False],['0']
16806,PMC4022270,30362,"Some, but not all, studies have found that orthogeriatric services provide better mobility [36,40,43,44].",Discussion|Comparison with other studies,[183229],[28075],[28180],[False],[0],[0],[False],['0']
16807,PMC4022270,30363,"In our study there was an overall trend that patients treated in the intervention group performed better at SPPB four months after surgery, and the difference was statistically significant in those living in their own homes before surgery.",Discussion|Comparison with other studies,[183235],[28181],[28420],[False],[0],[0],[False],['0']
16808,PMC4022270,30364,"A difference on SPPB of 0.5 is considered clinically meaningful, and the effect seen in our study (six versus four points) is likely to be important and should be further explored in future studies.",Discussion|Comparison with other studies,[183241],[28421],[28619],[False],[0],[0],[False],['0']
16809,PMC4022270,30365,Interpretation of the results,Discussion|Interpretation of the results,[183247],[28620],[28649],[False],[0],[0],[False],['0']
16810,PMC4022270,30366,"Despite our comprehensive intervention, the effect on the primary outcome was limited.",Discussion|Interpretation of the results,[183253],[28650],[28736],[False],[0],[0],[False],['0']
16811,PMC4022270,30367,There are several possible explanations for this.,Discussion|Interpretation of the results,[183259],[28737],[28786],[False],[0],[0],[False],['0']
16812,PMC4022270,30368,"First, the choice of cognitive function as the primary outcome may have been too ambitious.",Discussion|Interpretation of the results,[183265],[28787],[28878],[False],[0],[0],[False],['0']
16813,PMC4022270,30369,"For the intervention to be effective in this regard, two pre-suppositions had to be true.",Discussion|Interpretation of the results,[183271],[28879],[28968],[False],[0],[0],[False],['0']
16814,PMC4022270,30370,"First, the orthogeriatric intervention had to be effective in reducing delirium.",Discussion|Interpretation of the results,[183277],[28969],[29049],[False],[0],[0],[False],['0']
16815,PMC4022270,30371,"However, our intervention failed to prevent delirium or reduce delirium severity.",Discussion|Interpretation of the results,[183283],[29050],[29131],[False],[0],[0],[False],['0']
16816,PMC4022270,30372,"This might be explained by the good quality of usual care at the orthopedic ward in our hospital, combined with sub-optimal circumstances in an often over-crowded acute geriatric ward.",Discussion|Interpretation of the results,[183289],[29132],[29316],[False],[0],[0],[False],['0']
16817,PMC4022270,30373,"Secondly, the primary outcome assumes that delirium lies on the causal pathway towards the development of dementia.",Discussion|Interpretation of the results,[183295],[29317],[29432],[False],[0],[0],[False],['0']
16818,PMC4022270,30374,"Since delirium usually occurs in relation to acute illness, it is challenging to design studies that can address this question, but some evidence exits suggesting that delirium is associated with long term cognitive decline [13,45,46].",Discussion|Interpretation of the results,[183301],[29433],[29668],[False],[0],[0],[False],['0']
16819,PMC4022270,30375,"Our study is in keeping with this; the regression analysis showed that delirium was associated with a poorer score on the primary outcome, also when adjusting for potential confounders.",Discussion|Interpretation of the results,[183307],[29669],[29854],[False],[0],[0],[False],['0']
16820,PMC4022270,30376,The study may have influenced treatment in the control group.,Discussion|Interpretation of the results,[183313],[29855],[29916],[False],[0],[0],[False],['0']
16821,PMC4022270,30377,"The patients in the orthopedic ward were assessed daily, and in order to make a precise delirium diagnosis personnel in the orthopedic ward were interviewed regarding the patients cognitive status.",Discussion|Interpretation of the results,[183319],[29917],[30114],[False],[0],[0],[False],['0']
16822,PMC4022270,30378,This inevitably raised the awareness of delirium in the orthopedic ward.,Discussion|Interpretation of the results,[183330],[30115],[30187],[True],['Blinding'],['raised the awareness of delirium in the orthopedic ward'],[True],['Blinding']
16823,PMC4022270,30379,Conclusions,Conclusions,[183337],[30188],[30200],[False],[0],[0],[False],['0']
16824,PMC4022270,30380,"This randomized controlled trial of hip fracture patients found no evidence that cognitive function four months after surgery was improved in patients treated with pre- and postoperative orthogeriatric care provided in an acute geriatric ward, compared to usual care in an orthopedic ward.",Conclusions,[183343],[30201],[30490],[False],[0],[0],[False],['0']
16825,PMC4022270,30381,The intervention had a positive effect on mobility in patients not admitted from nursing homes.,Conclusions,[183349],[30491],[30586],[False],[0],[0],[False],['0']
16826,PMC4022270,30382,"Delirium had a strong negative impact on long-term cognitive performance, and delirium prevention and treatment should be given high priority in orthogeriatric care.",Conclusions,[183355],[30587],[30752],[False],[0],[0],[False],['0']
16827,PMC4022270,30383,"For further orthogeriatric improvements, we recommend a model with stronger integration of orthopedic and geriatric input than we achieved, in line with recommendations from recent reviews [5,7].",Conclusions,[183361],[30753],[30948],[False],[0],[0],[False],['0']
16828,PMC4022270,30384,Competing interests,Competing interests,[183367],[30949],[30969],[False],[0],[0],[False],['0']
16829,PMC4022270,30385,The authors declare that they have no competing interests.,Competing interests,[183373],[30970],[31028],[False],[0],[0],[False],['0']
16830,PMC4022270,30386,Authors' contributions,Authors' contributions,[183379],[31029],[31052],[False],[0],[0],[False],['0']
16831,PMC4022270,30387,"TBW initiated the study, led the work on the study design and was involved in analyzing and interpreting the data.",Authors' contributions,[183385],[31053],[31167],[False],[0],[0],[False],['0']
16832,PMC4022270,30388,TBW is the manuscript’s guarantor.,Authors' contributions,[183391],[31168],[31202],[False],[0],[0],[False],['0']
16833,PMC4022270,30389,LOW had the daily responsibility for running the study and collecting data.,Authors' contributions,[183397],[31203],[31278],[False],[0],[0],[False],['0']
16834,PMC4022270,30390,"LOW was also involved in planning of the study, has analyzed and interpreted the data and drafted the manuscript.",Authors' contributions,[183403],[31279],[31392],[False],[0],[0],[False],['0']
16835,PMC4022270,30391,ACT had particular responsibility for collecting nutritional data and was involved in planning the study.,Authors' contributions,[183409],[31393],[31498],[False],[0],[0],[False],['0']
16836,PMC4022270,30392,FF and GH had the primary responsibility to remind and motivate the orthopedic surgeons to include patients in the study.,Authors' contributions,[183415],[31499],[31620],[False],[0],[0],[False],['0']
16837,PMC4022270,30393,"KE participated in all aspects of the planning, in particular regarding the cognitive outcomes.",Authors' contributions,[183421],[31621],[31716],[False],[0],[0],[False],['0']
16838,PMC4022270,30394,ES carried out the randomization procedure and was extensively involved in the statistical planning and analyses.,Authors' contributions,[183427],[31717],[31830],[False],[0],[0],[False],['0']
16839,PMC4022270,30395,"Together with LOW and TBW, she wrote the statistical analysis plan.",Authors' contributions,[183433],[31831],[31898],[False],[0],[0],[False],['0']
16840,PMC4022270,30396,"FF, VJ, IS, JR, ES and SC all made important contributions to the planning of the study and writing the protocol.",Authors' contributions,[183439],[31899],[32012],[False],[0],[0],[False],['0']
16841,PMC4022270,30397,All authors participated in critical revision of the article for intellectual content.,Authors' contributions,[183445],[32013],[32099],[False],[0],[0],[False],['0']
16842,PMC4022270,30398,All authors read and approved the final version of the manuscript.,Authors' contributions,[183451],[32100],[32166],[False],[0],[0],[False],['0']
16843,PMC4022270,30399,Pre-publication history,Pre-publication history,[183457],[32167],[32191],[False],[0],[0],[False],['0']
16844,PMC4022270,30400,The pre-publication history for this paper can be accessed here:,Pre-publication history,[183463],[32192],[32256],[False],[0],[0],[False],['0']
16845,PMC4022270,30401,http://www.biomedcentral.com/1741-7015/12/63/prepub,Pre-publication history,[183469],[32257],[32308],[False],[0],[0],[False],['0']
16846,PMC4022270,30402,Acknowledgments,Acknowledgments,[183475],[32309],[32326],[False],[0],[0],[False],['0']
16847,PMC4022270,30403,The authors would like to thank the patients and staff at the Orthopedic Department and the Geriatric Department at Oslo University Hospital.,Acknowledgments,[183481],[32327],[32468],[False],[0],[0],[False],['0']
16848,PMC4022270,30404,"They also thank research nurses Elisabeth Fragaat, Tone Fredriksen, Camilla Marie Andersen, Julie Ask Ottesen and Linda Feldt for assisting in data collection.",Acknowledgments,[183487],[32469],[32628],[False],[0],[0],[False],['0']
16849,PMC4022270,30405,"The manuscript’s guarantor affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.",Acknowledgments,[183493],[32629],[32924],[False],[0],[0],[False],['0']
16850,PMC4022270,30406,The Oslo Orthogeriatric Trial was mainly funded by the Research Council of Norway through the program ‘Improving mental health of older people through multidisciplinary efforts’ (grant no.,Acknowledgments,[183499],[32925],[33113],[False],[0],[0],[False],['0']
16851,PMC4022270,30407,187980/H10).,Acknowledgments,[183505],[33114],[33126],[False],[0],[0],[False],['0']
16852,PMC4022270,30408,"Further, we have received funding from Oslo University Hospital, The Sophies Minde Foundation, The Norwegian Association for Public Health and Civitan’s Research Foundation.",Acknowledgments,[183511],[33127],[33300],[False],[0],[0],[False],['0']
16853,PMC4022270,30409,"The sponsors had no role in the design, methods, subject recruitment, data collection, analysis or preparation of the manuscript.",Acknowledgments,[183517],[33301],[33430],[False],[0],[0],[False],['0']
17256,PMC4066691,6737,"Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma",Title,[41557],[24431],[117],[False],[0],[0],[False],['0']
17257,PMC4066691,6738,Background,Abstract,[41559],[118],[129],[False],[0],[0],[False],['0']
17258,PMC4066691,6739,"Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists.",Abstract,[41561],[130],[497],[False],[0],[0],[False],['0']
17259,PMC4066691,6740,"To further explore the dose–response curve in asthma, we investigated the efficacy and safety of three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma.",Abstract,[41563],[498],[714],[False],[0],[0],[False],['0']
17260,PMC4066691,6741,Methods,Abstract,[41565],[715],[722],[False],[0],[0],[False],['0']
17261,PMC4066691,6742,"In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg or placebo Respimat®, once daily in the evening.",Abstract,[41567],[723],[924],[False],[0],[0],[False],['0']
17262,PMC4066691,6743,"Each treatment was administered for 4 weeks, without washout between treatment periods.",Abstract,[41569],[925],[1012],[False],[0],[0],[False],['0']
17263,PMC4066691,6744,Eligibility criteria included ≥60% and ≤90% of predicted normal forced expiratory volume in 1 second (FEV1) and seven-question Asthma Control Questionnaire mean score of ≥1.5.,Abstract,[41571],[1013],[1188],[False],[0],[0],[False],['0']
17264,PMC4066691,6745,Patients were required to continue maintenance treatment with stable medium-dose ICS for at least 4 weeks prior to and during the treatment period.,Abstract,[41573],[1189],[1336],[False],[0],[0],[False],['0']
17265,PMC4066691,6746,Long-acting β2-agonists were not permitted during the treatment phase.,Abstract,[41575],[1337],[1407],[False],[0],[0],[False],['0']
17266,PMC4066691,6747,"The primary efficacy end point was peak FEV1 measured within 3 hours after dosing (peak FEV1(0-3h)) at the end of each 4-week period, analysed as a response (change from study baseline).",Abstract,[41577],[1408],[1594],[False],[0],[0],[False],['0']
17267,PMC4066691,6748,Results,Abstract,[41579],[1595],[1602],[False],[0],[0],[False],['0']
17268,PMC4066691,6749,"In total, 149 patients were randomised and 141 completed the study.",Abstract,[41581],[1603],[1670],[False],[0],[0],[False],['0']
17269,PMC4066691,6750,Statistically significant improvements in peak FEV1(0-3h) response were observed with each tiotropium Respimat® dose versus placebo (all P < 0.0001).,Abstract,[41583],[1671],[1820],[False],[0],[0],[False],['0']
17270,PMC4066691,6751,The largest difference from placebo was with tiotropium Respimat® 5 μg (188 mL).,Abstract,[41585],[1821],[1901],[False],[0],[0],[False],['0']
17271,PMC4066691,6752,"Trough FEV1 and FEV1 area under the curve (AUC)(0-3h) responses were greater with each tiotropium Respimat® dose than with placebo (all P < 0.0001), and both were greatest with 5 μg.",Abstract,[41587],[1902],[2084],[False],[0],[0],[False],['0']
17272,PMC4066691,6753,"Peak forced vital capacity (FVC)(0-3h), trough FVC and FVC AUC(0-3h) responses, versus placebo, were greatest with tiotropium Respimat® 5 μg (P < 0.0001, P = 0.0012 and P < 0.0001, respectively).",Abstract,[41589],[2085],[2280],[False],[0],[0],[False],['0']
17273,PMC4066691,6754,Incidence of adverse events was comparable between placebo and all tiotropium Respimat® groups.,Abstract,[41591],[2281],[2376],[False],[0],[0],[False],['0']
17274,PMC4066691,6755,Conclusions,Abstract,[41593],[2377],[2388],[False],[0],[0],[False],['0']
17275,PMC4066691,6756,Once-daily tiotropium Respimat® add-on to medium-dose ICS improves lung function in symptomatic patients with moderate asthma.,Abstract,[41595],[2389],[2515],[False],[0],[0],[False],['0']
17276,PMC4066691,6757,"Overall, improvements were largest with tiotropium Respimat® 5 μg.",Abstract,[41597],[2516],[2582],[False],[0],[0],[False],['0']
17277,PMC4066691,6758,Trial registration,Abstract,[41599],[2583],[2601],[False],[0],[0],[False],['0']
17278,PMC4066691,6759,ClinicalTrials.gov identifier NCT01233284.,Abstract,[41601],[2602],[2644],[False],[0],[0],[False],['0']
17279,PMC4066691,6760,Background,Background,[41603],[2645],[2656],[False],[0],[0],[False],['0']
17280,PMC4066691,6761,"Currently, inhaled corticosteroids (ICS) are the de facto first-line therapy for the management of poorly controlled, persistent asthma.",Background,[41605],[2657],[2793],[False],[0],[0],[False],['0']
17281,PMC4066691,6762,"In accordance with the Global Initiative for Asthma guidelines , for patients with moderate asthma who remain symptomatic despite using ICS, therapy is typically ‘stepped up’ by increasing the ICS dose and/or adding a long-acting β2-agonist (LABA) to the maintenance treatment regimen.",Background,[41607],[2794],[3079],[False],[0],[0],[False],['0']
17282,PMC4066691,6763,"Leukotriene modifiers or sustained-release theophylline, added on to low-dose ICS, are alternative options for these patients.",Background,[41609],[3080],[3206],[False],[0],[0],[False],['0']
17283,PMC4066691,6764,"Despite this range of therapeutic choices, at least 40% of patients with asthma have poorly controlled disease .",Background,[41611],[3207],[3319],[False],[0],[0],[False],['0']
17284,PMC4066691,6765,"Further, in patients who fail to gain control with an ICS + LABA fixed-dose combination, the remaining options, such as further upwards titration of ICS, systemic glucocorticosteroids and anti-immunoglobulin E therapy, may have several limitations with respect to side effects, risk:benefit ratio, convenience and efficacy .",Background,[41613],[3320],[3644],[False],[0],[0],[False],['0']
17285,PMC4066691,6766,"Tiotropium, a once-daily long-acting anticholinergic bronchodilator, is the established first-line maintenance bronchodilator for the management of chronic obstructive pulmonary disease .",Background,[41615],[3645],[3832],[False],[0],[0],[False],['0']
17286,PMC4066691,6767,"Recently, a number of clinical trials have investigated tiotropium as add-on to at least ICS for the long-term control of asthma, across a range of severities.",Background,[41617],[3833],[3992],[False],[0],[0],[False],['0']
17287,PMC4066691,6768,"In the investigator-led TALC trial (Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid; three-way crossover, 14 weeks per treatment, 210 patients), improvements in lung function in patients with asthma treated with tiotropium (via HandiHaler®; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany) plus beclomethasone (two puffs of 40 μg, twice daily) were shown to be superior to a doubling of the ICS dose and similar to the addition of salmeterol .",Background,[41619],[3993],[4562],[False],[0],[0],[False],['0']
17288,PMC4066691,6769,"In a 16-week proof-of-concept trial in B16-Arg/Arg patients with symptomatic moderate asthma already receiving ICS, tiotropium 5 μg (administered via the Respimat® SoftMist™ inhaler [hereinafter referred to as tiotropium Respimat®; Boehringer Ingelheim Pharma GmbH & Co. KG]) was superior to placebo Respimat® and non-inferior to salmeterol .",Background,[41621],[4563],[4905],[False],[0],[0],[False],['0']
17289,PMC4066691,6770,"A second proof-of-concept study (three-way crossover, 8 weeks per treatment) in patients with more severe disease – severe persistent asthma, and receiving ICS + LABA – demonstrated that lung function improved significantly with tiotropium Respimat® 10 μg or 5 μg .",Background,[41623],[4906],[5171],[False],[0],[0],[False],['0']
17290,PMC4066691,6771,"Slightly higher peak forced expiratory volume in 1 second (FEV1) responses were observed in the 10 μg arm , and there were statistically significant improvements in pre-dose morning and evening peak expiratory flow (PEFam and PEFpm) with 10 μg versus 5 μg.",Background,[41625],[5172],[5428],[False],[0],[0],[False],['0']
17291,PMC4066691,6772,"Kerstjens and colleagues subsequently reported results from two long-term, replicate, 1-year Phase III trials of tiotropium Respimat® 5 μg, also in patients with symptomatic severe asthma despite using ICS + LABA.",Background,[41627],[5429],[5642],[False],[0],[0],[False],['0']
17292,PMC4066691,6773,"In this cohort of 912 patients, tiotropium Respimat® 5 μg, administered as add-on to ICS + LABA, significantly reduced the risk of severe exacerbations and improved lung function, compared with placebo Respimat® as add-on to ICS + LABA .",Background,[41629],[5643],[5880],[False],[0],[0],[False],['0']
17293,PMC4066691,6774,"In light of the findings with the 10 μg and 5 μg doses of tiotropium Respimat® (outlined above), the aim of the present study was to further explore the dose–response curve by comparing the efficacy and tolerability of once-daily evening dosing of tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg, versus placebo Respimat®, each added on to medium-dose ICS, in adult patients with symptomatic moderate asthma.",Background,[41631],[5881],[6286],[False],[0],[0],[False],['0']
17294,PMC4066691,6775,Methods,Methods,[41633],[6287],[6295],[False],[0],[0],[False],['0']
17295,PMC4066691,6776,"This was a Phase II, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy and safety of three doses of once-daily tiotropium Respimat®.",Methods,[41635],[6296],[6468],[False],[0],[0],[False],['0']
17296,PMC4066691,6777,"The study was conducted in 19 sites in three European countries (Germany, Austria and Ukraine; ClinicalTrials.gov identifier NCT01233284), and was carried out in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines.",Methods,[41637],[6469],[6777],[False],[0],[0],[False],['0']
17297,PMC4066691,6778,"All patients provided written, informed consent.",Methods,[41639],[6778],[6826],[False],[0],[0],[False],['0']
17298,PMC4066691,6779,Study design,Methods|Study design,[41641],[6827],[6839],[False],[0],[0],[False],['0']
17299,PMC4066691,6780,"After an initial screening visit and a 4-week run-in period, patients were randomised to one of four treatment sequences, during which they received each of the four treatments (tiotropium 5 μg, 2.5 μg or 1.25 μg or placebo, all delivered via the Respimat® SoftMist™ inhaler) (Figure  1).",Methods|Study design,[41643],[6840],[7128],[False],[0],[0],[False],['0']
17300,PMC4066691,6781,"Each treatment was administered for 4 weeks, and there was no washout between treatment periods as pharmacodynamic steady state with tiotropium is known to be achieved after 3 weeks in chronic obstructive pulmonary disease .",Methods|Study design,[41645],[7129],[7353],[False],[0],[0],[False],['0']
17301,PMC4066691,6782,Seven clinic visits were scheduled: at screening (Visit 0); prior to the 4-week run-in (Visit 1); at randomisation (after the 4-week run-in [Visit 2]); every 4 weeks at the end of each treatment period (Visits 3–6); and 21 days following the end of the final treatment period (Visit 7).,Methods|Study design,[41647],[7354],[7640],[False],[0],[0],[False],['0']
17302,PMC4066691,6783,Study design.,Methods|Study design.,[41649],[7641],[7654],[False],[0],[0],[False],['0']
17303,PMC4066691,6784,Tiotropium Respimat® (two puffs) or placebo Respimat® (two puffs) was administered once daily in the evening between 18:00 and 20:00.,Methods|Study design.,[41651],[7655],[7788],[False],[0],[0],[False],['0']
17304,PMC4066691,6785,All patients were required to continue maintenance treatment with stable medium-dose ICS (400–800 μg budesonide or equivalent) for at least 4 weeks prior to Visit 1 and until Visit 7.,Methods|Study design.,[41653],[7789],[7972],[False],[0],[0],[False],['0']
17305,PMC4066691,6786,"Patients using ICS plus short-acting β2-agonist or ICS + LABA fixed-dose combinations were switched to the same dose of ICS mono-product at least 8 or 24 hours, respectively, prior to Visit 1.",Methods|Study design.,[41655],[7973],[8165],[False],[0],[0],[False],['0']
17306,PMC4066691,6787,Study medication was to be taken immediately after ICS inhalation if normal ICS dosing was in the evening.,Methods|Study design.,[41657],[8166],[8272],[False],[0],[0],[False],['0']
17307,PMC4066691,6788,Concomitant use of the following was not permitted for maintenance treatment: systemic oral or depot corticosteroids; anticholinergics other than tiotropium; LABAs; ICS plus short-acting β2-agonist or ICS + LABA fixed-dose combinations; leukotriene modifiers; anti-immunoglobulin E treatment; chromone; methylxanthines; and phosphodiesterase-4 inhibitors.,Methods|Study design.,[41659],[8273],[8628],[False],[0],[0],[False],['0']
17308,PMC4066691,6789,Salbutamol hydrofluoroalkane metered-dose inhaler was provided by the sponsor as rescue medication for use as needed.,Methods|Study design.,[41661],[8629],[8746],[False],[0],[0],[False],['0']
17309,PMC4066691,6790,"Permitted medication for the treatment of acute asthma exacerbations included salbutamol hydrofluoroalkane metered-dose inhaler, systemic corticosteroids and short-acting theophylline preparations.",Methods|Study design.,[41663],[8747],[8944],[False],[0],[0],[False],['0']
17310,PMC4066691,6791,Randomisation,Methods|Randomisation,[41665],[8945],[8958],[False],[0],[0],[False],['0']
17311,PMC4066691,6792,Each patient received all treatments.,Methods|Randomisation,[41667],[8959],[8996],[False],[0],[0],[False],['0']
17312,PMC4066691,6793,Eligible patients were randomly allocated to one of the four treatment sequences at Visit 2 (Figure  1).,Methods|Randomisation,[41669],[8997],[9101],[False],[0],[0],[False],['0']
17313,PMC4066691,6794,"The randomisation list was generated by Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, using a validated pseudo-random number generator and a supplied seed number.",Methods|Randomisation,[41671],[9102],[9292],[False],[0],[0],[False],['0']
17314,PMC4066691,6795,"A fixed block randomisation, with a block size of 4, was used to ensure balanced and equal assignment.",Methods|Randomisation,[41673],[9293],[9395],[False],[0],[0],[False],['0']
17315,PMC4066691,6796,Study patients,Methods|Study patients,[41675],[9396],[9410],[False],[0],[0],[False],['0']
17316,PMC4066691,6797,"Male or female patients aged 18–75 years, with at least a 3-month history of asthma at the time of enrolment and an initial diagnosis of asthma made before the age of 40 years, were included in the study.",Methods|Study patients,[41677],[9411],[9615],[False],[0],[0],[False],['0']
17317,PMC4066691,6798,"Patients were required to have been on maintenance treatment with stable medium-dose ICS (400–800 μg budesonide or equivalent), alone or in a fixed-dose combination with a LABA or short-acting β2-agonist, for at least 4 weeks prior to Visit 1.",Methods|Study patients,[41679],[9616],[9859],[False],[0],[0],[False],['0']
17318,PMC4066691,6799,"A diagnosis of asthma confirmed at Visit 1 was required, with bronchodilator reversibility (15–30 minutes after 400 μg salbutamol) of ≥12% and ≥200 mL.",Methods|Study patients,[41681],[9860],[10011],[False],[0],[0],[False],['0']
17319,PMC4066691,6800,"Patients were required to have a seven-question Asthma Control Questionnaire (ACQ-7) mean score of ≥1.5 at Visits 1 and 2, to have a pre-bronchodilator FEV1 of ≥60% and ≤90% of predicted normal FEV1 at Visit 1, and to demonstrate absolute FEV1 variability within 30% between Visits 1 and 2.",Methods|Study patients,[41683],[10012],[10302],[False],[0],[0],[False],['0']
17320,PMC4066691,6801,"Patients were required never to have smoked, or to be ex-smokers who had stopped smoking at least 1 year prior to enrolment and had a smoking history of less than 10 pack-years.",Methods|Study patients,[41685],[10303],[10480],[False],[0],[0],[False],['0']
17321,PMC4066691,6802,Patients were excluded for any of the following reasons: a diagnosis of chronic obstructive pulmonary disease or any respiratory disease other than asthma; myocardial infarction within the last 6 months; hospitalisation due to cardiac failure or unstable cardiac arrhythmia within the past year; treatment with anti-immunoglobulin E antibodies within 6 months prior to Visit 1.,Methods|Study patients,[41687],[10481],[10858],[False],[0],[0],[False],['0']
17322,PMC4066691,6803,Study end points,Methods|Study end points,[41689],[10859],[10875],[False],[0],[0],[False],['0']
17323,PMC4066691,6804,All end points were determined at the end of each 4-week treatment period (Visits 3–6) and analysed as a response defined as change from study baseline (pre-treatment value measured at Visit 2 in the evening).,Methods|Study end points,[41691],[10876],[11085],[False],[0],[0],[False],['0']
17324,PMC4066691,6805,The primary efficacy end point was peak FEV1 measured within the first 3 hours after dosing (peak FEV1(0-3h)).,Methods|Study end points,[41693],[11086],[11196],[False],[0],[0],[False],['0']
17325,PMC4066691,6806,"The following secondary efficacy end points were investigated: trough FEV1; peak forced vital capacity (FVC) within the first 3 hours after dosing (FVC)(0-3h); trough FVC; FEV1 area under the curve (AUC) within the first 3 hours after dosing (FEV1 AUC(0-3h)); FVC AUC(0-3h); pre-dose PEFam and PEFpm using the Asthma Monitor2+ device (AM2+®; ERT, Philadelphia, Pennsylvania, USA) based on the mean of the final week of each treatment period.",Methods|Study end points,[41695],[11197],[11638],[False],[0],[0],[False],['0']
17326,PMC4066691,6807,"Control of asthma, as assessed by ACQ-7 self-administered at the end of each 4-week treatment period, was an additional exploratory end point.",Methods|Study end points,[41697],[11639],[11781],[False],[0],[0],[False],['0']
17327,PMC4066691,6808,"Safety and tolerability were assessed based on the incidence and intensity of adverse events, and on changes in vital signs.",Methods|Study end points,[41699],[11782],[11906],[False],[0],[0],[False],['0']
17328,PMC4066691,6809,Study assessments,Methods|Study assessments,[41701],[11907],[11924],[False],[0],[0],[False],['0']
17329,PMC4066691,6810,Spirometric lung function tests were conducted at all in-clinic visits (Visits 1–6).,Methods|Study assessments,[41703],[11925],[12009],[False],[0],[0],[False],['0']
17330,PMC4066691,6811,Pre-dose lung function tests were scheduled between 18:00 and 20:00.,Methods|Study assessments,[41705],[12010],[12078],[False],[0],[0],[False],['0']
17331,PMC4066691,6812,"At Visits 2–6, lung function tests were performed 10 minutes prior to and up to 3 hours after dosing of study treatment.",Methods|Study assessments,[41707],[12079],[12199],[False],[0],[0],[False],['0']
17332,PMC4066691,6813,ACQ-7 was self-administered at Visits 1–6 prior to lung function tests.,Methods|Study assessments,[41709],[12200],[12271],[False],[0],[0],[False],['0']
17333,PMC4066691,6814,"Measurement of PEFam and PEFpm was to be performed prior to ICS and study treatment inhalation, at approximately the same time each day, from 06:00 to 08:00 for PEFam and from 18:00 to 20:00 for PEFpm.",Methods|Study assessments,[41711],[12272],[12473],[False],[0],[0],[False],['0']
17334,PMC4066691,6815,Adverse events and concomitant medications were recorded on the electronic case report form at each visit.,Methods|Study assessments,[41713],[12474],[12580],[False],[0],[0],[False],['0']
17335,PMC4066691,6816,Vital signs were measured and recorded in conjunction with lung function tests at Visits 2–6.,Methods|Study assessments,[41715],[12581],[12674],[False],[0],[0],[False],['0']
17336,PMC4066691,6817,Statistical analyses,Methods|Statistical analyses,[41717],[12675],[12695],[False],[0],[0],[False],['0']
17337,PMC4066691,6818,"Efficacy data are reported for the full analysis set, which was defined as all randomised patients who were treated with at least one dose of study medication, had baseline data and had at least one on-treatment efficacy measurement after 4 weeks of treatment within a period.",Methods|Statistical analyses,[41719],[12696],[12972],[False],[0],[0],[False],['0']
17338,PMC4066691,6819,"Data are presented as adjusted mean change from baseline after 4 weeks of treatment (defined as response), unless noted otherwise.",Methods|Statistical analyses,[41721],[12973],[13103],[False],[0],[0],[False],['0']
17339,PMC4066691,6820,"Evaluation of safety and tolerability was performed on the treated set, defined as all randomised patients who received at least one dose of study medication.",Methods|Statistical analyses,[41723],[13104],[13262],[False],[0],[0],[False],['0']
17340,PMC4066691,6821,Analysis of adverse events and vital signs was descriptive in nature.,Methods|Statistical analyses,[41725],[13263],[13332],[False],[0],[0],[False],['0']
17341,PMC4066691,6822,"To control the probability of a type I error in the primary efficacy analysis, stepwise testing of the null hypothesis was used to test the efficacy of tiotropium Respimat® 5 μg, then 2.5 μg and then 1.25 μg, each over placebo Respimat®.",Methods|Statistical analyses,[41727],[13333],[13570],[False],[0],[0],[False],['0']
17342,PMC4066691,6823,"If the previous step was not successful, analysis of the current step was to be considered descriptive.",Methods|Statistical analyses,[41729],[13571],[13674],[False],[0],[0],[False],['0']
17343,PMC4066691,6824,"To detect a treatment difference of 80 mL for peak FEV1(0-3h) with 90% power, and assuming a standard deviation of 228 mL, it was calculated that 88 completed patients were required.",Methods|Statistical analyses,[41731],[13675],[13857],[False],[0],[0],[False],['0']
17344,PMC4066691,6825,Testing was performed with α = 0.025 (one-sided).,Methods|Statistical analyses,[41733],[13858],[13907],[False],[0],[0],[False],['0']
17345,PMC4066691,6826,The pre-specified hypotheses were tested using a mixed effects model with repeated measures.,Methods|Statistical analyses,[41735],[13908],[14000],[False],[0],[0],[False],['0']
17346,PMC4066691,6827,The statistical model included ‘treatment’ and ‘period’ as fixed effects and ‘patient’ as a random effect.,Methods|Statistical analyses,[41737],[14001],[14107],[False],[0],[0],[False],['0']
17347,PMC4066691,6828,"Study baseline, defined as pre-treatment values measured at Visit 2 in the evening, was included as covariate.",Methods|Statistical analyses,[41739],[14108],[14218],[False],[0],[0],[False],['0']
17348,PMC4066691,6829,Results,Results,[41741],[14219],[14227],[False],[0],[0],[False],['0']
17349,PMC4066691,6830,Baseline demographics and disposition,Results|Baseline demographics and disposition,[41743],[14228],[14265],[False],[0],[0],[False],['0']
17350,PMC4066691,6831,"A total of 149 patients were randomised to the study, and 141 patients completed the study.",Results|Baseline demographics and disposition,[41745],[14266],[14357],[False],[0],[0],[False],['0']
17351,PMC4066691,6832,The treated set comprised all 149 patients and the full analysis set comprised 148 patients (one patient had missing efficacy data and was lost to follow-up after Visit 2) (Figure  2).,Results|Baseline demographics and disposition,[41747],[14358],[14542],[False],[0],[0],[False],['0']
17352,PMC4066691,6833,"In the treated set, slightly more patients were female (55.0%) than male (45.0%), mean age was 49.3 years and mean body mass index was 26.9 kg/m2 (Table  1).",Results|Baseline demographics and disposition,[41749],[14543],[14700],[False],[0],[0],[False],['0']
17353,PMC4066691,6834,"Of the small proportion of patients who had previously smoked (19.5%; n = 29), the mean number of pack-years was 5.6.",Results|Baseline demographics and disposition,[41751],[14701],[14818],[False],[0],[0],[False],['0']
17354,PMC4066691,6835,The remainder of the study population had never smoked (80.5%; n = 120) (Table  1).,Results|Baseline demographics and disposition,[41753],[14819],[14902],[False],[0],[0],[False],['0']
17355,PMC4066691,6836,Patient disposition.,Results|Patient disposition.,[41755],[14903],[14923],[False],[0],[0],[False],['0']
17356,PMC4066691,6837,Baseline and demographic characteristics (treated set),Results|Baseline and demographic characteristics (treated set),[41757],[14924],[14978],[False],[0],[0],[False],['0']
17357,PMC4066691,6838," 	Total	 	(n = 149)	 	Age, yearsa	49.3 ± 13.3	 	Gender, n (%)	 	 	  Male	67 (45.0)	 	  Female	82 (55.0)	 	Body mass index, kg/m2 a	26.9 ± 4.3	 	Smoking status, n (%)	 	 	  Current smoker	0	 	  Ex-smoker	29 (19.5)	 	  Never smoked	120 (80.5)	 	Smoking history, pack-yearsa	5.6 ± 2.5	 	Duration of asthma, yearsa	23.8 ± 13.4	 	FEV1a	 	 	  % of predicted value pre-bronchodilation at screeningb	71.3 ± 7.1	 	  % of predicted value post-bronchodilation at screeningb	87.4 ± 10.2	 	  Reversibility, Lb	0.500 ± 0.239	 	  % reversibilityb	22.8 ± 10.2	 	  Pre-dose at study baseline, Lc	2.306 ± 0.689	 	FVC, pre-dose at baselinec, La	3.639 ± 0.978	 	FEV1/FVC ratio at baselinec, %a	63.7 ± 10.1	 	ICS dose of stable maintenance treatment, μga,d	659.2 ± 249.4",Results|Baseline and demographic characteristics (treated set),[41759],[14979],[15728],[False],[0],[0],[False],['0']
17358,PMC4066691,6839,aValues are mean ± standard deviation; bVisit 1; cMeasured 10 minutes prior to inhalation of study medication at Visit 2 (at randomisation); dBudesonide equipotent dose.,Results|Baseline and demographic characteristics (treated set),[41761],[15729],[15901],[False],[0],[0],[False],['0']
17359,PMC4066691,6840,"FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids.",Results|Baseline and demographic characteristics (treated set),[41763],[15902],[16003],[False],[0],[0],[False],['0']
17360,PMC4066691,6841,Efficacy,Results|Efficacy,[41765],[16004],[16012],[False],[0],[0],[False],['0']
17361,PMC4066691,6842,Primary analysis,Results|Primary analysis,[41767],[16013],[16029],[False],[0],[0],[False],['0']
17362,PMC4066691,6843,"The addition of tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg to stable medium-dose ICS therapy was associated with improved lung function: at the end of the 4-week treatment period, statistically significant differences from placebo Respimat® in adjusted mean peak FEV1(0-3h) responses were observed for all doses of tiotropium Respimat® (P < 0.0001 at all doses) (Figure  3).",Results|Primary analysis,[41769],[16030],[16406],[False],[0],[0],[False],['0']
17363,PMC4066691,6844,"The largest adjusted mean difference from placebo Respimat® was observed with tiotropium Respimat® 5 μg (188 mL, 95% confidence interval: 140, 236).",Results|Primary analysis,[41771],[16407],[16555],[False],[0],[0],[False],['0']
17364,PMC4066691,6845,Adjusted mean differences in lung function responses.,Results|Primary analysis,[41773],[16556],[16609],[False],[0],[0],[False],['0']
17365,PMC4066691,6846,(A) Peak FEV1(0-3h) response; (B) Trough FEV1 response; (C) Peak FVC(0-3h) response; (D) Trough FVC response.,Results|Primary analysis,[41775],[16610],[16719],[False],[0],[0],[False],['0']
17366,PMC4066691,6847,Response defined as change from study baseline (pre-treatment value measured at Visit 2 in the evening).,Results|Primary analysis,[41777],[16720],[16824],[False],[0],[0],[False],['0']
17367,PMC4066691,6848,Adjusted mean difference from placebo Respimat®: *P < 0.001; **P < 0.01; ***P < 0.05.,Results|Primary analysis,[41779],[16825],[16910],[False],[0],[0],[False],['0']
17368,PMC4066691,6849,Bars: standard error.,Results|Primary analysis,[41781],[16911],[16932],[False],[0],[0],[False],['0']
17369,PMC4066691,6850,"FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; NS, not significant; peak FEV1(0-3h), peak forced expiratory volume in 1 second measured within the first 3 hours after dosing; peak FVC(0-3h), peak forced vital capacity measured within the first 3 hours after dosing.",Results|Primary analysis,[41783],[16933],[17223],[False],[0],[0],[False],['0']
17370,PMC4066691,6851,Secondary analyses,Results|Secondary analyses,[41785],[17224],[17242],[False],[0],[0],[False],['0']
17371,PMC4066691,6852,"Trough FEV1, FEV1 AUC(0-3h), peak FVC(0-3h), trough FVC and FVC AUC(0-3h) responses with all doses of tiotropium Respimat® were larger than the responses observed with placebo Respimat®, and all were statistically significant except for trough FVC in the 1.25 μg group (Figure  3, Additional file 1: Table S1).",Results|Secondary analyses,[41787],[17243],[17553],[False],[0],[0],[False],['0']
17372,PMC4066691,6853,"Responses for each of these end points were all largest in the 5 μg group (Figure  3, Additional file 1: Table S1).",Results|Secondary analyses,[41789],[17554],[17669],[False],[0],[0],[False],['0']
17373,PMC4066691,6854,"Exploratory analysis of the difference in response between tiotropium Respimat® doses found that peak FEV1(0-3h), FEV1 AUC(0-3h), peak FVC(0-3h) and FVC AUC(0-3h) responses were all statistically significantly greater with tiotropium Respimat® 5 μg than with either of the two lower doses (Table  2).",Results|Secondary analyses,[41791],[17670],[17970],[False],[0],[0],[False],['0']
17374,PMC4066691,6855,Adjusted mean differences in lung function responses between tiotropium Respimat® doses,Results|Secondary analyses,[41793],[17971],[18058],[False],[0],[0],[False],['0']
17375,PMC4066691,6856,"Response parameter	Adjusted mean differences between treatments (95% CI), mL	 	 	Tiotropium Respimat® 5 μg versus tiotropium Respimat® 1.25 μg	Tiotropium Respimat® 5 μg versus tiotropium Respimat® 2.5 μg	Tiotropium Respimat® 2.5 μg versus tiotropium Respimat® 1.25 μg	 	FEV1	 	 Peak FEV1(0-3h)	50 (2, 98)	60 (12, 108)	-10 (-58, 38)	 	 Trough FEV1	18 (-30, 66)	11 (-36, 59)	7 (-41, 54)	 	 FEV1 AUC(0-3h)	49 (3, 95)	51 (5, 97)	-2 (-48, 44)	 	FVC	 	 Peak FVC(0-3h)	58 (5, 111)	67 (14, 120)	-9 (-61, 44)	 	 Trough FVC	44 (-15, 103)	27 (-33, 86)	17 (-42, 77)	 	 FVC AUC(0-3h)	74 (22, 0.125)	63 (11, 114)	11 (-40, 62)",Results|Secondary analyses,[41795],[18059],[18670],[False],[0],[0],[False],['0']
17376,PMC4066691,6857,"AUC, area under the curve; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FEV1 AUC(0-3h), forced expiratory volume in 1 second area under the curve measured within the first 3 hours after dosing; FVC, forced vital capacity; FVC AUC(0-3h), forced vital capacity area under the curve measured within the first 3 hours after dosing; peak FEV1(0-3h), peak forced expiratory volume in 1 second measured within the first 3 hours after dosing; peak FVC(0-3h), peak forced vital capacity measured within the first 3 hours after dosing.",Results|Secondary analyses,[41797],[18671],[19223],[False],[0],[0],[False],['0']
17377,PMC4066691,6858,"At the end of each 4-week treatment period, there was a statistically significant improvement in ACQ-7 score with all three tiotropium Respimat® doses (Additional file 1: Table S1).",Results|Secondary analyses,[41799],[19224],[19405],[False],[0],[0],[False],['0']
17378,PMC4066691,6859,"Higher mean pre-dose PEFam responses (measured with the AM2+® device) were observed with all three tiotropium Respimat® treatments compared with placebo Respimat® (difference from placebo: 5 μg, 20.846 L/min; 2.5 μg, 17.895 L/min; 1.25 μg, 18.550 L/min; all P < 0.0001).",Results|Secondary analyses,[41801],[19406],[19676],[False],[0],[0],[False],['0']
17379,PMC4066691,6860,"Higher mean pre-dose PEFpm responses were also observed with all three tiotropium Respimat® treatments compared with placebo Respimat® (difference from placebo: 5 μg, 21.581 L/min; 2.5 μg, 14.577 L/min; 1.25 μg, 21.251 L/min; all P < 0.0001).",Results|Secondary analyses,[41803],[19677],[19919],[False],[0],[0],[False],['0']
17380,PMC4066691,6861,No significant differences in PEFam or PEFpm responses were observed between the different tiotropium Respimat® doses.,Results|Secondary analyses,[41805],[19920],[20038],[False],[0],[0],[False],['0']
17381,PMC4066691,6862,Safety and tolerability,Results|Safety and tolerability,[41807],[20039],[20062],[False],[0],[0],[False],['0']
17382,PMC4066691,6863,Overall incidence of adverse events was comparable between placebo Respimat® and the three tiotropium Respimat® treatment doses (Table  3).,Results|Safety and tolerability,[41809],[20063],[20202],[False],[0],[0],[False],['0']
17383,PMC4066691,6864,Serious adverse events were reported for two patients (in the tiotropium Respimat® 5 μg group).,Results|Safety and tolerability,[41811],[20203],[20298],[False],[0],[0],[False],['0']
17384,PMC4066691,6865,Neither was considered to be drug-related.,Results|Safety and tolerability,[41813],[20299],[20341],[False],[0],[0],[False],['0']
17385,PMC4066691,6866,"One patient was reported with alcohol abuse and panic attack, which led to hospitalisation.",Results|Safety and tolerability,[41815],[20342],[20433],[False],[0],[0],[False],['0']
17386,PMC4066691,6867,Both of this patient’s adverse events accounted for discontinuation of the study drug (the only case of discontinuation during the trial).,Results|Safety and tolerability,[41817],[20434],[20572],[False],[0],[0],[False],['0']
17387,PMC4066691,6868,"The other patient was reported with inguinal hernia, which led to hospitalisation.",Results|Safety and tolerability,[41819],[20573],[20655],[False],[0],[0],[False],['0']
17388,PMC4066691,6869,Summary of adverse events in the treated set,Results|Summary of adverse events in the treated set,[41821],[20656],[20700],[False],[0],[0],[False],['0']
17389,PMC4066691,6870,"n (%)	Tiotropium Respimat® 5 μga	Tiotropium Respimat® 2.5 μga	Tiotropium Respimat® 1.25 μga	Placebo Respimat®a	 	 	(n = 146)	(n = 147)	(n = 146)	(n = 144)	 	Patients with any adverse event	23 (15.8)	20 (13.6)	14 (9.6)	21 (14.6)	 	Patients with severe adverse events	2 (1.4)	0	0	0	 	Patients with serious adverse eventsb	2 (1.4)	0	0	0	 	Patients with investigator-defined drug-related adverse events	3 (2.1)	0	2 (1.4)	2 (1.4)	 	Patients with adverse events leading to discontinuation of study medication	1 (0.7)	0	0	0	 	Most frequently reported adverse events (>1 patient on any treatment per treatment period)	 	Infections and infestations	9 (6.2)	4 (2.7)	6 (4.1)	7 (4.9)	 	  Nasopharyngitis	5 (3.4)	1 (0.7)	2 (1.4)	2 (1.4)	 	  Bronchitis	2 (1.4)	0	0	0	 	  Oral candidiasis	0	0	1 (0.7)	2 (1.4)	 	  Influenza	1 (0.7)	0	1 (0.7)	0	 	  Rhinitis	0	0	1 (0.7)	1 (0.7)	 	Respiratory, thoracic and mediastinal disorders	5 (3.4)	8 (5.4)	4 (2.7)	7 (4.9)	 	  Asthma exacerbation	4 (2.7)	3 (2.0)	1 (0.7)	5 (3.5)	 	  Dyspnoea	0	3 (2.0)	0	1 (0.7)	 	  Cough	0	1 (0.7)	2 (1.4)	0",Results|Summary of adverse events in the treated set,[41823],[20701],[21762],[False],[0],[0],[False],['0']
17390,PMC4066691,6871,aAll patients in all groups on a background of maintenance treatment with stable medium-dose inhaled corticosteroids (400–800 μg budesonide or equivalent); bBoth patients experiencing serious adverse events required hospitalisation.,Results|Summary of adverse events in the treated set,[41825],[21763],[21998],[False],[0],[0],[False],['0']
17391,PMC4066691,6872,The most commonly reported adverse events by preferred term were asthma exacerbation and nasopharyngitis.,Results|Summary of adverse events in the treated set,[41827],[21999],[22104],[False],[0],[0],[False],['0']
17392,PMC4066691,6873,"In the tiotropium Respimat® 5 μg group, one patient reported dry mouth.",Results|Summary of adverse events in the treated set,[41829],[22105],[22176],[False],[0],[0],[False],['0']
17393,PMC4066691,6874,No clinically relevant change in mean vital sign values was associated with tiotropium Respimat®.,Results|Summary of adverse events in the treated set,[41831],[22177],[22274],[False],[0],[0],[False],['0']
17394,PMC4066691,6875,Discussion,Discussion,[41833],[22275],[22286],[False],[0],[0],[False],['0']
17395,PMC4066691,6876,"In this dose-ranging study, tiotropium Respimat® was found to be an effective once-daily bronchodilator as add-on maintenance therapy in patients with symptomatic moderate asthma despite treatment with ICS.",Discussion,[41835],[22287],[22493],[False],[0],[0],[False],['0']
17396,PMC4066691,6877,"Once-daily doses of tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg, administered for 4 weeks per treatment, were each associated with statistically significant improvements in lung function compared with placebo Respimat®.",Discussion,[41837],[22494],[22714],[False],[0],[0],[False],['0']
17397,PMC4066691,6878,"Serious adverse events were rare and considered unrelated to treatment, and overall adverse-event incidence was comparable between all treatment groups.",Discussion,[41839],[22715],[22867],[False],[0],[0],[False],['0']
17398,PMC4066691,6879,All three doses of tiotropium Respimat® produced statistically significant improvements in the primary end point (peak FEV1(0-3h) response) compared with placebo Respimat®.,Discussion,[41841],[22868],[23040],[False],[0],[0],[False],['0']
17399,PMC4066691,6880,"However, the response to 5 μg was larger than the responses to 2.5 μg and 1.25 μg, both of which were similar in magnitude.",Discussion,[41843],[23041],[23164],[False],[0],[0],[False],['0']
17400,PMC4066691,6881,"Further, in all other lung function parameters that were assessed, responses were consistently largest with tiotropium Respimat® 5 μg.",Discussion,[41845],[23165],[23299],[False],[0],[0],[False],['0']
17401,PMC4066691,6882,"Peak FEV1(0-3h), FEV1 AUC(0-3h), peak FVC(0-3h) and FVC AUC(0-3h) responses were statistically significantly greater with tiotropium Respimat® 5 μg versus either of the lower doses.",Discussion,[41847],[23300],[23481],[False],[0],[0],[False],['0']
17402,PMC4066691,6883,The adverse-event profile for 5 μg was comparable with that for lower doses and placebo Respimat®.,Discussion,[41849],[23482],[23580],[False],[0],[0],[False],['0']
17403,PMC4066691,6884,"In exploratory analyses, we observed a statistically significant reduction in ACQ-7 scores at the end of each 4-week treatment period with each of the three tiotropium Respimat® doses.",Discussion,[41851],[23581],[23765],[False],[0],[0],[False],['0']
17404,PMC4066691,6885,"However, the crossover design and the relatively short, 4-week, treatment periods are limitations with respect to drawing conclusions from the ACQ-7 score analysis.",Discussion,"[41853, 41854]","[23766, 23766]","[23930, 23930]","[True, True]","['ExperimentalPhaseDuration', 'StudyDesign']","['the relatively short, 4-week, treatment periods', 'the crossover design']","[True, True]","['StudyDuration', 'StudyDesign']"
17405,PMC4066691,6886,The lung function and tolerability findings of the present trial are in accordance with those from previously published studies of tiotropium Respimat® as add-on to ICS ± LABA in patients with symptomatic asthma .,Discussion,[41855],[23931],[24144],[False],[0],[0],[False],['0']
17406,PMC4066691,6887,"We await the results of two larger, replicate, Phase III, 24-week, randomised, double-blind trials in patients receiving moderate-dose ICS (NCT01172808 and NCT01172821).",Discussion,[41857],[24145],[24314],[False],[0],[0],[False],['0']
17407,PMC4066691,6888,Conclusions,Conclusions,[41859],[24315],[24327],[False],[0],[0],[False],['0']
17408,PMC4066691,6889,"We have reported the first investigation of three different doses of tiotropium Respimat® (5 μg, 2.5 μg or 1.25 μg) in a patient population with symptomatic asthma treated with medium-dose ICS maintenance therapy.",Conclusions,[41861],[24328],[24541],[False],[0],[0],[False],['0']
17409,PMC4066691,6890,"Tiotropium Respimat® 5 μg was found to be the most effective and consistent dose, with a safety profile comparable with that of placebo, thereby providing support for further investigation of tiotropium Respimat® in larger and longer-term Phase III trials in this population.",Conclusions,[41863],[24542],[24817],[False],[0],[0],[False],['0']
17410,PMC4066691,6891,Abbreviations,Abbreviations,[41865],[24818],[24832],[False],[0],[0],[False],['0']
17411,PMC4066691,6892,ACQ-7: Seven-question Asthma Control Questionnaire; AM2+®: Asthma Monitor2+ device; AUC: Area under the curve; CI: Confidence interval; FEV1: Forced expiratory volume in 1 second; FEV1 AUC(0-3h): Forced expiratory volume in 1 second area under the curve measured within the first 3 hours after dosing; FVC: Forced vital capacity; FVC AUC(0-3h): Forced vital capacity area under the curve measured within the first 3 hours after dosing; ICS: Inhaled corticosteroids; LABA: Long-acting β2-agonist; Peak FEV1(0-3h): Peak forced expiratory volume in 1 second measured within the first 3 hours after dosing; Peak FVC(0-3h): Peak forced vital capacity measured within the first 3 hours after dosing; PEFam: Morning peak expiratory flow; PEFpm: Evening peak expiratory flow; SE: Standard error; TALC: Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid.,Abbreviations,[41867],[24833],[25778],[False],[0],[0],[False],['0']
17412,PMC4066691,6893,Competing interests,Competing interests,[41869],[25779],[25799],[False],[0],[0],[False],['0']
17413,PMC4066691,6894,"KMB has received compensation for organising or participating in advisory boards for Almirall Hermal, AstraZeneca, Boehringer Ingelheim, Cytos, Chiesi, Mundipharma, Novartis and Revotar Biopharmaceuticals, and in the past 3 years has participated as a speaker in scientific meetings or courses supported by Almirall Hermal, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer and Takeda.",Competing interests,[41871],[25800],[26187],[False],[0],[0],[False],['0']
17414,PMC4066691,6895,"KMB has also received consulting fees from Ablynx, Apellis Pharmaceuticals, Chiesi and Cytos.",Competing interests,[41873],[26188],[26281],[False],[0],[0],[False],['0']
17415,PMC4066691,6896,"The institution where KMB is employed has received compensation for the design, performance or participation in single- or multicentre clinical trials in the past 3 years from several companies, including Almirall, Boehringer Ingelheim, Cytos, GlaxoSmithKline, Mundipharma, Novartis, Pfizer, Revotar Biopharmaceuticals, Sterna AG and TEVA.",Competing interests,[41875],[26282],[26621],[False],[0],[0],[False],['0']
17416,PMC4066691,6897,"SK has received reimbursement for attending scientific conferences and fees for speaking or consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Novartis and Nycomed.",Competing interests,[41877],[26622],[26816],[False],[0],[0],[False],['0']
17417,PMC4066691,6898,"PMZ, AU, ZH and ME are employees of Boehringer Ingelheim.",Competing interests,[41879],[26817],[26874],[False],[0],[0],[False],['0']
17418,PMC4066691,6899,"OA has received reimbursement for speaking from Boehringer Ingelheim, GlaxoSmithKline and Menarini.",Competing interests,[41881],[26875],[26974],[False],[0],[0],[False],['0']
17419,PMC4066691,6900,Authors’ contributions,Authors’ contributions,[41883],[26975],[26998],[False],[0],[0],[False],['0']
17420,PMC4066691,6901,"KMB was the international coordinating investigator of the trial, contributed to the design of the study, recruited patients to the trial and contributed to the interpretation of data.",Authors’ contributions,[41885],[26999],[27183],[False],[0],[0],[False],['0']
17421,PMC4066691,6902,"PMZ, ME, ZH and AU each contributed to the study design, implementation, management and data analysis.",Authors’ contributions,[41887],[27184],[27286],[False],[0],[0],[False],['0']
17422,PMC4066691,6903,SK and OA contributed to acquisition and interpretation of the data.,Authors’ contributions,[41889],[27287],[27355],[False],[0],[0],[False],['0']
17423,PMC4066691,6904,All authors revised the article critically for intellectual content.,Authors’ contributions,[41891],[27356],[27424],[False],[0],[0],[False],['0']
17424,PMC4066691,6905,All authors provided final approval of the article prior to submission.,Authors’ contributions,[41893],[27425],[27496],[False],[0],[0],[False],['0']
17425,PMC4066691,6906,Supplementary Material,Supplementary Material,[41895],[27497],[27520],[False],[0],[0],[False],['0']
17426,PMC4066691,6907,Acknowledgements,Acknowledgements|Acknowledgements,[41897],[27521],[27538],[False],[0],[0],[False],['0']
17427,PMC4066691,6908,The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors.,Acknowledgements|Acknowledgements,[41899],[27539],[27653],[False],[0],[0],[False],['0']
17428,PMC4066691,6909,"They take full responsibility for the scope, direction, content of and editorial decisions relating to the manuscript, were involved at all stages of development and have approved the submitted manuscript.",Acknowledgements|Acknowledgements,[41901],[27654],[27859],[False],[0],[0],[False],['0']
17429,PMC4066691,6910,The authors received no compensation related to the development of the manuscript.,Acknowledgements|Acknowledgements,[41903],[27860],[27942],[False],[0],[0],[False],['0']
17430,PMC4066691,6911,This work was supported by Boehringer Ingelheim.,Acknowledgements|Acknowledgements,[41905],[27943],[27991],[False],[0],[0],[False],['0']
17431,PMC4066691,6912,"Medical writing assistance was provided by Sam Yarwood, PhD, of Complete HealthVizion, which was contracted and compensated by Boehringer Ingelheim Pharma GmbH & Co. KG.",Acknowledgements|Acknowledgements,[41907],[27992],[28161],[False],[0],[0],[False],['0']
18760,PMC4272792,11720,A school-based intervention improves physical fitness in Ecuadorian adolescents: a cluster-randomized controlled trial,Title,[71089],[36042],[118],[False],[0],[0],[False],['0']
18761,PMC4272792,11721,Background,Abstract,[71098],[119],[130],[False],[0],[0],[False],['0']
18762,PMC4272792,11722,Effective lifestyle interventions are needed to prevent noncommunicable diseases in low- and middle-income countries.,Abstract,[71107],[131],[248],[False],[0],[0],[False],['0']
18763,PMC4272792,11723,We analyzed the effects of a school-based health promotion intervention on physical fitness after 28 months and explored if the effect varied with important school characteristics.,Abstract,[71116],[249],[429],[False],[0],[0],[False],['0']
18764,PMC4272792,11724,"We also assessed effects on screen time, physical activity and BMI.",Abstract,[71125],[430],[497],[False],[0],[0],[False],['0']
18765,PMC4272792,11725,Methods and results,Methods and results,[71134],[498],[518],[False],[0],[0],[False],['0']
18766,PMC4272792,11726,We performed a cluster-randomized pair matched trial in schools in urban Ecuador.,Methods and results,[71143],[519],[600],[False],[0],[0],[False],['0']
18767,PMC4272792,11727,The intervention included an individual and environmental component tailored to the local context and resources.,Methods and results,[71152],[601],[713],[False],[0],[0],[False],['0']
18768,PMC4272792,11728,"Primary outcomes were physical fitness (EUROFIT battery), screen time (questionnaires) and physical activity (accelerometers).",Methods and results,[71161],[714],[840],[False],[0],[0],[False],['0']
18769,PMC4272792,11729,Change in BMI was a secondary outcome.,Methods and results,[71170],[841],[879],[False],[0],[0],[False],['0']
18770,PMC4272792,11730,"A total of 1440 grade 8 and 9 adolescents (intervention: n = 700, 48.6%) and 20 schools (intervention: n = 10, 50%) participated.",Methods and results,[71179],[880],[1009],[False],[0],[0],[False],['0']
18771,PMC4272792,11731,"Data of 1083 adolescents (intervention: n = 550, 50.8%) from 20 schools were analyzed.",Methods and results,[71188],[1010],[1096],[False],[0],[0],[False],['0']
18772,PMC4272792,11732,The intervention increased vertical jump (mean effect 2.5 cm; 95% CI 0.8-4.2; P = 0.01).,Methods and results,[71197],[1097],[1185],[False],[0],[0],[False],['0']
18773,PMC4272792,11733,"Marginally insignificant, adolescents from the intervention group needed less time for speed shuttle run (intervention effect = −0.8 s, 95% CI −1.58-0.07; P = 0.05).",Methods and results,[71206],[1186],[1351],[False],[0],[0],[False],['0']
18774,PMC4272792,11734,"The proportion of students achieving over 60 minutes of moderate-to-vigorous physical activity/day decreased over time with the change in proportion significantly less in the intervention schools (6 vs. 18 percentage points, P < 0.01).",Methods and results,[71215],[1352],[1587],[False],[0],[0],[False],['0']
18775,PMC4272792,11735,The intervention effect on speed shuttle run was significant in larger schools while the effect on vertical jump was larger in mixed gender school compared to small and female schools.,Methods and results,[71224],[1588],[1772],[False],[0],[0],[False],['0']
18776,PMC4272792,11736,The proportion of schools that met the recommendations for physical activity increased with 37% in intervention schools with half-day schedule compared to the controls in the pair.,Methods and results,[71233],[1773],[1953],[False],[0],[0],[False],['0']
18777,PMC4272792,11737,No significant effects were found on screen time and BMI.,Methods and results,[71242],[1954],[2011],[False],[0],[0],[False],['0']
18778,PMC4272792,11738,Measurement of physical activity in a subsample was a limitation.,Methods and results,[71251],[2012],[2077],[False],[0],[0],[False],['0']
18779,PMC4272792,11739,No adverse effects were reported.,Methods and results,[71260],[2078],[2111],[False],[0],[0],[False],['0']
18780,PMC4272792,11740,Conclusions,Conclusions,[71269],[2112],[2124],[False],[0],[0],[False],['0']
18781,PMC4272792,11741,A school-based intervention with an individual and environment component can improve physical fitness and can minimize the decline in physical activity levels from childhood into adolescence in urban Ecuador.,Conclusions,[71278],[2125],[2333],[False],[0],[0],[False],['0']
18782,PMC4272792,11742,Trial registration,Trial registration,[71287],[2334],[2353],[False],[0],[0],[False],['0']
18783,PMC4272792,11743,Clinicaltrials.gov identifier NCT01004367.,Trial registration,[71296],[2354],[2396],[False],[0],[0],[False],['0']
18784,PMC4272792,11744,Introduction,Introduction,[71305],[2397],[2411],[False],[0],[0],[False],['0']
18785,PMC4272792,11745,Lifestyle related noncommunicable diseases (NCDs) are a leading cause of death in low- and middle-income countries (LMICs) [1].,Introduction,[71314],[2412],[2539],[False],[0],[0],[False],['0']
18786,PMC4272792,11746,"This is unfortunate, as they could be prevented by tackling risk factors such as physical inactivity [2], sedentary behavior (i.e.",Introduction,[71323],[2540],[2670],[False],[0],[0],[False],['0']
18787,PMC4272792,11747,increased screen time) [3] and poor physical fitness [4].,Introduction,[71332],[2671],[2728],[False],[0],[0],[False],['0']
18788,PMC4272792,11748,It has been estimated that 1.3 million deaths worldwide can be prevented if the current physical activity recommendations were met [5].,Introduction,[71341],[2729],[2864],[False],[0],[0],[False],['0']
18789,PMC4272792,11749,Only a few LMICs have developed strategies to improve physical activity [6].,Introduction,[71350],[2865],[2941],[False],[0],[0],[False],['0']
18790,PMC4272792,11750,Adolescence is an important period for the prevention of NCDs [7] as physical inactivity [8] and poor physical fitness [9] at early adolescence are associated with the development of NCDs during adulthood.,Introduction,[71359],[2942],[3147],[False],[0],[0],[False],['0']
18791,PMC4272792,11751,"Furthermore, unhealthy lifestyles [10] and physical activity patterns [11] consolidate during adolescence and persist during adulthood.",Introduction,[71368],[3148],[3283],[False],[0],[0],[False],['0']
18792,PMC4272792,11752,"Schools are hence appropriate settings for health promotion programs [12,13].",Introduction,[71377],[3284],[3361],[False],[0],[0],[False],['0']
18793,PMC4272792,11753,"Current evidence indicates that the most effective school-based interventions to increase physical activity [13] or tackle obesity [12] are those that involve individual and physical environment component [12,13].",Introduction,[71386],[3362],[3575],[False],[0],[0],[False],['0']
18794,PMC4272792,11754,"However, evidence to prevent NCDs through school-based interventions in LMICs is of low quality [14,15].",Introduction,[71395],[3576],[3680],[False],[0],[0],[False],['0']
18795,PMC4272792,11755,"The few school-based interventions from LMICs that aimed to promote an active lifestyle had important methodological limitations such as the absence of a theoretical framework to guide the interventions, a weak study design, or a lack of objectively measured outcomes [14].",Introduction,[71404],[3681],[3954],[False],[0],[0],[False],['0']
18796,PMC4272792,11756,This is worrisome as adequate evidence is needed to guide allocation of scarce resources to tackle NCDs in LMICs [16].,Introduction,[71413],[3955],[4073],[False],[0],[0],[False],['0']
18797,PMC4272792,11757,"The results of a previous study among 12–15 year old adolescents in Cuenca, Ecuador showed that the prevalence of overweight/obesity was around 20% [17] and that 59% of adolescents had inadequate physical fitness levels [18].",Introduction,[71422],[4074],[4299],[False],[0],[0],[False],['0']
18798,PMC4272792,11758,We implemented a school-based health promotion intervention “ACTIVITAL” that aimed at improving diet and physical activity.,Introduction,[71431],[4300],[4423],[False],[0],[0],[False],['0']
18799,PMC4272792,11759,ACTIVITAL was developed using participatory approaches and tailored to the Ecuadorian school context.,Introduction,[71440],[4424],[4525],[False],[0],[0],[False],['0']
18800,PMC4272792,11760,"In the present paper, we present the effectiveness of the trial on one set of the primary outcomes, i.e.",Introduction,[71449],[4526],[4630],[False],[0],[0],[False],['0']
18801,PMC4272792,11761,"physical fitness, screen time, physical activity and the effect on body mass index (BMI) as secondary outcome.",Introduction,[71458],[4631],[4741],[False],[0],[0],[False],['0']
18802,PMC4272792,11762,"In addition, we analyzed if the effect of the intervention varied with important school characteristics i.e.",Introduction,[71467],[4742],[4850],[False],[0],[0],[False],['0']
18803,PMC4272792,11763,"size, type, class schedule, gender composition and space for physical activity.",Introduction,[71476],[4851],[4930],[False],[0],[0],[False],['0']
18804,PMC4272792,11764,"Other primary outcomes (dietary intake and factors influencing dietary and physical activity behavior) are presented elsewhere to ensure sufficient detail in presenting the findings of the trial on physical fitness, activity and sedentary lifestyle outcomes.",Introduction,[71485],[4931],[5189],[False],[0],[0],[False],['0']
18805,PMC4272792,11765,Methods,Methods,[71494],[5190],[5198],[False],[0],[0],[False],['0']
18806,PMC4272792,11766,"ACTIVITAL was a pair-matched cluster randomized controlled trial conducted from 2009 to 2012 in Cuenca, the third largest city in Ecuador and located at an altitude of ±2400 m. Cluster (school) randomization was chosen as the trial used a school-based approach.",Methods,[71503],[5199],[5460],[False],[0],[0],[False],['0']
18807,PMC4272792,11767,We report our findings according to the CONSORT guidelines [19].,Methods,[71512],[5461],[5525],[False],[0],[0],[False],['0']
18808,PMC4272792,11768,"This study was approved by two ethics committees, the “Comité de Biomedicina de la Universidad Central del Ecuador” from Quito - Ecuador (CBM/cobi-001 - 2008/462) and the Ghent University Hospital - Belgium (FWA00002482).",Methods,[71521],[5526],[5747],[False],[0],[0],[False],['0']
18809,PMC4272792,11769,"Participants, sampling, allocation and blinding","Participants, sampling, allocation and blinding",[71530],[5748],[5796],[False],[0],[0],[False],['0']
18810,PMC4272792,11770,"Schools were eligible if: (i) they had >90 students in 8th and 9th grade, and (ii) they were located in the urban area of Cuenca, Ecuador.","Participants, sampling, allocation and blinding",[71539],[5797],[5935],[False],[0],[0],[False],['0']
18811,PMC4272792,11771,"The eligible schools were paired according to four criteria: (i) total number of students of the school, (ii) monthly school fee (as proxy for the socio-economic status of the school), (iii) gender (male/female only or mixed gender) and (iv) time schedule of classes (morning: 7:00 to 13:00 or afternoon: 12:00 to 18:00).","Participants, sampling, allocation and blinding",[71548],[5936],[6257],[False],[0],[0],[False],['0']
18812,PMC4272792,11772,"In Ecuador, large schools might divide the students in two groups because of logistic constraints.","Participants, sampling, allocation and blinding",[71557],[6258],[6356],[False],[0],[0],[False],['0']
18813,PMC4272792,11773,In this case the youngest students attend classes in the afternoon and the oldest students in the morning.,"Participants, sampling, allocation and blinding",[71566],[6357],[6463],[False],[0],[0],[False],['0']
18814,PMC4272792,11774,Schools with no matching pair were excluded.,"Participants, sampling, allocation and blinding",[71575],[6464],[6508],[False],[0],[0],[False],['0']
18815,PMC4272792,11775,Sample size was calculated on a nutritional outcome.,"Participants, sampling, allocation and blinding",[71584],[6509],[6561],[False],[0],[0],[False],['0']
18816,PMC4272792,11776,"Ten pairs and a sample size of 65 children per school was required to detect a reduction of 40% to 30% energy from fat using a two side significance level α = 0.05, variation in clusters means K  = 0.15 and a power of 80% [20].","Participants, sampling, allocation and blinding",[71593],[6562],[6789],[False],[0],[0],[False],['0']
18817,PMC4272792,11777,We assessed if the trial was sufficiently powered for each of the outcomes analyzed.,"Participants, sampling, allocation and blinding",[71602],[6790],[6874],[False],[0],[0],[False],['0']
18818,PMC4272792,11778,All outcomes had a power >80% except for bent arm hang and 20 m shuttle run (65% and 64% respectively).,"Participants, sampling, allocation and blinding",[71611],[6875],[6978],[False],[0],[0],[False],['0']
18819,PMC4272792,11779,The power calculations were obtained using the formula for sample size calculations of pair matched trials [20].,"Participants, sampling, allocation and blinding",[71620],[6979],[7091],[False],[0],[0],[False],['0']
18820,PMC4272792,11780,"Figure 1  Enrolment, allocation, follow-up and analysis of Ecuadorian adolescents in a school-based health promotion intervention.","Participants, sampling, allocation and blinding",[71629],[7092],[7222],[False],[0],[0],[False],['0']
18821,PMC4272792,11781,.,"Participants, sampling, allocation and blinding",[71638],[7223],[7224],[False],[0],[0],[False],['0']
18822,PMC4272792,11782,A total of 28 out of 108 schools were paired (Figure 1).,"Participants, sampling, allocation and blinding",[71647],[7225],[7281],[False],[0],[0],[False],['0']
18823,PMC4272792,11783,"We randomly selected 10 pairs in Stata (version 12.0, Stata Corporation, Texas, USA) using a random number generation with random allocation of the intervention within each pair.","Participants, sampling, allocation and blinding",[71656],[7282],[7460],[False],[0],[0],[False],['0']
18824,PMC4272792,11784,"In each school, two 8th grades and two 9th grades were randomly selected and all students in those grades were invited to participate in the study.","Participants, sampling, allocation and blinding",[71665],[7461],[7608],[False],[0],[0],[False],['0']
18825,PMC4272792,11785,Pregnant adolescents and those with muscle or bone injuries or a concomitant disease were excluded at any time during the trial.,"Participants, sampling, allocation and blinding",[71674],[7609],[7737],[False],[0],[0],[False],['0']
18826,PMC4272792,11786,"In total we enrolled 1430 adolescents, including 10% of possible dropouts.","Participants, sampling, allocation and blinding",[71683],[7738],[7812],[False],[0],[0],[False],['0']
18827,PMC4272792,11787,After the pairs were selected and the school principal accepted to participate in the study (participation rate 100%) we obtained informed assent from adolescents (acceptance rate 85%) and written consent from caretakers (participation rate 90%).,"Participants, sampling, allocation and blinding",[71692],[7813],[8059],[False],[0],[0],[False],['0']
18828,PMC4272792,11788,Adolescents were not informed about the existence of a counterfactual school.,"Participants, sampling, allocation and blinding",[71701],[8060],[8137],[False],[0],[0],[False],['0']
18829,PMC4272792,11789,Interventions,Interventions,[71710],[8138],[8152],[False],[0],[0],[False],['0']
18830,PMC4272792,11790,The intervention program was developed using the results of needs assessment jointly with the intervention mapping (IM) protocol [21] and Comprehensive Participatory Planning and Evaluation (CPPE) [22].,Interventions,[71719],[8153],[8355],[False],[0],[0],[False],['0']
18831,PMC4272792,11791,A needs assessment was performed through qualitative (focus groups) and quantitative studies (physical fitness assessment).,Interventions,[71728],[8356],[8479],[False],[0],[0],[False],['0']
18832,PMC4272792,11792,"Results of focus groups with adolescents, parents and school staff showed that poor knowledge on physical activity and its importance, a preference for sedentary activities, laziness, time constraints, parent and peer support, and role modeling of famous Ecuadorian athletes were key individual and environmental determinants of physical activity in the study population [23].",Interventions,[71737],[8480],[8856],[False],[0],[0],[False],['0']
18833,PMC4272792,11793,The quantitative study (assessed using EUROFIT battery) showed that three out of five adolescents had a poor physical fitness [24].,Interventions,[71746],[8857],[8988],[False],[0],[0],[False],['0']
18834,PMC4272792,11794,"Once the needs were identified, the CPPE approach [22] and the IM [21] were used to define intervention objectives.",Interventions,[71755],[8989],[9104],[False],[0],[0],[False],['0']
18835,PMC4272792,11795,"Using the inputs of the needs assessment and the IM [21], the exact behavior expected from adolescents was identified for each intervention objective.",Interventions,[71764],[9105],[9255],[False],[0],[0],[False],['0']
18836,PMC4272792,11796,"The most important and modifiable factors to reach each intervention objective were selected from the local evidence collected during the needs assessment, input received from the CPPE and existing literature.",Interventions,[71773],[9256],[9465],[False],[0],[0],[False],['0']
18837,PMC4272792,11797,"Afterwards, by crossing the expected behavior and modifiable factors, specified change objectives were developed to guide what adolescent or environmental agents needed to do to reach the intervention objectives.",Interventions,[71782],[9466],[9678],[False],[0],[0],[False],['0']
18838,PMC4272792,11798,"Next, behavioral change techniques that have been reported as effective [21,25] were identified and mapped against each factors.",Interventions,[71791],[9679],[9807],[False],[0],[0],[False],['0']
18839,PMC4272792,11799,"Finally, the selected behavioral change techniques (the social cognitive theory, information-motivation behavioral skills model, control theory, trans- theoretical model and theory of planned behavior.)",Interventions,[71800],[9808],[10010],[False],[0],[0],[False],['0']
18840,PMC4272792,11800,were used together with input from CPPE to create strategies at individual and environmental level.,Interventions,[71809],[10011],[10110],[False],[0],[0],[False],['0']
18841,PMC4272792,11801,"Table 1  Physical activity intervention components of the ACTIVITAL study implemented among 12–15 year old adolescents in 10 schools of Cuenca – Ecuador during 2010–2012: description of strategies, dose and response * .",Interventions,[71818],[10111],[10330],[False],[0],[0],[False],['0']
18842,PMC4272792,11802,"For physical activity specifically, the intervention objectives were: i) adolescents decrease daily screen time (1–2 hours/day), ii) adolescents increase daily physical activity levels to reach 60 min/day, and iii) the school offers more opportunities for being active.",Interventions,[71827],[10331],[10600],[False],[0],[0],[False],['0']
18843,PMC4272792,11803,The individual strategy included the delivery of educational package organized at classroom level (Table 1).,Interventions,[71836],[10601],[10709],[False],[0],[0],[False],['0']
18844,PMC4272792,11804,The persons in charge of delivering the educational package received an introduction to the intervention objectives and a basic workshop on healthy eating and physical activity.,Interventions,[71845],[10710],[10887],[False],[0],[0],[False],['0']
18845,PMC4272792,11805,The physical activity environmental strategy included (i) workshops with parents that were organized at the same time as classes with adolescents and covering similar topics; (ii) organization of social events at school such as an interactive session with famous young athletes and (iii) environmental modification: a walking trail was drawn on the school playground in the second year of the intervention.,Interventions,[71854],[10888],[11294],[False],[0],[0],[False],['0']
18846,PMC4272792,11806,There was no minimum dose for the activities for each of the intervention strategies.,Interventions,[71863],[11295],[11380],[False],[0],[0],[False],['0']
18847,PMC4272792,11807,Details of the physical activity intervention are provided in Table 1.,Interventions,[71872],[11381],[11451],[False],[0],[0],[False],['0']
18848,PMC4272792,11808,The control schools received the standard curriculum as determined by the Ecuadorian government.,Interventions,[71881],[11452],[11548],[False],[0],[0],[False],['0']
18849,PMC4272792,11809,The latter is geared at increasing sports skills and schedules a mandatory 80 min of physical education per week.,Interventions,[71890],[11549],[11662],[False],[0],[0],[False],['0']
18850,PMC4272792,11810,ACTIVITAL started in October 2009 and finished in June 2012 i.e.,Interventions,[71899],[11663],[11727],[False],[0],[0],[False],['0']
18851,PMC4272792,11811,through the academic years 2010–2012 with a total duration of 28 months.,Interventions,[71908],[11728],[11800],[False],[0],[0],[False],['0']
18852,PMC4272792,11812,Once started it was only interrupted by annual break (July and August).,Interventions,[71917],[11801],[11872],[False],[0],[0],[False],['0']
18853,PMC4272792,11813,In the first academic year we started with the baseline measurements (October 2009 - February 2010) and the application of the IM protocol and CPPE (March-June 2010).,Interventions,[71926],[11873],[12039],[False],[0],[0],[False],['0']
18854,PMC4272792,11814,In the second year we implemented a first part of the intervention (September 2010 - February 2011) and performed an intermediate follow-up (March-June 2011) in which physical fitness and physical activity was not measured.,Interventions,[71935],[12040],[12263],[False],[0],[0],[False],['0']
18855,PMC4272792,11815,"In the third year, the second part of the intervention was implemented (September 2011- January 2012) and final measurements were performed (from February 2012 - June 2012).",Interventions,[71944],[12264],[12437],[False],[0],[0],[False],['0']
18856,PMC4272792,11816,"To assess progress, monitor potential adverse effects and coordinate the intervention activities, research staff met with schoolteachers and school managements every two to three weeks.",Interventions,[71953],[12438],[12623],[False],[0],[0],[False],['0']
18857,PMC4272792,11817,One person in each school (mostly the medical doctor or the school supervisor) was assigned as contact point between research staff and the schools.,Interventions,[71962],[12624],[12772],[False],[0],[0],[False],['0']
18858,PMC4272792,11818,Outcome measures,Outcome measures,[71971],[12773],[12790],[False],[0],[0],[False],['0']
18859,PMC4272792,11819,"The measurements were performed when students entered the 8th and 9th grade (12.3 and 13.3 years respectively) and after 28 months, at the end of the academic year.",Outcome measures,[71980],[12791],[12955],[False],[0],[0],[False],['0']
18860,PMC4272792,11820,"Medical doctors, nutritionists and health professionals with field experience received a 40-hour training session to assess outcomes.",Outcome measures,[71989],[12956],[13089],[False],[0],[0],[False],['0']
18861,PMC4272792,11821,Reliability and repeatability were assessed to assure precision and accuracy of the measurements.,Outcome measures,[71998],[13090],[13187],[False],[0],[0],[False],['0']
18862,PMC4272792,11822,The research team provided regular supervision.,Outcome measures,[72007],[13188],[13235],[False],[0],[0],[False],['0']
18863,PMC4272792,11823,Physical fitness,Physical fitness,[72016],[13236],[13253],[False],[0],[0],[False],['0']
18864,PMC4272792,11824,"The EUROFIT test battery was used to assess physical fitness in different dimensions with nine tests [26]: cardio-respiratory endurance (20 m shuttle run test), strength (handgrip and vertical jump test), muscular endurance (bent arm hang and sit-ups test), speed (speed shuttle run and plate tapping), flexibility (sit-and-reach) and balance (flamingo balance test).",Physical fitness,[72025],[13254],[13621],[False],[0],[0],[False],['0']
18865,PMC4272792,11825,"This battery was previously validated in adolescents [27,28] and applied in various Latin American countries [29-32] to assess physical fitness.",Physical fitness,[72034],[13622],[13766],[False],[0],[0],[False],['0']
18866,PMC4272792,11826,The vertical jump is a variation of the original item of EUROFIT (standing broad jump) and is valid for the assessment of muscular strength [33].,Physical fitness,[72043],[13767],[13912],[False],[0],[0],[False],['0']
18867,PMC4272792,11827,Physical fitness data were used as continuous variables.,Physical fitness,[72052],[13913],[13969],[False],[0],[0],[False],['0']
18868,PMC4272792,11828,"An increase in test results indicated higher physical fitness, apart from the speed shuttle run, the plate tapping and flamingo balance tests for which lower scores indicated better fitness.",Physical fitness,[72061],[13970],[14160],[False],[0],[0],[False],['0']
18869,PMC4272792,11829,Screen time,Screen time,[72070],[14161],[14173],[False],[0],[0],[False],['0']
18870,PMC4272792,11830,Screen time was assessed using a validated self-reported questionnaire [34].,Screen time,[72079],[14174],[14250],[False],[0],[0],[False],['0']
18871,PMC4272792,11831,"Adolescents reported the number of hours per typical week and weekend day that they spent watching television, playing videogames or using the computer.",Screen time,[72088],[14251],[14403],[False],[0],[0],[False],['0']
18872,PMC4272792,11832,"Response categories were “zero”, “30 min”, “1 hour”, “2 hours”, “3 hours”, “4 hours”, “5 hours” and “> 6 hours”.",Screen time,[72097],[14404],[14516],[False],[0],[0],[False],['0']
18873,PMC4272792,11833,Screen time was treated as a continuous variable.,Screen time,[72106],[14517],[14566],[False],[0],[0],[False],['0']
18874,PMC4272792,11834,We also assessed the proportion of adolescents with screen time >3 hours/day at the end of the trial as this cut-off has been shown to be associated with a higher likelihood of metabolic syndrome [34].,Screen time,[72115],[14567],[14768],[False],[0],[0],[False],['0']
18875,PMC4272792,11835,Physical activity and sedentary time,Physical activity and sedentary time,[72124],[14769],[14806],[False],[0],[0],[False],['0']
18876,PMC4272792,11836,"Physical activity and sedentary time were assessed using accelerometers (type GT-256 and GT1M Actigraph, Florida USA).",Physical activity and sedentary time,[72133],[14807],[14925],[False],[0],[0],[False],['0']
18877,PMC4272792,11837,"Due to the high cost of the accelerometers, we assessed physical activity in a subsample of adolescents that was selected using a random number in Stata.",Physical activity and sedentary time,[72142],[14926],[15079],[False],[0],[0],[False],['0']
18878,PMC4272792,11838,"The MAH/UFFE Analyzer (version 1.9.0.3) and a syntax in Stata were used for data reduction and to compute registered time, the time spend on sedentary (≤100 counts/min), light (100–759 counts/min) and moderate to vigorous physical activity (≥760 counts/min) [35].",Physical activity and sedentary time,[72151],[15080],[15343],[False],[0],[0],[False],['0']
18879,PMC4272792,11839,Accelerometers were worn for 5 weekdays.,Physical activity and sedentary time,[72160],[15344],[15384],[False],[0],[0],[False],['0']
18880,PMC4272792,11840,"As recommended, the first and last day of measurement were excluded from the analyses as well as those registrations with less than 540 min of registered time per day [35].",Physical activity and sedentary time,[72169],[15385],[15557],[False],[0],[0],[False],['0']
18881,PMC4272792,11841,Accelerometer data were adjusted for the total registered time.,Physical activity and sedentary time,[72178],[15558],[15621],[False],[0],[0],[False],['0']
18882,PMC4272792,11842,The proportion of adolescents who met the recommended 60 min [36] of moderate to vigorous physical activity per day was calculated.,Physical activity and sedentary time,[72187],[15622],[15753],[False],[0],[0],[False],['0']
18883,PMC4272792,11843,BMI,BMI,[72196],[15754],[15758],[False],[0],[0],[False],['0']
18884,PMC4272792,11844,"Weight was measured using a digital calibrated balance (SECA 803, Hamburg, Germany) and recorded to the nearest 100 g. Height was recorded to the nearest mm by using a mechanical stadiometer (PORTROD, Health o Meter, Illinois, USA).",BMI,[72205],[15759],[15991],[False],[0],[0],[False],['0']
18885,PMC4272792,11845,Students were measured with light clothing and without shoes in a separate room by a researcher of the same gender.,BMI,[72214],[15992],[16107],[False],[0],[0],[False],['0']
18886,PMC4272792,11846,All anthropometric measurements were done twice and average values were used.,BMI,[72223],[16108],[16185],[False],[0],[0],[False],['0']
18887,PMC4272792,11847,"BMI indices were calculated using Anthro plus (version 3.2.2, WHO Geneva, Switzerland) and established cut-offs [37].",BMI,[72232],[16186],[16303],[False],[0],[0],[False],['0']
18888,PMC4272792,11848,BMI z-score was used as an outcome.,BMI,[72241],[16304],[16339],[False],[0],[0],[False],['0']
18889,PMC4272792,11849,We also assessed the effect of the intervention on the proportion of adolescents with a BMI in the healthy range [37] at the end of the study.,BMI,[72250],[16340],[16482],[False],[0],[0],[False],['0']
18890,PMC4272792,11850,Other measurements,Other measurements,[72259],[16483],[16502],[False],[0],[0],[False],['0']
18891,PMC4272792,11851,The adolescent’s knowledge on recommendations and the importance of physical activity in adolescent health was assessed using a questionnaire before the classes.,Other measurements,[72268],[16503],[16664],[False],[0],[0],[False],['0']
18892,PMC4272792,11852,The socio-economic status of the adolescent’s household was defined according to the Integrated Social Indicator System for Ecuador [38].,Other measurements,[72277],[16665],[16802],[False],[0],[0],[False],['0']
18893,PMC4272792,11853,"The system classifies a household as “poor” when they report to have no access to education, health, nutrition, housing, urban services or employment, otherwise the household is classified as “better-off”.",Other measurements,[72286],[16803],[17008],[False],[0],[0],[False],['0']
18894,PMC4272792,11854,The following school characteristics were measured prior to the intervention: (i) school size as binary variable (0 = small schools; 1 = large schools) with the median (n = 695) of the school size as cut-off; (ii) type of school as a binary variable (0 = public; 1 = private); (iii) school schedule as a binary variable (0 = half day; 1 = full day schedule); (iv) school gender as a binary variable (0 = both genders; 1 = female only).,Other measurements,[72295],[17009],[17444],[False],[0],[0],[False],['0']
18895,PMC4272792,11855,"The sample did not contain schools with only male students; and (v) physical activity space, expressed number of students/m2 of space available for being physically active in each school.",Other measurements,[72304],[17445],[17632],[False],[0],[0],[False],['0']
18896,PMC4272792,11856,The median (4.07 students/m2) was used as a cut-off for this.,Other measurements,[72313],[17633],[17694],[False],[0],[0],[False],['0']
18897,PMC4272792,11857,"Using a pre-defined process evaluation framework and instruments, we also monitored the delivery of the intervention.",Other measurements,[72322],[17695],[17812],[False],[0],[0],[False],['0']
18898,PMC4272792,11858,Researchers recorded attendance and participation rates during classes and the receptiveness of the adolescents to the classes.,Other measurements,[72331],[17813],[17940],[False],[0],[0],[False],['0']
18899,PMC4272792,11859,Teachers in charge of a class filled out a questionnaire at the end of each class to assess their appreciation of the materials and the messages conveyed.,Other measurements,[72340],[17941],[18095],[False],[0],[0],[False],['0']
18900,PMC4272792,11860,"We assessed if adolescents noticed, liked and used the walking trail using a questionnaire in a convenience sample of 2 schools.",Other measurements,[72349],[18096],[18224],[False],[0],[0],[False],['0']
18901,PMC4272792,11861,"At the end of the workshop with parents, a questionnaire was administered to parents to measure satisfaction and to get general feedback of the workshops.",Other measurements,[72358],[18225],[18379],[False],[0],[0],[False],['0']
18902,PMC4272792,11862,In the present manuscript we describe the delivery and response of the intervention.,Other measurements,[72367],[18380],[18464],[False],[0],[0],[False],['0']
18903,PMC4272792,11863,A full process evaluation will be reported separately.,Other measurements,[72376],[18465],[18519],[False],[0],[0],[False],['0']
18904,PMC4272792,11864,Statistical analysis,Statistical analysis,[72385],[18520],[18541],[False],[0],[0],[False],['0']
18905,PMC4272792,11865,Differences at baseline between intervention groups as well as differences dropout and remainders groups were assessed using a t-test for continuous variables adjusted for the pair matched allocation and χ2 test for categorical variables.,Statistical analysis,[72394],[18542],[18780],[False],[0],[0],[False],['0']
18906,PMC4272792,11866,"To estimate the effect of the intervention, we used a difference in differences approach.",Statistical analysis,[72403],[18781],[18870],[False],[0],[0],[False],['0']
18907,PMC4272792,11867,An intention-to-treat analysis was performed to assess the intervention effect using mixed linear regression models with the pair-matching as random effect.,Statistical analysis,[72412],[18871],[19027],[False],[0],[0],[False],['0']
18908,PMC4272792,11868,"In such models, the Beta coefficient of the intervention variable indicates the difference in means for continuous dependent variables and the difference in absolute risks for dichotomic ones [39].",Statistical analysis,[72421],[19028],[19225],[False],[0],[0],[False],['0']
18909,PMC4272792,11869,"All models were adjusted for baseline BMI z-score, gender, adolescent socio-economic status and knowledge on recommendations and health benefits of physical activity.",Statistical analysis,[72430],[19226],[19392],[False],[0],[0],[False],['0']
18910,PMC4272792,11870,We adjusted the analysis for prior knowledge on physical activity as it influences on how much the new knowledge can be assimilated [40].,Statistical analysis,[72439],[19393],[19530],[False],[0],[0],[False],['0']
18911,PMC4272792,11871,Akaike-Schwartz criteria [41] were used to determine the optimal covariance structure.,Statistical analysis,[72448],[19531],[19617],[False],[0],[0],[False],['0']
18912,PMC4272792,11872,"To assess the effect of the adjusting, we also analyzed the effect of the intervention using crude models.",Statistical analysis,[72457],[19618],[19724],[False],[0],[0],[False],['0']
18913,PMC4272792,11873,We also tested variations of the effect by pairs of schools by a meta-analysis with visual appraisal of the forest plot and heterogeneity statistics (I2) [42].,Statistical analysis,[72466],[19725],[19884],[False],[0],[0],[False],['0']
18914,PMC4272792,11874,"Next, we tested if the intervention had a different effect in boys and girls using interaction term gender × allocation group.",Statistical analysis,[72475],[19885],[20011],[False],[0],[0],[False],['0']
18915,PMC4272792,11875,As there was substantial heterogeneity among the pairs we explored if the intervention effect was modified by school characteristics for outcomes with a P < 0.1 in the main analysis.,Statistical analysis,[72484],[20012],[20194],[False],[0],[0],[False],['0']
18916,PMC4272792,11876,"For each outcome, we first assessed the effect modification for the five school characteristics in separate models (bivariate models) by including the interaction term of the school characteristic × intervention.",Statistical analysis,[72493],[20195],[20407],[False],[0],[0],[False],['0']
18917,PMC4272792,11877,"Secondly, a final model was constructed with all school characteristics that were significantly (P < 0.05) associated with the outcome in the bivariate models.",Statistical analysis,[72502],[20408],[20567],[False],[0],[0],[False],['0']
18918,PMC4272792,11878,"Finally, the analysis was stratified when the interaction terms were significant (P   < 0.1).",Statistical analysis,[72511],[20568],[20661],[False],[0],[0],[False],['0']
18919,PMC4272792,11879,"In addition, we tested the effect of missing data for all outcomes with P < 0.1 using a multiple imputation method based on chained equations with 50 imputation runs.",Statistical analysis,[72520],[20662],[20828],[False],[0],[0],[False],['0']
18920,PMC4272792,11880,"Age, BMI z-score, gender, physical activity knowledge and socio-economic status were used as predictors in models to impute data in the pairs.",Statistical analysis,[72529],[20829],[20971],[False],[0],[0],[False],['0']
18921,PMC4272792,11881,All tests were performed with a significance level of 5% and models were evaluated for collinearity using variance inflation factors.,Statistical analysis,[72538],[20972],[21105],[False],[0],[0],[False],['0']
18922,PMC4272792,11882,"Given the small number of pairs (n = 10), we calculated the P-values from the multilevel analyses from a t-distribution with 9 degrees of freedom.",Statistical analysis,[72547],[21106],[21252],[False],[0],[0],[False],['0']
18923,PMC4272792,11883,Data were analyzed using Stata.,Statistical analysis,[72556],[21253],[21284],[False],[0],[0],[False],['0']
18924,PMC4272792,11884,Results,Results,[72565],[21285],[21293],[False],[0],[0],[False],['0']
18925,PMC4272792,11885,Table 2  Participant characteristics at baseline .,Results,[72574],[21294],[21344],[False],[0],[0],[False],['0']
18926,PMC4272792,11886,Table 3  School characteristics at baseline .,Results,[72583],[21345],[21390],[False],[0],[0],[False],['0']
18927,PMC4272792,11887,"A total of 1440 adolescents (intervention group: n = 700, 48.6%) and 20 schools (intervention group: n = 10, 50%) participated in the trial (Figure 1).",Results,[72592],[21391],[21542],[False],[0],[0],[False],['0']
18928,PMC4272792,11888,Baseline characteristics at individual and cluster level were comparable (Tables 2 and 3).,Results,[72601],[21543],[21633],[False],[0],[0],[False],['0']
18929,PMC4272792,11889,"Except for 20 m shuttle run, handgrip, plate tapping, sedentary time and light physical activity time, there were no significant differences in baseline characteristics.",Results,[72610],[21634],[21803],[False],[0],[0],[False],['0']
18930,PMC4272792,11890,"All schools completed the trial and the sample size included in the analyses was 1083 adolescents (63.2% girls, intervention group: n = 550, 50.8%).",Results,[72619],[21804],[21952],[False],[0],[0],[False],['0']
18931,PMC4272792,11891,"The attrition rate was higher (P < 0.001) in the control (28%, n = 207/740) compared to the intervention group (21%, n = 150/700).",Results,[72628],[21953],[22083],[False],[0],[0],[False],['0']
18932,PMC4272792,11892,"Most of the attrition was due to adolescents changing schools (73%, 262/357).",Results,[72637],[22084],[22161],[False],[0],[0],[False],['0']
18933,PMC4272792,11893,Physical activity could not be assessed in 47% (117/251) of the adolescents as accelerometers malfunctioned (n = 70) or participants were lost to follow-up (n = 39 left school).,Results,[72646],[22162],[22339],[False],[0],[0],[False],['0']
18934,PMC4272792,11894,Six students declined to participate and 2 were pregnant.,Results,[72655],[22340],[22397],[False],[0],[0],[False],['0']
18935,PMC4272792,11895,"In one school, no accelerometer readings were available for the same reasons.",Results,[72664],[22398],[22475],[False],[0],[0],[False],['0']
18936,PMC4272792,11896,"Adolescents lost to follow-up had a higher baseline score in the handgrip (P < 0.001) compared to adolescents who completed the trial, while the speed shuttle run (P = 0.01) and screen time during the week (P = 0.01) were better among the adolescents who completed the trial.",Results,[72673],[22476],[22751],[False],[0],[0],[False],['0']
18937,PMC4272792,11897,There was no difference for all other outcomes.,Results,[72682],[22752],[22799],[False],[0],[0],[False],['0']
18938,PMC4272792,11898,At the end of the intervention adolescents were on average 15.1 year ± 0.7.,Results,[72691],[22800],[22875],[False],[0],[0],[False],['0']
18939,PMC4272792,11899,Primary outcomes,Primary outcomes,[72700],[22876],[22893],[False],[0],[0],[False],['0']
18940,PMC4272792,11900,"Table 4  Group differences and mean changes in fitness, screen time, physical activity and BMI after intervention .",Primary outcomes,[72709],[22894],[23009],[False],[0],[0],[False],['0']
18941,PMC4272792,11901,Adolescents from the intervention group had a greater increase in vertical jump (intervention effect = 2.5 cm; 95%CI 0.78-4.23; P = 0.01).,Primary outcomes,[72718],[23010],[23148],[False],[0],[0],[False],['0']
18942,PMC4272792,11902,"Adolescents from the control group needed more time for speed shuttle run but this difference was small with borderline statistical significance (intervention effect = −0.8 s, CI-1.58-0.07; P = 0.05) compared to the intervention group indicating a deterioration of physical fitness for this component.",Primary outcomes,[72727],[23149],[23450],[False],[0],[0],[False],['0']
18943,PMC4272792,11903,Adolescents from the control group needed less attempts to keep their balance for the duration of one minute in flamingo balance test (P = 0.02) compared to intervention group (Table 4) i.e.,Primary outcomes,[72736],[23451],[23641],[False],[0],[0],[False],['0']
18944,PMC4272792,11904,the control group had a higher improvement in balance test compared to intervention group.,Primary outcomes,[72745],[23642],[23732],[False],[0],[0],[False],['0']
18945,PMC4272792,11905,Figure 2  Forest plot for vertical jump according to size and gender of the school pairs.,Primary outcomes,[72754],[23733],[23822],[False],[0],[0],[False],['0']
18946,PMC4272792,11906,.,Primary outcomes,[72763],[23823],[23824],[False],[0],[0],[False],['0']
18947,PMC4272792,11907,Except for a few outcomes only a small fraction (<10%) of the intervention effect was explained by the pairs (intraclass correlation reported in Table 4).,Primary outcomes,[72772],[23825],[23979],[False],[0],[0],[False],['0']
18948,PMC4272792,11908,"In addition, we observed a moderate to high (>25%) [42] heterogeneity in the intervention effect between pairs of schools for all but one outcome.",Primary outcomes,[72781],[23980],[24126],[False],[0],[0],[False],['0']
18949,PMC4272792,11909,Figure 2 illustrates this effect heterogeneity amongst pairs of schools for vertical jump (Table 4).,Primary outcomes,[72790],[24127],[24227],[False],[0],[0],[False],['0']
18950,PMC4272792,11910,"Over the intervention period, screen time increased around 2 hours in both intervention and control groups (Table 4).",Primary outcomes,[72799],[24228],[24345],[False],[0],[0],[False],['0']
18951,PMC4272792,11911,"Marginally insignificant however, the proportion of adolescents with >3 hours of screen time during the week decreased with 6% in the intervention group.",Primary outcomes,[72808],[24346],[24499],[False],[0],[0],[False],['0']
18952,PMC4272792,11912,"In the weekend days, this proportion increased with 4% respectively after the trial.",Primary outcomes,[72817],[24500],[24584],[False],[0],[0],[False],['0']
18953,PMC4272792,11913,Total physical activity level decreased in the intervention group and control group and both groups had a similar increase in sedentary time (Table 4).,Primary outcomes,[72826],[24585],[24736],[False],[0],[0],[False],['0']
18954,PMC4272792,11914,"At baseline, more than 90% of the adolescents had >60 min of moderate to vigorous physical activity per day.",Primary outcomes,[72835],[24737],[24845],[False],[0],[0],[False],['0']
18955,PMC4272792,11915,"After the intervention, the proportion of adolescents that met this recommendation decreased significantly less in the intervention group compared to the control group (6 vs. 18 percentage points, P < 0.01).",Primary outcomes,[72844],[24846],[25053],[False],[0],[0],[False],['0']
18956,PMC4272792,11916,Secondary outcomes,Secondary outcomes,[72853],[25054],[25073],[False],[0],[0],[False],['0']
18957,PMC4272792,11917,The intervention did not lead to differences in changes of BMI z-score or prevalence of overweight.,Secondary outcomes,[72862],[25074],[25173],[False],[0],[0],[False],['0']
18958,PMC4272792,11918,Ancillary analyses,Ancillary analyses,[72871],[25174],[25193],[False],[0],[0],[False],['0']
18959,PMC4272792,11919,Similar findings were obtained when analyzing the effect of the intervention with the crude models (Table 4).,Ancillary analyses,[72880],[25194],[25303],[False],[0],[0],[False],['0']
18960,PMC4272792,11920,"In addition, the intervention effect was not different among boys and girls.",Ancillary analyses,[72889],[25304],[25380],[False],[0],[0],[False],['0']
18961,PMC4272792,11921,"Table 5  Subgroup analysis of physical fitness, screen time, physical activity according to school characteristics .",Ancillary analyses,[72898],[25381],[25497],[False],[0],[0],[False],['0']
18962,PMC4272792,11922,School characteristics modified the intervention effect significantly for various outcomes (Table 5).,Ancillary analyses,[72907],[25498],[25599],[False],[0],[0],[False],['0']
18963,PMC4272792,11923,"In the full model the intervention effect on speed shuttle run was modified by school size (P   < 0.01), the effect on vertical jump by school gender (P   = 0.03), the effect on flamingo balance test by physical activity space (P   = 0.04), the effect on the proportion of adolescents with >3 h of screen time during the weekend by type of school (P   = 0.05) and the effect on the proportion of adolescents that met the recommendations for physical activity by school schedule (P   = 0.01).",Ancillary analyses,[72916],[25600],[26091],[False],[0],[0],[False],['0']
18964,PMC4272792,11924,"After the stratification, the speed shuttle run only showed an improvement in pairs of larger schools.",Ancillary analyses,[72925],[26092],[26194],[False],[0],[0],[False],['0']
18965,PMC4272792,11925,The speed shuttle run showed a decrease of 1.5 s (P < 0.01) in larger schools.,Ancillary analyses,[72934],[26195],[26273],[False],[0],[0],[False],['0']
18966,PMC4272792,11926,The improvement in the vertical jump was only significant in pairs of schools with both male and female children.,Ancillary analyses,[72943],[26274],[26387],[False],[0],[0],[False],['0']
18967,PMC4272792,11927,Vertical jump increased with about 3.6 cm (P < 0.01) in intervention schools vs. control schools in pairs of schools with both male and female students.,Ancillary analyses,[72952],[26388],[26540],[False],[0],[0],[False],['0']
18968,PMC4272792,11928,"In schools with a physical activity space ≤4.07 students/m2, control schools showed a significant (P = 0.01) improvement in the flamingo balance test.",Ancillary analyses,[72961],[26541],[26691],[False],[0],[0],[False],['0']
18969,PMC4272792,11929,The proportion of adolescents with >3 h of screen time during the weekend increased in 13% in private schools allocated in the intervention group (P = 0.01).,Ancillary analyses,[72970],[26692],[26849],[False],[0],[0],[False],['0']
18970,PMC4272792,11930,"In pairs of schools that offer half-day class only, the proportion of adolescents that met the recommendations for physical activity increased with 37% in intervention schools.",Ancillary analyses,[72979],[26850],[27026],[False],[0],[0],[False],['0']
18971,PMC4272792,11931,That proportion decreased with 29% in the intervention schools in pairs that provide full-day classes.,Ancillary analyses,[72988],[27027],[27129],[False],[0],[0],[False],['0']
18972,PMC4272792,11932,"The findings were similar after imputing missing variables and produced following estimates: vertical jump: β = 2.49, P = 0.01 (0.4% difference), speed shuttle run: β = −0.72, P = 0.07 (5.5% difference), flamingo balance test β = 2.26, P = 0.002 (24% difference), mean moderate to vigorous physical activity time: β = 12.0, P = 0.11 (11.6% difference) and the proportion meeting the recommended 60 min/day of moderate to vigorous physical activity β = 0.12, P = 0.05 (39% difference).",Ancillary analyses,[72997],[27130],[27614],[False],[0],[0],[False],['0']
18973,PMC4272792,11933,In the classes aimed to improve the physical activity there was large attendance and active participation (95% and 77% respectively).,Ancillary analyses,[73006],[27615],[27748],[False],[0],[0],[False],['0']
18974,PMC4272792,11934,All classes were delivered and teachers reported that 95% of content was explained as scheduled.,Ancillary analyses,[73015],[27749],[27845],[False],[0],[0],[False],['0']
18975,PMC4272792,11935,Most (79%) of the adolescents reported this to be new knowledge.,Ancillary analyses,[73024],[27846],[27910],[False],[0],[0],[False],['0']
18976,PMC4272792,11936,"The larger majority (85%) of adolescents that attended the classes, scored the quality of classes with >8/10.",Ancillary analyses,[73033],[27911],[28020],[False],[0],[0],[False],['0']
18977,PMC4272792,11937,Almost all (99%) adolescents attended the sessions with athletes and 78% were considered attentive.,Ancillary analyses,[73042],[28021],[28120],[False],[0],[0],[False],['0']
18978,PMC4272792,11938,The walking trails were drawn in all schools.,Ancillary analyses,[73051],[28121],[28166],[False],[0],[0],[False],['0']
18979,PMC4272792,11939,The majority of the adolescents had noticed the walking trail and liked it (91% and 60% respectively) but only 25% reported using it during breaks.,Ancillary analyses,[73060],[28167],[28314],[False],[0],[0],[False],['0']
18980,PMC4272792,11940,"Amongst the parents (10% of all parents) that attended the workshops, 90% scored the quality of the workshop high (≥80%) and most (76%) considered this to be new information.",Ancillary analyses,[73069],[28315],[28489],[False],[0],[0],[False],['0']
18981,PMC4272792,11941,"No harm or adverse effects were reported by adolescents, teachers or school management staff in the control or intervention group during the trial.",Ancillary analyses,[73078],[28490],[28637],[False],[0],[0],[False],['0']
18982,PMC4272792,11942,Discussion,Discussion,[73087],[28638],[28649],[False],[0],[0],[False],['0']
18983,PMC4272792,11943,We report how a school-based intervention had a positive effect on physical fitness parameters and recommendations for moderate to vigorous activity of adolescents in an urban area of Ecuador.,Discussion,[73096],[28650],[28842],[False],[0],[0],[False],['0']
18984,PMC4272792,11944,The increase in muscular strength as measured by vertical jump corresponds to 10% of the average score at baseline in the intervention group.,Discussion,[73105],[28843],[28984],[False],[0],[0],[False],['0']
18985,PMC4272792,11945,Ortega et al.,Discussion,[73114],[28985],[28998],[False],[0],[0],[False],['0']
18986,PMC4272792,11946,have shown that higher muscular strength during adolescence is associated with better cardiovascular and skeletal health at adulthood [9].,Discussion,[73123],[28999],[29137],[False],[0],[0],[False],['0']
18987,PMC4272792,11947,The intervention also resulted in an improvement of the speed shuttle run corresponding to a relative time decrease of 3% compared to the baseline values.,Discussion,[73132],[29138],[29292],[False],[0],[0],[False],['0']
18988,PMC4272792,11948,"Albeit marginally insignificant, this effect is considerable and compares to differences in speed-agility between non-obese and obese adolescents [43].",Discussion,[73141],[29293],[29444],[False],[0],[0],[False],['0']
18989,PMC4272792,11949,The effect on the balance component of physical fitness was in favor of the control group.,Discussion,[73150],[29445],[29535],[False],[0],[0],[False],['0']
18990,PMC4272792,11950,We attribute this counterintuitive finding to the fact that our intervention promoted physical activity and did not include specialized training for static activities needed for the balance test [44].,Discussion,[73159],[29536],[29736],[False],[0],[0],[False],['0']
18991,PMC4272792,11951,"We also observed that adolescents in the control group engaged more in static games during breaks like hacky sack and throwing coins near a target, while those in the intervention group were encouraged to engage in sports and use the walking trail.",Discussion,[73168],[29737],[29985],[False],[0],[0],[False],['0']
18992,PMC4272792,11952,"To our knowledge, trials in our age group from high-income countries have generally resulted in mixed effect on physical fitness [45-48].",Discussion,[73177],[29986],[30123],[False],[0],[0],[False],['0']
18993,PMC4272792,11953,Only one study in African American girls with high blood pressure led to a 1 min increase in step-test compared to children who only received physical education [49].,Discussion,[73186],[30124],[30290],[False],[0],[0],[False],['0']
18994,PMC4272792,11954,These results are less positive than those reported in the present study.,Discussion,[73195],[30291],[30364],[False],[0],[0],[False],['0']
18995,PMC4272792,11955,"This is surprising, as we did not provide an extra hour of physical education per week, exercises during the recess or specific equipment for physical activity.",Discussion,[73204],[30365],[30525],[False],[0],[0],[False],['0']
18996,PMC4272792,11956,"Instead, we developed a comprehensive approach to improve active lifestyles and healthy diet.",Discussion,[73213],[30526],[30619],[False],[0],[0],[False],['0']
18997,PMC4272792,11957,The activities were tailored to the local school context and delivered through existing school structures (e.g.,Discussion,[73222],[30620],[30731],[False],[0],[0],[False],['0']
18998,PMC4272792,11958,drawing of the walking trail on the courtyard).,Discussion,[73231],[30732],[30779],[False],[0],[0],[False],['0']
18999,PMC4272792,11959,The frequency and intensity of the classes were kept moderate to facilitate integration of the classes in curriculum after the intervention.,Discussion,[73240],[30780],[30920],[False],[0],[0],[False],['0']
19000,PMC4272792,11960,"Notwithstanding this, we report effects on muscular strength and speed measured by EUROFIT battery, which was not reported in a previous systematic review [13].",Discussion,[73249],[30921],[31081],[False],[0],[0],[False],['0']
19001,PMC4272792,11961,We note that our participants used more time for the speed shuttle run when getting older in both the intervention and control group.,Discussion,[73258],[31082],[31215],[False],[0],[0],[False],['0']
19002,PMC4272792,11962,"This tendency contradicts the current literature that states that (primarily European) adolescents decrease the time on speed shuttle through the transition from 12 to 15 years [43,50].",Discussion,[73267],[31216],[31401],[False],[0],[0],[False],['0']
19003,PMC4272792,11963,"The explanation of the different findings in Ecuadorian adolescents is speculative and perhaps due to a less favorable environmental conditions for physical activity found in Europe [51], differences in tradition of health promotion programs [15] and genetic factors [52,53].",Discussion,[73276],[31402],[31677],[False],[0],[0],[False],['0']
19004,PMC4272792,11964,"As observed in the present study, a decline in moderate to vigorous physical activity is common in early adolescence [15].",Discussion,[73285],[31678],[31800],[False],[0],[0],[False],['0']
19005,PMC4272792,11965,ACTIVITAL led to a significantly lower decrease in the proportion of adolescents that met the daily recommended 60 min of moderate to vigorous physical activity.,Discussion,[73294],[31801],[31962],[False],[0],[0],[False],['0']
19006,PMC4272792,11966,"Besides, although the intervention effect on the moderate or vigorous activities is borderline significant in the present manuscript, it is relevant as it comprises a quarter of the daily recommendations.",Discussion,[73303],[31963],[32167],[False],[0],[0],[False],['0']
19007,PMC4272792,11967,"Furthermore, this difference was almost three times higher than that reported in a meta-analysis of physical activity interventions in children and adolescents [54] which stated a small improvement on the moderate or vigorous activities of ~4 min/day as measured using accelerometers.",Discussion,[73312],[32168],[32452],[False],[0],[0],[False],['0']
19008,PMC4272792,11968,For screen time and sedentary behavior no intervention effects were found.,Discussion,[73321],[32453],[32527],[False],[0],[0],[False],['0']
19009,PMC4272792,11969,Specific components are needed to address sedentary behavior [55].,Discussion,[73330],[32528],[32594],[False],[0],[0],[False],['0']
19010,PMC4272792,11970,"We covered screen time in classes only during the first year of the trial, which was possibly insufficient to produce a significant effect.",Discussion,[73339],[32595],[32734],[True],['OutcomeMeasures'],['We covered screen time in classes only during the first year of the tria'],[True],['OutcomeMeasures']
19011,PMC4272792,11971,We found no effects of the intervention on mean BMI or prevalence of overweight.,Discussion,[73357],[32735],[32815],[False],[0],[0],[False],['0']
19012,PMC4272792,11972,"While some authors report favorable effects in girls [56,57] or boys only [58,59], others found no differences [48,49,60].",Discussion,[73366],[32816],[32938],[False],[0],[0],[False],['0']
19013,PMC4272792,11973,Only a study from Greece reported a significant effect in both groups after one year [61].,Discussion,[73375],[32939],[33029],[False],[0],[0],[False],['0']
19014,PMC4272792,11974,The effect size on these outcomes was possibly too small and our follow-up period was possibly too short to detect effects on BMI.,Discussion,[73384],[33030],[33160],[False],[0],[0],[False],['0']
19015,PMC4272792,11975,We observed a large heterogeneity in our intervention effect between the schools.,Discussion,[73393],[33161],[33242],[False],[0],[0],[False],['0']
19016,PMC4272792,11976,School characteristics could explain the variation on intervention effects among pairs.,Discussion,[73402],[33243],[33330],[False],[0],[0],[False],['0']
19017,PMC4272792,11977,Speed agility decreased significantly more in pairs with larger size schools.,Discussion,[73411],[33331],[33408],[False],[0],[0],[False],['0']
19018,PMC4272792,11978,"As size of secondary schools is associated with higher academic achievements [62], children from a larger sized school might have a comparative advantage and respond better to the intervention.",Discussion,[73420],[33409],[33602],[False],[0],[0],[False],['0']
19019,PMC4272792,11979,Educational classes were an important activity in this trial and the uptake of information could have been better in larger schools.,Discussion,[73430],[33603],[33735],[True],['Setting'],['the uptake of information could have been better in larger schools'],[True],['Setting']
19020,PMC4272792,11980,Larger sized schools also typically provide more extracurricular activities [62].,Discussion,[73447],[33736],[33817],[False],[0],[0],[False],['0']
19021,PMC4272792,11981,"In Cuenca, such extra activities are dedicated to sports and physical activity.",Discussion,[73456],[33818],[33897],[False],[0],[0],[False],['0']
19022,PMC4272792,11982,Vertical jump on the other hand only improved significantly in school pairs that had both male and female students.,Discussion,[73465],[33898],[34013],[False],[0],[0],[False],['0']
19023,PMC4272792,11983,Physical activity in adolescents is subjected to peer influence [63].,Discussion,[73474],[34014],[34083],[False],[0],[0],[False],['0']
19024,PMC4272792,11984,"A recent study reported that physical activity of male adolescents was associated with that of their female peers, while female physical activity was associated with physical activity of their male and female peers [64].",Discussion,[73483],[34084],[34304],[False],[0],[0],[False],['0']
19025,PMC4272792,11985,We therefore hypothesize that physical activity as well as physical fitness in female adolescents are mainly associated with the presence of males rather than the female peers in schools.,Discussion,[73492],[34305],[34492],[False],[0],[0],[False],['0']
19026,PMC4272792,11986,Space available for physical activity during recess did not influence the effects of our intervention on physical activity or physical fitness except for the flamingo balance test.,Discussion,[73501],[34493],[34673],[False],[0],[0],[False],['0']
19027,PMC4272792,11987,This finding is promising for schools with limited space available.,Discussion,[73510],[34674],[34741],[False],[0],[0],[False],['0']
19028,PMC4272792,11988,We hypothesize that the limited space in school with <4.07 students/m2 triggered the adolescents to engage in static games that improve the balance component of fitness [44].,Discussion,[73519],[34742],[34916],[False],[0],[0],[False],['0']
19029,PMC4272792,11989,The higher proportion of adolescents with >3 hours of screen time during weekdays in private schools is possibly explained by a higher access to computers at home in adolescents from private schools compared to adolescents from public schools (88% vs. 54% had a computer at home respectively).,Discussion,[73528],[34917],[35210],[False],[0],[0],[False],['0']
19030,PMC4272792,11990,"Also, our results indicate that a higher proportion of adolescents from schools with a half-day class schedule met the recommendations of 60 min physical activity per day compared to those from schools with a full day schedule.",Discussion,[73537],[35211],[35438],[False],[0],[0],[False],['0']
19031,PMC4272792,11991,"Probably, adolescents in schools with a half day schedule had more time to meet the recommendations for time spent on physical activity compared to schools with a full day schedule, as schools with a half day schedule usually have teaching sessions of 45 min with a recess of 35 min while schools with full day schedule have classes of 35 min and a recess of 30 min.",Discussion,[73546],[35439],[35805],[False],[0],[0],[False],['0']
19032,PMC4272792,11992,"However, as the trial was not designed to analyze the moderating effects of the school characteristics on the intervention effects, the explanations for these effects are speculative.",Discussion,[73557],[35806],[35989],[True],['UnderpoweredStudy'],['the trial was not designed to analyze the moderating effects of the school characteristics on the intervention effects'],[True],['UnderpoweredStudy']
19033,PMC4272792,11993,"In addition, we acknowledge a large variation of the effect in the pairs that was not explained by the recorded school characteristics, which merits further consideration in future trials.",Discussion,[73573],[35990],[36178],[False],[0],[0],[False],['0']
19034,PMC4272792,11994,This study has important strengths.,Discussion,[73582],[36179],[36214],[False],[0],[0],[False],['0']
19035,PMC4272792,11995,"First, we delivered a comprehensive intervention aimed at promoting both diet and physical activity.",Discussion,[73591],[36215],[36315],[False],[0],[0],[False],['0']
19036,PMC4272792,11996,"A second strength is the duration of our program, which is longer than most trials on the topic.",Discussion,[73600],[36316],[36412],[False],[0],[0],[False],['0']
19037,PMC4272792,11997,A third strength is the comprehensive assessment of physical fitness.,Discussion,[73609],[36413],[36482],[False],[0],[0],[False],['0']
19038,PMC4272792,11998,Most studies evaluate only a few physical fitness components [13].,Discussion,[73618],[36483],[36549],[False],[0],[0],[False],['0']
19039,PMC4272792,11999,"Finally, the positive findings and feedback from the parents, teachers and adolescents is encouraging and promising to scale up the approach.",Discussion,[73627],[36550],[36691],[False],[0],[0],[False],['0']
19040,PMC4272792,12000,We think the intervention was successful as it was new and responded to a latent need for activities that address healthy lifestyles.,Discussion,[73636],[36692],[36825],[False],[0],[0],[False],['0']
19041,PMC4272792,12001,The children and parents valued the practical nature of the recommendations and simplicity of the messages.,Discussion,[73645],[36826],[36933],[False],[0],[0],[False],['0']
19042,PMC4272792,12002,A limitation of this study is the large and unbalanced dropout.,Discussion,[73657],[36934],[36997],[True],['UnbalancedDropout'],['the large and unbalanced dropout'],[True],['MissingData']
19043,PMC4272792,12003,Frequently changing school is common in Ecuador.,Discussion,[73672],[36998],[37046],[False],[0],[0],[False],['0']
19044,PMC4272792,12004,Children lost to follow-up were similar to their peers at baseline and the missing data analysis showed no major differences.,Discussion,[73681],[37047],[37172],[False],[0],[0],[False],['0']
19045,PMC4272792,12005,One school in the control group had an exceptionally high dropout rate (12%) associated with overall very poor academic performance and drug misuse.,Discussion,[73690],[37173],[37321],[False],[0],[0],[False],['0']
19046,PMC4272792,12006,The assessment of physical activity in a sub-sample is an additional limitation.,Discussion,[73703],[37322],[37402],[True],['MissingData'],['The assessment of physical activity in a sub-sample'],[True],['MissingData']
19047,PMC4272792,12007,"Although we blinded staff that measured outcomes to the allocation of the schools, we cannot rule out that they observed elements of the interventions such as the posters or the walking trail.",Discussion,[73722],[37403],[37595],[True],['StudyTeam'],['we cannot rule out that they observed elements of the interventions'],[True],['Blinding']
19048,PMC4272792,12008,We could only assess the use of the walking trail in two schools due to logistical constraints.,Discussion,[73741],[37596],[37691],[True],['MissingData'],['We could only assess the use of the walking trail in two schools'],[True],['MissingData']
19049,PMC4272792,12009,"Although our results are encouraging for school interventions in LMICs, our findings are both mixed and modest.",Discussion,[73753],[37692],[37803],[False],[0],[0],[False],['0']
19050,PMC4272792,12010,The findings were also not consistent over the outcomes.,Discussion,[73762],[37804],[37860],[False],[0],[0],[False],['0']
19051,PMC4272792,12011,"In addition, the findings for the 20 m shuttle run and bent arm hang should be interpreted with caution since a post-hoc analysis showed a statistical power of 64% and 65% for these outcomes respectively.",Discussion,[73778],[37861],[38065],[True],['UnderpoweredStudy'],['a post-hoc analysis showed a statistical power of 64% and 65% for these outcomes'],[True],['UnderpoweredStudy']
19052,PMC4272792,12012,The trial included 13% of adolescents between 8th and 9th grade from urban schools in Cuenca that is characterized by mixed mestizo ethnicity and its high altitude.,Discussion,[73789],[38066],[38230],[False],[0],[0],[False],['0']
19053,PMC4272792,12013,Further generalization of our findings is hence limited to urban schools in the regions that share these characteristics [65].,Discussion,[73806],[38231],[38357],[True],['Generalization'],['generalization of our findings is hence limited'],[True],['Generalization']
19054,PMC4272792,12014,Conclusion,Conclusion,[73816],[38358],[38369],[False],[0],[0],[False],['0']
19055,PMC4272792,12015,"In conclusion, a comprehensive school-based program to improve diet and physical activity can improve physical fitness in adolescents from urban area of LMICs and can minimize the decline in physical activity levels during early adolescence.",Conclusion,[73825],[38370],[38611],[False],[0],[0],[False],['0']
19056,PMC4272792,12016,Abbreviations,Abbreviations,[73834],[38612],[38626],[False],[0],[0],[False],['0']
19057,PMC4272792,12017,BMI Body mass index,Abbreviations|BMI Body mass index,[73843],[38627],[38646],[False],[0],[0],[False],['0']
19058,PMC4272792,12018,CI Confidence intervals,Abbreviations|CI Confidence intervals,[73852],[38647],[38670],[False],[0],[0],[False],['0']
19059,PMC4272792,12019,LMICs Low- and middle- income countries,Abbreviations|LMICs Low- and middle- income countries,[73861],[38671],[38710],[False],[0],[0],[False],['0']
19060,PMC4272792,12020,NCDs Noncommunicable diseases,Abbreviations|NCDs Noncommunicable diseases,[73870],[38711],[38740],[False],[0],[0],[False],['0']
19061,PMC4272792,12021,WHO World Health OrganizationCompeting interests,Abbreviations|WHO World Health OrganizationCompeting interests,[73879],[38741],[38789],[False],[0],[0],[False],['0']
19062,PMC4272792,12022,The authors declare that they have no competing interests.Authors’ contributions,Abbreviations|WHO World Health OrganizationCompeting interests,[73888],[38790],[38870],[False],[0],[0],[False],['0']
19063,PMC4272792,12023,"Conceived and designed the study: VR, OA, KP.",Abbreviations|WHO World Health OrganizationCompeting interests,[73897],[38871],[38916],[False],[0],[0],[False],['0']
19064,PMC4272792,12024,"Performed the study: AS, OA, AD, RR, DS.",Abbreviations|WHO World Health OrganizationCompeting interests,[73906],[38917],[38957],[False],[0],[0],[False],['0']
19065,PMC4272792,12025,"Analyzed the data: AS, LC, HL, KP, CG, OA, RD.",Abbreviations|WHO World Health OrganizationCompeting interests,[73915],[38958],[39004],[False],[0],[0],[False],['0']
19066,PMC4272792,12026,"Wrote the first draft of the manuscript: AS, LC, OA.",Abbreviations|WHO World Health OrganizationCompeting interests,[73924],[39005],[39057],[False],[0],[0],[False],['0']
19067,PMC4272792,12027,"Contributed to the writing of the manuscript: AS, LC, OA, CG, VR, KP, HL, AD, RR, DS,VJ, RD.",Abbreviations|WHO World Health OrganizationCompeting interests,[73933],[39058],[39150],[False],[0],[0],[False],['0']
19068,PMC4272792,12028,"Agree with manuscript results and conclusion: AS, LC, OA, VR, HL, AD, VJ, RR, DS, CG, KP, RD.",Abbreviations|WHO World Health OrganizationCompeting interests,[73942],[39151],[39244],[False],[0],[0],[False],['0']
19069,PMC4272792,12029,"Enrolled participants: RR, AS, OA.",Abbreviations|WHO World Health OrganizationCompeting interests,[73951],[39245],[39279],[False],[0],[0],[False],['0']
19070,PMC4272792,12030,All authors read and approved the final manuscript.,Abbreviations|WHO World Health OrganizationCompeting interests,[73960],[39280],[39331],[False],[0],[0],[False],['0']
19071,PMC4272792,12031,Acknowledgements,Abbreviations|Acknowledgements,[73969],[39332],[39348],[False],[0],[0],[False],['0']
19072,PMC4272792,12032,This work was supported by generous financial support from VLIR-UOS and Nutrition Third World and conducted within the cooperation between the Cuenca University (Ecuador) and the Ghent University (Belgium).,Abbreviations|Acknowledgements,[73978],[39349],[39555],[False],[0],[0],[False],['0']
19073,PMC4272792,12033,We thank Joris Menten and Pierre Traissac for their statistical advice.,Abbreviations|Acknowledgements,[73987],[39556],[39627],[False],[0],[0],[False],['0']
19074,PMC4272792,12034,"We acknowledge the participation of the students, teachers and parents in all schools.",Abbreviations|Acknowledgements,[73996],[39628],[39714],[False],[0],[0],[False],['0']
19075,PMC4272792,12035,"This work would not have been possible without Patricia Ramirez, Diana Cordova, Juana Cabrera, Lourdes Jerves, Ma.",Abbreviations|Acknowledgements,[74005],[39715],[39829],[False],[0],[0],[False],['0']
19076,PMC4272792,12036,"Cecilia Vintimilla, Marlene Gia and all interviewers that participated in the collecting data.",Abbreviations|Acknowledgements,[74014],[39830],[39924],[False],[0],[0],[False],['0']
19718,PMC4392313,1142,"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study",Title,[8261],[34690],[145],[False],[0],[0],[False],['0']
19719,PMC4392313,1143,Objectives,Abstract,[8263],[146],[157],[False],[0],[0],[False],['0']
19720,PMC4392313,1144,The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients.,Abstract,[8265],[158],[337],[False],[0],[0],[False],['0']
19721,PMC4392313,1145,We aimed to characterise the impact of IL-6R inhibition on established and novel risk factors in active RA.,Abstract,[8267],[338],[445],[False],[0],[0],[False],['0']
19722,PMC4392313,1146,Methods,Abstract,[8269],[446],[453],[False],[0],[0],[False],['0']
19723,PMC4392313,1147,"Randomised, multicentre, two-part, phase III trial (24-week double-blind, 80-week open-label), MEASURE, evaluated lipid and lipoprotein levels, high-density lipoprotein (HDL) particle composition, markers of coagulation, thrombosis and vascular function by pulse wave velocity (PWV) in 132 patients with RA who received TCZ or placebo.",Abstract,[8271],[454],[789],[False],[0],[0],[False],['0']
19724,PMC4392313,1148,Results,Abstract,[8273],[790],[797],[False],[0],[0],[False],['0']
19725,PMC4392313,1149,"Median total-cholesterol, low-density lipoprotein-cholesterol (LDL-C) and triglyceride levels increased in TCZ versus placebo recipients by week 12 (12.6% vs 1.7%, 28.1% vs 2.2%, 10.6% vs −1.9%, respectively; all p<0.01).",Abstract,[8275],[798],[1019],[False],[0],[0],[False],['0']
19726,PMC4392313,1150,"There were no significant differences in mean small LDL, mean oxidised LDL or total HDL-C concentrations.",Abstract,[8277],[1020],[1125],[False],[0],[0],[False],['0']
19727,PMC4392313,1151,"However, HDL-associated serum amyloid A content decreased in TCZ recipients.",Abstract,[8279],[1126],[1202],[False],[0],[0],[False],['0']
19728,PMC4392313,1152,"TCZ also induced reductions (>30%) in secretory phospholipase A2-IIA, lipoprotein(a), fibrinogen and D-dimers and elevation of paraoxonase (all p<0.0001 vs placebo).",Abstract,[8281],[1203],[1368],[False],[0],[0],[False],['0']
19729,PMC4392313,1153,The ApoB/ApoA1 ratio remained stable over time in both groups.,Abstract,[8283],[1369],[1431],[False],[0],[0],[False],['0']
19730,PMC4392313,1154,PWV decreases were greater with placebo than TCZ at 12 weeks (adjusted mean difference 0.79 m/s (95% CI 0.22 to 1.35; p=0.0067)).,Abstract,[8285],[1432],[1561],[False],[0],[0],[False],['0']
19731,PMC4392313,1155,Conclusions,Abstract,[8287],[1562],[1573],[False],[0],[0],[False],['0']
19732,PMC4392313,1156,These data provide the first detailed evidence for the modulation of lipoprotein particles and other surrogates of vascular risk with IL-6R inhibition.,Abstract,[8289],[1574],[1725],[False],[0],[0],[False],['0']
19733,PMC4392313,1157,"When compared with placebo, TCZ induced elevations in LDL-C but altered HDL particles towards an anti-inflammatory composition and favourably modified most, but not all, measured vascular risk surrogates.",Abstract,[8291],[1726],[1930],[False],[0],[0],[False],['0']
19734,PMC4392313,1158,The net effect of such changes for cardiovascular risk requires determination.,Abstract,[8293],[1931],[2009],[False],[0],[0],[False],['0']
19735,PMC4392313,1159,Introduction,Introduction,[8295],[2010],[2023],[False],[0],[0],[False],['0']
19736,PMC4392313,1160,"Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with clinically important comorbidities, including accelerated cardiovascular risk.",Introduction,[8297],[2024],[2178],[False],[0],[0],[False],['0']
19737,PMC4392313,1161,"The latter is not explained by conventional risk factors (eg, hypertension, obesity), suggesting that additional pathways contribute to adverse outcomes.",Introduction,[8299],[2179],[2332],[False],[0],[0],[False],['0']
19738,PMC4392313,1162,"These may reflect common genetic or environmental aetiological factors or the impact of chronic inflammation on underlying atherosclerotic disease burden, operating through circulating cytokines, immune complexes, complement factors and acute-phase reactants.",Introduction,[8301],[2333],[2592],[False],[0],[0],[False],['0']
19739,PMC4392313,1163,"Furthermore, it is recognised that absolute circulating lipid concentrations are modified in RA, likely reflecting regulatory integration of metabolic and inflammatory molecular networks.",Introduction,[8303],[2593],[2780],[False],[0],[0],[False],['0']
19740,PMC4392313,1164,"In general, high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) levels are reduced in active disease and may increase on the initiation of effective therapeutics regardless of modality.",Introduction,[8305],[2781],[3007],[False],[0],[0],[False],['0']
19741,PMC4392313,1165,"Moreover, interpretation of lipid particle concentrations may be further complicated by changes in size and composition associated with inflammation.",Introduction,[8307],[3008],[3157],[False],[0],[0],[False],['0']
19742,PMC4392313,1166,"For example, small LDL-C particles may confer more atherogenic risk than larger LDL-C particles.",Introduction,[8309],[3158],[3254],[False],[0],[0],[False],['0']
19743,PMC4392313,1167,"In inflammatory conditions, HDL particles are associated with increased serum amyloid A (SAA) content, representing a potentially proatherogenic phenotype.",Introduction,[8311],[3255],[3410],[False],[0],[0],[False],['0']
19744,PMC4392313,1168,The impact of therapy on subparticle components in RA has not been well characterised.,Introduction,[8313],[3411],[3497],[False],[0],[0],[False],['0']
19745,PMC4392313,1169,"Similarly, the effect of therapy on other lipid particles causally associated with vascular disease, such as lipoprotein(a) (Lp[a]), and on clotting factors, such as fibrinogen or markers of activated clotting such as D-dimer, is poorly understood.",Introduction,[8315],[3498],[3746],[False],[0],[0],[False],['0']
19746,PMC4392313,1170,"Interleukin-6 (IL-6) plays an important role in various inflammatory effector pathways in RA through B-cell, fibroblast and osteoclast activation.",Introduction,[8317],[3747],[3893],[False],[0],[0],[False],['0']
19747,PMC4392313,1171,"Additionally, it mediates systemic manifestations of disease operating through hepatic and central neurological pathways.",Introduction,[8319],[3894],[4015],[False],[0],[0],[False],['0']
19748,PMC4392313,1172,"Intriguingly, elevated IL-6 levels are independently associated with increased cardiovascular risk, including fatal myocardial infarction and cerebrovascular accident, in the general population.",Introduction,[8321],[4016],[4210],[False],[0],[0],[False],['0']
19749,PMC4392313,1173,"The mechanisms mediating such epidemiological observations are poorly understood but are likely to be commensurate with the fundamental role played by inflammatory pathways in the pathogenesis of atherosclerosis, the systemic functional activities of IL-6 conferred by widespread gp130 receptor membrane expression and the existence of soluble IL-6 receptor (IL-6R).",Introduction,[8323],[4211],[4577],[False],[0],[0],[False],['0']
19750,PMC4392313,1174,"Moreover, loss-of-function IL-6R polymorphisms are associated with reduced vascular risk.",Introduction,[8325],[4578],[4667],[False],[0],[0],[False],['0']
19751,PMC4392313,1175,Tocilizumab (TCZ) is a monoclonal antibody targeting IL-6R (membrane-bound and soluble) that reduces inflammation and articular damage in patients with RA.,Introduction,[8327],[4668],[4825],[False],[0],[0],[False],['0']
19752,PMC4392313,1176,"In phase II and III trials, moderate elevations of LDL-C, HDL-C and triglycerides were apparent in RA patients treated with TCZ.",Introduction,[8329],[4826],[4954],[False],[0],[0],[False],['0']
19753,PMC4392313,1177,The atherogenic implications of these changes are unknown.,Introduction,[8331],[4955],[5013],[False],[0],[0],[False],['0']
19754,PMC4392313,1178,"Similarly, the effect of IL-6R blockade on vascular physiology parameters (eg, as assessed by pulse wave velocity (PWV)) has been minimally explored.",Introduction,[8333],[5014],[5163],[False],[0],[0],[False],['0']
19755,PMC4392313,1179,PWV is a measure of early structural vascular changes and has been shown to respond within 3 months to changes in vascular inflammation.,Introduction,[8335],[5164],[5300],[False],[0],[0],[False],['0']
19756,PMC4392313,1180,"Thus, given its mode of action, TCZ provides a highly specific molecular intervention with which to dissect the role of IL-6 in the modulation of lipid particles and the regulation of other vascular risk factors in patients with chronic inflammation.",Introduction,[8337],[5301],[5551],[False],[0],[0],[False],['0']
19757,PMC4392313,1181,We report herein the results of a placebo-controlled trial that sought to define the effects of TCZ on a range of vascular risk surrogates in patients with RA.,Introduction,[8339],[5552],[5711],[False],[0],[0],[False],['0']
19758,PMC4392313,1182,Our primary hypotheses were that PWV and small LDL particles would be significantly reduced by TCZ.,Introduction,[8341],[5712],[5811],[False],[0],[0],[False],['0']
19759,PMC4392313,1183,Methods,Methods,[8343],[5812],[5820],[False],[0],[0],[False],['0']
19760,PMC4392313,1184,Patients,Methods|Patients,[8345],[5821],[5829],[False],[0],[0],[False],['0']
19761,PMC4392313,1185,"This trial, conducted independently of the pivotal RA trials, was approved by an independent ethics committee or institutional review board, and all patients gave written informed consent for participation in the trial.",Methods|Patients,[8347],[5830],[6049],[False],[0],[0],[False],['0']
19762,PMC4392313,1186,Adult patients with moderately to severely active RA (diagnosed per American College of Rheumatology (ACR) criteria) of more than 6 months’ duration were recruited.,Methods|Patients,[8349],[6050],[6214],[False],[0],[0],[False],['0']
19763,PMC4392313,1187,"Enrolment criteria included inadequate response to stable methotrexate (MTX) therapy, exemplified by a swollen joint count (SJC) ≥6 and a tender joint count (TJC) ≥6, together with C-reactive protein (CRP) >10 mg/L or erythrocyte sedimentation rate (ESR) >28 mm/h.",Methods|Patients,[8351],[6215],[6479],[False],[0],[0],[False],['0']
19764,PMC4392313,1188,Patients with inadequate response to an antitumour necrosis factor-α (aTNF) agent during the 6 months before baseline or to more than two previous aTNF agents were ineligible.,Methods|Patients,[8353],[6480],[6655],[False],[0],[0],[False],['0']
19765,PMC4392313,1189,MTX therapy was continued during the study.,Methods|Patients,[8355],[6656],[6699],[False],[0],[0],[False],['0']
19766,PMC4392313,1190,"Initiation of lipid-lowering, oral antidiabetic or antihypertensive medications or change in dose within 12 weeks of baseline was prohibited, and glucocorticoid doses (≤10 mg) had to remain stable.",Methods|Patients,[8357],[6700],[6897],[False],[0],[0],[False],['0']
19767,PMC4392313,1191,"Patients were stratified at randomisation by age (<52 vs ≥52 years), mean arterial blood pressure (<93.3 vs ≥93.3 mm Hg) and CRP (<1.66 vs ≥1.66 mg/dL).",Methods|Patients,[8359],[6898],[7050],[False],[0],[0],[False],['0']
19768,PMC4392313,1192,Procedures,Methods|Procedures,[8361],[7051],[7061],[False],[0],[0],[False],['0']
19769,PMC4392313,1193,"This two-arm, randomised, multicentre, double-blind, placebo-controlled, parallel-group, phase III study was conducted in the USA, Canada and the UK (figure 1) at 34 sites (the MEASURE study).",Methods|Procedures,[8363],[7062],[7254],[False],[0],[0],[False],['0']
19770,PMC4392313,1194,"Patients were randomly assigned using an interactive voice response system to blinded (patient and treating clinical team) intravenous treatment with TCZ 8 mg/kg or placebo in a 1:1 ratio, both in combination with oral MTX, every 4 weeks for 6 months between November 2007 and June 2008.",Methods|Procedures,[8365],[7255],[7542],[False],[0],[0],[False],['0']
19771,PMC4392313,1195,"Patients who, despite scheduled infusions of double-blind study medication at weeks 8 and 12, did not achieve ≥20% improvement from baseline in SJC and TJC at week 16 were offered escape therapy with open-label TCZ 8 mg/kg.",Methods|Procedures,[8367],[7543],[7766],[False],[0],[0],[False],['0']
19772,PMC4392313,1196,"At completion of the 24-week randomised treatment period, all patients were offered open-label treatment with TCZ 8 mg/kg plus MTX.",Methods|Procedures,[8369],[7767],[7898],[False],[0],[0],[False],['0']
19773,PMC4392313,1197,"Assessments during part 1 (randomised phase) of the study were performed at day 1 and at weeks 1, 2, 4, 8, 12, 16, 20 and 24.",Methods|Procedures,[8371],[7899],[8024],[False],[0],[0],[False],['0']
19774,PMC4392313,1198,Open-label assessments were performed every 12 weeks to week 104 (ClinicalTrials.gov number NCT00535782).,Methods|Procedures,[8373],[8025],[8130],[False],[0],[0],[False],['0']
19775,PMC4392313,1199,"The study protocol (version C, 22 June 2009 (original protocol published 10 May 2007)) is available as online supplementary material.",Methods|Procedures,[8375],[8131],[8264],[False],[0],[0],[False],['0']
19776,PMC4392313,1200,Study design.,Methods|Procedures,[8377],[8265],[8278],[False],[0],[0],[False],['0']
19777,PMC4392313,1201,"MTX, methotrexate; TCZ, tocilizumab.",Methods|Procedures,[8379],[8279],[8315],[False],[0],[0],[False],['0']
19778,PMC4392313,1202,(A) *Patients who did not achieve ≥20% improvement from baseline in swollen and tender joint counts at week 16 were offered escape therapy with open-label TCZ 8 mg/kg.,Methods|Procedures,[8381],[8316],[8483],[False],[0],[0],[False],['0']
19779,PMC4392313,1203,†60 placebo+MTX and 65 TCZ+MTX patients completed 12 weeks.,Methods|Procedures,[8383],[8484],[8543],[False],[0],[0],[False],['0']
19780,PMC4392313,1204,‡59 placebo+MTX and 65 TCZ+MTX patients completed 24 weeks.,Methods|Procedures,[8385],[8544],[8603],[False],[0],[0],[False],['0']
19781,PMC4392313,1205,(B) *TCZ 8 mg/kg every 4 weeks+background MTX (7.5–25 mg weekly).,Methods|Procedures,[8387],[8604],[8669],[False],[0],[0],[False],['0']
19782,PMC4392313,1206,"†Escape therapy, open-label TCZ (8 mg/kg every 4 weeks+background MTX).",Methods|Procedures,[8389],[8670],[8741],[False],[0],[0],[False],['0']
19783,PMC4392313,1207,‡Patients who received at least one dose of TCZ (double-blind or open-label).,Methods|Procedures,[8391],[8742],[8819],[False],[0],[0],[False],['0']
19784,PMC4392313,1208,Lipid and biomarker assays,Methods|Lipid and biomarker assays,[8393],[8820],[8846],[False],[0],[0],[False],['0']
19785,PMC4392313,1209,"Commercial assays were used to measure cholesterol, triglycerides, apolipoproteins A1 and B (ApoA1 and ApoB), CRP (by high-sensitivity assay) and ESR (all assays conducted or facilitated by Covance Laboratories, Greenfield, Indiana, USA).",Methods|Lipid and biomarker assays,[8395],[8847],[9085],[False],[0],[0],[False],['0']
19786,PMC4392313,1210,"Serum lipid subclasses were characterised by nuclear magnetic resonance (NMR; LipoScience, Raleigh, North Carolina, USA).",Methods|Lipid and biomarker assays,[8397],[9086],[9207],[False],[0],[0],[False],['0']
19787,PMC4392313,1211,"Assays for HDL-associated SAA and serum paraoxonase, secretory phospholipase A2-IIA (sPLA2-IIA), oxidised LDL, d-dimer, fibrinogen, Lp(a) and haptoglobin were performed at Pacific Biomarkers, Inc. (Seattle, Washington, USA).",Methods|Lipid and biomarker assays,[8399],[9208],[9432],[False],[0],[0],[False],['0']
19788,PMC4392313,1212,Specific details are provided as online supplementary material.,Methods|Lipid and biomarker assays,[8401],[9433],[9496],[False],[0],[0],[False],['0']
19789,PMC4392313,1213,Vascular physiology,Methods|Vascular physiology,[8403],[9497],[9516],[False],[0],[0],[False],['0']
19790,PMC4392313,1214,"Arterial stiffness was assessed by PWV according to the manufacturer's instructions using a pulse wave analysis apparatus (SphygmoCor; AtCor, San Jose, California, USA).",Methods|Vascular physiology,[8405],[9517],[9686],[False],[0],[0],[False],['0']
19791,PMC4392313,1215,"Blinded assessors from all centres underwent training with an expert assessor, and certification was provided by AtCor.",Methods|Vascular physiology,[8407],[9687],[9806],[False],[0],[0],[False],['0']
19792,PMC4392313,1216,"All PWV scans were reviewed by AtCor, and only those meeting predetermined quality control measures were accepted for analysis (details in online supplementary material).",Methods|Vascular physiology,[8409],[9807],[9977],[False],[0],[0],[False],['0']
19793,PMC4392313,1217,Statistical analysis,Methods|Statistical analysis,[8411],[9978],[9998],[False],[0],[0],[False],['0']
19794,PMC4392313,1218,The primary objective was to investigate the effect of 12 weeks of treatment with TCZ on PWV and on small LDL particle number assessed by NMR compared with placebo.,Methods|Statistical analysis,[8413],[9999],[10163],[False],[0],[0],[False],['0']
19795,PMC4392313,1219,The secondary objective was to investigate the effect of TCZ compared with placebo on these measurements at week 24.,Methods|Statistical analysis,[8415],[10164],[10280],[False],[0],[0],[False],['0']
19796,PMC4392313,1220,"All other analyses, including lipid and lipoprotein parameters, were exploratory.",Methods|Statistical analysis,[8417],[10281],[10362],[False],[0],[0],[False],['0']
19797,PMC4392313,1221,"A sample size of 120 patients (60 per arm), calculated based on previous results in patients with RA,  was expected to provide sufficient power to detect a difference at week 12 in PWV (−1.14 m/s) and small LDL (−5.51 mg/dL (30% reduction)) in patients treated with TCZ compared with placebo.",Methods|Statistical analysis,[8419],[10363],[10655],[False],[0],[0],[False],['0']
19798,PMC4392313,1222,The co-primary efficacy end points of change from baseline in PWV and small LDL particle number were analysed by parametric analysis of covariance.,Methods|Statistical analysis,[8421],[10656],[10803],[False],[0],[0],[False],['0']
19799,PMC4392313,1223,The 12-week and 24-week efficacy analyses of primary and secondary end points were performed on the intent-to-treat (ITT) population using last-observation-carried-forward to impute missing data at the analysis time point.,Methods|Statistical analysis,[8423],[10804],[11026],[False],[0],[0],[False],['0']
19800,PMC4392313,1224,Only measurements recorded before escape therapy were carried forward.,Methods|Statistical analysis,[8425],[11027],[11097],[False],[0],[0],[False],['0']
19801,PMC4392313,1225,"All other exploratory end points were summarised for the ITT population observed cases, without imputation of missing data and excluding escape data.",Methods|Statistical analysis,[8427],[11098],[11247],[False],[0],[0],[False],['0']
19802,PMC4392313,1226,"All laboratory parameter values were converted to SI units; for lipid parameters, only the latest fasted values within the time window were included.",Methods|Statistical analysis,[8429],[11248],[11397],[False],[0],[0],[False],['0']
19803,PMC4392313,1227,"Assumptions of normality and homogeneity of the variance were assessed by inspecting normal probability plots, plots of standardised residual versus predicted values and plots of standardised residual versus continuous covariates.",Methods|Statistical analysis,[8431],[11398],[11628],[False],[0],[0],[False],['0']
19804,PMC4392313,1228,"Primary end points in the study were analysed based on a normal distribution; however, because baseline values for several laboratory assessments in this study demonstrated non-normal distributions, values for exploratory serum analytes are presented as medians or median percentage changes from baseline.",Methods|Statistical analysis,[8433],[11629],[11934],[False],[0],[0],[False],['0']
19805,PMC4392313,1229,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test.",Methods|Statistical analysis,[8435],[11935],[12042],[False],[0],[0],[False],['0']
19806,PMC4392313,1230,Hodges–Lehmann estimates of location shift and 95% CIs are presented.,Methods|Statistical analysis,[8437],[12043],[12112],[False],[0],[0],[False],['0']
19807,PMC4392313,1231,No adjustments for multiplicity were performed.,Methods|Statistical analysis,[8439],[12113],[12160],[False],[0],[0],[False],['0']
19808,PMC4392313,1232,Results,Results,[8441],[12161],[12169],[False],[0],[0],[False],['0']
19809,PMC4392313,1233,Sixty-nine patients were randomly assigned to receive TCZ+MTX and sixty-three to receive placebo+MTX (figure 1).,Results,[8443],[12170],[12282],[False],[0],[0],[False],['0']
19810,PMC4392313,1234,"Sixty-five and sixty patients, respectively, completed 12 weeks of therapy.",Results,[8445],[12283],[12358],[False],[0],[0],[False],['0']
19811,PMC4392313,1235,"One patient in each arm withdrew because of an adverse event; one patient on placebo withdrew because of insufficient therapeutic response, three patients in the TCZ arm refused treatment and one patient in the TCZ arm was withdrawn because of a protocol violation.",Results,[8447],[12359],[12624],[False],[0],[0],[False],['0']
19812,PMC4392313,1236,"Two patients in the TCZ arm had their lipid-lowering medications changed; though included in the ITT analyses, they were excluded from the per-protocol analyses.",Results,[8449],[12625],[12786],[False],[0],[0],[False],['0']
19813,PMC4392313,1237,"Of 124 patients who completed blinded treatment, 117 elected to continue to the open-label phase; 92 completed treatment for 96 weeks.",Results,[8451],[12787],[12921],[False],[0],[0],[False],['0']
19814,PMC4392313,1238,Demographic and baseline disease characteristics (table 1) were similar to those of the TCZ phase III cohort.,Results,[8453],[12922],[13031],[False],[0],[0],[False],['0']
19815,PMC4392313,1239,"Moreover, 30% and 39% of the patients in the placebo and TCZ arms, respectively, had previously received aTNFs.",Results,[8455],[13032],[13143],[False],[0],[0],[False],['0']
19816,PMC4392313,1240,"TCZ efficacy, assessed by change in disease activity score at 28 joints (DAS28) at weeks 12 and 24 or by ACR 20/50/70 proportional changes at week 24, was similar to that previously observed and differed significantly from that of placebo (see online supplementary figure S1).",Results,[8457],[13144],[13420],[False],[0],[0],[False],['0']
19817,PMC4392313,1241,Adverse events and serious adverse events occurring during the trial were similar to those observed in previous TCZ studies (see online supplementary table S1).,Results,[8459],[13421],[13581],[False],[0],[0],[False],['0']
19818,PMC4392313,1242,Demographic and disease factors at baseline,Results|Demographic and disease factors at baseline,[8461],[13582],[13625],[False],[0],[0],[False],['0']
19819,PMC4392313,1243,"	Placebo+MTX(n=63)*	TCZ+MTX(n=69)	 	Female, n (%)	47 (75)	57 (83)	 	Age, years	57.0 (50.0–64.0)	57.0 (49.0–62.0)	 	Weight, kg	82.0 (65.0–92.1)	77.4 (67.0–86.5)	 	BMI, kg/m2, median (range)	29.2 (18.5–49.6)	29.2 (19.4–57.3)	 	Current smoker, n (%)	14 (22)	19 (28)	 	History of diabetes, n (%)	4 (6)	6 (9)	 	Duration of RA, years	6.8 (2.4–9.9)	7.0 (2.0–16.2)	 	DAS28	6.6 (5.8–7.3)	6.8 (5.9–7.4)	 	CRP, mg/dL	0.88 (0.39–1.86)	0.94 (0.52–2.65)	 	Statin use, n (%)	10 (16)	10 (14)	 	Previous aTNF, n (%)	19 (30)	27 (39)	 	Oral steroid use, n (%)	17 (27)	20 (29)	 	Baseline MTX dose, mg/week	15.0 (15.0–20.0)	15.0 (15.0–20.0)",Results|Demographic and disease factors at baseline,[8463],[13626],[14245],[False],[0],[0],[False],['0']
19820,PMC4392313,1244,Data are presented as median (IQR) unless otherwise indicated.,Results|Demographic and disease factors at baseline,[8465],[14246],[14311],[False],[0],[0],[False],['0']
19821,PMC4392313,1245,*One patient randomly assigned to placebo+MTX actually received one dose of TCZ and was therefore included in the TCZ group for the safety analyses.,Results|Demographic and disease factors at baseline,[8467],[14312],[14460],[False],[0],[0],[False],['0']
19822,PMC4392313,1246,"aTNF, anti-tumour necrosis factor α; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score at 28 joints; MTX, methotrexate; RA, rheumatoid arthritis; TCZ, tocilizumab.",Results|Demographic and disease factors at baseline,[8469],[14461],[14651],[False],[0],[0],[False],['0']
19823,PMC4392313,1247,"Consistent with results from TCZ phase III clinical trials, median total cholesterol and LDL-C levels increased in TCZ recipients but did not change in placebo patients (table 2).",Results|Demographic and disease factors at baseline,[8471],[14652],[14831],[False],[0],[0],[False],['0']
19824,PMC4392313,1248,"In contrast, no statistically significant difference in the co-primary outcome of concentration of small LDL particles was observed at either week 12 (adjusted mean difference −0.0 (95% CI −115.0 to 115.0) nmol/L) or week 24 (adjusted mean difference 11.2 (95% CI −106.7 to 129.1) nmol/L) after treatment with TCZ compared with placebo (figure 2A).",Results|Demographic and disease factors at baseline,[8473],[14832],[15180],[False],[0],[0],[False],['0']
19825,PMC4392313,1249,Oxidised LDL exhibited a 7% increase on TCZ treatment that was not significantly different from the increase observed with placebo and did not persist at week 24 (figure 2B).,Results|Demographic and disease factors at baseline,[8475],[15181],[15355],[False],[0],[0],[False],['0']
19826,PMC4392313,1250,"By contrast, Lp(a) was reduced (by 37%) in TCZ recipients (figure 2C) compared with controls.",Results|Demographic and disease factors at baseline,[8477],[15356],[15449],[False],[0],[0],[False],['0']
19827,PMC4392313,1251,"Percentage change from baseline to week 12 in lipid parameters and lipid particles* (observed cases), ITT population",Results|Demographic and disease factors at baseline,[8479],[15450],[15566],[False],[0],[0],[False],['0']
19828,PMC4392313,1252,	Placebo+MTX(n=63)	TCZ 8 mg/kg+MTX(n=69)	Estimate* (95% CI) p for difference at week 12	 		Actual values	Change from baseline (%)	Actual values	Change from baseline (%)	 		n	Median	IQR	n†	Median	IQR	n	Median	IQR	n†	Median	IQR	 	Total cholesterol (mmol/L)												 	 Baseline	58	4.8	4.3–5.5	55	–	–	64	4.7	4.2–5.3	56	–	–		 	 Week 12	60	4.8	4.4–5.8	55	1.7	–9.0–11.6	60	5.3	4.6–6.1	56	12.6	–0.5–23.9	10.4 (4.8 to 16.9)p=0.0004	 	LDL-C (mmol/L)												 	 Baseline	55	3.1	2.5–3.5	50	–	–	56	2.8	2.4–3.4	48	–	–		 	 Week 12	56	3.1	2.5–3.8	50	–1.9	–8.7–12.7	57	3.1	2.5–3.8	48	10.6	1.0–28.9	11.0(3.8 to 18.6)p=0.0076	 	HDL-C (mmol/L)												 	 Baseline	58	1.3	1.1–1.6	54	–	–	62	1.3	1.1–1.6	53	–	–		 	 Week 12	60	1.4	1.1–1.6	54	2.4	–10.2–9.3	60	1.5	1.2–1.6	53	3.1	–6.6–12.7	3.0 (–2.4 to 8.6)p=0.2753	 	Triglycerides (mmol/L)												 	 Baseline	58	1.3	1.1–1.9	55	–	–	64	1.2	1.0–1.8	56	–	–		 	 Week 12	60	1.2	1.1–1.7	55	2.2	–18.7–18.7	60	1.5	1.1–2.3	56	28.1	–1.7–63.5	25.4 (10.1 to 40.8)p=0.0011	 	Total cholesterol/HDL (ratio)											 	 Baseline	58	3.8	3.2–4.4	55	–	–	62	3.6	2.8–4.5	54	–	–		 	 Week 12	60	3.9	3.2–4.8	55	0.9	–7.5–7.9	60	3.9	3.1–4.4	54	11.3	2.0–19.4	9.7 (4.3 to 14.5)p=0.0008	 	ApoB/ApoA1 (ratio)												 	 Baseline	58	0.67	0.57–0.77	55	–	–	64	0.68	0.49–0.80	56	–	–		 	 Week 12	60	0.70	0.56–0.79	55	2.5	–7.8–11.0	60	0.67	0.52–0.75	56	4.7	–4.2–15.8	2.1(–4.1 to 7.9)p=0.5108	 	Large VLDL/chylomicrons (nmol/L)											 	 Baseline	59	1.1	0.5–2.8	53	–	–	63	1.3	0.20–4.30	51	–	–		 	 Week 12	60	1.2	0.3–4.1	53	0.0	–50.0–67.5	59	3.7	1.30–7.40	51	205.6	0.0–700.0	167.5 (68.5 to 280.6)p<0.0001	 	Medium VLDL/chylomicrons (nmol/L)											 	 Baseline	59	22.1	12.0–38.3	56	–	–	63	22.0	11.0–32.7	55	–	–		 	 Week 12	60	21.9	12.1–30.5	56	–2.1	–31.8–56.0	59	28.2	17.2–47.4	55	57.7	–19.1–123.6	41.3(9.2 to 77.5)p=0.0088	 	Small VLDL/chylomicrons (nmol/L)											 	 Baseline	59	35.6	29.1–48.1	56	–	–	63	30.4	18.7–40.0	55	–	–		 	 Week 12	60	36.2	26.2–46.2	56	–6.1	–25.1–17.9	59	40.1	26.5–57.2	55	31.4	10.2–91.5	42.3 (24.1 to 60.5)p<0.0001	 	IDL particles (nmol/L)											 	 Baseline	59	33.0	9.0–57.0	51	–	–	63	31.0	7.0–71.0	46	–	–		 	 Week 12	60	36.0	9.0–59.5	51	–9.4	–49.6–133.3	59	39.0	11.0–92.0	46	33.5	–60.9–222.6	14.3 (–37.3 to 70.0)p=0.5853	 	Large LDL particles (nmol/L)											 	 Baseline	59	396.0	261.0–508.0	56	–	–	63	405.0	253.0–535.0	55	–	–		 	 Week 12	60	479.5	331.5–544.5	56	13.2	–9.4–35.3	59	495.0	306.0–605.0	55	18.6	–18.6–46.9	–0.16 (–17.9 to 17.2)p=0.9718	 	Large HDL particles (µmol/L)											 	 Baseline	59	6.9	4.7–9.9	56	–	–	63	7.0	4.6–10.6	55	–	–		 	 Week 12	60	7.8	5.5–11.0	56	1.8	–15.5–13.4	59	8.4	5.3–11.6	55	5.6	–8.6–23.7	4.8 (–5.9 to 15.1)p=0.4140	 	Medium HDL particles (µmol/L)											 	 Baseline	59	3.0	0.5–6.4	46	–	–	63	4.8	1.9–7.6	52	–	–		 	 Week 12	60	3.2	1.5–7.4	46	2.0	–30.4–56.5	59	4.2	1.2–7.5	52	–25.0	–71.5–25.8	–30.7 (–61.3 to –0.23)p=0.0454	 	Small HDL particles (µmol/L)											 	 Baseline	59	19.9	14.9–24.0	56	–	–	63	17.4	13.0–21.1	55	–	–		 	 Week 12	60	20.7	13.1–23.1	56	2.8	–10.8–21.9	59	20.9	18.2–25.7	55	23.0	0.0–55.4	20.3 (7.9 to 34.0)p=0.0012,Results|Demographic and disease factors at baseline,[8481],[15567],[18685],[False],[0],[0],[False],['0']
19829,PMC4392313,1253,Data were missing at time points (including baseline) for some parameters.,Results|Demographic and disease factors at baseline,[8483],[18686],[18763],[False],[0],[0],[False],['0']
19830,PMC4392313,1254,All values have been converted to SI units.,Results|Demographic and disease factors at baseline,[8485],[18764],[18807],[False],[0],[0],[False],['0']
19831,PMC4392313,1255,No imputation was used for missing values.,Results|Demographic and disease factors at baseline,[8487],[18808],[18850],[False],[0],[0],[False],['0']
19832,PMC4392313,1256,Only the latest fasted values within the time window are included.,Results|Demographic and disease factors at baseline,[8489],[18851],[18917],[False],[0],[0],[False],['0']
19833,PMC4392313,1257,*Hodges–Lehmann estimate of location shift (pseudo-median).,Results|Demographic and disease factors at baseline,[8491],[18918],[18977],[False],[0],[0],[False],['0']
19834,PMC4392313,1258,p was calculated from Kruskal–Wallis test.,Results|Demographic and disease factors at baseline,[8493],[18978],[19020],[False],[0],[0],[False],['0']
19835,PMC4392313,1259,†Percentage change from baseline values includes only patients with both baseline and 12-week values.,Results|Demographic and disease factors at baseline,[8495],[19021],[19122],[False],[0],[0],[False],['0']
19836,PMC4392313,1260,"Apo, apolipoprotein; C, cholesterol; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; ITT, intent-to-treat; LDL, low-density lipoprotein; MTX, methotrexate; TCZ, tocilizumab; VLDL, very low-density lipoprotein.",Results|Demographic and disease factors at baseline,[8497],[19123],[19354],[False],[0],[0],[False],['0']
19837,PMC4392313,1261,(A–F) Effects on lipoproteins (TCZ vs placebo).,Results|Demographic and disease factors at baseline,[8499],[19355],[19402],[False],[0],[0],[False],['0']
19838,PMC4392313,1262,"HDL, high-density lipoprotein; LDL, low-density lipoprotein; MTX, methotrexate; SAA, serum amyloid A; sPLA2-IIA, secretory phospholipase A2-IIA; TCZ, tocilizumab.",Results|Demographic and disease factors at baseline,[8501],[19403],[19565],[False],[0],[0],[False],['0']
19839,PMC4392313,1263,*p<0.0001 (TCZ vs placebo).,Results|Demographic and disease factors at baseline,[8503],[19566],[19593],[False],[0],[0],[False],['0']
19840,PMC4392313,1264,"Measurement of change in PWV (second co-primary outcome) over 12 weeks revealed a significant difference between groups (adjusted mean difference 0.79 m/s (95% CI 0.22 to 1.35; p=0.0067)), constituting a greater relative reduction in PWV in placebo compared with TCZ-treated patients (−0.99 vs −0.21 m/s).",Results|Demographic and disease factors at baseline,[8505],[19594],[19899],[False],[0],[0],[False],['0']
19841,PMC4392313,1265,The group difference was not sustained to week 24 (−0.47 vs −0.17 m/s; adjusted mean difference 0.30 m/s (95% CI −0.27 to 0.87; p=0.30)) (table 3).,Results|Demographic and disease factors at baseline,[8507],[19900],[20047],[False],[0],[0],[False],['0']
19842,PMC4392313,1266,Technical challenges across sites were recorded in a substantial number of case report forms.,Results|Demographic and disease factors at baseline,[8509],[20048],[20141],[False],[0],[0],[False],['0']
19843,PMC4392313,1267,There was no evidence of change in blood pressure by treatment arm before or after infusions (data available on request).,Results|Demographic and disease factors at baseline,[8511],[20142],[20263],[False],[0],[0],[False],['0']
19844,PMC4392313,1268,Ten (17.5%) patients who received placebo and nine (15.5%) who received TCZ did not meet the quality control standards established for all measured PWV parameters.,Results|Demographic and disease factors at baseline,[8513],[20264],[20427],[False],[0],[0],[False],['0']
19845,PMC4392313,1269,"Change from baseline in PWV (LOCF), ITT population",Results|Demographic and disease factors at baseline,[8515],[20428],[20478],[False],[0],[0],[False],['0']
19846,PMC4392313,1270,"	Placebo+MTX(n=63)	TCZ 8 mg/kg+MTX(n=69)	95% CI (p) for difference	 	Baseline	 	 n	59	69		 	 Mean (SD) PWV, m/s	9.0 (2.5)	9.0 (2.0)		 	Week 12	 	 n	62	69		 	 Mean (SD) PWV, m/s	8.4 (1.8)	8.9 (2.5)		 	 Mean change from baseline in PWV, m/s	–0.99	–0.21	0.22 to 1.35 (p=0.0067)	 	Week 24	 	 n	62	69		 	 Mean (SD) PWV, m/s	8.9 (2.0)	9.0 (2.3)		 	 Mean change from baseline in PWV, m/s	–0.47	–0.17	–0.27 to 0.87 (p=0.3042)",Results|Demographic and disease factors at baseline,[8517],[20479],[20896],[False],[0],[0],[False],['0']
19847,PMC4392313,1271,LOCF was used for missing values.,Results|Demographic and disease factors at baseline,[8519],[20897],[20933],[False],[0],[0],[False],['0']
19848,PMC4392313,1272,Only postbaseline and pre-escape therapy scores were carried forward.,Results|Demographic and disease factors at baseline,[8521],[20934],[21003],[False],[0],[0],[False],['0']
19849,PMC4392313,1273,All assessments were set to missing from the time of escape therapy.,Results|Demographic and disease factors at baseline,[8523],[21004],[21072],[False],[0],[0],[False],['0']
19850,PMC4392313,1274,"Mean change from baseline was adjusted for baseline age, C-reactive protein level and mean arterial pressure.",Results|Demographic and disease factors at baseline,[8525],[21073],[21182],[False],[0],[0],[False],['0']
19851,PMC4392313,1275,"ITT, intent-to-treat; LOCF, last-observation-carried-forward; MTX, methotrexate; PWV, pulse wave velocity; TCZ, tocilizumab.",Results|Demographic and disease factors at baseline,[8527],[21183],[21307],[False],[0],[0],[False],['0']
19852,PMC4392313,1276,No statistically significant changes occurred in total serum HDL-C levels in the study.,Results|Demographic and disease factors at baseline,[8529],[21308],[21395],[False],[0],[0],[False],['0']
19853,PMC4392313,1277,"NMR evaluation of HDL, however, revealed differential effects of TCZ versus placebo across particle sizes, with observed elevations in small HDL concentration and reductions in medium HDL (table 2).",Results|Demographic and disease factors at baseline,[8531],[21396],[21594],[False],[0],[0],[False],['0']
19854,PMC4392313,1278,A significant reduction (by 78%) was observed in the TCZ arm for HDL-associated SAA.,Results|Demographic and disease factors at baseline,[8533],[21595],[21679],[False],[0],[0],[False],['0']
19855,PMC4392313,1279,"In contrast, a significant increase (by 16%) was noted in the antioxidative enzyme paraoxonase I, which is almost exclusively carried in serum HDL (figure 2D–F).",Results|Demographic and disease factors at baseline,[8535],[21680],[21841],[False],[0],[0],[False],['0']
19856,PMC4392313,1280,sPLA2-IIA was reduced (by 61%) in TCZ recipients.,Results|Demographic and disease factors at baseline,[8537],[21842],[21891],[False],[0],[0],[False],['0']
19857,PMC4392313,1281,No changes were observed in the control population in these biomarkers.,Results|Demographic and disease factors at baseline,[8539],[21892],[21963],[False],[0],[0],[False],['0']
19858,PMC4392313,1282,Alterations occurred rapidly (by week 2) and were sustained throughout therapy.,Results|Demographic and disease factors at baseline,[8541],[21964],[22043],[False],[0],[0],[False],['0']
19859,PMC4392313,1283,Results of NMR subfractionation of other lipoprotein subclasses are shown in table 2.,Results|Demographic and disease factors at baseline,[8543],[22044],[22129],[False],[0],[0],[False],['0']
19860,PMC4392313,1284,"In patients treated with TCZ, changes in very low-density lipoprotein (VLDL) subclasses were elevated compared with placebo, with changes in the largest components of the VLDL subclasses most notable, though they constituted a small proportion of the total VLDL particles.",Results|Demographic and disease factors at baseline,[8545],[22130],[22402],[False],[0],[0],[False],['0']
19861,PMC4392313,1285,"Similarly, no significant changes in the concentrations of intermediate, buoyant particles (large LDL and intermediate-density lipoprotein) occurred in TCZ-treated patients compared with placebo patients.",Results|Demographic and disease factors at baseline,[8547],[22403],[22607],[False],[0],[0],[False],['0']
19862,PMC4392313,1286,Median triglyceride levels increased in TCZ-treated patients but did not change in placebo patients.,Results|Demographic and disease factors at baseline,[8549],[22608],[22708],[False],[0],[0],[False],['0']
19863,PMC4392313,1287,"Markers of inflammation, including CRP and haptoglobin, were elevated at baseline and markedly reduced within the first week of TCZ treatment (figure 3).",Results|Demographic and disease factors at baseline,[8551],[22709],[22862],[False],[0],[0],[False],['0']
19864,PMC4392313,1288,"Similarly, rapid and sustained reductions in fibrinogen (by 47% from baseline) and d-dimer (by 62% from baseline) were observed in recipients of TCZ, whereas no changes were observed in the control arm (figure 3).",Results|Demographic and disease factors at baseline,[8553],[22863],[23076],[False],[0],[0],[False],['0']
19865,PMC4392313,1289,All changes remained stable throughout TCZ treatment.,Results|Demographic and disease factors at baseline,[8555],[23077],[23130],[False],[0],[0],[False],['0']
19866,PMC4392313,1290,"Finally, the ApoB/ApoA1 ratio did not change throughout the study in either group (table 2).",Results|Demographic and disease factors at baseline,[8557],[23131],[23223],[False],[0],[0],[False],['0']
19867,PMC4392313,1291,(A–D) Effects on inflammatory and thrombotic markers (TCZ vs placebo).,Results|Demographic and disease factors at baseline,[8559],[23224],[23294],[False],[0],[0],[False],['0']
19868,PMC4392313,1292,"hs-CRP, high-sensitivity C-reactive protein; MTX, methotrexate; TCZ, tocilizumab.",Results|Demographic and disease factors at baseline,[8561],[23295],[23376],[False],[0],[0],[False],['0']
19869,PMC4392313,1293,*p<0.0001 (TCZ vs placebo).,Results|Demographic and disease factors at baseline,[8563],[23377],[23404],[False],[0],[0],[False],['0']
19870,PMC4392313,1294,Discussion,Discussion,[8565],[23405],[23416],[False],[0],[0],[False],['0']
19871,PMC4392313,1295,"We herein tested the primary hypotheses that TCZ in comparison to placebo would significantly lower PWV and the amount of small, dense LDL.",Discussion,[8567],[23417],[23556],[False],[0],[0],[False],['0']
19872,PMC4392313,1296,"However, neither hypothesis was supported.",Discussion,[8569],[23557],[23599],[False],[0],[0],[False],['0']
19873,PMC4392313,1297,"There was no change in the amount of small, dense LDL, and though PWV declined in both groups it did so more in placebo recipients.",Discussion,[8571],[23600],[23731],[False],[0],[0],[False],['0']
19874,PMC4392313,1298,We also performed extensive additional analyses to investigate the wider impact of IL-6R inhibition on a range of vascular risk factors.,Discussion,[8573],[23732],[23868],[False],[0],[0],[False],['0']
19875,PMC4392313,1299,"Thus, we report that TCZ did modulate lipid particle levels (LDL, HDL, VLDL) and composition (HDL-associated SAA), together with a number of other inflammatory (CRP, paraoxonase) and vascular (Lp(a), D-dimer, fibrinogen) risk factors, suggesting potential modulation of the net atherogenic risk profile.",Discussion,[8575],[23869],[24172],[False],[0],[0],[False],['0']
19876,PMC4392313,1300,"Consistent with results from other TCZ phase III clinical trials, total cholesterol, LDL-C and triglyceride levels increased in TCZ-treated patients but were minimally changed in placebo patients.",Discussion,[8577],[24173],[24369],[False],[0],[0],[False],['0']
19877,PMC4392313,1301,"In contrast, small LDL particle concentrations, considered proatherogenic, remained similar in TCZ-treated and placebo patients.",Discussion,[8579],[24370],[24498],[False],[0],[0],[False],['0']
19878,PMC4392313,1302,"Moreover, we observed a decrease (>30%) in Lp(a), a risk factor independently associated with vascular events.",Discussion,[8581],[24499],[24609],[False],[0],[0],[False],['0']
19879,PMC4392313,1303,"NMR assessment of lipoprotein subclasses revealed clear and sizeable changes in all classes of VLDL particles, the functional significance of which is yet unclear.",Discussion,[8583],[24610],[24773],[False],[0],[0],[False],['0']
19880,PMC4392313,1304,"By contrast, we did not see a reduction in PWV with TCZ but rather a significant reduction in the placebo group at 12 weeks relative to TCZ recipients, though this pattern was not sustained to the 24-week measurement.",Discussion,[8585],[24774],[24991],[False],[0],[0],[False],['0']
19881,PMC4392313,1305,"This finding, therefore, contradicts our original hypothesis.",Discussion,[8587],[24992],[25053],[False],[0],[0],[False],['0']
19882,PMC4392313,1306,"It should be noted, however, that technical challenges during the conduct of this multicentre trial led to approximately 15% of the measurements being substandard.",Discussion,[8589],[25054],[25217],[True],['PrecisionOfMeasurement'],['approximately 15% of the measurements being substandard'],[True],['OutcomeMeasures']
19883,PMC4392313,1307,"Because of the severity of disease in study participants who had reduced mobility, contractures and joint pain, the procedure proved more difficult than anticipated.",Discussion,[8594],[25218],[25383],[True],['OutcomeMeasures'],['the procedure proved more difficult than anticipated'],[True],['OutcomeMeasures']
19884,PMC4392313,1308,"Nevertheless, it appears that PWV is not necessarily reduced with TCZ, though further studies with other vascular function measures not influenced by limited mobility (eg, peripheral arterial tonometry as a measure of endothelial function) would be useful.",Discussion,[8597],[25384],[25640],[False],[0],[0],[False],['0']
19885,PMC4392313,1309,"Our findings contrast with those of Kume et al, who observed similar reductions in cardio-ankle vascular index and aortic augmentation index for patients treated with TCZ, adalimumab or etanercept.",Discussion,[8599],[25641],[25838],[False],[0],[0],[False],['0']
19886,PMC4392313,1310,"Speculatively, it remains possible that disease-related vascular changes in patients in the present study (in which mean DAS28 was high) were much more progressed (and, thus, less reversible) than in patients studied in other trials.",Discussion,[8601],[25839],[26072],[False],[0],[0],[False],['0']
19887,PMC4392313,1311,"Increases in HDL particle number, measured by NMR, occurred primarily in small particles.",Discussion,[8603],[26073],[26163],[False],[0],[0],[False],['0']
19888,PMC4392313,1312,Our demonstration of a significant increase in the concentration of small HDL particles with TCZ treatment is consistent with a potential ‘normalisation’ of small HDL particle levels.,Discussion,[8605],[26164],[26347],[False],[0],[0],[False],['0']
19889,PMC4392313,1313,"Small HDL particle numbers, measured by NMR, in two independent studies were lower in RA patients than in controls despite similar HDL-C concentrations.",Discussion,[8607],[26348],[26500],[False],[0],[0],[False],['0']
19890,PMC4392313,1314,"Furthermore, the observed significant reduction in medium HDL and HDL-SAA concentrations, along with the increase in paraoxonase, an antioxidant enzyme associated with HDL, suggests remodelling of HDL particles from a pro-inflammatory to an anti-inflammatory phenotype in response to TCZ treatment.",Discussion,[8609],[26501],[26799],[False],[0],[0],[False],['0']
19891,PMC4392313,1315,"Overall, such changes in HDL particle composition with TCZ are consistent with the results of a recent study of aTNFs in patients with ankylosing spondylitis.",Discussion,[8611],[26800],[26958],[False],[0],[0],[False],['0']
19892,PMC4392313,1316,"Although it is unclear to what extent small HDL particles measured by NMR corroborate with those measured by other methods, small HDL particles may be more active in cholesterol efflux and anti-inflammatory functions, though this observation remains debated.",Discussion,[8613],[26959],[27217],[False],[0],[0],[False],['0']
19893,PMC4392313,1317,Previous studies have demonstrated lower levels of LDL-C in patients with active RA than in controls.,Discussion,[8615],[27218],[27320],[False],[0],[0],[False],['0']
19894,PMC4392313,1318,"Such decreases may result from increased catabolism (including by scavenger receptors), increased particle retention in tissue, or both, rather than from decreased lipid production.",Discussion,[8617],[27321],[27502],[False],[0],[0],[False],['0']
19895,PMC4392313,1319,"Increased cholesterol retention under conditions of elevated IL-6/IL-6R levels have been hypothesised to result from increased surface density on multiple tissues of LDL receptor, VLDL receptor and scavenger receptors, leading to excess internalisation of VLDL and LDL.",Discussion,[8619],[27503],[27772],[False],[0],[0],[False],['0']
19896,PMC4392313,1320,"Furthermore, sPLA2-IIA expression, augmented by IL-6, leads to phospholipid hydrolysis of LDL and increases LDL uptake in tissues.",Discussion,[8621],[27773],[27903],[False],[0],[0],[False],['0']
19897,PMC4392313,1321,"Consistent with our results and the TCZ phase III programme, the TCZ-based IL-6 signal inhibition may reduce various receptor surface levels and sPLA2-IIA levels, leading to both decreased LDL and VLDL tissue retention and elevated circulating levels.",Discussion,[8623],[27904],[28155],[False],[0],[0],[False],['0']
19898,PMC4392313,1322,Decreased thrombotic potential in TCZ-treated RA patients is indicated by declines in circulating fibrinogen and D-dimer levels.,Discussion,[8625],[28156],[28284],[False],[0],[0],[False],['0']
19899,PMC4392313,1323,"Although the reduction in fibrinogen, an acute-phase protein, with TCZ is predictable, the reduction of D-dimer is of particular interest because it represents the most widely used clinical marker of activated blood coagulation.",Discussion,[8627],[28285],[28513],[False],[0],[0],[False],['0']
19900,PMC4392313,1324,"Moreover, several prospective studies  have linked elevated D-dimer levels to heightened risk for vascular events independently of established risk factors.",Discussion,[8629],[28514],[28670],[False],[0],[0],[False],['0']
19901,PMC4392313,1325,"Similarly, the sizeable reduction in Lp(a) observed with TCZ is of considerable interest because recent genetic and epidemiological evidence suggests Lp(a) is causally linked to cardiovascular events in the general population.",Discussion,[8631],[28671],[28897],[False],[0],[0],[False],['0']
19902,PMC4392313,1326,"Our Lp(a) observations also extend findings from an earlier randomised, placebo-controlled study linking aTNF blockade to dose-dependent reductions in Lp(a) in patients with psoriatic arthritis.",Discussion,[8633],[28898],[29092],[False],[0],[0],[False],['0']
19903,PMC4392313,1327,"Collectively, these changes suggest a reduction in thrombotic potential with TCZ in patients with active RA.",Discussion,[8635],[29093],[29201],[False],[0],[0],[False],['0']
19904,PMC4392313,1328,"Of course, the net effect of TCZ-induced changes to vascular outcomes can be robustly tested only in the context of vascular outcomes in prospective studies.",Discussion,[8637],[29202],[29359],[False],[0],[0],[False],['0']
19905,PMC4392313,1329,"In summary, the results of this randomised, placebo-controlled study suggest that IL-6R blockade with TCZ in patients with active RA not only reduces markers of inflammation but also affects quantitative and qualitative changes in lipids and lipoproteins.",Discussion,[8639],[29360],[29616],[False],[0],[0],[False],['0']
19906,PMC4392313,1330,"Such changes include a global increase in LDL-C concentration, in line with findings from other biological studies, and apparently favourable changes to HDL particle composition, rendering them less pro-inflammatory.",Discussion,[8641],[29617],[29833],[False],[0],[0],[False],['0']
19907,PMC4392313,1331,"In addition, marked reductions in haemostatic and Lp(a) markers were observed, though PWV did not change favourably.",Discussion,[8643],[29834],[29950],[False],[0],[0],[False],['0']
19908,PMC4392313,1332,"Future determination of the net vascular effect of such changes in RA patients—and potentially other groups of patients— is of major interest, particularly given the recent data from large-scale (>130 000 subjects, >25 000 coronary heart disease cases) genome-wide association studies  that suggest a potentially detrimental effect of IL-6R signalling on the risk for coronary heart disease.",Discussion,[8645],[29951],[30342],[False],[0],[0],[False],['0']
19909,PMC4392313,1333,Supplementary Material,Supplementary Material,[8647],[30343],[30366],[False],[0],[0],[False],['0']
19910,PMC4392313,1334,"Contributors: IBM was involved in the design of the study, conducting the research, analysis and interpretation of the data, drafting of the manuscript, and approval of the final draft to be published.",Supplementary Material,[8649],[30367],[30568],[False],[0],[0],[False],['0']
19911,PMC4392313,1335,"LT was involved in the design of the study, data collection, analysis and interpretation of the data, drafting of the manuscript and approval of the final draft to be published.",Supplementary Material,[8651],[30569],[30746],[False],[0],[0],[False],['0']
19912,PMC4392313,1336,"JTG was involved in conducting the research, analysis and interpretation of data, drafting of the manuscript and approval of the final draft to be published.",Supplementary Material,[8653],[30747],[30904],[False],[0],[0],[False],['0']
19913,PMC4392313,1337,"JMB and JSL were involved in the design of the study, analysis and interpretation of the data, drafting of the manuscript and approval of the final draft to be published.",Supplementary Material,[8655],[30905],[31075],[False],[0],[0],[False],['0']
19914,PMC4392313,1338,"JES and NS were involved in the design of the study, drafting of the manuscript, and approval of the final draft to be published.",Supplementary Material,[8657],[31076],[31205],[False],[0],[0],[False],['0']
19915,PMC4392313,1339,"ADB was involved in conducting the research, drafting of the manuscript and approval of the final draft to be published.",Supplementary Material,[8659],[31206],[31326],[False],[0],[0],[False],['0']
19916,PMC4392313,1340,"CEC was involved in conducting the research, review and revision of the manuscript, and approval of the final draft to be published.",Supplementary Material,[8661],[31327],[31459],[False],[0],[0],[False],['0']
19917,PMC4392313,1341,"THC was involved in the design of the study, conducting the research, drafting of the manuscript and approval of the final draft to be published.",Supplementary Material,[8663],[31460],[31605],[False],[0],[0],[False],['0']
19918,PMC4392313,1342,"CD was involved in the design of the study, conducting the research, analysis and interpretation of the data, review and revision of the manuscript, and approval of the final draft to be published.",Supplementary Material,[8665],[31606],[31803],[False],[0],[0],[False],['0']
19919,PMC4392313,1343,NS was also involved in analysis and interpretation of the data.,Supplementary Material,[8667],[31804],[31868],[False],[0],[0],[False],['0']
19920,PMC4392313,1344,Funding: This study was funded by Roche.,Supplementary Material,[8669],[31869],[31909],[False],[0],[0],[False],['0']
19921,PMC4392313,1345,"F. Hoffmann-La Roche was responsible for the study design together with several authors, principally IBM, JSL and NS.",Supplementary Material,[8671],[31910],[32027],[False],[0],[0],[False],['0']
19922,PMC4392313,1346,The other authors contributed to data interpretation and were responsible for the writing and review of the manuscript.,Supplementary Material,[8673],[32028],[32147],[False],[0],[0],[False],['0']
19923,PMC4392313,1347,The lead author had the final responsibility for the decision to submit the manuscript for publication.,Supplementary Material,[8675],[32148],[32251],[False],[0],[0],[False],['0']
19924,PMC4392313,1348,"Competing interests: IBM: research grants and honoraria from Roche, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, Abbott.",Supplementary Material,[8677],[32252],[32378],[False],[0],[0],[False],['0']
19925,PMC4392313,1349,LT: employee of Roche Products Ltd. JTG: consultant to Roche.,Supplementary Material,[8679],[32379],[32440],[False],[0],[0],[False],['0']
19926,PMC4392313,1350,"JES: consultant to Quidel and Alexion Pharmaceuticals, served on advisory board for Bristol-Myers Squibb, research grants to Hospital for Special Surgery from F. Hoffmann-La Roche and the National Institutes of Health.",Supplementary Material,[8681],[32441],[32659],[False],[0],[0],[False],['0']
19927,PMC4392313,1351,ADB: research grant from Roche.,Supplementary Material,[8683],[32660],[32691],[False],[0],[0],[False],['0']
19928,PMC4392313,1352,CEC: research grant to institution for study participation.,Supplementary Material,[8685],[32692],[32751],[False],[0],[0],[False],['0']
19929,PMC4392313,1353,JSL: employee of Roche.,Supplementary Material,[8687],[32752],[32775],[False],[0],[0],[False],['0']
19930,PMC4392313,1354,NS: consultant to and on speaker's bureau for Roche.,Supplementary Material,[8689],[32776],[32828],[False],[0],[0],[False],['0']
19931,PMC4392313,1355,Patient consent: Obtained.,Supplementary Material,[8691],[32829],[32855],[False],[0],[0],[False],['0']
19932,PMC4392313,1356,"Ethics approval: The trial was approved by an independent Ethics Committee or Institutional Review Board, and all patients gave written informed consent for participation in the trial.",Supplementary Material,[8693],[32856],[33040],[False],[0],[0],[False],['0']
19933,PMC4392313,1357,"This two-arm, randomised, multicentre, double-blind, placebo-controlled, parallel-group, phase III study was conducted in the USA, Canada and the UK (figure 1) at 34 sites (the MEASURE study).",Supplementary Material,[8695],[33041],[33233],[False],[0],[0],[False],['0']
19934,PMC4392313,1358,Provenance and peer review: Not commissioned; externally peer reviewed.,Supplementary Material,[8697],[33234],[33305],[False],[0],[0],[False],['0']
19935,PMC4392313,1359,"Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.",Supplementary Material,[8699],[33306],[33672],[False],[0],[0],[False],['0']
19936,PMC4392313,1360,See: http://creativecommons.org/licenses/by-nc/3.0/,Supplementary Material,[8701],[33673],[33724],[False],[0],[0],[False],['0']
21907,PMC4553934,11349,Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial,Title,[68948],[24256],[122],[False],[0],[0],[False],['0']
21908,PMC4553934,11350,Background,Abstract,[68951],[123],[134],[False],[0],[0],[False],['0']
21909,PMC4553934,11351,Pollen extracts and chemically modified allergoids are used successfully in allergen immunotherapy (AIT).,Abstract,[68954],[135],[240],[False],[0],[0],[False],['0']
21910,PMC4553934,11352,"Recombinant extracts offer potential advantages with respect to pharmaceutical quality, standardization and dosing.",Abstract,[68957],[241],[356],[False],[0],[0],[False],['0']
21911,PMC4553934,11353,A hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV) was compared with an established native birch preparation.,Abstract,[68960],[357],[509],[False],[0],[0],[False],['0']
21912,PMC4553934,11354,"A pre-seasonal, randomized, actively controlled phase II study was performed in birch pollen allergic rhino-conjunctivitis with or without asthma, GINA I/ II.",Abstract,[68963],[510],[668],[False],[0],[0],[False],['0']
21913,PMC4553934,11355,"51 patients (24 rBet v 1-FV, 27 native extract) started therapy with subcutaneous allergen immunotherapy (SCIT).",Abstract,[68966],[669],[781],[False],[0],[0],[False],['0']
21914,PMC4553934,11356,"Primary end-point was a combined symptom medication score (SMS), changes in nasal provocation test, visual rating score and specific antibody responses secondary end-points.",Abstract,[68969],[782],[955],[False],[0],[0],[False],['0']
21915,PMC4553934,11357,Findings,Findings,[68972],[956],[965],[False],[0],[0],[False],['0']
21916,PMC4553934,11358,After one pre-seasonal treatment course the combined SMS was 5.86 (median; IQR: 14.02) for the rBet v 1-FV group versus 12.40 (median; IQR: 9.32) for the comparator during the three weeks pollen season (p = 0.330).,Findings,[68975],[966],[1180],[False],[0],[0],[False],['0']
21917,PMC4553934,11359,"After treatment in the second year, scores were 3.00 (median; IQR: 6.50) and 2.93 (4.86) respectively.",Findings,[68978],[1181],[1283],[False],[0],[0],[False],['0']
21918,PMC4553934,11360,Allergen tolerance in a nasal provocation test improved to a comparable extent in both groups.,Findings,[68981],[1284],[1378],[False],[0],[0],[False],['0']
21919,PMC4553934,11361,Significant increases in birch pollen-specific IgG1 and IgG4 were observed in both treatment groups following the first treatment phase and remained significantly raised until the end of the study.,Findings,[68984],[1379],[1576],[False],[0],[0],[False],['0']
21920,PMC4553934,11362,Conclusion,Conclusion,[68987],[1577],[1588],[False],[0],[0],[False],['0']
21921,PMC4553934,11363,"In this first in man, proof of concept phase II trial no statistical difference between rBet v 1-FV and an established natural pollen extract could be observed.",Conclusion,[68990],[1589],[1749],[False],[0],[0],[False],['0']
21922,PMC4553934,11364,rBet v 1-FV could be administered in higher doses than the native protein with no increase in adverse effects.,Conclusion,[68993],[1750],[1860],[False],[0],[0],[False],['0']
21923,PMC4553934,11365,Trial registration,Trial registration,[68996],[1861],[1880],[False],[0],[0],[False],['0']
21924,PMC4553934,11366,The study was registered in clinicalTrials.gov (NCT00266526).,Trial registration,[68999],[1881],[1942],[False],[0],[0],[False],['0']
21925,PMC4553934,11367,Introduction,Introduction,[69002],[1943],[1957],[False],[0],[0],[False],['0']
21926,PMC4553934,11368,Subcutaneous immunotherapy (SCIT) has been shown to be clinically efficacious in numerous controlled clinical studies and is the only curative approach towards allergy treatment recommended in a WHO Position Paper [1].,Introduction,[69005],[1958],[2176],[False],[0],[0],[False],['0']
21927,PMC4553934,11369,"Recombinant preparations are an ideal basis for development of diagnostic and therapeutic preparations, since they are molecularly defined and can be produced in high purity with consistent quality, thereby circumventing many of the difficulties associated with natural allergen extracts and their standardization.",Introduction,[69008],[2177],[2491],[False],[0],[0],[False],['0']
21928,PMC4553934,11370,"In order to reduce the risk of IgE-mediated therapy-induced side effects a folding variant of recombinant Bet v 1 (rBet v 1-FV), the major birch pollen allergen, has been developed [2].",Introduction,[69011],[2492],[2677],[False],[0],[0],[False],['0']
21929,PMC4553934,11371,"This is the first report of a randomized, controlled, proof of concept study comparing two pre-seasonal treatment courses of SCIT with either rBet v 1-FV or an approved native birch pollen depot extract.",Introduction,[69014],[2678],[2881],[False],[0],[0],[False],['0']
21930,PMC4553934,11372,"The objective of the study was to determine the safety and efficacy of the recombinant preparation, and to investigate whether treatment with a single major allergen as opposed to a whole extract can be clinically effective.",Introduction,[69017],[2882],[3106],[False],[0],[0],[False],['0']
21931,PMC4553934,11373,The publication is performed according to CONSORT guidelines.,Introduction,[69020],[3107],[3168],[False],[0],[0],[False],['0']
21932,PMC4553934,11374,Materials and methods,Materials and methods,[69023],[3169],[3191],[False],[0],[0],[False],['0']
21933,PMC4553934,11375,The study was performed in accordance with the Guidelines for Good Clinical Practice [3] and approval of local ethics committees.,Materials and methods,[69026],[3192],[3321],[False],[0],[0],[False],['0']
21934,PMC4553934,11376,Treatment was conducted between October and March in two consecutive years.,Materials and methods,[69029],[3322],[3397],[False],[0],[0],[False],['0']
21935,PMC4553934,11377,"Dosage was increased progressively with 8 injections of aluminum hydroxide adsorbed rBet v 1-FV [4] (5 μg/mL Strength A, 100 μg/mL Strength B) at 7-day intervals, cumulative dose 157.5 μg; comparator: 14 injections, 3 strengths (50, 500 and 5,000 (therapeutic units) TU/mL), 16,325 TU, and continued until the onset of the birch pollen seasons.",Materials and methods,[69032],[3398],[3742],[False],[0],[0],[False],['0']
21936,PMC4553934,11378,Fig.,Materials and methods,[69035],[3743],[3747],[False],[0],[0],[False],['0']
21937,PMC4553934,11379,1 Flow chart documenting progress through the study of those patients included in the main data sets.,Materials and methods,[69038],[3748],[3849],[False],[0],[0],[False],['0']
21938,PMC4553934,11380,"Patients with birch pollen rhino-conjunctivitis, with or without asthma (GINA 1 or 2 [5]), requiring medication during the previous pollen season, with positive skin prick test for birch, specific IgE-RAST ≥ 2 (ImmunoCAP®) and a positive nasal provocation test (NPT) [6], fulfilling usual AIT exclusion criteria, were recruited (Fig.",Materials and methods,[69041],[3850],[4183],[False],[0],[0],[False],['0']
21939,PMC4553934,11381,1).,Materials and methods,[69044],[4184],[4187],[False],[0],[0],[False],['0']
21940,PMC4553934,11382,"Determination of outcome measures required that subjects achieved an adequate dose, defined as either at least one injection of the maintenance dose of rBet v 1-FV (strength B/0.8 mL, 80 μg) or 13 injections of the comparator (Novo-Helisen® Depot birch pollen, Allergopharma GmbH & Co. KG) with at least one dose of 2,000 TU.",Materials and methods,[69047],[4188],[4513],[False],[0],[0],[False],['0']
21941,PMC4553934,11383,Table 1 Demographic and baseline data.,Materials and methods,[69050],[4514],[4552],[False],[0],[0],[False],['0']
21942,PMC4553934,11384,"Main data set in the first year: 39 subjects (rBet v 1-FV 22, comparator 17), second year: 17 and 14 of those subjects respectively.",Materials and methods,[69053],[4553],[4685],[False],[0],[0],[False],['0']
21943,PMC4553934,11385,Demographic data is shown in Table 1.,Materials and methods,[69056],[4686],[4723],[False],[0],[0],[False],['0']
21944,PMC4553934,11386,Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA).,Materials and methods,[69059],[4724],[4821],[False],[0],[0],[False],['0']
21945,PMC4553934,11387,"Symptom Medication Score (SMS) in the birch pollen seasons was the primary outcome measure for efficacy, using a validated score [7].",Materials and methods,[69062],[4822],[4955],[False],[0],[0],[False],['0']
21946,PMC4553934,11388,"Subjects had access to short-acting, non-prophylactic symptomatic medication (short-acting topical antihistamine as first-line treatment, oral antihistamine for more severe symptoms; short-acting bronchodilator for asthma and inhaled steroids scored only if dose was changed).",Materials and methods,[69065],[4956],[5232],[False],[0],[0],[False],['0']
21947,PMC4553934,11389,"Final evaluation was based on a 21-day period of main birch pollen exposure (median area under the curve (AUC), 7 days before until 13 days after peak pollen count).",Materials and methods,[69068],[5233],[5398],[False],[0],[0],[False],['0']
21948,PMC4553934,11390,Nasal provocation test was performed at inclusion and prior to the birch pollen seasons according German guideline [6].,Materials and methods,[69071],[5399],[5518],[False],[0],[0],[False],['0']
21949,PMC4553934,11391,Immunoglobulin measurements,Immunoglobulin measurements,[69074],[5519],[5547],[False],[0],[0],[False],['0']
21950,PMC4553934,11392,"Birch pollen, Bet v 1, 2 and 4 specific IgE was measured at inclusion (ImmunoCAP®), birch pollen specific IgG1, IgG4 and IgE responses by ELISA [8]: 1, screening before SCIT; 2, after up-dosing first season; 3, after first pollen season; 4, after up-dosing second season; and 5, after second pollen season.",Immunoglobulin measurements,[69077],[5548],[5854],[False],[0],[0],[False],['0']
21951,PMC4553934,11393,"Pollen counts were provided by the European Aeroallergen Network (https://ean.polleninfo.eu/Ean/, (siegfried.jaeger@meduniwien.ac.at).",Immunoglobulin measurements,[69080],[5855],[5989],[False],[0],[0],[False],['0']
21952,PMC4553934,11394,Reference group,Reference group,[69083],[5990],[6006],[False],[0],[0],[False],['0']
21953,PMC4553934,11395,34 subjects participating in the baseline year of a separate birch pollen SCIT study being conducted under identical conditions in the same geographical region of Germany.,Reference group,[69086],[6007],[6178],[False],[0],[0],[False],['0']
21954,PMC4553934,11396,Statistical analysis,Statistical analysis,[69089],[6179],[6200],[False],[0],[0],[False],['0']
21955,PMC4553934,11397,"The AUC for the treatment groups were compared using confidence intervals to draw conclusions on possible superiority, non-inferiority or equivalence of efficacy.",Statistical analysis,[69092],[6201],[6363],[False],[0],[0],[False],['0']
21956,PMC4553934,11398,"The two-sided Wilcoxon-Mann–Whitney U-Test at α = 0.05 was applied in the analysis of antibody responses using SPSS Version 14.02 (SPSS Inc., Chicago, USA).",Statistical analysis,[69095],[6364],[6520],[False],[0],[0],[False],['0']
21957,PMC4553934,11399,Findings,Findings,[69098],[6521],[6530],[False],[0],[0],[False],['0']
21958,PMC4553934,11400,Application of study medication,Findings|Application of study medication,[69101],[6531],[6562],[False],[0],[0],[False],['0']
21959,PMC4553934,11401,"265 rBet v 1-FV injections were administered during the first treatment year, 228 during 2nd year (median 11 and 12 per patient); comparator 349 and 353 (median 14 and 18).",Findings|Application of study medication,[69104],[6563],[6735],[False],[0],[0],[False],['0']
21960,PMC4553934,11402,"The maximum dose of 80 μg rBet v 1-FV was achieved in 22/24 subjects in the 1st year, one achieved 20 μg, one 4 μg (2nd year: 17 (80 μg), 2 (2 μg)).",Findings|Application of study medication,[69107],[6736],[6884],[False],[0],[0],[False],['0']
21961,PMC4553934,11403,"Only 7/27 subjects achieved the recommended dose of 5,000 TU with the comparator, equivalent to 16 μg natural Bet v 1, 4/27 achieving 4,000 TU, 7/27 3,000 TU, 4/27 2,000 TU and 5/27 1,000 TU or less (2nd year: 18 (5,000 TU), 3 (4,000/3,000/40 TU).",Findings|Application of study medication,[69110],[6885],[7132],[False],[0],[0],[False],['0']
21962,PMC4553934,11404,Symptom medication score (SMS),Symptom medication score (SMS),[69113],[7133],[7164],[False],[0],[0],[False],['0']
21963,PMC4553934,11405,"Table 2 Median AUC of the symptom scores, medication scores and combined SMS for the 21 day observation period during main birch pollen exposure in each of the two seasons.",Symptom medication score (SMS),[69116],[7165],[7337],[False],[0],[0],[False],['0']
21964,PMC4553934,11406,Fig.,Symptom medication score (SMS),[69119],[7338],[7342],[False],[0],[0],[False],['0']
21965,PMC4553934,11407,"2 Course of daily median SMS and median pollen counts during the 21-day observational periods in the birch pollen season after one (above) and two courses (below) of SCIT, respectively.",Symptom medication score (SMS),[69122],[7343],[7528],[False],[0],[0],[False],['0']
21966,PMC4553934,11408,"With a peak pollen count of 834 grains/m3 during the first pollen season the median AUC of SMS for the rBet v 1-FV group was 5.86 (IQR: 14.02), substantially lower than the 12.40 (IQR: 9.32) recorded for the comparator group (p = 0.330), reference group 14.67 (IQR: 13.64) (Table 2 & Fig.",Symptom medication score (SMS),[69125],[7529],[7817],[False],[0],[0],[False],['0']
21967,PMC4553934,11409,2).,Symptom medication score (SMS),[69128],[7818],[7821],[False],[0],[0],[False],['0']
21968,PMC4553934,11410,"Substantial cross-reacting tree pollen counts occurred during the few weeks prior to the 21 day observation period, and probably accounted for the differences in SMS at the beginning of the 21 day observation period (7th April) (Fig.",Symptom medication score (SMS),[69131],[7822],[8055],[False],[0],[0],[False],['0']
21969,PMC4553934,11411,2).,Symptom medication score (SMS),[69134],[8056],[8059],[False],[0],[0],[False],['0']
21970,PMC4553934,11412,"The median SMS values for the three groups on 15th March, the first day on which data was collected, were 3.0, 3.0 and 5.5 respectively.",Symptom medication score (SMS),[69137],[8060],[8196],[False],[0],[0],[False],['0']
21971,PMC4553934,11413,In the second year (peak pollen count 827 grains/m3) the median SMS for the rBet v 1-FV and comparator groups were 3.00 (IQR: 6.50) and 2.93 (IQR: 4.86) respectively (Table 2).,Symptom medication score (SMS),[69140],[8197],[8373],[False],[0],[0],[False],['0']
21972,PMC4553934,11414,Specific antibody responses,Specific antibody responses,[69143],[8374],[8402],[False],[0],[0],[False],['0']
21973,PMC4553934,11415,Fig.,Specific antibody responses,[69146],[8403],[8407],[False],[0],[0],[False],['0']
21974,PMC4553934,11416,"3 Birch pollen-specific IgE, IgG1 and IgG4 concentrations.",Specific antibody responses,[69149],[8408],[8466],[False],[0],[0],[False],['0']
21975,PMC4553934,11417,"Median values with 25th/75th and 10th/90th percentiles represented by boxes and error bars respectively, outliers by points.",Specific antibody responses,[69152],[8467],[8591],[False],[0],[0],[False],['0']
21976,PMC4553934,11418,"Time points: 1, screening before SCIT; 2, after up-dosing first year; 3, after pollen season first year; 4, after up-dosing second year; and 5, after pollen season second year.",Specific antibody responses,[69155],[8592],[8768],[False],[0],[0],[False],['0']
21977,PMC4553934,11419,"Baseline birch pollen-specific IgE levels as well as levels during treatment were similar for rBet v 1-FV and the comparator groups; IgG1 and IgG4 levels were comparable at baseline, showed significant increases with marginally stronger responses in the rBet v 1-FV group (Fig.",Specific antibody responses,[69158],[8769],[9046],[False],[0],[0],[False],['0']
21978,PMC4553934,11420,3) and further increases in the second year.,Specific antibody responses,[69161],[9047],[9091],[False],[0],[0],[False],['0']
21979,PMC4553934,11421,Nasal provocation test,Nasal provocation test,[69164],[9092],[9115],[False],[0],[0],[False],['0']
21980,PMC4553934,11422,Table 3 Nasal provocation test response thresholds.,Nasal provocation test,[69167],[9116],[9167],[False],[0],[0],[False],['0']
21981,PMC4553934,11423,At entry there were no significant differences between the two groups in NPT.,Nasal provocation test,[69170],[9168],[9245],[False],[0],[0],[False],['0']
21982,PMC4553934,11424,"An enhanced tolerance threshold, with at least a three-fold increase in the tolerated allergen concentration, was seen in 8/15 subjects in the rBet v 1-FV group (8/14 comparator) after SCIT in the first year.",Nasal provocation test,[69173],[9246],[9454],[False],[0],[0],[False],['0']
21983,PMC4553934,11425,"In the second year enhanced tolerance was seen in 11/12 rBet v 1-FV (1 subject showing no change), as compared with only 6/11 in the comparator group (3 subjects no change, 2 deterioration (Table 3)).",Nasal provocation test,[69176],[9455],[9655],[False],[0],[0],[False],['0']
21984,PMC4553934,11426,Adverse events,Adverse events,[69179],[9656],[9671],[False],[0],[0],[False],['0']
21985,PMC4553934,11427,"During the two pre-seasonal treatment courses at least one local or systemic reaction with at least possible relationship to trial medication was recorded in 22/24 (91.7 %) of the rBet v 1-FV treated subjects and 23/27 (85.2 %) of comparator; systemic reactions in 42 % of rBet v 1-FV, 41 % comparator.",Adverse events,[69182],[9672],[9974],[False],[0],[0],[False],['0']
21986,PMC4553934,11428,"Two serious adverse events occurred during the study, both in the same patient on the same day 5 weeks after administration of the last rBet v 1-FV injection (bursitis, acute exacerbation right shoulder and trigger-thumb right) being assessed as not treatment related.",Adverse events,[69185],[9975],[10243],[False],[0],[0],[False],['0']
21987,PMC4553934,11429,"Table 4 Adverse events reported with a least a possible relationship to SCIT for both study groups, classified in accordance with MedDRA.",Adverse events,[69188],[10244],[10381],[False],[0],[0],[False],['0']
21988,PMC4553934,11430,All reactions (Table 4) are grouped according MedDRA system organ classes.,Adverse events,[69191],[10382],[10456],[False],[0],[0],[False],['0']
21989,PMC4553934,11431,Discussion,Discussion,[69194],[10457],[10468],[False],[0],[0],[False],['0']
21990,PMC4553934,11432,This is the first in man clinical study using a hypoallergenic recombinant folding-variant of Bet v 1 for the treatment of seasonal allergy.,Discussion,[69197],[10469],[10609],[False],[0],[0],[False],['0']
21991,PMC4553934,11433,"The study was designed as a randomized, controlled trial to determine potential clinical efficacy by open comparison (because of different up-dosing schemes) with an established birch pollen preparation.",Discussion,[69200],[10610],[10813],[False],[0],[0],[False],['0']
21992,PMC4553934,11434,The median daily SMS for the rBet v 1-FV group was substantially less than that for the birch pollen extract treated group 5.86 (median; IQR: 14.02) as compared with 12.40 (median; IQR: 9.32) after the first pre-seasonal treatment.,Discussion,[69203],[10814],[11045],[False],[0],[0],[False],['0']
21993,PMC4553934,11435,This difference equates to the daily use of one tablet anti-histamine.,Discussion,[69206],[11046],[11116],[False],[0],[0],[False],['0']
21994,PMC4553934,11436,"During the 2nd pollen season the SMS for the two groups were very comparable, indicating that the whole pollen extract was able to achieve the same effect as the recombinant molecule, but took longer to do so.",Discussion,[69209],[11117],[11326],[False],[0],[0],[False],['0']
21995,PMC4553934,11437,"The difference in SMS was not statistically significant, but it should be noted that this was a first in man study with a totally new product and because of safety reasons not powered to demonstrate differences between treatments.",Discussion,[69212],[11327],[11557],[True],['UnderpoweredStudy'],['not powered to demonstrate differences between treatments'],[True],['UnderpoweredStudy']
21996,PMC4553934,11438,"However, the lack of power calculation and the absence of a placebo group is an important limitation as it prevents any direct assessment of the significance of the clinical improvement.",Discussion,"[69219, 69220]","[11558, 11558]","[11744, 11744]","[True, True]","['UnderpoweredStudy', 'NoPlaceboGroup']","['the lack of power calculation', 'the absence of a placebo group']","[True, True]","['Control', 'UnderpoweredStudy']"
21997,PMC4553934,11439,The comparison with a reference group from the same geographical region from the baseline season of a phase III trial with rBet v 1-FV (NCT00309062) helps to put the data into perspective.,Discussion,[69224],[11745],[11933],[False],[0],[0],[False],['0']
21998,PMC4553934,11440,The enhanced tolerance threshold compared with baseline in NPT after the 2nd treatment course was more pronounced in rBet v 1-FV (11/12 subjects) compared to NHD (6/11).,Discussion,[69227],[11934],[12103],[False],[0],[0],[False],['0']
21999,PMC4553934,11441,"Single pre-seasonal treatments with either hypoallergenic fragments or a trimeric form of recombinant Bet v 1 showed increased tolerance within the groups, but not in comparison to placebo [9].",Discussion,[69230],[12104],[12297],[False],[0],[0],[False],['0']
22000,PMC4553934,11442,The advantage in favor of the recombinant preparation in the present study may reflect the higher therapeutic dose and/or its superior efficacy.,Discussion,[69233],[12298],[12442],[False],[0],[0],[False],['0']
22001,PMC4553934,11443,"There were no significant changes in birch pollen or Bet v 1 specific IgE in either group, although a slight downward trend was apparent in the 2nd year of the study.",Discussion,[69236],[12443],[12609],[False],[0],[0],[False],['0']
22002,PMC4553934,11444,"Such decreases have been seen with longer treatment protocols including recombinant grass pollen allergens after 20 months of therapy [10], and pre-seasonal treatment with a grass pollen allergoid over 2 years [11].",Discussion,[69239],[12610],[12825],[False],[0],[0],[False],['0']
22003,PMC4553934,11445,These results suggest that AIT can cause at least partial suppression of those Th2 cytokines essential for IgE-production.,Discussion,[69242],[12826],[12948],[False],[0],[0],[False],['0']
22004,PMC4553934,11446,"The large and significant increases of birch pollen specific IgG4 levels at maximum dosing, indicate that rBet v 1-FV has a strong immunogenic effect, slightly in excess of that of the allergen extract; possibly explained by the random coil structure facilitating processing by antigen presenting cells [12].",Discussion,[69245],[12949],[13257],[False],[0],[0],[False],['0']
22005,PMC4553934,11447,The rBet v 1-FV was well tolerated and the safety profile was comparable with that of the natural pollen preparation.,Discussion,[69248],[13258],[13375],[False],[0],[0],[False],['0']
22006,PMC4553934,11448,"A permanent dose-reduction was not necessary in subjects with systemic reactions, and the maintenance dose of 80 μg protein could be realized in nearly all subjects.",Discussion,[69251],[13376],[13541],[False],[0],[0],[False],['0']
22007,PMC4553934,11449,"The comparable safety data with the two preparations in the present study, despite the five-fold higher major allergen dose of the recombinant preparation, indicates a possible advantage for the hypoallergenic rBet v 1-FV.",Discussion,[69254],[13542],[13764],[False],[0],[0],[False],['0']
22008,PMC4553934,11450,This first in man proof of concept clinical study of SCIT using a folding-variant of an rBet v 1- vaccine for the treatment of seasonal hay fever has demonstrated good clinical tolerance and efficacy after just one pre-seasonal course comparable to a native birch pollen preparation.,Discussion,[69257],[13765],[14048],[False],[0],[0],[False],['0']
22009,PMC4553934,11451,The induction of strong allergen-specific IgG antibody responses demonstrates the immunogenicity of the rBet v 1-FV and confirms that the hypoallergenic characteristics are not detrimental to its immune-modulatory potential.,Discussion,[69260],[14049],[14273],[False],[0],[0],[False],['0']
22010,PMC4553934,11452,Subsequent clinical DBPC-trials are warranted to confirm its clinical efficacy.,Discussion,[69263],[14274],[14353],[False],[0],[0],[False],['0']
22011,PMC4553934,11453,Competing interests,Competing interests,[69266],[14354],[14374],[False],[0],[0],[False],['0']
22012,PMC4553934,11454,"L. Klimek (LK) has received research grants for his institution from ALK Abelló (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/ France), HAL Allergy (Germany/the Netherlands), Artu Biologicals (the Netherlands), Allergy Therapeutics/Bencard (UK/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (UK/Germany), Essex Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (UK), Biotech Tools s.a. (Belgium), and Meda Pharma GmbH (Germany); and/or he has served as an advisor and on speakers’ bureaus for some of the aforementioned companies.",Competing interests,[69269],[14375],[15053],[False],[0],[0],[False],['0']
22013,PMC4553934,11455,"LK has received travel grants from HAL Allergy (the Netherlands/Germany), Meda (Germany/Sweden) and Allergopharma (Germany), and he is a consultant for Bencard (Germany), Novartis/Leti (Germany), Meda (Germany), ALK Abelló (Germany/Denmark), Allergopharma (Germany) and Boehringer Ingelheim (Germany).",Competing interests,[69272],[15054],[15355],[False],[0],[0],[False],['0']
22014,PMC4553934,11456,"LK is Board Member of the ENT Section of the European Academy of Allergy and Clinical Immunology (EAACI), Vice-President of the German Academy of Allergology and Clinical Immunology, Vice-President German Union of Allergologists, Member of the Board of Directors of the German Society for Otorhinolaryngology HNS.",Competing interests,[69275],[15356],[15669],[False],[0],[0],[False],['0']
22015,PMC4553934,11457,"He is co-editor and author of different chapters of the textbook “Allergien bei Kindern und Jugendlichen” (publisher: Schattauer-Verlag, Germany), author of one chapter in “Allergologie” (publisher: Springer, Germany) and author of different chapters in “Allergologie” (publisher: Schattauer-Verlag).",Competing interests,[69278],[15670],[15970],[False],[0],[0],[False],['0']
22016,PMC4553934,11458,"Claus Bachert (CB) has received speaker or consultation fees from ALK (Germany), Allergopharma (Germany), Stallergenes (France), Bencard (Germany) and HAL-Allergy (The Netherlands).",Competing interests,[69281],[15971],[16152],[False],[0],[0],[False],['0']
22017,PMC4553934,11459,Karl-Friedrich Lukat states no conflict of interest with regard to the published work.,Competing interests,[69284],[16153],[16239],[False],[0],[0],[False],['0']
22018,PMC4553934,11460,"O. Pfaar (OP) has received research grants for his institution from ALK Abelló (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/ France), HAL Allergy (Germany/the Netherlands), Artu Biologicals (the Netherlands), Allergy Therapeutics/Bencard (UK/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (UK/Germany), Essex Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (UK), European Union (FP-7 Health-2013 Innovation 1), Biotech Tools s.a. (Belgium), and Meda Pharma GmbH (Germany); and/or he has served as an advisor and on speakers’ bureaus for some of the aforementioned companies.",Competing interests,[69287],[16240],[16965],[False],[0],[0],[False],['0']
22019,PMC4553934,11461,"OP has received travel grants from HAL Allergy (the Netherlands/Germany) and Allergopharma (Germany), and he is a consultant for Bencard (Germany), HAL Allergy (the Netherlands), Novartis/Leti (Germany), Meda (Germany), ALK Abelló (Germany/Denmark), Allergopharma (Germany), Biotech Tools s.a. (Belgium), GfK Bridgehead (UK), Navigant Consulting (USA), Sanofi (USA), Guidepoint Global Advisors (USA), Thermo Fisher (Germany) and Stallergenes (Germany/France); he is Scientific Board Member of Mobile Chamber Experts (MCX), a GA2LEN Partner.",Competing interests,[69290],[16966],[17506],[False],[0],[0],[False],['0']
22020,PMC4553934,11462,OP is the current chairman of the Immunotherapy Interest Group (IT IG) of the European Academy of Allergy and Clinical Immunology (EAACI) and is the secretary of the ENT section of the German Society for Allergology and Clinical Immunology (DGAKI).,Competing interests,[69293],[17507],[17755],[False],[0],[0],[False],['0']
22021,PMC4553934,11463,He has received grants for the “Spezifische Immuntherapie”-award 2014 and the “Nachwuchsförderpreis”- award 2010 of the DGAKI.,Competing interests,[69296],[17756],[17882],[False],[0],[0],[False],['0']
22022,PMC4553934,11464,"He is co-editor and author of different chapters of the textbook “Allergien bei Kindern und Jugendlichen” (publisher: Schattauer-Verlag, Germany), author of one chapter in “Allergologie” (publisher: Springer, Germany) and author of different chapters in “Allergologie” (publisher: Schattauer-Verlag).",Competing interests,[69299],[17883],[18183],[False],[0],[0],[False],['0']
22023,PMC4553934,11465,"He has received payment for development of educational presentations from GlaxoSmithKline (Germany), Bencard (Germany), and Novartis (Germany).",Competing interests,[69302],[18184],[18327],[False],[0],[0],[False],['0']
22024,PMC4553934,11466,"H. Meyer and A. Narkus are employees of Allergopharma GmbH & Co. KG, Reinbek, Germany.Authors’ contributions",Competing interests,[69305],[18328],[18436],[False],[0],[0],[False],['0']
22025,PMC4553934,11467,"LK, CB, KL and OP have made substantial contributions to the acquisition of data in this first in man (FIM) clinical trial, HM and AN have developed the concept/design and performed the analysis.",Competing interests,[69308],[18437],[18632],[False],[0],[0],[False],['0']
22026,PMC4553934,11468,In addition AN has been the principal investigator of this FIM study.,Competing interests,[69311],[18633],[18702],[False],[0],[0],[False],['0']
22027,PMC4553934,11469,"All authors have been involved in the interpretation of data, drafting the manuscript or revising it critically for important intellectual content and have given final approval of the version to be published.",Competing interests,[69314],[18703],[18911],[False],[0],[0],[False],['0']
22028,PMC4553934,11470,All authors read and approved the final manuscript.,Competing interests,[69317],[18912],[18963],[False],[0],[0],[False],['0']
22029,PMC4553934,11471,Acknowledgements,Competing interests|Acknowledgements,[69320],[18964],[18980],[False],[0],[0],[False],['0']
22030,PMC4553934,11472,The authors acknowledge the contributions of Claudia Doemer and Jens Kettner in the organization of the study and finalization of the clinical study report; Helmut Fiebig and Bernhard Weber for specific antibody measurements; and Oliver Cromwell for help in preparing the manuscript.,Competing interests|Acknowledgements,[69323],[18981],[19264],[False],[0],[0],[False],['0']
22031,PMC4553934,11473,"The study was sponsored by Allergopharma GmbH & Co. KG, Reinbek, Germany.",Competing interests|Acknowledgements,[69326],[19265],[19338],[False],[0],[0],[False],['0']
22032,PMC4553934,11474,The data has been presented at EAACI as well as German Allergy congresses.,Competing interests|Acknowledgements,[69329],[19339],[19413],[False],[0],[0],[False],['0']
22767,PMC4703201,31321,Two-Arm Randomized Pilot Intervention Trial to Decrease Sitting Time and Increase Sit-To-Stand Transitions in Working and Non-Working Older Adults,Title,[187761],[23864],[146],[False],[0],[0],[False],['0']
22768,PMC4703201,31322,Background,Abstract,[187766],[147],[158],[False],[0],[0],[False],['0']
22769,PMC4703201,31323,Excessive sitting has been linked to poor health.,Abstract,[187771],[159],[208],[False],[0],[0],[False],['0']
22770,PMC4703201,31324,It is unknown whether reducing total sitting time or increasing brief sit-to-stand transitions is more beneficial.,Abstract,[187776],[209],[323],[False],[0],[0],[False],['0']
22771,PMC4703201,31325,We conducted a randomized pilot study to assess whether it is feasible for working and non-working older adults to reduce these two different behavioral targets.,Abstract,[187781],[324],[485],[False],[0],[0],[False],['0']
22772,PMC4703201,31326,Methods,Methods,[187786],[486],[494],[False],[0],[0],[False],['0']
22773,PMC4703201,31327,Thirty adults (15 workers and 15 non-workers) age 50–70 years were randomized to one of two conditions (a 2-hour reduction in daily sitting or accumulating 30 additional brief sit-to-stand transitions per day).,Methods,[187791],[495],[705],[False],[0],[0],[False],['0']
22774,PMC4703201,31328,"Sitting time, standing time, sit-to-stand transitions and stepping were assessed by a thigh worn inclinometer (activPAL).",Methods,[187796],[706],[827],[False],[0],[0],[False],['0']
22775,PMC4703201,31329,Participants were assessed for 7 days at baseline and followed while the intervention was delivered (2 weeks).,Methods,[187801],[828],[938],[False],[0],[0],[False],['0']
22776,PMC4703201,31330,"Mixed effects regression analyses adjusted for days within participants, device wear time, and employment status.",Methods,[187806],[939],[1052],[False],[0],[0],[False],['0']
22777,PMC4703201,31331,Time by condition interactions were investigated.,Methods,[187811],[1053],[1102],[False],[0],[0],[False],['0']
22778,PMC4703201,31332,Results,Results,[187816],[1103],[1111],[False],[0],[0],[False],['0']
22779,PMC4703201,31333,"Recruitment, assessments, and intervention delivery were feasible.",Results,[187821],[1112],[1178],[False],[0],[0],[False],['0']
22780,PMC4703201,31334,"The ‘reduce sitting’ group reduced their sitting by two hours, the ‘increase sit-to-stand’ group had no change in sitting time (p < .001).",Results,[187826],[1179],[1317],[False],[0],[0],[False],['0']
22781,PMC4703201,31335,"The sit-to-stand transition group increased their sit-to-stand transitions, the sitting group did not (p < .001).",Results,[187831],[1318],[1431],[False],[0],[0],[False],['0']
22782,PMC4703201,31336,Conclusions,Conclusions,[187836],[1432],[1444],[False],[0],[0],[False],['0']
22783,PMC4703201,31337,This study was the first to demonstrate the feasibility and preliminary efficacy of specific sedentary behavioral goals.,Conclusions,[187841],[1445],[1565],[False],[0],[0],[False],['0']
22784,PMC4703201,31338,Trial Registration,Trial Registration,[187846],[1566],[1585],[False],[0],[0],[False],['0']
22785,PMC4703201,31339,clinicaltrials.gov NCT02544867,Trial Registration,[187851],[1586],[1616],[False],[0],[0],[False],['0']
22786,PMC4703201,31340,Introduction,Introduction,[187856],[1617],[1631],[False],[0],[0],[False],['0']
22787,PMC4703201,31341,The study of sedentary behavior as an independent risk factor for chronic disease morbidity and mortality has expanded rapidly in recent years [1].,Introduction,[187861],[1632],[1779],[False],[0],[0],[False],['0']
22788,PMC4703201,31342,"Although historically sedentary behavior has been conceptualized as the absence of physical activity (i.e., physical inactivity) [2], it is now recognized as a distinct behavioral domain, characterized by low energy expenditure (<1.5 METS) and a sitting or reclining posture [3].",Introduction,[187866],[1780],[2059],[False],[0],[0],[False],['0']
22789,PMC4703201,31343,"An emerging body of epidemiological evidence suggests that sedentary behaviors are associated with all-cause and cardiovascular mortality, overweight and obesity, type 2 diabetes, depression and psychological well-being [4–12].",Introduction,[187871],[2060],[2287],[False],[0],[0],[False],['0']
22790,PMC4703201,31344,"Importantly, many of these associations were observed independent of participation in moderate to vigorous intensity physical activity.",Introduction,[187876],[2288],[2423],[False],[0],[0],[False],['0']
22791,PMC4703201,31345,"Further, there is preliminary evidence that the physiological mechanisms through which sedentary behavior negatively impacts health are distinct from the pathways linked to physical activity [13,14].",Introduction,[187881],[2424],[2623],[False],[0],[0],[False],['0']
22792,PMC4703201,31346,"Surveillance data indicates that adults accumulate over 7 hours per day of sedentary time [15], yet the ‘dose’ of sedentary behavior that most accurately predicts health risk remains uncertain.",Introduction,[187886],[2624],[2817],[False],[0],[0],[False],['0']
22793,PMC4703201,31347,"There are multiple ways of disrupting sedentary time such as through movement, prolonged standing, or brief sit-to-stand transitions.",Introduction,[187891],[2818],[2951],[False],[0],[0],[False],['0']
22794,PMC4703201,31348,Approaches for disrupting sedentary time likely vary in terms of their acceptability by different populations and may have differential impacts on health outcomes.,Introduction,[187896],[2952],[3115],[False],[0],[0],[False],['0']
22795,PMC4703201,31349,A recent review suggests that physical activity interventions do not appreciably alter sedentary time [16].,Introduction,[187901],[3116],[3223],[False],[0],[0],[False],['0']
22796,PMC4703201,31350,"Thus, there are an emerging number of interventions that explicitly aim to reduce sedentary behavior.",Introduction,[187906],[3224],[3325],[False],[0],[0],[False],['0']
22797,PMC4703201,31351,The majority of interventions to date have targeted children or working adults.,Introduction,[187911],[3326],[3405],[False],[0],[0],[False],['0']
22798,PMC4703201,31352,"Among the adult studies, the workplace has been the primary setting and interventions have centered on environmental changes including implementing standing desks to promote less sitting [17,18].",Introduction,[187916],[3406],[3601],[False],[0],[0],[False],['0']
22799,PMC4703201,31353,"These interventions have shown some efficacy but may not be appropriate in nonworking populations, such as retired older adults.",Introduction,[187921],[3602],[3730],[False],[0],[0],[False],['0']
22800,PMC4703201,31354,"Further, most of the interventions have delivered mixed messages encouraging breaks from sitting, prolonged standing, and movement, making it difficult to determine which types of sedentary behavior are most feasible to improve and which types of intervention most effective.",Introduction,[187926],[3731],[4006],[False],[0],[0],[False],['0']
22801,PMC4703201,31355,"Most studies have observed reductions in sitting time and increases in standing time with little impact on sit-to-stand transitions [17,18].",Introduction,[187931],[4007],[4147],[False],[0],[0],[False],['0']
22802,PMC4703201,31356,"However, prolonged standing may not be feasible or safe for some populations (e.g., older adults), may not be convenient outside of workplaces, and may be more difficult to maintain long term compared to other approaches such as brief sit-to-stand transitions.",Introduction,[187936],[4148],[4408],[False],[0],[0],[False],['0']
22803,PMC4703201,31357,"Laboratory studies suggest that the frequency of disrupting sitting is important, and that sit-to-stand transitions can increase postural blood flow, contract muscles, and stimulate biological processes important in disease formation [19–22].",Introduction,[187941],[4409],[4651],[False],[0],[0],[False],['0']
22804,PMC4703201,31358,"Therefore, we developed two different intervention approaches for sedentary behavior reduction: 1) reducing overall sitting time and 2) frequent brief sit-to-stand transitions.",Introduction,[187946],[4652],[4828],[False],[0],[0],[False],['0']
22805,PMC4703201,31359,Working and non-working adults aged 50–70 were randomized to each condition to examine the feasibility of each target and preliminary efficacy on objectively measured sedentary behaviors and physical activity.,Introduction,[187951],[4829],[5038],[False],[0],[0],[False],['0']
22806,PMC4703201,31360,We hypothesized that each intervention would only affect the behavior targeted by the intervention content.,Introduction,[187956],[5039],[5146],[False],[0],[0],[False],['0']
22807,PMC4703201,31361,Materials and Methods,Materials and Methods,[187961],[5147],[5169],[False],[0],[0],[False],['0']
22808,PMC4703201,31362,S1 CONSORT Checklist outlines the CONSORT 2010 checklist for randomized trials and where the information is included in the manuscript.,Materials and Methods,[187966],[5170],[5305],[False],[0],[0],[False],['0']
22809,PMC4703201,31363,Participants and Recruitment,Participants and Recruitment,[187971],[5306],[5335],[False],[0],[0],[False],['0']
22810,PMC4703201,31364,We conducted a two arm randomized pilot trial with an equal number of workers (employed full time) and non-workers assigned to each condition.,Participants and Recruitment,[187976],[5336],[5478],[False],[0],[0],[False],['0']
22811,PMC4703201,31365,"This was to ensure variability in work status, not to explore differences by work status.",Participants and Recruitment,[187981],[5479],[5568],[False],[0],[0],[False],['0']
22812,PMC4703201,31366,The study was supported through a small departmental grant to determine the acceptability and feasibility of a sedentary behavior intervention.,Participants and Recruitment,[187986],[5569],[5712],[False],[0],[0],[False],['0']
22813,PMC4703201,31367,"Therefore, the sample size and intervention were designed to maximize funds and test the intervention in a small sample of 30 participants, as appropriate for a pilot trial.",Participants and Recruitment,[187991],[5713],[5886],[False],[0],[0],[False],['0']
22814,PMC4703201,31368,Increased power to detect differences was also derived from the continuous data collection of the primary outcome across multiple days per participant.,Participants and Recruitment,[187996],[5887],[6038],[False],[0],[0],[False],['0']
22815,PMC4703201,31369,Participants for the study were recruited starting in September 2013 and the final participant was seen in March 2014.,Participants and Recruitment,[188001],[6039],[6157],[False],[0],[0],[False],['0']
22816,PMC4703201,31370,Working participants were recruited to the ‘Take a Stand’ study through a flyer posted on a university listserv as well as word of mouth.,Participants and Recruitment,[188006],[6158],[6295],[False],[0],[0],[False],['0']
22817,PMC4703201,31371,Non-working participants from the local community responded to an online advertisement.,Participants and Recruitment,[188011],[6296],[6383],[False],[0],[0],[False],['0']
22818,PMC4703201,31372,Interested individuals called a study phone line and were screened for eligibility by a research assistant.,Participants and Recruitment,[188016],[6384],[6491],[False],[0],[0],[False],['0']
22819,PMC4703201,31373,"Participants were eligible if they were aged 50–70 years, spent at least 8 hours per day sitting on average over 5 days (assessed by ActivPAL), were able to attend 4 measurement visits with study staff in 4 consecutive weeks, were willing and able to wear a thigh mounted inclinometer 24 hours per day for 21 days (including the baseline monitoring week), were able to read and write in English, were able to provide written informed consent and did not have a serious chronic condition that would limit their ability to stand.",Participants and Recruitment,[188021],[6492],[7019],[False],[0],[0],[False],['0']
22820,PMC4703201,31374,Eligible participants came to the study office and were provided further information on the study and completed a written informed consent.,Participants and Recruitment,[188026],[7020],[7159],[False],[0],[0],[False],['0']
22821,PMC4703201,31375,"Once participants signed the consent form, they wore a thigh mounted inclinometer for 7 days to determine whether they met the 8 hour minimum sitting time eligibility criteria.",Participants and Recruitment,[188031],[7160],[7336],[False],[0],[0],[False],['0']
22822,PMC4703201,31376,8 hours was selected as it was above the US national average for sitting time (15) and a 2 hour reduction was possible.,Participants and Recruitment,[188036],[7337],[7456],[False],[0],[0],[False],['0']
22823,PMC4703201,31377,"Participants returned to the study office and, if they met the study criteria, were randomized to one of the two study conditions using a randomization table developed by a statistician.",Participants and Recruitment,[188041],[7457],[7643],[False],[0],[0],[False],['0']
22824,PMC4703201,31378,The table included 30 spots with masked group assignments and was password protected.,Participants and Recruitment,[188046],[7644],[7729],[False],[0],[0],[False],['0']
22825,PMC4703201,31379,The study coordinator added new participants to the table in the order in which they were enrolled and unmasked their group assignment.,Participants and Recruitment,[188051],[7730],[7865],[False],[0],[0],[False],['0']
22826,PMC4703201,31380,The participant’s assignment was given to study personnel who then notified the participant.,Participants and Recruitment,[188056],[7866],[7958],[False],[0],[0],[False],['0']
22827,PMC4703201,31381,"Once 15 workers had been enrolled, only non-workers were screened for eligibility.",Participants and Recruitment,[188061],[7959],[8041],[False],[0],[0],[False],['0']
22828,PMC4703201,31382,The statistician was blinded to the intervention assignment.,Participants and Recruitment,[188066],[8042],[8102],[False],[0],[0],[False],['0']
22829,PMC4703201,31383,"Data collection staff were not as they had to select the correct algorithm to process and visualize the data, according to the specific intervention.",Participants and Recruitment,[188071],[8103],[8252],[False],[0],[0],[False],['0']
22830,PMC4703201,31384,The data were then given to the health educator to provide in person feedback to the participant each week.,Participants and Recruitment,[188076],[8253],[8360],[False],[0],[0],[False],['0']
22831,PMC4703201,31385,Because the data were objectively collected with the ActivPAL we believed measured bias was limited.,Participants and Recruitment,[188081],[8361],[8461],[False],[0],[0],[False],['0']
22832,PMC4703201,31386,The study was registered with clinicaltrials.gov following study completion with results.,Participants and Recruitment,[188086],[8462],[8551],[False],[0],[0],[False],['0']
22833,PMC4703201,31387,"All study activities were approved by the University of California, San Diego institutional review board on July 18th, 2013.",Participants and Recruitment,[188091],[8552],[8676],[False],[0],[0],[False],['0']
22834,PMC4703201,31388,The authors confirm that all ongoing and related trials for this intervention are registered.,Participants and Recruitment,[188096],[8677],[8770],[False],[0],[0],[False],['0']
22835,PMC4703201,31389,The research protocol and consent documents can be found in the supplementary information (S1 Protocol).,Participants and Recruitment,[188101],[8771],[8875],[False],[0],[0],[False],['0']
22836,PMC4703201,31390,Procedures,Procedures,[188106],[8876],[8887],[False],[0],[0],[False],['0']
22837,PMC4703201,31391,"Following randomization, participants answered a short written survey, completed an in person interview about the feasibility and acceptability of wearing the thigh mounted inclinometer and met with the study health educator for one hour for their first intervention session.",Procedures,[188111],[8888],[9163],[False],[0],[0],[False],['0']
22838,PMC4703201,31392,"Participants then returned to the study office one and two weeks later to have data from their inclinometer downloaded by staff, have a follow-up session with the health educator, and complete study surveys and interview questions.",Procedures,[188116],[9164],[9395],[False],[0],[0],[False],['0']
22839,PMC4703201,31393,Intervention Conditions,Intervention Conditions,[188121],[9396],[9420],[False],[0],[0],[False],['0']
22840,PMC4703201,31394,Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions.,Intervention Conditions,[188126],[9421],[9529],[False],[0],[0],[False],['0']
22841,PMC4703201,31395,Each intervention lasted 14 days with three in person health educator sessions during that time.,Intervention Conditions,[188131],[9530],[9626],[False],[0],[0],[False],['0']
22842,PMC4703201,31396,"Both intervention arms drew from behavior change strategies highlighted as effective, including, self-monitoring, goal setting, feedback, problem-solving, and planning [23].",Intervention Conditions,[188136],[9627],[9800],[False],[0],[0],[False],['0']
22843,PMC4703201,31397,"In addition, the intervention was informed by the social ecological model [24,25] that considers the supportiveness of the physical and social environments in which behaviors occur.",Intervention Conditions,[188141],[9801],[9982],[False],[0],[0],[False],['0']
22844,PMC4703201,31398,"Information was provided in person, through written materials and by emails and phone calls in both conditions.",Intervention Conditions,[188146],[9983],[10094],[False],[0],[0],[False],['0']
22845,PMC4703201,31399,Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day.,Intervention Conditions,[188151],[10095],[10280],[False],[0],[0],[False],['0']
22846,PMC4703201,31400,"During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.",Intervention Conditions,[188156],[10281],[10554],[False],[0],[0],[False],['0']
22847,PMC4703201,31401,"At the end of each session, participants completed and signed a behavioral contract that outlined the goal for the upcoming week, their motivation to achieve the goal, and a potential barrier and solution to implementing the behavior.",Intervention Conditions,[188161],[10555],[10789],[False],[0],[0],[False],['0']
22848,PMC4703201,31402,Participants created an action plan with the health educator indicating how they would incorporate study tools to accomplish the goal during the upcoming week.,Intervention Conditions,[188166],[10790],[10949],[False],[0],[0],[False],['0']
22849,PMC4703201,31403,"At the end of the visit, participants rated their confidence in meeting the goal on a scale from 1 (not at all confident) to 10 (completely confident).",Intervention Conditions,[188171],[10950],[11101],[False],[0],[0],[False],['0']
22850,PMC4703201,31404,"If participants rated their confidence at a 5 or below, the health educator would revisit the action plan to develop different strategies to help the participant feel more confident.",Intervention Conditions,[188176],[11102],[11284],[False],[0],[0],[False],['0']
22851,PMC4703201,31405,Participants selected whether they wanted email or phone call check-ins in the second week of the intervention to test whether this mode of communication was also useful.,Intervention Conditions,[188181],[11285],[11455],[False],[0],[0],[False],['0']
22852,PMC4703201,31406,Reduce sitting condition,Reduce sitting condition,[188186],[11456],[11481],[False],[0],[0],[False],['0']
22853,PMC4703201,31407,"Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time).",Reduce sitting condition,[188191],[11482],[11699],[False],[0],[0],[False],['0']
22854,PMC4703201,31408,Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour.,Reduce sitting condition,[188196],[11700],[11800],[False],[0],[0],[False],['0']
22855,PMC4703201,31409,"The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.",Reduce sitting condition,[188201],[11801],[12010],[False],[0],[0],[False],['0']
22856,PMC4703201,31410,"During weekly meetings with the health educator, participants in this group reviewed feedback charts depicting their sitting and standing time, as measured by the thigh worn inclinometer, across each day of the previous week.",Reduce sitting condition,[188206],[12011],[12236],[False],[0],[0],[False],['0']
22857,PMC4703201,31411,"They discussed when they might be able to reduce their sitting during each day, how to incorporate extended standing breaks into their working and home lives, how to set up a social and physical environment to support this goal, and how to track their progress towards the goal over time.",Reduce sitting condition,[188211],[12237],[12525],[False],[0],[0],[False],['0']
22858,PMC4703201,31412,"Participants were provided with a choice of tools to support their behavior change including: standing desks, timers (e.g., phone apps, computer apps), physical timers that could be placed in a variety of locations (e.g., work desk, on top of TV, kitchen counter), a vibrating watch, a branded study bracelet with the study tagline to serve as a reminder, and texts, emails, or phone calls from study personnel.",Reduce sitting condition,[188216],[12526],[12937],[False],[0],[0],[False],['0']
22859,PMC4703201,31413,Increase sit-to-stand transitions condition,Increase sit-to-stand transitions condition,[188221],[12938],[12982],[False],[0],[0],[False],['0']
22860,PMC4703201,31414,Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day.,Increase sit-to-stand transitions condition,[188226],[12983],[13181],[False],[0],[0],[False],['0']
22861,PMC4703201,31415,"Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26–28].",Increase sit-to-stand transitions condition,[188231],[13182],[13459],[False],[0],[0],[False],['0']
22862,PMC4703201,31416,"An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.",Increase sit-to-stand transitions condition,[188236],[13460],[13643],[False],[0],[0],[False],['0']
22863,PMC4703201,31417,"During each weekly session with the health educator, participants in this group reviewed a feedback chart illustrating the number of sit-to-stand transitions they achieved each day, measured by the thigh worn inclinometer.",Increase sit-to-stand transitions condition,[188241],[13644],[13866],[False],[0],[0],[False],['0']
22864,PMC4703201,31418,Participants were told that each standing break could be brief and did not have to interrupt normal activities.,Increase sit-to-stand transitions condition,[188246],[13867],[13978],[False],[0],[0],[False],['0']
22865,PMC4703201,31419,"Thus, we felt that social or environmental supports were not required but that more frequent cues to remind participants to stand up would be more useful.",Increase sit-to-stand transitions condition,[188251],[13979],[14133],[False],[0],[0],[False],['0']
22866,PMC4703201,31420,Participants were provided with the same choice of reminder tools to support their behavior change as the ‘reduce sitting group’ except they were not given standing desks.,Increase sit-to-stand transitions condition,[188256],[14134],[14305],[False],[0],[0],[False],['0']
22867,PMC4703201,31421,"Instead, they were offered counters to help them track sit-to-stand transitions throughout the day (e.g., electronic counter, bracelet counter, dry erase board).",Increase sit-to-stand transitions condition,[188261],[14306],[14467],[False],[0],[0],[False],['0']
22868,PMC4703201,31422,The intervention materials and protocol are available on request from the authors.,Increase sit-to-stand transitions condition,[188266],[14468],[14550],[False],[0],[0],[False],['0']
22869,PMC4703201,31423,In person interviews,In person interviews,[188271],[14551],[14572],[False],[0],[0],[False],['0']
22870,PMC4703201,31424,"At each visit, participants completed a short semi-structured interview with study staff.",In person interviews,[188276],[14573],[14662],[False],[0],[0],[False],['0']
22871,PMC4703201,31425,"They were asked about the acceptability of the study device, their satisfaction with the intervention materials, and the feasibility of the intervention goals.",In person interviews,[188281],[14663],[14822],[False],[0],[0],[False],['0']
22872,PMC4703201,31426,"Questions probed the experience of wearing the device, their success following the action plan, barriers and facilitators to behavior change, the impact on other behaviors, and their goal progress.",In person interviews,[188286],[14823],[15020],[False],[0],[0],[False],['0']
22873,PMC4703201,31427,Responses to these questions were deemed secondary outcomes.,In person interviews,[188291],[15021],[15081],[False],[0],[0],[False],['0']
22874,PMC4703201,31428,Primary Outcome: Objective Measures of Behavior,In person interviews,[188296],[15082],[15130],[False],[0],[0],[False],['0']
22875,PMC4703201,31429,"The thigh worn inclinometer (the activPAL3, PAL Technologies Limited, Glasgow, UK) was employed as an intervention feedback tool as described above and provided the outcome measures, which included: daily sitting time, daily standing time, daily stepping time and number of sit-to-stand transitions per day.",In person interviews,[188301],[15131],[15438],[False],[0],[0],[False],['0']
22876,PMC4703201,31430,Participants completed a sleep log and daily waking hours were extracted to omit sleep time from the measures.,In person interviews,[188306],[15439],[15549],[False],[0],[0],[False],['0']
22877,PMC4703201,31431,"Since sleep time can greatly influence the number of waking hours available for sitting, it was important to analyze sitting time reductions irrespective of sleep time.",In person interviews,[188311],[15550],[15718],[False],[0],[0],[False],['0']
22878,PMC4703201,31432,Participants were shown how to attach the inclinometer to their mid-thigh and to waterproof the device with an adhesive surgical sleeve provided by study staff.,In person interviews,[188316],[15719],[15879],[False],[0],[0],[False],['0']
22879,PMC4703201,31433,"Replacement sleeves were provided, but participants were encouraged not to remove the device between study visits as the waterproofing allowed it to be worn during showering.",In person interviews,[188321],[15880],[16054],[False],[0],[0],[False],['0']
22880,PMC4703201,31434,"At each office visit, the device and covering were replaced.",In person interviews,[188326],[16055],[16115],[False],[0],[0],[False],['0']
22881,PMC4703201,31435,Analyses,Analyses,[188331],[16116],[16125],[False],[0],[0],[False],['0']
22882,PMC4703201,31436,All participants were analyzed according to the intention to treat (i.e.,Analyses,[188336],[16126],[16198],[False],[0],[0],[False],['0']
22883,PMC4703201,31437,the condition to which they were assigned).,Analyses,[188341],[16199],[16242],[False],[0],[0],[False],['0']
22884,PMC4703201,31438,There was no missing data as all participants were compliant with the 21 day wear protocol.,Analyses,[188346],[16243],[16334],[False],[0],[0],[False],['0']
22885,PMC4703201,31439,Statistical analyses were performed with SPSS v22.,Analyses,[188351],[16335],[16385],[False],[0],[0],[False],['0']
22886,PMC4703201,31440,"The four outcomes (sitting time, standing time, stepping time, and number of sit-to-stand transitions) were analyzed for their trajectories over time.",Analyses,[188356],[16386],[16536],[False],[0],[0],[False],['0']
22887,PMC4703201,31441,"Mixed effects regression analyses, with days nested within participants, were performed for each outcome separately.",Analyses,[188361],[16537],[16653],[False],[0],[0],[False],['0']
22888,PMC4703201,31442,A time by condition interaction was investigated.,Analyses,[188366],[16654],[16703],[False],[0],[0],[False],['0']
22889,PMC4703201,31443,Work status was entered as a covariate.,Analyses,[188371],[16704],[16743],[False],[0],[0],[False],['0']
22890,PMC4703201,31444,The number of sit-to-stand transitions was natural log transformed.,Analyses,[188376],[16744],[16811],[False],[0],[0],[False],['0']
22891,PMC4703201,31445,All analyses adjusted for activPAL wear time.,Analyses,[188381],[16812],[16857],[False],[0],[0],[False],['0']
22892,PMC4703201,31446,No formal analysis of the secondary interview data was performed.,Analyses,[188386],[16858],[16923],[False],[0],[0],[False],['0']
22893,PMC4703201,31447,We merely report here information that helps to explain the study findings and provide evidence of feasibility and acceptability.,Analyses,[188391],[16924],[17053],[False],[0],[0],[False],['0']
22894,PMC4703201,31448,Results,Results,[188396],[17054],[17062],[False],[0],[0],[False],['0']
22895,PMC4703201,31449,Fig 1 Flow diagram of progress through randomized pilot study..,Results,[188401],[17063],[17126],[False],[0],[0],[False],['0']
22896,PMC4703201,31450,Fig 1 provides a CONSORT diagram of recruitment for the pilot intervention.,Results,[188406],[17127],[17203],[False],[0],[0],[False],['0']
22897,PMC4703201,31451,A total of 51 people were screened for participation; 80% were eligible.,Results,[188411],[17204],[17276],[False],[0],[0],[False],['0']
22898,PMC4703201,31452,"Four participants were ineligible because they did not meet the minimum average 8 hour/day sitting time criteria during the enrollment week and 2 participants were ineligible based on work status (i.e., full-time employed after the working group was closed to enrollment).",Results,[188416],[17277],[17549],[False],[0],[0],[False],['0']
22899,PMC4703201,31453,"A total of 15 participants declined participation based on a health condition precluding participation, lack of interest in the study, and/or lack of time to attend study visits.",Results,[188421],[17550],[17728],[False],[0],[0],[False],['0']
22900,PMC4703201,31454,Table 1 highlights the demographic characteristics of the two intervention groups.,Results,[188426],[17729],[17811],[False],[0],[0],[False],['0']
22901,PMC4703201,31455,"The average age was 60.4 years old (SD 5.9), the average body mass index was 27.0 (SD 4.7).",Results,[188431],[17812],[17903],[False],[0],[0],[False],['0']
22902,PMC4703201,31456,"By design, half the participants were employed, 80% were white, 57% were married and 27% were male.",Results,[188436],[17904],[18003],[False],[0],[0],[False],['0']
22903,PMC4703201,31457,"All participants enrolled into the study completed the study, all health education sessions were delivered as anticipated, and all participants complied with activPAL wear time expectations (24 hours for 21days).",Results,[188441],[18004],[18216],[False],[0],[0],[False],['0']
22904,PMC4703201,31458,No adverse events were reported during the intervention period.,Results,[188446],[18217],[18280],[False],[0],[0],[False],['0']
22905,PMC4703201,31459,ActivPAL data,ActivPAL data,[188451],[18281],[18295],[False],[0],[0],[False],['0']
22906,PMC4703201,31460,Analyses were performed on 21 days of data for 15 participants in each arm.,ActivPAL data,[188456],[18296],[18371],[False],[0],[0],[False],['0']
22907,PMC4703201,31461,"Fig 2 shows the changes over time by condition for all the outcomes, regardless of their significance.",ActivPAL data,[188461],[18372],[18474],[False],[0],[0],[False],['0']
22908,PMC4703201,31462,"There was a significant time x condition interaction for sitting time (Beta 57.0 (SE 12.5): p < .0001), standing time (Beta -40.9 (SE 9.4): p < .0001), and number of sit-to-stand transitions (0.10 (0.04): p = .006).",ActivPAL data,[188466],[18475],[18690],[False],[0],[0],[False],['0']
22909,PMC4703201,31463,The interaction term describes the difference in change between groups over time in minutes or transitions per day.,ActivPAL data,[188471],[18691],[18806],[False],[0],[0],[False],['0']
22910,PMC4703201,31464,Those randomized to reduce their sitting time had a significant 130 minute decrease in sitting time but no change in sit-to-stand transitions.,ActivPAL data,[188476],[18807],[18949],[False],[0],[0],[False],['0']
22911,PMC4703201,31465,"Those randomized to increase sit-to-stand transitions had a significant increase in sit-to-stand transitions by about 13 transitions per day, but no change in total sitting time.",ActivPAL data,[188481],[18950],[19128],[False],[0],[0],[False],['0']
22912,PMC4703201,31466,There was no significant interaction for stepping time; all participants increased their physical activity level by 10 minutes/day.,ActivPAL data,[188486],[19129],[19260],[False],[0],[0],[False],['0']
22913,PMC4703201,31467,"Table 2 presents the full results of the statistical models, including 95% confidence intervals to inform future interventions.",ActivPAL data,[188491],[19261],[19388],[False],[0],[0],[False],['0']
22914,PMC4703201,31468,Data were available for a subset of participants (N = 22) processed with the sit-to-stand transition detection every second.,ActivPAL data,[188496],[19389],[19513],[False],[0],[0],[False],['0']
22915,PMC4703201,31469,The default setting is that only stands of 10 seconds are recorded.,ActivPAL data,[188501],[19514],[19581],[False],[0],[0],[False],['0']
22916,PMC4703201,31470,Our participants were not instructed to stand for that long.,ActivPAL data,[188506],[19582],[19642],[False],[0],[0],[False],['0']
22917,PMC4703201,31471,Data from the subset indicated that the average increase in stands achieved in the sit-to-stand group was 40.,ActivPAL data,[188511],[19643],[19752],[False],[0],[0],[False],['0']
22918,PMC4703201,31472,This demonstrates that participants met their goal of 30 additional sit-to-stand per day.,ActivPAL data,[188516],[19753],[19842],[False],[0],[0],[False],['0']
22919,PMC4703201,31473,Interview data,Interview data,[188521],[19843],[19858],[False],[0],[0],[False],['0']
22920,PMC4703201,31474,The in-person interviews revealed that the intervention was acceptable and feasible.,Interview data,[188526],[19859],[19943],[False],[0],[0],[False],['0']
22921,PMC4703201,31475,Participants were comfortable wearing the thigh worn inclinometer 24 hours a day for 21 days.,Interview data,[188531],[19944],[20037],[False],[0],[0],[False],['0']
22922,PMC4703201,31476,Participants understood their behavioral goals and found the information presented to them from the graphical data helpful.,Interview data,[188536],[20038],[20161],[False],[0],[0],[False],['0']
22923,PMC4703201,31477,They were also satisfied with the modes of intervention delivery and intervention content.,Interview data,[188541],[20162],[20252],[False],[0],[0],[False],['0']
22924,PMC4703201,31478,Participants chose from a range of tools to help them.,Interview data,[188546],[20253],[20307],[False],[0],[0],[False],['0']
22925,PMC4703201,31479,Most participants did not recognize how challenging the behavior change would be and selected few supportive tools in the first week.,Interview data,[188551],[20308],[20441],[False],[0],[0],[False],['0']
22926,PMC4703201,31480,"In the second week, they were more cognizant of the barriers and selected more tools to support their behavior.",Interview data,[188556],[20442],[20553],[False],[0],[0],[False],['0']
22927,PMC4703201,31481,The barriers that participants faced were context specific and varied by personal situations and day-to-day routines.,Interview data,[188561],[20554],[20671],[False],[0],[0],[False],['0']
22928,PMC4703201,31482,"This suggests that individualized support is required, at least in the early stages of behavior change.",Interview data,[188566],[20672],[20775],[False],[0],[0],[False],['0']
22929,PMC4703201,31483,"Participants found regular cues to behavior change helpful, e.g.",Interview data,[188571],[20776],[20840],[False],[0],[0],[False],['0']
22930,PMC4703201,31484,"a phone alert, but they had to remember to set the reminder.",Interview data,[188576],[20841],[20901],[False],[0],[0],[False],['0']
22931,PMC4703201,31485,Participants reported difficulty implementing the behavior on weekends because of the variability in activities they did compared to the weekdays.,Interview data,[188581],[20902],[21048],[False],[0],[0],[False],['0']
22932,PMC4703201,31486,It was challenging to integrate the targeted behavior change into activities that were outside their daily routines.,Interview data,[188586],[21049],[21165],[False],[0],[0],[False],['0']
22933,PMC4703201,31487,"During the interviews, participants reported a variety of benefits associated with either sitting less or increasing sit-to-stand transitions.",Interview data,[188591],[21166],[21308],[False],[0],[0],[False],['0']
22934,PMC4703201,31488,"For example, several participants mentioned drinking more water while working towards the goal because standing provided more opportunities to move around the home or office.",Interview data,[188596],[21309],[21483],[False],[0],[0],[False],['0']
22935,PMC4703201,31489,"Other participants mentioned more social interactions at work as they would opt to walk to a co-worker’s office to talk, as opposed to sending an email or using the phone.",Interview data,[188601],[21484],[21655],[False],[0],[0],[False],['0']
22936,PMC4703201,31490,"Additionally, participants also indicated that they accomplished more household chores during the study and were more productive in the evenings based on their motivation to achieve the study goals.",Interview data,[188606],[21656],[21854],[False],[0],[0],[False],['0']
22937,PMC4703201,31491,Discussion,Discussion,[188611],[21855],[21866],[False],[0],[0],[False],['0']
22938,PMC4703201,31492,This was the first randomized control trial of two different strategies to interrupt sitting conducted in older adults.,Discussion,[188616],[21867],[21986],[False],[0],[0],[False],['0']
22939,PMC4703201,31493,"Recruitment, measurement and intervention delivery all proved feasible and acceptable.",Discussion,[188621],[21987],[22073],[False],[0],[0],[False],['0']
22940,PMC4703201,31494,The results showed that each intervention group focused on the behavior goal they were given and only the targeted behavior changed.,Discussion,[188626],[22074],[22206],[False],[0],[0],[False],['0']
22941,PMC4703201,31495,"For example the reduce sitting time group decreased their daily sitting time on average by the recommended two hours (from 644 minutes to 514 per day) and increased their standing time, but their sit-to-stand transitions did not change.",Discussion,[188631],[22207],[22443],[False],[0],[0],[False],['0']
22942,PMC4703201,31496,"The sit-to-stand transition group increased their transitions (on average 10 extra transitions per day), but did not decrease their daily sitting time.",Discussion,[188636],[22444],[22595],[False],[0],[0],[False],['0']
22943,PMC4703201,31497,These findings support the paradigm that reducing sitting and increasing sit-to-stand transitions are independent behaviors and require distinct and specific goals.,Discussion,[188641],[22596],[22760],[False],[0],[0],[False],['0']
22944,PMC4703201,31498,"Although there was a significant increase in physical activity over time in both groups, the increase in minutes was small and was not sufficient to meet physical activity recommendations.",Discussion,[188646],[22761],[22949],[False],[0],[0],[False],['0']
22945,PMC4703201,31499,This lends support to the idea that sedentary behavior is independent of meeting daily physical activity guidelines.,Discussion,[188651],[22950],[23066],[False],[0],[0],[False],['0']
22946,PMC4703201,31500,"The increase in sit-to-stand transitions, although significant, was smaller than the 30 per day increase encouraged by the health educators.",Discussion,[188656],[23067],[23207],[False],[0],[0],[False],['0']
22947,PMC4703201,31501,The overall smaller success in this target behavior could have been due to the inclinometer default setting which only registered breaks lasting at least 10 seconds; thus a sit-to-stand transition that involved less than 10 seconds of standing would not have been captured by the measurement device.,Discussion,[188662],[23208],[23507],[True],['ResponsivenessOfMeasurement'],['a sit-to-stand transition that involved less than 10 seconds of standing would not have been captured by the measurement device'],[True],['OutcomeMeasures']
22948,PMC4703201,31502,Part way through the intervention we discovered this default could be changed and analyses in a subsample of participants indicated average increases of 40 stands per days.,Discussion,[188671],[23508],[23680],[False],[0],[0],[False],['0']
22949,PMC4703201,31503,"The eligibility criterion for the study was at least 8 hours of sitting on average, per day.",Discussion,[188676],[23681],[23773],[False],[0],[0],[False],['0']
22950,PMC4703201,31504,There was no criterion related to the number of sit-to-stand transitions participants took at baseline.,Discussion,[188681],[23774],[23877],[True],['DiagnosticCriteria'],['no criterion related to the number of sit-to-stand transitions participants took at baseline'],[True],['Population']
22951,PMC4703201,31505,"Therefore, some participants already had high numbers of sit-to-stand transitions at baseline, despite also meeting the daily 8 hour per day sitting time criteria.",Discussion,[188691],[23878],[24041],[False],[0],[0],[False],['0']
22952,PMC4703201,31506,Achieving the goal of 30 extra stands throughout the day was perhaps more difficult in these individuals.,Discussion,[188696],[24042],[24147],[False],[0],[0],[False],['0']
22953,PMC4703201,31507,"In future studies, eligibility criteria should also preclude participants with a high number of sit-to-stand transitions.",Discussion,[188701],[24148],[24269],[False],[0],[0],[False],['0']
22954,PMC4703201,31508,"Previous studies have shown similar reductions in sitting time and increases in standing time as seen in our ‘reduce sitting by two hours’ condition [17,18].",Discussion,[188706],[24270],[24427],[False],[0],[0],[False],['0']
22955,PMC4703201,31509,No previous study has targeted sit-to-stand transitions with a specific goal (e.g.,Discussion,[188711],[24428],[24510],[False],[0],[0],[False],['0']
22956,PMC4703201,31510,"30 additional transitions); although some studies did encourage frequent breaks [17,27] and only one previous study has achieved a significant change in this behavior but only increased transitions by about an additional 4 breaks per day [26,28].",Discussion,[188716],[24511],[24757],[False],[0],[0],[False],['0']
22957,PMC4703201,31511,"Other studies have shown no change in physical activity [17], or small changes as seen in our study [27].",Discussion,[188721],[24758],[24863],[False],[0],[0],[False],['0']
22958,PMC4703201,31512,Our study adds to this body of literature because few previous sedentary behavior intervention pilot studies have utilized a randomized design [29–32].,Discussion,[188726],[24864],[25015],[False],[0],[0],[False],['0']
22959,PMC4703201,31513,"Furthermore, most studies did not include participants over 65 years of age and were delivered exclusively in worksite settings [17,29].",Discussion,[188731],[25016],[25152],[False],[0],[0],[False],['0']
22960,PMC4703201,31514,Three previous studies in older adults used only pre-post designs and did not find as large a reduction in sitting as in our cohort [26–28].,Discussion,[188736],[25153],[25293],[False],[0],[0],[False],['0']
22961,PMC4703201,31515,"Our study strengths include the randomized group comparison, objective measures of behavior, inclusion of older adults, and a working and non-working population.",Discussion,[188741],[25294],[25455],[False],[0],[0],[False],['0']
22962,PMC4703201,31516,Limitations include the short intervention period and predominantly educated and white participant group.,Discussion,"[188748, 188749]","[25456, 25456]","[25561, 25561]","[True, True]","['ExperimentalPhaseDuration', 'VerySpecificPopulation']","['the short intervention period', 'predominantly educated and white participant group']","[True, True]","['Population', 'StudyDuration']"
22963,PMC4703201,31517,"Further, study staff were not blinded to the intervention because it involved weekly feedback to participants.",Discussion,[188760],[25562],[25672],[True],['StudyTeam'],['study staff were not blinded'],[True],['Blinding']
22964,PMC4703201,31518,Conclusions,Conclusions,[188766],[25673],[25685],[False],[0],[0],[False],['0']
22965,PMC4703201,31519,This is the first pilot study in older adult workers and non-workers to attempt to interrupt sitting behaviors in two different ways.,Conclusions,[188771],[25686],[25819],[False],[0],[0],[False],['0']
22966,PMC4703201,31520,One strategy was to reduce sitting time by 2 hours per day; the other was to increase daily sit-to-stand transitions by 30.,Conclusions,[188776],[25820],[25943],[False],[0],[0],[False],['0']
22967,PMC4703201,31521,Both groups changed the targeted behavior exclusively without changing the other behavior.,Conclusions,[188781],[25944],[26034],[False],[0],[0],[False],['0']
22968,PMC4703201,31522,Participants were compliant and satisfied with the intervention and measurement procedures.,Conclusions,[188786],[26035],[26126],[False],[0],[0],[False],['0']
22969,PMC4703201,31523,Future studies can build on our intervention procedures by testing the intervention strategies in larger samples for longer periods and adding health outcomes.,Conclusions,[188791],[26127],[26286],[False],[0],[0],[False],['0']
22970,PMC4703201,31524,Abbreviations,Abbreviations,[188796],[26287],[26302],[False],[0],[0],[False],['0']
22971,PMC4703201,31525,SD standard deviation,Abbreviations|SD standard deviation,[188801],[26303],[26324],[False],[0],[0],[False],['0']
22972,PMC4703201,31526,SE standard error,Abbreviations|SE standard error,[188806],[26325],[26342],[False],[0],[0],[False],['0']
23614,PMC4797126,7554,A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma,Title,[45320],[49984],[114],[False],[0],[0],[False],['0']
23615,PMC4797126,7555,Background,Abstract,[45324],[115],[126],[False],[0],[0],[False],['0']
23616,PMC4797126,7556,"Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells.",Abstract,[45328],[127],[289],[False],[0],[0],[False],['0']
23617,PMC4797126,7557,"In patients with mild asthma, quilizumab reduced serum IgE and attenuated the early and late asthmatic reaction following whole lung allergen challenge.",Abstract,[45332],[290],[442],[False],[0],[0],[False],['0']
23618,PMC4797126,7558,"This study evaluated the efficacy and safety of quilizumab in adults with allergic asthma, inadequately controlled despite high-dose inhaled corticosteroids (ICS) and a second controller.",Abstract,[45336],[443],[630],[False],[0],[0],[False],['0']
23619,PMC4797126,7559,Methods,Abstract,[45340],[631],[638],[False],[0],[0],[False],['0']
23620,PMC4797126,7560,"Five hundred seventy-eight patients were randomized to monthly or quarterly dosing regimens of subcutaneous quilizumab or placebo for 36 weeks, with a 48-week safety follow-up.",Abstract,[45344],[639],[815],[False],[0],[0],[False],['0']
23621,PMC4797126,7561,"Quilizumab was evaluated for effects on the rate of asthma exacerbations, lung function, patient symptoms, serum IgE, and pharmacokinetics.",Abstract,[45348],[816],[955],[False],[0],[0],[False],['0']
23622,PMC4797126,7562,"Exploratory analyses were conducted on biomarker subgroups (periostin, blood eosinophils, serum IgE, and exhaled nitric oxide).",Abstract,[45352],[956],[1083],[False],[0],[0],[False],['0']
23623,PMC4797126,7563,Results,Abstract,[45356],[1084],[1091],[False],[0],[0],[False],['0']
23624,PMC4797126,7564,"Quilizumab was well tolerated and reduced serum total and allergen-specific IgE by 30–40 %, but had no impact on asthma exacerbations, lung function, or patient-reported symptom measures.",Abstract,[45360],[1092],[1279],[False],[0],[0],[False],['0']
23625,PMC4797126,7565,"At Week 36, the 300 mg monthly quilizumab group showed a 19.6 % reduction (p = 0.38) in the asthma exacerbation rate relative to placebo, but this was neither statistically nor clinically significant.",Abstract,[45364],[1280],[1480],[False],[0],[0],[False],['0']
23626,PMC4797126,7566,Biomarker subgroups did not reveal meaningful efficacy benefits following quilizumab treatment.,Abstract,[45368],[1481],[1576],[False],[0],[0],[False],['0']
23627,PMC4797126,7567,Conclusions,Abstract,[45372],[1577],[1588],[False],[0],[0],[False],['0']
23628,PMC4797126,7568,Quilizumab had an acceptable safety profile and reduced serum IgE.,Abstract,[45376],[1589],[1655],[False],[0],[0],[False],['0']
23629,PMC4797126,7569,"However, targeting the IgE pathway via depletion of IgE-switched and memory B cells was not sufficient for a clinically meaningful benefit for adults with allergic asthma uncontrolled by standard therapy.",Abstract,[45380],[1656],[1860],[False],[0],[0],[False],['0']
23630,PMC4797126,7570,Trial registration,Abstract,[45384],[1861],[1879],[False],[0],[0],[False],['0']
23631,PMC4797126,7571,ClinicalTrials.gov NCT01582503,Abstract,[45388],[1880],[1910],[False],[0],[0],[False],['0']
23632,PMC4797126,7572,Electronic supplementary material,Abstract,[45392],[1911],[1944],[False],[0],[0],[False],['0']
23633,PMC4797126,7573,"The online version of this article (doi:10.1186/s12931-016-0347-2) contains supplementary material, which is available to authorized users.",Abstract,[45396],[1945],[2084],[False],[0],[0],[False],['0']
23634,PMC4797126,7574,Background,Background,[45400],[2085],[2096],[False],[0],[0],[False],['0']
23635,PMC4797126,7575,"Asthma, a chronic inflammatory disorder of the airways, affects over 300 million people worldwide.",Background,[45404],[2097],[2195],[False],[0],[0],[False],['0']
23636,PMC4797126,7576,Some patients have persistent symptoms despite the use of steroids and other therapies.,Background,[45408],[2196],[2283],[False],[0],[0],[False],['0']
23637,PMC4797126,7577,These patients are at the highest risk for future exacerbations and unscheduled use of healthcare resources.,Background,[45412],[2284],[2392],[False],[0],[0],[False],['0']
23638,PMC4797126,7578,"Asthma is a heterogeneous disorder with distinct endotypes, the pathogenic cellular and molecular mechanisms that drive disease in different patient subgroups.",Background,[45416],[2393],[2552],[False],[0],[0],[False],['0']
23639,PMC4797126,7579,"Allergic asthma is a hypersensitivity driven by the complex interaction of epithelial, dendritic, and type 2 innate lymphoid cells, leading to activation of CD4+ T helper 2 (Th2) cells in response to allergen exposure.",Background,[45420],[2553],[2771],[False],[0],[0],[False],['0']
23640,PMC4797126,7580,"Th2 cells produce interleukin (IL)-4, IL-5, IL-13, and other cytokines that promote immunoglobulin E (IgE) class switching of B cells, increased IgE synthesis by plasma B cells, and recruitment and activation of eosinophils and other inflammatory cells.",Background,[45424],[2772],[3025],[False],[0],[0],[False],['0']
23641,PMC4797126,7581,"When allergen cross-links IgE bound to IgE receptors on mast cells and basophils, cell activation and allergic mediator release occur, which may lead to mucus production and airway hyperreactivity.",Background,[45428],[3026],[3223],[False],[0],[0],[False],['0']
23642,PMC4797126,7582,"Biomarkers in sputum, bronchoalveolar lavage, blood, and bronchial biopsies may indicate a particular endotype and potentially identify patients with increased responsiveness to endotype-specific treatments.",Background,[45432],[3224],[3431],[False],[0],[0],[False],['0']
23643,PMC4797126,7583,"For example, elevated levels of serum periostin, an extracellular matrix protein induced by IL-4 and IL-13 in airway epithelium, identified a subset of asthma patients who responded better to lebrikizumab, an anti-IL-13 monoclonal antibody.",Background,[45436],[3432],[3672],[False],[0],[0],[False],['0']
23644,PMC4797126,7584,"Similarly, patients with high levels of exhaled nitric oxide (NO), blood eosinophils, or serum periostin, had fewer asthma exacerbations following treatment with omalizumab, a neutralizing anti-IgE antibody, than patients with low biomarker levels.",Background,[45440],[3673],[3921],[False],[0],[0],[False],['0']
23645,PMC4797126,7585,These data suggest that IgE may drive allergic asthma in a subset of patients.,Background,[45444],[3922],[4000],[False],[0],[0],[False],['0']
23646,PMC4797126,7586,"Quilizumab is a humanized, monoclonal IgG1 that binds to the M1-prime segment present only on membrane IgE, but not on soluble IgE in serum.",Background,[45448],[4001],[4141],[False],[0],[0],[False],['0']
23647,PMC4797126,7587,"Membrane IgE is expressed on IgE-switched B cells, IgE memory B cells, and IgE plasmablasts, but not on IgE plasma cells.",Background,[45452],[4142],[4263],[False],[0],[0],[False],['0']
23648,PMC4797126,7588,"In animal studies, anti-M1 prime bound membrane IgE on IgE-switched B cells and plasmablasts and depleted them through apoptosis and antibody-dependent cell-mediated cytotoxicity, leading to fewer IgE plasma cells and less production of soluble IgE.",Background,[45456],[4264],[4513],[False],[0],[0],[False],['0']
23649,PMC4797126,7589,"We previously evaluated the safety, tolerability, and activity of quilizumab in Phase Ia (31 healthy volunteers), Phase Ib (24 allergic rhinitis patients) and Phase IIa (15 mild asthma patients) studies.",Background,[45460],[4514],[4717],[False],[0],[0],[False],['0']
23650,PMC4797126,7590,"In these studies, quilizumab reduced serum total IgE by approximately 25 %.",Background,[45464],[4718],[4793],[False],[0],[0],[False],['0']
23651,PMC4797126,7591,"These decreases were sustained for at least 6 months after the last dose, in contrast to omalizumab, which must be administered every 2–4 weeks to maintain reduced IgE levels.",Background,[45468],[4794],[4969],[False],[0],[0],[False],['0']
23652,PMC4797126,7592,"Quilizumab also abrogated the increase in challenge-specific IgE in patients with mild asthma following a whole-lung allergen challenge, and reduced the early and late asthmatic reactions.",Background,[45472],[4970],[5158],[False],[0],[0],[False],['0']
23653,PMC4797126,7593,Quilizumab may reset the IgE repertoire by targeting IgE production and provide a more sustained effect with a lower dose frequency then omalizumab.,Background,[45476],[5159],[5307],[False],[0],[0],[False],['0']
23654,PMC4797126,7594,"The primary purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of quilizumab after 36 weeks of treatment in adults with allergic asthma inadequately controlled despite high-dose inhaled corticosteroids (ICS) and a second controller.",Background,[45480],[5308],[5570],[False],[0],[0],[False],['0']
23655,PMC4797126,7595,Methods,Methods,[45484],[5571],[5579],[False],[0],[0],[False],['0']
23656,PMC4797126,7596,Trial design,Methods|Trial design,[45488],[5580],[5592],[False],[0],[0],[False],['0']
23657,PMC4797126,7597,"The COSTA trial of quilizumab was a Phase II, randomized, double-blind, placebo-controlled study (including recruiting sites from 14 countries: Argentina, Belgium, Bulgaria, Canada, Germany, Hungary, Mexico, New Zealand, Peru, Poland, Romania, Russia, Ukraine, and the United States) that enrolled 578 adults with uncontrolled allergic asthma.",Methods|Trial design,[45492],[5593],[5936],[False],[0],[0],[False],['0']
23658,PMC4797126,7598,Patients were randomly assigned (1:1:1:1) to one of three dosing regimens of quilizumab or placebo using an interactive web response system.,Methods|Trial design,[45496],[5937],[6077],[False],[0],[0],[False],['0']
23659,PMC4797126,7599,"Randomization was stratified based on serum periostin level (<50 ng/mL, ≥50 ng/mL), exacerbation history (number of exacerbations (1, >1) requiring use of systemic corticosteroids in the prior 18 months), IgE level (≤75 IU/mL, 75–200 IU/mL, >200 IU/mL), and country.",Methods|Trial design,[45500],[6078],[6344],[False],[0],[0],[False],['0']
23660,PMC4797126,7600,Patients and study site personnel were blinded to treatment assignments until all follow-up data through Week 84 were collected and verified.,Methods|Trial design,[45504],[6345],[6486],[False],[0],[0],[False],['0']
23661,PMC4797126,7601,"Quilizumab (Genentech, Inc., South San Francisco, CA) was delivered subcutaneously at nine monthly intervals at 300 mg per dose (300 mg M), or at three quarterly intervals and at Week 4 at 150 or 450 mg per dose (150 or 450 mg Q).",Methods|Trial design,[45508],[6487],[6717],[False],[0],[0],[False],['0']
23662,PMC4797126,7602,The treatment period ended 36 weeks after randomization and was followed by a 48-week period to assess the sustained efficacy and safety of quilizumab (see Additional file 1: Figure S1).,Methods|Trial design,[45512],[6718],[6904],[False],[0],[0],[False],['0']
23663,PMC4797126,7603,"Ethics, consent, and permissions","Methods|Ethics, consent, and permissions",[45516],[6905],[6937],[False],[0],[0],[False],['0']
23664,PMC4797126,7604,"Quorum Review based in Seattle, WA was the primary central IRB used by sites in North America, however multiple other site-specific institutional review boards at other global sites approved the protocol and patients gave written, informed consent.","Methods|Ethics, consent, and permissions",[45520],[6938],[7186],[False],[0],[0],[False],['0']
23665,PMC4797126,7605,"The trial was conducted in full conformance with the International Conference on Harmonisation E6 guidelines and the Declaration of Helsinki, or laws and regulations of the country where the research was conducted, whichever afforded greater protection to the individual.","Methods|Ethics, consent, and permissions",[45524],[7187],[7458],[False],[0],[0],[False],['0']
23666,PMC4797126,7606,Participants,Methods|Participants,[45528],[7459],[7471],[False],[0],[0],[False],['0']
23667,PMC4797126,7607,Inclusion criteria,Methods|Inclusion criteria,[45532],[7472],[7490],[False],[0],[0],[False],['0']
23668,PMC4797126,7608,"Adult asthma patients, aged 18–75 years, were required to have: bronchodilator reversibility of either ≥12 % β-agonist reversibility using 4 puffs of a short-acting β − agonist (SABA) or a PC20 FEV1 methacholine (provocative concentration of methacholine producing a 20 % fall in FEV1 (forced expiratory volume in 1 s)) of 8 mg/mL or less, within the last 2 years; a pre-bronchodilator FEV1 at screening of 40–80 % predicted; daily use of ICS (≥400 μg/day total daily dose of fluticasone propionate or equivalent) and a second controller for a minimum of 3 consecutive months; inadequately-controlled asthma as documented by a 5-item Asthma Control Questionnaire (ACQ-5) score ≥1.50 at screening and randomization, despite compliance with asthma controller therapy; at least one positive aeroallergen-specific IgE (≥0.35 kU(A)/L), or a total serum IgE ≥75 IU/mL; and a history of at least one protocol-defined asthma exacerbation in the 18 months prior to screening.",Methods|Inclusion criteria,[45536],[7491],[8457],[False],[0],[0],[False],['0']
23669,PMC4797126,7609,"Asthma exacerbations were defined as new or increased asthma symptoms (wheezing, cough, chest tightness, shortness of breath, or nighttime awakening due to symptoms) that led to treatment with systemic corticosteroids for at least 3 days or to hospitalization.",Methods|Inclusion criteria,[45540],[8458],[8718],[False],[0],[0],[False],['0']
23670,PMC4797126,7610,Exclusion criteria,Methods|Exclusion criteria,[45544],[8719],[8737],[False],[0],[0],[False],['0']
23671,PMC4797126,7611,"Patients were excluded from the study if they had an asthma exacerbation requiring systemic steroids in the 30 days prior to screening, or between screening and randomization, a >20 % relative change in FEV1 between screening and randomization, any pre-existing active lung disease other than asthma, any infections, elevated IgE levels for reasons other than allergy, or were former or current smokers.",Methods|Exclusion criteria,[45548],[8738],[9141],[False],[0],[0],[False],['0']
23672,PMC4797126,7612,Outcome measures,Methods|Outcome measures,[45552],[9142],[9158],[False],[0],[0],[False],['0']
23673,PMC4797126,7613,The primary efficacy outcome was the annualized rate of protocol-defined asthma exacerbations from baseline to Week 36.,Methods|Outcome measures,[45556],[9159],[9278],[False],[0],[0],[False],['0']
23674,PMC4797126,7614,"Secondary efficacy outcomes included assessments of lung function using the relative change in pre-bronchodilator FEV1 from baseline to Weeks 12 and 36 and the change in asthma symptoms from baseline to Week 36, using total and daytime symptom severity scores derived from a daily patient diary.",Methods|Outcome measures,[45560],[9279],[9574],[False],[0],[0],[False],['0']
23675,PMC4797126,7615,The diary was also used to determine the proportion of patients who had no nighttime awakenings due to asthma symptoms and the proportion of patients with fewer than 2 days of SABA use per week by Week 36.,Methods|Outcome measures,[45564],[9575],[9780],[False],[0],[0],[False],['0']
23676,PMC4797126,7616,"Exploratory outcome measures included the change in asthma control from baseline to Week 36, as measured by the ACQ-5.",Methods|Outcome measures,[45568],[9781],[9899],[False],[0],[0],[False],['0']
23677,PMC4797126,7617,"To assess the change in allergy-related quality-of-life measures from baseline to Week 36, the Standardized Asthma Quality of Life Questionnaire (AQLQ(S)) and the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) were administered at patient visits throughout the treatment and follow-up periods.",Methods|Outcome measures,[45572],[9900],[10219],[False],[0],[0],[False],['0']
23678,PMC4797126,7618,"We also evaluated the ability of biomarkers (serum periostin, blood eosinophils, exhaled NO, and serum IgE) to predict benefit from quilizumab.",Methods|Outcome measures,[45576],[10220],[10363],[False],[0],[0],[False],['0']
23679,PMC4797126,7619,Safety outcomes were assessed throughout the 36-week treatment and 48-week follow-up periods.,Methods|Outcome measures,[45580],[10364],[10457],[False],[0],[0],[False],['0']
23680,PMC4797126,7620,Assessments,Methods|Assessments,[45584],[10458],[10469],[False],[0],[0],[False],['0']
23681,PMC4797126,7621,"The patient daily diary included two sections in addition to peak flow measurements: 1) a morning section capturing awakenings and rescue medication use at night, and symptoms on awakening; and 2) an evening section capturing daytime symptom severity, rescue medication use, preventive inhaler use, activity impairment during the day, and nasal symptoms.",Methods|Assessments,[45588],[10470],[10824],[False],[0],[0],[False],['0']
23682,PMC4797126,7622,"The modified total asthma symptom score (mTASS) was generated from a subset of diary questions adapted from a previous questionnaire, scoring nighttime awakenings (0–3), symptoms on awakening (0–1), and daytime symptom severity (0–4), for a total score range of 0–8.",Methods|Assessments,[45592],[10825],[11091],[False],[0],[0],[False],['0']
23683,PMC4797126,7623,"For the analyses of symptom scores, rescue medication use, and nighttime awakenings, daily scores were averaged over the previous 7 days prior to the time point of interest.",Methods|Assessments,[45596],[11092],[11265],[False],[0],[0],[False],['0']
23684,PMC4797126,7624,Baseline values were derived from a minimum of 10 days of patient diary entries during the 14 days prior to the first treatment.,Methods|Assessments,[45600],[11266],[11394],[False],[0],[0],[False],['0']
23685,PMC4797126,7625,Pharmacokinetics and immunogenicity,Methods|Pharmacokinetics and immunogenicity,[45604],[11395],[11430],[False],[0],[0],[False],['0']
23686,PMC4797126,7626,"Serum levels of quilizumab for pharmacokinetic assessments were measured using a validated enzyme-linked immunosorbent assay (ELISA; Genentech, Inc., South San Francisco, CA).",Methods|Pharmacokinetics and immunogenicity,[45608],[11431],[11606],[False],[0],[0],[False],['0']
23687,PMC4797126,7627,"The pharmacokinetic outcomes included: serum concentrations prior to dosing at Weeks 0, 4, 12, 24, and 32; serum concentrations at Week 5 and Week 25; maximum observed serum concentrations (Cmax,obs); time of maximum observed serum concentration (Tmax, obs); and terminal elimination half-life (t1/2).",Methods|Pharmacokinetics and immunogenicity,[45612],[11607],[11908],[False],[0],[0],[False],['0']
23688,PMC4797126,7628,"Serum anti-therapeutic antibodies (ATAs) were assessed in samples at Weeks 0, 4, 12, 24, 36, 48, 60, and 84 using a validated bridging ELISA (Genentech, Inc., South San Francisco, CA).",Methods|Pharmacokinetics and immunogenicity,[45616],[11909],[12093],[False],[0],[0],[False],['0']
23689,PMC4797126,7629,Biomarkers,Methods|Biomarkers,[45620],[12094],[12104],[False],[0],[0],[False],['0']
23690,PMC4797126,7630,Samples for biomarker assessments were collected throughout the study.,Methods|Biomarkers,[45624],[12105],[12175],[False],[0],[0],[False],['0']
23691,PMC4797126,7631,"Allergen-specific and total IgE were measured in serum by ImmunoCAP® Specific IgE blood tests (ViraCor-IBT Laboratories, Lee’s Summit, MO).",Methods|Biomarkers,[45628],[12176],[12315],[False],[0],[0],[False],['0']
23692,PMC4797126,7632,"Specific IgE was measured for the following allergens: cat, house dust mite (HDM) Dermatophagoides farinae, HDM Dermatophagoides pteronyssinus, ragweed, aspergillus, timothy grass, bermuda grass, oak, birch, plantain, and orchard grass.",Methods|Biomarkers,[45632],[12316],[12552],[False],[0],[0],[False],['0']
23693,PMC4797126,7633,The maximum specific IgE was defined as the specific IgE with the highest titer of specific IgEs pre-dose in each patient.,Methods|Biomarkers,[45636],[12553],[12675],[False],[0],[0],[False],['0']
23694,PMC4797126,7634,"Only observed values of IgE levels were analyzed, with no imputation performed for missing IgE data.",Methods|Biomarkers,[45640],[12676],[12776],[False],[0],[0],[False],['0']
23695,PMC4797126,7635,Peripheral blood eosinophil counts were obtained from standard complete blood counts.,Methods|Biomarkers,[45644],[12777],[12862],[False],[0],[0],[False],['0']
23696,PMC4797126,7636,"Serum periostin was measured by immunoassay using the Roche Elecsys platform (Roche Diagnostics Ltd., Rotkreuz, Switzerland).",Methods|Biomarkers,[45648],[12863],[12988],[False],[0],[0],[False],['0']
23697,PMC4797126,7637,"Fractional exhaled nitric oxide (FeNO) was measured using a hand-held portable device, NIOX MINO® (Niox; Morrisville, NC), according to American Thoracic Society/European Respiratory Society 2009 guidelines.",Methods|Biomarkers,[45652],[12989],[13196],[False],[0],[0],[False],['0']
23698,PMC4797126,7638,Statistical methods,Methods|Statistical methods,[45656],[13197],[13216],[False],[0],[0],[False],['0']
23699,PMC4797126,7639,"All patients received at least one dose of study drug (intention-to-treat, ITT population) and were included in all safety and efficacy analyses.",Methods|Statistical methods,[45660],[13217],[13362],[False],[0],[0],[False],['0']
23700,PMC4797126,7640,Demographic and baseline characteristics were summarized using descriptive statistics.,Methods|Statistical methods,[45664],[13363],[13449],[False],[0],[0],[False],['0']
23701,PMC4797126,7641,"The primary endpoint, the annualized exacerbation rate, was calculated by the total number of protocol-defined exacerbations observed in the group over the treatment period divided by total patient-weeks at risk (number of weeks from first study drug administration to the earliest of Week 36 or study discontinuation) for the group and multiplied by 52.",Methods|Statistical methods,[45668],[13450],[13804],[False],[0],[0],[False],['0']
23702,PMC4797126,7642,"For patients who discontinued the study prematurely, there was no imputation of additional exacerbations.",Methods|Statistical methods,[45672],[13805],[13910],[False],[0],[0],[False],['0']
23703,PMC4797126,7643,"The rates of asthma exacerbations were compared between study groups using a Poisson regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and IgE level (<200, ≥200 IU/mL).",Methods|Statistical methods,[45676],[13911],[14161],[False],[0],[0],[False],['0']
23704,PMC4797126,7644,"For biomarker subgroup analyses, unadjusted asthma exacerbation rates were calculated.",Methods|Statistical methods,[45680],[14162],[14248],[False],[0],[0],[False],['0']
23705,PMC4797126,7645,Corresponding two-sided p-values and 90 % confidence intervals (CI) were reported.,Methods|Statistical methods,[45684],[14249],[14331],[False],[0],[0],[False],['0']
23706,PMC4797126,7646,The relative change in pre-bronchodilator FEV1 from baseline was calculated as the absolute change in FEV1 (volume in liters) from baseline divided by the FEV1 at baseline.,Methods|Statistical methods,[45688],[14332],[14504],[False],[0],[0],[False],['0']
23707,PMC4797126,7647,"For secondary and exploratory end points, the means and standard deviations of all values for relative change were calculated according to study group at Weeks 12 and 36.",Methods|Statistical methods,[45692],[14505],[14675],[False],[0],[0],[False],['0']
23708,PMC4797126,7648,"The mean relative changes from baseline were compared between the study groups using the differences between the means for each group, with the associated two-sided 90 % CIs.",Methods|Statistical methods,[45696],[14676],[14850],[False],[0],[0],[False],['0']
23709,PMC4797126,7649,"Missing values were imputed using the last-observation-carried-forward (LOCF) approach, as prespecified in the statistical analysis plan.",Methods|Statistical methods,[45700],[14851],[14988],[False],[0],[0],[False],['0']
23710,PMC4797126,7650,"An analysis of covariance (ANCOVA) model with factors for baseline level, periostin status (<50 ng/mL, ≥50 ng/mL), number of prior exacerbations (1, >1), and IgE level (<200 IU/mL, ≥200 IU/mL) was fit to assess the treatment effect.",Methods|Statistical methods,[45704],[14989],[15221],[False],[0],[0],[False],['0']
23711,PMC4797126,7651,Sample size determination,Methods|Sample size determination,[45708],[15222],[15247],[False],[0],[0],[False],['0']
23712,PMC4797126,7652,We planned to randomize 560 patients to one of three dose regimens of quilizumab or placebo in a 1:1:1:1 ratio (140 patients per group).,Methods|Sample size determination,[45712],[15248],[15384],[False],[0],[0],[False],['0']
23713,PMC4797126,7653,"This sample size provided approximately 84 % power to detect a 50 % reduction in average exacerbation rates due to quilizumab, assuming 0.63 exacerbations per patient in the placebo group over a 36-week treatment period, and a significance level of α = 0.10.",Methods|Sample size determination,[45716],[15385],[15643],[False],[0],[0],[False],['0']
23714,PMC4797126,7654,"This sample size also provided approximately 70 % power to detect a 50 % reduction in average exacerbation rates in the subgroup of periostin-high patients, assuming 0.69 exacerbations per patient in the placebo group over the 36-week period, a significance level of 0.15, and 50 % of patients in each treatment arm to be periostin high.",Methods|Sample size determination,[45720],[15644],[15981],[False],[0],[0],[False],['0']
23715,PMC4797126,7655,Results,Results,[45724],[15982],[15990],[False],[0],[0],[False],['0']
23716,PMC4797126,7656,Patient demographics and study flow,Results|Patient demographics and study flow,[45728],[15991],[16026],[False],[0],[0],[False],['0']
23717,PMC4797126,7657,Study flow chart.,Results|Patient demographics and study flow,[45732],[16027],[16044],[False],[0],[0],[False],['0']
23718,PMC4797126,7658,"I/E, inclusion/exclusion; M, monthly; Q, quarterly",Results|Patient demographics and study flow,[45736],[16045],[16095],[False],[0],[0],[False],['0']
23719,PMC4797126,7659,Patient demographics/baseline characteristics,Results|Patient demographics/baseline characteristics,[45740],[16096],[16141],[False],[0],[0],[False],['0']
23720,PMC4797126,7660,	Placebo(n = 145)	Quilizumab 150 mg Q(n = 145)	Quilizumab450 mg Q(n = 145)	Quilizumab300 mg M(n = 143)	All Patients(N = 578)	 	Age (y)	47.9 (13.0)	46.8 (13.3)	47.0 (13.6)	44.8a (12.2)	46.6 (13.1)	 	Gender (Female)	84 (58 %)	89 (61 %)	98 (68 %)	86 (60 %)	357 (62 %)	 	Race (White)	122 (84 %)	119 (82 %)	117 (81 %)	114 (80 %)	472 (82 %)	 	Weight (kg)	82.8 (23.3)	81.4 (18.13)	80.3 (21.4)	81.3 (19.4)	81.4 (20.6)	 	Previous number of exacerbations	 	 1	90 (62 %)	88 (61 %)	91 (63 %)	89 (62 %)	358 (62 %)	 	 2	30 (21 %)	33 (23 %)	31 (21 %)	28 (20 %)	122 (21 %)	 	 ≥3	25 (17 %)	24 (17 %)	23 (16 %)	26 (18 %)	98 (17 %)	 	FEV1 % predicted	60.8 (11.9)	58.6 (12.2)	61.2 (12.8)	63 (12.7)	60.9 (12.5)	 	FEV1 % reversibility	19.6 (15.8)	23.3 (20.6)	21.6 (18.8)	23.4 (18.0)	22 (18.4)	 	IgE (IU/mL) median	234.0	254.0	249.5	190.0a	232.5	 	Periostin (ng/mL) median	51.0	53.4	52.4	52.1	51.9	 	FeNO (ppb)	33.4 (32.0)	35.7 (36.26)	33.8 (32.1)	35.2 (32.5)	34.5 (33.2)	 	Eosinophils (cells/μl) median	210	220	220	240	220,Results|Patient demographics/baseline characteristics,[45744],[16142],[17142],[False],[0],[0],[False],['0']
23721,PMC4797126,7661,Mean (SD) unless otherwise noted,Results|Mean (SD) unless otherwise noted,[45748],[17143],[17178],[False],[0],[0],[False],['0']
23722,PMC4797126,7662,aThe 300 mg M treatment group had a lower age and IgE level,Results|,[45752],[17179],[17239],[False],[0],[0],[False],['0']
23723,PMC4797126,7663,"M monthly, Q quarterly","M monthly, Q quarterly",[45756],[17240],[17263],[False],[0],[0],[False],['0']
23724,PMC4797126,7664,1212 patients were screened for eligibility and 578 adult asthma patients (18–75 years old) were enrolled (Fig.,"M monthly, Q quarterly",[45760],[17264],[17375],[False],[0],[0],[False],['0']
23725,PMC4797126,7665,1) from April 2012 to September 2013; the study was completed in November 2014.,"M monthly, Q quarterly",[45764],[17376],[17455],[False],[0],[0],[False],['0']
23726,PMC4797126,7666,"There were no major imbalances between treatment groups, but the 300 mg monthly quilizumab group had a lower mean age (45 versus 47–48 years) and a lower median IgE level (190 versus 234–254 IU/mL) compared to the other treatment arms (Table 1).","M monthly, Q quarterly",[45768],[17456],[17701],[False],[0],[0],[False],['0']
23727,PMC4797126,7667,89 % (384/433) of patients who received quilizumab and 91 % (132/145) of patients who received placebo completed the study treatment.,"M monthly, Q quarterly",[45772],[17702],[17835],[False],[0],[0],[False],['0']
23728,PMC4797126,7668,"The sponsor terminated the trial early because of the lack of efficacy for the primary end-point (asthma exacerbations) at Week 36, with the median time in the study at 72 weeks.","M monthly, Q quarterly",[45776],[17836],[18014],[False],[0],[0],[False],['0']
23729,PMC4797126,7669,Safety,"M monthly, Q quarterly|Safety",[45780],[18015],[18021],[False],[0],[0],[False],['0']
23730,PMC4797126,7670,"Safety, from first dose of study drug through end of study (Week 84)","M monthly, Q quarterly|Safety",[45784],[18022],[18090],[False],[0],[0],[False],['0']
23731,PMC4797126,7671,	Placebo(n = 145)	Quilizumab150 mg Q(n = 145)	Quilizumab450 mg Q(n = 145)	Quilizumab300 mg M(n = 143)	All Quilizumab(n = 433)	 	Any AE	114 (78.6 %)	110 (75.9 %)	108 (74.5 %)	103 (72.0 %)	321 (74.1 %)	 	Serious AE	12 (8.3 %)	11 (7.6 %)	10 (6.9 %)	16 (11.2 %)	37 (8.5 %)	 	Grade 3 AE or higher	21 (14.5 %)	28 (19.3 %)	30 (20.7 %)	24 (16.8 %)	82 (18.9 %)	 	Grade 2 AE or higher	86 (59.3 %)	78 (53.8 %)	80 (55.2 %)	82 (57.3 %)	240 (55.4 %)	 	Infections and infestations	76 (52.4 %)	73 (50.3 %)	71 (49.0 %)	68 (47.6 %)	212 (49.0 %)	 	Parasitic infections	0	0	0	1 (0.7 %)	1 (0.2 %)	 	Serious infections	3 (2.1 %)	3 (2.1 %)	1 (0.7 %)	2 (1.4 %)	6 (1.4 %)	 	Injection site reactions	12 (8.3 %)	10 (6.9 %)	13 (9.0 %)	7 (4.9 %)	30 (6.9 %)	 	Serious injection site reactions	0	0	0	0	0	 	AE leading to treatment withdrawal	1 (0.7 %)	4 (2.8 %)	1 (0.7 %)	1 (0.7 %)	6 (1.4 %)	 	Malignancies	0	2 (1.4 %)	2 (1.4 %)	0	4 (0.9 %)	 	Deaths	0	0	0	0	0,"M monthly, Q quarterly|Safety",[45788],[18091],[19018],[False],[0],[0],[False],['0']
23732,PMC4797126,7672,"AE adverse event, M monthly, Q quarterly","M monthly, Q quarterly",[45792],[19019],[19063],[False],[0],[0],[False],['0']
23733,PMC4797126,7673,"Quilizumab was well tolerated, and the number of patients experiencing at least one adverse event (AE) was comparable between all treatment groups (Table 2).","M monthly, Q quarterly",[45796],[19064],[19221],[False],[0],[0],[False],['0']
23734,PMC4797126,7674,"Through Week 36, the most frequent AEs across all quilizumab dose groups were worsening of asthma (27 %), nasopharyngitis (15 %), upper respiratory tract infection (7 %), bronchitis (5 %), sinusitis (5 %), and injection site pain (5 %).","M monthly, Q quarterly",[45800],[19222],[19458],[False],[0],[0],[False],['0']
23735,PMC4797126,7675,"The treatment-emergent ATA rate was 1.4 % in both the 150 mg Q and 300 mg M groups, and 2.1 % in the 450 mg Q group.","M monthly, Q quarterly",[45804],[19459],[19575],[False],[0],[0],[False],['0']
23736,PMC4797126,7676,ATA incidence for all dosing groups was 1.6 % (7 of 427 quilizumab-dosed patients).,"M monthly, Q quarterly",[45808],[19576],[19659],[False],[0],[0],[False],['0']
23737,PMC4797126,7677,There was no apparent impact of positive ATA results on either pharmacokinetic profiles or safety.,"M monthly, Q quarterly",[45812],[19660],[19758],[False],[0],[0],[False],['0']
23738,PMC4797126,7678,Pharmacokinetics,"AE adverse event, M monthly, Q quarterly|Pharmacokinetics",[45816],[19759],[19775],[False],[0],[0],[False],['0']
23739,PMC4797126,7679,Quilizumab displayed linear pharmacokinetics with a dose-proportional increase in exposure as shown by increases in Cmax values between the 150 and 450 mg Q doses at Weeks 5 and 25.,"AE adverse event, M monthly, Q quarterly|Pharmacokinetics",[45820],[19776],[19957],[False],[0],[0],[False],['0']
23740,PMC4797126,7680,(see Additional file 1: Figure S2).,"AE adverse event, M monthly, Q quarterly|Pharmacokinetics",[45824],[19958],[19993],[False],[0],[0],[False],['0']
23741,PMC4797126,7681,"At treatment Weeks 4, 12, and 24, the mean trough serum concentrations of quilizumab were: (150 mg Q) 5.7 ± 2.3 μg/mL, 2.6 ± 2.0 μg/mL, and 1.3 ± 4.6 μg/mL, respectively; (450 mg Q) 17.1 ± 7.0 μg/mL, 7.2 ± 3.8 μg/mL, and 2.3 ± 2.2 μg/mL, respectively; and (300 mg M) 11.6 ± 4.5 μg/mL, 16.7 ± 6.7 μg/mL, and 16.8 ± 7.7 μg/mL, respectively.","AE adverse event, M monthly, Q quarterly|Pharmacokinetics",[45828],[19994],[20332],[False],[0],[0],[False],['0']
23742,PMC4797126,7682,"For the 150 mg Q, 450 mg Q, and 300 mg M doses, the mean Cmax,obs values were 18 ± 7.8 μg/mL, 51.6 ± 19.5 μg/mL, and 34 ± 12.6 μg/mL, which occurred at Tmax,obs of 36.4 ± 4.3 days, 36.2 ± 3.0 days, and 36.2 ± 3.5 days, respectively, approximately 7 days following the second doses.","AE adverse event, M monthly, Q quarterly|Pharmacokinetics",[45832],[20333],[20614],[False],[0],[0],[False],['0']
23743,PMC4797126,7683,"Based on non-compartmental analysis, the mean t1/2 values of quilizumab across the dose groups ranged from 16.4 to 18.7 days, which suggests that steady-state was attained by the time the final doses were administered for both monthly and quarterly regimens.","AE adverse event, M monthly, Q quarterly|Pharmacokinetics",[45836],[20615],[20873],[False],[0],[0],[False],['0']
23744,PMC4797126,7684,Pharmacodynamic biomarkers,"AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45840],[20874],[20900],[False],[0],[0],[False],['0']
23745,PMC4797126,7685,Effect of quilizumab on serum total (a-c) and allergen-specific IgE (d-f) from baseline to Week 84.,"AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45844],[20901],[21000],[False],[0],[0],[False],['0']
23746,PMC4797126,7686,"IgE levels were represented as the mean ± standard error (SE) of the natural logarithm (a, d), the mean ± SE percent change from baseline (b, e), and median percent change from baseline (c, f).","AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45848],[21001],[21194],[False],[0],[0],[False],['0']
23747,PMC4797126,7687,All IgE data analysis was based on observed values.,"AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45852],[21195],[21246],[False],[0],[0],[False],['0']
23748,PMC4797126,7688,"M, monthly; Q, quarterly","AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45856],[21247],[21271],[False],[0],[0],[False],['0']
23749,PMC4797126,7689,"Quilizumab gradually reduced mean serum total and allergen-specific IgE, reaching a 30–40 % reduction at Week 36 in all three quilizumab cohorts (p < 0.01 compared to placebo; Fig.","AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45860],[21272],[21452],[False],[0],[0],[False],['0']
23750,PMC4797126,7690,2).,"AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45864],[21453],[21456],[False],[0],[0],[False],['0']
23751,PMC4797126,7691,The largest decreases in total and allergen-specific IgE were observed at Week 42 in the 300 mg M treatment cohort.,"AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45868],[21457],[21572],[False],[0],[0],[False],['0']
23752,PMC4797126,7692,"Serum total and allergen-specific IgE in quilizumab-treated patients gradually increased throughout the safety follow-up period, but did not return to pre-dose levels by the end of the study period (Week 84).","AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45872],[21573],[21781],[False],[0],[0],[False],['0']
23753,PMC4797126,7693,Peripheral blood eosinophils and FeNO levels were not modified following quilizumab treatment (see Additional file 1: Figure S3).,"AE adverse event, M monthly, Q quarterly|Pharmacodynamic biomarkers",[45876],[21782],[21911],[False],[0],[0],[False],['0']
23754,PMC4797126,7694,Asthma exacerbation rates,"AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45880],[21912],[21937],[False],[0],[0],[False],['0']
23755,PMC4797126,7695,Rate of protocol-defined asthma exacerbations through Week 36 for all patients.,"AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45884],[21938],[22017],[False],[0],[0],[False],['0']
23756,PMC4797126,7696,"M, monthly; Q, quarterly","AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45888],[22018],[22042],[False],[0],[0],[False],['0']
23757,PMC4797126,7697,Quilizumab treatment did not produce a clinically meaningful reduction of the rate of asthma exacerbations over the 36-week treatment period.,"AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45892],[22043],[22184],[False],[0],[0],[False],['0']
23758,PMC4797126,7698,"In the ITT population, the reduction in the asthma exacerbation rate relative to placebo was 19.6 % (90 % CI: −21 to 47; p = 0.38), −11.2 % (90 % CI: −63 to 24; p = 0.65), and −5.7 % (90%CI: −55 to 28; p = 0.81) in the 300 mg M, 450 mg Q, and 150 mg Q quilizumab treatment arms, respectively (Fig.","AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45896],[22185],[22482],[False],[0],[0],[False],['0']
23759,PMC4797126,7699,3).,"AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45900],[22483],[22486],[False],[0],[0],[False],['0']
23760,PMC4797126,7700,Rate of protocol-defined asthma exacerbations through Week 36 for patients stratified by biomarkers (a: periostin; b: blood eosinophils; c: FeNO; d: serum IgE).,"AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45904],[22487],[22647],[False],[0],[0],[False],['0']
23761,PMC4797126,7701,"Exac, exacerbation; M, monthly; Q, quarterly","AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45908],[22648],[22692],[False],[0],[0],[False],['0']
23762,PMC4797126,7702,"Subgroup analysis by baseline serum periostin (≥50 ng/ml, <50 ng/ml), blood eosinophils (≥300 cells/μl, <300 cells/μl), FeNO (≥20 ppb, <20 ppb) and serum total IgE (≥200 IU/mL, <200 IU/mL) demonstrated no consistent effect of quilizumab on the exacerbation rate across all doses when compared to the ITT population (Fig.","AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45912],[22693],[23013],[False],[0],[0],[False],['0']
23763,PMC4797126,7703,4).,"AE adverse event, M monthly, Q quarterly|Asthma exacerbation rates",[45916],[23014],[23017],[False],[0],[0],[False],['0']
23764,PMC4797126,7704,Lung function,"AE adverse event, M monthly, Q quarterly|Lung function",[45920],[23018],[23031],[False],[0],[0],[False],['0']
23765,PMC4797126,7705,Mean percent change in pre-bronchodilator FEV1 from baseline.,"AE adverse event, M monthly, Q quarterly|Lung function",[45924],[23032],[23093],[False],[0],[0],[False],['0']
23766,PMC4797126,7706,FEV1 for each treatment arm was measured through Week 36.,"AE adverse event, M monthly, Q quarterly|Lung function",[45928],[23094],[23151],[False],[0],[0],[False],['0']
23767,PMC4797126,7707,Error bars represent the standard error of the mean.,"AE adverse event, M monthly, Q quarterly|Lung function",[45932],[23152],[23204],[False],[0],[0],[False],['0']
23768,PMC4797126,7708,"M, monthly; Q, quarterly","AE adverse event, M monthly, Q quarterly|Lung function",[45936],[23205],[23229],[False],[0],[0],[False],['0']
23769,PMC4797126,7709,No significant evidence of improved FEV1 at Weeks 12 and 36 was observed in quilizumab-treated patients compared to placebo (Fig.,"AE adverse event, M monthly, Q quarterly|Lung function",[45940],[23230],[23359],[False],[0],[0],[False],['0']
23770,PMC4797126,7710,5).,"AE adverse event, M monthly, Q quarterly|Lung function",[45944],[23360],[23363],[False],[0],[0],[False],['0']
23771,PMC4797126,7711,"The highest relative improvement compared to placebo occurred in the lowest dose arm (150 mg Q), but no meaningful improvements were observed in the higher dose arms (450 mg Q and 300 mg M).","AE adverse event, M monthly, Q quarterly|Lung function",[45948],[23364],[23554],[False],[0],[0],[False],['0']
23772,PMC4797126,7712,"Relative changes from baseline in FEV1 compared to placebo were 3.8 % (90 % CI: −1.2 to 8.9, p = 0.21) at Week 12 and 5.6 % (90 % CI: 0.6 to 10.6, p = 0.07) at Week 36 in the 150 mg Q treatment arm; 2.2 % (90 % CI: −2.8 to 7.2, p = 0.48) at Week 12 and 0.1 % (90 % CI: −5.0 to 5.1, p = 0.98) at Week 36 in the 450 mg Q arm; and 1.1 % (90 % CI: −3.9 to 6.1, p = 0.72) at Week 12 and 0.1 % (90 % CI: −4.9 to 5.2, p = 0.96) at Week 36 in the 300 mg M arm (Fig.","AE adverse event, M monthly, Q quarterly|Lung function",[45952],[23555],[24012],[False],[0],[0],[False],['0']
23773,PMC4797126,7713,5; see Additional file 2: Table S1 and Additional file 3: Table S2).,"AE adverse event, M monthly, Q quarterly|Lung function",[45956],[24013],[24081],[False],[0],[0],[False],['0']
23774,PMC4797126,7714,Analysis of FEV1 in the biomarker subgroups demonstrated no consistent or meaningful improvements of FEV1 in the quilizumab-treated arms over placebo (see Additional file 2: Table S1 and Additional file 3: Table S2).,"AE adverse event, M monthly, Q quarterly|Lung function",[45960],[24082],[24298],[False],[0],[0],[False],['0']
23775,PMC4797126,7715,Patient-reported outcomes,"AE adverse event, M monthly, Q quarterly|Patient-reported outcomes",[45964],[24299],[24324],[False],[0],[0],[False],['0']
23776,PMC4797126,7716,Change over 36 weeks in patient-reported outcomes (ITT population),"AE adverse event, M monthly, Q quarterly|Patient-reported outcomes",[45968],[24325],[24391],[False],[0],[0],[False],['0']
23777,PMC4797126,7717,"	Quilizumab placebo-corrected changes	 	Endpoint	Placebo(n = 145)	150 mg Q(n = 145)	450 mg Q(n = 145)	300 mg M(n = 143)	 	Mean change in total asthma symptoms score (mTASS)	−1.5	0.1, p = 0.58	0.1, p = 0.55	−0.1, p = 0.51	 	Mean change in daytime asthma symptoms score (mTASS)	−0.7	0.1, p = 0.55	0, p = 0.70	0, p = 0.69	 	Mean change in ACQ-5 score	−1.2	0, p = 0.86	0, p = 0.83	−0.1, p = 0.52	 	Mean change in AQLQ(S) score	1.1	−0.1, p = 0.67	0.1, p = 0.73	0.3, p = 0.05	 	Mean change in RQLQ(S) score	−0.6	0, p = 0.96	−0.1, p = 0.35	−0.3, p = 0.04	 	Proportion of patients at Week 36 with no nighttime awakenings in the previous week	0.43	−0.07, p = 0.21	−0.02, p = 0.69	0, p = 0.97	 	Proportion of patients at Week 36 with ≤2 days of rescue medication use in the previous week	0.42	0.01, p = 0.88	0.01, p = 0.86	0.06, p = 0.33","AE adverse event, M monthly, Q quarterly|Patient-reported outcomes",[45972],[24392],[25219],[False],[0],[0],[False],['0']
23778,PMC4797126,7718,"ITT intention-to-treat, M monthly, Q quarterly","AE adverse event, M monthly, Q quarterly",[45976],[25220],[25270],[False],[0],[0],[False],['0']
23779,PMC4797126,7719,"During the 36-week treatment period, no meaningful differences were observed between the quilizumab dose groups compared with the placebo group for the total mTASS, daytime mTASS, ACQ-5, AQLQ(S), or RQLQ(S) scores (Table 3).","AE adverse event, M monthly, Q quarterly",[45980],[25271],[25495],[False],[0],[0],[False],['0']
23780,PMC4797126,7720,Treatment with quilizumab failed to increase either the proportion of patients who used a SABA for fewer than 2 days in the prior week or the proportion of patients who did not awaken at night due to asthma symptoms for all dosing levels relative to the placebo group at Week 36 (Table 3).,"AE adverse event, M monthly, Q quarterly",[45984],[25496],[25785],[False],[0],[0],[False],['0']
23781,PMC4797126,7721,Discussion,Discussion,[45988],[25786],[25797],[False],[0],[0],[False],['0']
23782,PMC4797126,7722,"In this study, we evaluated the efficacy and safety of quilizumab, a monoclonal antibody that targets the M1-prime segment of membrane IgE, in adult patients with allergic asthma that was inadequately controlled with standard therapy.",Discussion,[45992],[25798],[26032],[False],[0],[0],[False],['0']
23783,PMC4797126,7723,"After 36 weeks of treatment, quilizumab was well tolerated, with a safety profile consistent with previous clinical studies.",Discussion,[45996],[26033],[26157],[False],[0],[0],[False],['0']
23784,PMC4797126,7724,"Quilizumab demonstrated clear pharmacological activity by reducing both serum total and allergen-specific IgE an average of 30–40 % from baseline in all three treatment arms, in agreement with our previous work.",Discussion,[46000],[26158],[26369],[False],[0],[0],[False],['0']
23785,PMC4797126,7725,"However, quilizumab treatment did not show consistent and clinically meaningful benefits in reducing asthma exacerbations or improving lung function, symptoms, or quality of life.",Discussion,[46004],[26370],[26549],[False],[0],[0],[False],['0']
23786,PMC4797126,7726,"Subgroup analysis in patients with elevated serum periostin, blood eosinophils, FeNO, or serum IgE did not demonstrate a consistent treatment effect for quilizumab.",Discussion,[46008],[26550],[26714],[False],[0],[0],[False],['0']
23787,PMC4797126,7727,It is important to understand that reducing serum IgE levels is not quilizumab’s proposed mechanism of action.,Discussion,[46012],[26715],[26825],[False],[0],[0],[False],['0']
23788,PMC4797126,7728,"Quilizumab did not reduce serum IgE as effectively as omalizumab (89–98 % reduction of median free IgE), but these two antibodies target the IgE pathway in distinctly different ways.",Discussion,[46016],[26826],[27008],[False],[0],[0],[False],['0']
23789,PMC4797126,7729,"Quilizumab targets both B-cell switching to IgE and the new stimulation of IgE memory B cells and plasmablasts that lead to enhanced IgE production, processes that occur locally in the airways of allergic patients.",Discussion,[46020],[27009],[27223],[False],[0],[0],[False],['0']
23790,PMC4797126,7730,Quilizumab’s ability to suppress the challenge-specific increase in serum IgE in our whole lung allergen challenge study in mild asthmatics supports this mechanism.,Discussion,[46024],[27224],[27388],[False],[0],[0],[False],['0']
23791,PMC4797126,7731,We therefore hypothesize that quilizumab prevents the formation of short-lived IgE plasma cells in the airway.,Discussion,[46028],[27389],[27499],[False],[0],[0],[False],['0']
23792,PMC4797126,7732,"Long-lived IgE plasma cells, which lack IgE on the surface, are not targeted by quilizumab and may be responsible for the remaining serum IgE detected in our studies.",Discussion,[46032],[27500],[27666],[False],[0],[0],[False],['0']
23793,PMC4797126,7733,"Another source of IgE not eliminated by quilizumab may be a subpopulation of IgG1 memory B cells that undergo a secondary switch to IgE when reactivated, and thereby become IgE memory cells.",Discussion,[46036],[27667],[27857],[False],[0],[0],[False],['0']
23794,PMC4797126,7734,The current study assessed the relevance of this mechanism on exacerbations in patients with inadequately controlled allergic asthma.,Discussion,[46040],[27858],[27991],[False],[0],[0],[False],['0']
23795,PMC4797126,7735,"In the EXTRA study that examined a similar patient population, omalizumab significantly reduced asthma exacerbations by 25 % in the all-patients group, by 53 % in the FeNO-high subgroup, and by 32 % in the eosinophil-high subgroup, relative to placebo.",Discussion,[46044],[27992],[28244],[False],[0],[0],[False],['0']
23796,PMC4797126,7736,"In addition, asthma exacerbations were substantially reduced in the periostin-high subgroup (30 %) relative to placebo.",Discussion,[46048],[28245],[28364],[False],[0],[0],[False],['0']
23797,PMC4797126,7737,"In contrast, in our study, quilizumab did not show significant clinical benefit in this population (Fig.",Discussion,[46052],[28365],[28469],[False],[0],[0],[False],['0']
23798,PMC4797126,7738,3) or in any subgroup (Fig.,Discussion,[46056],[28470],[28497],[False],[0],[0],[False],['0']
23799,PMC4797126,7739,"4), possibly because local IgE production by short-lived IgE plasma cells is not critical for exacerbations and other clinical endpoints.",Discussion,[46060],[28498],[28635],[False],[0],[0],[False],['0']
23800,PMC4797126,7740,"For this to be true, we must assume that: 1) quilizumab depleted all M1-prime-positive B cells, and 2) the doses in this study were sufficient to deplete all M1-prime-positive cells.",Discussion,[46064],[28636],[28818],[False],[0],[0],[False],['0']
23801,PMC4797126,7741,"Despite our extensive efforts, we have not been able to accurately detect M1-prime-positive cells in patients with asthma, so we have no direct evidence of depletion.",Discussion,[46068],[28819],[28985],[False],[0],[0],[False],['0']
23802,PMC4797126,7742,"However, all three quilizumab dose regimens led to a similar reduction in serum IgE levels, suggesting that quilizumab depleted all target cells, and indicating that higher doses would not have provided additional activity.",Discussion,[46072],[28986],[29209],[False],[0],[0],[False],['0']
23803,PMC4797126,7743,"Interestingly, after stopping quilizumab dosing, serum IgE levels gradually increased, indicating that IgE-switching and formation of short-lived IgE plasma cells may occur continuously in this patient population, a finding not previously reported.",Discussion,[46076],[29210],[29458],[False],[0],[0],[False],['0']
23804,PMC4797126,7744,"The allergen-challenge model used in our previous studies where quilizumab was shown to be effective may not represent the asthma processes occurring in the patient population in this study, especially given that alternate sources of IgE appear to play a more dominant role.",Discussion,[46080],[29459],[29733],[False],[0],[0],[False],['0']
23805,PMC4797126,7745,"However, the model was key in first demonstrating the effectiveness of omalizumab in patients with mild asthma, where omalizumab significantly reduced both the early and late asthmatic responses following allergen challenge and reduced serum IgE almost completely.",Discussion,[46084],[29734],[29998],[False],[0],[0],[False],['0']
23806,PMC4797126,7746,"Although less effective than omalizumab in a similar population, quilizumab showed reductions of 26 and 36 % in the early and late asthmatic responses, respectively, and a 25 % reduction in serum IgE.",Discussion,[46088],[29999],[30199],[False],[0],[0],[False],['0']
23807,PMC4797126,7747,Allergen-challenge studies are generally exploratory and are designed to follow biomarkers that trend with early and late asthmatic responses.,Discussion,[46092],[30200],[30342],[False],[0],[0],[False],['0']
23808,PMC4797126,7748,"They are usually conducted in patients with mild asthma, which is not the typical target population for new biologic therapies.",Discussion,[46096],[30343],[30470],[False],[0],[0],[False],['0']
23809,PMC4797126,7749,"At least one therapy, mepolizumab (anti-IL-5), is effective for reducing asthma exacerbations in patients with eosinophilic asthma, yet does not appear to affect early/late asthmatic responses during allergen challenge.",Discussion,[46100],[30471],[30690],[False],[0],[0],[False],['0']
23810,PMC4797126,7750,It is therefore crucial that appropriate patient populations and outcome measures are selected for future trials.,Discussion,"[46104, 46105]","[30691, 30691]","[30804, 30804]","[True, True]","['Population', 'RelevantOutcomeExcluded']","['appropriate patient populations', 'outcome measures']","[True, True]","['OutcomeMeasures', 'Population']"
23811,PMC4797126,7751,"Whether quilizumab could have a clinically meaningful effect in another subgroup of allergic asthma patients or whether a treatment period beyond 36 weeks would show efficacy, are questions we are unable to address with the current study.",Discussion,"[46114, 46115]","[30805, 30805]","[31043, 31043]","[True, True]","['VerySpecificPopulation', 'ExperimentalPhaseDuration']","['another subgroup of allergic asthma patients', 'a treatment period beyond 36\xa0weeks']","[True, True]","['Population', 'StudyDuration']"
23812,PMC4797126,7752,"The type 2 biomarkers, serum periostin, blood eosinophils, and FeNO, which identified patients with increased clinical benefit from lebrikizumab and omalizumab, did not consistently enrich for increased benefit from quilizumab in this study.",Discussion,[46120],[31044],[31285],[False],[0],[0],[False],['0']
23813,PMC4797126,7753,"Similarly, patients with elevated serum IgE levels at baseline did not respond better to quilizumab nor was there a correlation between serum IgE reduction and exacerbation reduction or FEV1 improvement (data not shown).",Discussion,[46124],[31286],[31506],[False],[0],[0],[False],['0']
23814,PMC4797126,7754,Conclusions,Conclusions,[46128],[31507],[31519],[False],[0],[0],[False],['0']
23815,PMC4797126,7755,"In adults with uncontrolled allergic asthma, a 36-week treatment with quilizumab, an anti-M1-prime monoclonal antibody that targets IgE-switched and IgE memory B cells, did not result in a clinically significant impact on exacerbation rate, lung function, or quality of life.",Conclusions,[46132],[31520],[31795],[False],[0],[0],[False],['0']
23816,PMC4797126,7756,"Our data on quilizumab activity indicate that there are major pathological mechanisms that extend beyond the new, local production of IgE in patients with inadequately controlled allergic asthma.",Conclusions,[46136],[31796],[31991],[False],[0],[0],[False],['0']
23817,PMC4797126,7757,Additional files,Additional files,[46140],[31992],[32009],[False],[0],[0],[False],['0']
23818,PMC4797126,7758,Abbreviations,Additional files|Abbreviations,[46144],[32010],[32023],[False],[0],[0],[False],['0']
23819,PMC4797126,7759,ACQ-5,Additional files|Abbreviations,[46148],[32024],[32029],[False],[0],[0],[False],['0']
23820,PMC4797126,7760,5-item asthma control questionnaire,Additional files|Abbreviations,[46152],[32030],[32065],[False],[0],[0],[False],['0']
23821,PMC4797126,7761,AE,Additional files|AE,[46156],[32066],[32068],[False],[0],[0],[False],['0']
23822,PMC4797126,7762,adverse event,Additional files|adverse event,[46160],[32069],[32082],[False],[0],[0],[False],['0']
23823,PMC4797126,7763,ANCOVA,Additional files|ANCOVA,[46164],[32083],[32089],[False],[0],[0],[False],['0']
23824,PMC4797126,7764,analysis of covariance,Additional files|analysis of covariance,[46168],[32090],[32112],[False],[0],[0],[False],['0']
23825,PMC4797126,7765,AQLQ(S),Additional files|AQLQ(S),[46172],[32113],[32120],[False],[0],[0],[False],['0']
23826,PMC4797126,7766,standardized asthma quality-of-life questionnaire,Additional files|standardized asthma quality-of-life questionnaire,[46176],[32121],[32170],[False],[0],[0],[False],['0']
23827,PMC4797126,7767,ATA,Additional files|ATA,[46180],[32171],[32174],[False],[0],[0],[False],['0']
23828,PMC4797126,7768,anti-therapeutic antibody,Additional files|anti-therapeutic antibody,[46184],[32175],[32200],[False],[0],[0],[False],['0']
23829,PMC4797126,7769,Cmax:obs,Additional files|anti-therapeutic antibody,[46188],[32201],[32209],[False],[0],[0],[False],['0']
23830,PMC4797126,7770,maximum observed serum concentration,Additional files|maximum observed serum concentration,[46192],[32210],[32246],[False],[0],[0],[False],['0']
23831,PMC4797126,7771,ELISA,Additional files|ELISA,[46196],[32247],[32252],[False],[0],[0],[False],['0']
23832,PMC4797126,7772,enzyme-linked immunosorbent assay,Additional files|enzyme-linked immunosorbent assay,[46200],[32253],[32286],[False],[0],[0],[False],['0']
23833,PMC4797126,7773,FeNO,Additional files|FeNO,[46204],[32287],[32291],[False],[0],[0],[False],['0']
23834,PMC4797126,7774,fractional exhaled nitric oxide,Additional files|fractional exhaled nitric oxide,[46208],[32292],[32323],[False],[0],[0],[False],['0']
23835,PMC4797126,7775,FEV1,Additional files|fractional exhaled nitric oxide,[46212],[32324],[32328],[False],[0],[0],[False],['0']
23836,PMC4797126,7776,forced expiratory volume in 1 s,Additional files|fractional exhaled nitric oxide,[46216],[32329],[32360],[False],[0],[0],[False],['0']
23837,PMC4797126,7777,HDM,Additional files|HDM,[46220],[32361],[32364],[False],[0],[0],[False],['0']
23838,PMC4797126,7778,house dust mite,Additional files|house dust mite,[46224],[32365],[32380],[False],[0],[0],[False],['0']
23839,PMC4797126,7779,ICS,Additional files|ICS,[46228],[32381],[32384],[False],[0],[0],[False],['0']
23840,PMC4797126,7780,inhaled corticosteroid,Additional files|inhaled corticosteroid,[46232],[32385],[32407],[False],[0],[0],[False],['0']
23841,PMC4797126,7781,Ig,Additional files|Ig,[46236],[32408],[32410],[False],[0],[0],[False],['0']
23842,PMC4797126,7782,immunoglobulin,Additional files|immunoglobulin,[46240],[32411],[32425],[False],[0],[0],[False],['0']
23843,PMC4797126,7783,IL,Additional files|IL,[46244],[32426],[32428],[False],[0],[0],[False],['0']
23844,PMC4797126,7784,interleukin,Additional files|interleukin,[46248],[32429],[32440],[False],[0],[0],[False],['0']
23845,PMC4797126,7785,ITT,Additional files|ITT,[46252],[32441],[32444],[False],[0],[0],[False],['0']
23846,PMC4797126,7786,intention-to-treat,Additional files|intention-to-treat,[46256],[32445],[32463],[False],[0],[0],[False],['0']
23847,PMC4797126,7787,LOCF,Additional files|LOCF,[46260],[32464],[32468],[False],[0],[0],[False],['0']
23848,PMC4797126,7788,last observation carried forward,Additional files|last observation carried forward,[46264],[32469],[32501],[False],[0],[0],[False],['0']
23849,PMC4797126,7789,LSM,Additional files|LSM,[46268],[32502],[32505],[False],[0],[0],[False],['0']
23850,PMC4797126,7790,least squares mean,Additional files|least squares mean,[46272],[32506],[32524],[False],[0],[0],[False],['0']
23851,PMC4797126,7791,mTASS,Additional files|mTASS,[46276],[32525],[32530],[False],[0],[0],[False],['0']
23852,PMC4797126,7792,modified total asthma symptom score,Additional files|modified total asthma symptom score,[46280],[32531],[32566],[False],[0],[0],[False],['0']
23853,PMC4797126,7793,RQLQ(S),Additional files|RQLQ(S),[46284],[32567],[32574],[False],[0],[0],[False],['0']
23854,PMC4797126,7794,standardized rhinitis quality-of-life questionnaire,Additional files|standardized rhinitis quality-of-life questionnaire,[46288],[32575],[32626],[False],[0],[0],[False],['0']
23855,PMC4797126,7795,SABA,Additional files|SABA,[46292],[32627],[32631],[False],[0],[0],[False],['0']
23856,PMC4797126,7796,short-acting β-agonist,Additional files|short-acting β-agonist,[46296],[32632],[32654],[False],[0],[0],[False],['0']
23857,PMC4797126,7797,t1/2,Additional files|short-acting β-agonist,[46300],[32655],[32659],[False],[0],[0],[False],['0']
23858,PMC4797126,7798,terminal elimination half-life,Additional files|terminal elimination half-life,[46304],[32660],[32690],[False],[0],[0],[False],['0']
23859,PMC4797126,7799,Th2,Additional files|terminal elimination half-life,[46308],[32691],[32694],[False],[0],[0],[False],['0']
23860,PMC4797126,7800,T helper 2,Additional files|terminal elimination half-life,[46312],[32695],[32705],[False],[0],[0],[False],['0']
23861,PMC4797126,7801,Tmax:obs,Additional files|terminal elimination half-life,[46316],[32706],[32714],[False],[0],[0],[False],['0']
23862,PMC4797126,7802,time of maximum observed serum concentration,Additional files|time of maximum observed serum concentration,[46320],[32715],[32759],[False],[0],[0],[False],['0']
23863,PMC4797126,7803,Competing interests,Additional files|Competing interests,[46324],[32760],[32779],[False],[0],[0],[False],['0']
23864,PMC4797126,7804,"JMH, RM, MSB, CRC, HS, JL, FC, MK, XCL, DS, RZ, and CC are employed at Genentech, Inc., a member of the Roche Group, and own Roche stock.",Additional files|Competing interests,[46328],[32780],[32917],[False],[0],[0],[False],['0']
23865,PMC4797126,7805,"WS has received research support from Genentech, Inc., Astra-Zeneca, Teva, Merck, Novartis, Sanofi, Stallergens, Circassia, Regeneron, Pfizer, Symbio, and Amgen; has received speaking fees from Genentech, Inc., Teva, and Meda; and has received consulting fees from Regeneron and Teva.",Additional files|Competing interests,[46332],[32918],[33202],[False],[0],[0],[False],['0']
23866,PMC4797126,7806,"PP has received research support from Genentech, Inc., Astra-Zeneca, and Merck.",Additional files|Competing interests,[46336],[33203],[33282],[False],[0],[0],[False],['0']
23867,PMC4797126,7807,"JDD, DD, IA, MT, and SK declare that they have no competing interests.",Additional files|Competing interests,[46340],[33283],[33353],[False],[0],[0],[False],['0']
23868,PMC4797126,7808,Authors’ contributions,Additional files|Authors’ contributions,[46344],[33354],[33376],[False],[0],[0],[False],['0']
23869,PMC4797126,7809,"JMH, RM, HS, XCL, and MK contributed to the conception and design of the study.",Additional files|Authors’ contributions,[46348],[33377],[33456],[False],[0],[0],[False],['0']
23870,PMC4797126,7810,"CC, WS, JDD, PP, MT, DD, IA, and SK contributed to the acquisition of data.",Additional files|Authors’ contributions,[46352],[33457],[33532],[False],[0],[0],[False],['0']
23871,PMC4797126,7811,"JMH, RM, MSB, CRC, HS, JL, FC, MK, XCL, DS, and RZ analyzed and interpreted the data.",Additional files|Authors’ contributions,[46356],[33533],[33618],[False],[0],[0],[False],['0']
23872,PMC4797126,7812,"All authors contributed to the drafting and critical revision of the manuscript, and approved the final version to be published.",Additional files|Authors’ contributions,[46360],[33619],[33747],[False],[0],[0],[False],['0']
24910,PMC4967304,23283,Resistance exercise improves physical fatigue in women with fibromyalgia: a randomized controlled trial,Title,[137870],[27364],[103],[False],[0],[0],[False],['0']
24911,PMC4967304,23284,Background,Abstract,[137872],[104],[115],[False],[0],[0],[False],['0']
24912,PMC4967304,23285,Fibromyalgia (FM) affects approximately 1–3 % of the general population.,Abstract,[137874],[116],[188],[False],[0],[0],[False],['0']
24913,PMC4967304,23286,Fatigue limits the work ability and social life of patients with FM.,Abstract,[137876],[189],[257],[False],[0],[0],[False],['0']
24914,PMC4967304,23287,"A few studies of physical exercise have included measures of fatigue in FM, indicating that exercise can decrease fatigue levels.",Abstract,[137878],[258],[387],[False],[0],[0],[False],['0']
24915,PMC4967304,23288,There is limited knowledge about the effects of resistance exercise on multiple dimensions of fatigue in FM.,Abstract,[137880],[388],[496],[False],[0],[0],[False],['0']
24916,PMC4967304,23289,The present study is a sub-study of a multicenter randomized controlled trial in women with FM.,Abstract,[137882],[497],[592],[False],[0],[0],[False],['0']
24917,PMC4967304,23290,"The purpose of the present sub-study was to examine the effects of a person-centered progressive resistance exercise program on multiple dimensions of fatigue in women with FM, and to investigate predictors of the potential change in fatigue.",Abstract,[137884],[593],[835],[False],[0],[0],[False],['0']
24918,PMC4967304,23291,Methods,Abstract,[137886],[836],[843],[False],[0],[0],[False],['0']
24919,PMC4967304,23292,A total of 130 women with FM (age 22–64 years) were included in this assessor-blinded randomized controlled multicenter trial examining the effects of person-centered progressive resistance exercise compared with an active control group.,Abstract,[137888],[844],[1081],[False],[0],[0],[False],['0']
24920,PMC4967304,23293,The intervention was performed twice a week for 15 weeks.,Abstract,[137890],[1082],[1139],[False],[0],[0],[False],['0']
24921,PMC4967304,23294,Outcomes were five dimensions of fatigue measured with the Multidimensional Fatigue Inventory (MFI-20).,Abstract,[137892],[1140],[1243],[False],[0],[0],[False],['0']
24922,PMC4967304,23295,Information about background was collected and the women also completed several health-related questionnaires.,Abstract,[137894],[1244],[1354],[False],[0],[0],[False],['0']
24923,PMC4967304,23296,Multiple linear stepwise regression was used to analyze predictors of change in fatigue in the total population.,Abstract,[137896],[1355],[1467],[False],[0],[0],[False],['0']
24924,PMC4967304,23297,Results,Abstract,[137898],[1468],[1475],[False],[0],[0],[False],['0']
24925,PMC4967304,23298,"A higher improvement was found at the post-treatment examination for change in the resistance exercise group, as compared to change in the active control group in the MFI-20 subscale of physical fatigue (resistance group Δ –1.7, SD 4.3, controls Δ 0.0, SD 2.7, p = 0.013), with an effect size of 0.33.",Abstract,[137900],[1476],[1777],[False],[0],[0],[False],['0']
24926,PMC4967304,23299,"Sleep efficiency was the strongest predictor of change in the MFI-20 subscale general fatigue (beta = −0.54, p = 0.031, R2 = 0.05).",Abstract,[137902],[1778],[1909],[False],[0],[0],[False],['0']
24927,PMC4967304,23300,"Participating in resistance exercise (beta = 1.90, p = 0.010) and working fewer hours per week (beta = 0.84, p = 0.005) were independent significant predictors of change in physical fatigue (R2 = 0.14).",Abstract,[137904],[1910],[2112],[False],[0],[0],[False],['0']
24928,PMC4967304,23301,Conclusions,Abstract,[137906],[2113],[2124],[False],[0],[0],[False],['0']
24929,PMC4967304,23302,Person-centered progressive resistance exercise improved physical fatigue in women with FM when compared to an active control group.,Abstract,[137908],[2125],[2257],[False],[0],[0],[False],['0']
24930,PMC4967304,23303,Trial registration,Abstract,[137910],[2258],[2276],[False],[0],[0],[False],['0']
24931,PMC4967304,23304,ClinicalTrials.gov NCT01226784.,Abstract,[137912],[2277],[2308],[False],[0],[0],[False],['0']
24932,PMC4967304,23305,Registered 21 October 2010.,Abstract,[137914],[2309],[2336],[False],[0],[0],[False],['0']
24933,PMC4967304,23306,Background,Background,[137916],[2337],[2348],[False],[0],[0],[False],['0']
24934,PMC4967304,23307,"The prevalence of fibromyalgia (FM) is approximately 1–3 % in the general population, increases with age, and is more prevalent in women than in men [1].",Background,[137918],[2349],[2502],[False],[0],[0],[False],['0']
24935,PMC4967304,23308,"In addition to persistent widespread pain and allodynia, patients with FM often experience severe fatigue, sleep disturbances, stiffness, psychological distress and/or cognitive impairment [2–5].",Background,[137920],[2503],[2698],[False],[0],[0],[False],['0']
24936,PMC4967304,23309,Women with FM have been shown to have impaired physical capacity [6–8] and they are also less physically active compared to healthy controls [9].,Background,[137922],[2699],[2844],[False],[0],[0],[False],['0']
24937,PMC4967304,23310,"FM is a dominating cause of sick leave among female patients with musculoskeletal disorders and has a great impact on quality of life [6, 10].",Background,[137924],[2845],[2987],[False],[0],[0],[False],['0']
24938,PMC4967304,23311,"Fatigue is a prominent symptom in patients with FM, which limits their work ability and social life [11–13].",Background,[137926],[2988],[3096],[False],[0],[0],[False],['0']
24939,PMC4967304,23312,"Women with FM have described their fatigue in terms of sleepless nights, physical weakness, social withdrawal, loss of mental energy and overwhelming exhaustion [13].",Background,[137928],[3097],[3263],[False],[0],[0],[False],['0']
24940,PMC4967304,23313,"Socio-demographic aspects such as female gender, younger age, low working capacity and low level of education have been shown to be associated with higher levels of fatigue in FM [14].",Background,[137930],[3264],[3448],[False],[0],[0],[False],['0']
24941,PMC4967304,23314,"Fatigue is commonly assessed with a one-dimensional visual analog scale (VAS), which enables comparisons across studies.",Background,[137932],[3449],[3569],[False],[0],[0],[False],['0']
24942,PMC4967304,23315,"However, fatigue is a complex symptom that interacts with several other common FM symptoms.",Background,[137934],[3570],[3661],[False],[0],[0],[False],['0']
24943,PMC4967304,23316,"It is thus recommended to be assessed in multiple dimensions, such as physical, mental and general fatigue in patients with FM, especially in non-pharmacological studies [15, 16].",Background,[137936],[3662],[3841],[False],[0],[0],[False],['0']
24944,PMC4967304,23317,"Fatigue has been shown to be associated with increased distress, muscular tenderness, and poor sleep quality [14, 15, 17, 18].",Background,[137938],[3842],[3968],[False],[0],[0],[False],['0']
24945,PMC4967304,23318,"Higher ratings on the subscales of physical fatigue and reduced activity, which are included in the Multidimensional Fatigue Inventory (MFI-20), have been associated with low working capacity, low level of physical activity and impaired physical capacity in women with FM [15, 19, 20].",Background,[137940],[3969],[4254],[False],[0],[0],[False],['0']
24946,PMC4967304,23319,"Pain catastrophizing influences the perception of pain and other symptoms in many patients with FM, which complicates the treatment and could influence compliance with exercise [21].",Background,[137942],[4255],[4437],[False],[0],[0],[False],['0']
24947,PMC4967304,23320,Catastrophic thinking has also been suggested to have an influence on fatigue in FM and in other chronic conditions.,Background,[137944],[4438],[4554],[False],[0],[0],[False],['0']
24948,PMC4967304,23321,However previous research on this topic is scarce [22].,Background,[137946],[4555],[4610],[False],[0],[0],[False],['0']
24949,PMC4967304,23322,"The most beneficial treatment for FM requires a multidisciplinary approach combining education, pharmacological treatment, exercise and cognitive behavioral therapy [23, 24].",Background,[137948],[4611],[4785],[False],[0],[0],[False],['0']
24950,PMC4967304,23323,Exercise has been found to improve feelings of energy and fatigue in various medical conditions [25].,Background,[137950],[4786],[4887],[False],[0],[0],[False],['0']
24951,PMC4967304,23324,"Different types of exercise are being used for treatment in FM and chronic widespread pain (CWP) in health care, such as aerobic exercise, resistance training, flexibility exercise and body awareness therapy [26].",Background,[137952],[4888],[5101],[False],[0],[0],[False],['0']
24952,PMC4967304,23325,Few exercise studies have included measures of fatigue in patients with FM.,Background,[137954],[5102],[5177],[False],[0],[0],[False],['0']
24953,PMC4967304,23326,However the findings of these studies indicate that exercise could decrease fatigue levels [26–29].,Background,[137956],[5178],[5277],[False],[0],[0],[False],['0']
24954,PMC4967304,23327,"Aerobic exercise has been shown to improve the MFI-20 dimension of reduced motivation in female patients with FM [30, 31] and global outcome measures of physical capacity and, to some degree, pain and the number of tender points in FM [26].",Background,[137958],[5278],[5518],[False],[0],[0],[False],['0']
24955,PMC4967304,23328,"Resistance exercise has shown positive effects on limitations in activity, pain, global fatigue, depression and muscle strength in patients with FM.",Background,[137960],[5519],[5667],[False],[0],[0],[False],['0']
24956,PMC4967304,23329,"However, the quality of evidence of these effects is poor due to the limited number of studies [29].",Background,[137962],[5668],[5768],[False],[0],[0],[False],['0']
24957,PMC4967304,23330,"The present study is a sub-study of a randomized controlled trial (RCT) showing that resistance exercise improved muscle strength, overall health, and current pain intensity in women with FM, when compared to an active control group [32].",Background,[137964],[5769],[6007],[False],[0],[0],[False],['0']
24958,PMC4967304,23331,"The resistance exercise intervention was a person-centered approach, which emphasizes active involvement of the patient in planning the treatment that is suggested to enhance the patient’s ability to manage health problems [33].",Background,[137966],[6008],[6236],[False],[0],[0],[False],['0']
24959,PMC4967304,23332,The principles of person-centeredness were used in the previously published RCT.,Background,[137968],[6237],[6317],[False],[0],[0],[False],['0']
24960,PMC4967304,23333,The details of the exercise program were planned together with each patient to support each participant’s ability to manage the exercise and the progression in loads [32].,Background,[137970],[6318],[6489],[False],[0],[0],[False],['0']
24961,PMC4967304,23334,"As high levels of fatigue have been associated with low levels of physical activity and impaired physical capacity in FM [15, 19, 20], improvement in physical capacity in patients with FM may result in a reduction in fatigue.",Background,[137972],[6490],[6715],[False],[0],[0],[False],['0']
24962,PMC4967304,23335,"To our best knowledge, there is no previous study investigating the effects of resistance exercise on multiple dimensions of fatigue in FM.",Background,[137974],[6716],[6855],[False],[0],[0],[False],['0']
24963,PMC4967304,23336,"The primary aim of the present study was to examine the effects of a person-centered progressive resistance exercise program on multiple dimensions of fatigue in women with FM compared to an active control group, and to investigate predictors of the potential change in fatigue.",Background,[137976],[6856],[7134],[False],[0],[0],[False],['0']
24964,PMC4967304,23337,"Second, the effect of resistance exercise on sleep, pain catastrophizing, depression, and anxiety were also explored, as these variables have been shown previously to be associated with fatigue.",Background,[137978],[7135],[7329],[False],[0],[0],[False],['0']
24965,PMC4967304,23338,Methods,Methods,[137980],[7330],[7338],[False],[0],[0],[False],['0']
24966,PMC4967304,23339,Study design,Methods|Study design,[137982],[7339],[7351],[False],[0],[0],[False],['0']
24967,PMC4967304,23340,This is a sub-study of a multicenter randomized controlled trial in women with FM (ClinicalTrials.gov identification number: NCT01226784) [32].,Methods|Study design,[137984],[7352],[7495],[False],[0],[0],[False],['0']
24968,PMC4967304,23341,The present sub-study aimed to investigate the effects of resistance exercise on multidimensional fatigue in women with FM.,Methods|Study design,[137986],[7496],[7619],[False],[0],[0],[False],['0']
24969,PMC4967304,23342,Recruitment,Methods|Recruitment,[137988],[7620],[7631],[False],[0],[0],[False],['0']
24970,PMC4967304,23343,Inclusion and exclusion criteria have been described in detail previously [32].,Methods|Recruitment,[137990],[7632],[7711],[False],[0],[0],[False],['0']
24971,PMC4967304,23344,"In short, the inclusion criteria were women aged 20–65 years, meeting the American College of Rheumatology (ACR) 1990 classification criteria for FM [2], and the exclusion criteria were other severe somatic or psychiatric disorders, participation in a rehabilitation program within the past year, or inability to understand Swedish.",Methods|Recruitment,[137992],[7712],[8044],[False],[0],[0],[False],['0']
24972,PMC4967304,23345,Fig.,Methods|Recruitment,[137994],[8045],[8049],[False],[0],[0],[False],['0']
24973,PMC4967304,23346,1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the progress of the two groups in the randomized trial.,Methods|Recruitment,[137996],[8050],[8176],[False],[0],[0],[False],['0']
24974,PMC4967304,23347,Modified figure from [32].,Methods|Recruitment,[137998],[8177],[8203],[False],[0],[0],[False],['0']
24975,PMC4967304,23348,"FM fibromyalgia, OA osteoarthritis.",Methods|Recruitment,[138000],[8204],[8239],[False],[0],[0],[False],['0']
24976,PMC4967304,23349,"Female patients with FM were recruited by newspaper advertisement in the local newspapers of three cities in Sweden (Gothenburg, Stockholm, and Linköping) to the multicenter experimental study [32].",Methods|Recruitment,[138002],[8240],[8438],[False],[0],[0],[False],['0']
24977,PMC4967304,23350,"There were 130 patients with FM included in the study, and they were randomized to the resistance exercise group (n = 67) or the active control group (n = 63).",Methods|Recruitment,[138004],[8439],[8598],[False],[0],[0],[False],['0']
24978,PMC4967304,23351,The process of recruitment and randomization has been described in detail in a previous publication [32].,Methods|Recruitment,[138006],[8599],[8704],[False],[0],[0],[False],['0']
24979,PMC4967304,23352,No significant differences were found in sociodemographic data between the resistance exercise group (n = 67) and the active control group (n = 63) (Fig.,Methods|Recruitment,[138008],[8705],[8858],[False],[0],[0],[False],['0']
24980,PMC4967304,23353,1) [32].,Methods|Recruitment,[138010],[8859],[8867],[False],[0],[0],[False],['0']
24981,PMC4967304,23354,All participants were invited to a post-treatment examination after 15 weeks and 84 % (n = 56) in the resistance exercise group and 76 % (n = 49) in the active control group completed the test.,Methods|Recruitment,[138012],[8868],[9061],[False],[0],[0],[False],['0']
24982,PMC4967304,23355,Seventeen participants (25 %) in the resistance exercise group and 20 (32 %) in the active control group discontinued the intervention due to various reasons [32].,Methods|Recruitment,[138014],[9062],[9225],[False],[0],[0],[False],['0']
24983,PMC4967304,23356,Five participants in the resistance exercise group reported adverse effects and chose to discontinue the intervention due to increased pain.,Methods|Recruitment,[138016],[9226],[9366],[False],[0],[0],[False],['0']
24984,PMC4967304,23357,Two of these participants completed post-treatment examinations (Fig.,Methods|Recruitment,[138018],[9367],[9436],[False],[0],[0],[False],['0']
24985,PMC4967304,23358,1).,Methods|Recruitment,[138020],[9437],[9440],[False],[0],[0],[False],['0']
24986,PMC4967304,23359,Modified figure from [32].,Methods|Recruitment,[138022],[9441],[9467],[False],[0],[0],[False],['0']
24987,PMC4967304,23360,Interventions,Methods|Interventions,[138024],[9468],[9481],[False],[0],[0],[False],['0']
24988,PMC4967304,23361,Resistance exercise,Methods|Resistance exercise,[138026],[9482],[9501],[False],[0],[0],[False],['0']
24989,PMC4967304,23362,The person-centered progressive resistance exercise intervention was performed twice a week for 15 weeks at physiotherapy premises and at a local gym and was supervised by experienced physiotherapists.,Methods|Resistance exercise,[138028],[9502],[9703],[False],[0],[0],[False],['0']
24990,PMC4967304,23363,The exercise program was standardized and performed in groups of five to seven participants but the load was adjusted individually.,Methods|Resistance exercise,[138030],[9704],[9835],[False],[0],[0],[False],['0']
24991,PMC4967304,23364,The exercise session started with 10 minutes of warm up followed by 50 minutes of resistance exercises focused on large muscle groups in all four extremities and trunk.,Methods|Resistance exercise,[138032],[9836],[10004],[False],[0],[0],[False],['0']
24992,PMC4967304,23365,The resistance exercise was initiated at 40 % of 1 repetition maximum (RM) and progressed up to 80 % of 1 RM during the 15 weeks.,Methods|Resistance exercise,[138034],[10005],[10134],[False],[0],[0],[False],['0']
24993,PMC4967304,23366,Possibilities for progression of loads were evaluated every 3–4 weeks.,Methods|Resistance exercise,[138036],[10135],[10205],[False],[0],[0],[False],['0']
24994,PMC4967304,23367,Forty-two participants (62.7 %) in the resistance exercise group reached exercise loads of 80 % of 1 RM while seven participants (10.4 %) reached exercise loads of 60 % of 1 RM.,Methods|Resistance exercise,[138038],[10206],[10383],[False],[0],[0],[False],['0']
24995,PMC4967304,23368,The median attendance rate at the resistance exercise sessions was 71 % (range 0–100 %).,Methods|Resistance exercise,[138040],[10384],[10472],[False],[0],[0],[False],['0']
24996,PMC4967304,23369,The procedure of the resistance exercise and adjustment of loads in the present study has been described in detail previously [32].,Methods|Resistance exercise,[138042],[10473],[10604],[False],[0],[0],[False],['0']
24997,PMC4967304,23370,Active control group,Methods|Active control group,[138044],[10605],[10625],[False],[0],[0],[False],['0']
24998,PMC4967304,23371,"The active control treatment consisted of relaxation therapy, which was performed twice a week for 15 weeks, guided by experienced physiotherapists and conducted at physiotherapy premises in groups of five to eight participants.",Methods|Active control group,[138046],[10626],[10854],[False],[0],[0],[False],['0']
24999,PMC4967304,23372,"It was performed as autogenic training [34], which refers to a series of mental exercises including autosuggestion and relaxation.",Methods|Active control group,[138048],[10855],[10985],[False],[0],[0],[False],['0']
25000,PMC4967304,23373,"The relaxation therapy lasted for approximately 25 minutes, followed by stretching exercises.",Methods|Active control group,[138050],[10986],[11079],[False],[0],[0],[False],['0']
25001,PMC4967304,23374,The median attendance rate at the relaxation therapy sessions was 64 % (range 0–100 %).,Methods|Active control group,[138052],[11080],[11167],[False],[0],[0],[False],['0']
25002,PMC4967304,23375,The procedure in the active control group has been described in detail previously [32].,Methods|Active control group,[138054],[11168],[11255],[False],[0],[0],[False],['0']
25003,PMC4967304,23376,Measurements,Measurements,[138056],[11256],[11269],[False],[0],[0],[False],['0']
25004,PMC4967304,23377,"The patients were referred to a baseline examination which included a tender-point examination [2] by a physician, performance-based tests of physical capacity conducted by physical therapists, and a battery of self-reported questionnaires [32].",Measurements,[138058],[11270],[11515],[False],[0],[0],[False],['0']
25005,PMC4967304,23378,Background data,Measurements|Background data,[138060],[11516],[11531],[False],[0],[0],[False],['0']
25006,PMC4967304,23379,"Background data such as age, education, employment, duration of pain, sick leave, disability pension, and medication were obtained by a standardized interview.",Measurements|Background data,[138062],[11532],[11691],[False],[0],[0],[False],['0']
25007,PMC4967304,23380,Duration of widespread pain was reported in years and obtained by a standardized interview.,Measurements|Background data,[138064],[11692],[11783],[False],[0],[0],[False],['0']
25008,PMC4967304,23381,Employment was divided into four categories of percentage of full-time work: 0 %; 1–49 %; 50–79 %; and 80–100 %.,Measurements|Background data,[138066],[11784],[11896],[False],[0],[0],[False],['0']
25009,PMC4967304,23382,Full-time work was defined as 40 h per week.,Measurements|Background data,[138068],[11897],[11941],[False],[0],[0],[False],['0']
25010,PMC4967304,23383,Self-reported questionnaires,Measurements|Self-reported questionnaires,[138070],[11942],[11970],[False],[0],[0],[False],['0']
25011,PMC4967304,23384,Multidimensional Fatigue Inventory (4–20),Measurements|Self-reported questionnaires,[138072],[11971],[12012],[False],[0],[0],[False],['0']
25012,PMC4967304,23385,The MFI-20 comprises 20 statements on a 5-point Likert scale that addresses aspects of fatigue experienced during the most recent days.,Measurements|Self-reported questionnaires,[138074],[12013],[12148],[False],[0],[0],[False],['0']
25013,PMC4967304,23386,"The scores generate five subscales of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity.",Measurements|Self-reported questionnaires,[138076],[12149],[12288],[False],[0],[0],[False],['0']
25014,PMC4967304,23387,"The scores range from 4 to 20 for each subscale and higher scores refer to a higher degree of fatigue [35, 36].",Measurements|Self-reported questionnaires,[138078],[12289],[12400],[False],[0],[0],[False],['0']
25015,PMC4967304,23388,The MFI-20 has been shown to have satisfactory convergent construct validity and test-retest reliability in FM [37].,Measurements|Self-reported questionnaires,[138080],[12401],[12517],[False],[0],[0],[False],['0']
25016,PMC4967304,23389,FIQ fatigue (0–100),Measurements|Self-reported questionnaires,[138082],[12518],[12537],[False],[0],[0],[False],['0']
25017,PMC4967304,23390,"The VAS for fatigue included in the Fibromyalgia Impact Questionnaire (FIQ) [38] was used as a one-dimensional measure of fatigue in this study, ranging from 0 mm (no tiredness) to 100 mm (very tired).",Measurements|Self-reported questionnaires,[138084],[12538],[12739],[False],[0],[0],[False],['0']
25018,PMC4967304,23391,The FIQ for fatigue has been validated and shown satisfactory test-retest reliability in Swedish patients with FM [39].,Measurements|Self-reported questionnaires,[138086],[12740],[12859],[False],[0],[0],[False],['0']
25019,PMC4967304,23392,FIQ pain (0–100),Measurements|Self-reported questionnaires,[138088],[12860],[12876],[False],[0],[0],[False],['0']
25020,PMC4967304,23393,The VAS for pain is a subscale of the FIQ that measures current pain intensity.,Measurements|Self-reported questionnaires,[138090],[12877],[12956],[False],[0],[0],[False],['0']
25021,PMC4967304,23394,"The participant was asked to rate her current pain intensity, ranging from 0 mm (no pain at all) to 100 mm (worst imaginable pain) [38].",Measurements|Self-reported questionnaires,[138092],[12957],[13093],[False],[0],[0],[False],['0']
25022,PMC4967304,23395,The FIQ for pain was used only in the analyses of predictors of potential change in fatigue.,Measurements|Self-reported questionnaires,[138094],[13094],[13186],[False],[0],[0],[False],['0']
25023,PMC4967304,23396,Pittsburgh Sleep Quality Index (PSQI) (0–21),Measurements|Self-reported questionnaires,[138096],[13187],[13231],[False],[0],[0],[False],['0']
25024,PMC4967304,23397,The PSQI assesses sleep quality and disturbances over a 1-month period.,Measurements|Self-reported questionnaires,[138098],[13232],[13303],[False],[0],[0],[False],['0']
25025,PMC4967304,23398,"It comprises nineteen items (scored 0–3), which constitute seven subscales: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, need of medications to sleep (use of sleeping medication) and daytime dysfunction.",Measurements|Self-reported questionnaires,[138100],[13304],[13546],[False],[0],[0],[False],['0']
25026,PMC4967304,23399,The sum of scores for the seven subscales generate one total score (0–21).,Measurements|Self-reported questionnaires,[138102],[13547],[13621],[False],[0],[0],[False],['0']
25027,PMC4967304,23400,A PSQI total score >5 indicates poor sleep [40].,Measurements|Self-reported questionnaires,[138104],[13622],[13670],[False],[0],[0],[False],['0']
25028,PMC4967304,23401,"The PSQI has been used previously in studies of FM [41, 42].",Measurements|Self-reported questionnaires,[138106],[13671],[13731],[False],[0],[0],[False],['0']
25029,PMC4967304,23402,Pain catastrophizing scale (PCS) (0–52),Measurements|Self-reported questionnaires,[138108],[13732],[13771],[False],[0],[0],[False],['0']
25030,PMC4967304,23403,The PCS assesses pain-related catastrophic thinking.,Measurements|Self-reported questionnaires,[138110],[13772],[13824],[False],[0],[0],[False],['0']
25031,PMC4967304,23404,The patients estimate on a 5-point Likert scale (0 (not at all) to 4 (all the time)) the extent to which they experience 13 thoughts or feelings while they feel pain.,Measurements|Self-reported questionnaires,[138112],[13825],[13991],[False],[0],[0],[False],['0']
25032,PMC4967304,23405,The PCS total score (0–52) is the sum of the scores of the 13 items [43].,Measurements|Self-reported questionnaires,[138114],[13992],[14065],[False],[0],[0],[False],['0']
25033,PMC4967304,23406,A PCS total score >24 displays a high level of catastrophic thinking in patients with sub-acute whiplash-related pain [44].,Measurements|Self-reported questionnaires,[138116],[14066],[14189],[False],[0],[0],[False],['0']
25034,PMC4967304,23407,"The 13 items also generate three subscales; rumination, helplessness and magnification [43].",Measurements|Self-reported questionnaires,[138118],[14190],[14282],[False],[0],[0],[False],['0']
25035,PMC4967304,23408,"The three PCS subscales and the total score were used in the present study in between-group analyses of change over time, while only the PCS total score was used in the analyses of predictors of change in fatigue.",Measurements|Self-reported questionnaires,[138120],[14283],[14496],[False],[0],[0],[False],['0']
25036,PMC4967304,23409,"The PCS has been tested for validity and reliability [45, 46] and has been used in studies of FM [47–49]",Measurements|Self-reported questionnaires,[138122],[14497],[14601],[False],[0],[0],[False],['0']
25037,PMC4967304,23410,Hospital Anxiety and Depression Scale (HADS) (0–21),Measurements|Self-reported questionnaires,[138124],[14602],[14653],[False],[0],[0],[False],['0']
25038,PMC4967304,23411,"The HADS contains 14 statements, ranging from 0–3, and a higher score refers to a higher degree of distress.",Measurements|Self-reported questionnaires,[138126],[14654],[14762],[False],[0],[0],[False],['0']
25039,PMC4967304,23412,The scores of the 14 items build two subscales: HADS-A for anxiety (0–21) and HADS-D for depression (0–21) [50].,Measurements|Self-reported questionnaires,[138128],[14763],[14875],[False],[0],[0],[False],['0']
25040,PMC4967304,23413,A cutoff score of 8 is suggested to indicate possible anxiety or depression [51].,Measurements|Self-reported questionnaires,[138130],[14876],[14957],[False],[0],[0],[False],['0']
25041,PMC4967304,23414,Tests of physical capacity,Tests of physical capacity,[138132],[14958],[14985],[False],[0],[0],[False],['0']
25042,PMC4967304,23415,Leisure Time Physical Activity Instrument (LTPAI) (h),Tests of physical capacity,[138134],[14986],[15039],[False],[0],[0],[False],['0']
25043,PMC4967304,23416,The patients estimate their amount of physical activity in leisure time during a typical week [52].,Tests of physical capacity,[138136],[15040],[15139],[False],[0],[0],[False],['0']
25044,PMC4967304,23417,"The physical activities were divided into three categories: light, moderate, and heavy activities, and examples of such activities were given for each category.",Tests of physical capacity,[138138],[15140],[15300],[False],[0],[0],[False],['0']
25045,PMC4967304,23418,The LTPAI total score is the sum of hours in all three categories and was used in the present study only in the analyses of potential predictors of change in fatigue.,Tests of physical capacity,[138140],[15301],[15467],[False],[0],[0],[False],['0']
25046,PMC4967304,23419,The 6-minute walk test (6MWT) (m),Tests of physical capacity,[138142],[15468],[15501],[False],[0],[0],[False],['0']
25047,PMC4967304,23420,The patient was instructed to walk for 6 minutes as quickly as she could without running and the total walking distance was measured [53].,Tests of physical capacity,[138144],[15502],[15640],[False],[0],[0],[False],['0']
25048,PMC4967304,23421,The 6MWT was used in the present study only in the analyses of potential predictors of change in fatigue.,Tests of physical capacity,[138146],[15641],[15746],[False],[0],[0],[False],['0']
25049,PMC4967304,23422,Statistics,Statistics,[138148],[15747],[15758],[False],[0],[0],[False],['0']
25050,PMC4967304,23423,"Data were computerized and analyzed using the Statistical Package Software for the Social Sciences (SPSS version 22, Chicago, IL, USA).",Statistics,[138150],[15759],[15894],[False],[0],[0],[False],['0']
25051,PMC4967304,23424,"Descriptive statistics are presented as mean, standard deviation (SD) and range for continuous variables and as number (n) and percent (%) for categorical variables.",Statistics,[138152],[15895],[16060],[False],[0],[0],[False],['0']
25052,PMC4967304,23425,"For comparison between two groups, normal distribution of data collected with questionnaires could not be assumed and the non-parametric Mann–Whitney U test was used for continuous variables, Mantel Haenszel chi-squared test for ordered categorical variables and Fisher’s exact test for dichotomous variables.",Statistics,[138154],[16061],[16370],[False],[0],[0],[False],['0']
25053,PMC4967304,23426,Change over time from baseline to 15 weeks within groups was analyzed using the Wilcoxon signed rank test.,Statistics,[138156],[16371],[16477],[False],[0],[0],[False],['0']
25054,PMC4967304,23427,"Effect size was calculated with Cohen’s d for outcomes showing a significant change, by dividing the mean difference between the post-treatment score and baseline score in the resistance exercise group and in the active control group by the pooled SD for difference.",Statistics,[138158],[16478],[16744],[False],[0],[0],[False],['0']
25055,PMC4967304,23428,Effect sizes from 0.20 to <0.50 were regarded as small and effect sizes from 0.50 to <0.80 were regarded as moderate [54].,Statistics,[138160],[16745],[16867],[False],[0],[0],[False],['0']
25056,PMC4967304,23429,A baseline difference was found between the groups in the PSQI subscale of sleep efficiency.,Statistics,[138162],[16868],[16960],[False],[0],[0],[False],['0']
25057,PMC4967304,23430,The between-group analyses were therefore adjusted for PSQI sleep efficiency in linear regression analyses with outcome variables (mean difference post treatment compared to baseline) included as dependent variables and the group variable (intervention/active control) and PSQI sleep efficiency included as independent variables.,Statistics,[138164],[16961],[17290],[False],[0],[0],[False],['0']
25058,PMC4967304,23431,"The assumptions of normality in regression analyses were confirmed by checking the residual scatter plots and histograms of each variable, respectively.",Statistics,[138166],[17291],[17443],[False],[0],[0],[False],['0']
25059,PMC4967304,23432,"To control for possible type 1 errors, the upper limit of the expected number of false significant results for analyses of primary outcomes (the five subscales of the MFI-20) was calculated by the following formula: where α is the significance level.",Statistics,[138168],[17444],[17694],[False],[0],[0],[False],['0']
25060,PMC4967304,23433,"Correlation was assessed between the difference between post-treatment and baseline in the five subscales of the MFI-20 and the baseline values for the variables age, employment, duration of widespread pain, FIQ pain, the PCS, the HADS, the PSQI, the LTPAI and the 6MWT, using Spearman’s correlation coefficient (r ).",Statistics,[138170],[17695],[18012],[False],[0],[0],[False],['0']
25061,PMC4967304,23434,"These variables were chosen based on results from previous studies of correlation between fatigue and other patient characteristics [15, 22].",Statistics,[138172],[18013],[18154],[False],[0],[0],[False],['0']
25062,PMC4967304,23435,"In order to find independent baseline predictors of change in fatigue for each MFI-20 subscale, the variables with a Spearman’s correlation p value p <0.1 with the MFI-20 subscale and group of randomization were entered into a multiple linear stepwise regression analysis with change in the fatigue subscale as the dependent variable.",Statistics,[138174],[18155],[18489],[False],[0],[0],[False],['0']
25063,PMC4967304,23436,Multiple linear stepwise regression analyses were performed of the subscales of the MFI-20 that were found to be significantly correlated with more than one variable.,Statistics,[138176],[18490],[18656],[False],[0],[0],[False],['0']
25064,PMC4967304,23437,All tests were two-sided and conducted at the 5 % significance level.,Statistics,[138178],[18657],[18726],[False],[0],[0],[False],['0']
25065,PMC4967304,23438,Results,Results,[138180],[18727],[18735],[False],[0],[0],[False],['0']
25066,PMC4967304,23439,Between-group comparisons,Results|Between-group comparisons,[138182],[18736],[18761],[False],[0],[0],[False],['0']
25067,PMC4967304,23440,"Table 1 Baseline values, change from baseline in outcome variables, and within-group and between-group differences in change in the resistance exercise group and the active control group.",Results|Between-group comparisons,[138184],[18762],[18949],[False],[0],[0],[False],['0']
25068,PMC4967304,23441,Results of between-group comparisons are shown in Table 1.,Results|Between-group comparisons,[138186],[18950],[19008],[False],[0],[0],[False],['0']
25069,PMC4967304,23442,Multidimensional fatigue,Results|Multidimensional fatigue,[138188],[19009],[19033],[False],[0],[0],[False],['0']
25070,PMC4967304,23443,"There was significantly greater improvement at the post-treatment examination according to change in the MFI-20 subscales for general fatigue (p = 0.031), physical fatigue (p = 0.013) and mental fatigue (p = 0.008) in the resistance exercise group, as compared to the change over time in the active control group (Table 1).",Results|Multidimensional fatigue,[138190],[19034],[19357],[False],[0],[0],[False],['0']
25071,PMC4967304,23444,"The mean improvements in the resistance exercise group from baseline to post treatment were 7.5 % in general fatigue, 10.6 % in MFI-20 physical fatigue and 10.7 % in mental fatigue.",Results|Multidimensional fatigue,[138192],[19358],[19539],[False],[0],[0],[False],['0']
25072,PMC4967304,23445,There were no statistically significant differences between the two groups in change in the MFI-20 subscales for reduced motivation or reduced activity at the post-treatment examination (Table 1).,Results|Multidimensional fatigue,[138194],[19540],[19736],[False],[0],[0],[False],['0']
25073,PMC4967304,23446,"There was a baseline difference between the resistance exercise group and the active control group in the PSQI subscale of sleep efficiency (mean 1.9, SD 1.1 versus mean 1.4, SD 1.2, p = 0.027) (Table 1).",Results|Multidimensional fatigue,[138196],[19737],[19941],[False],[0],[0],[False],['0']
25074,PMC4967304,23447,"When the between-group analyses of the MFI-20 were adjusted for PSQI sleep efficiency, the difference between groups in change of fatigue was significant only for the MFI-20 subscale physical fatigue (p = 0.044) (Table 1).",Results|Multidimensional fatigue,[138198],[19942],[20164],[False],[0],[0],[False],['0']
25075,PMC4967304,23448,"The effect size of change in MFI-20 for physical fatigue in the resistance exercise group compared to the active control group was 0.33 (i.e., a small effect size).",Results|Multidimensional fatigue,[138200],[20165],[20329],[False],[0],[0],[False],['0']
25076,PMC4967304,23449,"Type 1 error: the between-group analyses of primary outcomes (the five subscales of the MFI-20) comprised a total of five statistical analyses, with one significant value at the significance level 0.05, and the upper level of the number of false significance results was 0.21, which indicates that 0–1 of the significant results observed might be false.",Results|Multidimensional fatigue,[138202],[20330],[20683],[False],[0],[0],[False],['0']
25077,PMC4967304,23450,Exploratory outcomes,Results|Exploratory outcomes,[138204],[20684],[20704],[False],[0],[0],[False],['0']
25078,PMC4967304,23451,"No statistically significant differences were found between the resistance exercise group and the relaxation group in change in the FIQ for fatigue, the PSQI, the PCS or the HADS at the post-treatment examination (Table 1).",Results|Exploratory outcomes,[138206],[20705],[20928],[False],[0],[0],[False],['0']
25079,PMC4967304,23452,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment",Results,[138208],[20929],[21019],[False],[0],[0],[False],['0']
25080,PMC4967304,23453,"Results of within-group analyses of outcomes, and change from baseline to post treatment are shown in Table 1.",Results,[138210],[21020],[21130],[False],[0],[0],[False],['0']
25081,PMC4967304,23454,The FIQ for fatigue,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The FIQ for fatigue",[138212],[21131],[21150],[False],[0],[0],[False],['0']
25082,PMC4967304,23455,"The resistance exercise group improved in the FIQ for fatigue over time from baseline to post treatment (mean difference −8.6, SD 21.2, p = 0.002) (Table 1).","Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The FIQ for fatigue",[138214],[21151],[21308],[False],[0],[0],[False],['0']
25083,PMC4967304,23456,The PSQI,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The PSQI",[138216],[21309],[21317],[False],[0],[0],[False],['0']
25084,PMC4967304,23457,"The resistance exercise group improved over time in the PSQI subscale for sleep quality (mean difference −0.2, SD 0.8, p = 0.047), while the active control group improved in the PSQI subscale for need of medications to sleep (mean difference 0.3 SD 1.0, p = 0.036) (Table 1).","Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The PSQI",[138218],[21318],[21593],[False],[0],[0],[False],['0']
25085,PMC4967304,23458,The PCS,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The PCS",[138220],[21594],[21601],[False],[0],[0],[False],['0']
25086,PMC4967304,23459,"The resistance exercise group improved significantly over time in all three PCS subscales and the PCS total score (mean difference in PCS total score −2.7 SD 7.6, p = 0.004).","Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The PCS",[138222],[21602],[21776],[False],[0],[0],[False],['0']
25087,PMC4967304,23460,In the active control group there was a tendency towards improvement in two PCS subscales and the PCS total score (p = 0.051–0.056) (Table 1).,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The PCS",[138224],[21777],[21919],[False],[0],[0],[False],['0']
25088,PMC4967304,23461,The HADS,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The HADS",[138226],[21920],[21928],[False],[0],[0],[False],['0']
25089,PMC4967304,23462,No significant changes during the study period were found within any of the groups for HADS anxiety or HADS depression (Table 1).,"Within-group analyses of exploratory outcomes, and change from baseline to post treatment|The HADS",[138228],[21929],[22058],[False],[0],[0],[False],['0']
25090,PMC4967304,23463,Predictors of change in fatigue,Predictors of change in fatigue,[138230],[22059],[22091],[False],[0],[0],[False],['0']
25091,PMC4967304,23464,"Table 2 Spearman’s correlation coefficients (r s) with p values for correlation between change (posttest-baseline) in the five subscales of the Multidimensional Fatigue Inventory-20 and patient characteristics, symptoms and physical function (n = 105).",Predictors of change in fatigue,[138232],[22092],[22344],[False],[0],[0],[False],['0']
25092,PMC4967304,23465,The baseline values of the variables included in the correlation analysis are presented in Table 1 and in a previous publication [32].,Predictors of change in fatigue,[138234],[22345],[22479],[False],[0],[0],[False],['0']
25093,PMC4967304,23466,The results of the correlation analysis are presented in Table 2.,Predictors of change in fatigue,[138236],[22480],[22545],[False],[0],[0],[False],['0']
25094,PMC4967304,23467,"Multiple linear stepwise regression analyses were carried out on the subscales of the MFI-20 that were found to be significantly correlated with more than one variable, which were general fatigue and physical fatigue.",Predictors of change in fatigue,[138238],[22546],[22763],[False],[0],[0],[False],['0']
25095,PMC4967304,23468,Variables correlated with change in MFI-20 subscales with a p value <0.1 were included together with intervention group (resistance/control) in the multiple linear stepwise regression analyses of predictors of change in the MFI-20 subscales.,Predictors of change in fatigue,[138240],[22764],[23005],[False],[0],[0],[False],['0']
25096,PMC4967304,23469,MFI-20 general fatigue,Predictors of change in fatigue,[138242],[23006],[23028],[False],[0],[0],[False],['0']
25097,PMC4967304,23470,"Intervention (resistance/control), employment, the PSQI for sleep efficiency and the FIQ for pain were associated (p < 0.1) with change in the MFI-20 for general fatigue (Tables 1 and 2) and were included in the multiple linear stepwise regression analysis for general fatigue.",Predictors of change in fatigue,[138244],[23029],[23306],[False],[0],[0],[False],['0']
25098,PMC4967304,23471,"After the PSQI for sleep efficiency was entered into the stepwise model as the first variable, no additional variable was entered (B = − 0.54, SE 0.25, p = 0.031).",Predictors of change in fatigue,[138246],[23307],[23470],[False],[0],[0],[False],['0']
25099,PMC4967304,23472,The R2 value for the model was 0.05.,Predictors of change in fatigue,[138248],[23471],[23507],[False],[0],[0],[False],['0']
25100,PMC4967304,23473,Poorer sleep efficiency at baseline predicted improvement in general fatigue.,Predictors of change in fatigue,[138250],[23508],[23585],[False],[0],[0],[False],['0']
25101,PMC4967304,23474,MFI-20 physical fatigue,Predictors of change in fatigue,[138252],[23586],[23609],[False],[0],[0],[False],['0']
25102,PMC4967304,23475,"Intervention (resistance/control), employment and the PSQI for sleep efficiency were associated (p < 0.1) with change in the MFI-20 for physical fatigue (Tables 1, 2) and were included in multiple linear stepwise regression analysis of physical fatigue.",Predictors of change in fatigue,[138254],[23610],[23863],[False],[0],[0],[False],['0']
25103,PMC4967304,23476,"Intervention (B = 1.90, SE = 0.73, p = 0.010) and employment status (B = 0.8, SE = 0.29, p = 0.005) were independent predictors of change in physical fatigue; R2 for the model was 0.14.",Predictors of change in fatigue,[138256],[23864],[24049],[False],[0],[0],[False],['0']
25104,PMC4967304,23477,Participating in the resistance exercise intervention and working fewer hours per week at baseline predicted improvement in physical fatigue.,Predictors of change in fatigue,[138258],[24050],[24191],[False],[0],[0],[False],['0']
25105,PMC4967304,23478,Discussion,Discussion,[138260],[24192],[24204],[False],[0],[0],[False],['0']
25106,PMC4967304,23479,The present randomized controlled trial investigated the effects of a 15-week person-centered progressive resistance exercise program on multiple dimensions of fatigue in 130 women with FM.,Discussion,[138262],[24205],[24394],[False],[0],[0],[False],['0']
25107,PMC4967304,23480,"Significant improvements were found for change in the MFI-20 subscales for general fatigue, physical fatigue, and mental fatigue in the resistance exercise group in comparison with the active control group.",Discussion,[138264],[24395],[24601],[False],[0],[0],[False],['0']
25108,PMC4967304,23481,When the analyses were adjusted for baseline differences in sleep efficiency the between-group difference was significant for MFI-20 physical fatigue only.,Discussion,[138266],[24602],[24757],[False],[0],[0],[False],['0']
25109,PMC4967304,23482,"The effect size for MFI-20 physical fatigue was small (0.33) but lies within the expected range according to a recent meta-analysis, which investigated the effects of exercise on fatigue in patients with FM [55].",Discussion,[138268],[24758],[24970],[False],[0],[0],[False],['0']
25110,PMC4967304,23483,"The MFI-20 physical subscale reflects fatigue related to “physical ability to do things” and “physical condition”, physical components that are expected to improve with exercise.",Discussion,[138270],[24971],[25149],[False],[0],[0],[False],['0']
25111,PMC4967304,23484,"Although the improvement in physical fatigue was small in effect size, it is valuable for patients describing themselves as physically weak and becoming fatigued after doing very little [56], which causes deterioration in their quality of life and ability to manage daily activities.",Discussion,[138272],[25150],[25433],[False],[0],[0],[False],['0']
25112,PMC4967304,23485,The MFI-20 subscale for physical fatigue has been used separately by the Outcome Measures in Rheumatology (OMERACT) group in analyses aiming to identify subgroups in FM [57].,Discussion,[138274],[25434],[25608],[False],[0],[0],[False],['0']
25113,PMC4967304,23486,"A previous study found that decreased fatigue in patients with FM engaging in exercise was associated with changes in adipokines and insulin-like growth factor-1, which appear to be biological correlates of exercise and fatigue [58].",Discussion,[138276],[25609],[25842],[False],[0],[0],[False],['0']
25114,PMC4967304,23487,We were also interested in investigating which variables could predict the possible change in fatigue.,Discussion,[138278],[25843],[25945],[False],[0],[0],[False],['0']
25115,PMC4967304,23488,Participating in resistance exercise combined with working fewer hours per week at baseline predicted greater improvement in the MFI-20 subscale for physical fatigue.,Discussion,[138280],[25946],[26112],[False],[0],[0],[False],['0']
25116,PMC4967304,23489,"The PSQI for sleep efficiency predicted improvement in the MFI-20 for general fatigue, which indicates that the women with FM who had worse sleep efficiency at baseline were more likely to improve their general fatigue regardless of whether they participated in resistance exercise or in the active control group.",Discussion,[138282],[26113],[26426],[False],[0],[0],[False],['0']
25117,PMC4967304,23490,Sleep efficiency in the PSQI refers to the time asleep per night in relation to the time spent in bed.,Discussion,[138284],[26427],[26529],[False],[0],[0],[False],['0']
25118,PMC4967304,23491,These findings indicate that women with FM who have the worst sleep efficiency might have the most to gain from any intervention.,Discussion,[138286],[26530],[26659],[False],[0],[0],[False],['0']
25119,PMC4967304,23492,"However, the explained variance ranged from 5 –4 % in the analyses of the MFI-20 subscales, and the improvement in fatigue was reasonably influenced by other factors not investigated in the present study.",Discussion,[138288],[26660],[26864],[False],[0],[0],[False],['0']
25120,PMC4967304,23493,"Variables that have been previously found to be associated with dimensions of fatigue were included in the correlation analyses; however, only a few variables appeared to be associated with change over time in fatigue.",Discussion,[138290],[26865],[27083],[False],[0],[0],[False],['0']
25121,PMC4967304,23494,"The participants’ age or duration of pain did not appear to have an influence on change in fatigue, nor did their level of psychological distress or physical capacity.",Discussion,[138292],[27084],[27251],[False],[0],[0],[False],['0']
25122,PMC4967304,23495,These results indicate that women with FM could gain improvements in fatigue by resistance exercise regardless of individual factors.,Discussion,[138294],[27252],[27385],[False],[0],[0],[False],['0']
25123,PMC4967304,23496,Similar results have also been found for improvements in pain disability [59].,Discussion,[138296],[27386],[27464],[False],[0],[0],[False],['0']
25124,PMC4967304,23497,"Fatigue is a symptom with a great negative effect on daily life in women with FM [11, 13, 60] and has been recommended to be assessed in multiple dimensions [15, 61], yet the effects of resistance exercise on multidimensional fatigue in FM have not been previously studied.",Discussion,[138298],[27465],[27738],[False],[0],[0],[False],['0']
25125,PMC4967304,23498,"However, a few studies have investigated the effect of resistance exercise on global fatigue assessed with a VAS [62, 63].",Discussion,[138300],[27739],[27861],[False],[0],[0],[False],['0']
25126,PMC4967304,23499,In the present study the FIQ for global fatigue was included for exploratory analysis.,Discussion,[138302],[27862],[27948],[False],[0],[0],[False],['0']
25127,PMC4967304,23500,There was significant improvement in the FIQ for global fatigue within the resistance exercise group but there were no significant differences in change in the FIQ for global fatigue between the resistance exercise group and the control group.,Discussion,[138304],[27949],[28192],[False],[0],[0],[False],['0']
25128,PMC4967304,23501,These results are in line with previous studies by Jones et al.,Discussion,[138306],[28193],[28256],[False],[0],[0],[False],['0']
25129,PMC4967304,23502,"[62] comparing resistance exercise with flexibility exercise, and by Häkkinen et al.",Discussion,[138308],[28257],[28341],[False],[0],[0],[False],['0']
25130,PMC4967304,23503,"[63] comparing resistance exercise with a control group in FM; both studies showed a significant change within the resistance exercise group in a VAS for global fatigue, but there were no significant differences in the change in global fatigue in comparison with controls.",Discussion,[138310],[28342],[28614],[False],[0],[0],[False],['0']
25131,PMC4967304,23504,"These findings endorse the use of a multidimensional assessment of fatigue in terms of physical fatigue, which was sensitive to change induced by resistance exercise.",Discussion,[138312],[28615],[28781],[False],[0],[0],[False],['0']
25132,PMC4967304,23505,"Exploratory analyses were carried out in the present study aiming at investigating the effects of resistance exercise on the PSQI, the PCS and the HADS as compared to the active control group.",Discussion,[138314],[28782],[28974],[False],[0],[0],[False],['0']
25133,PMC4967304,23506,"In the analyses of change over time in the PSQI, the resistance exercise group had significant within-group improvements in the subscale for sleep quality and the active control group reported significant improvement in the subscale for needing medications to sleep, after the 15-week intervention.",Discussion,[138316],[28975],[29273],[False],[0],[0],[False],['0']
25134,PMC4967304,23507,"However, there were no significant between-group differences in change for any of the PSQI subscales.",Discussion,[138318],[29274],[29375],[False],[0],[0],[False],['0']
25135,PMC4967304,23508,This is line with the results of a previous study of resistance exercise in women with FM [63].,Discussion,[138320],[29376],[29471],[False],[0],[0],[False],['0']
25136,PMC4967304,23509,There were significant within-group improvements over time in pain catastrophizing in the PCS total score and all three subscales in the resistance exercise group.,Discussion,[138322],[29472],[29635],[False],[0],[0],[False],['0']
25137,PMC4967304,23510,"However, there were no significant between-group differences in change, possibly because the control group also tended towards improvement in the PCS.",Discussion,[138324],[29636],[29786],[False],[0],[0],[False],['0']
25138,PMC4967304,23511,No significant changes were found for change in depression or anxiety assessed with the HADS in the resistance exercise group or the active control group.,Discussion,[138326],[29787],[29941],[False],[0],[0],[False],['0']
25139,PMC4967304,23512,"Also in previous exercise studies, the effect on depression and anxiety in FM has been found to be limited [31, 64].",Discussion,[138328],[29942],[30058],[False],[0],[0],[False],['0']
25140,PMC4967304,23513,"Recent publications have recommended resistance exercise for patients with FM [65, 66].",Discussion,[138330],[30059],[30146],[False],[0],[0],[False],['0']
25141,PMC4967304,23514,The resistance exercise program in the present study had a person-centered approach and was progressively increased over 15 weeks.,Discussion,[138332],[30147],[30277],[False],[0],[0],[False],['0']
25142,PMC4967304,23515,Over 60 % of the participants managed to increase the loads up to 80 % of 1 RM and the attendance was satisfactory at 71 %.,Discussion,[138334],[30278],[30401],[False],[0],[0],[False],['0']
25143,PMC4967304,23516,"Only 5 (7 %) of the participants in the resistance exercise group discontinued the intervention due to increased pain, which indicates that a majority of women with FM tolerate individually tailored resistance exercise twice a week for over 3 months.",Discussion,[138336],[30402],[30652],[False],[0],[0],[False],['0']
25144,PMC4967304,23517,"The resistance exercise program had a person-centered approach, which most likely contributed to the high attendance rate and low occurrence of adverse effects, as the approach enhances self-efficacy and sense of control in the participants.",Discussion,[138338],[30653],[30894],[False],[0],[0],[False],['0']
25145,PMC4967304,23518,The resistance exercise program in the present study had similarities with the programs in the studies by Jones et al.,Discussion,[138340],[30895],[31013],[False],[0],[0],[False],['0']
25146,PMC4967304,23519,[62] and Häkkinen et al.,Discussion,[138342],[31014],[31038],[False],[0],[0],[False],['0']
25147,PMC4967304,23520,"[63], which also were progressed and performed twice a week [62].",Discussion,[138344],[31039],[31104],[False],[0],[0],[False],['0']
25148,PMC4967304,23521,Relaxation therapy was chosen as the active control treatment in the present study and was assumed to improve overall wellbeing in the women with FM.,Discussion,[138346],[31105],[31254],[False],[0],[0],[False],['0']
25149,PMC4967304,23522,Limitations,Discussion|Limitations,[138348],[31255],[31266],[False],[0],[0],[False],['0']
25150,PMC4967304,23523,The present study is a sub-study and the statistical power was calculated with regards to the primary analysis published previously [32].,Discussion|Limitations,[138350],[31267],[31404],[False],[0],[0],[False],['0']
25151,PMC4967304,23524,"The number of included participants was also considered to be sufficient for the aim of the present study, and there was a significant difference between the groups in change in physical fatigue.",Discussion|Limitations,[138352],[31405],[31600],[False],[0],[0],[False],['0']
25152,PMC4967304,23525,"The results of the present study must be interpreted with caution because the upper limit of the expected number of false significant results was calculated to be 0.21 for the primary outcomes, which indicates that 0–1 of the significant results could be false.",Discussion|Limitations,[138355],[31601],[31862],[True],['StatisticalAnalysis'],"['the upper limit of the expected number of false significant results was calculated to be 0.21 for the primary outcomes, which indicates that 0–1 of the significant results could be false']",[True],['StatisticalAnalysis']
25153,PMC4967304,23526,"A large number of tests of correlation were also performed in the analyses of predictors, and the values of explained variance (R2) in the multiple linear regression analyses were low, ranging from 0.05 to 0.14, which could be in the margin of error for the subscales.",Discussion|Limitations,[138356],[31863],[32131],[False],[0],[0],[False],['0']
25154,PMC4967304,23527,Positive expectations of exercise have been found to play a role in the effect of exercise on psychological outcomes [67].,Discussion|Limitations,[138358],[32132],[32254],[False],[0],[0],[False],['0']
25155,PMC4967304,23528,"The participants in the present study were recruited by newspaper advertisement, which could have attracted persons with FM with expectations of improvement and a positive attitude towards resistance exercise.",Discussion|Limitations,[138360],[32255],[32464],[True],['VerySpecificPopulation'],['attracted persons with FM with expectations of improvement and a positive attitude towards resistance exercise'],[True],['Population']
25156,PMC4967304,23529,This might have influenced the magnitude of improvement and compliance with the exercise protocol.,Discussion|Limitations,[138362],[32465],[32563],[False],[0],[0],[False],['0']
25157,PMC4967304,23530,"However, the same recruitment method was used for both groups and they were recruited simultaneously, thus the recruitment method would not have affected the outcome in group comparisons.",Discussion|Limitations,[138364],[32564],[32751],[False],[0],[0],[False],['0']
25158,PMC4967304,23531,Conclusions,Conclusions,[138366],[32752],[32764],[False],[0],[0],[False],['0']
25159,PMC4967304,23532,The present study is the first to show that person-centered progressive resistance exercise contributed to improvement in physical fatigue in women with FM.,Conclusions,[138368],[32765],[32921],[False],[0],[0],[False],['0']
25160,PMC4967304,23533,Aspects of work and sleep were found to contribute to the improvement in fatigue.,Conclusions,[138370],[32922],[33003],[False],[0],[0],[False],['0']
25161,PMC4967304,23534,Abbreviations,Abbreviations,[138372],[33004],[33018],[False],[0],[0],[False],['0']
25162,PMC4967304,23535,"ACR, American College of Rheumatology; CWP, chronic widespread pain; FIQ, Fibromyalgia Impact Questionnaire; FM, fibromyalgia; HADS, Hospital Anxiety and Depression Scale; LTPAI, Leisure Time Physical Activity Instrument; MFI-20, Multidimensional Fatigue Inventory; PCS, Pain Catastrophizing Scale; PSQI, Pittsburgh Sleep Quality Index; RCT, randomized controlled trial; RM, repetition maximum; VAS, visual analog scale",Abbreviations,[138374],[33019],[33438],[False],[0],[0],[False],['0']
25163,PMC4967304,23536,Acknowledgements,Acknowledgements,[138376],[33439],[33456],[False],[0],[0],[False],['0']
25164,PMC4967304,23537,"We would like to thank all colleagues who performed examinations and supervised the groups in Gothenburg, Alingsås, Linköping, and Stockholm.",Acknowledgements,[138378],[33457],[33598],[False],[0],[0],[False],['0']
25165,PMC4967304,23538,"The study was supported by the Swedish Rheumatism Association, the Swedish Research Council, the Health and Medical Care Executive Board of Västra Götaland Region, ALF-LUA at Sahlgrenska University Hospital, Stockholm and Östergötland County Councils (ALF), and AFA Insurance and Gothenburg Center for Person Centered Care (GPCC).",Acknowledgements,[138380],[33599],[33929],[False],[0],[0],[False],['0']
25166,PMC4967304,23539,The authors declare no conflicts of interest.,Acknowledgements,[138382],[33930],[33975],[False],[0],[0],[False],['0']
25167,PMC4967304,23540,Availability of data and materials,Acknowledgements|Availability of data and materials,[138384],[33976],[34010],[False],[0],[0],[False],['0']
25168,PMC4967304,23541,"Data will not be shared, as more analyses are planned for the material.",Acknowledgements|Availability of data and materials,[138386],[34011],[34082],[False],[0],[0],[False],['0']
25169,PMC4967304,23542,Authors’ contributions,Acknowledgements|Authors’ contributions,[138388],[34083],[34105],[False],[0],[0],[False],['0']
25170,PMC4967304,23543,"The authors of this multicenter study have contributed as follows and their research site is also specified: AE (Gothenburg) worked with data analysis, interpretation of data and manuscript writing; AP and AL (Gothenburg) worked with study design and acquisition; ML (Stockholm) worked with acquisition; IB-L (Stockholm) participated in study design and acquisition; JB (Gothenburg) worked with acquisition and interpretation of data; BG (Linköping) worked with study conception, study design, and acquisition; EK (Stockholm) worked with study conception, study design, and acquisition; KM (Gothenburg) worked with study conception, study design, acquisition, data analysis, interpretation of data, and manuscript writing.",Acknowledgements|Authors’ contributions,[138390],[34106],[34828],[False],[0],[0],[False],['0']
25171,PMC4967304,23544,All the authors were involved in the drafting of the article and revising it critically for important intellectual content.,Acknowledgements|Authors’ contributions,[138392],[34829],[34952],[False],[0],[0],[False],['0']
25172,PMC4967304,23545,All the authors approved the final version of the article.,Acknowledgements|Authors’ contributions,[138394],[34953],[35011],[False],[0],[0],[False],['0']
25173,PMC4967304,23546,Competing interests,Acknowledgements|Competing interests,[138396],[35012],[35031],[False],[0],[0],[False],['0']
25174,PMC4967304,23547,The authors declare that they have no competing interests.,Acknowledgements|Competing interests,[138398],[35032],[35090],[False],[0],[0],[False],['0']
25175,PMC4967304,23548,Consent for publication,Acknowledgements|Consent for publication,[138400],[35091],[35114],[False],[0],[0],[False],['0']
25176,PMC4967304,23549,Not applicable.,Acknowledgements|Not applicable.,[138402],[35115],[35130],[False],[0],[0],[False],['0']
25177,PMC4967304,23550,Ethics approval and consent to participate,Acknowledgements|Ethics approval and consent to participate,[138404],[35131],[35173],[False],[0],[0],[False],['0']
25178,PMC4967304,23551,The study was approved by the Regional Ethics Committee in Stockholm (2010/1121-31/3).,Acknowledgements|Ethics approval and consent to participate,[138406],[35174],[35260],[False],[0],[0],[False],['0']
25179,PMC4967304,23552,Written and oral information was given to all participants and written consent was obtained from all participants.,Acknowledgements|Ethics approval and consent to participate,[138408],[35261],[35375],[False],[0],[0],[False],['0']
25180,PMC4984260,33669,ORGAN PRESERVATION FOR CLINICAL T2N0 DISTAL RECTAL CANCER USING NEOADJUVANT CHEMORADIOTHERAPY AND LOCAL EXCISION: RESULTS OF A MULTICENTER PHASE 2 STUDY,Title,[198313],[35535],[152],[False],[0],[0],[False],['0']
25181,PMC4984260,33670,Background,Abstract,[198318],[153],[164],[False],[0],[0],[False],['0']
25182,PMC4984260,33671,Local excision is an organ-preserving treatment alternative for patients with stage I rectal cancer.,Abstract,[198323],[165],[265],[False],[0],[0],[False],['0']
25183,PMC4984260,33672,"However, local excision alone is associated with a high risk of local recurrence and inferior survival compared to transabdominal rectal resection.",Abstract,[198328],[266],[413],[False],[0],[0],[False],['0']
25184,PMC4984260,33673,Here we investigate the oncologic and functional outcomes of neoadjuvant chemoradiotherapy and local excision for T2N0 rectal cancer.,Abstract,[198333],[414],[547],[False],[0],[0],[False],['0']
25185,PMC4984260,33674,Methods,Methods,[198338],[548],[556],[False],[0],[0],[False],['0']
25186,PMC4984260,33675,"This was a prospective, multi-institutional, single arm phase 2 trial for patients with clinically-staged T2N0 distal rectal cancer, treated with neoadjuvant chemoradiotherapy consisting of capecitabine (original dose 825mg/m2, twice daily, on days 1-14 and 22-35) , oxaliplatin (50mg/m2 weeks 1, 2, 4, 5), and radiation (5 days/week at 1.8 Gy/day for 5 weeks to a dose of 45 Gy, then a boost, for a total dose of 54 Gy) followed by local excision.",Methods,[198343],[557],[1005],[False],[0],[0],[False],['0']
25187,PMC4984260,33676,"Due to adverse events during chemoradiotherapy, the dose of capecitabine was reduced to 725 mg /m2, twice daily, 5 days/week, for 5 weeks, and the total dose of radiation to 50.4 Gy.",Methods,[198348],[1006],[1188],[False],[0],[0],[False],['0']
25188,PMC4984260,33677,Patients were followed at scheduled intervals and evaluated for recurrence and survival.,Methods,[198353],[1189],[1277],[False],[0],[0],[False],['0']
25189,PMC4984260,33678,"Anorectal function (ARF) and quality of life (QOL) were assessed at baseline and one year after surgery, using validated instruments.",Methods,[198358],[1278],[1411],[False],[0],[0],[False],['0']
25190,PMC4984260,33679,"The primary endpoint was 3-year disease-free survival for all eligible patients and for patients who completed chemotherapy and radiation, and had ypT0, ypT1, or ypT2 tumors, and negative resection margins.",Methods,[198363],[1412],[1618],[False],[0],[0],[False],['0']
25191,PMC4984260,33680,"This trial is registered with ClinicalTrials.gov, number NCT00114231.",Methods,[198368],[1619],[1688],[False],[0],[0],[False],['0']
25192,PMC4984260,33681,Findings,Findings,[198373],[1689],[1698],[False],[0],[0],[False],['0']
25193,PMC4984260,33682,"Seventy-nine eligible patients were accrued to the trial, and started nCRT.",Findings,[198378],[1699],[1774],[False],[0],[0],[False],['0']
25194,PMC4984260,33683,Three patients did not complete nCRT or LE per-protocol.,Findings,[198383],[1775],[1831],[False],[0],[0],[False],['0']
25195,PMC4984260,33684,"Four additional patients completed protocol treatment, but one had a positive margin and three had ypT3 tumours.",Findings,[198388],[1832],[1944],[False],[0],[0],[False],['0']
25196,PMC4984260,33685,Median follow-up was 56 months.,Findings,[198393],[1945],[1976],[False],[0],[0],[False],['0']
25197,PMC4984260,33686,"Of the 79 patients, five (6%) developed distant recurrence, and three (4%) recurred locally.",Findings,[198398],[1977],[2069],[False],[0],[0],[False],['0']
25198,PMC4984260,33687,All but two underwent salvage surgery.,Findings,[198403],[2070],[2108],[False],[0],[0],[False],['0']
25199,PMC4984260,33688,"Three-year disease-free survival and overall survival for the entire group were 88% (0.88 (95% CI: 0.81, 0.96) and 95% (95% CI: 0.90, 1.00), respectively.",Findings,[198408],[2109],[2263],[False],[0],[0],[False],['0']
25200,PMC4984260,33689,"Overall 14 (29%) of 79 patients had grade 3-4 gastrointestinal adverse events, 12 (16%) of 79 patients had grade 3-4 pain as an adverse event, 12 (16%) of 79 patients had grade 3-4 hematological adverse events, and 9 (11%) of 79 patients had grade 3 dermatologic adverse events during chemoradiation.",Findings,[198413],[2264],[2564],[False],[0],[0],[False],['0']
25201,PMC4984260,33690,"Six (8%) of the 77 patients who had surgery had grade 3 pain, 3(4%) of 77 patients had grade 3-4 hemorrhage, 3 (4%) of 77 patients had gastrointestinal adverse events, 2 (3%) of 77 patients had infectious/febrile neutropenia, 2 (3%) of 77 patients had hematological adverse events, and one (1%) had neurological adverse events.",Findings,[198418],[2565],[2892],[False],[0],[0],[False],['0']
25202,PMC4984260,33691,The rectum was preserved in 72 of the 79 (91%) patients.,Findings,[198423],[2893],[2949],[False],[0],[0],[False],['0']
25203,PMC4984260,33692,ARF and QOL were unchanged one year after surgery compared to baseline.,Findings,[198428],[2950],[3021],[False],[0],[0],[False],['0']
25204,PMC4984260,33693,Interpretation,Interpretation,[198433],[3022],[3037],[False],[0],[0],[False],['0']
25205,PMC4984260,33694,Most patients with T2N0 rectal cancer treated with nCRT and LE achieved organ preservation without deterioration of their quality of life.,Interpretation,[198438],[3038],[3176],[False],[0],[0],[False],['0']
25206,PMC4984260,33695,The estimated 3-year DFS rate was within the defined margin of efficacy.,Interpretation,[198443],[3177],[3249],[False],[0],[0],[False],['0']
25207,PMC4984260,33696,"Our data suggest that nCRT followed by LE may be considered as an organ-preserving alternative in carefully selected patients with clinically-staged T2N0 tumours who refuse, or are not candidates for, transabdominal resection.",Interpretation,[198448],[3250],[3476],[False],[0],[0],[False],['0']
25208,PMC4984260,33697,INTRODUCTION,INTRODUCTION,[198453],[3477],[3491],[False],[0],[0],[False],['0']
25209,PMC4984260,33698,"Transabdominal rectal resection following the principles of total mesorectal excision (TME) has been the mainstay treatment for patients with localized rectal cancer for decades.1 While effective in providing local tumour control, TME is associated with significant morbidity and long-lasting consequences.",INTRODUCTION,[198458],[3492],[3798],[False],[0],[0],[False],['0']
25210,PMC4984260,33699,"These include sexual and urinary dysfunction, significant defecatory problems, or a permanent stoma.2-4 Consequently, many patients experience a significant decline in quality of life QOL after TME.",INTRODUCTION,[198463],[3799],[3997],[False],[0],[0],[False],['0']
25211,PMC4984260,33700,"Alternatives to TME that are capable of achieving the same cure rate, while preserving function, would improve patients’ QOL significantly.",INTRODUCTION,[198468],[3998],[4137],[False],[0],[0],[False],['0']
25212,PMC4984260,33701,"The need for TME in patients with tumours localized to the bowel wall, which have not spread to the mesorectal lymph nodes, has long been questioned.5 Local excision (LE) has been proposed as an alternative for these patients.",INTRODUCTION,[198473],[4138],[4364],[False],[0],[0],[False],['0']
25213,PMC4984260,33702,"However, LE in early-stage cancer is associated with higher local recurrence (LR) rates than TME.6-8 Furthermore, while patients who develop LR after LE can theoretically undergo salvage TME, many have incomplete resections, with recurrence extending beyond the tissues removed by standard TME.9-11 Survival after LE is therefore inferior compared to TME, particularly in patients with T2N0 tumours.12-14",INTRODUCTION,[198478],[4365],[4769],[False],[0],[0],[False],['0']
25214,PMC4984260,33703,"A number of studies have proven that radiotherapy (RT) or chemoradiotherapy (CRT) before TME is associated with a lower rate of LR, compared to either TME alone, or TME followed by CRT.",INTRODUCTION,[198483],[4770],[4955],[False],[0],[0],[False],['0']
25215,PMC4984260,33704,"Based on these studies, neoadjuvant CRT (nCRT) followed by TME has become the standard treatment for patients with locally advanced rectal cancer (LARC).15, 16 The benefits of nCRT in LARC patients treated with TME have hastened interest in use of nCRT before LE for early-stage rectal cancer.",INTRODUCTION,[198488],[4956],[5249],[False],[0],[0],[False],['0']
25216,PMC4984260,33705,"Several retrospective case series, and a single-institution prospective study, have suggested that nCRT before LE may result in local tumour control comparable to that of TME for tumours of similar stage.17-20 However, these studies are limited by small size, variable clinical staging criteria, heterogeneous tumour characteristics, and varying nCRT regimens.",INTRODUCTION,[198493],[5250],[5610],[False],[0],[0],[False],['0']
25217,PMC4984260,33706,Prospective data from larger multi-center trials are needed.,INTRODUCTION,[198498],[5611],[5671],[False],[0],[0],[False],['0']
25218,PMC4984260,33707,"The American College of Surgeons Oncology Group (ACOSOG) designed a prospective multi-institutional, phase 2 trial to investigate the feasibility of using nCRT before LE to achieve organ preservation in patients with endorectal ultrasound (ERUS)- or endorectal coil magnetic resonance imaging (EC-MRI)-staged T2N0 rectal cancer located within 8 cm of the anal verge.",INTRODUCTION,[198503],[5672],[6038],[False],[0],[0],[False],['0']
25219,PMC4984260,33708,"Select secondary endpoints of this trial have already been reported.21 Given more mature follow-up on all patients enrolled, we now report the primary endpoints of tumour recurrence and survival at 3 years, and anorectal function and QOL at 1 year.",INTRODUCTION,[198508],[6039],[6287],[False],[0],[0],[False],['0']
25220,PMC4984260,33709,METHODS,METHODS,[198513],[6288],[6296],[False],[0],[0],[False],['0']
25221,PMC4984260,33710,Study Design and Participants,METHODS|Study Design and Participants,[198518],[6297],[6326],[False],[0],[0],[False],['0']
25222,PMC4984260,33711,"The study design has been reported previously.21 This was a phase 2, single arm, non-randomized, open-label trial conducted at American College Of Surgeons Oncology Group Institutions.",METHODS|Study Design and Participants,[198523],[6327],[6511],[False],[0],[0],[False],['0']
25223,PMC4984260,33712,"Patients with clinical T2N0 rectal adenocarcinoma staged by ERUS or EC-MRI, measuring < 4 cm in greatest diameter, involving < 40% of the circumference of the rectum, and located within 8 cm of the anal verge, were included.",METHODS|Study Design and Participants,[198528],[6512],[6736],[False],[0],[0],[False],['0']
25224,PMC4984260,33713,"All patients underwent complete colonoscopy, rigid proctoscopy, digital rectal exam (DRE), abdominal and pelvic CT, and chest x-ray or chest CT. All had Eastern Cooperative Oncology Group Performance Score (ECOG PS) of ≤ 2.",METHODS|Study Design and Participants,[198533],[6737],[6960],[False],[0],[0],[False],['0']
25225,PMC4984260,33714,Patients with tumours fixed to adjacent structures on DRE were ineligible.,METHODS|Study Design and Participants,[198538],[6961],[7035],[False],[0],[0],[False],['0']
25226,PMC4984260,33715,The protocol schema is shown in Figure 1.,METHODS|Study Design and Participants,[198543],[7036],[7077],[False],[0],[0],[False],['0']
25227,PMC4984260,33716,The study was approved by the Institutional Review Boards at all participating institutions.,METHODS|Study Design and Participants,[198548],[7078],[7170],[False],[0],[0],[False],['0']
25228,PMC4984260,33717,Data was submitted to the ACOSOG statistical center.,METHODS|Study Design and Participants,[198553],[7171],[7223],[False],[0],[0],[False],['0']
25229,PMC4984260,33718,Procedures,Procedures,[198558],[7224],[7235],[False],[0],[0],[False],['0']
25230,PMC4984260,33719,"External beam RT with megavoltage linear accelerators (≥ 6 MV) was delivered to a 3-4 field pelvis arrangement, following CT-based simulation and computer-assisted treatment planning.",Procedures,[198563],[7236],[7419],[False],[0],[0],[False],['0']
25231,PMC4984260,33720,Intensity-modulated RT (IMRT) was allowed (IMRT guidelines available at:http://www.acosog.org).,Procedures,[198568],[7420],[7515],[False],[0],[0],[False],['0']
25232,PMC4984260,33721,"The original dose (OD) of RT consisted of 1.8 Gy/day 5 days/week for 5 weeks to a dose of 45 Gy to PTV1, then a boost to PTV2 (defined as GTV plus 2cm) for a total dose of 54 Gy.",Procedures,[198573],[7516],[7694],[False],[0],[0],[False],['0']
25233,PMC4984260,33722,"This was accompanied by capecitabine (825mg/m2, twice daily, on days 1-14 and 22-35) and oxaliplatin (50mg/m2 weeks 1, 2, 4, 5).",Procedures,[198578],[7695],[7823],[False],[0],[0],[False],['0']
25234,PMC4984260,33723,The OD of nCRT was found to have unfavorable toxicities; this led to a revised dose (RD) regimen after 53 patients had been accrued.,Procedures,[198583],[7824],[7956],[False],[0],[0],[False],['0']
25235,PMC4984260,33724,"The RT was reduced to a total of 50.4 Gy, and capecitabine was reduced to 725 mg /m2, twice daily, 5 days/week, for 5 weeks.",Procedures,[198588],[7957],[8081],[False],[0],[0],[False],['0']
25236,PMC4984260,33725,The dose of oxaliplatin was not changed.,Procedures,[198593],[8082],[8122],[False],[0],[0],[False],['0']
25237,PMC4984260,33726,Surgery was performed 4-8 weeks after completion of nCRT.,Procedures,[198598],[8123],[8180],[False],[0],[0],[False],['0']
25238,PMC4984260,33727,LE was done using conventional transanal excision (TAE) or transanal endoscopic microsurgery (TEM).,Procedures,[198603],[8181],[8280],[False],[0],[0],[False],['0']
25239,PMC4984260,33728,Full-thickness excision of the tumour with a 1 cm surrounding margin of normal rectal wall was required.,Procedures,[198608],[8281],[8385],[False],[0],[0],[False],['0']
25240,PMC4984260,33729,"All participating surgeons had performed at least 3 LEs with negative margins, and completed a skills verification program.",Procedures,[198613],[8386],[8509],[False],[0],[0],[False],['0']
25241,PMC4984260,33730,Staging of surgical specimens was performed according to AJCC criteria.,Procedures,[198618],[8510],[8581],[False],[0],[0],[False],['0']
25242,PMC4984260,33731,Specimens without evidence of dysplastic epithelium or invasive cancer were classified as having pathologic complete response (pCR).,Procedures,[198623],[8582],[8714],[False],[0],[0],[False],['0']
25243,PMC4984260,33732,"Specimens with dysplastic epithelium at the original tumour site, but without evidence of invasion, were staged as ypTis (carcinoma in situ), rather than pCR.",Procedures,[198628],[8715],[8873],[False],[0],[0],[False],['0']
25244,PMC4984260,33733,Patients received an initial post-operative exam 1 month after surgery.,Procedures,[198633],[8874],[8945],[False],[0],[0],[False],['0']
25245,PMC4984260,33734,"DRE, proctoscopy and ERUS were given every 4 months for 3 years, and every 6 months for the next 2 years.",Procedures,[198638],[8946],[9051],[False],[0],[0],[False],['0']
25246,PMC4984260,33735,Colonoscopy was required at 3 years.,Procedures,[198643],[9052],[9088],[False],[0],[0],[False],['0']
25247,PMC4984260,33736,Other tests for LR or distant metastasis (DM) were performed if indicated.,Procedures,[198648],[9089],[9163],[False],[0],[0],[False],['0']
25248,PMC4984260,33737,Outcomes,Outcomes,[198653],[9164],[9173],[False],[0],[0],[False],['0']
25249,PMC4984260,33738,The primary endpoint was 3-year disease-free survival (DFS).,Outcomes,[198658],[9174],[9234],[False],[0],[0],[False],['0']
25250,PMC4984260,33739,"Evidence of LR, DM, or death from any cause within 3 years counted as events in the time-to-event Kaplan-Meier analysis22 of DFS.",Outcomes,[198663],[9235],[9364],[False],[0],[0],[False],['0']
25251,PMC4984260,33740,All protocol-eligible patients were considered on an intent-to-treat analysis.,Outcomes,[198668],[9365],[9443],[False],[0],[0],[False],['0']
25252,PMC4984260,33741,"Per-protocol analyses were also performed, for which patients were considered evaluable if they underwent nCRT and LE and had ypT0, ypT1, or ypT2 tumours with negative margins.",Outcomes,[198673],[9444],[9620],[False],[0],[0],[False],['0']
25253,PMC4984260,33742,"Secondary endpoints were the proportion of patients having negative resection margins after LR, the proportion of patients with a pCR, the procedure-specific morbidity and mortality following nCRT and LE, and the impact of nCRT followed by LE on anorectal function and QOL.",Outcomes,[198678],[9621],[9894],[False],[0],[0],[False],['0']
25254,PMC4984260,33743,Anorectal function and QOL were evaluated at the time of enrollment and 12 months after surgery using the Fecal Incontinence Severity Index (FISI)25 and the Functional Assessment of Cancer Therapy-Colorectal (FACT-C)26 questionnaires.,Outcomes,[198683],[9895],[10129],[False],[0],[0],[False],['0']
25255,PMC4984260,33744,"The FISI addresses varying frequencies of leakage of gas, mucus, liquid or solid stool, with higher scores indicative of worse anorectal function.",Outcomes,[198688],[10130],[10276],[False],[0],[0],[False],['0']
25256,PMC4984260,33745,"The FACT-C questionnaire comprises 5 subscales: 4 measuring concerns related to general health -related –QOL, Physical Well-Being (PWB), Social/Family Well Being (SFWB), Emotional Well-Being (EWB), Functional Well-Being (FWB); and 1 subscale measuring concerns related specifically to colorectal cancer - the Colorectal Cancer Subscale (CCS).",Outcomes,[198693],[10277],[10619],[False],[0],[0],[False],['0']
25257,PMC4984260,33746,The FACT-C total score is the sum of all 5 subscales.,Outcomes,[198698],[10620],[10673],[False],[0],[0],[False],['0']
25258,PMC4984260,33747,A higher score represents better QOL and overall function.,Outcomes,[198703],[10674],[10732],[False],[0],[0],[False],['0']
25259,PMC4984260,33748,Statistical analysis,Statistical analysis,[198708],[10733],[10754],[False],[0],[0],[False],['0']
25260,PMC4984260,33749,The sample size was calculated using the per-protocol patient set.,Statistical analysis,[198713],[10755],[10821],[False],[0],[0],[False],['0']
25261,PMC4984260,33750,"A 3-year DFS probability of < 0.80 was considered unacceptably low, while a probability of > 0.91 was considered clinically promising.",Statistical analysis,[198718],[10822],[10956],[False],[0],[0],[False],['0']
25262,PMC4984260,33751,"Assuming a significance level of 0.1, 70 evaluable patients were needed to distinguish a null 3-year DFS event rate of 0.80 from an alternative rate of 0.91 with 90% power.",Statistical analysis,[198723],[10957],[11129],[False],[0],[0],[False],['0']
25263,PMC4984260,33752,"We estimated that up to 5% of patients would not tolerate nCRT, up to 10% would exhibit pathological ypT3 tumours or positive resection margins, and up to 15% would not be evaluable for the primary endpoint; therefore, we targeted a total accrual of 83 patients, to ensure at least 70 evaluable patients for per-protocol analyses.",Statistical analysis,[198728],[11130],[11460],[False],[0],[0],[False],['0']
25264,PMC4984260,33753,"In addition to computation of 3-year DFS, the survival profile of enrolled patients was summarized graphically over 5 years of follow-up using the Kaplan-Meier estimator.",Statistical analysis,[198733],[11461],[11631],[False],[0],[0],[False],['0']
25265,PMC4984260,33754,Differences between grouped survival profiles were assessed with the Log-rank test22.,Statistical analysis,[198738],[11632],[11717],[False],[0],[0],[False],['0']
25266,PMC4984260,33755,The Wilcoxon rank-sum test23 and Fisher’s exact test24 were used to compare continuous and categorical variables between dose groups.,Statistical analysis,[198743],[11718],[11851],[False],[0],[0],[False],['0']
25267,PMC4984260,33756,All reported P-values were based on two-sided tests; confidence intervals assumed a significance of 0.05.,Statistical analysis,[198748],[11852],[11957],[False],[0],[0],[False],['0']
25268,PMC4984260,33757,"Anorectal function and QOL at baseline, and 12 months following surgery, were compared using the Wilcoxon Signed Rank test.",Statistical analysis,[198753],[11958],[12081],[False],[0],[0],[False],['0']
25269,PMC4984260,33758,"The trial is registered with ClinicalTrials.gov, number NCT00114231.",Statistical analysis,[198758],[12082],[12150],[False],[0],[0],[False],['0']
25270,PMC4984260,33759,Role of the Funding Source,Role of the Funding Source,[198763],[12151],[12178],[False],[0],[0],[False],['0']
25271,PMC4984260,33760,"The ACOSOG participated in the study design, data collection, data storage, and data analysis, but had no role in writing the report.",Role of the Funding Source,[198768],[12179],[12312],[False],[0],[0],[False],['0']
25272,PMC4984260,33761,"Only LAR, QS and XWC had access to the raw data.",Role of the Funding Source,[198773],[12313],[12361],[False],[0],[0],[False],['0']
25273,PMC4984260,33762,"The corresponding author had access to the analyzed data, not the raw data, but had final responsibility for the decision to submit the manuscript.",Role of the Funding Source,[198778],[12362],[12509],[False],[0],[0],[False],['0']
25274,PMC4984260,33763,RESULTS,RESULTS,[198783],[12510],[12518],[False],[0],[0],[False],['0']
25275,PMC4984260,33764,"Seventy-nine eligible patients were accrued to the trial from May 25th 2006 to October 22nd 2009, and began nCRT.",RESULTS,[198788],[12519],[12632],[False],[0],[0],[False],['0']
25276,PMC4984260,33765,They represent the intention-to-treat group (Table 1).,RESULTS,[198793],[12633],[12687],[False],[0],[0],[False],['0']
25277,PMC4984260,33766,Patient disposition and analysis groups are presented in Figure 2.,RESULTS,[198798],[12688],[12754],[False],[0],[0],[False],['0']
25278,PMC4984260,33767,Two patients did not have surgery.,RESULTS,[198803],[12755],[12789],[False],[0],[0],[False],['0']
25279,PMC4984260,33768,"The pathologic results for all 77 patients undergoing surgery have been previously published.21 Of these 77 patients, 38 (49%) had ypT0 or ypTis tumours; 11 (14%) ypT1 tumours; 24 (31%) ypT2 tumours; 3 (4%) ypT3 tumours; 1 (1%) ypTx tumour.",RESULTS,[198808],[12790],[13030],[False],[0],[0],[False],['0']
25280,PMC4984260,33769,The proportions of all patients experiencing AEs during nCRT and stratified by dose groups are presented in Table 2.,RESULTS,[198813],[13031],[13147],[False],[0],[0],[False],['0']
25281,PMC4984260,33770,Surgery-related toxicities are presented in Table 3.,RESULTS,[198818],[13148],[13200],[False],[0],[0],[False],['0']
25282,PMC4984260,33771,"In total, 76 patients had nCRT and LE, either TEM (29 patients or 38%) or TAE (47 patients or 62%).",RESULTS,[198823],[13201],[13300],[False],[0],[0],[False],['0']
25283,PMC4984260,33772,"One patient had positive resection margins and underwent APR, as required per protocol, with no residual tumour identified in the surgical specimen.",RESULTS,[198828],[13301],[13449],[False],[0],[0],[False],['0']
25284,PMC4984260,33773,The patient died 10 months later from surgery-related complications.,RESULTS,[198833],[13450],[13518],[False],[0],[0],[False],['0']
25285,PMC4984260,33774,"Three additional patients had ypT3 tumours, and two of these underwent APR within six weeks of LE.",RESULTS,[198838],[13519],[13617],[False],[0],[0],[False],['0']
25286,PMC4984260,33775,"Neither APR specimen revealed cancer; both patients were alive and without evidence of disease at 40 and 47 months from LE, respectively.",RESULTS,[198843],[13618],[13755],[False],[0],[0],[False],['0']
25287,PMC4984260,33776,The third patient refused APR and developed pelvic recurrence.,RESULTS,[198848],[13756],[13818],[False],[0],[0],[False],['0']
25288,PMC4984260,33777,"The remaining 72 patients underwent nCRT and LE and had ypT0-2 and negative resection margins, comprising the per-protocol group.",RESULTS,[198853],[13819],[13948],[False],[0],[0],[False],['0']
25289,PMC4984260,33778,"Patients have been followed for a median 56 months (IQR 46-63 months) after surgery, with no treatment-related deaths.",RESULTS,[198858],[13949],[14067],[False],[0],[0],[False],['0']
25290,PMC4984260,33779,Five died from non-cancer-related causes 8-38 months after surgery.,RESULTS,[198863],[14068],[14135],[False],[0],[0],[False],['0']
25291,PMC4984260,33780,"At the end of the follow-up period, eight of 79 patients (10%) have developed recurrence: five of 79 (6%) with DM and three of 79 (4%) with LR as initial sites of failure.",RESULTS,[198868],[14136],[14307],[False],[0],[0],[False],['0']
25292,PMC4984260,33781,None have developed both DM and LR.,RESULTS,[198873],[14308],[14343],[False],[0],[0],[False],['0']
25293,PMC4984260,33782,"Characteristics of the eight patients with recurrent tumour, salvage treatment received, and tumour and survival status at the end of follow-up are presented in Table 4.",RESULTS,[198878],[14344],[14513],[False],[0],[0],[False],['0']
25294,PMC4984260,33783,"Two patients with LR underwent salvage APR, with negative margins.",RESULTS,[198883],[14514],[14580],[False],[0],[0],[False],['0']
25295,PMC4984260,33784,"One patient whose APR specimen showed tumour limited to the muscularis propria developed further pelvic recurrence, and died of disease 48 months after LE.",RESULTS,[198888],[14581],[14736],[False],[0],[0],[False],['0']
25296,PMC4984260,33785,"The second patient had carcinoma in situ in the APR specimen, and remains alive and free of disease 48 months after LE.",RESULTS,[198893],[14737],[14856],[False],[0],[0],[False],['0']
25297,PMC4984260,33786,One patient with a ypT3 tumour in the surgical specimen refused TME and developed LR.,RESULTS,[198898],[14857],[14942],[False],[0],[0],[False],['0']
25298,PMC4984260,33787,"The estimated 3-year DFS for the intent-to-treat group was 0.88 (95% CI: 0.81, 0.96), and for the per-protocol group 0.87 (95% CI: 0.79, 0.95) (Figure 3).",RESULTS,[198903],[14943],[15097],[False],[0],[0],[False],['0']
25299,PMC4984260,33788,"Three-year OS for the intent-to-treat group was 0.96 (95% CI: 0.90, 1.00), and for the per-protocol group 0.96 (95% CI: 0.91, 1.00) (Figure 4).",RESULTS,[198908],[15098],[15241],[False],[0],[0],[False],['0']
25300,PMC4984260,33789,"Five of the recurrences developed in patients receiving the OD, three in patients receiving the RD.",RESULTS,[198913],[15242],[15341],[False],[0],[0],[False],['0']
25301,PMC4984260,33790,The 3-year DFS and OS by OD versus RD groups for the intent-to-treat group are presented in Supplemental Figure 1.,RESULTS,[198918],[15342],[15456],[False],[0],[0],[False],['0']
25302,PMC4984260,33791,We found no differences in 3-year DFS or overall survival between patients treated with TEM and TAE (Supplemental Figure 2).,RESULTS,[198923],[15457],[15581],[False],[0],[0],[False],['0']
25303,PMC4984260,33792,"At the end of follow-up, 72 (91%) of 79 patients receiving nCRT and LE had rectal preservation.",RESULTS,[198928],[15582],[15677],[False],[0],[0],[False],['0']
25304,PMC4984260,33793,"All 72 patients completed the baseline FISI and FACT-C questionnaires, but only 62 (86%) completed them one year after surgery.",RESULTS,[198933],[15678],[15805],[False],[0],[0],[False],['0']
25305,PMC4984260,33794,"We found no significant deterioration in the overall FISI scores or any of the subscales one year after surgery, compared to baseline (Table 5).",RESULTS,[198938],[15806],[15950],[False],[0],[0],[False],['0']
25306,PMC4984260,33795,We found no difference in the overall FACT-C scores between baseline and one-year evaluations (Table 5).,RESULTS,[198943],[15951],[16055],[False],[0],[0],[False],['0']
25307,PMC4984260,33796,"However, patients experienced deterioration in the physical well-being subscale, and an improvement in the emotional well-being subscales (Table 5).",RESULTS,[198948],[16056],[16204],[False],[0],[0],[False],['0']
25308,PMC4984260,33797,DISCUSSION,DISCUSSION,[198953],[16205],[16216],[False],[0],[0],[False],['0']
25309,PMC4984260,33798,The results of this multi-institutional prospective trial indicate that the vast majority of patients with clinically staged T2N0 rectal cancer treated with nCRT and LE preserved the rectum.,DISCUSSION,[198958],[16217],[16407],[False],[0],[0],[False],['0']
25310,PMC4984260,33799,"The LR rate for all patients was 4%, and the estimated 3-year DFS for the intention-to-treat group and for the per-protocol groups were within the margin of efficacy defined in the study design.",DISCUSSION,[198963],[16408],[16602],[False],[0],[0],[False],['0']
25311,PMC4984260,33800,"However, the lower limit of the 95% confidence interval of 3-years DFS for the per-protocol group, the one used for the sample size calculation, reached the threshold for considering it unacceptably low.",DISCUSSION,[198968],[16603],[16806],[False],[0],[0],[False],['0']
25312,PMC4984260,33801,"Thus, while the results are encouraging, the study did not achieve its goal using the strictly pre-set statistical parameters.",DISCUSSION,[198973],[16807],[16933],[False],[0],[0],[False],['0']
25313,PMC4984260,33802,"The results of this trial also demonstrated that nCRT and LE do not cause significant alterations in anorectal function and overall QOL measured one year after surgery, compared to baseline.",DISCUSSION,[198978],[16934],[17124],[False],[0],[0],[False],['0']
25314,PMC4984260,33803,"Furthermore, half of the clinically staged T2N0 patients treated with nCRT and LE had pCR, and only one in 76 had a positive resection margin.",DISCUSSION,[198983],[17125],[17267],[False],[0],[0],[False],['0']
25315,PMC4984260,33804,The changes in nCRT introduced in response to the unexpectedly high toxicity observed with the original nCRT regimen resulted in a reduction in the pCR and 3-year DFS rates.,DISCUSSION,[198988],[17268],[17441],[False],[0],[0],[False],['0']
25316,PMC4984260,33805,"The results of recent phase 3 trials indicate that adding oxaliplatin to a fluoropyrimidine as a radiosensitizer in patients with rectal cancer increases toxicity without enhancing tumour response, compared to fluoropyrimidine alone.27-29 Based on this information, discontinuing oxaliplatin altogether may have been more effective in preventing toxicity, without affecting tumour response, than reducing the dose of capecitabine and radiation.",DISCUSSION,[198993],[17442],[17886],[False],[0],[0],[False],['0']
25317,PMC4984260,33806,"A transabdominal rectal resection is the recommended treatment for patients with T2N0 rectal cancer, and TME is the gold standard against which other surgical procedures should be compared.1 The 3-year DFS and OS in this trial are within the range of the rates reported for Stage I tumours treated with either laparoscopic or open TME in the recently published COLOR II trial.30 However, the COLOR II trial did not stratify the results of patients with Stage I disease by T categories.",DISCUSSION,[198998],[17887],[18372],[False],[0],[0],[False],['0']
25318,PMC4984260,33807,"Retrospective case series and a cohort study from the National Cancer Database have reported 5-year LR rates ranging from 6% to 15% for T2N0 rectal cancers treated with transabdominal resection alone,12, 13, 31 higher than the 4% LR rate in this study.",DISCUSSION,[199003],[18373],[18625],[False],[0],[0],[False],['0']
25319,PMC4984260,33808,"Recent population-based analysis from the NCDB and the Surveillance, Epidemiology and End Results (SEER) database have reported 5-year OS rates close to 76% for patients with T2N0 rectal cancer treated with transabdominal resection alone, lower than the estimated 5-year overall survival observed in this trial.",DISCUSSION,[199008],[18626],[18937],[False],[0],[0],[False],['0']
25320,PMC4984260,33809,"However, comparisons between this trial and prospective studies or retrospective series of patients treated with transabdominal rectal resection are limited by patient selection bias.",DISCUSSION,[199013],[18938],[19121],[False],[0],[0],[False],['0']
25321,PMC4984260,33810,"Patients in the Z6041 trial had tumours located within 8 cm of the anal verge, while patients in the TME series had tumours located anywhere in the rectum.",DISCUSSION,[199018],[19122],[19277],[False],[0],[0],[False],['0']
25322,PMC4984260,33811,"As cancers located in the lower third of the rectum pose a higher risk of LR than cancers in the mid and upper rectum, a higher risk of recurrence should be expected in the Z6041 trial.",DISCUSSION,[199023],[19278],[19463],[False],[0],[0],[False],['0']
25323,PMC4984260,33812,"On the other hand, the Z6041 trial was limited to tumours smaller than 4 cm in diameter, a selection criterion not applied in the transabdominal rectal resection series.",DISCUSSION,[199028],[19464],[19633],[False],[0],[0],[False],['0']
25324,PMC4984260,33813,"In addition, results for the Z6041 trial are reported by clinical stage, whereas results in the transabdominal resection series were reported by pathological stage.",DISCUSSION,[199033],[19634],[19798],[False],[0],[0],[False],['0']
25325,PMC4984260,33814,"Both ERUS and EC-MRI are known to overstage or understage some tumours.32, 33 It is likely that some of the ypT0, ypTis or ypT1 tumours in this trial may have been initially overstaged as T2 by ERUS.",DISCUSSION,[199038],[19799],[19998],[False],[0],[0],[False],['0']
25326,PMC4984260,33815,"Conversely, the ypT3 tumours in this trial may represent either tumour progression during nCRT, or understaging by ERUS.",DISCUSSION,[199043],[19999],[20119],[False],[0],[0],[False],['0']
25327,PMC4984260,33816,"Finally, LR tends to occur later in patients treated with nCRT and surgery, compared to those treated with surgery alone.15 In our series all patients received neoadjuvant radiation, compared to 59% in the COLOR II trial.",DISCUSSION,[199048],[20120],[20341],[False],[0],[0],[False],['0']
25328,PMC4984260,33817,"Therefore, more patients in the Z6041 trial are likely to develop tumour relapse on longer follow-up.",DISCUSSION,[199053],[20342],[20443],[False],[0],[0],[False],['0']
25329,PMC4984260,33818,"Proving equivalence in oncologic efficacy between nCRT plus LE and TME for treatment of early rectal cancer would require a well-designed prospective, randomized trial.",DISCUSSION,[199058],[20444],[20612],[False],[0],[0],[False],['0']
25330,PMC4984260,33819,"Given the relatively good prognosis of stage I rectal cancer, the required sample size will be large.",DISCUSSION,[199063],[20613],[20714],[False],[0],[0],[False],['0']
25331,PMC4984260,33820,"In addition, patients’ acceptance of randomization between LE and TME is questionable.",DISCUSSION,[199068],[20715],[20801],[False],[0],[0],[False],['0']
25332,PMC4984260,33821,"Therefore, completion of such a study would be challenging.",DISCUSSION,[199073],[20802],[20861],[False],[0],[0],[False],['0']
25333,PMC4984260,33822,"Lezoche, et al.",DISCUSSION,[199078],[20862],[20877],[False],[0],[0],[False],['0']
25334,PMC4984260,33823,"reported the results of a prospective single-institution trial comparing nCRT and LE and transrectal partial mesorectal excision to nCRT and laparoscopic TME in patients with ultrasound-staged T2N0M0 rectal cancers, smaller than 3 cm in diameter, located within 6 cm of the anal verge, with well or moderately differentiated histology.19 After five years of follow-up, 8% of patients in the LE group and 6% in the TME group have developed LR, rates not very different than in this trial.",DISCUSSION,[199083],[20878],[21365],[False],[0],[0],[False],['0']
25335,PMC4984260,33824,"Although underpowered to prove equivalence between nCRT plus LE and nCRT plus TME in uT2uN0 rectal cancer, Lezoche’s study also suggests that nCRT plus LE may be an alternative to TME for patients with distal rectal cancer seeking organ-preserving treatment to avoid a permanent colostomy.",DISCUSSION,[199088],[21366],[21655],[False],[0],[0],[False],['0']
25336,PMC4984260,33825,The justification for CRT and LE as an alternative to TME in patients with early-stage rectal cancer is the possibility of achieving equivalent oncologic results while preserving QOL.,DISCUSSION,[199093],[21656],[21839],[False],[0],[0],[False],['0']
25337,PMC4984260,33826,The baseline FISI total score in our patients was equivalent to those reported in patients with low rectal cancer enrolled in a prospective trial comparing functional outcomes after TME and different types of colorectal anastomosis.,DISCUSSION,[199098],[21840],[22072],[False],[0],[0],[False],['0']
25338,PMC4984260,33827,"However, while in this study the FISI score remained essentially unaltered one year after CRT and LE, patients treated with TME had a significant deterioration in the FISI score at that time point, independent of the type of anastomosis.34 In this study the FACT-C overall score and the CCS subscale remained unchanged one year after surgery, compared to baseline.",DISCUSSION,[199103],[22073],[22437],[False],[0],[0],[False],['0']
25339,PMC4984260,33828,These findings are consistent with the recently published results of the NSABP R0435 trial that also reported no significant differences in the FACT-C scores (baseline vs. 1 year after surgery) in rectal cancer patients treated with nCRT and TME.,DISCUSSION,[199108],[22438],[22684],[False],[0],[0],[False],['0']
25340,PMC4984260,33829,The study has several important limitations.,DISCUSSION,[199113],[22685],[22729],[False],[0],[0],[False],['0']
25341,PMC4984260,33830,"This is a single arm phase II trial, and the possibility of selecting fitter patients for nCRT and LE cannot be excluded.",DISCUSSION,"[199118, 199119]","[22730, 22730]","[22851, 22851]","[True, True]","['StudyDesign', 'VerySpecificPopulation']","['single arm', 'the possibility of selecting fitter patients for nCRT and LE cannot be excluded']","[True, True]","['Population', 'StudyDesign']"
25342,PMC4984260,33831,The sample size is relatively small.,DISCUSSION,[199130],[22852],[22888],[True],['SampleSize'],['The sample size is relatively small'],[True],['UnderpoweredStudy']
25343,PMC4984260,33832,"The follow-up is still short and, while most recurrences tend to arise in the first three years after treatment, nCRT delays the appearance of LR and it is possible that more patients may develop recurrence in the future.",DISCUSSION,[199141],[22889],[23110],[True],['FollowUpDuration'],['The follow-up is still short'],[True],['StudyDuration']
25344,PMC4984260,33833,"Finally, not all patients completed the 1-year FISI and FACT-C questionnaires, either because they passed away, developed recurrence, or simply did not return them.",DISCUSSION,[199152],[23111],[23275],[True],['MissingData'],['not all patients completed the 1-year FISI and FACT-C questionnaires'],[True],['MissingData']
25345,PMC4984260,33834,"Therefore, our study may underestimate the real impact of nCRT and LE on ARF and QOL.",DISCUSSION,[199158],[23276],[23361],[False],[0],[0],[False],['0']
25346,PMC4984260,33835,"In conclusion, this study shows that nearly half of patients with clinically-staged T2N0 distal rectal cancer can achieve a pCR in response to nCRT.",DISCUSSION,[199163],[23362],[23510],[False],[0],[0],[False],['0']
25347,PMC4984260,33836,Rates of recurrence and survival are similar to patients with stage I tumours treated with TME.,DISCUSSION,[199168],[23511],[23606],[False],[0],[0],[False],['0']
25348,PMC4984260,33837,The majority of patients treated with nCRT and LE preserve the rectum with minimal deterioration in ARF and QOL up to one year after LE.,DISCUSSION,[199173],[23607],[23743],[False],[0],[0],[False],['0']
25349,PMC4984260,33838,"While follow-up is still short, this study suggests that nCRT followed by LE may be an alternative to transabdominal rectal resection for carefully selected patients with T2N0 distal rectal cancer.",DISCUSSION,[199178],[23744],[23941],[False],[0],[0],[False],['0']
25350,PMC4984260,33839,Acknowledgements,Acknowledgements,[199183],[23942],[23960],[False],[0],[0],[False],['0']
25351,PMC4984260,33840,"The authors thank Pam Fain-Pribyl, of the Mayo Clinic, for contributing her expertise in quality assurance.",Acknowledgements,[199188],[23961],[24068],[False],[0],[0],[False],['0']
25352,PMC4984260,33841,"We also thank Jen Levin, of Memorial Sloan Kettering Cancer Center, for her editorial support.",Acknowledgements,[199193],[24069],[24163],[False],[0],[0],[False],['0']
25353,PMC4984260,33842,Funding: National Cancer Institute Grant U10 CA 76001 to the American College of Surgeons Oncology Group (ACOSOG); Sanofi-Aventis.This is a PDF file of an unedited manuscript that has been accepted for publication.,Acknowledgements,[199198],[24164],[24378],[False],[0],[0],[False],['0']
25354,PMC4984260,33843,As a service to our customers we are providing this early version of the manuscript.,Acknowledgements,[199203],[24379],[24463],[False],[0],[0],[False],['0']
25355,PMC4984260,33844,"The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.",Acknowledgements,[199208],[24464],[24601],[False],[0],[0],[False],['0']
25356,PMC4984260,33845,"Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Disclosures",Acknowledgements,[199213],[24602],[24777],[False],[0],[0],[False],['0']
25357,PMC4984260,33846,"PC discloses honoraria from Richard Wolf Instruments, Co.Participating Surgeons and Institutions",Acknowledgements,[199218],[24778],[24874],[False],[0],[0],[False],['0']
25358,PMC4984260,33847,"Peter A. Cataldo (University of Vermont, Burlington, VT); Jorge E. Marcet (Tampa General Hospital, Tampa, FL); David S. Medich (Allegheny Medical Center, Pittsburgh, PA); Craig S. Johnson (St. Francis Hospital, Tulsa, OK); Samuel C. Oommen (John Muir Medical Center, Concord, CA); Bruce G. Wolff (Mayo Clinic, Rochester, MN); Alessio Pigazzi (City of Hope, Duarte, CA); Shane M. McNevin (Holy Family Hospital, Spokane, WA); Roger K. Pons (United Hospital Center; Bridgeport, WV); Ronald Bleday (Brigham and Women's Hospital, Boston, MA); Linda M. Farkas (Heritage Valley Health System); Jacques P. Heppell (Mayo Clinic, Phoenix, AZ); Najjia Mahmoud (University of Pennsylvania, Philadelphia, PA); Miguel Rodriguez-Bigas (MD Anderson Cancer Center, Houston, TX); Randolph H. Bailey (Methodist Hospital, Houston, TX); Alessandro Fichera (University of Chicago; Chicago, IL); Alan J. Herline (Vanderbilt University Medical Center; Nashville, TN); Richard A. Hoefer (Surgical Oncology Associates; Newport News, VA); Natalie Joseph (Fox Chase Cancer Center; Philadelphia, PA); Andreas Kaiser (University of Southern California, Los Angeles, CA); Kirk A. Ludwig (Duke University; Durham, NC); James McCormick (Western Pennsylvania Hospital, Pittsburg, PA); Bridget Sanders (Saint Francis Hospital Health Center; Indianapolis, IN); Robert Sticca (ACC-Grand Forks, ND); Eric Wiebke (Indiana University; Indianapolis, IN); Earl S. Yeager (St. Joseph Hospital, Savannah, GA).",Acknowledgements,[199223],[24875],[26340],[False],[0],[0],[False],['0']
25874,PMC5064025,6311,Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance,Title,[38006],[28993],[107],[False],[0],[0],[False],['0']
25875,PMC5064025,6312,Background,Abstract,[38012],[108],[119],[False],[0],[0],[False],['0']
25876,PMC5064025,6313,Evidence suggests that interleukin (IL)-1β is important in the pathogenesis of atherosclerosis and its complications and that inhibiting IL-1β may favorably affect vascular disease progression.,Abstract,[38018],[120],[313],[False],[0],[0],[False],['0']
25877,PMC5064025,6314,Objectives,Abstract,[38024],[314],[324],[False],[0],[0],[False],['0']
25878,PMC5064025,6315,"The goal of this study was to evaluate the effects of IL-1β inhibition with canakinumab versus placebo on arterial structure and function, determined by magnetic resonance imaging.",Abstract,[38030],[325],[505],[False],[0],[0],[False],['0']
25879,PMC5064025,6316,Methods,Abstract,[38036],[506],[513],[False],[0],[0],[False],['0']
25880,PMC5064025,6317,Patients (N = 189) with atherosclerotic disease and either type 2 diabetes mellitus or impaired glucose tolerance were randomized to receive placebo (n = 94) or canakinumab 150 mg monthly (n = 95) for 12 months.,Abstract,[38042],[514],[725],[False],[0],[0],[False],['0']
25881,PMC5064025,6318,They underwent magnetic resonance imaging of the carotid arteries and aorta.,Abstract,[38048],[726],[802],[False],[0],[0],[False],['0']
25882,PMC5064025,6319,Results,Abstract,[38054],[803],[810],[False],[0],[0],[False],['0']
25883,PMC5064025,6320,There were no statistically significant differences between canakinumab compared with placebo in the primary efficacy and safety endpoints.,Abstract,[38060],[811],[950],[False],[0],[0],[False],['0']
25884,PMC5064025,6321,"There was no statistically significant change in mean carotid wall area and no effect on aortic distensibility, measured at 3 separate anatomic sites.",Abstract,[38066],[951],[1101],[False],[0],[0],[False],['0']
25885,PMC5064025,6322,The change in mean carotid artery wall area was –3.37 mm2 after 12 months with canakinumab versus placebo.,Abstract,[38072],[1102],[1208],[False],[0],[0],[False],['0']
25886,PMC5064025,6323,High-sensitivity C-reactive protein was significantly reduced by canakinumab compared with placebo at 3 months (geometric mean ratio [GMR]: 0.568; 95% confidence interval [CI]: 0.436 to 0.740; p < 0.0001) and 12 months (GMR: 0.56; 95% CI: 0.414 to 0.758; p = 0.0002).,Abstract,[38078],[1209],[1476],[False],[0],[0],[False],['0']
25887,PMC5064025,6324,"Lipoprotein(a) levels were reduced by canakinumab compared with placebo (–4.30 mg/dl [range: –8.5 to –0.55 mg/dl]; p = 0.025] at 12 months), but triglyceride levels increased (GMR: 1.20; 95% CI: 1.046 to 1.380; p = 0.01).",Abstract,[38084],[1477],[1698],[False],[0],[0],[False],['0']
25888,PMC5064025,6325,"In these patients with type 2 diabetes mellitus or impaired glucose tolerance, canakinumab had no effect compared with placebo on any of the measures assessed by using a standard oral glucose tolerance test.",Abstract,[38090],[1699],[1906],[False],[0],[0],[False],['0']
25889,PMC5064025,6326,Conclusions,Abstract,[38096],[1907],[1918],[False],[0],[0],[False],['0']
25890,PMC5064025,6327,There were no statistically significant effects of canakinumab on measures of vascular structure or function.,Abstract,[38102],[1919],[2028],[False],[0],[0],[False],['0']
25891,PMC5064025,6328,"Canakinumab reduced markers of inflammation (high-sensitivity C-reactive protein and interleukin-6), and there were modest increases in levels of total cholesterol and triglycerides.",Abstract,[38108],[2029],[2211],[False],[0],[0],[False],['0']
25892,PMC5064025,6329,(Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients; NCT00995930),Abstract,[38114],[2212],[2345],[False],[0],[0],[False],['0']
25893,PMC5064025,6330,Atherosclerosis is well-established as a disease with an important inflammatory component.,Abstract,[38120],[2346],[2437],[False],[0],[0],[False],['0']
25894,PMC5064025,6331,Systemic markers of inflammation such as C-reactive protein and serum amyloid A are strongly related to cardiovascular prognosis in various populations and clinical settings.,Abstract,[38126],[2438],[2612],[False],[0],[0],[False],['0']
25895,PMC5064025,6332,"Furthermore, therapeutic interventions that reduce cardiovascular risk have also been associated with a reduction in systemic inflammatory markers.",Abstract,[38132],[2613],[2760],[False],[0],[0],[False],['0']
25896,PMC5064025,6333,"However, whether specifically targeting inflammation reduces cardiovascular risk remains unknown.",Abstract,[38138],[2761],[2858],[False],[0],[0],[False],['0']
25897,PMC5064025,6334,"Interleukins are important mediators of inflammation, both locally and systemically.",Abstract,[38144],[2859],[2943],[False],[0],[0],[False],['0']
25898,PMC5064025,6335,"Macrophages are key cellular components of atherosclerotic plaque and produce interleukin (IL)-1β, which is also promoted by cellular cholesterol activation of inflammasomes.",Abstract,[38150],[2944],[3118],[False],[0],[0],[False],['0']
25899,PMC5064025,6336,IL-1β and interleukin-1α exert proinflammatory effects that are inhibited by the endogenous antagonist interleukin-1 receptor antagonist (IL-1RA).,Abstract,[38156],[3119],[3265],[False],[0],[0],[False],['0']
25900,PMC5064025,6337,"Atherosclerosis-prone mice that are deficient in IL-1β develop smaller lesions, and administration of IL-1RA reduces early atherogenesis in mice.",Abstract,[38162],[3266],[3411],[False],[0],[0],[False],['0']
25901,PMC5064025,6338,"IL-1RA–deficient mice have shown increased atherosclerosis and vascular inflammation, associated with destruction of elastic tissues .",Abstract,[38168],[3412],[3546],[False],[0],[0],[False],['0']
25902,PMC5064025,6339,"Therefore, given the key role for IL-1β as a mediator of innate immunity and the effects of interleukin inhibition in experimental atherosclerosis, interventions to reduce inflammation through IL-1β have been proposed to treat atherosclerosis.",Abstract,[38174],[3547],[3790],[False],[0],[0],[False],['0']
25903,PMC5064025,6340,"Although evidence of benefit to vascular disease in humans remain sparse, administration of the IL-1RA anakinra to patients with rheumatoid arthritis improved several measures of vascular function, including aortic distensibility, flow-mediated vasodilation, and coronary flow reserve.",Abstract,[38180],[3791],[4076],[False],[0],[0],[False],['0']
25904,PMC5064025,6341,"In addition to its key role in vascular disease, IL-1β has been implicated in the pathogenesis of type 2 diabetes mellitus (T2DM).",Abstract,[38186],[4077],[4207],[False],[0],[0],[False],['0']
25905,PMC5064025,6342,"IL-1RA expression is reduced in pancreatic islets of patients with T2DM, and high glucose concentrations induce the production of IL-1β in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis.",Abstract,[38192],[4208],[4459],[False],[0],[0],[False],['0']
25906,PMC5064025,6343,Blockade of the interleukin-1 receptor with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation in patients with T2DM.,Abstract,[38198],[4460],[4631],[False],[0],[0],[False],['0']
25907,PMC5064025,6344,Patients with T2DM are at high risk for cardiovascular disease and have evidence of both increased plaque inflammation and reduced arterial distensibility.,Abstract,[38204],[4632],[4787],[False],[0],[0],[False],['0']
25908,PMC5064025,6345,"This group might, therefore, derive “metabolic” and “vascular” benefits from targeting IL-1β, including reduced risk of atherothrombotic complications.",Abstract,[38210],[4788],[4939],[False],[0],[0],[False],['0']
25909,PMC5064025,6346,A human monoclonal anti-human IL-1β antibody of the immunoglobulin G1/k isotype canakinumab functionally neutralizes IL-1β through steric hindrance of its receptor interaction.,Abstract,[38216],[4940],[5116],[False],[0],[0],[False],['0']
25910,PMC5064025,6347,"It is effective in reducing systemic markers of inflammation, including C-reactive protein and IL-6.",Abstract,[38222],[5117],[5217],[False],[0],[0],[False],['0']
25911,PMC5064025,6348,Its effects on cardiovascular outcomes are under investigation in the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial.,Abstract,[38228],[5218],[5359],[False],[0],[0],[False],['0']
25912,PMC5064025,6349,"Vascular magnetic resonance imaging (MRI) has emerged as a precise, highly reproducible, and versatile tool to assess both vascular structure and function at multiple arterial loci.",Abstract,[38234],[5360],[5541],[False],[0],[0],[False],['0']
25913,PMC5064025,6350,"Accordingly, we designed a randomized, placebo-controlled Phase II clinical trial to test the effects of IL-1β inhibition, using canakinumab, on: 1) MRI-derived measures of vascular structure and function; 2) measures of diabetes control; and 3) indicators of systemic inflammation in patients with atherosclerotic vascular disease and impaired glucose tolerance (IGT) or T2DM.",Abstract,[38240],[5542],[5919],[False],[0],[0],[False],['0']
25914,PMC5064025,6351,Methods,Methods,[38246],[5920],[5928],[False],[0],[0],[False],['0']
25915,PMC5064025,6352,"Novartis Pharmaceuticals (Cambridge, Massachusetts) initiated this Phase II, double-blind, randomized, placebo-controlled trial, with the final study protocol designed in collaboration with the investigators (R.P.C., J.-C.T., and Z.A.F.",Methods,[38252],[5929],[6165],[False],[0],[0],[False],['0']
25916,PMC5064025,6353,"), based on their previously published methods.",Methods,[38258],[6166],[6213],[False],[0],[0],[False],['0']
25917,PMC5064025,6354,"The study was undertaken at 9 centers in Canada, the United Kingdom, the United States, Germany, and Israel, in compliance with the principles of the Declaration of Helsinki and according to Good Clinical Practice guidelines.",Methods,[38264],[6214],[6439],[False],[0],[0],[False],['0']
25918,PMC5064025,6355,"The protocol was reviewed and approved by the institutional review board, or equivalent, for each center.",Methods,[38270],[6440],[6545],[False],[0],[0],[False],['0']
25919,PMC5064025,6356,All participants provided written informed consent before undertaking any study procedures.,Methods,[38276],[6546],[6637],[False],[0],[0],[False],['0']
25920,PMC5064025,6357,Patients,Methods|Patients,[38282],[6638],[6645],[False],[0],[0],[False],['0']
25921,PMC5064025,6358,Patients (ages 18 to 74 years) were eligible for inclusion if they had clinically evident atherosclerotic vascular disease: previous myocardial infarction; history of angina; carotid stenosis (>30%); peripheral vascular disease (ankle–brachial index <0.9); endarterectomy >3 months previously; or transient ischemic attack or stroke.,Methods|Patients,[38288],[6646],[6979],[False],[0],[0],[False],['0']
25922,PMC5064025,6359,"In addition, patients must also have had either T2DM (for ≤14 years and glycosylated hemoglobin [HbA1c] levels between 6% and 10%) or IGT (defined as a peak 2-h glucose reading ≥140 mg/dl but <200 mg/dl after an oral glucose tolerance test during screening).",Methods|Patients,[38294],[6980],[7238],[False],[0],[0],[False],['0']
25923,PMC5064025,6360,Patients were to have been on stable statin therapy for a period of ≥6 weeks before screening (or have physician-documented statin intolerance).,Methods|Patients,[38300],[7239],[7383],[False],[0],[0],[False],['0']
25924,PMC5064025,6361,"After consent, eligible patients were randomized (1:1) to receive canakinumab 150 mg or placebo, subcutaneously, monthly for 12 months.",Methods|Patients,[38306],[7384],[7519],[False],[0],[0],[False],['0']
25925,PMC5064025,6362,"Exclusion criteria included: pregnancy; systemic steroid use; baseline high-sensitivity C-reactive protein (hs-CRP) levels >30 mg/l; history of significant multiple drug allergies; history or evidence of chronic infection, including tuberculosis and liver disease; or a standard contraindication to MRI.",Methods|Patients,[38312],[7520],[7823],[False],[0],[0],[False],['0']
25926,PMC5064025,6363,Randomization occurred between December 2009 and November 2012.,Methods|Patients,[38318],[7824],[7887],[False],[0],[0],[False],['0']
25927,PMC5064025,6364,"Patient groups were assigned centrally according to a validated computer-generated randomization code, stratified according to glycemic status (T2DM or IGT).",Methods|Patients,[38324],[7888],[8045],[False],[0],[0],[False],['0']
25928,PMC5064025,6365,Imaging procedures,Methods|Imaging procedures,[38330],[8046],[8064],[False],[0],[0],[False],['0']
25929,PMC5064025,6366,An integrated vascular MRI was performed at baseline and after 3 and 12 months of treatment.,Methods|Imaging procedures,[38336],[8065],[8157],[False],[0],[0],[False],['0']
25930,PMC5064025,6367,"If the imaging data did not meet an evaluable standard at any time point, the patient was rescanned.",Methods|Imaging procedures,[38342],[8158],[8258],[False],[0],[0],[False],['0']
25931,PMC5064025,6368,Randomization required an evaluable baseline scan.,Methods|Imaging procedures,[38348],[8259],[8309],[False],[0],[0],[False],['0']
25932,PMC5064025,6369,"The imaging procedure comprised measures of aortic wall area and distensibility, as well as carotid wall area bilaterally.",Methods|Imaging procedures,[38354],[8310],[8432],[False],[0],[0],[False],['0']
25933,PMC5064025,6370,"The imaging protocol was adapted from Lee et al., and staff at each imaging site underwent individualized training to ensure consistency of method and data acquisition.",Methods|Imaging procedures,[38360],[8433],[8601],[False],[0],[0],[False],['0']
25934,PMC5064025,6371,"All trial sites used a 3.0-T whole-body MRI scanner, including Trio, TIM Trio, or Verio (Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania) or Achieva (Philips, Amsterdam, the Netherlands) platforms.",Methods|Imaging procedures,[38366],[8602],[8810],[False],[0],[0],[False],['0']
25935,PMC5064025,6372,"For carotid imaging, a bilateral 4-channel carotid array (Machnet B.V., Roden, the Netherlands) was used on the Siemens scanners and an equivalent multi-channel (4 to 8) phased array carotid coil (Shanghai Medical, Shanghai, China) was used on the Philips scanners.",Methods|Imaging procedures,[38372],[8811],[9076],[False],[0],[0],[False],['0']
25936,PMC5064025,6373,Detailed information regarding imaging protocols and analysis is available in the Online Appendix.,Methods|Imaging procedures,[38378],[9077],[9175],[False],[0],[0],[False],['0']
25937,PMC5064025,6374,The velocity at which the arterial pulse propagates is termed pulsed wave velocity (PWV).,Methods|Imaging procedures,[38384],[9176],[9265],[False],[0],[0],[False],['0']
25938,PMC5064025,6375,"A measure of arterial stiffness, it is an independent predictor of mortality in both T2DM and IGT.",Methods|Imaging procedures,[38390],[9266],[9364],[False],[0],[0],[False],['0']
25939,PMC5064025,6376,The Sphygmocor platform (AtCor Medical Pty.,Methods|Imaging procedures,[38396],[9365],[9408],[False],[0],[0],[False],['0']
25940,PMC5064025,6377,"Ltd., West Ryde, Australia) was applied immediately before MRI scanning to acquire the aortic central pulse pressure from radial artery applanation tonometry and the PWV from the carotid-femoral pulse waves.",Methods|Imaging procedures,[38402],[9409],[9616],[False],[0],[0],[False],['0']
25941,PMC5064025,6378,Safety assessments,Methods|Safety assessments,[38408],[9617],[9635],[False],[0],[0],[False],['0']
25942,PMC5064025,6379,"Monitoring of vital signs, electrocardiogram, standard hematology, and biochemistry (including measurement of lipoproteins, liver function, and creatine kinase) were conducted throughout the study.",Methods|Safety assessments,[38414],[9636],[9833],[False],[0],[0],[False],['0']
25943,PMC5064025,6380,A data monitoring committee oversaw subject safety on an ongoing basis.,Methods|Safety assessments,[38420],[9834],[9905],[False],[0],[0],[False],['0']
25944,PMC5064025,6381,"In addition, 3 adjudication committees made blinded assessments of adverse events in relation to cardiac, malignant, and infection-related events.",Methods|Safety assessments,[38426],[9906],[10052],[False],[0],[0],[False],['0']
25945,PMC5064025,6382,Endpoints,Methods|Endpoints,[38432],[10053],[10062],[False],[0],[0],[False],['0']
25946,PMC5064025,6383,The primary efficacy objectives were the effects of the drug on aortic distensibility and total plaque burden in the aorta and carotid arteries; the primary safety objective was the safety and tolerability of canakinumab in this population.,Methods|Endpoints,[38438],[10063],[10303],[False],[0],[0],[False],['0']
25947,PMC5064025,6384,Secondary objectives included the effects of canakinumab on aortic PWV; hs-CRP; HbA1c; homeostasis model assessment (HOMA)–insulin resistance; and peak blood glucose level 2 h after an oral glucose challenge.,Methods|Endpoints,[38444],[10304],[10512],[False],[0],[0],[False],['0']
25948,PMC5064025,6385,"Exploratory analyses of peripheral biomarkers of inflammation (including IL-6, serum amyloid A, and plasma lipoproteins) were also performed.",Methods|Endpoints,[38450],[10513],[10654],[False],[0],[0],[False],['0']
25949,PMC5064025,6386,Statistical analyses,Methods|Statistical analyses,[38456],[10655],[10675],[False],[0],[0],[False],['0']
25950,PMC5064025,6387,"Sample size was calculated from the study of Lee et al.. To detect a 35% change in aortic distensibility or an 11% change in plaque burden at 12 months to achieve a power of 0.8 and nominal p < 0.05 (2-sided), 60 patients per group were required.",Methods|Statistical analyses,[38462],[10676],[10922],[False],[0],[0],[False],['0']
25951,PMC5064025,6388,"To ensure 120 datasets with 12-month follow-up data, it was planned to randomize 190 patients.",Methods|Statistical analyses,[38468],[10923],[11017],[False],[0],[0],[False],['0']
25952,PMC5064025,6389,"Given the exploratory nature of the study, corrections were not made for the multiplicity of statistical tests.",Methods|Statistical analyses,[38474],[11018],[11129],[False],[0],[0],[False],['0']
25953,PMC5064025,6390,"As defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months.",Methods|Statistical analyses,[38480],[11130],[11393],[False],[0],[0],[False],['0']
25954,PMC5064025,6391,"To compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.",Methods|Statistical analyses,[38486],[11394],[11586],[False],[0],[0],[False],['0']
25955,PMC5064025,6392,"All data were checked for normality and log-transformed, if appropriate.",Methods|Statistical analyses,[38492],[11587],[11659],[False],[0],[0],[False],['0']
25956,PMC5064025,6393,"When a log transformation of the change from baseline was not possible because of negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed baseline as a covariate.",Methods|Statistical analyses,[38498],[11660],[11936],[False],[0],[0],[False],['0']
25957,PMC5064025,6394,We considered a p value <0.05 as significant.,Methods|Statistical analyses,[38504],[11937],[11982],[False],[0],[0],[False],['0']
25958,PMC5064025,6395,Results are reported as means with 95% confidence limits.,Methods|Statistical analyses,[38510],[11983],[12040],[False],[0],[0],[False],['0']
25959,PMC5064025,6396,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.",Methods|Statistical analyses,[38516],[12041],[12292],[False],[0],[0],[False],['0']
25960,PMC5064025,6397,The interim analyses were performed by independent personnel not directly associated with the study’s conduct.,Methods|Statistical analyses,[38522],[12293],[12403],[False],[0],[0],[False],['0']
25961,PMC5064025,6398,The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.,Methods|Statistical analyses,[38528],[12404],[12604],[False],[0],[0],[False],['0']
25962,PMC5064025,6399,"The trial design, endpoints, and statistical analyses were largely derived from the academic investigators’ previously published studies.",Methods|Statistical analyses,[38534],[12605],[12742],[False],[0],[0],[False],['0']
25963,PMC5064025,6400,"Following the final database lock, all patient data were analyzed independently by the Centre for Statistics in Medicine, Oxford (J.B.).",Methods|Statistical analyses,[38540],[12743],[12879],[False],[0],[0],[False],['0']
25964,PMC5064025,6401,"The manuscript was drafted by the academic investigators (R.P.C., J.S.B., J.-C.T., and Z.A.F.",Methods|Statistical analyses,[38546],[12880],[12973],[False],[0],[0],[False],['0']
25965,PMC5064025,6402,"), in accordance with the written agreement between Novartis and the academic institutions, and reviewed and revised by the writing committee.",Methods|Statistical analyses,[38552],[12974],[13116],[False],[0],[0],[False],['0']
25966,PMC5064025,6403,All authors had full access to all the data in the study and assume responsibility for publication.,Methods|Statistical analyses,[38558],[13117],[13216],[False],[0],[0],[False],['0']
25967,PMC5064025,6404,"All statistical analyses were performed by using Stata 14 (StataCorp LP, College Station, Texas).",Methods|Statistical analyses,[38564],[13217],[13313],[False],[0],[0],[False],['0']
25968,PMC5064025,6405,Results,Results,[38570],[13314],[13322],[False],[0],[0],[False],['0']
25969,PMC5064025,6406,"Of 450 patients screened, 189 were randomized to receive either placebo (n = 94) or canakinumab 150 mg (n = 95).",Results,[38576],[13323],[13435],[False],[0],[0],[False],['0']
25970,PMC5064025,6407,"The proportions of patients with diabetes, duration of diabetes, and glycemic control (estimated from HbA1c) were similar in the groups, and there was a high prevalence for each of hypertension, dyslipidemia, and background coronary artery disease (Table 1); the latter was slightly higher proportionately in the placebo group.",Results,[38582],[13436],[13763],[False],[0],[0],[False],['0']
25971,PMC5064025,6408,"There was no significant difference between the canakinumab group compared with the placebo group for the overall rate of completion of the study, which was 70.5% with canakinumab versus 77.7% for placebo (risk ratio: 1.32; 95% confidence interval [CI]: 0.81 to 2.15; p = 0.26) or the rate of discontinuation due to adverse events (14.7% vs. 11.7%; risk ratio: 1.26; 95% CI: 0.60 to 2.63; p = 0.54) (Table 2).",Results,[38588],[13764],[14173],[False],[0],[0],[False],['0']
25972,PMC5064025,6409,The most common cause for discontinuation was for adverse events.,Results,[38594],[14174],[14239],[False],[0],[0],[False],['0']
25973,PMC5064025,6410,A full list of adverse events is provided in Online Table 1.,Results,[38600],[14240],[14300],[False],[0],[0],[False],['0']
25974,PMC5064025,6411,"Seven patients withdrew consent, and 7 patients were excluded from analysis due to significant protocol deviation.",Results,[38606],[14301],[14415],[False],[0],[0],[False],['0']
25975,PMC5064025,6412,"As a biomarker of atherosclerotic plaque burden, vessel wall area was quantified in the aorta and carotid arteries (Table 3).",Results,[38612],[14416],[14541],[False],[0],[0],[False],['0']
25976,PMC5064025,6413,There was no statistically significant difference in mean carotid wall area between these 2 groups at either time point.,Results,[38618],[14542],[14662],[False],[0],[0],[False],['0']
25977,PMC5064025,6414,"Baseline mean carotid wall areas were 27.7 ± 9.79 mm2 and 27.1 ± 9.6 mm2 (p = NS) for the canakinumab and placebo groups, respectively.",Results,[38624],[14663],[14798],[False],[0],[0],[False],['0']
25978,PMC5064025,6415,Change in mean carotid artery wall area was –3.37 mm2 (p = 0.06) after 12 months for canakinumab versus placebo.,Results,[38630],[14799],[14911],[False],[0],[0],[False],['0']
25979,PMC5064025,6416,"There was an increase (12 months vs. baseline) in wall area for each of the left and right carotid arteries (and mean of the left and right) with placebo but, on average, neither progression nor regression in the canakinumab group (Figure 1A).",Results,[38636],[14912],[15155],[False],[0],[0],[False],['0']
25980,PMC5064025,6417,Change from baseline at 12 months was compared for individual patients between the left and right carotid arteries for both treatment groups.,Results,[38642],[15156],[15297],[False],[0],[0],[False],['0']
25981,PMC5064025,6418,"In each, there were strong correlations between changes in the left and right carotid arteries for canakinumab and placebo, respectively (p < 0.0001 for both) (Figure 1B).",Results,[38648],[15298],[15469],[False],[0],[0],[False],['0']
25982,PMC5064025,6419,The vessel lumen area was not changed by canakinumab treatment.,Results,[38654],[15470],[15533],[False],[0],[0],[False],['0']
25983,PMC5064025,6420,There was no statistically significant difference in wall area between canakinumab treatment and placebo at any of the 3 aortic sites at either 3 or 12 months.,Results,[38660],[15534],[15693],[False],[0],[0],[False],['0']
25984,PMC5064025,6421,Aortic distensibility was calculated from measurements made at 3 sites in the aorta.,Results,[38666],[15694],[15778],[False],[0],[0],[False],['0']
25985,PMC5064025,6422,"There were no statistically significant differences between canakinumab treatment and placebo for change in aortic distensibility, and no significant changes occurred in systolic or diastolic blood pressure at either 3 or 12 months of treatment versus baseline.",Results,[38672],[15779],[16040],[False],[0],[0],[False],['0']
25986,PMC5064025,6423,There were also no significant differences in measures of PWV between these 2 groups at either time point (Table 3).,Results,[38678],[16041],[16157],[False],[0],[0],[False],['0']
25987,PMC5064025,6424,"Compared with placebo, canakinumab reduced hs-CRP at 3 months (geometric mean ratio [GMR]: 0.568; 95% CI: 0.436 to 0.740; p < 0.0001) and 12 months (GMR: 0.56; 95% CI: 0.414 to 0.758; p = 0.0002) (Figure 2).",Results,[38684],[16158],[16365],[False],[0],[0],[False],['0']
25988,PMC5064025,6425,"Similarly, IL-6 was reduced by canakinumab at the 3-month time point (GMR: 0.580; 95% CI: 0.483 to 0.697; p < 0.0001).",Results,[38690],[16366],[16484],[False],[0],[0],[False],['0']
25989,PMC5064025,6426,Neither serum amyloid A nor adiponectin changed significantly in response to canakinumab treatment compared with placebo (Table 4).,Results,[38696],[16485],[16616],[False],[0],[0],[False],['0']
25990,PMC5064025,6427,"In this study population of patients with T2DM or IGT and near-universal statin use, canakinumab had no effect on either plasma low-density lipoprotein or high-density lipoprotein cholesterol levels compared with placebo at either of the 3- or 12-month time points.",Results,[38702],[16617],[16882],[False],[0],[0],[False],['0']
25991,PMC5064025,6428,Levels of total plasma cholesterol were mildly elevated from baseline in the canakinumab-treated patients at 3 months compared with the placebo group (GMR: 1.120; 95% CI: 1.050 to 1.195; p = 0.0008) but not at 12 months (GMR: 1.084; 95% CI: 0.991 to 1.185; p = 0.08).,Results,[38708],[16883],[17150],[False],[0],[0],[False],['0']
25992,PMC5064025,6429,"The elevation in total cholesterol level most likely reflected an elevation in triglyceride-rich lipoproteins, given the coinciding elevation in triglyceride level that also accompanied canakinumab treatment compared with placebo at 3 months (GMR: 1.21; 95% CI: 1.082 to 1.358; p = 0.001) and 12 months (GMR: 1.20; 95% CI: 1.046 to 1.380; p = 0.01).",Results,[38714],[17151],[17500],[False],[0],[0],[False],['0']
25993,PMC5064025,6430,Lipoprotein(a) levels were reduced by canakinumab compared with placebo.,Results,[38720],[17501],[17573],[False],[0],[0],[False],['0']
25994,PMC5064025,6431,"Changes from baseline values were as follows: at 3 months, mean change was –3.719 mg/dl (95% CI: –6.809 to –0.628; p = 0.02); at 12 months, mean change was –4.300 mg/dl (95% CI: –8.052 to –0.548; p = 0.025).",Results,[38726],[17574],[17781],[False],[0],[0],[False],['0']
25995,PMC5064025,6432,"In this population of patients with T2DM (86%) or IGT (14%) and with median baseline HbA1c levels <7%, canakinumab also had no significant effect compared with placebo on fasting blood glucose, HbA1c, HOMA–insulin resistance or HOMA-β, or 2-h glucose, obtained as part of an oral glucose tolerance test.",Results,[38732],[17782],[18085],[False],[0],[0],[False],['0']
25996,PMC5064025,6433,"Major adverse cardiovascular events occurred in 9.0% of patients, with no significant difference between the active treatment group (11%) compared with the placebo group (7%) (risk ratio: 1.41; 95% CI: 0.56 to 3.56; p = 0.46) (Table 5).",Results,[38738],[18086],[18322],[False],[0],[0],[False],['0']
25997,PMC5064025,6434,A full list of adverse events is given in Online Table 1.,Results,[38744],[18323],[18380],[False],[0],[0],[False],['0']
25998,PMC5064025,6435,Discussion,Discussion,[38750],[18381],[18392],[False],[0],[0],[False],['0']
25999,PMC5064025,6436,"Inflammation contributes to the pathogenesis of vascular dysfunction and atherogenesis, as well as to the complications of atherosclerosis.",Discussion,[38756],[18393],[18532],[False],[0],[0],[False],['0']
26000,PMC5064025,6437,Data from preclinical studies have suggested that inhibiting IL-1β may directly affect atherosclerosis and vascular inflammation.,Discussion,[38762],[18533],[18662],[False],[0],[0],[False],['0']
26001,PMC5064025,6438,"In the present randomized clinical trial of IL-1β inhibition in patients with T2DM or IGT, canakinumab 150 mg monthly reduced blood levels of IL-6 and hs-CRP (Central Illustration).",Discussion,[38768],[18663],[18844],[False],[0],[0],[False],['0']
26002,PMC5064025,6439,Similar reductions in inflammatory indexes have been reported previously in patients with T2DM.,Discussion,[38774],[18845],[18940],[False],[0],[0],[False],['0']
26003,PMC5064025,6440,"Significantly, given the target population, the present study showed that this effect persists even with near-universal statin use.",Discussion,[38780],[18941],[19072],[False],[0],[0],[False],['0']
26004,PMC5064025,6441,"Canakinumab had no effect on fasting glucose, HbA1c, or measures of insulin sensitivity.",Discussion,[38786],[19073],[19161],[False],[0],[0],[False],['0']
26005,PMC5064025,6442,"In common with earlier studies, atherosclerosis burden was quantified in the common carotid arteries and the aorta.",Discussion,[38792],[19162],[19277],[False],[0],[0],[False],['0']
26006,PMC5064025,6443,We found no statistically significant effect of 12 months’ treatment with canakinumab on magnetic resonance–derived measures of vascular structure or function.,Discussion,[38798],[19278],[19437],[False],[0],[0],[False],['0']
26007,PMC5064025,6444,"However, in each of the common carotid arteries individually, and in the combined vessel average, there was a suggestion of possible retarded progression of atherosclerotic burden.",Discussion,[38804],[19438],[19618],[False],[0],[0],[False],['0']
26008,PMC5064025,6445,"Because atherosclerosis is a systemic disease, we performed a further analysis, comparing changes in the right and left carotid arteries within individual patients.",Discussion,[38810],[19619],[19783],[False],[0],[0],[False],['0']
26009,PMC5064025,6446,There were strong relationships between changes in the left- versus right-sided vessels evident in both the canakinumab and the placebo groups but with a tendency toward progression bilaterally in the placebo group.,Discussion,[38816],[19784],[19999],[False],[0],[0],[False],['0']
26010,PMC5064025,6447,"As detailed earlier, analyses of wall area were conducted by operators who were blinded to the timing and treatment allocation of the images.",Discussion,[38822],[20000],[20141],[False],[0],[0],[False],['0']
26011,PMC5064025,6448,"Moreover, measurements were made separately on individual slices, but the data presented are for whole arteries.",Discussion,[38828],[20142],[20254],[False],[0],[0],[False],['0']
26012,PMC5064025,6449,"Given this high level of analytical stringency, these consistent correlations supported the technical robustness of the measurements.",Discussion,[38834],[20255],[20388],[False],[0],[0],[False],['0']
26013,PMC5064025,6450,"In common with previous studies, we chose to quantify vessel wall area in the tubular carotid arteries because they are less susceptible to error in serial measurements due to “volume averaging” effects.",Discussion,[38840],[20389],[20592],[False],[0],[0],[False],['0']
26014,PMC5064025,6451,"Previously described techniques allow plaque lipid quantification with the use of T2 mapping, but these were not current at the time of protocol design.",Discussion,[38846],[20593],[20745],[False],[0],[0],[False],['0']
26015,PMC5064025,6452,"Lipid elements may be the most readily mobilized components of atherosclerotic plaque, although the mechanisms by which IL-1β inhibition might affect plaque lipid are not clear.",Discussion,[38852],[20746],[20923],[False],[0],[0],[False],['0']
26016,PMC5064025,6453,"Vascular 18fludeoxyglucose positron emission tomography has been used effectively to evaluate carotid and aortic plaque macrophage activity in clinical trials, and this test may have been an alternative imaging modality.",Discussion,[38858],[20924],[21144],[False],[0],[0],[False],['0']
26017,PMC5064025,6454,"However, changes in macrophage function are associated with changes in substrate utilization and mode of energy generation.",Discussion,[38864],[21145],[21268],[False],[0],[0],[False],['0']
26018,PMC5064025,6455,"Therefore, using 18fludeoxyglucose positron emission tomography to identify macrophages on the basis of their glycolytic activity may provide only partial insight into the relevant biology with respect to IL-1β inhibition, and could even be misleading.",Discussion,[38870],[21269],[21521],[False],[0],[0],[False],['0']
26019,PMC5064025,6456,This study focused on changes in vessel wall structure and function.,Discussion,[38876],[21522],[21590],[False],[0],[0],[False],['0']
26020,PMC5064025,6457,"In doing so, we intended to obtain insights into the possible effects of canakinumab on different manifestations, or stages, of vessel wall pathology.",Discussion,[38882],[21591],[21741],[False],[0],[0],[False],['0']
26021,PMC5064025,6458,"Despite this expansive approach, we observed no significant effects on the vessel wall.",Discussion,[38888],[21742],[21829],[False],[0],[0],[False],['0']
26022,PMC5064025,6459,"Given the discordance with animal studies, one should also consider the possibility that previously observed beneficial effects of IL-1β inhibition need not have been realized directly at the arterial level.",Discussion,[38894],[21830],[22037],[False],[0],[0],[False],['0']
26023,PMC5064025,6460,Accumulating evidence suggests roles for peripheral monocytes in accelerating atherosclerosis in response to inflammatory stimuli.,Discussion,[38900],[22038],[22168],[False],[0],[0],[False],['0']
26024,PMC5064025,6461,"Indeed, IL-1β enhances hematopoietic stem cell proliferation and leukocyte production after acute myocardial infarction in mice and is reduced by administration of anti–IL-1β antibodies.",Discussion,[38906],[22169],[22355],[False],[0],[0],[False],['0']
26025,PMC5064025,6462,"In mice, most studies of IL-1β inhibition have shown reduced atherosclerosis and/or plaque inflammation; however, 1 study found that inactivation of IL-1 signaling through loss of the IL-1 receptor type 1 in apolipoprotein E–/– mice promoted multiple indexes of atherosclerotic plaque instability, including reduced plaque smooth muscle cell content, reduced plaque collagen content, and impaired outward vessel remodeling, leading to reduced lumen size.",Discussion,[38912],[22356],[22810],[False],[0],[0],[False],['0']
26026,PMC5064025,6463,Our study in humans found no evidence of changes in aortic characteristics according to distensibility measures at multiple sites.,Discussion,[38918],[22811],[22941],[False],[0],[0],[False],['0']
26027,PMC5064025,6464,"In theory, it would be possible for changes in lumen area/outward remodeling to be present despite no change in wall area, because wall area is derived by subtracting the lumen area from the total vessel area.",Discussion,[38924],[22942],[23151],[False],[0],[0],[False],['0']
26028,PMC5064025,6465,Examining these measures individually provides information on tendencies for luminal constriction or outward remodeling.,Discussion,[38930],[23152],[23272],[False],[0],[0],[False],['0']
26029,PMC5064025,6466,"In human atherosclerosis, we found no change in lumen area or adverse effect on outward vessel remodeling.",Discussion,[38936],[23273],[23379],[False],[0],[0],[False],['0']
26030,PMC5064025,6467,"Canakinumab had no effect on fasting glucose, HbA1c, or measures of insulin sensitivity in the present study.",Discussion,[38942],[23380],[23489],[False],[0],[0],[False],['0']
26031,PMC5064025,6468,"This outcome does not agree with the findings of Larsen et al., who used the IL-1RA anakinra.",Discussion,[38948],[23490],[23583],[False],[0],[0],[False],['0']
26032,PMC5064025,6469,"The apparent discrepancy may reflect better glycemic control at baseline in our study, in which >50% of patients had HbA1c levels <7% compared with a mean HbA1c level >8.5% in the treatment arm of the anakinra trial.",Discussion,[38954],[23584],[23800],[False],[0],[0],[False],['0']
26033,PMC5064025,6470,"However, canakinumab administration did result in an increase in plasma triglyceride levels, as reported previously for this agent.",Discussion,[38960],[23801],[23932],[False],[0],[0],[False],['0']
26034,PMC5064025,6471,The underlying mechanism is not clear.,Discussion,[38966],[23933],[23971],[False],[0],[0],[False],['0']
26035,PMC5064025,6472,Other treatments targeting inflammation have also been associated with elevated levels of very-low-density lipoprotein triglycerides.,Discussion,[38972],[23972],[24105],[False],[0],[0],[False],['0']
26036,PMC5064025,6473,"There was also a marginal but statistically significant elevation in total cholesterol levels, with an increase by 18.5 mg/dl after 3 months’ treatment.",Discussion,[38978],[24106],[24258],[False],[0],[0],[False],['0']
26037,PMC5064025,6474,"Conversely, lipoprotein(a) was significantly reduced by canakinumab at both time points.",Discussion,[38984],[24259],[24347],[False],[0],[0],[False],['0']
26038,PMC5064025,6475,Study limitations,Discussion|Study limitations,[38990],[24348],[24365],[False],[0],[0],[False],['0']
26039,PMC5064025,6476,"This study did not evaluate atherosclerosis at the carotid bifurcation, where the burden of disease is often greatest, nor did it quantify plaque lipid content.",Discussion|Study limitations,"[38996, 38997]","[24366, 24366]","[24526, 24526]","[True, True]","['RelevantOutcomeExcluded', 'RelevantOutcomeExcluded']","['This study did not evaluate atherosclerosis at the carotid bifurcation', 'nor did it quantify plaque lipid content']","[True, True]",['OutcomeMeasures']
26040,PMC5064025,6477,"Although MRI scans provide highly reproducible measures of plaque structure and vessel function, they offer no direct measure of plaque inflammation.",Discussion|Study limitations,[39010],[24527],[24676],[True],['RelevantOutcomeExcluded'],['they offer no direct measure of plaque inflammation'],[True],['OutcomeMeasures']
26041,PMC5064025,6478,"It is possible for drugs to markedly affect plaque biology without altering plaque size, particularly on short-term follow-up.",Discussion|Study limitations,[39020],[24677],[24803],[False],[0],[0],[False],['0']
26042,PMC5064025,6479,"In this study, no attempt was made to select subjects on the basis of inflammatory status.",Discussion|Study limitations,[39029],[24804],[24894],[True],['DiagnosticCriteria'],['no attempt was made to select subjects on the basis of inflammatory status'],[True],['Population']
26043,PMC5064025,6480,More refined patient selection may enhance the effectiveness of drugs that are directed toward specific processes and pathways.,Discussion|Study limitations,[39038],[24895],[25022],[False],[0],[0],[False],['0']
26044,PMC5064025,6481,"Finally, we cannot exclude the possibility that the dose of canakinumab was not high enough to generate a maximal effect on atherosclerotic burden, although the dose was sufficient to lower both hs-CRP and IL-6 levels.",Discussion|Study limitations,[39048],[25023],[25241],[True],['Intervention'],['the dose of canakinumab was not high enough to generate a maximal effect on atherosclerotic burden'],[True],['Intervention']
26045,PMC5064025,6482,"There were no significant differences in adverse events between the 2 groups, nor were any unexpected adverse outcomes identified.",Discussion|Study limitations,[39056],[25242],[25372],[False],[0],[0],[False],['0']
26046,PMC5064025,6483,"However, this small study cannot thoroughly or systematically evaluate the safety of canakinumab.",Discussion|Study limitations,[39067],[25373],[25470],[True],['SampleSize'],['this small study'],[True],['UnderpoweredStudy']
26047,PMC5064025,6484,The question of clinical efficacy clearly remains open.,Discussion|Study limitations,[39074],[25471],[25526],[False],[0],[0],[False],['0']
26048,PMC5064025,6485,"This question will be answered by the Phase III trial, CANTOS, which randomized >10,000 patients with hs-CRP ≥2 mg/l to treatment in a secondary prevention population; the goal is to evaluate the composite primary endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.",Discussion|Study limitations,[39080],[25527],[25826],[False],[0],[0],[False],['0']
26049,PMC5064025,6486,Conclusions,Conclusions,[39086],[25827],[25839],[False],[0],[0],[False],['0']
26050,PMC5064025,6487,COMPETENCY IN MEDICAL KNOWLEDGE: Markers of inflammation such as C-reactive protein and serum amyloid A are related to cardiovascular prognosis in patients with atherosclerosis.,Conclusions,[39092],[25840],[26017],[False],[0],[0],[False],['0']
26051,PMC5064025,6488,"Canakinumab, a monoclonal antibody that inhibits IL-1β, reduces these markers without measurable effects on arterial structure or function.",Conclusions,[39098],[26018],[26157],[False],[0],[0],[False],['0']
26052,PMC5064025,6489,TRANSLATIONAL OUTLOOK: The therapeutic efficacy of canakinumab in patients with vascular disease and T2DM or glucose intolerance will be assessed in a multicenter clinical trial.,Conclusions,[39104],[26158],[26336],[False],[0],[0],[False],['0']
26053,PMC5064025,6490,"In patients with T2DM and established cardiovascular disease, canakinumab reduced markers of inflammation (hs-CRP and IL-6) compared with placebo.",Conclusions,[39110],[26337],[26483],[False],[0],[0],[False],['0']
26054,PMC5064025,6491,Treatment with canakinumab also increased levels of triglycerides and total cholesterol but reduced lipoprotein(a) levels.,Conclusions,[39116],[26484],[26606],[False],[0],[0],[False],['0']
26055,PMC5064025,6492,"Despite measurable effects on systemic markers of inflammation, there was no statistically significant effect on measures of vascular structure or function.",Conclusions,[39122],[26607],[26763],[False],[0],[0],[False],['0']
26056,PMC5064025,6493,Effects of canakinumab on plaque inflammation or on leukocyte function elsewhere may be undetectable with current imaging technologies.,Conclusions,[39128],[26764],[26899],[False],[0],[0],[False],['0']
26057,PMC5064025,6494,"The results of this Phase II trial leave open the important question of clinical efficacy, which will be addressed by the multinational Phase III trial CANTOS.",Conclusions,[39134],[26900],[27059],[False],[0],[0],[False],['0']
26058,PMC5064025,6495,Appendix,Appendix,[39140],[27060],[27069],[False],[0],[0],[False],['0']
26059,PMC5064025,6496,This work was funded by Novartis.,Appendix,[39146],[27070],[27103],[False],[0],[0],[False],['0']
26060,PMC5064025,6497,"Dr. Choudhury has received honoraria/consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Isis Pharmaceuticals, GlaxoSmithKline, Merck, Roche, and Sanofi.",Appendix,[39152],[27104],[27269],[False],[0],[0],[False],['0']
26061,PMC5064025,6498,"Dr. Mani has received grant support from Novartis, Daiichi-Sankyo, Amgen, and Aegerion; has received honoraria from Aegerion; and he has served as a consultant for MedLion Inc. Dr. McLaughlin has received research support from AbbVie.",Appendix,[39158],[27270],[27504],[False],[0],[0],[False],['0']
26062,PMC5064025,6499,Drs.,Appendix,[39164],[27505],[27509],[False],[0],[0],[False],['0']
26063,PMC5064025,6500,"Basson, Svensson, Zhang, and Yates are employees of and hold equity shares in Novartis.",Appendix,[39170],[27510],[27597],[False],[0],[0],[False],['0']
26064,PMC5064025,6501,"Dr. Tardif has received research support from Novartis, AstraZeneca, Merck, Eli Lilly, Sanofi, DalCor, and Pharmascience; has received honoraria from Servier, Thrasos and DalCor; and holds equity interest in DalCor.",Appendix,[39176],[27598],[27813],[False],[0],[0],[False],['0']
26065,PMC5064025,6502,Dr. Schecter is an employee of Baxalta and Shire; during the study; and was an employee of Novartis.,Appendix,[39182],[27814],[27914],[False],[0],[0],[False],['0']
26066,PMC5064025,6503,Dr. Fayad has received research support from Novartis.,Appendix,[39188],[27915],[27969],[False],[0],[0],[False],['0']
26067,PMC5064025,6504,Prof. Choudhury was a Wellcome Trust Senior Research Fellow in Clinical Science.,Appendix,[39194],[27970],[28050],[False],[0],[0],[False],['0']
26068,PMC5064025,6505,Dr. Tardif holds the Canada Research Chair in translational and personalized medicine and the University of Montreal endowed research chair in atherosclerosis.,Appendix,[39200],[28051],[28210],[False],[0],[0],[False],['0']
26069,PMC5064025,6506,This work was also supported by the National Institute for Health Research Oxford Biomedical Research Centre (Drs.,Appendix,[39206],[28211],[28325],[False],[0],[0],[False],['0']
26070,PMC5064025,6507,"Choudhury, Biasiolli, and Robson and Ms. Birks).",Appendix,[39212],[28326],[28374],[False],[0],[0],[False],['0']
26071,PMC5064025,6508,All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.,Appendix,[39218],[28375],[28490],[False],[0],[0],[False],['0']
26072,PMC5064025,6509,"Chun Yuan, PhD, served as Guest Editor for this paper.",Appendix,[39224],[28491],[28545],[False],[0],[0],[False],['0']
26073,PMC5064025,6510,Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.,Appendix,[39230],[28546],[28632],[False],[0],[0],[False],['0']
26074,PMC5064025,6511,"For detailed information regarding imaging protocols and analysis as well as a supplemental table, please see the online version of this article.",Appendix,[39236],[28633],[28778],[False],[0],[0],[False],['0']
26075,PMC5064025,6512,Changes in Carotid Wall Area,Appendix|Changes in Carotid Wall Area,[39242],[28779],[28807],[False],[0],[0],[False],['0']
26076,PMC5064025,6513,We evaluated 12-month change from baseline in wall area as an indicator of atherosclerosis progression.,Appendix|Changes in Carotid Wall Area,[39248],[28808],[28911],[False],[0],[0],[False],['0']
26077,PMC5064025,6514,"(A) In both left and right carotid arteries, canakinumab retarded progression of wall area compared with placebo.",Appendix|Changes in Carotid Wall Area,[39254],[28912],[29025],[False],[0],[0],[False],['0']
26078,PMC5064025,6515,"Consistent in magnitude and direction, the changes did not reach statistical significance in the mean carotid wall area (pre-stated endpoint) or in either carotid artery analyzed separately.",Appendix|Changes in Carotid Wall Area,[39260],[29026],[29216],[False],[0],[0],[False],['0']
26079,PMC5064025,6516,Bars = means with 95% confidence intervals.,Appendix|Changes in Carotid Wall Area,[39266],[29217],[29260],[False],[0],[0],[False],['0']
26080,PMC5064025,6517,"(B) Within the same patient, there was a striking concordance of change in wall area between left- and right-sided arteries, which was maintained in both treatment groups (p < 0.0001 for each).",Appendix|Changes in Carotid Wall Area,[39272],[29261],[29454],[False],[0],[0],[False],['0']
26081,PMC5064025,6518,Upper right quadrant = patients with progression in both carotid arteries.,Appendix|Changes in Carotid Wall Area,[39278],[29455],[29529],[False],[0],[0],[False],['0']
26082,PMC5064025,6519,Figure 1,Appendix|Changes in Carotid Wall Area,[39284],[29530],[29538],[False],[0],[0],[False],['0']
26083,PMC5064025,6520,Changes in Lipids and C-Reactive Protein,Appendix|Changes in Lipids and C-Reactive Protein,[39290],[29539],[29579],[False],[0],[0],[False],['0']
26084,PMC5064025,6521,Absolute level or change from baseline at 3 and 12 months are shown for (A) C-reactive protein; (B) lipoprotein(a) (Lp[a]); (C) total cholesterol; (D) high-density lipoprotein (HDL) cholesterol; and (E) triglycerides.,Appendix|Changes in Lipids and C-Reactive Protein,[39296],[29580],[29797],[False],[0],[0],[False],['0']
26085,PMC5064025,6522,Figure 2,Appendix|Changes in Lipids and C-Reactive Protein,[39302],[29798],[29806],[False],[0],[0],[False],['0']
26086,PMC5064025,6523,Effects of IL-1β Inhibition,Appendix|Changes in Lipids and C-Reactive Protein,[39308],[29807],[29834],[False],[0],[0],[False],['0']
26087,PMC5064025,6524,Interleukin (IL)-1β seems important in the pathogenesis of atherosclerosis.,Appendix|Changes in Lipids and C-Reactive Protein,[39314],[29835],[29910],[False],[0],[0],[False],['0']
26088,PMC5064025,6525,"In this placebo-controlled trial in patients with evidence of clinical atherosclerosis and either type 2 diabetes mellitus or impaired glucose tolerance, the IL-1β inhibitor canakinumab reduced measures of inflammation but did not significantly affect measures of vascular structure or function.",Appendix|Changes in Lipids and C-Reactive Protein,[39320],[29911],[30206],[False],[0],[0],[False],['0']
26089,PMC5064025,6526,LDL = low-density lipoprotein.,Appendix|Changes in Lipids and C-Reactive Protein,[39326],[30207],[30237],[False],[0],[0],[False],['0']
26090,PMC5064025,6527,Central Illustration,Appendix|Central Illustration,[39332],[30238],[30258],[False],[0],[0],[False],['0']
26091,PMC5064025,6528,Baseline Characteristics,Appendix|Baseline Characteristics,[39338],[30259],[30283],[False],[0],[0],[False],['0']
26092,PMC5064025,6529,Table 1,Appendix|Baseline Characteristics,[39344],[30284],[30291],[False],[0],[0],[False],['0']
26093,PMC5064025,6530,"	Canakinumab(n = 95)	Placebo(n = 94)	 	Male	82 (86)	80 (85)	 	Age, yrs	61.7 ± 7.8	61.9 ± 6.9	 	Diabetes	81 (85)	81 (86)	 	Hypertension	81 (85)	83 (88)	 	Systolic blood pressure, mm Hg	128.7 ± 10.3	128.4 ± 10.0	 	Diastolic blood pressure, mm Hg	76.6 ± 8.1	76.9 ± 9.1	 	Current smoker	7 (7)	7 (7)	 	Peripheral vascular disease	8 (8)	8 (8)	 	Previous stroke	21 (22)	22 (23)	 	CAD	79 (83)	90 (96)	 	Medications			 	 ACE inhibitor	66 (69)	72 (77)	 	 Beta-blocker	62 (65)	75 (80)	 	 Statin	92 (97)	94 (100)	 	 Insulin	29 (31)	26 (28)	 	 Antiplatelet agent∗	90 (95)	89 (95)	 	BMI, kg/m2	30.3 ± 4.1	30.3 ± 4.0	 	hs-CRP, mg/l	1.77 (0.84–3.74)	1.85 (0.83–3.88)	 	IL-6, ng/l	2.20 (1.61–3.63)	2.24 (1.60–3.30)	 	Serum amyloid A, mg/l	3.8 (1.9–6.3)	3.0 (1.9–6.8)	 	Adiponectin, ng/ml	3,685 (2,860–5,740)	3,880 (2,620–4,950)	 	Lp(a), mg/dl	18.8 (4.1–37.7)	15.1 (2.0–40.7)	 	LDL cholesterol, mg/dl	90.5 ± 33.3	88.6 ± 36.3	 	HDL cholesterol, mg/dl	42.5 ± 10.4	41.8 ± 10.4	 	Triglycerides, mg/dl	147 ± 106	138 ± 72	 	Duration of diabetes, yrs			 	 ≤1	5	7	 	 >1 and <5	22	16	 	 ≥5	54	58	 	Fasting blood glucose, mg/dl	144 ± 48	146 ± 48	 	Insulin, pmol/l	77 (53–133)	72 (51–120)	 	HOMA-IR	3.7 (2.4–6.6)	3.6 (2.4–6.1)	 	HbA1c, %	7.03 ± 1.02	6.85 ± 0.93	 	HbA1c			 	 ≤7%	50	52	 	 >7% and <7.5%	14	20	 	 ≥7.5%	29	21",Appendix|Baseline Characteristics,[39350],[30292],[31588],[False],[0],[0],[False],['0']
26094,PMC5064025,6531,"Values are n (%), mean ± SD, or median (interquartile range).",Appendix|Baseline Characteristics,[39356],[31589],[31653],[False],[0],[0],[False],['0']
26095,PMC5064025,6532,ACE = angiotensin-converting enzyme; BMI = body mass index; CAD = coronary artery disease; HbA1c = glycosylated hemoglobin; HDL = high-density lipoprotein; HOMA-IR = homeostatic model assessment–insulin resistance; hs-CRP = high-sensitivity C-reactive protein; IL = interleukin; LDL = low-density lipoprotein; Lp(a) = lipoprotein(a).,Appendix|Baseline Characteristics,[39362],[31654],[31987],[False],[0],[0],[False],['0']
26096,PMC5064025,6533,"Aspirin, clopidogrel, prasugrel, or ticagrelor.",Appendix|Baseline Characteristics,[39368],[31988],[32035],[False],[0],[0],[False],['0']
26097,PMC5064025,6534,"For HbA1c, there are 2 missing values for canakinumab and 1 for the control group.",Appendix|Baseline Characteristics,[39374],[32036],[32118],[False],[0],[0],[False],['0']
26098,PMC5064025,6535,Subject Disposition,Appendix|Subject Disposition,[39380],[32119],[32138],[False],[0],[0],[False],['0']
26099,PMC5064025,6536,Table 2,Appendix|Subject Disposition,[39386],[32139],[32146],[False],[0],[0],[False],['0']
26100,PMC5064025,6537,	Placebo (n = 94)	Canakinumab (n = 95)	Total (N = 189)	 	Patients	 	 Completed	73 (77.7)	67 (70.5)	140 (74.1)	 	 Discontinued∗	21 (22.3)	28 (29.5)	49 (25.9)	 	Main cause of discontinuation	 	 Adverse event(s)∗	11 (11.7)	14 (14.7)	25 (13.2)	 	 Consent withdrawal	3 (3.2)	4 (4.2)	7 (3.7)	 	 Lost to follow-up	1 (1.1)	2 (2.1)	3 (3.2)	 	 Administrative	4 (4.3)	2 (2.1)	6 (3.2)	 	 Death	0 (0)	1 (1.1)	1 (0.5)	 	 Protocol deviation	2 (2.1)	5 (5.3)	7 (3.7),Appendix|Subject Disposition,[39392],[32147],[32599],[False],[0],[0],[False],['0']
26101,PMC5064025,6538,Values are n (%).,Appendix|Values are n (%).,[39398],[32600],[32620],[False],[0],[0],[False],['0']
26102,PMC5064025,6539,There was no significant difference between canakinumab compared with placebo for the overall rate of discontinuation from the study (risk ratio: 1.32; 95% confidence interval: 0.81 to 2.15; p = 0.26) or the rate of discontinuation due to adverse events (risk ratio: 1.26; 95% confidence interval: 0.60 to 2.63; p = 0.54).,Appendix|Values are n (%).,[39404],[32621],[32943],[False],[0],[0],[False],['0']
26103,PMC5064025,6540,Change From Baseline in MRI Measures,Appendix|Change From Baseline in MRI Measures,[39410],[32944],[32980],[False],[0],[0],[False],['0']
26104,PMC5064025,6541,Table 3,Appendix|Change From Baseline in MRI Measures,[39416],[32981],[32988],[False],[0],[0],[False],['0']
26105,PMC5064025,6542,	3 Months	12 Months	 	No.,Appendix|Change From Baseline in MRI Measures,[39422],[32989],[33017],[False],[0],[0],[False],['0']
26106,PMC5064025,6543,"of Patients: LSM (95% CI), p Value	No.",Appendix|Change From Baseline in MRI Measures,[39428],[33018],[33056],[False],[0],[0],[False],['0']
26107,PMC5064025,6544,"of Patients: LSM (95% CI), p Value	 	Mean (R & L) carotid wall area, mm2	 	 Canakinumab	n = 63; 0.97 (–1.55 to 3.48)	n = 48; 0.59 (–2.40 to 3.59)	 	 Placebo	n = 67; 2.13 (–0.37 to 4.64)	n = 55; 3.96 (0.94 to 6.98)	 	 Canakinumab vs. placebo	–1.17 (–4.17 to 1.84), p = 0.44	–3.37 (–6.90 to 0.16), p = 0.06	 	Proximal ascending aorta wall area, mm2	 	 Canakinumab	n = 64; 2.12 (–10.61 to 14.85)	n = 50; 11.20 (–9.77 to 32.16)	 	 Placebo	n = 69; 16.12 (2.90 to 29.34)	n = 59; 30.26 (9.57 to 50.96)	 	 Canakinumab vs. placebo	–14.00 (–29.82 to 1.82), p = 0.08	–19.07 (–44.00 to 5.87), p = 0.13	 	Proximal descending aorta wall area, mm2		 	 Canakinumab	n = 75; 9.01 (–2.17 to 20.19)	n = 63; 20.92 (5.06 to 36.78)	 	 Placebo	n = 80; 6.26 (–5.18 to 17.69)	n = 67; 25.28 (8.54 to 42.02)	 	 Canakinumab vs. placebo	2.75 (–10.57 to 16.08), p = 0.68	–4.36 (–23.63 to 14.92), p = 0.66	 	Distal descending aorta wall area, mm2		 	 Canakinumab	n = 67; 3.08 (–7.08 to 13.25)	n = 56; 14.65 (0.86 to 28.45)	 	 Placebo	n = 73; –4.41 (–14.76 to 5.95)	n = 64; 21.02 (6.67 to 35.36)	 	 Canakinumab vs. placebo	7.49 (–4.74 to 19.72), p = 0.23	–6.36 (–23.49 to 10.77), p = 0.46	 	Ascending aorta distensibility, × 103 mm Hg–1		 	 Canakinumab	n = 66; 0.00 (–0.26 to 0.27)	n = 51; –0.11 (–0.38 to 0.17)	 	 Placebo	n = 61; –0.13 (–0.41 to 0.16)	n = 53; –0.13 (–0.43 to 0.17)	 	 Canakinumab vs. placebo	0.13 (–0.20 to 0.46), p = 0.44	0.03 (–0.32 to 0.370), p = 0.87	 	Proximal descending aorta distensibility, × 103 mm Hg–1		 	 Canakinumab	n = 70; 0.08 (–0.23 to 0.39)	n = 56; –0.19 (–0.53 to 0.16)	 	 Placebo	n = 71; 0.10 (–0.22 to 0.41)	n = 62; –0.25 (–0.60 to 0.11)	 	 Canakinumab vs. placebo	–0.02 (–0.39 to 0.35), p = 0.93	0.06 (–0.36 to 0.48), p = 0.78	 	Distal descending aorta distensibility, × 103 mm Hg–1	 	Canakinumab	n = 72; 0.04 (–0.32 to 0.40)	n = 54; –0.14 (–0.59 to 0.31)	 	Placebo	n = 74; 0.12 (–0.24 to 0.49)	n = 64; –0.20 (–0.66 to 0.25)	 	Canakinumab vs. placebo	–0.09 (–0.51 to 0.34), p = 0.69	0.06 (–0.48 to 0.61), p = 0.82",Appendix|Change From Baseline in MRI Measures,[39434],[33057],[35076],[False],[0],[0],[False],['0']
26108,PMC5064025,6545,"Least squared means (LSM) of outcomes (95% confidence intervals [CIs]) and number of patients in each group reported from the analysis of covariance of the change from baseline at 3 and 12 months, adjusted for baseline of outcome and including the 2-level factor type 2 diabetes mellitus or impaired glucose tolerance as a covariate.",Appendix|Change From Baseline in MRI Measures,[39440],[35077],[35413],[False],[0],[0],[False],['0']
26109,PMC5064025,6546,Inclusion of patients is according to the protocol.,Appendix|Change From Baseline in MRI Measures,[39446],[35414],[35465],[False],[0],[0],[False],['0']
26110,PMC5064025,6547,Data from an end-of-study scan of 8 patients who left the trial early were included if the time of the scan was within the allowed time limits for the 3-month scan (82 to 130 days).,Appendix|Change From Baseline in MRI Measures,[39452],[35466],[35647],[False],[0],[0],[False],['0']
26111,PMC5064025,6548,L = left; MRI = magnetic resonance imaging; R = right; other abbreviations as in Table 2.,Appendix|Change From Baseline in MRI Measures,[39458],[35648],[35737],[False],[0],[0],[False],['0']
26112,PMC5064025,6549,"Blood Measures for Lipids, Diabetes Control, and Markers of Inflammation",Appendix|Change From Baseline in MRI Measures,[39464],[35738],[35810],[False],[0],[0],[False],['0']
26113,PMC5064025,6550,Table 4,Appendix|Change From Baseline in MRI Measures,[39470],[35811],[35818],[False],[0],[0],[False],['0']
26114,PMC5064025,6551,	3 Months	12 Months	 	No.,Appendix|Change From Baseline in MRI Measures,[39476],[35819],[35847],[False],[0],[0],[False],['0']
26115,PMC5064025,6552,"of Patients; LSM (95% CI), p Value	 	LDL cholesterol, mg/dl			 	 Log-transformed results			 	 Canakinumab	n = 64; 4.425 (4.343 to 4.508)	n = 55; 4.515 (4.414 to 4.616)	 	 Placebo	n = 75; 4.361 (4.278 to 4.444)	n = 65; 4.460 (4.357 to 4.563)	 	 Canakinumab vs. placebo	0.065 (–0.029 to 0.158), p = 0.18	0.055 (–0.064 to 0.174), p = 0.36	 	 Back-transformed results			 	 Canakinumab	83.52 (76.94 to 90.75)	91.38 (82.60 to 101.10)	 	 Placebo	78.34 (72.10 to 85.12)	86.49 (78.03 to 95.88)	 	 Canakinumab/placebo	1.067 (0.971 to 1.171)	1.057 (0.938 to 1.190)	 	Total cholesterol, mg/dl			 	 Log-transformed results			 	 Canakinumab	n = 49; 5.153 (5.098 to 5.208)	n = 40; 5.193 (5.119 to 5.267)	 	 Placebo	n = 58; 5.040 (4.983 to 5.096)	n = 52; 5.113 (5.037 to 5.188)	 	 Canakinumab vs. placebo	0.113 (0.048 to 0.178), p = 0.0008	0.081 (–0.009 to 0.170), p = 0.08	 	 Back-transformed results			 	 Canakinumab	173.0 (163.7 to 182.7)	180.0 (167.2 to 193.8)	 	 Placebo	154.5 (145.9 to 163.4)	166.2 (154.0 to 179.1)	 	 Canakinumab/placebo	1.120 (1.050 to 1.195)	1.084 (0.991 to 1.185)	 	Triglycerides, mg/dl			 	 Log-transformed results			 	 Canakinumab	n = 73; 4.938 (4.843 to 5.033)	n = 62; 4.979 (4.865 to 5.093)	 	 Placebo	n = 79; 4.746 (4.646 to 4.845)	n = 70; 4.795 (4.676 to 4.915)	 	 Canakinumab vs. placebo	0.192 (0.079 to 0.306), p = 0.001	0.184 (0.045 to 0.322), p = 0.01	 	 Back-transformed results			 	 Canakinumab	139.5 (126.8 to 153.4)	145.3 (129.7 to 162.9)	 	 Placebo	115.1 (104.2 to 127.1)	120.9 (107.3 to 136.3)	 	 Canakinumab/placebo	1.212 (1.082 to 1.358)	1.202 (1.046 to 1.380)	 	HDL cholesterol, mg/dl∗			 	 Canakinumab	n = 73; 1.779 (0.309 to 3.252)	n = 62; 0.731 (–1.017 to 2.479)	 	 Placebo	n = 79; –0.282 (–1.817 to 1.257)	n = 70; –0.182 (–1.910 to 1.640)	 	 Canakinumab vs. placebo	2.061 (0.302 to 3.821), p = 0.02	0.913 (–1.214 to 3.039), p = 0.40	 	Lp(a), mg/dl∗			 	 Canakinumab	n = 56; –3.325 (–5.835 to –0.816)	n = 47; –3.083 (–6.066 to –0.100)	 	 Placebo	n = 59; 0.394 (–2.333 to 3.120)	n = 51; 1.217 (–2.059 to 4.493)	 	 Canakinumab vs. placebo	–3.719 (–6.809 to –0.628), p = 0.02	–4.300 (–8.052 to –0.548), p = 0.025",Appendix|Change From Baseline in MRI Measures,[39482],[35848],[37990],[False],[0],[0],[False],['0']
26116,PMC5064025,6553,	No.,Appendix|Change From Baseline in MRI Measures,[39488],[37991],[37998],[False],[0],[0],[False],['0']
26117,PMC5064025,6554,"of Patients; Mean (95% CI on Log Scale)	 	HbA1c, %			 	 Log-transformed results			 	 Canakinumab	n = 73; 1.919 (1.900 to 1.942)	n = 60; 1.930 (1.897 to 1.963)	 	 Placebo	n = 80; 1.918 (1.894 to 1.943)	n = 69; 1.922 (1.886 to 1.958)	 	 Canakinumab vs. placebo	0.001 (–0.025 to 0.027), p = 0.95	0.008 (–0.031 to 0.047), p = 0.68	 	 Back-transformed results			 	 Canakinumab	6.814 (6.686 to 6.973)	6.890 (6.666 to 7.121)	 	 Placebo	6.807 (6.646 to 6.980)	6.835 (6.593 to 7.085)	 	 Canakinumab/placebo	1.001 (0.975 to 1.027)	1.008 (0.969 to 1.048)	 	Fasting blood glucose, mg/dl		 	 Log-transformed results			 	 Canakinumab	n = 71; 4.928 (4.868 to 4.989)	n = 58; 4.922 (4.845 to 4.999)	 	 Placebo	n = 78; 4.849 (4.786 to 4.912)	n = 68; 4.853 (4.773 to 4.934)	 	 Canakinumab vs. placebo	0.079 (0.013 to 0.145), p = 0.02	0.068 (–0.017 to 0.154), p = 0.12	 	 Back-transformed results			 	 Canakinumab	138 (130 to 147)	137 (127 to 148)	 	 Placebo	128 (120 to 136)	128 (118 to 139)	 	 Canakinumab/placebo	1.082 (1.013 to 1.156)	1.070 (0.983 to 1.166)	 	HOMA-IR			 	 Log-transformed results			 	 Canakinumab	n = 67; 1.443 (1.282 to 1.603)	n = 56; 1.324 (1.133 to 1.514)	 	 Placebo	n = 76; 1.358 (1.190 to 1.527)	n = 68; 1.278 (1.082 to 1.473)	 	 Canakinumab vs. placebo	0.084 (–0.094 to 0.262), p = 0.35	0.046 (–0.170 to 0.262), p = 0.67	 	 Back-transformed results			 	 Canakinumab	4.233 (3.604 to 4.968)	3.758 (3.105 to 4.545)	 	 Placebo	3.888 (3.287 to 4.604)	3.589 (2.951 to 4.362)	 	 Canakinumab/placebo	1.088 (0.910 to 1.300)	1.047 (0.844 to 1.300)	 	HOMA-B			 	 Log-transformed results			 	 Canakinumab	n = 66; 4.066 (3.886 to 4.247)	n = 56; 3.969 (3.773 to 4.165)	 	 Placebo	n = 76; 4.224 (4.033 to 4.415)	n = 68; 4.133 (3.929 to 4.337)	 	 Canakinumab vs. placebo	–0.158 (–0.361 to 0.046), p = 0.13	–0.164 (–0.389 to 0.062), p = 0.15	 	 Back-transformed results			 	 Canakinumab	58.32 (48.72 to 69.90)	52.93 (43.51 to 64.39)	 	 Placebo	68.31 (56.43 to 82.68)	62.36 (50.86 to 76.48)	 	 Canakinumab/placebo	0.854 (0.697 to 1.047)	0.849 (0.678 to 1.064)	 	C-reactive protein, mg/l			 	 Log-transformed results			 	 Canakinumab	n = 74; –0.278 (–0.500 to –0.056)	n = 61; –0.170 (–0.419 to 0.078)	 	 Placebo	n = 79; 0.287 (0.051 to 0.523)	n = 69; 0.409 (0.145 to 0.673)	 	 Canakinumab vs. placebo	–0.565 (–0.829 to –0.301), p < 0.0001	–0.579 (–0.881 to –0.277), p = 0.0002	 	 Back-transformed results			 	 Canakinumab	0.757 (0.607 to 0.946)	0.848 (0.658 to 1.081)	 	 Placebo	1.332 (1.052 to 1.687)	1.505 (1.156 to 1.9690)	 	 Canakinumab/placebo	0.568 (0.436 to 0.740)	0.561 (0.414 to 0.758)	 	IL-6, pg/ml			 	 Log-transformed results			 	 Canakinumab	n = 48; 0.367 (0.205 to 0.529)	n = 13; 0.744 (0.313 to 1.745)	 	 Placebo	n = 48; 0.913 (0.742 to 1.081)	n = 14; 1.147 (0.729 to 1.565)	 	 Canakinumab vs. placebo	–0.544 (–0.728 to –0.361), p < 0.0001	–0.403 (–0.888 to 0.081), p = 0.10	 	 Back-transformed results			 	 Canakinumab	1.443 (1.228 to 1.697)	2.104 (1.368 to 5.726)	 	 Placebo	2.492 (2.100 to 2.948)	3.149 (2.073 to 4.783)	 	 Canakinumab/placebo	0.580 (0.483 to 0.697)	0.668 (0.411 to 1.084)	 	Serum amyloid A, mg/l			 	 Log-transformed results			 	 Canakinumab	n = 67; 0.963 (0.760 to 1.166)	n = 56; 1.000 (0.795 to 1.205)	 	 Placebo	n = 76; 1.129 (0.922 to 1.336)	n = 69; 1.243 (1.032 to 1.453)	 	 Canakinumab vs. placebo	–0.166 (–0.408 to 0.077), p = 0.18	–0.243 (–0.493 to 0.008), p = 0.06	 	 Back-transformed results			 	 Canakinumab	2.620 (2.138 to 3.209)	2.718 (2.214 to 3.337)	 	 Placebo	3.093 (2.514 to 3.804)	3.466 (2.807 to 4.276)	 	 Canakinumab/placebo	0.847 (0.665 to 1.080)	0.784 (0.611 to 1.008)	 	Adiponectin, ng/ml			 	 Log-transformed results			 	 Canakinumab	n = 36; 8.265 (8.208 to 8.323)		 	 Placebo	n = 36; 8.284 (8.227 to 8.342)		 	 Canakinumab vs. placebo	–0.019 (–0.084 to 0.046), p = 0.57		 	 Back-transformed results			 	 Canakinumab	3,885 (3,670 to 4,117)		 	 Placebo	3,960 (3,741 to 4,196)		 	 Canakinumab/placebo	0.981 (0.919 to 1.047)",Appendix|Change From Baseline in MRI Measures,[39494],[37999],[41967],[False],[0],[0],[False],['0']
26118,PMC5064025,6555,Abbreviations as in Tables 1 and 3.,Appendix|Change From Baseline in MRI Measures,[39500],[41968],[42007],[False],[0],[0],[False],['0']
26119,PMC5064025,6556,"Change from baseline, not log-transformed.",Appendix|Change From Baseline in MRI Measures,[39506],[42008],[42050],[False],[0],[0],[False],['0']
26120,PMC5064025,6557,"LSMs of outcomes (95% CIs) with number of patients reported from the analysis of covariance of the log-transformed outcome at 3 and 12 months, adjusted for log-transformed baseline of outcome and including the 2-level factor type 2 diabetes mellitus or impaired glucose tolerance as a covariate.",Appendix|Change From Baseline in MRI Measures,[39512],[42051],[42346],[False],[0],[0],[False],['0']
26121,PMC5064025,6558,Inclusion of patients is according to the protocol.,Appendix|Change From Baseline in MRI Measures,[39518],[42347],[42398],[False],[0],[0],[False],['0']
26122,PMC5064025,6559,The treatment effect is reported as the difference between the canakinumab arm and the placebo arm and after back-transforming the treatment effect as the ratio of the levels in the canakinumab arm to the placebo arm.,Appendix|Change From Baseline in MRI Measures,[39524],[42399],[42616],[False],[0],[0],[False],['0']
26123,PMC5064025,6560,The LSMs are back-transformed (geometric means).,Appendix|Change From Baseline in MRI Measures,[39530],[42617],[42665],[False],[0],[0],[False],['0']
26124,PMC5064025,6561,MACE,Appendix|MACE,[39536],[42666],[42670],[False],[0],[0],[False],['0']
26125,PMC5064025,6562,Table 5,Appendix|MACE,[39542],[42671],[42678],[False],[0],[0],[False],['0']
26126,PMC5064025,6563,	MACE	Placebo	Canakinumab	p Value	 	Group	 	 All					 	 N		94	95		 		Yes	7 (7)	10 (11)	0.612	 		No	87 (93)	85 (89)		 	Type 2 diabetes mellitus			 	 N		81	81		 		Yes	6 (7)	9 (11)	0.589	 		No	75 (93)	72 (89)		 	Impaired glucose tolerance	 	 N		13	14		 		Yes	1 (8)	1 (7)	1.000	 		No	12 (92)	13 (93),Appendix|MACE,[39548],[42679],[42977],[False],[0],[0],[False],['0']
26127,PMC5064025,6564,Values are n (%) unless otherwise indicated.,Appendix|MACE,[39554],[42978],[43026],[False],[0],[0],[False],['0']
26128,PMC5064025,6565,MACE = major adverse cardiac events.,Appendix|MACE,[39560],[43027],[43063],[False],[0],[0],[False],['0']
27461,PMC5112179,3797,Effect of early supervised physiotherapy on recovery from acute ankle sprain: randomised controlled trial,Title,[21219],[26098],[105],[False],[0],[0],[False],['0']
27462,PMC5112179,3798,Objective To assess the efficacy of a programme of supervised physiotherapy on the recovery of simple grade 1 and 2 ankle sprains.,Abstract,[21225],[106],[237],[False],[0],[0],[False],['0']
27463,PMC5112179,3799,Design A randomised controlled trial of 503 participants followed for six months.,Abstract,[21231],[238],[319],[False],[0],[0],[False],['0']
27464,PMC5112179,3800,"Setting Participants were recruited from two tertiary acute care settings in Kingston, ON, Canada.",Abstract,[21237],[320],[418],[False],[0],[0],[False],['0']
27465,PMC5112179,3801,Participants The broad inclusion criteria were patients aged ≥16 presenting for acute medical assessment and treatment of a simple grade 1 or 2 ankle sprain.,Abstract,[21243],[419],[576],[False],[0],[0],[False],['0']
27466,PMC5112179,3802,"Exclusions were patients with multiple injuries, other conditions limiting mobility, and ankle injuries that required immobilisation and those unable to accommodate the time intensive study protocol.",Abstract,[21249],[577],[776],[False],[0],[0],[False],['0']
27467,PMC5112179,3803,"Intervention Participants received either usual care, consisting of written instructions regarding protection, rest, cryotherapy, compression, elevation, and graduated weight bearing activities, or usual care enhanced with a supervised programme of physiotherapy.",Abstract,[21255],[777],[1040],[False],[0],[0],[False],['0']
27468,PMC5112179,3804,Main outcome measures The primary outcome of efficacy was the proportion of participants reporting excellent recovery assessed with the foot and ankle outcome score (FAOS).,Abstract,[21261],[1041],[1213],[False],[0],[0],[False],['0']
27469,PMC5112179,3805,Excellent recovery was defined as a score ≥450/500 at three months.,Abstract,[21267],[1214],[1281],[False],[0],[0],[False],['0']
27470,PMC5112179,3806,A difference of at least 15% increase in the absolute proportion of participants with excellent recovery was deemed clinically important.,Abstract,[21273],[1282],[1419],[False],[0],[0],[False],['0']
27471,PMC5112179,3807,"Secondary analyses included the assessment of excellent recovery at one and six months; change from baseline using continuous scores at one, three, and six months; and clinical and biomechanical measures of ankle function, assessed at one, three, and six months.",Abstract,[21279],[1420],[1682],[False],[0],[0],[False],['0']
27472,PMC5112179,3808,"Results The absolute proportion of patients achieving excellent recovery at three months was not significantly different between the physiotherapy (98/229, 43%) and usual care (79/214, 37%) arms (absolute difference 6%, 95% confidence interval −3% to 15%).",Abstract,[21285],[1683],[1939],[False],[0],[0],[False],['0']
27473,PMC5112179,3809,The observed trend towards benefit with physiotherapy did not increase in the per protocol analysis and was in the opposite direction by six months.,Abstract,[21291],[1940],[2088],[False],[0],[0],[False],['0']
27474,PMC5112179,3810,These trends remained similar and were never statistically or clinically important when the FAOS was analysed as a continuous change score.,Abstract,[21297],[2089],[2228],[False],[0],[0],[False],['0']
27475,PMC5112179,3811,"Conclusions In a general population of patients seeking hospital based acute care for simple ankle sprains, there is no evidence to support a clinically important improvement in outcome with the addition of supervised physiotherapy to usual care, as provided in this protocol.",Abstract,[21303],[2229],[2505],[False],[0],[0],[False],['0']
27476,PMC5112179,3812,Trial registration ISRCTN 74033088 (www.isrctn.com/ISRCTN74033088),Abstract,[21309],[2506],[2572],[False],[0],[0],[False],['0']
27477,PMC5112179,3813,Introduction,Introduction,[21315],[2573],[2586],[False],[0],[0],[False],['0']
27478,PMC5112179,3814,Ankle sprains are one of the most common and burdensome musculoskeletal injuries and are associated with a high rate of visits to the emergency department.,Introduction,[21321],[2587],[2742],[False],[0],[0],[False],['0']
27479,PMC5112179,3815,"In our own setting of Kingston, Canada, ankle sprains account for 7.5% of injury related visits, about 725 cases annually, which represents an annual rate of presentation to an emergency department of five per 1000 people.",Introduction,[21327],[2743],[2965],[False],[0],[0],[False],['0']
27480,PMC5112179,3816,Nearly all ankle sprains are simple grade 1 (mechanically stable) or grade 2 (some joint laxity) ligament sprains.,Introduction,[21333],[2966],[3080],[False],[0],[0],[False],['0']
27481,PMC5112179,3817,Grade 3 sprains (clinical and/or radiological evidence of instability) represent a small minority.,Introduction,[21339],[3081],[3179],[False],[0],[0],[False],['0']
27482,PMC5112179,3818,"Although the prevalence of grade 3 sprains is low, there is good evidence to support the use of immobilisation and, occasionally, surgical correction in the management of these injuries.",Introduction,[21345],[3180],[3366],[False],[0],[0],[False],['0']
27483,PMC5112179,3819,Yet clinical standards for the acute management of grade 1 and 2 ankle sprains are not well defined.,Introduction,[21351],[3367],[3467],[False],[0],[0],[False],['0']
27484,PMC5112179,3820,The absence of high quality evidence to inform effective management of ankle sprains in acute care settings is related largely to perceptions that grade 1 and 2 ankle sprains are relatively benign injuries.,Introduction,[21357],[3468],[3683],[False],[0],[0],[False],['0']
27485,PMC5112179,3821,"Short and long term morbidity from simple ankle sprains, however, has been documented among 30-70% of patients, ranging from six months to seven years after injury.",Introduction,[21363],[3684],[3848],[False],[0],[0],[False],['0']
27486,PMC5112179,3822,"Morbidity is reflected in lost time from school, work, leisure, and sports activities  ; impairment in activities of daily living; and multiple medical contacts in the time after injury.",Introduction,[21369],[3849],[4035],[False],[0],[0],[False],['0']
27487,PMC5112179,3823,"In an effort to reduce the likelihood of short and long term morbidity, several trials have been undertaken in recent years to evaluate the efficacy of supervised programmes of physiotherapy in improving outcomes of ankle sprains and accelerating return to activity.",Introduction,[21375],[4036],[4306],[False],[0],[0],[False],['0']
27488,PMC5112179,3824,"A recent systematic review of these trials identified considerable potential for bias related to methods of randomisation, concealment, and outcome measurement and concluded that current evidence for early implementation of supervised exercise is limited in terms of breadth and quality.",Introduction,[21381],[4307],[4594],[False],[0],[0],[False],['0']
27489,PMC5112179,3825,"We carried out a randomised clinical trial to address the findings of systematic reviews, including a 2002 Cochrane review, of persisting controversy as to the role of supervised physiotherapy in the management of acute ankle sprains and their call for sufficiently powered trials designed to limit bias.",Introduction,[21387],[4595],[4899],[False],[0],[0],[False],['0']
27490,PMC5112179,3826,Methods,Methods,[21393],[4900],[4915],[False],[0],[0],[False],['0']
27491,PMC5112179,3827,We undertook a parallel group randomised controlled trial of adults attending the emergency department with ankle injuries.,Methods,[21399],[4916],[5039],[False],[0],[0],[False],['0']
27492,PMC5112179,3828,"We evaluated the efficacy of a standardised intervention of supervised physiotherapy plus usual emergency medical care versus usual emergency care alone in augmenting functional recovery from grade 1 or 2 ankle sprains at one, three, and six months.",Methods,[21405],[5040],[5289],[False],[0],[0],[False],['0']
27493,PMC5112179,3829,"Recovery was assessed with a standardised patient assessed outcome score of ankle function—the foot and ankle outcome score (FAOS), as well as clinical and biomechanical measures of ankle function.",Methods,[21411],[5290],[5487],[False],[0],[0],[False],['0']
27494,PMC5112179,3830,"The primary outcome of efficacy was defined, a priori, as “excellent” recovery (a total score ≥450/500) at three months.",Methods,[21417],[5488],[5608],[False],[0],[0],[False],['0']
27495,PMC5112179,3831,We hypothesised that a standardised evidence based programme of supervised physiotherapy    would improve the near term functional outcomes of ankle sprains.,Methods,[21423],[5609],[5766],[False],[0],[0],[False],['0']
27496,PMC5112179,3832,"In terms of clinical relevance, high quality evidence regarding the efficacy of physiotherapy would assist acute and primary care physicians in providing recommendations for treatment to patients with ankle sprains.",Methods,[21429],[5767],[5982],[False],[0],[0],[False],['0']
27497,PMC5112179,3833,Participants,Methods|Participants,[21435],[5983],[5996],[False],[0],[0],[False],['0']
27498,PMC5112179,3834,"Prospective participants were patients presenting for acute medical treatment of an ankle sprain to one of two acute care settings affiliated with Queen’s University in Kingston, Ontario, Canada.",Methods|Participants,[21441],[5997],[6192],[False],[0],[0],[False],['0']
27499,PMC5112179,3835,The Kingston General Hospital is a 450 bed tertiary care facility providing full emergency department care and the Hotel Dieu Hospital is an ambulatory care hospital with an urgent care setting.,Methods|Participants,[21447],[6193],[6387],[False],[0],[0],[False],['0']
27500,PMC5112179,3836,"Together, these partner facilities manage 95 000-100 000 encounters with acute care patients each year, of which 20% are injury related.",Methods|Participants,[21453],[6388],[6524],[False],[0],[0],[False],['0']
27501,PMC5112179,3837,We adopted broad inclusion criteria so that our trial cohort was representative of a general adult population presenting for assessment and treatment of ankle sprains.,Methods|Participants,[21459],[6525],[6692],[False],[0],[0],[False],['0']
27502,PMC5112179,3838,"Eligibility criteria were age ≥16; clinical diagnosis of grade 1 or 2 ankle sprain, which could include clinically unimportant avulsion fractures (<3 mm of displacement), with injury sustained less than 72 hours before presentation for assessment; fluency in spoken English; competent to provide informed consent, based on clinical judgment during interview with the patient; willingness to participate in the assessments in the Queen’s University motor performance laboratory as per protocol at baseline and at one, three, and six months after injury; and a total FAOS <450 measured at the baseline visit in the motor performance laboratory.",Methods|Participants,[21465],[6693],[7335],[False],[0],[0],[False],['0']
27503,PMC5112179,3839,The exclusion criteria were injury mechanisms that were inconsistent with a ligamentous sprain (such as direct impact); the attending emergency physician determining the need for immobilisation of the injured ankle or surgery based on clinical findings; presentation with concomitant injuries; other mobility limiting conditions; inability to accommodate the time intensive study protocol; and a declared plan to seek physiotherapy for treatment outside the study protocol.,Methods|Participants,[21471],[7336],[7809],[False],[0],[0],[False],['0']
27504,PMC5112179,3840,Participant involvement,Methods|Participant involvement,[21477],[7810],[7833],[False],[0],[0],[False],['0']
27505,PMC5112179,3841,"No patients were actively involved in setting the research question or the outcome measures nor were they involved in the analysis, interpretation, and writing of the results.",Methods|Participant involvement,[21483],[7834],[8009],[False],[0],[0],[False],['0']
27506,PMC5112179,3842,Their involvement in the design and implementation of the study was limited to providing informal feedback during a pilot phase to assess their tolerance and acceptance of data collection methods and procedures.,Methods|Participant involvement,[21489],[8010],[8221],[False],[0],[0],[False],['0']
27507,PMC5112179,3843,"Our findings from the trial will be shared with all participants, who will be provided a lay abstract of our study results and conclusions and access to the full manuscript.",Methods|Participant involvement,[21495],[8222],[8395],[False],[0],[0],[False],['0']
27508,PMC5112179,3844,Randomisation and follow-up,Methods|Randomisation and follow-up,[21501],[8396],[8423],[False],[0],[0],[False],['0']
27509,PMC5112179,3845,Eligible patients identified in the emergency department who were interested in participating in our trial provided consent to have their contact information shared with the research coordinator to schedule a baseline assessment in the motor performance laboratory at Queen’s University.,Methods|Randomisation and follow-up,[21507],[8424],[8711],[False],[0],[0],[False],['0']
27510,PMC5112179,3846,"Completion of the baseline assessment in the emergency department was impractical as the FAOS is not scored at the time of injury but rather is an assessment of dysfunction, and patients report limitations related to the injury over the previous week.",Methods|Randomisation and follow-up,[21513],[8712],[8963],[False],[0],[0],[False],['0']
27511,PMC5112179,3847,"The target appointment time for baseline assessment in the laboratory was, therefore, one week after injury.",Methods|Randomisation and follow-up,[21519],[8964],[9072],[False],[0],[0],[False],['0']
27512,PMC5112179,3848,All potential participants completed both the baseline assessments of the FAOS and clinical and biomechanical measures before randomisation so that they understood the procedures and time commitment involved.,Methods|Randomisation and follow-up,[21525],[9073],[9281],[False],[0],[0],[False],['0']
27513,PMC5112179,3849,"The research coordinator then reviewed entry criteria, confirmed eligibility, and obtained informed consent for the study protocol.",Methods|Randomisation and follow-up,[21531],[9282],[9413],[False],[0],[0],[False],['0']
27514,PMC5112179,3850,Participants’ personal information and FAOS were entered into a secure password protected web based central randomisation tool linked to a REDCap study database.,Methods|Randomisation and follow-up,[21537],[9414],[9575],[False],[0],[0],[False],['0']
27515,PMC5112179,3851,The tool then disclosed the treatment assignment of the current participant to the research coordinator.,Methods|Randomisation and follow-up,[21543],[9576],[9680],[False],[0],[0],[False],['0']
27516,PMC5112179,3852,"Participants were randomised to one of two arms of the study: the usual care arm, in which participants received usual care in the emergency department, or the physiotherapy arm, in which participants received usual care plus a regimen of supervised physiotherapy.",Methods|Randomisation and follow-up,[21549],[9681],[9945],[False],[0],[0],[False],['0']
27517,PMC5112179,3853,"The randomisation tool used a stratified randomisation list created electronically by the study statistician, who was not involved in recruitment or follow-up.",Methods|Randomisation and follow-up,[21555],[9946],[10105],[False],[0],[0],[False],['0']
27518,PMC5112179,3854,"A 1:1 allocation in permuted blocks was used within four strata defined by the baseline FAOS, where the four strata were based on the quartiles obtained from pilot study work.",Methods|Randomisation and follow-up,[21561],[10106],[10281],[False],[0],[0],[False],['0']
27519,PMC5112179,3855,"The permuted blocks were of variable random size of at most eight, with the size of the blocks unknown to anyone except the trial statistician.",Methods|Randomisation and follow-up,[21567],[10282],[10425],[False],[0],[0],[False],['0']
27520,PMC5112179,3856,"An audit trail was recorded, with concealment guaranteed for all future treatment assignments.",Methods|Randomisation and follow-up,[21573],[10426],[10520],[False],[0],[0],[False],['0']
27521,PMC5112179,3857,Participants assigned to either arm of the trial were booked for a follow-up assessment of outcome variables in the motor performance laboratory one month after the baseline appointment.,Methods|Randomisation and follow-up,[21579],[10521],[10707],[False],[0],[0],[False],['0']
27522,PMC5112179,3858,Participants randomised to the physiotherapy arm additionally had their contact information provided to the physiotherapy clinic at Queen’s University.,Methods|Randomisation and follow-up,[21585],[10708],[10859],[False],[0],[0],[False],['0']
27523,PMC5112179,3859,The clinic arranged the first appointment within two business days of the baseline laboratory visit to document history and clinical findings relevant to the care of the injured ankle.,Methods|Randomisation and follow-up,[21591],[10860],[11044],[False],[0],[0],[False],['0']
27524,PMC5112179,3860,Participants allocated to the physiotherapy arm were asked not to reveal this allocation to our research staff.,Methods|Randomisation and follow-up,[21597],[11045],[11156],[False],[0],[0],[False],['0']
27525,PMC5112179,3861,The research associate who performed the registration and randomisation also coordinated follow-up of participants.,Methods|Randomisation and follow-up,[21603],[11157],[11272],[False],[0],[0],[False],['0']
27526,PMC5112179,3862,Research staff blind to group allocation collected both follow-up and outcome data.,Methods|Randomisation and follow-up,[21609],[11273],[11356],[False],[0],[0],[False],['0']
27527,PMC5112179,3863,Description of the trial arms,Methods|Description of the trial arms,[21615],[11357],[11386],[False],[0],[0],[False],['0']
27528,PMC5112179,3864,"Participants assigned to the usual care arm received standard emergency department care, consisting of a medical assessment and a one page written summary of instruction for basic management of the injury at home, including ankle protection, rest, cryotherapy (ice), application of a compression bandage, elevation, use of analgesics as necessary, graduated weight bearing activities, and information about expected recovery.",Methods|Description of the trial arms,[21621],[11387],[11812],[False],[0],[0],[False],['0']
27529,PMC5112179,3865,No information regarding physiotherapy was discussed with patients in the usual care arm of the study.,Methods|Description of the trial arms,[21627],[11813],[11915],[False],[0],[0],[False],['0']
27530,PMC5112179,3866,Participants assigned to the physiotherapy arm were provided with usual care (as above) plus a regimen of supervised physiotherapy.,Methods|Description of the trial arms,[21633],[11916],[12047],[False],[0],[0],[False],['0']
27531,PMC5112179,3867,This intervention included a first appointment to assess the injury and establish a treatment plan and as many as seven subsequent clinic visits at no financial cost to participants.,Methods|Description of the trial arms,[21639],[12048],[12230],[False],[0],[0],[False],['0']
27532,PMC5112179,3868,"The physiotherapy intervention followed a standardised plan based on current evidence for the use of functional exercises progressed according to four general stages of recovery of ankle sprains      : decreased pain and swelling; increased range of motion, strength, and weight bearing; active range of motion and increased exercise tolerance; and restoration of full activities and dynamic ankle stability.",Methods|Description of the trial arms,[21645],[12231],[12639],[False],[0],[0],[False],['0']
27533,PMC5112179,3869,"Specific treatment goals and therapeutic interventions were provided for each stage of recovery, with clearly defined criteria for progression to the subsequent stage, or discharge.",Methods|Description of the trial arms,[21651],[12640],[12821],[False],[0],[0],[False],['0']
27534,PMC5112179,3870,Figure 1 summarises the intervention.,Methods|Description of the trial arms,[21657],[12822],[12859],[False],[0],[0],[False],['0']
27535,PMC5112179,3871,"Fig 1 Schematic representation of standardised programme of supervised physiotherapy, showing stages of progression, treatment goals for each stage, and criteria for progression or discharge.",Methods|Description of the trial arms,[21663],[12860],[13051],[False],[0],[0],[False],['0']
27536,PMC5112179,3872,"PRICE=protection, rest, ice, compression, elevation; ROM=range of motion; AROM=active ROM",Methods|Description of the trial arms,[21669],[13052],[13141],[False],[0],[0],[False],['0']
27537,PMC5112179,3873,"Treatment sessions were 30 minutes in length and were augmented by standardised home exercise plans of active ankle range of motion exercises, isometric strengthening, and resistance exercise, using therapeutic elastic resistance bands or body weight.",Methods|Description of the trial arms,[21675],[13142],[13393],[False],[0],[0],[False],['0']
27538,PMC5112179,3874,A home exercise programme was recommended based on each patient’s functional recovery.,Methods|Description of the trial arms,[21681],[13394],[13480],[False],[0],[0],[False],['0']
27539,PMC5112179,3875,"Icing was used when swelling persisted, but no manual therapies or immobilisation (for instance, taping) or brace devices were used.",Methods|Description of the trial arms,[21687],[13481],[13613],[False],[0],[0],[False],['0']
27540,PMC5112179,3876,"The treatment plan was implemented by one of three assigned physiotherapists, with a single therapist providing all treatment for an individual participant, whenever possible.",Methods|Description of the trial arms,[21693],[13614],[13789],[False],[0],[0],[False],['0']
27541,PMC5112179,3877,"At each session, the therapist assessed each individual’s stage of recovery and recorded compliance with appointments and home exercise programmes.",Methods|Description of the trial arms,[21699],[13790],[13937],[False],[0],[0],[False],['0']
27542,PMC5112179,3878,Outcome measurements,Methods|Outcome measurements,[21705],[13938],[13958],[False],[0],[0],[False],['0']
27543,PMC5112179,3879,The FAOS is a self administered questionnaire specific for feet and ankles developed to assess week-to-week change in symptoms and function after foot and ankle injuries.,Methods|Outcome measurements,[21711],[13959],[14129],[False],[0],[0],[False],['0']
27544,PMC5112179,3880,"The FAOS includes 42 items, assessing five domains of recovery from the ankle and/or foot injury: pain, symptoms, function in activities of daily living, function in sport and recreation, and quality of life.",Methods|Outcome measurements,[21717],[14130],[14338],[False],[0],[0],[False],['0']
27545,PMC5112179,3881,"Each scale is scored from 0 to 100, with a total best possible score of 500.",Methods|Outcome measurements,[21723],[14339],[14415],[False],[0],[0],[False],['0']
27546,PMC5112179,3882,"The primary outcome of efficacy, stated a priori, was “excellent recovery” from the ankle sprain, defined as a total score ≥450/500 at the three month time point of assessment after randomisation.",Methods|Outcome measurements,[21729],[14416],[14613],[False],[0],[0],[False],['0']
27547,PMC5112179,3883,An evidence based FAOS cut off score of excellent recovery has yet to be defined.,Methods|Outcome measurements,[21735],[14614],[14697],[False],[0],[0],[False],['0']
27548,PMC5112179,3884,"In our trial, we selected the score of 450/500 based on a previously published study by one of the authors of the FAOS.",Methods|Outcome measurements,[21741],[14698],[14817],[False],[0],[0],[False],['0']
27549,PMC5112179,3885,"Using the ankle function scoring scale, a precursor to the FAOS, Karlsson and Peterson used a scale score of 90% as the criterion for excellent recovery, which translates to a FAOS cut off of 450/500.",Methods|Outcome measurements,[21747],[14818],[15018],[False],[0],[0],[False],['0']
27550,PMC5112179,3886,All FAOS outcome data were collected by trained interviewers using a standard interview script and protocol.,Methods|Outcome measurements,[21753],[15019],[15127],[False],[0],[0],[False],['0']
27551,PMC5112179,3887,"Based on the FAOS, we additionally evaluated a series of secondary outcomes, also defined a priori.",Methods|Outcome measurements,[21759],[15128],[15227],[False],[0],[0],[False],['0']
27552,PMC5112179,3888,"These included excellent recovery at one and six months (score ≥450/500) and change from baseline on the total and domain specific FAOS, measured as a continuous variable at one, three, and six months.",Methods|Outcome measurements,[21765],[15228],[15429],[False],[0],[0],[False],['0']
27553,PMC5112179,3889,We included a six month time point of measurement based on previous studies that have shown considerable residual morbidity at six months after injury.,Methods|Outcome measurements,[21771],[15430],[15581],[False],[0],[0],[False],['0']
27554,PMC5112179,3890,"We also obtained selected clinical and biomechanical measures for secondary analysis, providing a quantitative assessment of ankle function and recovery from injury.",Methods|Outcome measurements,[21777],[15582],[15748],[False],[0],[0],[False],['0']
27555,PMC5112179,3891,"We assessed oedema, quantified using a figure of eight measurement (mm); manual muscle testing of the ankle dorsiflexors and plantar flexors to provide a grade from 0 (no visible contraction) to 5 (full strength through range of motion); and end range of dorsiflexion, assessed using the lunge test.",Methods|Outcome measurements,[21783],[15749],[16048],[False],[0],[0],[False],['0']
27556,PMC5112179,3892,"We used a Biodex System 3 dynamometer (Biodex Medical Systems, Shirley, NY) to quantify the biomechanical measures end range (in degrees) of passive and active dorsiflexion and plantar flexion, with the end point of passive range determined either as the point at which resistance reached 5 Newton metre (Nm) or the point at which the patient terminated the movement; and peak dorsiflexion and plantar flexion torque (Nm), defined as the highest torque produced over five dorsiflexion-plantar flexion cycles at a velocity of 30°/s.",Methods|Outcome measurements,[21789],[16049],[16580],[False],[0],[0],[False],['0']
27557,PMC5112179,3893,"We calculated change in clinical and biomechanical measures of ankle recovery from baseline at one, three, and six months.",Methods|Outcome measurements,[21795],[16581],[16703],[False],[0],[0],[False],['0']
27558,PMC5112179,3894,"Any recurrence of injury of the same ankle was monitored at the one, three, and six month follow-up assessments.",Methods|Outcome measurements,[21801],[16704],[16816],[False],[0],[0],[False],['0']
27559,PMC5112179,3895,"Additionally, all participants were asked whether they had accessed any other healthcare provider, including physiotherapy services that were not part of the study.",Methods|Outcome measurements,[21807],[16817],[16981],[False],[0],[0],[False],['0']
27560,PMC5112179,3896,Statistical analysis,Methods|Statistical analysis,[21813],[16982],[17002],[False],[0],[0],[False],['0']
27561,PMC5112179,3897,Sample size,Methods|Sample size,[21819],[17003],[17014],[False],[0],[0],[False],['0']
27562,PMC5112179,3898,"The study protocol targeted enrolment of 256 participants per arm to achieve a power of at least 80%, at a two sided α of 0.05, to detect an absolute increase in excellent recovery (that is, FAOS ≥450) from 60% to 75%.",Methods|Sample size,[21825],[17015],[17233],[False],[0],[0],[False],['0']
27563,PMC5112179,3899,This sample size estimation includes an inflation factor of 1.63 to allow for intent to treat analysis with a 15% loss to follow-up and 15% treatment cross over.,Methods|Sample size,[21831],[17234],[17395],[False],[0],[0],[False],['0']
27564,PMC5112179,3900,The estimated rate of excellent recovery in the control arm was based on our pilot work.,Methods|Sample size,[21837],[17396],[17484],[False],[0],[0],[False],['0']
27565,PMC5112179,3901,"The 15% difference between arms was based on previous literature and the results of our survey of 22 emergency department clinical physicians, most of whom responded that a 15% improvement in excellent recovery would be required to justify routine referral to physiotherapy.",Methods|Sample size,[21843],[17485],[17759],[False],[0],[0],[False],['0']
27566,PMC5112179,3902,Analysis of primary outcome,Methods|Analysis of primary outcome,[21849],[17760],[17787],[False],[0],[0],[False],['0']
27567,PMC5112179,3903,"Our primary test of efficacy compared the two arms at three months after randomisation using the Mantel-Haenszel test, stratified by baseline total FAOS quarter at a two sided 5% significance level.",Methods|Analysis of primary outcome,[21855],[17788],[17986],[False],[0],[0],[False],['0']
27568,PMC5112179,3904,"We calculated the absolute difference in excellent recovery rates between the two arms, adjusted for baseline quarter, with 95% confidence intervals.",Methods|Analysis of primary outcome,[21861],[17987],[18136],[False],[0],[0],[False],['0']
27569,PMC5112179,3905,Analysis of secondary outcomes,Methods|Analysis of secondary outcomes,[21867],[18137],[18167],[False],[0],[0],[False],['0']
27570,PMC5112179,3906,The primary analysis was repeated at one and six months after randomisation.,Methods|Analysis of secondary outcomes,[21873],[18168],[18244],[False],[0],[0],[False],['0']
27571,PMC5112179,3907,"Using continuous FAOS data, we estimated the expected mean changes in total and domain specific score from baseline to one, three, and six months after randomisation by arm, with differences between arms (and 95% confidence intervals) depicted graphically.",Methods|Analysis of secondary outcomes,[21879],[18245],[18501],[False],[0],[0],[False],['0']
27572,PMC5112179,3908,These estimates were obtained by restricted maximum likelihood from a repeated measures linear model as implemented in the MIXED procedure of SAS.,Methods|Analysis of secondary outcomes,[21885],[18502],[18648],[False],[0],[0],[False],['0']
27573,PMC5112179,3909,"This approach used all available assessments including baseline as outcomes, allowing for a flexible (unstructured) covariance structure within individual patients, which is less susceptible to bias from missing data than cross sectional approaches and is no less effective than using multiple imputation.",Methods|Analysis of secondary outcomes,[21891],[18649],[18954],[False],[0],[0],[False],['0']
27574,PMC5112179,3910,"Predictors in the model included baseline FAOS quarter as a factor, time as a factor, treatment arm as an indicator variable, and the interaction between time and treatment arm to allow the treatment effect to vary over time.",Methods|Analysis of secondary outcomes,[21897],[18955],[19180],[False],[0],[0],[False],['0']
27575,PMC5112179,3911,"We constructed contrasts to estimate the change from baseline within each arm and the difference in the change between arms at one, three, and six months.",Methods|Analysis of secondary outcomes,[21903],[19181],[19335],[False],[0],[0],[False],['0']
27576,PMC5112179,3912,We evaluated clinical and biomechanical measures from each time point using the same statistical method.,Methods|Analysis of secondary outcomes,[21909],[19336],[19440],[False],[0],[0],[False],['0']
27577,PMC5112179,3913,"The rate of re-injury of the same ankle was evaluated over the six month follow-up, with differences between arms evaluated by χ2 test.",Methods|Analysis of secondary outcomes,[21915],[19441],[19576],[False],[0],[0],[False],['0']
27578,PMC5112179,3914,"For all outcomes, we performed intent to treat analysis for our primary assessment of efficacy and a supplementary per protocol analysis.",Methods|Analysis of secondary outcomes,[21921],[19577],[19716],[False],[0],[0],[False],['0']
27579,PMC5112179,3915,"The per protocol analysis excluded contamination from participants who were randomised to the physiotherapy arm and did not attend at least one physiotherapy clinic visit in the first three months of the trial, as well as patients randomised to the usual care arm who independently received physiotherapy during the first three months.",Methods|Analysis of secondary outcomes,[21927],[19717],[20052],[False],[0],[0],[False],['0']
27580,PMC5112179,3916,"We performed the following subgroup analyses: sex, men versus women; age, comparing outcomes for participants aged ≤30 versus >30; injury characteristic, non-sports versus sports injury; and grade 1 versus grade 2 sprain.",Methods|Analysis of secondary outcomes,[21933],[20053],[20274],[False],[0],[0],[False],['0']
27581,PMC5112179,3917,"To estimate significance of the subgroup treatment effect modification we used a Wald test of the treatment by subgroup interaction term from a logistic regression model with excellent recovery (FAOS ≥450) as the outcome variable and baseline FAOS quarter, treatment arm, subgroup indicator, and the treatment by subgroup interaction term as predictors.",Methods|Analysis of secondary outcomes,[21939],[20275],[20628],[False],[0],[0],[False],['0']
27582,PMC5112179,3918,"To evaluate effects of missing data, we performed a sensitivity analysis, graphically reporting the difference in the three month recovery rate between the two arms of the study over the entire possible range of missing values.",Methods|Analysis of secondary outcomes,[21945],[20629],[20856],[False],[0],[0],[False],['0']
27583,PMC5112179,3919,"We considered the plausibility of missing values being extreme enough to result in a 15% difference in rate of excellent recovery between the two arms of the study, which we deemed would be large enough to warrant routine referral to physiotherapy.",Methods|Analysis of secondary outcomes,[21951],[20857],[21105],[False],[0],[0],[False],['0']
27584,PMC5112179,3920,"All analyses were conducted with SAS (version 9.3, SAS Institute, Cary, NC, 2010).",Methods|Analysis of secondary outcomes,[21957],[21106],[21188],[False],[0],[0],[False],['0']
27585,PMC5112179,3921,Results,Results,[21963],[21189],[21197],[False],[0],[0],[False],['0']
27586,PMC5112179,3922,"Between October 2009 and April 2013, we assessed 1969 patients with grade 1 or 2 ankle sprains for eligibility.",Results,[21969],[21198],[21309],[False],[0],[0],[False],['0']
27587,PMC5112179,3923,"Of these, 504 patients met our inclusion criteria, provided consent, and were randomised to the physiotherapy (n=254) or the usual care (n=250) arms of our study.",Results,[21975],[21310],[21472],[False],[0],[0],[False],['0']
27588,PMC5112179,3924,One patient in the physiotherapy arm withdrew consent after randomisation and was excluded from the analysis.,Results,[21981],[21473],[21582],[False],[0],[0],[False],['0']
27589,PMC5112179,3925,Figure 2 shows the flow of patients through the study.,Results,[21987],[21583],[21637],[False],[0],[0],[False],['0']
27590,PMC5112179,3926,"Table 1 shows relevant patient and injury related characteristics, with no significant differences identified between the two study arms.",Results,[21993],[21638],[21775],[False],[0],[0],[False],['0']
27591,PMC5112179,3927,"Fig 2 Patient flow showing loss to follow-up, withdrawal, and missing data by study arm and outcome assessment period.",Results,[21999],[21776],[21894],[False],[0],[0],[False],['0']
27592,PMC5112179,3928,"Counts below randomisation are accumulative, with numbers in each box adding up to total number of patients allocated to given arm.",Results,[22005],[21895],[22026],[False],[0],[0],[False],['0']
27593,PMC5112179,3929,Withdrawn=patients who actively refused to participate in further treatment or follow-up; lost to follow-up=patients who could not be contacted for current month assessment; missing FAOS=patients for whom FAOS at specified time point was not obtained,Results,[22011],[22027],[22277],[False],[0],[0],[False],['0']
27594,PMC5112179,3930,Relevant characteristics of study cohort of patients with acute ankle sprain randomised to usual care with physiotherapy or usual care alone.,Results,[22017],[22278],[22419],[False],[0],[0],[False],['0']
27595,PMC5112179,3931,Figures are numbers (percentage) of patients unless specified otherwise,Results,[22023],[22420],[22491],[False],[0],[0],[False],['0']
27596,PMC5112179,3932,	Physiotherapy (n=253)	Usual care (n=250)	 	Mean (SD) age (years)	31.1 (13.7)	30.3 (13.1)	 	Women	146 (58 )	134 (54 )	 	Men	107 (42 )	116 (46 )	 	Mean (SD) BMI	28.1 (6.3)	28.1 (6.8)	 	 Grade of sprain:	 	 1	69 (27 )	80 (32 )	 	 2	184 (73 )	170 (68 )	 	Injured ankle:	 	 Right	134 (53 )	129 (52 )	 	 Left	119 (47 )	121 (48 )	 	Previous injury to reference ankle	152 (60 )	147 (59 )	 	Past surgery on to reference ankle/foot	10 (4 )	7 (3 )	 	Plain radiographs ordered at acute care visit	213 (84 )	210 (84 )	 	Injured participating in sport	110 (43 )	105 (42 )	 	Median (IQR) time (days) between injury and MPL evaluation	5 (3-6)	5 (2-6)	 	Mean (SD) FAOS at baseline (MPL evaluation)	221.6 (66.2)	225.4 (74.4),Results,[22029],[22492],[23199],[False],[0],[0],[False],['0']
27597,PMC5112179,3933,MPL=motor performance laboratory; IQR=interquartile range; FAOS=foot ankle outcome score.,Results,[22035],[23200],[23292],[False],[0],[0],[False],['0']
27598,PMC5112179,3934,"Given the actual observed sample size and the rates of contamination and loss to follow-up, the power to detect a 15% improvement in our primary outcome was 78% for the intent to treat analyses and 82% for our per protocol analyses.",Results,[22041],[23293],[23525],[False],[0],[0],[False],['0']
27599,PMC5112179,3935,"Table 2 (intent to treat) and table 3 (per protocol analysis) show comparisons of the study arms for the primary outcome, FAOS ≥450 at three months, and the secondary outcomes of excellent FAOS at one and six months.",Results,[22047],[23526],[23742],[False],[0],[0],[False],['0']
27600,PMC5112179,3936,"The per protocol analysis excluded 69 participants in the physiotherapy arm who did not attend at least one protocol physiotherapy session in the first three months, as well as 26 participants in the control arm who received physiotherapy during the first three months.",Results,[22053],[23743],[24012],[False],[0],[0],[False],['0']
27601,PMC5112179,3937,"Neither analysis identified strong, consistent, or significant differences in primary or secondary FAOS outcomes by study arm.",Results,[22059],[24013],[24139],[False],[0],[0],[False],['0']
27602,PMC5112179,3938,Results of intent to treat analysis for primary outcome of excellent recovery (total FAOS ≥450) in patients with acute ankle sprain randomised to usual care with physiotherapy or usual care alone,Results,[22065],[24140],[24335],[False],[0],[0],[False],['0']
27603,PMC5112179,3939,Time point	No (%) of patients	Raw risk difference (95% CI)	P value*	 	Physiotherapy	Usual care	 	Baseline	0/253 (0)	0/250 (0)	—	—	 	1 month	26/239 (11)	34/239 (14)	−3% (−9% to 3%)	0.27	 	3 months	98/229 (43)	79/214 (37)	6% (−3% to 15%)	0.26†	 	6 months	118/208 (57)	120/195 (62)	−5% (−14% to 5%)	0.26†,Results,[22071],[24336],[24637],[False],[0],[0],[False],['0']
27604,PMC5112179,3940,*P value based on Mantel-Haenszel test stratified by quarter of FAOS at baseline.,Results,[22077],[24638],[24722],[False],[0],[0],[False],['0']
27605,PMC5112179,3941,"†Rounded to 0.26 by coincidence, with difference in their third decimal confirmed.",Results,[22083],[24723],[24805],[False],[0],[0],[False],['0']
27606,PMC5112179,3942,Results of per protocol* analysis for primary outcome of excellent recovery (total FAOS ≥450) in patients with acute ankle sprain randomised to usual care with physiotherapy or usual care alone,Results,[22089],[24806],[24999],[False],[0],[0],[False],['0']
27607,PMC5112179,3943,Time point	No (%) of patients	Raw risk difference (95% CI)	P value†	 	Physiotherapy	Usual care	 	Baseline	0/184 (0)	0/224 (0)	—	—	 	1 month	23/180 (13)	33/213 (15)	−3% (−10% to 4%)	0.65	 	3 months	75/177 (42)	75/188 (40)	2% (−8% to 13%)	0.42	 	6 months	92/165 (56)	113/174 (65)	−9% (−20% to 1%)	0.09,Results,[22095],[25000],[25299],[False],[0],[0],[False],['0']
27608,PMC5112179,3944,*Excludes participants randomised to physiotherapy arm who did not attend at least one protocol physiotherapy session in first 3 months and participants randomised to control arm who received any physiotherapy during first 3 months.,Results,[22101],[25300],[25535],[False],[0],[0],[False],['0']
27609,PMC5112179,3945,†P value based on Mantel-Haenszel test stratified by quarter of FAOS at baseline.,Results,[22107],[25536],[25617],[False],[0],[0],[False],['0']
27610,PMC5112179,3946,Figure 3 (intent to treat analysis) and figure 4 (per protocol analyses) show the change from baseline in total and domain specific continuous FAOS.,Results,[22113],[25618],[25766],[False],[0],[0],[False],['0']
27611,PMC5112179,3947,Differences between groups in the mean change were not significant at any follow-up time point for any FAOS domain.,Results,[22119],[25767],[25882],[False],[0],[0],[False],['0']
27612,PMC5112179,3948,Tables 4 and 5 show the results of the subgroup analysis.,Results,[22125],[25883],[25940],[False],[0],[0],[False],['0']
27613,PMC5112179,3949,"Although these indicate a benefit for physiotherapy at three months in the subgroup of patients aged <30, with a borderline significant (P=0.05) interaction between treatment and age at the three month assessment, this trend was not present at other time points and would not remain significant after any reasonable adjustment for multiple testing.",Results,[22131],[25941],[26289],[False],[0],[0],[False],['0']
27614,PMC5112179,3950,There was no significant treatment difference in any other subgroup.,Results,[22137],[26290],[26358],[False],[0],[0],[False],['0']
27615,PMC5112179,3951,Figure 5 characterises the missing data sensitivity analysis for the primary outcome of three month recovery (total FAOS ≥450).,Results,[22143],[26359],[26486],[False],[0],[0],[False],['0']
27616,PMC5112179,3952,"To reach a clinically important difference of 15% favouring the physiotherapy arm, we would have needed either of the following two conditions to be satisfied: at least 20/25 participants with a missing intervention in the physiotherapy arm to have excellent recovery and none of the 36 in the usual care arm achieving excellent recovery; or all 25 participants with a missing intervention in the physiotherapy arm and no more than five in the control arm achieving an excellent recovery.",Results,[22149],[26487],[26975],[False],[0],[0],[False],['0']
27617,PMC5112179,3953,"Based on the low rate of excellent recovery identified among the 88% of randomised participants with three month follow-up (tables 2 and 3), these conditions are exceedingly unlikely to be achieved.",Results,[22155],[26976],[27174],[False],[0],[0],[False],['0']
27618,PMC5112179,3954,Fig 3 Intent to treat analysis of change in FAOS from baseline.,Results,[22161],[27175],[27238],[False],[0],[0],[False],['0']
27619,PMC5112179,3955,Estimates are based on restricted maximum likelihood using all available FAOS scores from all patients,Results,[22167],[27239],[27341],[False],[0],[0],[False],['0']
27620,PMC5112179,3956,Fig 4 Per protocol analyses of change in FAOS from baseline.,Results,[22173],[27342],[27402],[False],[0],[0],[False],['0']
27621,PMC5112179,3957,Estimates are based on restricted maximum likelihood using all available FAOS scores from all patients,Results,[22179],[27403],[27505],[False],[0],[0],[False],['0']
27622,PMC5112179,3958,Subgroup analyses by sex and age for intent to treat analysis of primary outcome of excellent recovery (total FAOS ≥450) in patients with acute ankle sprain randomised to usual care with physiotherapy or usual care alone,Results,[22185],[27506],[27726],[False],[0],[0],[False],['0']
27623,PMC5112179,3959,Subgroup	No (%) of patients	Raw risk difference* (95% CI)	Adjusted risk difference* (95% CI)†	P value‡	 	Physiotherapy	Usual care	 	Men	 	Baseline	0/107 (0)	0/116 (0)	—	—	—	 	1 month	12/101 (12)	24/112 (21)	−10% (−19% to 0%)	−7% (−20% to 6%)	0.09	 	3 months	46/93 (49)	43/94 (46)	4% (−11% to 18%)	4% (−10% to 17%)	0.60	 	6 months	56/88 (64)	54/86 (63)	1% (−13% to 15%)	2% (−12% to 15%)	0.81	 	Women	 	Baseline	0/146 (0)	0/134 (0)	—	—	—	 	1 month	14/138 (10)	10/127 (8)	2% (−5% to 9%)	2% (−5% to 8%)	0.59	 	3 months	52/136 (38)	36/120 (30)	8% (−3% to 20%)	7% (−3% to 18%)	0.25	 	6 months	62/120 (52)	66/109 (61)	−9% (−22% to 4%)	−10% (−23% to 2%)	0.12	 	Age ≤30	 	Baseline	0/145 (0)	0/150 (0)	—	—	—	 	1 month	18/139 (13)	22/143 (15)	−2% (−11% to 6%)	−1% (−8% to 6%)	0.47	 	3 months	68/132 (52)	47/122 (39)	13% (1% to 5%)	14% (3% to 25%)	0.03**	 	6 months	75/118 (64)	74/106 (70)	−6% (−19% to 6%)	−6% (−17% to 6%)	0.37	 	Age >30	 	Baseline	0/108 (0)	0/100 (0)	—	—	—	 	1 month	8/144 (8)	12/96 (13)	−5% (−13% to 4%)	−3% (−14% to 8%)	0.43	 	3 months	30/97 (31)	32/92 (35)	−4% (−17% to 10%)	−4% (−16% to 9%)	0.52	 	6 months	43/90 (48)	46/89 (52)	−4% (−19% to 11%)	−6% (−19% to 6%)	0.52,Results,[22191],[27727],[28906],[False],[0],[0],[False],['0']
27624,PMC5112179,3960,*Positive risk difference favours physiotherapy arm.,Results,[22197],[28907],[28962],[False],[0],[0],[False],['0']
27625,PMC5112179,3961,†Adjusted risk difference uses generalised linear model with binomial outcome and identity link to control for quarter of FAOS at baseline.,Results,[22203],[28963],[29102],[False],[0],[0],[False],['0']
27626,PMC5112179,3962,‡P value based on Mantel-Haenszel test stratified by quarter of FAOS at baseline.,Results,[22209],[29103],[29184],[False],[0],[0],[False],['0']
27627,PMC5112179,3963,"§P value for subgroup by treatment interaction 0.14 at 1 month, 0.71 at 3 months, and 0.21 at 6 months.",Results,[22215],[29185],[29288],[False],[0],[0],[False],['0']
27628,PMC5112179,3964,"¶P value for subgroup by treatment interaction 0.73 at 1 month, 0.05 at 3 months, and 0.93 at 6 months.",Results,[22221],[29289],[29392],[False],[0],[0],[False],['0']
27629,PMC5112179,3965,"**Discrete treatment effect of P<0.05: these effects were not consistent across time points of measurement within the subgroups of age ≤30 and >30, and would not remain significant after any reasonable adjustment of multiple comparisons.",Results,[22227],[29393],[29630],[False],[0],[0],[False],['0']
27630,PMC5112179,3966,Subgroup analyses by injury characteristics for intent to treat analysis of primary outcome of excellent recovery (total FAOS ≥450) in patients with acute ankle sprain randomised to usual care with physiotherapy or usual care alone,Results,[22233],[29631],[29862],[False],[0],[0],[False],['0']
27631,PMC5112179,3967,Follow-up	No (%) of patients	Raw risk difference* (95% CI)	Adjusted risk difference* (95% CI)†	P value‡	 	Physiotherapy	Usual care	 	Non-sports injury	 	Baseline	0/143 (0)	0/145 (0)	—	—	—	 	1 month	13/135 (10)	18/137 (13)	−4% (−11% to 4%)	−2% (−9% to 4%)	0.32	 	3 months	56/131 (43)	48/124 (39)	4% (−8% to 16%)	3% (−8% to 14%)	0.66	 	6 months	63/117 (54)	70/112 (63)	−9% (−21% to 4%)	−9% (−21% to 3%)	0.13	 	Sports injury	 	Baseline	0/110 (0)	0/105 (0)	—	—	—	 	1 month	13/104 (13)	16/102 (16)	−3% (−13% to 6%)	−0% (−8% to 7%)	0.61	 	3 months	42/98 (43)	31/90 (34)	8% (−5% to 22%)	9% (−3% to 22%)	0.22	 	6 months	55/91 (60)	50/83 (60)	0% (−14% to 15%)	0% (−14% to 14%)	0.93	 	Grade 1	 	Baseline	0/69 (0)	0/80 (0)	—	—	—	 	1 month	10/66 (15)	15/75 (20)	−5% (−17% to 8%)	2% (−13% to 16%)	0.37	 	3 months	38/67 (57)	35/68 (51)	5% (−12% to 22%)	4% (−12% to 21%)	0.60	 	6 months	43/60 (72)	46/64 (72)	−0% (−16% to 16%)	−2% (−18% to 13%)	0.89	 	Grade 2	 	Baseline	0/184 (0)	0/170 (0)	—	—	—	 	1 month	16/173 (9)	19/164 (12)	−2% (−9% to 4%)	−2% (−7% to 3%)	0.42	 	3 months	60/162 (37)	44/146 (30)	7% (−4% to 17%)	6% (−3% to 16%)	0.26	 	6 months	75/148 (51)	74/131 (56)	−6% (−18% to 6%)	−6% (−18% to 5%)	0.26,Results,[22239],[29863],[31060],[False],[0],[0],[False],['0']
27632,PMC5112179,3968,*Positive risk difference favours physiotherapy arm.,Results,[22245],[31061],[31116],[False],[0],[0],[False],['0']
27633,PMC5112179,3969,†Adjusted risk difference uses generalised linear model with binomial outcome and identity link to control for quarter of FAOS at baseline.,Results,[22251],[31117],[31256],[False],[0],[0],[False],['0']
27634,PMC5112179,3970,"‡P value based on Mantel-Haenszel test, stratified by quarter of FAOS at baseline.",Results,[22257],[31257],[31339],[False],[0],[0],[False],['0']
27635,PMC5112179,3971,"§P value for subgroup by treatment interaction 0.77 at 1 month, 0.50 at 3 months, and 0.27 at 6 months.",Results,[22263],[31340],[31443],[False],[0],[0],[False],['0']
27636,PMC5112179,3972,"¶P value for subgroup by treatment interaction 0.97 at 1 month, 0.85 at 3 months, and 0.59 at 6 months.",Results,[22269],[31444],[31547],[False],[0],[0],[False],['0']
27637,PMC5112179,3973,"Fig 5 Sensitivity analysis for missing FAOS data to assess “excellent” recovery at three months, plotting predicted proportion of recovery among 25 unknown participants in physiotherapy arm to predicted proportion among 36 unknown participants in control arm.",Results,[22275],[31548],[31807],[False],[0],[0],[False],['0']
27638,PMC5112179,3974,Main axes (bottom and left) show percentages and secondary axes (top and right) show counts,Results,[22281],[31808],[31899],[False],[0],[0],[False],['0']
27639,PMC5112179,3975,Figure 6 (intent to treat analysis) and figure 7 (per protocol analyses) show the assessment of change from baseline in clinical and biomechanical measures at the three time points.,Results,[22287],[31900],[32081],[False],[0],[0],[False],['0']
27640,PMC5112179,3976,"In the intent to treat analysis, there were no significant differences among the 10 variables measured.",Results,[22293],[32082],[32185],[False],[0],[0],[False],['0']
27641,PMC5112179,3977,"In the per protocol analysis, measures of peak plantar flexor torque (Nm) and plantar flexor power (watts) favoured the physiotherapy arm, with no other clinically important or significant differences identified by treatment arm.",Results,[22299],[32186],[32415],[False],[0],[0],[False],['0']
27642,PMC5112179,3978,Fig 6 Intent to treat analysis of change in clinical and biomechanical measures from baseline.,Results,[22305],[32416],[32510],[False],[0],[0],[False],['0']
27643,PMC5112179,3979,"All estimates reported as increase from baseline, with exception of figure of eight measure of oedema, which is reported as decrease from baseline, so that greater increase is consistently favourable.",Results,[22311],[32511],[32711],[False],[0],[0],[False],['0']
27644,PMC5112179,3980,Estimates based on restricted maximum likelihood using all available measures from all randomised participants,Results,[22317],[32712],[32822],[False],[0],[0],[False],['0']
27645,PMC5112179,3981,Fig 7 Per protocol analyses of change in clinical and biomechanical measures from baseline.,Results,[22323],[32823],[32914],[False],[0],[0],[False],['0']
27646,PMC5112179,3982,"All estimates reported as increase from baseline, with exception of figure of eight measure of oedema, which is reported as decrease from baseline, so that greater increase is consistently favourable.",Results,[22329],[32915],[33115],[False],[0],[0],[False],['0']
27647,PMC5112179,3983,Estimates based on restricted maximum likelihood using all available measures from all randomised participants,Results,[22335],[33116],[33226],[False],[0],[0],[False],['0']
27648,PMC5112179,3984,"In the six month follow-up period, 19/254 (7.5%) participants in the physiotherapy arm and 21/250 (8.4%) in the usual care arm reported a re-injury of the same ankle, with no significant difference between the two trial arms (P=0.71).",Results,[22341],[33227],[33461],[False],[0],[0],[False],['0']
27649,PMC5112179,3985,Discussion,Discussion,[22347],[33462],[33473],[False],[0],[0],[False],['0']
27650,PMC5112179,3986,Principal findings,Discussion|Principal findings,[22353],[33474],[33492],[False],[0],[0],[False],['0']
27651,PMC5112179,3987,"With the participation of 503 patients, our trial is the largest randomised controlled trial to have evaluated the therapeutic benefits of supervised physiotherapy in the treatment of acute ankle sprains.",Discussion|Principal findings,[22359],[33493],[33697],[False],[0],[0],[False],['0']
27652,PMC5112179,3988,"Based on our outcomes, we conclude that among patients aged 16-79 presenting to an emergency department with a simple grade 1 or 2 ankle sprain within 72 hours of their injury, the addition of early supervised physiotherapy to usual care does not lead to clinically important improvements in functional recovery up to six months after injury, compared with usual care alone.",Discussion|Principal findings,[22365],[33698],[34072],[False],[0],[0],[False],['0']
27653,PMC5112179,3989,"The absence of a therapeutic benefit of supervised exercise was confirmed for our primary outcome of excellent functional recovery as assessed by the FAOS at three months, as well as for the FAOS (using both excellent recovery and continuous scores) and objective clinical and biomechanical measures at one, three, and six months after injury.",Discussion|Principal findings,[22371],[34073],[34416],[False],[0],[0],[False],['0']
27654,PMC5112179,3990,Our finding is clinically important as the recommendation of physiotherapy for the management of acute ankle sprains comes with substantial economic costs.,Discussion|Principal findings,[22377],[34417],[34572],[False],[0],[0],[False],['0']
27655,PMC5112179,3991,Strengths of the trial,Discussion|Strengths of the trial,[22383],[34573],[34595],[False],[0],[0],[False],['0']
27656,PMC5112179,3992,Our trial conformed to the CONSORT guidelines.,Discussion|Strengths of the trial,[22389],[34596],[34642],[False],[0],[0],[False],['0']
27657,PMC5112179,3993,"Our main findings are unlikely to be explained by imbalances in confounding factors, both known and unknown, between the trial arms.",Discussion|Strengths of the trial,[22395],[34643],[34775],[False],[0],[0],[False],['0']
27658,PMC5112179,3994,"Baseline group comparisons essentially showed equivalence on such factors, suggesting that the approach to randomisation and its administration were effective.",Discussion|Strengths of the trial,[22401],[34776],[34935],[False],[0],[0],[False],['0']
27659,PMC5112179,3995,"Although participants were volunteers, the study population was large and heterogeneous, and, because of the use and effectiveness of randomisation, it is unlikely that any forces of selection resulted in bias in the observed effect estimates.",Discussion|Strengths of the trial,[22407],[34936],[35179],[False],[0],[0],[False],['0']
27660,PMC5112179,3996,A participation rate of 88% at the three month primary endpoint and 80% at six months was maintained.,Discussion|Strengths of the trial,[22413],[35180],[35281],[False],[0],[0],[False],['0']
27661,PMC5112179,3997,Subgroup analyses suggested a benefit of physiotherapy at three months in younger patients (aged <30).,Discussion|Strengths of the trial,[22419],[35282],[35384],[False],[0],[0],[False],['0']
27662,PMC5112179,3998,"The direction of effect was not consistent, however, and favoured the usual care group at one and six months.",Discussion|Strengths of the trial,[22425],[35385],[35494],[False],[0],[0],[False],['0']
27663,PMC5112179,3999,"There were no significant differences between study arms in subgroup analyses by sex, cause of injury (such as sports related or not), and grade of injury (grade 1 or 2) at one, three, and six months after injury.",Discussion|Strengths of the trial,[22431],[35495],[35708],[False],[0],[0],[False],['0']
27664,PMC5112179,4000,"We also conducted a sensitivity analysis, as recommended by Thabane and colleagues, to verify the robustness of our findings.",Discussion|Strengths of the trial,[22437],[35709],[35834],[False],[0],[0],[False],['0']
27665,PMC5112179,4001,"Consideration of missing data from loss to follow-up, by re-estimating the treatment effect of the primary outcome over the entire possible range of missing values, did not change our findings.",Discussion|Strengths of the trial,[22443],[35835],[36028],[False],[0],[0],[False],['0']
27666,PMC5112179,4002,"We identified contamination, from non-compliance with the trial protocol in terms of not receiving assigned (27.3%) physiotherapy or by independently seeking physiotherapy when not assigned (10.4%) and conducted separate intent to treat and per protocol analyses.",Discussion|Strengths of the trial,[22449],[36029],[36292],[False],[0],[0],[False],['0']
27667,PMC5112179,4003,"Both analyses failed to show clinically important effects associated with the physiotherapy intervention, and the observed trends reversed from three months to six months.",Discussion|Strengths of the trial,[22455],[36293],[36464],[False],[0],[0],[False],['0']
27668,PMC5112179,4004,"Another potential source of bias is the effect of “social desirability,” where patients assigned to an active intervention are more prone to self report favourable outcomes during clinical interviews.",Discussion|Strengths of the trial,[22461],[36465],[36665],[False],[0],[0],[False],['0']
27669,PMC5112179,4005,Such bias would be expected to favour the physiotherapy intervention.,Discussion|Strengths of the trial,[22467],[36666],[36735],[False],[0],[0],[False],['0']
27670,PMC5112179,4006,"There were, however, no clinically important differences or consistent trends in outcomes over time for both the self reported FAOS and the clinical and biomechanical measures of ankle function.",Discussion|Strengths of the trial,[22473],[36736],[36930],[False],[0],[0],[False],['0']
27671,PMC5112179,4007,"Blinding was implemented when possible among the attending therapists, laboratory personnel, and interviewers.",Discussion|Strengths of the trial,[22479],[36931],[37041],[False],[0],[0],[False],['0']
27672,PMC5112179,4008,The FAOS is one outcome measurement available to determine patient assessed foot and ankle function.,Discussion|Strengths of the trial,[22485],[37042],[37142],[False],[0],[0],[False],['0']
27673,PMC5112179,4009,"We do recognise that although the FAOS has been refined and validated in various contexts,   the nature and extent of non-differential misclassification of the primary study outcome remains unknown.",Discussion|Strengths of the trial,[22491],[37143],[37341],[True],['ValidityOfMeasurement'],['the nature and extent of non-differential misclassification of the primary study outcome remains unknown'],[True],['OutcomeMeasures']
27674,PMC5112179,4010,"Therefore, any misclassification of outcomes in our trial is most likely to be non-differential in nature.",Discussion|Strengths of the trial,[22503],[37342],[37448],[False],[0],[0],[False],['0']
27675,PMC5112179,4011,"Also, our criterion of a score ≥450 denoting excellent recovery was based on studies that used similar self report questionnaires for lower extremities—namely, the lower extremity function score (LEFS) and the knee injury and osteoarthritis outcome score (KOOS).",Discussion|Strengths of the trial,[22509],[37449],[37711],[False],[0],[0],[False],['0']
27676,PMC5112179,4012,"The evaluation of the FAOS as a continuous variable, as we did in our secondary analyses, allows for a more statistically efficient analysis of this outcome.",Discussion|Strengths of the trial,[22515],[37712],[37869],[False],[0],[0],[False],['0']
27677,PMC5112179,4013,"The use of a cut off to dichotomise recovery as “excellent” or “not excellent,” however, provides a more clinically interpretable outcome.",Discussion|Strengths of the trial,[22521],[37870],[38008],[False],[0],[0],[False],['0']
27678,PMC5112179,4014,"It is likely that patient assessed measures of excellent recovery will be influenced by the characteristics of the clinical population under study, and, therefore, a range of cut offs might be appropriate.",Discussion|Strengths of the trial,[22527],[38009],[38214],[False],[0],[0],[False],['0']
27679,PMC5112179,4015,"Identification of those characteristics that modify patients’ assessment of recovery requires further research, though the stringent criterion adopted in our study provides confidence that patients classified as recovered were appropriately categorised as recovered.",Discussion|Strengths of the trial,[22533],[38215],[38481],[False],[0],[0],[False],['0']
27680,PMC5112179,4016,Comparison with other studies,Discussion|Comparison with other studies,[22539],[38482],[38513],[False],[0],[0],[False],['0']
27681,PMC5112179,4017,"Our results contradict those of Hultman and colleagues, who conducted a randomised controlled trial to evaluate the effectiveness of providing four physiotherapy visits in addition to usual emergency department care on recovery of ankle function measured at six weeks and at three months after injury.",Discussion|Comparison with other studies,[22545],[38514],[38815],[False],[0],[0],[False],['0']
27682,PMC5112179,4018,The physiotherapy visits were held within 14 days of attendance.,Discussion|Comparison with other studies,[22551],[38816],[38880],[False],[0],[0],[False],['0']
27683,PMC5112179,4019,"As in our study, the physiotherapy regimen was standardised and based on functional exercises, using the FAOS as the primary outcome.",Discussion|Comparison with other studies,[22557],[38881],[39014],[False],[0],[0],[False],['0']
27684,PMC5112179,4020,Hultman and colleagues reported a therapeutic benefit of physiotherapy in addition to information provided in the department.,Discussion|Comparison with other studies,[22563],[39015],[39140],[False],[0],[0],[False],['0']
27685,PMC5112179,4021,"Their trial was relatively small, with 33 patients in the intervention group and 32 in the control group.",Discussion|Comparison with other studies,[22569],[39141],[39246],[False],[0],[0],[False],['0']
27686,PMC5112179,4022,"Their protocol instructed patients to exercise to a pain level of 5 out of 10 on a visual analogue scale, according to Thomée’s model of pain control, whereas our patients were instructed to exercise as tolerated.",Discussion|Comparison with other studies,[22575],[39247],[39460],[False],[0],[0],[False],['0']
27687,PMC5112179,4023,"The role of training to a higher level of pain, and the reinforcement of this during physiotherapy, could warrant further evaluation.",Discussion|Comparison with other studies,[22581],[39461],[39594],[False],[0],[0],[False],['0']
27688,PMC5112179,4024,Limitations of the trial,Discussion|Limitations of the trial,[22587],[39595],[39619],[False],[0],[0],[False],['0']
27689,PMC5112179,4025,The limitations of our trial need to be acknowledged in the interpretation and application of our findings to practice.,Discussion|Limitations of the trial,[22593],[39620],[39739],[False],[0],[0],[False],['0']
27690,PMC5112179,4026,Our extensive protocol might have introduced bias in the characteristics of participants in our study group.,Discussion|Limitations of the trial,[22600],[39740],[39848],[True],['DiagnosticCriteria'],['bias in the characteristics of participants in our study group'],[True],['Population']
27691,PMC5112179,4027,"While we were successful in enrolling 504 patients, this represents a recruitment rate of one in three patients who met our clinical criteria of eligibility.",Discussion|Limitations of the trial,[22614],[39849],[40006],[True],['VerySpecificPopulation'],['a recruitment rate of one in three patients who met our clinical criteria of eligibility'],[True],['Population']
27692,PMC5112179,4028,We suspect that our time intensive appointments for outcome assessment might have contributed to the refusal of 232 eligible patients to participate.,Discussion|Limitations of the trial,[22627],[40007],[40156],[True],['VerySpecificPopulation'],['the refusal of 232 eligible patients to participate'],[True],['Population']
27693,PMC5112179,4029,"Another 129 eligible patients declined to participate because of travel distance, a consequence of our urgent care centres serving a large geographical region.",Discussion|Limitations of the trial,[22640],[40157],[40316],[True],['VerySpecificPopulation'],['Another 129 eligible patients declined to participate because of travel distance'],[True],['Population']
27694,PMC5112179,4030,"As such, our sample might not be generalisable to all those who experience grade 1 and 2 ankle injuries.",Discussion|Limitations of the trial,[22649],[40317],[40421],[True],['Generalization'],['our sample might not be generalisable to all those who experience grade 1 and 2 ankle injuries'],[True],['Generalization']
27695,PMC5112179,4031,Our high retention at the three month primary end point (88%) and at six months (80%) supports a high level of commitment among our study participants.,Discussion|Limitations of the trial,[22659],[40422],[40573],[False],[0],[0],[False],['0']
27696,PMC5112179,4032,Conclusions and implications for practice,Discussion|Conclusions and implications for practice,[22665],[40574],[40615],[False],[0],[0],[False],['0']
27697,PMC5112179,4033,"Our trial provides level I evidence that supervised physiotherapy, as described, does not provide clinically important benefit in the management of simple ankle sprains in a general population of patients seeking care in an acute care setting.",Discussion|Conclusions and implications for practice,[22671],[40616],[40859],[False],[0],[0],[False],['0']
27698,PMC5112179,4034,"Our comparator of usual care was the provision of written recommendations for initial rest, cryotherapy, compression, and limb elevation, with graduated mobility being encouraged as tolerated.",Discussion|Conclusions and implications for practice,[22677],[40860],[41052],[False],[0],[0],[False],['0']
27699,PMC5112179,4035,"These recommendations stem from basic principles of physiotherapy, which, to our knowledge, are commonly provided in emergency departments.",Discussion|Conclusions and implications for practice,[22683],[41053],[41192],[False],[0],[0],[False],['0']
27700,PMC5112179,4036,This format of usual care is associated with minimal cost and is unlikely to ever be assessed against no care.,Discussion|Conclusions and implications for practice,[22689],[41193],[41303],[False],[0],[0],[False],['0']
27701,PMC5112179,4037,We do note that 43% of participants in the physiotherapy arm and 38% in the control arm had not reached excellent recovery by six months; this being lower than anticipated.,Discussion|Conclusions and implications for practice,[22695],[41304],[41476],[False],[0],[0],[False],['0']
27702,PMC5112179,4038,"This suggests that while there was not a clinically important effect with the standardised physiotherapy regimen provided to our participants, there is potential for the investigation of alternative interventions that would reduce morbidity in patients with these injuries.",Discussion|Conclusions and implications for practice,[22701],[41477],[41750],[False],[0],[0],[False],['0']
27703,PMC5112179,4039,What is already known on this topic,Discussion|What is already known on this topic,[22707],[41751],[41786],[False],[0],[0],[False],['0']
27704,PMC5112179,4040,Ankle sprains are one of the most common and burdensome musculoskeletal injuries and are associated with a high rate of visits to an emergency department,Discussion|What is already known on this topic,[22713],[41787],[41940],[False],[0],[0],[False],['0']
27705,PMC5112179,4041,"Although most ankle sprains are simple grade 1 or grade 2 ligament sprains, the clinical standards for the acute management of these injuries are not well defined",Discussion|What is already known on this topic,[22719],[41941],[42104],[False],[0],[0],[False],['0']
27706,PMC5112179,4042,Current evidence regarding the role of supervised physiotherapy in the acute management of these injuries is limited,Discussion|What is already known on this topic,[22725],[42105],[42221],[False],[0],[0],[False],['0']
27707,PMC5112179,4043,What this study adds,Discussion|What this study adds,[22731],[42222],[42242],[False],[0],[0],[False],['0']
27708,PMC5112179,4044,"In the acute management of patients with grade 1 and 2 ankle sprains presenting to an emergency department within 72 hours of injury, a standard intervention of early supervised physiotherapy plus usual care does not lead to clinically important improvements in functional recovery up to six months after injury compared with usual care alone",Discussion|What this study adds,[22737],[42243],[42585],[False],[0],[0],[False],['0']
27709,PMC5112179,4045,"As 43% of participants in the physiotherapy arm and 38% in the control arm did not reach excellent recovery by six months, there is potential for the investigation of alternative interventions that would reduce morbidity associated with these injuries",Discussion|What this study adds,[22743],[42586],[42837],[False],[0],[0],[False],['0']
27710,PMC5112179,4046,"We thank D Emerton, who coordinated data collection, X Sun, who assisted with data analysis, S Dostaler, who assisted with trial development and registration, and I Bielska for maintaining literature reviews.",Discussion|What this study adds,[22749],[42838],[43046],[False],[0],[0],[False],['0']
27711,PMC5112179,4047,"We also thank all participants for their time and commitment to our study and participants involved in the pilot phase of our trial, who provided feedback on our methods and procedures.",Discussion|What this study adds,[22755],[43047],[43232],[False],[0],[0],[False],['0']
27712,PMC5112179,4048,Contributors: RJB and AGD were responsible for data integrity and analyses for the study.,Discussion|What this study adds,[22761],[43233],[43322],[False],[0],[0],[False],['0']
27713,PMC5112179,4049,All authors contributed to the study concept and design.,Discussion|What this study adds,[22767],[43323],[43379],[False],[0],[0],[False],['0']
27714,PMC5112179,4050,RJB and BB were responsible for data acquisition.,Discussion|What this study adds,[22773],[43380],[43429],[False],[0],[0],[False],['0']
27715,PMC5112179,4051,"AGD, RJB, BB, and WP were responsible for the statistical analysis and interpretation.",Discussion|What this study adds,[22779],[43430],[43516],[False],[0],[0],[False],['0']
27716,PMC5112179,4052,"RJB, AGD, LP, BB, and WP drafted the manuscript.",Discussion|What this study adds,[22785],[43517],[43565],[False],[0],[0],[False],['0']
27717,PMC5112179,4053,All authors contributed to the critical revision of the manuscript for intellectual content.,Discussion|What this study adds,[22791],[43566],[43658],[False],[0],[0],[False],['0']
27718,PMC5112179,4054,Study supervision was provided by RJB and BB.,Discussion|What this study adds,[22797],[43659],[43704],[False],[0],[0],[False],['0']
27719,PMC5112179,4055,RJB is guarantor.,Discussion|What this study adds,[22803],[43705],[43722],[False],[0],[0],[False],['0']
27720,PMC5112179,4056,Funding: The study was funded by the Canadian Institutes of Health Research (MCT-94833).,Discussion|What this study adds,[22809],[43723],[43811],[False],[0],[0],[False],['0']
27721,PMC5112179,4057,"The sponsors had no role in the design, conduct, and analysis or involvement in the preparation or submission of the manuscript for publication",Discussion|What this study adds,[22815],[43812],[43955],[False],[0],[0],[False],['0']
27722,PMC5112179,4058,Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.,Discussion|What this study adds,[22821],[43956],[44366],[False],[0],[0],[False],['0']
27723,PMC5112179,4059,Ethical approval: This study was approved by Queen’s University Health Sciences Research Ethics Board (file No 6004187) and informed consent was given by all patients.,Discussion|What this study adds,[22827],[44367],[44534],[False],[0],[0],[False],['0']
27724,PMC5112179,4060,"Data sharing: The investigators will share data (with associated coding library) used in developing the results presented in this manuscript on request (from AGD, daya@kgh.kari.net).",Discussion|What this study adds,[22833],[44535],[44717],[False],[0],[0],[False],['0']
27725,PMC5112179,4061,Anonymised record level data would be made available on request to investigators who have submitted a publicly available proposal for analysis and who have received ethical clearance from their host institution.,Discussion|What this study adds,[22839],[44718],[44929],[False],[0],[0],[False],['0']
27726,PMC5112179,4062,"Transparency: The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.",Discussion|What this study adds,[22845],[44930],[45228],[False],[0],[0],[False],['0']
28010,PMC5134798,5808,Transient ulnar artery compression facilitates transradial access,Title,[35506],[34734],[65],[False],[0],[0],[False],['0']
28011,PMC5134798,5809,Abstract,Abstract,[35510],[66],[75],[False],[0],[0],[False],['0']
28012,PMC5134798,5810,Background:,Abstract,[35514],[76],[87],[False],[0],[0],[False],['0']
28013,PMC5134798,5811,Unsuccessful radial artery puncture is one of the important causes of transradial procedure failure.,Abstract,[35518],[88],[188],[False],[0],[0],[False],['0']
28014,PMC5134798,5812,Ulnar artery compression made the radial artery pulse stronger.,Abstract,[35522],[189],[252],[False],[0],[0],[False],['0']
28015,PMC5134798,5813,"Whether it would make transradial access easier, however, is uncertain.",Abstract,[35526],[253],[324],[False],[0],[0],[False],['0']
28016,PMC5134798,5814,Methods:,Abstract,[35530],[325],[333],[False],[0],[0],[False],['0']
28017,PMC5134798,5815,A prospective randomized controlled trial was conducted among 446 patients who planned for transradial cardiac catheterization.,Abstract,[35534],[334],[461],[False],[0],[0],[False],['0']
28018,PMC5134798,5816,"Patients were randomized to receiving either transient ulnar artery compression (UC) or standard treatment (standard) for half an hour prior to needle insertion (217 UC, 229 standard).",Abstract,[35538],[462],[646],[False],[0],[0],[False],['0']
28019,PMC5134798,5817,The diameters of right radial artery and ulnar artery were measured by ultrasound on admission and before artery puncture.,Abstract,[35542],[647],[769],[False],[0],[0],[False],['0']
28020,PMC5134798,5818,"Primary endpoints included the number of attempts to access, the rate of first-pass success, and time for a successful access.",Abstract,[35546],[770],[896],[False],[0],[0],[False],['0']
28021,PMC5134798,5819,"Secondary endpoints were the number of difficult procedures, and the incidence of puncture failure.",Abstract,[35550],[897],[996],[False],[0],[0],[False],['0']
28022,PMC5134798,5820,Results:,Abstract,[35554],[997],[1005],[False],[0],[0],[False],['0']
28023,PMC5134798,5821,"The diameters of radial artery were larger after half an hour's ulnar artery compression, but there were no obvious changes in that of ulnar artery.",Abstract,[35558],[1006],[1154],[False],[0],[0],[False],['0']
28024,PMC5134798,5822,"As compared with standard group, the number of attempts was significantly decreased (1.42 ± 1.10 vs 2.97 ± 2.38, P <0.001), and the rate of first-pass success was greatly enhanced (73.27% vs 57.64%, P <0.001) in UC group.",Abstract,[35562],[1155],[1376],[False],[0],[0],[False],['0']
28025,PMC5134798,5823,"Meanwhile, the time for access was decreased (59 ± 15 seconds vs 71 ± 18 seconds, P <0.001) with UC.",Abstract,[35566],[1377],[1477],[False],[0],[0],[False],['0']
28026,PMC5134798,5824,"In addition, the proportion of difficult procedures of UC group was less than that of standard group (4.61% vs 10.92%, P = 0.013).",Abstract,[35570],[1478],[1608],[False],[0],[0],[False],['0']
28027,PMC5134798,5825,No significant differences were found in failure rates of sheath insertion and puncture between the 2 groups.,Abstract,[35574],[1609],[1718],[False],[0],[0],[False],['0']
28028,PMC5134798,5826,Conclusion:,Abstract,[35578],[1719],[1730],[False],[0],[0],[False],['0']
28029,PMC5134798,5827,Transient ulnar artery compression enhances the efficacy and feasibility of radial artery intubatton in transradial catheterization.,Abstract,[35582],[1731],[1863],[False],[0],[0],[False],['0']
28030,PMC5134798,5828,Introduction,Introduction,[35586],[1864],[1877],[False],[0],[0],[False],['0']
28031,PMC5134798,5829,"Transradial approach coronary procedures, including coronary angiography and percutaneous coronary intervention (PCI), that are associated with lower rates of bleeding complications compared with femoral approach, have increased around the world as well as in China over the past decade.",Introduction,[35590],[1878],[2165],[False],[0],[0],[False],['0']
28032,PMC5134798,5830,One of the important reasons of transradial procedure failure is unsuccessful to access the transradial artery.,Introduction,[35594],[2166],[2277],[False],[0],[0],[False],['0']
28033,PMC5134798,5831,"The weak pulse may make radial artery puncture difficult, whether caused by a small artery, a deep artery, or hypotension.",Introduction,[35598],[2278],[2400],[False],[0],[0],[False],['0']
28034,PMC5134798,5832,"Ulnar artery compression (UC) made the radial artery pulse stronger, could it make the access easier?",Introduction,[35602],[2401],[2502],[False],[0],[0],[False],['0']
28035,PMC5134798,5833,We tried to assess the efficacy and feasibility of transient ulnar artery compression on transradial arterial access.,Introduction,[35606],[2503],[2620],[False],[0],[0],[False],['0']
28036,PMC5134798,5834,Methods,Methods,[35610],[2621],[2629],[False],[0],[0],[False],['0']
28037,PMC5134798,5835,Study design,Methods|Study design,[35614],[2630],[2642],[False],[0],[0],[False],['0']
28038,PMC5134798,5836,"The study was a prospective, randomized controlled trial.",Methods|Study design,[35618],[2643],[2700],[False],[0],[0],[False],['0']
28039,PMC5134798,5837,Adult patients who were planned for transradial cardiac catheterization were included.,Methods|Study design,[35622],[2701],[2787],[False],[0],[0],[False],['0']
28040,PMC5134798,5838,The Allen test was performed and presence of dual circulation and patency of palmar arch was confirmed.,Methods|Study design,[35626],[2788],[2891],[False],[0],[0],[False],['0']
28041,PMC5134798,5839,"Patients with emergent procedures, nonpalpable radial pulse, abnormal Allen test, or chronic renal disease on hemodialysis were excluded from the study.",Methods|Study design,[35630],[2892],[3044],[False],[0],[0],[False],['0']
28042,PMC5134798,5840,Those having radial puncture within a week before the procedure were also excluded.,Methods|Study design,[35634],[3045],[3128],[False],[0],[0],[False],['0']
28043,PMC5134798,5841,"All patients who were included provided written informed consent, and the study was approved by the Beijing Anzhen Hospital Institutional Review Board.",Methods|Study design,[35638],[3129],[3280],[False],[0],[0],[False],['0']
28044,PMC5134798,5842,Operators,Methods|Operators,[35642],[3281],[3290],[False],[0],[0],[False],['0']
28045,PMC5134798,5843,"In total, 15 operators joined this study.",Methods|Operators,[35646],[3291],[3332],[False],[0],[0],[False],['0']
28046,PMC5134798,5844,"To avoid differences caused by operators, all operators who participated in this study had performed at least 100 radial artery catheterization per year in the last 5 years.",Methods|Operators,[35650],[3333],[3506],[False],[0],[0],[False],['0']
28047,PMC5134798,5845,Randomization,Methods|Randomization,[35654],[3507],[3520],[False],[0],[0],[False],['0']
28048,PMC5134798,5846,Patients were randomly allocated on a 1:1 basis to either UC or standard treatment through sealed envelopes.,Methods|Randomization,[35658],[3521],[3629],[False],[0],[0],[False],['0']
28049,PMC5134798,5847,"Briefly, random numbers were generated from discrete uniform distribution and the random numbers were then placed in the sealed envelopes.",Methods|Randomization,[35662],[3630],[3768],[False],[0],[0],[False],['0']
28050,PMC5134798,5848,One investigator was responsible for enrolling all patients and allocating them to either treatment according to the serial number of the randomized numbers.,Methods|Randomization,[35666],[3769],[3926],[False],[0],[0],[False],['0']
28051,PMC5134798,5849,The envelope was unsealed when a single operator was assigned to a special patient for the procedure.,Methods|Randomization,[35670],[3927],[4028],[False],[0],[0],[False],['0']
28052,PMC5134798,5850,Study procedures,Methods|Study procedures,[35674],[4029],[4045],[False],[0],[0],[False],['0']
28053,PMC5134798,5851,"Before the procedure, the hand circulation was assessed using Allen test among all the patients, by placing a hemostatic band over their right ulnar artery pulse with a silica gel (Xemex, Zeon Medical, Tokyo, Japan).",Methods|Study procedures,[35678],[4046],[4262],[False],[0],[0],[False],['0']
28054,PMC5134798,5852,"Patients in UC group received transient completely ulnar artery compression for half hour before the procedure, verified by pulse oximetry.",Methods|Study procedures,[35682],[4263],[4402],[False],[0],[0],[False],['0']
28055,PMC5134798,5853,Those patients in standard treatment group just received the band without compression.,Methods|Study procedures,[35686],[4403],[4489],[False],[0],[0],[False],['0']
28056,PMC5134798,5854,The diameters of the right radial artery and ulnar artery were evaluated by ultrasound on admission and before the intervention procedure.,Methods|Study procedures,[35690],[4490],[4628],[False],[0],[0],[False],['0']
28057,PMC5134798,5855,"The diameter of the radial artery was measured at 1 cm proximal to the styloid process of the radius, while that of the ulnar artery was measured at 1 cm proximal to the styloid process of the ulna.",Methods|Study procedures,[35694],[4629],[4827],[False],[0],[0],[False],['0']
28058,PMC5134798,5856,"After local anesthesia with 1% lidocaine, radial artery puncture was performed with a sheath set, including a 20-gauge 2-piece needle, 0.025-inch straight wire, and a 16 cm long 6Fr sheath (TERUMO, Tokyo, Japan).",Methods|Study procedures,[35698],[4828],[5040],[False],[0],[0],[False],['0']
28059,PMC5134798,5857,Double-wall technique was used per operator preference.,Methods|Study procedures,[35702],[5041],[5096],[False],[0],[0],[False],['0']
28060,PMC5134798,5858,"The guidewire would then be inserted, the skin nicked per operator practice, and the sheath inserted over the guidewire and flushed.",Methods|Study procedures,[35706],[5097],[5229],[False],[0],[0],[False],['0']
28061,PMC5134798,5859,Baseline patient demographics and comorbidities were recorded.,Methods|Study procedures,[35710],[5230],[5292],[False],[0],[0],[False],['0']
28062,PMC5134798,5860,"Procedural details including number of attempts, time to access, and incidence of puncture failure were tracked.",Methods|Study procedures,[35714],[5293],[5405],[False],[0],[0],[False],['0']
28063,PMC5134798,5861,Endpoints and power,Methods|Endpoints and power,[35718],[5406],[5425],[False],[0],[0],[False],['0']
28064,PMC5134798,5862,"The primary endpoints of the study were the number of attempts, the rate of first-pass success, and the time for a successful access.",Methods|Endpoints and power,[35722],[5426],[5559],[False],[0],[0],[False],['0']
28065,PMC5134798,5863,"Attempts were defined as needle punches separated by withdrawals, if only these performed in the skin or tissue above the plane of the artery.",Methods|Endpoints and power,[35726],[5560],[5702],[False],[0],[0],[False],['0']
28066,PMC5134798,5864,The number of attempts to access were first reported by the operator and then confirmed by a technician.,Methods|Endpoints and power,[35730],[5703],[5807],[False],[0],[0],[False],['0']
28067,PMC5134798,5865,The time to access was from the point of the first application of the operator's fingers to successful sheath placement and flushing.,Methods|Endpoints and power,[35734],[5808],[5941],[False],[0],[0],[False],['0']
28068,PMC5134798,5866,Secondary endpoints included difficult procedures and incidence of puncture failure.,Methods|Endpoints and power,[35738],[5942],[6026],[False],[0],[0],[False],['0']
28069,PMC5134798,5867,Difficult procedures were defined prospectively as either requiring no less than 5 attempts or 5 min for assess.,Methods|Endpoints and power,[35742],[6027],[6139],[False],[0],[0],[False],['0']
28070,PMC5134798,5868,Puncture failure was defined as the guidewire failed to insert.,Methods|Endpoints and power,[35746],[6140],[6203],[False],[0],[0],[False],['0']
28071,PMC5134798,5869,The estimated sample size was 430 patients.,Methods|Endpoints and power,[35750],[6204],[6247],[False],[0],[0],[False],['0']
28072,PMC5134798,5870,It was capable of showing a difference of 15% in first-pass success with an alpha of 5% and an estimated power of 90%.,Methods|Endpoints and power,[35754],[6248],[6366],[False],[0],[0],[False],['0']
28073,PMC5134798,5871,"In addition, it was sufficiently powered to study the other 2 primary endpoints, with >97.5% power to detect a 30-second difference with the standard deviation of 16 seconds in time for access, and >97.5% power to detect a difference of 1 with the standard deviation of 1.5 in the number of attempts.",Methods|Endpoints and power,[35758],[6367],[6667],[False],[0],[0],[False],['0']
28074,PMC5134798,5872,Statistical analysis,Methods|Statistical analysis,[35762],[6668],[6688],[False],[0],[0],[False],['0']
28075,PMC5134798,5873,Baseline demographic and clinical characteristics were compared between the 2 groups.,Methods|Statistical analysis,[35766],[6689],[6774],[False],[0],[0],[False],['0']
28076,PMC5134798,5874,"Categorical variables are presented as numbers and percentages, and continuous variables as the mean ± SD.",Methods|Statistical analysis,[35770],[6775],[6881],[False],[0],[0],[False],['0']
28077,PMC5134798,5875,Demographic characteristics were analyzed using the Student t test for independent continuous data and the Fischer exact test or χ2 test for categorical data.,Methods|Statistical analysis,[35774],[6882],[7040],[False],[0],[0],[False],['0']
28078,PMC5134798,5876,P values lower than 0.05 were considered statistically significant with 2 tailed tests.,Methods|Statistical analysis,[35778],[7041],[7128],[False],[0],[0],[False],['0']
28079,PMC5134798,5877,"Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC).",Methods|Statistical analysis,[35782],[7129],[7222],[False],[0],[0],[False],['0']
28080,PMC5134798,5878,Results,Results,[35786],[7223],[7231],[False],[0],[0],[False],['0']
28081,PMC5134798,5879,"In total, 446 patients who were planned for transradial cardiac catheterization procedures were consecutively recruited between January 2013 and August 2016 in Beijing Anzhen Hospital.",Results,[35790],[7232],[7416],[False],[0],[0],[False],['0']
28082,PMC5134798,5880,They were randomized to UC (n = 217) or standard (n = 229) treatment.,Results,[35794],[7417],[7486],[False],[0],[0],[False],['0']
28083,PMC5134798,5881,"Baseline clinical data and procedural characteristics are presented in Table 1, and there were no significant differences in the baseline characteristics of the patients.",Results,[35798],[7487],[7657],[False],[0],[0],[False],['0']
28084,PMC5134798,5882,"There were also no significant differences in clinical characteristics, such as the distribution of gender, BMI, and ages as well as prevalence of diabetes mellitus, hypertension, dyslipidemia, and cigarette smoking.",Results,[35802],[7658],[7874],[False],[0],[0],[False],['0']
28085,PMC5134798,5883,Baseline characteristics of participants.,Results|Baseline characteristics of participants.,[35806],[7875],[7916],[False],[0],[0],[False],['0']
28086,PMC5134798,5884,"The diameters were similar between 2 groups patients on admission (Table 2), of both radial artery (2.28 ± 0.44 mm vs 2.29 ± 0.39 mm, P = 0.799) and ulnar artery (2.31 ± 0.41 mm vs 2.30 ± 0.44 mm, P = 0.804).",Results|Baseline characteristics of participants.,[35810],[7917],[8125],[False],[0],[0],[False],['0']
28087,PMC5134798,5885,"However, the diameters of radial in UC group were larger by half an hour of ulnar artery compression than those in standard group (2.39 ± 0.50 mm vs 2.30 ± 0.45 mm, P = 0.046), whereas there are no obvious differences in that of ulnar artery between the 2 groups (2.30 ± 0.38 vs 2.31 ± 0.42, P = 0.793).",Results|Baseline characteristics of participants.,[35814],[8126],[8429],[False],[0],[0],[False],['0']
28088,PMC5134798,5886,"In addition, as compared with those on admission, the diameters of radial were significantly increased (2.39 ± 0.50 vs 2.28 ± 0.44, P = 0.042) after ulnar artery compression (Table 2), but the diameters of ulnar were slightly decreased (2.30 ± 0.38 vs 2.31 ± 0.41, P = 0.838).",Results|Baseline characteristics of participants.,[35818],[8430],[8706],[False],[0],[0],[False],['0']
28089,PMC5134798,5887,"Furthermore, no thrombus was detected in the 2 groups, and there were no ischemic events reported among these patients either.",Results|Baseline characteristics of participants.,[35822],[8707],[8833],[False],[0],[0],[False],['0']
28090,PMC5134798,5888,Diameters of RA and RU.,Results|Diameters of RA and RU.,[35826],[8834],[8857],[False],[0],[0],[False],['0']
28091,PMC5134798,5889,"There was a significant reduction in the number of attempts required for access the radial artery by UC versus standard (1.42 ± 1.10 vs 2.97 ± 2.38, P <0.001), as shown in Table 3.",Results|Diameters of RA and RU.,[35830],[8858],[9038],[False],[0],[0],[False],['0']
28092,PMC5134798,5890,"This was accompanied by increased rate of first-pass success (73.27% vs 57.64%, P <0.001).",Results|Diameters of RA and RU.,[35834],[9039],[9129],[False],[0],[0],[False],['0']
28093,PMC5134798,5891,"The difficult procedures that were defined as any procedures requiring >5 attempts, and/or requiring 5 minutes for access, were reduced by UC from 10.92% to 4.61%, P = 0.013.",Results|Diameters of RA and RU.,[35838],[9130],[9304],[False],[0],[0],[False],['0']
28094,PMC5134798,5892,"The vascular access time was shorter in patients with half hour's ulnar artery compression than patients with standard treatment (59 ± 15 seconds vs 71 ± 18 seconds, P <0.001).",Results|Diameters of RA and RU.,[35842],[9305],[9481],[False],[0],[0],[False],['0']
28095,PMC5134798,5893,"There was few incidences of puncture failure (none in UC and 3 cases in standard, P = 0.249), and failure of sheath insertion was rare (1 in UC and none in standard, P = 0.487), and no statistical difference existed between the 2 groups.",Results|Diameters of RA and RU.,[35846],[9482],[9719],[False],[0],[0],[False],['0']
28096,PMC5134798,5894,Parameter of clinical procedure data.,Results|Parameter of clinical procedure data.,[35850],[9720],[9757],[False],[0],[0],[False],['0']
28097,PMC5134798,5895,Discussion,Discussion|Discussion,[35854],[9758],[9769],[False],[0],[0],[False],['0']
28098,PMC5134798,5896,"The radial artery access failure was related to anatomic and technical factors, and the diameter of the target artery is an important factor in vascular puncture, especially to the operators with less experiences.",Discussion|Discussion,[35858],[9770],[9983],[False],[0],[0],[False],['0']
28099,PMC5134798,5897,"Our previous study showed that in Chinese adult patients the diameter of RRA ranges from 1.3 to 3.6 mm (mean 2.38 ± 0.56 mm), and the diameter of RUA is 1.1 to 3.5 mm (mean 2.36 ± 0.49 mm).",Discussion|Discussion,[35862],[9984],[10173],[False],[0],[0],[False],['0']
28100,PMC5134798,5898,These data were confirmed in this study.,Discussion|Discussion,[35866],[10174],[10214],[False],[0],[0],[False],['0']
28101,PMC5134798,5899,We try to seek a method to enlarge the diameter of radial artery.,Discussion|Discussion,[35870],[10215],[10280],[False],[0],[0],[False],['0']
28102,PMC5134798,5900,"The hand receives a dual arterial supply from the radial and ulnar arteries, which come together to form deep and superficial palmar arches.",Discussion|Discussion,[35874],[10281],[10421],[False],[0],[0],[False],['0']
28103,PMC5134798,5901,An arterial waveform was recorded by a pulse oximetry placed on the index finger.,Discussion|Discussion,[35878],[10422],[10503],[False],[0],[0],[False],['0']
28104,PMC5134798,5902,"The waveform maintained when the ulnar artery compressed by a hemostatic band, and disappeared when the radial artery simultaneously oppressed by hand.",Discussion|Discussion,[35882],[10504],[10655],[False],[0],[0],[False],['0']
28105,PMC5134798,5903,It verified that the blood flow could be completely obstructed on the ulnar artery by the compression of hemostatic band.,Discussion|Discussion,[35886],[10656],[10777],[False],[0],[0],[False],['0']
28106,PMC5134798,5904,"The phenomenon that compression on ulnar artery can increase the diameter radio artery, was a great inspiration to us.",Discussion|Discussion,[35890],[10778],[10896],[False],[0],[0],[False],['0']
28107,PMC5134798,5905,"In this study, the radial artery diameters were enlarged by this kind of simple and feasible method; it could be the reason for significant reduction in the number of attempts and improvement on first-pass success rate.",Discussion|Discussion,[35894],[10897],[11116],[False],[0],[0],[False],['0']
28108,PMC5134798,5906,"The proportion of difficult access procedures was reduced by UC too, it decreased from 10.92% to 4.61% at meantime.",Discussion|Discussion,[35898],[11117],[11232],[False],[0],[0],[False],['0']
28109,PMC5134798,5907,"These results suggest that “enlarging"" the radial artery by UC may have advantages in artery puncture over standard treatment, due to the small size of artery and discrimination limit of fingertip palpation.",Discussion|Discussion,[35902],[11233],[11440],[False],[0],[0],[False],['0']
28110,PMC5134798,5908,"UC is particularly useful in those patients with weak pulse caused by a small artery, a deep artery, or hypotension, which make palpation-guided access difficult.",Discussion|Discussion,[35906],[11441],[11603],[False],[0],[0],[False],['0']
28111,PMC5134798,5909,"There were a few incidences of puncture failure in both group patients, none in UC, and 3 cases in standard, P = 0.249.",Discussion|Discussion,[35910],[11604],[11723],[False],[0],[0],[False],['0']
28112,PMC5134798,5910,"The reason may be that the operators are all experienced in our study, if more operators were included, the successful rate of puncture would be different; however, the bigger diameter means the more easier for most operators, whatever the experienced one or the beginner.",Discussion|Discussion,[35914],[11724],[11996],[False],[0],[0],[False],['0']
28113,PMC5134798,5911,"As a matter of fact, the vascular access time may be a better issue that can represent the level of difficulty on artery puncture and sheath insertion; the duration may be longer in patients with several attempt puncture than those who were successful in the first time.",Discussion|Discussion,[35918],[11997],[12267],[False],[0],[0],[False],['0']
28114,PMC5134798,5912,"In this study, the vascular access time was shorter in the patients with half hour's ulnar artery compression than the others with standard treatment.",Discussion|Discussion,[35922],[12268],[12418],[False],[0],[0],[False],['0']
28115,PMC5134798,5913,"Failure of sheath insertion was reported rarely in both groups, 1 in UC and none in standard, P = 0.487, due to artery spasm, tortuosity, and needs to be crossover to another site (usually femoral); it could not be altered by the size of artery obviously.",Discussion|Discussion,[35926],[12419],[12674],[False],[0],[0],[False],['0']
28116,PMC5134798,5914,"There are concerns about whether a half-an-hour compression would have unfavorable impact on the ulnar artery, especially the possibility of thrombus forming.",Discussion|Discussion,[35930],[12675],[12833],[False],[0],[0],[False],['0']
28117,PMC5134798,5915,"Fortunately, there were no obvious changes in diameters of ulnar artery (2.30 ± 0.38 mm vs 2.31 ± 0.41 mm, P = 0.838).",Discussion|Discussion,[35934],[12834],[12952],[False],[0],[0],[False],['0']
28118,PMC5134798,5916,"Meanwhile, the safety of the method was verified, there was no thrombus case detected in this study, and there were no ischemic events on those patients too.",Discussion|Discussion,[35938],[12953],[13110],[False],[0],[0],[False],['0']
28119,PMC5134798,5917,It might be the effect of oral antiplatelet perioperative.,Discussion|Discussion,[35942],[13111],[13169],[False],[0],[0],[False],['0']
28120,PMC5134798,5918,"The findings of this study indicate that UC facilitated radial artery access as measured by the first-pass success rate, number of attempts, and time to access.",Discussion|Discussion,[35946],[13170],[13330],[False],[0],[0],[False],['0']
28121,PMC5134798,5919,UC is an efficacy and feasibility method that can improve the process of transradial catheterization.,Discussion|Discussion,[35950],[13331],[13432],[False],[0],[0],[False],['0']
28122,PMC5134798,5920,"In addition, the superficial course of the distal ulnar artery provides easy compression, even can be compressed by themselves, and the future is worth looking forward to.",Discussion|Discussion,[35954],[13433],[13604],[False],[0],[0],[False],['0']
28123,PMC5134798,5921,Study limitations,Discussion|Study limitations,[35958],[13605],[13622],[False],[0],[0],[False],['0']
28124,PMC5134798,5922,"This study is limited by its single-center study design; therefore, our findings should primarily be viewed as hypothesis generating.",Discussion|Study limitations,[35962],[13623],[13756],[True],['Unicentric'],['its single-center study design'],[True],['Setting']
28125,PMC5134798,5923,"Despite the use of an observer and the lab timer, we cannot exclude a bias in the performance, measurement, or recording of the procedure or clinical data.",Discussion|Study limitations,[35971],[13757],[13912],[True],['OutcomeMeasures'],"['cannot exclude a bias in the performance, measurement, or recording of the procedure or clinical data']",[True],['OutcomeMeasures']
28126,PMC5134798,5924,"The second, the open-label design may increase the possibility of bias.",Discussion|Study limitations,[35980],[13913],[13984],[True],['Blinding'],['the open-label design'],[True],['Blinding']
28127,PMC5134798,5925,"That is, patients or operators may be influenced by their knowledge of the procedure.",Discussion|Study limitations,[35989],[13985],[14070],[True],['Blinding'],['patients or operators may be influenced by their knowledge of the procedure'],[True],['Blinding']
28128,PMC5134798,5926,Acknowledgments,Acknowledgments,[35994],[14071],[14087],[False],[0],[0],[False],['0']
28129,PMC5134798,5927,The authors appreciate all subjects included in this study.,Acknowledgments,[35998],[14088],[14147],[False],[0],[0],[False],['0']
28130,PMC5134798,5928,"The authors are very much grateful to the staff from 12th Department of Cardiology, Beijing AnZhen Hospital.",Acknowledgments,[36002],[14148],[14256],[False],[0],[0],[False],['0']
28131,PMC5134798,5929,"Abbreviations: CA = coronary angiography, PCI = percutaneous coronary intervention, RRA = right radial artery, RUA = right ulnar artery, UC = ulnar artery compression.",Acknowledgments,[36006],[14257],[14424],[False],[0],[0],[False],['0']
28132,PMC5134798,5930,"This work was supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (code: ZYLX201303), National Key Clinical speciality Construction Project (2013-2014), and “Beijing Municipal Administration of Hospitals” Ascent Plan (Code: DFL20150601).",Acknowledgments,[36010],[14425],[14730],[False],[0],[0],[False],['0']
28133,PMC5134798,5931,The authors have no conflicts of interest to disclose.,Acknowledgments,[36014],[14731],[14785],[False],[0],[0],[False],['0']
29668,PMC5330033,34640,The search for the best infantry boot,Title,[202709],[38374],[37],[False],[0],[0],[False],['0']
29669,PMC5330033,34641,Background,Abstract,[202715],[38],[49],[False],[0],[0],[False],['0']
29670,PMC5330033,34642,The combat role of the twenty-first century infantry soldier has changed and accordingly their boots should evolve to meet these new needs and maximize soldier performance.,Abstract,[202721],[50],[222],[False],[0],[0],[False],['0']
29671,PMC5330033,34643,Objective,Objective,[202727],[223],[233],[False],[0],[0],[False],['0']
29672,PMC5330033,34644,To evaluate injuries and durability of the hot weather infantry boots (HWIB) in elite infantry training and assess the initial performance of newly designed Israeli infantry boots (NDIB).,Objective,[202733],[234],[421],[False],[0],[0],[False],['0']
29673,PMC5330033,34645,Methods,Methods,[202739],[422],[430],[False],[0],[0],[False],['0']
29674,PMC5330033,34646,"In Phase 1, the durability of the HWIB during elite infantry training was evaluated at weeks 10, 19 and 64 in a cohort of 67 recruits.",Methods,[202745],[431],[565],[False],[0],[0],[False],['0']
29675,PMC5330033,34647,At each exam recruits removed their boots which were assessed for wear and integrity and photographed.,Methods,[202751],[566],[668],[False],[0],[0],[False],['0']
29676,PMC5330033,34648,The number of times recruits changed their boots was recorded.,Methods,[202757],[669],[731],[False],[0],[0],[False],['0']
29677,PMC5330033,34649,"In Phase 2, foot injuries were assessed in a cohort of 73 elite infantry recruits wearing HWIB.",Methods,[202763],[732],[827],[False],[0],[0],[False],['0']
29678,PMC5330033,34650,"In Phase 3, 65 infantry recruits were issued the NDIB.",Methods,[202769],[828],[882],[False],[0],[0],[False],['0']
29679,PMC5330033,34651,Recruits feet were measured for width and shoe size using the Brannock device and then followed for problems associated with their boots.,Methods,[202775],[883],[1020],[False],[0],[0],[False],['0']
29680,PMC5330033,34652,Foot lesions were document by photographs.,Methods,[202781],[1021],[1063],[False],[0],[0],[False],['0']
29681,PMC5330033,34653,Results,Results,[202787],[1064],[1072],[False],[0],[0],[False],['0']
29682,PMC5330033,34654,"Phase 1: The mean longevity of HWIB in training was 5.2 ± 0.2 (SE) months, (95 % CI 4.83–5.61).",Results,[202793],[1073],[1168],[False],[0],[0],[False],['0']
29683,PMC5330033,34655,Phase 2: 38 % of the elite infantry recruits wearing HWIB had at least one complaint and 31 (42 %) were found to have boot related injuries in a total of 56 injured areas.,Results,[202799],[1169],[1340],[False],[0],[0],[False],['0']
29684,PMC5330033,34656,"Phase 3: The mean predicted boot size (42.8 ± 1.7) based on Brannock measurements, was less than the size of the NDIB actually worn, 43.1 ± 1.6.",Results,[202805],[1341],[1485],[False],[0],[0],[False],['0']
29685,PMC5330033,34657,Only 34.8 % of the feet were width D (the standard shoe width).,Results,[202811],[1486],[1549],[False],[0],[0],[False],['0']
29686,PMC5330033,34658,"At 9 day follow up, 55 of the 65 recruits who wore NDIB reported at least one problem with them (85 %, p < 0.0001, compared to HWIB).",Results,[202817],[1550],[1683],[False],[0],[0],[False],['0']
29687,PMC5330033,34659,"By 3 weeks, all but five recruits had returned to wearing the HWIB.",Results,[202823],[1684],[1751],[False],[0],[0],[False],['0']
29688,PMC5330033,34660,"Of the recruits wearing NDIB, 47 (72 %) were found to have had at least one boot related injury with a total number of 180 injured foot areas (p = 0.0004, compared to HWIB).",Results,[202829],[1752],[1925],[False],[0],[0],[False],['0']
29689,PMC5330033,34661,Conclusions,Conclusions,[202835],[1926],[1938],[False],[0],[0],[False],['0']
29690,PMC5330033,34662,The HWIB was well tolerated by the elite infantry recruits and associated with significantly less foot injuries than the NDIB.,Conclusions,[202841],[1939],[2065],[False],[0],[0],[False],['0']
29691,PMC5330033,34663,The longevity of the HWIB in demanding elite infantry training was five months.,Conclusions,[202847],[2066],[2145],[False],[0],[0],[False],['0']
29692,PMC5330033,34664," Trial registration: NCT02810002 retrospectively registered June 22, 2016",Conclusions,[202853],[2146],[2219],[False],[0],[0],[False],['0']
29693,PMC5330033,34665,Background,Background,[202859],[2220],[2232],[False],[0],[0],[False],['0']
29694,PMC5330033,34666,The operational tasks and logistics of modern infantry soldiers are constantly changing to accommodate to new combat needs.,Background,[202865],[2233],[2356],[False],[0],[0],[False],['0']
29695,PMC5330033,34667,Infantry soldiers are becoming increasingly specialized.,Background,[202871],[2357],[2413],[False],[0],[0],[False],['0']
29696,PMC5330033,34668,"They carry and operate more sophisticated weaponry, carry intelligence and communication systems and wear body armor [1].",Background,[202877],[2414],[2535],[False],[0],[0],[False],['0']
29697,PMC5330033,34669,Some of their traditional activities has been augmented or changed by technology.,Background,[202883],[2536],[2617],[False],[0],[0],[False],['0']
29698,PMC5330033,34670,Infantry boot design and materials should answer to these new needs so as to maximize soldier performance.,Background,[202889],[2618],[2724],[False],[0],[0],[False],['0']
29699,PMC5330033,34671,They need to be sufficiently comfortable so as not to interfere with training and combat activity.,Background,[202895],[2725],[2823],[False],[0],[0],[False],['0']
29700,PMC5330033,34672,To design infantry boots optimal for all infantry soldiers in all of their training and combat conditions is a challenge.,Background,[202901],[2824],[2945],[False],[0],[0],[False],['0']
29701,PMC5330033,34673,"General factors that need to be considered in boot design include: comfort, weight, water resistance, breathability, traction, durability, foot anatomy, foot protection, operational climate and cost.",Background,[202907],[2946],[3145],[False],[0],[0],[False],['0']
29702,PMC5330033,34674,A partial solution to these variables in the United States Army has been achieved by issuing separate 2 lb.,Background,[202913],[3146],[3253],[False],[0],[0],[False],['0']
29703,PMC5330033,34675,(0.9 kg) hot weather and 2.5 lb.,Background,[202919],[3254],[3286],[False],[0],[0],[False],['0']
29704,PMC5330033,34676,(1.1 kg) temperate weather boots to their soldiers.,Background,[202925],[3287],[3338],[False],[0],[0],[False],['0']
29705,PMC5330033,34677,Several years ago the Israel Defense Forces (IDF) Technological and Logistics Branch (TLB) changed the standard army boots in an attempt to answer the changing needs of their infantry soldiers.,Background,[202931],[3339],[3532],[False],[0],[0],[False],['0']
29706,PMC5330033,34678,"The bilayer rubber sole boots manufactured on lasts designed by the IDF in the 1990s [2] was replaced with the hot weather infantry boots (HWIB) used by the US Army and, manufactured in the USA.",Background,[202937],[3533],[3727],[False],[0],[0],[False],['0']
29707,PMC5330033,34679,The US HWIB are not traditional army boots and have features that are borrowed from athletic shoes.,Background,[202943],[3728],[3827],[False],[0],[0],[False],['0']
29708,PMC5330033,34680,The uppers are made of both soft leather and nylon.,Background,[202949],[3828],[3879],[False],[0],[0],[False],['0']
29709,PMC5330033,34681,"The sole is bilayer, with an inner layer of polyurethane and an outer covering of rubber for good shock absorption and traction with low weight [3, 4].",Background,[202955],[3880],[4031],[False],[0],[0],[False],['0']
29710,PMC5330033,34682,The boot has removable inserts.,Background,[202961],[4032],[4063],[False],[0],[0],[False],['0']
29711,PMC5330033,34683,These features make the boot lighter and more comfortable than traditionally designed military boots and more akin to a high top athletic shoe in its properties [5].,Background,[202967],[4064],[4229],[False],[0],[0],[False],['0']
29712,PMC5330033,34684,"Based on their experience with IDF soldiers, an Israeli manufacturer designed new boots on a new last using bilayer rubber soles (NDIB).",Background,[202973],[4230],[4366],[False],[0],[0],[False],['0']
29713,PMC5330033,34685,They intended their boot to serve the needs of the IDF soldiers better than the HWIB both in durability and comfort.,Background,[202979],[4367],[4483],[False],[0],[0],[False],['0']
29714,PMC5330033,34686,"After several years of successful use of the HWIB, the IDF decided to evaluate the durability of the boots in a field study (Phase 1) and in Phase 2 assess the foot injuries associated with HWIB use.",Background,[202985],[4484],[4683],[False],[0],[0],[False],['0']
29715,PMC5330033,34687,"Phase 3 was designed to compare the HWIB with the NDIB for comfort, injuries and durability.",Background,[202991],[4684],[4776],[False],[0],[0],[False],['0']
29716,PMC5330033,34688,We report the results of these three studies.,Background,[202997],[4777],[4822],[False],[0],[0],[False],['0']
29717,PMC5330033,34689,Methods,Methods,[203003],[4823],[4831],[False],[0],[0],[False],['0']
29718,PMC5330033,34690,Phase 1: Durability study of the HWIB,Methods,[203009],[4832],[4869],[False],[0],[0],[False],['0']
29719,PMC5330033,34691,Table 1 Specifications of military boots worn in trials.,Methods,[203015],[4870],[4926],[False],[0],[0],[False],['0']
29720,PMC5330033,34692,"This study was an observational, long term prospective study of the durability of the HWIB supplied to the IDF by the Belleville Boot Company (Belleville IL, USA).",Methods,[203021],[4927],[5090],[False],[0],[0],[False],['0']
29721,PMC5330033,34693,"Its design was based on their 390 Trop St, with adaptations according to IDF TLB-specifications.",Methods,[203027],[5091],[5187],[False],[0],[0],[False],['0']
29722,PMC5330033,34694,Elite infantry recruits (n = 67) who began their basic training in 2013 were enrolled in the study.,Methods,[203033],[5188],[5287],[False],[0],[0],[False],['0']
29723,PMC5330033,34695,"Their mean age was 19.5 ± 0.9, weight 75.2 ± 7.2 kg, and boot size 43.6 ± 1.5.",Methods,[203039],[5288],[5366],[False],[0],[0],[False],['0']
29724,PMC5330033,34696,Prior to beginning their basic training subjects had a general orthopaedic exam to determine that they had no orthopaedic abnormalities that might cause abnormal wear of their boots.,Methods,[203045],[5367],[5549],[False],[0],[0],[False],['0']
29725,PMC5330033,34697,"All data were recorded in a laptop computer using a custom designed Access® (Microsoft, Redmond WA) application.",Methods,[203051],[5550],[5662],[False],[0],[0],[False],['0']
29726,PMC5330033,34698,Each recruit was issued two pairs of HWIB before beginning basic training.,Methods,[203057],[5663],[5737],[False],[0],[0],[False],['0']
29727,PMC5330033,34699,"Recruits were examined at the first week of basic training and at weeks 10, 19 and 64 of training.",Methods,[203063],[5738],[5836],[False],[0],[0],[False],['0']
29728,PMC5330033,34700,At each exam recruits removed their boots to allow inspection of their boots.,Methods,[203069],[5837],[5914],[False],[0],[0],[False],['0']
29729,PMC5330033,34701,The boots were assessed for boot sole and upper wear and integrity.,Methods,[203075],[5915],[5982],[False],[0],[0],[False],['0']
29730,PMC5330033,34702,Boots were photographed to document their condition.,Methods,[203081],[5983],[6035],[False],[0],[0],[False],['0']
29731,PMC5330033,34703,The physical characteristics of the HWIB worn in Phase 1 to 3 of the study and the NDIB used in Phase 3 of the study are shown in Table 1.,Methods,[203087],[6036],[6174],[False],[0],[0],[False],['0']
29732,PMC5330033,34704,"At each review recruits were questioned whether they were still using their originally issued boots, and if not how many times they had changed boots.",Methods,[203093],[6175],[6325],[False],[0],[0],[False],['0']
29733,PMC5330033,34705,A recruit whose boots were worn out or needed a size change presented his boots to the base non-commissioned officer (NCO) in charge of boot logistics.,Methods,[203099],[6326],[6477],[False],[0],[0],[False],['0']
29734,PMC5330033,34706,"If the NCO agreed that the boots required changing, the damaged boots were sent to a central supply unit for exchange.",Methods,[203105],[6478],[6596],[False],[0],[0],[False],['0']
29735,PMC5330033,34707,The recruit then began to use his reserve pair of boots.,Methods,[203111],[6597],[6653],[False],[0],[0],[False],['0']
29736,PMC5330033,34708,Receiving new boots takes approximately 4 weeks.,Methods,[203117],[6654],[6702],[False],[0],[0],[False],['0']
29737,PMC5330033,34709,Data is presented per boot except where explicitly stated that data refers to pairs of boots.,Methods,[203123],[6703],[6796],[False],[0],[0],[False],['0']
29738,PMC5330033,34710,Phase 2: Assessment of foot injuries associated with the HWIB,Methods,[203129],[6797],[6860],[False],[0],[0],[False],['0']
29739,PMC5330033,34711,"Assessment of complaints and foot injuries associated with HWIB was performed in a company of 75 elite infantry recruits at weeks 4, 10 and 14 of infantry basic training.",Methods,[203135],[6861],[7031],[False],[0],[0],[False],['0']
29740,PMC5330033,34712,All recruits were questioned about foot problems.,Methods,[203141],[7032],[7081],[False],[0],[0],[False],['0']
29741,PMC5330033,34713,All recruits removed their shoes and socks and foot lesions were documented.,Methods,[203147],[7082],[7158],[False],[0],[0],[False],['0']
29742,PMC5330033,34714,Recruits were also reviewed for overuse injuries.,Methods,[203153],[7159],[7208],[False],[0],[0],[False],['0']
29743,PMC5330033,34715,Phase 3: Comparison of the HWIB with the NDIB,Phase 2: Assessment of foot injuries associated with the HWIB,[203159],[7209],[7255],[False],[0],[0],[False],['0']
29744,PMC5330033,34716,The HWIB that recruits used in Phase 3 were identical to those described in Phase 1.,Phase 2: Assessment of foot injuries associated with the HWIB,[203165],[7256],[7340],[False],[0],[0],[False],['0']
29745,PMC5330033,34717,"The NDIB used in Phase 3 were designed and manufactured especially for this study by Brill Shoe Industries Ltd (Rishon LeZion, Israel).",Phase 2: Assessment of foot injuries associated with the HWIB,[203171],[7341],[7476],[False],[0],[0],[False],['0']
29746,PMC5330033,34718,The overall assessment of the NDIB was planned and directed by the TLB and designed to encompass 5 infantry recruit companies inducted in August 2014.,Phase 2: Assessment of foot injuries associated with the HWIB,[203177],[7477],[7627],[False],[0],[0],[False],['0']
29747,PMC5330033,34719,All recruits were issued 2 pairs of HWIB at induction before they assembled in their infantry training base.,Phase 2: Assessment of foot injuries associated with the HWIB,[203183],[7628],[7736],[False],[0],[0],[False],['0']
29748,PMC5330033,34720,In the study design two recruit companies were scheduled to receive NDIB at week 2 of their basic training and two companies were to remain training in their already issued HWIB.,Phase 2: Assessment of foot injuries associated with the HWIB,[203189],[7737],[7915],[False],[0],[0],[False],['0']
29749,PMC5330033,34721,"An additional elite infantry company was scheduled for a randomized controlled trial (RCT), recruits being individually randomly assigned to either NDIB or HWIB.",Phase 2: Assessment of foot injuries associated with the HWIB,[203195],[7916],[8077],[False],[0],[0],[False],['0']
29750,PMC5330033,34722,The recruits in the elite infantry company were to be followed clinically during their basic training by a team of orthopaedists.,Phase 2: Assessment of foot injuries associated with the HWIB,[203201],[8078],[8207],[False],[0],[0],[False],['0']
29751,PMC5330033,34723,IDF institutional review board approval and written informed consent by the recruits in the elite company was required for participation in the study (the other 4 companies were not exposed to any medical procedure and were therefore exempt from IRB approval as in all studies on equipment comfort and longevity performed by the TLB without participation of medical personnel).,Phase 2: Assessment of foot injuries associated with the HWIB,[203207],[8208],[8585],[False],[0],[0],[False],['0']
29752,PMC5330033,34724,"Before beginning their training, consenting recruits of the elite company had measurements of weight and height.",Phase 2: Assessment of foot injuries associated with the HWIB,[203213],[8586],[8698],[False],[0],[0],[False],['0']
29753,PMC5330033,34725,"Foot length and width measurements were made bilaterally using a Brannock measuring device (Brannock Device Company, Liverpool, NY, USA).",Phase 2: Assessment of foot injuries associated with the HWIB,[203219],[8699],[8836],[False],[0],[0],[False],['0']
29754,PMC5330033,34726,This device measures the appropriate American shoe size (size 4 to 16) based on foot length.,Phase 2: Assessment of foot injuries associated with the HWIB,[203225],[8837],[8929],[False],[0],[0],[False],['0']
29755,PMC5330033,34727,"Shoe widths are measured 3A, 2A, A.",Phase 2: Assessment of foot injuries associated with the HWIB,[203231],[8930],[8965],[False],[0],[0],[False],['0']
29756,PMC5330033,34728,"B, C, D, E, 2E and 3E, progressing from the narrowest to the widest foot.",Phase 2: Assessment of foot injuries associated with the HWIB,[203237],[8966],[9039],[False],[0],[0],[False],['0']
29757,PMC5330033,34729,For the same shoe size each increase of shoe width corresponds to a 3/16 inch increase in foot width.,Phase 2: Assessment of foot injuries associated with the HWIB,[203243],[9040],[9141],[False],[0],[0],[False],['0']
29758,PMC5330033,34730,The American shoe size numbers were converted to their corresponding European numbers using standard conversion formulas.,Phase 2: Assessment of foot injuries associated with the HWIB,[203249],[9142],[9263],[False],[0],[0],[False],['0']
29759,PMC5330033,34731,Recruits in the elite company were questioned regarding use of the experimental boots allowing for up to 5 complaints.,Phase 2: Assessment of foot injuries associated with the HWIB,[203255],[9264],[9382],[False],[0],[0],[False],['0']
29760,PMC5330033,34732,Recruits’ feet were examined and findings recorded directly to the Access® application.,Phase 2: Assessment of foot injuries associated with the HWIB,[203261],[9383],[9470],[False],[0],[0],[False],['0']
29761,PMC5330033,34733,Statistical analysis,Statistical analysis,[203267],[9471],[9492],[False],[0],[0],[False],['0']
29762,PMC5330033,34734,"Table 2 Cumulative HWIB damage observed on inspections at 10, 19 and 64 weeks of training.",Statistical analysis,[203273],[9493],[9583],[False],[0],[0],[False],['0']
29763,PMC5330033,34735,"For Phase 1, data of HWIB damage was collected on weeks 10, 19 and 64 and were analyzed per boot and per pair.",Statistical analysis,[203279],[9584],[9694],[False],[0],[0],[False],['0']
29764,PMC5330033,34736,Data presented in Table 2 relate to the number of boots affected with the type of damage noted for the total number of single boots evaluated in the three visits.,Statistical analysis,[203285],[9695],[9857],[False],[0],[0],[False],['0']
29765,PMC5330033,34737,"The longevity of the boots was calculated based on the total number of pairs of boots that had to be replaced, taking into account the use of the spare pair and also the condition of the present pair of boots (if they were seriously damaged they were counted as replaced).",Statistical analysis,[203291],[9858],[10130],[False],[0],[0],[False],['0']
29766,PMC5330033,34738,"Survival analysis was performed with PROC LIFETEST in SAS using the latest known data, censoring at the time of the latest follow-up if no failure had occurred.",Statistical analysis,[203297],[10131],[10291],[False],[0],[0],[False],['0']
29767,PMC5330033,34739,"Each failure was entered as a separate observation, timed by the number of failures per follow-up time.",Statistical analysis,[203303],[10292],[10395],[False],[0],[0],[False],['0']
29768,PMC5330033,34740,For Phases 2 and 3 up to 5 fields of complaints and/or findings were coded.,Statistical analysis,[203309],[10396],[10472],[False],[0],[0],[False],['0']
29769,PMC5330033,34741,Complaints not related to the boots (e.g.,Statistical analysis,[203315],[10473],[10514],[False],[0],[0],[False],['0']
29770,PMC5330033,34742,"back pain, knee pain) were not included.",Statistical analysis,[203321],[10515],[10555],[False],[0],[0],[False],['0']
29771,PMC5330033,34743,Overall complaints (not recruits) are summarized in the tables.,Statistical analysis,[203327],[10556],[10619],[False],[0],[0],[False],['0']
29772,PMC5330033,34744,The physical examination was encoded on a dedicated Access® sheet with 20 separate areas for each foot.,Statistical analysis,[203333],[10620],[10723],[False],[0],[0],[False],['0']
29773,PMC5330033,34745,"Injuries were classified for each area as none, abrasion, blister, callous, hematoma, redness or wound, with more than one classification possible.",Statistical analysis,[203339],[10724],[10871],[False],[0],[0],[False],['0']
29774,PMC5330033,34746,Findings in the recruits wearing NDIB that were clearly in the recovery phase (and therefore from before initiation of wearing the NDIB) were disqualified.,Statistical analysis,[203345],[10872],[11027],[False],[0],[0],[False],['0']
29775,PMC5330033,34747,Comparison of groups was for total recruits with at least one complaint or at least one finding was estimated with Chi squares (complaints and finding separately).,Statistical analysis,[203351],[11028],[11191],[False],[0],[0],[False],['0']
29776,PMC5330033,34748,Results,Results,[203357],[11192],[11200],[False],[0],[0],[False],['0']
29777,PMC5330033,34749,Phase 1,Results,[203363],[11201],[11208],[False],[0],[0],[False],['0']
29778,PMC5330033,34750,Fig.,Results,[203369],[11209],[11213],[False],[0],[0],[False],['0']
29779,PMC5330033,34751,1 Damage to the heel counter of the HWIB.,Results,[203375],[11214],[11255],[False],[0],[0],[False],['0']
29780,PMC5330033,34752,Fig.,Results,[203381],[11256],[11260],[False],[0],[0],[False],['0']
29781,PMC5330033,34753,2 Delamination between the outer rubber and inner polyurethane layers of the HWIB sole.,Results,[203387],[11261],[11348],[False],[0],[0],[False],['0']
29782,PMC5330033,34754,"HWIB were examined at 10, 19 and 64 weeks of training.",Results,[203393],[11349],[11403],[False],[0],[0],[False],['0']
29783,PMC5330033,34755,"Sixty-four pairs of boots were examined at 10 weeks, 65 pairs at 19 weeks and 45 pairs at 64 weeks of training.",Results,[203399],[11404],[11515],[False],[0],[0],[False],['0']
29784,PMC5330033,34756,"The mean longevity of a pair of boots during the training was 5.2 ± 0.2 (SE) months, (95 % CI 4.83–5.61).",Results,[203405],[11516],[11621],[False],[0],[0],[False],['0']
29785,PMC5330033,34757,Table 2 shows the summary of the major boot damage observed at the three observation points during the training.,Results,[203411],[11622],[11734],[False],[0],[0],[False],['0']
29786,PMC5330033,34758,Figure 1 shows an example of a tear in the hind foot region of the boot.,Results,[203417],[11735],[11807],[False],[0],[0],[False],['0']
29787,PMC5330033,34759,Figure 2 shows delamination between the outer rubber and inner polyurethane of the sole.,Results,[203423],[11808],[11896],[False],[0],[0],[False],['0']
29788,PMC5330033,34760,Phase 2,Results,[203429],[11897],[11907],[False],[0],[0],[False],['0']
29789,PMC5330033,34761,"Of the 75 elite infantry recruits in the company, 73 were questioned and examined.",Results,[203435],[11908],[11990],[False],[0],[0],[False],['0']
29790,PMC5330033,34762,Twenty-eight (38 %) reported HWIB related problems at the four week follow-up.,Results,[203441],[11991],[12069],[False],[0],[0],[False],['0']
29791,PMC5330033,34763,Twenty-three reported one HWIB related problem and 5 reported two problems.,Results,[203447],[12070],[12145],[False],[0],[0],[False],['0']
29792,PMC5330033,34764,"On the basis of physical examination thirty-one (42 %) were found to have at least one boot related injury with a total number of 56 injured areas, 0.77 per recruit.",Results,[203453],[12146],[12311],[False],[0],[0],[False],['0']
29793,PMC5330033,34765,Phase 3,Phase 2,[203459],[12312],[12320],[False],[0],[0],[False],['0']
29794,PMC5330033,34766,All five of the study companies received the HWIB at the time of their induction prior to assembling on their basic training base.,Phase 2,[203465],[12321],[12451],[False],[0],[0],[False],['0']
29795,PMC5330033,34767,"According the IRB approved protocol, 98 recruits in the elite infantry company were explained the study details on the Friday of their first week on the base, following which they were given leave home and given an opportunity to consult their family about participating in the study.",Phase 2,[203471],[12452],[12736],[False],[0],[0],[False],['0']
29796,PMC5330033,34768,On their return to base on Sunday they were requested to sign informed consent.,Phase 2,[203477],[12737],[12816],[False],[0],[0],[False],['0']
29797,PMC5330033,34769,"Eighteen declined to participate, 79 (81 %) agreed to participate and one was not present because of sick leave.",Phase 2,[203483],[12817],[12929],[False],[0],[0],[False],['0']
29798,PMC5330033,34770,"The recruits were available for their anthropometric measurements for only 2 h including a supper break, instead of the scheduled 5 h but measurements of height, weight and foot length and width were completed for all recruits.",Phase 2,[203489],[12930],[13157],[False],[0],[0],[False],['0']
29799,PMC5330033,34771,Table 3 Number of recruits per European shoe size and width converted from measurements using the Brannock device.,Phase 2,[203495],[13158],[13272],[False],[0],[0],[False],['0']
29800,PMC5330033,34772,"The mean age of the recruits who participated in the study from the elite infantry company was 19.4 ± 1.3, their mean height was 174 ± 5.7 cm and their mean weight 70.4 ± 11.1 kg.",Phase 2,[203501],[13273],[13452],[False],[0],[0],[False],['0']
29801,PMC5330033,34773,Table 3 shows the distribution of recruit boot sizes and widths as measured by the Brannock device for these recruits.,Phase 2,[203507],[13453],[13571],[False],[0],[0],[False],['0']
29802,PMC5330033,34774,The mean predicted boot size from the Brannock measurements when converted to European size was size 42.8 ± 1.7.,Phase 2,[203513],[13572],[13684],[False],[0],[0],[False],['0']
29803,PMC5330033,34775,The mean boot size actually worn by recruits was 43.1 ± 1.6.,Phase 2,[203519],[13685],[13745],[False],[0],[0],[False],['0']
29804,PMC5330033,34776,"24.7 % of the feet were width B, 32.5 % of the feet were width C, 34.8 % were width D (the standard shoe width) and 7.9 % width E. Table 3 summarizes the distribution of the measured boot sizes and widths.",Phase 2,[203525],[13746],[13951],[False],[0],[0],[False],['0']
29805,PMC5330033,34777,"The morning after recruits signed informed consent, boots were distributed.",Phase 2,[203531],[13952],[14028],[False],[0],[0],[False],['0']
29806,PMC5330033,34778,The elite infantry company officers did not agree to a randomized distribution of boots to their recruits.,Phase 2,[203537],[14029],[14135],[False],[0],[0],[False],['0']
29807,PMC5330033,34779,Instead all those recruits in the elite infantry company who agreed to participate were issued NDIB.,Phase 2,[203543],[14136],[14236],[False],[0],[0],[False],['0']
29808,PMC5330033,34780,"Additionally, because of a problem of boot sizes there were only enough NDIB to supply one additional non-randomized company.",Phase 2,[203549],[14237],[14362],[False],[0],[0],[False],['0']
29809,PMC5330033,34781,For these logistic reasons the initial study protocol could not be fulfilled and accordingly needed to be modified.,Phase 2,[203555],[14363],[14478],[False],[0],[0],[False],['0']
29810,PMC5330033,34782,"Because of early reports that a number of recruits training with the NDIB were complaining about the boots, the initial scheduled orthopaedic follow up of the elite infantry company was done 9 days after the boot distribution instead of at 3 weeks as originally planned.",Phase 2,[203561],[14479],[14749],[False],[0],[0],[False],['0']
29811,PMC5330033,34783,All recruits filled out a questionnaire relating to the comfort and problems with their boots.,Phase 2,[203567],[14750],[14844],[False],[0],[0],[False],['0']
29812,PMC5330033,34784,Table 4 The recruits’ complaints associated with wearing NDIB in Phase 3 of the study with HWIB in Phase 2 of the study.,Phase 2,[203573],[14845],[14965],[False],[0],[0],[False],['0']
29813,PMC5330033,34785,Of the 79 recruits who agreed to participate in the study only 65 actually ever wore the NDIB and were available for follow-up.,Phase 2,[203579],[14966],[15093],[False],[0],[0],[False],['0']
29814,PMC5330033,34786,At the 9 day follow-up twelve recruits who had started to use the NDIB had already discontinued their use.,Phase 2,[203585],[15094],[15200],[False],[0],[0],[False],['0']
29815,PMC5330033,34787,Twenty-eight out of 65 recruits reported one problem with the NDIB.,Phase 2,[203591],[15201],[15268],[False],[0],[0],[False],['0']
29816,PMC5330033,34788,Twenty-two reported 2 problems.,Phase 2,[203597],[15269],[15300],[False],[0],[0],[False],['0']
29817,PMC5330033,34789,Three reported 3 problems and one reported 4 problems associated with boots.,Phase 2,[203603],[15301],[15377],[False],[0],[0],[False],['0']
29818,PMC5330033,34790,"The specific recruit complaints of the NDIB group in Phase 3 of the study, compared with those of recruits wearing the HWIB in Phase 2 of the study are presented in Table 4.",Phase 2,[203609],[15378],[15551],[False],[0],[0],[False],['0']
29819,PMC5330033,34791,"The number of recruits who reported problems with their shoes was significantly higher among soldiers who wore the NDIB, 55/65 (85 %), than among those who wore the HWIB, 28/73 (38 %), (p < 0.0001), Chi square).",Phase 2,[203615],[15552],[15763],[False],[0],[0],[False],['0']
29820,PMC5330033,34792,Fig.,Phase 2,[203621],[15764],[15769],[False],[0],[0],[False],['0']
29821,PMC5330033,34793,3 Heel lesion of recruit wearing NDIB.,Phase 2,[203627],[15770],[15808],[False],[0],[0],[False],['0']
29822,PMC5330033,34794,Fig.,Phase 2,[203633],[15809],[15813],[False],[0],[0],[False],['0']
29823,PMC5330033,34795,4 1st metarsophealngeal lesion of recruit wearing NDIB.,Phase 2,[203639],[15814],[15869],[False],[0],[0],[False],['0']
29824,PMC5330033,34796,Fig.,Phase 2,[203645],[15870],[15874],[False],[0],[0],[False],['0']
29825,PMC5330033,34797,5 Posterior heel blister of recruit wearing NDIB.,Phase 2,[203651],[15875],[15924],[False],[0],[0],[False],['0']
29826,PMC5330033,34798,The feet of all recruits were examined for skin irritation and wounds.,Phase 2,[203657],[15925],[15995],[False],[0],[0],[False],['0']
29827,PMC5330033,34799,Photographs were taken of all observed skin lesions.,Phase 2,[203663],[15996],[16048],[False],[0],[0],[False],['0']
29828,PMC5330033,34800,"Figures 3, 4, 5 show representative lesions found: Fig.",Phase 2,[203669],[16049],[16104],[False],[0],[0],[False],['0']
29829,PMC5330033,34801,3: a calcaneal lesion (wound); Fig.,Phase 2,[203675],[16105],[16140],[False],[0],[0],[False],['0']
29830,PMC5330033,34802,4: a 1st metatarsophalangeal joint lesion (redness); Fig.,Phase 2,[203681],[16141],[16198],[False],[0],[0],[False],['0']
29831,PMC5330033,34803,5: a posterior heel lesion (blister).,Phase 2,[203687],[16199],[16236],[False],[0],[0],[False],['0']
29832,PMC5330033,34804,Fig.,Phase 2,[203693],[16237],[16244],[False],[0],[0],[False],['0']
29833,PMC5330033,34805,6 Foot lesion comparison associated with wearing the HWIB (Phase 2) and the NDIB (Phase 3).,Phase 2,[203699],[16245],[16336],[False],[0],[0],[False],['0']
29834,PMC5330033,34806,Fig.,Phase 2,[203705],[16337],[16341],[False],[0],[0],[False],['0']
29835,PMC5330033,34807,7 Graphic presentation of the foot lesions in Fig.,Phase 2,[203711],[16342],[16392],[False],[0],[0],[False],['0']
29836,PMC5330033,34808,6 according to their anatomic location.,Phase 2,[203717],[16393],[16432],[False],[0],[0],[False],['0']
29837,PMC5330033,34809,"HWIB indicates the hot weather infantry boot, NDIB indicates the new design infantry boot.",Phase 2,[203723],[16433],[16523],[False],[0],[0],[False],['0']
29838,PMC5330033,34810,"Areas classified were (left to right): plantar 5th toe, plantar 2nd to 4th toe, plantar 1st toe, plantar metatarsal heads 2–5, plantar 1st metatarsal head, medial bunion, plantar midfoot, arch, plantar heel, lateral malleolus, anterior ankle, medial malleolus, upper forefoot, upper 2nd to 5th metatarsals, upper 1st metatarsal, upper 5th toe, upper 2nd to 4th toe, upper 1st toe, upper and lower Achilles tendon.",Phase 2,[203729],[16524],[16937],[False],[0],[0],[False],['0']
29839,PMC5330033,34811,Figure 6 shows a comparison of the types of foot lesions identified on physical examination associated with wearing the HWIB in Phase 2 of the study (inner doughnut of the figure) with wearing the NDIB in Phase 3 of the study (outer doughnut of the figure).,Phase 2,[203735],[16938],[17195],[False],[0],[0],[False],['0']
29840,PMC5330033,34812,"Forty-seven of the 65 recruits (72 %) wearing NDIB had at least one boot related injury with a total number of 180 injured areas of the foot, compared to 31/73 (42 %) with at least one boot related injury and a total number of 56 injured areas of recruits wearing HWIB, (p = 0.0004, Chi square per recruits with at least one injury).",Phase 2,[203741],[17196],[17529],[False],[0],[0],[False],['0']
29841,PMC5330033,34813,Figure 7 graphically illustrates the anatomical sites of the foot injuries presented in Fig.,Phase 2,[203747],[17530],[17622],[False],[0],[0],[False],['0']
29842,PMC5330033,34814,6.,Phase 2,[203753],[17623],[17625],[False],[0],[0],[False],['0']
29843,PMC5330033,34815,"Because of the lesions noted in the review and the multitude of complaints, it was decided to allow all recruits to return to training with the HWIB if they wished to do so.",Phase 2,[203759],[17626],[17801],[False],[0],[0],[False],['0']
29844,PMC5330033,34816,Recruits in the second company issued the NDIB were given the option to wear the boot a few days later than the elite infantry company.,Phase 2,[203765],[17802],[17937],[False],[0],[0],[False],['0']
29845,PMC5330033,34817,"By this time, the experience of the first company had already filtered through to the second company.",Phase 2,[203771],[17938],[18039],[False],[0],[0],[False],['0']
29846,PMC5330033,34818,Most of the recruits in the second company did not try the boots (a few tried them and quickly returned to the HWIB).,Phase 2,[203777],[18040],[18157],[False],[0],[0],[False],['0']
29847,PMC5330033,34819,At the 5 weeks follow-up only 5 recruits (7.7 %) in the elite infantry company remained training in the NDIB.,Phase 2,[203783],[18158],[18267],[False],[0],[0],[False],['0']
29848,PMC5330033,34820,"No complaints of boot problems were reported by any of the control soldiers wearing the HWIB, but their feet were not examined systematically due to the restrictions of our IRB approval and the inability to randomize the volunteers in the company due to the officers’ objection.",Phase 2,[203789],[18268],[18546],[False],[0],[0],[False],['0']
29849,PMC5330033,34821,Discussion,Discussion,[203795],[18547],[18558],[False],[0],[0],[False],['0']
29850,PMC5330033,34822,"In spite of marked methodological flaws, several clear conclusions can be drawn from this study.",Discussion,[203801],[18559],[18655],[False],[0],[0],[False],['0']
29851,PMC5330033,34823,The HWIB was found to be preferable by elite infantry recruits to the NDIB during their basic training which was in the warm weather.,Discussion,[203807],[18656],[18789],[False],[0],[0],[False],['0']
29852,PMC5330033,34824,Recruits training with the NDIB had a high number of foot problems associated with their boots from the beginning of their basic training.,Discussion,[203813],[18790],[18928],[False],[0],[0],[False],['0']
29853,PMC5330033,34825,The HWIB needed to be changed about every five months during elite infantry training because of wear and tear.,Discussion,[203819],[18929],[19039],[False],[0],[0],[False],['0']
29854,PMC5330033,34826,According to ongoing IDF TLB surveillance of boot returns due to wear and tear indicate HWIB worn by regular infantry soldiers have a boot life of about 10 months.,Discussion,[203825],[19040],[19203],[False],[0],[0],[False],['0']
29855,PMC5330033,34827,The HWIB represent a change from the traditional IDF infantry boots which are all seasonal.,Discussion,[203831],[19204],[19295],[False],[0],[0],[False],['0']
29856,PMC5330033,34828,The HWIB has an upper made from soft leather interspaced with nylon pieces.,Discussion,[203837],[19296],[19371],[False],[0],[0],[False],['0']
29857,PMC5330033,34829,This makes it breathable and light.,Discussion,[203843],[19372],[19407],[False],[0],[0],[False],['0']
29858,PMC5330033,34830,The soft upper construction also makes it maximally comfortable when first worn.,Discussion,[203849],[19408],[19488],[False],[0],[0],[False],['0']
29859,PMC5330033,34831,Traditional IDF boots are made of hard leather which is highly durable and protective but uncomfortable until the boot is “broken in” after some weeks of use.,Discussion,[203855],[19489],[19647],[False],[0],[0],[False],['0']
29860,PMC5330033,34832,"Another factor contributing to the light weight of the HWIB is its sole made from a sandwich of an inner layer of polyurethane for shock absorption and low weight [4] covered by an outer protective rubber layer, much like an athletic shoe.",Discussion,[203861],[19648],[19887],[False],[0],[0],[False],['0']
29861,PMC5330033,34833,These features make the HWIB more like a high top athletic shoe than a military boot.,Discussion,[203867],[19888],[19973],[False],[0],[0],[False],['0']
29862,PMC5330033,34834,It is therefore inherently more comfortable and better suited to running and lateral movement than the standard army boot.,Discussion,[203873],[19974],[20096],[False],[0],[0],[False],['0']
29863,PMC5330033,34835,"Each additional 100 g of shoe weight increases wearer physiological energy expenditure during walking by between 7/10ths of a percent to 1 % [6, 7].",Discussion,[203879],[20097],[20245],[False],[0],[0],[False],['0']
29864,PMC5330033,34836,Therefore the energy expenditure of a soldier wearing the NDIB is about 2 % higher than if he were wearing the HWIB.,Discussion,[203885],[20246],[20362],[False],[0],[0],[False],['0']
29865,PMC5330033,34837,A downside of the hot weather boot is its lower durability and protection against local trauma.,Discussion,[203891],[20363],[20458],[False],[0],[0],[False],['0']
29866,PMC5330033,34838,The current study did not directly compare the durability of the HWIB with the NDIB.,Discussion,[203897],[20459],[20543],[True],['RelevantOutcomeExcluded'],['did not directly compare the durability of the HWIB with the NDIB'],[True],['OutcomeMeasures']
29867,PMC5330033,34839,"The durability of the HWIB however can be compared with its predecessor in the IDF, the bilayer rubber–rubber sole boot, which has been monitored in a previous study in the same elite infantry basic training by the authors [2], though not yet reported.",Discussion,[203909],[20544],[20796],[False],[0],[0],[False],['0']
29868,PMC5330033,34840,That boot has the same sole composition and the same thick hard leather as the NDIB.,Discussion,[203915],[20797],[20881],[False],[0],[0],[False],['0']
29869,PMC5330033,34841,"Survival analysis shows that at the end of 14 weeks of training, 67 % of HWIB needed replacement because of shoe damage as compared with 9 % of the bilayer rubber–rubber IDF boot (p < 0.0001, Chi square).",Discussion,[203921],[20882],[21086],[False],[0],[0],[False],['0']
29870,PMC5330033,34842,"Another downside of the HWIB is that it was specifically designed for hot weather use and not for cold, wet weather use.",Discussion,[203927],[21087],[21207],[False],[0],[0],[False],['0']
29871,PMC5330033,34843,The HWIB performance in the cold weather was not evaluated in the current study and needs to be done.,Discussion,[203934],[21208],[21309],[True],['Generalization'],['The HWIB performance in the cold weather was not evaluated'],[True],['Generalization']
29872,PMC5330033,34844,An infantry soldier in the IDF serves 3 years in compulsory service.,Discussion,[203945],[21310],[21378],[False],[0],[0],[False],['0']
29873,PMC5330033,34845,After that he is subject to reserve army service for the next 15 or more years.,Discussion,[203951],[21379],[21458],[False],[0],[0],[False],['0']
29874,PMC5330033,34846,While in compulsory service the soldier has two pairs of boots.,Discussion,[203957],[21459],[21522],[False],[0],[0],[False],['0']
29875,PMC5330033,34847,After finishing compulsory service an infantry soldier is discharged with a single pair of boots for use in subsequent reserve service.,Discussion,[203963],[21523],[21658],[False],[0],[0],[False],['0']
29876,PMC5330033,34848,"For reserve service, boots need to have a long shelf life and be durable as it is logistically very difficult for the reserve soldier to change boots.",Discussion,[203969],[21659],[21809],[False],[0],[0],[False],['0']
29877,PMC5330033,34849,This requirement makes the use of HWIB a potential long term problem for IDF reserve soldiers.,Discussion,[203975],[21810],[21904],[False],[0],[0],[False],['0']
29878,PMC5330033,34850,The sole of the HWIB has an inner layer of polyurethane.,Discussion,[203981],[21905],[21961],[False],[0],[0],[False],['0']
29879,PMC5330033,34851,"This material is known to potentially undergo hydrolysis and disintegrate with time, especially if not stored at a cool temperature.",Discussion,[203987],[21962],[22094],[False],[0],[0],[False],['0']
29880,PMC5330033,34852,Such storage is likely to be a problem for most reservists in Israel.,Discussion,[203993],[22095],[22164],[False],[0],[0],[False],['0']
29881,PMC5330033,34853,"Indeed even in the short follow up in this study, at week 64, we found that 17 % of the pairs of boots had a split between the rubber and polyurethane layers in the anterior sole in one of the boots.",Discussion,[203999],[22165],[22364],[False],[0],[0],[False],['0']
29882,PMC5330033,34854,"Because this study monitored the orthopaedic effects of shoe gear using a medical team composed of orthopaedists, it required IRB approval.",Discussion,[204005],[22365],[22504],[False],[0],[0],[False],['0']
29883,PMC5330033,34855,"Accordingly, only recruits that volunteered and signed informed consent participated, and they had the right to withdraw from the study at any time.",Discussion,[204013],[22505],[22653],[True],['VerySpecificPopulation'],['only recruits that volunteered and signed informed consent participated'],[True],['Population']
29884,PMC5330033,34856,"Because so many soldiers dropped out quickly without allowing their shoes to “break in”, the study methodology could not be completed.",Discussion,[204026],[22654],[22788],[True],['MissingData'],['so many soldiers dropped out'],[True],['MissingData']
29885,PMC5330033,34857,"Testing boots, apparel or similar hazardless equipment is usually performed by the TLB without involving medical staff and does not use a randomized controlled trial design.",Discussion,[204035],[22789],[22962],[False],[0],[0],[False],['0']
29886,PMC5330033,34858,Therefore IRB approval is not required.,Discussion,[204041],[22963],[23002],[False],[0],[0],[False],['0']
29887,PMC5330033,34859,"When soldiers are aware of testing, it introduces biases (particularly a type of “position bias” where the new is assumed to be better).",Discussion,[204051],[23003],[23139],[True],['Patient'],['soldiers are aware of testing'],[True],['Blinding']
29888,PMC5330033,34860,"While using a study design that does not require IRB approval and informed consent has many drawbacks, it has a major advantage in terms of study completion.",Discussion,[204059],[23140],[23297],[False],[0],[0],[False],['0']
29889,PMC5330033,34861,"If the recruits in this MDIP study were issued boots without a choice as to whether to use them or not, it is likely that they would have completed their designated training with them.",Discussion,[204065],[23298],[23482],[False],[0],[0],[False],['0']
29890,PMC5330033,34862,The boot could have then been evaluated by a questionnaire administrated by non-medical staff at the end of the training period and fuller boot evaluation achieved than that of our study.,Discussion,[204071],[23483],[23670],[False],[0],[0],[False],['0']
29891,PMC5330033,34863,It is clear that designing the current study as a “medical intervention” necessitating medical regulations was not the optimal choice for initial evaluation of the new military boot [8].,Discussion,[204082],[23671],[23857],[True],['StudyDesign'],['designing the current study as a “medical intervention” necessitating medical regulations was not the optimal choice'],[True],['StudyDesign']
29892,PMC5330033,34864,It can be said that the soldiers in this study voted with their feet against the NDIB and for the HWIB.,Discussion,[204089],[23858],[23961],[False],[0],[0],[False],['0']
29893,PMC5330033,34865,"When first issued the NDIB boots, recruits had already worn the hot weather infantry foot for almost 2 weeks.",Discussion,[204095],[23962],[24071],[False],[0],[0],[False],['0']
29894,PMC5330033,34866,"Although this biased their experience with the NDIB boot, it also gave them a standard for comparison.",Discussion,[204101],[24072],[24174],[False],[0],[0],[False],['0']
29895,PMC5330033,34867,They reported almost immediately that the NDIB boot was much less comfortable.,Discussion,[204107],[24175],[24253],[False],[0],[0],[False],['0']
29896,PMC5330033,34868,81 % experienced problems with the NDIB within the first 9 days.,Discussion,[204113],[24254],[24318],[False],[0],[0],[False],['0']
29897,PMC5330033,34869,The feet of all recruits were examined and evidence of traumatic skin lesions were found in many of the NDIB wearers.,Discussion,[204119],[24319],[24436],[False],[0],[0],[False],['0']
29898,PMC5330033,34870,This may be a function of its hard leather upper and/or the boot last.,Discussion,[204125],[24437],[24507],[False],[0],[0],[False],['0']
29899,PMC5330033,34871,Male shoes are generally built around a last which is D width.,Discussion,[204131],[24508],[24570],[False],[0],[0],[False],['0']
29900,PMC5330033,34872,The distribution of the shoe widths as measured by the Brannock device indicates that many of the Israeli recruits in this study had narrower feet than the standard D shoe lasts.,Discussion,[204137],[24571],[24749],[False],[0],[0],[False],['0']
29901,PMC5330033,34873,Their shoe widths generally tended to be narrower than their counterparts in the Canadian Army [9].,Discussion,[204143],[24750],[24849],[False],[0],[0],[False],['0']
29902,PMC5330033,34874,The data indicates that a standard D last shoe is too wide for more than 50 % of the recruits in this study.,Discussion,[204149],[24850],[24958],[False],[0],[0],[False],['0']
29903,PMC5330033,34875,Inappropriate shoe fit can lead discomfort and to overuse injuries [10].,Discussion,[204155],[24959],[25031],[False],[0],[0],[False],['0']
29904,PMC5330033,34876,Conclusions,Conclusions,[204161],[25032],[25044],[False],[0],[0],[False],['0']
29905,PMC5330033,34877,No advantages to the NDIB were identified in the present study.,Conclusions,[204167],[25045],[25108],[False],[0],[0],[False],['0']
29906,PMC5330033,34878,"Greater durability might be expected, but we were not able to assess this variable due to the high dropout and early termination of the study.",Conclusions,[204173],[25109],[25251],[False],[0],[0],[False],['0']
29907,PMC5330033,34879,"The durability of HWIB when compared to the IDF boot it replaced is lower, probably related to the bilayer rubber sole of the previous boot and various differences to the upper that make the HWIB more like a sports shoe than a safety boot, the traditional concept of military boots.",Conclusions,[204179],[25252],[25534],[False],[0],[0],[False],['0']
29908,PMC5330033,34880,These differences are clearly preferred by the recruits and related to less “breaking in” injuries in basic training.,Conclusions,[204185],[25535],[25652],[False],[0],[0],[False],['0']
29909,PMC5330033,34881,The price of this improvement is less durability.,Conclusions,[204191],[25653],[25702],[False],[0],[0],[False],['0']
29910,PMC5330033,34882,"It is also possible that if the study had been done in cold wet weather, the recruit response to the NDIB boot might have been more favorable.",Conclusions,[204197],[25703],[25845],[False],[0],[0],[False],['0']
29911,PMC5330033,34883,Although the HWIB were well liked by the IDF infantry recruits in this study it remains to be determined if the boots are appropriate for IDF reserve army service.,Conclusions,[204203],[25846],[26009],[False],[0],[0],[False],['0']
29912,PMC5330033,34884,Abbreviations,Abbreviations,[204209],[26010],[26024],[False],[0],[0],[False],['0']
29913,PMC5330033,34885,HWIB hot weather infantry boots,Abbreviations|HWIB hot weather infantry boots,[204215],[26025],[26056],[False],[0],[0],[False],['0']
29914,PMC5330033,34886,NDIB newly designed Israeli infantry boots,Abbreviations|HWIB hot weather infantry boots,[204221],[26057],[26099],[False],[0],[0],[False],['0']
29915,PMC5330033,34887,IDF Israel Defense Forces,Abbreviations|IDF Israel Defense Forces,[204227],[26100],[26125],[False],[0],[0],[False],['0']
29916,PMC5330033,34888,TLB Technological and Logistics Branch,Abbreviations|TLB Technological and Logistics Branch,[204233],[26126],[26164],[False],[0],[0],[False],['0']
29917,PMC5330033,34889,NCO base non-commissioned officer,Abbreviations|NCO base non-commissioned officer,[204239],[26165],[26198],[False],[0],[0],[False],['0']
29918,PMC5330033,34890,RCT randomized controlled trial,Abbreviations|RCT randomized controlled trial,[204245],[26199],[26230],[False],[0],[0],[False],['0']
29919,PMC5330033,34891,IRB institutional review boardAuthors’ contributions,Abbreviations|RCT randomized controlled trial,[204251],[26231],[26283],[False],[0],[0],[False],['0']
29920,PMC5330033,34892,"CM: Study design, data collection and interpretation, manuscript preparation; AS: Subject recruitment, data collection, Phase 1.",Abbreviations|RCT randomized controlled trial,[204257],[26284],[26412],[False],[0],[0],[False],['0']
29921,PMC5330033,34893,"AG: Subject recruitment, data collection, data interpretation, Phase 2.",Abbreviations|RCT randomized controlled trial,[204263],[26413],[26484],[False],[0],[0],[False],['0']
29922,PMC5330033,34894,"JS: Data collection, phase 2, manuscript review.",Abbreviations|RCT randomized controlled trial,[204269],[26485],[26533],[False],[0],[0],[False],['0']
29923,PMC5330033,34895,"IN: Data collection and organization, phase 3.",Abbreviations|RCT randomized controlled trial,[204275],[26534],[26580],[False],[0],[0],[False],['0']
29924,PMC5330033,34896,"BK: Study design, logistics, phase 3.",Abbreviations|RCT randomized controlled trial,[204281],[26581],[26618],[False],[0],[0],[False],['0']
29925,PMC5330033,34897,"ASF: Study design, data collection and analysis, statistics, manuscript preparation.",Abbreviations|RCT randomized controlled trial,[204287],[26619],[26703],[False],[0],[0],[False],['0']
29926,PMC5330033,34898,All authors read and approved the final manuscript.,Abbreviations|RCT randomized controlled trial,[204293],[26704],[26755],[False],[0],[0],[False],['0']
29927,PMC5330033,34899,Acknowledgements,Abbreviations|Acknowledgements,[204299],[26756],[26772],[False],[0],[0],[False],['0']
29928,PMC5330033,34900,The authors would like to acknowledge Eng.,Abbreviations|Acknowledgements,[204305],[26773],[26815],[False],[0],[0],[False],['0']
29929,PMC5330033,34901,"Michael Sluzki and Ms. Liliana Moghrabi from the IDF TLB, Shimon Horowitz from Brill Shoe Industries and Michael Manheim CEO of Naveh Orthopaedic Labs for their valuable assistance in conducting this study.",Abbreviations|Acknowledgements,[204311],[26816],[27022],[False],[0],[0],[False],['0']
29930,PMC5330033,34902,Competing interests,Abbreviations|Competing interests,[204317],[27023],[27042],[False],[0],[0],[False],['0']
29931,PMC5330033,34903,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[204323],[27043],[27101],[False],[0],[0],[False],['0']
29932,PMC5330033,34904,All boots worn by soldiers in this study were purchased by the Ministry of Defense for use of the Israel Defense Forces.,Abbreviations|Competing interests,[204329],[27102],[27222],[False],[0],[0],[False],['0']
29933,PMC5330033,34905,Availability of data and material,Abbreviations|Availability of data and material,[204335],[27223],[27256],[False],[0],[0],[False],['0']
29934,PMC5330033,34906,Data sharing is subject to the approval of the IDF based on specific case.,Abbreviations|Availability of data and material,[204341],[27257],[27331],[False],[0],[0],[False],['0']
29935,PMC5330033,34907,Disclaimer,Abbreviations|Disclaimer,[204347],[27332],[27342],[False],[0],[0],[False],['0']
29936,PMC5330033,34908,"The opinions and assertions in this article are those of the authors and do not necessarily represent official interpretation, policy, or views of the IDF.",Abbreviations|Disclaimer,[204353],[27343],[27498],[False],[0],[0],[False],['0']
29937,PMC5330033,34909,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[204359],[27499],[27541],[False],[0],[0],[False],['0']
29938,PMC5330033,34910,"Approval of IDF IRB, IDF-1346-2014.",Abbreviations|Ethics approval and consent to participate,[204365],[27542],[27577],[False],[0],[0],[False],['0']
29939,PMC5330033,34911,Funding,Abbreviations|Funding,[204371],[27578],[27585],[False],[0],[0],[False],['0']
29940,PMC5330033,34912,Internal funding IDF.,Abbreviations|Internal funding IDF.,[204377],[27586],[27607],[False],[0],[0],[False],['0']
30136,PMC5381088,28118,Changes in fruit and vegetable consumption habits from pre-pregnancy to early pregnancy among Norwegian women,Title,[167646],[32913],[109],[False],[0],[0],[False],['0']
30137,PMC5381088,28119,Background,Abstract,[167661],[110],[121],[False],[0],[0],[False],['0']
30138,PMC5381088,28120,A healthy diet is important for pregnancy outcome and the current and future health of woman and child.,Abstract,[167676],[122],[225],[False],[0],[0],[False],['0']
30139,PMC5381088,28121,"The aims of the study were to explore the changes from pre-pregnancy to early pregnancy in consumption of fruits and vegetables (FV), and to describe associations with maternal educational level, body mass index (BMI) and age.",Abstract,[167691],[226],[452],[False],[0],[0],[False],['0']
30140,PMC5381088,28122,Methods,Abstract,[167706],[453],[460],[False],[0],[0],[False],['0']
30141,PMC5381088,28123,"Healthy nulliparous women were included in the Norwegian Fit for Delivery (NFFD) trial from September 2009 to February 2013, recruited from eight antenatal clinics in southern Norway.",Abstract,[167721],[461],[644],[False],[0],[0],[False],['0']
30142,PMC5381088,28124,"At inclusion, in median gestational week 15 (range 9–20), 575 participants answered a food frequency questionnaire (FFQ) where they reported consumption of FV, both current intake and recollection of pre-pregnancy intake.",Abstract,[167736],[645],[866],[False],[0],[0],[False],['0']
30143,PMC5381088,28125,Data were analysed using a linear mixed model.,Abstract,[167751],[867],[913],[False],[0],[0],[False],['0']
30144,PMC5381088,28126,Results,Abstract,[167766],[914],[921],[False],[0],[0],[False],['0']
30145,PMC5381088,28127,"The percentage of women consuming FV daily or more frequently in the following categories increased from pre-pregnancy to early pregnancy: vegetables on sandwiches (13 vs. 17%, p <0.01), other vegetables (11 vs. 14%, p = 0.01), fruits (apples, pears, oranges or bananas) (24 vs. 41%, p < 0.01), other fruits and berries (8 vs. 15%, p < 0.01) and fruits and vegetables as snacks (14 vs. 28%, p < 0.01).",Abstract,[167781],[922],[1323],[False],[0],[0],[False],['0']
30146,PMC5381088,28128,The percentage of women who reported at least daily consumption of vegetables with dinner (22% at both time points) was stable.,Abstract,[167796],[1324],[1451],[False],[0],[0],[False],['0']
30147,PMC5381088,28129,A higher proportion of older women increased their consumption of vegetables and fruits as snacks from pre-pregnancy to early pregnancy compared to younger women (p=0.04).,Abstract,[167811],[1452],[1623],[False],[0],[0],[False],['0']
30148,PMC5381088,28130,Conclusions,Abstract,[167826],[1624],[1635],[False],[0],[0],[False],['0']
30149,PMC5381088,28131,We found an increase in the proportion of women consuming FV daily or more frequently from pre-pregnancy to early pregnancy.,Abstract,[167841],[1636],[1760],[False],[0],[0],[False],['0']
30150,PMC5381088,28132,Trial registration,Abstract,[167856],[1761],[1779],[False],[0],[0],[False],['0']
30151,PMC5381088,28133,"ClinicalTrials.gov database, NCT01001689.",Abstract,[167871],[1780],[1821],[False],[0],[0],[False],['0']
30152,PMC5381088,28134,https://clinicaltrials.gov/ct2/show/NCT01001689?term=NCT01001689&rank=1.,Abstract,[167886],[1822],[1894],[False],[0],[0],[False],['0']
30153,PMC5381088,28135,Background,Background,[167901],[1895],[1906],[False],[0],[0],[False],['0']
30154,PMC5381088,28136,"Maternal diet pre-conception and during pregnancy may influence pregnancy outcome [1–5], and the future health of mother and child [6–8].",Background,[167916],[1907],[2044],[False],[0],[0],[False],['0']
30155,PMC5381088,28137,"Plant-based dietary patterns which contain a variety of fruit and vegetables (FV) are associated with reduced risk of congenital anomalies [9], preterm birth [3], and more favourable foetal growth [1–3, 5, 10], as well as lower frequency of maternal complications such as excessive gestational weight gain [3], preeclampsia [4] and gestational diabetes [11].",Background,[167931],[2045],[2403],[False],[0],[0],[False],['0']
30156,PMC5381088,28138,"Because of their high content of micronutrients, fibre and other bioactive compounds such as phytochemicals [12], FV are essential parts of a healthy and balanced diet.",Background,[167946],[2404],[2572],[False],[0],[0],[False],['0']
30157,PMC5381088,28139,"Thus, increasing the consumption of FV is an important public health goal [13, 14].",Background,[167961],[2573],[2656],[False],[0],[0],[False],['0']
30158,PMC5381088,28140,The Norwegian National Health Authorities advocate a dietary pattern rich in FV to the general population as well as to pregnant women.,Background,[167976],[2657],[2792],[False],[0],[0],[False],['0']
30159,PMC5381088,28141,"They recommend a minimum daily intake of five servings or 500 g of FV, of which at least one half should be vegetables [15].",Background,[167991],[2793],[2917],[False],[0],[0],[False],['0']
30160,PMC5381088,28142,"Although there has been an increase in the intake of FV over the last decades in Norway [16], large differences in intake of FV are described across different population groups [17].",Background,[168006],[2918],[3100],[False],[0],[0],[False],['0']
30161,PMC5381088,28143,"Despite public health recommendations [15], only 15% of Norwegian women were found to achieve the recommended amount of 250 g vegetables per day, whereas 41% reported to have an intake of at least 250 gram of fruit (including 100 ml of fruit juice) in a national survey conducted in 2010–2011 [17].",Background,[168021],[3101],[3399],[False],[0],[0],[False],['0']
30162,PMC5381088,28144,"Furthermore, in the Norwegian Mother and Child Cohort Study (MoBa), only 33 and 7% of participating pregnant women reported reaching the recommended intake of fruits and vegetables, respectively [18].",Background,[168036],[3400],[3600],[False],[0],[0],[False],['0']
30163,PMC5381088,28145,"The gap between recommendations and actual consumption is a global concern, both in low- and middle -income countries [19], and in more affluent parts of the world [18–20].",Background,[168051],[3601],[3773],[False],[0],[0],[False],['0']
30164,PMC5381088,28146,"Several longitudinal studies have reported that overall dietary patterns remain relatively stable from pre-pregnancy and throughout pregnancy [21, 22].",Background,[168066],[3774],[3925],[False],[0],[0],[False],['0']
30165,PMC5381088,28147,"However, women are known to increase their intake of fruits [21, 23, 24] from pre-pregnancy to the first half of pregnancy, whereas reports in changes in vegetables consumption are mixed [21, 23, 24].",Background,[168081],[3926],[4126],[False],[0],[0],[False],['0']
30166,PMC5381088,28148,Both the nutritional state in which women enter pregnancy and nutrition in pregnancy may influence pregnancy outcome and the health of the next generation.,Background,[168096],[4127],[4282],[False],[0],[0],[False],['0']
30167,PMC5381088,28149,"It is therefore important to identify particular groups of women with poor dietary habits, in order to provide more targeted interventions.",Background,[168111],[4283],[4422],[False],[0],[0],[False],['0']
30168,PMC5381088,28150,"The main aim of the present study was to explore the changes from pre-pregnancy to early pregnancy in consumption of FV, and to describe associations with maternal educational level, BMI, and age.",Background,[168126],[4423],[4619],[False],[0],[0],[False],['0']
30169,PMC5381088,28151,Methods,Methods,[168141],[4620],[4628],[False],[0],[0],[False],['0']
30170,PMC5381088,28152,Population and study design,Methods|Population and study design,[168156],[4629],[4656],[False],[0],[0],[False],['0']
30171,PMC5381088,28153,The present paper is based on data from the Norwegian Fit for Delivery (NFFD) study [25].,Methods|Population and study design,[168171],[4657],[4746],[False],[0],[0],[False],['0']
30172,PMC5381088,28154,"The NFFD is a randomised, blinded controlled trial performed in southern Norway.",Methods|Population and study design,[168186],[4747],[4827],[False],[0],[0],[False],['0']
30173,PMC5381088,28155,The intervention was a combination of antenatal counselling on diet and physical activity.,Methods|Population and study design,[168201],[4828],[4918],[False],[0],[0],[False],['0']
30174,PMC5381088,28156,"The main aims of the NFFD trial are to examine the effect of the intervention on maternal gestational weight gain and postnatal weight retention, glucose regulation during pregnancy, newborn birth weight and the incidence of operative deliveries.",Methods|Population and study design,[168216],[4919],[5165],[False],[0],[0],[False],['0']
30175,PMC5381088,28157,The NFFD trial has previously been described in detail [25].,Methods|Population and study design,[168231],[5166],[5226],[False],[0],[0],[False],['0']
30176,PMC5381088,28158,Between September 2009 and January 2013 midwives at eight local antenatal clinics consecutively recruited pregnant nulliparous women.,Methods|Population and study design,[168246],[5227],[5360],[False],[0],[0],[False],['0']
30177,PMC5381088,28159,"Other eligibility criteria were age ≥ 18 years, singleton pregnancy at ≤ 20 + 6 weeks of gestation, pre-pregnancy BMI ≥ 19.0 kg/m2, that the woman was fluent in Norwegian or English and was able to provide informed consent.",Methods|Population and study design,[168261],[5361],[5584],[False],[0],[0],[False],['0']
30178,PMC5381088,28160,"Exclusion criteria were on-going substance abuse, pre-existing diabetes mellitus, disabilities which precluded participation in a physical fitness program, and planned relocation outside the study area before delivery.",Methods|Population and study design,[168276],[5585],[5803],[False],[0],[0],[False],['0']
30179,PMC5381088,28161,Fig.,Methods|Population and study design,[168291],[5804],[5808],[False],[0],[0],[False],['0']
30180,PMC5381088,28162,1 Flow diagram of the inclusion of pregnant women in the present study.,Methods|Population and study design,[168306],[5809],[5880],[False],[0],[0],[False],['0']
30181,PMC5381088,28163,"Of 1610 nulliparous women, 606 were included into the study [26], and 575 participated in the present sub study (Fig.",Methods|Population and study design,[168321],[5881],[5998],[False],[0],[0],[False],['0']
30182,PMC5381088,28164,1).,Methods|Population and study design,[168336],[5999],[6002],[False],[0],[0],[False],['0']
30183,PMC5381088,28165,The study design was cross-sectional.,Methods|Population and study design,[168351],[6003],[6040],[False],[0],[0],[False],['0']
30184,PMC5381088,28166,"At inclusion, in median gestational-week 15.0 (range; 9.0–20.0), the women answered a 43-item food frequency questionnaire (FFQ) and reported how often they currently consumed the different foods, and in retrospect how often they ate the different foods before they got pregnant.",Methods|Population and study design,[168366],[6041],[6320],[False],[0],[0],[False],['0']
30185,PMC5381088,28167,Randomization took place after the women had answered the FFQ.,Methods|Population and study design,[168381],[6321],[6383],[False],[0],[0],[False],['0']
30186,PMC5381088,28168,Assessment of dietary changes,Methods|Assessment of dietary changes,[168396],[6384],[6414],[False],[0],[0],[False],['0']
30187,PMC5381088,28169,"The questionnaire items on fruit- and vegetable-intake have previously been used for assessing intake of FV among schoolchildren [27] and included the following six items; “vegetables at dinner”, “vegetables on your sandwich”, “other vegetables” (for example, carrots at lunchtime), “fruits” (apples, oranges, pears or bananas), “other fruits or berries” (fruits or berries other than apples, oranges, pears or bananas), “fruits or vegetables as snacks”.",Methods|Assessment of dietary changes,[168411],[6415],[6869],[False],[0],[0],[False],['0']
30188,PMC5381088,28170,The FFQ questions were; “How often do you eat…..now?,Methods|Assessment of dietary changes,[168426],[6870],[6922],[False],[0],[0],[False],['0']
30189,PMC5381088,28171,and in retrospect “How often did you eat… before pregnancy?”.,Methods|Assessment of dietary changes,[168441],[6923],[6984],[False],[0],[0],[False],['0']
30190,PMC5381088,28172,"There were ten response alternatives which were recoded into frequency of consumption (“0 = never”, “0.5 = less than once a week”, “1 = weekly”, “2 = twice weekly”,….”6 = six times weekly”, “7 = daily” and “10 = several times daily”).",Methods|Assessment of dietary changes,[168456],[6985],[7219],[False],[0],[0],[False],['0']
30191,PMC5381088,28173,"FV consumption frequency was categorized into three groups: i) ≤ 1/week, ii) 2–6/week and ≥1/day.",Methods|Assessment of dietary changes,[168471],[7220],[7317],[False],[0],[0],[False],['0']
30192,PMC5381088,28174,"Furthermore, FV consumption frequency was categorized into two groups: “≥1/day” vs. “<1/day” to examine potential associations between change in FV consumption and the women’s educational level, BMI and age.",Methods|Assessment of dietary changes,[168486],[7318],[7525],[False],[0],[0],[False],['0']
30193,PMC5381088,28175,A test-retest reliability study was performed in a sample of 105 pregnant women who completed the presented questionnaire 2 weeks apart [28].,Methods|Assessment of dietary changes,[168501],[7526],[7667],[False],[0],[0],[False],['0']
30194,PMC5381088,28176,The six included items in this paper (both before and in pregnancy yielding 12 correlations) were found to have acceptable test-retest correlations (Pearson’s correlation coefficients) ranging from r = 0.525 (p = <0.01) for the variable “other fruits before pregnancy” to r = 0.800 (p = <0.01) for “fruits before pregnancy”.,Methods|Assessment of dietary changes,[168516],[7668],[7992],[False],[0],[0],[False],['0']
30195,PMC5381088,28177,Other study variables,Methods|Other study variables,[168531],[7993],[8014],[False],[0],[0],[False],['0']
30196,PMC5381088,28178,"The questionnaire completed at inclusion also contained questions about lifestyle and background factors such as maternal educational level, pre-pregnancy BMI and age at inclusion.",Methods|Other study variables,[168546],[8015],[8195],[False],[0],[0],[False],['0']
30197,PMC5381088,28179,The following response options on level of education were; < 7 years of primary education; 7–10 years of primary education; trade school or 1–2 years of high school; completed high school; < 4 years at college/university and ≥ 4 years at college/university.,Methods|Other study variables,[168561],[8196],[8453],[False],[0],[0],[False],['0']
30198,PMC5381088,28180,Educational level was dichotomized into low education (not having attended college or university) and high education (having attended college or university).,Methods|Other study variables,[168576],[8454],[8611],[False],[0],[0],[False],['0']
30199,PMC5381088,28181,"Height was measured, using a stadiometer (Seca Leicester, Hamburg, Germany).",Methods|Other study variables,[168591],[8612],[8688],[False],[0],[0],[False],['0']
30200,PMC5381088,28182,Pre-pregnancy weight was self-reported and used for calculation of pre-pregnancy BMI (weight/height2).,Methods|Other study variables,[168606],[8689],[8791],[False],[0],[0],[False],['0']
30201,PMC5381088,28183,"In line with the World Health Organization’s definition of normal weight and overweight/obese [29], we dichotomized: BMI < 25 kg/m2 vs. BMI ≥ 25 kg/m2.",Methods|Other study variables,[168621],[8792],[8943],[False],[0],[0],[False],['0']
30202,PMC5381088,28184,Maternal age was dichotomized into < 25 years vs. ≥ 25 years.,Methods|Other study variables,[168636],[8944],[9005],[False],[0],[0],[False],['0']
30203,PMC5381088,28185,Statistical methods,Methods|Statistical methods,[168651],[9006],[9025],[False],[0],[0],[False],['0']
30204,PMC5381088,28186,"All statistical analyses were performed with SPSS for IBM statistical software packages version 22.0 (IBM Corporation, NY, USA).",Methods|Statistical methods,[168666],[9026],[9154],[False],[0],[0],[False],['0']
30205,PMC5381088,28187,A two-sided p value of 0.05 was considered significant.,Methods|Statistical methods,[168681],[9155],[9210],[False],[0],[0],[False],['0']
30206,PMC5381088,28188,Differences between responders and non-responders were tested with Pearson Chi-square test for categorical data and Student’s t test for continuous variables.,Methods|Statistical methods,[168696],[9211],[9369],[False],[0],[0],[False],['0']
30207,PMC5381088,28189,FV consumption and the changes in FV consumption from pre-pregnancy to median gestational week 15.0 were analysed using a linear mixed model with dichotomized FV consumption as the dependent variable [30].,Methods|Statistical methods,[168711],[9370],[9575],[False],[0],[0],[False],['0']
30208,PMC5381088,28190,"Differences in pregnant women’s FV consumption might be dependent on educational level, BMI and age [8, 31–36].",Methods|Statistical methods,[168726],[9576],[9687],[False],[0],[0],[False],['0']
30209,PMC5381088,28191,"Accordingly, the model included maternal educational level, BMI and age, as well as the following interaction terms: time*maternal education, time*BMI and time*age, to investigate potential difference in changes in the consumption of FV from pre-pregnancy to median gestational week 15 between low and high educational level, BMI and age.",Methods|Statistical methods,[168741],[9688],[10026],[False],[0],[0],[False],['0']
30210,PMC5381088,28192,A p value of the product term of less than 0.10 was defined as a significant effect.,Methods|Statistical methods,[168756],[10027],[10111],[False],[0],[0],[False],['0']
30211,PMC5381088,28193,Results,Results,[168771],[10112],[10120],[False],[0],[0],[False],['0']
30212,PMC5381088,28194,Sociodemographic characteristics,Results|Sociodemographic characteristics,[168786],[10121],[10153],[False],[0],[0],[False],['0']
30213,PMC5381088,28195,"Table 1 Sociodemographic characteristics at inclusion among pregnant, nulliparous women (N = 575).",Results|Sociodemographic characteristics,[168801],[10154],[10252],[False],[0],[0],[False],['0']
30214,PMC5381088,28196,Table 2 Changes in the frequency of fruit and vegetable consumption from pre-pregnancy to early pregnancy (N = 575).,Results|Sociodemographic characteristics,[168816],[10253],[10369],[False],[0],[0],[False],['0']
30215,PMC5381088,28197,The inclusion of pregnant women is shown in Fig.,Results|Sociodemographic characteristics,[168831],[10370],[10418],[False],[0],[0],[False],['0']
30216,PMC5381088,28198,1.,Results|Sociodemographic characteristics,[168846],[10419],[10421],[False],[0],[0],[False],['0']
30217,PMC5381088,28199,Sociodemographic characteristics of the 575 women who were included and answered the FFQ are reported in Table 1.,Results|Sociodemographic characteristics,[168861],[10422],[10535],[False],[0],[0],[False],['0']
30218,PMC5381088,28200,"Mean maternal age was 28.1 (SD 4.4) years, and mean pre-pregnancy BMI was 23.9 kg/m2 (SD 3.8).",Results|Sociodemographic characteristics,[168876],[10536],[10630],[False],[0],[0],[False],['0']
30219,PMC5381088,28201,"Pre-pregnancy, a larger proportion of women with higher educational attainment reported higher frequency in consumption of vegetables at dinner (p = 0.01) and fruits (p = 0.04) at least once daily than women with lower educational attainment.",Results|Sociodemographic characteristics,[168891],[10631],[10873],[False],[0],[0],[False],['0']
30220,PMC5381088,28202,"Furthermore, a larger proportion of older women reported eating vegetables on sandwich at least daily (p = 0.01) than younger women (Table 2).",Results|Sociodemographic characteristics,[168906],[10874],[11016],[False],[0],[0],[False],['0']
30221,PMC5381088,28203,Consumption of fruits and vegetables (FV),Results|Consumption of fruits and vegetables (FV),[168921],[11017],[11060],[False],[0],[0],[False],['0']
30222,PMC5381088,28204,Changes in FV consumption from pre-pregnancy to early pregnancy are presented in Table 2.,Results|Consumption of fruits and vegetables (FV),[168936],[11061],[11150],[False],[0],[0],[False],['0']
30223,PMC5381088,28205,"The percentage of women eating vegetables on sandwiches (13 vs. 17%, p <0.01), other vegetables (11 vs. 14%, p = 0.01), fruits (24 vs. 41%, p<0.01), other fruits and berries (8 vs. 15%, p <0.01), and fruits and vegetables as snacks (14 vs. 28%, p <0.01) daily or more frequently increased significantly from pre-pregnancy to early pregnancy.",Results|Consumption of fruits and vegetables (FV),[168951],[11151],[11492],[False],[0],[0],[False],['0']
30224,PMC5381088,28206,The percentage of women who reported at least daily consumption of vegetables with dinner (22% at both time points) was stable (Table 2).,Results|Consumption of fruits and vegetables (FV),[168966],[11493],[11630],[False],[0],[0],[False],['0']
30225,PMC5381088,28207,"A larger proportion of older women reported a significant increase of at least daily consumption of “vegetables and fruits as snacks” from pre-pregnancy to gestational week 15 (14 vs. 33%) compared to younger women (14 vs. 23%) (interaction time*age, p = 0.04).",Results|Consumption of fruits and vegetables (FV),[168981],[11631],[11892],[False],[0],[0],[False],['0']
30226,PMC5381088,28208,There were no significant interactions between neither BMI nor maternal education and changes in intake of FV pre-pregnancy to gestational week 15 (Table 2).,Results|Consumption of fruits and vegetables (FV),[168996],[11893],[12050],[False],[0],[0],[False],['0']
30227,PMC5381088,28209,Discussion,Discussion,[169011],[12051],[12062],[False],[0],[0],[False],['0']
30228,PMC5381088,28210,The present study showed that the proportion of women consuming FV daily or more frequently increased from pre-pregnancy to early pregnancy independent of educational level and pre-pregnant BMI.,Discussion,[169026],[12063],[12257],[False],[0],[0],[False],['0']
30229,PMC5381088,28211,"However, there was a rather strong sociodemographic gradient in the consumption of FV, as more women with high educational level reported the highest consumption frequencies.",Discussion,[169041],[12258],[12432],[False],[0],[0],[False],['0']
30230,PMC5381088,28212,"From pre-pregnancy to early pregnancy, the proportion of women consuming FV daily or more frequently increased significantly in the categories: “vegetables on sandwich”, “other vegetables” and “fruit and vegetables as snacks”.",Discussion,[169056],[12433],[12659],[False],[0],[0],[False],['0']
30231,PMC5381088,28213,"From pre-pregnancy to early pregnancy the highest increment in consumption frequency of FV was reported in the categories “fruits” (apples, pears, oranges or bananas) and “fruits or vegetables as snacks”.",Discussion,[169071],[12660],[12864],[False],[0],[0],[False],['0']
30232,PMC5381088,28214,"Furthermore, the most frequent way of consuming vegetables was “vegetables at dinner”.",Discussion,[169086],[12865],[12951],[False],[0],[0],[False],['0']
30233,PMC5381088,28215,"A low intake of FV may be explained by a variety of factors such as cost [19], availability, familiarity, and time for preparation [37–39].",Discussion,[169101],[12952],[13091],[False],[0],[0],[False],['0']
30234,PMC5381088,28216,"Worldwide, higher socio-economic status tends to be associated with healthier food choices [40, 41].",Discussion,[169116],[13092],[13192],[False],[0],[0],[False],['0']
30235,PMC5381088,28217,"In line with others, we found that a high intake of FV was associated with older age [8, 32–35, 42–44] and higher educational attainments [36, 42].",Discussion,[169131],[13193],[13340],[False],[0],[0],[False],['0']
30236,PMC5381088,28218,"Maternal diet pre-pregnancy might influence implantation, placentation and embryogenesis [45, 46].",Discussion,[169146],[13341],[13439],[False],[0],[0],[False],['0']
30237,PMC5381088,28219,"Thus, an increase in intake of various nutrients, including protein, folate, calcium, vitamin C and vitamin D, is recommended [47].",Discussion,[169161],[13440],[13571],[False],[0],[0],[False],['0']
30238,PMC5381088,28220,It is a concern that the present study seems to indicate a low consumption of FV pre-pregnancy.,Discussion,[169176],[13572],[13667],[False],[0],[0],[False],['0']
30239,PMC5381088,28221,"Similarly, Blumfield et al.",Discussion,[169191],[13668],[13695],[False],[0],[0],[False],['0']
30240,PMC5381088,28222,found no evidence that women trying to conceive increased their consumption on nutrient rich foods such as FV [48].,Discussion,[169206],[13696],[13811],[False],[0],[0],[False],['0']
30241,PMC5381088,28223,"In line with our results, several studies have found that only a small proportion of women consume the recommended number of vegetable servings per day, both pre-pregnancy [48] and during pregnancy [18, 35, 36, 44, 48, 49].",Discussion,[169221],[13812],[14035],[False],[0],[0],[False],['0']
30242,PMC5381088,28224,A national study from Australia showed that only 10% of pregnant women reported an intake of vegetables at or above recommendations [49].,Discussion,[169236],[14036],[14173],[False],[0],[0],[False],['0']
30243,PMC5381088,28225,Rodriguez-Bernal et al.,Discussion,[169251],[14174],[14197],[False],[0],[0],[False],['0']
30244,PMC5381088,28226,"reported that 47% of Spanish women had an intake of vegetables which was below recommendations in first trimester of pregnancy [43], while a Finnish study found that only between 16 and 30% of pregnant women consumed the daily recommendations of FV [44].",Discussion,[169266],[14198],[14452],[False],[0],[0],[False],['0']
30245,PMC5381088,28227,The observed increase in proportion of women who consume FV more frequently from pre-pregnancy to early pregnancy in the present study is in line with a recent study from Singapore which found that 46 to 67% of the women increased their consumption of FV from pre-pregnancy to late second trimester of pregnancy [24].,Discussion,[169281],[14453],[14770],[False],[0],[0],[False],['0']
30246,PMC5381088,28228,"Further, the reported large and significant increase in the consumption frequency of fruits from pre-pregnancy to early pregnancy is in accordance with other studies [21, 23, 24].",Discussion,[169296],[14771],[14950],[False],[0],[0],[False],['0']
30247,PMC5381088,28229,Crozier et al.,Discussion,[169311],[14951],[14965],[False],[0],[0],[False],['0']
30248,PMC5381088,28230,found that intake of fruits other than citrus fruit increased from pre-pregnancy to gestational week 11 [21].,Discussion,[169326],[14966],[15075],[False],[0],[0],[False],['0']
30249,PMC5381088,28231,"However, they reported little change in the overall intake of FV from pre-pregnancy to early pregnancy, as the proportion of women consuming less than the recommended five portions of FV was 46% pre-pregnancy and 47% in late first trimester of pregnancy [21].",Discussion,[169341],[15076],[15335],[False],[0],[0],[False],['0']
30250,PMC5381088,28232,"Fruits are often found to be more commonly consumed than vegetables, and daily recommendations are more frequently reached in pregnancy [18, 35, 36, 48, 49] compared to vegetables.",Discussion,[169356],[15336],[15516],[False],[0],[0],[False],['0']
30251,PMC5381088,28233,Reported fruit intake is nonetheless varied: Malek et al.,Discussion,[169371],[15517],[15574],[False],[0],[0],[False],['0']
30252,PMC5381088,28234,"reported that 56% of the pregnant women adhered to recommendations regarding fruit intake [49], whereas in a cohort of younger Australian women 82% failed to meet recommendations [48].",Discussion,[169386],[15575],[15759],[False],[0],[0],[False],['0']
30253,PMC5381088,28235,One reason could be that vegetables often need more preparation and cooking than fruits.,Discussion,[169401],[15760],[15848],[False],[0],[0],[False],['0']
30254,PMC5381088,28236,"However, this discrepancy between vegetable and fruit consumption has been reported to be less pronounced or absent in areas with a traditional food culture containing more plant-based food [43].",Discussion,[169416],[15849],[16044],[False],[0],[0],[False],['0']
30255,PMC5381088,28237,"Our finding that a higher proportion of older women increased their consumption of vegetables and fruits as snacks from pre-pregnancy to early pregnancy, compared to younger women is consistent with other studies reporting healthier food choices to be associated with increasing maternal age [8, 11, 32–35].",Discussion,[169431],[16045],[16352],[False],[0],[0],[False],['0']
30256,PMC5381088,28238,In the present study there were no associations between level of education and increase in the frequency of consumption of FV from pre-pregnancy to early pregnancy.,Discussion,[169446],[16353],[16517],[False],[0],[0],[False],['0']
30257,PMC5381088,28239,Similarly we did not identify any association between BMI and increase in frequency of FV consumption.,Discussion,[169461],[16518],[16620],[False],[0],[0],[False],['0']
30258,PMC5381088,28240,"Women with higher educational level have in other studies been found to adhere to a healthier diet [18], and to consume more FV than women with lower educational level [17, 32, 35, 50, 51].",Discussion,[169476],[16621],[16810],[False],[0],[0],[False],['0']
30259,PMC5381088,28241,"Furthermore, a healthier diet with a high content of fruit and vegetables are more commonly found among women with normal weight than those with overweight and obesity [18, 32].",Discussion,[169491],[16811],[16988],[False],[0],[0],[False],['0']
30260,PMC5381088,28242,"Even though pregnancy is looked upon as a time were women are motivated towards positive lifestyle changes, an Australian qualitative study reported that a high proportion of pregnant women regarded pregnancy as a difficult period to change to a healthier lifestyle [52].",Discussion,[169506],[16989],[17260],[False],[0],[0],[False],['0']
30261,PMC5381088,28243,"They point to pregnancy complications such as nausea, tiredness and cravings as possible barriers.",Discussion,[169521],[17261],[17359],[False],[0],[0],[False],['0']
30262,PMC5381088,28244,Most FV are high in fibre and have a low glycaemic index.,Discussion,[169536],[17360],[17417],[False],[0],[0],[False],['0']
30263,PMC5381088,28245,Foods with lower glycaemic index produce fewer and smaller postprandial glucose episodes which may decrease subsequent hunger and total energy intake and prevent weight gain [53].,Discussion,[169551],[17418],[17597],[False],[0],[0],[False],['0']
30264,PMC5381088,28246,"Further, FV are important sources of dietary compounds such as minerals, and a diversity of bioactive substances, including antioxidants and phytochemicals [54].",Discussion,[169566],[17598],[17759],[False],[0],[0],[False],['0']
30265,PMC5381088,28247,Dietary patterns comprising ample FVs are associated with decreased plasma concentrations of biochemical markers of endothelial dysfunction and inflammation [55–57].,Discussion,[169581],[17760],[17925],[False],[0],[0],[False],['0']
30266,PMC5381088,28248,"Favourable health effects might operate through a positive modulation of the gut microbiota [58], promoting an increased bacterial richness, which has been inversely associated with insulin sensitivity and inflammatory markers [59].",Discussion,[169596],[17926],[18158],[False],[0],[0],[False],['0']
30267,PMC5381088,28249,"Fertile women in Norway are reported to have an intake of fibre, vitamin D, folate and iron below recommended amounts [16].",Discussion,[169611],[18159],[18282],[False],[0],[0],[False],['0']
30268,PMC5381088,28250,"Recommended daily intake of fibre is 25–35 grams per day, whereas the average intake of fibre among Norwegian women was 22 g per day in 2013 [16].",Discussion,[169626],[18283],[18429],[False],[0],[0],[False],['0']
30269,PMC5381088,28251,Around one in two fertile women are not aware the Norwegian Directorate of Health’s recommendations for a healthy diet [16].,Discussion,[169641],[18430],[18554],[False],[0],[0],[False],['0']
30270,PMC5381088,28252,Increasing intake of FV both pre-pregnancy and in pregnancy are important to improve fertile women’s diet.,Discussion,[169656],[18555],[18661],[False],[0],[0],[False],['0']
30271,PMC5381088,28253,"This study shows that pregnant women change to a healthier diet, although there is potential for further improvement.",Discussion,[169671],[18662],[18779],[False],[0],[0],[False],['0']
30272,PMC5381088,28254,"As pre-pregnancy diet is an important predictor for diet during pregnancy as well as for pregnancy outcome and future health for the mother and child, future interventions should focus on women planning, or at risk for, pregnancy.",Discussion,[169686],[18780],[19010],[False],[0],[0],[False],['0']
30273,PMC5381088,28255,Strengths and limitations,Discussion|Strengths and limitations,[169701],[19011],[19036],[False],[0],[0],[False],['0']
30274,PMC5381088,28256,"The inclusion of women from public clinics attended by most of the pregnant women in Norway as part of the national antenatal care programme, and the high response rate are major strengths.",Discussion|Strengths and limitations,[169716],[19037],[19226],[False],[0],[0],[False],['0']
30275,PMC5381088,28257,"Our data were to a large extent collected electronically, which is shown to be more valid than data collected by interviewer or paper questionnaire [60].",Discussion|Strengths and limitations,[169731],[19227],[19380],[False],[0],[0],[False],['0']
30276,PMC5381088,28258,The present dataset has few missing data as the participants had to answer each question to progress in the questionnaire.,Discussion|Strengths and limitations,[169746],[19381],[19503],[False],[0],[0],[False],['0']
30277,PMC5381088,28259,The FFQ used in the present study was primarily designed to capture changes in diet related to the intervention in the NFFD study and not to measure the specific or absolute intake of FV.,Discussion|Strengths and limitations,[169761],[19504],[19691],[False],[0],[0],[False],['0']
30278,PMC5381088,28260,"The FFQ contained one item covering fruits with the highest intake in the Norwegian population (apples, oranges, pears or bananas) [17].",Discussion|Strengths and limitations,[169776],[19692],[19828],[False],[0],[0],[False],['0']
30279,PMC5381088,28261,"Intake of berries is low in most populations, berries are often not analysed as a separate entity, but are instead combined with fruits.",Discussion|Strengths and limitations,[169791],[19829],[19965],[False],[0],[0],[False],['0']
30280,PMC5381088,28262,"In line with this, one FFQ item in the present study covered fruits or berries other than apples, oranges, pears or bananas.",Discussion|Strengths and limitations,[169806],[19966],[20090],[False],[0],[0],[False],['0']
30281,PMC5381088,28263,"Further, three FFQ items covered solely vegetable consumption.",Discussion|Strengths and limitations,[169821],[20091],[20153],[False],[0],[0],[False],['0']
30282,PMC5381088,28264,"However, since one FFQ-item asked about “fruits and vegetables as snacks”, we were not able to describe the exact frequency of the consumption of vegetables and fruits.",Discussion|Strengths and limitations,[169836],[20154],[20322],[True],['PrecisionOfMeasurement'],['we were not able to describe the exact frequency of the consumption of vegetables and fruits'],[True],['OutcomeMeasures']
30283,PMC5381088,28265,"The rather comprehensive FFQ used in the NFFD study requires a certain level of cognitive function to complete, and might not represent the best approach for including respondents with poor reading skills.",Discussion|Strengths and limitations,[169867],[20323],[20528],[True],['PrecisionOfMeasurement'],['requires a certain level of cognitive function to complete'],[True],['OutcomeMeasures']
30284,PMC5381088,28266,"As the respondents were included in an intervention study aiming at optimising nutrition and physical activity, they might have over-reported their intake of FV.",Discussion|Strengths and limitations,[169898],[20529],[20690],[True],['PrecisionOfMeasurement'],['they might have over-reported their intake of FV'],[True],['OutcomeMeasures']
30285,PMC5381088,28267,"The study was limited to nulliparous women, and was biased towards older age and higher educational attainment.",Discussion|Strengths and limitations,[169929],[20691],[20802],[True],['VerySpecificPopulation'],"['limited to nulliparous women, and was biased towards older age and higher educational attainment']",[True],['Population']
30286,PMC5381088,28268,"Furthermore, the women in the NFFD study were mainly white European [26].",Discussion|Strengths and limitations,[169960],[20803],[20876],[True],['VerySpecificPopulation'],['the women in the NFFD study were mainly white European'],[True],['Population']
30287,PMC5381088,28269,"In Norway, 48% of women between 25 and 29 years had not attended university in 2011 [61], compared to 28% of the women in the present study.",Discussion|Strengths and limitations,[169986],[20877],[21017],[False],[0],[0],[False],['0']
30288,PMC5381088,28270,"Mean age of Norwegian nulliparous women at delivery was 28.2 years in 2011 [62], whereas mean age at inclusion in the present study was 28.1 years.",Discussion|Strengths and limitations,[170001],[21018],[21165],[False],[0],[0],[False],['0']
30289,PMC5381088,28271,This might reduce the external validity and the reproducibility of our results.,Discussion|Strengths and limitations,[170021],[21166],[21245],[True],['Generalization'],['reduce the external validity and the reproducibility of our results'],[True],['Generalization']
30290,PMC5381088,28272,"Although the present study was done in a relatively homogenous population, participants might define FV differently.",Discussion|Strengths and limitations,[170031],[21246],[21362],[False],[0],[0],[False],['0']
30291,PMC5381088,28273,"In an American study, adults from a diverse ethnic background reported significant differences on classification of a number of food groups, including FV [63], and potatoes were often included in the vegetable category [63].",Discussion|Strengths and limitations,[170046],[21363],[21587],[False],[0],[0],[False],['0']
30292,PMC5381088,28274,"The FFQ-item “vegetables at dinner”, might not capture mixed vegetable dishes, and thus underestimate intake of vegetables.",Discussion|Strengths and limitations,[170068],[21588],[21711],[True],['PrecisionOfMeasurement'],['might not capture mixed vegetable dishes'],[True],['OutcomeMeasures']
30293,PMC5381088,28275,"In line with the Norwegian Public Health dietary guidelines [15], potatoes were not included in the vegetable category in the present study.",Discussion|Strengths and limitations,[170091],[21712],[21852],[False],[0],[0],[False],['0']
30294,PMC5381088,28276,"The FFQ-item on potatoes was placed before the FV items [25], minimizing the probability of reporting potatoes as vegetables.",Discussion|Strengths and limitations,[170106],[21853],[21978],[False],[0],[0],[False],['0']
30295,PMC5381088,28277,"As the questionnaire was in Norwegian or English, few immigrant women attended the present study.",Discussion|Strengths and limitations,[170127],[21979],[22076],[True],['VerySpecificPopulation'],['few immigrant women attended the present study'],[True],['Population']
30296,PMC5381088,28278,"Some immigrants are known to be at risk of low FV consumption [34], while other immigrant groups have a higher intake of vegetables than non-immigrants [34, 43].",Discussion|Strengths and limitations,[170151],[22077],[22238],[False],[0],[0],[False],['0']
30297,PMC5381088,28279,Other limitations are the cross sectional design and the reliance on self-reported data.,Discussion|Strengths and limitations,"[170174, 170175]","[22239, 22239]","[22327, 22327]","[True, True]","['StudyDesign', 'PrecisionOfMeasurement']","['the cross sectional design', 'the reliance on self-reported data']","[True, True]","['OutcomeMeasures', 'StudyDesign']"
30298,PMC5381088,28280,"The data on pre-pregnancy diet was collected in retrospect, and thus we cannot rule out recall bias.",Discussion|Strengths and limitations,[170206],[22328],[22428],[True],['PrecisionOfMeasurement'],['we cannot rule out recall bias'],[True],['OutcomeMeasures']
30299,PMC5381088,28281,"The women who consented to participate in the NFFD trial might have been more health-conscious and more likely to adhere to a healthy lifestyle, including an increased intake of FV, than the average pregnant woman.",Discussion|Strengths and limitations,[170237],[22429],[22643],[True],['VerySpecificPopulation'],['The women who consented to participate in the NFFD trial might have been more health-conscious and more likely to adhere to a healthy lifestyle'],[True],['Population']
30300,PMC5381088,28282,We did not ask about motivation for changing dietary habits.,Discussion|Strengths and limitations,[170256],[22644],[22704],[False],[0],[0],[False],['0']
30301,PMC5381088,28283,"The increase in FV consumption might have been due to public health recommendations or symptoms specific to pregnancy such as cravings, tiredness or nausea [64].",Discussion|Strengths and limitations,[170283],[22705],[22866],[True],['ConfoundingFactors'],"['due to public health recommendations or symptoms specific to pregnancy such as cravings, tiredness or nausea']",[True],['StatisticalAnalysis']
30302,PMC5381088,28284,"Since the women were recruited at their first visit to the antenatal clinic, nutritional advice from health personnel is less likely to have influenced the change.",Discussion|Strengths and limitations,[170301],[22867],[23030],[False],[0],[0],[False],['0']
30303,PMC5381088,28285,Seasonal variations have been described in intake of FV [65].,Discussion|Strengths and limitations,[170316],[23031],[23092],[False],[0],[0],[False],['0']
30304,PMC5381088,28286,We did not take this into account.,Discussion|Strengths and limitations,[170344],[23093],[23127],[True],['ConfoundingFactors'],['take this into account'],[True],['StatisticalAnalysis']
30305,PMC5381088,28287,The present study was conducted in a country where a small proportion of the population is consuming the recommended amount of FV [17].,Discussion|Strengths and limitations,[170361],[23128],[23263],[False],[0],[0],[False],['0']
30306,PMC5381088,28288,"In populations with a higher intake the social gradients in consumption might have been less distinct [66, 67].",Discussion|Strengths and limitations,[170390],[23264],[23375],[True],['Generalization'],['In populations with a higher intake the social gradients in consumption might have been less distinct'],[True],['Generalization']
30307,PMC5381088,28289,Conclusion,Conclusion,[170406],[23376],[23387],[False],[0],[0],[False],['0']
30308,PMC5381088,28290,From pre-pregnancy to early pregnancy we found an increase in the proportion of women consuming FV daily or more frequently.,Conclusion,[170421],[23388],[23512],[False],[0],[0],[False],['0']
30309,PMC5381088,28291,"As pre-pregnancy diet is an important predictor for diet during pregnancy as well as for pregnancy outcome and future health for the mother and child, future interventions should focus on women planning, or at risk for, pregnancy.",Conclusion,[170436],[23513],[23743],[False],[0],[0],[False],['0']
30310,PMC5381088,28292,Abbreviations,Abbreviations,[170451],[23744],[23758],[False],[0],[0],[False],['0']
30311,PMC5381088,28293,BMI Body Mass Index,Abbreviations|BMI Body Mass Index,[170466],[23759],[23778],[False],[0],[0],[False],['0']
30312,PMC5381088,28294,CI Confidence interval,Abbreviations|CI Confidence interval,[170481],[23779],[23801],[False],[0],[0],[False],['0']
30313,PMC5381088,28295,FFQ Food frequency questionnaire,Abbreviations|FFQ Food frequency questionnaire,[170496],[23802],[23834],[False],[0],[0],[False],['0']
30314,PMC5381088,28296,FV Fruits and vegetables,Abbreviations|FV Fruits and vegetables,[170511],[23835],[23859],[False],[0],[0],[False],['0']
30315,PMC5381088,28297,GA Gestational age,Abbreviations|GA Gestational age,[170526],[23860],[23878],[False],[0],[0],[False],['0']
30316,PMC5381088,28298,MoBa Norwegian Mother and Child Cohort Study,Abbreviations|MoBa Norwegian Mother and Child Cohort Study,[170541],[23879],[23923],[False],[0],[0],[False],['0']
30317,PMC5381088,28299,NFFD Norwegian Fit for Delivery,Abbreviations|NFFD Norwegian Fit for Delivery,[170556],[23924],[23955],[False],[0],[0],[False],['0']
30318,PMC5381088,28300,SD Standard deviationAcknowledgements,Abbreviations|SD Standard deviationAcknowledgements,[170571],[23956],[23993],[False],[0],[0],[False],['0']
30319,PMC5381088,28301,The authors would like to thank the women who agreed to participate in the NFFD trial and the midwives at the healthcare clinic who recruited the women and provided and provided baseline data.,Abbreviations|SD Standard deviationAcknowledgements,[170586],[23994],[24186],[False],[0],[0],[False],['0']
30320,PMC5381088,28302,Funding,Abbreviations|Funding,[170601],[24187],[24194],[False],[0],[0],[False],['0']
30321,PMC5381088,28303,The NFFD trial was financed by a grant from South-Eastern Norway Regional Health Authority.,Abbreviations|Funding,[170616],[24195],[24286],[False],[0],[0],[False],['0']
30322,PMC5381088,28304,Additional funding is provided by the municipalities of southern Norway and by University of Agder.,Abbreviations|Funding,[170631],[24287],[24386],[False],[0],[0],[False],['0']
30323,PMC5381088,28305,"The funders had no role in design, analysis or writing of this paper.",Abbreviations|Funding,[170646],[24387],[24456],[False],[0],[0],[False],['0']
30324,PMC5381088,28306,Availability of data and materials,Abbreviations|Availability of data and materials,[170661],[24457],[24491],[False],[0],[0],[False],['0']
30325,PMC5381088,28307,Please contact the corresponding author.,Abbreviations|Please contact the corresponding author.,[170676],[24492],[24532],[False],[0],[0],[False],['0']
30326,PMC5381088,28308,Authors’ contribution,Abbreviations|Authors’ contribution,[170691],[24533],[24554],[False],[0],[0],[False],['0']
30327,PMC5381088,28309,"LRS, IV and EB conceived the FFD study.",Abbreviations|Authors’ contribution,[170706],[24555],[24594],[False],[0],[0],[False],['0']
30328,PMC5381088,28310,"MS, NCØ and EB designed the present study.",Abbreviations|Authors’ contribution,[170721],[24595],[24637],[False],[0],[0],[False],['0']
30329,PMC5381088,28311,MS drafted the rationale.,Abbreviations|Authors’ contribution,[170736],[24638],[24663],[False],[0],[0],[False],['0']
30330,PMC5381088,28312,LRS was responsible for the data collection.,Abbreviations|Authors’ contribution,[170751],[24664],[24708],[False],[0],[0],[False],['0']
30331,PMC5381088,28313,MS and EB carried out statistical procedures.,Abbreviations|Authors’ contribution,[170766],[24709],[24754],[False],[0],[0],[False],['0']
30332,PMC5381088,28314,MS drafted the paper.,Abbreviations|Authors’ contribution,[170781],[24755],[24776],[False],[0],[0],[False],['0']
30333,PMC5381088,28315,All the authors revised the paper critically.,Abbreviations|Authors’ contribution,[170796],[24777],[24822],[False],[0],[0],[False],['0']
30334,PMC5381088,28316,All authors read and approved the final manuscript.,Abbreviations|Authors’ contribution,[170811],[24823],[24874],[False],[0],[0],[False],['0']
30335,PMC5381088,28317,Competing interests,Abbreviations|Competing interests,[170826],[24875],[24894],[False],[0],[0],[False],['0']
30336,PMC5381088,28318,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[170841],[24895],[24953],[False],[0],[0],[False],['0']
30337,PMC5381088,28319,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[170856],[24954],[24996],[False],[0],[0],[False],['0']
30338,PMC5381088,28320,This study was conducted according to the guidelines laid down in the Declaration of Helsinki of 1975 as revised in 2008.,Abbreviations|Ethics approval and consent to participate,[170871],[24997],[25118],[False],[0],[0],[False],['0']
30339,PMC5381088,28321,Research clearance was obtained from the Norwegian Regional Committee for Medical Research Ethics South-East C (REK reference 2009/429).,Abbreviations|Ethics approval and consent to participate,[170886],[25119],[25255],[False],[0],[0],[False],['0']
30340,PMC5381088,28322,The Fit for Delivery trial has the Clinical Trials registration: clinicaltrial.gov NCT01001689.,Abbreviations|Ethics approval and consent to participate,[170901],[25256],[25351],[False],[0],[0],[False],['0']
30341,PMC5381088,28323,All women participating in this study were given written information and consented to participate.,Abbreviations|Ethics approval and consent to participate,[170916],[25352],[25450],[False],[0],[0],[False],['0']
30342,PMC5381088,28324,"They were informed of the possibility to withdraw their consent at any time without any consequences regarding care during pregnancy, birth and the postnatal period.",Abbreviations|Ethics approval and consent to participate,[170931],[25451],[25616],[False],[0],[0],[False],['0']
30343,PMC5381088,28325,Publisher’s Note,Abbreviations|Publisher’s Note,[170946],[25617],[25633],[False],[0],[0],[False],['0']
30344,PMC5381088,28326,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[170961],[25634],[25752],[False],[0],[0],[False],['0']
30345,PMC5390457,24839,Implementing 360° Quantified Self for childhood obesity: feasibility study and experiences from a weight loss camp in Qatar,Title,[145209],[37365],[123],[False],[0],[0],[False],['0']
30346,PMC5390457,24840,Background,Abstract,[145218],[124],[135],[False],[0],[0],[False],['0']
30347,PMC5390457,24841,"The explosion of consumer electronics and social media are facilitating the rise of the Quantified Self (QS) movement where millions of users are tracking various aspects of their daily life using social media, mobile technology, and wearable devices.",Abstract,[145227],[136],[387],[False],[0],[0],[False],['0']
30348,PMC5390457,24842,"Data from mobile phones, wearables and social media can facilitate a better understanding of the health behaviors of individuals.",Abstract,[145236],[388],[517],[False],[0],[0],[False],['0']
30349,PMC5390457,24843,"At the same time, there is an unprecedented increase in childhood obesity rates worldwide.",Abstract,[145245],[518],[608],[False],[0],[0],[False],['0']
30350,PMC5390457,24844,"This is a cause for grave concern due to its potential long-term health consequences (e.g., diabetes or cardiovascular diseases).",Abstract,[145254],[609],[738],[False],[0],[0],[False],['0']
30351,PMC5390457,24845,Childhood obesity is highly prevalent in Qatar and the Gulf Region.,Abstract,[145263],[739],[806],[False],[0],[0],[False],['0']
30352,PMC5390457,24846,"In this study we examine the feasibility of capturing quantified-self data from social media, wearables and mobiles within a weight lost camp for overweight children in Qatar.",Abstract,[145272],[807],[982],[False],[0],[0],[False],['0']
30353,PMC5390457,24847,Methods,Abstract,[145281],[983],[990],[False],[0],[0],[False],['0']
30354,PMC5390457,24848,"Over 50 children (9–12 years old) and parents used a wide range of technologies, including wearable sensors (actigraphy), mobile and social media (WhatsApp and Instagram) to collect data related to physical activity and food, that was then integrated with physiological data to gain insights about their health habits.",Abstract,[145290],[991],[1309],[False],[0],[0],[False],['0']
30355,PMC5390457,24849,Results,Abstract,[145299],[1310],[1317],[False],[0],[0],[False],['0']
30356,PMC5390457,24850,360QS allows for capturing insights on the behavioral patterns of children and serves as a mechanism to reinforce education of their mothers via social media.,Abstract,[145308],[1318],[1476],[False],[0],[0],[False],['0']
30357,PMC5390457,24851,"We also identified human factors, such as gender and cultural acceptability aspects that can affect the implementation of this technology beyond a feasibility study.",Abstract,[145317],[1477],[1642],[False],[0],[0],[False],['0']
30358,PMC5390457,24852,"Furthermore, technical challenges regarding the visualization and integration of heterogeneous and sparse data sets are described in the paper.",Abstract,[145326],[1643],[1786],[False],[0],[0],[False],['0']
30359,PMC5390457,24853,Conclusions,Abstract,[145335],[1787],[1798],[False],[0],[0],[False],['0']
30360,PMC5390457,24854,We proved the feasibility of using 360QS in childhood obesity through this pilot study.,Abstract,[145344],[1799],[1886],[False],[0],[0],[False],['0']
30361,PMC5390457,24855,"However, in order to fully implement the 360QS technology careful planning and integration in the health professionals’ workflow is needed.",Abstract,[145353],[1887],[2026],[False],[0],[0],[False],['0']
30362,PMC5390457,24856,Trial Registration,Abstract,[145362],[2027],[2045],[False],[0],[0],[False],['0']
30363,PMC5390457,24857,The trial where this study took place is registered at ClinicalTrials.gov on 14 November 2016 (NCT02972164).,Abstract,[145371],[2046],[2154],[False],[0],[0],[False],['0']
30364,PMC5390457,24858,Background,Background,[145380],[2155],[2166],[False],[0],[0],[False],['0']
30365,PMC5390457,24859,"Childhood obesity is a growing epidemic worldwide [1, 2].",Background,[145389],[2167],[2224],[False],[0],[0],[False],['0']
30366,PMC5390457,24860,"Rapid societal transformations in the Gulf Co-operation Council (GCC) region, which includes Qatar, has led to a commensurate rise in lifestyle related diseases and increased rates of childhood obesity.",Background,[145398],[2225],[2427],[False],[0],[0],[False],['0']
30367,PMC5390457,24861,"Unhealthy habits such as eating high caloric fast food, and a sedentary lifestyle starts at an early age and can have long term consequences.",Background,[145407],[2428],[2569],[False],[0],[0],[False],['0']
30368,PMC5390457,24862,"New technologies can help in tackling childhood obesity by providing tools to monitor and analyze the lifestyle factors, influencing an individual’s health and well-being, and providing a new channel for healthcare interventions.",Background,[145416],[2570],[2799],[False],[0],[0],[False],['0']
30369,PMC5390457,24863,"In this paper we present the experiences in deploying the 360° Quantified Self (360QS) system, a concept we introduced in [3], within a clinical study for tackling childhood obesity in Qatar [4].",Background,[145425],[2800],[2995],[False],[0],[0],[False],['0']
30370,PMC5390457,24864,"360QS is defined as a quantified-self approach providing a holistic view of the user, by integrating rich information about an individual’s health, including 1) health factors (e.g.",Background,[145434],[2996],[3177],[False],[0],[0],[False],['0']
30371,PMC5390457,24865,"social influences) gathered from social media, 2) physical activity sensed from mobile apps, 3) body sensing data from wearable activity tracker, 4) food image analysis and 5) general health data such as weight, height, or body composition.",Background,[145443],[3178],[3418],[False],[0],[0],[False],['0']
30372,PMC5390457,24866,We must notice that the 360QS approach as defined by Haddadi et al.,Background,[145452],[3419],[3486],[False],[0],[0],[False],['0']
30373,PMC5390457,24867,[3] also involves the capturing of data from individuals to help the decision making of both professionals and individuals.,Background,[145461],[3487],[3610],[False],[0],[0],[False],['0']
30374,PMC5390457,24868,"Although our approach is not focused on individuals who have decided to quantify themselves, we do focus on a health intervention where the individuals can take active role in capture information about their health.",Background,[145470],[3611],[3826],[False],[0],[0],[False],['0']
30375,PMC5390457,24869,360QS data can be extremely valuable since lifestyle related factors are often hard to acquire in a clinical encounter.,Background,[145479],[3827],[3946],[False],[0],[0],[False],['0']
30376,PMC5390457,24870,"Hence, 360QS data can provide a holistic view of the patients’ context that has health implications, in order to facilitate the decision making of patients, caregivers and healthcare professionals.",Background,[145488],[3947],[4144],[False],[0],[0],[False],['0']
30377,PMC5390457,24871,"In this feasibility study we also explored how human factors, in particular gender differences, have a major influence on technology acceptance and data collection.",Background,[145497],[4145],[4309],[False],[0],[0],[False],['0']
30378,PMC5390457,24872,Objectives,Background|Objectives,[145506],[4310],[4320],[False],[0],[0],[False],['0']
30379,PMC5390457,24873,"Traditionally, Quantified Self technologies have been used by empowered health consumers, which might not be the more representative type of individuals in need of behavioral change support.",Background|Objectives,[145515],[4321],[4511],[False],[0],[0],[False],['0']
30380,PMC5390457,24874,In our study we wanted to explore the feasibility of capturing health-related information using quantified self-technologies by overweight children and their families.,Background|Objectives,[145524],[4512],[4679],[False],[0],[0],[False],['0']
30381,PMC5390457,24875,"Our study is based on the Technology Acceptance Model [5], but instead of focusing on ”Perceived Usefulness”,”Perceived Easy of Use”,”Attitude Towards Using” or ”Behavioral Intention to Use” we focused on ”Actual System Usage” with regards to the 360QS technologies that were deployed during the obesity trial.",Background|Objectives,[145533],[4680],[4990],[False],[0],[0],[False],['0']
30382,PMC5390457,24876,Combining the actual 360QS system usage with the demographic data of the users would allow us to better understand how 360QS could be used for this type of population.,Background|Objectives,[145542],[4991],[5158],[False],[0],[0],[False],['0']
30383,PMC5390457,24877,"In order to evaluate ”Actual System Usage”, we can rely on the amount of data captured by individuals as an indicator of system usage.",Background|Objectives,[145551],[5159],[5293],[False],[0],[0],[False],['0']
30384,PMC5390457,24878,Childhood Obesity,Background|Childhood Obesity,[145560],[5294],[5311],[False],[0],[0],[False],['0']
30385,PMC5390457,24879,Obesity and the lack of physical activity are the major factors leading to the rise of non-communicable diseases such as diabetes.,Background|Childhood Obesity,[145569],[5312],[5442],[False],[0],[0],[False],['0']
30386,PMC5390457,24880,"Childhood obesity is a global epidemic that affects both developing and developed countries [1, 2].",Background|Childhood Obesity,[145578],[5443],[5542],[False],[0],[0],[False],['0']
30387,PMC5390457,24881,"Obesity among children is especially worrying, since the impact on healthcare costs can be a major burden in the future.",Background|Childhood Obesity,[145587],[5543],[5663],[False],[0],[0],[False],['0']
30388,PMC5390457,24882,"Furthermore, obesity has been found to increase the risk of a host of health conditions (e.g., sleep apnea, diabetes, cancer, or stroke) [2, 6–8] and also reduce mental well-being (e.g., leading to low self-esteem) [9].",Background|Childhood Obesity,[145596],[5664],[5883],[False],[0],[0],[False],['0']
30389,PMC5390457,24883,"Obesity is a highly complex condition where genetics, environment, education, socio-economic status, climate, schools, and many other factors play a role.",Background|Childhood Obesity,[145605],[5884],[6038],[False],[0],[0],[False],['0']
30390,PMC5390457,24884,Each of these factors can affect individuals differently.,Background|Childhood Obesity,[145614],[6039],[6096],[False],[0],[0],[False],['0']
30391,PMC5390457,24885,"Ideally, any health intervention to tackle childhood obesity should take into account all aspects to maximize its chance of success.",Background|Childhood Obesity,[145623],[6097],[6229],[False],[0],[0],[False],['0']
30392,PMC5390457,24886,"However, it is not always possible to obtain information about the environment of the affected youth.",Background|Childhood Obesity,[145632],[6230],[6331],[False],[0],[0],[False],['0']
30393,PMC5390457,24887,"Furthermore, asking the patient is not always a feasible solution.",Background|Childhood Obesity,[145641],[6332],[6398],[False],[0],[0],[False],['0']
30394,PMC5390457,24888,"For example, there is evidence that self-reported questionnaires for behaviors such as sleeping habits can be less reliable than data obtained from wearable devices [10].",Background|Childhood Obesity,[145650],[6399],[6569],[False],[0],[0],[False],['0']
30395,PMC5390457,24889,"For these reasons, designing interventions aimed at weight loss and physical activity promotion is a challenging task [11].",Background|Childhood Obesity,[145659],[6570],[6693],[False],[0],[0],[False],['0']
30396,PMC5390457,24890,"Many external factors (e.g., public transportation, diet, culture, family, schools) can positively or negatively affect the efficacy of public health interventions.",Background|Childhood Obesity,[145668],[6694],[6858],[False],[0],[0],[False],['0']
30397,PMC5390457,24891,Environmental contexts heavily affect decision making; for example social networks have been found to influence obesity [12] both positively and negatively.,Background|Childhood Obesity,[145677],[6859],[7015],[False],[0],[0],[False],['0']
30398,PMC5390457,24892,Another important factor to consider is the temporal aspect of when health decisions are made.,Background|Childhood Obesity,[145686],[7016],[7110],[False],[0],[0],[False],['0']
30399,PMC5390457,24893,Quantified self for personal health,Background|Quantified self for personal health,[145695],[7111],[7146],[False],[0],[0],[False],['0']
30400,PMC5390457,24894,Information about personal health and lifestyles can provide insights to patients and healthcare professionals to help them in decision making.,Background|Quantified self for personal health,[145704],[7147],[7290],[False],[0],[0],[False],['0']
30401,PMC5390457,24895,"Studies have been conducted to provide health behavioral change interventions to promote physical activity at the right time (i.e., Ecological Momentary Interventions) using mobile technology [13].",Background|Quantified self for personal health,[145713],[7291],[7488],[False],[0],[0],[False],['0']
30402,PMC5390457,24896,Personal health tracking is not new.,Background|Quantified self for personal health,[145722],[7489],[7525],[False],[0],[0],[False],['0']
30403,PMC5390457,24897,"A population survey in the USA found that most American adults keep track of at least one health parameter (e.g., weight, diet, or physical activity) [14].",Background|Quantified self for personal health,[145731],[7526],[7681],[False],[0],[0],[False],['0']
30404,PMC5390457,24898,Related to the behavior of tracking our own health is the concept of Quantified Self.,Background|Quantified self for personal health,[145740],[7682],[7767],[False],[0],[0],[False],['0']
30405,PMC5390457,24899,"In a 2009 paper, M. Swan defined Quantified Self (QS) as: Quantified self-tracking is the regular collection of any data that can be measured about the self such as biological, physical, behavioral or environmental information” [15].",Background|Quantified self for personal health,[145749],[7768],[8001],[False],[0],[0],[False],['0']
30406,PMC5390457,24900,The rationale behind QS is that quantifying aspects of a daily life through maintaining journals or logs that can help the individual (or the caregiver) to better understand hidden patterns.,Background|Quantified self for personal health,[145758],[8002],[8192],[False],[0],[0],[False],['0']
30407,PMC5390457,24901,"For example, patients suffering from migraines have been advised to keep diaries of daily activities to identify triggers.",Background|Quantified self for personal health,[145767],[8193],[8315],[False],[0],[0],[False],['0']
30408,PMC5390457,24902,"Other common examples are food logs, menstruation diaries, growth and vaccination charts for children, and so on.",Background|Quantified self for personal health,[145776],[8316],[8429],[False],[0],[0],[False],['0']
30409,PMC5390457,24903,"Quantified Self is also present in social media, where people share their weight diaries [16], sleep logs [17], blood glucose levels [18], photos about eating preferences [19], etc.",Background|Quantified self for personal health,[145785],[8430],[8611],[False],[0],[0],[False],['0']
30410,PMC5390457,24904,The Quantified self-movement in the health domain is also often part of a social context [20].,Background|Quantified self for personal health,[145794],[8612],[8706],[False],[0],[0],[False],['0']
30411,PMC5390457,24905,Sensors and wearable technologies are sources of data for Health Quantified Self [21].,Background|Quantified self for personal health,[145803],[8707],[8793],[False],[0],[0],[False],['0']
30412,PMC5390457,24906,"In recent years the production costs of wearable devices have reduced drastically as they became major consumer products, especially in the fitness and health sector [22].",Background|Quantified self for personal health,[145812],[8794],[8965],[False],[0],[0],[False],['0']
30413,PMC5390457,24907,"In parallel, smartphones with multiple sensors (e.g., accelerometers or light sensors) have become mainstream.",Background|Quantified self for personal health,[145821],[8966],[9076],[False],[0],[0],[False],['0']
30414,PMC5390457,24908,"Moreover, implantable devices are often integrated with wearable devices, such as implantable glucose meters.",Background|Quantified self for personal health,[145830],[9077],[9186],[False],[0],[0],[False],['0']
30415,PMC5390457,24909,Also mobile devices are integrating data from smart homes and Internet of Things devices such as smoke detectors.,Background|Quantified self for personal health,[145839],[9187],[9300],[False],[0],[0],[False],['0']
30416,PMC5390457,24910,These developments have all led to the Quantified Self movement becoming more mainstream and at a point where incorporating these technologies within the health domain.,Background|Quantified self for personal health,[145848],[9301],[9469],[False],[0],[0],[False],['0']
30417,PMC5390457,24911,The popularity of QS technologies for fitness and wellness is paving the way for the development of health applications to support health behavioral change.,Background|Quantified self for personal health,[145857],[9470],[9626],[False],[0],[0],[False],['0']
30418,PMC5390457,24912,This also highlights the need to study the use of QS to support behavioral change in populations such as overweight children.,Background|Quantified self for personal health,[145866],[9627],[9752],[False],[0],[0],[False],['0']
30419,PMC5390457,24913,The efforts towards the creation of data-driven holistic views of the individual are reaching unprecedented levels as part of the precision medicine and Big Data for Health initiatives [23].,Background|Quantified self for personal health,[145875],[9753],[9943],[False],[0],[0],[False],['0']
30420,PMC5390457,24914,"For example the Kavli HUMAN Project is an effort to aggregate health-related data from 10,000 individuals in New York City containing health, education, genetics, environmental and lifestyle information that will be collected over a period of 20 years [24].",Background|Quantified self for personal health,[145884],[9944],[10201],[False],[0],[0],[False],['0']
30421,PMC5390457,24915,Methods,Methods,[145893],[10202],[10210],[False],[0],[0],[False],['0']
30422,PMC5390457,24916,The 360QS technology was tested within a research project for childhood obesity in Qatar called ”Adaptive Cognitive Behavioral Approach to Addressing Overweight and Obesity among Qatari Youth” (ICAN Study) [4].,Methods,[145902],[10211],[10421],[False],[0],[0],[False],['0']
30423,PMC5390457,24917,The project was led by Qatar University and consequently received ethics approval from the Qatar University Institutional Review Board.,Methods,[145911],[10422],[10557],[False],[0],[0],[False],['0']
30424,PMC5390457,24918,"In addition, all participants and their parents/guardians, provided informed consent prior to participation.",Methods,[145920],[10558],[10666],[False],[0],[0],[False],['0']
30425,PMC5390457,24919,Table 1 Timeline of the ICAN Study.,Methods,[145929],[10667],[10702],[False],[0],[0],[False],['0']
30426,PMC5390457,24920,Table 1 lists the timeline and processes involved in the ICAN study.,Methods,[145938],[10703],[10771],[False],[0],[0],[False],['0']
30427,PMC5390457,24921,The 360QS technologies were deployed in the intervention group from January to August 2016 but not all of the participants consented to using the provided 360QS technologies.,Methods,[145947],[10772],[10946],[False],[0],[0],[False],['0']
30428,PMC5390457,24922,"Therefore, in this paper, we focus on the subset of participants from the study that interacted with the 360QS technologies and the feasibility of using such technology.",Methods,[145956],[10947],[11116],[False],[0],[0],[False],['0']
30429,PMC5390457,24923,Demographics,Methods|Demographics,[145965],[11117],[11130],[False],[0],[0],[False],['0']
30430,PMC5390457,24924,"Overweight and obese children from several male and female Qatari schools, in the age range of 9 to 12, participated in the interventions.",Methods|Demographics,[145974],[11131],[11269],[False],[0],[0],[False],['0']
30431,PMC5390457,24925,The schools were randomized between intervention groups and control groups.,Methods|Demographics,[145983],[11270],[11345],[False],[0],[0],[False],['0']
30432,PMC5390457,24926,There were 53 boys and 55 girls in the intervention group while the control group consisted of 60 boys and 59 girls.,Methods|Demographics,[145992],[11346],[11462],[False],[0],[0],[False],['0']
30433,PMC5390457,24927,Health intervention,Methods|Health intervention,[146001],[11463],[11482],[False],[0],[0],[False],['0']
30434,PMC5390457,24928,"The health intervention consisted of a set of health coaching and education actions as follows:Health camp: two-week weight management camp from January 24 to February 4, 2016, which included physical and social activities, lifestyle coaching and nutrition counseling..",Methods|Health intervention,[146010],[11483],[11752],[False],[0],[0],[False],['0']
30435,PMC5390457,24929,"Weekend clubs: ten-week program from February 20, 2016, where every weekend for four hours, participants received further reinforcement to acquire healthy behaviors.. Summer break: during the summer break (June - August 2016) a group of mothers participated in a mobile intervention using WhatsApp to reinforce healthy eating and behaviors.",Methods|Health intervention,[146019],[11753],[12093],[False],[0],[0],[False],['0']
30436,PMC5390457,24930,The 360QS implementation,Methods|Health intervention,[146028],[12094],[12120],[False],[0],[0],[False],['0']
30437,PMC5390457,24931,The 360QS implementation in the ICAN Study involved different technologies:Wearable devices: Wearable devices (actigraphy sensors) were used to monitor sleep and physical activity of the participants..,Methods|Health intervention,[146037],[12121],[12322],[False],[0],[0],[False],['0']
30438,PMC5390457,24932,"Mobile Social Media (Photos and Messaging): We incorporated the use of social media for tracking dietary habits of participants (Instagram) and health education of mothers (WhatsApp).. Health camp food Photos: We also captured photos of the food consumed by participants during the two-week health camp to gain insights on dietary preferences.. Physiological Data: Physical health of the participants was measured periodically via height, weight, etc.",Methods|Health intervention,[146046],[12323],[12774],[False],[0],[0],[False],['0']
30439,PMC5390457,24933,to obtain an overall picture of the impact of the intervention on participants’ health.,Methods|Health intervention,[146055],[12775],[12862],[False],[0],[0],[False],['0']
30440,PMC5390457,24934,The wearable devices and mobile social media are clear examples of QS technologies that can be used to capture data about individuals’ behaviors.,Methods|Health intervention,[146064],[12863],[13010],[False],[0],[0],[False],['0']
30441,PMC5390457,24935,"The health camp food photos and physiological data was not captured by the individuals, but the research team.",Methods|Health intervention,[146073],[13011],[13121],[False],[0],[0],[False],['0']
30442,PMC5390457,24936,The food photos can be combined with the other data sources to gain more insights on the health behaviors of the individuals.,Methods|Health intervention,[146082],[13122],[13247],[False],[0],[0],[False],['0']
30443,PMC5390457,24937,Fig.,Methods|Health intervention,[146091],[13248],[13252],[False],[0],[0],[False],['0']
30444,PMC5390457,24938,1 Datasets overview for the 360QS implementation - Volume of collected data from different sources per day.,Methods|Health intervention,[146100],[13253],[13360],[False],[0],[0],[False],['0']
30445,PMC5390457,24939,The volume is given in terms of number of participants from which data have been collected for a given day.,Methods|Health intervention,[146109],[13361],[13468],[False],[0],[0],[False],['0']
30446,PMC5390457,24940,Each row shows the volume from unique data sources (top five rows) and from combinations of two or three data sources (bottom rows).,Methods|Health intervention,[146118],[13469],[13601],[False],[0],[0],[False],['0']
30447,PMC5390457,24941,The combinations of sources are useful to show those data sources for which data is available for the same participants so the complementarity between various data sources can be analyzed in these cases.,Methods|Health intervention,[146127],[13602],[13805],[False],[0],[0],[False],['0']
30448,PMC5390457,24942,Figure 1 shows the data collected over time for the 2016 trial using each 360QS technology.,Methods|Health intervention,[146136],[13806],[13897],[False],[0],[0],[False],['0']
30449,PMC5390457,24943,It also indicates the time periods with data overlaps.,Methods|Health intervention,[146145],[13898],[13952],[False],[0],[0],[False],['0']
30450,PMC5390457,24944,"For example, between January 31, 2016 and February 4, 2016, for about 10 participants, we have food photos collected during the camp, physiological data, as well as actigraphy sensor data.",Methods|Health intervention,[146154],[13953],[14141],[False],[0],[0],[False],['0']
30451,PMC5390457,24945,"As explained below, we need to be aware that these technologies were not applied homogeneously in all the subjects.",Methods|Health intervention,[146163],[14142],[14257],[False],[0],[0],[False],['0']
30452,PMC5390457,24946,"Not all the mothers accepted to participate in the WhatsApp intervention, and only a subsets of subjects received mobile phones for taking food photos using Instagram.",Methods|Health intervention,[146172],[14258],[14425],[False],[0],[0],[False],['0']
30453,PMC5390457,24947,All the data collected during the trial was integrated using anonymized participant identifiers and stored in a secure database.,Methods|Health intervention,[146181],[14426],[14555],[False],[0],[0],[False],['0']
30454,PMC5390457,24948,This integration facilitated the study and analysis of the data.,Methods|Health intervention,[146190],[14556],[14620],[False],[0],[0],[False],['0']
30455,PMC5390457,24949,Physiological data,Methods|Physiological data,[146199],[14621],[14639],[False],[0],[0],[False],['0']
30456,PMC5390457,24950,"As part of the clinical research protocol, all the participants’ physiological parameters were measured over time.",Methods|Physiological data,[146208],[14640],[14754],[False],[0],[0],[False],['0']
30457,PMC5390457,24951,"That includes weight, height, body mass index (BMI), body fat percentage, waist circumference and blood pressure.",Methods|Physiological data,[146217],[14755],[14868],[False],[0],[0],[False],['0']
30458,PMC5390457,24952,"These parameters were taken during recruitment, start and end of the health camp, during the weekend clubs and also at the end of the program.",Methods|Physiological data,[146226],[14869],[15011],[False],[0],[0],[False],['0']
30459,PMC5390457,24953,Health camp: food photos,Methods|Physiological data,[146235],[15012],[15036],[False],[0],[0],[False],['0']
30460,PMC5390457,24954,Fig.,Methods|Physiological data,[146244],[15037],[15041],[False],[0],[0],[False],['0']
30461,PMC5390457,24955,2 Example of food tray before and after meal.,Methods|Physiological data,[146253],[15042],[15087],[False],[0],[0],[False],['0']
30462,PMC5390457,24956,"During the two-week health camp, before and after photos of food trays (breakfast and lunch) were manually taken for all participants for ten days, i.e.",Methods|Physiological data,[146262],[15088],[15240],[False],[0],[0],[False],['0']
30463,PMC5390457,24957,"twenty meals, as shown in Fig.",Methods|Physiological data,[146271],[15241],[15271],[False],[0],[0],[False],['0']
30464,PMC5390457,24958,2.,Methods|Physiological data,[146280],[15272],[15274],[False],[0],[0],[False],['0']
30465,PMC5390457,24959,"The goal of this data collection was to learn food preferences of participants, which could in turn assist the nutrition professionals in designing diet plans for weight loss, and also give calories estimates of the food consumed during the camp.",Methods|Physiological data,[146289],[15275],[15521],[False],[0],[0],[False],['0']
30466,PMC5390457,24960,Weekend clubs: actigraphy sensor,Methods|Physiological data,[146298],[15522],[15555],[False],[0],[0],[False],['0']
30467,PMC5390457,24961,"In order to study the physical activity and sleep patterns, we used actigraphy.",Methods|Physiological data,[146307],[15556],[15635],[False],[0],[0],[False],['0']
30468,PMC5390457,24962,Actigraphy sensors were given at the end of the health camp to be used during the weekend clubs.,Methods|Physiological data,[146316],[15636],[15732],[False],[0],[0],[False],['0']
30469,PMC5390457,24963,"An actigraphy device is a wearable medical device, which captures motion using accelerometers and other sensors to identify patterns in physical activity and sleep.",Methods|Physiological data,[146325],[15733],[15897],[False],[0],[0],[False],['0']
30470,PMC5390457,24964,We used the device Axivity AX3 (see product website: http://axivity.com/product/ax3) that has been used before in clinical studies [25].,Methods|Physiological data,[146334],[15898],[16034],[False],[0],[0],[False],['0']
30471,PMC5390457,24965,The Axivity device is waterproof and was given to participants to be worn at all times as a wristband.,Methods|Physiological data,[146343],[16035],[16137],[False],[0],[0],[False],['0']
30472,PMC5390457,24966,The device was given to 67 participants; 16 in the control group (8 boys and 8 girls) and 51 in the intervention group (26 boys and 25 girls).,Methods|Physiological data,[146352],[16138],[16280],[False],[0],[0],[False],['0']
30473,PMC5390457,24967,"Since the battery life of the device as well as its data storage memory is about four weeks, we recharged the devices and downloaded the data for participants in the intervention group multiple times during the weekend clubs.",Methods|Physiological data,[146361],[16281],[16506],[False],[0],[0],[False],['0']
30474,PMC5390457,24968,Weekend clubs: social media - instagram,Methods|Physiological data,[146370],[16507],[16546],[False],[0],[0],[False],['0']
30475,PMC5390457,24969,Fig.,Methods|Physiological data,[146379],[16547],[16551],[False],[0],[0],[False],['0']
30476,PMC5390457,24970,3 Instagram Photo uploaded by a participant.,Methods|Physiological data,[146388],[16552],[16596],[False],[0],[0],[False],['0']
30477,PMC5390457,24971,"A total of 50 mobile phones with a pre-configured Instagram account were given to parents of participants (30 boys and 20 girls) at the end of the health camp, to take photos of the food eaten by their children in the remaining duration of the program, and upload to the Instagram account.",Methods|Physiological data,[146397],[16597],[16886],[False],[0],[0],[False],['0']
30478,PMC5390457,24972,This was done in order to monitor impact of the health camp on the participants’ dietary habits and also capture dietary preferences of the families.,Methods|Physiological data,[146406],[16887],[17036],[False],[0],[0],[False],['0']
30479,PMC5390457,24973,Figure 3 shows one of the participants’ Instagram photo.,Methods|Physiological data,[146415],[17037],[17093],[False],[0],[0],[False],['0']
30480,PMC5390457,24974,Summer break: social media - WhatsApp,Methods|Physiological data,[146424],[17094],[17132],[False],[0],[0],[False],['0']
30481,PMC5390457,24975,Fig.,Methods|Physiological data,[146433],[17133],[17137],[False],[0],[0],[False],['0']
30482,PMC5390457,24976,4 Example of WhatsApp educational message sent by the moderator of the intervention.,Methods|Physiological data,[146442],[17138],[17222],[False],[0],[0],[False],['0']
30483,PMC5390457,24977,Translation for message 1:” Remember: restaurant food is high in calories and increases weight.” Message 2:” Can you promise to not let your kids eat out this week?,Methods|Physiological data,[146451],[17223],[17387],[False],[0],[0],[False],['0']
30484,PMC5390457,24978,Reply yes if you accept the challenge”.,Methods|Physiological data,[146460],[17388],[17427],[False],[0],[0],[False],['0']
30485,PMC5390457,24979,"In the ICAN study, face-to-face sessions with parents were organized for health education.",Methods|Physiological data,[146469],[17428],[17518],[False],[0],[0],[False],['0']
30486,PMC5390457,24980,"Furthermore, we contacted parents asking for their interest in using mobile technology or social media to reinforce the educational support.",Methods|Physiological data,[146478],[17519],[17659],[False],[0],[0],[False],['0']
30487,PMC5390457,24981,"Only the mothers showed interest in such additional support, with the majority mentioning WhatsApp as their preferred communication channel.",Methods|Physiological data,[146487],[17660],[17800],[False],[0],[0],[False],['0']
30488,PMC5390457,24982,We designed an educational intervention for mothers using WhatsApp for a 12-week period of the summer break.,Methods|Physiological data,[146496],[17801],[17909],[False],[0],[0],[False],['0']
30489,PMC5390457,24983,"Educational content was adapted to the WhatsApp channel (e.g., short educational messages, see Fig.",Methods|Physiological data,[146505],[17910],[18009],[False],[0],[0],[False],['0']
30490,PMC5390457,24984,4).,Methods|Physiological data,[146514],[18010],[18013],[False],[0],[0],[False],['0']
30491,PMC5390457,24985,"These messages also incorporated the use of behavioral nudges, in particular commitment to support the health changes of their children.",Methods|Physiological data,[146523],[18014],[18150],[False],[0],[0],[False],['0']
30492,PMC5390457,24986,"The group was moderated by a dietitian and a pharmacist who shared messages that included: daily reminders, weekly healthy tips, weekly commitment for a health change and answers to questions raised by mothers.",Methods|Physiological data,[146532],[18151],[18361],[False],[0],[0],[False],['0']
30493,PMC5390457,24987,"A total of 21 mothers were enrolled in this study, with 3 dropouts at the beginning of the study, resulting in 18 participants (mothers of 7 boys and 11 girls) who completed the study.",Methods|Physiological data,[146541],[18362],[18547],[False],[0],[0],[False],['0']
30494,PMC5390457,24988,"The data collected included the participation in the WhatsApp group, responses to the health tips and also whether the participants had seen the messages or not in order to evaluate the attrition of this intervention.",Methods|Physiological data,[146550],[18548],[18765],[False],[0],[0],[False],['0']
30495,PMC5390457,24989,Results,Results,[146559],[18766],[18774],[False],[0],[0],[False],['0']
30496,PMC5390457,24990,Health camp: food photos,Results,[146568],[18775],[18799],[False],[0],[0],[False],['0']
30497,PMC5390457,24991,"The dataset collected was cleaned and labeled using participant identifier, meal type (lunch or breakfast) and food tray state (before-meal or after-meal), resulting in 2,753 photos.",Results,[146577],[18800],[18982],[False],[0],[0],[False],['0']
30498,PMC5390457,24992,An extensive menu list was prepared by identifying all food items served during the camp.,Results,[146586],[18983],[19072],[False],[0],[0],[False],['0']
30499,PMC5390457,24993,The food photos were grouped into before-meal and after-meal photos per user per day per meal.,Results,[146595],[19073],[19167],[False],[0],[0],[False],['0']
30500,PMC5390457,24994,"The labeling tasks were then assigned to local volunteers via a web application where they labeled each task to indicate food items present on the participants’ trays, along with the amount left on the tray at the end of the meal for each food item.",Results,[146604],[19168],[19417],[False],[0],[0],[False],['0']
30501,PMC5390457,24995,Fig.,Results,[146613],[19418],[19422],[False],[0],[0],[False],['0']
30502,PMC5390457,24996,5 Percentage of food left on trays grouped by food type.,Results,[146622],[19423],[19479],[False],[0],[0],[False],['0']
30503,PMC5390457,24997,"Figure 5 shows the percentage of food left on participants trays grouped into six major food types - fruits; vegetables; dairy (milk, cheese, yogurt); fish, poultry, meat; grains and beans/legumes; desserts and sugary food like jam.",Results,[146631],[19480],[19712],[False],[0],[0],[False],['0']
30504,PMC5390457,24998,This data is then separated by gender to get food preferences of girls vs. boys.,Results,[146640],[19713],[19793],[False],[0],[0],[False],['0']
30505,PMC5390457,24999,"Vegetables and fruits are the food types most left on trays, where as meat and grains were left the least.",Results,[146649],[19794],[19900],[False],[0],[0],[False],['0']
30506,PMC5390457,25000,"This could indicate the food habits of the families of the participants where most meals might consist only of the main course, e.g., meat with rice/bread, with less focus on fruits and vegetables.",Results,[146658],[19901],[20098],[False],[0],[0],[False],['0']
30507,PMC5390457,25001,Fig.,Results,[146667],[20099],[20104],[False],[0],[0],[False],['0']
30508,PMC5390457,25002,6 Percentage of food left over all days of the camp.,Results,[146676],[20105],[20157],[False],[0],[0],[False],['0']
30509,PMC5390457,25003,"Calculating the amount of food left over the course of the health camp, it is evident from Fig.",Results,[146685],[20158],[20253],[False],[0],[0],[False],['0']
30510,PMC5390457,25004,"6 that more participants started finishing the food they took, indicating either that they stopped taking foods they realized they did not like, or that they got used to all the different food types and increased their intake of the healthier foods as well.",Results,[146694],[20254],[20511],[False],[0],[0],[False],['0']
30511,PMC5390457,25005,"Table 2 Correlation of the proportion of food eaten, grouped by a food type, to the child’s change in BMI.",Results,[146703],[20512],[20619],[False],[0],[0],[False],['0']
30512,PMC5390457,25006,"Table 2 shows the correlation of the proportion of foods eaten, grouped by food type at a lower granularity, to the change in a child’s BMI.",Results,[146712],[20620],[20760],[False],[0],[0],[False],['0']
30513,PMC5390457,25007,Most relationships are not significant.,Results,[146721],[20761],[20800],[False],[0],[0],[False],['0']
30514,PMC5390457,25008,"However, the negative relation of porridge and dairy at fairly low p values may point towards the importance of breakfast foods.",Results,[146730],[20801],[20929],[False],[0],[0],[False],['0']
30515,PMC5390457,25009,The BMI change is comparing the values from January (beginning of health camp) with the values from May (the end of Weekend clubs).,Results,[146739],[20930],[21061],[False],[0],[0],[False],['0']
30516,PMC5390457,25010,"Therefore, with regards to food photos the BMI just shows an overall tendency with regards to health habits.",Results,[146748],[21062],[21170],[False],[0],[0],[False],['0']
30517,PMC5390457,25011,Weekend clubs: actigraphy sensor,Results,[146757],[21171],[21204],[False],[0],[0],[False],['0']
30518,PMC5390457,25012,The actigraphy sensor was given to 51 participants.,Results,[146766],[21205],[21256],[False],[0],[0],[False],['0']
30519,PMC5390457,25013,Normally these sensors are given for periods of one week to do an assessment of the levels of physical activity and sleep patterns.,Results,[146775],[21257],[21388],[False],[0],[0],[False],['0']
30520,PMC5390457,25014,In our study we opted to ask the participants to wear it for a longer period (a total of 12 weeks) in order to be able to monitor changes in physical activity and sleep during the health interventions.,Results,[146784],[21389],[21590],[False],[0],[0],[False],['0']
30521,PMC5390457,25015,"As expected the adherence declined overtime, and 21 devices got lost.",Results,[146793],[21591],[21660],[False],[0],[0],[False],['0']
30522,PMC5390457,25016,Fig.,Results,[146802],[21661],[21665],[False],[0],[0],[False],['0']
30523,PMC5390457,25017,7 User interface of the visual analytic tool for actigraphy sensor data The interface allows comparing two participants’ activity level (left side) for the full time period and on daily-based average during week and weekend days (right side).,Results,[146811],[21666],[21908],[False],[0],[0],[False],['0']
30524,PMC5390457,25018,Specific clinical measurements like BMI or body fat can also be compared during the same time period (line charts).,Results,[146820],[21909],[22024],[False],[0],[0],[False],['0']
30525,PMC5390457,25019,Figure 7 shows the visual analytic tool we developed to explore the actigraphy sensor data.,Results,[146829],[22025],[22116],[False],[0],[0],[False],['0']
30526,PMC5390457,25020,It shows the level of physical activity recorded by the actigraphy device through time for all children.,Results,[146838],[22117],[22221],[False],[0],[0],[False],['0']
30527,PMC5390457,25021,It also shows the total activity for boys and girls separately and allows getting detailed activity averaged per day in a user-selected time window.,Results,[146847],[22222],[22370],[False],[0],[0],[False],['0']
30528,PMC5390457,25022,"Relating the activity levels to the change in the child’s BMI during the study period, we compute Pearson product–moment correlation coefficient r at different levels.",Results,[146856],[22371],[22539],[False],[0],[0],[False],['0']
30529,PMC5390457,25023,The raw average number of minutes logged per day did not have a statistically significant relationship with the change in BMI.,Results,[146865],[22540],[22666],[False],[0],[0],[False],['0']
30530,PMC5390457,25024,"However, the number of active days, defined as days in which active minutes is non-zero, correlates with BMI change at r = −0.263 (p = 0.101), meaning the more days are recorded as active, the more negative the BMI change is.",Results,[146874],[22667],[22892],[False],[0],[0],[False],['0']
30531,PMC5390457,25025,"The relationship becomes less strong as we define active days more strictly: more than 30 active minutes per day results in r = −0.201 (p = 0.214), and more than 4 h r = −0.140 (p = 0.377).",Results,[146883],[22893],[23082],[False],[0],[0],[False],['0']
30532,PMC5390457,25026,This suggests that mere adherence to wearing of the device correlates with beneficial health outcomes.,Results,[146892],[23083],[23185],[False],[0],[0],[False],['0']
30533,PMC5390457,25027,"This however might be caused by increased engagement of wearable device users, not necessarily implying causality.",Results,[146901],[23186],[23300],[False],[0],[0],[False],['0']
30534,PMC5390457,25028,Weekend clubs: social media - instagram,Results,[146910],[23301],[23340],[False],[0],[0],[False],['0']
30535,PMC5390457,25029,Fig.,Results,[146919],[23341],[23345],[False],[0],[0],[False],['0']
30536,PMC5390457,25030,8 Instagram posts uploaded by users.,Results,[146928],[23346],[23382],[False],[0],[0],[False],['0']
30537,PMC5390457,25031,"Of the 50 mobile phones with a pre-configured Instagram account, only 25 were used for such purpose.",Results,[146937],[23383],[23483],[False],[0],[0],[False],['0']
30538,PMC5390457,25032,"The number of photos acquired was 937 in total, but the top 3 contributors (1 girl and 2 boys) uploaded 70 percent of the photos, as shown in Fig.",Results,[146946],[23484],[23630],[False],[0],[0],[False],['0']
30539,PMC5390457,25033,8.,Results,[146955],[23631],[23633],[False],[0],[0],[False],['0']
30540,PMC5390457,25034,Correlating the extent of use of this Instagram account to the change of child’s BMI results in r = −0.179 (p = 0.425).,Results,[146964],[23634],[23754],[False],[0],[0],[False],['0']
30541,PMC5390457,25035,"To overcome the low p-value due to sparsity, we employ a permutation test to test whether the relationship is significant compared to a randomly permuted outcome variable (here discretized to below/above average BMI change).",Results,[146973],[23755],[23979],[False],[0],[0],[False],['0']
30542,PMC5390457,25036,This approach results in a permuted p-value = 0.026.,Results,[146982],[23980],[24032],[False],[0],[0],[False],['0']
30543,PMC5390457,25037,Again this shows that more active users tended to slightly have better health outcomes but that this is most likely related with a higher level of engagement in their health.,Results,[146991],[24033],[24207],[False],[0],[0],[False],['0']
30544,PMC5390457,25038,Summer break: social media - WhatsApp,Results,[147000],[24208],[24245],[False],[0],[0],[False],['0']
30545,PMC5390457,25039,A total of 18 mothers participated in the WhatsApp support group after the Weekend clubs.,Results,[147009],[24246],[24335],[False],[0],[0],[False],['0']
30546,PMC5390457,25040,This was done to provide educational support during the summer break.,Results,[147018],[24336],[24405],[False],[0],[0],[False],['0']
30547,PMC5390457,25041,We analyzed the already acquired weight loss at the time of enrollment in WhatsApp.,Results,[147027],[24406],[24489],[False],[0],[0],[False],['0']
30548,PMC5390457,25042,That BMI change is comparing the values at beginning of health camp with the values at the end of Weekend clubs.,Results,[147036],[24490],[24602],[False],[0],[0],[False],['0']
30549,PMC5390457,25043,The children of participating mothers got an average BMI change of −0.058 compared to 0.0455 for those not participating (the different was not significant with p = 0.7879 and permuted p = 0.5709).,Results,[147045],[24603],[24800],[False],[0],[0],[False],['0']
30550,PMC5390457,25044,This indicates a bias where more engaged mothers in terms of health are also more likely to opt-in for the enrollment in this social media intervention.,Results,[147054],[24801],[24953],[False],[0],[0],[False],['0']
30551,PMC5390457,25045,"The interaction declined overtime with regards of messages sent in the WhatsApp group (146 in June,108 in July and 23 in August).",Results,[147063],[24954],[25083],[False],[0],[0],[False],['0']
30552,PMC5390457,25046,"An important topic during June was the Holy Month of Ramadan and also its impact on nutrition (e.g., big family meals during evenings, fasting).",Results,[147072],[25084],[25228],[False],[0],[0],[False],['0']
30553,PMC5390457,25047,"It is common in Qatar that families travel abroad during the summer holidays, especially August, which might have also influenced mobile usage and resulted in reduced interactions.",Results,[147081],[25229],[25409],[False],[0],[0],[False],['0']
30554,PMC5390457,25048,June was also the month with more questions from the participating mothers.,Results,[147090],[25410],[25485],[False],[0],[0],[False],['0']
30555,PMC5390457,25049,Only four participants did not send questions or confirmations with regards to health tips and comments.,Results,[147099],[25486],[25590],[False],[0],[0],[False],['0']
30556,PMC5390457,25050,"Furthermore, 17 out of 18 participants received and read all the messages during the intervention.",Results,[147108],[25591],[25689],[False],[0],[0],[False],['0']
30557,PMC5390457,25051,"Only one dropout happened during this period, which was a month after the Whatsapp group started.",Results,[147117],[25690],[25787],[False],[0],[0],[False],['0']
30558,PMC5390457,25052,Discussion,Discussion,[147126],[25788],[25799],[False],[0],[0],[False],['0']
30559,PMC5390457,25053,Principal Results,Discussion|Principal Results,[147135],[25800],[25817],[False],[0],[0],[False],['0']
30560,PMC5390457,25054,Human factors and acceptability,Discussion|Human factors and acceptability,[147144],[25818],[25849],[False],[0],[0],[False],['0']
30561,PMC5390457,25055,"In order to minimize the participant burden, we did not perform questionnaire-based usability evaluation and rather focused on actual system usage.",Discussion|Human factors and acceptability,[147153],[25850],[25997],[False],[0],[0],[False],['0']
30562,PMC5390457,25056,Instead we looked into the attrition towards the use of the different types of technology.,Discussion|Human factors and acceptability,[147162],[25998],[26088],[False],[0],[0],[False],['0']
30563,PMC5390457,25057,Then our findings were discussed with the healthcare professionals that interacted directly with the children and their families to gain insights about the potential reasons.,Discussion|Human factors and acceptability,[147171],[26089],[26263],[False],[0],[0],[False],['0']
30564,PMC5390457,25058,We found significant differences with regards to the participation and acceptability across the genders.,Discussion|Human factors and acceptability,[147180],[26264],[26368],[False],[0],[0],[False],['0']
30565,PMC5390457,25059,"Overall, the engagement of the females was higher.",Discussion|Human factors and acceptability,[147189],[26369],[26419],[False],[0],[0],[False],['0']
30566,PMC5390457,25060,Girls used the wearable devices much more as instructed.,Discussion|Human factors and acceptability,[147198],[26420],[26476],[False],[0],[0],[False],['0']
30567,PMC5390457,25061,Mothers did enroll in the social media intervention where as not a single father showed interest in participating.,Discussion|Human factors and acceptability,[147207],[26477],[26591],[False],[0],[0],[False],['0']
30568,PMC5390457,25062,"Moreover, mothers of girls were the majority in the Whatsapp group.",Discussion|Human factors and acceptability,[147216],[26592],[26659],[False],[0],[0],[False],['0']
30569,PMC5390457,25063,This highlights the importance to take into account gender aspects when implementing eHealth solutions to reduce attrition.,Discussion|Human factors and acceptability,[147225],[26660],[26783],[False],[0],[0],[False],['0']
30570,PMC5390457,25064,Cultural acceptability is a crucial human factor to consider.,Discussion|Human factors and acceptability,[147234],[26784],[26845],[False],[0],[0],[False],['0']
30571,PMC5390457,25065,The design of the WhatsApp intervention had to be adapted to the religious and cultural traditions with special emphasis on the Holy Month of Ramadan.,Discussion|Human factors and acceptability,[147243],[26846],[26996],[False],[0],[0],[False],['0']
30572,PMC5390457,25066,"Nutritional advice had to take into account the religious month, which includes some aspects that can vary from family to family (e.g., at which age children start fasting).",Discussion|Human factors and acceptability,[147252],[26997],[27170],[False],[0],[0],[False],['0']
30573,PMC5390457,25067,"The retention rates of the mothers in this group were quite high (e.g., few dropouts, nearly all the content read), but participation declined after Ramadam and during school holidays.",Discussion|Human factors and acceptability,[147261],[27171],[27355],[False],[0],[0],[False],['0']
30574,PMC5390457,25068,"Further, the WhatsApp intervention was designed only for mothers, as it is not culturally acceptable for many to have mix-gender interactions even in social media.",Discussion|Human factors and acceptability,[147270],[27356],[27519],[False],[0],[0],[False],['0']
30575,PMC5390457,25069,Not a single father showed interest in participating in a social media group.,Discussion|Human factors and acceptability,[147279],[27520],[27597],[False],[0],[0],[False],['0']
30576,PMC5390457,25070,We noticed a tendency in which the use of technology correlated with lower BMI.,Discussion|Human factors and acceptability,[147288],[27598],[27677],[False],[0],[0],[False],['0']
30577,PMC5390457,25071,"We need to be very cautious about inferring causality though, since it is more likely to be a result of engaged children and families being more supportive of technological enhancements for the intervention.",Discussion|Human factors and acceptability,[147297],[27678],[27885],[False],[0],[0],[False],['0']
30578,PMC5390457,25072,The design of our study does not allow us to drawn conclusions about the efficacy of the use of technology for the behavioral change.,Discussion|Human factors and acceptability,[147314],[27886],[28019],[True],['StudyDesign'],['The design of our study'],[True],['StudyDesign']
30579,PMC5390457,25073,Future research will need to look at which technologies are more likely to be accepted by wider number of participants.,Discussion|Human factors and acceptability,[147324],[28020],[28139],[False],[0],[0],[False],['0']
30580,PMC5390457,25074,The healthcare professionals involved in the weight loss camp informed us that gender issues also affected the differences in terms of self-efficacy across genders.,Discussion|Human factors and acceptability,[147333],[28140],[28304],[False],[0],[0],[False],['0']
30581,PMC5390457,25075,This might also explain why girls used the QS technologies more than the boys.,Discussion|Human factors and acceptability,[147342],[28305],[28383],[False],[0],[0],[False],['0']
30582,PMC5390457,25076,"Overall, there is a need to study in deeper detail the psychosocial factors that are influencing technology acceptance for health behavioral change among Arabic youth.",Discussion|Human factors and acceptability,[147351],[28384],[28551],[False],[0],[0],[False],['0']
30583,PMC5390457,25077,"Our study can only highlight differences, but not the reasons behind the same.",Discussion|Human factors and acceptability,[147360],[28552],[28630],[False],[0],[0],[False],['0']
30584,PMC5390457,25078,"In this feasibility study we had continuous conversations with the health team involved in the intervention, who are also co-investigators in this study.",Discussion|Human factors and acceptability,[147369],[28631],[28784],[False],[0],[0],[False],['0']
30585,PMC5390457,25079,Our findings helped them make better decisions while providing health coaching to the participants of the study.,Discussion|Human factors and acceptability,[147378],[28785],[28897],[False],[0],[0],[False],['0']
30586,PMC5390457,25080,"As this is a feasibility study about the 360QS data collection, we did not have ready a tool that can assist them during the decision making process.",Discussion|Human factors and acceptability,[147387],[28898],[29047],[False],[0],[0],[False],['0']
30587,PMC5390457,25081,"Consequently, our study did not have an impact in the quality of the health intervention.",Discussion|Human factors and acceptability,[147396],[29048],[29137],[False],[0],[0],[False],['0']
30588,PMC5390457,25082,"In order to do that, implementation research will need to be performed to identify ways in which the 360QS can be incorporated in the workflow of a health camp such as ICAN.",Discussion|Human factors and acceptability,[147405],[29138],[29311],[False],[0],[0],[False],['0']
30589,PMC5390457,25083,"As explained below, visualization of the data will be a crucial aspect.",Discussion|Human factors and acceptability,[147414],[29312],[29383],[False],[0],[0],[False],['0']
30590,PMC5390457,25084,Technical challenges,Technical challenges,[147423],[29384],[29405],[False],[0],[0],[False],['0']
30591,PMC5390457,25085,There are complex challenges in statistically analyzing temporal and heterogeneous data.,Technical challenges,[147432],[29406],[29494],[False],[0],[0],[False],['0']
30592,PMC5390457,25086,"Measuring causality from an intervention is not trivial, despite access to diverse heterogeneous data [26].",Technical challenges,[147441],[29495],[29602],[False],[0],[0],[False],['0']
30593,PMC5390457,25087,"Moreover, integration of such datasets, is itself a complex challenge [27].",Technical challenges,[147450],[29603],[29678],[False],[0],[0],[False],['0']
30594,PMC5390457,25088,One of the main challenges is to aggregate highly heterogeneous data into a single platform.,Technical challenges,[147459],[29679],[29771],[False],[0],[0],[False],['0']
30595,PMC5390457,25089,We conducted meetings with the healthcare professionals involved in the trial in order to get their feedback about the utility of the different Quantified Self technologies tested in the study.,Technical challenges,[147468],[29772],[29965],[False],[0],[0],[False],['0']
30596,PMC5390457,25090,They highlighted that to integrate such technologies in the practice it is very important to create tools to visualize trends and gain insights about the behaviors of the participants.,Technical challenges,[147477],[29966],[30150],[False],[0],[0],[False],['0']
30597,PMC5390457,25091,"In terms of visualization, it requires careful construction of the interface to focus on the user needs, providing only the information required for the current analytic task.",Technical challenges,[147486],[30151],[30326],[False],[0],[0],[False],['0']
30598,PMC5390457,25092,"Interaction is key for understanding, so graphical elements and codes must be linked throughout the interface in a coherent manner.",Technical challenges,[147495],[30327],[30458],[False],[0],[0],[False],['0']
30599,PMC5390457,25093,"To handle large-scale data, especially coming from actigraphy sensors, it is necessary to aggregate data by time periods like days or hours, to segment activity patterns using automatic techniques, and to give details only on demand as standard according to the visualization mantra “Overview first, zoom and filter, then details-on-demand.” [28].",Technical challenges,[147504],[30459],[30806],[False],[0],[0],[False],['0']
30600,PMC5390457,25094,Accessing the useful data for a given analysis is as important as analyzing the selected data themselves.,Technical challenges,[147513],[30807],[30912],[False],[0],[0],[False],['0']
30601,PMC5390457,25095,"So another challenge is to give a legible visual overview of the available data for all and each individual, in terms of the data type (photos, messages, sensor data, physiological data) and number of data records, throughout the entire time range.",Technical challenges,[147522],[30913],[31161],[False],[0],[0],[False],['0']
30602,PMC5390457,25096,"After providing an overview, the tool should allow for a selection of specific records given the type of analytic task requested by the user.",Technical challenges,[147531],[31162],[31303],[False],[0],[0],[False],['0']
30603,PMC5390457,25097,"The collected data can be useful to healthcare providers to analyze children profiles and guide them to improve their health (for instance determining which food is preferred, or at which time a child is willing to be active and using this knowledge to orient the child’s behavior); but also for researchers to improve on the measurement protocols and techniques (for instance how to make children more diligent in wearing or using the devices?",Technical challenges,[147540],[31304],[31748],[False],[0],[0],[False],['0']
30604,PMC5390457,25098,how to develop analysis techniques to extract more relevant information from the data?,Technical challenges,[147549],[31749],[31835],[False],[0],[0],[False],['0']
30605,PMC5390457,25099,); and finally for the children to keep track of their progress in a specific attractive user interface (shall the children be put in competition with each other?,Technical challenges,[147558],[31836],[31998],[False],[0],[0],[False],['0']
30606,PMC5390457,25100,or only aware of their own results?,Technical challenges,[147567],[31999],[32034],[False],[0],[0],[False],['0']
30607,PMC5390457,25101,or be put in situation to help each other?,Technical challenges,[147576],[32035],[32077],[False],[0],[0],[False],['0']
30608,PMC5390457,25102,what kind of information to show to children?,Technical challenges,[147585],[32078],[32123],[False],[0],[0],[False],['0']
30609,PMC5390457,25103,and in which way to make it attractive for them?).,Technical challenges,[147594],[32124],[32174],[False],[0],[0],[False],['0']
30610,PMC5390457,25104,"Each of these needs require specific visual interfaces carefully designed in close collaboration with the targeted end-users and professional experts in children health, nutrition, pedagogy and psychology.",Technical challenges,[147603],[32175],[32380],[False],[0],[0],[False],['0']
30611,PMC5390457,25105,Comparison with prior work,Technical challenges|Comparison with prior work,[147612],[32381],[32406],[False],[0],[0],[False],['0']
30612,PMC5390457,25106,To our knowledge this is the first reported exploration of the use of Quantified Self for personal health in an Arab country.,Technical challenges|Comparison with prior work,[147621],[32407],[32532],[False],[0],[0],[False],['0']
30613,PMC5390457,25107,Our study is highlighting many of the societal challenges that can be faced in introducing digital health interventions in the younger Arab population.,Technical challenges|Comparison with prior work,[147630],[32533],[32684],[False],[0],[0],[False],['0']
30614,PMC5390457,25108,"There are previous studies in the region, but they have focused on a much narrower implementation of eHealth technologies [29] and specially focusing on diabetes and obesity in the adult population [30, 31].",Technical challenges|Comparison with prior work,[147639],[32685],[32892],[False],[0],[0],[False],['0']
30615,PMC5390457,25109,Another novelty of our study is the combination of social media as an additional source of health quantified-self data.,Technical challenges|Comparison with prior work,[147648],[32893],[33012],[False],[0],[0],[False],['0']
30616,PMC5390457,25110,This is increasingly important since consumers are using social media for health purposes.,Technical challenges|Comparison with prior work,[147657],[33013],[33103],[False],[0],[0],[False],['0']
30617,PMC5390457,25111,"There are other projects looking into the integration and visualization of Quantified Self health data [32, 33], but do not include the heterogeneous datasets as we have.",Technical challenges|Comparison with prior work,[147666],[33104],[33274],[False],[0],[0],[False],['0']
30618,PMC5390457,25112,"Apart from heterogeneity, our datasets have an added complexity of being sparse.",Technical challenges|Comparison with prior work,[147675],[33275],[33355],[False],[0],[0],[False],['0']
30619,PMC5390457,25113,Sparsity of the data poses significant challenges for visualization.,Technical challenges|Comparison with prior work,[147684],[33356],[33424],[False],[0],[0],[False],['0']
30620,PMC5390457,25114,This data sparsity can be attributed to human factors since we do not address visualization of data for people adherent to the ‘Quantified Self’ movement but rather individuals who are in need of a more active role in their health.,Technical challenges|Comparison with prior work,[147693],[33425],[33656],[False],[0],[0],[False],['0']
30621,PMC5390457,25115,This is a substantial difference if we consider that many Quantified Self users are highly motivated individuals [20] and that they do not represent the vast majority of people in need of support for behavioral change.,Technical challenges|Comparison with prior work,[147702],[33657],[33875],[False],[0],[0],[False],['0']
30622,PMC5390457,25116,An additional challenge that we describe is how to integrate that information into meaningful visualizations that can help understand the health patterns of the individuals.,Technical challenges|Comparison with prior work,[147711],[33876],[34049],[False],[0],[0],[False],['0']
30623,PMC5390457,25117,"This is not answered in our paper, but we provide some innovative examples of visualization of this type of data.",Technical challenges|Comparison with prior work,[147720],[34050],[34163],[False],[0],[0],[False],['0']
30624,PMC5390457,25118,"There are other studies looking in the visualization of Electronic Health Records (EHR) for helping decision making [34], also including Quantified Self data [35–37] but in those studies the QS data is limited to wearable sensors data.",Technical challenges|Comparison with prior work,[147729],[34164],[34399],[False],[0],[0],[False],['0']
30625,PMC5390457,25119,Folter et al.,Technical challenges|Comparison with prior work,[147738],[34400],[34413],[False],[0],[0],[False],['0']
30626,PMC5390457,25120,"studied the integration of health habit data (e.g., motion data for physical activity) to help decision making of healthcare professionals [36].",Technical challenges|Comparison with prior work,[147747],[34414],[34558],[False],[0],[0],[False],['0']
30627,PMC5390457,25121,Ledesma et al.,Technical challenges|Comparison with prior work,[147756],[34559],[34573],[False],[0],[0],[False],['0']
30628,PMC5390457,25122,"studied techniques for visualizing personal health data, but not including social media data.",Technical challenges|Comparison with prior work,[147765],[34574],[34667],[False],[0],[0],[False],['0']
30629,PMC5390457,25123,In our case we are looking into helping understand health behaviors (and not clinical aspects) in a more heterogeneous and sparse data set.,Technical challenges|Comparison with prior work,[147774],[34668],[34807],[False],[0],[0],[False],['0']
30630,PMC5390457,25124,Implementation Research methodologies [38–40] can provide a good framework for future work about the integration of 360QS in this type of health interventions.,Technical challenges|Comparison with prior work,[147783],[34808],[34967],[False],[0],[0],[False],['0']
30631,PMC5390457,25125,Limitations,Technical challenges|Limitations,[147792],[34968],[34979],[False],[0],[0],[False],['0']
30632,PMC5390457,25126,The implementation of the 360QS was not integrated in the workflow of the health intervention; therefore we have not studied how such an ecosystem can be implemented in a way that can enhance the intervention.,Technical challenges|Limitations,[147801],[34980],[35189],[True],['Intervention'],['The implementation of the 360QS was not integrated in the workflow of the health intervention'],[True],['Intervention']
30633,PMC5390457,25127,Further research should look into the best strategies to use the most promising 360QS technologies as part of the regular intervention.,Technical challenges|Limitations,[147819],[35190],[35325],[False],[0],[0],[False],['0']
30634,PMC5390457,25128,The clinical trial was registered after the recruitment.,Technical challenges|Limitations,[147828],[35326],[35382],[False],[0],[0],[False],['0']
30635,PMC5390457,25129,"However, in this study we do not look into the health outcomes derived from the use of the 360QS ecosystem.",Technical challenges|Limitations,[147837],[35383],[35490],[False],[0],[0],[False],['0']
30636,PMC5390457,25130,Our study design was not implemented to infer health outcomes that would have required a very different experimental setup.,Technical challenges|Limitations,[147849],[35491],[35614],[True],['StudyDesign'],['Our study design was not implemented to infer health outcomes'],[True],['StudyDesign']
30637,PMC5390457,25131,"We looked at statistical significance of health outcomes for descriptive purposes, overall the p-values were low and the mere fact that some correlation values are small is quite positive if we consider the very small sample size and the presence of multiple confounding factors.",Technical challenges|Limitations,"[147865, 147866]","[35615, 35615]","[35894, 35894]","[True, True]","['SampleSize', 'ConfoundingFactors']","['the very small sample size', 'the presence of multiple confounding factors']","[True, True]","['StatisticalAnalysis', 'UnderpoweredStudy']"
30638,PMC5390457,25132,"Our study focuses on 9 to 12 years old children, and consequently our findings might not be generalizable to the entire age spectrum of childhood obesity.",Technical challenges|Limitations,"[147886, 147887]","[35895, 35895]","[36049, 36049]","[True, True]","['VerySpecificPopulation', 'Generalization']","['Our study focuses on 9 to 12\xa0years old children', 'our findings might not be generalizable to the entire age spectrum of childhood obesity']","[True, True]","['Generalization', 'Population']"
30639,PMC5390457,25133,"Further, our study has taken place with Qatari public schools where the medium of education is Arabic.",Technical challenges|Limitations,[147906],[36050],[36152],[True],['VerySpecificPopulation'],['our study has taken place with Qatari public schools'],[True],['Population']
30640,PMC5390457,25134,"Consequently, our findings might not be applicable to the non-arabic speaking segments of the population in Qatar.",Technical challenges|Limitations,[147925],[36153],[36267],[True],['Generalization'],['our findings might not be applicable to the non-arabic speaking segments of the population in Qatar'],[True],['Generalization']
30641,PMC5390457,25135,"In order to be able to understand the reasons for low usage of some of the 360QS technologies, we will need to perform qualitative studies (e.g.",Technical challenges|Limitations,[147936],[36268],[36412],[False],[0],[0],[False],['0']
30642,PMC5390457,25136,"questionnaires, semi/structured interview) addressing different aspects of the Technology Acceptance Model [5] and Human Factor Engineering methods.",Technical challenges|Limitations,[147945],[36413],[36561],[False],[0],[0],[False],['0']
30643,PMC5390457,25137,"Further, ways to visualize the 360QS data to help decision-making were not addressed in this study and it is part of future work.",Technical challenges|Limitations,[147954],[36562],[36691],[False],[0],[0],[False],['0']
30644,PMC5390457,25138,Conclusions,Conclusions,[147963],[36692],[36704],[False],[0],[0],[False],['0']
30645,PMC5390457,25139,In this study we explored the feasibility of using the 360° Quantified Self technology to capture health-related data within a childhood obesity intervention.,Conclusions,[147972],[36705],[36863],[False],[0],[0],[False],['0']
30646,PMC5390457,25140,"The integration of mobile, social media, wearable and health data is feasible but there are many potential challenges related to human factors and technical issues (e.g.",Conclusions,[147981],[36864],[37033],[False],[0],[0],[False],['0']
30647,PMC5390457,25141,gender differences in technology usage).,Conclusions,[147990],[37034],[37074],[False],[0],[0],[False],['0']
30648,PMC5390457,25142,"It is not yet clear if the increased adherence to technology was more prevalent among motivated children and families, and this might affect the representative data derived from 360QS.",Conclusions,[147999],[37075],[37259],[False],[0],[0],[False],['0']
30649,PMC5390457,25143,"We proved the feasibility of using 360QS in childhood obesity studies to capture health-related data, but in order to implement it, careful planning and integration in workflow of the health professionals is needed.",Conclusions,[148008],[37260],[37475],[False],[0],[0],[False],['0']
30650,PMC5390457,25144,Abbreviations,Abbreviations,[148017],[37476],[37490],[False],[0],[0],[False],['0']
30651,PMC5390457,25145,360QS 360° Quantified Self,Abbreviations,[148026],[37491],[37517],[False],[0],[0],[False],['0']
30652,PMC5390457,25146,BMI Body Mass Index,Abbreviations|BMI Body Mass Index,[148035],[37518],[37537],[False],[0],[0],[False],['0']
30653,PMC5390457,25147,EHR Electronic Health Records,Abbreviations|EHR Electronic Health Records,[148044],[37538],[37567],[False],[0],[0],[False],['0']
30654,PMC5390457,25148,GCC Gulf Cooperation Council,Abbreviations|GCC Gulf Cooperation Council,[148053],[37568],[37596],[False],[0],[0],[False],['0']
30655,PMC5390457,25149,QS Quantified SelfAcknowledgements,Abbreviations|QS Quantified SelfAcknowledgements,[148062],[37597],[37631],[False],[0],[0],[False],['0']
30656,PMC5390457,25150,We would like to acknowledge the contributions of all the members of the ICAN project.,Abbreviations|QS Quantified SelfAcknowledgements,[148071],[37632],[37718],[False],[0],[0],[False],['0']
30657,PMC5390457,25151,We greatly appreciate the work done by Dr. H Haddadi during the first steps of the 360° Quantified Self project.,Abbreviations|QS Quantified SelfAcknowledgements,[148080],[37719],[37831],[False],[0],[0],[False],['0']
30658,PMC5390457,25152,The ICAN project was funded by the Qatar National Research Fund (a member of Qatar Foundation) under project number NPRP X- 036- 3–013 (Adapted Cognitive Behavioral Approach to Addressing Overweight and Obesity among Qatari Youth).,Abbreviations|QS Quantified SelfAcknowledgements,[148089],[37832],[38063],[False],[0],[0],[False],['0']
30659,PMC5390457,25153,Funding,Abbreviations|Funding,[148098],[38064],[38071],[False],[0],[0],[False],['0']
30660,PMC5390457,25154,The ICAN project was funded by the Qatar National Research Fund (a member of Qatar Foundation) under project number NPRP X- 036- 3–013 (Adapted Cognitive Behavioral Approach to Addressing Overweight and Obesity among Qatari Youth).,Abbreviations|Funding,[148107],[38072],[38303],[False],[0],[0],[False],['0']
30661,PMC5390457,25155,Availability of data and materials,Abbreviations|Availability of data and materials,[148116],[38304],[38338],[False],[0],[0],[False],['0']
30662,PMC5390457,25156,The datasets generated and analysed during the current study are not publicly available due to individuals’ privacy as they include demographic information about participants.,Abbreviations|Availability of data and materials,[148125],[38339],[38514],[False],[0],[0],[False],['0']
30663,PMC5390457,25157,Authors’ contributions,Abbreviations|Authors’ contributions,[148134],[38515],[38537],[False],[0],[0],[False],['0']
30664,PMC5390457,25158,"LFL, MS, FO, YM, IW were involved in all the research and manuscript preparation.",Abbreviations|Authors’ contributions,[148143],[38538],[38619],[False],[0],[0],[False],['0']
30665,PMC5390457,25159,MA designed and implemented the data visualization.,Abbreviations|Authors’ contributions,[148152],[38620],[38671],[False],[0],[0],[False],['0']
30666,PMC5390457,25160,AE and JS advised with the technical aspects and discussion of the study.,Abbreviations|Authors’ contributions,[148161],[38672],[38745],[False],[0],[0],[False],['0']
30667,PMC5390457,25161,LFL is also the Principal Investigator of the 360QS Project at Qatar Computing Research Institute.,Abbreviations|Authors’ contributions,[148170],[38746],[38844],[False],[0],[0],[False],['0']
30668,PMC5390457,25162,"MAH and SKJ participated in data collection, the institutional review board application, and reviewed the manuscript.",Abbreviations|Authors’ contributions,[148179],[38845],[38962],[False],[0],[0],[False],['0']
30669,PMC5390457,25163,MAH is also the Principal Investigator of the ICAN project at Qatar University.,Abbreviations|Authors’ contributions,[148188],[38963],[39042],[False],[0],[0],[False],['0']
30670,PMC5390457,25164,All the authors have participated in the manuscript preparation.,Abbreviations|Authors’ contributions,[148197],[39043],[39107],[False],[0],[0],[False],['0']
30671,PMC5390457,25165,The statements made herein are solely the responsibility of the authors.,Abbreviations|Authors’ contributions,[148206],[39108],[39180],[False],[0],[0],[False],['0']
30672,PMC5390457,25166,All authors read and approved the final manuscript.,Abbreviations|Authors’ contributions,[148215],[39181],[39232],[False],[0],[0],[False],['0']
30673,PMC5390457,25167,Competing interests,Abbreviations|Competing interests,[148224],[39233],[39252],[False],[0],[0],[False],['0']
30674,PMC5390457,25168,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[148233],[39253],[39311],[False],[0],[0],[False],['0']
30675,PMC5390457,25169,Consent for publication,Abbreviations|Consent for publication,[148242],[39312],[39335],[False],[0],[0],[False],['0']
30676,PMC5390457,25170,Not applicable.,Abbreviations|Not applicable.,[148251],[39336],[39351],[False],[0],[0],[False],['0']
30677,PMC5390457,25171,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[148260],[39352],[39394],[False],[0],[0],[False],['0']
30678,PMC5390457,25172,The project was led by Qatar University and consequently received ethics approval from the Qatar University Institutional Review Board.,Abbreviations|Ethics approval and consent to participate,[148269],[39395],[39530],[False],[0],[0],[False],['0']
30679,PMC5390457,25173,"In addition, all participants and their parents/guardians, provided written informed consent prior to participation as approved by the local IRB.",Abbreviations|Ethics approval and consent to participate,[148278],[39531],[39676],[False],[0],[0],[False],['0']
30680,PMC5390457,25174,Publisher’s Note,Abbreviations|Publisher’s Note,[148287],[39677],[39693],[False],[0],[0],[False],['0']
30681,PMC5390457,25175,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations,Abbreviations|Publisher’s Note,[148296],[39694],[39811],[False],[0],[0],[False],['0']
35408,PMC5704386,33848,Unloading shoes for intermittent claudication: a randomised crossover trial,Title,[199228],[26341],[75],[False],[0],[0],[False],['0']
35409,PMC5704386,33849,Background,Abstract,[199230],[76],[87],[False],[0],[0],[False],['0']
35410,PMC5704386,33850,The purpose of this study was to assess the functional effects and acceptability of rocker-soled shoes that were designed to relatively “unload” the calf muscles during walking in people with calf claudication due to peripheral arterial disease.,Abstract,[199232],[88],[333],[False],[0],[0],[False],['0']
35411,PMC5704386,33851,Methods,Methods,[199234],[334],[342],[False],[0],[0],[False],['0']
35412,PMC5704386,33852,"In this randomised AB/BA crossover trial, participants completed two assessment visits up to two weeks apart.",Methods,[199236],[343],[452],[False],[0],[0],[False],['0']
35413,PMC5704386,33853,"At each visit, participants completed walking tests whilst wearing the unloading shoes or visually-similar control shoes.",Methods,[199238],[453],[574],[False],[0],[0],[False],['0']
35414,PMC5704386,33854,"At the end of the second visit, participants were given either the unloading or control shoes to use in their home environment for 2 weeks, with the instruction to wear them for at least 4 h every day.",Methods,[199240],[575],[776],[False],[0],[0],[False],['0']
35415,PMC5704386,33855,The primary outcome was 6-min walk distance.,Methods,[199242],[777],[821],[False],[0],[0],[False],['0']
35416,PMC5704386,33856,"We also assessed pain-free walking distance and gait biomechanical variables during usual-pace walking, adverse events, and participants’ opinions about the shoes.",Methods,[199244],[822],[985],[False],[0],[0],[False],['0']
35417,PMC5704386,33857,Data for continuous outcomes are presented as mean difference between conditions with corresponding 95% confidence interval.,Methods,[199246],[986],[1110],[False],[0],[0],[False],['0']
35418,PMC5704386,33858,Results,Results,[199248],[1111],[1119],[False],[0],[0],[False],['0']
35419,PMC5704386,33859,"Thirty-four participants (27 males, mean age 68 years, mean ankle-brachial index 0.54) completed both assessment visits.",Results,[199250],[1120],[1240],[False],[0],[0],[False],['0']
35420,PMC5704386,33860,"On average, the 6-min walk distance was 11 m greater when participants wore the control shoes (95% CI -5 to 26), whereas mean pain-free walking distance was 7 m greater in the unloading shoes (95% CI -17 to 32).",Results,[199252],[1241],[1452],[False],[0],[0],[False],['0']
35421,PMC5704386,33861,"Neither of these differences were statistically significant (p = 0.18 and p = 0.55, respectively).",Results,[199254],[1453],[1551],[False],[0],[0],[False],['0']
35422,PMC5704386,33862,"This was despite the unloading shoes reducing peak ankle plantarflexion moment (mean difference 0.2 Nm/kg, 95% CI 0.0 to 0.3) and peak ankle power generation (mean difference 0.6 W/kg, 95% CI 0.2 to 1.0) during pain-free walking.",Results,[199256],[1552],[1781],[False],[0],[0],[False],['0']
35423,PMC5704386,33863,"The survey and interview data was mixed, with no clear differences between the unloading and control shoes.",Results,[199258],[1782],[1889],[False],[0],[0],[False],['0']
35424,PMC5704386,33864,Conclusions,Conclusions,[199260],[1890],[1902],[False],[0],[0],[False],['0']
35425,PMC5704386,33865,Shoes with modified soles to relatively unload the calf muscles during walking conferred no substantial acute functional benefit over control shoes.,Conclusions,[199262],[1903],[2051],[False],[0],[0],[False],['0']
35426,PMC5704386,33866,Trial registration,Trial registration,[199264],[2052],[2071],[False],[0],[0],[False],['0']
35427,PMC5704386,33867,"Clinicaltrials.gov, Trial Registration Number: NCT02505503, First registered 22 July 2015.",Trial registration,[199266],[2072],[2162],[False],[0],[0],[False],['0']
35428,PMC5704386,33868,Electronic supplementary material,Electronic supplementary material,[199268],[2163],[2197],[False],[0],[0],[False],['0']
35429,PMC5704386,33869,"The online version of this article (10.1186/s12872-017-0716-x) contains supplementary material, which is available to authorized users.",Electronic supplementary material,[199270],[2198],[2333],[False],[0],[0],[False],['0']
35430,PMC5704386,33870,Background,Background,[199272],[2334],[2346],[False],[0],[0],[False],['0']
35431,PMC5704386,33871,"Intermittent claudication, a common symptom of lower-limb peripheral arterial disease (PAD), is defined as leg pain or discomfort in the calf of one or both legs that occurs during walking and is relieved within 10 min of rest.",Background,[199274],[2347],[2574],[False],[0],[0],[False],['0']
35432,PMC5704386,33872,"Although intermittent claudication is not directly life threatening, it can markedly reduce quality of life by limiting walking and other activities of daily living [1].",Background,[199276],[2575],[2744],[False],[0],[0],[False],['0']
35433,PMC5704386,33873,"Qualitative research has identified that the intensity of claudication pain experienced during walking is influenced by several factors, such as the surface walked on (e.g., grass versus tarmac), the incline and speed of walking, and the type of shoes worn [2].",Background,[199278],[2745],[3006],[False],[0],[0],[False],['0']
35434,PMC5704386,33874,"Regarding the latter, it is thought that factors such as the pitch of the shoe and the amount of support that a shoe gives to the ankle joint may influence the metabolic demands of the calf musculature during walking, and thus the speed of occurrence and intensity of claudication pain [3].",Background,[199280],[3007],[3297],[False],[0],[0],[False],['0']
35435,PMC5704386,33875,"Therefore, if specific shoes could be designed to relatively “unload” the calf musculature during walking, then they might be a useful adjunct treatment for people with calf claudication.",Background,[199282],[3298],[3485],[False],[0],[0],[False],['0']
35436,PMC5704386,33876,Empirical evidence on footwear interventions for intermittent claudication is mixed and sparse [3–5].,Background,[199284],[3486],[3587],[False],[0],[0],[False],['0']
35437,PMC5704386,33877,"A recent pilot study indicated that pain-free walking distance was increased, and the intensity of claudication pain reduced, when participants with calf claudication (n = 8) walked at their self-selected walking speed in a specially-designed, rocker-soled shoe compared with when walking in an un-adapted control shoe [3].",Background,[199286],[3588],[3911],[False],[0],[0],[False],['0']
35438,PMC5704386,33878,The rocker sole used was shaped to place the foot in a relatively plantar-flexed position during the stance phase of gait while simultaneously reducing sagittal plane ankle range of motion.,Background,[199288],[3912],[4101],[False],[0],[0],[False],['0']
35439,PMC5704386,33879,Previous testing in healthy adults (n = 12) had suggested a calf-unloading effect of these shoes; peak ankle plantarflexion moment during walking being reduced by 25% versus control [6].,Background,[199290],[4102],[4288],[False],[0],[0],[False],['0']
35440,PMC5704386,33880,The present study sought to further explore the efficacy and acceptability of similar rocker-soled unloading shoes in a larger sample of people with calf claudication.,Background,[199292],[4289],[4456],[False],[0],[0],[False],['0']
35441,PMC5704386,33881,The primary objective was to assess the immediate effect of wearing the shoes on walking distances and gait.,Background,[199294],[4457],[4565],[False],[0],[0],[False],['0']
35442,PMC5704386,33882,We also sought participants’ opinions about the shoes following a 2-week period of use in the home environment.,Background,[199296],[4566],[4677],[False],[0],[0],[False],['0']
35443,PMC5704386,33883,Methods,Methods,[199298],[4678],[4686],[False],[0],[0],[False],['0']
35444,PMC5704386,33884,Study design and setting,Methods|Study design and setting,[199300],[4687],[4711],[False],[0],[0],[False],['0']
35445,PMC5704386,33885,YORVIC ( k study of unloading shoes for  ascular  ntermittent  laudication) was a single-centre randomised AB/BA crossover trial with a 2-week observational follow-up.,Methods|Study design and setting,[199302],[4712],[4879],[False],[0],[0],[False],['0']
35446,PMC5704386,33886,"Participants were recruited from vascular clinics at York Hospital, and all assessments were conducted at York St John University.",Methods|Study design and setting,[199304],[4880],[5010],[False],[0],[0],[False],['0']
35447,PMC5704386,33887,"Following a screening visit, participants completed two assessment visits up to 2 weeks apart.",Methods|Study design and setting,[199306],[5011],[5105],[False],[0],[0],[False],['0']
35448,PMC5704386,33888,"At each assessment visit, participants completed three standardised walking tests whilst wearing either the unloading shoes or visually-similar control shoes, the order of which was randomly assigned.",Methods|Study design and setting,[199308],[5106],[5306],[False],[0],[0],[False],['0']
35449,PMC5704386,33889,"At the end of the second assessment visit, participants were given either the unloading or control shoes to use in their home environment for 2 weeks, with the instruction to wear them for at least 4 h every day.",Methods|Study design and setting,[199310],[5307],[5519],[False],[0],[0],[False],['0']
35450,PMC5704386,33890,"At the end of this period, participants returned the shoes and a completed survey about them.",Methods|Study design and setting,[199312],[5520],[5613],[False],[0],[0],[False],['0']
35451,PMC5704386,33891,A sub-sample of participants was also interviewed about their experiences of using the shoes.,Methods|Study design and setting,[199314],[5614],[5707],[False],[0],[0],[False],['0']
35452,PMC5704386,33892,Participants were able to claim up to £15 per visit towards travel expenses.,Methods|Study design and setting,[199316],[5708],[5784],[False],[0],[0],[False],['0']
35453,PMC5704386,33893,"The study was approved by the NRES Committee for Yorkshire & The Humber - Leeds West (Ref: 15/YH/0107), and prospectively registered (ClinicalTrials.gov: NCT02505503).",Methods|Study design and setting,[199318],[5785],[5952],[False],[0],[0],[False],['0']
35454,PMC5704386,33894,Written informed consent was obtained from participants prior to enrolment.,Methods|Study design and setting,[199320],[5953],[6028],[False],[0],[0],[False],['0']
35455,PMC5704386,33895,Participants,Participants,[199322],[6029],[6042],[False],[0],[0],[False],['0']
35456,PMC5704386,33896,"Inclusion criteria were: aged ≥16 years; stable symptoms of intermittent claudication for ≥3 months; resting ankle-brachial index ≤0.9 and/or imaging evidence of PAD; pain-free walking distance <250 m on 6-min walk test with ambulation limited primarily by calf claudication (assessed at screening visit), and; able to read and speak English and provide written informed consent.",Participants,[199324],[6043],[6422],[False],[0],[0],[False],['0']
35457,PMC5704386,33897,"We excluded people with: absolute contraindications to exercise testing (as defined by the American College of Sports Medicine [7]); critical limb ischemia; lower-limb amputation; co-morbidities that limit walking to a greater extent than intermittent claudication (e.g., severe knee osteoarthritis); ambulation limited by claudication in regions other than the calf; major ankle or foot pathology, and; current or previous (within 6 months) use of shoe inserts, knee or ankle braces or customised shoes prescribed by a health professional.",Participants,[199326],[6423],[6963],[False],[0],[0],[False],['0']
35458,PMC5704386,33898,Interventions,Interventions,[199328],[6964],[6978],[False],[0],[0],[False],['0']
35459,PMC5704386,33899,Fig.,Interventions,[199330],[6979],[6983],[False],[0],[0],[False],['0']
35460,PMC5704386,33900,1 Unloading shoes (a) and control shoes (b).,Interventions,[199332],[6984],[7028],[False],[0],[0],[False],['0']
35461,PMC5704386,33901,The unloading and control shoes were produced and supplied by an established shoe manufacturer (Chaneco; www.chaneco.co.uk).,Interventions,[199334],[7029],[7153],[False],[0],[0],[False],['0']
35462,PMC5704386,33902,"Shoe size was assessed during the screening visit, and shoes were ordered after eligibility had been confirmed.",Interventions,[199336],[7154],[7265],[False],[0],[0],[False],['0']
35463,PMC5704386,33903,"The unloading shoe was a trainer-type shoe with a black leather upper section, laces, and a specially-designed rocker sole (Fig.",Interventions,[199338],[7266],[7394],[False],[0],[0],[False],['0']
35464,PMC5704386,33904,1a).,Interventions,[199340],[7395],[7399],[False],[0],[0],[False],['0']
35465,PMC5704386,33905,"The rocker soles, which were manually shaped according to the specifications of the patent that is owned by the University of York (Patent no.",Interventions,[199342],[7400],[7542],[False],[0],[0],[False],['0']
35466,PMC5704386,33906,": GB2458741B), comprised three circular curves with arc centres that are positioned at the anatomical ankle, hip and knee, respectively (assuming a vertical lower limb), and so forming a posteriorly-placed apex to the rocker shape.",Interventions,[199344],[7543],[7774],[False],[0],[0],[False],['0']
35467,PMC5704386,33907,This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb.,Interventions,[199346],[7775],[8023],[False],[0],[0],[False],['0']
35468,PMC5704386,33908,"Additionally, it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than, for instance, when placed in dorsiflexion.",Interventions,[199348],[8024],[8208],[False],[0],[0],[False],['0']
35469,PMC5704386,33909,"This is because it also increases the lever arm between the Achilles tendon and the ankle joint; so making propulsion, and therefore calf muscle power generation, more efficient.",Interventions,[199350],[8209],[8387],[False],[0],[0],[False],['0']
35470,PMC5704386,33910,It is also intended to unload the calf muscles by providing a simultaneous reduction in ankle range of motion in relative plantarflexion but still moving with a near-normal trajectory.,Interventions,[199352],[8388],[8572],[False],[0],[0],[False],['0']
35471,PMC5704386,33911,"To facilitate participant blinding, the control shoes were made to be similar in appearance to the unloading shoes (Fig.",Interventions,[199354],[8573],[8693],[False],[0],[0],[False],['0']
35472,PMC5704386,33912,1b).,Interventions,[199356],[8694],[8698],[False],[0],[0],[False],['0']
35473,PMC5704386,33913,"These shoes had the same upper section as the unloading shoes, but a different rocker sole.",Interventions,[199358],[8699],[8790],[False],[0],[0],[False],['0']
35474,PMC5704386,33914,"Here, the apex of the sole was anteriorly-placed, which is not designed to place the ankle in relative plantarflexion during stance phase of gait.",Interventions,[199360],[8791],[8937],[False],[0],[0],[False],['0']
35475,PMC5704386,33915,Participants were allowed to habituate to wearing each pair of shoes for 5 min before commencing the first walking test.,Interventions,[199362],[8938],[9058],[False],[0],[0],[False],['0']
35476,PMC5704386,33916,Assessment procedures and outcome measures,Assessment procedures and outcome measures,[199364],[9059],[9102],[False],[0],[0],[False],['0']
35477,PMC5704386,33917,"Both assessment visits involved three walking tests that were separated by 20-min periods of seated rest: (i) a 6-min corridor walk test to quantify 6-min walk distance (6MWD) [8], (ii) a usual-pace walk test to measure pain-free walking distance, and (iii) a “figure-of-8” walk test during which gait biomechanical parameters were quantified as described previously [9].",Assessment procedures and outcome measures,[199366],[9103],[9474],[False],[0],[0],[False],['0']
35478,PMC5704386,33918,"Heart rate (via telemetry: Polar T31 transmitter with Polar FT1 watch, Polar Electro, Oy, Finland), blood pressure (Omron M6 Comfort, Omron Healthcare Europe B.V., Hoofddorp, The Netherlands), and ratings of perceived exertion (Borg 6–20 scale [10]) and leg pain (Borg CR-10 scale [10]) were recorded before and immediately after each test.",Assessment procedures and outcome measures,[199368],[9475],[9815],[False],[0],[0],[False],['0']
35479,PMC5704386,33919,All participants had a leg pain score of 0 before commencing the next test.,Assessment procedures and outcome measures,[199370],[9816],[9891],[False],[0],[0],[False],['0']
35480,PMC5704386,33920,"For the 6-min walk test, we used a 30-m straight corridor and standardised instructions [11], which included to walk as far as possible within the 6 min.",Assessment procedures and outcome measures,[199372],[9892],[10045],[False],[0],[0],[False],['0']
35481,PMC5704386,33921,The same course was used for the usual-pace test.,Assessment procedures and outcome measures,[199374],[10046],[10095],[False],[0],[0],[False],['0']
35482,PMC5704386,33922,The figure-of-8 test was conducted in a gait laboratory.,Assessment procedures and outcome measures,[199376],[10096],[10152],[False],[0],[0],[False],['0']
35483,PMC5704386,33923,A figure-of-8 was chosen to minimise the potential for fatigue that might have been be caused through participants solely performing all clockwise or all counterclockwise turns.,Assessment procedures and outcome measures,[199378],[10153],[10330],[False],[0],[0],[False],['0']
35484,PMC5704386,33924,Reflective markers were positioned on anatomical landmarks of the lower extremities using double-sided sticky tape to allow 3D motion analysis [9].,Assessment procedures and outcome measures,[199380],[10331],[10478],[False],[0],[0],[False],['0']
35485,PMC5704386,33925,"Participants were instructed to walk at their usual pace along a figure-of-8 circuit, without slowing down, for a maximum of 12 min.",Assessment procedures and outcome measures,[199382],[10479],[10611],[False],[0],[0],[False],['0']
35486,PMC5704386,33926,"A force plate (9281EA, Kistler, Germany) positioned in the central straight portion of the course captured kinetic data.",Assessment procedures and outcome measures,[199384],[10612],[10732],[False],[0],[0],[False],['0']
35487,PMC5704386,33927,"The participants were naïve to the force plate, to help ensure a natural walking gait.",Assessment procedures and outcome measures,[199386],[10733],[10819],[False],[0],[0],[False],['0']
35488,PMC5704386,33928,"Infra-red 3D optical motion analysis cameras (Oqus, Qualisys, Sweden) captured kinematic data each time a participant approached and passed over the force plate.",Assessment procedures and outcome measures,[199388],[10820],[10981],[False],[0],[0],[False],['0']
35489,PMC5704386,33929,"Kinetic and sagittal plane kinematic data were exported to Visual 3D motion analysis software (C Motion, Rockville, MD, USA) for processing and analysis.",Assessment procedures and outcome measures,[199390],[10982],[11135],[False],[0],[0],[False],['0']
35490,PMC5704386,33930,Inverse dynamics were used to determine joint moments and powers.,Assessment procedures and outcome measures,[199392],[11136],[11201],[False],[0],[0],[False],['0']
35491,PMC5704386,33931,Participants indicated when they experienced the onset of claudication pain and continued walking until pain prevented them walking further.,Assessment procedures and outcome measures,[199394],[11202],[11342],[False],[0],[0],[False],['0']
35492,PMC5704386,33932,"Time-distance variables used to identify gait differences between the two shoe conditions during pain-free walking were walking speed, step length, step cadence, and time in stance phase, swing phase, and double support (% of gait cycle).",Assessment procedures and outcome measures,[199396],[11343],[11581],[False],[0],[0],[False],['0']
35493,PMC5704386,33933,"The potential calf unloading effect of the adapted shoes was also explored using the following variables for the most affected limb: ankle range of motion, peak plantarflexion angle, peak plantarflexion moment (in Nm per kg body mass), and peak plantarflexion power (in W per kg body mass).",Assessment procedures and outcome measures,[199398],[11582],[11872],[False],[0],[0],[False],['0']
35494,PMC5704386,33934,"After completing the second assessment visit, all participants were given the pair of shoes that they wore during that visit to wear for 2 weeks.",Assessment procedures and outcome measures,[199400],[11873],[12018],[False],[0],[0],[False],['0']
35495,PMC5704386,33935,"During this period, the participants were instructed to wear the allocated shoes as much as possible every day, with a minimum target of 4 h per day [12].",Assessment procedures and outcome measures,[199402],[12019],[12173],[False],[0],[0],[False],['0']
35496,PMC5704386,33936,"On completing the 2-week period, the participants were asked to return the shoes along with a completed survey about them.",Assessment procedures and outcome measures,[199404],[12174],[12296],[False],[0],[0],[False],['0']
35497,PMC5704386,33937,"In the survey, participants were asked to estimate, on average, how many hours per day they wore the shoes.",Assessment procedures and outcome measures,[199406],[12297],[12404],[False],[0],[0],[False],['0']
35498,PMC5704386,33938,"They also rated the overall level of shoe comfort using an 11-point (0–10) numeric rating scale (with terminal descriptors of ‘extremely uncomfortable’ and ‘extremely comfortable’), and perceived changes in walking ability and physical activity using 5-point (1–5) scales (with terminal descriptors of ‘much worse’ to ‘much better’ and ‘much less physically active’ to ‘much more physically active’, respectively).",Assessment procedures and outcome measures,[199408],[12405],[12819],[False],[0],[0],[False],['0']
35499,PMC5704386,33939,"Finally, participants recorded any benefits, negative aspects, and untoward medical events related to the shoes.",Assessment procedures and outcome measures,[199410],[12820],[12932],[False],[0],[0],[False],['0']
35500,PMC5704386,33940,A sub-sample of 12 participants also undertook a telephone-based interview to share their thoughts about the shoes.,Assessment procedures and outcome measures,[199412],[12933],[13048],[False],[0],[0],[False],['0']
35501,PMC5704386,33941,"Purposive sampling was used according to the following criteria: shoe type (unloading and control), age (above and below 65 years), sex, and walking ability (6MWD above and below 350 m).",Assessment procedures and outcome measures,[199414],[13049],[13235],[False],[0],[0],[False],['0']
35502,PMC5704386,33942,"The interviewer sought feedback regarding factors affecting shoe usage, benefits and negative consequences of wearing the shoes, and the design of the shoes.",Assessment procedures and outcome measures,[199416],[13236],[13393],[False],[0],[0],[False],['0']
35503,PMC5704386,33943,"All interviews were audio-recorded, transcribed, and analysed to identify themes.",Assessment procedures and outcome measures,[199418],[13394],[13475],[False],[0],[0],[False],['0']
35504,PMC5704386,33944,Adverse events,Adverse events,[199420],[13476],[13491],[False],[0],[0],[False],['0']
35505,PMC5704386,33945,"We recorded all serious adverse events (regardless of cause), and all non-serious adverse events that were believed to have occurred as a result of performing a study assessment, or from using the study shoes.",Adverse events,[199422],[13492],[13701],[False],[0],[0],[False],['0']
35506,PMC5704386,33946,The latter are subsequently termed ‘adverse device effects’.,Adverse events,[199424],[13702],[13762],[False],[0],[0],[False],['0']
35507,PMC5704386,33947,"Randomisation, allocation concealment and blinding","Randomisation, allocation concealment and blinding",[199426],[13763],[13814],[False],[0],[0],[False],['0']
35508,PMC5704386,33948,"The order of testing for each participant (i.e., unloading shoes first then control shoes, or vice versa) was determined using a computer-generated randomisation sequence created by a statistician at York Trials Unit, who was not otherwise involved in the study.","Randomisation, allocation concealment and blinding",[199428],[13815],[14077],[False],[0],[0],[False],['0']
35509,PMC5704386,33949,Blocked randomisation with a block size of 8 was used to ensure that the overall order of testing was balanced (ratio 1:1).,"Randomisation, allocation concealment and blinding",[199430],[14078],[14201],[False],[0],[0],[False],['0']
35510,PMC5704386,33950,The allocations were blinded (i.e.,"Randomisation, allocation concealment and blinding",[199432],[14202],[14236],[False],[0],[0],[False],['0']
35511,PMC5704386,33951,labelled AB and BA) before being passed to the trial statistician.,"Randomisation, allocation concealment and blinding",[199434],[14237],[14303],[False],[0],[0],[False],['0']
35512,PMC5704386,33952,"Once a participant had completed the screening visit, an investigator emailed the trial statistician who assigned the participant to the next available allocation.","Randomisation, allocation concealment and blinding",[199436],[14304],[14467],[False],[0],[0],[False],['0']
35513,PMC5704386,33953,"Participants were blinded to allocation by using control shoes that were visually-similar to the unloading shoes and by stating in the participant information sheet that the study was investigating two different types of shoes, rather than comparing normal and adapted shoes.","Randomisation, allocation concealment and blinding",[199438],[14468],[14743],[False],[0],[0],[False],['0']
35514,PMC5704386,33954,Our attempt to blind the outcome assessor was unsuccessful because they were not naïve to the true purpose of the study and therefore could tell which shoe was the unloading shoe when preparing the participant for the gait analysis.,"Randomisation, allocation concealment and blinding",[199440],[14744],[14976],[False],[0],[0],[False],['0']
35515,PMC5704386,33955,"However, the use of standardised testing procedures and objective outcomes (e.g., 6MWD) ensured that the risk of detection bias is low.","Randomisation, allocation concealment and blinding",[199442],[14977],[15112],[False],[0],[0],[False],['0']
35516,PMC5704386,33956,The researcher overseeing data entry and the statistician remained blinded until the analysis was complete.,"Randomisation, allocation concealment and blinding",[199444],[15113],[15220],[False],[0],[0],[False],['0']
35517,PMC5704386,33957,Sample size,Sample size,[199446],[15221],[15233],[False],[0],[0],[False],['0']
35518,PMC5704386,33958,The primary outcome was 6MWD measured in metres.,Sample size,[199448],[15234],[15282],[False],[0],[0],[False],['0']
35519,PMC5704386,33959,The cross-over ANOVA square root of the mean squared error for 6MWD was found to be 30 m in a recent trial [13].,Sample size,[199450],[15283],[15395],[False],[0],[0],[False],['0']
35520,PMC5704386,33960,A mean difference of 25 m has been suggested as the minimum clinically important difference [14].,Sample size,[199452],[15396],[15493],[False],[0],[0],[False],['0']
35521,PMC5704386,33961,Using these values at 90% power and 2-sided 5% significance level in a cross-over design would require 34 participants.,Sample size,[199454],[15494],[15613],[False],[0],[0],[False],['0']
35522,PMC5704386,33962,"Therefore, recruitment stopped once 6MWD had been collected at both assessment visits for 34 participants.",Sample size,[199456],[15614],[15720],[False],[0],[0],[False],['0']
35523,PMC5704386,33963,Statistical analysis,Statistical analysis,[199458],[15721],[15742],[False],[0],[0],[False],['0']
35524,PMC5704386,33964,"Formal analyses were conducted following the principles of intention-to-treat with participant’s outcomes analysed according to their original, randomised testing order irrespective of the order that they actually received the shoes, where data were available.",Statistical analysis,[199460],[15743],[16003],[False],[0],[0],[False],['0']
35525,PMC5704386,33965,Analyses were undertaken in Stata v13 using two-sided statistical tests at the 5% significance level.,Statistical analysis,[199462],[16004],[16105],[False],[0],[0],[False],['0']
35526,PMC5704386,33966,Participant baseline data are summarised descriptively overall and by testing order (AB or BA) both as randomised and as analysed in the primary analysis.,Statistical analysis,[199464],[16106],[16260],[False],[0],[0],[False],['0']
35527,PMC5704386,33967,No formal statistical comparisons between testing orders were undertaken on baseline data.,Statistical analysis,[199466],[16261],[16351],[False],[0],[0],[False],['0']
35528,PMC5704386,33968,"To allow for a possible period effect, analysis of the 6MWD was via a two-sample t-test to compare the difference between assessment 1 and assessment 2 for the two sequences.",Statistical analysis,[199468],[16352],[16526],[False],[0],[0],[False],['0']
35529,PMC5704386,33969,"Dividing the resultant difference (and corresponding 95% confidence limits) by two gives an estimate of the treatment effect (i.e., A minus B) and 95% CI.",Statistical analysis,[199470],[16527],[16681],[False],[0],[0],[False],['0']
35530,PMC5704386,33970,Pain-free walking distance at usual pace was analysed in the same manner.,Statistical analysis,[199472],[16682],[16755],[False],[0],[0],[False],['0']
35531,PMC5704386,33971,"Kinetic, kinematic and temporal-spatial measures of gait were taken at each assessment visit and calculated for each participant when pain free, at the onset of pain, and at absolute pain.",Statistical analysis,[199474],[16756],[16944],[False],[0],[0],[False],['0']
35532,PMC5704386,33972,"The difference between the measure as assessed at visit 1 and visit 2 was calculated for each participant at each point in time (pain free, pain onset, and absolute pain).",Statistical analysis,[199476],[16945],[17116],[False],[0],[0],[False],['0']
35533,PMC5704386,33973,"These three differences were modelled using a covariance pattern mixed model, with sequence allocation (AB or BA), time and an allocation-by-time interaction as fixed effects and participant as a random effect.",Statistical analysis,[199478],[17117],[17327],[False],[0],[0],[False],['0']
35534,PMC5704386,33974,"The mean differences (and 95% CI) between the two sequences were extracted for the pain-free, onset of pain, and absolute pain time points, and divided by two to obtain an estimate of the treatment effect A-B.",Statistical analysis,[199480],[17328],[17537],[False],[0],[0],[False],['0']
35535,PMC5704386,33975,Only the data for pain-free walking is presented in this manuscript; all other gait data will be published elsewhere.,Statistical analysis,[199482],[17538],[17655],[False],[0],[0],[False],['0']
35536,PMC5704386,33976,Results,Results,[199484],[17656],[17664],[False],[0],[0],[False],['0']
35537,PMC5704386,33977,Fig.,Results,[199486],[17665],[17669],[False],[0],[0],[False],['0']
35538,PMC5704386,33978,2 Flow of participants through the trial.,Results,[199488],[17670],[17711],[False],[0],[0],[False],['0']
35539,PMC5704386,33979,"Table 1 Baseline characteristics of the participants as randomised, and as included in the primary analysis.",Results,[199490],[17712],[17820],[False],[0],[0],[False],['0']
35540,PMC5704386,33980,"Between August 2015 and August 2016, 71 patients were approached to participate in the trial, of whom 42 (59%) were screened and 37 (52%) were randomised (Fig.",Results,[199492],[17821],[17980],[False],[0],[0],[False],['0']
35541,PMC5704386,33981,"2): 18 were allocated to the sequence AB (control, unloading) and 19 to BA (unloading, control).",Results,[199494],[17981],[18077],[False],[0],[0],[False],['0']
35542,PMC5704386,33982,"Two participants withdrew from the trial before the first assessment visit, and one participant withdrew during the second assessment visit due to an adverse device effect of feeling unbalanced whilst wearing the shoes; resulting in 34 participants being included in the primary analysis.",Results,[199496],[18078],[18366],[False],[0],[0],[False],['0']
35543,PMC5704386,33983,Characteristics of the 37 randomised participants and the 34 analysed participants are presented in Table 1.,Results,[199498],[18367],[18475],[False],[0],[0],[False],['0']
35544,PMC5704386,33984,"The majority of participants (as randomised) were male (n = 27, 73%), and the mean age was 67 years (range 31 to 86).",Results,[199500],[18476],[18593],[False],[0],[0],[False],['0']
35545,PMC5704386,33985,"All participants had experienced symptoms of intermittent claudication for at least 4 months (median 16 months) at screening, and had a resting ankle-brachial index for the most-affected limb of between 0.25 and 0.89 (mean 0.53, SD 0.14).",Results,[199502],[18594],[18832],[False],[0],[0],[False],['0']
35546,PMC5704386,33986,The mean distance walked during the 6-min walk test at screening was 373 m (SD 100).,Results,[199504],[18833],[18917],[False],[0],[0],[False],['0']
35547,PMC5704386,33987,Effects of the unloading shoes on walking ability and gait,Results,[199506],[18918],[18979],[False],[0],[0],[False],['0']
35548,PMC5704386,33988,"The first assessment visit took place between 3 and 26 days after screening (median 12 days for the AB group and 11 days for the BA group), and the second visit up to 14 days after the first (median 7 days for the AB group and 5 days for the BA group).",Results,[199508],[18980],[19232],[False],[0],[0],[False],['0']
35549,PMC5704386,33989,"All participants received their footwear in the allocated order, except for one participant allocated to BA, who was tested in the order AB (control, unloading) by mistake.",Results,[199510],[19233],[19405],[False],[0],[0],[False],['0']
35550,PMC5704386,33990,Table 2 Walking distance results.,Results,[199512],[19406],[19439],[False],[0],[0],[False],['0']
35551,PMC5704386,33991,The unadjusted mean 6MWD was 381 m (SD 99) for the control shoe condition (n = 35) and 372 m (SD 94) for the unloading shoe condition (n = 34).,Results,[199514],[19440],[19583],[False],[0],[0],[False],['0']
35552,PMC5704386,33992,"The analysis accounting for a possible period effect indicated that the 6MWD was on average 11 m greater when participants wore the control shoes (95% CI -5 to 26; Table 2); however, this was not statistically significant (p = 0.18).",Results,[199516],[19584],[19817],[False],[0],[0],[False],['0']
35553,PMC5704386,33993,The unadjusted mean pain-free walking distance during usual-pace walking was 160 m (SD 88) for the control condition (n = 35) and 164 m (SD 132) for the unloading condition (n = 34).,Results,[199518],[19818],[20000],[False],[0],[0],[False],['0']
35554,PMC5704386,33994,"On average, participants walked 7 m further before experiencing pain when wearing the unloading shoes (95% CI -17 to 32; Table 2).",Results,[199520],[20001],[20131],[False],[0],[0],[False],['0']
35555,PMC5704386,33995,"Again, this difference was not statistically significant (p = 0.55).",Results,[199522],[20132],[20200],[False],[0],[0],[False],['0']
35556,PMC5704386,33996,"Mean rating of perceived exertion at the end of the 6-min walk test in the first assessment was 12.1 (i.e., “light” to “somewhat hard”; SD 2.0) in the AB group and 12.1 (SD 1.9) in the BA group.",Results,[199524],[20201],[20396],[False],[0],[0],[False],['0']
35557,PMC5704386,33997,"In the second assessment, it was 12.4 (SD 1.9) in the AB group and 12.0 (SD 2.6) in the BA group.",Results,[199526],[20397],[20494],[False],[0],[0],[False],['0']
35558,PMC5704386,33998,The mean difference between conditions (control minus unloading) was −0.1 (95% CI -0.7 to 0.6).,Results,[199528],[20495],[20590],[False],[0],[0],[False],['0']
35559,PMC5704386,33999,"Mean rating of leg pain at the end of the 6-min walk test in the first assessment was 5.1 (i.e., “strong”; SD 2.5) in the AB group and 5.0 (SD 2.2) in the BA group.",Results,[199530],[20591],[20755],[False],[0],[0],[False],['0']
35560,PMC5704386,34000,"In the second assessment, it was 4.6 (SD 2.2) in the AB group and 5.3 (SD 2.1) in the BA group.",Results,[199532],[20756],[20851],[False],[0],[0],[False],['0']
35561,PMC5704386,34001,The mean difference was 0.5 (95% CI -0.1 to 1.1).,Results,[199534],[20852],[20901],[False],[0],[0],[False],['0']
35562,PMC5704386,34002,Heart rate responses were similar for both conditions (data not presented).,Results,[199536],[20902],[20977],[False],[0],[0],[False],['0']
35563,PMC5704386,34003,Table 3 Gait variables during pain-free walking.,Results,[199538],[20978],[21026],[False],[0],[0],[False],['0']
35564,PMC5704386,34004,Gait variables for pain-free walking are presented in Table 3.,Results,[199540],[21027],[21089],[False],[0],[0],[False],['0']
35565,PMC5704386,34005,"The temporal-spatial variables (e.g., walking speed, step length, step cadence) did not differ substantially between conditions.",Results,[199542],[21090],[21218],[False],[0],[0],[False],['0']
35566,PMC5704386,34006,This was also the case for ankle range of motion (mean difference 0.8°; 95% CI -0.5 to 2.2).,Results,[199544],[21219],[21311],[False],[0],[0],[False],['0']
35567,PMC5704386,34007,"However, relative to control, the unloading shoes caused a reduction in the peak values of plantarflexion angle (mean difference 2.5°; 95% CI 1.3 to 3.7), ankle plantarflexion moment (mean difference 0.2 Nm/kg, 95% CI 0.0 to 0.3), and ankle power generation (mean difference 0.6 W/kg, 95% CI 0.2 to 1.0).",Results,[199546],[21312],[21616],[False],[0],[0],[False],['0']
35568,PMC5704386,34008,Adverse events,Adverse events,[199548],[21617],[21633],[False],[0],[0],[False],['0']
35569,PMC5704386,34009,There were four non-serious adverse device effects: three for the unloading shoes and one for the control shoes.,Adverse events,[199550],[21634],[21746],[False],[0],[0],[False],['0']
35570,PMC5704386,34010,"The adverse device effects for the unloading shoes were foot and ankle pain (n = 1), perceived difficulty in balancing (n = 1), and irritation of a pre-existing bunion (n = 1).",Adverse events,[199552],[21747],[21923],[False],[0],[0],[False],['0']
35571,PMC5704386,34011,"For the control shoes, one participant reported experiencing ‘foot discomfort’.",Adverse events,[199554],[21924],[22003],[False],[0],[0],[False],['0']
35572,PMC5704386,34012,"There was also one protocol-related, non-serious adverse event.",Adverse events,[199556],[22004],[22067],[False],[0],[0],[False],['0']
35573,PMC5704386,34013,"Here, a participant experienced mild bruising to the medial aspect of the knee upon removal of the reflective marker that was used for the gait analysis.",Adverse events,[199558],[22068],[22221],[False],[0],[0],[False],['0']
35574,PMC5704386,34014,Survey and interview responses,Survey and interview responses,[199560],[22222],[22253],[False],[0],[0],[False],['0']
35575,PMC5704386,34015,"Thirty-one (91%) of the 34 participants who attended their second assessment visit were given a pair of shoes (13 unloading, 18 control) to use in their home environment for 2 weeks, of whom 29 (12 unloading, 17 control) returned a completed survey at the end of this period.",Survey and interview responses,[199562],[22254],[22529],[False],[0],[0],[False],['0']
35576,PMC5704386,34016,"Twelve participants (7 male, 5 female; 6 unloading, 6 control) were also interviewed after the 2-week home-wear period.",Survey and interview responses,[199564],[22530],[22649],[False],[0],[0],[False],['0']
35577,PMC5704386,34017,"Survey responses indicated a mean daily wear times of 4.8 h (SD 2.4) for the control shoes (n = 17) and 3.8 h (SD 1.8) for the unloading shoes (n = 11, one missing data point).",Survey and interview responses,[199566],[22650],[22826],[False],[0],[0],[False],['0']
35578,PMC5704386,34018,"The interview data also showed similar shoe usage, with responses ranging 3 to 7 h per day; however, one participant reported that she stopped using the unloading shoes after three days because they had irritated her bunion.",Survey and interview responses,[199568],[22827],[23051],[False],[0],[0],[False],['0']
35579,PMC5704386,34019,"Median survey comfort ratings were 8 (interquartile range (IQR) 5–10) and 6 (IQR 3–10) for the control and unloading shoes, respectively.",Survey and interview responses,[199570],[23052],[23189],[False],[0],[0],[False],['0']
35580,PMC5704386,34020,All survey respondents and 11 out of 12 interviewees perceived their walking ability as unchanged or better during the home-wear period.,Survey and interview responses,[199572],[23190],[23326],[False],[0],[0],[False],['0']
35581,PMC5704386,34021,"In the control group, six survey respondents (35%) and two interviewees (33%) reported an improvement versus six survey respondents (50%) and three interviewees (50%) in the unloading group.",Survey and interview responses,[199574],[23327],[23517],[False],[0],[0],[False],['0']
35582,PMC5704386,34022,"However, fewer people reported that their physical activity had increased during the home-wear period: four survey respondents (24%) and one interviewee (17%) from the control group and three survey respondents (25%) and two interviewees (33%) in the unloading group.",Survey and interview responses,[199576],[23518],[23785],[False],[0],[0],[False],['0']
35583,PMC5704386,34023,"From the survey, the most commonly cited barriers to using the shoes were “lack of comfort” (n = 3 [18%] vs. n = 2 [17%], respectively), “shoe appearance” (n = 5 [29%] vs. n = 2 [17%], respectively), and “impractical” (n = 2 [12%] vs. n = 3 [25%], respectively).",Survey and interview responses,[199578],[23786],[24048],[False],[0],[0],[False],['0']
35584,PMC5704386,34024,The interviews also gleaned mixed feedback about the comfort and design of the shoes.,Survey and interview responses,[199580],[24049],[24134],[False],[0],[0],[False],['0']
35585,PMC5704386,34025,"Six participants (50%; three from each group) reported the shoes as being comfortable, and that they would be willing to pay between £30 and £60 for them.",Survey and interview responses,[199582],[24135],[24289],[False],[0],[0],[False],['0']
35586,PMC5704386,34026,"However, three participants (1 control, 2 unloading) found them to be uncomfortable.",Survey and interview responses,[199584],[24290],[24374],[False],[0],[0],[False],['0']
35587,PMC5704386,34027,"Four interviewees in the unloading group commented on the heel being too big, whereas only one person from the control group commented on size, describing the shoes as “bulky”.",Survey and interview responses,[199586],[24375],[24551],[False],[0],[0],[False],['0']
35588,PMC5704386,34028,"Recommendations on design features included having a boot style rather than a shoe (n = 3), having Velcro instead of laces (n = 1), and having a choice of colours (n = 2).",Survey and interview responses,[199588],[24552],[24723],[False],[0],[0],[False],['0']
35589,PMC5704386,34029,All but one interviewee (from the control group) expressed a willingness to participate in a potential future study where participants would be required to use the shoes over a 6-month period.,Survey and interview responses,[199590],[24724],[24916],[False],[0],[0],[False],['0']
35590,PMC5704386,34030,Example quotes are shown in Additional file 1.,Survey and interview responses,[199592],[24917],[24963],[False],[0],[0],[False],['0']
35591,PMC5704386,34031,Discussion,Discussion,[199594],[24964],[24975],[False],[0],[0],[False],['0']
35592,PMC5704386,34032,"In this study, shoes with specially-designed rocker soles to reduce calf load during walking offered no immediate functional benefit when compared with control shoes in people with calf claudication due to peripheral arterial disease.",Discussion,[199596],[24976],[25210],[False],[0],[0],[False],['0']
35593,PMC5704386,34033,"The gait analysis data indicated that the rocker-soled shoes did indeed unload the calves of claudication patients during usual-pace, pain-free walking; however, this did not translate into improved walking distances during the standardised walking tests.",Discussion,[199598],[25211],[25466],[False],[0],[0],[False],['0']
35594,PMC5704386,34034,"Following the 2-week home-wear period, approximately one third of participants using the control shoes and one half of participants using the unloading shoes reported experiencing improved walking ability when wearing their allocated shoes.",Discussion,[199600],[25467],[25707],[False],[0],[0],[False],['0']
35595,PMC5704386,34035,"There was mixed feedback regarding the acceptability of the shoes; however, 11 out of 12 interviewees reported they would be willing to taking part in a longer-term shoe study, which suggests that patients are interested in footwear as an intervention for claudication.",Discussion,[199602],[25708],[25977],[False],[0],[0],[False],['0']
35596,PMC5704386,34036,Our findings contrast that of previous limited research.,Discussion,[199604],[25978],[26034],[False],[0],[0],[False],['0']
35597,PMC5704386,34037,"A smaller study of 21 people with calf claudication showed that commercially-made, rocker-soled unloading shoes acutely increased usual-pace walking ability, with both the total distance walked and the distance at which patients were initially bothered by symptoms being on average 77 m (37%, p < 0.01) and 89 m (91%, p < 0.01) further, respectively, compared with a standard shoe condition [5].",Discussion,[199606],[26035],[26430],[False],[0],[0],[False],['0']
35598,PMC5704386,34038,"The use of different walking assessments prevents a direct comparison with our findings; however, it is important to note that the “bothered distance” is highly subjective (and thus has poor reliability), and that the reported differences were largely explained by one outlier participant who showed improvements of 710 m and 850 m, respectively.",Discussion,[199608],[26431],[26777],[False],[0],[0],[False],['0']
35599,PMC5704386,34039,"A more recent study of 8 people with calf claudication also showed that unloading shoes, which were similar to those used in the current study, improved pain-free walking distance during usual-pace walking by an average of 19 m (39%, p < 0.05) relative to an un-adapted control shoe [3].",Discussion,[199610],[26778],[27065],[False],[0],[0],[False],['0']
35600,PMC5704386,34040,"Again, a direct comparison cannot be made because of different walking test procedures, but also because slightly different intervention and control shoes were used.",Discussion,[199612],[27066],[27231],[False],[0],[0],[False],['0']
35601,PMC5704386,34041,"Nevertheless, this previous study was limited by a small sample size and lack of participant and tester blinding, which may have biased the results.",Discussion,[199614],[27232],[27380],[False],[0],[0],[False],['0']
35602,PMC5704386,34042,The aforementioned limitations in the evidence base prompted the current investigation.,Discussion,[199616],[27381],[27468],[False],[0],[0],[False],['0']
35603,PMC5704386,34043,The current study was appropriately powered and assessed walking ability at both usual and forced walking paces.,Discussion,[199618],[27469],[27581],[False],[0],[0],[False],['0']
35604,PMC5704386,34044,"Despite the unloading shoes causing mean reductions in peak ankle plantarflexion moment and peak ankle power generation of 14% and 26%, respectively, the mean differences in walking distances between conditions were trivial and in varied direction (pain-free walking distance improved, 6MWD worsened; Table 2).",Discussion,[199620],[27582],[27892],[False],[0],[0],[False],['0']
35605,PMC5704386,34045,It is unclear why the beneficial effects of unloading shoes on ankle biomechanics seen here and elsewhere [6] did not translate to functional benefit.,Discussion,[199622],[27893],[28043],[False],[0],[0],[False],['0']
35606,PMC5704386,34046,One possibility is that 5 min was not long enough for the participants to habituate to wearing the different shoes.,Discussion,[199624],[28044],[28159],[True],['ExperimentalPhaseDuration'],['5\xa0min was not long enough for the participants'],[True],['StudyDuration']
35607,PMC5704386,34047,"Although we cannot rule this out, our approach was consistent with what others have done previously [3, 5].",Discussion,[199628],[28160],[28267],[False],[0],[0],[False],['0']
35608,PMC5704386,34048,"Alternatively, it may be that the biomechanical effects were generally too small to influence walking distances or that claudication symptoms are not as strongly influenced by manipulating ankle biomechanics as we originally suspected.",Discussion,[199630],[28268],[28503],[False],[0],[0],[False],['0']
35609,PMC5704386,34049,"Interestingly, the mean reduction in peak ankle plantarflexion moment was smaller than that reported previously in healthy younger adults (14% vs. 25%) [6].",Discussion,[199632],[28504],[28660],[False],[0],[0],[False],['0']
35610,PMC5704386,34050,"This difference may have been due to the slight alterations that were made for intervention and control shoes in the present study, e.g., the soles of the unloading shoes being made less deep to increase acceptability to participants, and the soles of the control shoes being “filled in” to facilitate participant blinding.",Discussion,[199634],[28661],[28984],[False],[0],[0],[False],['0']
35611,PMC5704386,34051,"However, given that the absolute reduction in peak ankle power generation was of similar magnitude to the difference previously reported between claudication patients and healthy controls (2.437 [SD 0.445] vs. 2.957 [SD 0.686], p < 0.01) [15], we are surprised that changes in walking distances were not observed.",Discussion,[199636],[28985],[29298],[False],[0],[0],[False],['0']
35612,PMC5704386,34052,"It is important to remember that there is no such thing as a “biomechanically inert” shoe to use as a placebo, and we are confident that the shoe design features we selected were appropriate for assessing the functional effects of unloading shoes while maintaining methodological rigor.",Discussion,[199638],[29299],[29585],[False],[0],[0],[False],['0']
35613,PMC5704386,34053,"Nevertheless, further research would be useful to determine the magnitude of calf unloading that is needed to observe an improved walking ability in different claudicants, and to see if engineering of the shoe can produce greater biomechanical effects without compromising safety and acceptability.",Discussion,[199640],[29586],[29884],[False],[0],[0],[False],['0']
35614,PMC5704386,34054,"Interestingly, the variable effects of footwear on the walking ability of claudicants in the literature [3, 5], and the fact that many of participants reported beneficial effects of both shoe types during the 2-week home-wear period, raises the possibility that some patients are more responsive to biomechanical interventions than others.",Discussion,[199642],[29885],[30224],[False],[0],[0],[False],['0']
35615,PMC5704386,34055,Placebo effects likely explain at least some of the reported benefits by survey respondents and interviewees for both types of shoes.,Discussion,[199644],[30225],[30358],[False],[0],[0],[False],['0']
35616,PMC5704386,34056,"The reported benefits of both shoe types might, however, also be related to other characteristics that were common to both shoes.",Discussion,[199646],[30359],[30488],[False],[0],[0],[False],['0']
35617,PMC5704386,34057,"Both were cushioned, lace-up shoes with flexible leather uppers, which for some participants may have represented a significant improvement over their usual footwear.",Discussion,[199648],[30489],[30655],[False],[0],[0],[False],['0']
35618,PMC5704386,34058,"Unfortunately, the usual footwear was not recorded.",Discussion,[199651],[30656],[30707],[True],['RelevantOutcomeExcluded'],['the usual footwear was not recorded'],[True],['OutcomeMeasures']
35619,PMC5704386,34059,"In conclusion, the main finding from this study was that the unloading shoes were relatively ineffective for improving walking ability in people with calf claudication.",Discussion,[199654],[30708],[30876],[False],[0],[0],[False],['0']
35620,PMC5704386,34060,"Although this finding is disappointing, the concept of a shoe reducing claudication pain remains good.",Discussion,[199656],[30877],[30979],[False],[0],[0],[False],['0']
35621,PMC5704386,34061,"The mainstay of current treatment for intermittent claudication, after best medical therapy, is invasive intervention.",Discussion,[199658],[30980],[31098],[False],[0],[0],[False],['0']
35622,PMC5704386,34062,We have a duty to continue to explore non-invasive options in the management of claudication to compliment/substitute the sporadic funding of supervised exercise programmes [16].,Discussion,[199660],[31099],[31277],[False],[0],[0],[False],['0']
35623,PMC5704386,34063,"Further preliminary studies are needed to optimise shoe design and confirm clinical efficacy before long-term effectiveness studies are pursued; however, we believe that the feasibility of a longer-term study is supported by our findings.",Discussion,[199662],[31278],[31516],[False],[0],[0],[False],['0']
35624,PMC5704386,34064,Abbreviations,Abbreviations,[199664],[31517],[31531],[False],[0],[0],[False],['0']
35625,PMC5704386,34065,6MWD 6-min walk distance,Abbreviations,[199666],[31532],[31556],[False],[0],[0],[False],['0']
35626,PMC5704386,34066,PAD peripheral arterial disease,Abbreviations|PAD peripheral arterial disease,[199668],[31557],[31588],[False],[0],[0],[False],['0']
35627,PMC5704386,34067,SD standard deviation,Abbreviations|SD standard deviation,[199670],[31589],[31610],[False],[0],[0],[False],['0']
35628,PMC5704386,34068,YORVIC York study of unloading shoes for vascular intermittent claudicationElectronic supplementary material,Abbreviations|SD standard deviation,[199672],[31611],[31719],[False],[0],[0],[False],['0']
35629,PMC5704386,34069,"The online version of this article (10.1186/s12872-017-0716-x) contains supplementary material, which is available to authorized users.",Abbreviations|SD standard deviation,[199674],[31720],[31855],[False],[0],[0],[False],['0']
35630,PMC5704386,34070,Acknowledgements,Abbreviations|Acknowledgements,[199676],[31856],[31872],[False],[0],[0],[False],['0']
35631,PMC5704386,34071,The authors would like to acknowledge the study participants for supporting this research.,Abbreviations|Acknowledgements,[199678],[31873],[31963],[False],[0],[0],[False],['0']
35632,PMC5704386,34072,Funding,Abbreviations|Funding,[199680],[31964],[31971],[False],[0],[0],[False],['0']
35633,PMC5704386,34073,"This study was supported by grants from the Yorkshire Vascular and Surgical Research Fund, York Teaching Hospital Charity, and the University of York.",Abbreviations|Funding,[199682],[31972],[32122],[False],[0],[0],[False],['0']
35634,PMC5704386,34074,The Sponsor was York Teaching Hospital NHS Foundation Trust.,Abbreviations|Funding,[199684],[32123],[32183],[False],[0],[0],[False],['0']
35635,PMC5704386,34075,Availability of data and materials,Abbreviations|Availability of data and materials,[199686],[32184],[32218],[False],[0],[0],[False],['0']
35636,PMC5704386,34076,The dataset for the current study is available from the corresponding author on reasonable request.,Abbreviations|Availability of data and materials,[199688],[32219],[32318],[False],[0],[0],[False],['0']
35637,PMC5704386,34077,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[199690],[32319],[32361],[False],[0],[0],[False],['0']
35638,PMC5704386,34078,"The study was approved by the NRES Committee for Yorkshire & The Humber - Leeds West (Ref: 15/YH/0107), and prospectively registered (ClinicalTrials.gov: NCT02505503).",Abbreviations|Ethics approval and consent to participate,[199692],[32362],[32529],[False],[0],[0],[False],['0']
35639,PMC5704386,34079,Written informed consent was obtained from participants prior to enrolment.,Abbreviations|Ethics approval and consent to participate,[199694],[32530],[32605],[False],[0],[0],[False],['0']
35640,PMC5704386,34080,Consent for publication,Abbreviations|Consent for publication,[199696],[32606],[32629],[False],[0],[0],[False],['0']
35641,PMC5704386,34081,Not applicable.,Abbreviations|Not applicable.,[199698],[32630],[32645],[False],[0],[0],[False],['0']
35642,PMC5704386,34082,Competing interests,Abbreviations|Competing interests,[199700],[32646],[32665],[False],[0],[0],[False],['0']
35643,PMC5704386,34083,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[199702],[32666],[32724],[False],[0],[0],[False],['0']
35644,PMC5704386,34084,Publisher’s Note,Abbreviations|Publisher’s Note,[199704],[32725],[32741],[False],[0],[0],[False],['0']
35645,PMC5704386,34085,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[199706],[32742],[32860],[False],[0],[0],[False],['0']
35646,PMC5718075,29913,Change in cardiac output during Trendelenburg maneuver is a reliable predictor of fluid responsiveness in patients with acute respiratory distress syndrome in the prone position under protective ventilation,Title,[180029],[22932],[206],[False],[0],[0],[False],['0']
35647,PMC5718075,29914,Background,Abstract,[180037],[207],[218],[False],[0],[0],[False],['0']
35648,PMC5718075,29915,Predicting fluid responsiveness may help to avoid unnecessary fluid administration during acute respiratory distress syndrome (ARDS).,Abstract,[180045],[219],[352],[False],[0],[0],[False],['0']
35649,PMC5718075,29916,"The aim of this study was to evaluate the diagnostic performance of the following methods to predict fluid responsiveness in ARDS patients under protective ventilation in the prone position: cardiac index variation during a Trendelenburg maneuver, cardiac index variation during an end-expiratory occlusion test, and both pulse pressure variation and change in pulse pressure variation from baseline during a tidal volume challenge by increasing tidal volume (VT) to 8 ml.kg-1.",Abstract,[180053],[353],[830],[False],[0],[0],[False],['0']
35650,PMC5718075,29917,Methods,Abstract,[180061],[831],[838],[False],[0],[0],[False],['0']
35651,PMC5718075,29918,"This study is a prospective single-center study, performed in a medical intensive care unit, on ARDS patients with acute circulatory failure in the prone position.",Abstract,[180069],[839],[1002],[False],[0],[0],[False],['0']
35652,PMC5718075,29919,"Patients were studied at baseline, during a 1-min shift to the Trendelenburg position, during a 15-s end-expiratory occlusion, during a 1-min increase in VT to 8 ml.kg-1, and after fluid administration.",Abstract,[180077],[1003],[1205],[False],[0],[0],[False],['0']
35653,PMC5718075,29920,Fluid responsiveness was deemed present if cardiac index assessed by transpulmonary thermodilution increased by at least 15% after fluid administration.,Abstract,[180085],[1206],[1358],[False],[0],[0],[False],['0']
35654,PMC5718075,29921,Results,Abstract,[180093],[1359],[1366],[False],[0],[0],[False],['0']
35655,PMC5718075,29922,"There were 33 patients included, among whom 14 (42%) exhibited cardiac arrhythmia at baseline and 15 (45%) were deemed fluid-responsive.",Abstract,[180101],[1367],[1503],[False],[0],[0],[False],['0']
35656,PMC5718075,29923,"The area under the receiver operating characteristic (ROC) curve of the pulse contour-derived cardiac index change during the Trendelenburg maneuver and the end-expiratory occlusion test were 0.90 (95% CI, 0.80–1.00) and 0.65 (95% CI, 0.46–0.84), respectively.",Abstract,[180109],[1504],[1764],[False],[0],[0],[False],['0']
35657,PMC5718075,29924,"An increase in cardiac index ≥ 8% during the Trendelenburg maneuver enabled diagnosis of fluid responsiveness with sensitivity of 87% (95% CI, 67–100), and specificity of 89% (95% CI, 72–100).",Abstract,[180117],[1765],[1957],[False],[0],[0],[False],['0']
35658,PMC5718075,29925,"The area under the ROC curve of pulse pressure variation and change in pulse pressure variation during the tidal volume challenge were 0.52 (95% CI, 0.24–0.80) and 0.59 (95% CI, 0.31–0.88), respectively.",Abstract,[180125],[1958],[2161],[False],[0],[0],[False],['0']
35659,PMC5718075,29926,Conclusions,Abstract,[180133],[2162],[2173],[False],[0],[0],[False],['0']
35660,PMC5718075,29927,"Change in cardiac index during a Trendelenburg maneuver is a reliable test to predict fluid responsiveness in ARDS patients in the prone position, while neither change in cardiac index during end-expiratory occlusion, nor pulse pressure variation during a VT challenge reached acceptable predictive performance to predict fluid responsiveness in this setting.",Abstract,[180141],[2174],[2533],[False],[0],[0],[False],['0']
35661,PMC5718075,29928,Trial registration,Abstract,[180149],[2534],[2552],[False],[0],[0],[False],['0']
35662,PMC5718075,29929,"ClinicalTrials.gov, NCT01965574.",Abstract,[180157],[2553],[2585],[False],[0],[0],[False],['0']
35663,PMC5718075,29930,Registered on 16 October 2013.,Abstract,[180165],[2586],[2616],[False],[0],[0],[False],['0']
35664,PMC5718075,29931,The trial was registered 6 days after inclusion of the first patient.,Abstract,[180173],[2617],[2686],[False],[0],[0],[False],['0']
35665,PMC5718075,29932,Electronic supplementary material,Abstract,[180181],[2687],[2720],[False],[0],[0],[False],['0']
35666,PMC5718075,29933,"The online version of this article (doi:10.1186/s13054-017-1881-0) contains supplementary material, which is available to authorized users.",Abstract,[180189],[2721],[2860],[False],[0],[0],[False],['0']
35667,PMC5718075,29934,Background,Background,[180197],[2861],[2872],[False],[0],[0],[False],['0']
35668,PMC5718075,29935,"Predicting fluid responsiveness is of paramount importance to avoid unnecessary fluid administration in patients with acute respiratory distress syndrome (ARDS), since a positive fluid balance is strongly associated with ARDS mortality [1, 2].",Background,[180205],[2873],[3116],[False],[0],[0],[False],['0']
35669,PMC5718075,29936,Several tests with high reliability in prediction of fluid responsiveness may help optimization of fluid administration to achieve a neutral or negative fluid balance in this condition.,Background,[180213],[3117],[3302],[False],[0],[0],[False],['0']
35670,PMC5718075,29937,"Pulse pressure variation (PPV) [3–5] and other related tests exploring intra-tidal cyclic changes in hemodynamics during mechanical ventilation [6–9] are highly reliable to detect fluid responsiveness, as long as the tidal volume (VT) is greater than 8 ml.kg-1, the cardiac rhythm is regular, the ratio of heart rate to respiratory rate remains high [10], and both compliance of the respiratory system and abdominal pressure stay in the normal range.",Background,[180221],[3303],[3753],[False],[0],[0],[False],['0']
35671,PMC5718075,29938,"However, all these validity criteria are strongly challenged in patients with ARDS under protective ventilation [11–13], even more so in the prone position (PP).",Background,[180229],[3754],[3915],[False],[0],[0],[False],['0']
35672,PMC5718075,29939,"Cardiac index variation during an end-expiratory occlusion (EEO), by transiently suppressing cardiopulmonary interaction, and hence the cyclic impediment to cardiac preload during inspiration, is reliable in supine patients with ARDS to detect fluid responsiveness [14], but has been validated with VT slightly higher than 6 ml.kg-1.",Background,[180237],[3916],[4249],[False],[0],[0],[False],['0']
35673,PMC5718075,29940,"Since low respiratory system compliance decreases airway pressure transmission to intravascular pressure [15], the validity of this test may be challenged in patients with severe ARDS under protective ventilation (VT of 6 ml.kg-1 predicted body weight (PBW) or lower).",Background,[180245],[4250],[4518],[False],[0],[0],[False],['0']
35674,PMC5718075,29941,"Cardiac index variation during passive leg raising is also a reliable method to identify fluid responsiveness [16], free of the limitations of the previously described tests, but is impracticable in the PP.",Background,[180253],[4519],[4725],[False],[0],[0],[False],['0']
35675,PMC5718075,29942,"The Trendelenburg maneuver may be an interesting alternative to transiently modify cardiac preload, and identify fluid responsiveness.",Background,[180261],[4726],[4860],[False],[0],[0],[False],['0']
35676,PMC5718075,29943,"None of the previous tests have been validated in the PP in patients with ARDS, although this treatment is now a therapeutic standard in severe ARDS [17].",Background,[180269],[4861],[5015],[False],[0],[0],[False],['0']
35677,PMC5718075,29944,Methods,Methods,[180277],[5016],[5024],[False],[0],[0],[False],['0']
35678,PMC5718075,29945,Study aim,Methods|Study aim,[180285],[5025],[5034],[False],[0],[0],[False],['0']
35679,PMC5718075,29946,The primary aim of this study was to evaluate the diagnostic performance of cardiac index variation during a Trendelenburg maneuver to predict fluid responsiveness in patients with ARDS under protective ventilation in the PP.,Methods|Study aim,[180293],[5035],[5260],[False],[0],[0],[False],['0']
35680,PMC5718075,29947,"Secondary objectives were to evaluate the diagnostic performance of cardiac index variation during an EEO, and both PPV and change in PPV from baseline during a VT challenge from 6 to 8 ml.kg-1 PBW.",Methods|Study aim,[180301],[5261],[5459],[False],[0],[0],[False],['0']
35681,PMC5718075,29948,Study design,Methods|Study design,[180309],[5460],[5472],[False],[0],[0],[False],['0']
35682,PMC5718075,29949,"This study is a prospective single-center study, performed between October 2013 and January 2017 in a 15-bed medical ICU and registered at ClinicalTrials.gov (NCT01965574).",Methods|Study design,[180317],[5473],[5645],[False],[0],[0],[False],['0']
35683,PMC5718075,29950,"The study protocol (see Additional file 1) was approved by the local ethics committee (Comité de Protection des Personnes Sud-Est IV, ID-RCB-2013-A00526-39).",Methods|Study design,[180325],[5646],[5803],[False],[0],[0],[False],['0']
35684,PMC5718075,29951,"Written consent from the patients’ closest relatives was required for inclusion, and eventually confirmed by the patient after ARDS resolution.",Methods|Study design,[180333],[5804],[5947],[False],[0],[0],[False],['0']
35685,PMC5718075,29952,Patients,Methods|Patients,[180341],[5948],[5956],[False],[0],[0],[False],['0']
35686,PMC5718075,29953,"The subjects had to fulfill all the following inclusion criteria: ARDS according to the Berlin definition [18], ongoing session of PP under invasive mechanical ventilation, ongoing monitoring with the PiCCO® device (Pulsion Medical Systems, Feldkirchen, Germany), and decision by the attending physician to administer fluids with at least one criterion of acute circulatory failure among the following: arterial lactate >2 mmol.L-1, mean arterial pressure <65 mm Hg, cardiac output decrease, urine output <0.5 ml.kg.h-1, heart rate >100 min-1 and skin mottling.",Methods|Patients,[180349],[5957],[6518],[False],[0],[0],[False],['0']
35687,PMC5718075,29954,"Non-inclusion criteria were the following: age <18 years, contra-indication to the Trendelenburg position, pregnancy, lower limbs amputation, known obstruction of inferior vena cava, previous inclusion in current study, and patient under a legal protection measure as required by French regulation.",Methods|Patients,[180357],[6519],[6817],[False],[0],[0],[False],['0']
35688,PMC5718075,29955,Patients exhibiting respiratory effort detected on the pressure-time curve displayed on the ventilator during a 15-s EEO were excluded from the study.,Methods|Patients,[180365],[6818],[6968],[False],[0],[0],[False],['0']
35689,PMC5718075,29956,Protocol description,Methods|Protocol description,[180373],[6969],[6989],[False],[0],[0],[False],['0']
35690,PMC5718075,29957,Fig.,Methods|Protocol description,[180381],[6990],[6994],[False],[0],[0],[False],['0']
35691,PMC5718075,29958,1 Trendelenburg maneuver.,Methods|Protocol description,[180389],[6995],[7020],[False],[0],[0],[False],['0']
35692,PMC5718075,29959,a Starting position of the Trendelenburg maneuver with bed angulation +13°.,Methods|Protocol description,[180397],[7021],[7096],[False],[0],[0],[False],['0']
35693,PMC5718075,29960,b Trendelenburg position with a −13° downward bed angulation.,Methods|Protocol description,[180405],[7097],[7158],[False],[0],[0],[False],['0']
35694,PMC5718075,29961,c Pressure transducers taped on the thorax at the phlebostatic reference point.,Methods|Protocol description,[180413],[7159],[7238],[False],[0],[0],[False],['0']
35695,PMC5718075,29962,"Patients were deeply sedated with a combination of morphine and midazolam targeting a Ramsay score of 6 [19], and remained in PP with a 13° upward bed angulation throughout the study, except during the Trendelenburg maneuver.",Methods|Protocol description,[180421],[7239],[7464],[False],[0],[0],[False],['0']
35696,PMC5718075,29963,They were ventilated in volume-controlled mode with a VT 6 ml.kg-1 PBW.,Methods|Protocol description,[180429],[7465],[7536],[False],[0],[0],[False],['0']
35697,PMC5718075,29964,"Patients were studied at baseline (baseline-1), during a 1-min postural change to the Trendelenburg position with a −13° downward bed angulation (Fig.",Methods|Protocol description,[180437],[7537],[7687],[False],[0],[0],[False],['0']
35698,PMC5718075,29965,"1), during a 1-min VT challenge at 8 ml.kg-1 PBW, during a 15-s EEO maneuver, and after intravenous infusion (IV) of 500 ml crystalloids over 15 min.",Methods|Protocol description,[180445],[7688],[7837],[False],[0],[0],[False],['0']
35699,PMC5718075,29966,Patients were returned to baseline settings for 1 min after each intervention (see Additional file 2).,Methods|Protocol description,[180453],[7838],[7940],[False],[0],[0],[False],['0']
35700,PMC5718075,29967,"The following adverse events were prospectively collected throughout the protocol: drop of systolic arterial pressure >30 mm Hg, increase in heart rate >10%, decrease in peripheral oxygen saturation <88%, new onset of cardiac arrhythmia, or any other adverse event considered relevant by investigators.",Methods|Protocol description,[180461],[7941],[8243],[False],[0],[0],[False],['0']
35701,PMC5718075,29968,Measurements,Methods|Measurements,[180469],[8244],[8257],[False],[0],[0],[False],['0']
35702,PMC5718075,29969,"Jugular central venous and femoral arterial lines were connected to an Intellivue MP40 monitor equipped with a PiCCO® module (Philips Healthcare, Andover, MA, USA).",Methods|Measurements,[180477],[8258],[8422],[False],[0],[0],[False],['0']
35703,PMC5718075,29970,Pressure transducers were taped on the thorax at the phlebostatic reference point (Fig.,Methods|Measurements,[180485],[8423],[8510],[False],[0],[0],[False],['0']
35704,PMC5718075,29971,1).,Methods|Measurements,[180493],[8511],[8514],[False],[0],[0],[False],['0']
35705,PMC5718075,29972,"The following hemodynamic variables were measured throughout the study: arterial pressure, central venous pressure (CVP), pulse contour-derived cardiac index (CCI), heart rate, and PPV.",Methods|Measurements,[180501],[8515],[8700],[False],[0],[0],[False],['0']
35706,PMC5718075,29973,Transpulmonary thermodilution measurements were performed at study onset (baseline-1) and after volume expansion using the PiCCO® device.,Methods|Measurements,[180509],[8701],[8838],[False],[0],[0],[False],['0']
35707,PMC5718075,29974,"Values were computed as the mean of four consecutive measurements, using a 15-ml bolus of cold saline serum.",Methods|Measurements,[180517],[8839],[8947],[False],[0],[0],[False],['0']
35708,PMC5718075,29975,"ΔCCI  was computed as the difference between the maximal value of CCI during Trendelenburg and baseline-1 CCI, normalized by baseline-1 CCI.",Methods|Measurements,[180525],[8948],[9088],[False],[0],[0],[False],['0']
35709,PMC5718075,29976,"ΔPPV  was computed as the difference between the maximal value of PPV during ventilation with VT 8 ml.kg-1 and baseline-2 PPV, normalized by baseline-2 PPV.",Methods|Measurements,[180533],[9089],[9245],[False],[0],[0],[False],['0']
35710,PMC5718075,29977,"ΔCCI  was computed as the difference between the maximal value of CCI during the EEO maneuver and baseline-3 CCI, normalized by baseline-3 CCI.",Methods|Measurements,[180541],[9246],[9389],[False],[0],[0],[False],['0']
35711,PMC5718075,29978,"Fluid responsiveness was deemed present if cardiac index assessed by transpulmonary thermodilution (CI ) increased by at least 15% after volume expansion, as compared to baseline-1 [20].",Methods|Measurements,[180549],[9390],[9576],[False],[0],[0],[False],['0']
35712,PMC5718075,29979,Study endpoints,Methods|Study endpoints,[180557],[9577],[9592],[False],[0],[0],[False],['0']
35713,PMC5718075,29980,The study primary endpoint was the diagnostic performance of ΔCCI  to predict fluid responsiveness.,Methods|Study endpoints,[180565],[9593],[9692],[False],[0],[0],[False],['0']
35714,PMC5718075,29981,"Secondary endpoints were diagnostic performance of ΔCCI  to predict fluid responsiveness, and both PPV and ΔPPV .",Methods|Study endpoints,[180573],[9693],[9806],[False],[0],[0],[False],['0']
35715,PMC5718075,29982,Statistical analysis,Methods|Statistical analysis,[180581],[9807],[9827],[False],[0],[0],[False],['0']
35716,PMC5718075,29983,Statistical analyses were performed using R [21].,Methods|Statistical analysis,[180589],[9828],[9877],[False],[0],[0],[False],['0']
35717,PMC5718075,29984,"Median (1st quartile to 3rd quartile) and counts with percentages are reported for quantitative and categorical variables, respectively.",Methods|Statistical analysis,[180597],[9878],[10014],[False],[0],[0],[False],['0']
35718,PMC5718075,29985,A p value below 0.05 was chosen for statistical significance.,Methods|Statistical analysis,[180605],[10015],[10076],[False],[0],[0],[False],['0']
35719,PMC5718075,29986,"We calculated that with a sample size of 33 patients, the study would provide at worst ± 0.15 precision for the 95% confidence interval (CI ) of the area under the receiver operating characteristic (ROC) curve (AUC), assuming a prevalence of fluid responsiveness of 50% [16, 22–24] and an AUC of at least 0.8 [25] (i.e.",Methods|Statistical analysis,[180613],[10077],[10396],[False],[0],[0],[False],['0']
35720,PMC5718075,29987,a lower bound for the AUC CI  amounting to at least 0.65).,Methods|Statistical analysis,[180621],[10397],[10455],[False],[0],[0],[False],['0']
35721,PMC5718075,29988,"Comparisons between groups of patients were performed with the Fisher’s exact test for categorical variables, and with the t test, Mann-Whitney test or analysis of variance (ANOVA) for continuous and ordinal variables when appropriate.",Methods|Statistical analysis,[180629],[10456],[10691],[False],[0],[0],[False],['0']
35722,PMC5718075,29989,"Hemodynamic parameters were compared using a linear mixed effects model [26, 27].",Methods|Statistical analysis,[180637],[10692],[10773],[False],[0],[0],[False],['0']
35723,PMC5718075,29990,Multiple comparisons between experimental conditions and baseline-1 were performed using Dunnett’s test [28].,Methods|Statistical analysis,[180645],[10774],[10883],[False],[0],[0],[False],['0']
35724,PMC5718075,29991,Diagnostic performance of tests under investigation was assessed by computation of the AUC [29].,Methods|Statistical analysis,[180653],[10884],[10980],[False],[0],[0],[False],['0']
35725,PMC5718075,29992,The CI  for the AUC was computed using the Delong method.,Methods|Statistical analysis,[180661],[10981],[11038],[False],[0],[0],[False],['0']
35726,PMC5718075,29993,The optimal cutoffs were computed by maximizing the Youden index.,Methods|Statistical analysis,[180669],[11039],[11104],[False],[0],[0],[False],['0']
35727,PMC5718075,29994,The CIs for optimal cutoffs were computed using the gray zone approach (area of uncertainty of optimal cutoffs) [23].,Methods|Statistical analysis,[180677],[11105],[11222],[False],[0],[0],[False],['0']
35728,PMC5718075,29995,"Response to each test below the lower or above the higher border of the gray zone were considered negative and positive, respectively.",Methods|Statistical analysis,[180685],[11223],[11357],[False],[0],[0],[False],['0']
35729,PMC5718075,29996,Responses to the test within the gray zone were considered inconclusive.,Methods|Statistical analysis,[180693],[11358],[11430],[False],[0],[0],[False],['0']
35730,PMC5718075,29997,"The CI  for sensitivity, specificity and medians were computed using bootstrapping and 10000 replicates [30, 31].",Methods|Statistical analysis,[180701],[11431],[11544],[False],[0],[0],[False],['0']
35731,PMC5718075,29998,Results,Results,[180709],[11545],[11553],[False],[0],[0],[False],['0']
35732,PMC5718075,29999,Population,Results|Population,[180717],[11554],[11564],[False],[0],[0],[False],['0']
35733,PMC5718075,30000,Table 1 Patients’ general characteristics at inclusion.,Results|Population,[180725],[11565],[11620],[False],[0],[0],[False],['0']
35734,PMC5718075,30001,Table 2 Cardiovascular and respiratory parameters at inclusion.,Results|Population,[180733],[11621],[11684],[False],[0],[0],[False],['0']
35735,PMC5718075,30002,"During the study period, 55 patients presented with inclusion criteria (see Additional file 3) and 33 were included, whose general characteristics, cardiovascular and respiratory parameters at inclusion are reported in Tables 1 and 2.",Results|Population,[180741],[11685],[11919],[False],[0],[0],[False],['0']
35736,PMC5718075,30003,There were 14 patients (42%) who exhibited cardiac arrhythmia at inclusion and were excluded in the analyses pertaining to PPV: 15 patients (45%) were classified as fluid responsive after fluid administration.,Results|Population,[180749],[11920],[12129],[False],[0],[0],[False],['0']
35737,PMC5718075,30004,Hemodynamic measurements,Results|Hemodynamic measurements,[180757],[12130],[12156],[False],[0],[0],[False],['0']
35738,PMC5718075,30005,Table 3 Hemodynamic parameters in each experimental condition.,Results|Hemodynamic measurements,[180765],[12157],[12219],[False],[0],[0],[False],['0']
35739,PMC5718075,30006,The total duration of the study amounted to 26 (24–30) min.,Results|Hemodynamic measurements,[180773],[12220],[12279],[False],[0],[0],[False],['0']
35740,PMC5718075,30007,None of the variables measured after return to baseline settings (baseline-2 to baseline-4) were significantly different from baseline-1 (Table 3).,Results|Hemodynamic measurements,[180781],[12280],[12427],[False],[0],[0],[False],['0']
35741,PMC5718075,30008,"Mean arterial pressure, CVP, CI  global end-diastolic volume index and global ejection fraction increased significantly after fluid administration.",Results|Hemodynamic measurements,[180789],[12428],[12575],[False],[0],[0],[False],['0']
35742,PMC5718075,30009,No adverse event was identified throughout the protocol.,Results|Hemodynamic measurements,[180797],[12576],[12632],[False],[0],[0],[False],['0']
35743,PMC5718075,30010,Trendelenburg maneuver,Results|Trendelenburg maneuver,[180805],[12633],[12656],[False],[0],[0],[False],['0']
35744,PMC5718075,30011,Fig.,Results|Trendelenburg maneuver,[180813],[12657],[12661],[False],[0],[0],[False],['0']
35745,PMC5718075,30012,2 Individual values from five diagnostic tests to detect fluid responsiveness in fluid responders and non-responders.,Results|Trendelenburg maneuver,[180821],[12662],[12779],[False],[0],[0],[False],['0']
35746,PMC5718075,30013,Closed circles are individual values.,Results|Trendelenburg maneuver,[180829],[12780],[12817],[False],[0],[0],[False],['0']
35747,PMC5718075,30014,Red dotted lines display optimal thresholds for each diagnostic test computed by receiver operating characteristic (ROC) curve analysis.,Results|Trendelenburg maneuver,[180837],[12818],[12954],[False],[0],[0],[False],['0']
35748,PMC5718075,30015,"a. ΔCCITREND, change in continuous cardiac index during the Trendelenburg maneuver; b. PPVBASELINE-1, pulse pressure variation during ventilation with 6 ml.kg-1 predicted body weight tidal volume; c. PPVVT8, pulse pressure variation during ventilation with 8 ml.kg-1 predicted body weight tidal volume; d. ΔPPV6-8, change in pulse pressure variation between ventilation with 6 and 8 ml.kg-1 predicted body weight tidal volume; e. ΔCCIEEO, change in continuous cardiac index during end-expiratory occlusion.",Results|Trendelenburg maneuver,[180845],[12955],[13461],[False],[0],[0],[False],['0']
35749,PMC5718075,30016,Fig.,Results|Trendelenburg maneuver,[180853],[13462],[13466],[False],[0],[0],[False],['0']
35750,PMC5718075,30017,3 Relationship between change in continuous cardiac index during the Trendelenburg maneuver (ΔCCITREND) and change in transpulmonary thermodilution-cardiac index by volume expansion (ΔCIVE).,Results|Trendelenburg maneuver,[180861],[13467],[13657],[False],[0],[0],[False],['0']
35751,PMC5718075,30018,The black line is the regression line.,Results|Trendelenburg maneuver,[180869],[13658],[13696],[False],[0],[0],[False],['0']
35752,PMC5718075,30019,The shaded area is the 95% confidence interval of the regression line.,Results|Trendelenburg maneuver,[180877],[13697],[13767],[False],[0],[0],[False],['0']
35753,PMC5718075,30020,There are 33 data points presented although some data points are overlapping.,Results|Trendelenburg maneuver,[180885],[13768],[13845],[False],[0],[0],[False],['0']
35754,PMC5718075,30021,Table 4 Diagnostic performance of five diagnostic tests to predict fluid responsiveness.,Results|Trendelenburg maneuver,[180893],[13846],[13934],[False],[0],[0],[False],['0']
35755,PMC5718075,30022,Fig.,Results|Trendelenburg maneuver,[180901],[13935],[13939],[False],[0],[0],[False],['0']
35756,PMC5718075,30023,4 Receiver operating characteristics curves from five diagnostics tests to detect fluid responsiveness.,Results|Trendelenburg maneuver,[180909],[13940],[14043],[False],[0],[0],[False],['0']
35757,PMC5718075,30024,"ΔCCITREND, change in continuous cardiac index during the Trendelenburg maneuver; ΔCCIEEO, change in continuous cardiac index during end-expiratory occlusion; PPVBASELINE-1, pulse pressure variation during ventilation with 6 ml.kg-1 predicted body weight tidal volume; PPVVT8, pulse pressure variation during ventilation with 8 ml.kg-1 predicted body weight tidal volume; ΔPPV6-8, change in pulse pressure variation between ventilation with 6 and 8 ml.kg-1 predicted body weight tidal volume.",Results|Trendelenburg maneuver,[180917],[14044],[14535],[False],[0],[0],[False],['0']
35758,PMC5718075,30025,Fig.,Results|Trendelenburg maneuver,[180925],[14536],[14540],[False],[0],[0],[False],['0']
35759,PMC5718075,30026,5 Sensitivity and specificity of each diagnostic test according to the value of the diagnostic cutoff.,Results|Trendelenburg maneuver,[180933],[14541],[14643],[False],[0],[0],[False],['0']
35760,PMC5718075,30027,"Blue and red data points are sensitivity and specificity, respectively, computed at each value of the diagnostic cutoff.",Results|Trendelenburg maneuver,[180941],[14644],[14764],[False],[0],[0],[False],['0']
35761,PMC5718075,30028,Blue and red curves are fitted curves to sensitivity and specificity computed values.,Results|Trendelenburg maneuver,[180949],[14765],[14850],[False],[0],[0],[False],['0']
35762,PMC5718075,30029,The 95% confidence intervals for optimal value of cutoff are depicted as a shaded zone (gray zone defining inconclusive response).,Results|Trendelenburg maneuver,[180957],[14851],[14981],[False],[0],[0],[False],['0']
35763,PMC5718075,30030,"ΔCCITREND, change in continuous cardiac index during the Trendelenburg maneuver; ΔCCIEEO, change in continuous cardiac index during end-expiratory occlusion; PPVBASELINE-1, pulse pressure variation during ventilation with 6 ml.kg-1 predicted body weight tidal volume; PPVVT8, pulse pressure variation during ventilation with 8 ml.kg-1 predicted body weight tidal volume; ΔPPV6-8, change in pulse pressure variation between ventilation with 6 and 8 ml.kg-1 predicted body weight tidal volume.",Results|Trendelenburg maneuver,[180965],[14982],[15473],[False],[0],[0],[False],['0']
35764,PMC5718075,30031,"CVP increased significantly during Trendelenburg, while heart rate remained unchanged (Table 3).",Results|Trendelenburg maneuver,[180973],[15474],[15570],[False],[0],[0],[False],['0']
35765,PMC5718075,30032,"Median ΔCCI  amounted to 6% (CI , 3–10%) and was significantly greater in responders than in non-responders (13% vs. 3%, p < 0.001, Fig.",Results|Trendelenburg maneuver,[180981],[15571],[15707],[False],[0],[0],[False],['0']
35766,PMC5718075,30033,2).,Results|Trendelenburg maneuver,[180989],[15708],[15711],[False],[0],[0],[False],['0']
35767,PMC5718075,30034,"ΔCCI  was significantly correlated with change in CI  related to volume expansion (R 2 = 0.41, Fig.",Results|Trendelenburg maneuver,[180997],[15712],[15811],[False],[0],[0],[False],['0']
35768,PMC5718075,30035,3).,Results|Trendelenburg maneuver,[181005],[15812],[15815],[False],[0],[0],[False],['0']
35769,PMC5718075,30036,"ΔCCI  predicted fluid responsiveness with an AUC of 0.90 (CI , 0.80–1.00, p < 0.001), with sensitivity of 87% and specificity of 89% at a threshold of 8% (gray zone, 5–12%) (Table 4, Figs.",Results|Trendelenburg maneuver,[181013],[15816],[16004],[False],[0],[0],[False],['0']
35770,PMC5718075,30037,4 and 5).,Results|Trendelenburg maneuver,[181021],[16005],[16014],[False],[0],[0],[False],['0']
35771,PMC5718075,30038,"Cardiac index response to volume expansion increased stepwise in patients with a negative response, those with an inconclusive response, and those with a positive response to the test (see Additional file 4).",Results|Trendelenburg maneuver,[181029],[16015],[16223],[False],[0],[0],[False],['0']
35772,PMC5718075,30039,Four patients were misclassified (Fig.,Results|Trendelenburg maneuver,[181037],[16224],[16262],[False],[0],[0],[False],['0']
35773,PMC5718075,30040,"2), and none of their hemodynamic and respiratory parameters were significantly different from those of the 29 correctly classified patients (data not shown).",Results|Trendelenburg maneuver,[181045],[16263],[16421],[False],[0],[0],[False],['0']
35774,PMC5718075,30041,Pulse pressure variation,Results|Pulse pressure variation,[181053],[16422],[16451],[False],[0],[0],[False],['0']
35775,PMC5718075,30042,PPV  PPV  and ΔPPV  did not significantly differ between fluid responders and non-responders (Fig.,Results|Pulse pressure variation,[181061],[16452],[16550],[False],[0],[0],[False],['0']
35776,PMC5718075,30043,2).,Results|Pulse pressure variation,[181069],[16551],[16554],[False],[0],[0],[False],['0']
35777,PMC5718075,30044,"None of the three PPV-derived diagnostic tests were statistically significant for AUC (Table 4, Fig.",Results|Pulse pressure variation,[181077],[16555],[16655],[False],[0],[0],[False],['0']
35778,PMC5718075,30045,4).,Results|Pulse pressure variation,[181085],[16656],[16659],[False],[0],[0],[False],['0']
35779,PMC5718075,30046,"ΔPPV  exhibited the greatest sensitivity (100% (CI , 100–100%)) at a threshold of 29%, but with a very low specificity (40% (CI , 10–70%)).",Results|Pulse pressure variation,[181093],[16660],[16799],[False],[0],[0],[False],['0']
35780,PMC5718075,30047,False positive patients with the PPV  test had significantly greater driving pressure while true negative had significantly lower PaO /FiO  ratio (data not shown).,Results|Pulse pressure variation,[181101],[16800],[16963],[False],[0],[0],[False],['0']
35781,PMC5718075,30048,CI  at inclusion was significantly lower in the 5 false positive patients as assessed by PPV .,Results|Pulse pressure variation,[181109],[16964],[17058],[False],[0],[0],[False],['0']
35782,PMC5718075,30049,End-expiratory occlusion,Results|End-expiratory occlusion,[181117],[17059],[17083],[False],[0],[0],[False],['0']
35783,PMC5718075,30050,"CVP decreased slightly but significantly from 7 (5–11) to 6 (4–10) mm Hg during EEO, while CCI remained unchanged (Table 3).",Results|End-expiratory occlusion,[181125],[17084],[17208],[False],[0],[0],[False],['0']
35784,PMC5718075,30051,ΔCCI  was not significantly different in responders and non-responders (Fig.,Results|End-expiratory occlusion,[181133],[17209],[17285],[False],[0],[0],[False],['0']
35785,PMC5718075,30052,2).,Results|End-expiratory occlusion,[181141],[17286],[17289],[False],[0],[0],[False],['0']
35786,PMC5718075,30053,"The AUC of ΔCCI  to predict fluid responsiveness amounted to 0.65 (CI , 0.46–0.84), and was not significantly different from 0.5 (Table 4, Fig.",Results|End-expiratory occlusion,[181149],[17290],[17433],[False],[0],[0],[False],['0']
35787,PMC5718075,30054,4).,Results|End-expiratory occlusion,[181157],[17434],[17437],[False],[0],[0],[False],['0']
35788,PMC5718075,30055,"ΔCCI  had sensitivity of 33% (CI , 13–60%) and specificity of 100% (CI , 100–100%) at a threshold of 10% (gray zone, –4% to 11%) to predict fluid responsiveness (Table 4, Fig.",Results|End-expiratory occlusion,[181165],[17438],[17613],[False],[0],[0],[False],['0']
35789,PMC5718075,30056,5).,Results|End-expiratory occlusion,[181173],[17614],[17617],[False],[0],[0],[False],['0']
35790,PMC5718075,30057,"In the 14 patients with change in CVP (ΔCVP) ≥0 mm Hg, the AUC of ΔCCI  amounted to 0.89 (CI , 0.70–1.00) (p < 0.05), while it was not statistically different from 0.5 in the 19 patients with ΔCVP <0 mm Hg (see Additional files 5 and 6).",Results|End-expiratory occlusion,[181181],[17618],[17855],[False],[0],[0],[False],['0']
35791,PMC5718075,30058,Discussion,Discussion,[181189],[17856],[17867],[False],[0],[0],[False],['0']
35792,PMC5718075,30059,This study is the first to evaluate the diagnostic performance of several diagnostic tests to predict fluid responsiveness in patients with ARDS in the PP under protective ventilation.,Discussion,[181197],[17868],[18052],[False],[0],[0],[False],['0']
35793,PMC5718075,30060,"The main findings are that: (1) change in cardiac index during the Trendelenburg maneuver is a highly reliable test to predict fluid responsiveness, with both sensitivity and specificity approximating 90%; (2) change in PPV during a transient increase in VT from 6 to 8 ml.kg-1 is highly sensitive to predict fluid responsiveness, but with low specificity; and (3) change in cardiac index during EEO has low sensitivity, but high specificity to predict fluid responsiveness in this clinical setting.",Discussion,[181205],[18053],[18552],[False],[0],[0],[False],['0']
35794,PMC5718075,30061,Reliability of the Trendelenburg maneuver to predict fluid responsiveness,Discussion,[181213],[18553],[18626],[False],[0],[0],[False],['0']
35795,PMC5718075,30062,"In the present study, ΔCCI  amounted to 6% (CI , 3–13%), and was in the range of the 9% increase observed in a recent systematic review [32], although performed in subjects in the supine position, with various degrees of head-down tilt angulation.",Discussion,[181221],[18627],[18874],[False],[0],[0],[False],['0']
35796,PMC5718075,30063,"An important issue in the reliability of the Trendelenburg maneuver to predict fluid responsiveness is related to baroreflex activation in this position, leading to systemic vasodilation, decreased heart rate and myocardial contractility.",Discussion,[181229],[18875],[19113],[False],[0],[0],[False],['0']
35797,PMC5718075,30064,"However, we did not observe a significant change in heart rate in the Trendelenburg position as compared to baseline, in keeping with the results of the aforementioned systematic review [32].",Discussion,[181237],[19114],[19305],[False],[0],[0],[False],['0']
35798,PMC5718075,30065,"While baroreflex activation is immediately evident after carotid declamping in patients who were awake and undergoing carotid surgery, the maximal effect on heart rate is observed 10 min later [33].",Discussion,[181245],[19306],[19504],[False],[0],[0],[False],['0']
35799,PMC5718075,30066,"Opposite to this, in healthy volunteers, midazolam has been shown to dose-dependently blunt the fast parasympathetic efferent pathway of the baroreflex [34, 35].",Discussion,[181253],[19505],[19666],[False],[0],[0],[False],['0']
35800,PMC5718075,30067,"Taken together, these data suggest that the 1-min duration of the maneuver may not have been long enough to significantly activate the baroreflex in deeply sedated patients with ARDS.",Discussion,[181261],[19667],[19850],[False],[0],[0],[False],['0']
35801,PMC5718075,30068,Reliability of PPV to predict fluid responsiveness,Discussion|Reliability of PPV to predict fluid responsiveness,[181269],[19851],[19901],[False],[0],[0],[False],['0']
35802,PMC5718075,30069,The present study confirmed the lack of predictive ability of PPV to predict fluid responsiveness in patients with ARDS under protective ventilation [11–13].,Discussion|Reliability of PPV to predict fluid responsiveness,[181277],[19902],[20059],[False],[0],[0],[False],['0']
35803,PMC5718075,30070,This finding is not unexpected since cardiopulmonary interactions under mechanical ventilation (the underlying physiological mechanism behind PPV) are dependent on both ventilatory settings and transmission of airway pressure to cardiac filling pressures.,Discussion|Reliability of PPV to predict fluid responsiveness,[181285],[20060],[20315],[False],[0],[0],[False],['0']
35804,PMC5718075,30071,"This transmission is inversely related to respiratory system elastance [15], and linearly related to the ratio of chest wall to respiratory system elastances [36].",Discussion|Reliability of PPV to predict fluid responsiveness,[181293],[20316],[20479],[False],[0],[0],[False],['0']
35805,PMC5718075,30072,"In conditions combining low VT and low respiratory system elastance as observed in patients with ARDS under protective ventilation, a high rate of false negative patients is expected.",Discussion|Reliability of PPV to predict fluid responsiveness,[181301],[20480],[20663],[False],[0],[0],[False],['0']
35806,PMC5718075,30073,"Performing a VT challenge did not significantly enhance the reliability of the PPV test, since sensitivity increased at the expense of specificity.",Discussion|Reliability of PPV to predict fluid responsiveness,[181309],[20664],[20811],[False],[0],[0],[False],['0']
35807,PMC5718075,30074,"While this VT challenge increased the reliability of the PPV test in one study performed on 22 ICU patients in the supine position (9% with ARDS) [13], our data suggest that this finding should not be extrapolated to patients with ARDS on PP.",Discussion|Reliability of PPV to predict fluid responsiveness,[181317],[20812],[21054],[False],[0],[0],[False],['0']
35808,PMC5718075,30075,"Previous studies have shown that false positive patients for PPV may occur in the context of right ventricular failure [7, 37], and the higher driving pressure in this group of the present study favors this hypothesis [38].",Discussion|Reliability of PPV to predict fluid responsiveness,[181325],[21055],[21278],[False],[0],[0],[False],['0']
35809,PMC5718075,30076,Reliability of EEO to predict fluid responsiveness,Discussion|Reliability of EEO to predict fluid responsiveness,[181333],[21279],[21329],[False],[0],[0],[False],['0']
35810,PMC5718075,30077,"The EEO test has been shown to accurately predict fluid responsiveness in the supine position in four studies [12, 14, 39, 40] including one restricted to patients with ARDS ventilated with VT slightly greater than 6 ml.kg-1 [14].",Discussion|Reliability of EEO to predict fluid responsiveness,[181341],[21330],[21560],[False],[0],[0],[False],['0']
35811,PMC5718075,30078,"However, its predictive performance was poor in a recent study in which 6 ml.kg-1 VT was first applied, but was restored during a VT challenge at 8 ml.kg-1 [13].",Discussion|Reliability of EEO to predict fluid responsiveness,[181349],[21561],[21722],[False],[0],[0],[False],['0']
35812,PMC5718075,30079,"Our results are in line with this study, and the high rate of false negative patients in our study (30%) suggests that the decrease in the cyclic stress applied to the cardiovascular system during ARDS under protective ventilation (due to both low VT and decreased respiratory system compliance) is not sufficient to generate a detectable effect on cardiac index in some patients.",Discussion|Reliability of EEO to predict fluid responsiveness,[181357],[21723],[22103],[False],[0],[0],[False],['0']
35813,PMC5718075,30080,"We therefore hypothesized that the PP-induced increase in intra-abdominal pressure [41] could generate an impediment to venous return, promoting a zone-2 condition in the inferior vena cava in some patients [42] (and hence a pressure gradient between the inferior vena cava and the right atrium), and could explain the high false negative rate in our study.",Discussion|Reliability of EEO to predict fluid responsiveness,[181365],[22104],[22461],[False],[0],[0],[False],['0']
35814,PMC5718075,30081,"The slight decrease in CVP during the EEO in 53% of the patients, combined with the low predictive value of ΔCCI  in this subpopulation favors this hypothesis, although the lack of direct measurement of intra-abdominal pressure and venous return precludes any definite conclusion.",Discussion|Reliability of EEO to predict fluid responsiveness,[181373],[22462],[22742],[False],[0],[0],[False],['0']
35815,PMC5718075,30082,"Finally, it should be emphasized that the EEO remains a highly specific test in patients with ARDS under protective ventilation in PP.",Discussion|Reliability of EEO to predict fluid responsiveness,[181381],[22743],[22877],[False],[0],[0],[False],['0']
35816,PMC5718075,30083,Limitations,Discussion|Limitations,[181389],[22878],[22889],[False],[0],[0],[False],['0']
35817,PMC5718075,30084,Some limitations of the present study should be acknowledged.,Discussion|Limitations,[181397],[22890],[22951],[False],[0],[0],[False],['0']
35818,PMC5718075,30085,"First, the monocentric feature of this study questions the generalizability of its results.",Discussion|Limitations,"[181405, 181406]","[22952, 22952]","[23043, 23043]","[True, True]","['Unicentric', 'Generalization']","['monocentric', 'the generalizability of its results']","[True, True]","['Generalization', 'Setting']"
35819,PMC5718075,30086,"Second, amplifying the postural change during the Trendelenburg maneuver (beyond 13° and −13°) could have maximized the blood transfer from the lower body parts towards the central circulation and may have further increased the sensitivity of this test.",Discussion|Limitations,[181415],[23044],[23297],[True],['ResponsivenessOfMeasurement'],['the sensitivity of this test'],[True],['OutcomeMeasures']
35820,PMC5718075,30087,"Third, the high number of patients with cardiac arrhythmia (therefore excluded from PPV analyses) makes the study strongly underpowered for all analyses pertaining to this test.",Discussion|Limitations,"[181432, 181433]","[23298, 23298]","[23475, 23475]","[True, True]","['VerySpecificPopulation', 'UnderpoweredStudy']","['the high number of patients with cardiac arrhythmia', 'underpowered for all analyses pertaining to this test']","[True, True]","['Population', 'UnderpoweredStudy']"
35821,PMC5718075,30088,"Fourth, the lack of blinding precludes control of a potential evaluation bias.",Discussion|Limitations,[181450],[23476],[23554],[True],['Blinding'],['the lack of blinding'],[True],['Blinding']
35822,PMC5718075,30089,"Fifth, cardiac output assessed from pulse contour analysis may be inaccurate in relation to change in resistive and elastic characteristics of the vascular system, although its reliability is acceptable during the hour following calibration [43].",Discussion|Limitations,[181467],[23555],[23801],[True],['PrecisionOfMeasurement'],['cardiac output assessed from pulse contour analysis may be inaccurate'],[True],['OutcomeMeasures']
35823,PMC5718075,30090,"Finally, the lack of randomization between the three maneuvers performed to predict fluid responsiveness (namely Trendelenburg maneuver, VT challenge and EEO) could have hampered a reliable evaluation of the latter two tests.",Discussion|Limitations,[181476],[23802],[24027],[True],['Randomization'],['the lack of randomization between the three maneuvers'],[True],['Randomization']
35824,PMC5718075,30091,Clinical implications,Discussion|Clinical implications,[181485],[24028],[24049],[False],[0],[0],[False],['0']
35825,PMC5718075,30092,"Risk minimization is an important issue in fluid administration in patients with severe ARDS, given the potential for harm of unnecessary fluid bolus.",Discussion|Clinical implications,[181493],[24050],[24200],[False],[0],[0],[False],['0']
35826,PMC5718075,30093,"Using the Trendelenburg test, 70% of the patients could be classified outside the gray zone, meaning that fluid responsiveness was assessed with near certainty in the majority of the patients.",Discussion|Clinical implications,[181501],[24201],[24393],[False],[0],[0],[False],['0']
35827,PMC5718075,30094,"Regarding the 30% of patients within the gray zone of the Trendelenburg test, fluid administration may be considered, although response to fluid therapy may be less intense in this group.",Discussion|Clinical implications,[181509],[24394],[24581],[False],[0],[0],[False],['0']
35828,PMC5718075,30095,"Finally, whether guiding fluid therapy using indices of fluid responsiveness improve ARDS prognosis remains unknown, although it may help to decrease fluid administration in patients with septic shock [44].",Discussion|Clinical implications,[181517],[24582],[24788],[False],[0],[0],[False],['0']
35829,PMC5718075,30096,Conclusions,Conclusions,[181525],[24789],[24801],[False],[0],[0],[False],['0']
35830,PMC5718075,30097,This study suggests that the Trendelenburg maneuver is reliable to predict fluid responsiveness in patients with ARDS under protective ventilation in the prone position.,Conclusions,[181533],[24802],[24971],[False],[0],[0],[False],['0']
35831,PMC5718075,30098,"Pulse pressure variation or change in pulse pressure variation from baseline during a tidal volume challenge, and the end-expiratory occlusion test, although reliable in other clinical settings, did not reach acceptable predictive performance for fluid responsiveness.",Conclusions,[181541],[24972],[25240],[False],[0],[0],[False],['0']
35832,PMC5718075,30099,Additional files,Additional files,[181549],[25241],[25258],[False],[0],[0],[False],['0']
35833,PMC5718075,30100, Study protocol.,Additional files,[181557],[25259],[25275],[False],[0],[0],[False],['0']
35834,PMC5718075,30101,Study protocol as it was submitted to ethics committee and French heath regulation authorities.,Additional files,[181565],[25276],[25371],[False],[0],[0],[False],['0']
35835,PMC5718075,30102,(DOC 330 kb)  Protocol description.,Additional files,[181573],[25372],[25407],[False],[0],[0],[False],['0']
35836,PMC5718075,30103,(DOCX 71 kb)  Study flow chart.,Additional files,[181581],[25408],[25439],[False],[0],[0],[False],['0']
35837,PMC5718075,30104,(DOCX 397 kb)  Change in transpulmonary thermodilution-cardiac index by volume expansion (ΔCIVE) as function of response to five diagnostic tests.,Additional files,[181589],[25440],[25586],[False],[0],[0],[False],['0']
35838,PMC5718075,30105,(DOCX 314 kb)  Diagnostic performance of end-expiratory occlusion to predict fluid responsiveness as a function of change in CVP (ΔCVP) during the test as compared to baseline.,Additional files,[181597],[25587],[25763],[False],[0],[0],[False],['0']
35839,PMC5718075,30106,(DOCX 14 kb)  Receiver operating characteristics curves of end-expiratory occlusion to predict fluid responsiveness as a function of change in CVP (ΔCVP) during the test as compared to baseline.,Additional files,[181605],[25764],[25958],[False],[0],[0],[False],['0']
35840,PMC5718075,30107,(DOCX 67 kb)  Dataset.,Additional files,[181613],[25959],[25981],[False],[0],[0],[False],['0']
35841,PMC5718075,30108,(XLSX 53 kb),Additional files,[181621],[25982],[25994],[False],[0],[0],[False],['0']
35842,PMC5718075,30109,Abbreviations,Abbreviations,[181629],[25995],[26011],[False],[0],[0],[False],['0']
35843,PMC5718075,30110,ARDS Acute respiratory distress syndrome,Abbreviations|ARDS Acute respiratory distress syndrome,[181637],[26012],[26052],[False],[0],[0],[False],['0']
35844,PMC5718075,30111,AUC Area under the receiver operating characteristic curve,Abbreviations|AUC Area under the receiver operating characteristic curve,[181645],[26053],[26111],[False],[0],[0],[False],['0']
35845,PMC5718075,30112,CCI Pulse contour-derived cardiac index,Abbreviations|CCI Pulse contour-derived cardiac index,[181653],[26112],[26151],[False],[0],[0],[False],['0']
35846,PMC5718075,30113,CI95% 95% Confidence interval,Abbreviations|CCI Pulse contour-derived cardiac index,[181661],[26152],[26181],[False],[0],[0],[False],['0']
35847,PMC5718075,30114,CITPTD Transpulmonary thermodilution,Abbreviations|CCI Pulse contour-derived cardiac index,[181669],[26182],[26218],[False],[0],[0],[False],['0']
35848,PMC5718075,30115,CVP Central venous pressure,Abbreviations|CVP Central venous pressure,[181677],[26219],[26246],[False],[0],[0],[False],['0']
35849,PMC5718075,30116,EEO End-expiratory occlusion,Abbreviations|EEO End-expiratory occlusion,[181685],[26247],[26275],[False],[0],[0],[False],['0']
35850,PMC5718075,30117,PBW Predicted body weight,Abbreviations|PBW Predicted body weight,[181693],[26276],[26301],[False],[0],[0],[False],['0']
35851,PMC5718075,30118,PP Prone position,Abbreviations|PP Prone position,[181701],[26302],[26319],[False],[0],[0],[False],['0']
35852,PMC5718075,30119,PPV Pulse pressure variation,Abbreviations|PPV Pulse pressure variation,[181709],[26320],[26348],[False],[0],[0],[False],['0']
35853,PMC5718075,30120,ROC Receiver operating characteristic,Abbreviations|ROC Receiver operating characteristic,[181717],[26349],[26386],[False],[0],[0],[False],['0']
35854,PMC5718075,30121,VT Tidal volume,Abbreviations|VT Tidal volume,[181725],[26387],[26402],[False],[0],[0],[False],['0']
35855,PMC5718075,30122,"ΔCCITREND Difference between the maximal value of CCI during Trendelenburg and baseline-1 CCI, Normalized by baseline-1 CCI",Abbreviations|VT Tidal volume,[181733],[26403],[26526],[False],[0],[0],[False],['0']
35856,PMC5718075,30123,"ΔPPV6-8 Difference between the maximal value of PPV during ventilation with tidal volume 8 ml.kg-1 and baseline-2 PPV, normalized by baseline-2 PPV",Abbreviations|VT Tidal volume,[181741],[26527],[26674],[False],[0],[0],[False],['0']
35857,PMC5718075,30124,"ΔCCIEEO Difference between the maximal value of CCI during the EEO maneuver and baseline-3 CCI, normalized by baseline-3 CCIElectronic supplementary material",Abbreviations|VT Tidal volume,[181749],[26675],[26832],[False],[0],[0],[False],['0']
35858,PMC5718075,30125,"The online version of this article (doi:10.1186/s13054-017-1881-0) contains supplementary material, which is available to authorized users.",Abbreviations|VT Tidal volume,[181757],[26833],[26972],[False],[0],[0],[False],['0']
35859,PMC5718075,30126,Acknowledgements,Abbreviations|Acknowledgements,[181765],[26973],[26989],[False],[0],[0],[False],['0']
35860,PMC5718075,30127,Not applicable.,Abbreviations|Not applicable.,[181773],[26990],[27005],[False],[0],[0],[False],['0']
35861,PMC5718075,30128,Availability of data and materials,Abbreviations|Availability of data and materials,[181781],[27006],[27040],[False],[0],[0],[False],['0']
35862,PMC5718075,30129,All data generated or analyzed during this study are included in this published article and its supplementary information files (see Additional file 7).,Abbreviations|Availability of data and materials,[181789],[27041],[27193],[False],[0],[0],[False],['0']
35863,PMC5718075,30130,Funding,Abbreviations|Funding,[181797],[27194],[27201],[False],[0],[0],[False],['0']
35864,PMC5718075,30131,None.,Abbreviations|None.,[181805],[27202],[27207],[False],[0],[0],[False],['0']
35865,PMC5718075,30132,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[181813],[27208],[27250],[False],[0],[0],[False],['0']
35866,PMC5718075,30133,"The study protocol was approved by the local ethics committee (Comité de Protection des Personnes Sud-Est IV, ID-RCB-2013-A00526-39).",Abbreviations|Ethics approval and consent to participate,[181821],[27251],[27384],[False],[0],[0],[False],['0']
35867,PMC5718075,30134,"Written consent from the patients’ closest relatives was required for inclusion, and eventually confirmed by the patient after ARDS resolution.",Abbreviations|Ethics approval and consent to participate,[181829],[27385],[27528],[False],[0],[0],[False],['0']
35868,PMC5718075,30135,Consent for publication,Abbreviations|Consent for publication,[181837],[27529],[27552],[False],[0],[0],[False],['0']
35869,PMC5718075,30136,Not applicable.,Abbreviations|Not applicable.,[181845],[27553],[27568],[False],[0],[0],[False],['0']
35870,PMC5718075,30137,Competing interests,Abbreviations|Competing interests,[181853],[27569],[27588],[False],[0],[0],[False],['0']
35871,PMC5718075,30138,The authors declare that they have no competing interests.,Abbreviations|Competing interests,[181861],[27589],[27647],[False],[0],[0],[False],['0']
35872,PMC5718075,30139,Publisher’s Note,Abbreviations|Publisher’s Note,[181869],[27648],[27664],[False],[0],[0],[False],['0']
35873,PMC5718075,30140,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[181877],[27665],[27783],[False],[0],[0],[False],['0']
36057,PMC5721882,22894,"Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome",Title,[134802],[32623],[148],[False],[0],[0],[False],['0']
36058,PMC5721882,22895,Background,Abstract,[134809],[149],[160],[False],[0],[0],[False],['0']
36059,PMC5721882,22896,"It is unknown whether short sleep duration, obstructive sleep apnea, and overnight shift work are associated with the risk of recurrent cardiovascular events in patients after an acute coronary syndrome.",Abstract,[134816],[161],[364],[False],[0],[0],[False],['0']
36060,PMC5721882,22897,Methods and Results,Abstract,[134823],[365],[384],[False],[0],[0],[False],['0']
36061,PMC5721882,22898,"SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome.",Abstract,[134830],[385],[621],[False],[0],[0],[False],['0']
36062,PMC5721882,22899,"At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey.",Abstract,[134837],[622],[766],[False],[0],[0],[False],['0']
36063,PMC5721882,22900,Median follow‐up was 2.5 years.,Abstract,[134844],[767],[798],[False],[0],[0],[False],['0']
36064,PMC5721882,22901,"The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization).",Abstract,[134851],[799],[933],[False],[0],[0],[False],['0']
36065,PMC5721882,22902,Cox models were adjusted for clinical predictors.,Abstract,[134858],[934],[983],[False],[0],[0],[False],['0']
36066,PMC5721882,22903,"Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep.",Abstract,[134865],[984],[1173],[False],[0],[0],[False],['0']
36067,PMC5721882,22904,Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive.,Abstract,[134872],[1174],[1327],[False],[0],[0],[False],['0']
36068,PMC5721882,22905,Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01).,Abstract,[134879],[1328],[1455],[False],[0],[0],[False],['0']
36069,PMC5721882,22906,A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor.,Abstract,[134886],[1456],[1572],[False],[0],[0],[False],['0']
36070,PMC5721882,22907,Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).,Abstract,[134893],[1573],[1683],[False],[0],[0],[False],['0']
36071,PMC5721882,22908,Conclusions,"SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome. At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey. Median follow‐up was 2.5 years. The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization). Cox models were adjusted for clinical predictors. Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep. Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive. Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01). A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor. Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).|Conclusions",[134900],[1684],[1695],[False],[0],[0],[False],['0']
36072,PMC5721882,22909,"Short sleep duration, obstructive sleep apnea, and overnight shift work are under‐recognized as predictors of adverse outcomes after acute coronary syndrome.","SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome. At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey. Median follow‐up was 2.5 years. The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization). Cox models were adjusted for clinical predictors. Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep. Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive. Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01). A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor. Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).|Conclusions",[134907],[1696],[1853],[False],[0],[0],[False],['0']
36073,PMC5721882,22910,"Increased efforts should be made to identify, treat, and educate patients about the importance of sleep for the potential prevention of cardiovascular events.","SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome. At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey. Median follow‐up was 2.5 years. The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization). Cox models were adjusted for clinical predictors. Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep. Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive. Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01). A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor. Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).|Conclusions",[134914],[1854],[2012],[False],[0],[0],[False],['0']
36074,PMC5721882,22911,Clinical Trial Registration,"SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome. At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey. Median follow‐up was 2.5 years. The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization). Cox models were adjusted for clinical predictors. Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep. Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive. Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01). A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor. Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).|Clinical Trial Registration",[134921],[2013],[2040],[False],[0],[0],[False],['0']
36075,PMC5721882,22912,URL: http://www.clinicaltrials.gov.,"SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome. At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey. Median follow‐up was 2.5 years. The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization). Cox models were adjusted for clinical predictors. Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep. Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive. Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01). A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor. Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).|Clinical Trial Registration",[134928],[2041],[2076],[False],[0],[0],[False],['0']
36076,PMC5721882,22913,Unique identifier: NCT01000727.,"SOLID‐TIMI 52 (The Stabilization of PLaques UsIng Darapladib‐Thrombolysis in Myocardial Infarction 52 Trial) was a multinational, double‐blind, placebo‐controlled trial that enrolled 13 026 patients ≤30 days of acute coronary syndrome. At baseline, all patients were to complete the Berlin questionnaire to assess risk of obstructive sleep apnea and a sleep and shift work survey. Median follow‐up was 2.5 years. The primary outcome was major coronary events (MCE; coronary heart disease death, myocardial infarction, or urgent revascularization). Cox models were adjusted for clinical predictors. Patients who reported <6 hours sleep per night had a 29% higher risk of MCE (adjusted hazard ratio, 1.29; 95% confidence interval, 1.12–1.49; P<0.001) compared with those with longer sleep. Patients who screened positive for obstructive sleep apnea had a 12% higher risk of MCE (1.12; 1.00–1.24; P=0.04) than those who did not screen positive. Overnight shift work (≥3 night shifts/week for ≥1 year) was associated with a 15% higher risk of MCE (1.15; 1.03–1.29; P=0.01). A step‐wise increase in cardiovascular risk was observed for individuals with more than 1 sleep‐related risk factor. Individuals with all 3 sleep‐related risk factors had a 2‐fold higher risk of MCE (2.01; 1.49–2.71; P<0.0001).|Clinical Trial Registration",[134935],[2077],[2108],[False],[0],[0],[False],['0']
36077,PMC5721882,22914,Introduction,Introduction,[134942],[2109],[2123],[False],[0],[0],[False],['0']
36078,PMC5721882,22915,"Inadequate sleep, whether caused by reduced sleep duration or obstructive sleep apnea (OSA), and recurrent circadian disruption induced by night shift work adversely affect cardiovascular regulation1, 2 and are associated with an increased risk of incident cardiovascular disease and death.3, 4 Thirty percent of employed adults in the United States and 44% of night shift workers report sleeping, on average, 6 or fewer hours on work nights.5 Short sleep duration has been associated with increased risk for incident calcification of the coronary arteries,6 incident stroke,7 coronary heart disease,3 and death.8, 9 In addition, prevalence of OSA has risen over the past 2 decades in the United States to an estimated 34% in men and 17% in women.10 In turn, OSA is associated with incident ventricular arrhythmias,11 incident cardiovascular risk,4 stroke,12 and all‐cause mortality.12, 13 Misalignment between the timing of the sleep‐wake cycle and endogenous circadian rhythms impairs cardiovascular regulation,2 and night shift work is associated with hypertension14, 15 and incident cardiovascular disease, including fatal and nonfatal myocardial infarctions (MIs).16 The adverse health consequences associated with short sleep duration, OSA, and shift work are similar, but it is not yet known whether they share common mechanisms of action.17",Introduction,[134949],[2124],[3472],[False],[0],[0],[False],['0']
36079,PMC5721882,22916,"In particular, high‐risk patients warrant further study.",Introduction,[134956],[3473],[3530],[False],[0],[0],[False],['0']
36080,PMC5721882,22917,Patients are at increased risk of adverse outcomes after an acute coronary syndrome (ACS).,Introduction,[134963],[3531],[3621],[False],[0],[0],[False],['0']
36081,PMC5721882,22918,"However, it remains unknown whether sleep and circadian disruption may further increase cardiovascular risk in patients recovering from an ACS event.",Introduction,[134970],[3622],[3771],[False],[0],[0],[False],['0']
36082,PMC5721882,22919,"We therefore prospectively hypothesized that there would be an association between short sleep duration, OSA, overnight shift work, and cardiovascular events in a large population of ACS patients.",Introduction,[134977],[3772],[3968],[False],[0],[0],[False],['0']
36083,PMC5721882,22920,Methods,Methods,[134984],[3969],[3977],[False],[0],[0],[False],['0']
36084,PMC5721882,22921,"The design and results of the SOLID‐TIMI 52 trial (Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52; ClinicalTrials.gov NCT 01000727) have been previously reported.18, 19 In brief, the SOLID‐TIMI 52 trial was a double‐blind, placebo‐controlled phase 3 trial that enrolled 13 026 patients across 868 sites in 36 countries and randomized them to the investigational therapy, darapladib (an Lp‐PLA  inhibitor), versus matching placebo.",Methods,[134991],[3978],[4444],[False],[0],[0],[False],['0']
36085,PMC5721882,22922,"To be eligible for participation in the study, patients had to: (1) have been hospitalized within 30 days or fewer with an ACS and (2) have 1 additional cardiovascular risk factor (eg, age of at least 60 years, history of MI before the qualifying event).",Methods,[134998],[4445],[4699],[False],[0],[0],[False],['0']
36086,PMC5721882,22923,The trial was approved by the Partners Human Research Committee and all relevant institutional review boards worldwide.,Methods,[135005],[4700],[4819],[False],[0],[0],[False],['0']
36087,PMC5721882,22924,All participants provided written informed consent.,Methods,[135012],[4820],[4871],[False],[0],[0],[False],['0']
36088,PMC5721882,22925,"At the randomization visit (median 14 days post‐ACS), each participant was to complete a short questionnaire about their sleep and shift work habits.",Methods,[135019],[4872],[5021],[False],[0],[0],[False],['0']
36089,PMC5721882,22926,"To assess sleep duration, participants were asked, “On average, how much sleep do you get in 24 hours?” This question was very similar to the validated Behavioral Risk Factor Surveillance System question on sleep duration.20 The validated Berlin Questionnaire was completed and standard scoring was used to designate individuals at increased risk of OSA regardless of whether or not they had a known history of OSA.21 The Berlin Questionnaire is scored as at risk for OSA if 2 of the 3 categories are positive (snoring and cessation of breathing, symptoms of excessive daytime sleepiness, and hypertension/body mass index [BMI] >30 kg/m2; see Figure S1 for questionnaire).",Methods,[135026],[5022],[5694],[False],[0],[0],[False],['0']
36090,PMC5721882,22927,"In 8 small studies of cardiovascular or cerebrovascular disease patients, the specificity (26–76%) and sensitivity (40–93%) of the Berlin questionnaire varied depending on the apnea–hypopnea index thresholds and definition of hypopnea.22 Shift work history was also queried (“How many years have you worked at least THREE overnight shifts per week?”).",Methods,[135033],[5695],[6046],[False],[0],[0],[False],['0']
36091,PMC5721882,22928,Outcomes,Methods|Outcomes,[135040],[6047],[6055],[False],[0],[0],[False],['0']
36092,PMC5721882,22929,"The primary outcome for the trial was major coronary events (MCE; coronary heart disease death, MI, or urgent coronary revascularization for myocardial ischemia).",Methods|Outcomes,[135047],[6056],[6218],[False],[0],[0],[False],['0']
36093,PMC5721882,22930,"Additional outcomes of interest for this analysis included major adverse cardiovascular events (MACE; cardiovascular death, MI, or stroke), MI (fatal or nonfatal), cardiovascular death, and all‐cause mortality.",Methods|Outcomes,[135054],[6219],[6429],[False],[0],[0],[False],['0']
36094,PMC5721882,22931,"All deaths, cardiac ischemic events, and cerebrovascular events were adjudicated by a clinical events committee who were blinded to treatment arm.",Methods|Outcomes,[135061],[6430],[6576],[False],[0],[0],[False],['0']
36095,PMC5721882,22932,Statistics,Methods|Statistics,[135068],[6577],[6587],[False],[0],[0],[False],['0']
36096,PMC5721882,22933,Baseline characteristics were compared using the Wilcoxon rank‐sum test for continuous variables and χ2 test for categorical variables.,Methods|Statistics,[135075],[6588],[6723],[False],[0],[0],[False],['0']
36097,PMC5721882,22934,"Prespecified dichotomous thresholds were applied to each sleep parameter to define short sleep duration (<6 hours), increased risk of OSA (high risk of OSA on Berlin questionnaire19), and circadian rhythm disruption (≥1 year working at least 3 overnight shifts per week).",Methods|Statistics,[135082],[6724],[6995],[False],[0],[0],[False],['0']
36098,PMC5721882,22935,Additional sensitivity analyses applied alternate sleep duration thresholds including <7 hours and >9 hours.23 Kaplan–Meier event rates are reported at 3 years.,Methods|Statistics,[135089],[6996],[7156],[False],[0],[0],[False],['0']
36099,PMC5721882,22936,"Cox proportional hazards models were adjusted for age, sex, current smoker, race (white versus nonwhite), region, BMI, hypertension, hyperlipidemia, diabetes mellitus, past MI, past percutaneous coronary intervention, index diagnosis (ST‐elevation myocardial infarction versus non‐ST‐elevation ACS), days from qualifying event, catheterization for qualifying event, baseline low‐density lipoprotein cholesterol cholesterol, Lp‐PLA  activity, baseline estimated glomerular filtration rate <60 mL/min per 1.73 m2, and randomized treatment arm.",Methods|Statistics,[135096],[7157],[7698],[False],[0],[0],[False],['0']
36100,PMC5721882,22937,"An integer risk score (0–3) was created based on the number of sleep‐related risk factors that were present (OSA risk, sleep duration, and shift work).",Methods|Statistics,[135103],[7699],[7850],[False],[0],[0],[False],['0']
36101,PMC5721882,22938,All tests were 2‐sided with P<0.05 considered significant.,Methods|Statistics,[135110],[7851],[7909],[False],[0],[0],[False],['0']
36102,PMC5721882,22939,"All statistical computations were done with the SAS System (V9.3, 2010; SAS Institute Inc, Cary, NC).",Methods|Statistics,[135117],[7910],[8011],[False],[0],[0],[False],['0']
36103,PMC5721882,22940,Results,Results,[135124],[8012],[8020],[False],[0],[0],[False],['0']
36104,PMC5721882,22941,"Overall, median age of the study population was 64 years and 74.5% were male.",Results,[135131],[8021],[8098],[False],[0],[0],[False],['0']
36105,PMC5721882,22942,"Patients with an elevated risk of OSA tended to be younger, white, and tended to have a higher BMI and a higher prevalence of hypertension and hyperlipidemia (Table).",Results,[135138],[8099],[8265],[False],[0],[0],[False],['0']
36106,PMC5721882,22943,"Patients with fewer hours of sleep tended to be younger, female, and nonwhite with higher BMI and more likely to have a history of hypertension and hyperlipidemia.",Results,[135145],[8266],[8429],[False],[0],[0],[False],['0']
36107,PMC5721882,22944,"Those individuals with more overnight shift work were more likely to be younger, male, and white, with higher BMI, and have a history of hypertension and hyperlipidemia (Table).",Results,[135152],[8430],[8607],[False],[0],[0],[False],['0']
36108,PMC5721882,22945,"Mean reported sleep duration was 7.4 (±1.5) hours (median=7.5 hours), with 9.7% of patients reporting that they slept fewer than 6 hours daily.",Results,[135159],[8608],[8751],[False],[0],[0],[False],['0']
36109,PMC5721882,22946,"After multivariable adjustment, patients who reported sleeping fewer than 6 hours per night had a 29% higher risk of MCE (adjusted hazard ratio [adj HR], 1.29; 95% confidence interval [CI], 1.12–1.49; P=0.001) and a 15% higher risk of MACE (adj HR, 1.15; 95% CI, 0.98–1.35; P=0.08) than those who reported sleeping 6 hours or more per night (Figure 1).",Results,[135166],[8752],[9104],[False],[0],[0],[False],['0']
36110,PMC5721882,22947,"Risk of MI (adj HR, 1.13; 95% CI, 0.93–1.37; P=0.20) and all‐cause mortality (adj HR, 1.03; 95% CI, 0.8, 1.32; P=0.83) were not significantly increased in patients who reported sleeping fewer than 6 hours per night.",Results,[135173],[9105],[9320],[False],[0],[0],[False],['0']
36111,PMC5721882,22948,"Sensitivity analyses comparing <7 hours of sleep to those with a normal sleep duration (7–9 hours) yielded qualitatively consistent results (MCE: adj HR, 1.18; 95% CI, 1.06–1.31; P=0.003; Table S1).",Results,[135180],[9321],[9519],[False],[0],[0],[False],['0']
36112,PMC5721882,22949,"Conversely, prolonged sleep duration >9 hours was associated with an increased risk of both all‐cause mortality (adj HR, 1.38; 95% CI, 1.08–1.74) and cardiovascular death (adj HR, 1.41; 95% CI, 1.05–1.9), including directionally consistent results for MI and stroke (Table S2).",Results,[135187],[9520],[9797],[False],[0],[0],[False],['0']
36113,PMC5721882,22950,"Of the 12 924 patients who completed the Berlin questionnaire, 37.4% (4840) screened positive for OSA.",Results,[135194],[9798],[9900],[False],[0],[0],[False],['0']
36114,PMC5721882,22951,"Within this group, by medical history, only 862 patients were reported to have a confirmed diagnosis of OSA at baseline and of whom 344 patients were described to be using noninvasive ventilation for OSA.",Results,[135201],[9901],[10105],[False],[0],[0],[False],['0']
36115,PMC5721882,22952,"After multivariable adjustment, patients at increased risk of OSA had a 12% higher risk of MCE (adj HR, 1.12; 95% CI, 1.00–1.24; P=0.04) and 13% higher risk of MACE (adj HR, 1.13; 95% CI, 1.01–1.27; P=0.03).",Results,[135208],[10106],[10313],[False],[0],[0],[False],['0']
36116,PMC5721882,22953,"Patients who screened positive for OSA had a borderline 14% higher risk of MI (adj HR, 1.14; 95% CI, 1.00–1.31; P=0.05) than patients who did not screen positive for OSA (Figure 2).",Results,[135215],[10314],[10495],[False],[0],[0],[False],['0']
36117,PMC5721882,22954,"All‐cause mortality (adj HR, 0.99; 95% CI, 0.84–1.17; P=0.89) was not significantly increased in patients who screened positive for OSA.",Results,[135222],[10496],[10632],[False],[0],[0],[False],['0']
36118,PMC5721882,22955,At least 1 previous year of overnight shift work (≥3 overnight shifts per week) was reported in 22.3% of the patients.,Results,[135229],[10633],[10751],[False],[0],[0],[False],['0']
36119,PMC5721882,22956,"Of those patients, 44.0% had worked overnight shifts for 1 to 5 years, 21.1% for 6 to 10 years, and 34.8% for more than 10 years.",Results,[135236],[10752],[10881],[False],[0],[0],[False],['0']
36120,PMC5721882,22957,"After multivariable adjustment, those patients who reported working overnight shifts for at least 1 year had a 15% increased risk of MCE (adj HR, 1.15; 95% CI, 1.03–1.29; P=0.01), a 12% increased risk of MACE (adj HR, 1.12; 95% CI, 1.00–1.27; P=0.06) and a 21% increased risk of MI (adj HR, 1.21; 95% CI, 1.04–1.39; P=0.01) than those who did not report working overnight shifts (Figure 3).",Results,[135243],[10882],[11272],[False],[0],[0],[False],['0']
36121,PMC5721882,22958,"All‐cause mortality risk was not increased in patients reporting overnight shift work (adj HR, 1.07; 95% CI, 0.89–1.29; P=0.44).",Results,[135250],[11273],[11401],[False],[0],[0],[False],['0']
36122,PMC5721882,22959,"An integer risk score was created for individuals who had ≥1 sleep‐related risk factors (risk of OSA, short sleep duration, or circadian disruption associated with shift work).",Results,[135257],[11402],[11578],[False],[0],[0],[False],['0']
36123,PMC5721882,22960,"A step‐wise increase in risk of MCE was observed for individuals with increasing sleep risk score, including >2‐fold higher risk of MCE for individuals with all 3 sleep‐related risk factors (adj HR, 2.01; 95% CI, 1.49–2.71; P<0.001) versus those with none.",Results,[135264],[11579],[11835],[False],[0],[0],[False],['0']
36124,PMC5721882,22961,"Similarly, individuals with 3 sleep‐related risk factors were at increased risk of MACE (adj HR, 1.66; 95% CI, 1.18–2.33; P=0.004), MI (adj HR, 1.81; 95% CI, 1.23–2.67; P=0.003), all‐cause mortality (adj HR, 2.01; 95% CI, 1.22–3.31; P=0.006), and cardiovascular death (adj HR, 2.53; 95% CI, 1.44–4.42; P=0.001; Figure 4).",Results,[135271],[11836],[12157],[False],[0],[0],[False],['0']
36125,PMC5721882,22962,Discussion,Discussion,[135278],[12158],[12169],[False],[0],[0],[False],['0']
36126,PMC5721882,22963,"In our global, prospective study of over 13 000 patients who recently suffered an ACS, we found that OSA, short sleep duration, and overnight shift work were each independently associated with increased risk of MCE.",Discussion,[135285],[12170],[12385],[False],[0],[0],[False],['0']
36127,PMC5721882,22964,"Furthermore, the presence of multiple sleep‐related risk factors led to an additive increase in cardiovascular risk.",Discussion,[135292],[12386],[12502],[False],[0],[0],[False],['0']
36128,PMC5721882,22965,"With cardiovascular disease being the leading cause of death worldwide overall24 and in those in the United States aged 65 years and older,25 our results indicate that short sleep duration, OSA, and recurrent circadian disruption induced by overnight shift work may be detrimental to cardiovascular health outcomes in this older population of post‐ACS patients independent of traditional risk factors.",Discussion,[135299],[12503],[12904],[False],[0],[0],[False],['0']
36129,PMC5721882,22966,Sleep Duration,Discussion|Sleep Duration,[135306],[12905],[12919],[False],[0],[0],[False],['0']
36130,PMC5721882,22967,"Almost 10% of this post‐ACS patient cohort reported an inadequate duration of sleep with fewer than 6 hours per night, on average, and those individuals were found to be at increased risk of MCE and MACE.",Discussion|Sleep Duration,[135313],[12920],[13124],[False],[0],[0],[False],['0']
36131,PMC5721882,22968,"Prevalence of inadequate sleep duration in the current study is comparable to adults in the general population who in the Multinational Time Use Survey reported sleeping 6 hours or fewer in Norway (6%), Italy (7%), Switzerland (7%), Sweden (5%), United Kingdom (10%), and United States 9 (%).26 Epidemiological data have demonstrated that sleep deficiency is associated with important negative health consequences, including increased incidence of obesity, diabetes mellitus, hypertension, and cardiovascular events.27, 28, 29, 30, 31, 32 To that end, in the Sleep Heart Health Study, risk of hypertension was higher in those sleeping <6 hours (odds ratio, 1.66) per night compared with 7‐ to 8‐hours sleepers.29 Moreover, in hypertensive patients, short sleep duration (<7.5 hours per night) is predictive of incident stroke or MI (HR, 1.68).31 In the general population, short sleep duration has also been shown to be associated with the presence of coronary artery calcification.6 Additionally, among the general population, all‐cause mortality has been shown to be higher in short‐duration (≤5 hours per night) and prolonged‐duration sleepers (>9 hours) as compared with those with more normal sleep duration.33, 34 Our data suggest that the association between short sleep duration and adverse cardiovascular events in the general population holds true for post‐ACS patients.",Discussion|Sleep Duration,[135320],[13125],[14505],[False],[0],[0],[False],['0']
36132,PMC5721882,22969,"Similarly, prolonged sleep duration was associated with an increased risk of both all‐cause mortality and cardiovascular mortality.",Discussion|Sleep Duration,[135327],[14506],[14637],[False],[0],[0],[False],['0']
36133,PMC5721882,22970,"In both instances, it remains unknown whether other comorbid conditions that contribute to either shortened or prolonged sleep may contribute to the observed findings, although the relationship remained significant after adjustment for known confounders.",Discussion|Sleep Duration,[135334],[14638],[14892],[False],[0],[0],[False],['0']
36134,PMC5721882,22971,Obstructive Sleep Apnea,Discussion|Obstructive Sleep Apnea,[135341],[14893],[14916],[False],[0],[0],[False],['0']
36135,PMC5721882,22972,We have found that more than 1 in 3 adults in this study screened positive for OSA.,Discussion|Obstructive Sleep Apnea,[135348],[14917],[15000],[False],[0],[0],[False],['0']
36136,PMC5721882,22973,This prevalence is generally consistent with the reported OSA prevalence in the United States of ≈1 in 3 adult men and 1 in 6 adult women.10 Risk of OSA has substantially increased over the past 2 decades and increases with increasing age.10 Surveys of ≈5000 police officers35 and nearly 7000 firefighters36 revealed that more than 80% of those identified at risk of OSA were undiagnosed and untreated.,Discussion|Obstructive Sleep Apnea,[135355],[15001],[15403],[False],[0],[0],[False],['0']
36137,PMC5721882,22974,"Even in this population of ACS patients, who likely have more extensive contact with physicians, 82% of those who screened positive were undiagnosed and 93% were untreated.",Discussion|Obstructive Sleep Apnea,[135362],[15404],[15576],[False],[0],[0],[False],['0']
36138,PMC5721882,22975,"Heart failure patients with OSA have a higher readmission rates than heart failure patients without OSA.37 In the general population, the observed relationship between OSA and recurrent cardiovascular events in this post‐ACS population is consistent with previously reported associations in the general population between OSA and incident cardiovascular health outcomes.4, 11, 12, 13",Discussion|Obstructive Sleep Apnea,[135369],[15577],[15960],[False],[0],[0],[False],['0']
36139,PMC5721882,22976,Overnight Shift Work,Discussion|Overnight Shift Work,[135376],[15961],[15982],[False],[0],[0],[False],['0']
36140,PMC5721882,22977,More than 20% of the ACS patient population reported working overnight shifts for at least 1 year in their lifetime.,Discussion|Overnight Shift Work,[135383],[15983],[16099],[False],[0],[0],[False],['0']
36141,PMC5721882,22978,"This is consistent with the ≈15% of full‐time workers in the United States who are shift workers; an estimated 8 million of these shift workers regularly working during the overnight hours.38 Japan, Australia, the United Kingdom, and France report similar rates of shift work.39 The current post‐ACS population with a history of overnight shift work was found to be at increased risk of MCE, MACE, and MI.",Discussion|Overnight Shift Work,[135390],[16100],[16505],[False],[0],[0],[False],['0']
36142,PMC5721882,22979,"Overnight shift work disrupts the alignment of the endogenous circadian clock, responsible for the 24‐hour rhythm of alertness, physiology, and behavior, and is associated with daytime sleep that is shorter and less consolidated.40 Past studies have suggested that overnight shift work is associated with a 40% increase in the risk of cardiovascular disease,41 as well as a higher prevalence of atherosclerosis,42 and increased triglycerides.43 Night shift work within the past 5 years was associated with an increased risk of MI.44 The increased risk of adverse cardiovascular outcomes in post‐ACS shift workers is consistent with these adverse outcomes in shift workers in general.",Discussion|Overnight Shift Work,[135397],[16506],[17189],[False],[0],[0],[False],['0']
36143,PMC5721882,22980,Combination of Sleep‐Related Factors,Discussion|Combination of Sleep‐Related Factors,[135404],[17190],[17226],[False],[0],[0],[False],['0']
36144,PMC5721882,22981,"Notably, we found that the presence of multiple sleep‐related risk factors has an additive effect in regards to cardiovascular risk.",Discussion|Combination of Sleep‐Related Factors,[135411],[17227],[17359],[False],[0],[0],[False],['0']
36145,PMC5721882,22982,"To our knowledge, this is the first study to evaluate the cumulative impact of short sleep duration, OSA risk, and shift work history on cardiovascular outcomes.",Discussion|Combination of Sleep‐Related Factors,[135418],[17360],[17521],[False],[0],[0],[False],['0']
36146,PMC5721882,22983,Further investigation of these inter‐related factors is important because these sleep‐related factors are often interconnected.,Discussion|Combination of Sleep‐Related Factors,[135425],[17522],[17649],[False],[0],[0],[False],['0']
36147,PMC5721882,22984,"For instance, those who work overnight shifts often have reduced sleep duration and quality during the daytime hours,40 and the frequent awakenings in individuals with OSA may result in overall shorter duration of sleep.",Discussion|Combination of Sleep‐Related Factors,[135432],[17650],[17870],[False],[0],[0],[False],['0']
36148,PMC5721882,22985,"Thus, it is important to evaluate the combined effect of these sleep‐related factors.",Discussion|Combination of Sleep‐Related Factors,[135439],[17871],[17956],[False],[0],[0],[False],['0']
36149,PMC5721882,22986,It should be noted that the ACS‐patient population in this study is already at very high risk for adverse cardiovascular outcomes as compared with the general population.,Discussion|Combination of Sleep‐Related Factors,[135446],[17957],[18127],[False],[0],[0],[False],['0']
36150,PMC5721882,22987,"Given the high likelihood of another cardiovascular event and the associations we reveal in this study, we believe there is a critical need to evaluate sleep‐related interventions in the post‐ACS population.",Discussion|Combination of Sleep‐Related Factors,[135453],[18128],[18335],[False],[0],[0],[False],['0']
36151,PMC5721882,22988,Mitigating Risk,Discussion|Mitigating Risk,[135460],[18336],[18351],[False],[0],[0],[False],['0']
36152,PMC5721882,22989,"Empirically supported sleep health interventions may include education on the importance of obtaining sleep of adequate quantity and quality as a critical first step in improving sleep health.23, 45 Easily administered screening tools, such as the 10‐item Berlin questionnaire that we used, together with simplified diagnostic methods such as home sleep testing for OSA,46 are becoming increasingly available and may be appropriate for screening in post‐ACS patients.",Discussion|Mitigating Risk,[135467],[18352],[18819],[False],[0],[0],[False],['0']
36153,PMC5721882,22990,"Interventions and education to treat sleep disorders, especially OSA, and to increase sleep duration47 may prove to be effective in reducing adverse cardiac events.",Discussion|Mitigating Risk,[135474],[18820],[18984],[False],[0],[0],[False],['0']
36154,PMC5721882,22991,"Although a recent report that 3.3 hours of nightly continuous positive airway pressure did not prevent cardiovascular events in patients with moderate‐to‐severe sleep apnea,48 the identification, diagnosis, and treatment of OSA should be further investigated.",Discussion|Mitigating Risk,[135481],[18985],[19244],[False],[0],[0],[False],['0']
36155,PMC5721882,22992,"A previous trial has shown that sleep was improved in ACS patients by treating depressive symptoms.49 Because of demands for business to be conducted around the clock, the need for overnight shift work will continue.",Discussion|Mitigating Risk,[135488],[19245],[19461],[False],[0],[0],[False],['0']
36156,PMC5721882,22993,"Therefore, mitigations must be made to stabilize sleep timing in order to minimize circadian disruption and thereby improve daytime sleep.",Discussion|Mitigating Risk,[135495],[19462],[19600],[False],[0],[0],[False],['0']
36157,PMC5721882,22994,These interventions should be evaluated in the vulnerable post‐ACS patient population.,Discussion|Mitigating Risk,[135502],[19601],[19687],[False],[0],[0],[False],['0']
36158,PMC5721882,22995,Limitations,Discussion|Limitations,[135509],[19688],[19699],[False],[0],[0],[False],['0']
36159,PMC5721882,22996,"The study design was limited to a self‐reported questionnaire, and there was a lack of objective confirmation of these reported sleep‐related factors.",Discussion|Limitations,"[135516, 135517]","[19700, 19700]","[19850, 19850]","[True, True]","['RelevantOutcomeExcluded', 'PrecisionOfMeasurement']","['there was a lack of objective confirmation of these reported sleep‐related factors', 'a self‐reported questionnaire']","[True, True]",['OutcomeMeasures']
36160,PMC5721882,22997,We did not assess how recently the overnight shift work was performed and whether the frequency of shift work changed after their ACS.,Discussion|Limitations,[135532],[19851],[19985],[True],['RelevantOutcomeExcluded'],['We did not assess how recently the overnight shift work was performed and whether the frequency of shift work changed after their ACS'],[True],['OutcomeMeasures']
36161,PMC5721882,22998,Further research is required to determine whether more‐recent shiftwork confers greater risk in the post‐ACS patient.,Discussion|Limitations,[135544],[19986],[20103],[False],[0],[0],[False],['0']
36162,PMC5721882,22999,"Although patients were followed for a median of more than 2 years, it is possible that additional cardiovascular risk would be more apparent with time.",Discussion|Limitations,[135554],[20104],[20255],[True],['FollowUpDuration'],['t is possible that additional cardiovascular risk would be more apparent with time'],[True],['StudyDuration']
36163,PMC5721882,23000,"Although we adjusted for multiple variables, we cannot exclude the possibility of residual confounding and therefore causality cannot be definitively demonstrated.",Discussion|Limitations,[135569],[20256],[20419],[True],['ConfoundingFactors'],['we cannot exclude the possibility of residual confounding'],[True],['StatisticalAnalysis']
36164,PMC5721882,23001,We also acknowledge that physiological or behavioral mechanisms that are indirectly related to sleep disorders may contribute to the elevated risk of cardiovascular outcomes.,Discussion|Limitations,[135584],[20420],[20594],[True],['ConfoundingFactors'],['physiological or behavioral mechanisms that are indirectly related to sleep disorders may contribute to the elevated risk of cardiovascular outcomes'],[True],['StatisticalAnalysis']
36165,PMC5721882,23002,"These additional mechanisms may include intermittent hypoxia in OSA, behavior, and lifestyle factors in short sleepers and shift workers and impaired metabolism in shift work.",Discussion|Limitations,[135593],[20595],[20770],[False],[0],[0],[False],['0']
36166,PMC5721882,23003,"Further research should explore the potential physiological link between sleep duration, sleep disruption, sleep disorders, and cardiovascular risk.",Discussion|Limitations,[135600],[20771],[20919],[False],[0],[0],[False],['0']
36167,PMC5721882,23004,"The Berlin questionnaire has not been validated in a population of post‐ACS patients, but has been validated in small studies of cardiovascular or cerebrovascular disease patients.22 There could potentially be increased central sleep apnea in heart failure patients or increased sleepiness attributed to medical conditions, which might affect the estimate on risk on this screening questionnaire.",Discussion|Limitations,[135613],[20920],[21316],[True],['ValidityOfMeasurement'],['The Berlin questionnaire has not been validated in a population of post‐ACS patients'],[True],['OutcomeMeasures']
36168,PMC5721882,23005,"Furthermore, sleep habits may or may not have changed post‐ACS.",Discussion|Limitations,[135621],[21317],[21380],[False],[0],[0],[False],['0']
36169,PMC5721882,23006,Conclusion,Conclusion,[135628],[21381],[21392],[False],[0],[0],[False],['0']
36170,PMC5721882,23007,"In patients post‐ACS, insufficient sleep, whether caused by reduced sleep duration, OSA, or recurrent circadian disruption induced by overnight shift work, is associated with an increased risk of recurrent cardiovascular events.",Conclusion,[135635],[21393],[21621],[False],[0],[0],[False],['0']
36171,PMC5721882,23008,"These sleep‐related factors are not routinely assessed and, as such, are under‐recognized as important predictors of adverse outcomes post‐ACS.",Conclusion,[135642],[21622],[21765],[False],[0],[0],[False],['0']
36172,PMC5721882,23009,Increased efforts should be made to educate patients and their healthcare providers about the importance of sleep and sleep health.,Conclusion,[135649],[21766],[21897],[False],[0],[0],[False],['0']
36173,PMC5721882,23010,"Given the elevated risk of patients post‐ACS, considerations should be made to screen all post‐ACS patients for sleep disorders and insufficient sleep in order to implement appropriate interventions and patient education.45",Conclusion,[135656],[21898],[22121],[False],[0],[0],[False],['0']
36174,PMC5721882,23011,Sources of Funding,Sources of Funding,[135663],[22122],[22142],[False],[0],[0],[False],['0']
36175,PMC5721882,23012,"The trial was sponsored by GlaxoSmithKline, and the protocol was designed by the TIMI Study Group jointly with the executive steering committee and study sponsor.",Sources of Funding,[135670],[22143],[22305],[False],[0],[0],[False],['0']
36176,PMC5721882,23013,The authors developed the statistical analysis plan.,Sources of Funding,[135677],[22306],[22358],[False],[0],[0],[False],['0']
36177,PMC5721882,23014,The TIMI Study Group conducted all analyses independently using raw data and assumes responsibility for the accuracy of the data reported in this article.,Sources of Funding,[135684],[22359],[22513],[False],[0],[0],[False],['0']
36178,PMC5721882,23015,The sponsor reviewed the article and made nonbinding suggestions for consideration.,Sources of Funding,[135691],[22514],[22597],[False],[0],[0],[False],['0']
36179,PMC5721882,23016,Disclosures,Disclosures,[135698],[22598],[22610],[False],[0],[0],[False],['0']
36180,PMC5721882,23017,Dr Barger reports receiving consulting fees from and serving as a paid member of the scientific advisory board for CurAegis.,Disclosures,[135705],[22611],[22735],[False],[0],[0],[False],['0']
36181,PMC5721882,23018,"Dr Rajaratnam reports consulting for Philips Respironics (pending), Alertness CRC, and research grant support from Shell, Teva Pharmaceuticals, Rio Tinto, and Seeing Machines.",Disclosures,[135712],[22736],[22911],[False],[0],[0],[False],['0']
36182,PMC5721882,23019,"Dr Cannon reports research grants from (all >10K) Amgen, Arisaph, Boehringer Ingelheim (BI), Bristol‐Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, and Takeda and consulting fees from Alnylam, Amgen, Amarin, Arisaph, Astra Zeneca, BI, BMS, Eisai, GlaxoSmithKline, Kowa, Lipimedix*, Merck, Pfizer, Regeneron*, Sanofi*, and Takeda.",Disclosures,[135719],[22912],[23246],[False],[0],[0],[False],['0']
36183,PMC5721882,23020,(* denotes >10K).,Disclosures,[135726],[23247],[23264],[False],[0],[0],[False],['0']
36184,PMC5721882,23021,Dr Lukas is an employee of GlaxoSmithKline.,Disclosures,[135733],[23265],[23308],[False],[0],[0],[False],['0']
36185,PMC5721882,23022,Dr Im reports research funding by the TIMI Study group and Brigham and Womens' Hospital from AstraZeneca during the conduct of the study.,Disclosures,[135740],[23309],[23446],[False],[0],[0],[False],['0']
36186,PMC5721882,23023,"Dr Czeisler reports receiving consulting fees from or serving as a paid member of scientific advisory boards for: Bose Corporation; Boston Celtics; Columbia River Bar Pilots; Institute of Digital Media and Child Development; Klarman Family Foundation; Quest Diagnostics, Inc.; Vanda Pharmaceuticals; and V‐Watch/PPRS.",Disclosures,[135747],[23447],[23764],[False],[0],[0],[False],['0']
36187,PMC5721882,23024,"Dr Czeisler has also received education/research support from Cephalon Inc., Mary Ann & Stanley Snider by Combined Jewish Philanthropies, Optum, Philips Respironics, Inc., ResMed Foundation, San Francisco Bar Pilots, Schneider Inc., and Sysco.",Disclosures,[135754],[23765],[24008],[False],[0],[0],[False],['0']
36188,PMC5721882,23025,"Dr Czeisler has received lecture fees from American Academy of Sleep Medicine (AADSM), CurtCo Media Labs LLC, Global Council on Brain Health/AARP, Hawaii Sleep Health and Wellness Foundation, National Sleep Foundation, University of Michigan, University of Washington, and Zurich Insurance Company, Ltd.",Disclosures,[135761],[24009],[24312],[False],[0],[0],[False],['0']
36189,PMC5721882,23026,"The Sleep and Health Education Program of the Harvard Medical School Division of Sleep Medicine (which Dr Czeisler directs) has received Educational Grant funding from Cephalon, Inc., Jazz Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Sanofi‐Aventis, Inc., Sepracor, Inc., and Wake Up Narcolepsy.",Disclosures,[135768],[24313],[24642],[False],[0],[0],[False],['0']
36190,PMC5721882,23027,"Dr Czeisler is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. and holds a number of process patents in the field of sleep/circadian rhythms (eg, photic resetting of the human circadian pacemaker).",Disclosures,[135775],[24643],[24883],[False],[0],[0],[False],['0']
36191,PMC5721882,23028,"Since 1985, Dr Czeisler has also served as an expert on various legal and technical cases related to sleep and/or circadian rhythms including those involving the following commercial entities: Bombardier, Inc.; Continental Airlines; FedEx; Greyhound; and United Parcel Service (UPS).",Disclosures,[135782],[24884],[25167],[False],[0],[0],[False],['0']
36192,PMC5721882,23029,"Dr Czeisler owns or owned an equity interest in Somnus Therapeutics, Inc., and Vanda Pharmaceuticals.",Disclosures,[135789],[25168],[25269],[False],[0],[0],[False],['0']
36193,PMC5721882,23030,"He received royalties from McGraw Hill and Koninklijke Philips Electronics, N.V. for the Actiwatch‐2 and Actiwatch‐Spectrum devices.",Disclosures,[135796],[25270],[25402],[False],[0],[0],[False],['0']
36194,PMC5721882,23031,Dr Czeisler's interests were reviewed and managed by Brigham and Women's Hospital and Partners HealthCare in accord with their conflict of interest policies.,Disclosures,[135803],[25403],[25560],[False],[0],[0],[False],['0']
36195,PMC5721882,23032,"Dr O'Donoghue reports grant support from GlaxoSmithKline, Eisai, Janssen, Merck, Amgen, and AstraZeneca.",Disclosures,[135810],[25561],[25665],[False],[0],[0],[False],['0']
36196,PMC5721882,23033,The remaining authors have no disclosures to report.,Disclosures,[135817],[25666],[25718],[False],[0],[0],[False],['0']
36197,PMC5721882,23034,Acknowledgments,Acknowledgments,[135824],[25719],[25736],[False],[0],[0],[False],['0']
36198,PMC5721882,23035,"The Berlin Questionnaire is used by permission from iONSLEEP LLC (Shaker Heights, OH) and is freely available for research and academic purposes.",Acknowledgments,[135831],[25737],[25882],[False],[0],[0],[False],['0']
36820,PMC5833494,41181,Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis,Title,[242456],[26074],[74],[False],[0],[0],[False],['0']
36821,PMC5833494,41182,Key Points,Abstract,[242462],[75],[85],[False],[0],[0],[False],['0']
36822,PMC5833494,41183,Question,Abstract,[242468],[86],[94],[False],[0],[0],[False],['0']
36823,PMC5833494,41184,What is the efficacy of venous percutaneous transluminal angioplasty (PTA) for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis?,Abstract,[242474],[95],[253],[False],[0],[0],[False],['0']
36824,PMC5833494,41185,Findings,Abstract,[242480],[254],[262],[False],[0],[0],[False],['0']
36825,PMC5833494,41186,"In the Brave Dreams trial, which included 115 patients with relapsing-remitting multiple sclerosis, venous PTA did not increase the proportion of patients who improved functionally nor did it reduce the mean number of new combined brain lesions on magnetic resonance imaging at 12 months.",Abstract,[242486],[263],[551],[False],[0],[0],[False],['0']
36826,PMC5833494,41187,"However, there was a tendency for more patients to become free of new lesions after venous PTA mainly because of a reduction in new lesions appearing 6 to 12 months after randomization.",Abstract,[242492],[552],[737],[False],[0],[0],[False],['0']
36827,PMC5833494,41188,Meaning,Abstract,[242498],[738],[745],[False],[0],[0],[False],['0']
36828,PMC5833494,41189,Venous PTA cannot be recommended for patients with relapsing-remitting multiple sclerosis.,Abstract,[242504],[746],[836],[False],[0],[0],[False],['0']
36829,PMC5833494,41190,Importance,Abstract,[242510],[837],[848],[False],[0],[0],[False],['0']
36830,PMC5833494,41191,Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by restricted venous outflow from the brain and spinal cord.,Abstract,[242516],[849],[977],[False],[0],[0],[False],['0']
36831,PMC5833494,41192,Whether this condition is associated with multiple sclerosis (MS) and whether venous percutaneous transluminal angioplasty (PTA) is beneficial in persons with MS and CCSVI is controversial.,Abstract,[242522],[978],[1167],[False],[0],[0],[False],['0']
36832,PMC5833494,41193,Objective,Abstract,[242528],[1168],[1177],[False],[0],[0],[False],['0']
36833,PMC5833494,41194,To determine the efficacy and safety of venous PTA in patients with MS and CCSVI.,Abstract,[242534],[1178],[1259],[False],[0],[0],[False],['0']
36834,PMC5833494,41195,"Design, Setting, and Participants",Abstract,[242540],[1260],[1293],[False],[0],[0],[False],['0']
36835,PMC5833494,41196,"We analyzed 177 patients with relapsing-remitting MS; 62 were ineligible, including 47 (26.6%) who did not have CCSVI on color Doppler ultrasonography screening.",Abstract,[242546],[1294],[1455],[False],[0],[0],[False],['0']
36836,PMC5833494,41197,A total of 115 patients were recruited in the study timeframe.,Abstract,[242552],[1456],[1518],[False],[0],[0],[False],['0']
36837,PMC5833494,41198,"All patients underwent a randomized, double-blind, sham-controlled, parallel-group trial in 6 MS centers in Italy.",Abstract,[242558],[1519],[1633],[False],[0],[0],[False],['0']
36838,PMC5833494,41199,The trial began in August 2012 and concluded in March 2016; data were analyzed from April 2016 to September 2016.,Abstract,[242564],[1634],[1747],[False],[0],[0],[False],['0']
36839,PMC5833494,41200,The analysis was intention to treat.,Abstract,[242570],[1748],[1784],[False],[0],[0],[False],['0']
36840,PMC5833494,41201,Interventions,Abstract,[242576],[1785],[1798],[False],[0],[0],[False],['0']
36841,PMC5833494,41202,Patients were randomly allocated (2:1) to either venous PTA or catheter venography without venous angioplasty (sham).,Abstract,[242582],[1799],[1916],[False],[0],[0],[False],['0']
36842,PMC5833494,41203,Main Outcomes and Measures,Abstract,[242588],[1917],[1943],[False],[0],[0],[False],['0']
36843,PMC5833494,41204,"Two primary end points were assessed at 12 months: (1) a composite functional measure (ie, walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity) and (2) a measure of new combined brain lesions on magnetic resonance imaging, including the proportion of lesion-free patients.",Abstract,[242594],[1944],[2258],[False],[0],[0],[False],['0']
36844,PMC5833494,41205,Combined lesions included T1 gadolinium-enhancing lesions plus new or enlarged T2 lesions.,Abstract,[242600],[2259],[2349],[False],[0],[0],[False],['0']
36845,PMC5833494,41206,Results,Abstract,[242606],[2350],[2358],[False],[0],[0],[False],['0']
36846,PMC5833494,41207,"Of the included 115 patients with relapsing-remitting MS, 76 were allocated to the PTA group (45 female [59%]; mean [SD] age, 40.0 [10.3] years) and 39 to the sham group (29 female [74%]; mean [SD] age, 37.5 [10.6] years); 112 (97.4%) completed follow-up.",Abstract,[242612],[2359],[2614],[False],[0],[0],[False],['0']
36847,PMC5833494,41208,No serious adverse events occurred.,Abstract,[242618],[2615],[2650],[False],[0],[0],[False],['0']
36848,PMC5833494,41209,Flow restoration was achieved in 38 of 71 patients (54%) in the PTA group.,Abstract,[242624],[2651],[2725],[False],[0],[0],[False],['0']
36849,PMC5833494,41210,"The functional composite measure did not differ between the PTA and sham groups (41.7% vs 48.7%; odds ratio, 0.75; 95% CI, 0.34-1.68; P = .49).",Abstract,[242630],[2726],[2869],[False],[0],[0],[False],['0']
36850,PMC5833494,41211,"The mean (SD) number of combined lesions on magnetic resonance imaging at 6 to 12 months were 0.47 (1.19) in the PTA group vs 1.27 (2.65) in the sham group (mean ratio, 0.37; 95% CI, 0.15-0.91; P = .03: adjusted P = .09) and were 1.40 (4.21) in the PTA group vs 1.95 (3.73) in the sham group at 0 to 12 months (mean ratio, 0.72; 95% CI, 0.32-1.63; P = .45; adjusted P = .45).",Abstract,[242636],[2870],[3245],[False],[0],[0],[False],['0']
36851,PMC5833494,41212,"At follow-up after 6 to 12 months, 58 of 70 patients (83%) in the PTA group and 22 of 33 (67%) in the sham group were free of new lesions on magnetic resonance imaging (odds ratio, 2.64; 95% CI, 1.11-6.28; P = .03; adjusted P = .09).",Abstract,[242642],[3246],[3479],[False],[0],[0],[False],['0']
36852,PMC5833494,41213,"At 0 to 12 months, 46 of 73 patients (63.0%) in the PTA group and 18 of 37 (49%) in the sham group were free of new lesions on magnetic resonance imaging (odds ratio, 1.80; 95% CI, 0.81-4.01; P = .15; adjusted P = .30).",Abstract,[242648],[3480],[3699],[False],[0],[0],[False],['0']
36853,PMC5833494,41214,Conclusion and Relevance,Abstract,[242654],[3700],[3724],[False],[0],[0],[False],['0']
36854,PMC5833494,41215,Venous PTA has proven to be a safe but largely ineffective technique; the treatment cannot be recommended in patients with MS.,Abstract,[242660],[3725],[3851],[False],[0],[0],[False],['0']
36855,PMC5833494,41216,Trial Registration,Abstract,[242666],[3852],[3870],[False],[0],[0],[False],['0']
36856,PMC5833494,41217,clinicaltrials.gov Identifier: NCT01371760,Abstract,[242672],[3871],[3913],[False],[0],[0],[False],['0']
36857,PMC5833494,41218,Introduction,Introduction,[242678],[3914],[3927],[False],[0],[0],[False],['0']
36858,PMC5833494,41219,"When intraluminal defects, compression, or hypoplasia are identified in the internal jugular or azygos veins, the condition is known as chronic cerebrospinal venous insufficiency (CCSVI).",Introduction,[242684],[3928],[4115],[False],[0],[0],[False],['0']
36859,PMC5833494,41220,An Italian open-label study published in 2009 including 65 patients with multiple sclerosis (MS) found an association between MS and CCSVI.,Introduction,[242690],[4116],[4255],[False],[0],[0],[False],['0']
36860,PMC5833494,41221,The study also found that venous percutaneous transluminal angioplasty (PTA) was associated with an improved Multiple Sclerosis Functional Composite (MSFC) score at 1 year in patients with relapsing-remitting MS (RRMS) and a reduction in the proportion of those with gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI).,Introduction,[242696],[4256],[4594],[False],[0],[0],[False],['0']
36861,PMC5833494,41222,"This preliminary study attracted considerable media attention in Italy and elsewhere; media-based groups formed to promote the treatment, and some called to make it freely available.",Introduction,[242702],[4595],[4777],[False],[0],[0],[False],['0']
36862,PMC5833494,41223,"Subsequent to the initial reports by Zamboni et al, prevalence studies of CCSVI in MS have reported conflicting results.",Introduction,[242708],[4778],[4898],[False],[0],[0],[False],['0']
36863,PMC5833494,41224,"A small 2012 case-control study further assessed the potential of venous PTA to benefit patients with MS. One year after venous PTA, the study found that functional score was improved compared with baseline, and the authors suggested that a double-blind randomized trial was justified.",Introduction,[242714],[4899],[5184],[False],[0],[0],[False],['0']
36864,PMC5833494,41225,Both the National Institute for Health and Care Excellence and the Italian Ministry of Health have urged that randomized clinical trials be conducted to assess the efficacy of venous PTA for CCSVI in MS.,Introduction,[242720],[5185],[5388],[False],[0],[0],[False],['0']
36865,PMC5833494,41226,"In response to these calls and to public pressure, the Directorate-General for Health and Welfare of the Italian Region of Emilia Romagna funded the Brain Venous Drainage Exploited Against Multiple Sclerosis (Brave Dreams) trial to investigate the efficacy and safety of venous PTA in patients with MS and CCSVI.",Introduction,[242726],[5389],[5701],[False],[0],[0],[False],['0']
36866,PMC5833494,41227,We report the results of that trial.,Introduction,[242732],[5702],[5738],[False],[0],[0],[False],['0']
36867,PMC5833494,41228,Methods,Methods,[242738],[5739],[5747],[False],[0],[0],[False],['0']
36868,PMC5833494,41229,Study Design,Methods|Study Design,[242744],[5748],[5760],[False],[0],[0],[False],['0']
36869,PMC5833494,41230,"The Brave Dreams trial was a multicenter, randomized, double-blind, sham-controlled, parallel-group trial to evaluate the efficacy and safety of venous PTA in patients with MS and CCSVI in extracranial or extravertebral veins.",Methods|Study Design,[242750],[5761],[5987],[False],[0],[0],[False],['0']
36870,PMC5833494,41231,"The study was conducted at 6 MS centers in Italy and their associated color Doppler ultrasonography (ECD) and angiography units, all of which were accredited by the Italian National Health Service.",Methods|Study Design,[242756],[5988],[6185],[False],[0],[0],[False],['0']
36871,PMC5833494,41232,"The Brave Dreams steering committee appointed an End Points Commission, which issued a detailed operations manual and trained trial physicians (who assessed primary functional outcomes, operated the ECD equipment, and performed catheter venography without venous angioplasty and venous PTA).",Methods|Study Design,[242762],[6186],[6477],[False],[0],[0],[False],['0']
36872,PMC5833494,41233,"After training, the commission issued an accreditation that was necessary for physicians to participate in the trial.",Methods|Study Design,[242768],[6478],[6595],[False],[0],[0],[False],['0']
36873,PMC5833494,41234,"Study monitoring was delegated to the company Medical Trials Analysis Italy in Ferrara, Italy.",Methods|Study Design,[242774],[6596],[6690],[False],[0],[0],[False],['0']
36874,PMC5833494,41235,A trial data coordinating center was established to oversee data collection and quality and to perform the statistical analyses.,Methods|Study Design,[242780],[6691],[6819],[False],[0],[0],[False],['0']
36875,PMC5833494,41236,The study adhered to the Helsinki Declaration and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines and was approved by the ethical committee of the University of Ferrara Hospital and subsequently by the ethical committees of the other participating centers.,Methods|Study Design,[242786],[6820],[7166],[False],[0],[0],[False],['0']
36876,PMC5833494,41237,The trial protocol has been published.,Methods|Study Design,[242792],[7167],[7205],[False],[0],[0],[False],['0']
36877,PMC5833494,41238,The trial protocol can be found in Supplement 1.,Methods|Study Design,[242798],[7206],[7254],[False],[0],[0],[False],['0']
36878,PMC5833494,41239,All participants provided written informed consent.,Methods|Study Design,[242804],[7255],[7306],[False],[0],[0],[False],['0']
36879,PMC5833494,41240,Participants,Methods|Participants,[242810],[7307],[7319],[False],[0],[0],[False],['0']
36880,PMC5833494,41241,Patients were recruited at the participating centers.,Methods|Participants,[242816],[7320],[7373],[False],[0],[0],[False],['0']
36881,PMC5833494,41242,"Eligibility criteria included age 18 to 65 years; a diagnosis of RRMS, according to the 2005 McDonald criteria; a diagnosis of secondary progressive MS, according to Lublin and Reingold; care provided by the recruiting center for at least 2 years; at least 1 relapse in RRMS in the 2 years prior to enrollment; a baseline Expanded Disability Status Scale (EDSS) score of 2 to 5.5; a disease duration of 15 years or less at baseline; stable neurological condition without relapse for at least 30 days before baseline; CCSVI, as determined by ECD examination carried out in accordance with a screening protocol; and not receiving MS-specific treatment, immunomodulating, or immunosuppressive therapy without changes for at least 6 months up to baseline.",Methods|Participants,[242822],[7374],[8125],[False],[0],[0],[False],['0']
36882,PMC5833494,41243,"Patients were ineligible if they had previous venous PTA or had received fingolimod therapy, cladribine therapy, laquinimod therapy, botulinum toxin therapy, infusion pump or neurostimulator implantation, or had participated in any clinical trial within 3 months of baseline.",Methods|Participants,[242828],[8126],[8401],[False],[0],[0],[False],['0']
36883,PMC5833494,41244,The complete list of exclusion criteria was published previously.,Methods|Participants,[242834],[8402],[8467],[False],[0],[0],[False],['0']
36884,PMC5833494,41245,Randomization and Blinding,Methods|Randomization and Blinding,[242840],[8468],[8495],[False],[0],[0],[False],['0']
36885,PMC5833494,41246,"The data coordinating center set up an internet-based computerized central randomization protocol stratified by participating center with variable length blocks, which assigned patients to the PTA or sham group in a 2:1 ratio.",Methods|Randomization and Blinding,[242846],[8496],[8722],[False],[0],[0],[False],['0']
36886,PMC5833494,41247,Treatment assignment was made known to the treating surgeon (via the electronic case report form) only on the day of the operation.,Methods|Randomization and Blinding,[242852],[8723],[8854],[False],[0],[0],[False],['0']
36887,PMC5833494,41248,"Patients, all other study investigators, and operating room and hospital personnel were blinded to assignment.",Methods|Randomization and Blinding,[242858],[8855],[8965],[False],[0],[0],[False],['0']
36888,PMC5833494,41249,"To maintain patient blinding, surgeons were trained to deliver a catheter venography intervention that simulated venous PTA.",Methods|Randomization and Blinding,[242864],[8966],[9090],[False],[0],[0],[False],['0']
36889,PMC5833494,41250,This involved sudden acceleration of the catheter as it passed through the internal jugular vein together with a comment from the radiologist suggesting that venous PTA had been performed.,Methods|Randomization and Blinding,[242870],[9091],[9279],[False],[0],[0],[False],['0']
36890,PMC5833494,41251,Procedures,Methods|Procedures,[242876],[9280],[9290],[False],[0],[0],[False],['0']
36891,PMC5833494,41252,"Participants underwent catheter venography without venous angioplasty of the azygos and internal jugular veins, with percutaneous access via the left femoral vein.",Methods|Procedures,[242882],[9291],[9454],[False],[0],[0],[False],['0']
36892,PMC5833494,41253,The presence and location of CCSVI was assessed as reported elsewhere.,Methods|Procedures,[242888],[9455],[9525],[False],[0],[0],[False],['0']
36893,PMC5833494,41254,"If venography was positive for CCSVI, participants randomized to the PTA group received venous PTA during the venography session.",Methods|Procedures,[242894],[9526],[9655],[False],[0],[0],[False],['0']
36894,PMC5833494,41255,"If CCSVI was absent, those assigned to the PTA group received catheter venography without venous angioplasty.",Methods|Procedures,[242900],[9656],[9765],[False],[0],[0],[False],['0']
36895,PMC5833494,41256,Those allocated to the sham group received catheter venography without venous angioplasty.,Methods|Procedures,[242906],[9766],[9856],[False],[0],[0],[False],['0']
36896,PMC5833494,41257,These procedures were performed via day surgery.,Methods|Procedures,[242912],[9857],[9905],[False],[0],[0],[False],['0']
36897,PMC5833494,41258,Overnight hospital stay was never required in this trial.,Methods|Procedures,[242918],[9906],[9963],[False],[0],[0],[False],['0']
36898,PMC5833494,41259,All patients received prophylactic low-molecular-weight heparin during the 3 subsequent weeks.,Methods|Procedures,[242924],[9964],[10058],[False],[0],[0],[False],['0']
36899,PMC5833494,41260,Outcomes,Methods|Outcomes,[242930],[10059],[10067],[False],[0],[0],[False],['0']
36900,PMC5833494,41261,There were 2 primary end points at 12 months: a functional end point and an MRI end point.,Methods|Outcomes,[242936],[10068],[10158],[False],[0],[0],[False],['0']
36901,PMC5833494,41262,Functional End Point,Methods|Functional End Point,[242942],[10159],[10179],[False],[0],[0],[False],['0']
36902,PMC5833494,41263,"In view of the psychometric limitations of the EDSS and the MSFC scores, the steering committee decided to use a new primary composite end point based on a range of the functional impairments commonly experienced by patients with MS.",Methods|Functional End Point,[242948],[10180],[10413],[False],[0],[0],[False],['0']
36903,PMC5833494,41264,"This composite included walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity (eMethods in Supplement 2).",Methods|Functional End Point,[242954],[10414],[10559],[False],[0],[0],[False],['0']
36904,PMC5833494,41265,"Statistically significant changes were adopted for defining changes in walking control, balance, and manual dexterity; a minimal real difference was used for postvoid residual urine volume and visual acuity.",Methods|Functional End Point,[242960],[10560],[10767],[False],[0],[0],[False],['0']
36905,PMC5833494,41266,"Based on the changes found, each index was considered improved, stable, or worsened.",Methods|Functional End Point,[242966],[10768],[10852],[False],[0],[0],[False],['0']
36906,PMC5833494,41267,"Patients were classified as (1) improved, which indicated improvement in 1 or more functions and stability in the remaining functions, (2) worsened, which indicated worsening of 1 or more functions and stability in nonworsening functions, (3) mixed, which indicated presence of improved and worsened functions, or (4) stable, which indicated no change in any function.",Methods|Functional End Point,[242972],[10853],[11221],[False],[0],[0],[False],['0']
36907,PMC5833494,41268,"Evaluations were performed by operators (2 per participating center) at baseline, within 15 days of venography, and 3, 6, and 12 months later.",Methods|Functional End Point,[242978],[11222],[11364],[False],[0],[0],[False],['0']
36908,PMC5833494,41269,Only results at 12 months were used in analyses.,Methods|Functional End Point,[242984],[11365],[11413],[False],[0],[0],[False],['0']
36909,PMC5833494,41270,"To ensure the reliability of the functional measurements, the End Points Commission made 1 or 2 visits to each site to monitor the functional assessments.",Methods|Functional End Point,[242990],[11414],[11568],[False],[0],[0],[False],['0']
36910,PMC5833494,41271,Assessors were required to make video recordings of the walking control and manual dexterity tests in 10% or more of patients and to send them to the commission for inspection.,Methods|Functional End Point,[242996],[11569],[11745],[False],[0],[0],[False],['0']
36911,PMC5833494,41272,"If a patient had a transient impairment that blocked performance of 1 or more functional tests, these were not performed until the next follow-up.",Methods|Functional End Point,[243002],[11746],[11892],[False],[0],[0],[False],['0']
36912,PMC5833494,41273,"In the event of a clinical relapse, all tests were deferred.",Methods|Functional End Point,[243008],[11893],[11953],[False],[0],[0],[False],['0']
36913,PMC5833494,41274,"As per study protocol, the final round of tests could take place up to 15 months after venography.",Methods|Functional End Point,[243014],[11954],[12052],[False],[0],[0],[False],['0']
36914,PMC5833494,41275,Magnetic Resonance Imaging End Point,Methods|Magnetic Resonance Imaging End Point,[243020],[12053],[12089],[False],[0],[0],[False],['0']
36915,PMC5833494,41276,Scans were acquired at baseline and at 6 and 12 months after venography.,Methods|Magnetic Resonance Imaging End Point,[243026],[12090],[12162],[False],[0],[0],[False],['0']
36916,PMC5833494,41277,The primary MRI end point was the number of new combined cerebral lesions at 12 months compared with baseline.,Methods|Magnetic Resonance Imaging End Point,[243032],[12163],[12273],[False],[0],[0],[False],['0']
36917,PMC5833494,41278,"New combined lesions included (1) new lesions on T2-weighted images, (2) preexisting lesions enlarged by greater than 30% on T2-weighted images, and (3) gadolinium-enhancing lesions in T1-weighted images of preexisting lesions.",Methods|Magnetic Resonance Imaging End Point,[243038],[12274],[12501],[False],[0],[0],[False],['0']
36918,PMC5833494,41279,An additional MRI end point was the proportion of patients free of new lesions.,Methods|Magnetic Resonance Imaging End Point,[243044],[12502],[12581],[False],[0],[0],[False],['0']
36919,PMC5833494,41280,"Before starting the study, each center acquired a set of MRI scans of a single individual on 2 separate occasions.",Methods|Magnetic Resonance Imaging End Point,[243050],[12582],[12696],[False],[0],[0],[False],['0']
36920,PMC5833494,41281,"The scans were assessed by the Department of Neurosciences at the University of Florence for image quality, repositioning accuracy, and signal-to-noise ratio to check that quality was sufficient.",Methods|Magnetic Resonance Imaging End Point,[243056],[12697],[12892],[False],[0],[0],[False],['0']
36921,PMC5833494,41282,"At each center, MRIs were always performed with the same device (at least 1.5 T) and with the same protocol.",Methods|Magnetic Resonance Imaging End Point,[243062],[12893],[13001],[False],[0],[0],[False],['0']
36922,PMC5833494,41283,The scans were assessed by an experienced specialist blinded to treatment assignment.,Methods|Magnetic Resonance Imaging End Point,[243068],[13002],[13087],[False],[0],[0],[False],['0']
36923,PMC5833494,41284,Secondary Outcomes,Secondary Outcomes,[243074],[13088],[13107],[False],[0],[0],[False],['0']
36924,PMC5833494,41285,"Secondary outcomes at 12 months were the proportion of patients with CCSVI diagnosed by ECD but not confirmed by venography, annualized relapse rate, change in EDSS score, proportion of patients with relapses, and proportion of patients who had venous PTA with restored flow on ECD at 12 months.",Secondary Outcomes,[243080],[13108],[13403],[False],[0],[0],[False],['0']
36925,PMC5833494,41286,Safety,Secondary Outcomes|Safety,[243086],[13404],[13410],[False],[0],[0],[False],['0']
36926,PMC5833494,41287,The types and grade of adverse events are reported according to the Good Clinical Practice guidelines.,Secondary Outcomes|Safety,[243092],[13411],[13513],[False],[0],[0],[False],['0']
36927,PMC5833494,41288,Stopping rules included serious adverse events and/or a false-positive rate for CCSVI on ECD exceeding 10%.,Secondary Outcomes|Safety,[243098],[13514],[13621],[False],[0],[0],[False],['0']
36928,PMC5833494,41289,Statistical Analysis,Secondary Outcomes|Statistical Analysis,[243104],[13622],[13642],[False],[0],[0],[False],['0']
36929,PMC5833494,41290,"To achieve a 90% power (SD = 7.6) to detect a hypothesized 2.1 fewer active MRI lesions in the PTA group (3.9 vs 6.0), 423 patients with RRMS were needed.",Secondary Outcomes|Statistical Analysis,[243110],[13643],[13797],[False],[0],[0],[False],['0']
36930,PMC5833494,41291,This number of patients was also sufficient (92% power) to detect a hypothesized 15% more patients in the PTA group than the sham group improving on the functional end point (α = .05; 2-sided test on proportions).,Secondary Outcomes|Statistical Analysis,[243116],[13798],[14011],[False],[0],[0],[False],['0']
36931,PMC5833494,41292,Patients in the sham group were themselves expected to improve by 15% over the year of follow-up.,Secondary Outcomes|Statistical Analysis,[243122],[14012],[14109],[False],[0],[0],[False],['0']
36932,PMC5833494,41293,"Because both primary end points were used to characterize treatment benefit, each null hypothesis had to be rejected at the same significance level (α = .05), with multiplicity adjustment only for the MRI end point, since this had 2 parameters (mean lesion number and proportion of lesion-free patients).",Secondary Outcomes|Statistical Analysis,[243128],[14110],[14414],[False],[0],[0],[False],['0']
36933,PMC5833494,41294,"Because of low enrollment (6 patients per month by November 2013), the protocol was amended in February 2014; 300 patients with RRMS (200 in PTA group and 100 in sham group) were required to reveal the same hypothesized differences in MRI and functional end points, with powers of 80% and 84%, respectively.",Secondary Outcomes|Statistical Analysis,[243134],[14415],[14722],[False],[0],[0],[False],['0']
36934,PMC5833494,41295,"The study closed in December 2014 because of slow recruitment, with 115 patients with RRMS recruited (38.3% of amended target).",Secondary Outcomes|Statistical Analysis,[243140],[14723],[14850],[False],[0],[0],[False],['0']
36935,PMC5833494,41296,The initial power calculation for patients with secondary progressive MS indicated that 222 patients were needed.,Secondary Outcomes|Statistical Analysis,[243146],[14851],[14964],[False],[0],[0],[False],['0']
36936,PMC5833494,41297,"Recruitment was stopped in February 2014, with only 15 patients recruited.",Secondary Outcomes|Statistical Analysis,[243152],[14965],[15039],[False],[0],[0],[False],['0']
36937,PMC5833494,41298,Stopping decisions were taken without knowledge of outcomes or treatment allocations.,Secondary Outcomes|Statistical Analysis,[243158],[15040],[15125],[False],[0],[0],[False],['0']
36938,PMC5833494,41299,"For descriptive purposes, we calculated percentage, mean (SD), and median (interquartile range), as appropriate.",Secondary Outcomes|Statistical Analysis,[243164],[15126],[15238],[False],[0],[0],[False],['0']
36939,PMC5833494,41300,The main analysis was intention to treat.,Secondary Outcomes|Statistical Analysis,[243170],[15239],[15280],[False],[0],[0],[False],['0']
36940,PMC5833494,41301,"The effect of PTA vs sham on the composite functional end point was assessed by comparing the proportions of improved patients at 1 year in the 2 groups, and the significance of differences in proportion was assessed by χ2 test.",Secondary Outcomes|Statistical Analysis,[243176],[15281],[15509],[False],[0],[0],[False],['0']
36941,PMC5833494,41302,The effect of PTA vs sham on the MRI end point was assessed by a negative binomial model that compared the mean number of MRI lesions in the 2 groups at 1 year.,Secondary Outcomes|Statistical Analysis,[243182],[15510],[15670],[False],[0],[0],[False],['0']
36942,PMC5833494,41303,The proportion of patients who were free of new brain lesions on MRI were compared by χ2 test.,Secondary Outcomes|Statistical Analysis,[243188],[15671],[15765],[False],[0],[0],[False],['0']
36943,PMC5833494,41304,Variables that were unbalanced at baseline were adjusted for using a logistic model on the functional end point and a negative binomial model on mean number of MRI lesions.,Secondary Outcomes|Statistical Analysis,[243194],[15766],[15938],[False],[0],[0],[False],['0']
36944,PMC5833494,41305,Relapse rates (secondary end point) in the 2 groups were compared assuming a Poisson distribution of events.,Secondary Outcomes|Statistical Analysis,[243200],[15939],[16047],[False],[0],[0],[False],['0']
36945,PMC5833494,41306,"Differences in EDSS scores at 1 year were compared by analysis of covariance testing, with adjustment for baseline scores.",Secondary Outcomes|Statistical Analysis,[243206],[16048],[16170],[False],[0],[0],[False],['0']
36946,PMC5833494,41307,"When analyzing components of the functional and MRI end points (including findings at 0 to 6 and 6 to 12 months), we adjusted for multiplicity using the Hommel method, since it is reasonable to assume that variables involved could be directly related (reported as adjusted P value).",Secondary Outcomes|Statistical Analysis,[243212],[16171],[16453],[False],[0],[0],[False],['0']
36947,PMC5833494,41308,"All tests were 2-tailed, with the significance level set at P < .05.",Secondary Outcomes|Statistical Analysis,[243218],[16454],[16522],[False],[0],[0],[False],['0']
36948,PMC5833494,41309,Analyses were performed with SAS version 9.3 (SAS Institute) and R version 3.2 (R Foundation for Statistical Computing).,Secondary Outcomes|Statistical Analysis,[243224],[16523],[16643],[False],[0],[0],[False],['0']
36949,PMC5833494,41310,Results,Results,[243230],[16644],[16652],[False],[0],[0],[False],['0']
36950,PMC5833494,41311,The Figure shows the study flowchart for patients with RRMS.,Results,[243236],[16653],[16713],[False],[0],[0],[False],['0']
36951,PMC5833494,41312,"A total of 177 were assessed for eligibility, and 62 were ineligible, including 47 (26.6%) who did not have CCSVI on ECD screening.",Results,[243242],[16714],[16845],[False],[0],[0],[False],['0']
36952,PMC5833494,41313,"One hundred fifteen patients were eligible and randomly assigned to the PTA group (n = 76) or the sham group (n = 39), which included catheter venography without venous angioplasty, between August 7, 2012, and December 15, 2014.",Results,[243248],[16846],[17074],[False],[0],[0],[False],['0']
36953,PMC5833494,41314,The 2 groups were similar for baseline characteristics except that patients in the sham group had more women and longer disease duration (Table 1).,Results,[243254],[17075],[17222],[False],[0],[0],[False],['0']
36954,PMC5833494,41315,"No serious adverse events attributable to catheter venography or venous PTA occurred, but 2 adverse events (1.7%) did occur: 1 vagal reaction and 1 episode of transient neck pain.",Results,[243260],[17223],[17402],[False],[0],[0],[False],['0']
36955,PMC5833494,41316,"A total of 112 of 115 patients (97.4%) completed the 12-month follow-up, with similar proportions completing in the 2 groups.",Results,[243266],[17403],[17528],[False],[0],[0],[False],['0']
36956,PMC5833494,41317,The eFigure in Supplement 2 shows the study flowchart for patients with secondary progressive MS.,Results,[243272],[17529],[17626],[False],[0],[0],[False],['0']
36957,PMC5833494,41318,Primary End Points,Results|Primary End Points,[243278],[17627],[17645],[False],[0],[0],[False],['0']
36958,PMC5833494,41319,Functional end point results were available for 109 patients with RRMS (Table 2).,Results|Primary End Points,[243284],[17646],[17727],[False],[0],[0],[False],['0']
36959,PMC5833494,41320,"A total of 30 of 73 patients (41%) in the PTA group and 18 of 37 (49%) in the sham group improved on the functional end point—a difference of −7% (95% CI, −26.7 to 10.1) in favor of the sham group.",Results|Primary End Points,[243290],[17728],[17925],[False],[0],[0],[False],['0']
36960,PMC5833494,41321,"The logistic model adjusted for sex and disease duration provided an odds ratio (OR) for improvement in the PTA group (compared with the sham group) of 0.70 (95% CI, 0.31-1.59; P = .40).",Results|Primary End Points,[243296],[17926],[18112],[False],[0],[0],[False],['0']
36961,PMC5833494,41322,"The OR for the unadjusted model was 0.75 (95% CI, 0.34-1.68; P = .49).",Results|Primary End Points,[243302],[18113],[18183],[False],[0],[0],[False],['0']
36962,PMC5833494,41323,Worsening occurred in 9 patients (12%) in the PTA group vs 7 (19%) in the sham group; functional stability was maintained in 17 (23%) in the PTA group and 8 (22%) in the sham group.,Results|Primary End Points,[243308],[18184],[18365],[False],[0],[0],[False],['0']
36963,PMC5833494,41324,A mixed outcome (improvement in one or more functions and worsening in one or more) occurred in 16 patients (22%) in the PTA group and 4 (11%) in the sham group.,Results|Primary End Points,[243314],[18366],[18527],[False],[0],[0],[False],['0']
36964,PMC5833494,41325,Results for individual components of the functional end point are shown in Table 3.,Results|Primary End Points,[243320],[18528],[18611],[False],[0],[0],[False],['0']
36965,PMC5833494,41326,"More patients in the PTA group than in the sham group improved in visual acuity and manual dexterity, while more patients in the PTA group worsened for postvoid residual urine volume and balance.",Results|Primary End Points,[243326],[18612],[18807],[False],[0],[0],[False],['0']
36966,PMC5833494,41327,Walking control remained stable in most patients of both groups.,Results|Primary End Points,[243332],[18808],[18872],[False],[0],[0],[False],['0']
36967,PMC5833494,41328,"The number of new lesions on MRI at 12 months compared with baseline was unrelated to venous PTA; there were a mean 1.40 new lesions in the PTA group vs 1.95 in the sham group (mean ratio, 0.72; 95% CI, 0.32-1.63; P = .45; adjusted P = .45) (Table 2).",Results|Primary End Points,[243338],[18873],[19124],[False],[0],[0],[False],['0']
36968,PMC5833494,41329,"In the regression analysis adjusted for sex and disease duration, the mean PTA-to-sham ratio was 0.50 (95% CI, 0.20-1.27; P = .30).",Results|Primary End Points,[243344],[19125],[19256],[False],[0],[0],[False],['0']
36969,PMC5833494,41330,"The proportion of patients free of new lesions did not differ significantly between the PTA and sham groups (63.0% vs 48.6%; OR, 1.80; 95% CI, 0.81-4.00; P = .15; adjusted P = .30) (Table 2).",Results|Primary End Points,[243350],[19257],[19448],[False],[0],[0],[False],['0']
36970,PMC5833494,41331,"At 12 months, 50 patients (68%) in the PTA group were free of new or enlarged T2 lesions compared with 21 (57%) in the sham group (OR, 1.66; 95% CI, 0.73-3.75; P = .22; adjusted P = .62), and 53 (73%) in the PTA group were free of gadolinium-enhancing lesions at 12 months compared with 18 (49%) in the sham group (OR, 2.76; 95% CI, 1.14-6.68; P = .02; adjusted P = .08) (Table 4).",Results|Primary End Points,[243356],[19449],[19830],[False],[0],[0],[False],['0']
36971,PMC5833494,41332,"A post hoc analysis investigating new brain lesions at 0 to 6 months (eTable 1 in Supplement 2) and at 6 to 12 months found that at 6 to 12 months, 58 of 70 patients (83%) in the PTA group and 22 of 33 (67%) in the sham group (OR, 2.64; 95% CI, 1.11-6.28; P = .03; adjusted P = .09) were free of combined brain lesions, while there were a mean (SD) 0.36 (0.98) new T2 lesions in the PTA group and 1.14 (2.63) in the sham group (P = .02; adjusted P = .06).",Results|Primary End Points,[243362],[19831],[20286],[False],[0],[0],[False],['0']
36972,PMC5833494,41333,"Finally, 61 patients (87%) in the PTA group and 24 (73%) in the sham group (OR, 2.75; 95% CI, 1.10-6.89; P = .03; adjusted P = .09) were free of new T2 lesions (Table 4).",Results|Primary End Points,[243368],[20287],[20457],[False],[0],[0],[False],['0']
36973,PMC5833494,41334,Secondary End Points,Results|Secondary End Points,[243374],[20458],[20478],[False],[0],[0],[False],['0']
36974,PMC5833494,41335,"Eight of 115 patients with RRMS (7.0%) diagnosed as having CCSVI by ECD had no abnormalities on venography, so the positive predictive value of ECD was 93.0% in patients with RRMS.",Results|Secondary End Points,[243380],[20479],[20659],[False],[0],[0],[False],['0']
36975,PMC5833494,41336,"The annualized relapse rate was 0.32 (95% CI, 0.2-0.4) in the PTA group and 0.39 (95% CI, 0.2-0.5) in the sham group, giving a relative rate of 0.82 (95% CI, 0.40-1.71; P = .60).",Results|Secondary End Points,[243386],[20660],[20838],[False],[0],[0],[False],['0']
36976,PMC5833494,41337,The median (interquartile range) baseline EDSS score was 2.5 (2.0-3.0) in the PTA group and 2.5 (2.0-3.5) in the sham group (Table 1).,Results|Secondary End Points,[243392],[20839],[20973],[False],[0],[0],[False],['0']
36977,PMC5833494,41338,"At 12 months, the median (interquartile range) EDSS score was 2.0 (1.5-3.0) in the PTA group and 2.0 (1.5-2.5) in the sham group (P = .49).",Results|Secondary End Points,[243398],[20974],[21113],[False],[0],[0],[False],['0']
36978,PMC5833494,41339,Seventeen of 73 patients (23%) in the PTA group had least 1 relapse over the 12 months compared with 12 of 39 (31%) in the sham group.,Results|Secondary End Points,[243404],[21114],[21248],[False],[0],[0],[False],['0']
36979,PMC5833494,41340,Blinded flow assessment at 12 months revealed restored flow in 38 of 71 patients (54%) in the PTA group and 14 of 37 (38%) in the sham group.,Results|Secondary End Points,[243410],[21249],[21390],[False],[0],[0],[False],['0']
36980,PMC5833494,41341,Secondary Progressive MS,Results|Secondary Progressive MS,[243416],[21391],[21415],[False],[0],[0],[False],['0']
36981,PMC5833494,41342,"Primary end points for the 15 patients with secondary progressive MS (10 in the PTA group and 5 in the sham group) are shown, in descriptive form only, in eTable 2 in Supplement 2.",Results|Secondary Progressive MS,[243422],[21416],[21596],[False],[0],[0],[False],['0']
36982,PMC5833494,41343,Discussion,Discussion,[243428],[21597],[21608],[False],[0],[0],[False],['0']
36983,PMC5833494,41344,"Venous PTA did not increase the proportion of patients with RRMS who improved on the functional composite measure compared with the sham procedure over the 12-month follow-up, nor did it significantly reduce the appearance of new combined brain lesions on MRI at 0 to 12 months.",Discussion,[243434],[21609],[21887],[False],[0],[0],[False],['0']
36984,PMC5833494,41345,"Expanded Disability Status Scale disability measures were stable and similar between the groups at 12 months, matching the composite functional outcome.",Discussion,[243440],[21888],[22040],[False],[0],[0],[False],['0']
36985,PMC5833494,41346,The annualized relapse rate was also similar between the groups.,Discussion,[243446],[22041],[22105],[False],[0],[0],[False],['0']
36986,PMC5833494,41347,Safety data indicated no serious adverse events attributable to venous PTA or the sham procedure.,Discussion,[243452],[22106],[22203],[False],[0],[0],[False],['0']
36987,PMC5833494,41348,"The functional outcome explored by the trial was reduction in disability as assessed by 5 functions (ie, walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity; eMethods in Supplement 2), which are the most frequent causes of disability in MS.",Discussion,[243458],[22204],[22486],[False],[0],[0],[False],['0']
36988,PMC5833494,41349,"The hypothesis that venous PTA can significantly reduce disability is rejected by findings from this study, which not only found no difference between the groups on the functional composite measure but also no difference for any of its 5 components (Table 3).",Discussion,[243464],[22487],[22746],[False],[0],[0],[False],['0']
36989,PMC5833494,41350,The primary MRI outcome measure was a difference in the number of new combined brain lesions.,Discussion,[243470],[22747],[22840],[False],[0],[0],[False],['0']
36990,PMC5833494,41351,Venous PTA had no effect on this measure (Table 2).,Discussion,[243476],[22841],[22892],[False],[0],[0],[False],['0']
36991,PMC5833494,41352,"However, at 12 months, more than 20% of patients in the PTA group were free of gadolinium-enhancing lesions compared with the sham group (OR, 2.76; 95% CI, 1.14-6.68) (Table 4).",Discussion,[243482],[22893],[23070],[False],[0],[0],[False],['0']
36992,PMC5833494,41353,"To explore this effect, which appears inconsistent with the other MRI data at 0 to 12 months, we performed an exploratory post hoc comparison of MRI findings at 0 to 6 months with those at 6 to 12 months (Table 4; eTable 1 in Supplement 2).",Discussion,[243488],[23071],[23311],[False],[0],[0],[False],['0']
36993,PMC5833494,41354,We found a reduction in the mean number of new brain lesions (corresponding to more lesion-free patients) in the PTA group compared with the sham group at 6 to 12 months.,Discussion,[243494],[23312],[23482],[False],[0],[0],[False],['0']
36994,PMC5833494,41355,The delayed and positive effect on the magnetic resonance biomarker suggests that PTA could affect the dynamic of the blood-brain barrier.,Discussion,[243500],[23483],[23621],[False],[0],[0],[False],['0']
36995,PMC5833494,41356,"Gadolinium enhancement is a marker of damage to the blood-brain barrier, whose time course depends on lymphatic drainage and hence on venous drainage from the skull.",Discussion,[243506],[23622],[23788],[False],[0],[0],[False],['0']
36996,PMC5833494,41357,"Previous studies have reported that venous pressure is lowered and cerebrospinal fluid dynamics is improved after venous PTA, thereby favoring the drainage of cerebrospinal fluid into the dural veins, which depends on a pressure gradient between the subarachnoid spaces and dural veins.",Discussion,[243512],[23789],[24075],[False],[0],[0],[False],['0']
36997,PMC5833494,41358,"Another study reported that white matter lesion load was inversely correlated with reduced cerebrospinal fluid dynamics, as measured by MRI.",Discussion,[243518],[24076],[24216],[False],[0],[0],[False],['0']
36998,PMC5833494,41359,"In addition, flow improvement through the internal jugular veins owing to venous PTA has been reported to improve brain perfusion in patients with RRMS.",Discussion,[243524],[24217],[24369],[False],[0],[0],[False],['0']
36999,PMC5833494,41360,It has also been reported that the development of a new MS plaque was preceded by sustained MRI-detected hypoperfusion before the plaque was identified on MRI.,Discussion,[243530],[24370],[24529],[False],[0],[0],[False],['0']
37000,PMC5833494,41361,"To our knowledge, few published data are available to compare with Brave Dreams findings.",Discussion,[243536],[24530],[24619],[False],[0],[0],[False],['0']
37001,PMC5833494,41362,The positive effect of venous PTA on disability found in the first open-label pilot study was not confirmed in the present study.,Discussion,[243542],[24620],[24749],[False],[0],[0],[False],['0']
37002,PMC5833494,41363,The first study was not blinded and used the MSFC and the EDSS scores as primary end points.,Discussion,[243548],[24750],[24842],[False],[0],[0],[False],['0']
37003,PMC5833494,41364,"There is some degree of subjectivity in assessing MSFC and EDSS scores, and with nonblinded patients and outcome assessors, detection bias may have been introduced.",Discussion,[243554],[24843],[25007],[False],[0],[0],[False],['0']
37004,PMC5833494,41365,"In a sham-controlled randomized trial, 19 patients with MS (9 assigned to PTA and 10 to sham) were assessed 1, 3, and 6 months after intervention.",Discussion,[243560],[25008],[25154],[False],[0],[0],[False],['0']
37005,PMC5833494,41366,It was found that clinical and MRI end points were closely similar in the 2 groups.,Discussion,[243566],[25155],[25238],[False],[0],[0],[False],['0']
37006,PMC5833494,41367,"However, the study was flawed by the small number of recruited patients and short follow-up.",Discussion,[243572],[25239],[25331],[False],[0],[0],[False],['0']
37007,PMC5833494,41368,"In an observational study, 29 patients with RRMS were observed for 2 years after venous PTA.A small improvement in mean EDSS score occurred over that time, and the mean annual relapse rate also lowered.",Discussion,[243578],[25332],[25534],[False],[0],[0],[False],['0']
37008,PMC5833494,41369,Magnetic resonance imaging data were not reported.,Discussion,[243584],[25535],[25585],[False],[0],[0],[False],['0']
37009,PMC5833494,41370,Limitations,Discussion|Limitations,[243590],[25586],[25597],[False],[0],[0],[False],['0']
37010,PMC5833494,41371,Our study has several limitations.,Discussion|Limitations,[243596],[25598],[25632],[False],[0],[0],[False],['0']
37011,PMC5833494,41372,"Despite being, to our knowledge, the largest randomized study on venous PTA in RRMS, the power of the study was limited.",Discussion|Limitations,[243602],[25633],[25753],[True],['UnderpoweredStudy'],['the power of the study was limited'],[True],['UnderpoweredStudy']
37012,PMC5833494,41373,There are at least 3 main reasons for this.,Discussion|Limitations,[243614],[25754],[25797],[False],[0],[0],[False],['0']
37013,PMC5833494,41374,"First, many MS centers are reluctant to propose patients for a trial exploring a controversial hypothesis.",Discussion|Limitations,[243620],[25798],[25904],[False],[0],[0],[False],['0']
37014,PMC5833494,41375,"Thus, of the 15 centers that initially joined the trial, only 6 actively recruited.",Discussion|Limitations,[243628],[25905],[25988],[True],['Population'],['only 6 actively recruited'],[True],['Population']
37015,PMC5833494,41376,"Second, many patients are reluctant to participate in a randomized sham-controlled study in spite of the fact that randomization was 2:1 in favor of angioplasty; this reluctance may have been exacerbated by the media, which overemphasized the effectiveness of venous PTA.",Discussion|Limitations,[243641],[25989],[26260],[True],['Population'],['many patients are reluctant to participate in a randomized sham-controlled study'],[True],['Population']
37016,PMC5833494,41377,"Third, the sudden widespread availability of venous PTA (and stenting) in private centers decreased the number of patients fulfilling the inclusion criterion of no previous angioplasty.",Discussion|Limitations,[243651],[26261],[26446],[True],['DiagnosticCriteria'],['decreased the number of patients fulfilling the inclusion criterion of no previous angioplasty'],[True],['Population']
37017,PMC5833494,41378,"A post hoc power calculation, based on control findings, indicated a power of 30% to detect a difference in the functional end point and 17% power to detect the target difference in the MRI end point.",Discussion|Limitations,[243662],[26447],[26647],[False],[0],[0],[False],['0']
37018,PMC5833494,41379,"In terms of effect size and clinical relevance, the 95% CI for the estimated 7% advantage of sham varied from 26.7% in favor of sham to 10.1% in favor of PTA, thereby excluding the 15% target threshold for a benefit of venous PTA on the functional end point.",Discussion|Limitations,[243668],[26648],[26906],[False],[0],[0],[False],['0']
37019,PMC5833494,41380,"However, the findings on new MRI lesions do not completely exclude an effect of venous PTA, since the 95% CI for the mean lesion ratio of 0.72 in favor of PTA includes the 0.65 target for PTA improvement (95% CI, 0.32-1.63).",Discussion|Limitations,[243674],[26907],[27131],[False],[0],[0],[False],['0']
37020,PMC5833494,41381,The use of a new composite functional outcome measure was a major challenge.,Discussion|Limitations,[243680],[27132],[27208],[False],[0],[0],[False],['0']
37021,PMC5833494,41382,"Although the outcomes and change thresholds (reflecting sensitivity to change) of the individual components have been validated (eMethods in Supplement 2), the composite is presented for the first time in this article.",Discussion|Limitations,[243686],[27209],[27427],[False],[0],[0],[False],['0']
37022,PMC5833494,41383,"Another limitation of the trial is that the severity of the enrolled patients in terms of EDSS score and lesion load was lower than anticipated, and patients with active disease may have been underrepresented in the study (Table 1).",Discussion|Limitations,[243696],[27428],[27660],[True],['VerySpecificPopulation'],['patients with active disease may have been underrepresented in the study'],[True],['Population']
37023,PMC5833494,41384,"Finally, the fact that venous PTA was largely ineffective in restoring blood flow in nearly half the patients in the PTA group suggests that it was inadequate for exploring our initial hypothesis.",Discussion|Limitations,[243709],[27661],[27857],[True],['Intervention'],['venous PTA was largely ineffective in restoring blood flow in nearly half the patients in the PTA group'],[True],['Intervention']
37024,PMC5833494,41385,Conclusions,Conclusions,[243716],[27858],[27870],[False],[0],[0],[False],['0']
37025,PMC5833494,41386,A number of neurologists and scientists expressed the opinion that the decision to conduct a trial on CCSVI in the absence of valid scientific evidence was unethical and a waste of resources.,Conclusions,[243722],[27871],[28062],[False],[0],[0],[False],['0']
37026,PMC5833494,41387,"However, we believe that the best way to provide useful information to patients (and regulatory authorities) on the benefit and safety of venous PTA was to conduct a randomized trial—as also recommended by NICE—that assessed outcomes directly relevant to patients.",Conclusions,[243728],[28063],[28327],[False],[0],[0],[False],['0']
37027,PMC5833494,41388,Venous PTA has proven to be a safe but ineffective technique in treating CCSVI in about half of patients.,Conclusions,[243734],[28328],[28433],[False],[0],[0],[False],['0']
37028,PMC5833494,41389,The procedure cannot be recommended for treatment of patients with MS; no further double-blinded clinical studies are needed.,Conclusions,[243740],[28434],[28559],[False],[0],[0],[False],['0']
37029,PMC5833494,41390,The delayed effect of venous PTA 6 months after the procedure on the magnetic resonance biomarker suggests a possibility that PTA may produce benefit for a subgroup of patients with MS.,Conclusions,[243746],[28560],[28745],[False],[0],[0],[False],['0']
37030,PMC5833494,41391,This should be further analyzed and investigated.,Conclusions,[243752],[28746],[28795],[False],[0],[0],[False],['0']
38371,PMC5975052,38214,A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease,Title,[222937],[35705],[123],[False],[0],[0],[False],['0']
38372,PMC5975052,38215,Background,Abstract,[222944],[124],[135],[False],[0],[0],[False],['0']
38373,PMC5975052,38216,"The lipoprotein-associated phospholipase A  inhibitor (Lp-PLA ), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD).",Abstract,[222951],[136],[320],[False],[0],[0],[False],['0']
38374,PMC5975052,38217,Methods,Methods,[222958],[321],[329],[False],[0],[0],[False],['0']
38375,PMC5975052,38218,"One hundred twenty-four subjects with possible mild AD and with neuroimaging evidence of cerebrovascular disease were randomized to placebo or 250-mg rilapladib once daily, for 24 weeks, in addition to stable background acetylcholinesterase inhibitor and/or memantine.",Methods,[222965],[330],[598],[False],[0],[0],[False],['0']
38376,PMC5975052,38219,"The study assessed the safety and tolerability of rilapladib and its effects on cognition, mechanistic, and disease-related biomarkers.",Methods,[222972],[599],[734],[False],[0],[0],[False],['0']
38377,PMC5975052,38220,"Although the overall intent behind the study was to take a broad exploratory view of the data, two primary end points of interest (cerebrospinal fluid [CSF] amyloid beta peptide 1–42 [Aβ ] and CogState executive function/working memory [EF/WM] composite score at week 24) were prespecified in the analysis plan for inferential statistical analysis.",Methods,[222979],[735],[1083],[False],[0],[0],[False],['0']
38378,PMC5975052,38221,Results,Results,[222986],[1084],[1092],[False],[0],[0],[False],['0']
38379,PMC5975052,38222,Rilapladib was well tolerated with no significant safety concerns.,Results,[222993],[1093],[1159],[False],[0],[0],[False],['0']
38380,PMC5975052,38223,"A significant difference from placebo was observed for rilapladib on change from baseline in EF/WM (effect size, 0.45; P = .026).",Results,[223000],[1160],[1289],[False],[0],[0],[False],['0']
38381,PMC5975052,38224,There was no significant difference between groups on the change from baseline in CSF Aβ  (P = .133).,Results,[223007],[1290],[1391],[False],[0],[0],[False],['0']
38382,PMC5975052,38225,Preliminary evidence of effects was detected on other mechanistic (albumin quotient) and disease-related biomarkers (tau/P-tau and neurofilament light chain).,Results,[223014],[1392],[1550],[False],[0],[0],[False],['0']
38383,PMC5975052,38226,Conclusion,Conclusion,[223021],[1551],[1562],[False],[0],[0],[False],['0']
38384,PMC5975052,38227,These data provide initial evidence supporting Lp-PLA  inhibition as a novel treatment for dementia.,Conclusion,[223028],[1563],[1663],[False],[0],[0],[False],['0']
38385,PMC5975052,38228,Clinical Trial Registration,Clinical Trial Registration,[223035],[1664],[1692],[False],[0],[0],[False],['0']
38386,PMC5975052,38229,Clinicaltrials.gov identifier: NCT01428453.,Clinical Trial Registration,[223042],[1693],[1736],[False],[0],[0],[False],['0']
38387,PMC5975052,38230,Introduction,Introduction,[223049],[1737],[1751],[False],[0],[0],[False],['0']
38388,PMC5975052,38231,Rilapladib (SB659032) is a potent and selective inhibitor of the enzyme lipoprotein-associated phospholipase A  (Lp-PLA ).,Introduction,[223056],[1752],[1874],[False],[0],[0],[False],['0']
38389,PMC5975052,38232,"Lp-PLA  is a calcium-independent phospholipase A  that is actively secreted by monocyte-derived macrophages, T lymphocytes, and mast cells and circulates in plasma as a complex with low-density lipoprotein (LDL) and, to a lesser extent, high-density lipoprotein [1].",Introduction,[223063],[1875],[2141],[False],[0],[0],[False],['0']
38390,PMC5975052,38233,"A range of studies demonstrate that inhibition of Lp-PLA  can reduce peripheral measures of inflammation in nonclinical [2] and clinical studies [3], [4], [5].",Introduction,[223070],[2142],[2301],[False],[0],[0],[False],['0']
38391,PMC5975052,38234,"Based on nonclinical data, rilapladib is not believed to be brain penetrant and has been evaluated previously in subjects with stable atherosclerosis [6].",Introduction,[223077],[2302],[2456],[False],[0],[0],[False],['0']
38392,PMC5975052,38235,"Lp-PLA  has substrate specificity toward oxidized phospholipids, in particular, those containing a polar fatty acid moiety that are generated during the oxidation of LDL (oxLDL) and apoptosis [1].",Introduction,[223084],[2457],[2653],[False],[0],[0],[False],['0']
38393,PMC5975052,38236,"Lp-PLA  rapidly cleaves oxidized phosphatidylcholine in tissue, generating proinflammatory lysophosphatidylcholine (lysoPC) and oxidized nonesterified fatty acids.",Introduction,[223091],[2654],[2817],[False],[0],[0],[False],['0']
38394,PMC5975052,38237,LysoPC has also been demonstrated to be a mediator of inflammatory stress on brain microvascular endothelial cells [7] and to increase the permeability of endothelial cells [8].,Introduction,[223098],[2818],[2995],[False],[0],[0],[False],['0']
38395,PMC5975052,38238,Literature supports that oxLDL can be detected in the central nervous system (CNS) after blood-brain barrier (BBB) disruption [9].,Introduction,[223105],[2996],[3126],[False],[0],[0],[False],['0']
38396,PMC5975052,38239,"In a diabetic mellitus (DM) and hypercholesterolaemic (HC) pig model, treatment with darapladib (another Lp-PLA  inhibitor) numerically reduced the extent of immunoglobulin G brain parenchyma penetration suggesting a reduction in BBB leakage and significantly lowered the total amount of brain amyloid beta peptide 1–42 (Aβ ) deposition compared with untreated DM/HC pigs [10].",Introduction,[223112],[3127],[3504],[False],[0],[0],[False],['0']
38397,PMC5975052,38240,"Both findings are relevant and potentially linked, through brain Aβ efflux mechanisms at the BBB, to the pathogenesis and progression of Alzheimer's disease (AD) [11], [12].",Introduction,[223119],[3505],[3678],[False],[0],[0],[False],['0']
38398,PMC5975052,38241,"Age-related cerebrovascular dysfunction, and associated cerebrovascular disease (CVD), plays an important role in the initiation and progression of AD [13], [14], [15].",Introduction,[223126],[3679],[3847],[False],[0],[0],[False],['0']
38399,PMC5975052,38242,"Cerebral small vessel disease (SVD) is a CVD subtype that is associated with a high proportion of AD cases [16], [17], [18].",Introduction,[223133],[3848],[3972],[False],[0],[0],[False],['0']
38400,PMC5975052,38243,"The associated pathologic changes in the parenchymal small arteries and arterioles (e.g., arteriolosclerotic changes such as fibrinoid necrosis, lipohylinosis, microatheroma, and microaneurysms) extend to the endothelial barriers of the small vessels and capillaries (i.e., the BBB) resulting in permeability changes and extravasation of plasma components into the vessel walls and brain parenchyma [19].",Introduction,[223140],[3973],[4377],[False],[0],[0],[False],['0']
38401,PMC5975052,38244,"Postmortem analyses of AD brain tissue have demonstrated changes to the microvasculature through the presence of extravasated serum proteins, such as albumin and immunoglobulin [20], [21], [22], [23], as well as white matter lesions and the widespread deposition of cerebral amyloid angiopathy, with associated microbleeds; all of which may contribute to decline in vascular integrity and function [19].",Introduction,[223147],[4378],[4781],[False],[0],[0],[False],['0']
38402,PMC5975052,38245,"These observations, together with the findings from the nonclinical models, informed on the choice of AD subjects with neuroimaging evidence of CVD (e.g., white matter lesions and/or lacunes, typical of SVD) in the present study.",Introduction,[223154],[4782],[5011],[False],[0],[0],[False],['0']
38403,PMC5975052,38246,"In summary, it is hypothesized that rilapladib will peripherally reduce the production of proinflammatory and toxic mediators, thereby restoring BBB integrity and reducing its permeability.",Introduction,[223161],[5012],[5201],[False],[0],[0],[False],['0']
38404,PMC5975052,38247,"Resultant, or downstream, effects may include reduced levels of neuroinflammation/toxicity and reductions in CNS Aβ, either through a reduction in influx or a restoration of efflux mechanisms.",Introduction,[223168],[5202],[5394],[False],[0],[0],[False],['0']
38405,PMC5975052,38248,The present study was designed to investigate the extent to which the mechanisms observed in preclinical models are present in subjects with AD and CVD and whether any downstream impact on neurodegenerative biomarkers or cognition could be detected over a 24-week treatment period.,Introduction,[223175],[5395],[5676],[False],[0],[0],[False],['0']
38406,PMC5975052,38249,Methods,Methods,[223182],[5677],[5685],[False],[0],[0],[False],['0']
38407,PMC5975052,38250,Study design,Methods|Study design,[223189],[5686],[5698],[False],[0],[0],[False],['0']
38408,PMC5975052,38251,"This exploratory study was a randomized, double-blind, placebo-controlled, parallel group, repeat dose study to evaluate the effect of rilapladib on biomarkers related to the pathogenesis and progression of AD and cognitive function.",Methods|Study design,[223196],[5699],[5932],[False],[0],[0],[False],['0']
38409,PMC5975052,38252,"Subjects were randomized to either 250 mg of rilapladib or placebo once daily for 24 weeks in addition to their stable background therapy (i.e., acetylcholinesterase inhibitor [AChEI] and/or memantine).",Methods|Study design,[223203],[5933],[6135],[False],[0],[0],[False],['0']
38410,PMC5975052,38253,"Study duration was 30 weeks comprising 4-week screening, 24-week treatment period, and 2-week follow-up.",Methods|Study design,[223210],[6136],[6240],[False],[0],[0],[False],['0']
38411,PMC5975052,38254,"The study was conducted at 24 sites in Germany, Spain, Italy, Sweden, Bulgaria, and Canada.",Methods|Study design,[223217],[6241],[6332],[False],[0],[0],[False],['0']
38412,PMC5975052,38255,The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and the ethical principles that are outlined in the Declaration of Helsinki 2008.,Methods|Study design,[223224],[6333],[6537],[False],[0],[0],[False],['0']
38413,PMC5975052,38256,The protocol was reviewed and approved by ethics committees or institutional review boards at each institution.,Methods|Study design,[223231],[6538],[6649],[False],[0],[0],[False],['0']
38414,PMC5975052,38257,Subjects,Subjects,[223238],[6650],[6659],[False],[0],[0],[False],['0']
38415,PMC5975052,38258,Eligible subjects were 50–80 years inclusive and met National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for possible AD [24].,Subjects,[223245],[6660],[6885],[False],[0],[0],[False],['0']
38416,PMC5975052,38259,"Subjects had radiological (magnetic resonance imaging [MRI] or computed tomography [CT]) evidence of significant CVD, assessed within the last 12 months, by meeting at least one of the criteria in the following:MRI evidence: White matter lesions: extending caps, irregular halo, diffusely confluent hyperintensities, or extensive white matter changes.. CT evidence: Extensive periventricular and deep white matter lesions: patchy or diffuse symmetrical areas of low attenuation (intermediate density between normal white matter and cerebrospinal fluid [CSF]), with ill-defined margins extending to the centrum semiovale, and at least one lacunar infarct.. MRI or CT evidence: Lacunar cases: multiple lacunes (e.g., >5) in the deep gray matter.",Subjects,[223252],[6886],[7629],[False],[0],[0],[False],['0']
38417,PMC5975052,38260,"Subjects were required to have a Mini-Mental Status Examination score of 20–26 at screening, a Clinical Dementia Rating of 0.5 or 1.0, and a documented history of ≥6-month AChEI therapy, with two months at a stable dose.",Subjects,[223259],[7630],[7851],[False],[0],[0],[False],['0']
38418,PMC5975052,38261,"Exclusion criteria included significant psychiatric illness; history/evidence of another cause of dementia; history of seizures; abnormal findings that would preclude participation; treatment with monoamine oxidase inhibitors, conventional antipsychotics, an investigational drug or treatment with a potential for interaction with rilapladib.",Subjects,[223266],[7852],[8194],[False],[0],[0],[False],['0']
38419,PMC5975052,38262,See Supplementary Materials for further details.,Subjects,[223273],[8195],[8243],[False],[0],[0],[False],['0']
38420,PMC5975052,38263,"Study procedures, outcomes, and assessments","Study procedures, outcomes, and assessments",[223280],[8244],[8288],[False],[0],[0],[False],['0']
38421,PMC5975052,38264,"CSF was collected at baseline and week 24 (or early withdrawal) for the assessment of Aβ  (primary end point of interest), Aβ , total tau (T-tau), 181 phosphorylated tau (P-tau), Lp-PLA  activity, and as an exploratory marker of axonal degeneration and white matter damage, neurofilament light chain (NF-L).","Study procedures, outcomes, and assessments",[223287],[8289],[8596],[False],[0],[0],[False],['0']
38422,PMC5975052,38265,Albumin quotient (AlbQ) was also determined as a marker of BBB permeability.,"Study procedures, outcomes, and assessments",[223294],[8597],[8673],[False],[0],[0],[False],['0']
38423,PMC5975052,38266,"Plasma samples were collected at baseline, week 1, week 12, and week 24 for the assessment of Aβ , Aβ , and Lp-PLA  activity.","Study procedures, outcomes, and assessments",[223301],[8674],[8799],[False],[0],[0],[False],['0']
38424,PMC5975052,38267,Pharmacokinetics (PKs) of rilapladib were assessed throughout the study from baseline to week 24.,"Study procedures, outcomes, and assessments",[223308],[8800],[8897],[False],[0],[0],[False],['0']
38425,PMC5975052,38268,Further details of assays used to measure these end points are provided in the Supplementary Materials.,"Study procedures, outcomes, and assessments",[223315],[8898],[9001],[False],[0],[0],[False],['0']
38426,PMC5975052,38269,"Cognitive assessment was performed at screening, baseline, week 12, and week 24 (or early withdrawal) using a battery of computerized (CogState [25]) as well as pen and paper neuropsychological assessments, with executive function/working memory composite score (EF/WM) as the primary end point of interest.","Study procedures, outcomes, and assessments",[223322],[9002],[9309],[False],[0],[0],[False],['0']
38427,PMC5975052,38270,The individual tests were selected on the basis of being relatively free of floor and ceiling effects and their ability to probe cognitive functions that were likely to demonstrate decline over 24 weeks in the selected population.,"Study procedures, outcomes, and assessments",[223329],[9310],[9540],[False],[0],[0],[False],['0']
38428,PMC5975052,38271,"The individual tests and composite scores are described in the following and in more detail in the Supplementary Materials.EF/WM composite: Controlled Oral Word Association Test, category naming, one back, Trails B, and Go-NoGo..","Study procedures, outcomes, and assessments",[223336],[9541],[9770],[False],[0],[0],[False],['0']
38429,PMC5975052,38272,"Attention composite: Identification (a choice reaction time task) and Trails A.. Episodic memory composite: International Shopping List Task (ISLT) immediate recall, ISLT delayed recall.","Study procedures, outcomes, and assessments",[223343],[9771],[9957],[False],[0],[0],[False],['0']
38430,PMC5975052,38273,Note: the reporting and analysis plan prespecified a change to the protocol before unbinding that the episodic memory composite would only include immediate recall..,"Study procedures, outcomes, and assessments",[223350],[9958],[10123],[False],[0],[0],[False],['0']
38431,PMC5975052,38274,Overall composite: all nine subtests.,"Study procedures, outcomes, and assessments",[223357],[10124],[10161],[False],[0],[0],[False],['0']
38432,PMC5975052,38275,"Safety was assessed throughout the study through collection of adverse events (AEs), assessment of vital signs, electrocardiograms, and routine laboratory assessments.","Study procedures, outcomes, and assessments",[223364],[10162],[10330],[False],[0],[0],[False],['0']
38433,PMC5975052,38276,"In addition, eye examinations (all sites) and electron microscopy of peripheral blood lymphocytes (in sites with appropriate facilities) were performed at screening and week 24 to identify any signs of potential phospholipidosis.","Study procedures, outcomes, and assessments",[223371],[10331],[10560],[False],[0],[0],[False],['0']
38434,PMC5975052,38277,Randomization and masking,Randomization and masking,[223378],[10561],[10587],[False],[0],[0],[False],['0']
38435,PMC5975052,38278,"After the run-in period, subjects were randomized in random permuted blocks of four in a 1:1 ratio to double-blind treatment with rilapladib of 250 mg or matching placebo which were provided by GlaxoSmithKline (GSK) as tablets to be taken once daily after breakfast.",Randomization and masking,[223385],[10588],[10854],[False],[0],[0],[False],['0']
38436,PMC5975052,38279,The randomization schedule was generated by GSK and implemented using an interactive voice-response system.,Randomization and masking,[223392],[10855],[10962],[False],[0],[0],[False],['0']
38437,PMC5975052,38280,"With the exception of two subjects for whom the investigator was unblinded (but not the sponsor) after a code break, all investigator and sponsor staff remained blinded to treatment until the database was finalized.",Randomization and masking,[223399],[10963],[11178],[False],[0],[0],[False],['0']
38438,PMC5975052,38281,Statistical analysis,Statistical analysis,[223406],[11179],[11200],[False],[0],[0],[False],['0']
38439,PMC5975052,38282,"Although the overall intent behind the study was to take a broad exploratory view of the data, two primary end points of interest were prespecified in the analysis plan for inferential statistical analysis: end of study/week 24 treatment differences between placebo and rilapladib of 250 mg for the ITT population for CSF Aβ  and CogState EF/WM.",Statistical analysis,[223413],[11201],[11546],[False],[0],[0],[False],['0']
38440,PMC5975052,38283,"Assuming a post randomization dropout rate of 15%, approximately 120 subjects were randomized to ensure a total of 102 evaluable subjects (51 per group).",Statistical analysis,[223420],[11547],[11700],[False],[0],[0],[False],['0']
38441,PMC5975052,38284,A sample size of 51 evaluable subjects per arm allowed a difference of 70 pg/mL in CSF Aβ  between placebo and rilapladib to be detected with 80% power at a 5% (two sided) significance level assuming an underlying standard deviation (SD) of 120.,Statistical analysis,[223427],[11701],[11946],[False],[0],[0],[False],['0']
38442,PMC5975052,38285,"Three populations were defined for efficacy and safety analyses: safety (subjects randomized who took at least one dose of study medication), intent-to treat (ITT; subjects in the safety population who also had at least one post-baseline efficacy assessment), and per protocol (PP; subjects in the ITT population who were not major protocol deviators).",Statistical analysis,[223434],[11947],[12299],[False],[0],[0],[False],['0']
38443,PMC5975052,38286,"Changes from baseline in CSF parameters were analyzed using an analysis of covariance, adjusting for baseline CSF parameter, age, and treatment.",Statistical analysis,[223441],[12300],[12444],[False],[0],[0],[False],['0']
38444,PMC5975052,38287,"Change from baseline in plasma biomarker parameters and CogState end points were analyzed using a mixed model for repeated measures, assuming an unstructured covariance matrix, with the following terms included in the model: treatment, visit, baseline, treatment by visit, and baseline by visit.",Statistical analysis,[223448],[12445],[12740],[False],[0],[0],[False],['0']
38445,PMC5975052,38288,Statistical significance was interpreted using a two-sided test at the 5% significance level for the two primary comparisons of interest only.,Statistical analysis,[223455],[12741],[12883],[False],[0],[0],[False],['0']
38446,PMC5975052,38289,No adjustments were made for multiplicity of these two coprimary end points.,Statistical analysis,[223462],[12884],[12960],[False],[0],[0],[False],['0']
38447,PMC5975052,38290,CSF Aβ  and CogState EF/WM were also analyzed using the PP population.,Statistical analysis,[223469],[12961],[13031],[False],[0],[0],[False],['0']
38448,PMC5975052,38291,"Results for the analysis of the cognitive end points are presented as differences in standardized scores (Z scores, using the mean and SD for the ITT population at baseline) and effect sizes (treatment difference divided by the standard error).",Statistical analysis,[223476],[13032],[13276],[False],[0],[0],[False],['0']
38449,PMC5975052,38292,Results of primary and some secondary end points are also presented as posterior probabilities (using a noninformative prior) for the treatment differences/effect sizes being above relevant thresholds.,Statistical analysis,[223483],[13277],[13478],[False],[0],[0],[False],['0']
38450,PMC5975052,38293,See Supplementary Materials for more details.,Statistical analysis,[223490],[13479],[13524],[False],[0],[0],[False],['0']
38451,PMC5975052,38294,Safety data were summarized using descriptive statistics.,Statistical analysis|Safety data were summarized using descriptive statistics.,[223497],[13525],[13582],[False],[0],[0],[False],['0']
38452,PMC5975052,38295,Results,Results,[223504],[13583],[13591],[False],[0],[0],[False],['0']
38453,PMC5975052,38296,Patient disposition and demographics,Results|Patient disposition and demographics,[223511],[13592],[13628],[False],[0],[0],[False],['0']
38454,PMC5975052,38297,"Of the 170 subjects screened for the study, 124 were randomized to treatment with rilapladib or placebo.",Results|Patient disposition and demographics,[223518],[13629],[13733],[False],[0],[0],[False],['0']
38455,PMC5975052,38298,Early withdrawal rates were 9/61 subjects (15%) for rilapladib and 6/62 subjects (10%) for placebo.,Results|Patient disposition and demographics,[223525],[13734],[13833],[False],[0],[0],[False],['0']
38456,PMC5975052,38299,The most common reasons for withdrawal were AEs (seven subjects [11%] for rilapladib and two subjects [3%] for placebo) and withdrawn consent (one subject [2%] for rilapladib and three subjects [5%] for placebo).,Results|Patient disposition and demographics,[223532],[13834],[14046],[False],[0],[0],[False],['0']
38457,PMC5975052,38300,Most subjects (93%) in the ITT population were compliant with treatment.,Results|Patient disposition and demographics,[223539],[14047],[14119],[False],[0],[0],[False],['0']
38458,PMC5975052,38301,Table 1 Populations and demographic and baseline characteristics (ITT population).,Results|Patient disposition and demographics,[223546],[14120],[14202],[False],[0],[0],[False],['0']
38459,PMC5975052,38302,Demographic and baseline characteristics were similar across treatment groups (Table 1).,Results|Patient disposition and demographics,[223553],[14203],[14291],[False],[0],[0],[False],['0']
38460,PMC5975052,38303,All subjects were Caucasian.,Results|Patient disposition and demographics,[223560],[14292],[14320],[False],[0],[0],[False],['0']
38461,PMC5975052,38304,Most subjects were receiving treatment with an AChEI with only 12%–13% receiving memantine (Supplementary Table 1).,Results|Patient disposition and demographics,[223567],[14321],[14436],[False],[0],[0],[False],['0']
38462,PMC5975052,38305,"Examination of baseline CSF profiles of Aβ , tau, and P-tau indicated that approximately 50%–60% of subjects met the biomarker thresholds for amyloid positivity and tau levels indicative of AD (Table 1).",Results|Patient disposition and demographics,[223574],[14437],[14640],[False],[0],[0],[False],['0']
38463,PMC5975052,38306,PKs and pharmacodynamics,PKs and pharmacodynamics,[223581],[14641],[14666],[False],[0],[0],[False],['0']
38464,PMC5975052,38307,Rilapladib plasma concentrations were within the range of observation from previous studies [6].,PKs and pharmacodynamics,[223588],[14667],[14763],[False],[0],[0],[False],['0']
38465,PMC5975052,38308,"The mean plasma exposure to SB-664601, one of the major metabolites of rilapladib, was about 16% of rilapladib.",PKs and pharmacodynamics,[223595],[14764],[14875],[False],[0],[0],[False],['0']
38466,PMC5975052,38309,Target engagement in the plasma was confirmed by approximately 80% reduction in plasma Lp-PLA  activity in the rilapladib group.,PKs and pharmacodynamics,[223602],[14876],[15004],[False],[0],[0],[False],['0']
38467,PMC5975052,38310,See Supplementary Table 2 for further details.,PKs and pharmacodynamics,[223609],[15005],[15051],[False],[0],[0],[False],['0']
38468,PMC5975052,38311,CSF Lp-PLA  activity was an exploratory measure.,PKs and pharmacodynamics,[223616],[15052],[15100],[False],[0],[0],[False],['0']
38469,PMC5975052,38312,"Mean change from baseline at the end of study was −0.464 μmol/min/L in the rilapladib group and 0.026 μmol/min/L in the placebo group, although the data were variable (SD of 5.4263 and 7.2657 for rilapladib and placebo, respectively).",PKs and pharmacodynamics,[223623],[15101],[15335],[False],[0],[0],[False],['0']
38470,PMC5975052,38313,See Supplementary Table 3 for further details.,PKs and pharmacodynamics,[223630],[15336],[15382],[False],[0],[0],[False],['0']
38471,PMC5975052,38314,Efficacy assessments,Efficacy assessments,[223637],[15383],[15404],[False],[0],[0],[False],['0']
38472,PMC5975052,38315,Aβ biomarkers,Efficacy assessments|Aβ biomarkers,[223644],[15405],[15418],[False],[0],[0],[False],['0']
38473,PMC5975052,38316,Table 2 Statistical analysis of change from baseline in CSF and plasma biomarkers at week 24/end of study (ITT population).,Efficacy assessments|Aβ biomarkers,[223651],[15419],[15542],[False],[0],[0],[False],['0']
38474,PMC5975052,38317,"No statistically significant differences were observed for the change in baseline at week 24 for CSF Aβ  (P = .133; ITT Population, Table 2).",Efficacy assessments|Aβ biomarkers,[223658],[15543],[15684],[False],[0],[0],[False],['0']
38475,PMC5975052,38318,"PP analysis of CSF Aβ  was consistent with the ITT analysis, as was a sensitivity analysis excluding subjects who provided CSF at the early withdrawal visit or follow-up visit (See Supplementary Table 4).",Efficacy assessments|Aβ biomarkers,[223665],[15685],[15889],[False],[0],[0],[False],['0']
38476,PMC5975052,38319,Based on model checking a number of outliers for CSF Aβ  and Aβ  were identified.,Efficacy assessments|Aβ biomarkers,[223672],[15890],[15971],[False],[0],[0],[False],['0']
38477,PMC5975052,38320,A sensitivity analysis excluding these outliers from the ITT population was also conducted and found to reduce the observed differences between treatments for both CSF Aβ  and Aβ  but still supported the overall interpretation of the ITT analysis (Supplementary Table 4).,Efficacy assessments|Aβ biomarkers,[223679],[15972],[16243],[False],[0],[0],[False],['0']
38478,PMC5975052,38321,Changes in plasma Aβ were small with no differences detected between treatment groups (Table 2).,Efficacy assessments|Aβ biomarkers,[223686],[16244],[16340],[False],[0],[0],[False],['0']
38479,PMC5975052,38322,Albumin quotient,Albumin quotient,[223693],[16341],[16358],[False],[0],[0],[False],['0']
38480,PMC5975052,38323,AlbQ was assessed as a mechanistic biomarker of BBB integrity.,Albumin quotient,[223700],[16359],[16421],[False],[0],[0],[False],['0']
38481,PMC5975052,38324,"Bayesian posterior probability that there was a true treatment difference in favor of rilapladib for AlbQ, given the observed data, was approximately 83%.",Albumin quotient,[223707],[16422],[16576],[False],[0],[0],[False],['0']
38482,PMC5975052,38325,See Table 2.,Albumin quotient,[223714],[16577],[16589],[False],[0],[0],[False],['0']
38483,PMC5975052,38326,Other disease-related biomarkers,Other disease-related biomarkers,[223721],[16590],[16623],[False],[0],[0],[False],['0']
38484,PMC5975052,38327,"T-tau and P-tau were assessed as markers of neurodegeneration and Alzheimer-specific neurodegeneration, respectively.",Other disease-related biomarkers,[223728],[16624],[16741],[False],[0],[0],[False],['0']
38485,PMC5975052,38328,NF-L was assessed as a marker of white matter damage.,Other disease-related biomarkers,[223735],[16742],[16795],[False],[0],[0],[False],['0']
38486,PMC5975052,38329,"Bayesian posterior probabilities that there was a true treatment difference in favor of rilapladib, given the observed data, were approximately 90% for T-tau and P-tau and approximately 80% for NF-L. See Table 2.",Other disease-related biomarkers,[223742],[16796],[17008],[False],[0],[0],[False],['0']
38487,PMC5975052,38330,Cognition,Cognition,[223749],[17009],[17019],[False],[0],[0],[False],['0']
38488,PMC5975052,38331,Table 3 Statistical analysis of change from baseline in cognitive data at week 24 (ITT population).,Cognition,[223756],[17020],[17119],[False],[0],[0],[False],['0']
38489,PMC5975052,38332,Inferential testing on the EF/WM composite score showed that the treatment difference at week 24 was statistically significant (P = .026).,Cognition,[223763],[17120],[17258],[False],[0],[0],[False],['0']
38490,PMC5975052,38333,"Consistent findings were observed for the overall composite score with both end points showing an effect size of >0.4 and a Bayesian posterior probability of >98% that given the observed data, the true effect size was >0.",Cognition,[223770],[17259],[17480],[False],[0],[0],[False],['0']
38491,PMC5975052,38334,Effect sizes for attention and episodic memory were smaller (Table 3).,Cognition,[223777],[17481],[17551],[False],[0],[0],[False],['0']
38492,PMC5975052,38335,Fig.,Cognition,[223784],[17552],[17556],[False],[0],[0],[False],['0']
38493,PMC5975052,38336,1 Subject disposition (safety population).,Cognition,[223791],[17557],[17599],[False],[0],[0],[False],['0']
38494,PMC5975052,38337,*One subject was randomized in error and did not receive any study treatment.,Cognition,[223798],[17600],[17677],[False],[0],[0],[False],['0']
38495,PMC5975052,38338,Two further subjects (one in each treatment group) were randomized and received treatment but withdrew before any postbaseline measurements and are therefore excluded from the ITT population.,Cognition,[223805],[17678],[17869],[False],[0],[0],[False],['0']
38496,PMC5975052,38339,"Abbreviations: AE, adverse event; ITT, intent-to-treat..",Cognition,[223812],[17870],[17926],[False],[0],[0],[False],['0']
38497,PMC5975052,38340,Fig.,Cognition,[223819],[17927],[17931],[False],[0],[0],[False],['0']
38498,PMC5975052,38341,2 Time profile of executive function/working memory composite score (adjusted mean change from baseline in Z score ± 95% confidence intervals [MMRM analysis]).,Cognition,[223826],[17932],[18091],[False],[0],[0],[False],['0']
38499,PMC5975052,38342,"Abbreviation: MMRM, mixed model repeated measures..",Cognition,[223833],[18092],[18143],[False],[0],[0],[False],['0']
38500,PMC5975052,38343,The time profile for the EF/WM composite is shown in Fig.,Cognition,[223840],[18144],[18201],[False],[0],[0],[False],['0']
38501,PMC5975052,38344,2.,Cognition,[223847],[18202],[18204],[False],[0],[0],[False],['0']
38502,PMC5975052,38345,The profile for other composite scores was similar.,Cognition,[223854],[18205],[18256],[False],[0],[0],[False],['0']
38503,PMC5975052,38346,PP analysis of CogState EF/WM was consistent with the ITT analysis.,Cognition,[223861],[18257],[18324],[False],[0],[0],[False],['0']
38504,PMC5975052,38347,A number of ad hoc sensitivity analyses were performed on the cognitive data to explore the impact of missing data; these analyses supported the interpretation of the ITT analysis (see Supplementary Table 5 for further details).,Cognition,[223868],[18325],[18553],[False],[0],[0],[False],['0']
38505,PMC5975052,38348,"In addition to the treatment by baseline covariate interaction testing performed for the two primary end points, interaction graphics were produced to explore the relationship between baseline CSF Aβ  and the change from baseline in CogState executive function/working memory.",Cognition,[223875],[18554],[18830],[False],[0],[0],[False],['0']
38506,PMC5975052,38349,None of these interactions were significant; further visual inspection of the interaction graphs did not suggest that baseline Aβ  impacted the level of response to rilapladib.,Cognition,[223882],[18831],[19007],[False],[0],[0],[False],['0']
38507,PMC5975052,38350,Safety and tolerability,Safety and tolerability,[223889],[19008],[19032],[False],[0],[0],[False],['0']
38508,PMC5975052,38351,Table 4 Summary of on treatment AEs occurring in ≥5%∗ of subjects (safety population).,Safety and tolerability,[223896],[19033],[19119],[False],[0],[0],[False],['0']
38509,PMC5975052,38352,On-treatment AEs were reported by 63% of placebo subjects and 64% of rilapladib subjects.,Safety and tolerability,[223903],[19120],[19209],[False],[0],[0],[False],['0']
38510,PMC5975052,38353,Most AEs were of mild-to-moderate intensity.,Safety and tolerability,[223910],[19210],[19254],[False],[0],[0],[False],['0']
38511,PMC5975052,38354,Most common AEs are summarized in Table 4.,Safety and tolerability,[223917],[19255],[19297],[False],[0],[0],[False],['0']
38512,PMC5975052,38355,The incidence of AEs where investigators determined there was a reasonable possibility of a relationship to study drug was 15% in each treatment group.,Safety and tolerability,[223924],[19298],[19449],[False],[0],[0],[False],['0']
38513,PMC5975052,38356,More rilapladib subjects reported a serious adverse event (SAE; eight subjects [13%]) than placebo (five subjects [8%]).,Safety and tolerability,[223931],[19450],[19570],[False],[0],[0],[False],['0']
38514,PMC5975052,38357,No individual SAE was reported by more than one subject.,Safety and tolerability,[223938],[19571],[19627],[False],[0],[0],[False],['0']
38515,PMC5975052,38358,Two deaths occurred.,Safety and tolerability,[223945],[19628],[19648],[False],[0],[0],[False],['0']
38516,PMC5975052,38359,"One subject in the rilapladib group died of a cerebral hemorrhage, 125 days after starting drug and 8 days after their last dose.",Safety and tolerability,[223952],[19649],[19778],[False],[0],[0],[False],['0']
38517,PMC5975052,38360,One subject in the placebo group completed the 24-week treatment period and died of pulmonary embolism 23 days later.,Safety and tolerability,[223959],[19779],[19896],[False],[0],[0],[False],['0']
38518,PMC5975052,38361,See Supplementary Table 6 for further details.,Safety and tolerability,[223966],[19897],[19943],[False],[0],[0],[False],['0']
38519,PMC5975052,38362,Table 5 Summary of SAEs and AEs leading to withdrawal (safety population).,Safety and tolerability,[223973],[19944],[20018],[False],[0],[0],[False],['0']
38520,PMC5975052,38363,More rilapladib subjects had an AE leading to withdrawal (seven subjects [11%]) than placebo (two subjects [3%]; Table 5).,Safety and tolerability,[223980],[20019],[20141],[False],[0],[0],[False],['0']
38521,PMC5975052,38364,"Mean changes in hematology, clinical chemistry, urinalysis, vital signs, and ECG parameters were generally small and comparable across treatment groups with no excess of clinically significant changes on rilapladib compared to placebo.",Safety and tolerability,[223987],[20142],[20377],[False],[0],[0],[False],['0']
38522,PMC5975052,38365,There was no evidence of phospholipidosis as evaluated by eye examinations and electron microscopy of peripheral blood lymphocytes.,Safety and tolerability,[223994],[20378],[20509],[False],[0],[0],[False],['0']
38523,PMC5975052,38366,Discussion,Discussion,[224001],[20510],[20521],[False],[0],[0],[False],['0']
38524,PMC5975052,38367,"The aim of this exploratory study was to assess whether evidence of the findings from nonclinical studies could be detected in a relevant AD population and to test the hypothesis that rilapladib, through restoration of BBB integrity (i.e., a reduced AlbQ), would affect downstream markers of Aβ metabolism (i.e., CSF and plasma Aβ), neurodegeneration (i.e., tau, P-tau, and NF-L) and cognition.",Discussion,[224008],[20522],[20916],[False],[0],[0],[False],['0']
38525,PMC5975052,38368,The study demonstrated an improved outcome on cognition with rilapladib.,Discussion,[224015],[20917],[20989],[False],[0],[0],[False],['0']
38526,PMC5975052,38369,There was no biomarker evidence supporting an effect of Lp-PLA  inhibition on Aβ.,Discussion,[224022],[20990],[21071],[False],[0],[0],[False],['0']
38527,PMC5975052,38370,"The study also provided preliminary evidence of directionally consistent, effects on AlbQ and all the measured neurodegenerative biomarkers, although the confidence intervals of differences between treatments encompassed zero.",Discussion,[224029],[21072],[21298],[False],[0],[0],[False],['0']
38528,PMC5975052,38371,"The study, therefore, provides partial translational support for the nonclinical observations [10].",Discussion,[224036],[21299],[21398],[False],[0],[0],[False],['0']
38529,PMC5975052,38372,"However, given the atypical nature of the preclinical model, the findings on cognition and neurodegenerative markers in this present study provide a rationale for the further evaluation of this novel mechanism.",Discussion,[224043],[21399],[21609],[False],[0],[0],[False],['0']
38530,PMC5975052,38373,"The plasma PKs and pharmacodynamics of rilapladib were similar to that observed in a previous clinical study in atherosclerosis [6] with plasma Lp-PLA  activity reduced by approximately 80% and to a level consistent with the effects observed in the nonclinical model [1], [10].",Discussion,[224050],[21610],[21887],[False],[0],[0],[False],['0']
38531,PMC5975052,38374,Two germane features of the study population are the inclusion of subjects with a clinical diagnosis of possible AD and the requirement for neuroimaging evidence of significant CVD.,Discussion,[224057],[21888],[22069],[False],[0],[0],[False],['0']
38532,PMC5975052,38375,"Examination of baseline CSF profiles of Aβ , tau, and P-tau indicated that approximately 50% of these subjects met the assay thresholds for AD.",Discussion,[224064],[22070],[22213],[False],[0],[0],[False],['0']
38533,PMC5975052,38376,This may reflect the early stage of the disease and/or an impact of cerebrovascular lesions on the presenting dementia.,Discussion,[224071],[22214],[22333],[False],[0],[0],[False],['0']
38534,PMC5975052,38377,"Although amyloid scans were not performed, the baseline CSF Aβ  profile indicates that approximately 60% of the study population may have been amyloid positive.",Discussion,[224078],[22334],[22494],[False],[0],[0],[False],['0']
38535,PMC5975052,38378,"Exploratory interaction testing, for the two primary end points, did not suggest that baseline Aβ  impacts the level of treatment response.",Discussion,[224085],[22495],[22634],[False],[0],[0],[False],['0']
38536,PMC5975052,38379,"This may indicate that the effect of rilapladib on cognition is not dependent on the presence of cerebral amyloidosis, although this will require further review after larger studies in a similar dementia population.",Discussion,[224092],[22635],[22850],[False],[0],[0],[False],['0']
38537,PMC5975052,38380,"The neuroimaging evidence (i.e., white matter abnormalities and lacunes) required for the study is typical of those associated with SVD, as it was hypothesized that this may have increased the potential to detect treatment effects because of the pathologic changes associated with these lesions (e.g., increased BBB permeability and extravasation of plasma components into the brain) reflecting the changes in the nonclinical model [10].",Discussion,[224099],[22851],[23288],[False],[0],[0],[False],['0']
38538,PMC5975052,38381,The neuroimaging evidence associated with the study population was largely related to white matter changes (approximately 90%).,Discussion,[224106],[23289],[23416],[False],[0],[0],[False],['0']
38539,PMC5975052,38382,No further information was collected regarding the nature of the cerebrovascular disease.,Discussion,[224113],[23417],[23506],[True],['RelevantOutcomeExcluded'],['No further information was collected regarding the nature of the cerebrovascular disease'],[True],['OutcomeMeasures']
38540,PMC5975052,38383,"Consequently, it is a recognised weakness of the study that it is not possible to further examine the data to understand the relationship of the underlying CVD pathology of the dementia to any effect of rilapladib.",Discussion,[224128],[23507],[23721],[True],['OutcomeMeasures'],['it is not possible to further examine the data to understand the relationship of the underlying CVD pathology of the dementia to any effect of rilapladib'],[True],['OutcomeMeasures']
38541,PMC5975052,38384,Future studies should seek to address these questions.,Discussion,[224141],[23722],[23776],[False],[0],[0],[False],['0']
38542,PMC5975052,38385,"A bespoke cognitive battery targeting the domains of executive function, working memory, attention, and episodic memory was used to maximize the possibility of identifying a placebo decline and a treatment response in this small, short duration study.",Discussion,[224148],[23777],[24028],[False],[0],[0],[False],['0']
38543,PMC5975052,38386,An EF/WM composite was the primary comparison of interest within the cognitive battery based on its relevance to the study population [26].,Discussion,[224155],[24029],[24168],[False],[0],[0],[False],['0']
38544,PMC5975052,38387,"By week 24, decline in cognition was evident across the composite scores assessed for placebo but not for rilapladib.",Discussion,[224162],[24169],[24286],[False],[0],[0],[False],['0']
38545,PMC5975052,38388,"This effect on cognition is noteworthy as it was achieved in addition to stable symptomatic therapy, and it was the maximum achievable under the constraints of the study design for a mechanism that may slow disease progression and not anticipated to be procognitive.",Discussion,[224169],[24287],[24553],[False],[0],[0],[False],['0']
38546,PMC5975052,38389,This profile was supported by the absence of procognitive effects at 12 weeks.,Discussion,[224176],[24554],[24632],[False],[0],[0],[False],['0']
38547,PMC5975052,38390,"The effects on CSF neurodegenerative markers are encouraging with 80%–90% Bayesian posterior probabilities that, given the observed data, at this early time point there was a true difference between treatments.",Discussion,[224183],[24633],[24843],[False],[0],[0],[False],['0']
38548,PMC5975052,38391,"Tau and P-tau are considered measures of neuronal damage and neurodegeneration, and both biomarkers are increased early in the disease and remain elevated during the course of the disease [27].",Discussion,[224190],[24844],[25037],[False],[0],[0],[False],['0']
38549,PMC5975052,38392,"NF-L was assessed as an exploratory measure of white matter (axonal) damage, as it has been reported to be increased in some forms of dementia with subcortical involvement [28] and in demyelinating diseases, such as multiple sclerosis where treatment-related reductions in this marker have been noted [29].",Discussion,[224197],[25038],[25344],[False],[0],[0],[False],['0']
38550,PMC5975052,38393,The consistent directional pattern of changes in the disease-related biomarkers in the present study is supportive of the cognitive findings and suggests the potential for an underlying slowing of the progression of the disease [27].,Discussion,[224204],[25345],[25578],[False],[0],[0],[False],['0']
38551,PMC5975052,38394,The underlying mechanism behind these changes is not certain as the study provided only partial support to the nonclinical observations in the pig model [10].,Discussion,[224211],[25579],[25737],[False],[0],[0],[False],['0']
38552,PMC5975052,38395,The small decrease in AlbQ is supportive of a reduction in BBB permeability but it is unclear whether the magnitude of the change is clinically significant.,Discussion,[224218],[25738],[25894],[False],[0],[0],[False],['0']
38553,PMC5975052,38396,"Although a number of studies have reported increases in BBB permeability in AD, vascular forms of dementia and SVD, there are limited data on longitudinal changes and their impact on disease progression [30].",Discussion,[224225],[25895],[26103],[False],[0],[0],[False],['0']
38554,PMC5975052,38397,"Additional supporting evidence of an effect of LpPLA  inhibition on reducing the permeability of CNS barriers has been provided from the investigation of the structurally related compound darapladib (SB480848) in a phase 2a study of diabetic macular edema patients (Clinicaltrials.gov identifier: NCT01506895), which demonstrated treatment-related reductions in macular edema [31].",Discussion,[224232],[26104],[26485],[False],[0],[0],[False],['0']
38555,PMC5975052,38398,The observed effects on CSF and plasma Aβ are not supportive of an effect of rilapladib on Aβ metabolism.,Discussion,[224239],[26486],[26591],[False],[0],[0],[False],['0']
38556,PMC5975052,38399,"This may reflect the insensitivity of the Aβ-related measures used in the present study, a lack of translation from the nonclinical model or a more dominant role of the cerebrovascular mechanisms on the observed treatment responses.",Discussion,[224252],[26592],[26824],[True],['ResponsivenessOfMeasurement'],['the insensitivity of the Aβ-related measures used in the present study'],[True],['OutcomeMeasures']
38557,PMC5975052,38400,Rilapladib was generally well tolerated in this study although there were a greater number of subjects with SAEs and a greater number of subjects who withdrew due to AEs.,Discussion,[224260],[26825],[26995],[False],[0],[0],[False],['0']
38558,PMC5975052,38401,One subject died in each treatment group.,Discussion,[224267],[26996],[27037],[False],[0],[0],[False],['0']
38559,PMC5975052,38402,"No SAE was experienced by more than one subject, and there was no obvious pattern associated with the SAEs.",Discussion,[224274],[27038],[27145],[False],[0],[0],[False],['0']
38560,PMC5975052,38403,"A number of the AEs leading to withdrawal in the rilapladib group were psychiatric events (agitation, anxiety, confusion, and disorientation).",Discussion,[224281],[27146],[27288],[False],[0],[0],[False],['0']
38561,PMC5975052,38404,"These events did not individually lead to withdrawal in more than one subject in the rilapladib group, and they were experienced as frequently by subjects in the placebo group but did not lead to withdrawal.",Discussion,[224288],[27289],[27496],[False],[0],[0],[False],['0']
38562,PMC5975052,38405,"Given the small size of the study and the correspondingly small number of events, it is not possible to draw wider conclusions on these findings and this will need to be monitored in future studies.",Discussion,"[224297, 224298]","[27497, 27497]","[27695, 27695]","[True, True]","['SampleSize', 'UnderpoweredStudy']","['the small size', 'small number of events']","[True, True]",['UnderpoweredStudy']
38563,PMC5975052,38406,"Although these findings are encouraging, a note of caution is required.",Discussion,[224309],[27696],[27767],[False],[0],[0],[False],['0']
38564,PMC5975052,38407,This is the first study to investigate Lp-PLA  inhibition in AD.,Discussion,[224316],[27768],[27832],[False],[0],[0],[False],['0']
38565,PMC5975052,38408,"Replication of data in AD has been notoriously difficult in recent years particularly for disease-modifying compounds and particularly when moving from small, experimental phase 2 studies to longer term clinical studies.",Discussion,[224323],[27833],[28053],[False],[0],[0],[False],['0']
38566,PMC5975052,38409,The study was a small study of short duration and was not intended to definitively determine the likelihood of long-term benefit.,Discussion,"[224334, 224335]","[28054, 28054]","[28183, 28183]","[True, True]","['SampleSize', 'ExperimentalPhaseDuration']","['The study was a small study', 'short duration']","[True, True]","['UnderpoweredStudy', 'StudyDuration']"
38567,PMC5975052,38410,Important next steps to build on the findings here will be to more fully understand the mechanism and its relationship to different segments of the dementia population; to further evaluate the cognitive profile over a longer time course and across a wider range of domains; and to assess the impact on other clinically established outcomes such as function and quality of life.,Discussion,[224344],[28184],[28561],[False],[0],[0],[False],['0']
38568,PMC5975052,38411,"As a whole, the findings provide initial evidence supportive that rilapladib and inhibition of Lp-PLA  may have the potential to slow the progression of AD and alter the underlying pathology in a subpopulation of AD patients with neuroimaging evidence of CVD.1.Systematic review: Changes to the neurovascular unit are an increasingly recognised pathologic feature of Alzheimer's disease, which may be linked to changes in amyloid beta peptide (Aβ) metabolism in the brain.",Discussion,[224351],[28562],[29034],[False],[0],[0],[False],['0']
38569,PMC5975052,38412,Findings from a nonclinical model suggested that inhibition of lipoprotein phospholipase A2 (Lp-PLA2) might provide therapeutic benefit through effects on the blood-brain barrier (BBB) and (Aβ).,Discussion,[224358],[29035],[29229],[False],[0],[0],[False],['0']
38570,PMC5975052,38413,"An exploratory study was designed to examine whether these nonclinical findings were translatable using a subgroup of AD patients with neuroimaging evidence of cerebrovascular disease through the use of a targeted battery of mechanism based and disease-related biomarkers and cognitive tests.2.Interpretation: A consistent pattern of improved cognitive outcomes was observed across all assessed domains, which was statistically significant on the Executive Function/Working Memory composite score compared to placebo.",Discussion,[224365],[29230],[29747],[False],[0],[0],[False],['0']
38571,PMC5975052,38414,"Although there was no biomarker evidence supporting an effect of Lp-PLA2 inhibition on any of the Aβ-related mechanism-based biomarkers, there was preliminary evidence of directionally consistent effects on BBB permeability (i.e., albumin quotient) and neurodegenerative biomarkers (i.e., tau, P-tau, and neurofilament light chain).",Discussion,[224372],[29748],[30080],[False],[0],[0],[False],['0']
38572,PMC5975052,38415,"Together these findings provide preliminary evidence that Lp-PLA2 inhibition may play a role in reducing BBB permeability, which may lead to an effect on the underlying disease process.",Discussion,[224379],[30081],[30266],[False],[0],[0],[False],['0']
38573,PMC5975052,38416,"It is uncertain at this point whether Aβ plays a role in this mechanism.3.Future directions: Although the study provides preliminary evidence that rilapladib and inhibition of Lp-PLA2 may have the potential to slow the progression of AD, these findings require replication and extension in longer term clinical trials to fully evaluate the safety and therapeutic potential of Lp-PLA2 inhibition as a treatment approach for AD..",Discussion,[224386],[30267],[30694],[False],[0],[0],[False],['0']
38574,PMC5975052,38417,"Systematic review: Changes to the neurovascular unit are an increasingly recognised pathologic feature of Alzheimer's disease, which may be linked to changes in amyloid beta peptide (Aβ) metabolism in the brain.",Discussion,[224393],[30695],[30906],[False],[0],[0],[False],['0']
38575,PMC5975052,38418,Findings from a nonclinical model suggested that inhibition of lipoprotein phospholipase A2 (Lp-PLA2) might provide therapeutic benefit through effects on the blood-brain barrier (BBB) and (Aβ).,Discussion,[224400],[30907],[31101],[False],[0],[0],[False],['0']
38576,PMC5975052,38419,An exploratory study was designed to examine whether these nonclinical findings were translatable using a subgroup of AD patients with neuroimaging evidence of cerebrovascular disease through the use of a targeted battery of mechanism based and disease-related biomarkers and cognitive tests..,Discussion,[224407],[31102],[31395],[False],[0],[0],[False],['0']
38577,PMC5975052,38420,"Interpretation: A consistent pattern of improved cognitive outcomes was observed across all assessed domains, which was statistically significant on the Executive Function/Working Memory composite score compared to placebo.",Discussion,[224414],[31396],[31619],[False],[0],[0],[False],['0']
38578,PMC5975052,38421,"Although there was no biomarker evidence supporting an effect of Lp-PLA2 inhibition on any of the Aβ-related mechanism-based biomarkers, there was preliminary evidence of directionally consistent effects on BBB permeability (i.e., albumin quotient) and neurodegenerative biomarkers (i.e., tau, P-tau, and neurofilament light chain).",Discussion,[224421],[31620],[31952],[False],[0],[0],[False],['0']
38579,PMC5975052,38422,"Together these findings provide preliminary evidence that Lp-PLA2 inhibition may play a role in reducing BBB permeability, which may lead to an effect on the underlying disease process.",Discussion,[224428],[31953],[32138],[False],[0],[0],[False],['0']
38580,PMC5975052,38423,"It is uncertain at this point whether Aβ plays a role in this mechanism.. Future directions: Although the study provides preliminary evidence that rilapladib and inhibition of Lp-PLA2 may have the potential to slow the progression of AD, these findings require replication and extension in longer term clinical trials to fully evaluate the safety and therapeutic potential of Lp-PLA2 inhibition as a treatment approach for AD.",Discussion,[224435],[32139],[32565],[False],[0],[0],[False],['0']
38581,PMC5975052,38424,Supplementary data,Supplementary data,[224442],[32566],[32586],[False],[0],[0],[False],['0']
38582,PMC5975052,38425,Supplementary Material and Supplementary Tables 1–6Acknowledgments,Supplementary data,[224449],[32587],[32653],[False],[0],[0],[False],['0']
38583,PMC5975052,38426,The authors thank the study investigators and staff at each center and the subjects and caregivers who participated in the study.,Supplementary data,[224456],[32654],[32783],[False],[0],[0],[False],['0']
38584,PMC5975052,38427,"GlaxoSmithKline(China) R&D Company Limited, Halei Road, Shanghai, China provided funding for design and conduct of this study, the collection, management, analysis, and interpretation of the data, and coordination of the preparation and review of the manuscript.",Supplementary data,[224463],[32784],[33046],[False],[0],[0],[False],['0']
38585,PMC5975052,38428,"Study investigators: Bulgaria: L Traykov; Canada: S Cohen; Germany: W Albrecht, K Hager, T Lauter, T Leyhe, A Mahler, G Nelles, A Safavi, I Schoell, A Siever, and C von Arnim; Italy: G Bruno, S Milleri, P Odetti, E Scarpini, and O Zanetti; Spain: M Boada Rovira, MT Carreras Rodriguez, M Fernández Martínez, J Gascón Bayarri, MD Martínez Lozano, and R Petidier Torregosa; Sweden: N Andreasen.All authors are employees of GlaxoSmithKline and receive payment and stock remuneration as part of that employment, but have no other financial interests or conflicts of interest.Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.trci.2015.06.003.",Supplementary data,[224470],[33047],[33722],[False],[0],[0],[False],['0']
39384,PMC6082539,31527,Erectile dysfunction in obstructive sleep apnea patients: A randomized trial on the effects of Continuous Positive Airway Pressure (CPAP),Title,[188811],[26343],[137],[False],[0],[0],[False],['0']
39385,PMC6082539,31528,Objectives,Abstract,[188824],[138],[149],[False],[0],[0],[False],['0']
39386,PMC6082539,31529,Obstructive sleep apnea (OSA) is among the least studied risk factors for erectile dysfunction (ED).,Abstract,[188837],[150],[250],[False],[0],[0],[False],['0']
39387,PMC6082539,31530,"We aimed to determine ED prevalence in newly-diagnosed OSA patients, describe their main characteristics and assess continuous positive airway pressure (CPAP) effects on ED.",Abstract,[188850],[251],[424],[False],[0],[0],[False],['0']
39388,PMC6082539,31531,Methods,Methods,[188863],[425],[433],[False],[0],[0],[False],['0']
39389,PMC6082539,31532,"Cross-sectional study assessing ED prevalence in OSA patients and open-label, parallel, prospective randomized controlled trial evaluating 3-month CPAP treatment effects on sexual function, satisfaction, and psychological, hormonal and biochemical profiles.",Methods,[188876],[434],[691],[False],[0],[0],[False],['0']
39390,PMC6082539,31533,"Male patients newly diagnosed with moderate/severe OSA (apnea-hypopnea index >20 events·h−1), aged 18–70 years, attending the sleep unit of a Spanish hospital during 2013–2016 were considered.",Methods,[188889],[692],[884],[False],[0],[0],[False],['0']
39391,PMC6082539,31534,A total of 150 patients were recruited (75 randomized ED patients).,Methods,[188902],[885],[952],[False],[0],[0],[False],['0']
39392,PMC6082539,31535,ED was defined as scores <25 on International Index Erectile Function 15 test.,Methods,[188915],[953],[1031],[False],[0],[0],[False],['0']
39393,PMC6082539,31536,Wilcoxon’s matched-pairs signed-ranks and rank-sum tests were used.,Methods,[188928],[1032],[1099],[False],[0],[0],[False],['0']
39394,PMC6082539,31537,Results,Results,[188941],[1100],[1108],[False],[0],[0],[False],['0']
39395,PMC6082539,31538,ED prevalence was 51%.,Results,[188954],[1109],[1131],[False],[0],[0],[False],['0']
39396,PMC6082539,31539,"Patients with ED were older (p<0.001), had greater waist-to-hip ratios (p<0.001), were more frequently undergoing pharmacological treatment (p<0.001) and had higher glucose levels (p = 0.024) than non-ED patients.",Results,[188967],[1132],[1345],[False],[0],[0],[False],['0']
39397,PMC6082539,31540,"Although significant increases in erectile function (mean(SD) change: +4.6(7.9); p = 0.002), overall satisfaction (+1(2.2); p = 0.035), and sexual satisfaction (+2.1(4.3); p = 0.003) were found after CPAP treatment, only differences in sexual satisfaction (p = 0.027) and erectile function (p = 0.060) were found between study arms.",Results,[188980],[1346],[1678],[False],[0],[0],[False],['0']
39398,PMC6082539,31541,"CPAP treatment did not impact psychological, hormonal or biochemical profiles.",Results,[188993],[1679],[1757],[False],[0],[0],[False],['0']
39399,PMC6082539,31542,Conclusions,Conclusions,[189006],[1758],[1770],[False],[0],[0],[False],['0']
39400,PMC6082539,31543,"This study confirmed the relationship between OSA and ED, suggesting the potential usefulness of ED screening in OSA patients, but could not determine conclusively whether CPAP is an effective stand-alone ED treatment, regardless of positive results on sexual satisfaction.",Conclusions,[189019],[1771],[2044],[False],[0],[0],[False],['0']
39401,PMC6082539,31544,Trial registration,Trial registration,[189032],[2045],[2064],[False],[0],[0],[False],['0']
39402,PMC6082539,31545,ClinicalTrials.gov NCT03086122,Trial registration,[189045],[2065],[2095],[False],[0],[0],[False],['0']
39403,PMC6082539,31546,Introduction,Introduction,[189058],[2096],[2110],[False],[0],[0],[False],['0']
39404,PMC6082539,31547,"Obstructive sleep apnea (OSA), defined as the presence of repetitive episodes of upper airway collapse during sleep, is a common chronic condition affecting 10% of middle-aged men [1].",Introduction,[189071],[2111],[2295],[False],[0],[0],[False],['0']
39405,PMC6082539,31548,"Although OSA can be asymptomatic, it is usually characterized by intermittent hypoxia, daytime sleepiness, and an overall decrease in quality of life.",Introduction,[189084],[2296],[2446],[False],[0],[0],[False],['0']
39406,PMC6082539,31549,"OSA has been related to many pathologies, such as cardiovascular diseases [2], stroke [3] and hypertension [4].",Introduction,[189097],[2447],[2558],[False],[0],[0],[False],['0']
39407,PMC6082539,31550,"Interestingly, the vascular implications of recurrent airway obstruction, intermittent hypoxemia and arousal from sleep, together with OSA-induced hormonal and psychological changes, have been suggested to increase the risk for erectile dysfunction (ED) [5–7].",Introduction,[189110],[2559],[2819],[False],[0],[0],[False],['0']
39408,PMC6082539,31551,"ED, defined as the persistent inability to attain and maintain an erection sufficient to allow for satisfactory sexual performance [8], is a frequent phenomenon estimated to be present in 20% of men aged 30–70 years old, with a steep age-related increase in prevalence [9–11].",Introduction,[189123],[2820],[3096],[False],[0],[0],[False],['0']
39409,PMC6082539,31552,"However, ED prevalence has been described as being as high as 69% among OSA patients [7], and in such patients, ED is considered to be a risk factor for future cardiovascular complications.",Introduction,[189136],[3097],[3286],[False],[0],[0],[False],['0']
39410,PMC6082539,31553,"Few studies to date have assessed whether continuous positive airway pressure (CPAP) treatment, one of the therapeutic options for OSA, could improve ED in OSA patients.",Introduction,[189149],[3287],[3456],[False],[0],[0],[False],['0']
39411,PMC6082539,31554,"Two reviews of the subject analyzing data through December 2014 concluded that although CPAP could improve sexual function and sexual satisfaction, randomized controlled trials (RCTs) were needed to confirm these potential benefits [12,13].",Introduction,[189162],[3457],[3697],[False],[0],[0],[False],['0']
39412,PMC6082539,31555,"To increase knowledge on OSA-related ED, we first designed a cross-sectional study assessing ED prevalence in newly diagnosed OSA patients, comparing the hormonal, biological and psychological profiles of OSA patients with and without ED.",Introduction,[189175],[3698],[3936],[False],[0],[0],[False],['0']
39413,PMC6082539,31556,"Next, with the hypothesis that CPAP treatment could effectively reverse OSA-related ED, improving sexual function, hormonal profiles and sexual satisfaction, we designed an RCT randomizing OSA patients with ED to receive CPAP treatment or not.",Introduction,[189188],[3937],[4180],[False],[0],[0],[False],['0']
39414,PMC6082539,31557,Methods,Methods,[189201],[4181],[4189],[False],[0],[0],[False],['0']
39415,PMC6082539,31558,Study design and population,Methods|Study design and population,[189214],[4190],[4217],[False],[0],[0],[False],['0']
39416,PMC6082539,31559,"Cross-sectional study considering consecutive male patients newly diagnosed with moderate to severe OSA, aged 18 to 70 years and in a current relationship who were attending the sleep unit of Hospital Univ Arnau de Vilanova-Santa Maria, Spain, between April 1st 2013 and July 31th 2016.",Methods|Study design and population,[189227],[4218],[4504],[False],[0],[0],[False],['0']
39417,PMC6082539,31560,"Followed by an open-label, parallel, prospective RCT, including only those OSA patients that were diagnosed of ED, with a 3-month follow-up ending between September 1st 2013 and September 30th 2016.",Methods|Study design and population,[189240],[4505],[4703],[False],[0],[0],[False],['0']
39418,PMC6082539,31561,"Exclusion criteria: previous CPAP treatment; previously diagnosed sleep disorders; patients with >50% central apneas; Cheyne-Stokes respiration; daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS) score >10 (S1 Questionnaires); psychophysical inability to complete questionnaires; uncontrolled or advanced chronic diseases (cardiovascular disease, multiple sclerosis, Parkinson's disease, spinal disc disease, schizophrenia, bipolar disorder, chronic renal failure and inflammatory bowel disease); pelvic surgery (radical prostatectomy); congenital or acquired malformations (Peyronie's disease, hypospadias, epispadias, and penile fracture); hormonal alterations (hypogonadism, hyperprolactinemia, hyper- or hypothyroidism, and Cushing's disease); and drug abuse (alcohol, cocaine, and heroin).",Methods|Study design and population,[189253],[4704],[5516],[False],[0],[0],[False],['0']
39419,PMC6082539,31562,"OSA patients fulfilling inclusion criteria were referred to the Urology Department, where they were informed about the project and asked to participate.",Methods|Study design and population,[189266],[5517],[5669],[False],[0],[0],[False],['0']
39420,PMC6082539,31563,Recruited patients were assessed for ED and answered to the study questionnaires.,Methods|Study design and population,[189279],[5670],[5751],[False],[0],[0],[False],['0']
39421,PMC6082539,31564,"Web-based randomization of the ED patients (non-ED patients did not participate in the RCT) was performed using a secure, automated, password-protected system based on a permuted block design with a computer random number generator and a fixed block size of 10.",Methods|Study design and population,[189292],[5752],[6013],[False],[0],[0],[False],['0']
39422,PMC6082539,31565,Allocation was revealed only at the time of each subject randomization.,Methods|Study design and population,[189305],[6014],[6085],[False],[0],[0],[False],['0']
39423,PMC6082539,31566,No blinding measures were implemented.,Methods|Study design and population,[189318],[6086],[6124],[False],[0],[0],[False],['0']
39424,PMC6082539,31567,The ED patients were randomly assigned at a 1:1 ratio to immediately begin CPAP treatment (ED CPAP group) or to postpone CPAP treatment for 3 months (ED non-CPAP group).,Methods|Study design and population,[189331],[6125],[6294],[False],[0],[0],[False],['0']
39425,PMC6082539,31568,"Afterwards, the recruited patients returned to the sleep unit for additional measurements and CPAP titration when required.",Methods|Study design and population,[189344],[6295],[6418],[False],[0],[0],[False],['0']
39426,PMC6082539,31569,"All of the patients included in the RCT were followed up for 3 months and were reassessed in terms of ED-related clinical, biological and psychological aspects.",Methods|Study design and population,[189357],[6419],[6579],[False],[0],[0],[False],['0']
39427,PMC6082539,31570,The ethics committee of Hospital Univ Arnau de Vilanova approved the study (CEIC-996; Mar.,Methods|Study design and population,[189370],[6580],[6670],[False],[0],[0],[False],['0']
39428,PMC6082539,31571,"27th 2012), and all patients provided written informed consent.",Methods|Study design and population,[189383],[6671],[6734],[False],[0],[0],[False],['0']
39429,PMC6082539,31572,The RCT was registered at ClinicalTrials.gov (NCT03086122).,Methods|Study design and population,[189396],[6735],[6794],[False],[0],[0],[False],['0']
39430,PMC6082539,31573,"Unfortunately, although the authors believed the trial to be registered on 2012, a successful registration was not achieved before the inclusion of the first patient due to administrative mistakes.",Methods|Study design and population,[189409],[6795],[6992],[False],[0],[0],[False],['0']
39431,PMC6082539,31574,"Nevertheless, this study was performed according to the protocol submitted for ethical review on Mar.",Methods|Study design and population,[189422],[6993],[7094],[False],[0],[0],[False],['0']
39432,PMC6082539,31575,2012.,Methods|Study design and population,[189435],[7095],[7100],[False],[0],[0],[False],['0']
39433,PMC6082539,31576,The authors confirm that all ongoing and related trials for this intervention are registered.,Methods|Study design and population,[189448],[7101],[7194],[False],[0],[0],[False],['0']
39434,PMC6082539,31577,Data collection,Data collection,[189461],[7195],[7211],[False],[0],[0],[False],['0']
39435,PMC6082539,31578,"OSA was defined by means of a valid complete polysomnography reporting an apnea–hypopnea index (AHI) >20 events·h−1 with ≤50% of central apneas, according to the Spanish Respiratory Society (SEPAR) guidelines [14].",Data collection,[189474],[7212],[7426],[False],[0],[0],[False],['0']
39436,PMC6082539,31579,Obstructive apnea was defined as an absence or reduction (>90%) of airflow lasting ⩾10 s in presence of abdominal and thoracic movements.,Data collection,[189487],[7427],[7564],[False],[0],[0],[False],['0']
39437,PMC6082539,31580,"Obstructive hypopnoea was defined as a reduction (30% to 90%) in airflow lasting ⩾10 s associated with a decrease in arterial oxygen saturation ⩾3% and/or a micro-awakening on the electroencephalogram, in presence of both thoracic and abdominal movements.",Data collection,[189500],[7565],[7820],[False],[0],[0],[False],['0']
39438,PMC6082539,31581,The AHI was defined as the number of episodes of apnea and hypopnea per hour of recording.,Data collection,[189513],[7821],[7911],[False],[0],[0],[False],['0']
39439,PMC6082539,31582,Central apneas were defined as an absence airflow lasting at least 10 s in absence of thoracic and abdominal wall movements.,Data collection,[189526],[7912],[8036],[False],[0],[0],[False],['0']
39440,PMC6082539,31583,A minimum of 3 hours of satisfactory signal recording was required to consider the test as valid.,Data collection,[189539],[8037],[8134],[False],[0],[0],[False],['0']
39441,PMC6082539,31584,"CPAP titration was performed using an auto-CPAP device (Autoset-T, ResMed, Sydney, Australia) as previously validated by the Spanish Sleep and Breathing Group [15].",Data collection,[189552],[8135],[8299],[False],[0],[0],[False],['0']
39442,PMC6082539,31585,Up to two additional night recordings were attempted if the original recording was unacceptable.,Data collection,[189565],[8300],[8396],[False],[0],[0],[False],['0']
39443,PMC6082539,31586,"The determination of the optimal pressure was assessed by visually analyzing the pressure curve, which included the periods with a leak lower than 0.4 L/s (90th centile).",Data collection,[189578],[8397],[8567],[False],[0],[0],[False],['0']
39444,PMC6082539,31587,At-home treatment was initiated with a fixed CPAP level after the optimal pressure was determined.,Data collection,[189591],[8568],[8666],[False],[0],[0],[False],['0']
39445,PMC6082539,31588,"ED was assessed by means of the International Index Erectile Function 15 (IIEF15) test [16], in its Spanish version [17], which allows for the assessment of sexual function broadly encompassing erectile function, orgasmic function, sexual desire, sexual satisfaction and overall satisfaction (S1 Questionnaires).",Data collection,[189604],[8667],[8979],[False],[0],[0],[False],['0']
39446,PMC6082539,31589,The test was administered by a Urology department physician.,Data collection,[189617],[8980],[9040],[False],[0],[0],[False],['0']
39447,PMC6082539,31590,Patients were classified as having ED when their erectile function domain score was less than 25 points.,Data collection,[189630],[9041],[9145],[False],[0],[0],[False],['0']
39448,PMC6082539,31591,"Sociodemographic variables, as well as lifestyle habits, clinical background and usual pharmacological treatment, were recorded using questionnaires.",Data collection,[189643],[9146],[9295],[False],[0],[0],[False],['0']
39449,PMC6082539,31592,"Anthropometric measurements included weight; height; body mass index (BMI); neck, waist and hip circumferences; and waist to hip ratio (WHR).",Data collection,[189656],[9296],[9437],[False],[0],[0],[False],['0']
39450,PMC6082539,31593,Fasting blood samples were obtained between 8:00h and 9:00h a.m. in the span of few days between recruitment and polysomnography.,Data collection,[189669],[9438],[9567],[False],[0],[0],[False],['0']
39451,PMC6082539,31594,Serum and plasma samples were stored at -80°C.,Data collection,[189682],[9568],[9614],[False],[0],[0],[False],['0']
39452,PMC6082539,31595,"Biochemical profiling included glucose, lipids (triglycerides, total cholesterol, and high-density lipoprotein  HDL) and low-density lipoprotein (LDL) cholesterol), creatinine, urate, sodium, potassium, proteins, glutamyl pyruvic transaminase (GPT), gamma-glutamyl transferase (GGT) and C-reactive protein (CRP).",Data collection,[189695],[9615],[9927],[False],[0],[0],[False],['0']
39453,PMC6082539,31596,"Hormonal profiling included total testosterone, free testosterone, sex hormone binding globulin (sHBG), prolactin, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), all measured by RIA (R&D Systems Europe, Abingdon, UK).",Data collection,[189708],[9928],[10163],[False],[0],[0],[False],['0']
39454,PMC6082539,31597,"Additionally, a basic hemogram was performed.",Data collection,[189721],[10164],[10209],[False],[0],[0],[False],['0']
39455,PMC6082539,31598,Blood pressure was routinely measured.,Data collection,[189734],[10210],[10248],[False],[0],[0],[False],['0']
39456,PMC6082539,31599,Continuous recording of night-time oxygen saturation by means of pulse oximetry was conducted routinely at the time of polysomnography.,Data collection,[189747],[10249],[10384],[False],[0],[0],[False],['0']
39457,PMC6082539,31600,"Finally, the Self-esteem and Relationship (SEAR) test [18], a self-administered test designed to specifically evaluate psychosocial aspects associated with ED, was administered to all patients during their Urology Department visits (S1 Questionnaires).",Data collection,[189760],[10385],[10637],[False],[0],[0],[False],['0']
39458,PMC6082539,31601,"The patients included in the RCT underwent reassessments of IIEF15 and SEAR, biochemical and hormonal profiles and CPAP-related variables after 3 months (in the CPAP arm), during a follow-up visit.",Data collection,[189773],[10638],[10835],[False],[0],[0],[False],['0']
39459,PMC6082539,31602,Fasting blood samples were obtained between 8:00h and 9:00h a.m. on the same day of the follow-up visit.,Data collection,[189786],[10836],[10940],[False],[0],[0],[False],['0']
39460,PMC6082539,31603,Statistical analyses,Statistical analyses,[189799],[10941],[10962],[False],[0],[0],[False],['0']
39461,PMC6082539,31604,"Means ± standard deviation (SD), medians (IQR) or frequencies (%) were computed to evaluate the differences between OSA patients with and without ED, assessing the significance of such differences with the chi-square test, independent samples Student’s t test or Mann-Whitney U test, as appropriate.",Statistical analyses,[189812],[10963],[11262],[False],[0],[0],[False],['0']
39462,PMC6082539,31605,The effects of CPAP treatment in the RCT were assessed on an intention to treat basis by comparing the differences between baseline and 3-month measurements using Wilcoxon’s matched-pairs signed-ranks test.,Statistical analyses,[189825],[11263],[11469],[False],[0],[0],[False],['0']
39463,PMC6082539,31606,The comparison of changes between non-CPAP and CPAP patients was performed by means of Wilcoxon’s rank-sum test.,Statistical analyses,[189838],[11470],[11582],[False],[0],[0],[False],['0']
39464,PMC6082539,31607,"Finally, as a complementary analysis, multivariate ordered logistic regression models were constructed to ensure that key variables differing between ED and non-ED patients were not confounding the results on CPAP treatment effect.",Statistical analyses,[189851],[11583],[11814],[False],[0],[0],[False],['0']
39465,PMC6082539,31608,"Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 63 subjects were necessary in each RCT study arm to recognize as statistically significant a 2-unit difference in the erectile function score (IIEF15) after the intervention.",Statistical analyses,[189864],[11815],[12065],[False],[0],[0],[False],['0']
39466,PMC6082539,31609,The 2-unit minimal clinically important difference was defined according to the results by Rosen et al for mild ED patients [19].,Statistical analyses,[189877],[12066],[12195],[False],[0],[0],[False],['0']
39467,PMC6082539,31610,The common SD was assumed to be 4 units.,Statistical analyses,[189890],[12196],[12236],[False],[0],[0],[False],['0']
39468,PMC6082539,31611,"Assuming a 69% prevalence of ED among OSA patients [7,20], 183 OSA patients needed to be assessed to obtain the required 126 ED patients.",Statistical analyses,[189903],[12237],[12374],[False],[0],[0],[False],['0']
39469,PMC6082539,31612,"However, although having a randomization goal of 126 ED patients, the study was stopped at 75.",Statistical analyses,[189916],[12375],[12469],[False],[0],[0],[False],['0']
39470,PMC6082539,31613,"The main reasons for not reaching the recruitment goal were, first, the lower-than-expected prevalence of ED coupled with tight inclusion criteria, causing a very slow recruitment pace (a planned 2-year study turned out having a 3.5 years recruitment phase); second, the financial constrains caused by the extended recruitment phase; and third, the need to avoid biases caused by changes in the personnel assessing the patients.",Statistical analyses,[189929],[12470],[12898],[False],[0],[0],[False],['0']
39471,PMC6082539,31614,"Data analysis was conducted using Stata software, version 12.1 (StataCorp, College Station, TX, USA).",Statistical analyses,[189942],[12899],[13000],[False],[0],[0],[False],['0']
39472,PMC6082539,31615,The threshold for significance was set at 0.05.,Statistical analyses,[189955],[13001],[13048],[False],[0],[0],[False],['0']
39473,PMC6082539,31616,Results,Results,[189968],[13049],[13057],[False],[0],[0],[False],['0']
39474,PMC6082539,31617,Up to 487 newly diagnosed male OSA patients were screened.,Results,[189981],[13058],[13116],[False],[0],[0],[False],['0']
39475,PMC6082539,31618,"After excluding patients who did not meet the inclusion criteria, a total of 150 patients (77 with ED and 73 without ED) were included in the analyses, and 75 ED patients were randomized (Fig 1).",Results,[189994],[13117],[13312],[False],[0],[0],[False],['0']
39476,PMC6082539,31619,The prevalence of ED among the OSA patients in our study was 51% (95% CI: 43%-60%).Table 1 shows the main characteristics of the OSA patients according to ED presence.,Results,[190007],[13313],[13480],[False],[0],[0],[False],['0']
39477,PMC6082539,31620,"ED patients were older, had greater WHRs and were more frequently undergoing pharmacological treatment than patients without ED.",Results,[190020],[13481],[13609],[False],[0],[0],[False],['0']
39478,PMC6082539,31621,None of the patients reported use of Type 5 phosphodiesterase inhibitors.,Results,[190033],[13610],[13683],[False],[0],[0],[False],['0']
39479,PMC6082539,31622,"No differences in hormonal or biochemical profiles were found, except for higher glucose levels in ED patients (Table 2).",Results,[190046],[13684],[13805],[False],[0],[0],[False],['0']
39480,PMC6082539,31623,"Finally, Table 3 shows IIEF15 and SEAR scores.",Results,[190059],[13806],[13852],[False],[0],[0],[False],['0']
39481,PMC6082539,31624,"The median (IQR) erectile function score for non-ED patients was 29 (27–30), and the total SEAR score was 78 (71–86).",Results,[190072],[13853],[13970],[False],[0],[0],[False],['0']
39482,PMC6082539,31625,"In contrast, ED patients had an erectile function score of 18 (6–22) and a SEAR score of 62 (50–77).",Results,[190085],[13971],[14071],[False],[0],[0],[False],['0']
39483,PMC6082539,31626,After randomization 40 patients were treated with CPAP for 3 months with a median (IQR) CPAP use of 5.3 (3.2–6.0) h/night.,Results,[190098],[14072],[14194],[False],[0],[0],[False],['0']
39484,PMC6082539,31627,Eight non-CPAP and 10 CPAP subjects had no IIEF15 measurements at the end of the follow-up and were excluded from the primary outcome analyses.,Results,[190111],[14195],[14338],[False],[0],[0],[False],['0']
39485,PMC6082539,31628,"A baseline comparison between study arms revealed no significant differences except for AHI (mean (SD) events·h−1: CPAP patients 55.8 (20.6); non-CPAP patients 45.3 (19.2); p = 0.037), although no statistically significant differences were found in the proportion of severe (AHI > 30 events·h−1) OSA patients.",Results,[190124],[14339],[14648],[False],[0],[0],[False],['0']
39486,PMC6082539,31629,"Significant increases in erectile function (mean (SD) change: +4.6 (7.9); p = 0.002), sexual satisfaction (mean (SD) change: +2.1 (4.3); p = 0.003) and overall satisfaction (mean (SD) change: +1 (2.2); p = 0.035) were found (Table 4).",Results,[190137],[14649],[14883],[False],[0],[0],[False],['0']
39487,PMC6082539,31630,"Between-arm differences in sexual satisfaction changes were statistically significant (p = 0.027), while differences in erectile function changes were borderline non-significant (p = 0.060).",Results,[190150],[14884],[15074],[False],[0],[0],[False],['0']
39488,PMC6082539,31631,"Regardless of statistical significance, dose-response relationships could be seen for Erectile function and Sexual satisfaction when considering 3 CPAP compliance categories: non-users, user below median (5.3 h/night) and users above median (Table A in S1 Additional Results).",Results,[190163],[15075],[15351],[False],[0],[0],[False],['0']
39489,PMC6082539,31632,"CPAP treatment did not have any relevant impacts on the psychological, hormonal or biochemical profiles of ED patients (Tables 5 and 6).",Results,[190176],[15352],[15488],[False],[0],[0],[False],['0']
39490,PMC6082539,31633,"Finally, ordered logistic regression adjusting for age, WHR, and use of hypolipidemics, that were the most differing variables between ED and non-ED patients, showed very similar results (data not shown).",Results,[190189],[15489],[15693],[False],[0],[0],[False],['0']
39491,PMC6082539,31634,Discussion,Discussion,[190202],[15694],[15705],[False],[0],[0],[False],['0']
39492,PMC6082539,31635,"In this double-purpose study, we determined an ED prevalence of 51% among newly diagnosed OSA patients.",Discussion,[190215],[15706],[15809],[False],[0],[0],[False],['0']
39493,PMC6082539,31636,"Patients with ED were older, had a greater WHR, were more frequently undergoing pharmacological treatment and had higher glucose levels than patients without ED.",Discussion,[190228],[15810],[15971],[False],[0],[0],[False],['0']
39494,PMC6082539,31637,"Although after 3 months of CPAP treatment patients improved on erectile function, sexual satisfaction and overall satisfaction, only changes in sexual satisfaction were significantly different than changes in the control group.",Discussion,[190241],[15972],[16199],[False],[0],[0],[False],['0']
39495,PMC6082539,31638,"Changes in erectile function among study arms were on the borderline of statistical significance, likely due to difficulties in achieving the planned sample size.",Discussion,[190254],[16200],[16362],[True],['SampleSize'],['difficulties in achieving the planned sample size'],[True],['UnderpoweredStudy']
39496,PMC6082539,31639,"Finally, CPAP treatment did not have any relevant impacts on the psychological, hormonal or biochemical profiles of OSA patients with ED.",Discussion,[190280],[16363],[16500],[False],[0],[0],[False],['0']
39497,PMC6082539,31640,The prevalence of ED among newly diagnosed OSA patients in our study was 51%.,Discussion,[190293],[16501],[16578],[False],[0],[0],[False],['0']
39498,PMC6082539,31641,This prevalence was lower than those reported by Budweiser (69%) [7] and Giner (69%) [20].,Discussion,[190306],[16579],[16669],[False],[0],[0],[False],['0']
39499,PMC6082539,31642,"These differences could be explained by the inclusion in previous studies of patients with known ED risk factors, such as uncontrolled or advanced chronic conditions, drug addiction, or age greater than 70 years.",Discussion,[190319],[16670],[16882],[False],[0],[0],[False],['0']
39500,PMC6082539,31643,"As expected and according to the previous literature, we found a higher ED prevalence among the oldest patients.",Discussion,[190332],[16883],[16995],[False],[0],[0],[False],['0']
39501,PMC6082539,31644,"Similarly, ED patients more commonly used drugs, specifically hypolipidemic, angiotensin-converting enzyme inhibitors and oral antidiabetics.",Discussion,[190345],[16996],[17137],[False],[0],[0],[False],['0']
39502,PMC6082539,31645,"Differences in WHR, but not in weight or BMI, were found, in agreement with studies showing that central obesity is an independent ED risk factor [21,22].",Discussion,[190358],[17138],[17292],[False],[0],[0],[False],['0']
39503,PMC6082539,31646,The absence of differences in the biochemical profiles of OSA patients with and without ED validated the decision to exclude all patients with uncontrolled cardiovascular risk factors for ED.,Discussion,[190371],[17293],[17484],[False],[0],[0],[False],['0']
39504,PMC6082539,31647,"Regarding hormonal profiles, ED patients had slightly higher sHBG and lower free testosterone levels than non-ED patients.",Discussion,[190384],[17485],[17607],[False],[0],[0],[False],['0']
39505,PMC6082539,31648,"These differences were most likely explained by age differences because plasma sHBG concentration increases and total testosterone decreases with age, leaving less free testosterone available [23].",Discussion,[190397],[17608],[17805],[False],[0],[0],[False],['0']
39506,PMC6082539,31649,"Finally, although some studies have suggested that OSA could be related to dysfunction in the hypothalamic-pituitary axis [24], no differences in prolactin, LH or FSH levels were found, probably due to hormonally active testosterone levels being within normal ranges and gonadotrophins therefore not being activated.",Discussion,[190410],[17806],[18122],[False],[0],[0],[False],['0']
39507,PMC6082539,31650,"Although improvements in erectile function, sexual satisfaction and overall satisfaction were found after 3 months of CPAP treatment, only the change in sexual satisfaction was significantly different between study arms while changes in erectile function were on the borderline of statistical significance.",Discussion,[190423],[18123],[18429],[False],[0],[0],[False],['0']
39508,PMC6082539,31651,"After CPAP treatment, the IIEF15 erectile function score was 19.8, which was almost the same as that reported by Taskin in 2010, after 1 month of CPAP treatment [25], and it did not reach the 25 points that is the threshold for normal values.",Discussion,[190436],[18430],[18672],[False],[0],[0],[False],['0']
39509,PMC6082539,31652,"Other studies to date have reported different degrees of ED improvement after CPAP treatment [7,26–35].",Discussion,[190449],[18673],[18776],[False],[0],[0],[False],['0']
39510,PMC6082539,31653,"It is noteworthy that the most similar previous study in terms of design, an RCT assessing the effect of 3 months of CPAP / sham CPAP on IIEF15 domains by Melehan et al in 2018, showed a similar increase in sexual satisfaction and non-significant changes on erectile function [27].",Discussion,[190462],[18777],[19058],[False],[0],[0],[False],['0']
39511,PMC6082539,31654,"Both RCT [29,31] and observational [28,30,35] studies assessing the short-term (1 to 3 months) effect of CPAP on ED as measured by IIEF5, that cannot assess the different domains of ED, have reported moderately positive results, with the exception of Shin et al that found no effect of CPAP treatment [32].",Discussion,[190475],[19059],[19365],[False],[0],[0],[False],['0']
39512,PMC6082539,31655,"On the other hand, the only study assessing long-term effects of CPAP treatment on ED, an observational study by Budweiser et al using IIEF15 as primary end point, showed that CPAP treatment increased overall IIEF15 score and was able to halt the decrease in sexual function seen among controls [34].",Discussion,[190488],[19366],[19666],[False],[0],[0],[False],['0']
39513,PMC6082539,31656,"Treatment with sildenafil has proved to be more effective than CPAP [31,36,37] in improving ED symptoms in OSA patients, although the combination of CPAP and sildenafil has been reported to provide some additional improvements [38].",Discussion,[190501],[19667],[19899],[False],[0],[0],[False],['0']
39514,PMC6082539,31657,"In contrast, the effect of CPAP on sexual satisfaction in our RCT suggested an increase in the patient’s perception of well-being.",Discussion,[190514],[19900],[20030],[False],[0],[0],[False],['0']
39515,PMC6082539,31658,"Moreover, the positive effects of CPAP treatment, both in terms of snoring reduction and sleep quality, could have a positive impact on the partner’s sleep quality and overall intimacy levels.",Discussion,[190527],[20031],[20223],[False],[0],[0],[False],['0']
39516,PMC6082539,31659,This is a novel and relevant result because previous studies assessing ED with the abbreviated version of the IIEF could not assess ED dimensions beyond erectile function [25].,Discussion,[190540],[20224],[20400],[False],[0],[0],[False],['0']
39517,PMC6082539,31660,The relationship between OSA and ED is well established [5–7].,Discussion,[190553],[20401],[20463],[False],[0],[0],[False],['0']
39518,PMC6082539,31661,"Testosterone, which peaks during the Rapid Eyes Movements (REM) phase, is usually lower in OSA patients due to sleep fragmentation [39] and, along with repeated hypoxia episodes, could lead to a decrease in protective nocturnal erectile activity [40].",Discussion,[190566],[20464],[20715],[False],[0],[0],[False],['0']
39519,PMC6082539,31662,"However, the current study did not find significant differences in total or free testosterone levels between non-ED and ED groups.",Discussion,[190579],[20716],[20846],[False],[0],[0],[False],['0']
39520,PMC6082539,31663,Adequate compliance with CPAP treatment could potentially reverse or stop the detrimental effects of OSA on ED.,Discussion,[190592],[20847],[20958],[False],[0],[0],[False],['0']
39521,PMC6082539,31664,"However, in our RCT, patients receiving CPAP treatment did not perform better than patients in the control arm.",Discussion,[190605],[20959],[21070],[False],[0],[0],[False],['0']
39522,PMC6082539,31665,"This finding could be partially explained by the characteristics of the included patients, who consulted the hospital because of sleep problems and not ED-related symptoms.",Discussion,[190618],[21071],[21243],[False],[0],[0],[False],['0']
39523,PMC6082539,31666,"In such patients, questions regarding sexual function (that until that time had not caused the patient any reason for consultation) could increase awareness of the situation and promote attitude changes toward any ED-related problems.",Discussion,[190631],[21244],[21478],[False],[0],[0],[False],['0']
39524,PMC6082539,31667,"Our results emphasize the importance of OSA screening in patients undergoing consultations for ED, and vice versa, given the high prevalence of ED among OSA patients even after excluding patients with many known ED risk factors.",Discussion,[190644],[21479],[21707],[False],[0],[0],[False],['0']
39525,PMC6082539,31668,"Accordingly, measurements such as WHR could be used for the identification of OSA patients at higher risk for ED.",Discussion,[190657],[21708],[21821],[False],[0],[0],[False],['0']
39526,PMC6082539,31669,"In contrast, CPAP treatment showed limited success in ameliorating ED, suggesting that CPAP treatment should probably be combined with other therapeutic options, such as weight reduction or sildenafil, depending on ED severity, to fully overcome ED.",Discussion,[190670],[21822],[22071],[False],[0],[0],[False],['0']
39527,PMC6082539,31670,"In any case, patients’ awareness of both OSA and ED could potentially be useful for achieving better treatment adherence.",Discussion,[190683],[22072],[22193],[False],[0],[0],[False],['0']
39528,PMC6082539,31671,"The current study had several strengths: (i) the inclusion of newly diagnosed OSA patients, all of whom had undergone complete polysomnography; (ii) the exclusion of patients with many well-known ED risk factors, such as uncontrolled or advanced chronic conditions, drug addiction, and age greater than 70 years, in an effort to study OSA-related ED without additional confounding variables; (iii) comprehensive determination of the profiles of OSA patients with and without ED, including a broad range of sociodemographic, anthropometric, lifestyle, hormonal, biochemical, clinical and pharmacological variables; and (iv) the use of an RCT design to assess the potential effects of CPAP treatment on ED.",Discussion,[190696],[22194],[22898],[False],[0],[0],[False],['0']
39529,PMC6082539,31672,"In contrast, several limitations should be acknowledged: (i) Although having a randomization goal of 126 ED patients, the study was stopped at 75.",Discussion,[190710],[22899],[23045],[True],['SampleSize'],"['randomization goal of 126 ED patients, the study was stopped at 75']",[True],['UnderpoweredStudy']
39530,PMC6082539,31673,"The main reasons for not reaching the recruitment goal were, first, the lower-than-expected prevalence of ED coupled with tight inclusion criteria, causing a very slow recruitment pace (a planned 2-year study turned out having a 3.5 years recruitment phase); second, the financial constrains caused by the extended recruitment phase; and third, the need to avoid biases caused by changes in the personnel assessing the patients.",Discussion,"[190737, 190738, 190739, 190740]","[23046, 23046, 23046, 23046]","[23474, 23474, 23474, 23474]","[True, True, True, True]","['SampleSize', 'Population', 'VerySpecificPopulation', 'Funding']","['not reaching the recruitment goal', 'the lower-than-expected prevalence of ED', 'tight inclusion criteria', 'the financial constrains']","[True, True, True, True]","['Funding', 'Population', 'UnderpoweredStudy']"
39531,PMC6082539,31674,"This fact diminished the statistical power of the RCT, most likely precluding statistical significance of the differences in changes in erectile function between CPAP and non-CPAP patients.",Discussion,[190767],[23475],[23664],[True],['UnderpoweredStudy'],['diminished the statistical power of the RCT'],[True],['UnderpoweredStudy']
39532,PMC6082539,31675,"Nevertheless, it is unlikely that increasing the sample size would alter the null results in the psychosocial aspects or hormonal and biochemical profiles investigated; (ii) there were no repeated measures of hormonal profile.",Discussion,[190787],[23665],[23891],[False],[0],[0],[False],['0']
39533,PMC6082539,31676,This could cause some degree of measurement error specially in hormones such as testosterone that are subject to short-term fluctuations; (iii) the RCT phase of this study had a non-blind design.,Discussion,"[190807, 190808]","[23892, 23892]","[24087, 24087]","[True, True]","['PrecisionOfMeasurement', 'Blinding']","['measurement error', 'non-blind design']","[True, True]","['OutcomeMeasures', 'Blinding']"
39534,PMC6082539,31677,"Although the use of sham CPAP could allow for a blind design, this option was rejected both to avoid unnecessary discomfort to patients and to avoid neglecting the potential negative implications of using a medical device while sleeping in relation to sexual behavior and/or performance; and, (iv) the Ethics Committee approving the study precluded the inclusion of sleepy patients (ESS score >10) and limited the follow-up time to 3 months, as not providing CPAP treatment to sleepy patients or delaying CPAP treatment initiation beyond 3 months in non-sleepy patients is considered unethical.",Discussion,"[190835, 190836]","[24088, 24088]","[24682, 24682]","[True, True]","['VerySpecificPopulation', 'FollowUpDuration']","['precluded the inclusion of sleepy patients', 'limited the follow-up time to 3 months']","[True, True]","['Population', 'StudyDuration']"
39535,PMC6082539,31678,This implied that the current study could not provide insight into the long-term effects of CPAP treatment on ED.,Discussion,[190864],[24683],[24796],[True],['FollowUpDuration'],['could not provide insight into the long-term effects of CPAP treatment on ED'],[True],['StudyDuration']
39536,PMC6082539,31679,"Moreover, this excluded from the study a part of OSA patients (usually with a more severe disease).",Discussion,[190889],[24797],[24896],[True],['VerySpecificPopulation'],['excluded from the study a part of OSA patients'],[True],['Population']
39537,PMC6082539,31680,"Nevertheless, the inclusion of sleepy patients would most provably favor the authors hypotheses, enhancing the bonds between OSA and ED, and potentially magnifying the beneficial effects of CPAP on ED.",Discussion,[190904],[24897],[25098],[False],[0],[0],[False],['0']
39538,PMC6082539,31681,"To conclude, we found a 51% prevalence of ED among newly diagnosed OSA patients, even when excluding patients with many known ED risk factors.",Discussion,[190917],[25099],[25241],[False],[0],[0],[False],['0']
39539,PMC6082539,31682,"Age, WHR and pharmacological treatment were identified as the main differences between OSA patients with and without ED.",Discussion,[190930],[25242],[25362],[False],[0],[0],[False],['0']
39540,PMC6082539,31683,"Finally, 3 months of CPAP treatment significantly increased sexual satisfaction but had no impact on the psychological, hormonal or biochemical profiles of patients.",Discussion,[190943],[25363],[25528],[False],[0],[0],[False],['0']
39541,PMC6082539,31684,"Overall, this study confirms the close relationship between OSA and ED, suggesting the potential usefulness of ED screening in OSA patients, but could not determine conclusively whether CPAP is an effective stand-alone ED treatment despite positive results on sexual satisfaction.",Discussion,[190956],[25529],[25809],[False],[0],[0],[False],['0']
40273,PMC6371462,41734,Illness management and recovery: one-year follow-up of a randomized controlled trial in Danish community mental health centers: long-term effects on clinical and personal recovery,Title,[246582],[27281],[179],[False],[0],[0],[False],['0']
40274,PMC6371462,41735,Abstract,Abstract,[246590],[180],[189],[False],[0],[0],[False],['0']
40275,PMC6371462,41736,Background: Illness Management and Recovery (IMR) is a curriculum-based rehabilitation program for people with severe mental illness with the short-term aim of improving illness self-management and the long-term aim of helping people achieve clinical and personal recovery.,Abstract,[246598],[190],[463],[False],[0],[0],[False],['0']
40276,PMC6371462,41737,Method,Abstract,[246606],[464],[470],[False],[0],[0],[False],['0']
40277,PMC6371462,41738,Participants with schizophrenia or bipolar disorders were recruited from three community mental health centers in the Capital Region of Denmark and randomized to receive group-based IMR and treatment as usual or only the usual intervention.,Abstract,[246614],[471],[711],[False],[0],[0],[False],['0']
40278,PMC6371462,41739,"All outcomes were assessed at baseline, postintervention, and the one-year follow-up.",Abstract,[246622],[712],[797],[False],[0],[0],[False],['0']
40279,PMC6371462,41740,"Long-term outcomes were categorized according to clinical recovery (i.e., symptoms, global functioning, and hospitalization) and personal recovery (i.e., hope and personal agency).",Abstract,[246630],[798],[978],[False],[0],[0],[False],['0']
40280,PMC6371462,41741,Generalized linear mixed model regression analyses were used in the intent-to-treat analysis.,Abstract,[246638],[979],[1072],[False],[0],[0],[False],['0']
40281,PMC6371462,41742,Results,Abstract,[246646],[1073],[1080],[False],[0],[0],[False],['0']
40282,PMC6371462,41743,A total of 198 participants were included.,Abstract,[246654],[1081],[1123],[False],[0],[0],[False],['0']
40283,PMC6371462,41744,"No significant differences were found between the IMR and control groups in the Global Assessment of Functioning one year after the intervention, nor were there significant differences in symptoms, number of hospital admissions, emergency room visits, or outpatient treatment.",Abstract,[246662],[1124],[1400],[False],[0],[0],[False],['0']
40284,PMC6371462,41745,Conclusion,Abstract,[246670],[1401],[1411],[False],[0],[0],[False],['0']
40285,PMC6371462,41746,The present IMR trial showed no significant effect on clinical and personal recovery at the one-year follow-up.,Abstract,[246678],[1412],[1523],[False],[0],[0],[False],['0']
40286,PMC6371462,41747,"Together with the results of other IMR studies, the present study indicates that the effect of IMR on symptom severity is unclear, which raises questions regarding the impact of IMR on functioning.",Abstract,[246686],[1524],[1721],[False],[0],[0],[False],['0']
40287,PMC6371462,41748,"Additionally, IMR did not affect personal recovery.",Abstract,[246694],[1722],[1773],[False],[0],[0],[False],['0']
40288,PMC6371462,41749,"Although more research is needed, the results indicate that the development of other interventions should be considered to help people with severe mental illness achieve a better level of functioning and personal recovery.",Abstract,[246702],[1774],[1996],[False],[0],[0],[False],['0']
40289,PMC6371462,41750,Trial registration,Abstract,[246710],[1997],[2015],[False],[0],[0],[False],['0']
40290,PMC6371462,41751,Trial registered at http://www.clinicaltrials.gov (NCT01361698).,Abstract,[246718],[2016],[2080],[False],[0],[0],[False],['0']
40291,PMC6371462,41752,Background,Background,[246726],[2081],[2092],[False],[0],[0],[False],['0']
40292,PMC6371462,41753,Fig.,Background,[246734],[2093],[2097],[False],[0],[0],[False],['0']
40293,PMC6371462,41754,1 Hypothesized short-term and long-term outcome of the Illness Management and Recovery Program.,Background,[246742],[2098],[2193],[False],[0],[0],[False],['0']
40294,PMC6371462,41755,"The Illness Management and Recovery (IMR) program is a manualized, curriculum-based, recovery-oriented, rehabilitation program for people with schizophrenia or a major mood disorder [1].",Background,[246750],[2194],[2380],[False],[0],[0],[False],['0']
40295,PMC6371462,41756,"Typically, IMR is delivered by mental healthcare professionals with an aim of helping individuals set and pursue personal recovery goals and learn illness management skills to facilitate their attainment of these goals [1].",Background,[246758],[2381],[2604],[False],[0],[0],[False],['0']
40296,PMC6371462,41757,"Clinical recovery refers to a reduction in the signs and symptoms of the mental illness and restoration of cognitive, social, and occupational functioning, whereas personal recovery refers to the process of constructing a personally meaningful life within and beyond the limits of one’s mental illness [2–5].",Background,[246766],[2605],[2913],[False],[0],[0],[False],['0']
40297,PMC6371462,41758,The IMR program is based on two theoretical models: the transtheoretical model and the stress-vulnerability model.,Background,[246774],[2914],[3028],[False],[0],[0],[False],['0']
40298,PMC6371462,41759,"The transtheoretical model proposes that motivation to change develops over a series of stages (precontemplation, contemplation, preparation, action, maintenance) and that facilitating change requires stage-specific interventions.",Background,[246782],[3029],[3259],[False],[0],[0],[False],['0']
40299,PMC6371462,41760,"The stress-vulnerability model posits that the course and outcome of schizophrenia is determined by the dynamic interplay of biological vulnerability, stress, and coping.",Background,[246790],[3260],[3430],[False],[0],[0],[False],['0']
40300,PMC6371462,41761,"The IMR-program is aimed at interrupting the cycle of stress and vulnerability that leads to relapse and poor functioning [1, 4, 6].",Background,[246798],[3431],[3563],[False],[0],[0],[False],['0']
40301,PMC6371462,41762,"Therefore, the long-term outcomes of IMR are to improve both personal and clinical recovery, as illustrated in Fig.",Background,[246806],[3564],[3679],[False],[0],[0],[False],['0']
40302,PMC6371462,41763,1.,Background,[246814],[3680],[3682],[False],[0],[0],[False],['0']
40303,PMC6371462,41764,The present study focuses on the long-term effects of the IMR program.,Background,[246822],[3683],[3753],[False],[0],[0],[False],['0']
40304,PMC6371462,41765,The literature review on the IMR program by McGuire et al.,Background,[246830],[3754],[3812],[False],[0],[0],[False],['0']
40305,PMC6371462,41766,"(2014) [7] found two randomized clinical trials (RCTs) [8, 9] and one quasi-experimental trial [10] with results on the long-term effects of IMR.",Background,[246838],[3813],[3958],[False],[0],[0],[False],['0']
40306,PMC6371462,41767,"Two subsequent RCTs examined the long-term effects of IMR [11, 12], and one RCT preplanned a long-term follow-up but instead conducted a qualitative study at one year of follow-up [13].",Background,[246846],[3959],[4144],[False],[0],[0],[False],['0']
40307,PMC6371462,41768,"Three of the trials revealed that the participants who received IMR had greater reductions in symptoms and increases in functioning posttreatment than those who received the usual services and that they maintained these improvements during follow-up [8, 9, 12].",Background,[246854],[4145],[4406],[False],[0],[0],[False],['0']
40308,PMC6371462,41769,"However, all three trials had methodological limitations, such as not establishing a primary outcome, conducting assessments with nonblinded interviewers, and failing to perform a sample size calculation.",Background,[246862],[4407],[4611],[False],[0],[0],[False],['0']
40309,PMC6371462,41770,"In contrast, two RCTs by Salyers et al.",Background,[246870],[4612],[4651],[False],[0],[0],[False],['0']
40310,PMC6371462,41771,"(2010/2014) reported no group differences in favor of IMR at either the posttreatment or follow-up time points [10, 11].",Background,[246878],[4652],[4772],[False],[0],[0],[False],['0']
40311,PMC6371462,41772,"However, these two RCTs also had methodological limitations (i.e., not including assessor-blinded interviews and primary outcomes, as noted below).",Background,[246886],[4773],[4920],[False],[0],[0],[False],['0']
40312,PMC6371462,41773,"The early systematic review concluded that the IMR-program was an effective intervention, but later studies have cast doubt.",Background,[246894],[4921],[5045],[False],[0],[0],[False],['0']
40313,PMC6371462,41774,Two important issues must be considered when evaluating research on the IMR-program.,Background,[246902],[5046],[5130],[False],[0],[0],[False],['0']
40314,PMC6371462,41775,"The first issue is exposure to IMR, which can be measured by the number of IMR sessions attended.",Background,[246910],[5131],[5228],[False],[0],[0],[False],['0']
40315,PMC6371462,41776,"The second issue is fidelity to the principles of the IMR program, which can be measured with the IMR Fidelity Scale [14].",Background,[246918],[5229],[5351],[False],[0],[0],[False],['0']
40316,PMC6371462,41777,"One RCT that also used a modified IMR (i.e., it excluded three IMR modules) did not report the number of sessions attended or the fidelity score [15].",Background,[246926],[5352],[5502],[False],[0],[0],[False],['0']
40317,PMC6371462,41778,"Another RCT reported a high degree of exposure to IMR; however, the study did not perform fidelity assessments, which limited the ability to estimate the quality of IMR implementation [9].",Background,[246934],[5503],[5691],[False],[0],[0],[False],['0']
40318,PMC6371462,41779,Levitt et al.,Background,[246942],[5692],[5705],[False],[0],[0],[False],['0']
40319,PMC6371462,41780,(2009) reported high fidelity but a lower degree of exposure than Färdig et al.,Background,[246950],[5706],[5785],[False],[0],[0],[False],['0']
40320,PMC6371462,41781,"(2011), with 54% of participants attending more than 20 sessions [8, 9].",Background,[246958],[5786],[5858],[False],[0],[0],[False],['0']
40321,PMC6371462,41782,The two studies by Salyers et al.,Background,[246966],[5859],[5892],[False],[0],[0],[False],['0']
40322,PMC6371462,41783,"(2010/2014) showed a good to high fidelity score; however, the authors reported low exposure to IMR [10, 11].",Background,[246974],[5893],[6002],[False],[0],[0],[False],['0']
40323,PMC6371462,41784,"Together, the five RCTs had limitations in either IMR exposure or fidelity assessment.",Background,[246982],[6003],[6089],[False],[0],[0],[False],['0']
40324,PMC6371462,41785,The present RCT was designed to improve upon the methodological limitations of previous IMR research and to evaluate whether participants in the IMR program exhibited improved clinical and personal recovery and illness management postintervention and at the one-year follow-up [16].,Background,[246990],[6090],[6372],[False],[0],[0],[False],['0']
40325,PMC6371462,41786,"The IMR program was implemented with high fidelity but, unfortunately, with lower exposure to IMR than desired and reported in the study by Levitt et al.",Background,[246998],[6373],[6526],[False],[0],[0],[False],['0']
40326,PMC6371462,41787,"(2009), with 47% of the participants attending more than 20 sessions.",Background,[247006],[6527],[6596],[False],[0],[0],[False],['0']
40327,PMC6371462,41788,No differences in any postintervention outcomes were found [17].,Background,[247014],[6597],[6661],[False],[0],[0],[False],['0']
40328,PMC6371462,41789,This article reports the one-year follow-up outcomes for clinical and personal recovery.,Background,[247022],[6662],[6750],[False],[0],[0],[False],['0']
40329,PMC6371462,41790,Methods,Methods,[247030],[6751],[6759],[False],[0],[0],[False],['0']
40330,PMC6371462,41791,Design,Methods|Design,[247038],[6760],[6766],[False],[0],[0],[False],['0']
40331,PMC6371462,41792,"This study was a prospective, assessor-blinded, RCT performed in three community mental health centers (CMHCs) in the Capital Region of Denmark, which covers a population of approximately 1.8 million people.",Methods|Design,[247046],[6767],[6974],[False],[0],[0],[False],['0']
40332,PMC6371462,41793,The IMR program was provided as an add-on to treatment as usual (TAU) care in the intervention group.,Methods|Design,[247054],[6975],[7076],[False],[0],[0],[False],['0']
40333,PMC6371462,41794,The trial design is described in detail elsewhere and therefore will only be described briefly here [16].,Methods|Design,[247062],[7077],[7182],[False],[0],[0],[False],['0']
40334,PMC6371462,41795,Participants were included from March 2011 to December 2013.,Methods|Design,[247070],[7183],[7243],[False],[0],[0],[False],['0']
40335,PMC6371462,41796,"Assessments were conducted at baseline, posttreatment, and one year following the end of treatment, with follow-up data collection conducted between December 2013 and December 2014.",Methods|Design,[247078],[7244],[7425],[False],[0],[0],[False],['0']
40336,PMC6371462,41797,The present article focuses on the one-year follow-up data.,Methods|Design,[247086],[7426],[7485],[False],[0],[0],[False],['0']
40337,PMC6371462,41798,Participants,Methods|Participants,[247094],[7486],[7498],[False],[0],[0],[False],['0']
40338,PMC6371462,41799,We included participants based on diagnostic interviews with the Present State Examination [18] conducted by a psychiatrist or trained psychologist to verify the diagnosis of schizophrenia (F20.x) or bipolar disorder (F31.x) according to the ICD-10 criteria.,Methods|Participants,[247102],[7499],[7757],[False],[0],[0],[False],['0']
40339,PMC6371462,41800,"Additional inclusion criteria were as follows: a) 18 years of age or older, b) sufficient fluency in Danish to participate in the IMR program, and c) willingness to provide informed consent.",Methods|Participants,[247110],[7758],[7948],[False],[0],[0],[False],['0']
40340,PMC6371462,41801,"The exclusion criteria were as follows: a) having a guardian or a forensic arrangement, b) meeting the criteria for the ICD-10 diagnosis of dementia or mental retardation, c) having an active substance use disorder, d) living in a community residential home, or e) being involved in a psychoeducational course at the time of inclusion.",Methods|Participants,[247118],[7949],[8284],[False],[0],[0],[False],['0']
40341,PMC6371462,41802,Randomization and blinding,Methods|Randomization and blinding,[247126],[8285],[8311],[False],[0],[0],[False],['0']
40342,PMC6371462,41803,Patients were recruited from three CMHCs in the Capital Region of Denmark.,Methods|Randomization and blinding,[247134],[8312],[8386],[False],[0],[0],[False],['0']
40343,PMC6371462,41804,"Diagnostic eligibility for the study was established with the Present State Examination (PSE) administered by a trained psychiatrist or a psychologist [16, 17].",Methods|Randomization and blinding,[247142],[8387],[8547],[False],[0],[0],[False],['0']
40344,PMC6371462,41805,The randomization was performed centrally and by telephone by the Copenhagen Trial Unit to conceal the allocation sequence.,Methods|Randomization and blinding,[247150],[8548],[8671],[False],[0],[0],[False],['0']
40345,PMC6371462,41806,"The allocation sequence was computer-generated using permuted blocks in varying sizes of 6, 8, and 10.",Methods|Randomization and blinding,[247158],[8672],[8774],[False],[0],[0],[False],['0']
40346,PMC6371462,41807,"The level of blinding at the one-year follow-up was focused on the assessor-blinded interviews, because blinding at the data analysis level was compromised during the posttreatment investigation.",Methods|Randomization and blinding,[247166],[8775],[8970],[False],[0],[0],[False],['0']
40347,PMC6371462,41808,Interventions,Interventions,[247174],[8971],[8985],[False],[0],[0],[False],['0']
40348,PMC6371462,41809,The IMR program,Interventions|The IMR program,[247182],[8986],[9001],[False],[0],[0],[False],['0']
40349,PMC6371462,41810,Table 1 Modules in the Illness Management and Recovery Program.,Interventions|The IMR program,[247190],[9002],[9065],[False],[0],[0],[False],['0']
40350,PMC6371462,41811,Participants randomized to the IMR intervention group were offered an IMR course in addition to TAU as provided by CMHCs in the Capital Region of Denmark.,Interventions|The IMR program,[247198],[9066],[9220],[False],[0],[0],[False],['0']
40351,PMC6371462,41812,"The IMR program lasted 9 months with weekly group sessions, and each closed-enrollment group included ten patients.",Interventions|The IMR program,[247206],[9221],[9336],[False],[0],[0],[False],['0']
40352,PMC6371462,41813,The group sessions were conducted by two or three clinicians at CMHCs.,Interventions|The IMR program,[247214],[9337],[9407],[False],[0],[0],[False],['0']
40353,PMC6371462,41814,All patients receiving IMR were given educational hand-outs corresponding to the eleven different module topics (see Table 1).,Interventions|The IMR program,[247222],[9408],[9534],[False],[0],[0],[False],['0']
40354,PMC6371462,41815,Treatment as usual (TAU),Interventions|Treatment as usual (TAU),[247230],[9535],[9559],[False],[0],[0],[False],['0']
40355,PMC6371462,41816,"TAU consisted of an individually adapted interdisciplinary treatment containing medication, individual case manager support, individual and group therapy, and unstandardized psychoeducation.",Interventions|Treatment as usual (TAU),[247238],[9560],[9750],[False],[0],[0],[False],['0']
40356,PMC6371462,41817,"The staff of the CMHCs were trained mental health professionals, including nurses, psychiatrists, psychologists, physiotherapists, occupational therapists, and licensed social workers.",Interventions|Treatment as usual (TAU),[247246],[9751],[9935],[False],[0],[0],[False],['0']
40357,PMC6371462,41818,Every patient in the CMHC had a case manager who together with the patient selected the elements of the individual’s treatment plan.,Interventions|Treatment as usual (TAU),[247254],[9936],[10068],[False],[0],[0],[False],['0']
40358,PMC6371462,41819,"The patient met with the case manager once a week (or more or less frequently depending on the state and preference of the patient) [16, 17].",Interventions|Treatment as usual (TAU),[247262],[10069],[10210],[False],[0],[0],[False],['0']
40359,PMC6371462,41820,IMR Fidelity scale,Interventions|IMR Fidelity scale,[247270],[10211],[10229],[False],[0],[0],[False],['0']
40360,PMC6371462,41821,The IMR fidelity assessments were performed four months after initiating the study and again at the end of each IMR group.,Interventions|IMR Fidelity scale,[247278],[10230],[10352],[False],[0],[0],[False],['0']
40361,PMC6371462,41822,Staff specially trained in IMR fidelity assessment from one participating community mental health centers was conducting the assessments at the other community mental health centers’ groups and vice versa.,Interventions|IMR Fidelity scale,[247286],[10353],[10558],[False],[0],[0],[False],['0']
40362,PMC6371462,41823,"A multiple data approach was used including: interviews, observation of the IMR group, an audit of the patient’s service records as well as audit of the IMR notes of progress.",Interventions|IMR Fidelity scale,[247294],[10559],[10734],[False],[0],[0],[False],['0']
40363,PMC6371462,41824,Two raters independently scored each session and then discussed any discrepancies and reached a consensus rating.,Interventions|IMR Fidelity scale,[247302],[10735],[10848],[False],[0],[0],[False],['0']
40364,PMC6371462,41825,Outcomes,Outcomes,[247310],[10849],[10858],[False],[0],[0],[False],['0']
40365,PMC6371462,41826,"The assessment of clinical recovery (i.e., functioning and symptoms) was conducted through interviews with an assessor who was blinded to the treatment group allocation.",Outcomes,[247318],[10859],[11028],[False],[0],[0],[False],['0']
40366,PMC6371462,41827,Assessment of personal recovery was obtained through the participants’ self-reports.,Outcomes,[247326],[11029],[11113],[False],[0],[0],[False],['0']
40367,PMC6371462,41828,Information on illness management and recovery was obtained by the staff and was self-reported by the participants.,Outcomes,[247334],[11114],[11229],[False],[0],[0],[False],['0']
40368,PMC6371462,41829,All outcomes were assessed postintervention and again at the one-year follow-up.,Outcomes,[247342],[11230],[11310],[False],[0],[0],[False],['0']
40369,PMC6371462,41830,The primary outcome was the Global Assessment of Functioning (GAF) assessed by the GAF-F postintervention.,Outcomes,[247350],[11311],[11417],[False],[0],[0],[False],['0']
40370,PMC6371462,41831,"Therefore, all one-year follow-up outcomes are secondary or explorative outcomes.",Outcomes,[247358],[11418],[11499],[False],[0],[0],[False],['0']
40371,PMC6371462,41832,"The GAF is a generic rating scale ranging from 1 (lowest) to 100 (highest) that was developed as an overall measure of the patient’s social, psychological, and occupational functioning.",Outcomes,[247366],[11500],[11685],[False],[0],[0],[False],['0']
40372,PMC6371462,41833,The GAF can be rated with a single score that reflects both the symptom severity and functional impairment or with separate scores for symptoms (GAF-S) and functioning (GAF-F) [19].,Outcomes,[247374],[11686],[11867],[False],[0],[0],[False],['0']
40373,PMC6371462,41834,"For the present study, both the GAF-F and GAF-S scores were obtained.",Outcomes,[247382],[11868],[11937],[False],[0],[0],[False],['0']
40374,PMC6371462,41835,"The Personal and Social Performance (PSP) scale measures social functioning within four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.",Outcomes,[247390],[11938],[12148],[False],[0],[0],[False],['0']
40375,PMC6371462,41836,The PSP provides a score between one and one hundred using a six-point severity scale for each domain.,Outcomes,[247398],[12149],[12251],[False],[0],[0],[False],['0']
40376,PMC6371462,41837,The ratings are based on the outcome of a structured clinical interview.,Outcomes,[247406],[12252],[12324],[False],[0],[0],[False],['0']
40377,PMC6371462,41838,A high score indicates higher personal and social functioning [20].,Outcomes,[247414],[12325],[12392],[False],[0],[0],[False],['0']
40378,PMC6371462,41839,"The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview pertaining to the patient’s symptoms over the past month [21, 22].",Outcomes,[247422],[12393],[12539],[False],[0],[0],[False],['0']
40379,PMC6371462,41840,The PANSS includes 30 items with a seven-point rating that represents increasing levels of psychopathology.,Outcomes,[247430],[12540],[12647],[False],[0],[0],[False],['0']
40380,PMC6371462,41841,"The PANSS includes three subscales: the Positive Scale (7 items), the Negative Scale (7 items), and the General Psychopathology Scale (16 items).",Outcomes,[247438],[12648],[12793],[False],[0],[0],[False],['0']
40381,PMC6371462,41842,"The PANSS total and subscales scores are calculated by summing the ratings of all items on the total scale and each subscale (range for total: 30–210, range for Positive and Negative Scales: 7–49, and range for General Psychopathology Scale: 16–112) [22].",Outcomes,[247446],[12794],[13049],[False],[0],[0],[False],['0']
40382,PMC6371462,41843,"The 6-item Hamilton Rating Scale for Depression (HAM) is an interview-based measure of depression that includes the following six items: depressed mood, work and activities, sleep disturbance, guilt, anxiety, and retardation [23].",Outcomes,[247454],[13050],[13280],[False],[0],[0],[False],['0']
40383,PMC6371462,41844,"The HAM-D6 is interview-based and clinician-rated on a five-point scale (0–4), except for sleep disturbance, which is rated on a three-point scale (0–2).",Outcomes,[247462],[13281],[13434],[False],[0],[0],[False],['0']
40384,PMC6371462,41845,"The HAM-D6 minimum score is zero, and the maximum score is 22.",Outcomes,[247470],[13435],[13497],[False],[0],[0],[False],['0']
40385,PMC6371462,41846,The Young Mania Rating Scale (YMRS) are composed of the following 11 item scale as follows: 1.,Outcomes,[247478],[13498],[13592],[False],[0],[0],[False],['0']
40386,PMC6371462,41847,"Elevated Mood, 2.",Outcomes,[247486],[13593],[13610],[False],[0],[0],[False],['0']
40387,PMC6371462,41848,"Increased Motor Activity-Energy, 3.",Outcomes,[247494],[13611],[13646],[False],[0],[0],[False],['0']
40388,PMC6371462,41849,"Sexual Interest, 4.",Outcomes,[247502],[13647],[13666],[False],[0],[0],[False],['0']
40389,PMC6371462,41850,"Sleep, 5.",Outcomes,[247510],[13667],[13676],[False],[0],[0],[False],['0']
40390,PMC6371462,41851,"Irritability, 6.",Outcomes,[247518],[13677],[13693],[False],[0],[0],[False],['0']
40391,PMC6371462,41852,"Speech Rate and Amount, 7.",Outcomes,[247526],[13694],[13720],[False],[0],[0],[False],['0']
40392,PMC6371462,41853,"Language Thought Disorder, 8.",Outcomes,[247534],[13721],[13750],[False],[0],[0],[False],['0']
40393,PMC6371462,41854,"Content, 9.",Outcomes,[247542],[13751],[13762],[False],[0],[0],[False],['0']
40394,PMC6371462,41855,"Disruptive-Aggressive Behavior, 10.",Outcomes,[247550],[13763],[13798],[False],[0],[0],[False],['0']
40395,PMC6371462,41856,"Appearance, and 11.",Outcomes,[247558],[13799],[13818],[False],[0],[0],[False],['0']
40396,PMC6371462,41857,Insight [24].,Outcomes,[247566],[13819],[13832],[False],[0],[0],[False],['0']
40397,PMC6371462,41858,"The YMRS is a clinician-rated instrument that is used to assess the severity of mania; items 1, 2, 3, 4, 7, 10, and 11 use a five-point scale, and items 5, 6, 8, and 9 use a nine-point scale.",Outcomes,[247574],[13833],[14024],[False],[0],[0],[False],['0']
40398,PMC6371462,41859,"The YMRS minimum score is zero, and the maximum score is sixty [25].",Outcomes,[247582],[14025],[14093],[False],[0],[0],[False],['0']
40399,PMC6371462,41860,The IMR scale (IMRS) was developed to measure illness self-management outcomes based on the stress-vulnerability model and is an integrated part of the IMR program’s Implementation Toolkit.,Outcomes,[247590],[14094],[14283],[False],[0],[0],[False],['0']
40400,PMC6371462,41861,"Each item is rated on a five-point scale, with lower scores reflecting lower levels of illness management.",Outcomes,[247598],[14284],[14390],[False],[0],[0],[False],['0']
40401,PMC6371462,41862,"The IMRS can be scored by summing up all items on the scale for the total score (range: 15–75) or for three subscales based on factor analyses with a three-factor solution for the subscales (Recovery scale, Management scale, and Biology scale) [13, 26].",Outcomes,[247606],[14391],[14644],[False],[0],[0],[False],['0']
40402,PMC6371462,41863,The Mental Health Recovery Measure (MHRM) is a self-reported 30-item scale that assesses perceived recovery for individuals with a serious mental illness [27].,Outcomes,[247614],[14645],[14804],[False],[0],[0],[False],['0']
40403,PMC6371462,41864,"The items are rated on a five-point scale ranging from zero (strongly disagree) to four (strongly agree), creating a total score range of zero to 120.",Outcomes,[247622],[14805],[14955],[False],[0],[0],[False],['0']
40404,PMC6371462,41865,Higher MHRM scores indicate higher self-reported levels of mental health recovery.,Outcomes,[247630],[14956],[15038],[False],[0],[0],[False],['0']
40405,PMC6371462,41866,The Adult Hope Scale is a self-reported six-item scale that assesses the level of hope.,Outcomes,[247638],[15039],[15126],[False],[0],[0],[False],['0']
40406,PMC6371462,41867,The items are assessed using an eight-point Likert scale ranging from definitely false to definitely true [28].,Outcomes,[247646],[15127],[15238],[False],[0],[0],[False],['0']
40407,PMC6371462,41868,The measure consists of two subscales: agency (goal determination) and pathways (extent of belief in ability to achieve goals).,Outcomes,[247654],[15239],[15366],[False],[0],[0],[False],['0']
40408,PMC6371462,41869,"The Hope Scale minimum score is six, and the maximum score is 48.",Outcomes,[247662],[15367],[15432],[False],[0],[0],[False],['0']
40409,PMC6371462,41870,"The Client’s Satisfaction Questionnaire measures the participants’ satisfaction with community mental health treatment [29], with a score range of 8–32.",Outcomes,[247670],[15433],[15585],[False],[0],[0],[False],['0']
40410,PMC6371462,41871,"Finally, we collected data from the following national registers for all participants regarding their service utilization: the Civil Registration System (CPR-register), Danish Psychiatric Central Research Register (PCRR), Danish Register of Causes of Death, and Danish National Patient Register-Psychiatry [30].",Outcomes,[247678],[15586],[15897],[False],[0],[0],[False],['0']
40411,PMC6371462,41872,"We collected data on the number of hospital admissions, length of admissions in days, and number of emergency service visits.",Outcomes,[247686],[15898],[16023],[False],[0],[0],[False],['0']
40412,PMC6371462,41873,"Every inhabitant of Denmark is given a unique ten-digital personal identification number, and therefore, complete follow-up using national databases is possible.",Outcomes,[247694],[16024],[16185],[False],[0],[0],[False],['0']
40413,PMC6371462,41874,Statistical analysis,Statistical analysis,[247702],[16186],[16207],[False],[0],[0],[False],['0']
40414,PMC6371462,41875,A detailed statistical analysis plan was created before performing any analyses.,Statistical analysis,[247710],[16208],[16288],[False],[0],[0],[False],['0']
40415,PMC6371462,41876,The sample size calculation was conducted for the posttreatment investigation but not for the one-year follow-up.,Statistical analysis,[247718],[16289],[16402],[False],[0],[0],[False],['0']
40416,PMC6371462,41877,"The analyses were conducted according to the intent-to-treat principle, with the two-tailed level of significance for all statistical tests set at 0.05.",Statistical analysis,[247726],[16403],[16555],[False],[0],[0],[False],['0']
40417,PMC6371462,41878,"For the one-year follow-up analyses, we used generalized linear mixed-effects regression analyses.",Statistical analysis,[247734],[16556],[16654],[False],[0],[0],[False],['0']
40418,PMC6371462,41879,"The relative changes in the GAF-F and social scores, psychiatric symptoms and illness management, and recovery were evaluated postintervention and at the one-year follow-up using the baseline data as covariates.",Statistical analysis,[247742],[16655],[16866],[False],[0],[0],[False],['0']
40419,PMC6371462,41880,"Missing data were handled through multiple imputations, which were conducted with a linear mixed model, with post-intervention and follow-up as repeated measurements, baseline as a fixed effect covariate, and an unstructured covariance matrix.",Statistical analysis,[247750],[16867],[17110],[False],[0],[0],[False],['0']
40420,PMC6371462,41881,We assumed and estimated a time trend for the measures for the postintervention and one-year follow-up measurements.,Statistical analysis,[247758],[17111],[17227],[False],[0],[0],[False],['0']
40421,PMC6371462,41882,"Furthermore, the linear mixed models were selected for their capacity to handle missing longitudinal data.",Statistical analysis,[247766],[17228],[17334],[False],[0],[0],[False],['0']
40422,PMC6371462,41883,"The fixed values were the baseline values of GAF-F, GAF-S, PSP, PANSS, subscale PANSS, Negative Scale, Subscale PANSS Positive Scale, Subscale PANSS General Psychopathology Scale, HAM-D6, YMRS, CSQ, IMRS-P, IMRS-S, AHS, randomizing, sex, age, diagnosis, and CMHC.",Statistical analysis,[247774],[17335],[17598],[False],[0],[0],[False],['0']
40423,PMC6371462,41884,The automatic procedure in SPSS to produce missing imputed data values was used with 100 imputation estimates.,Statistical analysis,[247782],[17599],[17709],[False],[0],[0],[False],['0']
40424,PMC6371462,41885,"Outliers were identified through Cooks’ D Diagram, and all outliers were included in all analyses.",Statistical analysis,[247790],[17710],[17808],[False],[0],[0],[False],['0']
40425,PMC6371462,41886,"Residuals were tested for normality, linearity, and homoscedasticity, including using Spearman’s rank-order correlation.",Statistical analysis,[247798],[17809],[17929],[False],[0],[0],[False],['0']
40426,PMC6371462,41887,"Also, complete case analysis was conducted where it is assumed that the missing data are missing completely at random and excluded in the analysis.",Statistical analysis,[247806],[17930],[18077],[False],[0],[0],[False],['0']
40427,PMC6371462,41888,In complete case analysis it is presumed to describe data where the observed complete cases are representative of the sample [31].,Statistical analysis,[247814],[18078],[18208],[False],[0],[0],[False],['0']
40428,PMC6371462,41889,The per-protocol analysis was performed to explore whether attendance at the IMR groups influenced the results.,Statistical analysis,[247822],[18209],[18320],[False],[0],[0],[False],['0']
40429,PMC6371462,41890,One-way ANOVA was conducted to evaluate attendance at the IMR groups as a continuous variable and to treat attendance as a dichotomous variable (0–10 sessions vs. > 10 sessions); the latter measure was used for non-exposure vs. exposure.,Statistical analysis,[247830],[18321],[18558],[False],[0],[0],[False],['0']
40430,PMC6371462,41891,Subgroup analyses were conducted to evaluate whether the diagnosis or sex interacted with treatment for the secondary outcomes.,Statistical analysis,[247838],[18559],[18686],[False],[0],[0],[False],['0']
40431,PMC6371462,41892,"In addition, a post hoc analysis was performed to determine whether the subscale measurements of symptoms were influenced by IMR attendance as shown in other trials using one-way ANOVA [26].",Statistical analysis,[247846],[18687],[18877],[False],[0],[0],[False],['0']
40432,PMC6371462,41893,The other post hoc analysis analyzed the IMRS as a three-factor solution.,Statistical analysis,[247854],[18878],[18951],[False],[0],[0],[False],['0']
40433,PMC6371462,41894,"Also, we examined within-group changes at long-term follow-up by linear mixed model, with post-intervention and follow-up as repeated measurements, baseline as a fixed effect covariate, and an unstructured covariance matrix only focusing on time effect within groups.",Statistical analysis,[247862],[18952],[19219],[False],[0],[0],[False],['0']
40434,PMC6371462,41895,"Poisson regression analysis was used for the count outcomes (i.e., hospital admission, emergency room visits, and outpatient treatment).",Statistical analysis,[247870],[19220],[19356],[False],[0],[0],[False],['0']
40435,PMC6371462,41896,"Descriptive analyses were used to explore whether the data were zero-inflated, and a negative binominal model was conducted when the data were zero-inflated.",Statistical analysis,[247878],[19357],[19514],[False],[0],[0],[False],['0']
40436,PMC6371462,41897,IBM SPSS Statistics (version 19) for Windows was used for the statistical analysis.,Statistical analysis,[247886],[19515],[19598],[False],[0],[0],[False],['0']
40437,PMC6371462,41898,Results,Results,[247894],[19599],[19607],[False],[0],[0],[False],['0']
40438,PMC6371462,41899,Fig.,Results,[247902],[19608],[19612],[False],[0],[0],[False],['0']
40439,PMC6371462,41900,2 Flow Diagram for the Danish Illness Management and Recovery trial.,Results,[247910],[19613],[19681],[False],[0],[0],[False],['0']
40440,PMC6371462,41901,Table 2 Demographic and clinical characteristics of the patients at the baseline.,Results,[247918],[19682],[19763],[False],[0],[0],[False],['0']
40441,PMC6371462,41902,Figure 2 shows the trial flowchart.,Results,[247926],[19764],[19799],[False],[0],[0],[False],['0']
40442,PMC6371462,41903,"A total of 198 patients completed the baseline interview, and 69% of the participants were available at the one-year follow-up.",Results,[247934],[19800],[19927],[False],[0],[0],[False],['0']
40443,PMC6371462,41904,"In total, 31 participants from the IMR group and 33 from the control group did not participate in the one-year follow-up.",Results,[247942],[19928],[20049],[False],[0],[0],[False],['0']
40444,PMC6371462,41905,No differences were found in the demographic and clinical characteristics between the IMR and TAU groups at the one-year follow-up and Table 2 presents the baseline demographics on the participants.,Results,[247950],[20050],[20248],[False],[0],[0],[False],['0']
40445,PMC6371462,41906,Intent-to-treat analyses,Results|Intent-to-treat analyses,[247958],[20249],[20273],[False],[0],[0],[False],['0']
40446,PMC6371462,41907,Table 3 Recovery and illness self-management outcomes at the one-year follow-up.,Results|Intent-to-treat analyses,[247966],[20274],[20354],[False],[0],[0],[False],['0']
40447,PMC6371462,41908,"Table 3 shows the results of the one-year follow-up, intent-to-treat analysis, and complete case analysis.",Results|Intent-to-treat analyses,[247974],[20355],[20461],[False],[0],[0],[False],['0']
40448,PMC6371462,41909,"In the GAF-F, a nonsignificant group indicated a difference of 0.8 in favor of the IMR group (95% confidence interval [CI]: − 4.7 to 3.0 points, t = − 0.42 p = 0.45).",Results|Intent-to-treat analyses,[247982],[20462],[20628],[False],[0],[0],[False],['0']
40449,PMC6371462,41910,"Table 3 summarized the analysis of the group means over time and revealed no significant differences between the IMR and control groups in clinical recovery symptoms (i.e., GAF-S, PSP, PANSS, HAM-D, and YMRS).",Results|Intent-to-treat analyses,[247990],[20629],[20838],[False],[0],[0],[False],['0']
40450,PMC6371462,41911,"Analyses of changes in personal recovery based on the MHRM, Hope, and Client’s Satisfaction Questionnaire also showed no differences between the IMR and control groups between either the baseline and one-year follow-up or the postintervention and one-year follow-up time points.",Results|Intent-to-treat analyses,[247998],[20839],[21117],[False],[0],[0],[False],['0']
40451,PMC6371462,41912,"As a post hoc analysis, we examined the time effect and while both groups improved on functioning and personal recovery, there was no differences on symptoms and illness management (data not shown).n",Results|Intent-to-treat analyses,[248006],[21118],[21317],[False],[0],[0],[False],['0']
40452,PMC6371462,41913,Complete case analyses,Results|Complete case analyses,[248014],[21318],[21340],[False],[0],[0],[False],['0']
40453,PMC6371462,41914,"Similar results were found between the complete case analyses and the intent-to-treat analyses for the GAF-F, PSP, and PANSS.",Results|Complete case analyses,[248022],[21341],[21466],[False],[0],[0],[False],['0']
40454,PMC6371462,41915,"Furthermore, no between-group differences were observed in any of the other assessments, including the GAF-S, HAM-D, YMRS, Adult State of Hope, MHRM, Client’s Satisfaction Questionnaire, or the two versions of the IMRS.",Results|Complete case analyses,[248030],[21467],[21686],[False],[0],[0],[False],['0']
40455,PMC6371462,41916,Service utilization,Results|Service utilization,[248038],[21687],[21706],[False],[0],[0],[False],['0']
40456,PMC6371462,41917,"No significant differences were found in the number of hospital admissions (mean difference 0.49, 95% CI: 0.67–1.48, p = 1.0), days of hospital admission (mean difference 19.4 95% CI: -0.76-0.5, p = 0.5), or number of emergency room visits (mean difference 0.63, 95% CI: 0.81–1.54, p = 0.51) between the IMR and control groups.",Results|Service utilization,[248046],[21707],[22034],[False],[0],[0],[False],['0']
40457,PMC6371462,41918,Fidelity,Results|Fidelity,[248054],[22035],[22043],[False],[0],[0],[False],['0']
40458,PMC6371462,41919,"The IMR Fidelity mean scores across the three participating CMHCs assessed half-way at 4 months were CMHC 1: 4.3 (SD 0.9), CMHC 2: 4.1 (SD 0,1) and CMHC 3: 4.1 (SD 0.3) indicating good fidelity.",Results|Fidelity,[248062],[22044],[22238],[False],[0],[0],[False],['0']
40459,PMC6371462,41920,"The mean scores at the end assessment were CMHC 1: 4.2 (SD 0.7), CMHC 2: 4.0 (SD 0.8), and CMHC 3: 4.2 (SD 0.9) indicating high fidelity.",Results|Fidelity,[248070],[22239],[22376],[False],[0],[0],[False],['0']
40460,PMC6371462,41921,For further information see Dalum et al.,Results|Fidelity,[248078],[22377],[22417],[False],[0],[0],[False],['0']
40461,PMC6371462,41922,(2018) [17].,Results|Fidelity,[248086],[22418],[22430],[False],[0],[0],[False],['0']
40462,PMC6371462,41923,Subgroup and subscale analyses,Results|Subgroup and subscale analyses,[248094],[22431],[22461],[False],[0],[0],[False],['0']
40463,PMC6371462,41924,Table 4 Per-protocol and post-hoc subgroup analysis at one-year-follow-up.,Results|Subgroup and subscale analyses,[248102],[22462],[22536],[False],[0],[0],[False],['0']
40464,PMC6371462,41925,No association was found between a higher number of sessions attended and the GAF-F score at the one-year follow-up (see Table 4).,Results|Subgroup and subscale analyses,[248110],[22537],[22667],[False],[0],[0],[False],['0']
40465,PMC6371462,41926,"The subgroup analyses showed no differences in the effect of IMR according to the participant diagnosis or sex on the outcomes of the GAF-F, PSP, or PANSS (see Table 4).",Results|Subgroup and subscale analyses,[248118],[22668],[22837],[False],[0],[0],[False],['0']
40466,PMC6371462,41927,"We also performed post hoc analyses to investigate whether specific symptoms were influenced by IMR, as shown in other trials.",Results|Subgroup and subscale analyses,[248126],[22838],[22964],[False],[0],[0],[False],['0']
40467,PMC6371462,41928,"When performing complete case analyses using univariate ANOVA with postintervention as a covariate, no significant difference was found between the intervention and control groups.",Results|Subgroup and subscale analyses,[248134],[22965],[23145],[False],[0],[0],[False],['0']
40468,PMC6371462,41929,"A p-value of 0.05 was found for the PANSS positive symptoms favoring the TAU group; however, when considering the multiple statistical tests conducted, this result cannot be considered significant.",Results|Subgroup and subscale analyses,[248142],[23146],[23343],[False],[0],[0],[False],['0']
40469,PMC6371462,41930,"We planned to analyze the IMRS as the total scale score (see Table 3), but post hoc we also analyzed the IMRS as three-factor solution subscales (the Recovery, Management, and Biology scales) [26]; however, the results were not significant (data not shown).",Results|Subgroup and subscale analyses,[248150],[23344],[23601],[False],[0],[0],[False],['0']
40470,PMC6371462,41931,Discussion,Discussion,[248158],[23602],[23613],[False],[0],[0],[False],['0']
40471,PMC6371462,41932,"The aim of the present study was to examine the long-term outcomes of an IMR trial, because the hypothesis behind the IMR program is that clinical and personal recovery can occur over a considerable timeframe after attending the program (Fig.",Discussion,[248166],[23614],[23856],[False],[0],[0],[False],['0']
40472,PMC6371462,41933,1).,Discussion,[248174],[23857],[23860],[False],[0],[0],[False],['0']
40473,PMC6371462,41934,"Overall, the study revealed no difference between the IMR and TAU groups in clinical recovery, personal recovery, illness self-management, and service utilization at the one-year follow-up.",Discussion,[248182],[23861],[24050],[False],[0],[0],[False],['0']
40474,PMC6371462,41935,This result was similar to the findings at the end of the intervention [17].,Discussion,[248190],[24051],[24127],[False],[0],[0],[False],['0']
40475,PMC6371462,41936,Fidelity and exposure to IMR,Discussion|Fidelity and exposure to IMR,[248198],[24128],[24156],[False],[0],[0],[False],['0']
40476,PMC6371462,41937,"As mentioned in the introduction, two important issues should be considered in addition to the RCT design when interpreting the results: the fidelity of the IMR program and the participant’s exposure to the IMR program.",Discussion|Fidelity and exposure to IMR,[248206],[24157],[24376],[False],[0],[0],[False],['0']
40477,PMC6371462,41938,The fidelity assessments showed good implementation at the program level [32].,Discussion|Fidelity and exposure to IMR,[248214],[24377],[24455],[False],[0],[0],[False],['0']
40478,PMC6371462,41939,"The high fidelity can be explained by that all IMR facilitators went through a specific course of education prior to the intervention, had supervision during the intervention and held planned meetings during the intervention with the research team, leaders of the CMHC and IMR-instructors to evaluate the implementation of the IMR-program.",Discussion|Fidelity and exposure to IMR,[248222],[24456],[24795],[False],[0],[0],[False],['0']
40479,PMC6371462,41940,"Among the participants randomized to the IMR group, 13% did not attend a single IMR session, and 46.5% attended more than 20 sessions, resulting in an average session number of 16.4 (SD ±13.3) [17].",Discussion|Fidelity and exposure to IMR,[248230],[24796],[24994],[False],[0],[0],[False],['0']
40480,PMC6371462,41941,We had hoped for a higher participation rate.,Discussion|Fidelity and exposure to IMR,[248238],[24995],[25040],[True],['Population'],['We had hoped for a higher participation rate'],[True],['Population']
40481,PMC6371462,41942,"This result is a limitation, although the analyses showed no differences in the outcomes at the one-year follow-up between the participants who attended 0–10 sessions and those who attended 10+ sessions.",Discussion|Fidelity and exposure to IMR,[248254],[25041],[25244],[False],[0],[0],[False],['0']
40482,PMC6371462,41943,Trial results in the context of previous IMR trials,Discussion|Fidelity and exposure to IMR,[248262],[25245],[25296],[False],[0],[0],[False],['0']
40483,PMC6371462,41944,"In terms of symptoms, the review by McGuire et al.",Discussion|Fidelity and exposure to IMR,[248270],[25297],[25347],[False],[0],[0],[False],['0']
40484,PMC6371462,41945,"(2014) [7] found two RCTs [8, 9] supporting the hypothesis that IMR reduced symptoms, which aligned with the conclusion of a later study using a modified version of the IMR program [12].",Discussion|Fidelity and exposure to IMR,[248278],[25348],[25534],[False],[0],[0],[False],['0']
40485,PMC6371462,41946,"However, the findings of the present study align with those of the study by Salyers et al.",Discussion|Fidelity and exposure to IMR,[248286],[25535],[25625],[False],[0],[0],[False],['0']
40486,PMC6371462,41947,(2014) [11].,Discussion|Fidelity and exposure to IMR,[248294],[25626],[25638],[False],[0],[0],[False],['0']
40487,PMC6371462,41948,"Thus, the results appear to be contradictory.",Discussion|Fidelity and exposure to IMR,[248302],[25639],[25684],[False],[0],[0],[False],['0']
40488,PMC6371462,41949,"Currently, a Cochrane review of IMR is being conducted; a meta-analysis will be conducted as part of this review if the symptom data are adequate, which will provide a better understanding of the effect of IMR on symptoms [33].",Discussion|Fidelity and exposure to IMR,[248310],[25685],[25912],[False],[0],[0],[False],['0']
40489,PMC6371462,41950,"Furthermore, after a Dutch feasibility study of the IMR program, the authors proceeded to a RCT; the results from this RCT will contribute to clarifying the effect of IMR on symptoms [34].",Discussion|Fidelity and exposure to IMR,[248318],[25913],[26101],[False],[0],[0],[False],['0']
40490,PMC6371462,41951,"The present study found no effect of IMR on improved functioning, which was in accordance with the study by Salyers et al.",Discussion|Fidelity and exposure to IMR,[248326],[26102],[26224],[False],[0],[0],[False],['0']
40491,PMC6371462,41952,(2014) [11] but differed from the study by Levitt et al.,Discussion|Fidelity and exposure to IMR,[248334],[26225],[26281],[False],[0],[0],[False],['0']
40492,PMC6371462,41953,(2009) [8].,Discussion|Fidelity and exposure to IMR,[248342],[26282],[26293],[False],[0],[0],[False],['0']
40493,PMC6371462,41954,"Altogether, the results raise questions regarding the impact of IMR on functioning as a long-term effect.",Discussion|Fidelity and exposure to IMR,[248350],[26294],[26399],[False],[0],[0],[False],['0']
40494,PMC6371462,41955,"Personal recovery, such as hope [28], and a person’s experience with recovery (i.e., pursuing personal goals or taking social initiatives) were measured in three other trials, none of which reported significant improvement for the participants in IMR [9–11].",Discussion|Fidelity and exposure to IMR,[248358],[26400],[26658],[False],[0],[0],[False],['0']
40495,PMC6371462,41956,"Therefore, the results of the present trial are in accordance with these results and suggest that IMR does not seem to impact the participants’ personal recovery at the long-term follow-up.",Discussion|Fidelity and exposure to IMR,[248366],[26659],[26848],[False],[0],[0],[False],['0']
40496,PMC6371462,41957,"According to the conceptual framework underlying the IMR program, illness self-management is central for the ability of individuals to achieve clinical and personal recovery from mental illness [1].",Discussion|Fidelity and exposure to IMR,[248374],[26849],[27047],[False],[0],[0],[False],['0']
40497,PMC6371462,41958,All five trials assessed illness self-management with the IMRS.,Discussion|Fidelity and exposure to IMR,[248382],[27048],[27111],[False],[0],[0],[False],['0']
40498,PMC6371462,41959,"In three of the trials, both the patient (IMR-patient) and staff (IMR-staff) versions were used [8–10].",Discussion|Fidelity and exposure to IMR,[248390],[27112],[27215],[False],[0],[0],[False],['0']
40499,PMC6371462,41960,"In contrast to our study, these three studies reported significant improvements resulting from IMR.",Discussion|Fidelity and exposure to IMR,[248398],[27216],[27315],[False],[0],[0],[False],['0']
40500,PMC6371462,41961,"Because the other RCTs had methodological limitations regarding the effect of IMR on illness self-management, examining the effect of IMR in a meta-analysis to obtain an integrated view of the effect is important [33].",Discussion|Fidelity and exposure to IMR,[248406],[27316],[27534],[False],[0],[0],[False],['0']
40501,PMC6371462,41962,The review by McGuire et al.,Discussion|Fidelity and exposure to IMR,[248414],[27535],[27563],[False],[0],[0],[False],['0']
40502,PMC6371462,41963,"(2014) [7] found that independent-assessor rated outcomes were more likely to show significant changes, although the present trial did not support these results.",Discussion|Fidelity and exposure to IMR,[248422],[27564],[27725],[False],[0],[0],[False],['0']
40503,PMC6371462,41964,"In our study we found time effect in both groups on functioning and personal recovery, but not on symptoms and illness management, indicating that services and/or time were generally associated with some improvement but IMR was not associated with additional benefit.",Discussion|Fidelity and exposure to IMR,[248430],[27726],[27993],[False],[0],[0],[False],['0']
40504,PMC6371462,41965,One possible explanation for our null findings may be that the IMR-program is not as effective as earlier reviewer concluded.,Discussion|Fidelity and exposure to IMR,[248438],[27994],[28119],[False],[0],[0],[False],['0']
40505,PMC6371462,41966,A recent Cochrane review showed that psychoeducational programs affected the participants’ symptom severity but not their daily functioning [35].,Discussion|Fidelity and exposure to IMR,[248446],[28120],[28265],[False],[0],[0],[False],['0']
40506,PMC6371462,41967,IMR is more than a psychoeducational program.,Discussion|Fidelity and exposure to IMR,[248454],[28266],[28311],[False],[0],[0],[False],['0']
40507,PMC6371462,41968,"In psychoeducational programs strategies are considered to be important for shared decision-making; however, other behavioral-based illness management strategies are also included in IMR, such as relapse prevention training and training in coping skills [36].",Discussion|Fidelity and exposure to IMR,[248462],[28312],[28571],[False],[0],[0],[False],['0']
40508,PMC6371462,41969,The results on the Cochran review on psychoeducational programs together with the results from IMR trials indicate the necessity of considering the need for programs with other conceptual frameworks to support people with severe mental illnesses in achieving functional and personal recovery.,Discussion|Fidelity and exposure to IMR,[248470],[28572],[28864],[False],[0],[0],[False],['0']
40509,PMC6371462,41970,"The results of present trial indicate that the IMR-program’s theoretical foundation, which is listed in Fig.",Discussion|Fidelity and exposure to IMR,[248478],[28865],[28973],[False],[0],[0],[False],['0']
40510,PMC6371462,41971,1 may be flawed.,Discussion|Fidelity and exposure to IMR,[248486],[28974],[28990],[False],[0],[0],[False],['0']
40511,PMC6371462,41972,Strengths and limitations,Discussion|Strengths and limitations,[248494],[28991],[29016],[False],[0],[0],[False],['0']
40512,PMC6371462,41973,The present RCT has several strengths.,Discussion|Strengths and limitations,[248502],[29017],[29055],[False],[0],[0],[False],['0']
40513,PMC6371462,41974,"The trial was conducted according to the best methods available to reduce the risk of systematic, random, and design errors.",Discussion|Strengths and limitations,[248510],[29056],[29180],[False],[0],[0],[False],['0']
40514,PMC6371462,41975,"The trial was conducted with adequate generation of the allocation sequence, adequate allocation concealment, adequate blinding wherever possible, adequate reporting of all relevant outcomes, and an intent-to-treat-analysis [37–40].",Discussion|Strengths and limitations,[248518],[29181],[29413],[False],[0],[0],[False],['0']
40515,PMC6371462,41976,"Moreover, sample size calculations were conducted prior to participant recruitment.",Discussion|Strengths and limitations,[248526],[29414],[29497],[False],[0],[0],[False],['0']
40516,PMC6371462,41977,"However, the trial also has some limitations.",Discussion|Strengths and limitations,[248534],[29498],[29543],[False],[0],[0],[False],['0']
40517,PMC6371462,41978,"Although all centers reported high fidelity, reflecting good implementation of IMR in the CMHCs [32], none scored high on the fidelity item pertaining to the involvement of participants’ families or significant others [32].",Discussion|Strengths and limitations,[248542],[29544],[29767],[False],[0],[0],[False],['0']
40518,PMC6371462,41979,A limitation in the fidelity assessment was that the IMR treatment integrity scale (IT-IS) to measure the therapeutic skills of the IMR-instructors or assessment to measure the implementation of IMR at organization level by the General organizational index (GOI-scale) was not applied in this trial.,Discussion|Strengths and limitations,[248552],[29768],[30067],[True],['RelevantOutcomeExcluded'],['the IMR treatment integrity scale (IT-IS) to measure the therapeutic skills of the IMR-instructors or assessment to measure the implementation of IMR at organization level by the General organizational index (GOI-scale) was not applied'],[True],['OutcomeMeasures']
40519,PMC6371462,41980,"As previously mentioned, another limitation was that exposure to IMR was lower than we had hoped.",Discussion|Strengths and limitations,[248569],[30068],[30165],[True],['Population'],['exposure to IMR was lower than we had hoped'],[True],['Population']
40520,PMC6371462,41981,"However, no difference between the non-exposed participants (attending 0–10 sessions) and the exposed participants (attending 10+ sessions) was found at the one-year follow-up, which was in accordance with the fact that we also found no postintervention differences between the two groups.",Discussion|Strengths and limitations,[248582],[30166],[30455],[False],[0],[0],[False],['0']
40521,PMC6371462,41982,"Postintervention, we performed post hoc analyses to address the exposure issue; however, none of our findings indicated that this problem had affected our results [17].",Discussion|Strengths and limitations,[248590],[30456],[30624],[False],[0],[0],[False],['0']
40522,PMC6371462,41983,The exposure to IMR in the present study may better reflect a “real-world setting” than high IMR exposure.,Discussion|Strengths and limitations,[248598],[30625],[30731],[False],[0],[0],[False],['0']
40523,PMC6371462,41984,We can expect that some participants may not want to continue after a few IMR sessions and that some may not be able to participate in all sessions over a nine-month period.,Discussion|Strengths and limitations,[248606],[30732],[30905],[False],[0],[0],[False],['0']
40524,PMC6371462,41985,"Furthermore, the waiting time from randomization to the first IMR group session was, on average, 87 days, which might have affected the results; indeed, providing psychosocial treatment when an individual is interested in and motivated to participate in such treatment is important.",Discussion|Strengths and limitations,[248618],[30906],[31188],[True],['ExperimentalPhaseDuration'],"['the waiting time from randomization to the first IMR group session was, on average, 87\u2009days, which might have affected the results']",[True],['StudyDuration']
40525,PMC6371462,41986,"However, analyses to determine whether this wait affected the results did not indicate any effect [17].",Discussion|Strengths and limitations,[248630],[31189],[31292],[False],[0],[0],[False],['0']
40526,PMC6371462,41987,"In the present RCT, some of the IMR instructors were case managers for patients in the control group, and therefore, a spill-over effect in the control group was possible.",Discussion|Strengths and limitations,[248644],[31293],[31464],[True],['NonstandardTreatmentCharacteristics'],['a spill-over effect in the control group was possible'],[True],['Intervention']
40527,PMC6371462,41988,"However, the IMR instructors were educated to use only the IMR material for the IMR group participants.",Discussion|Strengths and limitations,[248654],[31465],[31568],[False],[0],[0],[False],['0']
40528,PMC6371462,41989,"Furthermore, they were told to consult a well-experienced psychiatrist in only performing TAU, in case they were unsure whether specific elements could be regarded as part of TAU.",Discussion|Strengths and limitations,[248662],[31569],[31748],[False],[0],[0],[False],['0']
40529,PMC6371462,41990,A critical limitation is the high number of incomplete observed data due to a high lost to follow-up rate.,Discussion|Strengths and limitations,[248675],[31749],[31855],[True],['HighLossToFollowUp'],['a high lost to follow-up rate'],[True],['MissingData']
40530,PMC6371462,41991,"Furthermore, a limitation is that nearly one-third of the participants did not complete the self-report instruments a long-term follow-up.",Discussion|Strengths and limitations,[248693],[31856],[31994],[True],['MissingData'],['nearly one-third of the participants did not complete the self-report instruments a long-term follow-up'],[True],['MissingData']
40531,PMC6371462,41992,"To address these missing data, a mixed model with multiple imputations was generated to estimate and improve the statistical test values.",Discussion|Strengths and limitations,[248702],[31995],[32132],[False],[0],[0],[False],['0']
40532,PMC6371462,41993,"Furthermore, the analyses were conducted according to the intent-to-treat principle, with the two-tailed level of significance for all statistical tests set at 0.05.",Discussion|Strengths and limitations,[248710],[32133],[32298],[False],[0],[0],[False],['0']
40533,PMC6371462,41994,"Because all outcomes were exploratory, the risk of type 1 error was considerable.",Discussion|Strengths and limitations,[248718],[32299],[32380],[False],[0],[0],[False],['0']
40534,PMC6371462,41995,"However, because none of the outcomes were statistically significant, the risk of type 1 error was ruled out.",Discussion|Strengths and limitations,[248726],[32381],[32490],[False],[0],[0],[False],['0']
40535,PMC6371462,41996,"The participants who did not attend at the one-year follow-up may have recovered; however, these participants had significantly more hospitalizations, longer hospital admissions, and low attendance to the IMR program (see Table 4.",Discussion|Strengths and limitations,[248734],[32491],[32721],[False],[0],[0],[False],['0']
40536,PMC6371462,41997,"When we conducted the present trial, we might have been too optimistic, because the trial was based on the number of participants needed to assess a 6-point difference on the GAF-F scale postintervention.",Discussion|Strengths and limitations,[248742],[32722],[32926],[False],[0],[0],[False],['0']
40537,PMC6371462,41998,"Therefore, our sample size may be too small to state whether an observed difference of 0.8 is in fact a true difference at the one-year follow-up, but this finding most likely does not have clinical relevance.",Discussion|Strengths and limitations,[248751],[32927],[33136],[True],['SampleSize'],['our sample size may be too small'],[True],['UnderpoweredStudy']
40538,PMC6371462,41999,Conclusion,Conclusion,[248766],[33137],[33148],[False],[0],[0],[False],['0']
40539,PMC6371462,42000,The present study showed no significant effect of IMR on clinical and personal recovery at the one-year follow-up.,Conclusion,[248774],[33149],[33263],[False],[0],[0],[False],['0']
40540,PMC6371462,42001,"Together with previous RCTs with long-term follow-up, the findings raise questions about the effect of IMR on symptom severity.",Conclusion,[248782],[33264],[33391],[False],[0],[0],[False],['0']
40541,PMC6371462,42002,"Altogether, the results of existing RCTs that have investigated IMR raise questions regarding the impact of IMR on functioning and do not suggest any effects on personal recovery.",Conclusion,[248790],[33392],[33571],[False],[0],[0],[False],['0']
40542,PMC6371462,42003,One possible explanation for our null findings is that the IMR-program is not as effective as earlier reviewer concluded.,Conclusion,[248798],[33572],[33693],[False],[0],[0],[False],['0']
40543,PMC6371462,42004,"Hopefully, ongoing research on IMR [33, 41] will provide a more solid answer on this matter.",Conclusion,[248806],[33694],[33786],[False],[0],[0],[False],['0']
40544,PMC6371462,42005,"However, the results suggest the need to consider the development of interventions based on other conceptual frameworks to help people with severe mental illnesses gain a better level of functioning and achieve personal recovery.",Conclusion,[248814],[33787],[34016],[False],[0],[0],[False],['0']
40545,PMC6371462,42006,Abbreviations,Abbreviations,[248822],[34017],[34031],[False],[0],[0],[False],['0']
40546,PMC6371462,42007,GAF-F Global Assessment of Functioning–Functioning scale,Abbreviations,[248830],[34032],[34088],[False],[0],[0],[False],['0']
40547,PMC6371462,42008,GAF-S Global Assessment of Symptom–Symptom scale,Abbreviations,[248838],[34089],[34137],[False],[0],[0],[False],['0']
40548,PMC6371462,42009,HAM Hamilton Scale of Depression six items,Abbreviations|HAM Hamilton Scale of Depression six items,[248846],[34138],[34180],[False],[0],[0],[False],['0']
40549,PMC6371462,42010,Hope Snider’ Adult Hope scale,Abbreviations|Hope Snider’ Adult Hope scale,[248854],[34181],[34210],[False],[0],[0],[False],['0']
40550,PMC6371462,42011,IMR The Illness Management and Recovery Program,Abbreviations|IMR The Illness Management and Recovery Program,[248862],[34211],[34258],[False],[0],[0],[False],['0']
40551,PMC6371462,42012,IMRS The Illness Management and Recovery Scale,Abbreviations|IMRS The Illness Management and Recovery Scale,[248870],[34259],[34305],[False],[0],[0],[False],['0']
40552,PMC6371462,42013,MHRM Mental Health Recovery Measure,Abbreviations|MHRM Mental Health Recovery Measure,[248878],[34306],[34341],[False],[0],[0],[False],['0']
40553,PMC6371462,42014,NS Not Significant,Abbreviations|NS Not Significant,[248886],[34342],[34360],[False],[0],[0],[False],['0']
40554,PMC6371462,42015,PSP Personal and Social Performance scale,Abbreviations|PSP Personal and Social Performance scale,[248894],[34361],[34402],[False],[0],[0],[False],['0']
40555,PMC6371462,42016,RCT Randomized Clinical Trial,Abbreviations|RCT Randomized Clinical Trial,[248902],[34403],[34432],[False],[0],[0],[False],['0']
40556,PMC6371462,42017,TAU Treatment as Usual,Abbreviations|TAU Treatment as Usual,[248910],[34433],[34455],[False],[0],[0],[False],['0']
40557,PMC6371462,42018,YMRS Young’s Mania Rating ScaleAcknowledgements,Abbreviations|TAU Treatment as Usual,[248918],[34456],[34503],[False],[0],[0],[False],['0']
40558,PMC6371462,42019,We are grateful for the participation of the patients and the assistance of the clinical staff at each community mental health center.,Abbreviations|TAU Treatment as Usual,[248926],[34504],[34638],[False],[0],[0],[False],['0']
40559,PMC6371462,42020,Funding,Abbreviations|Funding,[248934],[34639],[34646],[False],[0],[0],[False],['0']
40560,PMC6371462,42021,This study was sponsored by grants from the Residential Skovvaenget from the Mental Health Services in the Capital Region of Denmark and the TRYG Foundation.,Abbreviations|Funding,[248942],[34647],[34804],[False],[0],[0],[False],['0']
40561,PMC6371462,42022,Availability of data and materials,Abbreviations|Availability of data and materials,[248950],[34805],[34839],[False],[0],[0],[False],['0']
40562,PMC6371462,42023,The data are not publicly available because permission to release the data was not gained from the participants.,Abbreviations|Availability of data and materials,[248958],[34840],[34952],[False],[0],[0],[False],['0']
40563,PMC6371462,42024,This restriction has been imposed by the Danish Data Protection Agency.,Abbreviations|Availability of data and materials,[248966],[34953],[35024],[False],[0],[0],[False],['0']
40564,PMC6371462,42025,"However, the data can be requested by contacting videnscenterfordataanmeldelser.rigshospitalet@regionh.dk.",Abbreviations|Availability of data and materials,[248974],[35025],[35131],[False],[0],[0],[False],['0']
40565,PMC6371462,42026,Ethics approval and consent to participate,Abbreviations|Ethics approval and consent to participate,[248982],[35132],[35174],[False],[0],[0],[False],['0']
40566,PMC6371462,42027,"The trial was approved by the Ethics Committee in the Capital Region of Denmark (H-1-2010-134), reported to the Danish Data Protection Agency (RHP-2011-09), and registered on www.clinicaltrials.gov (NCT01361698) before recruitment began.",Abbreviations|Ethics approval and consent to participate,[248990],[35175],[35412],[False],[0],[0],[False],['0']
40567,PMC6371462,42028,The trial followed the international ethical guidelines for informed consent in clinical trials.,Abbreviations|Ethics approval and consent to participate,[248998],[35413],[35509],[False],[0],[0],[False],['0']
40568,PMC6371462,42029,"Consent was voluntary, informed, and given both verbally and in writing.",Abbreviations|Ethics approval and consent to participate,[249006],[35510],[35582],[False],[0],[0],[False],['0']
40569,PMC6371462,42030,The participants did not receive a fee for their participation.,Abbreviations|Ethics approval and consent to participate,[249014],[35583],[35646],[False],[0],[0],[False],['0']
40570,PMC6371462,42031,Consent for publication,Abbreviations|Consent for publication,[249022],[35647],[35670],[False],[0],[0],[False],['0']
40571,PMC6371462,42032,Not applicable.,Abbreviations|Not applicable.,[249030],[35671],[35686],[False],[0],[0],[False],['0']
40572,PMC6371462,42033,Competing interests,Abbreviations|Competing interests,[249038],[35687],[35706],[False],[0],[0],[False],['0']
40573,PMC6371462,42034,"The sponsors played no role in the study design, data collection, data analysis, data interpretation, or writing of the report.",Abbreviations|Competing interests,[249046],[35707],[35834],[False],[0],[0],[False],['0']
40574,PMC6371462,42035,"Except for Professor Kim Mueser, all authors declare that they have no conflicts of interests.",Abbreviations|Competing interests,[249054],[35835],[35929],[False],[0],[0],[False],['0']
40575,PMC6371462,42036,Professor Kim Mueser declares that he was one of the original developers of the IMR program but holds no financial interest in its use.,Abbreviations|Competing interests,[249062],[35930],[36065],[False],[0],[0],[False],['0']
40576,PMC6371462,42037,Publisher’s Note,Abbreviations|Publisher’s Note,[249070],[36066],[36082],[False],[0],[0],[False],['0']
40577,PMC6371462,42038,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|Publisher’s Note,[249078],[36083],[36201],[False],[0],[0],[False],['0']
40889,PMC6814122,39625,Implementing integrated services in routine behavioral health care: primary outcomes from a cluster randomized controlled trial,Title,[230292],[27030],[127],[False],[0],[0],[False],['0']
40890,PMC6814122,39626,Background,Abstract,[230299],[128],[139],[False],[0],[0],[False],['0']
40891,PMC6814122,39627,An estimated 8.2 million adults in the United States live with co-occurring mental health and substance use disorders.,Abstract,[230306],[140],[258],[False],[0],[0],[False],['0']
40892,PMC6814122,39628,"Although the benefits of integrated treatment services for persons with co-occurring disorders has been well-established, gaps in access to integrated care persist.",Abstract,[230313],[259],[423],[False],[0],[0],[False],['0']
40893,PMC6814122,39629,Implementation research can address this gap.,Abstract,[230320],[424],[469],[False],[0],[0],[False],['0']
40894,PMC6814122,39630,We evaluated if the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy was effective in increasing integrated services capacity among organizations treating persons with co-occurring disorders.,Abstract,[230327],[470],[695],[False],[0],[0],[False],['0']
40895,PMC6814122,39631,Methods,Abstract,[230334],[696],[703],[False],[0],[0],[False],['0']
40896,PMC6814122,39632,This study employed a cluster randomized waitlist control group design.,Abstract,[230341],[704],[775],[False],[0],[0],[False],['0']
40897,PMC6814122,39633,"Forty-nine addiction treatment organizations from the State of Washington were randomized into one of two study arms: (1) NIATx strategy (active implementation strategy), or (2) waitlist (control).",Abstract,[230348],[776],[973],[False],[0],[0],[False],['0']
40898,PMC6814122,39634,The primary outcome was a standardized organizational measure of integrated service capability: the Dual Diagnosis in Addiction Treatment (DDCAT) Index.,Abstract,[230355],[974],[1126],[False],[0],[0],[False],['0']
40899,PMC6814122,39635,Intent-to-treat analyses and per-protocol analyses were conducted to address the following questions: (1) Is NIATx effective in increasing integrated service capacity?,Abstract,[230362],[1127],[1294],[False],[0],[0],[False],['0']
40900,PMC6814122,39636,and (2) Are there differences in organizations that actually use NIATx per-protocol versus those that do not?,Abstract,[230369],[1295],[1404],[False],[0],[0],[False],['0']
40901,PMC6814122,39637,Results,Abstract,[230376],[1405],[1412],[False],[0],[0],[False],['0']
40902,PMC6814122,39638,"From baseline to one-year post active implementation, both the NIATx strategy and waitlist arms demonstrated improvements over time in DDCAT Index total and DDCAT dimension scores.",Abstract,[230383],[1413],[1593],[False],[0],[0],[False],['0']
40903,PMC6814122,39639,"In intent-to-treat analyses, a moderate but statistically significant difference in improvement between study arms was seen only in the Program Milieu dimension (p = 0.020, Cohen’s d = 0.54).",Abstract,[230390],[1594],[1785],[False],[0],[0],[False],['0']
40904,PMC6814122,39640,"In per-protocol analyses, moderate-to-large effects in Program Milieu (p = 0.002, Cohen’s d = 0.91) and Continuity of Care (p = 0.026, Cohen’s d = 0.63) dimensions, and in total DDCAT Index (p = 0.046, Cohen’s d = 0.51) were found.",Abstract,[230397],[1786],[2017],[False],[0],[0],[False],['0']
40905,PMC6814122,39641,Conclusions,Abstract,[230404],[2018],[2029],[False],[0],[0],[False],['0']
40906,PMC6814122,39642,"Overall, organizations in both study arms improved DDCAT Index scores over time.",Abstract,[230411],[2030],[2110],[False],[0],[0],[False],['0']
40907,PMC6814122,39643,Organizations in the NIATx strategy arm with full adherence to the NIATx protocol had significantly greater improvements in the primary outcome measure of integrated service capacity for persons with co-occurring disorders.,Abstract,[230418],[2111],[2334],[False],[0],[0],[False],['0']
40908,PMC6814122,39644,Trail registration,Abstract,[230425],[2335],[2353],[False],[0],[0],[False],['0']
40909,PMC6814122,39645,"ClinicalTrials.gov, NCT03007940.",Abstract,[230432],[2354],[2386],[False],[0],[0],[False],['0']
40910,PMC6814122,39646,Retrospectively registered January 2017,Abstract,[230439],[2387],[2426],[False],[0],[0],[False],['0']
40911,PMC6814122,39647,Background,Background,[230446],[2427],[2438],[False],[0],[0],[False],['0']
40912,PMC6814122,39648,An estimated 8.2 million adults in the United States live with co-occurring mental health and substance use disorders [1].,Background,[230453],[2439],[2561],[False],[0],[0],[False],['0']
40913,PMC6814122,39649,The strong association between substance use disorders and other psychiatric disorders is well-documented [2–5].,Background,[230460],[2562],[2674],[False],[0],[0],[False],['0']
40914,PMC6814122,39650,"Research evidence supports the effectiveness of integrated treatment: both substance use and mental health disorders are treated at the same time, during the same treatment episode, and by the same providers [6–11].",Background,[230467],[2675],[2890],[False],[0],[0],[False],['0']
40915,PMC6814122,39651,"The benefits of integrated treatment include, improved health outcomes for patients [12]; higher patient satisfaction levels compared to standard treatment [13]; substantial reduction in utilization and costs of acute care services such as emergency room visits and hospital stays [14]; and cost-effectiveness [15].",Background,[230474],[2891],[3206],[False],[0],[0],[False],['0']
40916,PMC6814122,39652,Longstanding efforts to improve access to integrated treatment services have been made.,Background,[230481],[3207],[3294],[False],[0],[0],[False],['0']
40917,PMC6814122,39653,"However, barriers to delivery of integrated care still persist.",Background,[230488],[3295],[3358],[False],[0],[0],[False],['0']
40918,PMC6814122,39654,"The current state of access to adequate treatment for co-occurring disorders remains profoundly limited, and the percentage of specialty addiction programs and mental health programs offering integrated services remain low and highly variable [1, 10, 16–20].",Background,[230495],[3359],[3617],[False],[0],[0],[False],['0']
40919,PMC6814122,39655,"Implementation science may serve to address this gap in treatment access [21]  A relatively new discipline, the goal of implementation research is to identify processes and factors related to successful implementation and sustainment of evidence-based practices, programs and policies [22].",Background,[230502],[3618],[3908],[False],[0],[0],[False],['0']
40920,PMC6814122,39656,"Given the lack of treatment availability for co-occurring disorders, a clear need exists to employ implementation research to understand how to scale-up evidence-based integrated treatment effectively [20, 23, 24]",Background,[230509],[3909],[4122],[False],[0],[0],[False],['0']
40921,PMC6814122,39657,Several studies have demonstrated the effectiveness of the Network for the Improvement of Addiction Treatment (NIATx) for simple practice change in behavioral health settings [25–30].,Background,[230516],[4123],[4307],[False],[0],[0],[False],['0']
40922,PMC6814122,39658,"The NIATx model is a multi-faceted implementation strategy, which combines process improvement with principles from industrial engineering.",Background,[230523],[4308],[4447],[False],[0],[0],[False],['0']
40923,PMC6814122,39659,"The process improvement tools and techniques include Plan-Do-Study-Act (PDSA) rapid change cycles and consumer-centered walk-through, and quality improvement interventions include learning sessions, coaching, and interest circle calls [31–33].",Background,[230530],[4448],[4691],[False],[0],[0],[False],['0']
40924,PMC6814122,39660,"However, NIATx has not been evaluated in terms of fidelity or adherence--the extent of key activity completion--or been connected with a range of implementation outcomes.",Background,[230537],[4692],[4862],[False],[0],[0],[False],['0']
40925,PMC6814122,39661,"This is the first study to evaluate a well-documented implementation strategy, in this case NIATx, to install and hopefully sustain integrated treatment services for individuals with co-occurring disorders.",Background,[230544],[4863],[5069],[False],[0],[0],[False],['0']
40926,PMC6814122,39662,The study described aims to address the following research questions: (1) Is NIATx effective in improving integrated services?,Background,[230551],[5070],[5196],[False],[0],[0],[False],['0']
40927,PMC6814122,39663,and (2) Are there differences in organizations that actually use NIATx per-protocol versus those that do not?,Background,[230558],[5197],[5306],[False],[0],[0],[False],['0']
40928,PMC6814122,39664,"Herein, we report primary outcome results from a cluster randomized controlled trial to evaluate the effectiveness of NIATx in implementing integrated services for persons with co-occurring substance use and mental health disorders.",Background,[230565],[5307],[5539],[False],[0],[0],[False],['0']
40929,PMC6814122,39665,"The primary outcome measure is the Dual Diagnosis in Addiction Treatment (DDCAT) Index, a widely used instrument to evaluate integrated services capacity at the organizational level.",Background,[230572],[5540],[5722],[False],[0],[0],[False],['0']
40930,PMC6814122,39666,"The DDCAT has established psychometric properties, includes an overall total score and subscale scores on seven dimensions that assess policy, clinical practices and workforce domains.",Background,[230579],[5723],[5907],[False],[0],[0],[False],['0']
40931,PMC6814122,39667,It is a comprehensive and objective measure with an established track record of guiding addiction treatment services organizations and systems.,Background,[230586],[5908],[6051],[False],[0],[0],[False],['0']
40932,PMC6814122,39668,"In this study, the specific objectives included examination of the primary outcome, DDCAT Index, by conducting: (1) Intent-to-treat analyses by study arm; and (2) Per-protocol analyses by level of NIATx participation.",Background,[230593],[6052],[6269],[False],[0],[0],[False],['0']
40933,PMC6814122,39669,"We hypothesized that organizations in the active NIATx study arm would demonstrate greater gains in integrated service capacity, as measured by the DDCAT, compared to the waitlist group.",Background,[230600],[6270],[6456],[False],[0],[0],[False],['0']
40934,PMC6814122,39670,Methods,Methods,[230607],[6457],[6465],[False],[0],[0],[False],['0']
40935,PMC6814122,39671,Design and setting,Methods|Design and setting,[230614],[6466],[6484],[False],[0],[0],[False],['0']
40936,PMC6814122,39672,The study employed a cluster randomized waitlist control group design to evaluate the effectiveness of NIATx in implementing integrated services for persons with co-occurring substance use and mental health disorders.,Methods|Design and setting,[230621],[6485],[6702],[False],[0],[0],[False],['0']
40937,PMC6814122,39673,This multi-faceted implementation strategy was used to install and sustain integrated treatment services for programs within community addiction treatment organizations.,Methods|Design and setting,[230628],[6703],[6872],[False],[0],[0],[False],['0']
40938,PMC6814122,39674,Agencies were randomized at baseline into either the NIATx strategy or waitlist study arm.,Methods|Design and setting,[230635],[6873],[6963],[False],[0],[0],[False],['0']
40939,PMC6814122,39675,"NIATx strategies were initiated in the first 12 months for agencies in the NIATx strategy arm, while agencies in the control arm were waitlisted.",Methods|Design and setting,[230642],[6964],[7109],[False],[0],[0],[False],['0']
40940,PMC6814122,39676,"At the end of year 1, the NIATx strategy group transitioned into the sustainment phase, while the waitlist group began utilizing NIATx strategies.",Methods|Design and setting,[230649],[7110],[7256],[False],[0],[0],[False],['0']
40941,PMC6814122,39677,More information on study methods is available in the protocol paper [34].,Methods|Design and setting,[230656],[7257],[7331],[False],[0],[0],[False],['0']
40942,PMC6814122,39678,Participants,Methods|Participants,[230663],[7332],[7344],[False],[0],[0],[False],['0']
40943,PMC6814122,39679,Study participants were programs within community addiction treatment agencies across the State of Washington.,Methods|Participants,[230670],[7345],[7455],[False],[0],[0],[False],['0']
40944,PMC6814122,39680,"Eligibility criteria included: outpatient and/or intensive outpatient services; tax-exempt status; government status or at least 50% publicly funded (e.g., block grants, Medicare, Medicaid); and no prior enrollment in NIATx research studies.",Methods|Participants,[230677],[7456],[7697],[False],[0],[0],[False],['0']
40945,PMC6814122,39681,"In addition, agencies were required to use the state clinical information system to provide the necessary standardized patient-level data.",Methods|Participants,[230684],[7698],[7836],[False],[0],[0],[False],['0']
40946,PMC6814122,39682,"State representatives sent a recruitment letter to all eligible organizations, which included 468 state-licensed addiction treatment providers.",Methods|Participants,[230691],[7837],[7980],[False],[0],[0],[False],['0']
40947,PMC6814122,39683,"In response to this letter, 53 (11.3%) agencies were recruited or volunteered to participate in the study.",Methods|Participants,[230698],[7981],[8087],[False],[0],[0],[False],['0']
40948,PMC6814122,39684,Four of these agencies declined to continue study participation prior to randomization.,Methods|Participants,[230705],[8088],[8175],[False],[0],[0],[False],['0']
40949,PMC6814122,39685,The remaining 49 agencies were assigned at baseline to either the NIATx strategy (n = 25) or waitlist (n = 24) study arms.,Methods|Participants,[230712],[8176],[8298],[False],[0],[0],[False],['0']
40950,PMC6814122,39686,Primary outcome measure,Methods|Primary outcome measure,[230719],[8299],[8322],[False],[0],[0],[False],['0']
40951,PMC6814122,39687,DDCAT index,Methods|DDCAT index,[230726],[8323],[8334],[False],[0],[0],[False],['0']
40952,PMC6814122,39688,The DDCAT Index (Version 4.0) is a quantitative measure of addiction treatment programs capacity for integrated services for persons with co-occurring substance use and mental health disorders [35].,Methods|DDCAT index,[230733],[8335],[8533],[False],[0],[0],[False],['0']
40953,PMC6814122,39689,This organizational measure consists of 35 benchmark items across seven dimensions: (1) Program Structure; (2) Program Milieu; (3) Clinical Process: Assessment; (4) Clinical Process: Treatment; (5) Continuity of Care; (6) Staffing; and (7) Training.,Methods|DDCAT index,[230740],[8534],[8783],[False],[0],[0],[False],['0']
40954,PMC6814122,39690,"Each item is rated on a Likert scale ranging from 1 to 5 with scoring anchors of 1 (Addiction Only Services – AOS), 3 (Dual Diagnosis Capable – DDC), and 5 (Dual Diagnosis Enhanced – DDE); an intermediate score of 2 or 4 is given to items that fall between these anchor scores.",Methods|DDCAT index,[230747],[8784],[9061],[False],[0],[0],[False],['0']
40955,PMC6814122,39691,All items are scored based on data collected by independent evaluators during onsite visits.,Methods|DDCAT index,[230754],[9062],[9154],[False],[0],[0],[False],['0']
40956,PMC6814122,39692,"DDCAT Index dimension and overall scores are derived by calculating the mean of items within a dimension and mean of dimensions, respectively.",Methods|DDCAT index,[230761],[9155],[9297],[False],[0],[0],[False],['0']
40957,PMC6814122,39693,"Using the standard of 80%, addiction treatment programs are categorized as: (1) AOS if less than 80% of scores are rated a 3 or higher; (2) DDC if at least 80% of scores are at a 3 or higher; and (3) DDE if at least 80% of scores are at a 5.",Methods|DDCAT index,[230768],[9298],[9539],[False],[0],[0],[False],['0']
40958,PMC6814122,39694,"Psychometric studies have supported the reliability and validity of the DDCAT Index measure [16, 19, 35–37].",Methods|DDCAT index,[230775],[9540],[9648],[False],[0],[0],[False],['0']
40959,PMC6814122,39695,The DDCAT Index Toolkit (Version 4.0) [38] is available at https://www.centerforebp.case.edu/resouces/tools/ddcat-toolkit.,Methods|DDCAT index,[230782],[9649],[9771],[False],[0],[0],[False],['0']
40960,PMC6814122,39696,The current version of the DDCAT Index measure (Version 4.1) is public domain and available upon request.,Methods|DDCAT index,[230789],[9772],[9877],[False],[0],[0],[False],['0']
40961,PMC6814122,39697,"To illustrate the characteristics of programs that are categorized as AOS, DDC or DDE, the following brief examples are provided.",Methods|DDCAT index,[230796],[9878],[10007],[False],[0],[0],[False],['0']
40962,PMC6814122,39698,AOS programs typically either do not screen or treat psychiatric disorders either independent or co-morbid with substance use disorders.,Methods|DDCAT index,[230803],[10008],[10144],[False],[0],[0],[False],['0']
40963,PMC6814122,39699,"The entire focus of the organization’s policy, treatment and workforce is to address substance-related issues only.",Methods|DDCAT index,[230810],[10145],[10260],[False],[0],[0],[False],['0']
40964,PMC6814122,39700,"In fact, AOS programs may exclude patients with known psychiatric disorders from admission.",Methods|DDCAT index,[230817],[10261],[10352],[False],[0],[0],[False],['0']
40965,PMC6814122,39701,"Whereas, DDC programs do provide integrated services for co-occurring psychiatric disorders, but generally only admit patients with a mild to moderate or stable psychiatric condition such as depression or anxiety.",Methods|DDCAT index,[230824],[10353],[10566],[False],[0],[0],[False],['0']
40966,PMC6814122,39702,"Finally, DDE programs typically can provide integrated services to patients with more severe and potentially more acute psychiatric conditions, ranging from depression and anxiety to bipolar and psychotic spectrum diagnoses.",Methods|DDCAT index,[230831],[10567],[10791],[False],[0],[0],[False],['0']
40967,PMC6814122,39703,"DDE programs integrate addiction and mental health services across policy, practice and workforce domains.",Methods|DDCAT index,[230838],[10792],[10898],[False],[0],[0],[False],['0']
40968,PMC6814122,39704,Implementation strategy – NIATx,Implementation strategy – NIATx,[230845],[10899],[10931],[False],[0],[0],[False],['0']
40969,PMC6814122,39705,"Table 1 NIATx Multi-component Implementation Strategy: Components, Timing and Activities.",Implementation strategy – NIATx,[230852],[10932],[11021],[False],[0],[0],[False],['0']
40970,PMC6814122,39706,"The NIATx implementation strategy included a coach led site visit, individual coaching calls, group coaching calls and learning sessions (Table 1).",Implementation strategy – NIATx,[230859],[11022],[11169],[False],[0],[0],[False],['0']
40971,PMC6814122,39707,"For a typical program, the coach made contact approximately two weeks after the DDCAT visit and followed that call up with a site visit planning call two weeks later.",Implementation strategy – NIATx,[230866],[11170],[11336],[False],[0],[0],[False],['0']
40972,PMC6814122,39708,"Typically, the site visit occurred a month after the site visit planning call but the actual timing was dependent on program staff member availability.",Implementation strategy – NIATx,[230873],[11337],[11488],[False],[0],[0],[False],['0']
40973,PMC6814122,39709,The first cohort-wide learning session occurred in October/November which was after the site visit for all but three programs.,Implementation strategy – NIATx,[230880],[11489],[11615],[False],[0],[0],[False],['0']
40974,PMC6814122,39710,"After the site visit, individual coach calls occurred approximately every 40 days but the actual number of calls varied by program.",Implementation strategy – NIATx,[230887],[11616],[11747],[False],[0],[0],[False],['0']
40975,PMC6814122,39711,Two group coaching calls occurred in February and May.,Implementation strategy – NIATx,[230894],[11748],[11802],[False],[0],[0],[False],['0']
40976,PMC6814122,39712,The NIATx intervention concluded at the end of June after the wrap-up learning session.,Implementation strategy – NIATx,[230901],[11803],[11890],[False],[0],[0],[False],['0']
40977,PMC6814122,39713,Procedures,Implementation strategy – NIATx|Procedures,[230908],[11891],[11902],[False],[0],[0],[False],['0']
40978,PMC6814122,39714,Data collection,Implementation strategy – NIATx|Data collection,[230915],[11903],[11918],[False],[0],[0],[False],['0']
40979,PMC6814122,39715,Data were obtained during independent site visits conducted by evaluators at baseline and one-year follow-up.,Implementation strategy – NIATx|Data collection,[230922],[11919],[12028],[False],[0],[0],[False],['0']
40980,PMC6814122,39716,The evaluators were blind to the study arm.,Implementation strategy – NIATx|Data collection,[230929],[12029],[12072],[False],[0],[0],[False],['0']
40981,PMC6814122,39717,"On average, site visits ranged from 3 to 4 h and gathered data via rapid ethnographic observations, key informant interviews and document review.",Implementation strategy – NIATx|Data collection,[230936],[12073],[12218],[False],[0],[0],[False],['0']
40982,PMC6814122,39718,Site visit arrangements were prepared in advance with program leadership.,Implementation strategy – NIATx|Data collection,[230943],[12219],[12292],[False],[0],[0],[False],['0']
40983,PMC6814122,39719,"Evaluators conducted brief group and individual interviews with as many program leaders, staff and patients as possible during the half-day visit.",Implementation strategy – NIATx|Data collection,[230950],[12293],[12439],[False],[0],[0],[False],['0']
40984,PMC6814122,39720,Interviews were semi-structured and included participant-specific questions used to elicit information necessary to complete the DDCAT assessment.,Implementation strategy – NIATx|Data collection,[230957],[12440],[12586],[False],[0],[0],[False],['0']
40985,PMC6814122,39721,"Document review included extracting information from medical records, brochures, policies and procedures manuals, and other supporting documents.",Implementation strategy – NIATx|Data collection,[230964],[12587],[12732],[False],[0],[0],[False],['0']
40986,PMC6814122,39722,"At the end of each site visit, evaluators provided preliminary feedback to program leadership, which was followed up with a formal written report including program strengths, areas for improvement, and DDCAT Index scores.",Implementation strategy – NIATx|Data collection,[230971],[12733],[12954],[False],[0],[0],[False],['0']
40987,PMC6814122,39723,All sources of data were synthesized and summarized to score items on the DDCAT Index.,Implementation strategy – NIATx|Data collection,[230978],[12955],[13041],[False],[0],[0],[False],['0']
40988,PMC6814122,39724,"Evaluators independently scored items after each site visit, reviewed together, and discussed to resolve scoring discrepancies.",Implementation strategy – NIATx|Data collection,[230985],[13042],[13169],[False],[0],[0],[False],['0']
40989,PMC6814122,39725,Evaluators,Implementation strategy – NIATx|Evaluators,[230992],[13170],[13180],[False],[0],[0],[False],['0']
40990,PMC6814122,39726,Independent and trained evaluators were from the Washington State Department of Social and Health Services within the Division of Behavioral Health and Recovery (DBHR).,Implementation strategy – NIATx|Evaluators,[230999],[13181],[13349],[False],[0],[0],[False],['0']
40991,PMC6814122,39727,A pair of evaluators conducted each site visit independently and one-year post active implementation assessments were completed within a two-month window.,Implementation strategy – NIATx|Evaluators,[231006],[13350],[13504],[False],[0],[0],[False],['0']
40992,PMC6814122,39728,All evaluators (n = 10) received the same one-day training at the start of the study as well as annual refresher trainings.,Implementation strategy – NIATx|Evaluators,[231013],[13505],[13628],[False],[0],[0],[False],['0']
40993,PMC6814122,39729,"Trainings incorporated didactic, observational, and experiential approaches, where evaluators observed a site visit and were evaluated conducting a site visit.",Implementation strategy – NIATx|Evaluators,[231020],[13629],[13788],[False],[0],[0],[False],['0']
40994,PMC6814122,39730,Ethics,Implementation strategy – NIATx|Ethics,[231027],[13789],[13795],[False],[0],[0],[False],['0']
40995,PMC6814122,39731,"Institutional Review Boards at Stanford University School of Medicine, the University of Wisconsin-Madison, and the State of Washington Department of Social and Health Services reviewed and deemed the study exempt.",Implementation strategy – NIATx|Ethics,[231034],[13796],[14010],[False],[0],[0],[False],['0']
40996,PMC6814122,39732,Data analysis,Data analysis,[231041],[14011],[14025],[False],[0],[0],[False],['0']
40997,PMC6814122,39733,"First, we conducted descriptive statistics of baseline characteristics of participating programs.",Data analysis,[231048],[14026],[14123],[False],[0],[0],[False],['0']
40998,PMC6814122,39734,"Next, standard linear mixed effects modeling [39, 40] was employed to estimate changes in DDCAT Index scores from baseline to one-year post active implementation.",Data analysis,[231055],[14124],[14286],[False],[0],[0],[False],['0']
40999,PMC6814122,39735,"Following the intent-to-treat principle, all randomized organizations were included in analyses as long as data from at least one of the two assessments/time periods were available.",Data analysis,[231062],[14287],[14468],[False],[0],[0],[False],['0']
41000,PMC6814122,39736,"Therefore, a total of 49 organizations in NIATx strategy (n = 25) and waitlist (n = 24) study arms were included in the longitudinal modeling of the primary outcome, DDCAT Index.",Data analysis,[231069],[14469],[14647],[False],[0],[0],[False],['0']
41001,PMC6814122,39737,Maximum likelihood embedded in the Mplus program Version 8 [41] was used for all model estimations.,Data analysis,[231076],[14648],[14747],[False],[0],[0],[False],['0']
41002,PMC6814122,39738,"Specifically, we employed a random intercept model assuming linear change over time.",Data analysis,[231083],[14748],[14832],[False],[0],[0],[False],['0']
41003,PMC6814122,39739,Initial comparisons included assessment of the estimated trajectories across study arms as randomized (intent-to-treat).,Data analysis,[231090],[14833],[14953],[False],[0],[0],[False],['0']
41004,PMC6814122,39740,"In subsequent secondary per-protocol analyses, we compared the two study arms after excluding organizations that were assigned to the NIATx strategy study arm but did not meet the criteria for full participation in NIATx strategies.",Data analysis,[231097],[14954],[15186],[False],[0],[0],[False],['0']
41005,PMC6814122,39741,"NIATx participation was determined based on careful consideration of three main components of the Stages of Implementation Completion (SIC), which included: (1) Proportion of completed NIATx activities (e.g., coach calls, webinars, and in-person attendance); (2) Duration of NIATx activities; and (3) Total time from initial to last NIATx activity.",Data analysis,[231104],[15187],[15535],[False],[0],[0],[False],['0']
41006,PMC6814122,39742,"Based on these factors, per protocol was defined as organizations in the NIATx strategy group with full adherence (i.e., values above or equal to the average across all three categories) versus organizations in the waitlist group.",Data analysis,[231111],[15536],[15766],[False],[0],[0],[False],['0']
41007,PMC6814122,39743,"For full adherence, an agency would complete all NIATx related activities.",Data analysis,[231118],[15767],[15841],[False],[0],[0],[False],['0']
41008,PMC6814122,39744,"Since duration of activities and total time are related to the activities completed, full adherence, as measured by duration or total time, is not a construct that can be determined.",Data analysis,[231125],[15842],[16024],[False],[0],[0],[False],['0']
41009,PMC6814122,39745,A univariate GLM examined differences in the three SIC variables based on level of adherence.,Data analysis,[231132],[16025],[16118],[False],[0],[0],[False],['0']
41010,PMC6814122,39746,"Given that per-protocol comparisons do not compare groups as randomized, a causal approach known as complier average causal effect (CACE) [42–45] estimation was also employed as a way of sensitivity analysis.",Data analysis,[231139],[16119],[16327],[False],[0],[0],[False],['0']
41011,PMC6814122,39747,"In addition, NIATx adherence was examined by the magnitude of DDCAT Index total change scores from baseline to one-year post active implementation.",Data analysis,[231146],[16328],[16475],[False],[0],[0],[False],['0']
41012,PMC6814122,39748,DDCAT Index change categories were defined as: (1) Large positive change (score ≥ 1.5); (2) Moderate positive change (1.5 > score ≥ 0.5); (3) Small positive change (0.0 ≤ score < 0.5); and (4) Negative change (score < 0.0).,Data analysis,[231153],[16476],[16699],[False],[0],[0],[False],['0']
41013,PMC6814122,39749,Results,Results,[231160],[16700],[16708],[False],[0],[0],[False],['0']
41014,PMC6814122,39750,CONSORT extension for cluster designs,Results|CONSORT extension for cluster designs,[231167],[16709],[16746],[False],[0],[0],[False],['0']
41015,PMC6814122,39751,Fig.,Results|CONSORT extension for cluster designs,[231174],[16747],[16751],[False],[0],[0],[False],['0']
41016,PMC6814122,39752,1 Extended CONSORT Diagram.,Results|CONSORT extension for cluster designs,[231181],[16752],[16779],[False],[0],[0],[False],['0']
41017,PMC6814122,39753,"In 2016, a total of 53 community addiction treatment organizations volunteered or were recruited into the study (Fig.",Results|CONSORT extension for cluster designs,[231188],[16780],[16897],[False],[0],[0],[False],['0']
41018,PMC6814122,39754,1).,Results|CONSORT extension for cluster designs,[231195],[16898],[16901],[False],[0],[0],[False],['0']
41019,PMC6814122,39755,"Of those, 49 organizations were randomized to either NIATx strategy (n = 25) or waitlist (n = 24).",Results|CONSORT extension for cluster designs,[231202],[16902],[17000],[False],[0],[0],[False],['0']
41020,PMC6814122,39756,"At the end of the one-year post active implementation strategy, 23 organizations in each study arm remained.",Results|CONSORT extension for cluster designs,[231209],[17001],[17109],[False],[0],[0],[False],['0']
41021,PMC6814122,39757,"Reasons for dropping out included: deprioritized (n = 1), refused ((n = 1), and facility closed ((n = 1).",Results|CONSORT extension for cluster designs,[231216],[17110],[17215],[False],[0],[0],[False],['0']
41022,PMC6814122,39758,"Follow-up DDCAT assessments were conducted one-year post-baseline, i.e.",Results|CONSORT extension for cluster designs,[231223],[17216],[17287],[False],[0],[0],[False],['0']
41023,PMC6814122,39759,2017.,Results|CONSORT extension for cluster designs,[231230],[17288],[17293],[False],[0],[0],[False],['0']
41024,PMC6814122,39760,Baseline characteristics of participating organizations,Results|Baseline characteristics of participating organizations,[231237],[17294],[17350],[False],[0],[0],[False],['0']
41025,PMC6814122,39761,"Overall, the majority of organizations were publicly funded and provided outpatient/intensive outpatient (IOP) care.",Results|Baseline characteristics of participating organizations,[231244],[17351],[17467],[False],[0],[0],[False],['0']
41026,PMC6814122,39762,"The addiction treatment agencies were located across the State of Washington in 21 of the 39 counties, located predominantly in cities with medium sized populations (i.e., 26,000 – 249,000).",Results|Baseline characteristics of participating organizations,[231251],[17468],[17658],[False],[0],[0],[False],['0']
41027,PMC6814122,39763,"Across the state, of the ten regional behavioral health networks providing funding and treatment services oversite to behavioral health agencies, nine were represented in this study.",Results|Baseline characteristics of participating organizations,[231258],[17659],[17841],[False],[0],[0],[False],['0']
41028,PMC6814122,39764,"Across both study arms, most agencies (55.1%) operated within a medically underserved area.",Results|Baseline characteristics of participating organizations,[231265],[17842],[17933],[False],[0],[0],[False],['0']
41029,PMC6814122,39765,"Healthcare shortages in primary care and behavioral health were also identified by participating organizations (71.4 and 75.5%, respectively), with no significant difference by study arm.",Results|Baseline characteristics of participating organizations,[231272],[17934],[18121],[False],[0],[0],[False],['0']
41030,PMC6814122,39766,Primary outcome: DDCAT index,Results|Baseline characteristics of participating organizations,[231279],[18122],[18150],[False],[0],[0],[False],['0']
41031,PMC6814122,39767,"Outcomes were analyzed in two ways, with and without consideration of NIATx adherence.",Results|Baseline characteristics of participating organizations,[231286],[18151],[18237],[False],[0],[0],[False],['0']
41032,PMC6814122,39768,"Based on the study definition of full NIATx adherence, 13 out of 25 agencies (54%) assigned to NIATx strategy did not show adequate participation (per-protocol) with the intervention.",Results|Baseline characteristics of participating organizations,[231293],[18238],[18421],[False],[0],[0],[False],['0']
41033,PMC6814122,39769,Intent-to-treat comparison of changes in DDCAT index,Results|Baseline characteristics of participating organizations,[231300],[18422],[18474],[False],[0],[0],[False],['0']
41034,PMC6814122,39770,Table 2 Estimated DDCAT means at baseline (T1) and post (T2) based on mixed effects modeling.,Results|Baseline characteristics of participating organizations,[231307],[18475],[18568],[False],[0],[0],[False],['0']
41035,PMC6814122,39771,Table 3 Intent-to-treat DDCAT Index change scores by dimension and total (baseline to one-year post) based on mixed effects modeling ((n = 49).,Results|Baseline characteristics of participating organizations,[231314],[18569],[18712],[False],[0],[0],[False],['0']
41036,PMC6814122,39772,"Intent-to-treat (ITT) analyses were conducted by including all randomized agencies in NIATx strategy (n = 25) and waitlist (n = 24), regardless of their adherence status.",Results|Baseline characteristics of participating organizations,[231321],[18713],[18883],[False],[0],[0],[False],['0']
41037,PMC6814122,39773,Results from longitudinal mixed effects modeling in line with the ITT principle are summarized in Tables 2 and 3.,Results|Baseline characteristics of participating organizations,[231328],[18884],[18997],[False],[0],[0],[False],['0']
41038,PMC6814122,39774,"In Table 3, Cohen’s d is calculated based on observed standard deviation pooled across the NIATx strategy and waitlist study arms at one-year post active implementation.",Results|Baseline characteristics of participating organizations,[231335],[18998],[19167],[False],[0],[0],[False],['0']
41039,PMC6814122,39775,"At baseline, organizations in the active NIATx condition arm had higher DDCAT Index total and dimension scores compared to waitlist.",Results|Baseline characteristics of participating organizations,[231342],[19168],[19300],[False],[0],[0],[False],['0']
41040,PMC6814122,39776,Both study arms showed improvements over time in the DDCAT Index total and in all of the seven dimensions scores.,Results|Baseline characteristics of participating organizations,[231349],[19301],[19414],[False],[0],[0],[False],['0']
41041,PMC6814122,39777,"However, the two study arms were generally not significantly different in their rate of change, except in the Program Milieu dimension, in which organizations in the NIATx strategy arm showed significantly greater improvement in Program Milieu compared to the waitlist (p = 0.020).",Results|Baseline characteristics of participating organizations,[231356],[19415],[19696],[False],[0],[0],[False],['0']
41042,PMC6814122,39778,Fig.,Results|Baseline characteristics of participating organizations,[231363],[19697],[19703],[False],[0],[0],[False],['0']
41043,PMC6814122,39779,2 a-h Intent-to-treat trajectories of DDCAT Index dimension and total change scores (baseline to one-year post) based on mixed effects modeling (n = 49) * Group by time interaction effect p ≤ 0.05.,Results|Baseline characteristics of participating organizations,[231370],[19704],[19901],[False],[0],[0],[False],['0']
41044,PMC6814122,39780,Figure 2a–h present estimated trajectories of DDCAT Index total and dimension scores based on ITT analyses (graphic depiction of Table 3 data).,Results|Baseline characteristics of participating organizations,[231377],[19902],[20045],[False],[0],[0],[False],['0']
41045,PMC6814122,39781,The two study arms improved similarly in the DDCAT Index total and most dimension scores.,Results|Baseline characteristics of participating organizations,[231384],[20046],[20135],[False],[0],[0],[False],['0']
41046,PMC6814122,39782,"In the Program Milieu dimension, moderate difference in terms of improvement were found among the two groups.",Results|Baseline characteristics of participating organizations,[231391],[20136],[20245],[False],[0],[0],[False],['0']
41047,PMC6814122,39783,"Overall, the effect of NIATx was less evident in ITT comparisons versus the per-protocol analyses presented below.",Results|Baseline characteristics of participating organizations,[231398],[20246],[20360],[False],[0],[0],[False],['0']
41048,PMC6814122,39784,Just less than half (47.8%) of organizations assigned to NIATx were categorized as protocol adherent,Results|Baseline characteristics of participating organizations,[231405],[20361],[20461],[False],[0],[0],[False],['0']
41049,PMC6814122,39785,Per-protocol comparison of changes in DDCAT index accounting for NIATx adherence,Results|Baseline characteristics of participating organizations,[231412],[20462],[20543],[False],[0],[0],[False],['0']
41050,PMC6814122,39786,Table 4 NIATx protocol adherence among organizations (n = 24).,Results|Baseline characteristics of participating organizations,[231419],[20544],[20606],[False],[0],[0],[False],['0']
41051,PMC6814122,39787,Table 5 Per-protocol DDCAT Index change scores by dimension and total (baseline to one-year post) based on mixed effects modeling (n = 35).,Results|Baseline characteristics of participating organizations,[231426],[20607],[20746],[False],[0],[0],[False],['0']
41052,PMC6814122,39788,Fig.,Results|Baseline characteristics of participating organizations,[231433],[20747],[20751],[False],[0],[0],[False],['0']
41053,PMC6814122,39789,3 NIATx adherence among organizations by magnitude of DDCAT Index total change score (n = 23).,Results|Baseline characteristics of participating organizations,[231440],[20752],[20846],[False],[0],[0],[False],['0']
41054,PMC6814122,39790,NIATx participation varied between organizations within the NIATx strategy study arm (see Table 4).,Results|Baseline characteristics of participating organizations,[231447],[20847],[20946],[False],[0],[0],[False],['0']
41055,PMC6814122,39791,"Of the 23 organizations that completed NIATx strategy, a total of 11 (47.8%) had full NIATx adherence.",Results|Baseline characteristics of participating organizations,[231454],[20947],[21049],[False],[0],[0],[False],['0']
41056,PMC6814122,39792,"The remaining organizations had partial or no adherence to NIATx, both 26.1% respectively.",Results|Baseline characteristics of participating organizations,[231461],[21050],[21140],[False],[0],[0],[False],['0']
41057,PMC6814122,39793,Fully NIATx adherent agencies were more likely to complete NIATx activities (85%) versus agencies with no NIATx adherence (41%)(Table 5).,Results|Baseline characteristics of participating organizations,[231468],[21141],[21278],[False],[0],[0],[False],['0']
41058,PMC6814122,39794,Similar significant differences were found for the duration of activities completed (296 versus 128 days) and the total time (291 versus 125 days) between fully adherent and non-adherent NIATx agencies.,Results|Baseline characteristics of participating organizations,[231475],[21279],[21481],[False],[0],[0],[False],['0']
41059,PMC6814122,39795,Partially adherent agencies had a higher proportion of completed activities and a longer duration than non-adherent agencies.,Results|Baseline characteristics of participating organizations,[231482],[21482],[21607],[False],[0],[0],[False],['0']
41060,PMC6814122,39796,Figure 3 depicts NIATx strategy adherence among organizations by magnitude of DDCAT Index total change score.,Results|Baseline characteristics of participating organizations,[231489],[21608],[21717],[False],[0],[0],[False],['0']
41061,PMC6814122,39797,"Organizations with large positive (i.e., score ≥ 1.5) and moderate positive (i.e., 1.5 > score ≥ 0.5) DDCAT Index change scores had more organizations with full adherence than those with small positive (i.e., 0.0 ≤ score < 0.5) or negative (i.e., score < 0.0) change scores.",Results|Baseline characteristics of participating organizations,[231496],[21718],[21992],[False],[0],[0],[False],['0']
41062,PMC6814122,39798,"Although two of the six organizations with no NIATx adherence had moderate to large change scores, the majority of non-adherent organizations had either small or negative changes.",Results|Baseline characteristics of participating organizations,[231503],[21993],[22172],[False],[0],[0],[False],['0']
41063,PMC6814122,39799,Per-protocol analyses where NIATx strategy organizations showing insufficient adherence were excluded from mixed effects analyses are presented in Table 5.,Results|Baseline characteristics of participating organizations,[231510],[22173],[22331],[False],[0],[0],[False],['0']
41064,PMC6814122,39800,"In per-protocol analyses, the difference in improvement for DDCAT Index total scores between the two study arms becomes statistically significant (p = 0.046), with a clinically meaningful effect size (Cohen’s d = 0.51).",Results|Baseline characteristics of participating organizations,[231517],[22332],[22551],[False],[0],[0],[False],['0']
41065,PMC6814122,39801,"Among the seven DDCAT Index dimensions, Program Milieu showed the largest effect (p = 0.002, Cohen’s d = 0.91) and Continuity of Care showed the second largest effect (p = 0.026, Cohen’s d = 0.63).",Results|Baseline characteristics of participating organizations,[231524],[22552],[22749],[False],[0],[0],[False],['0']
41066,PMC6814122,39802,Fig.,Results|Baseline characteristics of participating organizations,[231531],[22750],[22754],[False],[0],[0],[False],['0']
41067,PMC6814122,39803,4 a-h Per-protocol trajectories of DDCAT Index dimension and total change scores (baseline to one-year post) based on mixed effects modeling (n = 49) * Group by time interaction effect (p ≤ 0.05); ** Group by time interaction effect (p ≤ 0.01).,Results|Baseline characteristics of participating organizations,[231538],[22755],[22999],[False],[0],[0],[False],['0']
41068,PMC6814122,39804,Figure 4a–h present estimated trajectories of DDCAT Index total and dimension scores based on per-protocol analyses.,Results|Baseline characteristics of participating organizations,[231545],[23000],[23116],[False],[0],[0],[False],['0']
41069,PMC6814122,39805,The comparison between Figs.,Results|Baseline characteristics of participating organizations,[231552],[23117],[23145],[False],[0],[0],[False],['0']
41070,PMC6814122,39806,2 and 4 illustrates how group differences varied noticeably depending on whether inadequate adherence among organizations in the NIATx strategy group were included or excluded.,Results|Baseline characteristics of participating organizations,[231559],[23146],[23322],[False],[0],[0],[False],['0']
41071,PMC6814122,39807,"In per-protocol analyses, the NIATx strategy group improved considerably more than the waitlist group.",Results|Baseline characteristics of participating organizations,[231566],[23323],[23425],[False],[0],[0],[False],['0']
41072,PMC6814122,39808,The two groups show a remarkably large difference in improvement in the Program Milieu dimension.,Results|Baseline characteristics of participating organizations,[231573],[23426],[23523],[False],[0],[0],[False],['0']
41073,PMC6814122,39809,"Sensitivity analysis using a causal approach known as complier average causal effect (CACE) [42–44] revealed similar results, supporting the validity of the findings based on per-protocol comparisons.",Results|Baseline characteristics of participating organizations,[231580],[23524],[23724],[False],[0],[0],[False],['0']
41074,PMC6814122,39810,There were no statistically significant differences between NIATx adherent and non-adherent programs on baseline characteristics including DDCAT total or dimension scores.,Results|Baseline characteristics of participating organizations,[231587],[23725],[23896],[False],[0],[0],[False],['0']
41075,PMC6814122,39811,Discussion,Discussion,[231594],[23897],[23910],[False],[0],[0],[False],['0']
41076,PMC6814122,39812,Summary of findings,Discussion|Summary of findings,[231601],[23911],[23930],[False],[0],[0],[False],['0']
41077,PMC6814122,39813,Changes in DDCAT Index scores were observed for both study arms.,Discussion|Summary of findings,[231608],[23931],[23995],[False],[0],[0],[False],['0']
41078,PMC6814122,39814,"Improvements in DDCAT Index total and dimension scores at one-year post active implementation may indicate that even the audit and feedback of DDCAT Index scores alone, which were also provided to both the active NIATx and the waitlist control group, were useful to initiate important and significant changes in both study arms.",Discussion|Summary of findings,[231615],[23996],[24324],[False],[0],[0],[False],['0']
41079,PMC6814122,39815,"In this study, just over one half of organizations (52.2%) assigned to NIATx strategy failed to sufficiently adhere to NIATx protocol and therefore, fully benefit from the implementation support.",Discussion|Summary of findings,[231622],[24325],[24520],[False],[0],[0],[False],['0']
41080,PMC6814122,39816,Fully adherent agencies reported having prior experience using NIATx implementation strategies (27% vs. 15%) versus non-adherent (i.e.,Discussion|Summary of findings,[231629],[24521],[24655],[False],[0],[0],[False],['0']
41081,PMC6814122,39817,partial or no adherence) agencies.,Discussion|Summary of findings,[231636],[24656],[24690],[False],[0],[0],[False],['0']
41082,PMC6814122,39818,"Prior staff knowledge of NIATx benefits may have contributed, on average, to the implementation of more change projects (2.5 vs. 1.3), participation in coaching calls (7.0 vs. 5.1), and greater meeting attendance (75% vs. 55%) for fully adherent agencies versus other non-adherent agencies.",Discussion|Summary of findings,[231643],[24691],[24981],[False],[0],[0],[False],['0']
41083,PMC6814122,39819,"In addition, fully adherent agencies were less likely to be located in medically underserved areas or healthcare shortage areas for behavioral health and primary care.",Discussion|Summary of findings,[231650],[24982],[25149],[False],[0],[0],[False],['0']
41084,PMC6814122,39820,Geographic location may have impacted the type and number of change projects implemented by non-adherent organizations.,Discussion|Summary of findings,[231657],[25150],[25269],[False],[0],[0],[False],['0']
41085,PMC6814122,39821,"As a result, the differential impact of NIATx was limited via intent-to-treat analyses.",Discussion|Summary of findings,[231664],[25270],[25357],[False],[0],[0],[False],['0']
41086,PMC6814122,39822,"Nevertheless, Program Milieu showed significant difference with meaningful effect size (d = 0.54).",Discussion|Summary of findings,[231671],[25358],[25456],[False],[0],[0],[False],['0']
41087,PMC6814122,39823,"One possible explanation is that within the context of the one-year strategy, some of the implementation focus could have been on Program Milieu, such as displaying brochures, and therefore, may have been an easier change to make when compared to more complex integrated treatments or policy and staffing changes found within the other dimensions.",Discussion|Summary of findings,[231678],[25457],[25804],[False],[0],[0],[False],['0']
41088,PMC6814122,39824,"But in so far as adherence to NIATx was taken into account, as demonstrated in the per-protocol analyses results, NIATx implementation strategy effects on DDCAT Index outcomes were more robust (Cohen’s d = 0.51 for DDCAT Index total, d = 0.91 for Program Milieu dimension, and d = 0.63 for Continuity of Care dimension).",Discussion|Summary of findings,[231685],[25805],[26125],[False],[0],[0],[False],['0']
41089,PMC6814122,39825,"Of interest, a few of the other DDCAT Index dimensions, although not statistically significant (perhaps because of other unaccounted variation), still had varying small-to-moderate effect sizes (d = 0.31–0.42).",Discussion|Summary of findings,[231692],[26126],[26336],[False],[0],[0],[False],['0']
41090,PMC6814122,39826,"Previous studies have published results using the DDCAT Index to assess addiction treatment programs across the United States [16, 18, 19, 35–37, 46].",Discussion|Summary of findings,[231699],[26337],[26487],[False],[0],[0],[False],['0']
41091,PMC6814122,39827,"Results have varied, but most report the need for sustained improvements to addiction treatment programs.",Discussion|Summary of findings,[231706],[26488],[26593],[False],[0],[0],[False],['0']
41092,PMC6814122,39828,"For example, Lambert-Harris et al.",Discussion|Summary of findings,[231713],[26594],[26628],[False],[0],[0],[False],['0']
41093,PMC6814122,39829,"[37], conducted DDCAT Index assessments in 180 community addiction treatment programs.",Discussion|Summary of findings,[231720],[26629],[26715],[False],[0],[0],[False],['0']
41094,PMC6814122,39830,"In this study, most programs (81.8%) offered addition-only services.",Discussion|Summary of findings,[231727],[26716],[26784],[False],[0],[0],[False],['0']
41095,PMC6814122,39831,"In yet another study [18], approximately 18% of the 256 addiction treatment programs across the United States met the criteria for dual diagnosis capable services.",Discussion|Summary of findings,[231734],[26785],[26948],[False],[0],[0],[False],['0']
41096,PMC6814122,39832,"A study of 30 California treatment programs found that 43% of the programs were at dual diagnosis capable or higher, but still faced ongoing barriers to overcome [46].",Discussion|Summary of findings,[231741],[26949],[27116],[False],[0],[0],[False],['0']
41097,PMC6814122,39833,"In this sample, the majority of NIATx strategy and waitlist organizations met the criteria for addiction-only services at baseline (61 and 83%, respectively).",Discussion|Summary of findings,[231748],[27117],[27275],[False],[0],[0],[False],['0']
41098,PMC6814122,39834,"However, by the end of one-year follow-up, approximately 22% of NIATx strategy organization provided dual diagnosis enhanced services and only 26% still providing addiction-only services.",Discussion|Summary of findings,[231755],[27276],[27463],[False],[0],[0],[False],['0']
41099,PMC6814122,39835,The waitlist arm also saw a reduction in the number of organizations providing addiction-only services (52%).,Discussion|Summary of findings,[231762],[27464],[27573],[False],[0],[0],[False],['0']
41100,PMC6814122,39836,"For both arms, these improvements are meaningful.",Discussion|Summary of findings,[231769],[27574],[27623],[False],[0],[0],[False],['0']
41101,PMC6814122,39837,Two-year follow-up data is needed to determine if organizations in the NIATx strategy are able to sustain improvements and if those in the waitlist are able to make substantial improvements.,Discussion|Summary of findings,[231776],[27624],[27814],[False],[0],[0],[False],['0']
41102,PMC6814122,39838,Strengths and limitations,Discussion|Strengths and limitations,[231783],[27815],[27840],[False],[0],[0],[False],['0']
41103,PMC6814122,39839,"One strength of the study is the experimental design, including randomization at the organizational level.",Discussion|Strengths and limitations,[231790],[27841],[27947],[False],[0],[0],[False],['0']
41104,PMC6814122,39840,Another strength is the robust primary outcome measure.,Discussion|Strengths and limitations,[231797],[27948],[28003],[False],[0],[0],[False],['0']
41105,PMC6814122,39841,"Furthermore, to date, this is the first study to evaluate a well-documented implementation strategy, NIATx, to install and hopefully sustain integrated treatment services.",Discussion|Strengths and limitations,[231804],[28004],[28175],[False],[0],[0],[False],['0']
41106,PMC6814122,39842,The study had some limitations.,Discussion|Strengths and limitations,[231811],[28176],[28207],[False],[0],[0],[False],['0']
41107,PMC6814122,39843,"First, sampling biases due to volunteer or Hawthorne effects were possible.",Discussion|Strengths and limitations,[231818],[28208],[28283],[True],['Patient'],['volunteer or Hawthorne effects'],[True],['Blinding']
41108,PMC6814122,39844,"Because of keen interest among participating organizations to integrate behavioral health services in both groups, there may have been some volunteer bias.",Discussion|Strengths and limitations,[231833],[28284],[28439],[True],['Patient'],['volunteer bias'],[True],['Blinding']
41109,PMC6814122,39845,"Second, because of the convenience sampling used, the external validity of the finds will depend on future studies in different populations.",Discussion|Strengths and limitations,"[231848, 231849]","[28440, 28440]","[28580, 28580]","[True, True]","['ConvenienceSampling', 'Generalization']","['convenience sampling', 'the external validity of the finds']","[True, True]","['Generalization', 'Population']"
41110,PMC6814122,39846,Replication in other settings are needed to verify internal validity.,Discussion|Strengths and limitations,[231860],[28581],[28650],[False],[0],[0],[False],['0']
41111,PMC6814122,39847,The DDCAT has excellent psychometric properties and higher scores associated with higher rates of integrated services delivery and improved outcomes for patients with co-occurring disorders.,Discussion|Strengths and limitations,[231867],[28651],[28841],[False],[0],[0],[False],['0']
41112,PMC6814122,39848,"However, in this study it served as the omnibus and proxy outcome of integrated service capacity.",Discussion|Strengths and limitations,[231878],[28842],[28939],[True],['OutcomeMeasures'],['proxy outcome of integrated service capacity'],[True],['OutcomeMeasures']
41113,PMC6814122,39849,Additional measures of outcome would add to the strength of interpretation of findings.,Discussion|Strengths and limitations,[231893],[28940],[29027],[True],['RelevantOutcomeExcluded'],['Additional measures of outcome'],[True],['OutcomeMeasures']
41114,PMC6814122,39850,"Lastly, because assessments were conducted by evaluators from the State of Washington, it may have prevented some organizations to speak freely about their progress in the study and reveal relevant information during the course of the half-day site visit.",Discussion|Strengths and limitations,[231908],[29028],[29283],[True],['PrecisionOfMeasurement'],['it may have prevented some organizations to speak freely about their progress'],[True],['OutcomeMeasures']
41115,PMC6814122,39851,"To mitigate this, all evaluators stated clearly the purpose of the study, and that evaluations were conducted in their capacity as members of the research team and not as official state employees.",Discussion|Strengths and limitations,[231916],[29284],[29480],[False],[0],[0],[False],['0']
41116,PMC6814122,39852,Conclusions,Conclusions,[231923],[29481],[29493],[False],[0],[0],[False],['0']
41117,PMC6814122,39853,Many of the agencies enrolled in the study were “early adopters” and participation in the study was partially motivated by the announcement of a new state mandate requiring agencies to transition to integrated behavioral health services for persons with co-occurring disorders.,Conclusions,[231930],[29494],[29771],[False],[0],[0],[False],['0']
41118,PMC6814122,39854,This is evident by the overall improvements found in DDCAT Index scores over time.,Conclusions,[231937],[29772],[29854],[False],[0],[0],[False],['0']
41119,PMC6814122,39855,"This level of interest among participating organizations in implementing integrated behavioral health services might also explain the positive DDCAT Index change scores, galvanizing not only organizations in the NIATx strategy arm, but also those in the waitlist.",Conclusions,[231944],[29855],[30118],[False],[0],[0],[False],['0']
41120,PMC6814122,39856,"Therefore, these study findings may be specific to this setting.",Conclusions,[231951],[30119],[30183],[False],[0],[0],[False],['0']
41121,PMC6814122,39857,Replication in different contexts and settings may be warranted.,Conclusions,[231958],[30184],[30248],[False],[0],[0],[False],['0']
41122,PMC6814122,39858,"An important finding is that there were hardly robust differences between the NIATx and the waitlist groups on change in integrated service capability, as measured by the DDCAT, using intent-to-treat analyses.",Conclusions,[231965],[30249],[30458],[False],[0],[0],[False],['0']
41123,PMC6814122,39859,"Baseline differences between the groups were not eliminated by randomization, so it’s possible that ceiling effects may have undermined a fair comparison.",Conclusions,[231972],[30459],[30613],[False],[0],[0],[False],['0']
41124,PMC6814122,39860,"However, if examining the impact of NIATx adherence or participation, much like the dose response effect with medications or psychosocial treatments, more differences between the groups were displayed.",Conclusions,[231979],[30614],[30815],[False],[0],[0],[False],['0']
41125,PMC6814122,39861,"Future research might consider designs such as Sequential Multiple Assignment Randomized Trial, such as utilized by Kilbourne et al.",Conclusions,[231986],[30816],[30948],[False],[0],[0],[False],['0']
41126,PMC6814122,39862,[47].,Conclusions,[231993],[30949],[30954],[False],[0],[0],[False],['0']
41127,PMC6814122,39863,Measuring the impact of an initial discrete strategy (e.g.,Conclusions,[232000],[30955],[31013],[False],[0],[0],[False],['0']
41128,PMC6814122,39864,"DDCAT assessment as audit and feedback), and then adapting strategies based on primary outcome measure response or participant adherence, would add a level of rigor and real-world application that this project did not feature.",Conclusions,[232007],[31014],[31240],[False],[0],[0],[False],['0']
41129,PMC6814122,39865,This study is currently completing two-year follow-up data.,Conclusions,[232014],[31241],[31300],[False],[0],[0],[False],['0']
41130,PMC6814122,39866,"Further analysis on sustainment of improvements in follow-up assessments can be examined, and the impact of active implementation for organizations in the waitlist group remains to be seen.",Conclusions,[232021],[31301],[31490],[False],[0],[0],[False],['0']
41131,PMC6814122,39867,"To summarize, providing integrated treatment for persons with co-occurring disorders is important.",Conclusions,[232028],[31491],[31589],[False],[0],[0],[False],['0']
41132,PMC6814122,39868,Its benefits have been demonstrated and yet gaps in integrated services persist.,Conclusions,[232035],[31590],[31670],[False],[0],[0],[False],['0']
41133,PMC6814122,39869,Our findings show that NIATx is effective in implementing integrated services for persons with co-occurring substance use and mental health disorders.,Conclusions,[232042],[31671],[31821],[False],[0],[0],[False],['0']
41134,PMC6814122,39870,It also demonstrates the importance of adherence to the NIATx protocol for significant improvements to be made.,Conclusions,[232049],[31822],[31933],[False],[0],[0],[False],['0']
41135,PMC6814122,39871,"To evaluate whether these improvements in DDCAT Index scores correlate with improved patient outcomes, additional analyses will be conducted.",Conclusions,[232056],[31934],[32075],[False],[0],[0],[False],['0']
41136,PMC6814122,39872,"Possible implications for behavioral health include determining co-occurring capacity at baseline  guiding and measuring evidence-based practice implementation initiatives, and improving patient outcomes.",Conclusions,[232063],[32076],[32280],[False],[0],[0],[False],['0']
41137,PMC6814122,39873,Abbreviations,Abbreviations,[232070],[32281],[32295],[False],[0],[0],[False],['0']
41138,PMC6814122,39874,CACE Complier average causal effect,Abbreviations|CACE Complier average causal effect,[232077],[32296],[32331],[False],[0],[0],[False],['0']
41139,PMC6814122,39875,DDCAT Dual diagnosis capability in addiction treatment,Abbreviations|DDCAT Dual diagnosis capability in addiction treatment,[232084],[32332],[32386],[False],[0],[0],[False],['0']
41140,PMC6814122,39876,DSHS Department of social and health services,Abbreviations|DSHS Department of social and health services,[232091],[32387],[32432],[False],[0],[0],[False],['0']
41141,PMC6814122,39877,IOP Intensive outpatient,Abbreviations|IOP Intensive outpatient,[232098],[32433],[32457],[False],[0],[0],[False],['0']
41142,PMC6814122,39878,IRB Institutional review board,Abbreviations|IRB Institutional review board,[232105],[32458],[32488],[False],[0],[0],[False],['0']
41143,PMC6814122,39879,NIATx Network for the Improvement of addiction treatment,Abbreviations|IRB Institutional review board,[232112],[32489],[32545],[False],[0],[0],[False],['0']
41144,PMC6814122,39880,NIDA National Institute on drug abuse,Abbreviations|NIDA National Institute on drug abuse,[232119],[32546],[32583],[False],[0],[0],[False],['0']
41145,PMC6814122,39881,PDSA Plan-Do-Study-Act,Abbreviations|NIDA National Institute on drug abuse,[232126],[32584],[32606],[False],[0],[0],[False],['0']
41146,PMC6814122,39882,SIC Stages of implementation completionPublisher’s Note,Abbreviations|NIDA National Institute on drug abuse,[232133],[32607],[32662],[False],[0],[0],[False],['0']
41147,PMC6814122,39883,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|NIDA National Institute on drug abuse,[232140],[32663],[32781],[False],[0],[0],[False],['0']
42798,PMC9171654,41392,Effect of Psychiatric Advance Directives Facilitated by Peer Workers on Compulsory Admission Among People With Mental Illness,Title,[243758],[28796],[125],[False],[0],[0],[False],['0']
42799,PMC9171654,41393,Key Points,Abstract,[243766],[126],[136],[False],[0],[0],[False],['0']
42800,PMC9171654,41394,Question,Abstract,[243774],[137],[145],[False],[0],[0],[False],['0']
42801,PMC9171654,41395,"Do psychiatric advance directives facilitated by peer workers (PW-PAD) reduce coercion and improve clinical outcomes among people with schizophrenia, bipolar I disorder, or schizoaffective disorder?",Abstract,[243782],[146],[344],[False],[0],[0],[False],['0']
42802,PMC9171654,41396,Findings,Abstract,[243790],[345],[353],[False],[0],[0],[False],['0']
42803,PMC9171654,41397,"In this randomized clinical trial, 394 adults with schizophrenia, bipolar I disorder, or schizoaffective disorder with a previous compulsory hospitalization were randomized into 2 groups (ratio 1:1).",Abstract,[243798],[354],[553],[False],[0],[0],[False],['0']
42804,PMC9171654,41398,Participants in the PW-PAD group experienced significantly fewer compulsory admissions than those in the control group.,Abstract,[243806],[554],[673],[False],[0],[0],[False],['0']
42805,PMC9171654,41399,Meaning,Abstract,[243814],[674],[681],[False],[0],[0],[False],['0']
42806,PMC9171654,41400,These findings support the use of peer worker–facilitated psychiatric advance directives to prevent compulsory rehospitalization in people with severe mental illness.,Abstract,[243822],[682],[848],[False],[0],[0],[False],['0']
42807,PMC9171654,41401,Importance,Abstract,[243830],[849],[860],[False],[0],[0],[False],['0']
42808,PMC9171654,41402,Reducing the use of coercion in mental health care is crucial from a human rights and public health perspective.,Abstract,[243838],[861],[973],[False],[0],[0],[False],['0']
42809,PMC9171654,41403,Psychiatric advance directives (PADs) are promising tools that may reduce compulsory admissions.,Abstract,[243846],[974],[1070],[False],[0],[0],[False],['0']
42810,PMC9171654,41404,Assessments of PADs have included facilitation by health care agents but not facilitation by peer workers.,Abstract,[243854],[1071],[1177],[False],[0],[0],[False],['0']
42811,PMC9171654,41405,Objective,Abstract,[243862],[1178],[1187],[False],[0],[0],[False],['0']
42812,PMC9171654,41406,To determine the efficacy of PADs facilitated by peer workers (PW-PAD) in people with mental disorders.,Abstract,[243870],[1188],[1291],[False],[0],[0],[False],['0']
42813,PMC9171654,41407,"Design, Setting, and Participants",Abstract,[243878],[1292],[1325],[False],[0],[0],[False],['0']
42814,PMC9171654,41408,A multicenter randomized clinical trial was conducted in 7 French mental health facilities.,Abstract,[243886],[1326],[1417],[False],[0],[0],[False],['0']
42815,PMC9171654,41409,"Adults with a DSM-5 diagnosis of schizophrenia, bipolar I disorder, or schizoaffective disorder who had a compulsory admission in the past 12 months and the capacity to consent were enrolled between January 2019 and June 2020 and followed up for 12 months.",Abstract,[243894],[1418],[1674],[False],[0],[0],[False],['0']
42816,PMC9171654,41410,Interventions,Abstract,[243902],[1675],[1688],[False],[0],[0],[False],['0']
42817,PMC9171654,41411,The PW-PAD group was invited to fill out a PAD form and meet a peer worker who was trained to assist in completing and sharing the form with relatives and psychiatrists.,Abstract,[243910],[1689],[1858],[False],[0],[0],[False],['0']
42818,PMC9171654,41412,Main Outcomes and Measures,Abstract,[243918],[1859],[1885],[False],[0],[0],[False],['0']
42819,PMC9171654,41413,The primary outcome was the rate of compulsory admission at 12 months after randomization.,Abstract,[243926],[1886],[1976],[False],[0],[0],[False],['0']
42820,PMC9171654,41414,"The overall psychiatric admission rate, therapeutic alliance, quality of life, mental health symptoms, empowerment, and recovery outcomes were also investigated.",Abstract,[243934],[1977],[2138],[False],[0],[0],[False],['0']
42821,PMC9171654,41415,Results,Abstract,[243942],[2139],[2146],[False],[0],[0],[False],['0']
42822,PMC9171654,41416,"Among 394 allocated participants (median age, 39 years; 39.3% female; 45% with schizophrenia, 36% bipolar I disorder, and 19% schizoaffective disorder), 196 were assigned to the PW-PAD group and 198 to the control group.",Abstract,[243950],[2147],[2367],[False],[0],[0],[False],['0']
42823,PMC9171654,41417,"In the PW-PAD group, 27.0% had compulsory admissions compared with 39.9% in the control group (risk difference, −0.13; 95% CI, −0.22 to −0.04; P = .007).",Abstract,[243958],[2368],[2521],[False],[0],[0],[False],['0']
42824,PMC9171654,41418,"No significant differences were found in the rate of overall admissions, therapeutic alliance score, and quality of life.",Abstract,[243966],[2522],[2643],[False],[0],[0],[False],['0']
42825,PMC9171654,41419,"Participants in the PW-PAD group exhibited fewer symptoms (effect size, −0.20; 95% CI, −0.40 to 0.00), greater empowerment (effect size, 0.30; 95% CI, 0.10 to 0.50), and a higher recovery score (effect size, 0.44; 95% CI, 0.24 to 0.65), compared with those in the control group.",Abstract,[243974],[2644],[2922],[False],[0],[0],[False],['0']
42826,PMC9171654,41420,Conclusions and Relevance,Abstract,[243982],[2923],[2948],[False],[0],[0],[False],['0']
42827,PMC9171654,41421,"Peer worker–facilitated PADs are effective in decreasing compulsory hospital admissions and increasing some mental health outcomes (self-perceived symptoms, empowerment, and recovery).",Abstract,[243990],[2949],[3133],[False],[0],[0],[False],['0']
42828,PMC9171654,41422,Involving peer workers in the completion of PADs supports the current shift of mental health care from substitute decision-making to supported decision-making.,Abstract,[243998],[3134],[3293],[False],[0],[0],[False],['0']
42829,PMC9171654,41423,Trial Registration,Abstract,[244006],[3294],[3312],[False],[0],[0],[False],['0']
42830,PMC9171654,41424,ClinicalTrials.gov Identifier: NCT03630822,Abstract,[244014],[3313],[3355],[False],[0],[0],[False],['0']
42831,PMC9171654,41425,Introduction,Introduction,[244022],[3356],[3369],[False],[0],[0],[False],['0']
42832,PMC9171654,41426,Respect for patient autonomy is such a strong pillar of health care that involuntary treatment should be unusual.,Introduction,[244030],[3370],[3483],[False],[0],[0],[False],['0']
42833,PMC9171654,41427,"Despite this ethical and clinical principle, compulsory psychiatric admissions are far too common in countries of all income levels.1,2,3",Introduction,[244038],[3484],[3621],[False],[0],[0],[False],['0']
42834,PMC9171654,41428,"In the last 20 years, several randomized clinical trials (RCTs) have assessed the effectiveness of interventions in reducing compulsory psychiatric admissions, and systematic reviews showed that the most effective were psychiatric advance statements.4 Psychiatric advance statements are written documents that allow adults who have mental illness to state their will and preferences in advance so their choices can be applied if further mental health crises impair their decision-making capacity.",Introduction,[244046],[3622],[4118],[False],[0],[0],[False],['0']
42835,PMC9171654,41429,A meta-analysis of the 5 most robust RCTs on this topic was published in 2019.5 Molyneaux et al5 suggested that (1) psychiatric advance statements reduced the risk of compulsory admission among individuals with mental disorders by 25% compared with usual care; (2) RCTs did not provide firm conclusions on other criteria such as therapeutic alliance or psychiatric outcomes; and (3) similar and higher effectiveness was found in pooled studies that addressed interventions with crisis planning and facilitation by health care professionals.,Introduction,[244054],[4119],[4659],[False],[0],[0],[False],['0']
42836,PMC9171654,41430,"Other research highlights the importance of facilitation in completing psychiatric advance statements,6 but having health care professionals serve as facilitators is not an obvious choice.",Introduction,[244062],[4660],[4848],[False],[0],[0],[False],['0']
42837,PMC9171654,41431,"Indeed, a climate of coercion in psychiatry has been described, with informal coercion and use of power beyond formal coercion, that is, involuntary admissions and compulsory treatment.7,8 The relationship between patients and health care professionals is permeated by this coercive climate more than clinicians realize.9 Because autonomy and self-determination are the main tenets of psychiatric advance statements,10 this system can be improved if facilitation is provided by other types of professionals who are less likely to exert undue influence.",Introduction,[244070],[4849],[5401],[False],[0],[0],[False],['0']
42838,PMC9171654,41432,"To date, RCTs have assessed facilitation by researchers11 and patient advocates,12 but their results are not as significant as those where health care professionals were the facilitators.",Introduction,[244078],[5402],[5589],[False],[0],[0],[False],['0']
42839,PMC9171654,41433,"In France, advance directives were created by law in 2005 and primarily used in end-of-life health care.",Introduction,[244086],[5590],[5694],[False],[0],[0],[False],['0']
42840,PMC9171654,41434,Psychiatric advance directives (PADs) have been used without a formal legal or practical framework.,Introduction,[244094],[5695],[5794],[False],[0],[0],[False],['0']
42841,PMC9171654,41435,"We hypothesized that PADs could be implemented with facilitation by peer workers, ie, people with personal experiences of mental distress and psychiatric services who are employed and trained to support others.13 Interest in the facilitation of PADs by peer workers is increasing, and a comparison between peer workers and health care agents found no differences in PAD completion rate and quality.14 Recent studies showed that PADs facilitated by peer workers were more prescriptive than those facilitated by nonpeer clinicians and had high feasibility and consistency as rated by experts.15",Introduction,[244102],[5795],[6387],[False],[0],[0],[False],['0']
42842,PMC9171654,41436,"To our knowledge, no study has been conducted of the effect on clinical outcomes of peer worker–facilitated PADs (PW-PADs).",Introduction,[244110],[6388],[6511],[False],[0],[0],[False],['0']
42843,PMC9171654,41437,"The current study addresses this evidence gap to determine whether PW-PADs for people with severe mental illness reduce compulsory admissions and provide significant benefits in terms of therapeutic alliance, quality of life, mental illness symptoms, empowerment, and recovery.",Introduction,[244118],[6512],[6789],[False],[0],[0],[False],['0']
42844,PMC9171654,41438,Methods,Methods,[244126],[6790],[6798],[False],[0],[0],[False],['0']
42845,PMC9171654,41439,Ethics,Methods|Ethics,[244134],[6799],[6805],[False],[0],[0],[False],['0']
42846,PMC9171654,41440,"The trial was submitted and approved June 6, 2018, by the French ethics committee Sud-Ouest et Outre-mer 4 (2018-A00146-49).",Methods|Ethics,[244142],[6806],[6930],[False],[0],[0],[False],['0']
42847,PMC9171654,41441,"The study was conducted in compliance with the Declaration of Helsinki, sixth revision; Good Clinical Practice guidelines; and local regulatory requirements.",Methods|Ethics,[244150],[6931],[7088],[False],[0],[0],[False],['0']
42848,PMC9171654,41442,The participants provided both oral and written consent before their enrollment and allocation to the study groups.,Methods|Ethics,[244158],[7089],[7204],[False],[0],[0],[False],['0']
42849,PMC9171654,41443,Trial Design,Methods|Trial Design,[244166],[7205],[7217],[False],[0],[0],[False],['0']
42850,PMC9171654,41444,"The study, which has the English name description Peer Worker–Facilitated Psychiatric Advance Directive Study (French acronym DAiP), was a multicenter nonblinded RCT conducted in 7 mental health facilities (aka centers) of 3 cities (aka sites) in France (Lyon, Paris, and Marseille) between January 2019 and June 2021.",Methods|Trial Design,[244174],[7218],[7536],[False],[0],[0],[False],['0']
42851,PMC9171654,41445,Participants were referred by their treating psychiatrists in mental health institutions.,Methods|Trial Design,[244182],[7537],[7626],[False],[0],[0],[False],['0']
42852,PMC9171654,41446,"At the time of study inclusion, most participants were discharged from the hospital, but some were still hospitalized.",Methods|Trial Design,[244190],[7627],[7745],[False],[0],[0],[False],['0']
42853,PMC9171654,41447,Psychiatrists checked the eligibility criteria and referred eligible participants to research assistants.,Methods|Trial Design,[244198],[7746],[7851],[False],[0],[0],[False],['0']
42854,PMC9171654,41448,Research assistants and psychiatrists reviewed the patient information and validated the inclusion and exclusion criteria.,Methods|Trial Design,[244206],[7852],[7974],[False],[0],[0],[False],['0']
42855,PMC9171654,41449,Research assistants met participants from both groups at a location of their choice for face-to-face interviews at the time of inclusion and at 6 and 12 months.,Methods|Trial Design,[244214],[7975],[8135],[False],[0],[0],[False],['0']
42856,PMC9171654,41450,The 12-month follow-up timeline started directly after randomization.,Methods|Trial Design,[244222],[8136],[8205],[False],[0],[0],[False],['0']
42857,PMC9171654,41451,The recruitment period was planned for 12 months but extended by 6 months because of the COVID-19 pandemic.,Methods|Trial Design,[244230],[8206],[8313],[False],[0],[0],[False],['0']
42858,PMC9171654,41452,The study was stopped as originally planned 12 months after the last recruitment.,Methods|Trial Design,[244238],[8314],[8395],[False],[0],[0],[False],['0']
42859,PMC9171654,41453,Full details are available in the published protocol (Supplement 2).16,Methods|Trial Design,[244246],[8396],[8466],[False],[0],[0],[False],['0']
42860,PMC9171654,41454,The study is registered at ClinicalTrials.gov (NCT03630822).,Methods|Trial Design,[244254],[8467],[8527],[False],[0],[0],[False],['0']
42861,PMC9171654,41455,This article follows the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.,Methods|Trial Design,[244262],[8528],[8627],[False],[0],[0],[False],['0']
42862,PMC9171654,41456,Population and Randomization,Methods|Population and Randomization,[244270],[8628],[8656],[False],[0],[0],[False],['0']
42863,PMC9171654,41457,"Eligible participants were older than 18 years; were involuntarily admitted to the hospital within the past 12 months; had a diagnosis of schizophrenia, bipolar I disorder, or schizoaffective disorder according to DSM-5 criteria17; had decision-making capacity assessed by a psychiatrist according to the MacArthur Competence Assessment Tool for Clinical Research18; were covered by French government health insurance; and understood French.",Methods|Population and Randomization,[244278],[8657],[9098],[False],[0],[0],[False],['0']
42864,PMC9171654,41458,The exclusion criteria included being considered unable to provide informed consent and being under tutorship (the more restrictive of 2 levels of guardianship in France).,Methods|Population and Randomization,[244286],[9099],[9270],[False],[0],[0],[False],['0']
42865,PMC9171654,41459,"Immediately after signing the consent form, participants were randomly assigned using a web-based system at a 1:1 ratio.",Methods|Population and Randomization,[244294],[9271],[9391],[False],[0],[0],[False],['0']
42866,PMC9171654,41460,The randomization list used a permuted block design and was stratified by the center.,Methods|Population and Randomization,[244302],[9392],[9477],[False],[0],[0],[False],['0']
42867,PMC9171654,41461,"Research assistants, treating clinicians, and participants were aware of the assigned randomization group.",Methods|Population and Randomization,[244310],[9478],[9584],[False],[0],[0],[False],['0']
42868,PMC9171654,41462,Intervention Group (PW-PAD),Methods|Intervention Group (PW-PAD),[244318],[9585],[9612],[False],[0],[0],[False],['0']
42869,PMC9171654,41463,"After randomization, all PW-PAD participants received the PAD document from research assistants.",Methods|Intervention Group (PW-PAD),[244326],[9613],[9709],[False],[0],[0],[False],['0']
42870,PMC9171654,41464,"The PAD documents included future treatment and support preferences, early signs of relapse, and coping strategies.",Methods|Intervention Group (PW-PAD),[244334],[9710],[9825],[False],[0],[0],[False],['0']
42871,PMC9171654,41465,The research assistant proposed organizing the meeting with the peer worker and distributed the contact details.,Methods|Intervention Group (PW-PAD),[244342],[9826],[9938],[False],[0],[0],[False],['0']
42872,PMC9171654,41466,"Depending on their preferences, the PW-PAD participants could:",Methods|Intervention Group (PW-PAD),[244350],[9939],[10001],[False],[0],[0],[False],['0']
42873,PMC9171654,41467,The PADs were completed and signed in paper format.,Methods|Intervention Group (PW-PAD),[244358],[10002],[10053],[False],[0],[0],[False],['0']
42874,PMC9171654,41468,"They were stored by the health care agent or the psychiatrist, depending on the choice of the participant, and uploaded to electronic medical records if available and requested.",Methods|Intervention Group (PW-PAD),[244366],[10054],[10231],[False],[0],[0],[False],['0']
42875,PMC9171654,41469,"In case of crisis, the existence of a PAD was reported by the patient, their companions, or informed caregivers.",Methods|Intervention Group (PW-PAD),[244374],[10232],[10344],[False],[0],[0],[False],['0']
42876,PMC9171654,41470,Control Group,Methods|Control Group,[244382],[10345],[10358],[False],[0],[0],[False],['0']
42877,PMC9171654,41471,People assigned to the control group were followed up as usual.,Methods|Control Group,[244390],[10359],[10422],[False],[0],[0],[False],['0']
42878,PMC9171654,41472,They received comprehensive information about the PAD concept during the inclusion step and were free to complete a PAD.,Methods|Control Group,[244398],[10423],[10543],[False],[0],[0],[False],['0']
42879,PMC9171654,41473,They were not introduced to a peer worker from the study.,Methods|Control Group,[244406],[10544],[10601],[False],[0],[0],[False],['0']
42880,PMC9171654,41474,Outcomes,Methods|Outcomes,[244414],[10602],[10610],[False],[0],[0],[False],['0']
42881,PMC9171654,41475,"We collected data from the computerized patient administrative system and through participant interviews, which were scheduled every 6 months.",Methods|Outcomes,[244422],[10611],[10753],[False],[0],[0],[False],['0']
42882,PMC9171654,41476,"The primary outcome was the rate of compulsory admissions to a psychiatric hospital at 12 months of follow-up, calculated as the number of participants with at least 1 compulsory admission divided by the number of participants.",Methods|Outcomes,[244430],[10754],[10981],[False],[0],[0],[False],['0']
42883,PMC9171654,41477,"Secondary outcomes were care-related, patient-reported, and mental health outcomes.",Methods|Outcomes,[244438],[10982],[11065],[False],[0],[0],[False],['0']
42884,PMC9171654,41478,"The care-related outcomes included overall hospital admission rate (including voluntary and involuntary admissions), total number of admissions per patient (including voluntary and involuntary admissions), and rate of noncompulsory admissions per patient (ie, the proportion of total admissions per patient that was noncompulsory).",Methods|Outcomes,[244446],[11066],[11397],[False],[0],[0],[False],['0']
42885,PMC9171654,41479,Therapeutic alliance was assessed using the 4-point ordinal Alliance Scale.19 Higher scores indicate higher therapeutic alliance.,Methods|Outcomes,[244454],[11398],[11527],[False],[0],[0],[False],['0']
42886,PMC9171654,41480,"Among the patient-reported outcomes, quality of life was assessed using the Schizophrenia Quality-of-Life scale.20 Dimension and index scores range from 0, which indicates the lowest quality of life, to 100, which indicates the highest quality of life.",Methods|Outcomes,[244462],[11528],[11780],[False],[0],[0],[False],['0']
42887,PMC9171654,41481,"Health status was assessed using the EuroQol scale (5 dimensions and 3 Likert).21 The index score ranges from 0, which indicates the worst health, to 1, which indicates the best health.",Methods|Outcomes,[244470],[11781],[11966],[False],[0],[0],[False],['0']
42888,PMC9171654,41482,Mental-health outcomes included symptomatology assessed with the self-reported modified Colorado Symptom Index.22 Higher scores indicate a greater likelihood of mental health problems.,Methods|Outcomes,[244478],[11967],[12151],[False],[0],[0],[False],['0']
42889,PMC9171654,41483,"Empowerment was assessed using the Empowerment Scale.23 The index scores are 0 to 100, where higher scores correspond to higher empowerment.",Methods|Outcomes,[244486],[12152],[12292],[False],[0],[0],[False],['0']
42890,PMC9171654,41484,Recovery was assessed using the Recovery Assessment Scale.,Methods|Outcomes,[244494],[12293],[12351],[False],[0],[0],[False],['0']
42891,PMC9171654,41485,A higher score indicates better recovery.,Methods|Outcomes,[244502],[12352],[12393],[False],[0],[0],[False],['0']
42892,PMC9171654,41486,Other individual data collected at baseline included sociodemographic information and clinical data.,Methods|Outcomes,[244510],[12394],[12494],[False],[0],[0],[False],['0']
42893,PMC9171654,41487,"Gender, age, education level, nationality, social benefits, wages, employment status, and housing conditions were collected.",Methods|Outcomes,[244518],[12495],[12619],[False],[0],[0],[False],['0']
42894,PMC9171654,41488,"Deprivation was assessed using the EPICES score (English description of score name: Evaluation of Deprivation and Inequalities in Health Examination Centers).24 Clinical data assessed by the psychiatrist included somatic and addictive comorbidity and overall condition using the Clinical Global Impression scale, scored from 1 (healthy, not ill) to 7 (severely ill).",Methods|Outcomes,[244526],[12620],[12986],[False],[0],[0],[False],['0']
42895,PMC9171654,41489,Secondary outcomes are described in more detail in the eMethods in Supplement 1.,Methods|Outcomes,[244534],[12987],[13067],[False],[0],[0],[False],['0']
42896,PMC9171654,41490,Sample Size,Methods|Sample Size,[244542],[13068],[13079],[False],[0],[0],[False],['0']
42897,PMC9171654,41491,"The sample size was calculated to detect a reduction of 30% in the rate of compulsory admissions to psychiatric hospitals during the follow-up period of 12 months between the 2 groups12,25,26 with a reference point of 42.6%.27 To obtain a significance level of 2.5% and power of 80% with equal allocation to 2 groups, each group of the trial required 182 people.",Methods|Sample Size,[244550],[13080],[13442],[False],[0],[0],[False],['0']
42898,PMC9171654,41492,"To allow for a potential 10% of people being lost to follow-up, the planned sample was 200 per group, for a total of 400.",Methods|Sample Size,[244558],[13443],[13564],[False],[0],[0],[False],['0']
42899,PMC9171654,41493,Statistical Analysis,Methods|Statistical Analysis,[244566],[13565],[13585],[False],[0],[0],[False],['0']
42900,PMC9171654,41494,The intention-to-treat analysis included all randomized participants.,Methods|Statistical Analysis,[244574],[13586],[13655],[False],[0],[0],[False],['0']
42901,PMC9171654,41495,Data on compulsory admissions were obtained for all participants; no imputation was performed for the primary outcome.,Methods|Statistical Analysis,[244582],[13656],[13774],[False],[0],[0],[False],['0']
42902,PMC9171654,41496,"For secondary outcomes, missing data due to withdrawal, loss to follow-up, or nonresponse to specific items were 10% to 37.2% at 12 months.",Methods|Statistical Analysis,[244590],[13775],[13914],[False],[0],[0],[False],['0']
42903,PMC9171654,41497,"Missing data were addressed using multiple imputations,28 which creates multiple “complete” data sets with predictions for each missing value.",Methods|Statistical Analysis,[244598],[13915],[14057],[False],[0],[0],[False],['0']
42904,PMC9171654,41498,This procedure takes into account uncertainty and yields accurate standard errors.29 Fifty imputed data sets were implemented using MICE by chained equations and mitools R packages.,Methods|Statistical Analysis,[244606],[14058],[14239],[False],[0],[0],[False],['0']
42905,PMC9171654,41499,"The multiple imputation approach was compared with existing methods for handing missing data; for complete cases, imputed data were compared with the mean or the last observation carried forward.",Methods|Statistical Analysis,[244614],[14240],[14435],[False],[0],[0],[False],['0']
42906,PMC9171654,41500,Data analysis was conducted in 3 steps.,Methods|Statistical Analysis,[244622],[14436],[14475],[False],[0],[0],[False],['0']
42907,PMC9171654,41501,"First, we performed a collinearity test on potential confounding factors based on unbalanced baseline characteristics.",Methods|Statistical Analysis,[244630],[14476],[14594],[False],[0],[0],[False],['0']
42908,PMC9171654,41502,No collinearity was observed; the variance inflation factor ranged from 1.041 to 1.112.,Methods|Statistical Analysis,[244638],[14595],[14682],[False],[0],[0],[False],['0']
42909,PMC9171654,41503,"Second, the proportion of patients with compulsory admission was compared between groups using generalized estimating equations (GENLIN function), applying a binomial distribution with a link logit and adjusting for unbalanced baseline covariates (age, diagnosis, and Clinical Global Impression score), as well as site and site × group interaction.",Methods|Statistical Analysis,[244646],[14683],[15031],[False],[0],[0],[False],['0']
42910,PMC9171654,41504,No group × covariate interactions were kept in the model (they were nonsignificant).,Methods|Statistical Analysis,[244654],[15032],[15116],[False],[0],[0],[False],['0']
42911,PMC9171654,41505,"Further, the subsequent model applied a logistic regression that provided a high goodness of fit.",Methods|Statistical Analysis,[244662],[15117],[15214],[False],[0],[0],[False],['0']
42912,PMC9171654,41506,Adjusted odds ratios and risk differences with 95% CI were calculated.,Methods|Statistical Analysis,[244670],[15215],[15285],[False],[0],[0],[False],['0']
42913,PMC9171654,41507,"For secondary outcomes, between-group differences were estimated using generalized estimating equations (GENLIN function), applying a normal distribution with a link identity for score variables or Poisson distribution with a link log for count variables.",Methods|Statistical Analysis,[244678],[15286],[15541],[False],[0],[0],[False],['0']
42914,PMC9171654,41508,The β coefficient and effect sizes (Cohen d) with 95% CI were calculated.,Methods|Statistical Analysis,[244686],[15542],[15615],[False],[0],[0],[False],['0']
42915,PMC9171654,41509,Statistical analysis was performed using SPSS 12 for Windows and RStudio version 3.2.1.,Methods|Statistical Analysis,[244694],[15616],[15703],[False],[0],[0],[False],['0']
42916,PMC9171654,41510,Results,Results,[244702],[15704],[15712],[False],[0],[0],[False],['0']
42917,PMC9171654,41511,Participants,Results|Participants,[244710],[15713],[15725],[False],[0],[0],[False],['0']
42918,PMC9171654,41512,"As depicted in the Figure, 401 patients were randomized in total, of whom 7 (1.7%) were excluded from the study by the data board (4 patients allocated to the PW-PAD group and 3 patients allocated to the control group).",Results|Participants,[244718],[15726],[15945],[False],[0],[0],[False],['0']
42919,PMC9171654,41513,Two were excluded because of noneligible inclusion criteria and 4 because they withdrew before any data collection.,Results|Participants,[244726],[15946],[16061],[False],[0],[0],[False],['0']
42920,PMC9171654,41514,"Of the 394 patients included in the study, 196 were assigned to the intervention group, and 198 were assigned to the control group (Figure).",Results|Participants,[244734],[16062],[16202],[False],[0],[0],[False],['0']
42921,PMC9171654,41515,Interviews at the 12-month follow-up were completed for 127 (65%) in the PW-PAD group and 139 (70%) in the control group.,Results|Participants,[244742],[16203],[16324],[False],[0],[0],[False],['0']
42922,PMC9171654,41516,"Baseline characteristics were similar between groups, except for age and severity (Table 1).",Results|Participants,[244750],[16325],[16417],[False],[0],[0],[False],['0']
42923,PMC9171654,41517,"Most patients were male (239, 60.7%) and had completed postsecondary school education (261, 66.4%).",Results|Participants,[244758],[16418],[16517],[False],[0],[0],[False],['0']
42924,PMC9171654,41518,"Of the 3 diagnoses assessed, 139 participants (36%) had bipolar I disorder, 178 (45%) schizophrenia, and 76 (19%) schizoaffective disorder.",Results|Participants,[244766],[16518],[16657],[False],[0],[0],[False],['0']
42925,PMC9171654,41519,"The median (IQR) age of the sample was 39 (29-48) years, and participants in the intervention group were younger (mean [SD], 37.4 [11.7] years vs 41.0 [12.7] years; P = .003).",Results|Participants,[244774],[16658],[16833],[False],[0],[0],[False],['0']
42926,PMC9171654,41520,Baseline characteristics per site are provided in eTable 1 in Supplement 1.,Results|Participants,[244782],[16834],[16909],[False],[0],[0],[False],['0']
42927,PMC9171654,41521,"Characteristics at baseline were compared between complete and incomplete cases at the 12-month follow-up; significant differences were found in EPICES score, comorbidities, and previous hospital admissions (eTable 2 in Supplement 1).",Results|Participants,[244790],[16910],[17144],[False],[0],[0],[False],['0']
42928,PMC9171654,41522,"Sixty-three participants in the intervention group (31.2%) and 67 in the control group (33.8%) were included during a hospitalization, with no significant differences in median (IQR) number of inpatient days between inclusion and discharge (34 [7-76] days vs 36 [11-67] days; P = .73).",Results|Participants,[244798],[17145],[17430],[False],[0],[0],[False],['0']
42929,PMC9171654,41523,Completion of PADs,Results|Completion of PADs,[244806],[17431],[17449],[False],[0],[0],[False],['0']
42930,PMC9171654,41524,"In the PW-PAD group, 107 participants completed a PAD document (54.6%) compared with 14 (7.1%) in the control group (P < .001).",Results|Completion of PADs,[244814],[17450],[17577],[False],[0],[0],[False],['0']
42931,PMC9171654,41525,"Among those, 81 met facilitators (75.7%), and 29 used PADs during a crisis in the 12-month follow-up period (27.1%) (Table 2).",Results|Completion of PADs,[244822],[17578],[17704],[False],[0],[0],[False],['0']
42932,PMC9171654,41526,Primary Outcome,Results|Primary Outcome,[244830],[17705],[17720],[False],[0],[0],[False],['0']
42933,PMC9171654,41527,Table 3 presents the number and percentage of patients who had compulsory admissions to the hospital during the 12-month follow-up.,Results|Primary Outcome,[244838],[17721],[17852],[False],[0],[0],[False],['0']
42934,PMC9171654,41528,"The rate of compulsory admission was significantly lower in the PW-PAD group than in the control group: 27.0% (53 patients) vs 39.9% (79 patients), respectively (adjusted odds ratio, 0.58; 95% CI, 0.37 to 0.92; risk difference, −0.13; 95% CI, −0.22 to −0.04; P = .007).",Results|Primary Outcome,[244846],[17853],[18122],[False],[0],[0],[False],['0']
42935,PMC9171654,41529,Secondary Outcomes,Results|Secondary Outcomes,[244854],[18123],[18141],[False],[0],[0],[False],['0']
42936,PMC9171654,41530,Secondary outcomes are presented in Table 3.,Results|Secondary Outcomes,[244862],[18142],[18186],[False],[0],[0],[False],['0']
42937,PMC9171654,41531,"Participants in the PW-PAD group exhibited lower symptoms as measured by modified Colorado Symptom Index score (effect size, −0.20; 95% CI, −0.40 to 0.00; P = .03), greater empowerment through Empowerment Scale scores (0.30; 95% CI, 0.10 to 0.50; P = .003), and higher recovery through Recovery Assessment Scale scores (0.44; 95% CI, 0.24 to 0.65; P < .001), compared with the control group.",Results|Secondary Outcomes,[244870],[18187],[18578],[False],[0],[0],[False],['0']
42938,PMC9171654,41532,"We found no statistically significant differences between groups for overall admission rate, therapeutic alliance, and quality-of-life measures.",Results|Secondary Outcomes,[244878],[18579],[18723],[False],[0],[0],[False],['0']
42939,PMC9171654,41533,Sensitivity analyses showed that the use of multiple imputations rather than other methods of handling missing data had little effect on the results (eTable 3 in Supplement 1).,Results|Secondary Outcomes,[244886],[18724],[18900],[False],[0],[0],[False],['0']
42940,PMC9171654,41534,Discussion,Discussion,[244894],[18901],[18912],[False],[0],[0],[False],['0']
42941,PMC9171654,41535,"Among 394 participants living with schizophrenia, bipolar I disorder, or schizoaffective disorder who had compulsory hospital admissions during the past year, use of PADs facilitated by peer workers was associated with a significant decrease in compulsory admissions and an increase in mental health outcomes (self-perceived symptoms, empowerment, and recovery) at 12 months.",Discussion,[244902],[18913],[19288],[False],[0],[0],[False],['0']
42942,PMC9171654,41536,"In the PW-PAD group, 54.6% of participants completed PADs (vs 7.1% in control group), among whom 75.7% used the support of peer workers.",Discussion,[244910],[19289],[19425],[False],[0],[0],[False],['0']
42943,PMC9171654,41537,This study is the first to our knowledge to show that PADs facilitated by peer workers are effective in reducing compulsory admissions.,Discussion,[244918],[19426],[19561],[False],[0],[0],[False],['0']
42944,PMC9171654,41538,"With a decrease of 32% of compulsory admissions, these results exceed the 25% pooled estimates from the meta-analysis.",Discussion,[244926],[19562],[19680],[False],[0],[0],[False],['0']
42945,PMC9171654,41539,"As in all other comparable studies, we found little effect on overall admissions, which supported that PADs might reduce compulsory admissions by making participants more willing to consider a voluntary admission when a crisis occurs instead of preventing hospital admissions.5 This result is important because minimizing compulsory admissions reduces its many widely described negative consequences.30,31,32 The qualitative research conducted in parallel with this study will provide insight into the mechanisms and drivers of the intervention’s effectiveness.",Discussion,[244934],[19681],[20242],[False],[0],[0],[False],['0']
42946,PMC9171654,41540,"We found high rates of involuntary hospitalizations in both groups, which are consistent with published French data.27 France ranked above the international median calculated in 2017 among 22 countries, with an annual rate of 140.0 involuntary hospitalizations per 100 000 people compared with a median rate of 106.4 (IQR, 58.5-150.9).33",Discussion,[244942],[20243],[20580],[False],[0],[0],[False],['0']
42947,PMC9171654,41541,"No previous RCTs on the efficacy of advance statements reported results of mental health outcomes, except Papageorgiou et al11 and Lay et al,34 who did not find any differences in psychiatric symptoms and psychiatric functioning at 12 months.",Discussion,[244950],[20581],[20823],[False],[0],[0],[False],['0']
42948,PMC9171654,41542,"In our study, PW-PAD was associated with improvement in mental health outcomes, with improvements in symptoms, empowerment, and recovery.",Discussion,[244958],[20824],[20961],[False],[0],[0],[False],['0']
42949,PMC9171654,41543,"Research on recovery-oriented services distinguishes between health-related outcome measures (such as symptoms) and recovery-oriented outcome measures (such as self-assessment of recovery, empowerment, or quality of life), which capture the efficacy of peer support more accurately.35 Research on peer support demonstrates substantial heterogeneity in terms of quality36 and encompasses many activities,37 but reviews have shown that the involvement of peers in various services is associated with mixed and limited improvements in recovery-oriented outcomes.37,38,39 Because the PW-PAD intervention had the greatest effect on several of these indicators, we hypothesize that peer-worker involvement plays a role in these results.",Discussion,[244966],[20962],[21692],[False],[0],[0],[False],['0']
42950,PMC9171654,41544,Further studies should directly compare facilitation by health care professionals and facilitation by peer workers using a measurement of perceived coercion.,Discussion,[244974],[21693],[21850],[False],[0],[0],[False],['0']
42951,PMC9171654,41545,"Furthermore, the high rates of completion in the PW-PAD group show the importance of encouragement (explanation, distribution of the document) and facilitation, which reinforces previous research.5,6,14",Discussion,[244982],[21851],[22053],[False],[0],[0],[False],['0']
42952,PMC9171654,41546,Strengths and Limitations,Discussion|Strengths and Limitations,[244990],[22054],[22079],[False],[0],[0],[False],['0']
42953,PMC9171654,41547,Our study has 2 major strengths.,Discussion|Strengths and Limitations,[244998],[22080],[22112],[False],[0],[0],[False],['0']
42954,PMC9171654,41548,"First, the nature of this research is highly participatory because it involved patients at all levels from the beginning.16 Second, it was deployed through more than 40 psychiatrists from all backgrounds with current practices.",Discussion|Strengths and Limitations,[245006],[22113],[22340],[False],[0],[0],[False],['0']
42955,PMC9171654,41549,"Because peer workers were independently recruited by research teams, participating units were not only recovery-oriented but reflected a variety of services.",Discussion|Strengths and Limitations,[245014],[22341],[22498],[False],[0],[0],[False],['0']
42956,PMC9171654,41550,"Thus, the study suggests that PW-PADs can be easily implemented and our results are generalizable to other services.",Discussion|Strengths and Limitations,[245022],[22499],[22615],[False],[0],[0],[False],['0']
42957,PMC9171654,41551,This trial had several limitations.,Discussion|Strengths and Limitations,[245030],[22616],[22651],[False],[0],[0],[False],['0']
42958,PMC9171654,41552,"First, the follow-up was complicated by the COVID-19 health crisis, and the loss of 31% of participants at the 12-month follow-up and resulting decrease in power for secondary outcomes are important limitations.",Discussion|Strengths and Limitations,"[245038, 245039]","[22652, 22652]","[22863, 22863]","[True, True]","['HighLossToFollowUp', 'UnderpoweredStudy']","['the loss of 31% of participants at the 12-month follow-up', 'resulting decrease in power for secondary outcomes']","[True, True]","['UnderpoweredStudy', 'MissingData']"
42959,PMC9171654,41553,"Fortunately, our primary outcome was based on administrative data and consequently not affected.",Discussion|Strengths and Limitations,[245054],[22864],[22960],[False],[0],[0],[False],['0']
42960,PMC9171654,41554,"Second, the recruitment was unequal among centers, and we did not have the power to make comparisons across the 7 different centers.",Discussion|Strengths and Limitations,"[245064, 245065]","[22961, 22961]","[23093, 23093]","[True, True]","['Population', 'UnderpoweredStudy']","['the recruitment was unequal among centers', 'we did not have the power to make comparisons across the 7 different centers']","[True, True]","['Population', 'UnderpoweredStudy']"
42961,PMC9171654,41555,"Third, the profession of peer worker is relatively new in France, and the PAD was a new tool.",Discussion|Strengths and Limitations,"[245084, 245085]","[23094, 23094]","[23187, 23187]","[True, True]","['Intervention', 'Intervention']","['the PAD was a new tool', 'the profession of peer worker is relatively new in France']","[True, True]",['Intervention']
42962,PMC9171654,41556,"The study has led to the development of specific training for peer workers and teams, which should help improve the results of such interventions.",Discussion|Strengths and Limitations,[245094],[23188],[23334],[False],[0],[0],[False],['0']
42963,PMC9171654,41557,"Further, we had notably restrictive criteria, and the findings may not be generalizable to other psychiatric populations.",Discussion|Strengths and Limitations,"[245106, 245107]","[23335, 23335]","[23456, 23456]","[True, True]","['DiagnosticCriteria', 'Generalization']","['we had notably restrictive criteria', 'the findings may not be generalizable to other psychiatric populations']","[True, True]","['Generalization', 'Population']"
42964,PMC9171654,41558,Conclusions,Conclusions,[245118],[23457],[23469],[False],[0],[0],[False],['0']
42965,PMC9171654,41559,"Among people living with schizophrenia, bipolar I disorder, or schizoaffective disorder, the use of PW-PADs was associated with a significant decrease in compulsory admissions and a significant increase in some mental health outcomes (self-perceived symptoms, empowerment, and recovery).",Conclusions,[245126],[23470],[23757],[False],[0],[0],[False],['0']
42966,PMC9171654,41560,"These findings support the use of PW-PADs for people with schizophrenia, bipolar I disorder, or schizoaffective disorder.",Conclusions,[245134],[23758],[23879],[False],[0],[0],[False],['0']
42967,PMC9171654,41561,Legal and organizational initiatives that promote supported decision-making can develop the activity of peer workers to fulfill this mission.,Conclusions,[245142],[23880],[24021],[False],[0],[0],[False],['0']
42968,PMC9380327,42531,Medium- and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial,Title,[253256],[35257],[133],[False],[0],[0],[False],['0']
42969,PMC9380327,42532,Background,Abstract,[253260],[134],[145],[False],[0],[0],[False],['0']
42970,PMC9380327,42533,Smoking is a major risk factor for cardiovascular disease and smoking cessation reduces excess risk.,Abstract,[253264],[146],[246],[False],[0],[0],[False],['0']
42971,PMC9380327,42534,E-cigarettes are popular for smoking cessation but there is little evidence on their cardiovascular health effect.,Abstract,[253268],[247],[361],[False],[0],[0],[False],['0']
42972,PMC9380327,42535,Our objective was to compare the medium- and longer-term cardiovascular effects in smokers attempting to quit smoking using e-cigarettes with or without nicotine or prescription nicotine replacement therapy (NRT).,Abstract,[253272],[362],[575],[False],[0],[0],[False],['0']
42973,PMC9380327,42536,Methods,Abstract,[253276],[576],[583],[False],[0],[0],[False],['0']
42974,PMC9380327,42537,"This was a single-center, pragmatic three-arm randomized (1:1:1) controlled trial, which recruited adult smokers (≥ 10 cigarettes/day), who were willing to attempt to stop smoking with support (n = 248).",Abstract,[253280],[584],[787],[False],[0],[0],[False],['0']
42975,PMC9380327,42538,Results,Abstract,[253284],[788],[795],[False],[0],[0],[False],['0']
42976,PMC9380327,42539,"At 3- and 6-month follow-up, %FMD showed an improvement over baseline in all three groups (e.g., p < 0.0001 at 6 months).",Abstract,[253288],[796],[917],[False],[0],[0],[False],['0']
42977,PMC9380327,42540,"Similarly, ACh, SNP, and MAP improved significantly over baseline in all groups both at 3 and 6 months (e.g., ACh: p = 0.004, at 6 months).",Abstract,[253292],[918],[1057],[False],[0],[0],[False],['0']
42978,PMC9380327,42541,Conclusions,Abstract,[253296],[1058],[1069],[False],[0],[0],[False],['0']
42979,PMC9380327,42542,Smokers attempting to quit experienced positive cardiovascular impact after both a 3- and 6-month period.,Abstract,[253300],[1070],[1175],[False],[0],[0],[False],['0']
42980,PMC9380327,42543,"None of the groups (i.e., nicotine-containing and nicotine-free e-cigarettes or NRT) offered superior cardiovascular benefits to the others.",Abstract,[253304],[1176],[1316],[False],[0],[0],[False],['0']
42981,PMC9380327,42544,Trial registration,Abstract,[253308],[1317],[1335],[False],[0],[0],[False],['0']
42982,PMC9380327,42545,ClinicalTrials.gov NCT03061253.,Abstract,[253312],[1336],[1367],[False],[0],[0],[False],['0']
42983,PMC9380327,42546,Registered on 17 February 2017.,Abstract,[253316],[1368],[1399],[False],[0],[0],[False],['0']
42984,PMC9380327,42547,Supplementary Information,Supplementary Information,[253320],[1400],[1426],[False],[0],[0],[False],['0']
42985,PMC9380327,42548,The online version contains supplementary material available at 10.1186/s12916-022-02451-9.,Supplementary Information,[253324],[1427],[1518],[False],[0],[0],[False],['0']
42986,PMC9380327,42549,Background,Background,[253328],[1519],[1530],[False],[0],[0],[False],['0']
42987,PMC9380327,42550,"Smoking remains the second-leading mortality risk factor in the world [1], mainly due to cancer, lung disease, and cardiovascular disease (CVD).",Background,[253332],[1531],[1675],[False],[0],[0],[False],['0']
42988,PMC9380327,42551,Smoking prevalence in the UK has declined substantially over the last decades to 14% in 2019 [2].,Background,[253336],[1676],[1773],[False],[0],[0],[False],['0']
42989,PMC9380327,42552,"Nonetheless, smoking-caused deaths remain high (78,000 deaths in 2017 [3]), with smoking being the leading risk factor for loss of healthy life years [1].",Background,[253340],[1774],[1928],[False],[0],[0],[False],['0']
42990,PMC9380327,42553,Smoking is a major CVD risk factor.,Background,[253344],[1929],[1964],[False],[0],[0],[False],['0']
42991,PMC9380327,42554,This is because it causes endothelial injury and dysfunction in both coronary and peripheral arteries and an increased risk of thrombosis.,Background,[253348],[1965],[2103],[False],[0],[0],[False],['0']
42992,PMC9380327,42555,Smoking also produces a chronic inflammatory state that contributes to atherogenic disease processes and elevated levels of biomarkers of inflammation [4].,Background,[253352],[2104],[2259],[False],[0],[0],[False],['0']
42993,PMC9380327,42556,The negative effects upon cardiovascular function are not limited to smokers; passive smoking increases heart disease death-risk by almost 30% [5].,Background,[253356],[2260],[2407],[False],[0],[0],[False],['0']
42994,PMC9380327,42557,"Thankfully, smoking cessation offers CVD risk-reduction benefits, which increase as time since cessation increases [6].",Background,[253360],[2408],[2527],[False],[0],[0],[False],['0']
42995,PMC9380327,42558,"A combination of behavioral support and pharmacological interventions, particularly using two forms of nicotine replacement therapy (NRT) or varenicline, is the most effective approach to smoking cessation [7–9].",Background,[253364],[2528],[2740],[False],[0],[0],[False],['0']
42996,PMC9380327,42559,"However, even the best methods have high relapse rates of over 75% within a year [10].",Background,[253368],[2741],[2827],[False],[0],[0],[False],['0']
42997,PMC9380327,42560,"In the UK, stop-smoking services offer behavioral support and medication; however, the number of services has been reduced year on year [11].",Background,[253372],[2828],[2969],[False],[0],[0],[False],['0']
42998,PMC9380327,42561,"Vaping products or electronic cigarettes (e-cigarettes) have been the most popular choice of support for smoking cessation in England, and by 2020 were being used by 27% of smokers making a cessation attempt [12], compared with for example 18% who used nicotine replacement therapy (NRT).",Background,[253376],[2970],[3258],[False],[0],[0],[False],['0']
42999,PMC9380327,42562,"A recent Cochrane review concluded cessation was higher with nicotine-containing e-cigarettes than with NRT, nicotine-free e-cigarettes, or behavioral support [13].",Background,[253380],[3259],[3423],[False],[0],[0],[False],['0']
43000,PMC9380327,42563,"Population-level survey data show that cessation attempts with the use of an e-cigarette had increased odds of success (OR = 1.95, 95% confidence interval (CI): 1.69–2.24) compared with those using any other support [14].",Background,[253384],[3424],[3645],[False],[0],[0],[False],['0']
43001,PMC9380327,42564,"Per year, an additional 50,000–70,000 smokers in England have stopped smoking successfully, who without e-cigarettes would have continued smoking [15].",Background,[253388],[3646],[3797],[False],[0],[0],[False],['0']
43002,PMC9380327,42565,"Routine monitoring data from stop-smoking services indicate that clients using e-cigarettes in their supported quit attempt are at least as likely to stop smoking as those using prescription medication [3, 12].",Background,[253392],[3798],[4008],[False],[0],[0],[False],['0']
43003,PMC9380327,42566,"Nevertheless, evidence on the effect of e-cigarettes on cardiovascular health remains limited [16, 17].",Background,[253396],[4009],[4112],[False],[0],[0],[False],['0']
43004,PMC9380327,42567,"Systematic reviews of e-cigarettes and cardiovascular effects suggest a negative effect [18]; however, in general, e-cigarettes are considered less harmful than traditional smoking [19].",Background,[253400],[4113],[4299],[False],[0],[0],[False],['0']
43005,PMC9380327,42568,"One randomized controlled trial found that after 1-month, endothelial function and vascular stiffness improved significantly in participants who switched from smoking to using e-cigarettes compared with those who continued to smoke.",Background,[253404],[4300],[4532],[False],[0],[0],[False],['0']
43006,PMC9380327,42569,The improvement was larger if participants switched to e-cigarettes completely and very similar for nicotine-containing and nicotine-free e-cigarettes [20].,Background,[253408],[4533],[4689],[False],[0],[0],[False],['0']
43007,PMC9380327,42570,"Our own work on e-cigarettes’ short-term, physiological effects suggests that positive indications appear earlier in the smoking cessation time-line, and that they are similar to those offered by NRT [21].",Background,[253412],[4690],[4895],[False],[0],[0],[False],['0']
43008,PMC9380327,42571,"Nevertheless, to date, no evidence has been published on the stability of improvements over time, particularly in comparison to NRT, and the range of outcome measures has been limited.",Background,[253416],[4896],[5080],[False],[0],[0],[False],['0']
43009,PMC9380327,42572,"The present study therefore aimed to compare medium- (3 months) and longer-term (6 months) cardiovascular effects in smokers who attempted to quit smoking using behavioral support and (a) e-cigarettes with nicotine, (b) e-cigarettes without nicotine, and (c) prescription NRT.",Background,[253420],[5081],[5357],[False],[0],[0],[False],['0']
43010,PMC9380327,42573,Methods,Methods,[253424],[5358],[5366],[False],[0],[0],[False],['0']
43011,PMC9380327,42574,"The full protocol, alongside sample size calculations, has been published previously [22].",Methods,[253428],[5367],[5457],[False],[0],[0],[False],['0']
43012,PMC9380327,42575,Design and setting,Methods|Design and setting,[253432],[5458],[5476],[False],[0],[0],[False],['0']
43013,PMC9380327,42576,"This single-center pragmatic three-arm randomized controlled trial was conducted in Sheffield, UK; recruitment took place between June 2017 and July 2019.",Methods|Design and setting,[253436],[5477],[5631],[False],[0],[0],[False],['0']
43014,PMC9380327,42577,Participant recruitment,Methods|Participant recruitment,[253440],[5632],[5655],[False],[0],[0],[False],['0']
43015,PMC9380327,42578,Participants were recruited from the community [22].,Methods|Participant recruitment,[253444],[5656],[5708],[False],[0],[0],[False],['0']
43016,PMC9380327,42579,"Eligible were smokers who had smoked ≥ 10 cigarettes per day for the last year, were aged ≥ 18, and willing to make a cessation attempt using a stop-smoking service or e-cigarettes.",Methods|Participant recruitment,[253448],[5709],[5890],[False],[0],[0],[False],['0']
43017,PMC9380327,42580,"Exclusion criteria were (i) inability to walk; (ii) recent (within 6 months) CVD events or cardiac surgery; (iii) insulin-controlled diabetes mellitus; (iv) coexisting skin conditions, leg ulcers, vasculitis, or deep venous occlusion; (v) pregnancy; (vi) major surgery scheduled during the study; (vii) contraindications /unsuitability for NRT; (viii) current daily use of e-cigarettes; and (ix) current cessation attempt supported by a stop-smoking service.",Methods|Participant recruitment,[253452],[5891],[6349],[False],[0],[0],[False],['0']
43018,PMC9380327,42581,Procedures,Methods|Procedures,[253456],[6350],[6360],[False],[0],[0],[False],['0']
43019,PMC9380327,42582,"Following a telephone pre-screening and information about study procedures, participants were invited to Sheffield Hallam University to provide informed consent and undertake baseline assessments.",Methods|Procedures,[253460],[6361],[6557],[False],[0],[0],[False],['0']
43020,PMC9380327,42583,"They were enrolled by a researcher not involved in group allocation, intervention delivery, or assessments.",Methods|Procedures,[253464],[6558],[6665],[False],[0],[0],[False],['0']
43021,PMC9380327,42584,"Following baseline, participants were randomized remotely into three groups by an independent statistician using a computer-generated (nQuery Advisor 6.0, Statistical Solutions, Ireland) block-randomization stratified by gender and “pack-years” (number of packs (20 cigarettes per pack) per day times number of years smoked).",Methods|Procedures,[253468],[6666],[6991],[False],[0],[0],[False],['0']
43022,PMC9380327,42585,The study statistician allocated a unique trial number to each participant for the study duration.,Methods|Procedures,[253472],[6992],[7090],[False],[0],[0],[False],['0']
43023,PMC9380327,42586,Outcome assessors were blinded to group allocation and participants were reminded regularly not to share their group allocation with assessors or those providing behavioral support.,Methods|Procedures,[253476],[7091],[7272],[False],[0],[0],[False],['0']
43024,PMC9380327,42587,The study statistician/health economist was blinded to group allocation.,Methods|Procedures,[253480],[7273],[7345],[False],[0],[0],[False],['0']
43025,PMC9380327,42588,Those delivering the intervention were only blinded in relation to which e-cigarette group the participants belonged to as the NRT group was receiving support through the stop-smoking service.,Methods|Procedures,[253484],[7346],[7538],[False],[0],[0],[False],['0']
43026,PMC9380327,42589,"No blinding existed for participants, as NRT was delivered separately and as experienced users of nicotine, the e-cigarette groups were able to determine the presence or absence of nicotine.",Methods|Procedures,[253488],[7539],[7729],[False],[0],[0],[False],['0']
43027,PMC9380327,42590,"During their initial behavioral support sessions, participants set a “quit date” to stop smoking completely.",Methods|Procedures,[253492],[7730],[7838],[False],[0],[0],[False],['0']
43028,PMC9380327,42591,This defined timing of follow-up visits.,Methods|Procedures,[253496],[7839],[7879],[False],[0],[0],[False],['0']
43029,PMC9380327,42592,Intervention,Methods|Intervention,[253500],[7880],[7892],[False],[0],[0],[False],['0']
43030,PMC9380327,42593,Nicotine-containing e-cigarettes group and nicotine-free e-cigarettes group,Methods|Intervention,[253504],[7893],[7968],[False],[0],[0],[False],['0']
43031,PMC9380327,42594, Behavioral support was offered for a 3-month period through the research team.,Methods|Intervention,[253508],[7969],[8048],[False],[0],[0],[False],['0']
43032,PMC9380327,42595,This was necessary as e-cigarettes were not part of the treatments offered by the local stop-smoking services at the time of the study.,Methods|Intervention,[253512],[8049],[8184],[False],[0],[0],[False],['0']
43033,PMC9380327,42596,"Both groups received complimentary e-cigarette equipment and refills (Tornado V5, Totally Wicked, Blackburn, UK), together with instructions on correct usage.",Methods|Intervention,[253516],[8185],[8343],[False],[0],[0],[False],['0']
43034,PMC9380327,42597,"Participants, on average, received 20 bottles of 10 ml during the intervention period.",Methods|Intervention,[253520],[8344],[8430],[False],[0],[0],[False],['0']
43035,PMC9380327,42598,"The nicotine-containing e-cigarette group received liquids with nicotine strength of up to 18 mg/ml, the nicotine-free e-cigarette group received nicotine-free liquids (0 mg/ml).",Methods|Intervention,[253524],[8431],[8609],[False],[0],[0],[False],['0']
43036,PMC9380327,42599,"Participants could choose ice menthol or tobacco flavor (Red Label, Totally Wicked, Blackburn, UK).",Methods|Intervention,[253528],[8610],[8709],[False],[0],[0],[False],['0']
43037,PMC9380327,42600,Prescription NRT group,Methods|Prescription NRT group,[253532],[8710],[8732],[False],[0],[0],[False],['0']
43038,PMC9380327,42601,"Following allocation, participants were referred to Sheffield stop-smoking services for behavioral support for three months.",Methods|Prescription NRT group,[253536],[8733],[8857],[False],[0],[0],[False],['0']
43039,PMC9380327,42602,They received money or shopping vouchers (depending on personal preference) as reimbursement for NRT prescription charges.,Methods|Prescription NRT group,[253540],[8858],[8980],[False],[0],[0],[False],['0']
43040,PMC9380327,42603,"To ensure comparability of behavioral support provided, all groups received the same level and type of behavioral support as currently offered as standard by stop-smoking services, in the form of regular face-to-face or telephone appointments as per relevant guidelines, e.g., minimum of 6 support sessions within the 3-month period [23].",Methods|Prescription NRT group,[253544],[8981],[9319],[False],[0],[0],[False],['0']
43041,PMC9380327,42604,All advisors had completed the same behavioral support training.,Methods|Prescription NRT group,[253548],[9320],[9384],[False],[0],[0],[False],['0']
43042,PMC9380327,42605,"To support the successful participation of our participants, we used our “six pillars of adherence” framework (based upon “social support,” “education,” “reachability,” “small groups intervention implementation,” “reminders,” and “simplicity”).",Methods|Prescription NRT group,[253552],[9385],[9629],[False],[0],[0],[False],['0']
43043,PMC9380327,42606,None of the participants experienced side effects due to their participation in the intervention.,Methods|Prescription NRT group,[253556],[9630],[9727],[False],[0],[0],[False],['0']
43044,PMC9380327,42607,Measures,Measures,[253560],[9728],[9738],[False],[0],[0],[False],['0']
43045,PMC9380327,42608,"Age, gender, carbon monoxide (CO—to confirm smoking status), body mass index, blood pressure, number of cigarettes and years smoked, and physical activity measured using the SF-IPAQ [24] were recorded at baseline.",Measures,[253564],[9739],[9952],[False],[0],[0],[False],['0']
43046,PMC9380327,42609,"Body mass index, CO, blood pressure, and physical activity assessments were repeated at 3 and 6-month follow-up.",Measures,[253568],[9953],[10065],[False],[0],[0],[False],['0']
43047,PMC9380327,42610,Primary outcome,Measures|Primary outcome,[253572],[10066],[10081],[False],[0],[0],[False],['0']
43048,PMC9380327,42611,Macrovascular function was assessed using percentage change in flow-mediated dilation.,Measures|Primary outcome,[253576],[10082],[10168],[False],[0],[0],[False],['0']
43049,PMC9380327,42612,Smoking is associated with reduced FMD.,Measures|Primary outcome,[253580],[10169],[10208],[False],[0],[0],[False],['0']
43050,PMC9380327,42613,"Reduced altered brachial artery FMD is an early marker for endothelial dysfunction, a CVD risk factor [6], and considered a predictor for long-term, adverse cardiovascular events [25].",Measures|Primary outcome,[253584],[10209],[10393],[False],[0],[0],[False],['0']
43051,PMC9380327,42614,"FMD is a non-invasive, nitric oxide-mediated measure.",Measures|Primary outcome,[253588],[10394],[10447],[False],[0],[0],[False],['0']
43052,PMC9380327,42615,"Baseline scanning to assess resting vessel diameter was recorded over 3 min, following a 10-min resting period, using a Nemio XG (Toshiba, Tokyo, Japan) ultrasound machine, according to the International Brachial Artery Reactivity Task Force guidelines [26].",Measures|Primary outcome,[253592],[10448],[10706],[False],[0],[0],[False],['0']
43053,PMC9380327,42616,Fixed anatomic landmarks (side branches) were used to ensure that the same artery portion was assessed on each occasion.,Measures|Primary outcome,[253596],[10707],[10827],[False],[0],[0],[False],['0']
43054,PMC9380327,42617,The technical error in our lab for FMD is 5% [26].,Measures|Primary outcome,[253600],[10828],[10878],[False],[0],[0],[False],['0']
43055,PMC9380327,42618,FMD is presented as change in post-stimulus diameter as a percentage of the baseline diameter (%FMD).,Measures|Primary outcome,[253604],[10879],[10980],[False],[0],[0],[False],['0']
43056,PMC9380327,42619,Secondary outcomes,Measures|Secondary outcomes,[253608],[10981],[10999],[False],[0],[0],[False],['0']
43057,PMC9380327,42620,"Upper-body microvascular function was assessed using peak cutaneous vascular conductance (CVC) responses to acetylcholine (ACh) and sodium nitroprusside (SNP) as indicators of microvascular endothelial-dependent and endothelial-independent vasodilation, respectively, measured using Laser Doppler Fluximetry and Iontophoresis, using a standardized procedure [27].",Measures|Secondary outcomes,[253612],[11000],[11363],[False],[0],[0],[False],['0']
43058,PMC9380327,42621,"Cutaneous red cell flux was measured by placing an iontophoresis laser Doppler probe (PF481-1; Perimed AB), connected to a laser Doppler fluxmeter (PF5001; Perimed AB), in the center of each of two drug delivery electrodes ((PF383; Perimed AB, Jarfalla, Sweden) positioned over healthy-looking skin, approximately 4 cm apart with one containing 100 μL of 1% ACh (Miochol-E, Novartis, Stein – endothelium-dependent vasodilator) and the other 100 μl of 1% SNP (Nitroprussiat, Rottapharm – endothelium-independent vasodilator).",Measures|Secondary outcomes,[253616],[11364],[11888],[False],[0],[0],[False],['0']
43059,PMC9380327,42622,"Measurements of red cell flux (recorded in arbitrary units, AU) were divided by corresponding MAP values (in mmHg) to give CVC in AU/mmHg.",Measures|Secondary outcomes,[253620],[11889],[12027],[False],[0],[0],[False],['0']
43060,PMC9380327,42623,Here we present ACh and SNP peak CVC responses.,Measures|Secondary outcomes,[253624],[12028],[12075],[False],[0],[0],[False],['0']
43061,PMC9380327,42624,The technical error of measurement for drug-induced peak flux responses in our laboratory is 15% [28].,Measures|Secondary outcomes,[253628],[12076],[12178],[False],[0],[0],[False],['0']
43062,PMC9380327,42625,Mean arterial pressure (MAP) was calculated using the following formula:,Measures|Secondary outcomes,[253632],[12179],[12251],[False],[0],[0],[False],['0']
43063,PMC9380327,42626,MAP was not included in the original list of outcomes as a separate outcome.,Measures|Secondary outcomes,[253636],[12252],[12329],[False],[0],[0],[False],['0']
43064,PMC9380327,42627,"However, it was decided to be analyzed and presented separately, due to its common use as surrogate marker for arterial stiffness [28].",Measures|Secondary outcomes,[253640],[12330],[12465],[False],[0],[0],[False],['0']
43065,PMC9380327,42628,"All cardiovascular outcomes (following, micro- and macro-vascular assessments) were assessed by the same researcher, at all time-points.",Measures|Secondary outcomes,[253644],[12466],[12602],[False],[0],[0],[False],['0']
43066,PMC9380327,42629,"Additional outcome measures include the following: (i) quality of life and health economics; preferences were calculated using EQ-5D-5L Index values and visual analog scale (VAS) scores, and the five discrete EQ-5D dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) were assessed [29]; (ii) Q-Risk to assess risk of CVD; [30] and (iii) “Finger prick” test to calculate the total cholesterol (TC) over high-density lipoprotein (HDL) ratio [31].",Measures|Secondary outcomes,[253648],[12603],[13083],[False],[0],[0],[False],['0']
43067,PMC9380327,42630,"All outcomes were assessed with participants abstaining from caffeine, main meals, supplements, and e-cigarettes and smoking for at least 3 h prior to the assessments.",Measures|Secondary outcomes,[253652],[13084],[13251],[False],[0],[0],[False],['0']
43068,PMC9380327,42631,Premenopausal women were studied during days 1–7 of their menstrual cycle to minimize the influence of cyclical changes in female hormones and strenuous exercise was avoided for at least 12 h prior to the assessments.,Measures|Secondary outcomes,[253656],[13252],[13469],[False],[0],[0],[False],['0']
43069,PMC9380327,42632,Outcomes were assessed at baseline and repeated at 3 and 6 months after the quit date.,Measures|Secondary outcomes,[253660],[13470],[13556],[False],[0],[0],[False],['0']
43070,PMC9380327,42633,"Resource use (e.g., GP practice and clinic visits) and personal out-of-pocket expenditure (e.g., travel for appointments, prescriptions, and products purchased to quit smoking) were collected via participants’ diaries maintained from baseline to the end of intervention (3 months) period using standard procedures.",Measures|Secondary outcomes,[253664],[13557],[13871],[False],[0],[0],[False],['0']
43071,PMC9380327,42634,Sample,Sample,[253668],[13872],[13879],[False],[0],[0],[False],['0']
43072,PMC9380327,42635,Fig.,Sample,[253672],[13880],[13884],[False],[0],[0],[False],['0']
43073,PMC9380327,42636,1 Flowchart of the study population.,Sample,[253676],[13885],[13921],[False],[0],[0],[False],['0']
43074,PMC9380327,42637,"In total, 248 participants were randomized (Fig.",Sample,[253680],[13922],[13970],[False],[0],[0],[False],['0']
43075,PMC9380327,42638,1).,Sample,[253684],[13971],[13974],[False],[0],[0],[False],['0']
43076,PMC9380327,42639,"Data of four were removed following their withdrawal from the study (1 in the nicotine-containing, 1 in the nicotine-free, 2 in the NRT group).",Sample,[253688],[13975],[14118],[False],[0],[0],[False],['0']
43077,PMC9380327,42640,"The 3-month follow-up was completed by 207 participants, the 6-month follow-up by 202 participants.",Sample,[253692],[14119],[14218],[False],[0],[0],[False],['0']
43078,PMC9380327,42641,Participants were included whether they stopped smoking or not.,Sample,[253696],[14219],[14282],[False],[0],[0],[False],['0']
43079,PMC9380327,42642,Statistical analysis,Sample|Statistical analysis,[253700],[14283],[14303],[False],[0],[0],[False],['0']
43080,PMC9380327,42643,"Data were analyzed in SPSS 24 (IBM U.K. Limited, Hampshire, UK) on an intention-to-treat basis, using the “last observation carried forward” method for those participants that had no data for the 3- and 6-month follow-ups, respectively.",Sample|Statistical analysis,[253704],[14304],[14540],[False],[0],[0],[False],['0']
43081,PMC9380327,42644,"We developed a multiple linear regression model for our repeated continuous outcome measures (%FMD, ACh, SNP, MAP), using a generalized estimating equations (GEE) approach.",Sample|Statistical analysis,[253708],[14541],[14713],[False],[0],[0],[False],['0']
43082,PMC9380327,42645,"We made this change from the ANOVA specified in the protocol as GEE is more robust to misspecification of the dependency structure, which results from the repeated assessments of individual over time [32].",Sample|Statistical analysis,[253712],[14714],[14919],[False],[0],[0],[False],['0']
43083,PMC9380327,42646,"GEE used age (in completed years), gender and baseline measurements (or 3-month values for change over 6-month analysis) to control for and predict net-changes in these outcome measures over the 3- and 6-month periods, across our three randomized groups.",Sample|Statistical analysis,[253716],[14920],[15174],[False],[0],[0],[False],['0']
43084,PMC9380327,42647,"To explore the interaction between our repeated assessments and our treatment groups, we introduced treatment groups dummy variables, which were assessed over each time-point (i.e., 3 and 6 months), using an established methodology as described in Twisk et al.",Sample|Statistical analysis,[253720],[15175],[15435],[False],[0],[0],[False],['0']
43085,PMC9380327,42648,[33].,Sample|Statistical analysis,[253724],[15436],[15441],[False],[0],[0],[False],['0']
43086,PMC9380327,42649,"Our analysis was also varied against our original protocol, in that we decided against including pack years in the model, due to the excellent balance between groups; age was included instead.",Sample|Statistical analysis,[253728],[15442],[15634],[False],[0],[0],[False],['0']
43087,PMC9380327,42650,A separate analysis using mixed effect models repeat measurement (MMRM) was completed after using multiple imputation for missing values for four outcome variables at 3- and 6- month follow-ups; findings did not differ to those obtained through the GEE modeling.,Sample|Statistical analysis,[253732],[15635],[15897],[False],[0],[0],[False],['0']
43088,PMC9380327,42651,"As additional post hoc analyses, separate GEE models were run for the “cessation” sub-group, which included those that stated that they had stopped smoking and had their status biochemically validated by exhaled air measurement of < 10 ppm CO in line with the Russell Standard [34].",Sample|Statistical analysis,[253736],[15898],[16180],[False],[0],[0],[False],['0']
43089,PMC9380327,42652,"Unadjusted mean differences (d) were calculated as the mean change from baseline to a given time point, for the %FMD, ACh, SNP, and MAP.",Sample|Statistical analysis,[253740],[16181],[16317],[False],[0],[0],[False],['0']
43090,PMC9380327,42653,"For health-related quality of life (HRQoL), mean values for the three participant groups were compared, and the net changes from baseline to 3 and 6 months were estimated.",Sample|Statistical analysis,[253744],[16318],[16489],[False],[0],[0],[False],['0']
43091,PMC9380327,42654,"Also, the proportion of patients with sub-optimal levels (i.e., levels 2–5) on each of the five dimensions was compared at baseline, 3, and 6 months.",Sample|Statistical analysis,[253748],[16490],[16639],[False],[0],[0],[False],['0']
43092,PMC9380327,42655,"Quality-adjusted life-years (QALYs) were calculated by multiplying the duration of time spent in various health states by the HRQoL weight (i.e., utility score) associated with that health state.",Sample|Statistical analysis,[253752],[16640],[16835],[False],[0],[0],[False],['0']
43093,PMC9380327,42656,"A similar approach (i.e., paired t-tests used to compare differences in means at two points in time (3 and 6 months over baseline values) across three quit-smoking groups) was chosen for the other secondary outcomes, including Q-Risk and the total cholesterol (TC) over high-density lipoprotein (HDL) ratio.",Sample|Statistical analysis,[253756],[16836],[17143],[False],[0],[0],[False],['0']
43094,PMC9380327,42657,"Health economics were assessed using participants’ resource use diaries alongside costs for the delivery of 12 weeks of behavioral change intervention (researcher’s time, room hire charges, and travel expenses), and costs for the intervention materials (electronic cigarette, adapter, atomizer & liquids).",Sample|Statistical analysis,[253760],[17144],[17449],[False],[0],[0],[False],['0']
43095,PMC9380327,42658,NHS smoking cessation delivery costs were estimated to include clinic nurse time and the number of sessions delivered to NRT participants.,Sample|Statistical analysis,[253764],[17450],[17588],[False],[0],[0],[False],['0']
43096,PMC9380327,42659,Participants’ use of NHS services was priced using 2020 PSSRU costings or Department of Health reference costs [35].,Sample|Statistical analysis,[253768],[17589],[17705],[False],[0],[0],[False],['0']
43097,PMC9380327,42660,Role of the funding source,Sample|Role of the funding source,[253772],[17706],[17732],[False],[0],[0],[False],['0']
43098,PMC9380327,42661,The trial was funded by Heart Research UK under a Translational Research Grant (RG2658).,Sample|Role of the funding source,[253776],[17733],[17821],[False],[0],[0],[False],['0']
43099,PMC9380327,42662,"The funder had no role in the study’s design, conduct, and reporting.",Sample|Role of the funding source,[253780],[17822],[17891],[False],[0],[0],[False],['0']
43100,PMC9380327,42663,Results,Results,[253784],[17892],[17900],[False],[0],[0],[False],['0']
43101,PMC9380327,42664,Participants,Results|Participants,[253788],[17901],[17913],[False],[0],[0],[False],['0']
43102,PMC9380327,42665,Table 1  Baseline characteristics of participants (n = 248).,Results|Participants,[253792],[17914],[17974],[False],[0],[0],[False],['0']
43103,PMC9380327,42666,Baseline characteristics are presented in Table 1.,Results|Participants,[253796],[17975],[18025],[False],[0],[0],[False],['0']
43104,PMC9380327,42667,Primary outcome: macrovascular assessment,Results|Participants,[253800],[18026],[18067],[False],[0],[0],[False],['0']
43105,PMC9380327,42668,"Table 2 Results of model estimating change in % flow-mediated dilation, cutaneous vascular conductance in response to acetylcholine and to sodium nitroprusside, and mean arterial pressure at 3 and 6 months follow-up: all participants.",Results|Participants,[253804],[18068],[18302],[False],[0],[0],[False],['0']
43106,PMC9380327,42669,Fig.,Results|Participants,[253808],[18303],[18307],[False],[0],[0],[False],['0']
43107,PMC9380327,42670,2 Central illustration: Changes from baseline to follow-up by treatment arm in (A): Flow mediated dilation (%FMD); (B): Peak cutaneous vascular conductance responses to acetylcholine (ACh); (C):Peak cutaneous vascular conductance responses to sodium nitroprusside (SNP); (D): Mean arterial pressure (MAP).,Results|Participants,[253812],[18308],[18613],[False],[0],[0],[False],['0']
43108,PMC9380327,42671,"Compared to baseline, %FMD was improved at both 3- and 6-month follow-ups in all three groups.",Results|Participants,[253816],[18614],[18708],[False],[0],[0],[False],['0']
43109,PMC9380327,42672,"There was an improvement in %FMD  at 3 months (β=3.33; 95% CI: 2.61 to 4.05, p < 0.0001) and at 6 months (β=2.69; 95% CI: 2.02 to 3.35, p < 0.0001).",Results|Participants,[253820],[18709],[18857],[False],[0],[0],[False],['0']
43110,PMC9380327,42673,"There was no statistically significant difference in %FMD between the intervention groups (Table 2, Fig.",Results|Participants,[253824],[18858],[18962],[False],[0],[0],[False],['0']
43111,PMC9380327,42674,2 Central Illustration Graph A).,Results|Participants,[253828],[18963],[18995],[False],[0],[0],[False],['0']
43112,PMC9380327,42675,"Age did not appear to affect our findings, although gender did, as females had a greater gain in macrovascular function improvement than males (β=-1.32, 95% CI:−2.24 to−0.4; p=0.005).",Results|Participants,[253832],[18996],[19179],[False],[0],[0],[False],['0']
43113,PMC9380327,42676,"There was also a significant combined effect of group and follow-up visits (β=3.17, 95% CI: 1.37 to 3.59; p  = 0.001).",Results|Participants,[253836],[19180],[19298],[False],[0],[0],[False],['0']
43114,PMC9380327,42677,"Unadjusted mean differences from baseline (d) were high for all groups both at 3 (d = 4.14, 95% CI: 2.57 to 5.51, p < 0.001 for the nicotine-free e-cigarette group, d = 3.50, 95% CI: 2.28 to 4.72 for the nicotine-containing e-cigarette group, d = 2.36, 95% CI: 1.17 to 3.56, p < 0.001, for the NRT group) and 6 months (d = 2.48, 95% CI: 1.35 to 3.62 for the nicotine-free e-cigarette group, d = 2.78, 95% CI: 1.66 to 3.90, p < 0.001 for the nicotine-containing e-cigarette group, d = 2.79, 95% CI: 1.52 to 4.06 for the NRT group).",Results|Participants,[253840],[19299],[19830],[False],[0],[0],[False],['0']
43115,PMC9380327,42678,Secondary outcomes: microvascular assessment,Results|Participants,[253844],[19831],[19875],[False],[0],[0],[False],['0']
43116,PMC9380327,42679,Acetylcholine (ACh),Results|Acetylcholine (ACh),[253848],[19876],[19895],[False],[0],[0],[False],['0']
43117,PMC9380327,42680,"Similar to %FMD, CVC values for ACh improved significantly over baseline in all three groups both at 3 and 6 months.",Results|Acetylcholine (ACh),[253852],[19896],[20012],[False],[0],[0],[False],['0']
43118,PMC9380327,42681,"There was an improvement at 3 (β=0.2, 95% CI: 0.01 to 0.4, p = 0.04) and 6 months (β=0.27, 95% CI: 0.09 to 0.45, p = 0.004).",Results|Acetylcholine (ACh),[253856],[20013],[20137],[False],[0],[0],[False],['0']
43119,PMC9380327,42682,There were no statistically significant differences between groups at follow-up (Table 2).,Results|Acetylcholine (ACh),[253860],[20138],[20228],[False],[0],[0],[False],['0']
43120,PMC9380327,42683,Neither age nor gender affected the outcome in endothelial-dependent microvascular vasodilation (Table 2; Fig.,Results|Acetylcholine (ACh),[253864],[20229],[20339],[False],[0],[0],[False],['0']
43121,PMC9380327,42684,2 Central Illustration Graph B).,Results|Acetylcholine (ACh),[253868],[20340],[20372],[False],[0],[0],[False],['0']
43122,PMC9380327,42685,"Nevertheless, the combination of group and follow-up visits did (β=0.32, 95% CI: 0.23 to 0.4; p = 0.03).",Results|Acetylcholine (ACh),[253872],[20373],[20477],[False],[0],[0],[False],['0']
43123,PMC9380327,42686,"Unadjusted d values were high, particularly at 6 months (d = 0.19, 95% CI: − 0.08 to 0.41, p = 0.29 for the nicotine-free e-cigarette group, d = 0.30, 95% CI: − 0.01 to 0.61, p = 0.04 for the Nicotine-containing e-cigarette group, d = 0.41, 95% CI: 0.08 to 0.74, p = 0.02 for the NRT group).",Results|Acetylcholine (ACh),[253876],[20478],[20769],[False],[0],[0],[False],['0']
43124,PMC9380327,42687,Sodium nitroprusside (SNP),Results|Sodium nitroprusside (SNP),[253880],[20770],[20796],[False],[0],[0],[False],['0']
43125,PMC9380327,42688,"As with the previous outcomes, SNP improved over baseline, at both follow-up visits.",Results|Sodium nitroprusside (SNP),[253884],[20797],[20881],[False],[0],[0],[False],['0']
43126,PMC9380327,42689,"There was an improvement at both 3 (β=0.26, 95% CI: 0.09 to 0.42, p = 0.001) and 6 months (β=0.28, 95% CI: 0.11 to 0.45, p = 0.002), with the combination of group and visit bearing an effect to the outcome (β=0.49, 95% CI: 0.15 to 0.67, p = 0.002).",Results|Sodium nitroprusside (SNP),[253888],[20882],[21130],[False],[0],[0],[False],['0']
43127,PMC9380327,42690,There were no significant differences between groups (Table 2; Fig.,Results|Sodium nitroprusside (SNP),[253892],[21131],[21198],[False],[0],[0],[False],['0']
43128,PMC9380327,42691,2 Central Illustration Graph C) and neither age nor gender significantly affected this outcome.,Results|Sodium nitroprusside (SNP),[253896],[21199],[21294],[False],[0],[0],[False],['0']
43129,PMC9380327,42692,"The positive improvement trend observed in other outcomes was also observed for SNP in unadjusted d as well, particularly at the 6-month follow-up: (d = 0.40, 95% CI: 0.13 to 0.65, p = 0.004 for the nicotine-free e-cigarette group, d = 0.22, 95% CI: − 0.08 to 0.52, p = 0.14 for the nicotine-containing e-cigarette group, d = 0.21, 95% CI: − 0.55 to 0.12, p = 0.21 for the NRT group).",Results|Sodium nitroprusside (SNP),[253900],[21295],[21679],[False],[0],[0],[False],['0']
43130,PMC9380327,42693,Mean arterial pressure (MAP),Results|Mean arterial pressure (MAP),[253904],[21680],[21708],[False],[0],[0],[False],['0']
43131,PMC9380327,42694,"MAP readings were reduced in all three intervention groups at both follow-ups (β =  − 1.74, 95% CI: − 2.57 to − 0.91; p = 0.001 and β =  − 1.41, 95% CI: − 2.31 to − 0.51; p = 0.002).",Results|Mean arterial pressure (MAP),[253908],[21709],[21891],[False],[0],[0],[False],['0']
43132,PMC9380327,42695,"There were no statistically significant differences between groups (Table 2, Fig.",Results|Mean arterial pressure (MAP),[253912],[21892],[21973],[False],[0],[0],[False],['0']
43133,PMC9380327,42696,"2 Central Illustration Graph D) and no combined effect of group and follow-up visit (β=0.26, 95% CI:−1.22 to 1.74; p = 0.73).",Results|Mean arterial pressure (MAP),[253916],[21974],[22099],[False],[0],[0],[False],['0']
43134,PMC9380327,42697,"The reduction was affected by gender (β = 4.33, 95% CI: 1.86 to 6.79; p = 0.001) and age (β = 0.23, 95% CI: 0.14 to 0.33; p = 0.001), with females and lower age groups benefiting the most.",Results|Mean arterial pressure (MAP),[253920],[22100],[22288],[False],[0],[0],[False],['0']
43135,PMC9380327,42698,"As with the other measures, unadjusted d values suggest an improvement particularly at 6 months (d =  − 0.26, 95% CI: − 1.24 to 1.79, p = 0.53 for the nicotine-free e-cigarette group, d =  − 2.23, 95% CI: − 3.74 to − 0.71, p = 0.004 for the nicotine-containing e-cigarette group, d =  − 2.18, 95% CI: − 3.86 to − 0.49, p = 0.01 for the NRT group).",Results|Mean arterial pressure (MAP),[253924],[22289],[22636],[False],[0],[0],[False],['0']
43136,PMC9380327,42699,Cessation subgroup,Cessation subgroup,[253928],[22637],[22656],[False],[0],[0],[False],['0']
43137,PMC9380327,42700,Table 3 Results of model estimating change in % FMD at 3- and 6-month follow-ups of cessation subgroup (upper section) and changes in means (difference over baseline) in %FMD for the cessation subgroup for 3- and 6-month follow-ups (lower section).,Cessation subgroup,[253932],[22657],[22905],[False],[0],[0],[False],['0']
43138,PMC9380327,42701,"In the nicotine-containing e-cigarette group, 39 successfully stopped smoking at 3 and 36 at 6 months.",Cessation subgroup,[253936],[22906],[23008],[False],[0],[0],[False],['0']
43139,PMC9380327,42702,"In the nicotine-free e-cigarette group, it was 34 and 30 at 3 and 6 months, respectively; and in the NRT group 33 and 25 at 3 and 6 months respectively.",Cessation subgroup,[253940],[23009],[23161],[False],[0],[0],[False],['0']
43140,PMC9380327,42703,"The post hoc subgroup analysis showed strong effects for %FMD at both follow-up sessions (β = 2.40, 95% CI: 1.66 to 3.14; p < 0.0001 for 3 months and β = 2.99, 95% CI: 2.22 to 3.77; p < 0.0001 for 6 months).",Cessation subgroup,[253944],[23162],[23369],[False],[0],[0],[False],['0']
43141,PMC9380327,42704,No differences were observed between groups at both time-points (Table 3).,Cessation subgroup,[253948],[23370],[23444],[False],[0],[0],[False],['0']
43142,PMC9380327,42705,"Unadjusted mean differences from baseline (d) were high for all groups both at 3 (e.g., d = 4.78, 95% CI: 2.27 to 7.29, p < 0.0001 for the nicotine-free e-cigarette group) and 6 months (e.g., d = 4.40, 95% CI: 2.14 to 6.66, p = 0.001 for the NRT group) (Table 3).",Cessation subgroup,[253952],[23445],[23708],[False],[0],[0],[False],['0']
43143,PMC9380327,42706,Secondary outcomes: other measures,Cessation subgroup,[253956],[23709],[23743],[False],[0],[0],[False],['0']
43144,PMC9380327,42707,"Table 4 Quality of life by domain at baseline, 3 and 6 months follow-ups of all participants.",Cessation subgroup,[253960],[23744],[23837],[False],[0],[0],[False],['0']
43145,PMC9380327,42708,"For Quality of life, post-quit improvements were observed in QALYs, both in % and actual values [e.g., F = 4.17, p = 0.02, df = 2,243 at 3 and F = 5.03, p = 0.01, df = 2,243 at 6 months respectively for QALY (%)].",Cessation subgroup,[253964],[23838],[24051],[False],[0],[0],[False],['0']
43146,PMC9380327,42709,"Improvements were also detected for pain (%) (F = 3.43, p = 0.03, df = 2,243 at 3 months) and depression and anxiety (%) (F = 4.54, p = 0.01, df = 2,243 at 3 and F = 6.25, p = 0.01, df = 2,243 at 6 months respectively).",Cessation subgroup,[253968],[24052],[24271],[False],[0],[0],[False],['0']
43147,PMC9380327,42710,"No changes were detected in mobility (%), movement (%), self-care (%) or the participants’ self-rated health (VAS) (Table 4).",Cessation subgroup,[253972],[24272],[24397],[False],[0],[0],[False],['0']
43148,PMC9380327,42711,Table 5 Change of secondary outcome variables over baseline.,Cessation subgroup,[253976],[24398],[24458],[False],[0],[0],[False],['0']
43149,PMC9380327,42712,Reductions were observed for Q-Risk at 3 and 6 months for all three groups with the exception of the Q-risk % at 6 months for NRT.,Cessation subgroup,[253980],[24459],[24589],[False],[0],[0],[False],['0']
43150,PMC9380327,42713,No statistically significant changes were observed for TC/HDL Ratio (Table 5).,Cessation subgroup,[253984],[24590],[24668],[False],[0],[0],[False],['0']
43151,PMC9380327,42714,"Our health economics’ assessment suggests a lower per-participant cost for e-cigarettes (nicotine-containing = £192.55, nicotine-free = £177.63) in comparison to NRT (£246.92), due to a higher resource-use cost observed in the NRT group (Please see Online Supplement).",Cessation subgroup,[253988],[24669],[24937],[False],[0],[0],[False],['0']
43152,PMC9380327,42715,Discussion,Discussion,[253992],[24938],[24949],[False],[0],[0],[False],['0']
43153,PMC9380327,42716,"Participants improved their cardiovascular health prospects, irrespective of whether they used NRT or e-cigarettes with or without nicotine.",Discussion,[253996],[24950],[25090],[False],[0],[0],[False],['0']
43154,PMC9380327,42717,These improvements appear both overall and in those that quit successfully.,Discussion,[254000],[25091],[25166],[False],[0],[0],[False],['0']
43155,PMC9380327,42718,"Most of our findings (driven by the improvements in those that quit successfully, as our sub-group analysis shows) suggest endothelial function improvements, which appear quite early in the smoking cessation timeline [21], continue to exist in both smaller and larger conduits, at least up to 6 months after smokers quit.",Discussion,[254004],[25167],[25488],[False],[0],[0],[False],['0']
43156,PMC9380327,42719,"This potentially happens via a reduction in the production of oxidative stress and ultimately an increase of NO bioavailability, an imbalance between which is known to be created via smoking [36].",Discussion,[254008],[25489],[25685],[False],[0],[0],[False],['0']
43157,PMC9380327,42720,"ACh is an endothelial-dependent vasodilator primarily associated with an increase in NO bioavailability, particularly at higher ACh doses [27].",Discussion,[254012],[25686],[25829],[False],[0],[0],[False],['0']
43158,PMC9380327,42721,"Additionally, endothelium-derived NO is considered as a principal FMD mediator [26], although this view is debated [27].",Discussion,[254016],[25830],[25950],[False],[0],[0],[False],['0']
43159,PMC9380327,42722,"Considering that SNP is a direct NO donor [27], our findings suggest that smoking cessation offers further NO-bioavailability benefits through an improvement in smooth muscle cell vascular function, as the observed improvement in SNP-induced vasodilation suggests.",Discussion,[254020],[25951],[26215],[False],[0],[0],[False],['0']
43160,PMC9380327,42723,"This is a change from our short-term observations, in which we found no improvements from the baseline, in any of our groups [25].",Discussion,[254024],[26216],[26346],[False],[0],[0],[False],['0']
43161,PMC9380327,42724,"Therefore, it is possible that although e-cigarettes are known to have a negative acute effect on NO-bioavailability and endothelial function of healthy adults [37] or when comparing e-cigarette users with healthy adults [38], they appear to support the reversal of the smoking-induced endothelial dysfunction, in a similar manner to NRT.",Discussion,[254028],[26347],[26685],[False],[0],[0],[False],['0']
43162,PMC9380327,42725,"This happens, however, at a later stage of the smoking cessation process, suggesting that the smooth muscle cell damage, which is caused by cigarettes (possibly via inducing a pro-inflammatory/matrix remodeling phenotype in smooth muscle cells [39]), is more persistent.",Discussion,[254032],[26686],[26956],[False],[0],[0],[False],['0']
43163,PMC9380327,42726,"The slow reversal is a positive sign, which could also reduce the risk of atherosclerosis and stroke [39].",Discussion,[254036],[26957],[27063],[False],[0],[0],[False],['0']
43164,PMC9380327,42727,"Although the assessment of vascular stiffness is a complex process, and a simple, surrogate measure cannot fully determine whether a change occurs or not, recent work suggests the predictive role of MAP for arterial stiffness [39], with increases in the former suggesting also an increase to the latter [40].",Discussion,[254040],[27064],[27372],[False],[0],[0],[False],['0']
43165,PMC9380327,42728,"Thus, the observed MAP reduction in all three trial groups may well suggest an improvement in vascular stiffness as well.",Discussion,[254044],[27373],[27494],[False],[0],[0],[False],['0']
43166,PMC9380327,42729,"Direct testing, which was not possible in our study, due to the high participant burden of the assessments that we used, can confirm our findings.",Discussion,[254048],[27495],[27641],[False],[0],[0],[False],['0']
43167,PMC9380327,42730,Our findings agree with recent work by George et al.,Discussion,[254052],[27642],[27694],[False],[0],[0],[False],['0']
43168,PMC9380327,42731,"[20], who reported that endothelial function and arterial stiffness in smokers improved within 1 month of switching to e-cigarettes.",Discussion,[254056],[27695],[27827],[False],[0],[0],[False],['0']
43169,PMC9380327,42732,"Our work goes some steps further, showing that endothelial function is markedly improved in small veins and arteries, if smokers continue to abstain, for longer periods, from cigarettes, using NRT as well.",Discussion,[254060],[27828],[28033],[False],[0],[0],[False],['0']
43170,PMC9380327,42733,"This is an important finding, which can be potentially encouraging for those who wish to stop smoking, especially as impaired vascular function—even at pre-clinical groups—is associated with a higher CVD risk [41].",Discussion,[254064],[28034],[28248],[False],[0],[0],[False],['0']
43171,PMC9380327,42734,Stronger improvement in women than men found both by George et al.,Discussion,[254068],[28249],[28315],[False],[0],[0],[False],['0']
43172,PMC9380327,42735,"[20] and in the present study, indicate that physiological reasons should be further explored.",Discussion,[254072],[28316],[28410],[False],[0],[0],[False],['0']
43173,PMC9380327,42736,"In line with previous evidence [42, 43] a lower age was associated with marginally larger beneficial changes, highlighting that while it is never too late to stop smoking, the earlier this happens, the easier it is to reverse the negative effects of cigarettes.",Discussion,[254076],[28411],[28672],[False],[0],[0],[False],['0']
43174,PMC9380327,42737,"Finally, our Health Economics analysis suggests a lower cost for e-cigarettes to that required for NRT (£192.55 and £177.63 vs £246.92).",Discussion,[254080],[28673],[28809],[False],[0],[0],[False],['0']
43175,PMC9380327,42738,QoL findings confirm previously reported benefits of smoking cessation [20] including among people using e-cigarettes [20].,Discussion,[254084],[28810],[28933],[False],[0],[0],[False],['0']
43176,PMC9380327,42739,Limitations,Discussion|Limitations,[254088],[28934],[28945],[False],[0],[0],[False],['0']
43177,PMC9380327,42740,There are many different devices and liquid manufacturers and a wide range of liquids available.,Discussion|Limitations,[254092],[28946],[29042],[False],[0],[0],[False],['0']
43178,PMC9380327,42741,We chose a single device and manufacturer to ensure consistency and standardization.,Discussion|Limitations,[254098],[29043],[29127],[True],['Generalization'],['We chose a single device'],[True],['Generalization']
43179,PMC9380327,42742,We did not include a group of continuing cigarette smokers as it would not have been ethical to do due to the dangers of continued smoking.,Discussion|Limitations,[254104],[29128],[29267],[True],['VerySpecificPopulation'],['We did not include a group of continuing cigarette smokers'],[True],['Population']
43180,PMC9380327,42743,"However, all participants were smokers initially and therefore de-facto acted as controls for themselves, while no improvements are to be expected over time in the vasculature of smokers [20].",Discussion|Limitations,[254112],[29268],[29460],[False],[0],[0],[False],['0']
43181,PMC9380327,42744,"Finally, the trial was not designed to perform a “quitters” vs “continuous smokers” sub-group comparison, which would have added to our knowledge on the topic.",Discussion|Limitations,[254117],[29461],[29620],[True],['StudyDesign'],['the trial was not designed to perform a “quitters” vs “continuous smokers” sub-group comparison'],[True],['StudyDesign']
43182,PMC9380327,42745,This should be the focus of a future study.,Discussion|Limitations,[254124],[29621],[29664],[False],[0],[0],[False],['0']
43183,PMC9380327,42746,Strengths,Discussion|Strengths,[254128],[29665],[29674],[False],[0],[0],[False],['0']
43184,PMC9380327,42747,"This is the first study to compare the medium- and longer-term cardiovascular effects of smoking cessation attempts supported using e-cigarettes and NRT and is being complimented by an exploration of the participants' experiences in the intervention, published separately [44].",Discussion|Strengths,[254132],[29675],[29952],[False],[0],[0],[False],['0']
43185,PMC9380327,42748,"Our intervention was conducted in a way which would be followed if e-cigarettes were widely adopted as a smoking cessation aid, in supported smoking cessation attempts.",Discussion|Strengths,[254136],[29953],[30121],[False],[0],[0],[False],['0']
43186,PMC9380327,42749,It enabled comparison with a licensed and widely accepted route for smoking cessation.,Discussion|Strengths,[254140],[30122],[30208],[False],[0],[0],[False],['0']
43187,PMC9380327,42750,"The success rate of our intervention (which can be attributed to the flexibility of the behavioral support offered, and the intense way that the intervention was delivered), although it cannot be traced for a period longer than 6 months, suggests the need of healthcare investment in these services.",Discussion|Strengths,[254144],[30209],[30508],[False],[0],[0],[False],['0']
43188,PMC9380327,42751,"Finally, the inclusion of micro-circulation outcomes is another strength as pathological changes in the microcirculation mirror changes in arteries, making it an appropriate area to study to achieve early detection.",Discussion|Strengths,[254148],[30509],[30724],[False],[0],[0],[False],['0']
43189,PMC9380327,42752,Future research,Discussion|Future research,[254152],[30725],[30740],[False],[0],[0],[False],['0']
43190,PMC9380327,42753,The next step would be to explore outcomes beyond 6 months.,Discussion|Future research,[254159],[30741],[30800],[True],['FollowUpDuration'],['explore outcomes beyond 6\xa0months'],[True],['StudyDuration']
43191,PMC9380327,42754,"It would also be interesting to explore the cardiovascular effects of different devices and liquids, although long-term stability would likely be difficult to achieve.",Discussion|Future research,[254164],[30801],[30968],[False],[0],[0],[False],['0']
43192,PMC9380327,42755,Conclusions,Conclusions,[254168],[30969],[30981],[False],[0],[0],[False],['0']
43193,PMC9380327,42756,Smokers attempting to quit experienced a positive cardiovascular impact after both a 3- and 6-month period.,Conclusions,[254172],[30982],[31089],[False],[0],[0],[False],['0']
43194,PMC9380327,42757,"None of the groups (i.e., nicotine-containing and nicotine-free e-cigarettes or NRT) offered superior cardiovascular benefits to the others.",Conclusions,[254176],[31090],[31230],[False],[0],[0],[False],['0']
43195,PMC9380327,42758,Supplementary Information,Supplementary Information,[254180],[31231],[31257],[False],[0],[0],[False],['0']
43196,PMC9380327,42759, Additional file 1.,Supplementary Information,[254184],[31258],[31277],[False],[0],[0],[False],['0']
43197,PMC9380327,42760,Abbreviations,Abbreviations|Abbreviations,[254188],[31278],[31293],[False],[0],[0],[False],['0']
43198,PMC9380327,42761,ACh Acetylcholine,Abbreviations|ACh Acetylcholine,[254192],[31294],[31311],[False],[0],[0],[False],['0']
43199,PMC9380327,42762,BMI Body mass index,Abbreviations|BMI Body mass index,[254196],[31312],[31331],[False],[0],[0],[False],['0']
43200,PMC9380327,42763,CVC Cutaneous vascular conductance,Abbreviations|CVC Cutaneous vascular conductance,[254200],[31332],[31366],[False],[0],[0],[False],['0']
43201,PMC9380327,42764,CVD Cardiovascular disease,Abbreviations|CVD Cardiovascular disease,[254204],[31367],[31393],[False],[0],[0],[False],['0']
43202,PMC9380327,42765,E-cigarettes Electronic cigarettes,Abbreviations|E-cigarettes Electronic cigarettes,[254208],[31394],[31428],[False],[0],[0],[False],['0']
43203,PMC9380327,42766,FMD Flow-mediated dilation,Abbreviations|FMD Flow-mediated dilation,[254212],[31429],[31455],[False],[0],[0],[False],['0']
43204,PMC9380327,42767,MAP Mean arterial pressure,Abbreviations|MAP Mean arterial pressure,[254216],[31456],[31482],[False],[0],[0],[False],['0']
43205,PMC9380327,42768,NRT Nicotine replacement therapy,Abbreviations|NRT Nicotine replacement therapy,[254220],[31483],[31515],[False],[0],[0],[False],['0']
43206,PMC9380327,42769,SNP Sodium nitroprussidePublisher's Note,Abbreviations|NRT Nicotine replacement therapy,[254224],[31516],[31556],[False],[0],[0],[False],['0']
43207,PMC9380327,42770,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.,Abbreviations|NRT Nicotine replacement therapy,[254228],[31557],[31675],[False],[0],[0],[False],['0']
